PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Muraoka, O; Shimizu, T; Yabe, T; Nojima, H; Bae, YK; Hashimoto, H; Hibi, M				Muraoka, O; Shimizu, T; Yabe, T; Nojima, H; Bae, YK; Hashimoto, H; Hibi, M			Sizzled controls dorso-ventral polarity by repressing cleavage of the Chordin protein	NATURE CELL BIOLOGY			English	Article							FRIZZLED-RELATED PROTEINS; NEGATIVE FEEDBACK REGULATOR; ZEBRAFISH EMBRYO; PATTERN-FORMATION; SPEMANN ORGANIZER; XENOPUS EMBRYOS; TWISTED GASTRULATION; BMP; GENES; NOGGIN	The Bone morphogenetic protein (Bmp) signalling gradient has a major function in the formation of the dorso-ventral axis. The zebrafish ventralized mutant, ogon, encodes Secreted Frizzled ( Sizzled). sizzled is ventrally expressed in a Bmp-dependent manner and is required for the suppression of Bmp signalling on the ventral side of zebrafish embryos. However, it remains unclear how Sizzled inhibits Bmp signalling and controls ventro-lateral cell fate. We found that Sizzled stabilizes Chordin, a Bmp antagonist, by binding and inhibiting the Tolloid-family metalloproteinase, Bmp1a, which cleaves and inactivates Chordin. The cysteine-rich domain of Sizzled is required for inhibition of Bmp1a activity. Loss of both Bmp1a and Tolloid-like1 (Tll1; another Tolloid-family metalloproteinase) function leads to a complete suppression and reversal of the ogon mutant phenotype. These results indicate that Sizzled represses the activities of Tolloid-family proteins, thereby creating the Chordin - Bmp activity gradient along the dorso-ventral axis. Here, we describe a previously unrecognized role for a secreted Frizzled-related protein.	RIKEN, Ctr Dev Biol, Lab Vertebrate Axis Format, Chuo Ku, Kobe, Hyogo 6500047, Japan; Nagoya Univ, Biosci & Biotechnol Ctr, Aichi 4648601, Japan	RIKEN; Nagoya University	Hibi, M (corresponding author), RIKEN, Ctr Dev Biol, Lab Vertebrate Axis Format, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	hibi@cdb.riken.jp	Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444; Yabe, Taijiro/0000-0002-0843-7472				Banyai L, 1999, PROTEIN SCI, V8, P1636, DOI 10.1110/ps.8.8.1636; Bauer H, 2001, DEVELOPMENT, V128, P849; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Bradley L, 2000, DEV BIOL, V227, P118, DOI 10.1006/dbio.2000.9873; Collavin L, 2003, DEVELOPMENT, V130, P805, DOI 10.1242/dev.00306; Connors SA, 1999, DEVELOPMENT, V126, P3119; De Robertis EM, 2004, ANNU REV CELL DEV BI, V20, P285, DOI 10.1146/annurev.cellbio.20.011403.154124; Dick A, 2000, DEVELOPMENT, V127, P343; Furthauer M, 1999, DEV BIOL, V214, P181, DOI 10.1006/dbio.1999.9401; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Hashimoto H, 2004, DEVELOPMENT, V131, P1741, DOI 10.1242/dev.01070; Hibi M, 2002, RES PRO CEL, V40, P48; Hild M, 1999, DEVELOPMENT, V126, P2149; Jones CM, 1998, DEV BIOL, V194, P12, DOI 10.1006/dbio.1997.8752; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kishimoto Y, 1997, DEVELOPMENT, V124, P4457; Kramer C, 2002, DEV BIOL, V250, P263, DOI 10.1006/dbio.2002.0805; Larrain J, 2001, DEVELOPMENT, V128, P4439; Lekven AC, 2001, DEV CELL, V1, P103, DOI 10.1016/S1534-5807(01)00007-7; Lele Z, 2001, GENESIS, V30, P190, DOI 10.1002/gene.1063; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Martyn U, 2003, DEV BIOL, V260, P58, DOI 10.1016/S0012-1606(03)00221-5; Miller-Bertoglio VE, 1997, DEV BIOL, V192, P537, DOI 10.1006/dbio.1997.8788; Mintzer KA, 2001, DEVELOPMENT, V128, P859; Mullins MC, 1996, DEVELOPMENT, V123, P81; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nikaido M, 1999, DEVELOPMENT, V126, P181; Nikaido M, 2002, NAT GENET, V31, P195, DOI 10.1038/ng899; Oelgeschlager M, 2003, DEV CELL, V4, P219, DOI 10.1016/S1534-5807(02)00404-5; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Salic AN, 1997, DEVELOPMENT, V124, P4739; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schier AF, 2005, ANNU REV GENET, V39, P561, DOI 10.1146/annurev.genet.37.110801.143752; Schmid B, 2000, DEVELOPMENT, V127, P957; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; Shimizu T, 2000, MECH DEVELOP, V91, P293, DOI 10.1016/S0925-4773(99)00319-6; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Xie J, 2005, DEVELOPMENT, V132, P383, DOI 10.1242/dev.01577; Yabe T, 2003, DEVELOPMENT, V130, P2705, DOI 10.1242/dev.00506; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	46	83	86	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					329	U9		10.1038/ncb1379	http://dx.doi.org/10.1038/ncb1379			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16518392				2022-12-25	WOS:000236560000011
J	Zeuschner, D; Geerts, WJC; van Donselaar, E; Humbel, BM; Slot, JW; Koster, AJ; Klumperman, J				Zeuschner, D; Geerts, WJC; van Donselaar, E; Humbel, BM; Slot, JW; Koster, AJ; Klumperman, J			Immuno-electron tomography of ER exit sites reveals the existence of free COPII-coated transport carriers	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; ELECTRON TOMOGRAPHY; GOLGI; LOCALIZATION; PROTEINS; RECONSTITUTION; FIXATION; DYNAMICS; VESICLES; PATHWAY	Transport from the endoplasmic reticulum ( ER) to the Golgi complex requires assembly of the COPII coat complex at ER exit sites. Recent studies have raised the question as to whether in mammalian cells COPII coats give rise to COPII-coated transport vesicles or instead form ER sub-domains that collect proteins for transport via non-coated carriers. To establish whether COPII-coated vesicles do exist in vivo, we developed approaches to combine quantitative immunogold labelling ( to identify COPII) and three-dimensional electron tomography ( to reconstruct entire membrane structures). In tomograms of both chemically fixed and high-pressure-frozen HepG2 cells, immuno-labelled COPII was found on ER-associated buds as well as on free similar to 50-nm diameter vesicles. In addition, we identified a novel type of COPII-coated structure that consists of partially COPII-coated, 150 - 200-nm long, dumb-bell-shaped tubules. Both COPII-coated carriers also contain the SNARE protein Sec22b, which is necessary for downstream fusion events. Our studies unambiguously establish the existence of free, bona fide COPII-coated transport carriers at the ER - Golgi interface, suggesting that assembly of COPII coats in vivo can result in vesicle formation.	UMC Utrecht, Inst Biomembranes, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University	Klumperman, J (corresponding author), UMC Utrecht, Inst Biomembranes, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	J.Klumperman@lab.azu.nl	Geerts, Willie J.C./B-7640-2011; Koster, Abraham/I-7665-2017	Geerts, Willie J.C./0000-0002-4530-7458; Koster, Abraham/0000-0003-1717-2549				Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; DEGRAAF A, 1991, J HISTOCHEM CYTOCHEM, V39, P1035, DOI 10.1177/39.8.1856453; Fan JY, 2003, HISTOCHEM CELL BIOL, V120, P455, DOI 10.1007/s00418-003-0597-1; Fromme JC, 2005, CURR OPIN CELL BIOL, V17, P345, DOI 10.1016/j.ceb.2005.06.004; GEERTS WJC, 2005, ELECT MICROSCOPY TOM; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Klumperman J, 1998, J CELL SCI, V111, P3411; Koster AJ, 2003, NAT REV MOL CELL BIO, pSS6, DOI 10.1038/nrm1194; Koster AJ, 1997, J STRUCT BIOL, V120, P276, DOI 10.1006/jsbi.1997.3933; Koster G, 2003, P NATL ACAD SCI USA, V100, P15583, DOI 10.1073/pnas.2531786100; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Leapman RD, 2004, CURR OPIN NEUROBIOL, V14, P591, DOI 10.1016/j.conb.2004.08.004; LEUNISSEN JL, 1993, IMMUNOGOLD ELECT MIC; Lucic V, 2005, ANNU REV BIOCHEM, V74, P833, DOI 10.1146/annurev.biochem.73.011303.074112; Mastronarde DN, 1997, J STRUCT BIOL, V120, P343, DOI 10.1006/jsbi.1997.3919; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Mironov AA, 2003, DEV CELL, V5, P583, DOI 10.1016/S1534-5807(03)00294-6; Murk JLAN, 2003, J MICROSC-OXFORD, V212, P81, DOI 10.1046/j.1365-2818.2003.01238.x; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; Roux A, 2005, EMBO J, V24, P1537, DOI 10.1038/sj.emboj.7600631; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sato K, 2005, NAT STRUCT MOL BIOL, V12, P167, DOI 10.1038/nsmb893; SESSO A, 1994, J CELL SCI, V107, P517; Simpson JC, 2006, MOL BIOL CELL, V17, P723, DOI 10.1091/mbc.E05-06-0580; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stephens DJ, 2000, J CELL SCI, V113, P2177; Walther P, 2002, J MICROSC-OXFORD, V208, P3, DOI 10.1046/j.1365-2818.2002.01064.x; Watson P, 2005, NAT CELL BIOL, V7, P48, DOI 10.1038/ncb1206; WILLINGHAM MC, 1983, J HISTOCHEM CYTOCHEM, V31, P791, DOI 10.1177/31.6.6404984; Xu DL, 2004, J CELL BIOL, V167, P997, DOI 10.1083/jcb.200408135; Ziese U, 2002, J MICROSC-OXFORD, V205, P187, DOI 10.1046/j.0022-2720.2001.00987.x	38	135	138	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					377	U49		10.1038/ncb1371	http://dx.doi.org/10.1038/ncb1371			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16531996				2022-12-25	WOS:000236560000016
J	Ben-Maimon, CS; Garnick, R				Ben-Maimon, CS; Garnick, R			Biogenerics at the crossroads	NATURE BIOTECHNOLOGY			English	Editorial Material								Two executives-one from a leading generics manufacturer, the other from a leading brand manufacturer-argue the pros and cons of implementing an abbreviated US regulatory framework for the approval of biogeneric products.	Barr Pharmaceut, Woodcliff Lake, NJ 07677 USA		Ben-Maimon, CS (corresponding author), Barr Pharmaceut, 400 Chestnut Ridge Rd, Woodcliff Lake, NJ 07677 USA.	amanno@barrlabs.com							0	13	14	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2006	24	3					268	269		10.1038/nbt0306-268a	http://dx.doi.org/10.1038/nbt0306-268a			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	019WQ	16525381	Bronze			2022-12-25	WOS:000235868600018
J	Kaji, K; Caballero, IM; MacLeod, R; Nichols, J; Wilson, VA; Hendrich, B				Kaji, K; Caballero, IM; MacLeod, R; Nichols, J; Wilson, VA; Hendrich, B			The NuRD component Mbd3 is required for pluripotency of embryonic stem cells	NATURE CELL BIOLOGY			English	Letter							DNA METHYLATION; BINDING DOMAIN; MESSENGER-RNA; EXPRESSION; GENE; DIFFERENTIATION; IDENTIFICATION; PROTEINS; MESODERM; COMPLEX	Cells of early mammalian embryos have the potential to develop into any adult cell type, and are thus said to be pluripotent. Pluripotency is lost during embryogenesis as cells commit to specific developmental pathways. Although restriction of developmental potential is often associated with repression of inappropriate genetic programmes(1), the role of epigenetic silencing during early lineage commitment remains undefined. Here, we used mouse embryonic stem cells to study the function of epigenetic silencing in pluripotent cells. Embryonic stem cells lacking Mbd3 - a component of the nucleosome remodelling and histone deacetylation (NuRD) complex(2,3) - were viable but failed to completely silence genes that are expressed before implantation of the embryo. Mbd3-deficient embryonic stem cells could be maintained in the absence of leukaemia inhibitory factor (LIF) and could initiate differentiation in embryoid bodies or chimeric embryos, but failed to commit to developmental lineages. Our findings define a role for epigenetic silencing in the cell-fate commitment of pluripotent cells.	Univ Edinburgh, Sch Biol Sci, Inst Stem Cell Res, Ctr Dev Stem Cell Biol, Edinburgh EH9 3JQ, Midlothian, Scotland	University of Edinburgh	Hendrich, B (corresponding author), Univ Edinburgh, Sch Biol Sci, Inst Stem Cell Res, Ctr Dev Stem Cell Biol, Edinburgh EH9 3JQ, Midlothian, Scotland.	Brian.Hendrich@ed.ac.uk	Wilson, Valerie A/H-5427-2011; Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073; Nichols, Jennifer/0000-0002-8650-1388; Kaji, Keisuke/0000-0001-5946-8415; , Val/0000-0003-4182-5159	MRC [G9806702, G0300058] Funding Source: UKRI; Medical Research Council [G0300058, G9806702] Funding Source: Medline; Wellcome Trust [064623, 073621] Funding Source: Medline; Medical Research Council [G0300723B] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Bortvin A, 2003, DEVELOPMENT, V130, P1673, DOI 10.1242/dev.00366; Busslinger M, 2000, CURR OPIN IMMUNOL, V12, P151, DOI 10.1016/S0952-7915(99)00065-5; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003; Gibson-Brown JJ, 1998, MECH DEVELOP, V74, P165, DOI 10.1016/S0925-4773(98)00056-2; HEBERT JM, 1991, DEVELOPMENT, V112, P407; Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Huang JQ, 2001, J IMMUNOL, V167, P6073, DOI 10.4049/jimmunol.167.11.6073; Iscove NN, 2002, NAT BIOTECHNOL, V20, P940, DOI 10.1038/nbt729; Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Li L, 2004, DEVELOPMENT, V131, P5277, DOI 10.1242/dev.01415; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Sato M, 2002, MECH DEVELOP, V113, P91, DOI 10.1016/S0925-4773(02)00002-3; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Tam PPL, 2003, DEVELOPMENT, V130, P6155, DOI 10.1242/dev.00893; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	34	285	292	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2006	8	3					285	292		10.1038/ncb1372	http://dx.doi.org/10.1038/ncb1372			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	017QL	16462733				2022-12-25	WOS:000235708000015
J	Li, HJ; Sethuraman, N; Stadheim, TA; Zha, DX; Prinz, B; Ballew, N; Bobrowicz, P; Choi, BK; Cook, WJ; Cukan, M; Houston-Cummings, NR; Davidson, R; Gong, B; Hamilton, SR; Hoopes, JP; Jiang, YW; Kim, N; Mansfield, R; Nett, JH; Rios, S; Strawbridge, R; Wildt, S; Gerngross, TU				Li, HJ; Sethuraman, N; Stadheim, TA; Zha, DX; Prinz, B; Ballew, N; Bobrowicz, P; Choi, BK; Cook, WJ; Cukan, M; Houston-Cummings, NR; Davidson, R; Gong, B; Hamilton, SR; Hoopes, JP; Jiang, YW; Kim, N; Mansfield, R; Nett, JH; Rios, S; Strawbridge, R; Wildt, S; Gerngross, TU			Optimization of humanized IgGs in glycoengineered Pichia pastoris	NATURE BIOTECHNOLOGY			English	Article							FC-GAMMA-RIII; ANTIBODY; GLYCOSYLATION; CELLS; YEAST; GLYCOPROTEINS; CYTOTOXICITY; GALACTOSE; BINDING; FUCOSE	As the fastest growing class of therapeutic proteins, monoclonal antibodies (mAbs) represent a major potential drug class(1). Human antibodies are glycosylated in their native state and all clinically approved mAbs are produced by mammalian cell lines, which secrete mAbs with glycosylation structures that are similar, but not identical, to their human counterparts. Glycosylation of mAbs influences their interaction with immune effector cells that kill antibody-targeted cells(2-6). Here we demonstrate that human antibodies with specific human N-glycan structures can be produced in glycoengineered lines of the yeast Pichia pastoris and that antibody-mediated effector functions can be optimized by generating specific glycoforms. Glycoengineered P. pastoris provides a general platform for producing recombinant antibodies with human N-glycosylation.	Dartmouth Coll, Thayer Sch Engn, Dept Biol Sci, Hanover, NH 03755 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Dept Surg, Lebanon, NH 03766 USA; GlycoFi Inc, Lebanon, NH 03766 USA	Dartmouth College; Dartmouth College; Dartmouth College	Gerngross, TU (corresponding author), Dartmouth Coll, Thayer Sch Engn, Dept Biol Sci, Hanover, NH 03755 USA.	tillman.gerngross@dartmouth.edu		Cukan, Michael/0000-0002-7376-0428				ANDERSON DR, 1994, Patent No. 6682734; Bobrowicz P, 2004, GLYCOBIOLOGY, V14, P757, DOI 10.1093/glycob/cwh104; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Gerngross TU, 2004, NAT BIOTECHNOL, V22, P1409, DOI 10.1038/nbt1028; Hamilton SR, 2003, SCIENCE, V301, P1244, DOI 10.1126/science.1088166; Hong K, 2004, J IMMUNOL METHODS, V294, P189, DOI 10.1016/j.jim.2004.09.003; Lifely MR, 1995, GLYCOBIOLOGY, V5, P813, DOI 10.1093/glycob/5.8.813; ROTHMAN RJ, 1989, MOL IMMUNOL, V26, P1113, DOI 10.1016/0161-5890(89)90055-2; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; Vugmeyster YL, 2004, INT IMMUNOPHARMACOL, V4, P1117, DOI 10.1016/j.intimp.2004.04.015; Weiner LM, 2005, NAT BIOTECHNOL, V23, P556, DOI 10.1038/nbt0505-556; Wright A, 1998, J IMMUNOL, V160, P3393; Wright A, 2000, GLYCOBIOLOGY, V10, P1347, DOI 10.1093/glycob/10.12.1347	18	307	457	3	81	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2006	24	2					210	215		10.1038/nbt1178	http://dx.doi.org/10.1038/nbt1178			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	010XW	16429149				2022-12-25	WOS:000235232300039
J	Ferrante, MI; Zullo, A; Barra, A; Bimonte, S; Messaddeq, N; Studer, M; Dolle, P; Franco, B				Ferrante, MI; Zullo, A; Barra, A; Bimonte, S; Messaddeq, N; Studer, M; Dolle, P; Franco, B			Oral-facial-digital type I protein is required for primary cilia formation and left-right axis specification	NATURE GENETICS			English	Article							INTRAFLAGELLAR TRANSPORT PROTEINS; MOUSE; HEDGEHOG; MICE; GLI3; LIMB; MORPHOGENESIS; ACTIVATOR; GRADIENT; GENES	The oral-facial-digital type I (OFD1) syndrome ( OMIM 311200) is a human developmental disorder; affected individuals have craniofacial and digital abnormalities and, in 15% of cases, polycystic kidney(1,2). The disease is inherited as an X-linked dominant male-lethal trait. Using a Cre-loxP system, we generated knockout animals lacking Ofd1 and reproduced the main features of the disease, albeit with increased severity, possibly owing to differences of X inactivation patterns between human and mouse. We found failure of left-right axis specification in mutant male embryos, and ultrastructural analysis showed a lack of cilia in the embryonic node. Formation of cilia was defective in cystic kidneys from heterozygous females, implicating ciliogenesis as a mechanism underlying cyst development. In addition, we found impaired patterning of the neural tube and altered expression of the 5' Hoxa and Hoxd genes in the limb buds of mice lacking Ofd1, suggesting that Ofd1 could have a role beyond primary cilium organization and assembly.	Telethon Inst Genet & Med, I-80131 Naples, Italy; Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Univ Naples Federico II, Dept Pediat, Naples, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Naples Federico II	Franco, B (corresponding author), Telethon Inst Genet & Med, Via P Castellino 111, I-80131 Naples, Italy.	franco@tigem.it	Studer, Michele/P-4580-2016; Dolle, Pascal/A-8037-2010; FRANCO, Brunella/S-2882-2018	Studer, Michele/0000-0001-7105-2957; Dolle, Pascal/0000-0002-9294-9090; bimonte, sabrina/0000-0002-5408-9675; Ferrante, Maria Immacolata/0000-0002-8102-8018; FRANCO, Brunella/0000-0001-5588-4569	Telethon [TGM06S01, TGM06A01] Funding Source: Medline	Telethon(Fondazione Telethon)		Agulnik AI, 1999, MAMM GENOME, V10, P926, DOI 10.1007/s003359901116; Bai CB, 2004, DEV CELL, V6, P103, DOI 10.1016/S1534-5807(03)00394-0; Beales PL, 2005, CURR OPIN GENET DEV, V15, P315, DOI 10.1016/j.gde.2005.04.006; Choi DS, 1997, DEVELOPMENT, V124, P1745; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; de Conciliis L, 1998, GENOMICS, V51, P243, DOI 10.1006/geno.1998.5348; Feather SA, 1997, NEPHROL DIAL TRANSPL, V12, P1354, DOI 10.1093/ndt/12.7.1354; Ferrante MI, 2003, GENOMICS, V81, P560, DOI 10.1016/S0888-7543(03)00091-0; Ferrante MI, 2001, AM J HUM GENET, V68, P569, DOI 10.1086/318802; Garcia-Garcia MJ, 2005, P NATL ACAD SCI USA, V102, P5913, DOI 10.1073/pnas.0501071102; Gorlin R.J., 1990, BIRTH DEFECTS ENCY, VII, P1309; Grove EA, 1998, DEVELOPMENT, V125, P2315; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; Harlow E., 1988, ANTIBODIES LAB MANUA; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Jensen CG, 2004, CELL BIOL INT, V28, P101, DOI 10.1016/j.cellbi.2003.11.007; Joyner AL, 1993, GENE TARGETING PRACT; Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Masuya H, 1997, DEV BIOL, V182, P42, DOI 10.1006/dbio.1996.8457; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; OBrien TP, 1996, GENETICS, V143, P447; Pennekamp P, 2002, CURR BIOL, V12, P938, DOI 10.1016/S0960-9822(02)00869-2; Romio L, 2004, J AM SOC NEPHROL, V15, P2556, DOI 10.1097/01.ASN.0000140220.46477.5C; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Stamataki D, 2005, GENE DEV, V19, P626, DOI 10.1101/gad.325905; Tanaka Y, 2005, NATURE, V435, P172, DOI 10.1038/nature03494; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Watnick T, 2003, NAT GENET, V34, P355, DOI 10.1038/ng0803-355; Welscher PT, 2002, SCIENCE, V298, P827, DOI 10.1126/science.1075620	30	230	236	2	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					112	117		10.1038/ng1684	http://dx.doi.org/10.1038/ng1684			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16311594				2022-12-25	WOS:000234227200026
J	Spiegel, AM; Nabel, EG				Spiegel, AM; Nabel, EG			NIH research on obesity and type 2 diabetes: providing the scientific evidence base for actions to improve health	NATURE MEDICINE			English	Editorial Material									NIDDK, NIH, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Spiegel, AM (corresponding author), NIDDK, NIH, Bldg 31,Room 9A52,31 Ctr Dr,MSC 2560, Bethesda, MD 20892 USA.	spiegela@extra.niddk.nih.gov			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200334, ZIAHG200334] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))			0	8	10	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2006	12	1					67	69		10.1038/nm0106-67	http://dx.doi.org/10.1038/nm0106-67			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397572				2022-12-25	WOS:000234419000052
J	Bell, DW; Gore, I; Okimoto, RA; Godin-Heymann, N; Sordella, R; Mulloy, R; Sharma, SV; Brannigan, BW; Mohapatra, G; Settleman, J; Haber, DA				Bell, DW; Gore, I; Okimoto, RA; Godin-Heymann, N; Sordella, R; Mulloy, R; Sharma, SV; Brannigan, BW; Mohapatra, G; Settleman, J; Haber, DA			Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR	NATURE GENETICS			English	Article							ACQUIRED-RESISTANCE; KINASE INHIBITORS; TYROSINE KINASE; RECEPTOR GENE; GEFITINIB; SENSITIVITY; ERLOTINIB	Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that respond to tyrosine kinase inhibitors. Acquisition of drug resistance is linked to a specific secondary somatic mutation, EGFR T790M. Here we describe a family with multiple cases of non-small cell lung cancer associated with germline transmission of this mutation. Four of six tumors analyzed showed a secondary somatic activating EGFR mutation, arising in cis with the germline EGFR mutation T790M. These observations implicate altered EGFR signaling in genetic susceptibility to lung cancer.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; St Vincents Hosp, Bruno Canc Ctr, Birmingham, AL 35205 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Haber, DA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, 13th St, Charlestown, MA 02129 USA.	haber@helix.mgh.harvard.edu						Blencke S, 2004, CHEM BIOL, V11, P691, DOI 10.1016/j.chembiol.2004.02.029; Blencke S, 2003, J BIOL CHEM, V278, P15435, DOI 10.1074/jbc.M211158200; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V319, P1272, DOI 10.1016/j.bbrc.2004.05.113; Zhang C, 2005, NAT METHODS, V2, P435, DOI 10.1038/NMETH764	15	363	394	0	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2005	37	12					1315	1316		10.1038/ng1671	http://dx.doi.org/10.1038/ng1671			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16258541				2022-12-25	WOS:000233657300008
J	Sablina, AA; Budanov, AV; Ilyinskaya, GV; Agapova, LS; Kravchenko, JE; Chumakov, PM				Sablina, AA; Budanov, AV; Ilyinskaya, GV; Agapova, LS; Kravchenko, JE; Chumakov, PM			The antioxidant function of the p53 tumor suppressor	NATURE MEDICINE			English	Article							OXIDATIVE DNA-DAMAGE; ATM-DEFICIENT MICE; TRANSCRIPTIONAL ACTIVATION; P53-INDUCED APOPTOSIS; CALORIE RESTRICTION; P53-DEFICIENT MICE; CHECKPOINT CONTROL; MITOCHONDRIAL-DNA; GROWTH ARREST; HUMAN-CELLS	It is widely accepted that the p53 tumor suppressor restricts abnormal cells by induction of growth arrest or by triggering apoptosis. Here we show that, in addition, p53 protects the genome from oxidation by reactive oxygen species (ROS), a major cause of DNA damage and genetic instability. In the absence of severe stresses, relatively low levels of p53 are sufficient for upregulation of several genes with antioxidant products, which is associated with a decrease in intracellular ROS. Downregulation of p53 results in excessive oxidation of DNA, increased mutation rate and karyotype instability, which are prevented by incubation with the antioxidant N-acetylcysteine (NAC). Dietary supplementation with NAC prevented frequent lymphomas characteristic of Trp53-knockout mice, and slowed the growth of lung cancer xenografts deficient in p53. Our results provide a new paradigm for a nonrestrictive tumor suppressor function of p53 and highlight the potential importance of antioxidants in the prophylaxis and treatment of cancer.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Canc Res Ctr, Moscow 115478, Russia; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia; Univ Calif San Diego, La Jolla, CA 92093 USA	Cleveland Clinic Foundation; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of California System; University of California San Diego	Chumakov, PM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	chumakp@ccf.org	Budanov, Andrei V/HGD-5487-2022; Chumakov, Peter M/E-7731-2014; Sablina, Anna/P-2818-2019; Sablina, Anna/B-2217-2017	Budanov, Andrei V/0000-0002-7943-1000; Sablina, Anna/0000-0001-9526-4014; Sablina, Anna/0000-0001-9526-4014; Chumakov, Peter/0000-0002-8078-2908	NCI NIH HHS [R01 CA104903-02, R01 CA10490, R01 CA104903] Funding Source: Medline; NIA NIH HHS [R01 AG025278-01A1, R01 AG025278] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025278] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; Agapova LS, 1996, MUTAT RES-FUND MOL M, V354, P129, DOI 10.1016/0027-5107(96)00062-0; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Balansky R, 1996, CANCER RES, V56, P1642; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bishop AJR, 2003, CANCER RES, V63, P5335; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; HAVRE PA, 1995, CANCER RES, V55, P4420; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Hursting SD, 2004, J NUTR, V134, p2482S, DOI 10.1093/jn/134.9.2482S; Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kim HJ, 2002, MECH AGEING DEV, V123, P1589, DOI 10.1016/S0047-6374(02)00094-5; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KNAAP AGAC, 1975, MUTAT RES, V30, P97; Kovar H, 2000, ONCOGENE, V19, P4096, DOI 10.1038/sj.onc.1203780; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; OSOVSKAYA VS, 1995, MOL BIOL+, V29, P32; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reliene R, 2004, CANCER RES, V64, P5148, DOI 10.1158/0008-5472.CAN-04-0442; Schubert R, 2004, HUM MOL GENET, V13, P1793, DOI 10.1093/hmg/ddh189; Seo YR, 2004, EXP MOL MED, V36, P505, DOI 10.1038/emm.2004.64; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wahl GM, 1997, CANCER SURV, V29, P183; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yoon KA, 2004, J HUM GENET, V49, P134, DOI 10.1007/s10038-003-0122-3; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	49	855	888	3	80	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1306	1313		10.1038/nm1320	http://dx.doi.org/10.1038/nm1320			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16286925	Green Accepted			2022-12-25	WOS:000233774400029
J	Villarejo, A; Buren, S; Larsson, S; Dejardin, A; Monne, M; Rudhe, C; Karlsson, J; Jansson, S; Lerouge, P; Rolland, N; von Heijne, G; Grebe, M; Bako, L; Samuelsson, G				Villarejo, A; Buren, S; Larsson, S; Dejardin, A; Monne, M; Rudhe, C; Karlsson, J; Jansson, S; Lerouge, P; Rolland, N; von Heijne, G; Grebe, M; Bako, L; Samuelsson, G			Evidence for a protein transported through the secretory pathway en route to the higher plant chloroplast	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; ARABIDOPSIS; IDENTIFICATION; TRAFFICKING; IMPORT; PREDICTION; MEMBRANE; REVEALS; GLYCANS; AMYLASE	In contrast to animal and fungal cells, green plant cells contain one or multiple chloroplasts, the organelle(s) in which photosynthetic reactions take place. Chloroplasts are believed to have originated from an endosymbiotic event and contain DNA that codes for some of their proteins. Most chloroplast proteins are encoded by the nuclear genome and imported with the help of sorting signals that are intrinsic parts of the polypeptides. Here, we show that a chloroplast-located protein in higher plants takes an alternative route through the secretory pathway, and becomes N-glycosylated before entering the chloroplast.	Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, S-90187 Umea, Sweden; Stockholm Univ, Arrhenius Lab, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Univ Rouen, UFR Sci, CNRS, UMR 6037,IFRMP 23, F-76821 Mont St Aignan, France; Univ Grenoble 1, CEA Grenoble, INRA, CNRS,UMR 5168,Lab Physiol Cellulaire Vegetale, F-38054 Grenoble, France; Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, Lab Plant Sci Ctr, S-90183 Umea, Sweden; Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, H-6701 Szeged, Hungary	Umea University; Stockholm University; Centre National de la Recherche Scientifique (CNRS); Universite de Rouen Normandie; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Swedish University of Agricultural Sciences; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center	Samuelsson, G (corresponding author), Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, S-90187 Umea, Sweden.	goran.samuelsson@plantphys.umu.se	Monné, Magnus/D-5642-2012; Karlsson, Jan/E-7199-2015; Jansson, Stefan/A-1119-2009; ROLLAND, Norbert/B-4405-2012; Burén, Stefan/L-6705-2014; von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011; Samuelsson, Goran/E-1824-2015	Monné, Magnus/0000-0003-2344-3878; Karlsson, Jan/0000-0002-6002-929X; Jansson, Stefan/0000-0002-7906-6891; ROLLAND, Norbert/0000-0003-1959-6636; Burén, Stefan/0000-0002-8487-2732; von Heijne, Gunnar/0000-0002-4490-8569; Dejardin, Annabelle/0000-0002-7576-5476; Grebe, Markus/0000-0001-7571-0670				Abdallah F, 2000, TRENDS PLANT SCI, V5, P141, DOI 10.1016/S1360-1385(00)01574-0; Asatsuma S, 2005, PLANT CELL PHYSIOL, V46, P858, DOI 10.1093/pcp/pci091; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; Chen MH, 2004, PLANT PHYSIOL, V135, P1367, DOI 10.1104/pp.104.042184; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Delwiche CF, 1999, AM NAT, V154, pS164, DOI 10.1086/303291; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Gasparian M, 2000, PLANT PHYSIOL, V122, P25, DOI 10.1104/pp.122.1.25; Hermansson M, 2001, J MOL BIOL, V313, P1171, DOI 10.1006/jmbi.2001.5108; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; Jarvis P, 2001, BBA-MOL CELL RES, V1541, P64, DOI 10.1016/S0167-4889(01)00147-1; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; Kilian O, 2005, PLANT J, V41, P175, DOI 10.1111/j.1365-313X.2004.02294.x; Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kunst L, 1998, METH MOL B, V82, P43; Lee MH, 2002, PLANT PHYSIOL, V129, P1507, DOI 10.1104/pp.003624; Leister D, 2003, TRENDS GENET, V19, P47, DOI 10.1016/S0168-9525(02)00003-3; Lerouge P, 1998, PLANT MOL BIOL, V38, P31, DOI 10.1023/A:1006012005654; Levitan A, 2005, P NATL ACAD SCI USA, V102, P6225, DOI 10.1073/pnas.0500676102; Monne M, 1999, J MOL BIOL, V293, P807, DOI 10.1006/jmbi.1999.3183; Moreau P, 1998, PROG LIPID RES, V37, P371, DOI 10.1016/S0163-7827(98)00016-2; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Rayon C, 1999, PLANT PHYSIOL, V119, P725, DOI 10.1104/pp.119.2.725; Ritzenthaler C, 2002, PLANT CELL, V14, P237, DOI 10.1105/tpc.010237; Soll J, 2002, CURR OPIN PLANT BIOL, V5, P529, DOI 10.1016/S1369-5266(02)00296-0; SULLI C, 1995, J BIOL CHEM, V270, P13084, DOI 10.1074/jbc.270.22.13084; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Xu CC, 2003, EMBO J, V22, P2370, DOI 10.1093/emboj/cdg234; Zheng HQ, 2004, PLANT J, V37, P398, DOI 10.1046/j.1365-313X.2003.01969.x	33	236	254	0	27	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1224	1231		10.1038/ncb1330	http://dx.doi.org/10.1038/ncb1330			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16284624	Green Published			2022-12-25	WOS:000233748900016
J	Cole, C; Qiao, J; Kottke, T; Diaz, RM; Ahmed, A; Sanchez-Perez, L; Brunn, G; Thompson, J; Chester, J; Vile, RG				Cole, C; Qiao, J; Kottke, T; Diaz, RM; Ahmed, A; Sanchez-Perez, L; Brunn, G; Thompson, J; Chester, J; Vile, RG			Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells	NATURE MEDICINE			English	Article							CANCER GENE-THERAPY; MURINE LEUKEMIA-VIRUS; THYMIDINE KINASE GENE; RETROVIRAL VECTORS; HEPARAN-SULFATE; IN-VIVO; ANTITUMOR LYMPHOCYTES; MAMMALIAN HEPARANASE; HIGH-TITER; EXPRESSION	Antigen-specific T cells circulate freely and accumulate specifically at sites of antigen expression. To enhance the survival and targeting of systemically delivered viral vectors, we exploited the observation that retroviral particles adhere nonspecifically, or 'hitchhike,' to the surface of T cells. Adoptive transfer of antigen-specific T cells, loaded with viruses encoding interleukin (IL)-12 or Herpes Simplex Virus thymidine kinase (HSVtk), cured established metastatic disease where adoptive T-cell transfer alone was not effective. Productive hand off correlated with local heparanase expression either from malignant tumor cells and/or as a result of T-cell activation by antigen, providing high levels of selectivity for viral transfer to metastatic tumors in vivo. Protection, concentration and targeting of viruses by adsorption to cell carriers represent a new technique for systemic delivery of vectors, in fully immunocompetent hosts, for a variety of diseases in which delivery of genes may be therapeutically beneficial.	Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Transplantat Biol, Rochester, MN 55905 USA; St James Univ Hosp, Div Canc Med Res, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England	Mayo Clinic; Mayo Clinic; Mayo Clinic; Cancer Research UK; Saint James's University Hospital; University of Leeds	Vile, RG (corresponding author), Mayo Clin & Mayo Fdn, Program Mol Med, 200 1st St SW, Rochester, MN 55905 USA.	vile.richard@mayo.edu			NCI NIH HHS [1R01CA94180, 1R01CA107082] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107082, R01CA094180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman DG, 1991, PRACTICAL STAT MED R, P365; Blomer U, 2005, GENE THER, V12, P67, DOI 10.1038/sj.gt.3302384; Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Chernajovsky Y, 2004, NAT REV IMMUNOL, V4, P800, DOI 10.1038/nri1459; Chester J, 2002, NAT BIOTECHNOL, V20, P256, DOI 10.1038/nbt0302-256; Chong H, 1998, GENE THER, V5, P223, DOI 10.1038/sj.gt.3300584; Crittenden M, 2003, CANCER RES, V63, P3173; Daniels GA, 2004, NAT BIOTECHNOL, V22, P1125, DOI 10.1038/nbt1007; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; Diaz RM, 1998, J VIROL, V72, P789, DOI 10.1128/JVI.72.1.789-795.1998; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Dudley ME, 2001, J IMMUNOTHER, V24, P363, DOI 10.1097/00002371-200107000-00012; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Harrington K, 2002, HUM GENE THER, V13, P1263, DOI 10.1089/104303402760128504; Harrington KJ, 2000, ADV DRUG DELIVER REV, V44, P167, DOI 10.1016/S0169-409X(00)00093-4; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Linardakis E, 2002, CANCER RES, V62, P5495; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Palmer DC, 2004, J IMMUNOL, V173, P7209, DOI 10.4049/jimmunol.173.12.7209; Pizzato M, 1999, J VIROL, V73, P8599, DOI 10.1128/JVI.73.10.8599-8611.1999; Pizzato M, 2001, GENE THER, V8, P1088, DOI 10.1038/sj.gt.3301494; Qiao J, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-237; Reiland J, 2004, J BIOL CHEM, V279, P8047, DOI 10.1074/jbc.M304872200; Robbins PF, 2004, J IMMUNOL, V173, P7125, DOI 10.4049/jimmunol.173.12.7125; Rosenberg SA, 2004, P NATL ACAD SCI USA, V101, P14639, DOI 10.1073/pnas.0405730101; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; Tatsumi T, 2002, CANCER RES, V62, P5853; Todryk S, 1999, J IMMUNOL, V163, P1398; VILE R, 1994, GENE THER, V1, P307; Vile RG, 2000, GENE THER, V7, P2, DOI 10.1038/sj.gt.3301084; VILE RG, 1993, CANCER RES, V53, P3860; Vile RG, 1997, INT J CANCER, V71, P267; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; Walker SJ, 2002, J VIROL, V76, P6909, DOI 10.1128/JVI.76.14.6909-6918.2002; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637; Yee C, 2001, CURR OPIN IMMUNOL, V13, P141, DOI 10.1016/S0952-7915(00)00196-5; Yotnda P, 2004, BLOOD, V104, P2272, DOI 10.1182/blood-2003-11-3803	50	110	122	4	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1073	1081		10.1038/nm1297	http://dx.doi.org/10.1038/nm1297			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16170322				2022-12-25	WOS:000232492500028
J	Munoz, P; Blanco, R; Flores, JM; Blasco, MA				Munoz, P; Blanco, R; Flores, JM; Blasco, MA			XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer	NATURE GENETICS			English	Article							NUCLEOTIDE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM; EXPRESSION; DEFICIENT; ABNORMALITIES; PROTEINS; DEFECTS; LACKING; LENGTH; TUMORS	TRF2 is a telomere-binding protein that has a role in telomere protection. We generated mice that overexpress TRF2 in the skin. These mice had a severe phenotype in the skin in response to light, consisting of premature skin deterioration, hyperpigmentation and increased skin cancer, which resembles the human syndrome xeroderma pigmentosum. Keratinocytes from these mice were hypersensitive to ultraviolet irradiation and DNA crosslinking agents. The skin cells of these mice had marked telomere shortening, loss of the telomeric G-strand overhang and increased chromosomal instability. Telomere loss in these mice was mediated by XPF, a structure-specific nuclease involved in ultraviolet-induced damage repair and mutated in individuals with xeroderma pigmentosum. These findings suggest that TRF2 provides a crucial link between telomere function and ultraviolet-induced damage repair, whose alteration underlies genomic instability, cancer and aging. Finally, we show that a number of human skin tumors have increased expression of TRF2, further highlighting a role for TRF2 in skin cancer.	Spanish Natl Canc Ctr, Telomeres & Telomeres Grp, Mol Oncol Program, Madrid, Spain; Univ Complutense Madrid, Fac Vet, Anim Surg & Med Dept, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid	Blasco, MA (corresponding author), Spanish Natl Canc Ctr, Telomeres & Telomeres Grp, Mol Oncol Program, Madrid, Spain.	mblasco@cnio.es	Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X				Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bessler M, 2004, CURR OPIN PEDIATR, V16, P23, DOI 10.1097/00008480-200402000-00006; BRADLEY SM, 1993, SOLID STATE NUCL MAG, V2, P37, DOI 10.1016/0926-2040(93)90061-Q; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; Dantzer F, 2004, MOL CELL BIOL, V24, P1595, DOI 10.1128/MCB.24.4.1595-1607.2004; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Espejel S, 2004, EMBO REP, V5, P503, DOI 10.1038/sj.embor.7400127; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2002, MOL CELL BIOL, V22, P7291, DOI 10.1128/MCB.22.20.7291-7301.2002; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Matsutani N, 2001, INT J ONCOL, V19, P507; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Oh BK, 2005, AM J PATHOL, V166, P73, DOI 10.1016/S0002-9440(10)62233-X; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tian M, 2004, MOL CELL BIOL, V24, P1200, DOI 10.1128/MCB.24.3.1200-1205.2004; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	34	181	185	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1063	1071		10.1038/ng1633	http://dx.doi.org/10.1038/ng1633			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16142233				2022-12-25	WOS:000232185600017
J	Liu, SL; Premont, RT; Kontos, CD; Zhu, SK; Rockey, DC				Liu, SL; Premont, RT; Kontos, CD; Zhu, SK; Rockey, DC			A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension	NATURE MEDICINE			English	Article							COUPLED RECEPTOR KINASE; GENE-TRANSFER; BETA-GAMMA; AKT; ACTIVATION; EXPRESSION; CAVEOLIN; LIVER; RAT; PHOSPHORYLATION	Nitric oxide ( NO) production by endothelial cell nitric oxide synthase ( eNOS) in sinusoidal endothelial cells is reduced in the injured liver and leads to intrahepatic portal hypertension. We sought to understand the mechanism underlying defective eNOS function. Phosphorylation of the serine- threonine kinase Akt, which activates eNOS, was substantially reduced in sinusoidal endothelial cells from injured livers. Overexpression of Akt in vivo restored phosphorylation of Akt and production of NO and reduced portal pressure in portal hypertensive rats. We found that Akt physically interacts with G- protein- coupled receptor kinase- 2 ( GRK2), and that this interaction inhibits Akt activity. Furthermore, GRK2 expression increased in sinusoidal endothelial cells from portal hypertensive rats and knockdown of GRK2 restored Akt phosphorylation and NO production, and normalized portal pressure. Finally, after liver injury, GRK2- deficient mice developed less severe portal hypertension than control mice. Thus, an important mechanism underlying impaired activity of eNOS in injured sinusoidal endothelial cells is defective phosphorylation of Akt caused by overexpression of GRK2 after injury.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Rockey, DC (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	don.rockey@utsouthwestern.edu		Premont, Richard/0000-0002-8053-5026; Kontos, Christopher/0000-0002-8056-3115	NHLBI NIH HHS [HL 03557] Funding Source: Medline; NIDA NIH HHS [DA 16347] Funding Source: Medline; NIDDK NIH HHS [R01 DK 50574, R01 DK057830, R01 DK 57830] Funding Source: Medline; NIGMS NIH HHS [R01 GM 59989] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057830, R01DK050574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016347] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Cao S, 2001, J BIOL CHEM, V276, P14249, DOI 10.1074/jbc.M006258200; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Dzimiri N, 2004, EUR J PHARMACOL, V489, P167, DOI 10.1016/j.ejphar.2004.03.015; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; KOUNTOURAS J, 1984, BRIT J EXP PATHOL, V65, P305; Lawlor MA, 2001, J CELL SCI, V114, P2903; Liu SL, 2003, J BIOL CHEM, V278, P49929, DOI 10.1074/jbc.M306930200; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; Ramos-Ruiz R, 2000, CIRCULATION, V101, P2083, DOI 10.1161/01.CIR.101.17.2083; Rockey DC, 1998, GASTROENTEROLOGY, V114, P344, DOI 10.1016/S0016-5085(98)70487-1; Shah V, 1999, GASTROENTEROLOGY, V117, P1222, DOI 10.1016/S0016-5085(99)70408-7; Teshima S, 2004, J HEPATOL, V40, P616, DOI 10.1016/j.jhep.2003.12.018; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; TSUKAHARA H, 1994, J BIOL CHEM, V269, P21778; Williams ML, 2004, CIRCULATION, V109, P1590, DOI 10.1161/01.CIR.0000125521.40985.28; WOLFRUM S, 2004, ARTERIOSCLER THROMB; YOKOI Y, 1984, HEPATOLOGY, V4, P709, DOI 10.1002/hep.1840040425; Yu Q, 2000, J CLIN INVEST, V105, P741, DOI 10.1172/JCI7997; Yu Q, 2002, AM J PHYSIOL-GASTR L, V282, pG565, DOI 10.1152/ajpgi.00512.2000	38	195	206	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					952	958		10.1038/nm1289	http://dx.doi.org/10.1038/nm1289			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16142243				2022-12-25	WOS:000231724700022
J	Meetei, AR; Medhurst, AL; Ling, C; Xue, YT; Singh, TR; Bier, P; Steltenpool, J; Stone, S; Dokal, I; Mathew, CG; Hoatlin, M; Joenje, H; de Winter, JP; Wang, WD				Meetei, AR; Medhurst, AL; Ling, C; Xue, YT; Singh, TR; Bier, P; Steltenpool, J; Stone, S; Dokal, I; Mathew, CG; Hoatlin, M; Joenje, H; de Winter, JP; Wang, WD			A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M	NATURE GENETICS			English	Article							HOMOLOGOUS RECOMBINATION; ENDONUCLEASE; HELICASE; GENE; DEFICIENT; MUTATION; COMPLEX; GENOME; ATPASE; BRCA2	Fanconi anemia is a genetic disease characterized by genomic instability and cancer predisposition(1). Nine genes involved in Fanconi anemia have been identified; their products participate in a DNA damage - response network involving BRCA1 and BRCA2 ( refs. 2,3). We previously purified a Fanconi anemia core complex containing the FANCL ubiquitin ligase and six other Fanconi anemia associated proteins(4 - 6). Each protein in this complex is essential for monoubiquitination of FANCD2, a key reaction in the Fanconi anemia DNA damage - response pathway(2,7). Here we show that another component of this complex, FAAP250, is mutant in individuals with Fanconi anemia of a new complementation group ( FA- M). FAAP250 or FANCM has sequence similarity to known DNA- repair proteins, including archaeal Hef, yeast MPH1 and human ERCC4 or XPF. FANCM can dissociate DNA triplex, possibly owing to its ability to translocate on duplex DNA. FANCM is essential for monoubiquitination of FANCD2 and becomes hyperphosphorylated in response to DNA damage. Our data suggest an evolutionary link between Fanconi anemia associated proteins and DNA repair; FANCM may act as an engine that translocates the Fanconi anemia core complex along DNA.	Vrije Univ Amsterdam Med Ctr, Dept Clin Genet & Human Genet, NL-1081 BT Amsterdam, Netherlands; Cincinnati Childrens Hosp, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; NIA, Genet Lab, NIH, Baltimore, MD 21224 USA; Oregon Hlth & Sci Univ, Div Mol Med & Mol & Med Genet NRC3, Portland, OR 97239 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London, England; Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Med & Mol Genet, London WC2R 2LS, England	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Oregon Health & Science University; Imperial College London; University of London; King's College London	de Winter, JP (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Clin Genet & Human Genet, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	j.dewinter@vumc.nl; wangw@grc.nia.nih.gov	Ittershagen, Stacie/X-7658-2019; Mathew, Christopher G/G-3434-2015; Wang, Weidong/AAV-2446-2021	Mathew, Christopher G/0000-0003-4178-1838; Dokal, Inderjeet/0000-0003-4462-4782; Ittershagen, Stacie (Stone)/0000-0003-3834-176X; Wang, Weidong/0000-0002-0658-7928; singh, thiyam/0000-0002-0441-6818	NATIONAL CANCER INSTITUTE [R01CA112775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000688] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01 CA112775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bruun D, 2003, DNA REPAIR, V2, P1007, DOI 10.1016/S1568-7864(03)00112-5; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Demuth I, 2004, ONCOGENE, V23, P8611, DOI 10.1038/sj.onc.1207895; Enzlin JH, 2002, EMBO J, V21, P2045, DOI 10.1093/emboj/21.8.2045; Garcia-Cabeza I, 2001, BMC PSYCHIATRY, V1, DOI 10.1186/1471-244X-1-7; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Komori K, 2004, J BIOL CHEM, V279, P53175, DOI 10.1074/jbc.M409243200; Komori K, 2002, GENES GENET SYST, V77, P227, DOI 10.1266/ggs.77.227; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; LEVITUS M, 2005, J NAT GENET, V37, P934, DOI DOI 10.1038/NG1625; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Prakash R, 2005, J BIOL CHEM, V280, P7854, DOI 10.1074/jbc.M413898200; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; Scheller J, 2000, GENETICS, V155, P1069; Schurer KA, 2004, GENETICS, V166, P1673, DOI 10.1534/genetics.166.4.1673; Sgouros J, 1999, TRENDS BIOCHEM SCI, V24, P95, DOI 10.1016/S0968-0004(99)01355-9; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	30	339	360	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					958	963		10.1038/ng1626	http://dx.doi.org/10.1038/ng1626			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16116422	Green Accepted			2022-12-25	WOS:000231591900020
J	Repping, S; van Daalen, SKM; Brown, LG; Korver, CM; Lange, J; Marszalek, JD; Pyntikova, T; van der Veen, F; Skaletsky, H; Page, DC; Rozen, S				Repping, S; van Daalen, SKM; Brown, LG; Korver, CM; Lange, J; Marszalek, JD; Pyntikova, T; van der Veen, F; Skaletsky, H; Page, DC; Rozen, S			High mutation rates have driven extensive structural polymorphism among human Y chromosomes	NATURE GENETICS			English	Article							AZFC REGION; SEQUENCE; DELETION; FAMILY	Although much structural polymorphism in the human genome has been catalogued(1-5), the kinetics of underlying change remain largely unexplored. Because human Y chromosomes are clonally inherited, it has been possible to capture their detailed relationships in a robust, worldwide genealogical tree(6,7). Examination of structural variation across this tree opens avenues for investigating rates of underlying mutations. We selected one Y chromosome from each of 47 branches of this tree and searched for large-scale variation. Four chromosomal regions showed extensive variation resulting from numerous large-scale mutations. Within the tree encompassed by the studied chromosomes, the distal-Yq heterochromatin changed length >= 12 times, the TSPY gene array changed length >= 23 times, the 3.6-Mb IR3/IR3 region changed orientation >= 12 times and the AZFc region was rearranged >= 20 times. After determining the total time spanned by all branches of this tree (similar to 1.3 million years or 52,000 generations), we converted these mutation counts to lower bounds on rates: >= 2.3x10(-4), >= 4.4x10(-4), >= 2.3x10(-4) and >= 3.8x10(-4) large-scale mutations per father-to-son Y transmission, respectively. Thus, high mutation rates have driven extensive structural polymorphism among human Y chromosomes. At the same time, we found limited variation in the copy number of Y-linked genes, which raises the possibility of selective constraints.	MIT, Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynecol, Ctr Reprod Med, NL-1105 AZ Amsterdam, Netherlands	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Amsterdam; Academic Medical Center Amsterdam	Page, DC (corresponding author), MIT, Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge, MA 02142 USA.	page_admin@wi.mit.edu	Rozen, Steven G./J-5939-2013	Rozen, Steven G./0000-0002-4288-0056; Repping, Sjoerd/0000-0002-6959-149X				AFFARA NA, 1986, NUCLEIC ACIDS RES, V14, P5375, DOI 10.1093/nar/14.13.5375; BERNSTEIN R, 1986, HUM GENET, V74, P223; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; de Llanos M, 2005, HUM REPROD, V20, P216, DOI 10.1093/humrep/deh582; Ellis N, 2002, GENOME RES, V12, P339; Ferlin A, 2005, J MED GENET, V42, P209, DOI 10.1136/jmg.2004.025833; GRACE HJ, 1972, J MED GENET, V9, P293, DOI 10.1136/jmg.9.3.293; Hughes JF, 2005, NATURE, V437, P101, DOI 10.1038/nature04101; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Kawaguchi TK, 2001, NAT GENET, V29, P279, DOI 10.1038/ng757; Kucklenbroich K, 2005, HUM REPROD, V20, P191, DOI 10.1098/humrep/deh558; Lynch M, 2005, MOL HUM REPROD, V11, P507, DOI 10.1093/molehr/gah191; Machev N, 2004, J MED GENET, V41, P814, DOI 10.1136/jmg.2004.022111; MANZ E, 1993, GENOMICS, V17, P726, DOI 10.1006/geno.1993.1393; PAGE DC, 1986, COLD SPRING HARB SYM, V51, P229, DOI 10.1101/SQB.1986.051.01.028; Repping S, 2003, NAT GENET, V35, P247, DOI 10.1038/ng1250; Repping S, 2004, GENOMICS, V83, P1046, DOI 10.1016/j.ygeno.2003.12.018; Rozen S, 2003, NATURE, V423, P873, DOI 10.1038/nature01723; SANKOFF D, 1975, SIAM J APPL MATH, V28, P35, DOI 10.1137/0128004; Saxena R, 2000, GENOMICS, V67, P256, DOI 10.1006/geno.2000.6260; SCHNEDL W, 1971, HUMANGENETIK, V12, P188, DOI 10.1007/BF00702774; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Stefansson H, 2005, NAT GENET, V37, P129, DOI 10.1038/ng1508; Tilford CA, 2001, NATURE, V409, P943, DOI 10.1038/35057170; Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562; TYLERSMITH C, 1988, J MOL BIOL, V203, P837, DOI 10.1016/0022-2836(88)90110-6; Underhill PA, 2000, NAT GENET, V26, P358, DOI 10.1038/81685; Vignaud P, 2002, NATURE, V418, P152, DOI 10.1038/nature00880	30	204	214	2	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2006	38	4					463	467		10.1038/ng1754	http://dx.doi.org/10.1038/ng1754			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16501575				2022-12-25	WOS:000236340500020
J	Bacher, CP; Guggiari, M; Brors, B; Augui, S; Clerc, P; Avner, P; Eils, R; Heard, E				Bacher, CP; Guggiari, M; Brors, B; Augui, S; Clerc, P; Avner, P; Eils, R; Heard, E			Transient colocalization of X-inactivation centres accompanies the initiation of X inactivation	NATURE CELL BIOLOGY			English	Letter							CHROMOSOME INACTIVATION; XIST GENE; TSIX; TRANSCRIPTION; MICE	The initial differential treatment of the two X chromosomes during X-chromosome inactivation is controlled by the X-inactivation centre (Xic). This locus determines how many X chromosomes are present in a cell ('counting') and which X chromosome will be inactivated in female cells ('choice'). Critical control sequences in the Xic include the non-coding RNAs Xist and Tsix, and long-range chromatin elements. However, little is known about the process that ensures that X inactivation is triggered appropriately when more than one Xic is present in a cell. Using three-dimensional fluorescence in situ hybridization (FISH) analysis, we showed that the two Xics transiently colocalize, just before X inactivation, in differentiating female embryonic stem cells. Using Xic transgenes capable of imprinted but not random X inactivation, and Xic deletions that disrupt random X inactivation, we demonstrated that Xic colocalization is linked to Xic function in random X inactivation. Both long-range sequences and the Tsix element, which generates the antisense transcript to Xist, are required for the transient interaction of Xics. We propose that transient colocalization of Xics may be necessary for a cell to determine Xic number and to ensure the correct initiation of X inactivation.	Inst Curie, CNRS, UMR 218, F-75248 Paris 05, France; German Canc Res Ctr, D-69120 Heidelberg, Germany; Inst Pasteur, F-75015 Paris, France; Univ Heidelberg, IPMB, D-69120 Heidelberg, Germany	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; German Cancer Research Center (DKFZ); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ruprecht Karls University Heidelberg	Eils, R (corresponding author), Inst Curie, CNRS, UMR 218, 26 Rue Ulm, F-75248 Paris 05, France.	r.eils@dkfz-heidelberg.de; Edith.Heard@curie.fr	Heard, Edith/D-7197-2017; Brors, Benedikt/E-5620-2013; Eils, Roland/B-6121-2009	Heard, Edith/0000-0001-8052-7117; Brors, Benedikt/0000-0001-5940-3101; Eils, Roland/0000-0002-0034-4036				Bacher CP, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-45; Becker R, 1988, COMPUTER SCI SERIES; Boumil RM, 2001, HUM MOL GENET, V10, P2225; Chambeyron S, 2004, CURR OPIN CELL BIOL, V16, P256, DOI 10.1016/j.ceb.2004.03.004; Clerc P, 2003, SEMIN CELL DEV BIOL, V14, P85, DOI 10.1016/S1084-9521(02)00140-4; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; COMINGS DE, 1968, AM J HUM GENET; Conover W.J., 1971, PRACTICAL NONPARAMET, P295; Heard E, 1999, MOL CELL BIOL, V19, P3156; HOLLANDER M, 1973, NONPARAMETRIC STAT I; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; Marahrens Y, 1999, GENE DEV, V13, P2624, DOI 10.1101/gad.13.20.2624; Morey C, 2004, EMBO J, V23, P594, DOI 10.1038/sj.emboj.7600071; Morey C, 2001, HUM MOL GENET, V10, P1403, DOI 10.1093/hmg/10.13.1403; Navarro P, 2005, GENE DEV, V19, P1474, DOI 10.1101/gad.341105; Okamoto I, 2005, NATURE, V438, P369, DOI 10.1038/nature04155; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; Rougeulle C, 2004, MOL CELL BIOL, V24, P5475, DOI 10.1128/MCB.24.12.5475-5484.2004; Sado T, 2005, DEV CELL, V9, P159, DOI 10.1016/j.devcel.2005.05.015; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Stavropoulos N, 2005, MOL CELL BIOL, V25, P2757, DOI 10.1128/MCB.25.7.2757-2769.2005; Taddei A, 2004, ANNU REV GENET, V38, P305, DOI 10.1146/annurev.genet.37.110801.142705; Tvarusko W, 1999, P NATL ACAD SCI USA, V96, P7950, DOI 10.1073/pnas.96.14.7950	27	273	284	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2006	8	3					293	299		10.1038/ncb1365	http://dx.doi.org/10.1038/ncb1365			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	017QL	16434960				2022-12-25	WOS:000235708000016
J	Kalantry, S; Mills, KC; Yee, D; Otte, AP; Panning, B; Magnuson, T				Kalantry, S; Mills, KC; Yee, D; Otte, AP; Panning, B; Magnuson, T			The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation	NATURE CELL BIOLOGY			English	Article							EMBRYONIC STEM-CELLS; EARLY MOUSE EMBRYOS; XIST RNA; GROUP-COMPLEXES; HISTONE H2A; GIANT-CELLS; GENE; STABILIZATION; ACETYLATION; ASSOCIATION	The Polycomb group (PcG) encodes an evolutionarily conserved set of chromatin-modifying proteins that are thought to maintain cellular transcriptional memory by stably silencing gene expression(1). In mouse embryos that are mutated for the PcG protein Eed, X-chromosome inactivation (XCI) is not stably maintained in extra-embryonic tissues(2). Eed is a component of a histone-methyltransferase complex that is thought to contribute to stable silencing in undifferentiated cells due to its enrichment on the inactive X-chromosome in cells of the early mouse embryo and in stem cells of the extra-embryonic trophectoderm lineage(3-8). Here, we demonstrate that the inactive X-chromosome in Eed(-/-) trophoblast stem cells and in cells of the trophectoderm-derived extra-embryonic ectoderm in Eed(-/-) embryos remain transcriptionally silent, despite lacking the PcG-mediated histone modifications that normally characterize the facultative heterochromatin of the inactive X-chromosome. Whereas undifferentiated Eed(-/-) trophoblast stem cells maintained XCI, reactivation of the inactive X-chromosome occurred when these cells were differentiated. These results indicate that PcG complexes are not necessary to maintain transcriptional silencing of the inactive X-chromosome in undifferentiated stem cells. Instead, PcG proteins seem to propagate cellular memory by preventing transcriptional activation of facultative heterochromatin during differentiation.	Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA; Univ Amsterdam, Swammerdam Inst Life Sci, NL-1098 SM Amsterdam, Netherlands; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Amsterdam; University of California System; University of California San Francisco	Magnuson, T (corresponding author), Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.	trm4@med.unc.edu			NICHD NIH HHS [R37 HD024462] Funding Source: Medline; NIGMS NIH HHS [R01 GM063671] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD024462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063671] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Boggs BA, 1996, CHROMOSOMA, V105, P303, DOI 10.1007/BF02524648; Carrington EA, 1996, DEVELOPMENT, V122, P4073; Costanzi C, 2000, DEVELOPMENT, V127, P2283; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; Erhardt S, 2003, DEVELOPMENT, V130, P4235, DOI 10.1242/dev.00625; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; Hadjantonakis AK, 1998, NAT GENET, V19, P220, DOI 10.1038/896; Hadjantonakis AK, 2001, GENESIS, V29, P133, DOI 10.1002/gene.1016; Hattori N, 2000, MOL BIOL CELL, V11, P1037, DOI 10.1091/mbc.11.3.1037; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Huynh KD, 2003, NATURE, V426, P857, DOI 10.1038/nature02222; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Mak W, 2004, SCIENCE, V303, P666, DOI 10.1126/science.1092674; Mak W, 2002, CURR BIOL, V12, P1016, DOI 10.1016/S0960-9822(02)00892-8; Ng J, 2000, MOL CELL BIOL, V20, P3069, DOI 10.1128/MCB.20.9.3069-3078.2000; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Plath K, 2004, J CELL BIOL, V167, P1025, DOI 10.1083/jcb.200409026; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; RINCHIK EM, 1993, MAMM GENOME, V4, P349, DOI 10.1007/BF00360583; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Sado T, 2001, DEVELOPMENT, V128, P1275; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; Stavropoulos N, 2001, P NATL ACAD SCI USA, V98, P10232, DOI 10.1073/pnas.171243598; Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574	39	118	124	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2006	8	2					195	U66		10.1038/ncb1351	http://dx.doi.org/10.1038/ncb1351			19	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	008SA	16415857	Green Submitted, Green Accepted			2022-12-25	WOS:000235059800015
J	Bentires-Alj, M; Gil, SG; Chan, R; Wang, ZGC; Wang, YP; Imanaka, N; Harris, LN; Richardson, A; Neel, BG; Gu, HH				Bentires-Alj, M; Gil, SG; Chan, R; Wang, ZGC; Wang, YP; Imanaka, N; Harris, LN; Richardson, A; Neel, BG; Gu, HH			A role for the scaffolding adapter GAB2 in breast cancer	NATURE MEDICINE			English	Article							TYROSINE PHOSPHATASE; PROTEIN GAB2; GENE; MUTATIONS; TUMORS; TRANSFORMATION; EXPRESSION; PTPN11; PHOSPHORYLATION; PROLIFERATION	The scaffolding adapter GAB2 maps to a region (11q13-14) commonly amplified in human breast cancer, and is overexpressed in breast cancer cell lines and primary tumors, but its functional role in mammary carcinogenesis has remained unexplored. We found that overexpression of GAB2 (Grb2-associated binding protein 2) increases proliferation of MCF10A mammary cells in three-dimensional culture. Coexpression of GAB2 with antiapoptotic oncogenes causes lumenal filling, whereas coexpression with Neu (also known as ErbB2 and HER2) results in an invasive phenotype. These effects of GAB2 are mediated by hyperactivation of the Shp2-Erk pathway. Furthermore, overexpression of Gab2 potentiates, whereas deficiency of Gab2 ameliorates, Neu-evoked breast carcinogenesis in mice. Finally, GAB2 is amplified in some GAB2-overexpressing human breast tumors. Our data suggest that GAB2 may be a key gene within an 11q13 amplicon in human breast cancer and propose a role for overexpression of GAB2 in mammary carcinogenesis. Agents that target GAB2 or GAB2-dependent pathways may be useful for treating breast tumors that overexpress GAB2 or HER2 or both.	Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Liege, Lab Med Chem & Human Genet, Ctr Biomed Integrat Genoproteom, B-4000 Liege, Belgium; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Liege; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Bentires-Alj, M (corresponding author), Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, NRB 1030,77 Ave Louis Pasteur, Boston, MA 02115 USA.	mbentire@bidmc.harvard.edu	Mohamed, Bentires-Alj/F-4484-2015	Mohamed, Bentires-Alj/0000-0001-6344-1127	NIAID NIH HHS [AI 51612] Funding Source: Medline; NIDDK NIH HHS [DK50693] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050693] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 2003, J CELL BIOL, V161, P1151, DOI 10.1083/jcb.200212158; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nishida K, 2002, BLOOD, V99, P1866, DOI 10.1182/blood.V99.5.1866; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Reyal F, 2005, CANCER RES, V65, P1376, DOI 10.1158/0008-5472.CAN-04-2706; RICHARDSON A, IN PRESS CANC CELL; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Yamada K, 2001, CYTOGENET CELL GENET, V94, P39, DOI 10.1159/000048780; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	155	166	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					114	121		10.1038/nm1341	http://dx.doi.org/10.1038/nm1341			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16369543				2022-12-25	WOS:000234419000060
J	Bulina, ME; Chudakov, DM; Britanova, OV; Yanushevich, YG; Staroverov, DB; Chepurnykh, TV; Merzlyak, EM; Shkrob, MA; Lukyanov, S; Lukyanov, KA				Bulina, ME; Chudakov, DM; Britanova, OV; Yanushevich, YG; Staroverov, DB; Chepurnykh, TV; Merzlyak, EM; Shkrob, MA; Lukyanov, S; Lukyanov, KA			A genetically encoded photosensitizer	NATURE BIOTECHNOLOGY			English	Article							ASSISTED LASER INACTIVATION; PHOSPHOLIPASE C-DELTA-1; CELL-DEATH; PROTEINS; EVOLUTION; DOMAIN; DAMAGE	Photosensitizers are chromophores that generate reactive oxygen species (ROS) upon light irradiation(1). They are used for inactivation of specific proteins by chromophore-assisted light inactivation (CALI) and for light-induced cell killing in photodynamic therapy. Here we report a genetically encoded photosensitizer, which we call KillerRed, developed from the hydrozoan chromoprotein anm2CP, a homolog of green fluorescent protein (GFP). KillerRed generates ROS upon irradiation with green light. Whereas known photosensitizers must be added to living systems exogenously, KillerRed is fully genetically encoded. We demonstrate the utility of KillerRed for light-induced killing of Escherichia coli and eukaryotic cells and for inactivating fusions to beta-galactosidase and phospholipase C delta 1 pleckstrin homology domain.	RAS, Inst Bioorgan Chem, Moscow 117997, Russia; Evrogen JSC, Moscow 117997, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Lukyanov, KA (corresponding author), RAS, Inst Bioorgan Chem, Miklukho Maklaya 16-10, Moscow 117997, Russia.	kluk@ibch.ru	Boulina, Maria/F-3124-2013; Oka, Yoshitaka/C-9670-2010; Merzlyak, Ekaterina/AAN-8272-2020; Lukyanov, Sergey/F-9140-2014; Lukyanov, Konstantin A/D-4030-2013; Yanushevich, Yurii/AAF-9750-2020; Chudakov, Dmitriy M/G-7741-2014	Oka, Yoshitaka/0000-0002-3482-3051; Lukyanov, Konstantin A/0000-0001-9845-2088; Chudakov, Dmitriy M/0000-0003-0430-790X; Merzlyak, Ekaterina/0000-0001-5695-0396; Yanushevich, Yurii/0000-0001-9061-752X; Staroverov, Dmitry/0000-0001-6789-9442				Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; BEERMANN AEL, 1994, METHOD CELL BIOL, V44, P715, DOI 10.1016/S0091-679X(08)60940-1; Calin Mihaela Antonina, 2004, J Exp Ther Oncol, V4, P247; Cho KS, 1999, INVEST OPHTH VIS SCI, V40, P911; Dixit R, 2003, PLANT J, V36, P280, DOI 10.1046/j.1365-313X.2003.01868.x; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Filippin L, 2005, CELL CALCIUM, V37, P129, DOI 10.1016/j.ceca.2004.08.002; FOOTE CS, 1991, PHOTOCHEM PHOTOBIOL, V54, P659, DOI 10.1111/j.1751-1097.1991.tb02071.x; Fujii M, 1999, BIOCHEM BIOPH RES CO, V254, P284, DOI 10.1006/bbrc.1998.9936; Greenbaum L, 2000, BIOL CHEM, V381, P1251, DOI 10.1515/BC.2000.153; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; Gurskaya NG, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-6; Hauptschein RS, 2005, CANCER RES, V65, P1887, DOI 10.1158/0008-5472.CAN-04-3571; Horstkotte E, 2005, PHOTOCHEM PHOTOBIOL, V81, P358, DOI 10.1562/2004-07-22-RA-240.1; JAY DG, 1988, P NATL ACAD SCI USA, V85, P5454, DOI 10.1073/pnas.85.15.5454; Kremser L, 2004, ANAL CHEM, V76, P7360, DOI 10.1021/ac048999m; Labas YA, 2002, P NATL ACAD SCI USA, V99, P4256, DOI 10.1073/pnas.062552299; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; Loschenov VB, 2000, LASER PHYS, V10, P1188; Lukyanov KA, 2000, J BIOL CHEM, V275, P25879, DOI 10.1074/jbc.C000338200; Marek KW, 2002, NEURON, V36, P805, DOI 10.1016/S0896-6273(02)01068-1; Milano J, 2000, NUCLEIC ACIDS RES, V28, P968, DOI 10.1093/nar/28.4.968; Moor ACE, 2000, J PHOTOCH PHOTOBIO B, V57, P1, DOI 10.1016/S1011-1344(00)00065-8; Plaetzer K, 2002, PHOTOCH PHOTOBIO SCI, V1, P172, DOI 10.1039/b108816e; Poskanzer KE, 2003, NATURE, V426, P559, DOI 10.1038/nature02184; POSNER GH, 1984, BIOCHEM BIOPH RES CO, V123, P869, DOI 10.1016/0006-291X(84)90311-5; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; Rubenwolf S, 2002, PROTEOMICS, V2, P241, DOI 10.1002/1615-9861(200203)2:3<241::AID-PROT241>3.0.CO;2-7; Shagin DA, 2004, MOL BIOL EVOL, V21, P841, DOI 10.1093/molbev/msh079; Shimohama S, 1998, BIOCHEM BIOPH RES CO, V245, P722, DOI 10.1006/bbrc.1998.8307; Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-73; Surrey T, 1998, P NATL ACAD SCI USA, V95, P4293, DOI 10.1073/pnas.95.8.4293; THOMPSON A, 1986, BIOCHEM BIOPH RES CO, V140, P888, DOI 10.1016/0006-291X(86)90718-7; Tour O, 2003, NAT BIOTECHNOL, V21, P1505, DOI 10.1038/nbt914; Wong EV, 2003, J NEUROSCI, V23, P3112; Yu YA, 2003, ANAL BIOANAL CHEM, V377, P964, DOI 10.1007/s00216-003-2065-0; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	37	427	444	2	128	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2006	24	1					95	99		10.1038/nbt1175	http://dx.doi.org/10.1038/nbt1175			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	001SE	16369538				2022-12-25	WOS:000234555800030
J	Lerner-Ellis, JP; Tirone, JC; Pawelek, PD; Dore, C; Atkinson, JL; Watkins, D; Morel, CF; Fujiwara, TM; Moras, E; Hosack, AR; Dunbar, GV; Antonicka, H; Forgetta, V; Dobson, CM; Leclerc, D; Gravel, RA; Shoubridge, EA; Coulton, JW; Lepage, P; Rommens, JM; Morgan, K; Rosenblatt, DS				Lerner-Ellis, JP; Tirone, JC; Pawelek, PD; Dore, C; Atkinson, JL; Watkins, D; Morel, CF; Fujiwara, TM; Moras, E; Hosack, AR; Dunbar, GV; Antonicka, H; Forgetta, V; Dobson, CM; Leclerc, D; Gravel, RA; Shoubridge, EA; Coulton, JW; Lepage, P; Rommens, JM; Morgan, K; Rosenblatt, DS			Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type	NATURE GENETICS			English	Article							C-TERMINAL DOMAIN; HAPLOTYPE RECONSTRUCTION; COBALAMIN METABOLISM; CRYSTAL-STRUCTURE; INBORN ERROR; PROTEIN; TONB; REVEALS	Methylmalonic aciduria and homocystinuria, cblC type ( OMIM 277400), is the most common inborn error of vitamin B-12 ( cobalamin) metabolism, with about 250 known cases. Affected individuals have developmental, hematological, neurological, metabolic, ophthalmologic and dermatologic clinical findings(1). Although considered a disease of infancy or childhood, some individuals develop symptoms in adulthood(2). The cblC locus was mapped to chromosome region 1p by linkage analysis(3). We refined the chromosomal interval using homozygosity mapping and haplotype analyses and identified the MMACHC gene. In 204 individuals, 42 different mutations were identified, many consistent with a loss of function of the protein product. One mutation, 271dupA, accounted for 40% of all disease alleles. Transduction of wild-type MMACHC into immortalized cblC fibroblast cell lines corrected the cellular phenotype. Molecular modeling predicts that the C-terminal region of the gene product folds similarly to TonB, a bacterial protein involved in energy transduction for cobalamin uptake.	McGill Univ, Dept Human Genet, Montreal, PQ H3G 1B1, Canada; McGill Univ, Ctr Hlth, Div Med Genet, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; Genome Quebec Innovat Ctr, Montreal, PQ H3A 1A4, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	McGill University; McGill University; McGill University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; University of Calgary	Rosenblatt, DS (corresponding author), McGill Univ, Dept Human Genet, Montreal, PQ H3G 1B1, Canada.	david.rosenblatt@mcgill.ca	Lerner-Ellis, Jordan/J-5559-2016; Leclerc, Daniel/AAB-4524-2021; Pawelek, Peter/E-7950-2014; Leclerc, Daniel/B-6375-2012; Rommens, Johanna/AAT-7465-2021	Leclerc, Daniel/0000-0002-9766-8941; Pawelek, Peter/0000-0002-8361-6593; Forgetta, Vincenzo/0000-0002-6061-4720; Antonicka, Hana/0000-0002-2525-2867				Andersson HC, 1998, J PEDIATR-US, V132, P121, DOI 10.1016/S0022-3476(98)70496-2; ATKINSON J, 2003, THESIS U TORONTO; BELL PE, 1990, J BACTERIOL, V172, P3826, DOI 10.1128/jb.172.7.3826-3829.1990; Brudno M, 2003, GENOME RES, V13, P721, DOI 10.1101/gr.926603; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Carmel R., 2001, HOMOCYSTEINE HLTH DI; Chang CS, 2001, J BIOL CHEM, V276, P27535, DOI 10.1074/jbc.M102778200; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Kodding J, 2005, J BIOL CHEM, V280, P3022, DOI 10.1074/jbc.M411155200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; MELLMAN I, 1979, J BIOL CHEM, V254, P1847; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Peacock RS, 2005, J MOL BIOL, V345, P1185, DOI 10.1016/j.jmb.2004.11.026; Pezacka E. H., 1994, ADV THOMAS ADDISONS, P315; Rosenblatt D. S., 2001, METABOLIC MOL BASES, V8th, P3897; ROSENBLATT DS, 1985, SCIENCE, V228, P1319, DOI 10.1126/science.4001945; Rosenblatt DS, 1997, J INHERIT METAB DIS, V20, P528, DOI 10.1023/A:1005353530303; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Templeton AR, 2000, AM J HUM GENET, V66, P69, DOI 10.1086/302699; Watkins D, 1998, CLIN INVEST MED, V21, P151; Watkins D, 2000, J MED GENET, V37, P510, DOI 10.1136/jmg.37.7.510; Yao JB, 1999, HUM MOL GENET, V8, P2541, DOI 10.1093/hmg/8.13.2541	29	251	294	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					93	100		10.1038/ng1683	http://dx.doi.org/10.1038/ng1683			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16311595				2022-12-25	WOS:000234227200023
J	Floto, RA; Clatworthy, MR; Heilbronn, KR; Rosner, DR; MacAry, PA; Rankin, A; Lehner, PJ; Ouwehand, WH; Allen, JM; Watkins, NA; Smith, KGC				Floto, RA; Clatworthy, MR; Heilbronn, KR; Rosner, DR; MacAry, PA; Rankin, A; Lehner, PJ; Ouwehand, WH; Allen, JM; Watkins, NA; Smith, KGC			Loss of function of a lupus-associated Fc gamma RIIb polymorphism through exclusion from lipid rafts	NATURE MEDICINE			English	Article							RECEPTOR IIB; ERYTHEMATOSUS; SUSCEPTIBILITY; AUTOIMMUNITY; TRAFFICKING; CELLS; GENE	Dysfunction of receptors for IgG (Fc gamma Rs) has been thought to be involved in the pathogenesis of systemic lupus erythematosus (SLE). We show that a recently described SLE-associated polymorphism of Fc gamma RIIb (Fc gamma RIIbT(232)), encoding a single transmembrane amino acid substitution, is functionally impaired. Fc gamma RIIbT(232) is unable to inhibit activatory receptors because it is excluded from sphingolipid rafts, resulting in the unopposed proinflammatory signaling thought to promote SLE.	Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Med, Cambridge CB2 2XY, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XY, England; UCL, Dept Pharmacol, London WC1E 6BT, England	University of Cambridge; University of Cambridge; University of Cambridge; University of London; University College London	Floto, RA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England.	arf27@cam.ac.uk		MacAry, Paul/0000-0002-1139-8996; Lehner, Paul Joseph/0000-0001-9383-1054; Smith, Kenneth/0000-0003-3829-4326	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barabe F, 2002, J BIOL CHEM, V277, P13473, DOI 10.1074/jbc.M112149200; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Brauweiler AM, 2004, IMMUNOL LETT, V92, P75, DOI 10.1016/j.imlet.2003.11.028; Cameron AJM, 2002, IMMUNOL LETT, V83, P171, DOI 10.1016/S0165-2478(02)00118-9; Chu ZT, 2004, TISSUE ANTIGENS, V63, P21, DOI 10.1111/j.1399-0039.2004.00142.x; Clatworthy MR, 2004, J EXP MED, V199, P717, DOI 10.1084/jem.20032197; Fukuyama H, 2005, NAT IMMUNOL, V6, P99, DOI 10.1038/ni1151; Kyogoku C, 2002, ARTHRITIS RHEUM, V46, P1242, DOI 10.1002/art.10257; Li XL, 2003, ARTHRITIS RHEUM, V48, P3242, DOI 10.1002/art.11313; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Siriboonrit U, 2003, TISSUE ANTIGENS, V61, P374, DOI 10.1034/j.1399-0039.2003.00047.x; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; Wakeland EK, 2001, IMMUNITY, V15, P397, DOI 10.1016/S1074-7613(01)00201-1	15	237	261	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1056	1058		10.1038/nm1288	http://dx.doi.org/10.1038/nm1288			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16170323				2022-12-25	WOS:000232492500025
J	Camps, M; Ruckle, T; Ji, H; Ardissone, V; Rintelen, F; Shaw, J; Ferrandi, C; Chabert, C; Gillieron, C; Francon, B; Martin, T; Gretener, D; Perrin, D; Leroy, D; Vitte, PA; Hirsch, E; Wymann, MP; Cirillo, R; Schwarz, MK; Rommel, C				Camps, M; Ruckle, T; Ji, H; Ardissone, V; Rintelen, F; Shaw, J; Ferrandi, C; Chabert, C; Gillieron, C; Francon, B; Martin, T; Gretener, D; Perrin, D; Leroy, D; Vitte, PA; Hirsch, E; Wymann, MP; Cirillo, R; Schwarz, MK; Rommel, C			Blockade of PI3K gamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; PHOSPHOINOSITIDE 3-KINASE; B-CELL; EMBRYONIC LETHALITY; MONOCLONAL-ANTIBODY; MAST-CELLS; NEUTROPHILS; P110-DELTA; SUBUNIT; MICE	Phosphoinositide 3- kinases ( PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases. But the lack of specificity, isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors have so far hampered rigorous disease- relevant target validation. Here we describe the identification and development of specific, selective and orally active small- molecule inhibitors of PI3K gamma ( encoded by Pik3cg). We show that Pik3cg(-/-) mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3K gamma as a therapeutic target. We also describe that oral treatment with a PI3K gamma inhibitor suppresses the progression of joint inflammation and damage in two distinct mouse models of rheumatoid arthritis, reproducing the protective effects shown by Pik3cg(-/-) mice. Our results identify selective PI3K gamma inhibitors as potential therapeutic molecules for the treatment of chronic inflammatory disorders such as rheumatoid arthritis.	Serono Int SA, Serono Pharmaceut Res Inst, Geneva, Switzerland; Serono Int SA, LCG RBM, I-10010 Colleretto Giacosa, Italy; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy; Univ Basel, Dept Clin & Biol Sci, Inst Biochem & Genet, Biomed Ctr, CH-4058 Basel, Switzerland	Merck & Company; Serono International S.A.; Merck & Company; Serono International S.A.; University of Turin; University of Basel	Rommel, C (corresponding author), Serono Int SA, Serono Pharmaceut Res Inst, 14,Chemin Aulx,1288 Plan Ouates, Geneva, Switzerland.	christian.rommel@serono.com	Hirsch, Emilio/F-4848-2013; Wymann, Matthias P/C-3227-2008	Hirsch, Emilio/0000-0002-9073-6024; Wymann, Matthias P/0000-0003-3349-4281; Camps, Montserrat/0000-0002-9849-8657				Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; CAMPS M, 2002, Patent No. 2002101084; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHATHAM WW, 1993, ARTHRITIS RHEUM, V36, P51; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Del Prete A, 2004, EMBO J, V23, P3505, DOI 10.1038/sj.emboj.7600361; Edwards SW, 1997, IMMUNOL TODAY, V18, P320, DOI 10.1016/S0167-5699(97)01087-6; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; Henderson RB, 2003, BLOOD, V102, P328, DOI 10.1182/blood-2002-10-3228; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Johnson Z, 2004, BIOCHEM SOC T, V32, P366, DOI 10.1042/BST0320366; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; KERWAR SS, 1983, ARTHRITIS RHEUM, V26, P1120, DOI 10.1002/art.1780260910; KITSIS E, 1991, CLIN ORTHOP RELAT R, P63; Kowanko IC, 1996, J CLIN IMMUNOL, V16, P216, DOI 10.1007/BF01541227; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MOHR W, 1984, RHEUMATOL INT, V5, P39, DOI 10.1007/BF00541364; Nandakumar KS, 2003, AM J PATHOL, V163, P1827, DOI 10.1016/S0002-9440(10)63542-0; Okkenhaug K, 2002, SCIENCE, V297, P1031; RUECKLE T, 2004, Patent No. 2004007491; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SEKI N, 1988, J IMMUNOL, V140, P1477; Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109; STUART JM, 1984, ANNU REV IMMUNOL, V2, P199, DOI 10.1146/annurev.iy.02.040184.001215; Szekanecz Z, 2003, SEMIN IMMUNOL, V15, P15, DOI 10.1016/S1044-5323(02)00124-0; TERATO K, 1992, J IMMUNOL, V148, P2103; TRENTHAM DE, 1982, ARTHRITIS RHEUM, V25, P911, DOI 10.1002/art.1780250801; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Weiss-Haljiti C, 2004, J BIOL CHEM, V279, P43273, DOI 10.1074/jbc.M402924200; Wetzker R, 2004, CURR PHARM DESIGN, V10, P1915, DOI 10.2174/1381612043384402; Wipke BT, 2001, J IMMUNOL, V167, P1601, DOI 10.4049/jimmunol.167.3.1601; YOSHINO S, 1992, J EXP MED, V175, P907, DOI 10.1084/jem.175.4.907	42	634	757	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					936	943		10.1038/nm1284	http://dx.doi.org/10.1038/nm1284			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16127437				2022-12-25	WOS:000231724700020
J	Zhang, HL; Kim, JK; Edwards, CA; Xu, ZH; Taichman, R; Wang, CY				Zhang, HL; Kim, JK; Edwards, CA; Xu, ZH; Taichman, R; Wang, CY			Clusterin inhibits apoptosis by interacting with activated Bax	NATURE CELL BIOLOGY			English	Article							MYC-INDUCED APOPTOSIS; C-MYC; PROSTATE-CANCER; CLUSTERIN/APOLIPOPROTEIN-J; OXIDATIVE STRESS; INDUCE APOPTOSIS; DEATH; CELLS; BCL-2; GENE	Clusterin is an enigmatic glycoprotein that is overexpressed in several human cancers such as prostate and breast cancers, and squamous cell carcinoma(1,2). Because the suppression of clusterin expression renders human cancer cells sensitive to chemotherapeutic drug- mediated apoptosis, it is currently an antisense target in clinical trials for prostate cancer. However, the molecular mechanisms by which clusterin inhibits apoptosis in human cancer cells are unknown. Here we report that intracellular clusterin inhibits apoptosis by interfering with Bax activation in mitochondria. Intriguingly, in contrast to other inhibitors of Bax, clusterin specifically interacts with conformation- altered Bax in response to chemotherapeutic drugs. This interaction impedes Bax oligomerization, which leads to the release of cytochrome c from mitochondria and caspase activation. Moreover, we also find that clusterin inhibits oncogenic c- Myc- mediated apoptosis by interacting with conformation- altered Bax. Clusterin promotes c- Myc-mediated transformation in vitro and tumour progression in vivo. Taken together, our results suggest that the elevated level of clusterin in human cancers may promote oncogenic transformation and tumour progression by interfering with Bax pro- apoptotic activities.	Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Cell & Dev Biol, Microscopy & Image Anal Core, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Wang, CY (corresponding author), Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, Ann Arbor, MI 48109 USA.	cunywang@umich.edu		Taichman, Russell S./0000-0002-7890-0020				Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Gleave M, 2003, ANN NY ACAD SCI, V1002, P95, DOI 10.1196/annals.1281.020; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Miyake H, 2003, ONCOL REP, V10, P469; O'Sullivan J, 2003, CELL DEATH DIFFER, V10, P914, DOI 10.1038/sj.cdd.4401254; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Viard I, 1999, J INVEST DERMATOL, V112, P290, DOI 10.1046/j.1523-1747.1999.00531.x; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	27	370	389	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2005	7	9					909	U69		10.1038/ncb1291	http://dx.doi.org/10.1038/ncb1291			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	960NY	16113678				2022-12-25	WOS:000231601600015
J	Spitz, F; Herkenne, C; Morris, MA; Duboule, D				Spitz, F; Herkenne, C; Morris, MA; Duboule, D			Inversion-induced disruption of the Hoxd cluster leads to the partition of regulatory landscapes	NATURE GENETICS			English	Article							GLOBAL CONTROL REGION; GENE-EXPRESSION; MICE DEFICIENT; CRE-LOXP; COMPLEX; MURINE; RANGE; ORGANIZATION; COLINEARITY; CHROMOSOMES	The developmental regulation of vertebrate Hox gene transcription relies on the interplay between local and long-range controls. To study this complex genomic organization, we designed a strategy combining meiotic and targeted recombinations to induce large chromosomal rearrangements in vivo without manipulating embryonic stem cells. With this simple approach (called STRING), we engineered a large 7-cM inversion, which split the Hoxd cluster into two independent pieces. Expression analyses showed a partition of global enhancers, allowing for their precise topographic allocation on either side of the cluster. Such a functional organization probably contributed to keeping these genes clustered in the course of vertebrate evolution. This approach can be used to study the relationship between genome architecture and gene expression, such as the effects of genome rearrangements in human diseases or during evolution.	Univ Geneva, Dept Zool & Anim Biol, Natl Res Ctr Frontiers Genet, CH-1211 Geneva, Switzerland; Univ Geneva, Sch Med, Dept Med Genet & Dev, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Serv Med Genet, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva	Duboule, D (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Natl Res Ctr Frontiers Genet, Quai Ernest Ansermet 30, CH-1211 Geneva, Switzerland.	Denis.Duboule@zoo.unige.ch	Morris, Michael/AAD-2458-2022	Morris, Michael/0000-0002-9660-505X; duboule, denis/0000-0001-9961-2960; Spitz, Francois/0000-0002-1960-829X				AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1998, CURR OPIN GENET DEV, V8, P514, DOI 10.1016/S0959-437X(98)80004-X; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; Gimond C, 1998, J CELL BIOL, V143, P253, DOI 10.1083/jcb.143.1.253; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Herault Y, 1998, NAT GENET, V20, P381, DOI 10.1038/3861; Hurst LD, 2004, NAT REV GENET, V5, P299, DOI 10.1038/nrg1319; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Kmita M, 2000, NAT GENET, V26, P451, DOI 10.1038/82593; Kmita M, 2002, NATURE, V420, P145, DOI 10.1038/nature01189; Kondo T, 1998, MOL CELL, V1, P289, DOI 10.1016/S1097-2765(00)80029-5; Kulnane LS, 2002, MAMM GENOME, V13, P223, DOI 10.1007/s00335-001-2128-5; Lettice LA, 2003, HUM MOL GENET, V12, P1725, DOI 10.1093/hmg/ddg180; Monge I, 2003, DEV BIOL, V256, P212, DOI 10.1016/S0012-1606(02)00136-7; Puech A, 2000, P NATL ACAD SCI USA, V97, P10090, DOI 10.1073/pnas.97.18.10090; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Spitz F, 2002, GENOMICS, V79, P493, DOI 10.1006/geno.2002.6735; Spitz F, 2001, GENE DEV, V15, P2209, DOI 10.1101/gad.205701; VOGELS R, 1993, DEVELOPMENT, V118, P71; Wittig BM, 2000, J EXP MED, V191, P2053, DOI 10.1084/jem.191.12.2053; Yu YJ, 2001, NAT REV GENET, V2, P780, DOI 10.1038/35093564; Zakany J, 1997, EMBO J, V16, P4393, DOI 10.1093/emboj/16.14.4393; Zhang F, 1997, MECH DEVELOP, V67, P49, DOI 10.1016/S0925-4773(97)00104-4; Zheng BH, 2000, MOL CELL BIOL, V20, P648, DOI 10.1128/MCB.20.2.648-655.2000; Zuniga AE, 2004, GENE DEV, V18, P1553, DOI 10.1101/gad.299904	29	116	121	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					889	893		10.1038/ng1597	http://dx.doi.org/10.1038/ng1597			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	15995706				2022-12-25	WOS:000230880400021
J	Bordeleau, ME; Mori, A; Oberer, M; Lindqvist, L; Chard, LS; Higa, T; Belsham, GJ; Wagner, G; Tanaka, J; Pelletier, J				Bordeleau, ME; Mori, A; Oberer, M; Lindqvist, L; Chard, LS; Higa, T; Belsham, GJ; Wagner, G; Tanaka, J; Pelletier, J			Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A	NATURE CHEMICAL BIOLOGY			English	Article							DEAD-BOX PROTEIN; EUKARYOTIC INITIATION FACTOR-4A; RIBOSOME ENTRY SITES; HEPATITIS-C VIRUS; TRANSLATION INITIATION; MESSENGER-RNA; MAMMALIAN TRANSLATION; CRYSTAL-STRUCTURE; ATP; BINDING	RNA helicases are molecular motors that are involved in virtually all aspects of RNA metabolism. Eukaryotic initiation factor (eIF) 4A is the prototypical member of the DEAD-box family of RNA helicases. It is thought to use energy from ATP hydrolysis to unwind mRNA structure and, in conjunction with other translation factors, it prepares mRNA templates for ribosome recruitment during translation initiation. In screening marine extracts for new eukaryotic translation initiation inhibitors, we identified the natural product hippuristanol. We show here that this compound is a selective and potent inhibitor of eIF4A RNA-binding activity that can be used to distinguish between eIF4A-dependent and -independent modes of translation initiation in vitro and in vivo. We also show that poliovirus replication is delayed when infected cells are exposed to hippuristanol. Our study demonstrates the feasibility of selectively targeting members of the DEAD-box helicase family with small-molecule inhibitors.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Ryukyus, Dept Chem Biol & Marine Sci, Okinawa 9030213, Japan; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; AFRC, Inst Anim Hlth, Woking GU24 0NF, Surrey, England; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; University of the Ryukyus; Harvard University; Harvard Medical School; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; McGill University	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg Rm 810,3655 Promenade Sir W, Montreal, PQ H3G 1Y6, Canada.	jerry.pelletier@mcgill.ca	Belsham, Graham J./H-8589-2019; Belsham, Graham/J-3132-2019	Belsham, Graham J./0000-0003-1187-4873; Belsham, Graham/0000-0003-1187-4873; Oberer, Monika/0000-0003-2525-9513; Tanaka, Junichi/0000-0002-8672-7379; Chard, Louisa/0000-0003-2380-0900	NCI NIH HHS [CA114475, CA068262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114475, R01CA068262] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMANN M, 1990, GENE, V91, P127, DOI 10.1016/0378-1119(90)90173-O; ALTMANN M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P155, DOI 10.1016/0167-4781(90)90158-X; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; BLUM S, 1992, P NATL ACAD SCI USA, V89, P7664, DOI 10.1073/pnas.89.16.7664; BODIAN D, 1959, VIRAL RICKETTSIAL IN, P479; Bordeleau ME, 2005, P NATL ACAD SCI USA, V102, P10460, DOI 10.1073/pnas.0504249102; Chard LS, 2006, J VIROL, V80, P1271, DOI 10.1128/JVI.80.3.1271-1279.2006; Cheng ZH, 2005, RNA, V11, P1258, DOI 10.1261/rna.2920905; CONROY SC, 1990, ARCH BIOCHEM BIOPHYS, V282, P363, DOI 10.1016/0003-9861(90)90130-Q; DANIELSMCQUEEN S, 1983, J BIOL CHEM, V258, P7195; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1983, J BIOL CHEM, V258, P1398; GEHRKE L, 1983, BIOCHEMISTRY-US, V22, P5157, DOI 10.1021/bi00291a015; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HIGA T, 1981, TETRAHEDRON LETT, V22, P2777, DOI 10.1016/S0040-4039(01)90550-7; HIGA T, 1981, CHEM LETT, P1647, DOI 10.1246/cl.1981.1647; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kauder SE, 2004, J CLIN INVEST, V113, P1743, DOI 10.1172/JCI200421323; Korneeva NL, 2005, J BIOL CHEM, V280, P1872, DOI 10.1074/jbc.M406168200; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; Novac O, 2004, NUCLEIC ACIDS RES, V32, P902, DOI 10.1093/nar/gkh235; Oberer M, 2005, GENE DEV, V19, P2212, DOI 10.1101/gad.1335305; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pestova TV, 2003, GENE DEV, V17, P181, DOI 10.1101/gad.1040803; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Pisarev AV, 2004, J VIROL, V78, P4487, DOI 10.1128/JVI.78.9.4487-4497.2004; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; RAY BK, 1985, J BIOL CHEM, V260, P7651; Richter-Cook NJ, 1998, J BIOL CHEM, V273, P7579, DOI 10.1074/jbc.273.13.7579; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; SEAL SN, 1983, P NATL ACAD SCI-BIOL, V80, P6562, DOI 10.1073/pnas.80.21.6562; Shi H, 2004, P NATL ACAD SCI USA, V101, P17628, DOI 10.1073/pnas.0408172101; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; SONENBERG N, 1981, NUCLEIC ACIDS RES, V9, P1643, DOI 10.1093/nar/9.7.1643; Story RM, 2001, P NATL ACAD SCI USA, V98, P1465, DOI 10.1073/pnas.98.4.1465; Svitkin YV, 2001, RNA, V7, P1743; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Wilson JE, 2000, MOL CELL BIOL, V20, P4990, DOI 10.1128/MCB.20.14.4990-4999.2000; YODERHILL J, 1993, J BIOL CHEM, V268, P5566	50	270	280	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	APR	2006	2	4					213	220		10.1038/nchembio776	http://dx.doi.org/10.1038/nchembio776			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	023QU	16532013				2022-12-25	WOS:000236142100014
J	Kassen, R; Bataillon, T				Kassen, R; Bataillon, T			Distribution of fitness effects among beneficial mutations before selection in experimental populations of bacteria	NATURE GENETICS			English	Article							ESCHERICHIA-COLI; ANTIBIOTIC-RESISTANCE; ADAPTATION; EVOLUTION; VIRUS; MECHANISMS; LANDSCAPE; MUTANTS	The extent to which a population diverges from its ancestor through adaptive evolution depends on variation supplied by novel beneficial mutations. Extending earlier work(1,2), recent theory makes two predictions that seem to be robust to biological details: the distribution of fitness effects among beneficial mutations before selection should be (i) exponential and (ii) invariant, meaning it is always exponential regardless of the fitness rank of the wild-type allele(3,4). Here we test these predictions by assaying the fitness of 665 independently derived single-step mutations in the bacterium Pseudomonas fluorescens across a range of environments. We show that the distribution of fitness effects among beneficial mutations is indistinguishable from an exponential despite marked variation in the fitness rank of the wild type across environments. These results suggest that the initial step in adaptive evolution-the production of novel beneficial mutants from which selection sorts-is very general, being characterized by an approximately exponential distribution with many mutations of small effect and few of large effect. We also document substantial variation in the pleiotropic costs of antibiotic resistance, a result that may have implications for strategies aimed at eliminating resistant pathogens in animal and human populations.	Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Ctr Adv Res Environm Genom, Ottawa, ON K1N 6N5, Canada; Unite Mixte Rech 1097, Montpellier, France	University of Ottawa; University of Ottawa	Kassen, R (corresponding author), Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada.	rkassen@uottawa.ca	Bataillon, Thomas/AAK-1822-2020; Bataillon, Thomas/AAJ-7652-2020	Bataillon, Thomas/0000-0002-4730-2538				Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3; Bagel S, 1999, ANTIMICROB AGENTS CH, V43, P868, DOI 10.1128/AAC.43.4.868; BENNETT AF, 1993, EVOLUTION INT J ORG, V46, P16; Fisher R.A., 1930, GENETICAL THEORY NAT; GILLESPIE JH, 1984, EVOLUTION, V38, P1116, DOI 10.1111/j.1558-5646.1984.tb00380.x; Hawkey PM, 2003, J ANTIMICROB CHEMOTH, V51, P29, DOI 10.1093/jac/dkg207; HEISIG P, 1994, ANTIMICROB AGENTS CH, V38, P1284, DOI 10.1128/AAC.38.6.1284; Holder KK, 2001, GENETICS, V159, P1393; Imhof M, 2001, P NATL ACAD SCI USA, V98, P1113, DOI 10.1073/pnas.98.3.1113; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; Luria SE, 1943, GENETICS, V28, P491; Orr HA, 2003, GENETICS, V163, P1519; Orr HA, 2002, EVOLUTION, V56, P1317, DOI 10.1111/j.0014-3820.2002.tb01446.x; Reynolds MG, 2000, GENETICS, V156, P1471; Rokyta DR, 2005, NAT GENET, V37, P441, DOI 10.1038/ng1535; Rosche WA, 2000, METHODS, V20, P4, DOI 10.1006/meth.1999.0901; Rozen DE, 2002, CURR BIOL, V12, P1040, DOI 10.1016/S0960-9822(02)00896-5; Ruiz J, 2003, J ANTIMICROB CHEMOTH, V51, P1109, DOI 10.1093/jac/dkg222; Sanjuan R, 2004, P NATL ACAD SCI USA, V101, P8396, DOI 10.1073/pnas.0400146101; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; SMITH JM, 1970, NATURE, V225, P563, DOI 10.1038/225563a0; Wolfram S., 1996, MATH BOOK; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1273, DOI 10.1128/AAC.34.6.1273	23	178	179	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	2006	38	4					484	488		10.1038/ng1751	http://dx.doi.org/10.1038/ng1751			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16550173				2022-12-25	WOS:000236340500024
J	Kissler, S; Stern, P; Takahashi, K; Hunter, K; Peterson, LB; Wicker, LS				Kissler, S; Stern, P; Takahashi, K; Hunter, K; Peterson, LB; Wicker, LS			In vivo RNA interference demonstrates a role for Nramp1 in modifying susceptibility to type 1 diabetes	NATURE GENETICS			English	Article							INTRACELLULAR PARASITES; RHEUMATOID-ARTHRITIS; NATURAL-RESISTANCE; AUTOIMMUNE-DISEASE; LENTIVIRAL VECTORS; MAMMALIAN-CELLS; GENE; POLYMORPHISM; EXPRESSION; PROMOTER	Type 1 diabetes is an autoimmune disease influenced by multiple genetic loci. Although more than 20 insulin-dependent diabetes (Idd) loci have been implicated in the nonobese diabetic (NOD) mouse model(1,2), few causal gene variants have been identified(3,4). Here we show that RNA interference(5,6) (RNAi) can be used to probe candidate genes in this disease model. Slc11a1 encodes a phagosomal ion transporter, Nramp1, that affects resistance to intracellular pathogens and influences antigen presentation(7-9). This gene is the strongest candidate among the 42 genes in the Idd5.2 region; a naturally occurring mutation in the protective Idd5.2 haplotype results in loss of function of the Nramp1 protein(10). Using lentiviral transgenesis(11), we generated NOD mice in which Slc11a1 is silenced by RNAi. Silencing reduced the frequency of type 1 diabetes, mimicking the protective Idd5.2 region. Our results demonstrate a role for Slc11a1 in modifying susceptibility to type 1 diabetes and illustrate that RNAi can be used to study causal genes in a mammalian model organism.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Harvard Univ, Massachusetts Gen Hosp Children, Sch Med, Lab Dev Immunol, Boston, MA 02114 USA; Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Diabet & Inflammat Lab, Cambridge CB2 2XY, England; Merck Res Labs, Dept Pharmacol, Rahway, NJ 07065 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; University of Cambridge; Merck & Company	Kissler, S (corresponding author), MIT, Ctr Canc Res, Cambridge, MA 02139 USA.	skissler@mit.edu	Wicker, Linda S/F-7384-2010	/0000-0003-3062-7800	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hill NJ, 2000, DIABETES, V49, P1744, DOI 10.2337/diabetes.49.10.1744; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Kanagawa O, 2000, J IMMUNOL, V164, P3919, DOI 10.4049/jimmunol.164.7.3919; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; Kwaks THJ, 2003, NAT BIOTECHNOL, V21, P553, DOI 10.1038/nbt814; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; Nishino M, 2005, METABOLISM, V54, P628, DOI 10.1016/j.metabol.2004.12.006; Qiu S, 2005, NUCLEIC ACIDS RES, V33, P1834, DOI 10.1093/nar/gki324; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Sanjeevi CB, 2000, ARTHRITIS RHEUM-US, V43, P1397, DOI 10.1002/1529-0131(200006)43:6<1397::AID-ANR25>3.0.CO;2-6; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Searle S, 1999, J MED GENET, V36, P295; Shaw MA, 1996, J MED GENET, V33, P672, DOI 10.1136/jmg.33.8.672; Steinman L, 2005, TRENDS IMMUNOL, V26, P565, DOI 10.1016/j.it.2005.08.014; Takahashi K, 2004, TISSUE ANTIGENS, V63, P231, DOI 10.1111/j.1399-0039.2004.000172.x; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Todd JA, 2001, IMMUNITY, V15, P387, DOI 10.1016/S1074-7613(01)00202-3; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; Vijayakrishnan L, 2004, IMMUNITY, V20, P563, DOI 10.1016/S1074-7613(04)00110-4; Wicker LS, 2004, J IMMUNOL, V173, P164, DOI 10.4049/jimmunol.173.1.164; Wojciechowski W, 1999, J IMMUNOL, V163, P2688	29	100	102	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	2006	38	4					479	483		10.1038/ng1766	http://dx.doi.org/10.1038/ng1766			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16550170				2022-12-25	WOS:000236340500023
J	Herrera, S				Herrera, S			Price controls: preparing for the unthinkable	NATURE BIOTECHNOLOGY			English	Editorial Material								The momentum in the United States to impose price controls is growing. Stephan Herrera lists some of the reasons why.										*DHHS, STAT AG POP INTR; HARRIS GG, 2005, NY TIMES        0616; HEFFLER S, 2005, US HLTH SPENDING PRO; *KAIS FAM FDN, 2005, PRESCR DRUG TRENDS; National Association of Chain Drug Stores, IND FACTS GLANC; 2005, FORTUNE         0418; 2006, JP MORG 24 ANN HEALT; 2006, WORLD EC FOR DAV SWI	8	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2006	24	3					257	260		10.1038/nbt0306-257	http://dx.doi.org/10.1038/nbt0306-257			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	019WQ	16525374				2022-12-25	WOS:000235868600014
J	Drake, JA; Bird, C; Nemesh, J; Thomas, DJ; Newton-Cheh, C; Reymond, A; Excoffier, L; Attar, H; Antonarakis, SE; Dermitzakis, ET; Hirschhorn, JN				Drake, JA; Bird, C; Nemesh, J; Thomas, DJ; Newton-Cheh, C; Reymond, A; Excoffier, L; Attar, H; Antonarakis, SE; Dermitzakis, ET; Hirschhorn, JN			Conserved noncoding sequences are selectively constrained and not mutation cold spots	NATURE GENETICS			English	Article							NON-GENIC SEQUENCES; NONGENIC SEQUENCES; DISEASE; IDENTIFICATION; DELETIONS; ELEMENTS; REGIONS; NUMBER	Noncoding genetic variants are likely to influence human biology and disease, but recognizing functional noncoding variants is difficult. Approximately 3% of noncoding sequence is conserved among distantly related mammals(1-4), suggesting that these evolutionarily conserved noncoding regions (CNCs) are selectively constrained and contain functional variation. However, CNCs could also merely represent regions with lower local mutation rates. Here we address this issue and show that CNCs are selectively constrained in humans by analyzing HapMap genotype data. Specifically, new ( derived) alleles of SNPs within CNCs are rarer than new alleles in nonconserved regions (P = 3 x 10(-18)), indicating that evolutionary pressure has suppressed CNC-derived allele frequencies. Intronic CNCs and CNCs near genes show greater allele frequency shifts, with magnitudes comparable to those for missense variants. Thus, conserved noncoding variants are more likely to be functional. Allele frequency distributions highlight selectively constrained genomic regions that should be intensively surveyed for functionally important variation.	Childrens Hosp, Program Genom, Boston, MA 02115 USA; Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02139 USA; MIT, Cambridge, MA 02139 USA; Wellcome Trust Sanger Inst, Hinxton CB10 1SA, England; Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA; Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland; Univ Bern, Inst Zool, CH-3012 Bern, Switzerland; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Wellcome Trust Sanger Institute; University of California System; University of California Santa Cruz; Harvard University; Massachusetts General Hospital; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Geneva; University of Bern; Harvard University; Harvard Medical School	Hirschhorn, JN (corresponding author), Childrens Hosp, Program Genom, 300 Longwood Ave, Boston, MA 02115 USA.	md4@sanger.ac.uk; joelh@broad.mit.edu	Antonarakis, Stylianos E/N-8866-2014; Excoffier, Laurent/D-3498-2013; Kutalik, Zoltan/HHZ-5697-2022; Dermitzakis, Emmanouil/B-7687-2013	Antonarakis, Stylianos E/0000-0001-8907-5823; Excoffier, Laurent/0000-0002-7507-6494; Kutalik, Zoltan/0000-0001-8285-7523; Reymond, Alexandre/0000-0003-1030-8327; Fosker, Christine/0000-0002-3799-9474	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Beysen D, 2005, AM J HUM GENET, V77, P205, DOI 10.1086/432083; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; CHARLESWORTH B, 1993, GENETICS, V134, P1289; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Dermitzakis ET, 2005, NAT REV GENET, V6, P151, DOI 10.1038/nrg1527; Dermitzakis ET, 2004, GENOME RES, V14, P852, DOI 10.1101/gr.1934904; Dermitzakis ET, 2003, SCIENCE, V302, P1033, DOI 10.1126/science.1087047; Emison ES, 2005, NATURE, V434, P857, DOI 10.1038/nature03467; Fay JC, 2001, GENETICS, V158, P1227; Frazer KA, 2004, GENOME RES, V14, P367, DOI 10.1101/gr.1961204; Hirakawa M, 2002, NUCLEIC ACIDS RES, V30, P158, DOI 10.1093/nar/30.1.158; Keightley PD, 2005, GENOME RES, V15, P1373, DOI 10.1101/gr.3942005; Keightley PD, 2005, PLOS BIOL, V3, P282, DOI 10.1371/journal.pbio.0030042; King DC, 2005, GENOME RES, V15, P1051, DOI 10.1101/gr.3642605; Kryukov GV, 2005, HUM MOL GENET, V14, P2221, DOI 10.1093/hmg/ddi226; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Margulies EH, 2003, GENOME RES, V13, P2507, DOI 10.1101/gr.1602203; Marth GT, 2004, GENETICS, V166, P351, DOI 10.1534/genetics.166.1.351; MARUYAMA T, 1985, GENETICS, V111, P675; Nobrega MA, 2004, NATURE, V431, P988, DOI 10.1038/nature03022; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Zar JH, 1999, BIOSTATISTICAL ANAL	30	175	180	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					223	227		10.1038/ng1710	http://dx.doi.org/10.1038/ng1710			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16380714				2022-12-25	WOS:000234953200019
J	Maheshri, N; Koerber, JT; Kaspar, BK; Schaffer, DV				Maheshri, N; Koerber, JT; Kaspar, BK; Schaffer, DV			Directed evolution of adeno-associated virus yields enhanced gene delivery vectors	NATURE BIOTECHNOLOGY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; ADENO-ASSOCIATED VIRUS; FACTOR-IX; IN-VITRO; INSERTIONAL MUTAGENESIS; PERSISTENT EXPRESSION; QUANTITATIVE-ANALYSIS; SERUM ANTIBODIES; VIRAL VECTORS; HEMOPHILIA-B	Adeno-associated viral vectors are highly safe and efficient gene delivery vehicles. However, numerous challenges in vector design remain, including neutralizing antibody responses, tissue transport and infection of resistant cell types. Changes must be made to the viral capsid to overcome these problems; however, very often insufficient information is available for rational design of improvements. We therefore applied a directed evolution approach involving the generation of large mutant capsid libraries and selection of adeno-associated virus (AAV) 2 variants with enhanced properties. High-throughput selection processes were designed to isolate mutants within the library with altered affinities for heparin or the ability to evade antibody neutralization and deliver genes more efficiently than wild-type capsid in the presence of anti-AAV serum. This approach, which can be extended to additional gene delivery challenges and serotypes, directs viral evolution to generate 'designer' gene delivery vectors with specified, enhanced properties.	Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; Columbus Childrens Res Inst, Dept Gene Therapy, Columbus, OH 43205 USA; Columbus Childrens Res Inst, Div Mol Med, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43205 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Schaffer, DV (corresponding author), Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA.	schaffer@berkeley.edu	Kaspar, Brian/E-6490-2010; Kaspar, Brian/E-3349-2011					Batard P, 2001, GENE, V270, P61, DOI 10.1016/S0378-1119(01)00467-X; BERNS KI, 1995, BIOESSAYS, V17, P237, DOI 10.1002/bies.950170310; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Chiorini JA, 1999, J VIROL, V73, P1309, DOI 10.1128/JVI.73.2.1309-1319.1999; Daugherty PS, 2000, P NATL ACAD SCI USA, V97, P2029, DOI 10.1073/pnas.030527597; Davidson BL, 2000, P NATL ACAD SCI USA, V97, P3428, DOI 10.1073/pnas.050581197; Dong JY, 1996, HUM GENE THER, V7, P2101, DOI 10.1089/hum.1996.7.17-2101; Erles K, 1999, J MED VIROL, V59, P406, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;406::AID-JMV22&gt;3.0.CO;2-N; Gao GP, 2003, P NATL ACAD SCI USA, V100, P6081, DOI 10.1073/pnas.0937739100; Gao GP, 2004, J VIROL, V78, P6381, DOI 10.1128/JVI.78.12.6381-6388.2004; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; Girod A, 1999, NAT MED, V5, P1052, DOI 10.1038/12491; Halbert CL, 2000, J VIROL, V74, P1524, DOI 10.1128/JVI.74.3.1524-1532.2000; Hansen J, 2000, J VIROL, V74, P992, DOI 10.1128/JVI.74.2.992-996.2000; HERMONAT PL, 1984, J VIROL, V51, P329, DOI 10.1128/JVI.51.2.329-339.1984; Hewat E, 2001, CURR TOP MICROBIOL, V260, P29; Hughes SM, 2002, MOL THER, V5, P16, DOI 10.1006/mthe.2001.0512; Huttner NA, 2003, GENE THER, V10, P2139, DOI 10.1038/sj.gt.3302123; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kern A, 2003, J VIROL, V77, P11072, DOI 10.1128/JVI.77.20.11072-11081.2003; Koeberl DD, 1997, P NATL ACAD SCI USA, V94, P1426, DOI 10.1073/pnas.94.4.1426; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296; May O, 2000, NAT BIOTECHNOL, V18, P317, DOI 10.1038/73773; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; Moskalenko M, 2000, J VIROL, V74, P1761, DOI 10.1128/JVI.74.4.1761-1766.2000; Moss RB, 2004, CHEST, V125, P509, DOI 10.1378/chest.125.2.509; Muller OJ, 2003, NAT BIOTECHNOL, V21, P1040, DOI 10.1038/nbt856; Nguyen JB, 2001, NEUROREPORT, V12, P1961, DOI 10.1097/00001756-200107030-00037; Opie SR, 2003, J VIROL, V77, P6995, DOI 10.1128/JVI.77.12.6995-7006.2003; Peden CS, 2004, J VIROL, V78, P6344, DOI 10.1128/JVI.78.12.6344-6359.2004; Perabo L, 2003, MOL THER, V8, P151, DOI 10.1016/S1525-0016(03)00123-0; Rabinowitz JE, 1999, VIROLOGY, V265, P274, DOI 10.1006/viro.1999.0045; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; Shi WF, 2001, HUM GENE THER, V12, P1697, DOI 10.1089/104303401750476212; Smith-Arica JR, 2003, CLONING STEM CELLS, V5, P51, DOI 10.1089/153623003321512166; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Soong NW, 2000, NAT GENET, V25, P436, DOI 10.1038/78132; SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Sun JY, 2003, GENE THER, V10, P964, DOI 10.1038/sj.gt.3302039; Walters RW, 2004, J VIROL, V78, P3361, DOI 10.1128/JVI.78.7.3361-3371.2004; Walters RW, 2001, J BIOL CHEM, V276, P20610, DOI 10.1074/jbc.M101559200; Wobus CE, 2000, J VIROL, V74, P9281, DOI 10.1128/JVI.74.19.9281-9293.2000; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Xie Q, 2002, P NATL ACAD SCI USA, V99, P10405, DOI 10.1073/pnas.162250899; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	50	350	412	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2006	24	2					198	204		10.1038/nbt1182	http://dx.doi.org/10.1038/nbt1182			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	010XW	16429148				2022-12-25	WOS:000235232300037
J	Chan, VSF; Chan, KYK; Chen, YX; Poon, LLM; Cheung, ANY; Zheng, BJ; Chan, KH; Mak, W; Ngan, HYS; Xu, XN; Screaton, G; Tam, PKH; Austyn, JM; Chan, LC; Yip, SP; Peiris, M; Khoo, US; Lin, CLS				Chan, VSF; Chan, KYK; Chen, YX; Poon, LLM; Cheung, ANY; Zheng, BJ; Chan, KH; Mak, W; Ngan, HYS; Xu, XN; Screaton, G; Tam, PKH; Austyn, JM; Chan, LC; Yip, SP; Peiris, M; Khoo, US; Lin, CLS			Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection	NATURE GENETICS			English	Article							ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING DOMAIN; LECTINS DC-SIGN; DENDRITIC CELL; SPIKE GLYCOPROTEIN; ENDOTHELIAL-CELLS; STRUCTURAL BASIS; HONG-KONG; IN-SITU; IDENTIFICATION	Severe acute respiratory syndrome (SARS) is caused by infection of a previously undescribed coronavirus (CoV). L-SIGN, encoded by CLEC4M ( also known as CD209L), is a SARS-CoV binding receptor that has polymorphism in its extracellular neck region encoded by the tandem repeat domain in exon 4. Our genetic risk association study shows that individuals homozygous for CLEC4M tandem repeats are less susceptible to SARS infection. L-SIGN is expressed in both non-SARS and SARS-CoV-infected lung. Compared with cells heterozygous for L-SIGN, cells homozygous for L-SIGN show higher binding capacity for SARS-CoV, higher proteasome-dependent viral degradation and a lower capacity for trans infection. Thus, homozygosity for L-SIGN plays a protective role during SARS infection.	Univ Hong Kong, Queen Mary Hosp, Hong Kong Jockey Club Clin Res Ctr, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hong Kong Jockey Club Clin Res Ctr, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hong Kong Jockey Club Clin Res Ctr, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hong Kong Jockey Club Clin Res Ctr, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hong Kong Jockey Club Clin Res Ctr, Genome Res Ctr, Hong Kong, Hong Kong, Peoples R China; Univ Oxford, Weatherall Inst Mol Med, Human Immunol Unit, Oxford, England; Univ London Imperial Coll Sci & Technol, Div Med, London, England; Univ Oxford, Nuffield Dept Surg, Oxford, England; Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Oxford; Imperial College London; University of Oxford; Hong Kong Polytechnic University	Khoo, US (corresponding author), Univ Hong Kong, Queen Mary Hosp, Hong Kong Jockey Club Clin Res Ctr, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	uskhoo@pathology.hku.hk; clin@hkucc.hku.hk	Chan, Kwok Hung/ABD-5399-2021; Poon, Leo Lit Man/C-4382-2009; Khoo, Ui Soon/C-4293-2009; Poon, Leo/AAP-6887-2020; Khoo, Ui Soon/K-2041-2019; Chan, Kelvin/HGA-3097-2022; Khoo, Ui Soon/C-1345-2014; Yip, Shea Ping/A-1185-2016; /C-4405-2009; Peiris, Joseph Sriyal Malik/C-4380-2009; Cheung, Annie Nga Yin/C-4231-2009; /B-3419-2011	Poon, Leo Lit Man/0000-0002-9101-7953; Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Yip, Shea Ping/0000-0002-2170-8185; /0000-0001-6231-3035; Screaton, Gavin/0000-0002-3549-4309; Ngan, Hextan Y S/0000-0003-3945-159X; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; Cheung, Annie Nga Yin/0000-0002-1584-7568; /0000-0001-6985-6227	Medical Research Council [G0400720] Funding Source: Medline; MRC [G0400720] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003; Breslin JJ, 2003, J VIROL, V77, P4435, DOI 10.1128/JVI.77.7.4435-4438.2003; Chan-Yeung M, 2004, INT J OCCUP ENV HEAL, V10, P421, DOI 10.1179/oeh.2004.10.4.421; Drosten C, 2004, J CLIN MICROBIOL, V42, P2043, DOI 10.1128/JCM.42.5.2043-2047.2004; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Guan M, 2004, CLIN DIAGN LAB IMMUN, V11, P699, DOI 10.1128/CDLI.11.4.699-703.2004; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101; Kliger Y, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-20; Koppel EA, 2004, IMMUNOBIOLOGY, V209, P117, DOI 10.1016/j.imbio.2004.03.003; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Lichterfeld M, 2003, CLIN IMMUNOL, V107, P55, DOI 10.1016/S1521-6616(02)00050-5; Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003; Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Marzi A, 2004, J VIROL, V78, P12090, DOI 10.1128/JVI.78.21.12090-12095.2004; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; NARDONE LL, 1979, BIOCHIM BIOPHYS ACTA, V573, P276, DOI 10.1016/0005-2760(79)90061-4; Ng MHL, 2004, J INFECT DIS, V190, P515, DOI 10.1086/421523; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Poon LLM, 2003, CLIN CHEM, V49, P953, DOI 10.1373/49.6.953; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Soilleux EJ, 2003, CLIN SCI, V104, P437, DOI 10.1042/CS20020092; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; To K, 2004, J PATHOL, V202, P157, DOI 10.1002/path.1510; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Xiong HQ, 2002, GENOMICS, V80, P96, DOI 10.1006/geno.2002.6802; Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004	37	110	118	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					38	46		10.1038/ng1698	http://dx.doi.org/10.1038/ng1698			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16369534	Bronze, Green Published			2022-12-25	WOS:000234227200015
J	Statsuk, AV; Bai, RL; Baryza, JL; Verma, VA; Hamel, E; Wender, PA; Kozmin, SA				Statsuk, AV; Bai, RL; Baryza, JL; Verma, VA; Hamel, E; Wender, PA; Kozmin, SA			Actin is the primary cellular receptor of bistramide A	NATURE CHEMICAL BIOLOGY			English	Article							SKELETAL-MUSCLE FIBERS; KINASE-C-DELTA; LISSOCLINUM-BISTRATUM; MARINE MACROLIDES; PROTEIN; CELLS; CYTOKINESIS; BINDING; DEPSIPEPTIDE; BRYOSTATIN	Bistramide A ( 1) is a marine natural product with broad, potent antiproliferative effects(1-7). Bistramide A has been reported to selectively activate protein kinase C (PKC) delta, leading to the view that PKC delta is the principal mediator of antiproliferative activity of this natural product(8). Contrary to this observation, we established that bistramide A binds PKCd with low affinity, does not activate this kinase in vitro and does not translocate GFP- PKCd. Furthermore, we identified actin as the cellular receptor of bistramide A. We report that bistramide A disrupts the actin cytoskeleton, inhibits actin polymerization, depolymerizes filamentous F-actin in vitro and binds directly to monomeric G-actin in a 1:1 ratio with a K-d of 7 nM. We also constructed a fully synthetic(9) bistramide A - based affinity matrix and isolated actin as a specific bistramide A - binding protein. This activity provides a molecular explanation for the potent antiproliferative effects of bistramide A, identifying it as a new biochemical tool for studies of the actin cytoskeleton and as a potential lead for development of a new class of antitumor agents(7,10).	Univ Chicago, Dept Chem, Chicago, IL 60637 USA; NCI, Toxicol & Pharmacol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,NIH, Frederick, MD 21702 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	University of Chicago; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University; Stanford University	Kozmin, SA (corresponding author), Univ Chicago, Dept Chem, 5735 S Ellis Ave, Chicago, IL 60637 USA.	skozmin@uchicago.edu	Chen, Yao/AAJ-2409-2020	Verma, Vishal/0000-0001-7600-4372	NATIONAL CANCER INSTITUTE [R37CA031845, R01CA031845] Funding Source: NIH RePORTER; NCI NIH HHS [CA31845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai RL, 2002, J BIOL CHEM, V277, P32165, DOI 10.1074/jbc.M205076200; Bai RL, 2001, MOL PHARMACOL, V59, P462, DOI 10.1124/mol.59.3.462; Baryza JL, 2004, CHEM BIOL, V11, P1261, DOI 10.1016/j.chembiol.2004.06.014; BIARD JF, 1994, J NAT PROD, V57, P1336, DOI 10.1021/np50112a002; BUBB MR, 1995, J BIOL CHEM, V270, P3463, DOI 10.1074/jbc.270.8.3463; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Chatterjee AK, 2000, J AM CHEM SOC, V122, P3783, DOI 10.1021/ja9939744; DEGNAN BM, 1989, J MED CHEM, V32, P1354, DOI 10.1021/jm00126a035; Frey MR, 2001, BIOCHEM PHARMACOL, V61, P1093, DOI 10.1016/S0006-2952(01)00596-2; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; GOUIFFES D, 1988, TOXICON, V26, P1129, DOI 10.1016/0041-0101(88)90297-8; GOUIFFES D, 1988, TETRAHEDRON, V44; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Klenchin VA, 2003, NAT STRUCT BIOL, V10, P1058, DOI 10.1038/nsb1006; Marquez BL, 2002, J NAT PROD, V65, P866, DOI 10.1021/np0106283; RIOU D, 1993, ANTICANCER RES, V13, P2331; ROUSSAKIS C, 1991, CANCER CHEMOTH PHARM, V28, P283; SAITO S, 1994, J BIOL CHEM, V269, P29710; Saito SY, 1996, J BIOCHEM-TOKYO, V120, P552; SAUVIAT MP, 1993, GEN PHYSIOL BIOPHYS, V12, P465; SAUVIAT MP, 1992, BIOCHIM BIOPHYS ACTA, V1103, P109, DOI 10.1016/0005-2736(92)90063-R; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Statsuk AV, 2004, J AM CHEM SOC, V126, P9546, DOI 10.1021/ja046588h; Sun HY, 2005, ANAL CHEM, V77, P2043, DOI 10.1021/ac048280e; Terry DR, 1997, J BIOL CHEM, V272, P7841, DOI 10.1074/jbc.272.12.7841; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; WATTERS DJ, 1994, CANCER CHEMOTH PHARM, V33, P399, DOI 10.1007/BF00686269; Wender PA, 1998, P NATL ACAD SCI USA, V95, P6624, DOI 10.1073/pnas.95.12.6624; Yeung KS, 2002, ANGEW CHEM INT EDIT, V41, P4632, DOI 10.1002/anie.200290057	30	65	68	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	DEC	2005	1	7					383	388		10.1038/nchembio748	http://dx.doi.org/10.1038/nchembio748			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986KE	16372404				2022-12-25	WOS:000233447700010
J	Bruce, LJ; Robinson, HC; Guizouarn, H; Borgese, F; Harrison, P; King, MJ; Goede, JS; Coles, SE; Gore, DM; Lutz, HU; Ficarella, R; Layton, DM; Iolascon, A; Ellory, JC; Stewart, GW				Bruce, LJ; Robinson, HC; Guizouarn, H; Borgese, F; Harrison, P; King, MJ; Goede, JS; Coles, SE; Gore, DM; Lutz, HU; Ficarella, R; Layton, DM; Iolascon, A; Ellory, JC; Stewart, GW			Monovalent cation leaks in human red cells caused by single amino-acid substitutions in the transport domain of the band 3 chloride-bicarbonate exchanger, AE1	NATURE GENETICS			English	Article							HEREDITARY STOMATOCYTOSIS; ANION-EXCHANGER; CRYOHYDROCYTOSIS FORM; HUMAN-ERYTHROCYTES; BRITISH FAMILIES; SICKLE CELLS; GENE DEFECTS; SPHEROCYTOSIS; MECHANISM; PROTEIN	We identified 11 human pedigrees with dominantly inherited hemolytic anemias in both the hereditary stomatocytosis and spherocytosis classes. Affected individuals in these families had an increase in membrane permeability to Na and K that is particularly marked at 0 degrees C. We found that disease in these pedigrees was associated with a series of single amino-acid substitutions in the intramembrane domain of the erythrocyte band 3 anion exchanger, AE1. Anion movements were reduced in the abnormal red cells. The 'leak' cation fluxes were inhibited by SITS, dipyridamole and NS1652, chemically diverse inhibitors of band 3. Expression of the mutated genes in Xenopus laevis oocytes induced abnormal Na and K fluxes in the oocytes, and the induced Cl transport was low. These data are consistent with the suggestion that the substitutions convert the protein from an anion exchanger into an unregulated cation channel.	UCL, Dept Med, London WC1E 6JJ, England; Natl Blood Serv, Bristol Inst Transfus Sci, Bristol BS10 5ND, Avon, England; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Univ Nice, Lab Physiol Membranes Cellulaires, CNRS, FRE 2721, F-06108 Nice, France; Univ Zurich Hosp, Dept Internal Med, Div Hematol, CH-8091 Zurich, Switzerland; ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland; Telethon Inst Genet & Med, I-80131 Naples, Italy; Hammersmith Hosp, Imperial Coll, Dept Haematol, London W12 0HS, England; Univ Naples Federico 2, CEINGE Biotecnol Avanzante, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy	University of London; University College London; University of Oxford; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Imperial College London; CEINGE Biotecnologie Avanzate; University of Naples Federico II	Stewart, GW (corresponding author), UCL, Dept Med, Univ St, London WC1E 6JJ, England.	g.stewart@ucl.ac.uk	Iolascon, Achille/A-4461-2014; Coles, Simon/A-1795-2009	Coles, Simon/0000-0001-8414-9272; Bruce, Lesley/0000-0001-5922-7072; Guizouarn, Helene/0000-0002-8757-6672; BORGESE, Franck/0000-0001-7718-2111	Telethon [GGP02202] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Telethon(Fondazione Telethon); Wellcome Trust(Wellcome TrustEuropean Commission)		Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Bennekou P, 2000, BLOOD, V95, P1842, DOI 10.1182/blood.V95.5.1842.005a37_1842_1848; Bruce LJ, 1998, BIOCHEM CELL BIOL, V76, P723, DOI 10.1139/bcb-76-5-723; BRUCE LJ, 1994, J BIOL CHEM, V269, P16155; Bruce LJ, 1999, BBA-BIOMEMBRANES, V1416, P258, DOI 10.1016/S0005-2736(98)00231-4; Coles SE, 1999, BRIT J HAEMATOL, V104, P275, DOI 10.1046/j.1365-2141.1999.01191.x; Coles SE, 1999, BRIT J HAEMATOL, V105, P1055, DOI 10.1046/j.1365-2141.1999.01444.x; DeFelice LJ, 2004, TRENDS NEUROSCI, V27, P352, DOI 10.1016/j.tins.2004.04.007; Dhermy D, 1997, BRIT J HAEMATOL, V98, P32, DOI 10.1046/j.1365-2141.1997.1893005.x; Eber S, 2004, SEMIN HEMATOL, V41, P118, DOI 10.1053/j.seminhematol.2004.01.002; Fricke B, 2003, BLOOD, V102, P2268, DOI 10.1182/blood-2002-06-1705; Fricke B, 2004, BRIT J HAEMATOL, V125, P796, DOI 10.1111/j.1365-2141.2004.04965.x; Gore D. M., 2002, British Journal of Haematology, V117, P9; Gore DA, 2004, BRIT J HAEMATOL, V125, P521, DOI 10.1111/j.1365-2141.2004.04944.x; Guizouarn H, 2001, J PHYSIOL-LONDON, V535, P497, DOI 10.1111/j.1469-7793.2001.t01-1-00497.x; Haines PG, 2001, BRIT J HAEMATOL, V113, P932, DOI 10.1046/j.1365-2141.2001.02792.x; Jarolim P, 1996, BLOOD, V88, P4366; JOHNSON RM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P7, DOI 10.1016/0005-2736(93)90154-R; Joiner CH, 2001, BLOOD, V97, P3976, DOI 10.1182/blood.V97.12.3976; JOINER CH, 1990, BLOOD, V76, P212; JONES GS, 1985, J GEN PHYSIOL, V86, P721, DOI 10.1085/jgp.86.5.721; KNAUF PA, 2003, RED CELL MEMBRANE TR, P253; Lew VL, 2005, PHYSIOL REV, V85, P179, DOI 10.1152/physrev.00052.2003; Meredith D, 2004, J BIOL CHEM, V279, P15795, DOI 10.1074/jbc.M313922200; Popov M, 1999, BIOCHEM J, V339, P269, DOI 10.1042/0264-6021:3390269; Stewart GN, 1904, AM J PHYSIOL, V11, P0250; Stewart GW, 1996, BRIT J HAEMATOL, V93, P303, DOI 10.1046/j.1365-2141.1996.4881033.x; Stuart MJ, 2004, LANCET, V364, P1343, DOI 10.1016/S0140-6736(04)17192-4; TOSTESON MT, 1991, J GEN PHYSIOL, V98, P969, DOI 10.1085/jgp.98.5.969; YANNOUKAKOS D, 1991, BLOOD, V78, P1117	30	117	122	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2005	37	11					1258	1263		10.1038/ng1656	http://dx.doi.org/10.1038/ng1656			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16227998				2022-12-25	WOS:000233045200027
J	Davis, PK; Kelley, JJ; Caltrider, SP; Heinig, SJ				Davis, PK; Kelley, JJ; Caltrider, SP; Heinig, SJ			ESTs stumble at the utility threshold	NATURE BIOTECHNOLOGY			English	Editorial Material							DNA		Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA; Assoc Amer Med Coll, Washington, DC 20037 USA	Eli Lilly; Association of American Medical Colleges	Davis, PK (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA.	paula.davis@lilly.com; sheinig@aamc.org						ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALBERTS B, 2000, COMMUNICATION   0322; Doll JJ, 1998, SCIENCE, V280, P689, DOI 10.1126/science.280.5364.689; Eisenberg RS, 2002, ACAD MED, V77, P1381, DOI 10.1097/00001888-200212001-00009; SHREEVE J, 2004, GENOME WAR, P85; *USPTO, 1999, REV INT UT GUID TRAI; USPTO, 2001, UT EX GUID; 1999, NAT GENET, V21, P145	8	4	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2005	23	10					1227	1229		10.1038/nbt1005-1227	http://dx.doi.org/10.1038/nbt1005-1227			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QZ	16211059	Bronze			2022-12-25	WOS:000232469600019
J	Fleming, C; Maldjian, A; Da Costa, D; Rullay, AK; Haddleton, DM; John, JS; Penny, P; Noble, RC; Cameron, NR; Davis, BG				Fleming, C; Maldjian, A; Da Costa, D; Rullay, AK; Haddleton, DM; John, JS; Penny, P; Noble, RC; Cameron, NR; Davis, BG			A carbohydrate-antioxidant hybrid polymer reduces oxidative damage in spermatozoa and enhances fertility	NATURE CHEMICAL BIOLOGY			English	Article							MULTIVALENT LIGANDS; SPERM DNA; FERTILIZATION; ACID; GENERATION; INHIBITORS; VIABILITY; TRANSPORT; RESIDUES; DELIVERY	Gamete-gamete interactions are critically modulated by carbohydrate-protein interactions that rely on the carbohydrate-selective recognition of polyvalent carbohydrate structures(1,2). A galactose-binding protein has been identified in mammalian spermatozoa(3) that has similarity to the well-characterized hepatic asialoglycoprotein receptor(4). With the aim of exploiting the ability of this class of proteins to bind and internalize macromolecules displaying galactose, we designed hybrid carbohydrate-antioxidant polymers to deliver antioxidant vitamin E (alpha-tocopherol) to porcine spermatozoa. Treatment of sperm cells with one hybrid polymer in particular produced large increases in intracellular sperm levels of alpha-tocopherol and greatly reduced endogenous fatty acid degradation under oxidative stress. The polymer-treated spermatozoa had enhanced physiological properties and longer half-lives, which resulted in enhanced fertilization rates. Our results indicate that hybrid polymer delivery systems can prolong the functional viability of mammalian spermatozoa and improve fertility rates, and that our functionally guided optimization strategy can be applied to the discovery of active glycoconjugate ligands.	Univ Oxford, Chem Res Lab, Dept Chem, Oxford OX1 3TA, England; Univ Birmingham, Sch Med, Mitochondrial & Reprod Genet Grp, Birmingham B15 2TT, W Midlands, England; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England; JSR Healthbred, Driffield YO25 9ED, E Yorkshire, England; Univ Milan, Fac Med Vet, VSA Dept, I-20134 Milan, Italy; Univ Durham, Dept Chem, Durham DH1 3LE, England	University of Oxford; University of Birmingham; University of Warwick; University of Milan; Durham University	Davis, BG (corresponding author), Univ Oxford, Chem Res Lab, Dept Chem, Mansfield Rd, Oxford OX1 3TA, England.	n.r.cameron@durham.ac.uk; Ben.Davis@chem.ox.ac.uk	Haddleton, David M/A-6233-2009; Davis, Benjamin G/C-5281-2011; St. John, Justin C/A-2942-2010; Cameron, Neil/D-7263-2011	Davis, Benjamin G/0000-0002-5056-407X; Cameron, Neil/0000-0003-3679-7667; St. John, Jus/0000-0002-3993-1449; Haddleton, David/0000-0002-4965-0827	Biotechnology and Biological Sciences Research Council [BB/C510824/1, EGA17763] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/D023335/1, EP/D023343/1, GR/T26542/01] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		ABDULLAH M, 1991, MOL CELL BIOCHEM, V103, P155; Aitken RJ, 2002, INT J ANDROL, V25, P191, DOI 10.1046/j.1365-2605.2002.03521.x; Ambrosi M, 2005, ORG BIOMOL CHEM, V3, P1593, DOI 10.1039/b414350g; Ambrosi M, 2005, ORG BIOMOL CHEM, V3, P1476, DOI 10.1039/b411555b; Ambrosi M, 2002, J CHEM SOC PERK T 1, P45, DOI 10.1039/b108421f; Arranz-Plaza E, 2002, J AM CHEM SOC, V124, P13035, DOI 10.1021/ja020536f; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; Benoff S, 1997, MOL HUM REPROD, V3, P599, DOI 10.1093/molehr/3.7.599; British Nutrition Foundation, 1992, UNS FATT AC NUTR PHY; Cerolini S, 2000, ANIM REPROD SCI, V58, P99, DOI 10.1016/S0378-4320(99)00035-4; Choi SK, 1997, J AM CHEM SOC, V119, P4103, DOI 10.1021/ja963519x; COHN W, 1992, P NUTR SOC, V51, P179, DOI 10.1079/PNS19920028; Davis BG, 2002, CURR OPIN DRUG DISC, V5, P279; DUNCAN R, 1983, BIOCHIM BIOPHYS ACTA, V755, P518, DOI 10.1016/0304-4165(83)90258-1; Evenson DP, 2002, J ANDROL, V23, P25, DOI 10.1002/j.1939-4640.2002.tb02599.x; Fraga CG, 1996, MUTAT RES-FUND MOL M, V351, P199, DOI 10.1016/0027-5107(95)00251-0; Gabius HJ, 2004, CHEMBIOCHEM, V5, P740, DOI 10.1002/cbic.200300753; Hoyes KP, 1998, J NUCL MED, V39, P895; Ladmiral V, 2004, EUR POLYM J, V40, P431, DOI 10.1016/j.eurpolymj.2003.10.019; LEE YC, 1983, J BIOL CHEM, V258, P199; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; MILLER F, 1971, KLIC ZVIRENY CSSR, V4, P51; Morales CR, 1998, MOL REPROD DEV, V51, P156, DOI 10.1002/(SICI)1098-2795(199810)51:2&lt;156::AID-MRD5&gt;3.0.CO;2-P; Nixon B, 2001, CELLS TISSUES ORGANS, V168, P46, DOI 10.1159/000016805; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Perez-Pe R, 2002, REPRODUCTION, V123, P869, DOI 10.1530/reprod/123.6.869; Rihova B, 1998, ADV DRUG DELIVER REV, V29, P273; Ringsdorf H., 1975, J POLYM SCI POLYM S, V51, P135; Topfer-Petersen E, 1999, HUM REPROD UPDATE, V5, P314, DOI 10.1093/humupd/5.4.314; Tulsiani DRP, 2001, ZYGOTE, V9, P51, DOI 10.1017/S096719940100106X	30	57	59	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2005	1	5					270	274		10.1038/nchembio730	http://dx.doi.org/10.1038/nchembio730			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GN	16408056				2022-12-25	WOS:000232649100011
J	Frentsch, M; Arbach, O; Kirchhoff, D; Moewes, B; Worm, M; Rothe, M; Scheffold, A; Thiel, A				Frentsch, M; Arbach, O; Kirchhoff, D; Moewes, B; Worm, M; Rothe, M; Scheffold, A; Thiel, A			Direct access to CD4(+) T cells specific for defined antigens according to CD154 expression	NATURE MEDICINE			English	Article							FLOW-CYTOMETRIC METHOD; HUMAN CYTOMEGALOVIRUS; CD40 LIGAND; MOLECULES; RECEPTOR; SUPERANTIGENS; LYMPHOCYTES; INDUCTION; PROTEINS; TRAP	The direct assessment of T helper (T-H)-cell responses specific for antigens is essential to evaluate pathogenic and protective immunity. Presently, analysis and isolation of antigen-specific T-H cells is restricted to cells that produce cytokines, or can be performed only with a rare selection of specific peptide major histocompatibility complex class II (MHC II) multimers. Here we report a new method that enables the assessment and isolation of T-H cells specific for a defined antigen according to CD154 expression induced after stimulation in vitro. We show that antigen-induced CD154 expression is highly sensitive and specific for human and mouse antigen-specific T-H cells. Moreover, the isolation of antigen-specific CD154(+) T-H cells necessitates only surface staining with antibodies, thereby enabling the fast generation of antigen-specific T-H cell lines. Our approach allows assessment of T-H cells with a defined specificity for the combined quantitative and qualitative analysis of T-H-cell immunity as well as for the isolation of specific T-H cells for targeted cellular immunotherapies.	Deutsch Rheuma Forschungszentrum, Clin Immunol Grp, D-10117 Berlin, Germany; Deutsch Rheuma Forschungszentrum, Immunomodulat Grp, D-10117 Berlin, Germany; Clin Dermatol Venerol & Allergol, D-10117 Berlin, Germany	Deutsches Rheuma-Forschungszentrum (DRFZ); Deutsches Rheuma-Forschungszentrum (DRFZ)	Thiel, A (corresponding author), Deutsch Rheuma Forschungszentrum, Clin Immunol Grp, Schumannstr 21-22, D-10117 Berlin, Germany.	thiel@drfz.de	Scheffold, Alexander/S-2090-2016; Thiel, Andreas/F-1539-2013	Scheffold, Alexander/0000-0002-0626-343X; Thiel, Andreas/0000-0002-5515-4002; Worm, Margitta/0000-0002-3449-1245				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BENINGA J, 1995, J GEN VIROL, V76, P153, DOI 10.1099/0022-1317-76-1-153; Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO;2-3; Casares S, 2002, NAT IMMUNOL, V3, P383, DOI 10.1038/ni770; Casares S, 2001, PROTEIN ENG, V14, P195, DOI 10.1093/protein/14.3.195; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; Hackett CJ, 2002, NAT IMMUNOL, V3, P887, DOI 10.1038/ni1002-887; Hong SC, 1996, J EXP MED, V183, P1437, DOI 10.1084/jem.183.4.1437; Kahi S, 1998, CLIN DIAGN LAB IMMUN, V5, P745, DOI 10.1128/CDLI.5.6.745-748.1998; Lindgren H, 2001, J IMMUNOL, V166, P4578, DOI 10.4049/jimmunol.166.7.4578; Ludewig B, 1996, EUR J IMMUNOL, V26, P3137, DOI 10.1002/eji.1830261246; MAINO VC, 1995, CYTOMETRY, V20, P127, DOI 10.1002/cyto.990200205; MANZ R, 1995, P NATL ACAD SCI USA, V92, P1921, DOI 10.1073/pnas.92.6.1921; Michalek J, 2003, P NATL ACAD SCI USA, V100, P1180, DOI 10.1073/pnas.0337543100; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; STINSKI MF, 1978, J VIROL, V26, P686, DOI 10.1128/JVI.26.3.686-701.1978; Suni MA, 1998, J IMMUNOL METHODS, V212, P89, DOI 10.1016/S0022-1759(98)00004-0; Thiel A, 2004, CLIN IMMUNOL, V111, P155, DOI 10.1016/j.clim.2003.12.017; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996; YELLIN MJ, 1994, J IMMUNOL, V152, P598	26	355	374	2	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1118	1124		10.1038/nm1292	http://dx.doi.org/10.1038/nm1292			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16186818				2022-12-25	WOS:000232492500035
J	Maitra, A; Arking, DE; Shivapurkar, N; Ikeda, M; Stastny, V; Kassauei, K; Sui, GP; Cutler, DJ; Liu, Y; Brimble, SN; Noaksson, K; Hyllner, J; Schulz, TC; Zeng, XM; Freed, WJ; Crook, J; Abraham, S; Colman, A; Sartipy, P; Matsui, SI; Carpenter, M; Gazdar, AF; Rao, M; Chakravarti, A				Maitra, A; Arking, DE; Shivapurkar, N; Ikeda, M; Stastny, V; Kassauei, K; Sui, GP; Cutler, DJ; Liu, Y; Brimble, SN; Noaksson, K; Hyllner, J; Schulz, TC; Zeng, XM; Freed, WJ; Crook, J; Abraham, S; Colman, A; Sartipy, P; Matsui, SI; Carpenter, M; Gazdar, AF; Rao, M; Chakravarti, A			Genomic alterations in cultured human embryonic stem cells	NATURE GENETICS			English	Article							EPIGENETIC INACTIVATION; METHYLATION; CANCER; GENE; AMPLIFICATION; TUMORIGENESIS; MUTATIONS; PHENOTYPE; FREQUENT; TUMORS	Cultured human embryonic stem cell (hESC) lines are an invaluable resource because they provide a uniform and stable genetic system for functional analyses and therapeutic applications. Nevertheless, these dividing cells, like other cells, probably undergo spontaneous mutation at a rate of 10(-9) per nucleotide. Because each mutant has only a few progeny, the overall biological properties of the cell culture are not altered unless a mutation provides a survival or growth advantage. Clonal evolution that leads to emergence of a dominant mutant genotype may potentially affect cellular phenotype as well. We assessed the genomic fidelity of paired early- and late-passage hESC lines in the course of tissue culture. Relative to early-passage lines, eight of nine late-passage hESC lines had one or more genomic alterations commonly observed in human cancers, including aberrations in copy number (45%), mitochondrial DNA sequence (22%) and gene promoter methylation (90%), although the latter was essentially restricted to 2 of 14 promoters examined. The observation that hESC lines maintained in vitro develop genetic and epigenetic alterations implies that periodic monitoring of these lines will be required before they are used in in vivo applications and that some late-passage hESC lines may be unusable for therapeutic purposes.	Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Oncol, Baltimore, MD 21205 USA; Univ Texas, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; NIA, Neurosci Lab, Baltimore, MD 21224 USA; BresaGen Inc, Athens, GA USA; Cellartis AB, Gothenburg, Sweden; NIDA, Cellular Neurobiol Branch, Baltimore, MD USA; ES Cell Int, Singapore, Singapore; SUNY Buffalo, Roswell Pk Canc Inst, Buffalo, NY 14260 USA; Robarts Res Inst, London, ON N6A 5C1, Canada	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Dallas; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Takara Bio Inc.; Cellartis; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Western University (University of Western Ontario)	Chakravarti, A (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, 733 N Broadway Res Bldg, Baltimore, MD 21205 USA.	raomah@grc.nia.nih.gov; aravinda@jhmi.edu	Crook, Jeremy Micah/AAH-8441-2020	Crook, Jeremy Micah/0000-0002-6415-1639; Constable, Sandii/0000-0002-3809-4976	NATIONAL INSTITUTE ON AGING [ZIAAG000688, Z01AG000688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000472, Z01DA000472] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Brimble SN, 2004, STEM CELLS DEV, V13, P585, DOI 10.1089/scd.2004.13.585; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Buzzard JJ, 2004, NAT BIOTECHNOL, V22, P381, DOI 10.1038/nbt0404-381; Cutler DJ, 2001, GENOME RES, V11, P1913, DOI 10.1101/gr.197201; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hodgson JG, 2003, BREAST CANCER RES TR, V78, P337, DOI 10.1023/A:1023085825042; Huang Jing, 2004, Human Genomics, V1, P287; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504; Matsuzaki H, 2004, NAT METHODS, V1, P109, DOI 10.1038/nmeth718; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Popescu NC, 2002, J CELL MOL MED, V6, P151, DOI 10.1111/j.1582-4934.2002.tb00183.x; Reddy J, 2005, ONCOGENE, V24, P732, DOI 10.1038/sj.onc.1208032; Rosler ES, 2004, DEV DYNAM, V229, P259, DOI 10.1002/dvdy.10430; Rugg-Gunn PJ, 2005, NAT GENET, V37, P585, DOI 10.1038/ng1556; Sait SNJ, 2002, GENE CHROMOSOME CANC, V34, P42, DOI 10.1002/gcc.10038; Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041; Toyooka KO, 2002, AM J PATHOL, V161, P629, DOI 10.1016/S0002-9440(10)64218-6; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598	26	458	501	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1099	1103		10.1038/ng1631	http://dx.doi.org/10.1038/ng1631			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16142235				2022-12-25	WOS:000232185600021
J	Tian, GF; Azmi, H; Takano, T; Xu, QW; Peng, WG; Lin, J; Oberheim, N; Lou, NH; Wang, XH; Zielke, HR; Kang, J; Nedergaard, M				Tian, GF; Azmi, H; Takano, T; Xu, QW; Peng, WG; Lin, J; Oberheim, N; Lou, NH; Wang, XH; Zielke, HR; Kang, J; Nedergaard, M			An astrocytic basis of epilepsy	NATURE MEDICINE			English	Article							DEPENDENT GLUTAMATE RELEASE; FIELD BURST ACTIVITY; EPILEPTIFORM ACTIVITY; ANTIEPILEPTIC DRUGS; IN-VIVO; EXTRACELLULAR GLUTAMATE; CALCIUM-CHANNELS; MODULATION; NEURONS; BRAIN	Hypersynchronous neuronal firing is a hallmark of epilepsy, but the mechanisms underlying simultaneous activation of multiple neurons remains unknown. Epileptic discharges are in part initiated by a local depolarization shift that drives groups of neurons into synchronous bursting. In an attempt to define the cellular basis for hypersynchronous bursting activity, we studied the occurrence of paroxysmal depolarization shifts after suppressing synaptic activity using tetrodotoxin ( TTX) and voltage- gated Ca2+ channel blockers. Here we report that paroxysmal depolarization shifts can be initiated by release of glutamate from extrasynaptic sources or by photolysis of caged Ca2+ in astrocytes. Two- photon imaging of live exposed cortex showed that several antiepileptic agents, including valproate, gabapentin and phenytoin, reduced the ability of astrocytes to transmit Ca2+ signaling. Our results show an unanticipated key role for astrocytes in seizure activity. As such, these findings identify astrocytes as a proximal target for the treatment of epileptic disorders.	Univ Rochester, Med Ctr, Dept Neurosurg, Ctr Aging & Dev Biol, Rochester, NY 14642 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosurg, Newark, NJ 07103 USA; New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA; Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; New York Med Coll, Dept Cell Biol, Valhalla, NY 10595 USA	University of Rochester; Rutgers State University New Brunswick; Rutgers State University Medical Center; New York Medical College; University System of Maryland; University of Maryland Baltimore; New York Medical College	Tian, GF (corresponding author), Univ Rochester, Med Ctr, Dept Neurosurg, Ctr Aging & Dev Biol, 601 Elmwood Ave, Rochester, NY 14642 USA.	guo-feng_tian@urmc.rochester.edu		Takano, Takahiro/0000-0002-6235-6673; Wang, Xiaohai/0000-0001-5814-4072	NICHD NIH HHS [HD16596] Funding Source: Medline; NINDS NIH HHS [NS38073, R01 NS038073, NS39997, R01 NS030007, R01 NS039997, NS30007] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039997, R01NS038073, R29NS030007, R01NS030007] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Ayala GX, 2003, NEUROPHARMACOLOGY, V45, P649, DOI 10.1016/S0028-3908(03)00230-2; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Bikson M, 1999, J NEUROPHYSIOL, V82, P2262, DOI 10.1152/jn.1999.82.5.2262; Boothe DM, 1998, VET CLIN N AM-SMALL, V28, P411, DOI 10.1016/S0195-5616(98)82011-1; Carmignoto G, 1998, J NEUROSCI, V18, P4637; CONTINA ML, 2000, J NEUROSCI, V20, P2835; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Drew GM, 2004, NEUROPHARMACOLOGY, V46, P927, DOI 10.1016/j.neuropharm.2004.01.015; Duffy S, 1999, Adv Neurol, V79, P573; Elmslie KS, 2003, J BIOENERG BIOMEMBR, V35, P477, DOI 10.1023/B:JOBB.0000008021.55853.18; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Grimaldi M, 2001, J NEUROSCI, V21, P3135, DOI 10.1523/JNEUROSCI.21-09-03135.2001; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Heinemann U, 1986, Adv Neurol, V44, P641; Heinemann U, 1999, Adv Neurol, V79, P583; Hirase H, 2004, NEUROSCIENCE, V128, P209, DOI 10.1016/j.neuroscience.2004.07.002; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; Jones MS, 2002, J NEUROPHYSIOL, V88, P1016, DOI 10.1152/jn.2002.88.2.1016; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Liu QS, 2004, P NATL ACAD SCI USA, V101, P3172, DOI 10.1073/pnas.0306731101; Luhmann HJ, 2000, EUR J NEUROSCI, V12, P2757, DOI 10.1046/j.1460-9568.2000.00156.x; Meldrum BS, 1996, EPILEPSIA, V37, pS4, DOI 10.1111/j.1528-1157.1996.tb06038.x; Mena FV, 2000, J NEUROSCI RES, V60, P632, DOI 10.1002/(SICI)1097-4547(20000601)60:5<632::AID-JNR8>3.0.CO;2-3; MILES R, 1983, NATURE, V306, P371, DOI 10.1038/306371a0; NAJM IM, 2001, TREATMENT EPILEPSY P, P33; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; Nimmerjahn A, 2004, NAT METHODS, V1, P31, DOI 10.1038/nmeth706; Obrenovitch TP, 1996, J NEUROCHEM, V66, P2446; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PEREZVELAZQUEZ JL, 1994, J NEUROSCI, V14, P4308; Ransom B, 2003, TRENDS NEUROSCI, V26, P520, DOI 10.1016/j.tins.2003.08.006; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Rogawski MA, 2004, NAT MED, V10, P685, DOI 10.1038/nm1074; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Schneiderman JH, 1997, NEUROSCIENCE, V81, P1111, DOI 10.1016/S0306-4522(97)00209-1; Schuchmann S, 2002, NEUROBIOL DIS, V11, P96, DOI 10.1006/nbdi.2002.0533; Stout C, 2003, GLIA, V43, P265, DOI 10.1002/glia.10257; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Tashiro A, 2002, J NEUROBIOL, V50, P45, DOI 10.1002/neu.10019; Urenjak J, 2000, J NEUROCHEM, V75, P2427, DOI 10.1046/j.1471-4159.2000.0752427.x; VALIANTE TA, 1995, J NEUROSCI, V15, P6946; YAMAGUCHI S, 1992, EPILEPSY RES, V11, P9, DOI 10.1016/0920-1211(92)90016-M; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980	49	606	632	3	84	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2005	11	9					973	981		10.1038/nm1277	http://dx.doi.org/10.1038/nm1277			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16116433	Green Accepted			2022-12-25	WOS:000231724700025
J	Badorrek, CS; Weeks, KM				Badorrek, CS; Weeks, KM			RNA flexibility in the dimerization domain of a gamma retrovirus	NATURE CHEMICAL BIOLOGY			English	Article							MURINE LEUKEMIA-VIRUS; DIMER LINKAGE STRUCTURE; MOMULV GENOMIC RNA; NUCLEOCAPSID PROTEIN; INITIATION SITE; SARCOMA-VIRUS; SECONDARY STRUCTURE; BASE-PAIRS; SEQUENCE; SIGNAL	Retroviruses are the causative agents of serious diseases, such as acquired immunodeficiency syndromes and several cancers, and are also useful gene therapy vectors. Retroviruses contain two sense-strand RNA genomes, which become linked at their 5 ' ends to form an RNA dimer. Understanding the molecular basis for dimerization may yield new approaches for controlling viral infectivity. Because this RNA domain is highly conserved within retrovirus groups, it has not been possible to define a consensus structure for the 5 ' dimerization domain by comparative sequence analysis. Here, we defined a 170-nucleotide minimal dimerization active sequence (MiDAS) for a representative gamma retrovirus, the Moloney murine sarcoma virus, by stringent competitive dimerization. We then analyzed the structure at every nucleotide in the MiDAS monomeric starting state with quantitative selective 2 '-hydroxyl acylation analyzed by primer extension (SHAPE) chemistry. Notably, SHAPE analysis demonstrated that the RNA monomer contains an extensive flexible domain spanning 50 nucleotides. These findings support a structural model in which RNA flexibility directly facilitates retroviral genome dimerization by reducing the energetic cost of disrupting pre- existing base pairings in the monomer.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Weeks, KM (corresponding author), Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA.	weeks@unc.edu			NIGMS NIH HHS [GM64803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064803] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aagaard L, 2004, VIROLOGY, V318, P360, DOI 10.1016/j.virol.2003.09.008; Chamberlin SI, 2002, P NATL ACAD SCI USA, V99, P14688, DOI 10.1073/pnas.212527799; D'Souza V, 2004, J MOL BIOL, V337, P427, DOI 10.1016/j.jmb.2004.01.037; D'Souza V, 2001, J MOL BIOL, V314, P217, DOI 10.1006/jmbi.2001.5139; D'Souza V, 2004, NATURE, V431, P586, DOI 10.1038/nature02944; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Das R, 2005, RNA, V11, P344, DOI 10.1261/rna.7214405; De Tapia M, 1998, BIOCHEMISTRY-US, V37, P6077, DOI 10.1021/bi9800303; Dowell RD, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-71; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; GIRARD PM, 1995, BIOCHEMISTRY-US, V34, P9785, DOI 10.1021/bi00030a016; Gutell RR, 2002, CURR OPIN STRUC BIOL, V12, P301, DOI 10.1016/S0959-440X(02)00339-1; Hibbert CS, 2004, J VIROL, V78, P10927, DOI 10.1128/JVI.78.20.10927-10938.2004; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; Kim CH, 2000, P NATL ACAD SCI USA, V97, P9396, DOI 10.1073/pnas.170283697; KONINGS DAM, 1992, J VIROL, V66, P632, DOI 10.1128/JVI.66.2.632-640.1992; Laughrea M, 1997, J VIROL, V71, P3397, DOI 10.1128/JVI.71.5.3397-3406.1997; Ly H, 2002, J VIROL, V76, P3135, DOI 10.1128/JVI.76.7.3135-3144.2002; Ly H, 1999, J VIROL, V73, P7255, DOI 10.1128/JVI.73.9.7255-7261.1999; Ly H, 2000, J VIROL, V74, P9937, DOI 10.1128/JVI.74.21.9937-9945.2000; Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101; Merino EJ, 2005, J AM CHEM SOC, V127, P4223, DOI 10.1021/ja043822v; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; Mikkelsen JG, 1998, J VIROL, V72, P6967, DOI 10.1128/JVI.72.9.6967-6978.1998; Mikkelsen JG, 2000, J VIROL, V74, P600, DOI 10.1128/JVI.74.2.600-610.2000; Monie TP, 2005, BIOCHEMISTRY-US, V44, P294, DOI 10.1021/bi048529m; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; Oroudjev EM, 1999, J MOL BIOL, V291, P603, DOI 10.1006/jmbi.1999.2984; Paillart JC, 1996, BIOCHIMIE, V78, P639, DOI 10.1016/S0300-9084(96)80010-1; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; Rasmussen SV, 2002, J MOL BIOL, V323, P613, DOI 10.1016/S0022-2836(02)00966-X; REIN A, 1994, J VIROL, V68, P6124, DOI 10.1128/JVI.68.9.6124-6129.1994; TOUNEKTI N, 1992, J MOL BIOL, V223, P205, DOI 10.1016/0022-2836(92)90726-Z; Wild K, 1999, STRUCTURE, V7, P1345, DOI 10.1016/S0969-2126(00)80024-6; Wilkinson KA, 2005, J AM CHEM SOC, V127, P4659, DOI 10.1021/ja0436749	35	35	39	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2005	1	2					104	111		10.1038/nchembio712	http://dx.doi.org/10.1038/nchembio712			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GE	16408007				2022-12-25	WOS:000232648200015
J	Li, J; Lee, WL; Cooper, JA				Li, J; Lee, WL; Cooper, JA			NudEL targets dynein to microtubule ends through LIS1	NATURE CELL BIOLOGY			English	Letter							ASPERGILLUS-NIDULANS; CYTOPLASMIC DYNEIN; SACCHAROMYCES-CEREVISIAE; LISSENCEPHALY GENE; NUCLEAR MIGRATION; PROTEIN; ACETYLHYDROLASE; LOCALIZATION; ACTIVATION; SUBUNIT	Dynein is a minus- end- directed microtubule motor with critical roles in mitosis, membrane transport and intracellular transport. Several proteins regulate dynein activity, including dynactin(1), LIS1 ( refs 2, 3) and NudEL ( NudE- like)(2,4 - 8). Here, we identify a NUDEL homologue in budding yeast and name it Ndl1. The ndl1 Delta. null mutant shows decreased targeting of dynein to microtubule plus ends, an essential element of the model for dynein function. We find that Ndl1 regulates dynein targeting through LIS1, with which it interacts biochemically, but not through CLIP170, another plus- end protein involved in dynein targeting(9). Ndl1 is found at far fewer microtubule ends than are LIS1 and dynein. However, when Ndl1 is present at a plus end, the molar amount of Ndl1 approaches that of LIS1 and dynein. We propose a model in which Ndl1 binds transiently to the plus end to promote targeting of LIS1, which cooperatively recruits dynein.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Cooper, JA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, POB 8228, St Louis, MO 63110 USA.	jcooper@wustl.edu	Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Cooper, John/0000-0002-0933-4571	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047337] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47337, R01 GM047337] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Carvalho P, 2004, DEV CELL, V6, P815, DOI 10.1016/j.devcel.2004.05.001; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; Efimov VP, 2003, MOL BIOL CELL, V14, P871, DOI 10.1091/mbc.E02-06-0359; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2004, NEURON, V44, P279, DOI 10.1016/j.neuron.2004.09.023; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Kaiser C., 1994, METHODS YEAST GENETI; Lee WL, 2005, J CELL BIOL, V168, P201, DOI 10.1083/jcb.200407036; Lee WL, 2003, J CELL BIOL, V160, P355, DOI 10.1083/jcb.200209022; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Sheeman B, 2003, CURR BIOL, V13, P364, DOI 10.1016/S0960-9822(03)00013-7; Shu TZ, 2004, NEURON, V44, P263, DOI 10.1016/j.neuron.2004.09.030; Sweeney KJ, 2001, MECH DEVELOP, V101, P21, DOI 10.1016/S0925-4773(00)00543-8; Tarricone C, 2004, NEURON, V44, P809, DOI 10.1016/S0896-6273(04)00751-2; Vallee RB, 2001, TRENDS CELL BIOL, V11, P155, DOI 10.1016/S0962-8924(01)01956-0; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297	24	81	90	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2005	7	7					686	U68		10.1038/ncb1273	http://dx.doi.org/10.1038/ncb1273			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	941BX	15965467	Green Accepted			2022-12-25	WOS:000230190800012
J	Okada, M; Sato, I; Cho, SJ; Iwata, H; Nishio, T; Dubnau, D; Sakagami, Y				Okada, M; Sato, I; Cho, SJ; Iwata, H; Nishio, T; Dubnau, D; Sakagami, Y			Structure of the Bacillus subtilis quorum-sensing peptide pheromone ComX	NATURE CHEMICAL BIOLOGY			English	Article							SPECIFICITY	The ComX pheromone is an extracellular signaling molecule that stimulates natural competence in response to crowding in the Gram-positive bacterium Bacillus subtilis. The pheromone is formed by isoprenylation of an inactive precursor peptide, but its precise structure is not known. Here we report the structure of the ComX pheromone, showing that addition of a geranyl group to a tryptophan residue results in the formation of an unusual ring structure.	Publ Hlth Res Inst, Newark, NJ 07103 USA; Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan	Nagoya University	Dubnau, D (corresponding author), Publ Hlth Res Inst, 225 Warren St, Newark, NJ 07103 USA.	dubnau@phri.org; ysaka@agr.nagoya-u.ac.jp	Iwata, Hidehisa/K-7493-2019	Iwata, Hidehisa/0000-0002-0950-6388	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057720] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM057720, GM57720] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ansaldi M, 2004, J BACTERIOL, V186, P15, DOI 10.1128/JB.186.1.15-21.2004; Ansaldi M, 2002, MOL MICROBIOL, V44, P1561, DOI 10.1046/j.1365-2958.2002.02977.x; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; MAGNUSON R, 1994, CELL, V77, P207, DOI 10.1016/0092-8674(94)90313-1; Okada M, 2004, BIOSCI BIOTECH BIOCH, V68, P2374, DOI 10.1271/bbb.68.2374; Piazza F, 1999, J BACTERIOL, V181, P4540, DOI 10.1128/JB.181.15.4540-4548.1999; SAKAGAMI Y, 1981, SCIENCE, V212, P1525, DOI 10.1126/science.212.4502.1525; Schneider KB, 2002, J BACTERIOL, V184, P410, DOI 10.1128/JB.184.2.410-419.2002; Tortosa P, 2001, J BACTERIOL, V183, P451, DOI 10.1128/JB.183.2.451-460.2001	9	109	118	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2005	1	1					23	24		10.1038/nchembio709	http://dx.doi.org/10.1038/nchembio709			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	974WC	16407988				2022-12-25	WOS:000232621100007
J	Feyerabend, TB; Li, JP; Lindahl, U; Rodewald, HR				Feyerabend, TB; Li, JP; Lindahl, U; Rodewald, HR			Heparan sulfate C5-epimerase is essential for heparin biosynthesis in mast cells	NATURE CHEMICAL BIOLOGY			English	Article							ACID	Biosynthesis of heparin, a mast cell-derived glycosaminoglycan with widespread importance in medicine, has not been fully elucidated. In biosynthesis of heparan sulfate (HS), a structurally related polysaccharide, HS glucuronyl C5-epimerase (Hsepi) converts D-glucuronic acid (GlcA) to L-iduronic acid (IdoA) residues. We have generated Hsepi-null mouse mutant mast cells, and we show that the same enzyme catalyzes the generation of IdoA in heparin and that 'heparin' lacking IdoA shows a distorted O-sulfation pattern.	Univ Uppsala, Dept Med Biochem & Microbiol, Biomed Ctr, SE-75123 Uppsala, Sweden; Univ Ulm, Dept Immunol, D-89070 Ulm, Germany	Uppsala University; Ulm University	Li, JP (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, Biomed Ctr, Box 582, SE-75123 Uppsala, Sweden.	jin-ping.li@imbim.uu.se; hans-reimer.rodewald@uni-ulm.de						Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Kolset SO, 2004, BIOCHEM J, V379, P217, DOI 10.1042/BJ20031230; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Yamada N, 2003, J INVEST DERMATOL, V121, P1425, DOI 10.1046/j.1523-1747.2003.12613.x	7	38	41	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	APR	2006	2	4					195	196		10.1038/nchembio777	http://dx.doi.org/10.1038/nchembio777			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	023QU	16532012				2022-12-25	WOS:000236142100010
J	Sirbu, IO; Duester, G				Sirbu, IO; Duester, G			Retinoic-acid signalling in node ectoderm and posterior neural plate directs left-right patterning of somitic mesoderm	NATURE CELL BIOLOGY			English	Article							SEGMENTATION CLOCK; BINDING-PROTEINS; MOUSE; SOMITOGENESIS; TRANSCRIPTION; EXPRESSION; RALDH2; FGF; MORPHOGENESIS; ACTIVATION	Somitogenesis requires bilateral rhythmic segmentation of paraxial mesoderm along the antero-posterior axis(1). The location of somite segmentation depends on opposing signalling gradients of retinoic acid (generated by retinaldehyde dehydrogenase-2; Raldh2) anteriorly and fibroblast growth factor (FGF; generated by Fgf8) posteriorly(2,3). Retinoic-acid-deficient embryos exhibit somite left-right asymmetry(4-6), but it remains unclear how retinoic acid mediates left-right patterning. Here, we demonstrate that retinoic-acid signalling is uniform across the left-right axis and occurs in node ectoderm but not node mesoderm. In Raldh2(-/-) mouse embryos, ectodermal Fgf8 expression encroaches anteriorly into node ectoderm and neural plate, but its expression in presomitic mesoderm is initially unchanged. The late stages of somitogenesis were rescued in Raldh2(-/-) mouse embryos when the maternal diet was supplemented with retinoic acid until only the 6-somite stage, demonstrating that retinoic acid is only needed during node stages. A retinoic-acid-reporter transgene marking the action of maternal retinoic acid in rescued Raldh2(-/-) embryos revealed that the targets of retinoic-acid signalling during somitogenesis are the node ectoderm and the posterior neural plate, not the presomitic mesoderm. Our findings suggest that antagonism of Fgf8 expression by retinoic acid occurs in the ectoderm and that failure of this mechanism generates excessive FGF8 signalling to adjacent mesoderm, resulting initially in smaller somites and then left-right asymmetry.	Burnham Inst Med Res, OncoDev Biol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Duester, G (corresponding author), Burnham Inst Med Res, OncoDev Biol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	duester@burnham.org	Sirbu, Ioan Ovidiu/AAP-1290-2021; Sirbu, Ioan Ovidiu/F-1841-2010	Sirbu, Ioan Ovidiu/0000-0003-1618-9656; Sirbu, Ioan Ovidiu/0000-0003-1618-9656; Duester, Gregg/0000-0003-4335-3650	NIGMS NIH HHS [R01 GM062848, GM62848, R01 GM062848-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062848] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aulehla A, 2004, GENE DEV, V18, P2060, DOI 10.1101/gad.1217404; Bussen M, 2004, GENE DEV, V18, P1209, DOI 10.1101/gad.300104; Diez del Corral R, 2003, NEURON, V40, P65; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Kawakami Y, 2005, NATURE, V435, P165, DOI 10.1038/nature03512; Kim SH, 1998, DEVELOPMENT, V125, P4681; MacLean G, 2001, MECH DEVELOP, V107, P195, DOI 10.1016/S0925-4773(01)00463-4; Mansouri A, 1997, DEV DYNAM, V210, P53, DOI 10.1002/(SICI)1097-0177(199709)210:1<53::AID-AJA6>3.0.CO;2-0; Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403; Mic FA, 2002, DEVELOPMENT, V129, P2271; Mic FA, 2003, P NATL ACAD SCI USA, V100, P7135, DOI 10.1073/pnas.1231422100; Molotkov A, 2005, DEV DYNAM, V232, P950, DOI 10.1002/dvdy.20256; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Molotkova N, 2005, MECH DEVELOP, V122, P145, DOI 10.1016/j.mod.2004.10.008; Moreno TA, 2004, DEV CELL, V6, P205, DOI 10.1016/S1534-5807(04)00026-7; Morimoto M, 2005, NATURE, V435, P354, DOI 10.1038/nature03591; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 2001, DEVELOPMENT, V128, P1019; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Perantoni AO, 2005, DEVELOPMENT, V132, P3859, DOI 10.1242/dev.01945; Pourquie O, 2003, SCIENCE, V301, P328, DOI 10.1126/science.1085887; QIU YH, 1994, TRENDS ENDOCRIN MET, V5, P234, DOI 10.1016/1043-2760(94)P3081-H; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Sirbu IO, 2005, DEVELOPMENT, V132, P2611, DOI 10.1242/dev.01845; Tanaka Y, 2005, NATURE, V435, P172, DOI 10.1038/nature03494; Vermot J, 2005, SCIENCE, V308, P563, DOI 10.1126/science.1108363; Vermot J, 2005, NATURE, V435, P215, DOI 10.1038/nature03488	28	126	132	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2006	8	3					271	277		10.1038/ncb1374	http://dx.doi.org/10.1038/ncb1374			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	017QL	16489341	Green Accepted			2022-12-25	WOS:000235708000013
J	Ikeda, Y; Dick, KA; Weatherspoon, MR; Gincel, D; Armbrust, KR; Dalton, JC; Stevanin, G; Durr, A; Zuhlke, C; Burk, K; Clark, HB; Brice, A; Rothstein, JD; Schut, LJ; Day, JW; Ranum, LPW				Ikeda, Y; Dick, KA; Weatherspoon, MR; Gincel, D; Armbrust, KR; Dalton, JC; Stevanin, G; Durr, A; Zuhlke, C; Burk, K; Clark, HB; Brice, A; Rothstein, JD; Schut, LJ; Day, JW; Ranum, LPW			Spectrin mutations cause spinocerebellar ataxia type 5	NATURE GENETICS			English	Article							GLUTAMATE-RECEPTOR GENE; PURKINJE-CELLS; TRANSPORT; DISEASE; PATHOGENESIS; MEMBRANE; DYNACTIN; FEATURES; LURCHER; NEURONS	We have discovered that beta-III spectrin (SPTBN2) mutations cause spinocerebellar ataxia type 5 (SCA5) in an 11-generation American kindred descended from President Lincoln's grandparents and two additional families. Two families have separate in-frame deletions of 39 and 15 bp, and a third family has a mutation in the actin/ARP1 binding region. beta-III spectrin is highly expressed in Purkinje cells and has been shown to stabilize the glutamate transporter EAAT4 at the surface of the plasma membrane. We found marked differences in EAAT4 and GluR delta 2 by protein blot and cell fractionation in SCA5 autopsy tissue. Cell culture studies demonstrate that wild-type but not mutant beta-III spectrin stabilizes EAAT4 at the plasma membrane. Spectrin mutations are a previously unknown cause of ataxia and neurodegenerative disease that affect membrane proteins involved in glutamate signaling.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Johns Hopkins Univ, Dept Neurol & Neurosci, Baltimore, MD 21287 USA; Univ Paris 06, INSERM, UMR679, F-75013 Paris, France; Hop La Pitie Salpetriere, Dept Genet Cytogenet & Embryol, AP HP, F-75013 Paris, France; Med Univ Lubeck, Inst Human Genet, D-23538 Lubeck, Germany; Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Centra Care Clin, St Cloud, MN 56303 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Lubeck; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Ranum, LPW (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, 321 Church St SE, Minneapolis, MN 55455 USA.	ranum001@umn.edu	rothstein, jeffrey d/C-9470-2013; Stevanin, Giovanni/E-5038-2016; Brice, Alexis/A-2170-2009; brice, alexis/AAE-8275-2019	Stevanin, Giovanni/0000-0001-9368-8657; brice, alexis/0000-0002-0941-3990; Day, John/0000-0002-0086-9529; Armbrust, Karen/0000-0001-9381-4756				Burk K, 2004, NEUROLOGY, V62, P327, DOI 10.1212/01.WNL.0000103293.63340.C1; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gold DA, 2003, NEURON, V40, P1119, DOI 10.1016/S0896-6273(03)00769-4; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Holleran EA, 2001, J BIOL CHEM, V276, P36598, DOI 10.1074/jbc.M104838200; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Knight MA, 2004, BRAIN, V127, P1172, DOI 10.1093/brain/awh139; KRAWCZAK M, 1991, HUM GENET, V86, P425; Lalouette A, 1998, GENOMICS, V50, P9, DOI 10.1006/geno.1998.5314; Lee SH, 2001, NEUROPHARMACOLOGY, V41, P680, DOI 10.1016/S0028-3908(01)00124-1; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Liquori C, 2002, CEREBELLUM ITS DISOR, P445; MCKUSICK VA, 1991, NATURE, V352, P279, DOI 10.1038/352279a0; Ohara O, 1998, MOL BRAIN RES, V57, P181, DOI 10.1016/S0169-328X(98)00068-0; PAPADOPOULOS N, 1995, NAT GENET, V11, P99, DOI 10.1038/ng0995-99; PARK EC, 1986, GENETICS, V113, P821; Parkinson NJ, 2001, NAT GENET, V29, P61, DOI 10.1038/ng710; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Raiteri L, 2002, PROG NEUROBIOL, V68, P287, DOI 10.1016/S0301-0082(02)00059-X; RANUM LPW, 1994, NAT GENET, V8, P280, DOI 10.1038/ng1194-280; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; Serra HG, 2004, HUM MOL GENET, V13, P2535, DOI 10.1093/hmg/ddh268; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; Stevanin G, 2004, ANN NEUROL, V55, P97, DOI 10.1002/ana.10798; Stevanin G, 1999, NEUROLOGY, V53, P1355, DOI 10.1212/WNL.53.6.1355; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Welsh JP, 2002, ADV NEUROL, V89, P331; Worth PF, 1999, AM J HUM GENET, V65, P420, DOI 10.1086/302495; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	30	252	264	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					184	190		10.1038/ng1728	http://dx.doi.org/10.1038/ng1728			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16429157				2022-12-25	WOS:000234953200012
J	Luders, J; Patel, UK; Stearns, T				Luders, J; Patel, UK; Stearns, T			GCP-WD is a gamma-tubulin targeting factor required for centrosomal and chromatin-mediated microtubule nucleation	NATURE CELL BIOLOGY			English	Article							SMALL GTPASE RAN; RING COMPLEX; MINUS-END; KINETOCHORE MICROTUBULES; CAENORHABDITIS-ELEGANS; SPINDLE MICROTUBULES; ORGANIZING CENTERS; MITOTIC SPINDLE; CELL-CYCLE; PROTEIN	The gamma-tubulin ring complex (gamma TuRC) is a large multi-protein complex that is required for microtubule nucleation from the centrosome. Here, we show that the GCP-WD protein ( originally named NEDD1) is the orthologue of the Drosophila Dgrip71WD protein, and is a subunit of the human gamma TuRC. GCP- WD has the properties of an attachment factor for the gamma TuRC: depletion or inhibition of GCP-WD results in loss of the gamma TuRC from the centrosome, abolishing centrosomal microtubule nucleation, although the gamma TuRC is intact and able to bind to microtubules. GCP-WD depletion also blocks mitotic chromatin-mediated microtubule nucleation, resulting in failure of spindle assembly. Mitotic phosphorylation of GCP-WD is required for association of gamma-tubulin with the spindle, separately from association with the centrosome. Our results indicate that GCP-WD broadly mediates targeting of the gamma TuRC to sites of microtubule nucleation and to the mitotic spindle, which is essential for spindle formation.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Stearns, T (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	stearns@stanford.edu	Lüders, Jens/H-2812-2015	Lüders, Jens/0000-0002-9018-7977; Stearns, Tim/0000-0002-0671-6582	NIGMS NIH HHS [GM52022] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bugnard E, 2005, CELL MOTIL CYTOSKEL, V60, P1, DOI 10.1002/cm.20042; Buster D, 2002, J CELL SCI, V115, P1083; CZABAN BB, 1985, J CELL SCI, V79, P1; Dammermann A, 2003, CURR BIOL, V13, pR614, DOI 10.1016/S0960-9822(03)00530-X; DEBRABANDER M, 1981, CELL MOTIL CYTOSKEL, V1, P469, DOI 10.1002/cm.970010407; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; Fava F, 1999, J CELL BIOL, V147, P857, DOI 10.1083/jcb.147.4.857; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Groen AC, 2004, CURR BIOL, V14, P1801, DOI 10.1016/j.cub.2004.10.002; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Gunawardane RN, 2003, MOL BIOL CELL, V14, P1017, DOI 10.1091/mbc.E02-01-0034; Gunawardane RN, 2000, J CELL BIOL, V151, P1513, DOI 10.1083/jcb.151.7.1513; Hannak E, 2002, J CELL BIOL, V157, P591, DOI 10.1083/jcb.200202047; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Jeng R, 1999, TRENDS CELL BIOL, V9, P339, DOI 10.1016/S0962-8924(99)01621-9; Jorde W, 2001, ALLERGOLOGIE, V24, P596; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Khodjakov A, 1999, J CELL BIOL, V146, P585, DOI 10.1083/jcb.146.3.585; KUMAR S, 1994, J BIOL CHEM, V269, P11318; LAJOIEMAZENC I, 1994, J CELL SCI, V107, P2825; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LI QQ, 1995, J CELL BIOL, V131, P207, DOI 10.1083/jcb.131.1.207; LIU B, 1993, J CELL SCI, V104, P1217; MASTRONARDE DN, 1993, J CELL BIOL, V123, P1475, DOI 10.1083/jcb.123.6.1475; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Murphy SM, 2001, MOL BIOL CELL, V12, P3340, DOI 10.1091/mbc.12.11.3340; Murphy SM, 1998, J CELL BIOL, V141, P663, DOI 10.1083/jcb.141.3.663; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; TAKAI S, 1995, HUM GENET, V95, P96; Tassin AM, 1998, J CELL BIOL, V141, P689, DOI 10.1083/jcb.141.3.689; TASSIN AM, 1985, J CELL BIOL, V100, P35, DOI 10.1083/jcb.100.1.35; Vaughn KC, 1998, INT REV CYTOL, V181, P75, DOI 10.1016/S0074-7696(08)60417-9; Wiese C, 2000, NAT CELL BIOL, V2, P358, DOI 10.1038/35014051; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; WITT PL, 1980, CHROMOSOMA, V81, P483, DOI 10.1007/BF00368158; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0; Zimmerman WC, 2004, MOL BIOL CELL, V15, P3642, DOI 10.1091/mbc.E03-11-0796	42	247	249	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2006	8	2					137	U10		10.1038/ncb1349	http://dx.doi.org/10.1038/ncb1349			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	008SA	16378099				2022-12-25	WOS:000235059800008
J	Stockwell, BR				Stockwell, BR			Preventing protein secretion with chemical glue	NATURE CHEMICAL BIOLOGY			English	News Item							MOLECULES	A small-molecule inhibitor of protein secretion has been found that targets Cdc42, a regulator of the secretory pathway. This compound acts through a previously undescribed mechanism-by recruiting a protein inhibitor.	Columbia Univ, Dept Biol Sci, Fairchildr Ctr MC2406, New York, NY 10027 USA	Columbia University	Stockwell, BR (corresponding author), Columbia Univ, Dept Biol Sci, Fairchildr Ctr MC2406, MC2406,1212 Amsterdam Ave, New York, NY 10027 USA.	stockwell@biology.columbia.edu	Stockwell, Brent R/AAE-7200-2019	Stockwell, Brent R/0000-0002-3532-3868				Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Gane PJ, 2000, CURR OPIN STRUC BIOL, V10, P401, DOI 10.1016/S0959-440X(00)00105-6; Pelish HE, 2006, NAT CHEM BIOL, V2, P221, DOI 10.1038/nchembio0406-221b; Pelish HE, 2001, J AM CHEM SOC, V123, P6740, DOI 10.1021/ja016093h; Stockwell BR, 2004, NATURE, V432, P846, DOI 10.1038/nature03196; Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001	6	1	1	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2006	2	1					7	8		10.1038/nchembio0106-7	http://dx.doi.org/10.1038/nchembio0106-7			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993RC	16408080				2022-12-25	WOS:000233971600003
J	Gupta, PB; Kuperwasser, C; Brunet, JP; Ramaswamy, S; Kuo, WL; Gray, JW; Naber, SP; Weinberg, RA				Gupta, PB; Kuperwasser, C; Brunet, JP; Ramaswamy, S; Kuo, WL; Gray, JW; Naber, SP; Weinberg, RA			The melanocyte differentiation program predisposes to metastasis after neoplastic transformation	NATURE GENETICS			English	Article							TYROSINE KINASE RECEPTOR; NEURAL CREST; MALIGNANT-MELANOMA; LESS-THAN-OR-EQUAL-TO-1 MM; TUMOR PROGRESSION; EPITHELIAL-CELLS; NERVOUS-SYSTEM; BREAST-CANCER; GENE-TRANSFER; LYMPH-NODES	The aggressive clinical behavior of melanoma suggests that the developmental origins of melanocytes in the neural crest might be relevant to their metastatic propensity. Here we show that primary human melanocytes, transformed using a specific set of introduced genes, form melanomas that frequently metastasize to multiple secondary sites, whereas human fibroblasts and epithelial cells transformed using an identical set of genes generate primary tumors that rarely do so. Notably, these melanomas have a metastasis spectrum similar to that observed in humans with melanoma. These observations indicate that part of the metastatic proclivity of melanoma is attributable to lineage-specific factors expressed in melanocytes and not in other cell types analyzed. Analysis of microarray data from human nevi shows that the expression pattern of Slug, a master regulator of neural crest cell specification and migration, correlates with those of other genes that are important for neural crest cell migrations during development. Moreover, Slug is required for the metastasis of the transformed melanoma cells. These findings indicate that melanocyte-specific factors present before neoplastic transformation can have a pivotal role in governing melanoma progression.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Cambridge, MA 02142 USA; Tufts Univ, Sch Med, New England Med Ctr, Dept Anat & Cellular Biol, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; MIT, Broad Inst, Cambridge, MA 02141 USA; Harvard Univ, Broad Inst, Cambridge, MA 02141 USA; Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Tufts Univ, Sch Med, New England Med Ctr, Dept Pathol, Boston, MA 02111 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Tufts Medical Center; Tufts University	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	weinberg@wi.mit.edu			NCI NIH HHS [R01 CA078461] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078461] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartkova J, 1996, CANCER RES, V56, P5475; Beddingfield FC, 2003, ONCOLOGIST, V8, P459, DOI 10.1634/theoncologist.8-5-459; Bedrosian I, 2000, ANN SURG ONCOL, V7, P262, DOI 10.1007/s10434-000-0262-z; BORTOLANI A, 1994, ANN PLAS SURG, V33, P426, DOI 10.1097/00000637-199410000-00013; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Bronner-Fraser Marianne, 1993, Trends in Cell Biology, V3, P392, DOI 10.1016/0962-8924(93)90089-J; Carl TF, 1999, DEV BIOL, V213, P101, DOI 10.1006/dbio.1999.9320; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Corsetti RL, 2000, ANN SURG ONCOL, V7, P456, DOI 10.1007/s10434-000-0456-4; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Cruz J, 2003, ONCOLOGY-BASEL, V65, P72, DOI 10.1159/000071207; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Elsayed AM, 1996, AM J GASTROENTEROL, V91, P1001; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hajra KM, 2002, CANCER RES, V62, P1613; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Ikeda K, 1996, NEUROREPORT, V7, P1713; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; JOHNSON WT, 1969, CANCER, V23, P747, DOI 10.1002/1097-0142(196903)23:3<747::AID-CNCR2820230331>3.0.CO;2-9; Kuperwasser C, 2000, CANCER RES, V60, P2723; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; Lee HO, 2003, DEV BIOL, V259, P162, DOI 10.1016/S0012-1606(03)00160-X; Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; NESBIT M, 1998, CUTANEOUS MELANOMA, P463; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Petersen SL, 1996, ENDOCRINOLOGY, V137, P234, DOI 10.1210/en.137.1.234; PHILLIPS DL, 1987, J CLIN GASTROENTEROL, V9, P563, DOI 10.1097/00004836-198710000-00017; Rich JN, 2001, CANCER RES, V61, P3556; SHAW HM, 1987, ARCH SURG-CHICAGO, V122, P1147; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; SUBRAMONY C, 1985, AM J CLIN PATHOL, V84, P220, DOI 10.1093/ajcp/84.2.220; Tietze MK, 2000, MOL MED TODAY, V6, P408, DOI 10.1016/S1357-4310(00)01781-0	42	359	363	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1047	1054		10.1038/ng1634	http://dx.doi.org/10.1038/ng1634			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16142232	Green Accepted			2022-12-25	WOS:000232185600015
J	Xu, SZ; Zeng, F; Lei, M; Li, J; Gao, B; Xiong, CL; Sivaprasadarao, A; Beech, DJ				Xu, SZ; Zeng, F; Lei, M; Li, J; Gao, B; Xiong, CL; Sivaprasadarao, A; Beech, DJ			Generation of functional ion-channel tools by E3 targeting	NATURE BIOTECHNOLOGY			English	Article							ARTERIOLAR SMOOTH-MUSCLE; GATED SODIUM-CHANNELS; POTASSIUM CHANNELS; K+ CHANNELS; CA2+ ENTRY; ANTIBODY; CANCER; RECEPTOR; THERAPY; TRPC5	Here we describe a strategy for generating ion-channel inhibitors. It takes advantage of antibody specificity combined with a pattern recognition approach that targets the third extracellular region (E3) of a channel. To test the concept, we first focused on TRPC5, a member of the transient receptor potential ( TRP) calcium channel family, the study of which has been hindered by poor pharmacological tools. Extracellular application of E3-targeted anti-TRPC5 antibody led to a specific TRPC5 inhibitor, enabling TRPC5 to be distinguished from its closest family members, and TRPC5 function to be explored in a relatively intractable physiological system. E3 targeting was further applied to voltage-gated sodium channels, leading to discovery of a subtype-specific inhibitor of Na(v)1.5. These examples illustrate the potential power of E3 targeting as a systematic method for producing gene-type specific ion-channel inhibitors for use in routine assays on cells or tissues from a range of species and having therapeutic potential.	Univ Leeds, Membrane & Syst Biol Res Inst, Leeds LS2 9JT, W Yorkshire, England; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; UCL, Inst Child Hlth, Rheumatol Unit, London WC1N 1EH, England; Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan 430022, Peoples R China	University of Leeds; University of Oxford; University of London; University College London; Huazhong University of Science & Technology	Beech, DJ (corresponding author), Univ Leeds, Membrane & Syst Biol Res Inst, Leeds LS2 9JT, W Yorkshire, England.	d.j.beech@leeds.ac.uk	Lei, Ming/G-3686-2011; Xu, Shang-Zhong/P-2807-2015	Xu, Shang-Zhong/0000-0002-7295-9347; Beech, David/0000-0002-7683-9422; Sivaprasadarao, Asipu/0000-0002-6755-3502	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200; Alexander SPH, 2004, BRIT J PHARMACOL, V141, pS1; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Catterall WA, 2003, PHARMACOL REV, V55, P575, DOI 10.1124/pr.55.4.7; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Dumoulin M, 2003, NATURE, V424, P783, DOI 10.1038/nature01870; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Flemming R, 2003, BRIT J PHARMACOL, V139, P955, DOI 10.1038/sj.bjp.0705327; Flemming R, 2002, J PHYSIOL-LONDON, V543, P455, DOI 10.1113/jphysiol.2002.023366; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Grunwald V, 2003, JNCI-J NATL CANCER I, V95, P851, DOI 10.1093/jnci/95.12.851; Harris M, 2004, LANCET ONCOL, V5, P292, DOI 10.1016/S1470-2045(04)01467-6; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li RA, 2004, TOXICON, V44, P117, DOI 10.1016/j.toxicon.2004.03.028; Mak TW, 2001, NAT REV IMMUNOL, V1, P11, DOI 10.1038/35095551; MEIRI H, 1989, METHOD ENZYMOL, V178, P714; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P17533, DOI 10.1073/pnas.0403711101; Ong ACM, 2003, LANCET, V361, P774, DOI 10.1016/S0140-6736(03)12662-1; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rogawski MA, 2000, TRENDS NEUROSCI, V23, P393, DOI 10.1016/S0166-2236(00)01629-5; Roque ACA, 2004, BIOTECHNOL PROGR, V20, P639, DOI 10.1021/bp030070k; Rosado JA, 2002, J BIOL CHEM, V277, P42157, DOI 10.1074/jbc.M207320200; Salfeld JG, 2004, BEST PRACT RES CL RH, V18, P81, DOI 10.1016/j.berh.2003.10.001; Sanz L, 2004, TRENDS IMMUNOL, V25, P85, DOI 10.1016/j.it.2003.12.001; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Triggle DJ, 2003, ASSAY DRUG DEV TECHN, V1, P719, DOI 10.1089/154065803770381075; Tsavaler L, 2001, CANCER RES, V61, P3760; Utku N, 1998, IMMUNITY, V9, P509, DOI 10.1016/S1074-7613(00)80634-2; Vandenberg JI, 2001, TRENDS PHARMACOL SCI, V22, P240, DOI 10.1016/S0165-6147(00)01662-X; Vennekamp J, 2004, MOL PHARMACOL, V65, P1364, DOI 10.1124/mol.65.6.1364; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wehrens XHT, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9136; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wood JN, 2004, J NEUROBIOL, V61, P55, DOI 10.1002/neu.20094; Wyatt CN, 1997, J PHYSIOL-LONDON, V502, P307, DOI 10.1111/j.1469-7793.1997.307bk.x; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Zan YH, 2003, NAT BIOTECHNOL, V21, P645, DOI 10.1038/nbt830; Zeng FN, 2004, J PHYSIOL-LONDON, V559, P739, DOI 10.1113/jphysiol.2004.065391; Zhou BY, 1998, J GEN PHYSIOL, V111, P555, DOI 10.1085/jgp.111.4.555	41	98	110	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2005	23	10					1289	1293		10.1038/nbt1148	http://dx.doi.org/10.1038/nbt1148			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QZ	16170312				2022-12-25	WOS:000232469600031
J	del Pozo, MA; Balasubramanian, N; Alderson, NB; Kiosses, WB; Grande-Garcia, A; Anderson, RGW; Schwartz, MA				del Pozo, MA; Balasubramanian, N; Alderson, NB; Kiosses, WB; Grande-Garcia, A; Anderson, RGW; Schwartz, MA			Phospho-caveolin-1 mediates integrin-regulated membrane domain internalization	NATURE CELL BIOLOGY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; CAVEOLIN-1-NULL MICE; BREAST-CANCER; IN-VIVO; CELLS; RAC; PHOSPHORYLATION; INVASIVENESS; TRAFFICKING; HYPERPLASIA	Growth of normal cells is anchorage dependent because signalling through multiple pathways including Erk, phosphatidylinositol- 3- OH kinase ( PI( 3) K) and Rac requires integrin- mediated cell adhesion(1). Components of these pathways localize to low- density, cholesterol- rich domains in the plasma membrane named ' lipid rafts'(2,3) or 'cholesterol-enriched membrane microdomains' ( CEMM)(4). We previously reported that integrin- mediated adhesion regulates CEMM transport such that cell detachment from the extracellular matrix triggers CEMM internalization and clearance from the plasma membrane(5). We now report that this internalization is mediated by dynamin- 2 and caveolin- 1. Internalization requires phosphorylation of caveolin- 1 on Tyr 14. A shift in localization of phospho- caveolin- 1 from focal adhesions to caveolae induces CEMM internalization upon cell detachment, which mediates inhibition of Erk, PI( 3) K and Rac. These data define a novel molecular mechanism for growth and tumour suppression by caveolin- 1.	CNIC, Madrid 28029, Spain; Univ Virginia, Mellon Prostate Canc Res Inst, Dept Microbiol & Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Scripps Res Inst, Microscopy Facil, La Jolla, CA 92037 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA	Centro Nacional de Investigaciones Cardiovasculares (CNIC); University of Virginia; University of Virginia; Scripps Research Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	del Pozo, MA (corresponding author), CNIC, Madrid 28029, Spain.	madelpozo@cnic.es	Grande-García, Araceli/ABH-3169-2020; del Pozo, Miguel Angel/L-2861-2014	Grande-García, Araceli/0000-0003-2619-5013; del Pozo, Miguel Angel/0000-0001-9077-391X; Balasubramanian, Nagaraj/0000-0002-8219-8844; schwartz, martin/0000-0002-2071-1243	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM47214, R01 GM047214] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652; Boyd ND, 2003, BIOCHEM CELL BIOL, V81, P335, DOI 10.1139/O03-063; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0; Damm EM, 2005, J CELL BIOL, V168, P477, DOI 10.1083/jcb.200407113; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fielding CJ, 2001, ADV DRUG DELIVER REV, V49, P251, DOI 10.1016/S0169-409X(01)00140-5; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Grande-Garcia A, 2005, BIOCHEM SOC T, V33, P609, DOI 10.1042/BST0330609; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Lagerholm BC, 2005, ANNU REV PHYS CHEM, V56, P309, DOI 10.1146/annurev.physchem.56.092503.141211; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Razani B, 2001, J BIOL CHEM, V276, P38121; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200	30	327	332	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2005	7	9					901	U57		10.1038/ncb1293	http://dx.doi.org/10.1038/ncb1293			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	960NY	16113676	Green Accepted			2022-12-25	WOS:000231601600014
J	Weber, M; Davies, JJ; Wittig, D; Oakeley, EJ; Haase, M; Lam, WL; Schubeler, D				Weber, M; Davies, JJ; Wittig, D; Oakeley, EJ; Haase, M; Lam, WL; Schubeler, D			Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells	NATURE GENETICS			English	Article							INACTIVE X-CHROMOSOME; HUMAN GENOME; METHYLTRANSFERASE GENE; REGULATORY NETWORKS; HIGH-RESOLUTION; CPG ISLANDS; EXPRESSION; CANCER; CHROMATIN; MOUSE	Cytosine methylation is required for mammalian development and is often perturbed in human cancer. To determine how this epigenetic modification is distributed in the genomes of primary and transformed cells, we used an immunocapturing approach followed by DNA microarray analysis to generate methylation profiles of all human chromosomes at 80-kb resolution and for a large set of CpG islands. In primary cells we identified broad genomic regions of differential methylation with higher levels in gene-rich neighborhoods. Female and male cells had indistinguishable profiles for autosomes but differences on the X chromosome. The inactive X chromosome ( Xi) was hypermethylated at only a subset of gene-rich regions and, unexpectedly, overall hypomethylated relative to its active counterpart. The chromosomal methylation profile of transformed cells was similar to that of primary cells. Nevertheless, we detected large genomic segments with hypomethylation in the transformed cell residing in gene-poor areas. Furthermore, analysis of 6,000 CpG islands showed that only a small set of promoters was methylated differentially, suggesting that aberrant methylation of CpG island promoters in malignancy might be less frequent than previously hypothesized.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; Tech Univ Dresden, Dept Pathol, D-8027 Dresden, Germany	Friedrich Miescher Institute for Biomedical Research; British Columbia Cancer Agency; Technische Universitat Dresden	Schubeler, D (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	dirk@fmi.ch	Weber, Michael/P-1914-2016; jia, xu/A-8386-2016	Weber, Michael/0000-0003-3484-5821; 				Adorjan P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21; Bernardino J, 2000, CHROMOSOME RES, V8, P513, DOI 10.1023/A:1009271706488; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Chadwick BP, 2004, P NATL ACAD SCI USA, V101, P17450, DOI 10.1073/pnas.0408021101; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GIACALONE J, 1992, NAT GENET, V1, P137, DOI 10.1038/ng0592-137; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; GROOT GSP, 1979, BIOCHIM BIOPHYS ACTA, V564, P355, DOI 10.1016/0005-2787(79)90233-8; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; Louro R, 2004, BIOCHEM BIOPH RES CO, V316, P618, DOI 10.1016/j.bbrc.2004.02.091; MIGEON BR, 1994, TRENDS GENET, V10, P230, DOI 10.1016/0168-9525(94)90169-4; Oakes CC, 2003, P NATL ACAD SCI USA, V100, P1775, DOI 10.1073/pnas.0437971100; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rabinowicz PD, 2003, GENOME RES, V13, P2658, DOI 10.1101/gr.1784803; Rakyan VK, 2004, PLOS BIOL, V2, P2170, DOI 10.1371/journal.pbio.0020405; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Schubeler D, 2002, NAT GENET, V32, P438, DOI 10.1038/ng1005; Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342; Svoboda P, 2004, NUCLEIC ACIDS RES, V32, P3601, DOI 10.1093/nar/gkh697; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; VIEGASPEQUIGNOT E, 1988, P NATL ACAD SCI USA, V85, P7657, DOI 10.1073/pnas.85.20.7657; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Weber M, 2001, MECH DEVELOP, V101, P133, DOI 10.1016/S0925-4773(00)00573-6; White EJ, 2004, P NATL ACAD SCI USA, V101, P17771, DOI 10.1073/pnas.0408170101; Woodfine K, 2004, HUM MOL GENET, V13, P191, DOI 10.1093/hmg/ddh016; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yan PS, 2000, CLIN CANCER RES, V6, P1432; Yen PS, 2000, BRIT J CANCER, V82, P514, DOI 10.1054/bjoc.1999.0955	50	1265	1383	5	149	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					853	862		10.1038/ng1598	http://dx.doi.org/10.1038/ng1598			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16007088				2022-12-25	WOS:000230880400015
J	Zsurka, G; Kraytsberg, Y; Kudina, T; Kornblum, C; Elger, CE; Khrapko, K; Kunz, WS				Zsurka, G; Kraytsberg, Y; Kudina, T; Kornblum, C; Elger, CE; Khrapko, K; Kunz, WS			Recombination of mitochondrial DNA in skeletal muscle of individuals with multiple mitochondrial DNA heteroplasmy	NATURE GENETICS			English	Article							PATERNAL INHERITANCE; MTDNA; MUTATIONS	Experimental evidence for human mitochondrial DNA ( mtDNA) recombination was recently obtained in an individual with paternal inheritance of mtDNA(1) and in an in vitro cell culture system(2). Whether mtDNA recombination is a common event in humans remained to be determined. To detect mtDNA recombination in human skeletal muscle, we analyzed the distribution of alleles in individuals with multiple mtDNA heteroplasmy using single-cell PCR and allele-specific PCR. In all ten individuals who carried a heteroplasmic D-loop mutation and a distantly located tRNA point mutation or a large deletion, we observed a mixture of four allelic combinations (tetraplasmy), a hallmark of recombination. Twelve of 14 individuals with closely located heteroplasmic D-loop mutation pairs contained a mixture of only three types of mitochondrial genomes (triplasmy), consistent with the absence of recombination between adjacent markers. These findings indicate that mtDNA recombination is common in human skeletal muscle.	Univ Bonn, Med Ctr, Dept Epileptol, D-5300 Bonn, Germany; Harvard Univ, Sch Med, Boston, MA USA; Univ Bonn, Med Ctr, Dept Neurol, D-5300 Bonn, Germany	University of Bonn; Harvard University; Harvard Medical School; University of Bonn	Kunz, WS (corresponding author), Univ Bonn, Med Ctr, Dept Epileptol, D-5300 Bonn, Germany.	khrapko@hms.harvard.edu; wolfram.kunz@ukb.uni-bonn.de	Khrapko, Konstantin/A-3244-2009; Kunz, Wolfram/K-1232-2019	Kunz, Wolfram/0000-0003-1113-3493; Zsurka, Gabor/0000-0002-6379-849X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019787] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG019787, R01 AG018388] Funding Source: Medline; NIEHS NIH HHS [R01 ES011343] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Arctander P, 1999, SCIENCE, V284, P2090; Awadalla P, 1999, SCIENCE, V286, P2524, DOI 10.1126/science.286.5449.2524; Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; D'Aurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326; Elson JL, 2001, AM J HUM GENET, V68, P145, DOI 10.1086/316938; Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709; Hagelberg E, 2003, TRENDS GENET, V19, P84, DOI 10.1016/S0168-9525(02)00048-3; Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933; Jorde L B, 2000, Science, V288, P1931; Khrapko K, 2003, MUTAT RES-FUND MOL M, V522, P13, DOI 10.1016/S0027-5107(02)00306-8; Kivisild T, 2000, Science, V288, P1931; Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342; Merriweather DA, 1999, SCIENCE, V285, P837; Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199; Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612; PAABO S, 1990, J BIOL CHEM, V265, P4718; Rokas A, 2003, TRENDS ECOL EVOL, V18, P411, DOI 10.1016/S0169-5347(03)00125-3; Sato A, 2005, P NATL ACAD SCI USA, V102, P6057, DOI 10.1073/pnas.0408666102; Schwartz M, 2004, J NEUROL SCI, V218, P99, DOI 10.1016/j.jns.2003.11.008; Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350; Sharma A, 2000, SCIENCE, V288, P977; Smith JM, 2002, MOL BIOL EVOL, V19, P2330, DOI 10.1093/oxfordjournals.molbev.a004058; Zsurka G, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.022566	25	50	50	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					873	877		10.1038/ng1606	http://dx.doi.org/10.1038/ng1606			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16025113	Green Accepted			2022-12-25	WOS:000230880400018
J	Maley, CC; Galipeau, PC; Finley, JC; Wongsurawat, VJ; Li, XH; Sanchez, CA; Paulson, TG; Blount, PL; Risques, RA; Rabinovitch, PS; Reid, BJ				Maley, CC; Galipeau, PC; Finley, JC; Wongsurawat, VJ; Li, XH; Sanchez, CA; Paulson, TG; Blount, PL; Risques, RA; Rabinovitch, PS; Reid, BJ			Genetic clonal diversity predicts progression to esophageal adenocarcinoma	NATURE GENETICS			English	Article							BARRETTS-ESOPHAGUS; NEOPLASTIC PROGRESSION; GENOMIC INSTABILITY; CANCER; SURVEILLANCE; EVOLUTION; EPITHELIUM; EXPANSION; DYSPLASIA; LESIONS	Neoplasms are thought to progress to cancer through genetic instability generating cellular diversity(1,2) and clonal expansions driven by selection for mutations in cancer genes(3,4). Despite advances in the study of molecular biology of cancer genes(5), relatively little is known about evolutionary mechanisms that drive neoplastic progression. It is unknown, for example, which may be more predictive of future progression of a neoplasm: genetic homogenization of the neoplasm, possibly caused by a clonal expansion, or the accumulation of clonal diversity. Here, in a prospective study, we show that clonal diversity measures adapted from ecology and evolution can predict progression to adenocarcinoma in the premalignant condition known as Barrett's esophagus, even when controlling for established genetic risk factors, including lesions in TP53 (p53; ref. 6) and ploidy abnormalities(7). Progression to cancer through accumulation of clonal diversity, on which natural selection acts, may be a fundamental principle of neoplasia with important clinical implications.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA	The Wistar Institute; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Maley, CC (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	cmaley@alum.mit.edu	Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X; Galipeau, Patricia/0000-0001-7961-7430	NCI NIH HHS [P01 CA91955, K01 CA89267-02, K07 CA89147-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA089267, P01CA091955, K07CA089147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Boland CR, 1998, CANCER RES, V58, P5248; Breivik J, 2005, SEMIN CANCER BIOL, V15, P51, DOI 10.1016/j.semcancer.2004.09.008; Clarke KR, 1998, J APPL ECOL, V35, P523, DOI 10.1046/j.1365-2664.1998.3540523.x; Conio M, 2003, AM J GASTROENTEROL, V98, P1931, DOI 10.1016/S0002-9270(03)00629-4; Doak SH, 2003, GUT, V52, P623, DOI 10.1136/gut.52.5.623; Gonzalez-Garcia I, 2002, P NATL ACAD SCI USA, V99, P13085, DOI 10.1073/pnas.202139299; HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Levine DS, 2000, AM J GASTROENTEROL, V95, P1152; Macdonald CE, 2000, BMJ-BRIT MED J, V321, P1252, DOI 10.1136/bmj.321.7271.1252; MAGURRAN A. E., 2004, MEASURING BIOLOGICAL; Maley CC, 2004, CANCER RES, V64, P3414, DOI 10.1158/0008-5472.CAN-03-3249; Maley CC, 2004, CANCER RES, V64, P7629, DOI 10.1158/0008-5472.CAN-04-1738; Nei M., 1987, MOL EVOLUTIONARY GEN; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Palanca-Wessels MCA, 2003, CARCINOGENESIS, V24, P1183, DOI 10.1093/carcin/bgg076; Rabinovitch PS, 2001, AM J GASTROENTEROL, V96, P3071, DOI 10.1111/j.1572-0241.2001.05261.x; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Reid BJ, 2001, AM J GASTROENTEROL, V96, P2839; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Rudolph RE, 2000, ANN INTERN MED, V132, P612, DOI 10.7326/0003-4819-132-8-200004180-00003; Sampliner RE, 2002, AM J GASTROENTEROL, V97, P1888; Shackney SE, 1997, CYTOMETRY, V29, P1; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Tsao JL, 2000, P NATL ACAD SCI USA, V97, P1236, DOI 10.1073/pnas.97.3.1236; Wong DJ, 2001, CANCER RES, V61, P8284	30	523	538	1	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	2006	38	4					468	473		10.1038/ng1768	http://dx.doi.org/10.1038/ng1768			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16565718				2022-12-25	WOS:000236340500021
J	Prescott, JH; Lipka, S; Baldwin, S; Sheppard, NF; Maloney, JM; Coppeta, J; Yomtov, B; Staples, MA; Santini, JT				Prescott, JH; Lipka, S; Baldwin, S; Sheppard, NF; Maloney, JM; Coppeta, J; Yomtov, B; Staples, MA; Santini, JT			Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device	NATURE BIOTECHNOLOGY			English	Article							DRUG-DELIVERY	Implanted drug delivery systems are being increasingly used to realize the therapeutic potential of peptides and proteins. Here we describe the controlled pulsatile release of the polypeptide leuprolide from microchip implants over 6 months in dogs. Each microchip contains an array of discrete reservoirs from which dose delivery can be controlled by telemetry.	MicroCHIPS Inc, Bedford, MA 01730 USA		Santini, JT (corresponding author), MicroCHIPS Inc, 6-B Preston Court, Bedford, MA 01730 USA.	jsantini@mchips.com	Maloney, John/B-6153-2008	/0000-0002-6853-811X				Cukierski MJ, 2001, INT J TOXICOL, V20, P369, DOI 10.1080/109158101753333659; Langer R, 2003, SCI AM, V288, P50, DOI 10.1038/scientificamerican0403-50; LaVan DA, 2003, NAT BIOTECHNOL, V21, P1184, DOI 10.1038/nbt876; Li YW, 2005, J CONTROL RELEASE, V106, P138, DOI 10.1016/j.jconrel.2005.04.009; Maloney JM, 2005, J CONTROL RELEASE, V109, P244, DOI 10.1016/j.jconrel.2005.09.035; OKADA H, 1991, PHARMACEUT RES, V8, P787, DOI 10.1023/A:1015818504906; Santini JT, 1999, NATURE, V397, P335, DOI 10.1038/16898; Scavini M, 1997, DIABETES CARE, V20, P610, DOI 10.2337/diacare.20.4.610; Shastri V. Prasad, 2003, Current Pharmaceutical Biotechnology, V4, P331; Urquhart J, 2000, J INTERN MED, V248, P357, DOI 10.1046/j.1365-2796.2000.00758.x; Werkmeister JA, 2001, CURR OPIN SOLID ST M, V5, P185, DOI 10.1016/S1359-0286(01)00007-9	11	158	182	1	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2006	24	4					437	438		10.1038/nbt1199	http://dx.doi.org/10.1038/nbt1199			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	032HU	16531991				2022-12-25	WOS:000236766300027
J	Rohmann, E; Brunner, HG; Kayserili, H; Uyguner, O; Nurnberg, G; Lew, ED; Dobbie, A; Eswarakumar, VP; Uzumcu, A; Ulubil-Emeroglu, M; Leroy, JG; Li, Y; Becker, C; Lehnerdt, K; Cremers, CWRJ; Yuksel-Apak, M; Nurnberg, P; Kubisch, C; Schlessinger, J; van Bokhoven, H; Wollnik, B				Rohmann, E; Brunner, HG; Kayserili, H; Uyguner, O; Nurnberg, G; Lew, ED; Dobbie, A; Eswarakumar, VP; Uzumcu, A; Ulubil-Emeroglu, M; Leroy, JG; Li, Y; Becker, C; Lehnerdt, K; Cremers, CWRJ; Yuksel-Apak, M; Nurnberg, P; Kubisch, C; Schlessinger, J; van Bokhoven, H; Wollnik, B			Mutations in different components of FGF signaling in LADD syndrome	NATURE GENETICS			English	Article							DENTO-DIGITAL SYNDROME; PATERNAL ORIGIN; RECEPTORS; ANOMALIES	Lacrimo-auriculo-dento-digital (LADD) syndrome is characterized by lacrimal duct aplasia, malformed ears and deafness, small teeth and digital anomalies. We identified heterozygous mutations in the tyrosine kinase domains of the genes encoding fibroblast growth factor receptors 2 and 3 (FGFR2, FGFR3) in LADD families, and in one further LADD family, we detected a mutation in the gene encoding fibroblast growth factor 10 (FGF10), a known FGFR ligand. These findings increase the spectrum of anomalies associated with abnormal FGF signaling.	Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; Univ Cologne, Inst Human Genet, D-50931 Cologne, Germany; Radboud Univ Nijmegen Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Istanbul Univ, Istanbul Fac Med, Dept Med Genet, TR-34390 Istanbul, Turkey; Univ Cologne, Cologne Ctr Genom, D-50674 Cologne, Germany; RZPD Deutsch Ressourcenzentrum Genomforsch GmbH, D-14059 Berlin, Germany; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; St Jamess Univ Hosp, Genet Serv, Leeds LS9 7TS, W Yorkshire, England; Istanbul Univ, Istanbul Fac Med, Dept Ear Nose & Throat, TR-34390 Istanbul, Turkey; State Univ Ghent Hosp, Dept Med Genet, B-9000 Ghent, Belgium; Klinikum Dortmund, HNO Abt, D-44137 Dortmund, Germany; Univ Cologne, Inst Genet, D-5000 Cologne, Germany	University of Cologne; University of Cologne; Radboud University Nijmegen; Istanbul University; University of Cologne; Yale University; Saint James's University Hospital; University of Leeds; Istanbul University; Ghent University; Ghent University Hospital; Klinikum Dortmund; University of Cologne	Wollnik, B (corresponding author), Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany.	bwollnik@uni-koeln.de	van Bokhoven, Hans/D-8764-2012; Kubisch, Christian/F-1893-2011; Cremers, C.W.R.J./L-4254-2015; UYGUNER, OYA Z/Y-3899-2018; Wollnik, Bernd/GRY-6062-2022; Bokhoven, J.H.L.M. van van/H-8015-2014; Brunner, Han/C-9928-2013	Kubisch, Christian/0000-0003-4220-0978; Wollnik, Bernd/0000-0003-2589-0364; Bokhoven, J.H.L.M. van van/0000-0002-2153-9254; Eswarakumar, Jacob/0000-0003-0784-0507; Eswarakumar, V.P./0000-0001-7941-8714; Uyguner, Zehra Oya/0000-0002-2035-4338	NIAMS NIH HHS [R01-AR051886, R01-AR051448] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051448, R01AR051886] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAMFORTH JS, 1992, AM J MED GENET, V43, P932, DOI 10.1002/ajmg.1320430605; Coumoul X, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni100; Entesarian M, 2005, NAT GENET, V37, P125, DOI 10.1038/ng1507; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Glaser RL, 2000, AM J HUM GENET, V66, P768, DOI 10.1086/302831; Gorivodsky M, 2003, DEVELOPMENT, V130, P5471, DOI 10.1242/dev.00795; HOLLISTER DW, 1973, J PEDIATR-US, V83, P438, DOI 10.1016/S0022-3476(73)80268-9; Kan S, 2002, AM J HUM GENET, V70, P472, DOI 10.1086/338758; Legeai-Mallet L, 2004, BONE, V34, P26, DOI 10.1016/j.bone.2003.09.002; LEVY WJ, 1967, AM J OPHTHALMOL, V63, P978, DOI 10.1016/0002-9394(67)90043-8; Moloney DM, 1996, NAT GENET, V13, P48, DOI 10.1038/ng0596-48; Steinberg Z, 2005, DEVELOPMENT, V132, P1223, DOI 10.1242/dev.01690; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775	14	139	148	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2006	38	4					414	417		10.1038/ng1757	http://dx.doi.org/10.1038/ng1757			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16501574				2022-12-25	WOS:000236340500012
J	Hering, BJ; Wijkstrom, M; Graham, ML; Harstedt, M; Aasheim, TC; Jie, T; Ansite, JD; Nakano, M; Cheng, J; Li, W; Moran, K; Christians, U; Finnegan, C; Mills, CD; Sutherland, DE; Bansal-Pakala, P; Murtaugh, MP; Kirchhof, N; Schuurman, HJ				Hering, BJ; Wijkstrom, M; Graham, ML; Harstedt, M; Aasheim, TC; Jie, T; Ansite, JD; Nakano, M; Cheng, J; Li, W; Moran, K; Christians, U; Finnegan, C; Mills, CD; Sutherland, DE; Bansal-Pakala, P; Murtaugh, MP; Kirchhof, N; Schuurman, HJ			Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates	NATURE MEDICINE			English	Article							COSTIMULATORY BLOCKADE; REJECTION; SURVIVAL; CELL; TRANSPLANTATION; LEFLUNOMIDE; RECOGNITION; XENOGRAFTS; EXPRESSION; INDUCTION	Cell-based diabetes therapy requires an abundant cell source. Here, we report reversal of diabetes for more than 100 d in cynomolgus macaques after intraportal transplantation of cultured islets from genetically unmodified pigs without GaI-specific antibody manipulation. Immunotherapy with CD25-specific and CD154-specific monoclonal antibodies, FTY720 (or tacrolimus), everolimus and leflunomide suppressed indirect activation of T cells, elicitation of non-GaI pig-specific IgG antibody, intragraft expression of proinflammatory cytokines and invasion of infiltrating mononuclear cells into islets.	Univ Minnesota, Diabet Inst Immunol & Transplantat, Dept Surg, Minneapolis, MN 55455 USA; Immerge BioTherapeut Inc, Charlestown, MA 02129 USA; Univ Colorado, Hlth Sci Ctr, Dept Anesthesia, Denver, CO 80262 USA; Univ Minnesota, Dept Vet & Biomed Sci, St Paul, MN 55108 USA; Univ Minnesota, Dept Vet Populat Med, Vet Med Ctr 225, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Hering, BJ (corresponding author), Univ Minnesota, Diabet Inst Immunol & Transplantat, Dept Surg, 424 Harvard St SE, Minneapolis, MN 55455 USA.	bhering@umn.edu	Sano, Michael/E-1715-2011; Graham, Melanie L/M-2536-2017	Graham, Melanie L/0000-0002-2475-6975				GILL RG, 1992, TRANSPLANT P, V24, P642; GROTH CG, 1994, LANCET, V344, P1402, DOI 10.1016/S0140-6736(94)90570-3; Hancock WW, 1997, TRANSPLANTATION, V64, P696, DOI 10.1097/00007890-199709150-00006; Kirchhof N, 2004, XENOTRANSPLANTATION, V11, P396, DOI 10.1111/j.1399-3089.2004.00157.x; Kuwaki K, 2005, NAT MED, V11, P29, DOI 10.1038/nm1171; Manna SK, 2000, J IMMUNOL, V165, P5962, DOI 10.4049/jimmunol.165.10.5962; Nyqvist D, 2005, DIABETES, V54, P2287, DOI 10.2337/diabetes.54.8.2287; Olack B, 2000, J IMMUNOL, V165, P1294, DOI 10.4049/jimmunol.165.3.1294; Rayat GR, 2003, DIABETES, V52, P1433, DOI 10.2337/diabetes.52.6.1433; Rayat GR, 2003, J ENDOCRINOL, V177, P127, DOI 10.1677/joe.0.1770127; Rijkelijkhuizen JKRA, 2003, TRANSPLANTATION, V76, P1359, DOI 10.1097/01.TP.0000085290.60182.6B; Rogers NJ, 2000, NAT IMMUNOL, V1, P163, DOI 10.1038/77853; Schuler W, 2004, TRANSPLANTATION, V77, P717, DOI 10.1097/01.TP.0000116563.72763.83; Wijkstrom M, 2004, TRANSPLANTATION, V77, P827, DOI 10.1097/01.TP.0000116390.76425.20; Yamada A, 2001, J IMMUNOL, V167, P5522, DOI 10.4049/jimmunol.167.10.5522	15	400	421	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2006	12	3					301	303		10.1038/nm1369	http://dx.doi.org/10.1038/nm1369			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16491083				2022-12-25	WOS:000235802900027
J	Yanez-Munoz, RJ; Balaggan, KS; MacNeil, A; Howe, SJ; Schmidt, M; Smith, AJ; Buch, P; MacLaren, RE; Anderson, PN; Barker, SE; Duran, Y; Bartholomae, C; von Kalle, C; Heckenlively, JR; Kinnon, C; Ali, RR; Thrasher, AJ				Yanez-Munoz, RJ; Balaggan, KS; MacNeil, A; Howe, SJ; Schmidt, M; Smith, AJ; Buch, P; MacLaren, RE; Anderson, PN; Barker, SE; Duran, Y; Bartholomae, C; von Kalle, C; Heckenlively, JR; Kinnon, C; Ali, RR; Thrasher, AJ			Effective gene therapy with nonintegrating lentiviral vectors	NATURE MEDICINE			English	Article							RETINAL-PIGMENT EPITHELIUM; TYPE-1 INTEGRASE MUTANTS; RCS RAT MODEL; IN-VIVO; RETINITIS-PIGMENTOSA; STABLE TRANSDUCTION; NONDIVIDING CELLS; ADULT-RAT; EXPRESSION; DNA	Retroviral and lentiviral vector integration into host-cell chromosomes carries with it a finite chance of causing insertional mutagenesis(1). This risk has been highlighted by the induction of malignancy in mouse models, and development of lymphoproliferative disease in three individuals with severe combined immunodeficiency-X1 (refs. 2,3). Therefore, a key challenge for clinical therapies based on retroviral vectors is to achieve stable transgene expression while minimizing insertional mutagenesis. Recent in vitro studies have shown that integration-deficient lentiviral vectors can mediate stable transduction(4-6). With similar vectors, we now show efficient and sustained transgene expression in vivo in rodent ocular and brain tissues. We also show substantial rescue of clinically relevant rodent models of retinal degeneration. Therefore, the high efficiency of gene transfer and expression mediated by lentiviruses can be harnessed in vivo without a requirement for vector integration. For therapeutic application to postmitotic tissues, this system substantially reduces the risk of insertional mutagenesis.	Inst Canc Res, Ctr Med Oncol, London EC1M 6BQ, England; Barts & London Queen Marys Sch Med & Dent, Ctr Clin, John Vane Sci Ctr, London EC1M 6BQ, England; UCL, Inst Ophthalmol, Div Mol Therapy, London EC1V 9EL, England; Univ Hosp Freiburg, Dept Internal Med 1, D-79106 Freiburg, Germany; Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; Cincinnati Childrens Res Fdn, Mol & Gene Therapy Program, Cincinnati, OH 45229 USA; Kellogg Eye Ctr, Ann Arbor, MI 48105 USA; Hosp Sick Children, Dept Immunol, Great Ormond St Hosp Children NHS Trust, London WC1N 3JH, England; UCL, Inst Child Hlth, Mol Immunol Unit, London WC1N 1EH, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Queen Mary University London; University of London; University College London; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of London; University College London; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Yanez-Munoz, RJ (corresponding author), Guys Hosp, Kings Coll London Sch Med, Nucl Biol Grp, Dept Med & Mol Genet, London SE1 9RT, England.	rafael.yanez@genetics.kcl.ac.uk; r.ali@ucl.ac.uk	Kinnon, Christine/A-1585-2010; Smith, Alexander/A-5142-2009; Howe, Steven J/C-4801-2008	Howe, Steven J/0000-0003-2940-2874; MacLaren, Robert/0000-0002-3096-4682; Thrasher, Adrian/0000-0002-6097-6115; Yanez-Munoz, Rafael J/0000-0001-7113-1938; Ali, Robin/0000-0003-3126-6517	Medical Research Council [G0601588] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Abordo-Adesida E, 2005, HUM GENE THER, V16, P741, DOI 10.1089/hum.2005.16.741; Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068; Bainbridge JWB, 2001, GENE THER, V8, P1665, DOI 10.1038/sj.gt.3301574; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; Bemelmans AP, 2005, J GENE MED, V7, P1367, DOI 10.1002/jgm.788; Butler SL, 2002, J VIROL, V76, P3739, DOI 10.1128/JVI.76.8.3739-3747.2002; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Case SS, 1999, P NATL ACAD SCI USA, V96, P2988, DOI 10.1073/pnas.96.6.2988; Dejneka NS, 2004, MOL THER, V9, P182, DOI 10.1016/j.ymthe.2003.11.013; Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; Gruter O, 2005, GENE THER, V12, P942, DOI 10.1038/sj.gt.3302485; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; HSU TW, 1978, J VIROL, V28, P810, DOI 10.1128/JVI.28.3.810-818.1978; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Loewen N, 2003, J GENE MED, V5, P1009, DOI 10.1002/jgm.447; Lu R, 2004, J VIROL, V78, P658, DOI 10.1128/JVI.78.2.658-668.2004; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Pang JJ, 2005, MOL VIS, V11, P152; Park F, 2000, BLOOD, V96, P1173, DOI 10.1182/blood.V96.3.1173.015k34_1173_1176; Pierson TC, 2002, J VIROL, V76, P4138, DOI 10.1128/JVI.76.8.4138-4144.2002; Saenz DT, 2004, J VIROL, V78, P2906, DOI 10.1128/JVI.78.6.2906-2920.2004; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; SHANK PR, 1978, CELL, V15, P1383, DOI 10.1016/0092-8674(78)90063-6; Smith AJ, 2003, MOL THER, V8, P188, DOI 10.1016/S1525-0016(03)00144-8; Tschernutter M, 2005, GENE THER, V12, P694, DOI 10.1038/sj.gt.3302460; Vargas J, 2004, HUM GENE THER, V15, P361, DOI 10.1089/104303404322959515	30	351	374	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					348	353		10.1038/nm1365	http://dx.doi.org/10.1038/nm1365			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16491086				2022-12-25	WOS:000235802900036
J	Goto, H; Kiyono, T; Tomono, Y; Kawajiri, A; Urano, T; Furukawa, K; Nigg, EA; Inagaki, M				Goto, H; Kiyono, T; Tomono, Y; Kawajiri, A; Urano, T; Furukawa, K; Nigg, EA; Inagaki, M			Complex formation of Plk1 and INCENP required for metaphase-anaphase transition	NATURE CELL BIOLOGY			English	Article							POLO-LIKE KINASE-1; SPINDLE-CHECKPOINT PROTEINS; AURORA-B; CELL-DIVISION; CYTOKINESIS; KINETOCHORES; ACTIVATION; PHOSPHORYLATION; ASSOCIATION; REGULATORS	Mitotic chromosomal dynamics is regulated by the coordinated activities of many mitotic kinases(1), such as cyclin-dependent kinase 1 (Cdk1)(2,3), Aurora-B-4 or Polo-like kinase 1 (Plk1)(5), but the mechanisms of their coordination remain unknown. Here, we report that Cdk1 phosphorylates Thr 59 and Thr 388 on inner centromere protein (INCENP), which regulates the localization(4) and kinase activity(6-8) of Aurora-B from prophase to metaphase. INCENP depletion disrupts Plk1 localization specifically at the kinetochore. This phenotype is rescued by the exogenous expression of INCENP wild type and INCENP mutated at Thr 59 to Ala (T59A), but not at Thr 388 to Ala (T388A). The replacement of endogenous INCENP with T388A resulted in the delay of progression from metaphase to anaphase. We propose that INCENP phosphorylation by Cdk1 is necessary for the recruitment of Plk1 to the kinetochore, and that the complex formation of Plk1 and Aurora-B on INCENP may play crucial roles in the regulation of chromosomal dynamics.	Aichi Canc Ctr, Res Inst, Div Biochem, Nagoya, Aichi 4648681, Japan; Natl Canc Ctr, Res Inst, Div Virol, Chuo Ku, Tokyo 1040045, Japan; Shigei Med Res Inst, Div Mol & Cell Biol, Okayama 7010202, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem 2, Aichi 4668550, Japan; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany	Aichi Cancer Center; National Cancer Center - Japan; Nagoya University; Max Planck Society	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, Nagoya, Aichi 4648681, Japan.	minagaki@aichi-cc.jp	Kiyono, Tohru/H-5834-2011; Inagaki, Masaki/B-9920-2016	Urano, Takeshi/0000-0003-3383-3554; Goto, Hidemasa/0000-0002-6796-4467; nigg, erich/0000-0003-4835-5719				Ahonen LJ, 2005, CURR BIOL, V15, P1078, DOI 10.1016/j.cub.2005.05.026; Aumais JP, 2003, J CELL SCI, V116, P1991, DOI 10.1242/jcs.00412; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Doree M, 2002, J CELL SCI, V115, P2461; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Li XY, 2004, J BIOL CHEM, V279, P47201, DOI 10.1074/jbc.M403029200; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Maiato H, 2004, J CELL SCI, V117, P5461, DOI 10.1242/jcs.01536; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; Nurse P, 2002, CHEMBIOCHEM, V3, P596, DOI 10.1002/1439-7633(20020703)3:7<596::AID-CBIC596>3.0.CO;2-U; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Wong OK, 2005, J CELL BIOL, V170, P709, DOI 10.1083/jcb.200502163; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200	30	143	147	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2006	8	2					180	U52		10.1038/ncb1350	http://dx.doi.org/10.1038/ncb1350			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	008SA	16378098				2022-12-25	WOS:000235059800013
J	Kawano, T; Anrather, J; Zhou, P; Park, L; Wang, G; Frys, KA; Kunz, A; Cho, SH; Orio, M; Iadecola, C				Kawano, T; Anrather, J; Zhou, P; Park, L; Wang, G; Frys, KA; Kunz, A; Cho, SH; Orio, M; Iadecola, C			Prostaglandin E-2 EP1 receptors: downstream effectors of COX-2 neurotoxicity	NATURE MEDICINE			English	Article							NA+/CA2+ EXCHANGER; CEREBRAL-ISCHEMIA; NEURONS; PGE(2); OVERLOAD; INJURY; NEUROPROTECTION; EXCITOTOXICITY; PHARMACOLOGY; CONTRIBUTES	Cyclooxygenase-2 (COX-2), a rate-limiting enzyme for prostanoid synthesis, has been implicated in the neurotoxicity resulting from hypoxia-ischemia, and its inhibition has therapeutic potential for ischemic stroke. However, COX-2 inhibitors increase the risk of cardiovascular complications. We therefore sought to identify the downstream effectors of COX-2 neurotoxicity, and found that prostaglandin E-2 EP1 receptors are essential for the neurotoxicity mediated by COX-2-derived prostaglandin E-2. EP1 receptors disrupt Ca2+ homeostasis by impairing Na+-Ca2+ exchange, a key mechanism by which neurons cope with excess Ca2+ accumulation after an excitotoxic insult. Thus, EP1 receptors contribute to neurotoxicity by augmenting the Ca2+ dysregulation underlying excitotoxic neuronal death. Pharmacological inhibition or gene inactivation of EP1 receptors ameliorates brain injury induced by excitotoxicity, oxygen glucose deprivation and middle cerebral artery (MCA) occlusion. An EP1 receptor inhibitor reduces brain injury when administered 6 hours after MCA occlusion, suggesting that EP1 receptor inhibition may be a viable therapeutic option in ischemic stroke.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Div Neurobiol, New York, NY 10021 USA	Cornell University	Iadecola, C (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Div Neurobiol, 411 E 69th St, New York, NY 10021 USA.	coi2001@med.cornell.edu	Iadecola, c/ABB-8377-2020	Iadecola, Costantino/0000-0001-9797-073X; PARK, LAIBAIK/0000-0001-7601-663X	NINDS NIH HHS [NS34179, NS35806] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034179, R37NS034179, R01NS035806] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad AS, 2005, BRAIN RES, V1066, P71, DOI 10.1016/j.brainres.2005.10.068; Annunziato L, 2004, PHARMACOL REV, V56, P633, DOI 10.1124/pr.56.4.5; Audoly LP, 1999, AM J PHYSIOL-HEART C, V277, pH924, DOI 10.1152/ajpheart.1999.277.3.H924; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bilak M, 2004, ANN NEUROL, V56, P240, DOI 10.1002/ana.20179; Caggiano AO, 1999, J NEUROCHEM, V72, P565, DOI 10.1046/j.1471-4159.1999.0720565.x; Carlson NG, 2003, J NEUROSCI RES, V71, P79, DOI 10.1002/jnr.10465; Chen C, 2005, PROSTAG OTH LIPID M, V77, P65, DOI 10.1016/j.prostaglandins.2005.07.001; Cho S, 2005, J NEUROSCI, V25, P2504, DOI 10.1523/JNEUROSCI.0035-05.2005; Choi DW, 2005, NATURE, V433, P696, DOI 10.1038/433696a; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; FUNK CD, 1993, J BIOL CHEM, V268, P26767; Hallinan EA, 1996, J MED CHEM, V39, P609, DOI 10.1021/jm950454k; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; KHODOROV B, 1993, FEBS LETT, V324, P271, DOI 10.1016/0014-5793(93)80132-E; Kiedrowski L, 1999, MOL PHARMACOL, V56, P619, DOI 10.1124/mol.56.3.619; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Niwa K, 2000, J NEUROSCI, V20, P763, DOI 10.1523/JNEUROSCI.20-02-00763.2000; Nogawa S, 1997, J NEUROSCI, V17, P2746; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Suganami T, 2003, HYPERTENSION, V42, P1183, DOI 10.1161/01.HYP.0000101689.64849.97; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U	30	317	329	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					225	229		10.1038/nm1362	http://dx.doi.org/10.1038/nm1362			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16432513				2022-12-25	WOS:000235160600028
J	Nieminen, M; Henttinen, T; Merinen, M; Marttila-Ichihara, F; Eriksson, JE; Jalkanen, S				Nieminen, M; Henttinen, T; Merinen, M; Marttila-Ichihara, F; Eriksson, JE; Jalkanen, S			Vimentin function in lymphocyte adhesion and transcellular migration	NATURE CELL BIOLOGY			English	Article							INTERMEDIATE-FILAMENTS; ENDOTHELIAL-CELLS; VENULES	Although the adhesive interactions of leukocytes with endothelial cells are well understood, little is known about the detailed mechanisms underlying the actual migration of leukocytes across the endothelium ( diapedesis). Leukocytes have been shown to use both paracellular and transcellular routes for transendothelial migration. Here we show that peripheral blood mononuclear cells (PBMCs; T- and B-lymphocytes) preferentially use the transcellular route. The intermediate filaments of both endothelial cells and lymphocytes formed a highly dynamic anchoring structure at the site of contact between these two cell types. The initiation of this process was markedly reduced in vimentin-deficient (vim(-/-)) PBMCs and endothelial cells. When compared with wild-type PBMCs, vim(-/-) PBMCs showed a markedly reduced capacity to home to mesenteric lymph nodes and spleen. Furthermore, endothelial integrity was compromised in vim(-/-) mice, demonstrating that intermediate filaments also regulate the barrier that governs leukocyte extravasation. Absence of vimentin resulted in highly aberrant expression and distribution of surface molecules critical for homing (ICAM-1 and VCAM-1 on endothelial cells and integrin-beta 1 on PBMCs). These data show that intermediate filaments are active in lymphocyte adhesion and transmigration.	Univ Turku, Ctr Biotechnol, FIN-20521 Turku, Finland; Abo Akad Univ, FIN-20521 Turku, Finland; Univ Turku, Dept Biol, FIN-20014 Turku, Finland; Univ Turku, Med Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Med Microbiol, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; University of Turku; University of Turku; University of Turku; Finland National Institute for Health & Welfare	Eriksson, JE (corresponding author), Univ Turku, Ctr Biotechnol, POB 123, FIN-20521 Turku, Finland.	john.eriksson@btk.utu.fi		Karikoski, Marika/0000-0001-6512-6331				Ager A, 2003, NATURE, V421, P703, DOI 10.1038/421703a; Ameen NA, 2001, J CELL SCI, V114, P563; Brown MJ, 2001, J IMMUNOL, V166, P6640, DOI 10.4049/jimmunol.166.11.6640; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; COOKE BM, 1993, PARASITOLOGY, V107, P359, DOI 10.1017/S0031182000067706; Coulombe PA, 2004, NAT CELL BIOL, V6, P699, DOI 10.1038/ncb0804-699; Engelhardt B, 2004, EUR J IMMUNOL, V34, P2955, DOI 10.1002/eji.200425327; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; HOGG N, 1995, IMMUNOL TODAY, V16, P327, DOI 10.1016/0167-5699(95)80147-2; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Mamdouh Z, 2003, NATURE, V421, P748, DOI 10.1038/nature01300; MARCHESI VT, 1964, PROC R SOC SER B-BIO, V159, P283, DOI 10.1098/rspb.1964.0002; Runembert I, 2004, AM J PHYSIOL-RENAL, V287, pF960, DOI 10.1152/ajprenal.00064.2004; Runembert I, 2002, J CELL SCI, V115, P713; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stolen CM, 2005, IMMUNITY, V22, P105, DOI 10.1016/j.immuni.2004.12.006; Toivola DM, 2004, J CELL BIOL, V164, P911, DOI 10.1083/jcb.200308103; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; WANHONG S, 2002, BLOOD, V100, P3597; Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942	26	333	354	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2006	8	2					156	U41		10.1038/ncb1355	http://dx.doi.org/10.1038/ncb1355			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	008SA	16429129				2022-12-25	WOS:000235059800010
J	Ioannidis, JPA; Gwinn, M; Little, J; Higgins, JPT; Bernstein, JL; Boffetta, P; Bondy, M; Bray, MS; Brenchley, PE; Buffler, PA; Casas, JP; Chokkalingam, A; Danesh, J; Smith, GD; Dolan, S; Duncan, R; Gruis, NA; Hartge, P; Hashibe, M; Hunter, DJ; Jarvelin, MR; Malmer, B; Maraganore, DM; Newton-Bishop, JA; O'Brien, TR; Petersen, G; Riboli, E; Salanti, G; Seminara, D; Smeeth, L; Taioli, E; Timpson, N; Uitterlinden, AG; Vineis, P; Wareham, N; Winn, DM; Zimmern, R; Khoury, MJ				Ioannidis, JPA; Gwinn, M; Little, J; Higgins, JPT; Bernstein, JL; Boffetta, P; Bondy, M; Bray, MS; Brenchley, PE; Buffler, PA; Casas, JP; Chokkalingam, A; Danesh, J; Smith, GD; Dolan, S; Duncan, R; Gruis, NA; Hartge, P; Hashibe, M; Hunter, DJ; Jarvelin, MR; Malmer, B; Maraganore, DM; Newton-Bishop, JA; O'Brien, TR; Petersen, G; Riboli, E; Salanti, G; Seminara, D; Smeeth, L; Taioli, E; Timpson, N; Uitterlinden, AG; Vineis, P; Wareham, N; Winn, DM; Zimmern, R; Khoury, MJ		Human Genome Epidemiology Network; Network Investigtor Networks	A road map for efficient and reliable human genome epidemiology	NATURE GENETICS			English	Editorial Material							GENETIC EPIDEMIOLOGY; RANDOMIZED-TRIALS; PUBLICATION; ASSOCIATION; GUIDELINES; BIAS; ENVIRONMENT; FALSE	Networks of investigators have begun sharing best practices, tools and methods for analysis of associations between genetic variation and common diseases. A Network of Investigator Networks has been set up to drive the process, sponsored by the Human Genome Epidemiology Network. A workshop is planned to develop consensus guidelines for reporting results of genetic association studies. Published literature databases will be integrated, and unpublished data, including 'negative' studies, will be captured by online journals and through investigator networks. Systematic reviews will be expanded to include more meta-analyses of individual-level data and prospective meta-analyses. Field synopses will offer regularly updated overviews.	Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece; Fdn Res & Technol Hellas, Biomed Res Inst, GR-45110 Ioannina, Greece; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Ctr Dis Control & Prevent, Off Genom & Dis Prevent, Atlanta, GA 30333 USA; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1H 8M5, Canada; Univ Cambridge, MRC, Biostat Unit, Cambridge CB2 2SR, England; Strangeways Res Lab, Publ Hlth Genet Unit, Cambridge CB1 8RN, England; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Int Agcy Res Canc, F-69008 Lyon, France; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Royal Infirm, Manchester Inst Nephrol & Transplantat, Renal Res Labs, Manchester M13 9WL, Lancs, England; Univ Calif Berkeley, Berkeley, CA 94720 USA; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England; Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; March Dimes, White Plains, NY 10605 USA; WHO, CH-1211 Geneva, Switzerland; Leiden Univ Med Ctr, Dept Dermatol, NL-2333 AL Leiden, Netherlands; NCI, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ London Imperial Coll Sci & Technol, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Univ Oulu, Dept Publ Hlth Sci & Gen Practice, Oulu, Finland; Umea Univ Hosp, Dept Radiat Sci, Umea, Sweden; Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; CR UK Clin Ctr, Genet Epidemiol Div, Leeds LS8 7FT, W Yorkshire, England; Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15232 USA; Erasmus MC, Dept Internal Med, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Inst Sci Interchange Fdn, Turin, Italy; MRC, Epidemiol Unit, Elsie Widdowson Labs, Cambridge CB1 9NL, England	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Tufts University; Centers for Disease Control & Prevention - USA; University of Ottawa; MRC Biostatistics Unit; University of Cambridge; Memorial Sloan Kettering Cancer Center; World Health Organization; International Agency for Research on Cancer (IARC); University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; United States Department of Agriculture (USDA); University of California System; University of California Berkeley; University of London; London School of Hygiene & Tropical Medicine; University of Cambridge; University of Bristol; World Health Organization; Leiden University; Leiden University Medical Center (LUMC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health; Imperial College London; University of Oulu; Umea University; Mayo Clinic; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Davey Smith, George/A-7407-2013; Boffetta, Paolo/AAI-7767-2021; Timpson, Nicholas John/O-7548-2015; Little, Julian/AAR-6117-2020; Higgins, Julian PT/H-4008-2011; Ioannidis, John P. A./G-9836-2011; Attrill, Lauren/V-1688-2018; Fox, Laura J/C-6249-2016; Smeeth, Liam/X-5862-2018	Davey Smith, George/0000-0002-1407-8314; Boffetta, Paolo/0000-0002-3811-2791; Timpson, Nicholas John/0000-0002-7141-9189; Little, Julian/0000-0001-5026-5531; Higgins, Julian PT/0000-0002-8323-2514; Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Brenchley, Paul/0000-0003-1290-9919; Gruis, Nelleke/0000-0002-5210-9150; Smeeth, Liam/0000-0002-9168-6022; Newton-Bishop, Julia/0000-0001-9147-6802; Salanti, Georgia/0000-0002-3830-8508; s, hema/0000-0002-3440-9475; Riboli, Elio/0000-0001-6795-6080	NATIONAL CANCER INSTITUTE [Z01CP010170] Funding Source: NIH RePORTER; MRC [G108/492] Funding Source: UKRI; Medical Research Council [MC_U106179471, G108/492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 2005, NAT GENET, V37, P1153, DOI 10.1038/ng1105-1153; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Cooper DN, 2002, HUM GENET, V110, P207, DOI 10.1007/s00439-001-0672-4; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Freimer NB, 2005, HUM MOL GENET, V14, P2481, DOI 10.1093/hmg/ddi251; Greenland S, 2005, J R STAT SOC A STAT, V168, P267, DOI 10.1111/j.1467-985X.2004.00349.x; Huizinga TWJ, 2004, ARTHRITIS RHEUM, V50, P2066, DOI 10.1002/art.20360; IOANNIDIS JP, IN PRESS INT J EPIDE; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Ioannidis JPA, 2005, AM J EPIDEMIOL, V162, P302, DOI 10.1093/aje/kwi201; Ioannidis JPA, 2002, AM J EPIDEMIOL, V156, P204, DOI 10.1093/aje/kwf031; Little J, 2003, AM J EPIDEMIOL, V157, P667, DOI 10.1093/aje/kwg048; Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537; Pan ZL, 2005, PLOS MED, V2, P1309, DOI 10.1371/journal.pmed.0020334; Patsopoulos NA, 2005, JAMA-J AM MED ASSOC, V293, P2362, DOI 10.1001/jama.293.19.2362; Patterson M, 2005, PLOS BIOL, V3, P1511, DOI 10.1371/journal.pbio.0030327; Rebbeck TR, 2004, CANCER EPIDEM BIOMAR, V13, P1985; Thorn CF, 2005, METH MOL B, V311, P179; von Elm E, 2004, BMJ-BRIT MED J, V329, P868, DOI 10.1136/bmj.329.7471.868; Wacholder S, 2005, CANCER EPIDEM BIOMAR, V14, P1361, DOI 10.1158/1055-9965.EPI-05-0404; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Weiss ST, 2001, AM J RESP CRIT CARE, V164, P2014, DOI 10.1164/ajrccm.164.11.2110043b	24	174	179	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					3	5		10.1038/ng0106-3	http://dx.doi.org/10.1038/ng0106-3			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16468121				2022-12-25	WOS:000234227200002
J	Lee, HS; Bong, YS; Moore, KB; Soria, K; Moody, SA; Daar, IO				Lee, HS; Bong, YS; Moore, KB; Soria, K; Moody, SA; Daar, IO			Dishevelled mediates ephrinB1 signalling in the eye field through the planar cell polarity pathway	NATURE CELL BIOLOGY			English	Article							FORMATION REQUIRE; XENOPUS; RECEPTOR; GENE; MORPHOGENESIS; GASTRULATION; PROGENITORS; ACTIVATION; EXPRESSION; MOVEMENTS	An important step in retinal development is the positioning of progenitors within the eye field where they receive the local environmental signals that will direct their ultimate fate(1). Recent evidence indicates that ephrinB1 functions in retinal progenitor movement, but the signalling pathway is unclear. We present evidence that ephrinB1 signals through its intracellular domain to control retinal progenitor movement into the eye field by interacting with Xenopus Dishevelled ( Xdsh), and by using the planar cell polarity ( PCP) pathway. Blocking Xdsh translation prevents retinal progeny from entering the eye field, similarly to the morpholino- mediated loss of ephrinB1 ( ref. 2). Overexpression of Xdsh can rescue the phenotype induced by loss of ephrinB1, and this rescue ( as well as a physical association between Xdsh and ephrinB1) is completely dependent on the DEP ( Dishevelled, Egl- 10, Pleckstrin) domain of Xdsh. Similar gain- and loss- of- function experiments suggest that Xdsh associates with ephrinB1 and mediates ephrinB1 signalling through downstream members of the PCP pathway during eye field formation.	NCI, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA; Univ Utah, Sch Med, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Utah System of Higher Education; University of Utah; George Washington University	Daar, IO (corresponding author), NCI, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA.	daar@ncifcrf.gov	Moody, Sally A./AAI-3660-2020; Lee, Hyun-Shik/G-3555-2011	Moody, Sally A./0000-0003-4192-1087; Moore, Kathryn/0000-0002-6993-152X; Daar, Ira/0000-0003-2657-526X	NATIONAL CANCER INSTITUTE [Z01BC010006] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY010096] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NEI NIH HHS [EY10096] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Cavodeassi F, 2005, NEURON, V47, P43, DOI 10.1016/j.neuron.2005.05.026; Chin-Sang ID, 1999, CELL, V99, P781, DOI 10.1016/S0092-8674(00)81675-X; Chong LD, 2000, MOL CELL BIOL, V20, P724, DOI 10.1128/MCB.20.2.724-734.2000; Cowan CA, 2002, TRENDS CELL BIOL, V12, P339, DOI 10.1016/S0962-8924(02)02317-6; Davy A, 2004, GENE DEV, V18, P572, DOI 10.1101/gad.1171704; De Calisto J, 2005, DEVELOPMENT, V132, P2587, DOI 10.1242/dev.01857; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Heller N, 1999, DEV GENET, V24, P208, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<208::AID-DVG4>3.0.CO;2-J; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Hirsch N, 1997, J NEUROBIOL, V32, P45, DOI 10.1002/(SICI)1097-4695(199701)32:1<45::AID-NEU5>3.3.CO;2-V; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HUANG S, 1993, J NEUROSCI, V13, P3193; Itoh K, 1997, MECH DEVELOP, V61, P113, DOI 10.1016/S0925-4773(96)00627-2; Kenyon KL, 2001, DEV BIOL, V240, P77, DOI 10.1006/dbio.2001.0464; Kinoshita N, 2003, GENE DEV, V17, P1663, DOI 10.1101/gad.1101303; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; Maurus D, 2005, EMBO J, V24, P1181, DOI 10.1038/sj.emboj.7600603; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; MOODY SA, 1999, METHODS MOL BIOL DEV, P331; Moore KB, 2004, DEV CELL, V6, P55, DOI 10.1016/S1534-5807(03)00395-2; Murakami MS, 2004, DEVELOPMENT, V131, P571, DOI 10.1242/dev.00971; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; SAHA MS, 1992, NEURON, V8, P1003, DOI 10.1016/0896-6273(92)90123-U; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Sive Hazel L., 2000, EARLY DEV XENOPUS LA; Small EM, 2000, MECH DEVELOP, V96, P259, DOI 10.1016/S0925-4773(00)00400-7; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; Tanaka M, 2003, EMBO J, V22, P847, DOI 10.1093/emboj/cdg088; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zygar CA, 1998, DEVELOPMENT, V125, P3509	34	89	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					55	U21		10.1038/ncb1344	http://dx.doi.org/10.1038/ncb1344			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	16362052				2022-12-25	WOS:000234651500012
J	Ono, R; Nakamura, K; Inoue, K; Naruse, M; Usami, T; Wakisaka-Saito, N; Hino, T; Suzuki-Migishima, R; Ogonuki, N; Miki, H; Kohda, T; Ogura, A; Yokoyama, M; Kaneko-Ishino, T; Ishino, F				Ono, R; Nakamura, K; Inoue, K; Naruse, M; Usami, T; Wakisaka-Saito, N; Hino, T; Suzuki-Migishima, R; Ogonuki, N; Miki, H; Kohda, T; Ogura, A; Yokoyama, M; Kaneko-Ishino, T; Ishino, F			Deletion of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality	NATURE GENETICS			English	Article							TRANSPOSABLE ELEMENTS; MAMMALIAN GENOMES; RETROVIRAL GAG; IDENTIFICATION; EVOLUTION; ORIGIN; SYNCYTIN; FAMILY; GROWTH; MICE	By comparing mammalian genomes, we and others have identified actively transcribed Ty3/gypsy retrotransposon-derived genes with highly conserved DNA sequences and insertion sites(1-6). To elucidate the functions of evolutionarily conserved retrotransposon-derived genes in mammalian development, we produced mice that lack one of these genes, Peg10 ( paternally expressed 10)(1-3,7), which is a paternally expressed imprinted gene on mouse proximal chromosome 6. The Peg10 knockout mice showed early embryonic lethality owing to defects in the placenta. This indicates that Peg10 is critical for mouse parthenogenetic development and provides the first direct evidence of an essential role of an evolutionarily conserved retrotransposon-derived gene in mammalian development.	Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320011, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Epigenet, Chiyoda Ku, Tokyo 1010062, Japan; Mitsubishi Kagaku Inst Life Sci, Tokyo 1948511, Japan; RIKEN, BioResouce Ctr, Tsukuba, Ibaraki 3050074, Japan; Tokyo Med & Dent Univ, Med Res Inst, Fac Recombinant Mice, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Inst Technol, Ctr Biol Resources & Informat, Div Gene Res, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokai Univ, Sch Hlth Sci, Kanagawa 2591193, Japan	Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); Mitsubishi Kagaku Institute of Life Sciences (MITILS); RIKEN; Tokyo Medical & Dental University (TMDU); Tokyo Institute of Technology; Tokai University	Kaneko-Ishino, T (corresponding author), Japan Sci & Technol Agcy, CREST, 4-1-8 Hon Machi, Kawaguchi, Saitama 3320011, Japan.	tkanekoi@is.icc.u-tokai.ac.jp; fishino.epgn@mri.tmd.ac.jp	Ishino（Kaneko-Ishino）, Tomoko/AGY-0742-2022; Ogura, Atsuo/J-3916-2014; Kohda, Takashi/C-2879-2014	Ogura, Atsuo/0000-0003-0447-1988; Kohda, Takashi/0000-0002-6856-5601				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; BEECHEY C, 2003, MOUSE IMPRINTING DAT; Brandt J, 2005, GENE, V345, P101, DOI 10.1016/j.gene.2004.11.022; Butler M, 2001, J MOL EVOL, V52, P260, DOI 10.1007/s002390010154; Charlier C, 2001, GENOME RES, V11, P850, DOI 10.1101/gr.172701; Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819; Dupressoir A, 2005, P NATL ACAD SCI USA, V102, P725, DOI 10.1073/pnas.0406509102; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; Lux A, 2005, J BIOL CHEM, V280, P8482, DOI 10.1074/jbc.M409197200; Lynch C, 2003, CURR BIOL, V13, P1518, DOI 10.1016/S0960-9822(03)00618-3; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; Nagasaki K, 1999, CANCER LETT, V140, P227, DOI 10.1016/S0304-3835(99)00087-7; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Okabe H, 2003, CANCER RES, V63, P3043; Ono R, 2003, GENOME RES, V13, P1696, DOI 10.1101/gr.906803; Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494; Poulter R, 1998, GENE, V215, P241, DOI 10.1016/S0378-1119(98)00296-0; Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171; Shigemoto K, 2001, NUCLEIC ACIDS RES, V29, P4079, DOI 10.1093/nar/29.19.4079; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; STURM KS, 1994, DEV DYNAM, V201, P11, DOI 10.1002/aja.1002010103; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; TOH H, 1985, NATURE, V318, P388, DOI 10.1038/318388a0; Tsou AP, 2003, J BIOMED SCI, V10, P625, DOI 10.1159/000073528; Volff JN, 2001, MOL BIOL EVOL, V18, P266, DOI 10.1093/oxfordjournals.molbev.a003801	30	286	304	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					101	106		10.1038/ng1699	http://dx.doi.org/10.1038/ng1699			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16341224				2022-12-25	WOS:000234227200024
J	Raeder, H; Johansson, S; Holm, PI; Haldorsen, IS; Mas, E; Sbarra, V; Nermoen, I; Eide, SA; Grevle, L; Bjorkhaug, L; Sagen, JV; Aksnes, L; Sovik, O; Lombardo, D; Molven, A; Njolstad, PR				Raeder, H; Johansson, S; Holm, PI; Haldorsen, IS; Mas, E; Sbarra, V; Nermoen, I; Eide, SA; Grevle, L; Bjorkhaug, L; Sagen, JV; Aksnes, L; Sovik, O; Lombardo, D; Molven, A; Njolstad, PR			Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction	NATURE GENETICS			English	Article							SALT-DEPENDENT LIPASE; CARBOXYL ESTER LIPASE; FECAL ELASTASE-1 CONCENTRATIONS; SITE-DIRECTED MUTAGENESIS; STIMULATED LIPASE; CHOLESTEROL ESTERASE; GENE; MICE; MELLITUS; AGENESIS	Dysfunction of the exocrine pancreas is observed in diabetes, but links between concurrent exocrine and endocrine pancreatic disease and contributing genetic factors are poorly characterized. We studied two families with diabetes and exocrine pancreatic dysfunction by genetic, physiological and in vitro functional studies. A genome-wide screen in Family 1 linked diabetes to chromosome 9q34 ( maximal lod score 5.07). Using fecal elastase deficiency as a marker of exocrine pancreatic dysfunction refined the critical chromosomal region to 1.16 Mb ( maximal lod score 11.6). Here, we identified a single-base deletion in the variable number of tandem repeats (VNTR)-containing exon 11 of the carboxyl ester lipase (CEL) gene, a major component of pancreatic juice and responsible for the duodenal hydrolysis of cholesterol esters. Screening subjects with maturity-onset diabetes of the young identified Family 2, with another single-base deletion in CEL and a similar phenotype with beta-cell failure and pancreatic exocrine disease. The in vitro catalytic activities of wild-type and mutant CEL protein were comparable. The mutant enzyme was, however, less stable and secreted at a lower rate. Furthermore, we found some evidence for an association between common insertions in the CEL VNTR and exocrine dysfunction in a group of 182 unrelated subjects with diabetes ( odds ratio 4.2 (1.6, 11.5)). Our findings link diabetes to the disrupted function of a lipase in the pancreatic acinar cells.	Univ Bergen, Dept Clin Med, Sect Pediat, Bergen, Norway; Univ Bergen, Dept Clin Med, Sect Med Genet & Mol Med, Bergen, Norway; Univ Bergen, Dept Internal Med, Endocrinol Sect, Bergen, Norway; Haukeland Univ Hosp, Hormone Lab, N-5021 Bergen, Norway; Univ Bergen, Dept Surg, Sect Radiol, N-5014 Bergen, Norway; INSERM, U559, Fac Med Timone, F-13258 Marseille, France; Akershus Univ Hosp, Dept Endocrinol, Oslo, Norway; Univ Bergen, Gade Inst, Sect Pathol, Bergen, Norway; Haukeland Univ Hosp, Dept Pathol, N-5021 Bergen, Norway; Haukeland Univ Hosp, Dept Pediat, N-5021 Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Oslo; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital	Njolstad, PR (corresponding author), Univ Bergen, Dept Clin Med, Sect Pediat, Bergen, Norway.	pal.njolstad@uib.no	Raeder, Helge/AFQ-6279-2022; Mas, Eric/AAC-9837-2022; Raeder, Helge/ABE-3601-2020; Johansson, Stefan/C-4394-2011; Bjørkhaug, Lise/AAA-4356-2021; Mas, Eric/O-9569-2017	Johansson, Stefan/0000-0002-2298-7008; Bjørkhaug, Lise/0000-0002-9695-4559; Mas, Eric/0000-0002-8925-9195; Haldorsen, Ingfrid S./0000-0001-9313-7564				Aubert E, 2002, J BIOL CHEM, V277, P34987, DOI 10.1074/jbc.M202893200; Aubert-Jousset E, 2004, J BIOL CHEM, V279, P39697, DOI 10.1074/jbc.M407646200; Auge N, 2003, CIRCULATION, V108, P86, DOI 10.1161/01.CIR.0000079101.69806.47; Bellanne-Chantelot C, 2004, ANN INTERN MED, V140, P510, DOI 10.7326/0003-4819-140-7-200404060-00009; Bengtsson-Ellmark SH, 2004, EUR J HUM GENET, V12, P627, DOI 10.1038/sj.ejhg.5201204; Bjorkhaug L, 2003, J CLIN ENDOCR METAB, V88, P920, DOI 10.1210/jc.2002-020945; Cavalot F, 2004, DIABETES CARE, V27, P2052, DOI 10.2337/diacare.27.8.2052; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DOWNS D, 1994, BIOCHEMISTRY-US, V33, P7979, DOI 10.1021/bi00192a001; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Gleghorn L, 2005, AM J HUM GENET, V77, P484, DOI 10.1086/444401; Goda K, 2001, ACTA DIABETOL, V38, P145, DOI 10.1007/s005920170012; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; Hardt PD, 2003, PANCREATOLOGY, V3, P395, DOI 10.1159/000073655; Haumaitre C, 2005, P NATL ACAD SCI USA, V102, P1490, DOI 10.1073/pnas.0405776102; HENDERSON JR, 1969, LANCET, V2, P469; Herman Gail E, 2002, ILAR J, V43, P55; Higuchi S, 2002, J HUM GENET, V47, P213, DOI 10.1007/s100380200027; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200; Icks A, 2001, Z GASTROENTEROL, V39, P823, DOI 10.1055/s-2001-17867; Iglesias A, 2004, J CLIN INVEST, V113, P1398, DOI 10.1172/JCI200418879; Kim SK, 2002, NAT GENET, V30, P430, DOI 10.1038/ng860; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; Lindquist S, 2002, EUR J BIOCHEM, V269, P759, DOI 10.1046/j.0014-2956.2001.02666.x; Lombardo D, 2001, BBA-MOL CELL BIOL L, V1533, P1, DOI 10.1016/S1388-1981(01)00130-5; Lombardo F, 2003, EUR J ENDOCRINOL, V149, P53, DOI 10.1530/eje.0.1490053; Mitchell RMS, 2003, LANCET, V361, P1447, DOI 10.1016/S0140-6736(03)13139-X; Panicot L, 1999, DIABETES, V48, P2316, DOI 10.2337/diabetes.48.12.2316; Poorkhalkali N, 1998, HISTOCHEM CELL BIOL, V110, P367, DOI 10.1007/s004180050297; Rathmann W, 2001, SCAND J GASTROENTERO, V36, P1056; Sellick GS, 2004, NAT GENET, V36, P1301, DOI 10.1038/ng1475; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; Verine A, 2001, J BIOL CHEM, V276, P12356, DOI 10.1074/jbc.M008658200; Wang Feng, 2003, Mol Cancer, V2, P4, DOI 10.1186/1476-4598-2-4; Weng W, 1999, BIOCHEMISTRY-US, V38, P4143, DOI 10.1021/bi981679a	38	215	232	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					54	62		10.1038/ng1708	http://dx.doi.org/10.1038/ng1708			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16369531				2022-12-25	WOS:000234227200017
J	Zhang, GJ; Brokx, S; Weiner, JH				Zhang, GJ; Brokx, S; Weiner, JH			Extracellular accumulation of recombinant proteins fused to the carrier protein YebF in Escherichia coli	NATURE BIOTECHNOLOGY			English	Article							GENERAL SECRETORY PATHWAY; EXPRESSION; K-12	Bacterial protein secretion is important in the life cycles of most bacteria, in which it contributes to the formation of pili and flagella and makes available extracellular enzymes to digest polymers for nutritional purposes and toxins to kill host cells in infections of humans, animals and plants. It is generally accepted that nonpathogenic laboratory strains of Escherichia coli, particularly K12 strains, do not secrete proteins into the extracellular medium under routine growth conditions(1,2). In this study, we report that commonly used laboratory strains secrete YebF, a small (10.8 kDa in the native form), soluble endogenous protein into the medium, challenging the status quo view that laboratory strains do not secrete proteins to the medium. We further show that 'passenger' proteins linked to the carboxyl end of YebF are efficiently secreted. The function of YebF is unknown, but its use as a carrier for transgenic proteins provides a tool to circumvent toxicity and other contamination issues associated with protein production in E. coli.	Univ Alberta, Dept Biochem, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	University of Alberta	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, Membrane Prot Res Grp, 474 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	joel.weiner@ualberta.ca						Brokx SJ, 2004, J BACTERIOL, V186, P3254, DOI 10.1128/JB.186.10.3254-3258.2004; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Francetic O, 1996, J BACTERIOL, V178, P3544, DOI 10.1128/jb.178.12.3544-3549.1996; Francetic O, 2000, EMBO J, V19, P6697, DOI 10.1093/emboj/19.24.6697; HE SY, 1991, P NATL ACAD SCI USA, V88, P1079, DOI 10.1073/pnas.88.3.1079; Lattemann CT, 2000, J BACTERIOL, V182, P3726, DOI 10.1128/JB.182.13.3726-3733.2000; Lei H, 2000, GENE THER, V7, P707, DOI 10.1038/sj.gt.3301162; MASUI Y, 1989, CURRENT COMMUNICATIO, P167; NEU HC, 1965, J BIOL CHEM, V240, P3685; Ohdan K, 1999, APPL ENVIRON MICROB, V65, P4652; POQUET I, 1993, EMBO J, V12, P271, DOI 10.1002/j.1460-2075.1993.tb05653.x; Pugsley AP, 1998, CELL MOL LIFE SCI, V54, P347, DOI 10.1007/s000180050162; ROBB RJ, 1984, IMMUNOL TODAY, V5, P203, DOI 10.1016/0167-5699(84)90224-X; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shokri A, 2003, APPL MICROBIOL BIOT, V60, P654, DOI 10.1007/s00253-002-1156-8; Stathopoulos C, 2000, MICROBES INFECT, V2, P1061, DOI 10.1016/S1286-4579(00)01260-0; STRACK B, 1992, J BIOL CHEM, V267, P13062; TABOR S, 1987, J BIOL CHEM, V262, P16212; Thanassi DG, 2000, CURR OPIN CELL BIOL, V12, P420, DOI 10.1016/S0955-0674(00)00111-3; Weiner JH, 2000, BIOTECHNIQUES, V29, P982, DOI 10.2144/00295bm11	21	83	92	3	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2006	24	1					100	104		10.1038/nbt1174	http://dx.doi.org/10.1038/nbt1174			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	001SE	16369539				2022-12-25	WOS:000234555800031
J	Adereth, Y; Dammai, V; Kose, N; Li, RZ; Hsu, T				Adereth, Y; Dammai, V; Kose, N; Li, RZ; Hsu, T			RNA-dependent integrin alpha(3) protein localization regulated by the Muscleblind-like protein MLP1	NATURE CELL BIOLOGY			English	Article							ACTIN MESSENGER-RNA; EXPANDED-REPEAT TRANSCRIPTS; IN-VIVO; DROSOPHILA; CELLS; ORGANIZATION; LAMININ-5; MIGRATION; MBNL	We show that localized expression of the integrin alpha(3) protein is regulated at the level of RNA localization by the human homologue of Drosophila Muscleblind, MLP1/MBLL/MBNL2, a unique Cys(3)His zinc-finger protein. This is supported by the following observations: MLP1 knockdown abolishes localization of integrin alpha(3) to the adhesion complexes; MLP1 is localized in adhesion plaques that contain phospho-focal adhesion kinase; this localization is microtubule-dependent; integrin alpha(3) transcripts colocalize with MLP1 in distinct cytoplasmic loci; integrin alpha(3) transcripts are physically associated with MLP1 in cells and MLP1 binds to a specific ACACCC motif in the integrin alpha(3) 3' untranslated region (UTR) in vitro; and a green fluorescent protein (GFP) open reading frame-integrin alpha(3) 3' UTR chimeric gene directs GFP protein localization to distinct cytoplasmic loci near the cell periphery, which is dependent on MLP1 and is mediated by the ACACCC motif but is independent of the integrin alpha(3) signal peptide.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Hsu, T (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 86 Jonathan Lucas St,Room 330, Charleston, SC 29425 USA.	hsut@musc.edu		Hsu, Tien/0000-0003-2308-4297	NCI NIH HHS [K22CA109577, R01CA109860, P01 CA078582, R01 CA109860, P01 CA078582-070005, K22 CA109577, R01 CA109860-03, P01CA78582] Funding Source: Medline; NIGMS NIH HHS [R01 GM057843-06, R01 GM057843] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA109577, R01CA109860, P01CA078582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artero R, 1998, DEV BIOL, V195, P131, DOI 10.1006/dbio.1997.8833; Bassell GJ, 1998, J NEUROSCI, V18, P251; Begemann G, 1997, DEVELOPMENT, V124, P4321; de Hoog CL, 2004, CELL, V117, P649, DOI 10.1016/S0092-8674(04)00456-8; Fardaei M, 2002, HUM MOL GENET, V11, P805, DOI 10.1093/hmg/11.7.805; Fardaei M, 2001, NUCLEIC ACIDS RES, V29, P2766, DOI 10.1093/nar/29.13.2766; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; FULTON AB, 1993, J CELL BIOCHEM, V52, P148, DOI 10.1002/jcb.240520206; Gu W, 2002, J CELL BIOL, V156, P41, DOI 10.1083/jcb.200105133; Johnstone O, 2001, ANNU REV GENET, V35, P365, DOI 10.1146/annurev.genet.35.102401.090756; Juschke C, 2004, CURR BIOL, V14, P406, DOI 10.1016/j.cub.2004.02.034; Kino Y, 2004, HUM MOL GENET, V13, P495, DOI 10.1093/hmg/ddh056; Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; Ladd AN, 2005, DEV DYNAM, V233, P783, DOI 10.1002/dvdy.20382; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Micklem DR, 1995, DEV BIOL, V172, P377, DOI 10.1006/dbio.1995.8048; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; SINGER R H, 1992, Current Opinion in Cell Biology, V4, P15, DOI 10.1016/0955-0674(92)90053-F; Waterman-Storer CM, 1998, CURR BIOL, V8, P798, DOI 10.1016/S0960-9822(98)70321-5	22	109	111	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1240	1247		10.1038/ncb1335	http://dx.doi.org/10.1038/ncb1335			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16273094	Green Accepted			2022-12-25	WOS:000233748900018
J	D'Amour, KA; Agulnick, AD; Eliazer, S; Kelly, OG; Kroon, E; Baetge, EE				D'Amour, KA; Agulnick, AD; Eliazer, S; Kelly, OG; Kroon, E; Baetge, EE			Efficient differentiation of human embryonic stem cells to definitive endoderm	NATURE BIOTECHNOLOGY			English	Article							MOUSE EMBRYO; PRIMITIVE STREAK; EXPRESSION PATTERNS; MESODERM FORMATION; GENE-EXPRESSION; AXIS FORMATION; N-CADHERIN; GASTRULATION; GROWTH; REQUIREMENT	The potential of human embryonic stem (hES) cells to differentiate into cell types of a variety of organs has generated much excitement over the possible use of hES cells in therapeutic applications. Of great interest are organs derived from definitive endoderm, such as the pancreas. We have focused on directing hES cells to the definitive endoderm lineage as this step is a prerequisite for efficient differentiation to mature endoderm derivatives. Differentiation of hES cells in the presence of activin A and low serum produced cultures consisting of up to 80% definitive endoderm cells. This population was further enriched to near homogeneity using the cell-surface receptor CXCR4. The process of definitive endoderm formation in differentiating hES cell cultures includes an apparent epithelial-to-mesenchymal transition and a dynamic gene expression profile that are reminiscent of vertebrate gastrulation. These findings may facilitate the use of hES cells for therapeutic purposes and as in vitro models of development.	CyThera Inc, San Diego, CA 92121 USA		Baetge, EE (corresponding author), CyThera Inc, 3550 Gen Atom Ct, San Diego, CA 92121 USA.	emmbaetge@cytheraco.com		KROON, EVERT/0000-0002-4069-3644				Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147; ANG SL, 1993, DEVELOPMENT, V119, P1301; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beattie GM, 2005, STEM CELLS, V23, P489, DOI 10.1634/stemcells.2004-0279; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; Brennan J, 2001, NATURE, V411, P965, DOI 10.1038/35082103; Candia AF, 1996, INT J DEV BIOL, V40, P1179; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; CONLON FL, 1994, DEVELOPMENT, V120, P1919; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; DZIADEK MA, 1983, EMBO J, V2, P549, DOI 10.1002/j.1460-2075.1983.tb01461.x; Elms P, 2004, GENE EXPR PATTERNS, V4, P505, DOI 10.1016/j.modgep.2004.03.003; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hart AH, 2002, DEVELOPMENT, V129, P3597; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Kelly OG, 2004, DEVELOPMENT, V131, P2803, DOI 10.1242/dev.01137; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; Lacroix MC, 2002, ENDOCRINE, V19, P73, DOI 10.1385/ENDO:19:1:73; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Lowe LA, 2001, DEVELOPMENT, V128, P1831; Lu CC, 2001, CURR OPIN GENET DEV, V11, P384, DOI 10.1016/S0959-437X(00)00208-2; Mahlapuu M, 2001, DEVELOPMENT, V128, P155; McGrath KE, 1997, MOL REPROD DEV, V48, P145, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;145::AID-MRD1&gt;3.0.CO;2-S; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; MEYER BI, 1993, DEVELOPMENT, V117, P191; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; NISWANDER L, 1992, DEVELOPMENT, V114, P755; Ormestad M, 2004, DEV DYNAM, V229, P328, DOI 10.1002/dvdy.10426; Pearce JJH, 1999, MECH DEVELOP, V87, P189, DOI 10.1016/S0925-4773(99)00135-5; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970; Pevny LH, 1998, DEVELOPMENT, V125, P1967; Radice GL, 1997, DEV BIOL, V181, P64, DOI 10.1006/dbio.1996.8443; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Robb L, 2004, SEMIN CELL DEV BIOL, V15, P543, DOI 10.1016/j.semcdb.2004.04.005; SASAKI H, 1993, DEVELOPMENT, V118, P47; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shawlot W, 1998, P NATL ACAD SCI USA, V95, P6198, DOI 10.1073/pnas.95.11.6198; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; Stainier DYR, 2002, GENE DEV, V16, P893, DOI 10.1101/gad.974902; Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801; Sun X, 1999, GENE DEV, V13, P1834, DOI 10.1101/gad.13.14.1834; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Vincent SD, 2003, GENE DEV, V17, P1646, DOI 10.1101/gad.1100503; Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004-0162; WeilerGuettler H, 1996, DEVELOPMENT, V122, P2271; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032	61	1221	1397	2	105	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2005	23	12					1534	1541		10.1038/nbt1163	http://dx.doi.org/10.1038/nbt1163			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	992ED	16258519				2022-12-25	WOS:000233866300030
J	Dunoyer, P; Himber, C; Voinnet, O				Dunoyer, P; Himber, C; Voinnet, O			DICER-LIKE 4 is required for RNA interference and produces the 21-nucleotide small interfering RNA component of the plant cell-to-cell silencing signal	NATURE GENETICS			English	Article							TRANS-ACTING SIRNAS; GENE; ARABIDOPSIS; VIRUS; BIOGENESIS; MICRORNAS; ELEGANS; SGS3	In RNA interference(1,2), the RNase-III enzyme Dicer(3) processes exogenous double-stranded RNA into small interfering RNAs (siRNAs). siRNAs guide RNA-induced silencing complexes to cleave homologous transcripts, enabling gene-specific knockdown(4). In plants, double-stranded RNA is processed into siRNA species of 21 nucleotides (nt) and 24 nt (ref. 5), but, unlike in nematodes(6), the Dicer enzymes involved in this processing have not been identified. Additionally, in both plants and nematodes, systemic signals(7-10) with RNA components convey the sequence-specific effects of RNA interference between cells. Here, we describe Arabidopsis thaliana mutants with altered silencing cell-to-cell movement beyond the vasculature. At least three SILENCING MOVEMENT DEFICIENT genes (SMD1, SMD2 and SMD3) are required for trafficking, the extent of which correlates with siRNA levels in the veins. Five alleles defective in synthesis of 21-nt, but not 24-nt, siRNAs carry mutations in Dicer-like 4 (DCL4) that are involved in biogenesis of trans-acting siRNAs(11,12). We show that the biogenesis and function of trans-acting siRNA can be genetically uncoupled from a bona fide DCL4-dependent pathway that accounts for RNA interference and for production of the 21-nt siRNA component of the plant cell-to-cell silencing signal.	CNRS, UPR 2357, Inst Biol Mol Plantes, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Voinnet, O (corresponding author), CNRS, UPR 2357, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.	olivier.voinnet@ibmp-ulp.u-strasbg.fr		Voinnet, Olivier/0000-0001-6982-9544				Allen E, 2005, CELL, V121, P207, DOI 10.1016/j.cell.2005.04.004; Bartel B, 2003, PLANT PHYSIOL, V132, P709, DOI 10.1104/pp.103.023630; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gasciolli V, 2005, CURR BIOL, V15, P1494, DOI 10.1016/j.cub.2005.07.024; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Himber C, 2003, EMBO J, V22, P4523, DOI 10.1093/emboj/cdg431; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Peragine A, 2004, GENE DEV, V18, P2368, DOI 10.1101/gad.1231804; Schwach F, 2005, PLANT PHYSIOL, V138, P1842, DOI 10.1104/pp.105.063537; Szittya G, 2002, PLANT CELL, V14, P359, DOI 10.1105/tpc.010366; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Waterhouse PM, 2003, NAT REV GENET, V4, P29, DOI 10.1038/nrg982; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Xie ZX, 2005, P NATL ACAD SCI USA, V102, P12984, DOI 10.1073/pnas.0506426102; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104	25	314	340	1	46	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2005	37	12					1356	1360		10.1038/ng1675	http://dx.doi.org/10.1038/ng1675			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16273107				2022-12-25	WOS:000233657300016
J	Fatkenheuer, G; Pozniak, AL; Johnson, MA; Plettenberg, A; Staszewski, S; Hoepelman, AIM; Saag, MS; Goebel, FD; Rockstroh, JK; Dezube, BJ; Jenkins, TM; Medhurst, C; Sullivan, JF; Ridgway, C; Abel, S; James, IT; Youle, M; van der Ryst, E				Fatkenheuer, G; Pozniak, AL; Johnson, MA; Plettenberg, A; Staszewski, S; Hoepelman, AIM; Saag, MS; Goebel, FD; Rockstroh, JK; Dezube, BJ; Jenkins, TM; Medhurst, C; Sullivan, JF; Ridgway, C; Abel, S; James, IT; Youle, M; van der Ryst, E			Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1	NATURE MEDICINE			English	Article							IN-VITRO; INHIBITOR; DELETION; SAFETY; ADULTS; GENE; AIDS	We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >= 1.6 log(10) copies/ml at all twice daily doses >= 100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.	Pfizer Ltd, Global Res & Dev, Sandwich CT13 9NJ, Kent, England; Univ Cologne, Div Infect Dis, Dept Internal Med, D-50924 Cologne, Germany; Chelsea & Westminster Hosp, London SW10 974, England; Royal Free Hosp, Dept Thorac Med, London NW3 2QG, England; St Georg Hosp, Ifi Inst Interdisziplinare Infektiol & Immunol, D-20099 Hamburg, Germany; Klinikum Johann Wolfgang Goethe Univ, Zentrum Inneren Med, D-60596 Frankfurt, Germany; Univ Utrecht Hosp, Head Div Infect Dis & AIDS, NL-3508 GA Utrecht, Netherlands; Univ Alabama, Birmingham, AL 35294 USA; Univ Munich, Med Poliklin, Munich, Germany; Univ Bonn, D-53105 Bonn, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Pfizer; University of Cologne; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Asklepios Klinik St. Georg; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Utrecht University; Utrecht University Medical Center; University of Alabama System; University of Alabama Birmingham; University of Munich; University of Bonn; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	van der Ryst, E (corresponding author), Pfizer Ltd, Global Res & Dev, Sandwich CT13 9NJ, Kent, England.	Elna.Van.Der.Ryst@pfizer.com						Adkins JC, 1998, DRUGS, V56, P1055, DOI 10.2165/00003495-199856060-00014; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DORR PK, IN PRESS ANTIMICROB; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Kuhmann SE, 2004, J VIROL, V78, P2790, DOI 10.1128/JVI.78.6.2790-2807.2004; Lalezari J, 2005, AIDS, V19, P1443, DOI 10.1097/01.aids.0000183633.06580.8a; Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004; Maggiolo Franco, 2002, HIV Clin Trials, V3, P371, DOI 10.1310/98B3-PWG8-PMYW-W5BP; McCallister S, 2004, JAIDS-J ACQ IMM DEF, V35, P376, DOI 10.1097/00126334-200404010-00007; MEYER L, 1997, AIDS, V11, P73; Strizki JM, 2001, P NATL ACAD SCI USA, V98, P12718, DOI 10.1073/pnas.221375398; Struble K, 2005, AIDS, V19, P747, DOI 10.1097/01.aids.0000168968.34810.ca; Takashima K, 2001, ANTIMICROB AGENTS CH, V45, P3538, DOI 10.1128/AAC.45.12.3538-3543.2001	14	423	439	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1170	1172		10.1038/nm1319	http://dx.doi.org/10.1038/nm1319			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16205738				2022-12-25	WOS:000233115400028
J	Habedanck, R; Stierhof, YD; Wilkinson, CJ; Nigg, EA				Habedanck, R; Stierhof, YD; Wilkinson, CJ; Nigg, EA			The Polo kinase Plk4 functions in centriole duplication	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE PROGRESSION; XENOPUS EGG EXTRACTS; CENTROSOME DUPLICATION; MAMMALIAN-CELLS; C-ELEGANS; SAK; PROLIFERATION; REQUIREMENT; CDK2-CYCLIN; EXPRESSION	The human Polo-like kinase 1 (PLK1) and its functional homologues that are present in other eukaryotes have multiple, crucial roles in meiotic and mitotic cell division(1,2). By contrast, the functions of other mammalian Polo family members remain largely unknown. Plk4 is the most structurally divergent Polo family member; it is maximally expressed in actively dividing tissues and is essential for mouse embryonic development(3). Here, we identify Plk4 as a key regulator of centriole duplication. Both gain- and loss-of-function experiments demonstrate that Plk4 is required - in cooperation with Cdk2, CP110 and Hs-SAS6 - for the precise reproduction of centrosomes during the cell cycle. These findings provide an attractive explanation for the crucial function of Plk4 in cell proliferation and have implications for the role of Polo kinases in tumorigenesis.	Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Univ Tubingen, Ctr Plant Mol Biol, Electron Microscopy Unit, D-72076 Tubingen, Germany	Max Planck Society; Eberhard Karls University of Tubingen	Nigg, EA (corresponding author), Max Planck Inst Biochem, Dept Cell Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	nigg@biochem.mpg.de		nigg, erich/0000-0003-4835-5719; Wilkinson, Christopher/0000-0002-7448-0938				BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Dammermann A, 2004, DEV CELL, V7, P815, DOI 10.1016/j.devcel.2004.10.015; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Fode C, 1996, MOL CELL BIOL, V16, P4665; Glover DM, 2005, ONCOGENE, V24, P230, DOI 10.1038/sj.onc.1208279; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Karn T, 1997, ONCOL REP, V4, P505; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Leidel S, 2005, NAT CELL BIOL, V7, P115, DOI 10.1038/ncb1220; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumoto Y, 2002, SCIENCE, V295, P499, DOI 10.1126/science.1065693; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; SLUDER G, 2004, CENTROSOMES DEV DIS, P167, DOI DOI 10.1002/3527603808.CH9; Swallow CJ, 2005, ONCOGENE, V24, P306, DOI 10.1038/sj.onc.1208275; VANKREEVELD S, 2004, CENTROSOMES DEV DIS, P43; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059	32	602	618	4	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1140	1146		10.1038/ncb1320	http://dx.doi.org/10.1038/ncb1320			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16244668				2022-12-25	WOS:000232930400019
J	Schwartz, D; Gygi, SP				Schwartz, D; Gygi, SP			An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets	NATURE BIOTECHNOLOGY			English	Article							TYROSINE PHOSPHORYLATION; SEQUENCE MOTIFS; SITES; PHOSPHOPROTEOMICS; GENOMES; CYCLE	With the recent exponential increase in protein phosphorylation sites identified by mass spectrometry, a unique opportunity has arisen to understand the motifs surrounding such sites. Here we present an algorithm designed to extract motifs from large data sets of naturally occurring phosphorylation sites. The methodology relies on the intrinsic alignment of phospho-residues and the extraction of motifs through iterative comparison to a dynamic statistical background. Results show the identification of dozens of novel and known phosphorylation motifs from recently published serine, threonine and tyrosine phosphorylation studies. When applied to a linguistic data set to test the versatility of the approach, the algorithm successfully extracted hundreds of language motifs. This method, in addition to shedding light on the consensus sequences of identified and as yet unidentified kinases and modular protein domains, may also eventually be used as a tool to determine potential phosphorylation sites in proteins of interest.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Schwartz, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	dschwartz@hms.harvard.edu			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003456] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG03456] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Ballif BA, 2004, MOL CELL PROTEOMICS, V3, P1093, DOI 10.1074/mcp.M400085-MCP200; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Boucher L, 2001, RNA, V7, P1693; BRANCH DR, 1995, J IMMUNOL, V154, P3678; Bussemaker HJ, 2000, P NATL ACAD SCI USA, V97, P10096, DOI 10.1073/pnas.180265397; Collins MO, 2005, J BIOL CHEM, V280, P5972, DOI 10.1074/jbc.M411220200; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Diella F, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-79; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Fujioka H, 2002, CHEM IMMUNOL, V80, P1; Gruhler A, 2005, MOL CELL PROTEOMICS, V4, P310, DOI 10.1074/mcp.M400219-MCP200; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; JONASSEN I, 1995, PROTEIN SCI, V4, P1587, DOI 10.1002/pro.5560040817; Loyet KM, 2005, MOL CELL PROTEOMICS, V4, P235, DOI 10.1074/mcp.R400011-MCP200; MANNING BD, 2002, SCI STKE, pPE49; Melville Herman, 1998, MOBY DICK WHALE; Nevill-Manning CG, 1998, P NATL ACAD SCI USA, V95, P5865, DOI 10.1073/pnas.95.11.5865; Nuhse TS, 2004, PLANT CELL, V16, P2394, DOI 10.1105/tpc.104.023150; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pawson T, 2005, TRENDS BIOCHEM SCI, V30, P286, DOI 10.1016/j.tibs.2005.04.013; Rigoutsos I, 1998, BIOINFORMATICS, V14, P55, DOI 10.1093/bioinformatics/14.1.55; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016	29	703	710	0	63	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2005	23	11					1391	1398		10.1038/nbt1146	http://dx.doi.org/10.1038/nbt1146			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	984FN	16273072				2022-12-25	WOS:000233288000034
J	Weissleder, R; Kelly, K; Sun, EY; Shtatland, T; Josephson, L				Weissleder, R; Kelly, K; Sun, EY; Shtatland, T; Josephson, L			Cell-specific targeting of nanoparticles by multivalent attachment of small molecules	NATURE BIOTECHNOLOGY			English	Article							QUANTUM DOTS; IN-VIVO; FLUORESCENT; PROBES; EXPRESSION; AGENTS	Nanomaterials with precise biological functions have considerable potential for use in biomedical applications. Here we investigate whether multivalent attachment of small molecules can increase specific binding affinity and reveal new biological properties of such nanomaterials. We describe the parallel synthesis of a library comprising 146 nanoparticles decorated with different synthetic small molecules. Using fluorescent magnetic nanoparticles, we rapidly screened the library against different cell lines and discovered a series of nanoparticles with high specificity for endothelial cells, activated human macrophages or pancreatic cancer cells. Hits from the last-mentioned screen were shown to target pancreatic cancer in vivo. The method and described materials could facilitate development of functional nanomaterials for applications such as differentiating cell lines, detecting distinct cellular states and targeting specific cell types.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Weissleder, R (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Bldg 149,13th St,Room 5403, Charlestown, MA 02129 USA.	weissleder@helix.mgh.harvard.edu		/0000-0003-0828-4143				Akerman ME, 2002, P NATL ACAD SCI USA, V99, P12617, DOI 10.1073/pnas.152463399; Anderson DG, 2004, NAT BIOTECHNOL, V22, P863, DOI 10.1038/nbt981; Boullier A, 2001, ANN NY ACAD SCI, V947, P214; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Denis MC, 2004, P NATL ACAD SCI USA, V101, P12634, DOI 10.1073/pnas.0404307101; Gao XH, 2003, TRENDS BIOTECHNOL, V21, P371, DOI 10.1016/S0167-7799(03)00209-9; Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; Hogemann D, 2002, BIOCONJUGATE CHEM, V13, P116, DOI 10.1021/bc015549h; Huber MM, 1998, BIOCONJUGATE CHEM, V9, P242, DOI 10.1021/bc970153k; Josephson L, 2002, BIOCONJUGATE CHEM, V13, P554, DOI 10.1021/bc015555d; Kang HW, 2002, BIOCONJUGATE CHEM, V13, P122, DOI 10.1021/bc0155521; Kelly KA, 2004, ANAL BIOCHEM, V330, P181, DOI 10.1016/j.ab.2004.02.035; Kelly KA, 2005, CIRC RES, V96, P327, DOI 10.1161/01.RES.0000155722.17881.dd; Kircher MF, 2004, BIOCONJUGATE CHEM, V15, P242, DOI 10.1021/bc034151d; Libby P, 2002, NAT MED, V8, P1257, DOI 10.1038/nm1102-1257; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; Modo M, 2004, NEUROIMAGE, V21, P311, DOI 10.1016/j.neuroimage.2003.08.030; Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755; Pham W, 2004, CHEMBIOCHEM, V5, P1148, DOI 10.1002/cbic.200400063; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Santra S, 2005, J AM CHEM SOC, V127, P1656, DOI 10.1021/ja0464140; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; SHEN T, 1993, MAGN RESON MED, V29, P599, DOI 10.1002/mrm.1910290504; Tsapis N, 2002, P NATL ACAD SCI USA, V99, P12001, DOI 10.1073/pnas.182233999; Whitesides GM, 2003, NAT BIOTECHNOL, V21, P1161, DOI 10.1038/nbt872; Wu Y, 2004, NATURE, V430, P61, DOI 10.1038/nature02674; Wunderbaldinger P, 2002, ACAD RADIOL, V9, pS304, DOI 10.1016/S1076-6332(03)80210-6; Zorov DB, 2004, CIRC RES, V95, P239, DOI 10.1161/01.RES.0000137875.42385.8e	29	764	805	7	244	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2005	23	11					1418	1423		10.1038/nbt1159	http://dx.doi.org/10.1038/nbt1159			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	984FN	16244656				2022-12-25	WOS:000233288000038
J	Beilke, JN; Kuhl, NR; Van Kaer, L; Gill, RG				Beilke, JN; Kuhl, NR; Van Kaer, L; Gill, RG			NK cells promote islet allograft tolerance via a perforin-dependent mechanism	NATURE MEDICINE			English	Article							NATURAL-KILLER-CELLS; REGULATORY T-CELLS; DENDRITIC CELLS; IN-VIVO; TRANSPLANTATION TOLERANCE; IMMUNE-RESPONSES; MUTANT MICE; ACTIVATION; DEFICIENT; INDUCTION	Although major histocompatibility complex (MHC) class II-restricted CD4 T cells are well appreciated for their contribution to peripheral tolerance to tissue allografts, little is known regarding MHC class I-dependent reactivity in this process. Here we show a crucial role for host MHC class I-dependent NK cell reactivity for allograft tolerance in mice induced through either costimulation blockade using CD154-specific antibody therapy or by targeting LFA-1 (also known as CD11a). Tolerance induction absolutely required host expression of MHC class I, but was independent of CD8 T cell-dependent immunity. Rather, tolerance required innate immunity involving NK1.1(+) cells, but was independent of CD1d-restricted NKT cells. Therefore, NK cells seem to be generally required for induction of tolerance to islet allografts. Additional studies indicate that CD154-specific antibody-induced allograft tolerance is perforin dependent. Notably, NK cells that are perforin competent are sufficient to restore allograft tolerance in perforin-deficient recipients. Together, these results show an obligatory role for NK cells, through perforin, for induction of tolerance to islet allografts.	Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Aurora, CO 80010 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Vanderbilt University	Gill, RG (corresponding author), Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, 1775 Ursula St,Box B-140, Aurora, CO 80010 USA.	ron.g.gill@uchsc.edu	Van Kaer, Luc/H-1033-2015; Gill, Ronald/GWM-5338-2022	Van Kaer, Luc/0000-0001-5275-2309; 				Bose A, 2003, J IMMUNOL, V170, P1611, DOI 10.4049/jimmunol.170.4.1611; Carbone E, 1997, J EXP MED, V185, P2053, DOI 10.1084/jem.185.12.2053; Ciubotariu R, 1998, J IMMUNOL, V161, P5193; Coudert RD, 2002, J IMMUNOL, V169, P2979, DOI 10.4049/jimmunol.169.6.2979; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Dowdell KC, 2003, J IMMUNOL, V171, P234, DOI 10.4049/jimmunol.171.1.234; Ferlazzo G, 2003, EUR J IMMUNOL, V33, P306, DOI 10.1002/immu.200310004; Fort MM, 1998, J IMMUNOL, V161, P3256; Gilliet M, 2002, J EXP MED, V195, P695, DOI 10.1084/jem.20011603; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Hayakawa Y, 2004, J IMMUNOL, V172, P123, DOI 10.4049/jimmunol.172.1.123; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Kondo T, 2000, TRANSPLANTATION, V69, P969; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; Le Moine A, 2003, AM J TRANSPLANT, V3, P101, DOI 10.1034/j.1600-6143.2002.00026.x; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Maier S, 2001, NAT MED, V7, P557, DOI 10.1038/87880; Matsuda JL, 2003, P NATL ACAD SCI USA, V100, P8395, DOI 10.1073/pnas.1332805100; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Nicolls MR, 2002, J IMMUNOL, V169, P4831, DOI 10.4049/jimmunol.169.9.4831; Piccioli D, 2002, J EXP MED, V195, P335, DOI 10.1084/jem.20010934; Pietra G, 2003, EUR J IMMUNOL, V33, P3427, DOI 10.1002/eji.200324515; Rabinovich BA, 2003, J IMMUNOL, V170, P3572, DOI 10.4049/jimmunol.170.7.3572; Raulet DH, 2004, NAT IMMUNOL, V5, P996, DOI 10.1038/ni1114; Seino K, 2001, P NATL ACAD SCI USA, V98, P2577, DOI 10.1073/pnas.041608298; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Sonoda KH, 2002, J IMMUNOL, V168, P2028, DOI 10.4049/jimmunol.168.4.2028; Sun WJ, 2004, IMMUNOL LETT, V94, P191, DOI 10.1016/j.imlet.2004.05.001; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Trambley J, 1999, J CLIN INVEST, V104, P1715, DOI 10.1172/JCI8082; Van Kaer L, 2004, IMMUNOL RES, V30, P139, DOI 10.1385/IR:30:2:139; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; Vankayalapati R, 2004, J IMMUNOL, V172, P130, DOI 10.4049/jimmunol.172.1.130; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Yokoyama WM, 2004, ANNU REV IMMUNOL, V22, P405, DOI 10.1146/annurev.immunol.22.012703.104711; Zhai YA, 2003, J IMMUNOL, V170, P3024, DOI 10.4049/jimmunol.170.6.3024; Zhou J, 2001, J IMMUNOL, V167, P107, DOI 10.4049/jimmunol.167.1.107	40	156	161	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1059	1065		10.1038/nm1296	http://dx.doi.org/10.1038/nm1296			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16155578				2022-12-25	WOS:000232492500026
J	Ren, ZH; Gao, JP; Li, LG; Cai, XL; Huang, W; Chao, DY; Zhu, MZ; Wang, ZY; Luan, S; Lin, HX				Ren, ZH; Gao, JP; Li, LG; Cai, XL; Huang, W; Chao, DY; Zhu, MZ; Wang, ZY; Luan, S; Lin, HX			A rice quantitative trait locus for salt tolerance encodes a sodium transporter	NATURE GENETICS			English	Article							HIGH-AFFINITY POTASSIUM; HKT TRANSPORTERS; K+ NUTRITION; NA+; GENE; ATHKT1; ROOTS; ANTIPORTER; SEQUENCE; GENOME	Many important agronomic traits in crop plants, including stress tolerance, are complex traits controlled by quantitative trait loci (QTLs). Isolation of these QTLs holds great promise to improve world agriculture but is a challenging task. We previously mapped a rice QTL, SKC1, that maintained K+ homeostasis in the salt-tolerant variety under salt stress(1), consistent with the earlier finding that K+ homeostasis is important in salt tolerance(2,3). To understand the molecular basis of this QTL, we isolated the SKC1 gene by map-based cloning and found that it encoded a member of HKT-type transporters. SKC1 is preferentially expressed in the parenchyma cells surrounding the xylem vessels. Voltage-clamp analysis showed that SKC1 protein functions as a Na+-selective transporter. Physiological analysis suggested that SKC1 is involved in regulating K+/Na+ homeostasis under salt stress, providing a potential tool for improving salt tolerance in crops.	Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Plant Physiol & Ecol, Natl key Lab Plant Mol Genet, Shanghai 200032, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; UC Berkeley Ctr Mol Life Sci, Shanghai Inst Biol Sci, Shanghai 200032, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Plant Physiol & Ecol, SHARF Lab, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; University of California System; University of California Berkeley; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Lin, HX (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Plant Physiol & Ecol, Natl key Lab Plant Mol Genet, 300 Fenglin Rd, Shanghai 200032, Peoples R China.	sluan@nature.berkeley.edu; hxlin@sibs.ac.cn	Chao, Dai-Yin/H-1357-2012; Lin, Hong-Xuan/AEQ-6607-2022; Ren, Zhonghai/N-6944-2019; Chao, Daiyin/A-5213-2013	Lin, Hong-Xuan/0000-0002-2818-023X; Ren, Zhonghai/0000-0002-0759-3668; ?, ??/0000-0003-2832-4800; cai, xiu ling/0000-0001-8333-4556; Gao, Ji-Ping/0000-0002-8968-4423				Akbar M., 1986, PROGR RAINFED LOWLAN; Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; Berthomieu P, 2003, EMBO J, V22, P2004, DOI 10.1093/emboj/cdg207; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; EPSTEIN E, 1961, PLANT PHYSIOL, V36, P437, DOI 10.1104/pp.36.4.437; Garciadeblas B, 2003, PLANT J, V34, P788, DOI 10.1046/j.1365-313X.2003.01764.x; Gassmann W, 1996, PLANT J, V10, P869, DOI 10.1046/j.1365-313X.1996.10050869.x; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; Horie T, 2001, PLANT J, V27, P129, DOI 10.1046/j.1365-313x.2001.01077.x; Kato Y, 2001, P NATL ACAD SCI USA, V98, P6488, DOI 10.1073/pnas.101556598; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; LANDER ES, 1989, GENETICS, V121, P185; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; Lin HX, 2004, THEOR APPL GENET, V108, P253, DOI 10.1007/s00122-003-1421-y; Liu K, 2001, PLANT CELL, V13, P1453, DOI 10.1105/tpc.13.6.1453; Maathuis FJM, 1999, ANN BOT-LONDON, V84, P123, DOI 10.1006/anbo.1999.0912; Mao J, 2005, P NATL ACAD SCI USA, V102, P12270, DOI 10.1073/pnas.0501011102; MOONS A, 1995, PLANT PHYSIOL, V107, P177, DOI 10.1104/pp.107.1.177; Qi Z, 2004, PLANT PHYSIOL, V136, P2548, DOI 10.1104/pp.104.049213; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Rus A, 2004, PLANT PHYSIOL, V136, P2500, DOI 10.1104/pp.104.042234; Sasaki T, 2002, NATURE, V420, P312, DOI 10.1038/nature01184; Schachtman D, 1999, TRENDS PLANT SCI, V4, P281, DOI 10.1016/S1360-1385(99)01428-4; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; Shi HZ, 2002, PLANT CELL, V14, P465, DOI 10.1105/tpc.010371; Subramanian VS, 2001, AM J PHYSIOL-GASTR L, V281, pG1477, DOI 10.1152/ajpgi.2001.281.6.G1477; Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249; Wang TB, 1998, PLANT PHYSIOL, V118, P651, DOI 10.1104/pp.118.2.651; Zhu JK, 2001, TRENDS PLANT SCI, V6, P66, DOI 10.1016/S1360-1385(00)01838-0	30	881	1052	18	324	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1141	1146		10.1038/ng1643	http://dx.doi.org/10.1038/ng1643			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16155566				2022-12-25	WOS:000232185600029
J	Carson, KL				Carson, KL			Flexibility - the guiding principle for antibody manufacturing	NATURE BIOTECHNOLOGY			English	Editorial Material									Williamsburg Bioproc Fdn, Virginia Beach, VA 23451 USA		Carson, KL (corresponding author), Williamsburg Bioproc Fdn, Fdn POB 1229,1206 Laskin Rd,Suite 201, Virginia Beach, VA 23451 USA.	kcarson@wilbio.com							0	46	57	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1054	1058		10.1038/nbt0905-1054	http://dx.doi.org/10.1038/nbt0905-1054			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16151390				2022-12-25	WOS:000231790600016
J	Song, S; Ewald, AJ; Stallcup, W; Werb, Z; Bergers, G				Song, S; Ewald, AJ; Stallcup, W; Werb, Z; Bergers, G			PDGFR beta(+) perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival	NATURE CELL BIOLOGY			English	Article							BLOOD-VESSEL FORMATION; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; ENDOTHELIAL-CELL; PDGF-B; NG2 PROTEOGLYCAN; TGF-BETA; TUMORIGENESIS; ANGIOGENESIS; RECRUITMENT	The microvasculature consists of endothelial cells and their surrounding pericytes. Few studies on the regulatory mechanisms of tumour angiogenesis have focused on pericytes. Here we report the identification of tumour- derived PDGFR beta(+) ( platelet- derived growth factor receptor beta) progenitor perivascular cells ( PPCs) that have the ability to differentiate into pericytes and regulate vessel stability and vascular survival in tumours. A subset of PDGFR beta(+) PPCs is recruited from bone marrow to perivascular sites in tumours. Specific inhibition of PDGFR beta signalling eliminates PDGFR beta(+) PPCs and mature pericytes around tumour vessels, leading to vascular hyperdilation and endothelial cell apoptosis in pancreatic islet tumours of transgenic Rip1Tag2 mice.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Sanford Burnham Prebys Medical Discovery Institute	Bergers, G (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 513 Parnassus Ave, San Francisco, CA 94143 USA.	bergers@itsa.ucsf.edu	Bergers, Gabriele/AAJ-5535-2020		NCI NIH HHS [P01 CA072006-07, R01 CA95287, R01 CA109390-01, R01 CA095287-05, P01 CA72006, R01 CA099948, P01 CA072006, R01 CA095287, R01 CA109390, R01 CA99948] Funding Source: Medline; NHLBI NIH HHS [T32 HL007731, 5T32HL007731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109390, P01CA072006, R01CA099948, R01CA095287] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bergers G, 1998, INT J DEV BIOL, V42, P995; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Betsholtz C, 2005, EXP SUPPL, V94, P115; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Bondjers C, 2003, AM J PATHOL, V162, P721, DOI 10.1016/S0002-9440(10)63868-0; Chen SY, 2004, CIRC RES, V94, P1195, DOI 10.1161/01.RES.0000126897.41658.81; Cho H, 2003, FASEB J, V17, P440, DOI 10.1096/fj.02-0340fje; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Darland DC, 2001, CURR TOP DEV BIOL, V52, P107, DOI 10.1016/S0070-2153(01)52010-4; Ding RB, 2004, STEM CELLS DEV, V13, P509, DOI 10.1089/1547328042417336; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Lindahl P, 1997, SCIENCE, V126, P3047; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nishishita T, 2004, J CELL BIOCHEM, V91, P584, DOI 10.1002/jcb.10718; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Ozerdem Ugur, 2003, Angiogenesis, V6, P241, DOI 10.1023/B:AGEN.0000021401.58039.a9; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093; Rabbany SY, 2003, TRENDS MOL MED, V9, P109, DOI 10.1016/S1471-4914(03)00021-2; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Rajantie I, 2004, BLOOD, V104, P2084, DOI 10.1182/blood-2004-01-0336; Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje; Shaheen RM, 2001, CANCER RES, V61, P1464; Sims DE, 2000, CLIN EXP PHARMACOL P, V27, P842, DOI 10.1046/j.1440-1681.2000.03343.x; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	43	422	434	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2005	7	9					870	U16		10.1038/ncb1288	http://dx.doi.org/10.1038/ncb1288			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	960NY	16113679	Green Accepted			2022-12-25	WOS:000231601600010
J	Bovenberg, J				Bovenberg, J			Whose tissue is it anyway?	NATURE BIOTECHNOLOGY			English	Editorial Material							GENETICS	The current legal system fails to provide an equitable balance between the rights of researchers and the rights of donors of biological materials. Could the tax system provide a solution?	Leiden Univ, Netherlands NWO Genom Initiat, Fac Law, NL-2300 RA Leiden, Netherlands; Ctr Med Syst Biol, Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Bovenberg, J (corresponding author), Leiden Univ, Netherlands NWO Genom Initiat, Fac Law, NL-2300 RA Leiden, Netherlands.	jabovenberg@xs4all.nl						[Anonymous], 2002, STAT HUM GEN DAT; BOVENBERG JA, 2004, SCRIPT ED, V4, P591; Cairney R, 1998, CAN MED ASSOC J, V159, P1451; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; FREDRICKSON JK, 1998, J CONT HLTH L POLICY, V477, P496; Gitter Donna, 2004, WASHINGTON LEE LAW R, V61, P257; Harrison CH, 2002, AM J LAW MED, V28, P77; *HUM GEN ORG ETH C, 2000, STAT BEN SHAR APR 9; Interim Advisory Group on Ethics and Governance, 2003, UK BIOB ETH GOV FRAM; Laurie Graeme, 2002, GENETIC PRIVACY CHAL; Looney Barbara, 1994, Law Policy Int Bus, V26, P231; Marshall E, 2004, SCIENCE, V305, P1226; Merz JF, 2002, AM J HUM GENET, V70, P965, DOI 10.1086/339767; Munzer SR, 1999, RUTGERS LAW REV, V51, P493; PETRONE J, 2004, BALTIC TIMES    0129; PORTER G, 2004, BLOOD DATA ETHICAL L, P85; TERRY PF, 2003, POPULATIONS GENETICS, P377; *UK BIOB, 2004, SAMPL HANDL STOR SUB; *UNESCO, 1997, DECL HUM GEN REC GEN, V1; United Nations Educational Scientific and Cultural Organisation (UNESCO), 2003, INT DECL HUM GEN DAT; *US C, 1987, NEW DEV BIOT OWN HUM, P79; *US NAT RES COUNC, 1997, EV HUM GEN DIV; Winickoff DE, 2003, NEW ENGL J MED, V349, P1180, DOI 10.1056/NEJMsb030036	23	19	19	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2005	23	8					929	933		10.1038/nbt0805-929	http://dx.doi.org/10.1038/nbt0805-929			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	952QF	16082356				2022-12-25	WOS:000231019900015
J	Luo, MK; Fadeev, EA; Groves, JT				Luo, MK; Fadeev, EA; Groves, JT			Mycobactin-mediated iron acquisition within macrophages	NATURE CHEMICAL BIOLOGY			English	Article							SIDEROPHORE BIOSYNTHESIS; AMPHIPHILIC SIDEROPHORE; LIPID BODIES; METABOLISM; TRANSFERRIN; TUBERCULOSIS; INTERFERON; ACTIVATION; EXPRESSION; DYNAMICS	Restricting the availability of iron is an important strategy for defense against bacterial infection(1-3). Mycobacterium tuberculosis survives within the phagosomes of macrophages; consequently, iron acquisition is particularly difficult for M. tuberculosis, because the phagosomal membrane is an additional barrier for its iron access(4,5). However, little is known about the iron transport and acquisition pathways adapted by this microbe in vivo(6). Extracellular iron sources are usually mobilized by hydrophilic siderophores(7,8). Here, we describe direct evidence that mycobactins, the lipophilic siderophores of mycobacteria, efficiently extract intracellular macrophage iron. The metal-free siderophore is diffusely associated with the macrophage membrane, ready for iron chelation. Notably, the mycobactin-metal complex accumulates with high selectivity in macrophage lipid droplets, intracellular domains for lipid storage and sorting(9,10). In our experiments, these mycobactin-targeted lipid droplets were found in direct contact with phagosomes, poised for iron delivery. The existence of this previously undescribed iron acquisition pathway indicates that mycobacteria have taken advantage of endogenous macrophage mechanisms for iron mobilization and lipid sorting for iron acquisition during infection. The pathway could represent a new target for the control of mycobacterial infection.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	Princeton University	Groves, JT (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	jtgroves@princeton.edu	Groves, John T./GPP-7588-2022	Groves, John T./0000-0002-9944-5899				Albrecht-Gary AM, 1998, MET IONS BIOL SYST, V35, P239; Burke B., 2002, MACROPHAGE; BYRD TF, 1993, J CLIN INVEST, V91, P969, DOI 10.1172/JCI116318; Crosa JH, 2002, MICROBIOL MOL BIOL R, V66, P223, DOI 10.1128/MMBR.66.2.223-249.2002; De Voss JJ, 1999, J BACTERIOL, V181, P4443, DOI 10.1128/JB.181.15.4443-4451.1999; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; DVORAK AM, 1983, J IMMUNOL, V131, P2965; Fadeev EA, 2004, J AM CHEM SOC, V126, P12065, DOI 10.1021/ja048145j; Ferreras JA, 2005, NAT CHEM BIOL, V1, P29, DOI 10.1038/nchembio706; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Fluckinger M, 2004, ANTIMICROB AGENTS CH, V48, P3367, DOI 10.1128/AAC.48.9.3367-3372.2004; Luo M, 2005, J AM CHEM SOC, V127, P1726, DOI 10.1021/ja044230f; Melo RCN, 2003, TISSUE CELL, V35, P59, DOI 10.1016/S0040-8166(02)00105-2; Moody DB, 2004, SCIENCE, V303, P527, DOI 10.1126/science.1089353; Mulero V, 1999, BLOOD, V94, P2383, DOI 10.1182/blood.V94.7.2383.419k20_2383_2389; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Olakanmi O, 2002, J BIOL CHEM, V277, P49727, DOI 10.1074/jbc.M209768200; Olakanmi O, 2000, INFECT IMMUN, V68, P5619, DOI 10.1128/IAI.68.10.5619-5627.2000; Pieters J, 2001, MICROBES INFECT, V3, P249, DOI 10.1016/S1286-4579(01)01376-4; Ratledge C, 2004, TUBERCULOSIS, V84, P110, DOI 10.1016/j.tube.2003.08.012; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Rhoades ER, 2000, IMMUNOL CELL BIOL, V78, P301, DOI 10.1046/j.1440-1711.2000.00938.x; Schaible ME, 2004, NAT REV MICROBIOL, V2, P946, DOI 10.1038/nrmicro1046; Sun HZ, 1999, CHEM REV, V99, P2817, DOI 10.1021/cr980430w; TESTA U, 1989, J BIOL CHEM, V264, P13181; TORTI SV, 1988, J BIOL CHEM, V263, P12638; Vergne AF, 2000, NAT PROD REP, V17, P99, DOI 10.1039/a809397k; WEISS G, 1995, IMMUNOL TODAY, V16, P495, DOI 10.1016/0167-5699(95)80034-4; Xu GF, 2002, J AM CHEM SOC, V124, P13408, DOI 10.1021/ja026768w; Yu WG, 1998, AM J PATHOL, V152, P759	30	105	130	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2005	1	3					149	153		10.1038/nchembio717	http://dx.doi.org/10.1038/nchembio717			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GJ	16408019				2022-12-25	WOS:000232648700014
J	Phan, AT; Kuryavyi, V; Gaw, HY; Patel, DJ				Phan, AT; Kuryavyi, V; Gaw, HY; Patel, DJ			Small-molecule interaction with a five-guanine-tract G-quadruplex structure from the human MYC promoter	NATURE CHEMICAL BIOLOGY			English	Article							HUMAN C-MYC; DNA QUADRUPLEX; TELOMERIC DNA; G-TETRAPLEX; G-QUARTETS; ELEMENT; GENE; REGION; BINDING; TARGET	It has been widely accepted that DNA can adopt other biologically relevant structures beside the Watson-Crick double helix. One recent important example is the guanine-quadruplex (G-quadruplex) structure formed by guanine tracts found in the MYC (or c-myc) promoter region, which regulates the transcription of the MYC oncogene. Stabilization of this G-quadruplex by ligands, such as the cationic porphyrin TMPyP4, decreases the transcriptional level of MYC. Here, we report the first structure of a DNA fragment containing five guanine tracts from this region. An unusual G-quadruplex fold, which was derived from NMR restraints using unambiguous model-independent resonance assignment approaches, involves a core of three stacked guanine tetrads formed by four parallel guanine tracts with all anti guanines and a snapback 3'-end syn guanine. We have determined the structure of the complex formed between this G-quadruplex and TMPyP4. This structural information, combined with details of small-molecule interaction, provides a platform for the design of anticancer drugs targeting multi-guanine-tract sequences that are found in the MYC and other oncogenic promoters, as well as in telomeres.	Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Patel, DJ (corresponding author), Mem Sloan Kettering Canc Ctr, Struct Biol Program, 1275 York Ave, New York, NY 10021 USA.	phantuan@mskcc.org; pateld@mskcc.org	Phan, Anh Tuan/A-3673-2010	Phan, Anh Tuan/0000-0002-4970-3861	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034504, P41GM066354] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline; NIGMS NIH HHS [R01 GM034504, GM66354, GM34504, P41 GM066354] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrus A, 2005, BIOCHEMISTRY-US, V44, P2048, DOI 10.1021/bi048242p; Bennett M, 2000, P NATL ACAD SCI USA, V97, P9476, DOI 10.1073/pnas.160271897; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Clark GR, 2003, J AM CHEM SOC, V125, P4066, DOI 10.1021/ja0297988; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; Dang CV, 1999, MOL CELL BIOL, V19, P1; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Davis JT, 2004, ANGEW CHEM INT EDIT, V43, P668, DOI 10.1002/anie.200300589; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; Grand CL, 2004, P NATL ACAD SCI USA, V101, P6140, DOI 10.1073/pnas.0400460101; GUO Q, 1992, BIOCHEMISTRY-US, V31, P2451, DOI 10.1021/bi00124a002; Hazel P, 2004, J AM CHEM SOC, V126, P16405, DOI 10.1021/ja045154j; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Kettani A, 2000, J MOL BIOL, V297, P627, DOI 10.1006/jmbi.2000.3524; Kettani A, 2000, J MOL BIOL, V301, P129, DOI 10.1006/jmbi.2000.3932; Kettani A, 1997, NAT STRUCT BIOL, V4, P382, DOI 10.1038/nsb0597-382; Koeppel F, 2001, NUCLEIC ACIDS RES, V29, P1087, DOI 10.1093/nar/29.5.1087; Kuryavyi V, 2000, J MOL BIOL, V295, P455, DOI 10.1006/jmbi.1999.3345; KURYAVYI VV, 1996, BIOL STRUCTURE DYNAM, V2, P91; Levens D, 1997, CURR TOP MICROBIOL, V224, P33; Maiti S, 2003, BIOCHEM BIOPH RES CO, V310, P505, DOI 10.1016/j.bbrc.2003.09.052; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Matsugami A, 2001, J MOL BIOL, V313, P255, DOI 10.1006/jmbi.2001.5047; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102; Phan AT, 2004, J AM CHEM SOC, V126, P8710, DOI 10.1021/ja048805k; Phan AT, 2002, J AM CHEM SOC, V124, P1160, DOI 10.1021/ja011977m; Phan AT, 2001, METHOD ENZYMOL, V338, P341; Seenisamy J, 2005, J AM CHEM SOC, V127, P2944, DOI 10.1021/ja0444482; Seenisamy J, 2004, J AM CHEM SOC, V126, P8702, DOI 10.1021/ja040022b; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; WANG Y, 1994, STRUCTURE, V2, P1141, DOI 10.1016/S0969-2126(94)00117-0; Yamashita T, 2005, BIOORGAN MED CHEM, V13, P2423, DOI 10.1016/j.bmc.2005.01.041; Zhang N, 2001, J MOL BIOL, V311, P1063, DOI 10.1006/jmbi.2001.4916	45	419	427	1	134	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2005	1	3					167	173		10.1038/nchembio723	http://dx.doi.org/10.1038/nchembio723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GJ	16408022	Green Accepted			2022-12-25	WOS:000232648700017
J	Han, JDJ; Dupuy, D; Bertin, N; Cusick, ME; Vidal, M				Han, JDJ; Dupuy, D; Bertin, N; Cusick, ME; Vidal, M			Effect of sampling on topology predictions of protein-protein interaction networks	NATURE BIOTECHNOLOGY			English	Article							SCALE-FREE; YEAST; COMPLEXES; STRATEGY; BIOLOGY; MODULES; MAP	Currently available protein-protein interaction (PPI) network or 'interactome' maps, obtained with the yeast two-hybrid (Y2H) assay or by co-affinity purification followed by mass spectrometry (co-AP/MS), only cover a fraction of the complete PPI networks. These partial networks display scale-free topologies-most proteins participate in only a few interactions whereas a few proteins have many interaction partners. Here we analyze whether the scale-free topologies of the partial networks obtained from Y2H assays can be used to accurately infer the topology of complete interactomes. We generated four theoretical interaction networks of different topologies ( random, exponential, power law, truncated normal). Partial sampling of these networks resulted in sub-networks with topological characteristics that were virtually indistinguishable from those of currently available Y2H-derived partial interactome maps. We conclude that given the current limited coverage levels, the observed scale-free topology of existing interactome maps cannot be confidently extrapolated to complete interactomes.	Harvard Univ, Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA; Harvard Univ, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Vidal, M (corresponding author), Harvard Univ, Dana Farber Canc Inst, Ctr Canc Syst Biol, 44 Binney St, Boston, MA 02115 USA.	marc_vidal@dfci.harvard.edu	Dupuy, Denis/M-7299-2014; Bertin, Nicolas/O-9602-2019; Bertin, Nicolas/C-3025-2008	Dupuy, Denis/0000-0002-4781-5595; Han, Jing-Dong J./0000-0002-9270-7139; Bertin, Nicolas/0000-0002-9835-9606				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Apic G, 2005, FEBS LETT, V579, P1872, DOI 10.1016/j.febslet.2005.02.023; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 2000, PHYSICA A, V281, P69, DOI 10.1016/S0378-4371(00)00018-2; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bork P, 2004, CURR OPIN STRUC BIOL, V14, P292, DOI 10.1016/j.sbi.2004.05.003; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Dunn R, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-39; Edwards AM, 2002, TRENDS GENET, V18, P529, DOI 10.1016/S0168-9525(02)02763-4; Eisenberg E, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.138701; ERDOS P, 1960, B INT STATIST INST, V38, P343; Formstecher E, 2005, GENOME RES, V15, P376, DOI 10.1101/gr.2659105; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Grigoriev A, 2003, NUCLEIC ACIDS RES, V31, P4157, DOI 10.1093/nar/gkg466; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2002, MOL CELL PROTEOMICS, V1, P561, DOI 10.1074/mcp.R200005-MCP200; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Lappe M, 2004, NAT BIOTECHNOL, V22, P98, DOI 10.1038/nbt921; Legrain P, 2001, TRENDS GENET, V17, P346, DOI 10.1016/S0168-9525(01)02323-X; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Pereira-Leal JB, 2005, MOL BIOL EVOL, V22, P421, DOI 10.1093/molbev/msi024; Pereira-Leal JB, 2004, PROTEINS, V54, P49, DOI 10.1002/prot.10505; Poyatos JF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-11-r93; Przulj N, 2004, BIOINFORMATICS, V20, P3508, DOI 10.1093/bioinformatics/bth436; Qin H, 2003, P NATL ACAD SCI USA, V100, P12820, DOI 10.1073/pnas.2235584100; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Rives AW, 2003, P NATL ACAD SCI USA, V100, P1128, DOI 10.1073/pnas.0237338100; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; STUMPF MP, 2005, P NATL ACAD SCI US; Thomas A, 2003, BIOCHEM SOC T, V31, P1491; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vidalain PO, 2004, METHODS, V32, P363, DOI 10.1016/j.ymeth.2003.10.001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wagner A, 2000, NAT GENET, V24, P355, DOI 10.1038/74174; Walhout AJM, 1999, GENOME RES, V9, P1128, DOI 10.1101/gr.9.11.1128; Walhout AJM, 2000, YEAST, V17, P88, DOI 10.1002/1097-0061(20000630)17:2<88::AID-YEA20>3.0.CO;2-Y; Yook SH, 2004, PROTEOMICS, V4, P928, DOI 10.1002/pmic.200300636; Yook SH, 2002, P NATL ACAD SCI USA, V99, P13382, DOI 10.1073/pnas.172501399; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	51	246	257	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2005	23	7					839	844		10.1038/nbt1116	http://dx.doi.org/10.1038/nbt1116			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	944KT	16003372				2022-12-25	WOS:000230427700031
J	Wong, S; Wolfe, KH				Wong, S; Wolfe, KH			Birth of a metabolic gene cluster in yeast by adaptive gene relocation	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; RECRUITMENT; LINKAGE	Although most eukaryotic genomes lack operons, they contain some physical clusters of genes that are related in function despite being unrelated in sequence(1-5). How these clusters are formed during evolution is unknown. The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source(6). We show here that the DAL cluster was assembled, quite recently in evolutionary terms, through a set of genomic rearrangements that happened almost simultaneously. Six of the eight genes involved in allantoin degradation, which were previously scattered around the genome, became relocated to a single subtelomeric site in an ancestor of S. cerevisiae and Saccharomyces castellii. These genomic rearrangements coincided with a biochemical reorganization of the purine degradation pathway, which switched to importing allantoin instead of urate. This change eliminated urate oxidase, one of several oxygen- consuming enzymes that were lost by yeasts that can grow vigorously in anaerobic conditions. The DAL cluster is located in a domain of modified chromatin involving both H2A. Z histone exchange and Hst1- Sum1 - mediated histone deacetylation, and it may be a coadapted gene complex formed by epistatic selection.	Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Dublin 2, Ireland	Trinity College Dublin	Wolfe, KH (corresponding author), Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Dublin 2, Ireland.	khwolfe@tcd.ie	Wolfe, Kenneth H/B-4653-2009	Wolfe, Kenneth/0000-0003-4992-4979				Blumenthal T, 2003, NAT REV GENET, V4, P110, DOI 10.1038/nrg995; Bursell, 1967, ADV INSECT PHYSIOL, V4, P33, DOI [10.1016/S0065-2806(08)60207-6, DOI 10.1016/S0065-2806(08)60207-6]; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; Cooper TG, 1996, MYCOTA, V3, P139; Daran-Lapujade P, 2003, FEMS YEAST RES, V4, P259, DOI 10.1016/S1567-1356(03)00156-9; Deak T., 1996, HDB FOOD SPOILAGE YE; Gerton JL, 2000, P NATL ACAD SCI USA, V97, P11383, DOI 10.1073/pnas.97.21.11383; HARTIG A, 1992, NUCLEIC ACIDS RES, V20, P5677, DOI 10.1093/nar/20.21.5677; Hittinger CT, 2004, P NATL ACAD SCI USA, V101, P14144, DOI 10.1073/pnas.0404319101; Hurst LD, 2004, NAT REV GENET, V5, P299, DOI 10.1038/nrg1319; Hurst LD, 2002, TRENDS GENET, V18, P604, DOI 10.1016/S0168-9525(02)02813-5; Keller NP, 1997, FUNGAL GENET BIOL, V21, P17, DOI 10.1006/fgbi.1997.0970; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Kurtzman CP, 2003, FEMS YEAST RES, V3, P417, DOI 10.1016/S1567-1356(03)00012-6; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; LARUE TA, 1968, CAN J MICROBIOL, V14, P79, DOI 10.1139/m68-012; Lee JM, 2003, GENOME RES, V13, P875, DOI 10.1101/gr.737703; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; NEI M, 1967, GENETICS, V57, P625; Pal C, 2003, NAT GENET, V33, P392, DOI 10.1038/ng1111; People M., 1997, PLANT METABOLISM, P525; Pierce M, 2003, MOL CELL BIOL, V23, P4814, DOI 10.1128/MCB.23.14.4814-4825.2003; Piskur J, 2004, MOL MICROBIOL, V53, P381, DOI 10.1111/j.1365-2958.2004.04182.x; Qi X, 2004, P NATL ACAD SCI USA, V101, P8233, DOI 10.1073/pnas.0401301101; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; TAKADA Y, 1987, J BACTERIOL, V169, P2284, DOI 10.1128/jb.169.5.2284-2286.1987; van der Klei IJ, 1997, TRENDS MICROBIOL, V5, P502, DOI 10.1016/S0966-842X(97)01156-6	30	151	153	3	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					777	782		10.1038/ng1584	http://dx.doi.org/10.1038/ng1584			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15951822				2022-12-25	WOS:000230196400028
J	Waters, MF; Minassian, NA; Stevanin, G; Figueroa, KP; Bannister, JPA; Nolte, D; Mock, AF; Evidente, VGH; Fee, DB; Muller, U; Durr, A; Brice, A; Papazian, DM; Pulst, SM				Waters, MF; Minassian, NA; Stevanin, G; Figueroa, KP; Bannister, JPA; Nolte, D; Mock, AF; Evidente, VGH; Fee, DB; Muller, U; Durr, A; Brice, A; Papazian, DM; Pulst, SM			Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes	NATURE GENETICS			English	Article							CEREBELLAR PURKINJE-CELLS; SHAKER K+ CHANNEL; MICE LACKING; KV3.3; SUBUNIT; DYSFUNCTION; ACTIVATION; RESIDUES; SEGMENTS; NEURONS	Potassium channel mutations have been described in episodic neurological diseases(1). We report that K+ channel mutations cause disease phenotypes with neurodevelopmental and neurodegenerative features. In a Filipino adult-onset ataxia pedigree, the causative gene maps to 19q13, overlapping the SCA13 disease locus described in a French pedigree with childhood-onset ataxia and cognitive delay(2). This region contains KCNC3 (also known as Kv3.3), encoding a voltage-gated Shaw channel with enriched cerebellar expression(3). Sequencing revealed two missense mutations, both of which alter KCNC3 function in Xenopus laevis expression systems. KCNC3(R420H), located in the voltage-sensing domain(4), had no channel activity when expressed alone and had a dominant-negative effect when co-expressed with the wild-type channel. KCNC3(F448L) shifted the activation curve in the negative direction and slowed channel closing. Thus, KCNC3(R420H) and KCNC3(F448L) are expected to change the output characteristics of fast-spiking cerebellar neurons, in which KCNC channels confer capacity for high-frequency firing. Our results establish a role for KCNC3 in phenotypes ranging from developmental disorders to adult-onset neurodegeneration and suggest voltage-gated K+ channels as candidates for additional neurodegenerative diseases.	Cedars Sinai Med Ctr, Div Neurol, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Rose Moss Lab Parkinsons & Neurodegenerat Dis, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90024 USA; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Genet Cytogenet & Embryol, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, U679, F-75013 Paris, France; Univ Giessen, Inst Humangenet, D-35392 Giessen, Germany; Mayo Clin, Dept Neurol, Scottsdale, AZ 85259 USA; Univ Kentucky, Coll Med, Dept Neurol, Lexington, KY 40536 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Justus Liebig University Giessen; Mayo Clinic; Mayo Clinic Phoenix; University of Kentucky; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pulst, SM (corresponding author), Cedars Sinai Med Ctr, Div Neurol, Los Angeles, CA 90048 USA.	stefan.pulst@cshs.org	Stevanin, Giovanni/E-5038-2016; Brice, Alexis/A-2170-2009; brice, alexis/AAE-8275-2019	Stevanin, Giovanni/0000-0001-9368-8657; brice, alexis/0000-0002-0941-3990	NIGMS NIH HHS [R01 GM043459-17, R01GM43459, R01 GM043459-16, R01GM66686, T32GM065823, R01 GM043459] Funding Source: Medline; PHS HHS [R01N533123] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043459, T32GM065823, R01GM066686] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Angulo E, 2004, J NEUROCHEM, V91, P547, DOI 10.1111/j.1471-4159.2004.02771.x; Ariano MA, 2005, J NEUROPHYSIOL, V93, P2565, DOI 10.1152/jn.00791.2004; Baranauskas G, 1999, J NEUROSCI, V19, P6394; DEMIERA EV, 1992, BIOCHEM BIOPH RES CO, V186, P1681; DUPRAT F, 1995, P NATL ACAD SCI USA, V92, P11796, DOI 10.1073/pnas.92.25.11796; Espinosa F, 2001, J NEUROSCI, V21, P6657, DOI 10.1523/JNEUROSCI.21-17-06657.2001; GHANSHANI S, 1992, GENOMICS, V12, P190, DOI 10.1016/0888-7543(92)90365-Y; GOLDMANWOHL DS, 1994, J NEUROSCI, V14, P511; Graves TD, 2005, POSTGRAD MED J, V81, P20, DOI 10.1136/pgmj.2004.022012; Herman-Bert A, 2000, AM J HUM GENET, V67, P229, DOI 10.1086/302958; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Martina M, 2003, J NEUROSCI, V23, P5698; Matsukawa H, 2003, J NEUROSCI, V23, P7677; McKay BE, 2005, J PHYSIOL-LONDON, V567, P829, DOI 10.1113/jphysiol.2005.089383; McKay BE, 2004, EUR J NEUROSCI, V20, P729, DOI 10.1111/j.1460-9568.2004.03539.x; McMahon A, 2004, EUR J NEUROSCI, V19, P3317, DOI 10.1111/j.0953-816X.2004.03385.x; PULST SM, 2003, GENETICS MOVEMENT DI, pCH2; Rae JL, 2000, EXP EYE RES, V70, P339, DOI 10.1006/exer.1999.0796; Rudy B, 2001, TRENDS NEUROSCI, V24, P517, DOI 10.1016/S0166-2236(00)01892-0; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; Shieh CC, 1997, J GEN PHYSIOL, V109, P767, DOI 10.1085/jgp.109.6.767; Silverman WR, 2000, J GEN PHYSIOL, V116, P663, DOI 10.1085/jgp.116.5.663; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P421, DOI 10.1085/jgp.111.3.421; Waters MF, 2005, NEUROLOGY, V65, P1111, DOI 10.1212/01.wnl.0000177490.05162.41; WEISER M, 1994, J NEUROSCI, V14, P949, DOI 10.1523/JNEUROSCI.14-03-00949.1994	30	214	232	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2006	38	4					447	451		10.1038/ng1758	http://dx.doi.org/10.1038/ng1758			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16501573				2022-12-25	WOS:000236340500017
J	Hao, E; Tyrberg, B; Itkin-Ansari, P; Lakey, JRT; Geron, I; Monosov, EZ; Barcova, M; Mercola, M; Levine, F				Hao, E; Tyrberg, B; Itkin-Ansari, P; Lakey, JRT; Geron, I; Monosov, EZ; Barcova, M; Mercola, M; Levine, F			Beta-cell differentiation from nonendocrine epithelial cells of the adult human pancreas	NATURE MEDICINE			English	Article							HUMAN-FETAL PANCREAS; ISLET PRECURSOR CELLS; STEM-CELLS; PROGENITOR CELLS; IN-VITRO; ENDOCRINE PANCREAS; NESTIN EXPRESSION; ENDOTHELIAL-CELLS; POSITIVE CELLS; RAT PANCREAS	The nature and even existence of adult pancreatic endocrine stem or progenitor cells is a subject of controversy in the field of beta-cell replacement for diabetes. One place to search for such cells is in the nonendocrine fraction of cells that remain after islet isolation, which consist of a mixture of epithelia and mesenchyme. Culture in G418 resulted in elimination of the mesenchymal cells, leaving a highly purified population of nonendocrine pancreatic epithelial cells (NEPECs). To evaluate their differentiation potential, NEPECs were heritably marked and transplanted under the kidney capsule of immunodeficient mice. When cotransplanted with fetal pancreatic cells, NEPECs were capable of endocrine differentiation. We found no evidence of beta-cell replication or cell fusion that could have explained the appearance of insulin positive cells from a source other than NEPECs. Nonendocrine-to-endocrine differentiation of NEPECs supports the existence of endocrine stem or progenitor cells within the epithelial compartment of the adult human pancreas.	Univ Calif San Diego, Rebecca & John Moores UCSD Canc Ctr, La Jolla, CA 92093 USA; Burnham Inst, Stem Cells & Regenerat Program, La Jolla, CA 92037 USA; Univ Alberta, Clin Islet Isolat Lab, Edmonton, AB T6G 2N8, Canada	University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University of Alberta	Levine, F (corresponding author), Univ Calif San Diego, Rebecca & John Moores UCSD Canc Ctr, 9500 Gilman Dr,MC 0816, La Jolla, CA 92093 USA.	flevine@ucsd.edu	; Levine, Fred/L-2693-2013	Tyrberg, Bjorn/0000-0003-0976-1220; Levine, Fred/0000-0002-7336-2526				Abraham EJ, 2002, ENDOCRINOLOGY, V143, P3152, DOI 10.1210/en.143.8.3152; Beattie GM, 1996, DIABETES, V45, P1223, DOI 10.2337/diabetes.45.9.1223; BEATTIE GM, 1994, J CLIN ENDOCR METAB, V78, P1232, DOI 10.1210/jc.78.5.1232; BEATTIE GM, 1994, CELL TRANSPLANT, V3, P421, DOI 10.1177/096368979400300509; Bogdani M, 2003, DIABETOLOGIA, V46, P830, DOI 10.1007/s00125-003-1118-4; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; BONNERWEIR S, 1993, DIABETES, V42, P1715, DOI 10.2337/diabetes.42.12.1715; Bouwens L, 1997, DIABETOLOGIA, V40, P398, DOI 10.1007/s001250050693; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Delacour A, 2004, MECH DEVELOP, V121, P3, DOI 10.1016/j.mod.2003.11.004; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Esni F, 2004, MECH DEVELOP, V121, P15, DOI 10.1016/j.mod.2003.08.010; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Gao R, 2005, DIABETOLOGIA, V48, P2296, DOI 10.1007/s00125-005-1935-8; Gao R, 2003, DIABETES, V52, P2007, DOI 10.2337/diabetes.52.8.2007; Gershengorn MC, 2004, SCIENCE, V306, P2261, DOI 10.1126/science.1101968; Guz Y, 2001, ENDOCRINOLOGY, V142, P4956, DOI 10.1210/en.142.11.4956; HALABAN R, 1984, IN VITRO CELL DEV B, V20, P447; Halban PA, 2004, NAT CELL BIOL, V6, P1021, DOI 10.1038/ncb1104-1021; Halvorsen TL, 2000, J ENDOCRINOL, V166, P103, DOI 10.1677/joe.0.1660103; Heimberg H, 2000, DIABETES, V49, P571, DOI 10.2337/diabetes.49.4.571; Heremans Y, 2002, J CELL BIOL, V159, P303, DOI 10.1083/jcb.200203074; Hirshberg B, 2003, DIABETES CARE, V26, P3288, DOI 10.2337/diacare.26.12.3288; Humphrey RK, 2003, DIABETES, V52, P2519, DOI 10.2337/diabetes.52.10.2519; Jensen J, 2004, DEV DYNAM, V229, P176, DOI 10.1002/dvdy.10460; Klein T, 2003, J HISTOCHEM CYTOCHEM, V51, P697, DOI 10.1177/002215540305100601; Lardon J, 2004, VIRCHOWS ARCH, V444, P61, DOI 10.1007/s00428-003-0930-z; Lardon J, 2002, HISTOCHEM CELL BIOL, V117, P535, DOI 10.1007/s00418-002-0412-4; Lechner A, 2004, DIABETES, V53, P616, DOI 10.2337/diabetes.53.3.616; Lechner A, 2002, BIOCHEM BIOPH RES CO, V293, P670, DOI 10.1016/S0006-291X(02)00275-9; Leibowitz G, 1999, DIABETES, V48, P745, DOI 10.2337/diabetes.48.4.745; Levine F, 2004, NEW ENGL J MED, V351, P1024, DOI 10.1056/NEJMcibr041779; Rajagopal J, 2003, SCIENCE, V299, P363; SANDLER S, 1987, DIABETES, V36, P1401, DOI 10.2337/diabetes.36.12.1401; SARVETNICK NE, 1992, ADV EXP MED BIOL, V321, P85; Scharfmann R, 2000, DIABETOLOGIA, V43, P1083, DOI 10.1007/s001250051498; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Street Cale N, 2004, Rev Diabet Stud, V1, P66, DOI 10.1900/RDS.2004.1.66; TUCH BE, 1984, DIABETES, V33, P1180, DOI 10.2337/diabetes.33.12.1180; Tyrberg B, 2001, GEN COMP ENDOCR, V122, P238, DOI 10.1006/gcen.2001.7638; Wang S, 1997, CELL TRANSPLANT, V6, P59, DOI 10.1016/S0963-6897(96)00120-0; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Zulewski H, 2001, DIABETES, V50, P521, DOI 10.2337/diabetes.50.3.521	46	178	208	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2006	12	3					310	316		10.1038/nm1367	http://dx.doi.org/10.1038/nm1367			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16491084				2022-12-25	WOS:000235802900030
J	L'Heureux, N; Dusserre, N; Konig, G; Victor, B; Keire, P; Wight, TN; Chronos, NAF; Kyles, AE; Gregory, CR; Hoyt, G; Robbins, RC; McAllister, TN				L'Heureux, N; Dusserre, N; Konig, G; Victor, B; Keire, P; Wight, TN; Chronos, NAF; Kyles, AE; Gregory, CR; Hoyt, G; Robbins, RC; McAllister, TN			Human tissue-engineered blood vessels for adult arterial revascularization	NATURE MEDICINE			English	Article							CULTURED VASCULAR CELLS; MECHANICAL-PROPERTIES; SMOOTH-MUSCLE; IN-VITRO; INVITRO; MODEL; ULTRASOUND; COLLAGEN; GRAFTS	There is a crucial need for alternatives to native vein or artery for vascular surgery. The clinical efficacy of synthetic, allogeneic or xenogeneic vessels has been limited by thrombosis, rejection, chronic inflammation and poor mechanical properties. Using adult human fibroblasts extracted from skin biopsies harvested from individuals with advanced cardiovascular disease, we constructed tissue-engineered blood vessels (TEBVs) that serve as arterial bypass grafts in long-term animal models. These TEBVs have mechanical properties similar to human blood vessels, without relying upon synthetic or exogenous scaffolding. The TEBVs are antithrombogenic and mechanically stable for 8 months in vivo. Histological analysis showed complete tissue integration and formation of vasa vasorum. The endothelium was confluent and positive for von Willebrand factor. A smooth muscle-specific alpha-actin-positive cell population developed within the TEBV, suggesting regeneration of a vascular media. Electron microscopy showed an endothelial basement membrane, elastogenesis and a complex collagen network. These results indicate that a completely biological and clinically relevant TEBV can be assembled exclusively from an individual's own cells.	Cytograft Tissue Engn Inc, Novato, CA 94949 USA; Capitol Cardiovasc Imaging Ctr, Sacramento, CA 95816 USA; Benaroya Res Inst Virginia Mason, Hope Heart Program, Seattle, WA 98101 USA; Amer Cardiovasc Res Inst, Atlanta, GA 30342 USA; Univ Calif Davis, Dept Surg & Radiol Sci, Sch Vet Med, Davis, CA 95616 USA; Stanford Univ, Dept Cardiothorac Surg, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA	Benaroya Research Institute; Virginia Mason Medical Center; University of California System; University of California Davis; Stanford University	L'Heureux, N (corresponding author), Cytograft Tissue Engn Inc, 3 Hamilton Landing,Suite 220, Novato, CA 94949 USA.	nico@cytograft.com; todd@cytograft.com	Dusserre, Nathalie/AAG-9108-2019; L'Heureux, Nicolas/K-8669-2015	Dusserre, Nathalie/0000-0002-4699-3365; L'Heureux, Nicolas/0000-0001-8602-3948	NHLBI NIH HHS [2R44HL64462, R44 HL064462-02A1, R44 HL064462] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL064462] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berglund JD, 2003, BIOMATERIALS, V24, P1241, DOI 10.1016/S0142-9612(02)00506-9; CAMBRIA RP, 1987, ANN SURG, V205, P167, DOI 10.1097/00000658-198702000-00011; Chamiot-Clerc P, 1998, CARDIOVASC RES, V37, P811, DOI 10.1016/S0008-6363(97)00267-8; Chue WL, 2004, J VASC SURG, V39, P859, DOI 10.1016/j.jvs.2003.03.003; Davis C, 2003, J THROMB HAEMOST, V1, P1699, DOI 10.1046/j.1538-7836.2003.00292.x; DOBRIN PB, 1984, ANN BIOMED ENG, V12, P497, DOI 10.1007/BF02363919; GIRERD XJ, 1992, J HYPERTENS, V10, pS111; Gittenberger-de Groot AC, 1999, ARTERIOSCL THROM VAS, V19, P1589; Grenier G, 2003, IN VITRO CELL DEV-AN, V39, P131; Kakisis JD, 2005, J VASC SURG, V41, P349, DOI 10.1016/j.jvs.2004.12.026; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; L'Heureux N, 2001, FASEB J, V15, P515, DOI 10.1096/fj.00-0283com; Lamm P, 2001, CIRCULATION, V104, pI108; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; McKee JA, 2003, EMBO REP, V4, P633, DOI 10.1038/sj.embor.embor847; Michel M, 1999, IN VITRO CELL DEV-AN, V35, P318; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Niklason LE, 1999, SCIENCE, V286, P1493, DOI 10.1126/science.286.5444.1493; Poh M, 2005, LANCET, V365, P2122, DOI 10.1016/S0140-6736(05)66735-9; Shin'oka T, 2001, NEW ENGL J MED, V344, P532, DOI 10.1056/NEJM200102153440717; van Andel CJ, 2003, ANN THORAC SURG, V76, P58, DOI 10.1016/S0003-4975(03)00263-7; VAN SJ, 1990, J THORAC CARDIOVASC, V99, P703; VANDERLUGT A, 1995, EUR J VASC ENDOVASC, V9, P394, DOI 10.1016/S1078-5884(05)80006-1; Varty K, 1996, BRIT J SURG, V83, P1375, DOI 10.1002/bjs.1800831015; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; WIGHT TN, 1996, ATHEROSCLEROSIS CORO, P421	26	652	681	1	208	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					361	365		10.1038/nm1364	http://dx.doi.org/10.1038/nm1364			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16491087	Green Accepted			2022-12-25	WOS:000235802900038
J	Lewis, JD; Destito, G; Zijlstra, A; Gonzalez, MJ; Quigley, JP; Manchester, M; Stuhlmann, H				Lewis, JD; Destito, G; Zijlstra, A; Gonzalez, MJ; Quigley, JP; Manchester, M; Stuhlmann, H			Viral nanoparticles as tools for intravital vascular imaging	NATURE MEDICINE			English	Article							COWPEA MOSAIC-VIRUS; 2.8 ANGSTROM RESOLUTION; IN-VIVO; CRYSTAL-STRUCTURE; PLANT-VIRUSES; ANGIOGENESIS; PEPTIDES; SURFACE; CELLS	A significant impediment to the widespread use of noninvasive in vivo vascular imaging techniques is the current lack of suitable intravital imaging probes. We describe here a new strategy to use viral nanoparticles as a platform for the multivalent display of fluorescent dyes to image tissues deep inside living organisms. The bioavailable cowpea mosaic virus (CPMV) can be fluorescently labeled to high densities with no measurable quenching, resulting in exceptionally bright particles with in vivo dispersion properties that allow high-resolution intravital imaging of vascular endothelium for periods of at least 72 h. We show that CPMV nanoparticles can be used to visualize the vasculature and blood flow in living mouse and chick embryos to a depth of up to 500 mu m. Furthermore, we show that the intravital visualization of human fibrosarcoma-mediated tumor angiogenesis using fluorescent CPMV provides a means to identify arterial and venous vessels and to monitor the neovascularization of the tumor microenvironment.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Div Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Ctr Integrat Mol Biosci, Scripps Res Inst, La Jolla, CA 92037 USA; Univ Studi Magna Graecia Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Manchester, M (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	marim@scripps.edu; hstuhlm@scripps.edu	zijlstra, andries/G-4564-2013	zijlstra, andries/0000-0001-8460-8803; Stuhlmann, Heidi/0000-0001-7217-768X; Manchester, Marianne/0000-0002-7143-5744	NATIONAL CANCER INSTITUTE [R01CA055852, R01CA112075, R01CA105412] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065738, R21HL072270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047823] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112075, R01 CA105412, CA112075, N01-CO-27181, R01 CA055852, R01 CA55852] Funding Source: Medline; NHLBI NIH HHS [R01 HL065738, R21 HL072270-02, R01 HL065738-04, R21 HL072270-03, R01 HL65738, R21 HL72270, R21 HL072270] Funding Source: Medline; NIAID NIH HHS [AI47823, R01 AI047823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brennan FR, 2001, MOL BIOTECHNOL, V17, P15, DOI 10.1385/MB:17:1:15; Chatterji A, 2004, BIOCONJUGATE CHEM, V15, P807, DOI 10.1021/bc0402888; Chatterji A, 2004, CHEM BIOL, V11, P855, DOI 10.1016/j.chembiol.2004.04.011; DESSENS JT, 1993, J GEN VIROL, V74, P889, DOI 10.1099/0022-1317-74-5-889; GOLDBACH R, 1985, MOL PLANT VIROLOGY, V2, P83; Gref R, 1997, Pharm Biotechnol, V10, P167; Hahm B, 2004, VIROLOGY, V323, P292, DOI 10.1016/j.virol.2004.03.011; Jilani SM, 2003, J HISTOCHEM CYTOCHEM, V51, P597, DOI 10.1177/002215540305100505; Johnson J, 1997, ANNU REV PHYTOPATHOL, V35, P67, DOI 10.1146/annurev.phyto.35.1.67; Jones EAV, 2002, GENESIS, V34, P228, DOI 10.1002/gene.10162; Josephson L, 2002, BIOCONJUGATE CHEM, V13, P554, DOI 10.1021/bc015555d; Kirchner C, 2005, NANO LETT, V5, P331, DOI 10.1021/nl047996m; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Lee PJ, 2003, METHOD ENZYMOL, V373, P214; Lin TW, 1999, VIROLOGY, V265, P20, DOI 10.1006/viro.1999.0038; Lin TW, 1996, FOLD DES, V1, P179, DOI 10.1016/S1359-0278(96)00030-2; LOMONOSSOFF GP, 1983, EMBO J, V2, P2253, DOI 10.1002/j.1460-2075.1983.tb01731.x; LOMONOSSOFF GP, 1991, PROG BIOPHYS MOL BIO, V55, P107, DOI 10.1016/0079-6107(91)90003-B; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Nicholas BL, 2002, VACCINE, V20, P2727, DOI 10.1016/S0264-410X(02)00200-1; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; Porta C, 2003, VIROLOGY, V310, P50, DOI 10.1016/S0042-6822(03)00140-5; Rae CS, 2005, VIROLOGY, V343, P224, DOI 10.1016/j.virol.2005.08.017; Reddy VS, 2001, J VIROL, V75, P11943, DOI 10.1128/JVI.75.24.11943-11947.2001; RIZZO V, 1993, MICROVASC RES, V46, P320, DOI 10.1006/mvre.1993.1056; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; Tsourkas A, 2005, BIOCONJUGATE CHEM, V16, P576, DOI 10.1021/bc050002e; Wang Q, 2002, CHEM BIOL, V9, P805, DOI 10.1016/S1074-5521(02)00165-5; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; Yang CS, 2004, ANAL CHEM, V76, P4465, DOI 10.1021/ac035491v; Zijlstra A, 2004, J BIOL CHEM, V279, P27633, DOI 10.1074/jbc.M313617200	33	295	305	2	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					354	360		10.1038/nm1368	http://dx.doi.org/10.1038/nm1368			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16501571	Green Accepted			2022-12-25	WOS:000235802900037
J	Mills, PB; Struys, E; Jakobs, C; Plecko, B; Baxter, P; Baumgartner, M; Willemsen, MAAP; Omran, H; Tacke, U; Uhlenberg, B; Weschke, B; Clayton, PT				Mills, PB; Struys, E; Jakobs, C; Plecko, B; Baxter, P; Baumgartner, M; Willemsen, MAAP; Omran, H; Tacke, U; Uhlenberg, B; Weschke, B; Clayton, PT			Mutations in antiquitin in individuals with pyridoxine-dependent seizures	NATURE MEDICINE			English	Article							ALDEHYDE DEHYDROGENASES; EPILEPSY; ACID; PURIFICATION; PHOSPHATE; PROTEIN; GENE	We show here that children with pyridoxine-dependent seizures (PDS) have mutations in the ALDH7A1 gene, which encodes antiquitin; these mutations abolish the activity of antiquitin as a Delta(1)-piperideine-6-carboxylate (P6C)-alpha-aminoadipic semialdehyde (alpha-AASA) dehydrogenase. The accumulating P6C inactivates pyridoxal 5'-phosphate (PLP) by forming a Knoevenagel condensation product. Measurement of urinary alpha-AASA provides a simple way of confirming the diagnosis of PDS and ALDH7A1 gene analysis provides a means for prenatal diagnosis.	UCL, Great Ormond St Hosp Children Children, Natl Hlth Serv Trust, Inst Child Hlth, London, England; Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, Metab Unit, NL-1081 HV Amsterdam, Netherlands; Univ Hosp Graz, Dept Pediat, A-8036 Graz, Austria; Sheffields Childrens Hosp, Sheffield S10 2TH, S Yorkshire, England; Univ Childrens Hosp, Div Metab & Mol Pediat, CH-8032 Zurich, Switzerland; Univ Nijmegen, Med Ctr, Dept Pediat Neurol, NL-6500 HB Nijmegen, Netherlands; Univ Freiburg, Dept Neuropediat, D-79106 Freiburg, Germany; Charite Univ Med Berlin, Dept Neuropediat, D-13353 Berlin, Germany	University of London; University College London; Vrije Universiteit Amsterdam; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University Children's Hospital Zurich; Radboud University Nijmegen; University of Freiburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Clayton, PT (corresponding author), UCL, Great Ormond St Hosp Children Children, Natl Hlth Serv Trust, Inst Child Hlth, 30 Guilford St, London, England.	clayton@ich.ucl.ac.uk	Clayton, Peter T/C-1523-2008; Willemsen, Michel A.A.P./H-8119-2014; Baumgartner, Matthias R/Q-2855-2017	Baumgartner, Matthias R/0000-0002-9270-0826; Mills, Philippa/0000-0002-9704-1268; Omran, Heymut/0000-0003-0282-6765; Plecko, Barbara/0000-0002-3203-1325; Clayton, Peter/0000-0001-7592-4302; Weschke, Bernhard/0000-0003-4533-0743				Baxter P, 2001, VITAMIN RESPONSIVE C, P109; Cormier-Daire V, 2000, AM J HUM GENET, V67, P991, DOI 10.1086/303087; Farrant RD, 2001, J BIOL CHEM, V276, P15107, DOI 10.1074/jbc.M010860200; Kure S, 1998, J HUM GENET, V43, P128, DOI 10.1007/s100380050053; LEE P, 1994, GENOMICS, V21, P371, DOI 10.1006/geno.1994.1279; Mann CJ, 1999, PROTEIN SCI, V8, P1922, DOI 10.1110/ps.8.10.1922; Nabbout R, 1999, ARCH DIS CHILD-FETAL, V81, pF125, DOI 10.1136/fn.81.2.F125; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; Plecko B, 2000, ANN NEUROL, V48, P121, DOI 10.1002/1531-8249(200007)48:1<121::AID-ANA20>3.0.CO;2-V; Rodriguez-Zavala J, 2001, CHEM-BIOL INTERACT, V130, P151, DOI 10.1016/S0009-2797(00)00230-1; Tang WK, 2002, FEBS LETT, V516, P183, DOI 10.1016/S0014-5793(02)02553-X; TSAI CH, 1974, J BIOL CHEM, V249, P5790; Wang HS, 2005, ARCH DIS CHILD, V90, P512, DOI 10.1136/adc.2003.045963; Wilkinson MF, 2005, TRENDS GENET, V21, P143, DOI 10.1016/j.tig.2005.01.007	15	366	379	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2006	12	3					307	309		10.1038/nm1366	http://dx.doi.org/10.1038/nm1366			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16491085				2022-12-25	WOS:000235802900029
J	Puthenveedu, MA; Bachert, C; Puri, S; Lanni, F; Linstedt, AD				Puthenveedu, MA; Bachert, C; Puri, S; Lanni, F; Linstedt, AD			GM130 and GRASP65-dependent lateral cisternal fusion allows uniform Golgi-enzyme distribution	NATURE CELL BIOLOGY			English	Article							CELL-FREE SYSTEM; ENDOPLASMIC-RETICULUM; RIBBON FORMATION; MATRIX PROTEIN; HELA-CELLS; COMPLEX; APPARATUS; STACKING; DISRUPTION; DROSOPHILA	The mammalian Golgi apparatus exists as stacks of cisternae that are laterally linked to form a continuous membrane ribbon, but neither the molecular requirements for, nor the purpose of, Golgi ribbon formation are known. Here, we demonstrate that ribbon formation is mediated by specific membrane-fusion events that occur during Golgi assembly, and require the Golgi proteins GM130 and GRASP65. Furthermore, these GM130 and GRASP65-dependent lateral cisternal-fusion reactions are necessary to achieve uniform distribution of enzymes in the Golgi ribbon. The membrane continuity created by ribbon formation facilitates optimal processing conditions in the biosynthetic pathway.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University	Linstedt, AD (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA.	linstedt@andrew.cmu.edu	Puthenveedu, Manojkumar/A-3795-2016	Puthenveedu, Manojkumar/0000-0002-3177-4231	NIGMS NIH HHS [GM-56779-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056779] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; de Graffenried CL, 2004, CURR OPIN CELL BIOL, V16, P356, DOI 10.1016/j.ceb.2004.06.007; Diao A, 2003, J CELL BIOL, V160, P201, DOI 10.1083/jcb.200207045; Fridmann-Sirkis Y, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-18; Jesch SA, 1998, MOL BIOL CELL, V9, P623, DOI 10.1091/mbc.9.3.623; Kano F, 2000, J CELL BIOL, V149, P357, DOI 10.1083/jcb.149.2.357; Kondylis V, 2005, MOL BIOL CELL, V16, P4061, DOI 10.1091/mbc.E04-10-0938; Kondylis V, 2003, J CELL BIOL, V162, P185, DOI 10.1083/jcb.200301136; Larocca MC, 2004, MOL BIOL CELL, V15, P2771, DOI 10.1091/mbc.E03-10-0757; Linstedt AD, 1999, CURR BIOL, V9, pR893, DOI 10.1016/S0960-9822(00)80077-9; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Natarajan R, 2004, MOL BIOL CELL, V15, P4798, DOI 10.1091/mbc.E04-05-0366; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; Perez F, 2002, J CELL BIOL, V156, P631, DOI 10.1083/jcb.200111003; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Puri S, 2003, MOL BIOL CELL, V14, P5011, DOI 10.1091/mbc.E03-06-0437; Puri S, 2002, TRAFFIC, V3, P641, DOI 10.1034/j.1600-0854.2002.30906.x; Puthenveedu MA, 2004, P NATL ACAD SCI USA, V101, P1253, DOI 10.1073/pnas.0306373101; Puthenveedu MA, 2001, EXP CELL RES, V271, P22, DOI 10.1006/excr.2001.5367; Puthenveedu MA, 2001, J CELL BIOL, V155, P227, DOI 10.1083/jcb.200105005; Rios RM, 2003, CURR OPIN CELL BIOL, V15, P60, DOI 10.1016/S0955-0674(02)00013-3; Rios RM, 2004, CELL, V118, P323; Roti ECR, 2002, J BIOL CHEM, V277, P47779, DOI 10.1074/jbc.M206638200; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; Shorter J, 1999, J CELL BIOL, V146, P57, DOI 10.1083/jcb.146.1.57; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Sutterlin C, 2005, MOL BIOL CELL, V16, P3211, DOI 10.1091/mbc.E04-12-1065; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Vasile E, 2003, TRAFFIC, V4, P254, DOI 10.1034/j.1600-0854.2003.00080.x; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923; Wang YZ, 2003, EMBO J, V22, P3279, DOI 10.1093/emboj/cdg317; Wright R, 2000, MICROSC RES TECHNIQ, V51, P496, DOI 10.1002/1097-0029(20001215)51:6<496::AID-JEMT2>3.3.CO;2-0; Yano H, 2005, P NATL ACAD SCI USA, V102, P13467, DOI 10.1073/pnas.0506681102; Zolov SN, 2005, J CELL BIOL, V168, P747, DOI 10.1083/jcb.200412003	42	246	264	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2006	8	3					238	248		10.1038/ncb1366	http://dx.doi.org/10.1038/ncb1366			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	017QL	16489344				2022-12-25	WOS:000235708000009
J	Shiba, H; Kakizaki, T; Iwano, M; Tarutani, Y; Watanabe, M; Isogai, A; Takayama, S				Shiba, H; Kakizaki, T; Iwano, M; Tarutani, Y; Watanabe, M; Isogai, A; Takayama, S			Dominance relationships between self-incompatibility alleles controlled by DNA methylation	NATURE GENETICS			English	Article							NUCLEOLAR DOMINANCE; BRASSICA; TRANSCRIPTION; PROMOTER; BINDING; HYBRID; POLLEN	In crucifers, the pollen S-determinant gene, SP11, is sporophytically expressed in the anther tapetum, and the pollen self-incompatibility phenotype is determined by the dominance relationships between the two S-haplotypes it carries. We report here that 5' promoter sequences of recessive SP11 alleles are specifically methylated in the tapetum before the initiation of SP11 transcription. These results suggest that tissue-specific monoallelic de novo DNA methylation is involved in determining the dominance interactions that determine the cruciferous self-incompatibility phenotype.	Grad Sch Biol Sci, Nara Inst Sci & Technol, Ikoma 6300101, Japan; Iwate Univ, Fac Agr, Morioka, Iwate 0208550, Japan; Tohoku Univ, Grad Sch Life Sci, Aoba Ku, Tohoku 9808577, Japan	Nara Institute of Science & Technology; Iwate University; Tohoku University	Shiba, H (corresponding author), Grad Sch Biol Sci, Nara Inst Sci & Technol, 8916-5 Takayama, Ikoma 6300101, Japan.	hshiba@salk.edu; takayama@bs.naist.jp	KAKIZAKI, Tomohiro/E-6304-2011; Watanabe, Masao/E-6300-2011; Isogai, Akira/O-8897-2017; Watanabe, Masao/N-1465-2019	KAKIZAKI, Tomohiro/0000-0002-3636-6616; Watanabe, Masao/0000-0002-9419-5149; Isogai, Akira/0000-0001-8095-0441; Watanabe, Masao/0000-0002-9419-5149				Bender J, 2004, ANNU REV PLANT BIOL, V55, P41, DOI 10.1146/annurev.arplant.55.031903.141641; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Brennan AC, 2003, PHILOS T ROY SOC B, V358, P1047, DOI 10.1098/rstb.2003.1300; Chen ZJ, 1998, P NATL ACAD SCI USA, V95, P14891, DOI 10.1073/pnas.95.25.14891; Frieman M, 1999, GENETICS, V152, P451; Hatakeyama K, 1998, HEREDITY, V80, P241, DOI 10.1046/j.1365-2540.1998.00295.x; Kakizaki T, 2003, PLANT CELL PHYSIOL, V44, P70, DOI 10.1093/pcp/pcg009; Kim SY, 1997, PLANT J, V11, P1237, DOI 10.1046/j.1365-313X.1997.11061237.x; Kinoshita T, 2004, SCIENCE, V303, P521, DOI 10.1126/science.1089835; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; Shiba H, 2002, PLANT CELL, V14, P491, DOI 10.1105/tpc.010378; Shimizu KK, 2004, SCIENCE, V306, P2081, DOI 10.1126/science.1103776; Shiota K, 2004, CYTOGENET GENOME RES, V105, P325, DOI 10.1159/000078205; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	15	71	77	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					297	299		10.1038/ng1734	http://dx.doi.org/10.1038/ng1734			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16444272				2022-12-25	WOS:000235589600009
J	Feldman, N; Gerson, A; Fang, J; Li, E; Zhang, Y; Shinkai, Y; Cedar, H; Bergman, Y				Feldman, N; Gerson, A; Fang, J; Li, E; Zhang, Y; Shinkai, Y; Cedar, H; Bergman, Y			G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis	NATURE CELL BIOLOGY			English	Article							DE-NOVO METHYLATION; HISTONE METHYLTRANSFERASE; TRANSCRIPTION FACTOR; LYSINE-9 METHYLATION; GENE-EXPRESSION; DNA METHYLATION; STEM-CELLS; GERMLINE; BINDING; NUCLEI	Oct-3/4 is a POU domain homeobox gene that is expressed during gametogenesis and in early embryonic cells(1,2), where it has been shown to be important for maintaining pluripotency(3). Following implantation, this gene undergoes a novel multi-step programme of inactivation. Transcriptional repression is followed by a pronounced increase in histone H3 methylation on Lys 9 that is mediated by the SET-containing protein, G9a. This step sets the stage for local heterochromatinization via the binding of HP1 and is required for subsequent de novo methylation at the promoter by the enzymes Dnmt3a/3b. Genetic studies show that these epigenetic changes actually have an important role in the inhibition of Oct-3/4 reexpression, thereby preventing reprogramming.	Hebrew Univ Jerusalem, Sch Med, Dept Expt Med, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Kyoto Univ, Inst Virus Res, Expt Res Ctr Infect Dis, Sakyo Ku, Kyoto 6068507, Japan	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Massachusetts General Hospital; Kyoto University	Bergman, Y (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Expt Med, IL-91120 Jerusalem, Israel.	yberg@md.huji.ac.il	Shinkai, Yoichi/N-3909-2014	Shinkai, Yoichi/0000-0002-6051-2484; Zhang, Yi/0000-0002-2789-0811; Fang, Jia/0000-0001-8583-1652				Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; Boiani M, 2002, GENE DEV, V16, P1209, DOI 10.1101/gad.966002; Bortvin A, 2003, DEVELOPMENT, V130, P1673, DOI 10.1242/dev.00366; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brehm A, 1998, APMIS, V106, P114, DOI 10.1111/j.1699-0463.1998.tb01326.x; Fahrner JA, 2003, GENE DEV, V17, P1805, DOI 10.1101/gad.1123303; Freitag M, 2005, CURR OPIN GENET DEV, V15, P191, DOI 10.1016/j.gde.2005.02.003; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Gidekel S, 2002, J BIOL CHEM, V277, P34521, DOI 10.1074/jbc.M203338200; Goldmit M, 2005, NAT IMMUNOL, V6, P198, DOI 10.1038/ni1154; Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200; Ji YH, 2003, P NATL ACAD SCI USA, V100, P7557, DOI 10.1073/pnas.0932635100; Jorgensen HF, 2004, MOL CELL BIOL, V24, P3387, DOI 10.1128/MCB.24.8.3387-3395.2004; Kimura H, 2004, MOL CELL BIOL, V24, P5710, DOI 10.1128/MCB.24.13.5710-5720.2004; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Osipovich O, 2004, NAT IMMUNOL, V5, P309, DOI 10.1038/ni1042; Pesce M, 2000, MOL REPROD DEV, V55, P452, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;452::AID-MRD14&gt;3.0.CO;2-S; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Simonsson S, 2004, NAT CELL BIOL, V6, P984, DOI 10.1038/ncb1176; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200	30	498	524	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2006	8	2					188	U55		10.1038/ncb1353	http://dx.doi.org/10.1038/ncb1353			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	008SA	16415856				2022-12-25	WOS:000235059800014
J	Ludwig, TE; Levenstein, ME; Jones, JM; Berggren, WT; Mitchen, ER; Frane, JL; Crandall, LJ; Daigh, CA; Conard, KR; Piekarczyk, MS; Llanas, RA; Thomson, JA				Ludwig, TE; Levenstein, ME; Jones, JM; Berggren, WT; Mitchen, ER; Frane, JL; Crandall, LJ; Daigh, CA; Conard, KR; Piekarczyk, MS; Llanas, RA; Thomson, JA			Derivation of human embryonic stem cells in defined conditions	NATURE BIOTECHNOLOGY			English	Article							CULTURE; DIFFERENTIATION; PLURIPOTENCY; ACID; GABA	We have previously reported that high concentrations of basic fibroblast growth factor (bFGF) support feeder-independent growth of human embryonic stem (ES) cells, but those conditions included poorly defined serum and matrix components. Here we report feeder-independent human ES cell culture that includes protein components solely derived from recombinant sources or purified from human material. We describe the derivation of two new human ES cell lines in these defined culture conditions.	WiCell Res Inst, Madison, WI 53707 USA; Genome Ctr Wisconsin, Madison, WI 53706 USA; Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA; Univ Wisconsin, Dept Obstet & Gynecol, Sch Med, Madison, WI 53715 USA; Univ Wisconsin, Dept Anat, Sch Med, Madison, WI 53715 USA	WiCell Research Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Thomson, JA (corresponding author), WiCell Res Inst, POB 7365, Madison, WI 53707 USA.	Thomson@primate.wisc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR017721] Funding Source: NIH RePORTER; NCRR NIH HHS [R24-RR017721] Funding Source: Medline; PHS HHS [P20-GMO69981] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Klimanskaya I, 2005, LANCET, V365, P1636, DOI 10.1016/S0140-6736(05)66473-2; Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181; PUCK TT, 1955, P NATL ACAD SCI USA, V41, P432, DOI 10.1073/pnas.41.7.432; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; TAKAHAMA K, 1986, NEUROPHARMACOLOGY, V25, P339, DOI 10.1016/0028-3908(86)90263-7; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Watanabe M, 2002, INT REV CYTOL, V213, P1; Xu CH, 2005, STEM CELLS, V23, P315, DOI 10.1634/stemcells.2004-0211; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	15	795	1000	0	99	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2006	24	2					185	187		10.1038/nbt1177	http://dx.doi.org/10.1038/nbt1177			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	010XW	16388305				2022-12-25	WOS:000235232300034
J	Dalhoff, C; Lukinavicius, G; Klimasauskas, S; Weinhold, E				Dalhoff, C; Lukinavicius, G; Klimasauskas, S; Weinhold, E			Direct transfer of extended groups from synthetic cofactors by DNA methyltransferases	NATURE CHEMICAL BIOLOGY			English	Article							S-ADENOSYLMETHIONINE; METHYLASE; BINDING	Adenosyl-L-methionine (AdoMet) is the major methyl donor for biological methylation reactions catalyzed by methyltransferases. We report the first chemical synthesis of AdoMet analogs with extended carbon chains replacing the methyl group and their evaluation as cofactors for all three classes of DNA methyltransferases. Extended groups containing a double or triple bond in the beta position to the sulfonium center were transferred onto DNA in a catalytic and sequence-specific manner, demonstrating a high utility of such synthetic cofactors for targeted functionalization of biopolymers.	Inst Biotechnol, Lab Biol DNA Modificat, LT-02241 Vilnius, Lithuania; Rhein Westfal TH Aachen, Inst Organ Chem, D-52056 Aachen, Germany	Vilnius University; RWTH Aachen University	Klimasauskas, S (corresponding author), Inst Biotechnol, Lab Biol DNA Modificat, V Graiciuno 8, LT-02241 Vilnius, Lithuania.	klimasau@ibt.it; elmar.weinhold@oc.rwth-aachen.de	Lukinavicius, Grazvydas/H-9799-2017; Klimasauskas, Saulius/M-3053-2016; Lukinavicius, Grazvydas/B-8061-2013	Lukinavicius, Grazvydas/0000-0002-7176-1793; Klimasauskas, Saulius/0000-0002-1395-2030; Lukinavicius, Grazvydas/0000-0002-7176-1793				BORCHARDT RT, 1976, J MED CHEM, V19, P1099, DOI 10.1021/jm00231a004; CANTONI GL, 1952, J AM CHEM SOC, V74, P2942, DOI 10.1021/ja01131a519; CHENG X, 1999, S ADENOSYLMETHIONINE, P392; DELAHABA G, 1959, J AM CHEM SOC, V81, P3975, DOI 10.1021/ja01524a039; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; HO DK, 1991, ARCH BIOCHEM BIOPHYS, V284, P264, DOI 10.1016/0003-9861(91)90294-S; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Merkiene E, 1998, BIOL CHEM, V379, P569; MI S, 1993, NUCLEIC ACIDS RES, V21, P2459, DOI 10.1093/nar/21.10.2459; Pljevaljcic G, 2004, CHEMBIOCHEM, V5, P265, DOI 10.1002/cbic.200300739; Roberts RJ, 2005, NUCLEIC ACIDS RES, V33, pD230; SCHLENK F, 1975, BIOCHIM BIOPHYS ACTA, V385, P312, DOI 10.1016/0304-4165(75)90359-1; SCHLENK F, 1977, BIOCH ADENOSYLMETHIO, P3; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2	15	161	167	9	65	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2006	2	1					31	32		10.1038/nchembio754	http://dx.doi.org/10.1038/nchembio754			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993RC	16408089				2022-12-25	WOS:000233971600011
J	Glenz, K; Bouchon, B; Stehle, T; Wallich, R; Simon, MM; Warzecha, H				Glenz, K; Bouchon, B; Stehle, T; Wallich, R; Simon, MM; Warzecha, H			Production of a recombinant bacterial lipoprotein in higher plant chloroplasts	NATURE BIOTECHNOLOGY			English	Article							SURFACE PROTEIN-A; BORRELIA-BURGDORFERI; LYME-DISEASE; OSPA; INFECTION; MICE	Little is known about the potential of plastids to accomplish post-translational modifications of foreign proteins. In the present study we generated transplastomic tobacco plants that accumulate the outer surface lipoprotein A (OspA) - the basic constituent of the first generation monovalent human vaccine against Lyme disease. The recombinant OspA exhibits a lipid modification typical for bacteria and induced protective antibodies in mice, demonstrating that functionally active bacterial lipoproteins can be processed in plants.	Univ Wurzburg, Julius Von Sachs Inst Biowissensch, Dept Pharmaceut Biol, D-97082 Wurzburg, Germany; Univ Auvergne, INSERM, UMR 484, F-63005 Clermont Ferrand, France; Max Planck Inst Immunbiol, Metschnikoff Lab, D-79108 Freiburg, Germany; Univ Heidelberg, Inst Immunol, D-69120 Heidelberg, Germany	University of Wurzburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); Max Planck Society; Ruprecht Karls University Heidelberg	Warzecha, H (corresponding author), Univ Wurzburg, Julius Von Sachs Inst Biowissensch, Dept Pharmaceut Biol, Julius Von Sachs Pl 2, D-97082 Wurzburg, Germany.	warzecha@biozentrum.uni-wuerzburg.de	Bouchon, Bernadette/L-5698-2015; Warzecha, Heribert/B-1960-2009					Bouchon B, 1997, ANAL BIOCHEM, V246, P52, DOI 10.1006/abio.1996.9982; Daniell H, 2005, VACCINE, V23, P1779, DOI 10.1016/j.vaccine.2004.11.004; ERDILE LF, 1993, INFECT IMMUN, V61, P81, DOI 10.1128/IAI.61.1.81-90.1993; Golde WT, 1997, INFECT IMMUN, V65, P882, DOI 10.1128/IAI.65.3.882-889.1997; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177; Nassal M, 2005, EUR J IMMUNOL, V35, P655, DOI 10.1002/eji.200425449; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; SCHAIBLE UE, 1990, P NATL ACAD SCI USA, V87, P3768, DOI 10.1073/pnas.87.10.3768; SIMON MM, 1991, J INFECT DIS, V164, P123, DOI 10.1093/infdis/164.1.123; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Tacket CO, 2000, J INFECT DIS, V182, P302, DOI 10.1086/315653; Warzecha H, 2003, J PLANT PHYSIOL, V160, P755, DOI 10.1078/0176-1617-01125	14	56	63	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2006	24	1					76	77		10.1038/nbt1170	http://dx.doi.org/10.1038/nbt1170			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	001SE	16327810				2022-12-25	WOS:000234555800027
J	Mercer, AC; Burkart, MD				Mercer, AC; Burkart, MD			Chemical expansion of cofactor activity	NATURE CHEMICAL BIOLOGY			English	News Item							PROTEINS; METHYLATION; ANALOG; ACID	Methylation is a key regulatory event in several biological processes. The enzymatic transfer by methyltransferases of extended carbon chain analogs of S-adenosylmethionine to DNA opens up new avenues for investigating biological methylation.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Mercer, AC (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mburkart@ucsd.edu		Mercer, Andrew/0000-0002-9873-1519				Chen I, 2005, NAT METHODS, V2, P99, DOI 10.1038/NMETH735; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; Clarke KM, 2005, J AM CHEM SOC, V127, P11234, DOI 10.1021/ja052911k; Dalhoff C, 2006, NAT CHEM BIOL, V2, P31, DOI 10.1038/nchembio754; Dean Wendy, 2005, Birth Defects Res C Embryo Today, V75, P98, DOI 10.1002/bdrc.20037; Hindley AD, 2004, FEBS LETT, V556, P26, DOI 10.1016/S0014-5793(03)01352-8; IMPERIALI B, 1994, J AM CHEM SOC, V116, P12083, DOI 10.1021/ja00105a071; Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5; MCALINDEN TP, 1991, BIOCHEMISTRY-US, V30, P5674, DOI 10.1021/bi00237a006; RAINIER S, 1994, JNCI-J NATL CANCER I, V86, P753, DOI 10.1093/jnci/86.10.753; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2	11	4	4	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2006	2	1					8	10		10.1038/nchembio0106-8	http://dx.doi.org/10.1038/nchembio0106-8			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993RC	16408081				2022-12-25	WOS:000233971600004
J	Nakagawa, Y; Shimano, H; Yoshikawa, T; Ide, T; Tamura, M; Furusawa, M; Yamamoto, T; Inoue, N; Matsuzaka, T; Takahashi, A; Hasty, AH; Suzuki, H; Sone, H; Toyoshima, H; Yahagi, N; Yamada, N				Nakagawa, Y; Shimano, H; Yoshikawa, T; Ide, T; Tamura, M; Furusawa, M; Yamamoto, T; Inoue, N; Matsuzaka, T; Takahashi, A; Hasty, AH; Suzuki, H; Sone, H; Toyoshima, H; Yahagi, N; Yamada, N			TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes	NATURE MEDICINE			English	Article							ELEMENT-BINDING PROTEIN-1; LOOP-HELIX PROTEIN; HEXOKINASE II GENE; LIVER; MICE; RESISTANCE; PROMOTER; RECEPTOR; EXPRESSION; SREBPS	Using an expression cloning strategy, we have identified TFE3, a basic helix-loop-helix protein, as a transactivator of metabolic genes that are regulated through an E-box in their promoters. Adenovirus-mediated expression of TFE3 in hepatocytes in culture and in vivo strongly activated expression of IRS-2 and Akt and enhanced phosphorylation of insulin-signaling kinases such as Akt, glycogen synthase kinase 3 beta and p70S6 kinase. TFE3 also induced hexokinase II (HK2) and insulin-induced gene 1 (INSIG1). These changes led to metabolic consequences, such as activation of glycogen and protein synthesis, but not lipogenesis, in liver. Collectively, plasma glucose levels were markedly reduced both in normal mice and in different mouse models of diabetes, including streptozotocin-treated, db/db and KK mice. Promoter analyses showed that IRS2, HK2 and INSIG1 are direct targets of TFE3. Activation of insulin signals in both insulin depletion and resistance suggests that TFE3 could be a therapeutic target for diabetes.	Univ Tsukuba, Dept Internal Med Metab & Endocrinol, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of Tsukuba; University of Tsukuba; Vanderbilt University	Shimano, H (corresponding author), Univ Tsukuba, Dept Internal Med Metab & Endocrinol, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020; Sone, Hirohito/ABC-9346-2021; Hasty, Alyssa/AAA-2757-2020; Yahagi, Naoya/D-2360-2014	Shimano, Hitoshi/0000-0002-5562-5572; Sone, Hirohito/0000-0003-1263-2817; Hasty, Alyssa/0000-0001-7302-8045; Yahagi, Naoya/0000-0002-1823-1865				Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Grinberg AV, 2003, J BIOL CHEM, V278, P11227, DOI 10.1074/jbc.M211734200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heikkinen S, 2000, MAMM GENOME, V11, P91, DOI 10.1007/s003350010019; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Matsuzaka T, 2004, DIABETES, V53, P560, DOI 10.2337/diabetes.53.3.560; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Peng Y, 1997, GENOMICS, V43, P278, DOI 10.1006/geno.1997.4821; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Riu E, 2003, FASEB J, V17, P1715, DOI 10.1096/fj.02-1163fje; Riu E, 1996, P NATL ACAD SCI USA, V93, P2198, DOI 10.1073/pnas.93.5.2198; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	36	90	94	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					107	113		10.1038/nm1334	http://dx.doi.org/10.1038/nm1334			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16327801				2022-12-25	WOS:000234419000059
J	Tu, S; McStay, GP; Boucher, LM; Mak, T; Beere, HM; Green, DR				Tu, S; McStay, GP; Boucher, LM; Mak, T; Beere, HM; Green, DR			In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis	NATURE CELL BIOLOGY			English	Article							CELL-DEATH; INDEPENDENT MECHANISMS; CYTOCHROME-C; FAS LIGAND; MITOCHONDRIA; EXPRESSION; UPSTREAM; RELEASE; PROTEIN	Activation of 'initiator' ( or 'apical') caspases- 2, - 8 or - 9 ( refs 1 - 3) is crucial for induction of apoptosis. These caspases function to activate executioner caspapses that, in turn, orchestrate apoptotic cell death. Here, we show that a cell-permeable, biotinylated pan- caspase inhibitor ( bVAD - fmk) both inhibited and ' trapped' the apical caspase activated when apoptosis was triggered. As expected, only caspase- 8 was trapped in response to ligation of death receptors, whereas only caspase- 9 was trapped in response to a variety of other apoptosis- inducing agents. Caspase- 2 was exclusively activated in heat shock- induced apoptosis. This activation of caspase- 2 was also observed in cells protected from heat- shock- induced apoptosis by Bcl- 2 or Bcl- xL. Reduced sensitivity to heat-shock-induced death was observed in caspase- 2(-/-) cells. Furthermore, cells lacking the adapter molecule RAIDD failed to activate caspase- 2 after heat shock treatment and showed resistance to apoptosis in this setting. This approach unambiguously identifies the apical caspase activated in response to apoptotic stimuli, and establishes caspase- 2 as a proximal mediator of heat shock- induced apoptosis.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	La Jolla Institute for Immunology; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Green, DR (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, MS 351,332 N Lauderdale St, Memphis, TN 38105 USA.	helen.beere@stjude.org; douglas.green@stjude.org	Green, Douglas R/N-8083-2018; McStay, Gavin/K-9574-2013	Green, Douglas R/0000-0002-7332-1417; McStay, Gavin/0000-0003-1363-8719; Tu, S. Sean/0000-0003-0391-8186; Boucher, Louis-Martin/0000-0003-2802-2124	NIAID NIH HHS [AI58422, AI47891, AI44828, AI40646] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646, R37AI044828, R01AI044828, R01AI047891, F32AI058422] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Baliga BC, 2003, J BIOL CHEM, V278, P4899, DOI 10.1074/jbc.M211512200; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Cippitelli M, 2005, J IMMUNOL, V174, P223, DOI 10.4049/jimmunol.174.1.223; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lassus P, 2004, SCIENCE, V306, P1683; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lin CF, 2005, J BIOL CHEM, V280, P23758, DOI 10.1074/jbc.M412292200; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Petak I, 2000, CANCER RES, V60, P2643; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Troy CM, 1997, J NEUROSCI, V17, P1911; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	32	164	169	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					72	U24		10.1038/ncb1340	http://dx.doi.org/10.1038/ncb1340			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	16362053				2022-12-25	WOS:000234651500014
J	Yamamoto, K; Sokabe, T; Matsumoto, T; Yoshimura, K; Shibata, M; Ohura, N; Fukuda, T; Sato, T; Sekine, K; Kato, S; Isshiki, M; Fujita, T; Kobayashi, M; Kawamura, K; Masuda, H; Kamiya, A; Ando, J				Yamamoto, K; Sokabe, T; Matsumoto, T; Yoshimura, K; Shibata, M; Ohura, N; Fukuda, T; Sato, T; Sekine, K; Kato, S; Isshiki, M; Fujita, T; Kobayashi, M; Kawamura, K; Masuda, H; Kamiya, A; Ando, J			Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice	NATURE MEDICINE			English	Article							FLUID SHEAR-STRESS; ENDOTHELIAL-CELLS; NITRIC-OXIDE; P2X RECEPTORS; ATP; ACTIVATION; MUSCLE; CHANNELS; SYNTHASE; RELEASE	The structure and function of blood vessels adapt to environmental changes such as physical development and exercise(1-3). This phenomenon is based on the ability of the endothelial cells to sense and respond to blood flow(4-6); however, the underlying mechanisms remain unclear. Here we show that the ATP-gated P2X4 ion channel(7,8), expressed on endothelial cells and encoded by P2rx4 in mice, has a key role in the response of endothelial cells to changes in blood flow. P2rx4(-/-) mice do not have normal endothelial cell responses to flow, such as influx of Ca2+ and subsequent production of the potent vasodilator nitric oxide (NO). Additionally, vessel dilation induced by acute increases in blood flow is markedly suppressed in P2rx4(-/-) mice. Furthermore, P2rx4(-/-) mice have higher blood pressure and excrete smaller amounts of NO products in their urine than do wild-type mice. Moreover, no adaptive vascular remodeling, that is, a decrease in vessel size in response to a chronic decrease in blood flow, was observed in P2rx4(-/-) mice. Thus, endothelial P2X4 channels are crucial to flow-sensitive mechanisms that regulate blood pressure and vascular remodeling.	Univ Tokyo, Dept Biomed Engn, Grad Sch Med, Tokyo 1130033, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Univ Tokyo, Dept Nephrol & Endocrinol, Grad Sch Med, Tokyo 1138655, Japan; Akita Univ, Sch Med, Dept Pathol 2, Akita 0108543, Japan; Nihon Univ, Interdisciplinary Sci Ctr, Tokyo 1020074, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Akita University; Nihon University	Ando, J (corresponding author), Univ Tokyo, Dept Biomed Engn, Grad Sch Med, Tokyo 1130033, Japan.	joji@m.u-tokyo.ac.jp		Sekine, Keisuke/0000-0001-5133-0876; Sokabe, Takaaki/0000-0003-1280-9424				Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Butz GM, 2001, PHYSIOL GENOMICS, V5, P89, DOI 10.1152/physiolgenomics.2001.5.2.89; Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Fleming I, 1997, J VASC RES, V34, P165, DOI 10.1159/000159220; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Glass R, 2001, J ANAT, V198, P569, DOI 10.1046/j.1469-7580.2001.19850569.x; GUYTON JR, 1985, AM J PHYSIOL, V248, P540; HUDLICKA O, 1992, PHYSIOL REV, V72, P369, DOI 10.1152/physrev.1992.72.2.369; KAMIYA A, 1980, AM J PHYSIOL, V239, P14; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; KOLLER A, 1994, AM J PHYSIOL, V267, pH326, DOI 10.1152/ajpheart.1994.267.1.H326; Kuhlencordt PJ, 2004, AM J PHYSIOL-CELL PH, V286, pC1195, DOI 10.1152/ajpcell.00546.2002; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; MASUDA H, 1989, ARTERIOSCLEROSIS, V9, P812, DOI 10.1161/01.ATV.9.6.812; MILNER P, 1990, BIOCHEM BIOPH RES CO, V170, P649, DOI 10.1016/0006-291X(90)92141-L; MO M, 1991, AM J PHYSIOL, V260, pH1698, DOI 10.1152/ajpheart.1991.260.5.H1698; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Ray FR, 2002, ATHEROSCLEROSIS, V162, P55, DOI 10.1016/S0021-9150(01)00681-5; Resnick N, 2003, PROG BIOPHYS MOL BIO, V81, P177, DOI 10.1016/S0079-6107(02)00052-4; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Vial C, 2004, TRENDS PHARMACOL SCI, V25, P487, DOI 10.1016/j.tips.2004.07.008; Vlaskovska M, 2001, J NEUROSCI, V21, P5670, DOI 10.1523/JNEUROSCI.21-15-05670.2001; Yamamoto K, 2000, CIRC RES, V87, P385; Yamamoto K, 2000, AM J PHYSIOL-HEART C, V279, pH285, DOI 10.1152/ajpheart.2000.279.1.H285	30	259	270	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					133	137		10.1038/nm1338	http://dx.doi.org/10.1038/nm1338			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16327800				2022-12-25	WOS:000234419000063
J	Iannacone, M; Sitia, G; Isogawa, M; Marchese, P; Castro, MG; Lowenstein, PR; Chisari, FV; Ruggeri, ZM; Guidotti, LG				Iannacone, M; Sitia, G; Isogawa, M; Marchese, P; Castro, MG; Lowenstein, PR; Chisari, FV; Ruggeri, ZM; Guidotti, LG			Platelets mediate cytotoxic T lymphocyte-induced liver damage	NATURE MEDICINE			English	Article							HEPATITIS-B-VIRUS; IN-VIVO; CELLS	We found that platelet depletion reduces intrahepatic accumulation of virus-specific cytotoxic T lymphocytes ( CTLs) and organ damage in mouse models of acute viral hepatitis. Transfusion of normal but not activation-blocked platelets in platelet-depleted mice restored accumulation of CTLs and severity of disease. In contrast, anticoagulant treatment that prevented intrahepatic fibrin deposition without reducing platelet counts did not avert liver injury. Thus, activated platelets contribute to CTL-mediated liver immunopathology independently of procoagulant function.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; San Raffaele Sci Inst, Immunopathogenesis Liver Infect Unit, I-20132 Milan, Italy; Cedars Sinai Med Ctr, Board Governors, Gene Therapeut Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Scripps Research Institute; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Cedars Sinai Medical Center; University of California System; University of California Los Angeles	Guidotti, LG (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	guidotti@scripps.edu	Iannacone, Matteo/I-8507-2018; Guidotti, Luca G. G/I-8542-2018; Chisari, Francis V/A-3086-2008; Castro, Maria/ABC-5182-2021; Isogawa, Masanori/AAN-8969-2021; Sitia, Giovanni/U-2114-2019; Sitia, Giovanni/K-1036-2016	Iannacone, Matteo/0000-0002-9370-2671; Guidotti, Luca G. G/0000-0002-0205-2678; Castro, Maria/0000-0003-2237-2756; Isogawa, Masanori/0000-0001-8730-4303; Sitia, Giovanni/0000-0003-1024-9128; Sitia, Giovanni/0000-0003-1024-9128; Chisari, Francis/0000-0002-4832-1044	NATIONAL CANCER INSTITUTE [R01CA040489, R37CA040489] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042846, P01HL078784, P01HL031950, R01HL042846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057711, U01NS052465, R21NS054143, R01NS054193, R01NS061107, R01NS042893] Funding Source: NIH RePORTER; NCI NIH HHS [CA40489, R37 CA040489, R01 CA040489] Funding Source: Medline; NHLBI NIH HHS [HL31950, R01 HL042846, HL78784, P01 HL078784, R37 HL042846, HL42846, P01 HL031950] Funding Source: Medline; NIAID NIH HHS [R01 AI040696, AI40696] Funding Source: Medline; NINDS NIH HHS [U01 NS052465-01A2, R21 NS054143, R01 NS042893, R01 NS057711, R01 NS061107-01A1, R01 NS042893-01A1, R01 NS054193, R21 NS054143-01A2, U01 NS052465, R01 NS061107, R01 NS054193-01A1, R01 NS057711-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO K, 1994, J IMMUNOL, V152, P3245; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; Kakimi K, 2001, J EXP MED, V194, P1755, DOI 10.1084/jem.194.12.1755; McClary H, 2000, J VIROL, V74, P2255, DOI 10.1128/JVI.74.5.2255-2264.2000; Shoukry NH, 2004, ANNU REV MICROBIOL, V58, P391, DOI 10.1146/annurev.micro.58.030603.123836; Sitia G, 2004, J CLIN INVEST, V113, P1158, DOI 10.1172/JCI200421087; Ware J, 2000, P NATL ACAD SCI USA, V97, P2803, DOI 10.1073/pnas.050582097; Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003; Weyrich AS, 2003, J THROMB HAEMOST, V1, P1897, DOI 10.1046/j.1538-7836.2003.00304.x; Wilson JM, 2001, ADV DRUG DELIVER REV, V46, P205, DOI 10.1016/S0169-409X(00)00125-3	12	248	261	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1167	1169		10.1038/nm1317	http://dx.doi.org/10.1038/nm1317			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16258538	Green Accepted			2022-12-25	WOS:000233115400027
J	Lim, JE; Jin, O; Bennett, C; Morgan, K; Wang, FD; Trenor, CC; Fleming, MD; Andrews, NC				Lim, JE; Jin, O; Bennett, C; Morgan, K; Wang, FD; Trenor, CC; Fleming, MD; Andrews, NC			A mutation in Sec15l1 causes anemia in hemoglobin deficit (hbd) mice	NATURE GENETICS			English	Article							TRANSFERRIN RECEPTOR; RAT RETICULOCYTES; EPITHELIAL-CELLS; EXOCYST COMPLEX; RAB11; MEMBRANE; DELIVERY; PATHWAY; MOUSE; IRON	Hemoglobin deficit (hbd) mice carry a spontaneous mutation that impairs erythroid iron assimilation but does not cause other defects. Normal delivery of iron to developing erythroid precursors is highly dependent on the transferrin cycle. Through genetic mapping and complementation experiments, we show that the hbd mutation is an in-frame deletion of a conserved exon of the mouse gene Sec15l1, encoding one of two Sec15 proteins implicated in the mammalian exocyst complex. Sec15l1 is linked to the transferrin cycle through its interaction with Rab11, a GTPase involved in vesicular trafficking. We propose that inactivation of Sec15l1 alters recycling of transferrin cycle endosomes and increases the release of transferrin receptor exocytic vesicles. This in turn decreases erythroid iron uptake. Determining the molecular basis of the hbd phenotype provides new insight into the intricate mechanisms necessary for normal erythroid iron uptake and the function of a mammalian exocyst protein.	Childrens Hosp, Div Hematol Oncol, Karp Family Res Labs RM 8 125, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Andrews, NC (corresponding author), Childrens Hosp, Div Hematol Oncol, Karp Family Res Labs RM 8 125, Boston, MA 02115 USA.	nancy_andrews@hms.harvard.edu	Wang, Fudi/L-7888-2018	Wang, Fudi/0000-0001-8730-0003; Andrews, Nancy/0000-0003-0243-4462; Fleming, Mark/0000-0003-0948-4024				Andrews HK, 2002, TRAFFIC, V3, P906, DOI 10.1034/j.1600-0854.2002.31206.x; Andrews NC, 2000, NAT REV GENET, V1, P208, DOI 10.1038/35042073; BANNERMAN RM, 1986, P SOC EXP BIOL MED, V182, P52, DOI 10.3181/00379727-182-42307; Bloom ML, 1998, MAMM GENOME, V9, P666, DOI 10.1007/s003359900841; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Chen J, 2005, BLOOD, V106, P328, DOI 10.1182/blood-2004-09-3686; Friedrich GA, 1997, DEV BIOL, V192, P364, DOI 10.1006/dbio.1997.8727; GARRICK LM, 1987, EXP HEMATOL, V15, P671; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; HARDING C, 1984, EUR J CELL BIOL, V35, P256; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; JOHNSTONE RM, 1991, J CELL PHYSIOL, V147, P27, DOI 10.1002/jcp.1041470105; Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727; Lipschutz JH, 2000, MOL BIOL CELL, V11, P4259, DOI 10.1091/mbc.11.12.4259; Mehta SQ, 2005, NEURON, V46, P219, DOI 10.1016/j.neuron.2005.02.029; Murthy M, 2003, NEURON, V37, P433, DOI 10.1016/S0896-6273(03)00031-X; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Savina A, 2005, TRAFFIC, V6, P131, DOI 10.1111/j.1600-0854.2004.00257.x; Savina A, 2002, J CELL SCI, V115, P2505; SCHEUFLER VH, 1969, Z VERSUCHSTIERKD, V11, P348; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; TORRANCE J, 1980, TISSUE IRON STORES; Trenor CC, 2000, BLOOD, V96, P1113, DOI 10.1182/blood.V96.3.1113.015k03_1113_1118; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Yeaman C, 2004, J CELL SCI, V117, P559, DOI 10.1242/jcs.00893; Zhang J, 2004, BLOOD, V104, P1679, DOI 10.1182/blood-2004-04-1362; Zhang XM, 2004, J BIOL CHEM, V279, P43027, DOI 10.1074/jbc.M402264200	29	77	83	2	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2005	37	11					1270	1273		10.1038/ng1659	http://dx.doi.org/10.1038/ng1659			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16227995				2022-12-25	WOS:000233045200029
J	Wei, FY; Nagashima, K; Ohshima, T; Saheki, Y; Lu, YF; Matsushita, M; Yamada, Y; Mikoshiba, K; Seino, Y; Matsui, H; Tomizawa, K				Wei, FY; Nagashima, K; Ohshima, T; Saheki, Y; Lu, YF; Matsushita, M; Yamada, Y; Mikoshiba, K; Seino, Y; Matsui, H; Tomizawa, K			Cdk5-dependent regulation of glucose-stimulated insulin secretion	NATURE MEDICINE			English	Article							CYCLIN-DEPENDENT KINASE-5; DIFFERENTIAL GENE-EXPRESSION; CHANNEL ACTIVITY; MIN6 SUBLINES; ACTIVATOR; PHOSPHORYLATION; CDK5; P35; EXOCYTOSIS; SUBUNIT	Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications(1). Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (K-ATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often associated with the side effect of hypoglycemia. Here we show that inhibition of the activity of cyclin-dependent kinase 5 (Cdk5) enhanced insulin secretion under conditions of stimulation by high glucose but not low glucose in MIN6 cells and pancreatic islets. The role of Cdk5 in regulation of insulin secretion was confirmed in pancreatic beta cells deficient in p35, an activator of Cdk5. p35-knockout mice also showed enhanced insulin secretion in response to a glucose challenge. Cdk5 kinase inhibition enhanced the inward whole-cell Ca2+ channel current and increased Ca2+ influx across the L-type voltage-dependent Ca2+ channel ( L-VDCC) upon stimulation with high glucose in beta cells, but had no effect on Ca2+ influx without glucose stimulation. The inhibitory regulation by Cdk5 on the L-VDCC was attributed to the phosphorylation of loop II-III of the alpha(1C) subunit of L-VDCC at Ser783, which prevented the binding to SNARE proteins and subsequently resulted in a decrease of the activity of L-VDCC. These results suggest that Cdk5/p35 may be a drug target for the regulation of glucose-stimulated insulin secretion.	Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Physiol, Okayama 7008558, Japan; Kyoto Univ, Grad Sch Med, Dept Diabet & Clin Nutr, Kyoto 6068507, Japan; RIKEN, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, Prot Therapy, Preventure Program, Off Technol Transfer, Okayama 7008558, Japan	Okayama University; Kyoto University; RIKEN; Japan Science & Technology Agency (JST)	Tomizawa, K (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Physiol, Okayama 7008558, Japan.	tomikt@md.okayama-u.ac.jp	Tomizawa, Kazuhito/F-2405-2015; Wei, Fan-Yan/AAD-8461-2021; Mikoshiba, Katsuhiko/N-7943-2015; Saheki, Yasunori/D-5430-2016	Tomizawa, Kazuhito/0000-0002-5663-2627; Saheki, Yasunori/0000-0002-1229-6668; Wei, Fan-Yan/0000-0002-4843-724X				Bratanova-Tochkova TK, 2002, DIABETES, V51, pS83, DOI 10.2337/diabetes.51.2007.S83; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kawaki J, 1999, DIABETES, V48, P2001, DOI 10.2337/diabetes.48.10.2001; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lilja L, 2004, J BIOL CHEM, V279, P29534, DOI 10.1074/jbc.M312711200; Lilla V, 2003, ENDOCRINOLOGY, V144, P1368, DOI 10.1210/en.2002-220916; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Ohshima T, 2001, P NATL ACAD SCI USA, V98, P2764, DOI 10.1073/pnas.051628498; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; WOLLHEIM CB, 1990, METHOD ENZYMOL, V192, P188; Yokoyama CT, 1997, J NEUROSCI, V17, P6929	22	149	190	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1104	1108		10.1038/nm1299	http://dx.doi.org/10.1038/nm1299			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16155576				2022-12-25	WOS:000232492500032
J	Platta, HW; Grunau, S; Rosenkranz, K; Girzalsky, W; Erdmann, R				Platta, HW; Grunau, S; Rosenkranz, K; Girzalsky, W; Erdmann, R			Functional role of the AAA peroxins in dislocation of the cycling PTS1 receptor back to the cytosol	NATURE CELL BIOLOGY			English	Letter							MATRIX PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; PEROXISOMAL MATRIX; PEX5P; YEAST; BIOGENESIS; PEX6P; FRUCTOSE-1,6-BISPHOSPHATASE; UBIQUITINATION; TRANSLOCATION	Peroxisomal import receptors bind their cargo proteins in the cytosol and target them to docking and translocation machinery at the peroxisomal membrane (reviewed in ref. 1). The receptors release the cargo proteins into the peroxisomal lumen and, according to the model of cycling receptors, they are supposed to shuttle back to the cytosol. This shuttling of the receptors has been assigned to peroxins including the AAA peroxins Pex1p and Pex6p, as well as the ubiquitin-conjugating enzyme Pex4p (reviewed in ref. 2). One possible target for Pex4p is the PTS1 receptor Pex5p, which has recently been shown to be ubiquitinated(3-5). Pex1p and Pex6p are both cytosolic and membrane-associated AAA ATPases of the peroxisomal protein import machinery, the exact function of which is still unknown. Here we demonstrate that the AAA peroxins mediate the ATP-dependent dislocation of the peroxisomal targeting signal-1 (PTS1) receptor from the peroxisomal membrane to the cytosol.	Ruhr Univ Bochum, Inst Physiol Chem, Abt Syst Biochem, D-44780 Bochum, Germany	Ruhr University Bochum	Erdmann, R (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, Abt Syst Biochem, D-44780 Bochum, Germany.	Ralf.Erdmann@rub.de	Platta, Harald Wolfgang/G-7423-2014	Platta, Harald Wolfgang/0000-0001-8968-7280				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; BIGL M, 1994, BIOL CHEM H-S, V375, P153, DOI 10.1515/bchm3.1994.375.3.153; Birschmann I, 2005, FEBS J, V272, P47, DOI 10.1111/j.1432-1033.2004.04393.x; Birschmann I, 2003, MOL BIOL CELL, V14, P2226, DOI 10.1091/mbc.E02-11-0752; Brown KA, 2000, J NUCL CARDIOL, V7, P388, DOI 10.1067/mnc.2000.108031; Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; Costa-Rodrigues J, 2004, J BIOL CHEM, V279, P46573, DOI 10.1074/jbc.M406399200; ENTIAN KD, 1988, FEBS LETT, V236, P195, DOI 10.1016/0014-5793(88)80313-2; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gouveia AM, 2003, ADV EXP MED BIOL, V544, P219; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Holroyd C, 2001, FEBS LETT, V501, P6, DOI 10.1016/S0014-5793(01)02617-5; Kiel JAKW, 2005, J BIOL CHEM, V280, P1921, DOI 10.1074/jbc.M403632200; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kragt A, 2005, J BIOL CHEM, V280, P7867, DOI 10.1074/jbc.M413553200; Lazarow PB, 2003, CURR OPIN CELL BIOL, V15, P489, DOI 10.1016/S0955-0674(03)00082-6; Lee RJ, 2004, EMBO J, V23, P2206, DOI 10.1038/sj.emboj.7600232; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; Oliveira ME, 2003, J BIOL CHEM, V278, P39483, DOI 10.1074/jbc.M305089200; Platta H, 2004, BIOCHEM J, V384, P37, DOI 10.1042/BJ20040572; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Schafer A, 2004, MOL CELL BIOL, V24, P8895, DOI 10.1128/MCB.24.20.8895-8906.2004; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399	30	175	180	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2005	7	8					817	U83		10.1038/ncb1281	http://dx.doi.org/10.1038/ncb1281			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	950TU	16007078				2022-12-25	WOS:000230881500016
J	Ule, J; Ule, A; Spencer, J; Williams, A; Hu, JS; Cline, M; Wang, H; Clark, T; Fraser, C; Ruggiu, M; Zeeberg, BR; Kane, D; Weinstein, JN; Blume, J; Darnell, RB				Ule, J; Ule, A; Spencer, J; Williams, A; Hu, JS; Cline, M; Wang, H; Clark, T; Fraser, C; Ruggiu, M; Zeeberg, BR; Kane, D; Weinstein, JN; Blume, J; Darnell, RB			Nova regulates brain-specific splicing to shape the synapse	NATURE GENETICS			English	Article							RNA-BINDING PROTEIN; MESSENGER-RNAS; GENOME; CAMKII; DOMAIN; IDENTIFICATION; EXPRESSION; PLASTICITY; SEQUENCE; ISOFORMS	Alternative RNA splicing greatly increases proteome diversity and may thereby contribute to tissue-specific functions. We carried out genome-wide quantitative analysis of alternative splicing using a custom Affymetrix microarray to assess the role of the neuronal splicing factor Nova in the brain. We used a stringent algorithm to identify 591 exons that were differentially spliced in the brain relative to immune tissues, and 6.6% of these showed major splicing defects in the neocortex of Nova2(-/-) mice. We tested 49 exons with the largest predicted Nova-dependent splicing changes and validated all 49 by RT-PCR. We analyzed the encoded proteins and found that all those with defined brain functions acted in the synapse (34 of 40, including neurotransmitter receptors, cation channels, adhesion and scaffold proteins) or in axon guidance ( 8 of 40). Moreover, of the 35 proteins with known interaction partners, 74% (26) interact with each other. Validating a large set of Nova RNA targets has led us to identify a multi-tiered network in which Nova regulates the exon content of RNAs encoding proteins that interact in the synapse.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA; Univ Amsterdam, Fac Econ & Econometr, NL-1012 WX Amsterdam, Netherlands; Affymetrix Inc, Emeryville, CA USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; SRA Int Inc, Fairfax, VA 22033 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; University of Amsterdam; Affymetrix; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); SRA International	Darnell, RB (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.	darnelr@rockefeller.edu	Darnell, Robert B/B-9022-2008; zeeberg, barry/AAO-1246-2020; Ule, Jernej/C-6315-2013	Darnell, Robert B/0000-0002-5134-8088; Ule, Jernej/0000-0002-2452-4277; Blume, John/0000-0003-3026-953X; Ruggiu, Matteo/0000-0002-6404-1210; Spencer-Segal, Joanna/0000-0003-0467-2173; Clark, Tyson/0000-0002-7779-3227; Weinstein, John/0000-0001-9401-6908	NATIONAL CANCER INSTITUTE [Z01BC007349] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; ARGO F, 2004, CELL, V119, P257; Balla Z, 2002, J BIOL CHEM, V277, P21306, DOI 10.1074/jbc.M200553200; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Buckanovich RJ, 1996, J NEUROSCI, V16, P1114; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; Clark TA, 2002, SCIENCE, V296, P907, DOI 10.1126/science.1069415; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Dateki M, 2005, J BIOL CHEM, V280, P20503, DOI 10.1074/jbc.M414033200; Dredge BK, 2005, EMBO J, V24, P1608, DOI 10.1038/sj.emboj.7600630; Dredge BK, 2003, MOL CELL BIOL, V23, P4687, DOI 10.1128/MCB.23.13.4687-4700.2003; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Gao WQ, 1998, MOL CELL NEUROSCI, V11, P247, DOI 10.1006/mcne.1998.0696; Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hieronymus H, 2003, NAT GENET, V33, P155, DOI 10.1038/ng1080; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; HUANG CS, IN PRESS CELL; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; Kim S, 2003, NUCLEIC ACIDS RES, V31, P1955, DOI 10.1093/nar/gkg286; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Le K, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh173; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Lu CS, 2003, NEURON, V40, P1185, DOI 10.1016/S0896-6273(03)00786-4; McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; Pan Q, 2004, MOL CELL, V16, P929, DOI 10.1016/j.molcel.2004.12.004; Parra M, 2004, GENOMICS, V84, P637, DOI 10.1016/j.ygeno.2004.06.004; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; Waggoner SA, 2003, MOL CELL BIOL, V23, P7055, DOI 10.1128/MCB.23.19.7055-7067.2003; Wang H, 2003, BIOINFORMATICS, V19, pi315, DOI 10.1093/bioinformatics/btg1044; Wheeler R, 2002, LECT NOTES COMPUT SC, V2452, P201; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254; Zeeberg BR, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-168; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	50	378	391	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					844	852		10.1038/ng1610	http://dx.doi.org/10.1038/ng1610			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16041372				2022-12-25	WOS:000230880400014
J	Dentice, M; Bandyopadhyay, A; Gereben, B; Callebaut, I; Christoffolete, MA; Kim, BW; Nissim, S; Mornon, JP; Zavacki, AM; Zeold, A; Capelo, LP; Curcio-Morelli, C; Ribeiro, R; Harney, JW; Tabin, CJ; Bianco, AC				Dentice, M; Bandyopadhyay, A; Gereben, B; Callebaut, I; Christoffolete, MA; Kim, BW; Nissim, S; Mornon, JP; Zavacki, AM; Zeold, A; Capelo, LP; Curcio-Morelli, C; Ribeiro, R; Harney, JW; Tabin, CJ; Bianco, AC			The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate	NATURE CELL BIOLOGY			English	Letter							RETICULUM-ASSOCIATED DEGRADATION; TYPE-2 IODOTHYRONINE DEIODINASE; INDIAN HEDGEHOG; PROTEIN; COMPLEX; DIFFERENTIATION; SOCS; CHONDROCYTES; REPEAT; CELLS	WSB- 1 is a SOCS- box- containing WD- 40 protein of unknown function that is induced by Hedgehog signalling in embryonic structures during chicken development. Here we show that WSB- 1 is part of an E3 ubiquitin ligase for the thyroid- hormone-activating type 2 iodothyronine deiodinase ( D2). The WD- 40 propeller of WSB- 1 recognizes an 18- amino- acid loop in D2 that confers metabolic instability, whereas the SOCS- box domain mediates its interaction with a ubiquitinating catalytic core complex, modelled as Elongin BC - Cul5 - Rbx1 ( ECSWSB- 1). In the developing tibial growth plate, Hedgehog- stimulated D2 ubiquitination via ECSWSB- 1 induces parathyroid hormone- related peptide ( PTHrP), thereby regulating chondrocyte differentiation. Thus, ECSWSB- 1 mediates a mechanism by which ' systemic' thyroid hormone can effect local control of the Hedgehog PTHrP negative feedback loop and thus skeletogenesis.	Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Thyroid Sect, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Hungarian Acad Sci, Inst Expt Med, Lab Endocrine Neurobiol, H-1083 Budapest, Hungary; Univ Paris 06, Dept Biol Struct, LMCP, CNRS,UMR7590, F-75252 Paris, France; Univ Paris 07, Dept Biol Struct, LMCP, CNRS,UMR7590, F-75252 Paris, France	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Universite Paris Cite	Bianco, AC (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Thyroid Sect, 75 Francis St, Boston, MA 02115 USA.	abianco@partners.org	Bandyopadhyay, Amitabha/B-9735-2008; Capelo, Luciane/AAV-2593-2020; Capelo, Luciane/AFW-4604-2022; Bianco, Antonio C/A-4965-2008; Bianco, Antonio/AAK-6336-2020	Capelo, Luciane/0000-0002-3004-1220; Bianco, Antonio C/0000-0001-7737-6813; Bianco, Antonio/0000-0001-7737-6813; Bandyopadhyay, Amitabha/0000-0002-0429-438X; Christoffolete, Marcelo/0000-0003-0374-0795; Nissim, Sahar/0000-0002-2303-6415	FOGARTY INTERNATIONAL CENTER [R03TW006467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056246, R01DK058538] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW006467, TW006467] Funding Source: Medline; NIDDK NIH HHS [R01 DK058538, DK56246, P01 DK056246, DK058538] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Botero D, 2002, MOL ENDOCRINOL, V16, P1999, DOI 10.1210/me.2002-0135; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Callebaut I, 2003, J BIOL CHEM, V278, P36887, DOI 10.1074/jbc.M305725200; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Curcio-Morelli C, 2003, J CLIN INVEST, V112, P189, DOI 10.1172/JCI200318348; Curcio-Morelli C, 2003, ENDOCRINOLOGY, V144, P937, DOI 10.1210/en.2002-220960; Gereben B, 2000, MOL ENDOCRINOL, V14, P1697, DOI 10.1210/me.14.11.1697; Hamilton KS, 2000, J BIOMOL NMR, V18, P319, DOI 10.1023/A:1026773008237; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kim BW, 2003, MOL ENDOCRINOL, V17, P2603, DOI 10.1210/me.2003-0082; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Long FX, 2001, DEVELOPMENT, V128, P5099; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Robson H, 2000, ENDOCRINOLOGY, V141, P3887, DOI 10.1210/en.141.10.3887; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Steinsapir J, 1998, J CLIN INVEST, V102, P1895, DOI 10.1172/JCI4672; Stevens DA, 2000, J BONE MINER RES, V15, P2431, DOI 10.1359/jbmr.2000.15.12.2431; Vasiliauskas D, 1999, MECH DEVELOP, V82, P79, DOI 10.1016/S0925-4773(99)00014-3; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	35	176	182	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2005	7	7					698	U87		10.1038/ncb1272	http://dx.doi.org/10.1038/ncb1272			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	941BX	15965468	Green Accepted			2022-12-25	WOS:000230190800014
J	Jacobs, T; Fischer, J				Jacobs, T; Fischer, J			When a long shot is worth a shot	NATURE BIOTECHNOLOGY			English	Editorial Material												Tom@completegrowth.com; Jeff@completegrowth.com							0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2005	23	7					805	805		10.1038/nbt0705-805	http://dx.doi.org/10.1038/nbt0705-805			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	944KT	16003361				2022-12-25	WOS:000230427700021
J	Adler, AS; Lin, MH; Horlings, H; Nuyten, DSA; van de Vijver, MJ; Chang, HY				Adler, AS; Lin, MH; Horlings, H; Nuyten, DSA; van de Vijver, MJ; Chang, HY			Genetic regulators of large-scale transcriptional signatures in cancer	NATURE GENETICS			English	Article							MYC PROTEIN STABILITY; HUMAN BREAST-TUMORS; DNA COPY NUMBER; C-MYC; EXPRESSION SIGNATURE; UBIQUITIN LIGASES; HUMAN FIBROBLASTS; GROWTH-FACTOR; DEGRADATION; TRANSFORMATION	Gene expression signatures encompassing dozens to hundreds of genes have been associated with many important parameters of cancer, but mechanisms of their control are largely unknown. Here we present a method based on genetic linkage that can prospectively identify functional regulators driving large-scale transcriptional signatures in cancer. Using this method we show that the wound response signature, a poor-prognosis expression pattern of 512 genes in breast cancer, is induced by coordinate amplifications of MYC and CSN5 (also known as JAB1 or COPS5). This information enabled experimental recapitulation, functional assessment and mechanistic elucidation of the wound signature in breast epithelial cells.	Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands	Stanford University; Stanford University; Netherlands Cancer Institute	Chang, HY (corresponding author), Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA.	howchang@stanford.edu		van de Vijver, Marc/0000-0002-0385-4787; Adler, Adam/0000-0001-9301-0037	NCI NIH HHS [CA09302, T32 CA009302] Funding Source: Medline; NIAMS NIH HHS [AR050007, K08 AR050007] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR050007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bemis L, 2004, GENE DEV, V18, P739, DOI 10.1101/gad.1180104; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cooper L, 2005, GENOME BIOL, V6; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Ginzinger DG, 2000, CANCER RES, V60, P5405; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kim BC, 2004, MOL CELL BIOL, V24, P2251, DOI 10.1128/MCB.24.6.2251-2262.2004; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Liu ET, 2003, CURR OPIN GENET DEV, V13, P97, DOI 10.1016/S0959-437X(03)00008-X; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; SOULE HD, 1990, CANCER RES, V50, P6075; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang ZGC, 2004, CANCER RES, V64, P64, DOI 10.1158/0008-5472.CAN-03-2570; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Wee S, 2005, NAT CELL BIOL, V7, P387, DOI 10.1038/ncb1241; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6	47	173	179	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	2006	38	4					421	430		10.1038/ng1752	http://dx.doi.org/10.1038/ng1752			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16518402	Green Accepted			2022-12-25	WOS:000236340500014
J	Williamson, CM; Turner, MD; Ball, ST; Nottingham, WT; Glenister, P; Fray, M; Tymowska-Lalanne, Z; Plagge, A; Powles-Glover, N; Kelsey, G; Maconochie, M; Peters, J				Williamson, CM; Turner, MD; Ball, ST; Nottingham, WT; Glenister, P; Fray, M; Tymowska-Lalanne, Z; Plagge, A; Powles-Glover, N; Kelsey, G; Maconochie, M; Peters, J			Identification of an imprinting control region affecting the expression of all transcripts in the Gnas cluster	NATURE GENETICS			English	Article							XL-ALPHA-S; G-PROTEIN; ANTISENSE; NESP; SUBUNIT; MICE; MARK	Genomic imprinting results in allele-specific silencing according to parental origin(1). Silencing is brought about by imprinting control regions (ICRs) that are differentially marked in gametogenesis(2). The group of imprinted transcripts in the mouse Gnas cluster (Nesp, Nespas, Gnasxl, Exon1A and Gnas) provides a model for analyzing the mechanisms of imprint regulation. We previously identified an ICR that specifically regulates the tissue-specific imprinted expression of the Gnas gene(3). Here we identify a second ICR at the Gnas cluster. We show that a paternally derived targeted deletion of the germline differentially methylated region (DMR) associated with the antisense Nespas transcript unexpectedly affects both the expression of all transcripts in the cluster and methylation of two DMRs. Our results establish that the Nespas DMR is the principal ICR at the Gnas cluster and functions bidirectionally as a switch for modulating expression of the antagonistically acting genes Gnasxl and Gnas. Uniquely, the Nespas DMR acts on the downstream ICR at exon 1A to regulate tissue-specific imprinting of the Gnas gene.	MRC, Mammalian Genet Unit, Harwell OX11 0RD, Oxon, England; Babraham Inst, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Peters, J (corresponding author), MRC, Mammalian Genet Unit, Harwell OX11 0RD, Oxon, England.	j.peters@har.mrc.ac.uk	Williamson, Christine/GSE-3696-2022; Plagge, Antonius/AAH-3877-2019; Turner, Martin/N-9976-2014	Plagge, Antonius/0000-0001-6592-1343; Turner, Martin/0000-0002-3801-9896; Kelsey, Gavin/0000-0002-9762-5634	Medical Research Council [MC_UP_1502/1, MC_U142636336] Funding Source: Medline; MRC [MC_UP_1502/1, MC_U142636336] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abramowitz J, 2004, P NATL ACAD SCI USA, V101, P8366, DOI 10.1073/pnas.0308758101; Bastepe M, 2005, NAT GENET, V37, P25, DOI 10.1038/ng1487; Bastepe M, 2003, J CLIN INVEST, V112, P1255, DOI 10.1172/JCI200319159; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; Cattanach BM, 2000, HUM MOL GENET, V9, P2263, DOI 10.1093/oxfordjournals.hmg.a018917; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; Coombes C, 2003, MOL CELL BIOL, V23, P5475, DOI 10.1128/MCB.23.16.5475-5488.2003; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Ischia R, 1997, J BIOL CHEM, V272, P11657; Judson H, 2002, NATURE, V416, P539, DOI 10.1038/416539a; KEHLENBACH RH, 1994, NATURE, V372, P804; Kelsey G, 1999, GENOMICS, V62, P129, DOI 10.1006/geno.1999.6022; Li T, 2000, GENOMICS, V69, P295, DOI 10.1006/geno.2000.6337; Liu J, 2000, MOL CELL BIOL, V20, P5808, DOI 10.1128/MCB.20.16.5808-5817.2000; Liu J, 2000, J CLIN INVEST, V106, P1167, DOI 10.1172/JCI10431; Liu J, 2005, P NATL ACAD SCI USA, V102, P5513, DOI 10.1073/pnas.0408262102; Liu J, 2005, HUM MOL GENET, V14, P95, DOI 10.1093/hmg/ddi009; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; Peters J, 1999, P NATL ACAD SCI USA, V96, P3830, DOI 10.1073/pnas.96.7.3830; Plagge A, 2004, NAT GENET, V36, P818, DOI 10.1038/ng1397; RIVERAPEREZ JA, 1995, DEVELOPMENT, V121, P3005; Skinner JA, 2002, GENOMICS, V80, P373, DOI 10.1006/geno.2002.6842; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Spahn L, 2003, NAT GENET, V35, P11, DOI 10.1038/ng0903-11; Weinstein LS, 2004, ENDOCRINOLOGY, V145, P5459, DOI 10.1210/en.2004-0865; Williamson CM, 2004, NAT GENET, V36, P894, DOI 10.1038/ng1398; Williamson CM, 2002, MAMM GENOME, V13, P74, DOI 10.1007/s00335-001-2102-2; Wroe SF, 2000, P NATL ACAD SCI USA, V97, P3342, DOI 10.1073/pnas.050015397; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715	30	147	162	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					350	355		10.1038/ng1731	http://dx.doi.org/10.1038/ng1731			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16462745				2022-12-25	WOS:000235589600018
J	Zhu, LM; Vranckx, R; Van Kien, PK; Lalande, A; Boisset, N; Mathieu, F; Wegman, M; Glancy, L; Gasc, JM; Brunotte, FO; Bruneval, P; Wolf, JE; Michel, JB; Jeunemaitre, X				Zhu, LM; Vranckx, R; Van Kien, PK; Lalande, A; Boisset, N; Mathieu, F; Wegman, M; Glancy, L; Gasc, JM; Brunotte, FO; Bruneval, P; Wolf, JE; Michel, JB; Jeunemaitre, X			Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus	NATURE GENETICS			English	Article							HEAVY-CHAIN ISOFORMS; COILED-COILS; LOCUS; ANEURYSM/DISSECTION; DISEASE	We have recently described two kindreds presenting thoracic aortic aneurysm and/or aortic dissection ( TAAD) and patent ductus arteriosus (PDA)(1,2) and mapped the disease locus to 16p12.2-p13.13 (ref. 3). We now demonstrate that the disease is caused by mutations in the MYH11 gene affecting the C-terminal coiled-coil region of the smooth muscle myosin heavy chain, a specific contractile protein of smooth muscle cells (SMC). All individuals bearing the heterozygous mutations, even if asymptomatic, showed marked aortic stiffness. Examination of pathological aortas showed large areas of medial degeneration with very low SMC content. Abnormal immunological recognition of SM-MHC and the colocalization of wild-type and mutant rod proteins in SMC, in conjunction with differences in their coimmunoprecipitation capacities, strongly suggest a dominant-negative effect. Human MYH11 gene mutations provide the first example of a direct change in a specific SMC protein leading to an inherited arterial disease.	Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Dept Genet, F-75015 Paris, France; INSERM, U36, F-75005 Paris, France; INSERM, U772, F-75005 Paris, France; Coll France, F-75005 Paris, France; Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, French Chinese Genom Pole, Shanghai, Peoples R China; INSERM, U698, Paris, France; Univ Paris 07, Fac Med Xavier Bichat, F-75018 Paris, France; Univ Bourgogne, Lab Physiopathol & Pharmacol Cardiovasc Expt, F-21000 Dijon, France; CHU Dijon, Serv Cardiol 2, F-21000 Dijon, France; CHU Dijon, Ctr Imagerie Resonance Magnet, F-21000 Dijon, France; CNRS, UMR 158, Lab Elect & Informat Image, F-21000 Dijon, France; CNRS, UMR 7590, Dept Biol Struct, IMPMC, F-75005 Paris, France; Univ Paris 06, F-75005 Paris, France; Louisiana State Univ, Hlth Sci Ctr, Dept Med, Cardiol Sect, New Orleans, LA 70112 USA; Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Serv Anatomopathol, F-75015 Paris, France; Univ Paris 05, Fac Med, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Shanghai Jiao Tong University; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut Agro; AgroSup Dijon; Universite de Bourgogne; CHU Dijon Bourgogne; CHU Dijon Bourgogne; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Sorbonne Universite; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Jeunemaitre, X (corresponding author), Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Dept Genet, F-75015 Paris, France.	xavier.jeunemaitre@epg.aphp.fr	JEUNEMAITRE, Xavier/AAQ-4853-2021; Mathieu, Flavie/M-9855-2017; Michel, Jean-Baptiste/AAH-9336-2020; ZHU, Limin/AAZ-9201-2020; Lalande, Alain/T-1050-2017	JEUNEMAITRE, Xavier/0000-0001-5925-381X; Mathieu, Flavie/0000-0002-3386-0299; Lalande, Alain/0000-0002-7970-366X; KHAU VAN KIEN, Philippe/0000-0001-7754-969X				AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Babu GJ, 2000, MICROSC RES TECHNIQ, V50, P532, DOI 10.1002/1097-0029(20000915)50:6<532::AID-JEMT10>3.0.CO;2-E; Boileau C, 2005, CURR OPIN CARDIOL, V20, P194, DOI 10.1097/01.hco.0000162398.21972.cd; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ching YH, 2005, NAT GENET, V37, P423, DOI 10.1038/ng1526; Coady MA, 1999, ARCH SURG-CHICAGO, V134, P361, DOI 10.1001/archsurg.134.4.361; Franke JD, 2005, BLOOD, V105, P161, DOI 10.1182/blood-2004-06-2067; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Glancy DL, 2001, AM J CARDIOL, V87, P813, DOI 10.1016/S0002-9149(00)01515-0; Guo DC, 2001, CIRCULATION, V103, P2461; Hasham SN, 2003, CIRCULATION, V107, P3184, DOI 10.1161/01.CIR.0000078634.33124.95; Hoffman JIE, 2002, J AM COLL CARDIOL, V39, P1890, DOI 10.1016/S0735-1097(02)01886-7; HORNBLAD PY, 1967, CARDIOLOGIA, V51, P262, DOI 10.1159/000165823; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalande A, 2002, INVEST RADIOL, V37, P685, DOI 10.1097/00004424-200212000-00008; Laurent S, 2005, HYPERTENSION, V45, P1050, DOI 10.1161/01.HYP.0000164580.39991.3d; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mani A, 2002, P NATL ACAD SCI USA, V99, P15054, DOI 10.1073/pnas.192582999; Meloni I, 2001, Hum Mutat, V18, P85, DOI 10.1002/humu.1157; Meredith C, 2004, AM J HUM GENET, V75, P703, DOI 10.1086/424760; Morano I, 2000, NAT CELL BIOL, V2, P371, DOI 10.1038/35014065; NACHTIGAL M, 1989, IN VITRO CELL DEV B, V25, P892; Pannu H, 2005, CIRCULATION, V112, P513, DOI 10.1161/CIRCULATIONAHA.105.537340; Quevillon-Cheruel S, 1999, FEBS LETT, V454, P303, DOI 10.1016/S0014-5793(99)00827-3; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; Slomp J, 1997, ARTERIOSCL THROM VAS, V17, P1003, DOI 10.1161/01.ATV.17.5.1003; Straussman R, 2005, J MOL BIOL, V353, P613, DOI 10.1016/j.jmb.2005.08.010; Van Kien PK, 2005, CIRCULATION, V112, P200, DOI 10.1161/CIRCULATIONAHA.104.506345; Van Kien PK, 2004, EUR J HUM GENET, V12, P173, DOI 10.1038/sj.ejhg.5201119; Vaughan CJ, 2001, CIRCULATION, V103, P2469	30	407	421	2	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					343	349		10.1038/ng1721	http://dx.doi.org/10.1038/ng1721			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16444274				2022-12-25	WOS:000235589600017
J	Amino, R; Thiberge, S; Martin, B; Celli, S; Shorte, S; Frischknecht, F; Menard, R				Amino, R; Thiberge, S; Martin, B; Celli, S; Shorte, S; Frischknecht, F; Menard, R			Quantitative imaging of Plasmodium transmission from mosquito to mammal	NATURE MEDICINE			English	Article							ANOPHELES-STEPHENSI; BERGHEI SPOROZOITES; MALARIA PARASITES; LYMPH-NODES; VACCINE; YOELII; DYNAMICS; IMMUNITY; PROTEIN; BITE	Plasmodium, the parasite that causes malaria, is transmitted by a mosquito into the dermis and must reach the liver before infecting erythrocytes and causing disease. We present here a quantitative, real-time analysis of the fate of parasites transmitted in a rodent system. We show that only a proportion of the parasites enter blood capillaries, whereas others are drained by lymphatics. Lymph sporozoites stop at the proximal lymph node, where most are degraded inside dendritic leucocytes, but some can partially differentiate into exoerythrocytic stages. This previously unrecognized step of the parasite life cycle could influence the immune response of the host, and may have implications for vaccination strategies against the preerythrocytic stages of the parasite.	Inst Pasteur, Unite Biol & Genet Paludisme, F-75724 Paris 15, France; Inst Pasteur, Grp Dynam Reponses Immunes, F-75724 Paris 15, France; Inst Pasteur, Plate Forme Imagerie Dynam, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Amino, R (corresponding author), Univ Fed Sao Paulo, Dept Bioquim, Rua Tres Maio 100, BR-04044020 Sao Paulo, Brazil.	roti@ecb.epm.br; freddy.frischknecht@med.uni-heidelberg.de; rmenard@pasteur.fr	Celli, Susanna/M-7138-2014	Thiberge, Sabine/0000-0001-5507-0602; Frischknecht, Friedrich/0000-0002-8332-6668; Shorte, Spencer/0000-0002-2125-8663				Beier JC, 1998, ANNU REV ENTOMOL, V43, P519, DOI 10.1146/annurev.ento.43.1.519; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; BOYD MARK F., 1939, AMER JOUR TROP MED, V19, P27; CHAROENVIT Y, 1995, EXP PARASITOL, V80, P419, DOI 10.1006/expr.1995.1054; Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007; Frischknecht F, 2004, CELL MICROBIOL, V6, P687, DOI 10.1111/j.1462-5822.2004.00395.x; Good MF, 2005, TRENDS IMMUNOL, V26, P295, DOI 10.1016/j.it.2005.04.005; Gruner AC, 2005, MOL BIOCHEM PARASIT, V142, P184, DOI 10.1016/j.molbiopara.2005.03.019; Hugues S, 2004, NAT IMMUNOL, V5, P1235, DOI 10.1038/ni1134; Krettli AU, 2000, INFECT IMMUN, V68, P3064, DOI 10.1128/IAI.68.5.3064-3065.2000; Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644; Matsuoka H, 2002, PARASITOL INT, V51, P17, DOI 10.1016/S1383-5769(01)00095-2; MEIS JFGM, 1988, ADV PARASIT, V27, P1, DOI 10.1016/S0065-308X(08)60352-8; Mueller AK, 2005, NATURE, V433, P164, DOI 10.1038/nature03188; Mueller AK, 2005, P NATL ACAD SCI USA, V102, P3022, DOI 10.1073/pnas.0408442102; Natarajan R, 2001, CELL MICROBIOL, V3, P371, DOI 10.1046/j.1462-5822.2001.00117.x; PONNUDURAI T, 1991, T ROY SOC TROP MED H, V85, P175, DOI 10.1016/0035-9203(91)90012-N; Sacci JB, 2005, MOL BIOCHEM PARASIT, V142, P177, DOI 10.1016/j.molbiopara.2005.03.018; Sidjanski S, 1997, AM J TROP MED HYG, V57, P426, DOI 10.4269/ajtmh.1997.57.426; Sumen C, 2004, IMMUNITY, V21, P315, DOI 10.1016/S1074-7613(04)00237-7; Tongren JE, 2004, TRENDS PARASITOL, V20, P604, DOI 10.1016/j.pt.2004.09.005; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; Vaughan JA, 1999, INFECT IMMUN, V67, P4285, DOI 10.1128/IAI.67.8.4285-4289.1999	23	376	391	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					220	224		10.1038/nm1350	http://dx.doi.org/10.1038/nm1350			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16429144				2022-12-25	WOS:000235160600027
J	Butcher, RA; Bhullar, BS; Perlstein, EO; Marsischky, G; LaBaer, J; Schreiber, SL				Butcher, RA; Bhullar, BS; Perlstein, EO; Marsischky, G; LaBaer, J; Schreiber, SL			Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway	NATURE CHEMICAL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; MAMMALIAN PROTEIN; RAPAMYCIN; RECEPTOR; INTEGRATION; DATABASE; COMPLEX; CYCLASE; FKBP12	Identification of the cellular targets of small-molecule hits in phenotypic screens is a central challenge in the development of small molecules as biological tools and potential therapeutics. To facilitate the process of small-molecule target identification, we developed a global, microarray-based method for monitoring the growth of pools of yeast strains, each overexpressing a different protein, in the presence of small molecules. Specifically, the growth of Saccharomyces cerevisiae strains harboring similar to 3,900 different overexpression plasmids was monitored in the presence of rapamycin, which inhibits the target of rapamycin ( TOR) proteins. TOR was successfully identified as a candidate rapamycin target, and many additional gene products were implicated in the TOR signaling pathway. We also characterized the mechanism of LY-83583, a small-molecule suppressor of rapamycin-induced growth inhibition. These data enabled functional links to be drawn between groups of genes implicated in the TOR pathway, identified several candidate targets for LY-83583, and suggested a role for mitochondrial respiration in mediating rapamycin sensitivity.	Harvard Univ, Dept Chem & Biol Chem, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Broad Inst Harvard, Cambridge, MA 02141 USA; MIT, Cambridge, MA 02141 USA; Harvard Inst Prote, Cambridge, MA 02141 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University	Schreiber, SL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Howard Hughes Med Inst, 12 Oxford St, Cambridge, MA 02138 USA.	stuart_schreiber@harvard.edu		Perlstein, Ethan/0000-0002-4734-4391	NHGRI NIH HHS [R01-HG002923] Funding Source: Medline; NIGMS NIH HHS [GM38627] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; Giaever G, 2004, P NATL ACAD SCI USA, V101, P793, DOI 10.1073/pnas.0307490100; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Huang J, 2004, P NATL ACAD SCI USA, V101, P16594, DOI 10.1073/pnas.0407117101; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; KISER GL, 1995, YEAST, V11, P1311, DOI 10.1002/yea.320111312; LeindersZufall T, 1995, J NEUROPHYSIOL, V74, P2759, DOI 10.1152/jn.1995.74.6.2759; Liu CL, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-19; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; MULSCH A, 1988, J PHARMACOL EXP THER, V247, P283; MULSCH A, 1989, N-S ARCH PHARMACOL, V340, P119; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Prasad RK, 1999, EUR J PHARMACOL, V366, P101, DOI 10.1016/S0014-2999(98)00893-0; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xie MW, 2005, P NATL ACAD SCI USA, V102, P7215, DOI 10.1073/pnas.0500297102	30	79	88	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2006	2	2					103	109		10.1038/nchembio762	http://dx.doi.org/10.1038/nchembio762			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	005DA	16415861				2022-12-25	WOS:000234801600013
J	Day, SM; Westfall, MV; Fomicheva, EV; Hoyer, K; Yasuda, S; La Cross, NC; D'Alecy, LG; Ingwall, JS; Metzger, JM				Day, SM; Westfall, MV; Fomicheva, EV; Hoyer, K; Yasuda, S; La Cross, NC; D'Alecy, LG; Ingwall, JS; Metzger, JM			Histidine button engineered into cardiac troponin I protects the ischemic and failing heart	NATURE MEDICINE			English	Article							GENE-TRANSFER; MYOFILAMENT TENSION; CONTRACTILE FAILURE; CHIMERA ANALYSIS; PH SENSITIVITY; MOUSE MODEL; ADULT; REPERFUSION; EXPRESSION; MICE	The myofilament protein troponin I (TnI) has a key isoform-dependent role in the development of contractile failure during acidosis and ischemia. Here we show that cardiac performance in vitro and in vivo is enhanced when a single histidine residue present in the fetal cardiac TnI isoform is substituted into the adult cardiac TnI isoform at codon 164. The most marked effects are observed under the acute challenges of acidosis, hypoxia, ischemia and ischemia-reperfusion, in chronic heart failure in transgenic mice and in myocytes from failing human hearts. In the isolated heart, histidine-modified TnI improves systolic and diastolic function and mitigates reperfusion-associated ventricular arrhythmias. Cardiac performance is markedly enhanced in transgenic hearts during reperfusion despite a high-energy phosphate content similar to that in nontransgenic hearts, providing evidence for greater energetic economy. This pH-sensitive 'histidine button' engineered in TnI produces a titratable molecular switch that 'senses' changes in the intracellular milieu of the cardiac myocyte and responds by preferentially augmenting acute and long-term function under pathophysiological conditions. Myofilament-based inotropy may represent a therapeutic avenue to improve myocardial performance in the ischemic and failing heart.	Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Cardiac Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,NMR Lab Physiol Chem, Boston, MA 02115 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Metzger, JM (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 1150 W Med Ctr Dr,7301 MSRB 3, Ann Arbor, MI 48109 USA.	metzgerj@umich.edu		Westfall, Margaret/0000-0001-9491-0125	NHLBI NIH HHS [HL52320, HL059301, HL63985, HL67254] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067254, P50HL052320, R01HL063985, R01HL059301] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cave AC, 2000, CIRCULATION, V101, P2090, DOI 10.1161/01.CIR.101.17.2090; Chaudhary KW, 2004, J AM COLL CARDIOL, V44, P837, DOI 10.1016/j.jacc.2004.05.049; Coutu P, 2004, CIRC RES, V94, P1235, DOI 10.1161/01.RES.0000126923.46786.FD; Cross HR, 1998, CIRC RES, V83, P1215, DOI 10.1161/01.RES.83.12.1215; Cross HR, 2003, AM J PHYSIOL-HEART C, V284, pH683, DOI 10.1152/ajpheart.00567.2002; Dargis R, 2002, J BIOL CHEM, V277, P34662, DOI 10.1074/jbc.C200419200; Deedwania PC, 2003, CIRCULATION, V107, P1719, DOI 10.1161/01.CIR.0000014688.12415.C0; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; del Monte F, 2002, CIRCULATION, V105, P904, DOI 10.1161/hc0802.105564; del Monte F, 2004, P NATL ACAD SCI USA, V101, P5622, DOI 10.1073/pnas.0305778101; Dewald O, 2003, P NATL ACAD SCI USA, V100, P2700, DOI 10.1073/pnas.0438035100; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; Gould KE, 2002, AM J PHYSIOL-HEART C, V282, pH615, DOI 10.1152/ajpheart.00206.2001; HASENFUSS G, 1994, CIRC RES, V75, P434, DOI 10.1161/01.RES.75.3.434; Heerdt PM, 2000, CIRCULATION, V102, P2713, DOI 10.1161/01.CIR.102.22.2713; Jain M, 2004, CIRCULATION, V109, P898, DOI 10.1161/01.CIR.0000112605.43318.CA; Javadpour MM, 2003, J CLIN INVEST, V112, P768, DOI 10.1172/JC1200315967; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; LEE JA, 1991, J CLIN INVEST, V88, P361, DOI 10.1172/JCI115311; Metzger JM, 2004, CIRC RES, V94, P146, DOI 10.1161/01.RES.0000110083.17024.60; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; Michele DE, 1999, J CELL BIOL, V145, P1483, DOI 10.1083/jcb.145.7.1483; Michele DE, 2002, CIRC RES, V91, P255, DOI 10.1161/01.RES.0000027530.58419.82; Mogensen J, 2003, J CLIN INVEST, V111, P209, DOI 10.1172/JCI200316336; MULIERI LA, 1992, CIRCULATION, V85, P1743, DOI 10.1161/01.CIR.85.5.1743; MUNDINAWEILENMA.C, 1996, AM J PHYSIOL, V39, pC107; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; Naito H, 2000, EUR J PHARMACOL, V388, P171, DOI 10.1016/S0014-2999(99)00845-6; PERUTZ MF, 1985, J MOL BIOL, V183, P491, DOI 10.1016/0022-2836(85)90016-6; Pieske B, 1999, CIRC RES, V85, P38; Piper HM, 2003, ANN THORAC SURG, V75, pS644, DOI 10.1016/S0003-4975(02)04686-6; Robbins J, 2000, ANNU REV PHYSIOL, V62, P261, DOI 10.1146/annurev.physiol.62.1.261; Rossman EI, 2004, J MOL CELL CARDIOL, V36, P33, DOI 10.1016/j.yjmcc.2003.09.001; Rotzschke O, 2002, P NATL ACAD SCI USA, V99, P16946, DOI 10.1073/pnas.212643999; Sakamoto J, 1999, BASIC RES CARDIOL, V94, P489, DOI 10.1007/s003950050165; Saupe KW, 1998, CIRC RES, V82, P898; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; Steg PG, 2004, CIRCULATION, V109, P494, DOI 10.1161/01.CIR.0000109691.16944.DA; Szatkowski ML, 2001, J CLIN INVEST, V107, P191, DOI 10.1172/JCI9862; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tarnavski O, 2004, PHYSIOL GENOMICS, V16, P349, DOI 10.1152/physiolgenomics.00041.2003; Wainwright CL, 2002, BRIT J PHARMACOL, V135, P1882, DOI 10.1038/sj.bjp.0704646; Westfall MV, 1997, P NATL ACAD SCI USA, V94, P5444, DOI 10.1073/pnas.94.10.5444; Westfall MV, 2000, CIRC RES, V86, P470, DOI 10.1161/01.RES.86.4.470; Westfall MV, 2002, CIRC RES, V91, P525, DOI 10.1161/01.RES.0000034710.46739.C0; Westfall MV, 2001, BIOPHYS J, V80, p356A; Westfall MV, 2001, AM J PHYSIOL-CELL PH, V280, pC324, DOI 10.1152/ajpcell.2001.280.2.C324; Westfall MV, 1997, METHOD CELL BIOL, V52, P307, DOI 10.1016/S0091-679X(08)60385-4; Zong XG, 2001, J BIOL CHEM, V276, P6313, DOI 10.1074/jbc.M010326200	50	89	90	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					181	189		10.1038/nm1346	http://dx.doi.org/10.1038/nm1346			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16429145				2022-12-25	WOS:000235160600022
J	Hoeller, D; Crosetto, N; Blagoev, B; Raiborg, C; Tikkanen, R; Wagner, S; Kowanetz, K; Breitling, R; Mann, M; Stenmark, H; Dikic, I				Hoeller, D; Crosetto, N; Blagoev, B; Raiborg, C; Tikkanen, R; Wagner, S; Kowanetz, K; Breitling, R; Mann, M; Stenmark, H; Dikic, I			Regulation of ubiquitin-binding proteins by monoubiquitination	NATURE CELL BIOLOGY			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; C-CBL; INTERACTING MOTIF; ENDOCYTIC PATHWAY; CLATHRIN; UBIQUITYLATION; DEGRADATION; RECRUITMENT; PROTEOMICS	Proteins containing ubiquitin-binding domains (UBDs) interact with ubiquitinated targets and regulate diverse biological processes, including endocytosis, signal transduction, transcription and DNA repair(1-3). Many of the UBD-containing proteins are also themselves monoubiquitinated, but the functional role and the mechanisms that underlie this modification are less well understood. Here, we demonstrate that monoubiquitination of the endocytic proteins Sts1, Sts2, Eps15 and Hrs results in intramolecular interactions between ubiquitin and their UBDs, thereby preventing them from binding in trans to ubiquitinated targets. Permanent monoubiquitination of these proteins, mimicked by the fusion of ubiquitin to their carboxyl termini, impairs their ability to regulate trafficking of ubiquitinated receptors. Moreover, we mapped the in vivo monoubiquitination site in Sts2 and demonstrated that its mutation enhances the Sts2-mediated effects of epidermal-growth-factor-receptor downregulation. We propose that monoubiquitination of ubiquitin-binding proteins inhibits their capacity to bind to and control the functions of ubiquitinated targets in vivo.	Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Univ So Denmark Odense, Ctr Expt Bioinformat, DK-5230 Odense, Denmark; Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Univ Groningen, Groningen Bioinformat Ctr, NL-9751 NN Haren, Netherlands; MPI, Dept Proteom & Signal Transduct, D-82152 Martinsried, Germany	Goethe University Frankfurt; University of Southern Denmark; University of Oslo; Ludwig Institute for Cancer Research; University of Groningen; Max Planck Society	Dikic, I (corresponding author), Univ Frankfurt, Sch Med, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	ivan.dikic@biochem2.de	Mann, Matthias/A-3454-2013; Stenmark, Harald/B-8868-2008; Wagner, Sebastian/B-9056-2012; Hoeller, Daniela/GVT-8953-2022; Dikic, Ivan/O-4650-2015	Mann, Matthias/0000-0003-1292-4799; Dikic, Ivan/0000-0001-8156-9511; Breitling, Rainer/0000-0001-7173-0922; Tikkanen, Ritva/0000-0002-8393-1825; Blagoev, Blagoy/0000-0002-3596-0066				Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Blagoev B, 2004, NAT BIOTECHNOL, V22, P1139, DOI 10.1038/nbt1005; Carpino N, 2004, IMMUNITY, V20, P37, DOI 10.1016/S1074-7613(03)00351-0; Chen H, 2005, P NATL ACAD SCI USA, V102, P2766, DOI 10.1073/pnas.0409719102; Chen H, 2003, P NATL ACAD SCI USA, V100, P14908, DOI 10.1073/pnas.2136625100; Clague MJ, 2002, CURR BIOL, V12, pR529, DOI 10.1016/S0960-9822(02)01030-8; de Melker AA, 2004, J BIOL CHEM, V279, P55465, DOI 10.1074/jbc.M409765200; de Melker AA, 2004, J CELL SCI, V117, P5001, DOI 10.1242/jcs.01354; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Feshchenko EA, 2004, ONCOGENE, V23, P4690, DOI 10.1038/sj.onc.1207627; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Honda A, 2005, FRONT BIOSCI-LANDMRK, V10, P1290, DOI 10.2741/1619; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Olsen JV, 2004, P NATL ACAD SCI USA, V101, P13417, DOI 10.1073/pnas.0405549101; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723	25	250	253	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2006	8	2					163	U45		10.1038/ncb1354	http://dx.doi.org/10.1038/ncb1354			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	008SA	16429130	Green Published			2022-12-25	WOS:000235059800011
J	Hurtado-Lorenzo, A; Skinner, M; El Annan, J; Futai, M; Sun-Wada, GH; Bourgoin, S; Casanova, J; Wildeman, A; Bechoua, S; Ausiello, DA; Brown, D; Marshansky, V				Hurtado-Lorenzo, A; Skinner, M; El Annan, J; Futai, M; Sun-Wada, GH; Bourgoin, S; Casanova, J; Wildeman, A; Bechoua, S; Ausiello, DA; Brown, D; Marshansky, V			V-ATPase interacts with ARNO and Arf6 in early endosomes and regulates the protein degradative pathway	NATURE CELL BIOLOGY			English	Article							ADP-RIBOSYLATION FACTOR; VACUOLAR H+-ATPASE; PROTON PUMP ATPASE; NUCLEOTIDE EXCHANGE; PROXIMAL TUBULES; PLASMA-MEMBRANE; A3 ISOFORM; KIDNEY; ACIDIFICATION; SUBUNIT	The recruitment of the small GTPase Arf6 and ARNO from cytosol to endosomal membranes is driven by V-ATPase-dependent intra-endosomal acidification. The molecular mechanism that mediates this pH-sensitive recruitment and its role are unknown. Here, we demonstrate that Arf6 interacts with the c-subunit, and ARNO with the a2-isoform of V-ATPase. The a2-isoform is targeted to early endosomes, interacts with ARNO in an intra-endosomal acidification-dependent manner, and disruption of this interaction results in reversible inhibition of endocytosis. Inhibition of endosomal acidification abrogates protein trafficking between early and late endosomal compartments. These data demonstrate the crucial role of early endosomal acidification and V-ATPase/ARNO/Arf6 interactions in the regulation of the endocytic degradative pathway. They also indicate that V-ATPase could modulate membrane trafficking by recruiting and interacting with ARNO and Arf6; characteristics that are consistent with the role of V-ATPase as an essential component of the endosomal pH-sensing machinery.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Richard Simches Res Ctr,Program Membrane Biol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Richard Simches Res Ctr,Nephrol Div, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada; Microbial Chem Res Ctr, Futai Special Lab, Tokyo 1410021, Japan; Doshisha Womens Coll, Dept Biochem, Kyoto 6100395, Japan; Univ Laval, CHUL, Quebec City, PQ G1V 4G2, Canada; Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Guelph; Laval University; University of Virginia	Marshansky, V (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Richard Simches Res Ctr,Program Membrane Biol, Boston, MA 02114 USA.	Vladimir_Marshansky@hms.harvard.edu	Marshansky, Vladimir/AAZ-7890-2020; Hurtado-Lorenzo, Ph.D., Andres/A-8331-2009	Bourgoin, Sylvain/0000-0001-9779-0368	NIDDK NIH HHS [DK43341, DK57521, DK42956, DK38452] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043341, R01DK042956, R37DK042956, P01DK038452, P30DK057521] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Baravalle G, 2005, CELL TISSUE RES, V320, P99, DOI 10.1007/s00441-004-1060-x; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Brown D., 2004, HDB ATPASES BIOCH CE, P413; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Christensen EI, 2002, NAT REV MOL CELL BIO, V3, P258, DOI 10.1038/nrm778; D'SOUZA-SCHOREY C, 1995, EXP CELL RES, V221, P153, DOI 10.1006/excr.1995.1362; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Donaldson JG, 2005, BBA-MOL CELL RES, V1744, P364, DOI 10.1016/j.bbamcr.2005.03.001; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; El Annan J, 2004, AM J PHYSIOL-CELL PH, V286, pC768, DOI 10.1152/ajpcell.00250.2003; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Gu F, 2000, J BIOL CHEM, V275, P8154, DOI 10.1074/jbc.275.11.8154; Gu F, 1999, FEBS LETT, V452, P61, DOI 10.1016/S0014-5793(99)00561-X; Hryciw DH, 2003, J BIOL CHEM, V278, P40169, DOI 10.1074/jbc.M307890200; Jentsch TJ, 2004, NAT CELL BIOL, V6, P1039, DOI 10.1038/ncb1104-1039; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Mansour M, 2002, J BIOL CHEM, V277, P32302, DOI 10.1074/jbc.M202898200; Maranda B, 2001, J BIOL CHEM, V276, P18540, DOI 10.1074/jbc.M011577200; Marshansky V, 1997, ELECTROPHORESIS, V18, P538, DOI 10.1002/elps.1150180334; Marshansky V, 1996, BBA-BIOMEMBRANES, V1284, P171, DOI 10.1016/S0005-2736(96)00123-X; Marshansky V, 1997, ELECTROPHORESIS, V18, P2661, DOI 10.1002/elps.1150181423; Marshansky V, 2002, CURR OPIN NEPHROL HY, V11, P527, DOI 10.1097/00041552-200209000-00009; Marshansky V, 1996, J MEMBRANE BIOL, V153, P59, DOI 10.1007/s002329900110; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MELLMAN I, 1992, J EXP BIOL, V172, P39; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Paleotti O, 2005, J BIOL CHEM, V280, P21661, DOI 10.1074/jbc.m503099200; Peters PJ, 2001, TRAFFIC, V2, P885, DOI 10.1034/j.1600-0854.2001.21204.x; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Santy LC, 1999, CURR BIOL, V9, P1173, DOI 10.1016/S0960-9822(00)80019-6; Skinner MA, 2001, J BIOL CHEM, V276, P48451, DOI 10.1074/jbc.M103569200; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sun-Wada GH, 2004, BBA-BIOENERGETICS, V1658, P106, DOI 10.1016/j.bbabio.2004.04.013; Sun-Wada GH, 2003, J BIOL CHEM, V278, P44843, DOI 10.1074/jbc.M307197200; Sun-Wada GH, 2003, CELL STRUCT FUNCT, V28, P455, DOI 10.1247/csf.28.455; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; VINAY P, 1981, AM J PHYSIOL, V241, pF403, DOI 10.1152/ajprenal.1981.241.4.F403; Wagner CA, 2004, PHYSIOL REV, V84, P1263, DOI 10.1152/physrev.00045.2003; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZEUZEM S, 1992, J MEMBRANE BIOL, V125, P231; Zhai XY, 2000, KIDNEY INT, V58, P1523, DOI 10.1046/j.1523-1755.2000.00314.x	49	360	367	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2006	8	2					124	U8		10.1038/ncb1348	http://dx.doi.org/10.1038/ncb1348			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	008SA	16415858				2022-12-25	WOS:000235059800007
J	Muthumani, K; Choo, AY; Zong, WX; Madesh, M; Hwang, DS; Premkumar, A; Thieu, KP; Emmanuel, J; Kumar, S; Thompson, CB; Weiner, DB				Muthumani, K; Choo, AY; Zong, WX; Madesh, M; Hwang, DS; Premkumar, A; Thieu, KP; Emmanuel, J; Kumar, S; Thompson, CB; Weiner, DB			The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1	NATURE CELL BIOLOGY			English	Article							VIRAL PROTEIN-R; NF-KAPPA-B; CELL-CYCLE; DNA-BINDING; T-CELLS; VIRUS; TRANSCRIPTION; ACTIVATION; EXPRESSION; MECHANISM	The Vpr protein of HIV-1 functions as a vital accessory gene by regulating various cellular functions, including cell differentiation, apoptosis, nuclear factor of kappa B (NF-kappa B) suppression and cell-cycle arrest of the host cell. Several reports have indicated that Vpr complexes with the glucocorticoid receptor (GR), but it remains unclear whether the GR pathway is required for Vpr to function(1). Here, we report that Vpr uses the GR pathway as a recruitment vehicle for the NF-kappa B co-activating protein, poly(ADP-ribose) polymerase(1) (PARP-1). The GR interaction with Vpr is both necessary and sufficient to facilitate this interaction by potentiating the formation of a Vpr-GR-PARP-1 complex. The recruitment of PARP-1 by the Vpr-GR complex prevents its nuclear localization, which is necessary for Vpr to suppress NF-kappa B. The association of GR with PARP-1 is not observed with steroid (glucocorticoid) treatment, indicating that the GR association with PARP-1 is a gain of function that is solely attributed to HIV-1 Vpr. These data provide important insights into Vpr biology and its role in HIV pathogenesis.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Mem Sloan Kettering Canc Ctr, Lab Mol Neuropharmacol, New York, NY 10021 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center	Weiner, DB (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	dbweiner@mail.med.upenn.edu	Muthumani, Kar/AAQ-4939-2020; Muthumani, Kar/C-8252-2017; Muthumani, Karuppiah/D-1092-2009; Weiner, David B/H-8579-2014	Muthumani, Kar/0000-0002-6807-2065; Muthumani, Kar/0000-0002-6807-2065; 	NCI NIH HHS [K01 CA098092-01A2, K01 CA098092, K01 CA098092-04, K01 CA098092-03, K01 CA098092-06, K01 CA098092-05, K01 CA098092-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA098092] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arad G, 2000, NAT MED, V6, P414, DOI 10.1038/74672; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; Doppler W, 2001, MOL CELL BIOL, V21, P3266, DOI 10.1128/MCB.21.9.3266-3279.2001; Gandhi RT, 2002, ANNU REV MED, V53, P149, DOI 10.1146/annurev.med.53.082901.104011; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; Muthumani K, 2005, MOL THER, V12, P910, DOI 10.1016/j.ymthe.2005.05.009; Muthumani K, 2005, CELL DEATH DIFFER, V12, P962, DOI 10.1038/sj.cdd.4401583; Muthumani K, 2003, BIOCHEM BIOPH RES CO, V304, P583, DOI 10.1016/S0006-291X(03)00631-4; Muthumani K, 2002, J BIOL CHEM, V277, P37820, DOI 10.1074/jbc.M205313200; Muthumani K, 2005, INT IMMUNOL, V17, P103, DOI 10.1093/intimm/dxh190; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Parent M, 2005, J BIOL CHEM, V280, P448, DOI 10.1074/jbc.M408435200; Ramanathan MP, 2002, J BIOL CHEM, V277, P47854, DOI 10.1074/jbc.M203905200; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sherman MP, 2002, VIROLOGY, V302, P95, DOI 10.1006/viro.2002.1576; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	34	57	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2006	8	2					170	U48		10.1038/ncb1352	http://dx.doi.org/10.1038/ncb1352			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	008SA	16429131	Green Published, Green Accepted			2022-12-25	WOS:000235059800012
J	Monsuur, AJ; de Bakker, PIW; Alizadeh, BZ; Zhernakova, A; Bevova, MR; Strengman, E; Franke, L; van't Slot, R; van Belzen, MJ; Lavrijsen, ICM; Diosdado, B; Daly, MJ; Mulder, CJJ; Mearin, ML; Meijer, JWR; Meijer, GA; van Oort, E; Wapenaar, MC; Koeleman, BPC; Wijmenga, C				Monsuur, AJ; de Bakker, PIW; Alizadeh, BZ; Zhernakova, A; Bevova, MR; Strengman, E; Franke, L; van't Slot, R; van Belzen, MJ; Lavrijsen, ICM; Diosdado, B; Daly, MJ; Mulder, CJJ; Mearin, ML; Meijer, JWR; Meijer, GA; van Oort, E; Wapenaar, MC; Koeleman, BPC; Wijmenga, C			Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect	NATURE GENETICS			English	Article							EPITHELIAL BARRIER; PREVALENCE; MAPS	Celiac disease is probably the best-understood immune-related disorder. The disease presents in the small intestine and results from the interplay between multiple genes and gluten, the triggering environmental factor(1). Although HLA class II genes explain 40% of the heritable risk, non-HLA genes accounting for most of the familial clustering have not yet been identified. Here we report significant and replicable association (P = 2.1 x 10(-6)) to a common variant located in intron 28 of the gene myosin IXB (MYO9B), which encodes an unconventional myosin molecule that has a role in actin remodeling of epithelial enterocytes(2,3). Individuals homozygous with respect to the at-risk allele have a 2.3-times higher risk of celiac disease ( P = 1.55 x 10(-5)). This result is suggestive of a primary impairment of the intestinal barrier in the etiology of celiac disease, which may explain why immunogenic gluten peptides are able to pass through the epithelial barrier.	Univ Med Ctr Utrecht, DBG Dept Med Genet, Complex Genet Sect, NL-3584 CG Utrecht, Netherlands; Harvard Univ, Broad Inst, Cambridge, MA 02141 USA; MIT, Broad Inst, Cambridge, MA 02141 USA; Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; VU Univ Med Ctr, Dept Gastroenterol, NL-1007 MB Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RC Leiden, Netherlands; Rijnstate Hosp, Dept Pathol, NL-6800 TA Arnhem, Netherlands; VU Univ Med ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Rijnstate Hospital; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Wijmenga, C (corresponding author), Univ Med Ctr Utrecht, DBG Dept Med Genet, Complex Genet Sect, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	t.n.wijmenga@med.uu.nl	Wijmenga, Cisca/D-2173-2009; Alizadeh, Behrooz Z Ziad/J-2921-2017; de Bakker, Paul IW/B-8730-2009; Daly, Mark J/B-2453-2017; Wijmenga, Cisca/AAE-7719-2019; Zhernakova, Alexandra/ABA-9372-2020; Franke, Lude/P-7036-2016	Alizadeh, Behrooz Z Ziad/0000-0002-1415-8007; de Bakker, Paul IW/0000-0001-7735-7858; Daly, Mark J/0000-0002-0949-8752; Wijmenga, Cisca/0000-0002-5635-1614; Meijer, Gerrit/0000-0003-0330-3130; Zhernakova, Alexandra/0000-0002-4574-0841; Franke, Lude/0000-0002-5159-8802				Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Babron MC, 2003, EUR J HUM GENET, V11, P828, DOI 10.1038/sj.ejhg.5201051; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bitti PP, 2001, GENET EPIDEMIOL, V20, P271, DOI 10.1002/1098-2272(200102)20:2<271::AID-GEPI9>3.0.CO;2-L; Bruewer M, 2004, AM J PHYSIOL-CELL PH, V287, pC327, DOI 10.1152/ajpcell.00087.2004; Catassi C, 2001, EUR J GASTROEN HEPAT, V13, P1123; Chiano MN, 1998, ANN HUM GENET, V62, P55, DOI 10.1046/j.1469-1809.1998.6210055.x; DEBAKKER PI, 2005, NAT GENET       1023; Dube C, 2005, GASTROENTEROLOGY, V128, pS57, DOI 10.1053/j.gastro.2005.02.014; FALCHUK ZM, 1972, LANCET, V2, P1310; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Green PHR, 2005, GASTROENTEROLOGY, V128, pS74, DOI 10.1053/j.gastro.2005.02.016; Greenland, 1998, MODERN EPIDEMIOLOGY, P47; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; Post PL, 2002, J BIOL CHEM, V277, P11679, DOI 10.1074/jbc.M111173200; Rewers M, 2005, GASTROENTEROLOGY, V128, pS47, DOI 10.1053/j.gastro.2005.02.030; SCHULZKE JD, 1995, GUT, V37, P777, DOI 10.1136/gut.37.6.777; Smecuol E, 2005, CLIN GASTROENTEROL H, V3, P335, DOI 10.1016/S1542-3565(04)00778-5; Uil JJ, 1996, EUR J GASTROEN HEPAT, V8, P219, DOI 10.1097/00042737-199603000-00006; Van Belzen MJ, 2003, GASTROENTEROLOGY, V125, P1032, DOI 10.1016/S0016-5085(03)01205-8; van Heel DA, 2005, BEST PRACT RES CL GA, V19, P323, DOI 10.1016/j.bpg.2005.01.001; VANELBURG RM, 1993, GUT, V34, P354, DOI 10.1136/gut.34.3.354	24	176	185	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2005	37	12					1341	1344		10.1038/ng1680	http://dx.doi.org/10.1038/ng1680			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16282976				2022-12-25	WOS:000233657300013
J	Kun, A; Santos, M; Szathmary, E				Kun, A; Santos, M; Szathmary, E			Real ribozymes suggest a relaxed error threshold	NATURE GENETICS			English	Article							RNA; ADDITIVITY; EVOLUTION; PROTEIN	The error threshold for replication, the critical copying fidelity below which the fittest genotype deterministically disappears, limits the length of the genome that can be maintained by selection. Primordial replication must have been error- prone, and so early replicators are thought to have been necessarily short(1). The error threshold also depends on the fitness landscape. In an RNA world(2), many neutral and compensatory mutations can raise the threshold, below which the functional phenotype(3), rather than a particular sequence, is still present(4,5). Here we show, on the basis of comparative analysis of two extensively mutagenized ribozymes, that with a copying fidelity of 0.999 per digit per replication the phenotypic error threshold rises well above 7,000 nucleotides, which permits the selective maintenance of a functionally rich riboorganism(6) with a genome of more than 100 different genes, the size of a tRNA. This requires an order of magnitude of improvement in the accuracy of in vitro - generated polymerase ribozymes(7,8). Incidentally, this genome size coincides with that estimated for a minimal cell achieved by top- down analysis(9), omitting the genes dealing with translation.	Collegium Budapest, Inst Adv Study, H-1014 Budapest, Hungary; Eotvos Lorand Univ, Dept Plant Taxon & Ecol, H-1117 Budapest, Hungary; Univ Autonoma Barcelona, Dept Genet & Microbiol, Grp Biol Evolut, E-08193 Barcelona, Spain; Eotvos Lorand Univ, Hungarian Acad Sci, Res Grp Ecol & Theoret Biol, H-1117 Budapest, Hungary	Eotvos Lorand University; Autonomous University of Barcelona; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Centre for Agricultural Research; Eotvos Lorand University	Szathmary, E (corresponding author), Collegium Budapest, Inst Adv Study, Szentharomsag 2, H-1014 Budapest, Hungary.	szathmary@colbud.hu	Szathmáry, Eörs/A-5007-2011; Szathmary, Eors/AAS-1202-2021; Kun, Ádám/A-5571-2011; Santos, Mauro/A-8044-2008	Szathmary, Eors/0000-0001-5227-2997; Kun, Ádám/0000-0002-8409-8521; Santos, Mauro/0000-0002-6478-6570				BEATTIE TL, 1995, P NATL ACAD SCI USA, V92, P4686, DOI 10.1073/pnas.92.10.4686; BENNER SA, 1987, COLD SPRING HARB SYM, V52, P53, DOI 10.1101/SQB.1987.052.01.009; BUTCHER SE, 1994, BIOCHEMISTRY-US, V33, P992, DOI 10.1021/bi00170a018; BUTCHER SE, 1994, J MOL BIOL, V244, P52, DOI 10.1006/jmbi.1994.1703; Domingo Esteban, 1994, P161; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; EIGEN M, 1989, ADV CHEM PHYS, V75, P149; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; Gil R, 2004, MICROBIOL MOL BIOL R, V68, P518, DOI 10.1128/MMBR.68.3.518-537.2004; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Huynen MA, 1996, P NATL ACAD SCI USA, V93, P397, DOI 10.1073/pnas.93.1.397; Jeffares DC, 1998, J MOL EVOL, V46, P18, DOI 10.1007/PL00006280; Johnston WK, 2001, SCIENCE, V292, P1319, DOI 10.1126/science.1060786; Lafontaine DA, 2002, BIOCHEM SOC T, V30, P1170, DOI 10.1042/bst0301170; LEHMAN N, 1993, CURR BIOL, V3, P723, DOI 10.1016/0960-9822(93)90019-K; Muller UF, 2003, CHEM BIOL, V10, P799, DOI 10.1016/S1074-5521(03)00171-6; Reidys C, 2001, B MATH BIOL, V63, P57, DOI 10.1006/bulm.2000.0206; SANDBERG WS, 1993, P NATL ACAD SCI USA, V90, P8367, DOI 10.1073/pnas.90.18.8367; Santos M, 2004, J MOL EVOL, V59, P507, DOI 10.1007/s00239-004-2642-7; Skinner MM, 1996, P NATL ACAD SCI USA, V93, P10753, DOI 10.1073/pnas.93.20.10753; SMITH JM, 1983, PROC R SOC SER B-BIO, V219, P315, DOI 10.1098/rspb.1983.0076; SMITH JM, 1979, NATURE, V280, P445, DOI 10.1038/280445a0; Szathmary E, 1995, MAJOR TRANSITIONS EV; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; Takeuchi N, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-9	27	92	95	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					1008	1011		10.1038/ng1621	http://dx.doi.org/10.1038/ng1621			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16127452				2022-12-25	WOS:000231591900029
J	Bayliss, PE; Bellavance, KL; Whitehead, GG; Abrams, JM; Aegerter, S; Robbins, HS; Cowan, DB; Keating, MT; O'Reilly, T; Wood, JM; Roberts, TM; Chan, J				Bayliss, PE; Bellavance, KL; Whitehead, GG; Abrams, JM; Aegerter, S; Robbins, HS; Cowan, DB; Keating, MT; O'Reilly, T; Wood, JM; Roberts, TM; Chan, J			Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish	NATURE CHEMICAL BIOLOGY			English	Article							ENDOTHELIAL-GROWTH-FACTOR; DRUG DISCOVERY; KINASE INHIBITORS; FIN REGENERATION; TYROSINE KINASES; SONIC-HEDGEHOG; VEGF; MORPHOGENESIS; EXPRESSION; GRIDLOCK	We examined the role of angiogenesis and the need for receptor signaling using chemical inhibition of the vascular endothelial growth factor receptor in the adult zebrafish tail fin. Using a small-molecule inhibitor, we were able to exert precise control over blood vessel regeneration. An angiogenic limit to tissue regeneration was determined, as avascular tissue containing skin, pigment, neuronal axons and bone precursors could regenerate up to about 1 mm. This indicates that tissues can regenerate without direct interaction with endothelial cells and at a distance from blood supply. We also investigated whether the effects of chemical inhibition could be enhanced in zebrafish vascular mutants. We found that adult zebrafish, heterozygous for a mutation in the critical receptor effector phospholipase C gamma 1, show a greater sensitivity to chemical inhibition. This study illustrates the utility of the adult zebrafish as a new model system for receptor signaling and chemical biology.	Harvard Univ, Sch Med, Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Dept Cardiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Novartis Pharma AG, CH-4002 Basel, Switzerland	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Novartis	Chan, J (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA.	joanne.chan@childrens.harvard.edu		Bayliss, Peter/0000-0003-4807-6365; Abrams, Joshua/0000-0003-1834-6782; Cowan, Douglas/0000-0002-6309-2737	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068915] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL068915-05A1, R01 HL068915] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimenko MA, 2003, DEV DYNAM, V226, P190, DOI 10.1002/dvdy.10248; AKIMENKO MA, 1995, DEVELOPMENT, V121, P347; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Bold G, 2000, J MED CHEM, V43, P2310, DOI 10.1021/jm9909443; Chan J, 2002, CANCER CELL, V1, P257, DOI 10.1016/S1535-6108(02)00042-9; Chan J, 2001, DEV BIOL, V234, P470, DOI 10.1006/dbio.2001.0281; Chanda SK, 2003, DRUG DISCOV TODAY, V8, P168, DOI 10.1016/S1359-6446(02)02595-3; Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Han MJ, 2003, DEVELOPMENT, V130, P5123, DOI 10.1242/dev.00710; Huang CC, 2003, DEV BIOL, V264, P263, DOI 10.1016/j.ydbio.2003.08.016; JOHNSON SL, 1995, GENETICS, V141, P1583; Keating MT, 2004, PHILOS T R SOC B, V359, P795, DOI 10.1098/rstb.2004.1469; Laforest L, 1998, DEVELOPMENT, V125, P4175; Lawson ND, 2003, GENE DEV, V17, P1346, DOI 10.1101/gad.1072203; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Lenz GR, 2000, DRUG DISCOV TODAY, V5, P145, DOI 10.1016/S1359-6446(00)01468-9; Liao AT, 2002, BLOOD, V100, P585, DOI 10.1182/blood-2001-12-0350; Liao W, 1997, DEVELOPMENT, V124, P381; Manley PW, 2004, BBA-PROTEINS PROTEOM, V1697, P17, DOI 10.1016/j.bbapap.2003.11.010; MCKIM J, 1985, TOXICOL APPL PHARM, V77, P1, DOI 10.1016/0041-008X(85)90262-5; METCALFE WK, 1990, DEVELOPMENT, V110, P491; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; Nechiporuk A, 2002, DEVELOPMENT, V129, P2607; Parichy DM, 1999, DEVELOPMENT, V126, P3425; Peterson RT, 2004, NAT BIOTECHNOL, V22, P595, DOI 10.1038/nbt963; Peterson RT, 2000, P NATL ACAD SCI USA, V97, P12965, DOI 10.1073/pnas.97.24.12965; Poss FD, 2000, DEV BIOL, V222, P347, DOI 10.1006/dbio.2000.9722; Poss KD, 2003, DEV DYNAM, V226, P202, DOI 10.1002/dvdy.10220; Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857; Quint E, 2002, P NATL ACAD SCI USA, V99, P8713, DOI 10.1073/pnas.122571799; REGINELLI AD, 1995, DEVELOPMENT, V121, P1065; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; STAINIER DYR, 1995, DEVELOPMENT, V121, P3141; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Wood JM, 2000, CANCER RES, V60, P2178; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599; Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606	48	100	106	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAY	2006	2	5					265	273		10.1038/nchembio778	http://dx.doi.org/10.1038/nchembio778			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	034VE	16565716	Green Accepted			2022-12-25	WOS:000236957900013
J	Bosco, DA; Fowler, DM; Zhang, QH; Nieva, J; Powers, ET; Wentworth, P; Lerner, RA; Kelly, JW				Bosco, DA; Fowler, DM; Zhang, QH; Nieva, J; Powers, ET; Wentworth, P; Lerner, RA; Kelly, JW			Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization	NATURE CHEMICAL BIOLOGY			English	Article							PARKINSONS-DISEASE; IN-VITRO; DOPAMINE; SUSCEPTIBILITY; PATHOGENESIS; NUCLEATION; DEMENTIA; BODIES; SYSTEM	Oxidative stress, inflammation and alpha-synuclein overexpression(1) confer risk for development of alpha-synucleinopathies neurodegenerative diseases that include Parkinson disease and Lewy body dementia(2). Dopaminergic neurons undergo degeneration in these diseases and are particularly susceptible to oxidative stress because dopamine metabolism itself creates reactive oxygen species(3). Intraneuronal deposition of alpha-synuclein as amyloid fibrils or Lewy bodies is the hallmark of these diseases(2). Herein, we demonstrate that concentrations of oxidative cholesterol metabolites derived from reactive oxygen species are elevated in the cortices of individuals with Lewy body dementia relative to those of age-matched controls, and we show that these metabolites accelerate alpha-synuclein aggregation in vitro. The increase in the production of these cytotoxic cholesterol metabolites is also observed in a dopaminergic cell line that overexpresses alpha-synuclein(4). By extension, these data lead to the hypothesis that oxidative stress produces cholesterol aldehydes that enable alpha-synuclein aggregation, leading to a pathologic cycle.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, Oxford OX1 2JD, England	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of Oxford	Kelly, JW (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jkelly@scripps.edu			NINDS NIH HHS [NS050636] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050636] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Bieschke J, 2005, BIOCHEMISTRY-US, V44, P4977, DOI 10.1021/bi0501030; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Necula M, 2003, J BIOL CHEM, V278, P46674, DOI 10.1074/jbc.M308231200; Rampello L, 2004, ARCH GERONTOL GERIAT, V39, P1, DOI 10.1016/j.archger.2003.11.003; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Suh MD, 2004, ARCH PHARM RES, V27, P850, DOI 10.1007/BF02980178; Wentworth P, 2003, SCIENCE, V302, P1053, DOI 10.1126/science.1089525; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Zhang QH, 2004, P NATL ACAD SCI USA, V101, P4752, DOI 10.1073/pnas.0400924101	15	247	259	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAY	2006	2	5					249	253		10.1038/nchembio782	http://dx.doi.org/10.1038/nchembio782			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	034VE	16565714				2022-12-25	WOS:000236957900009
J	Grant, SFA; Thorleifsson, G; Reynisdottir, I; Benediktsson, R; Manolescu, A; Sainz, J; Helgason, A; Stefansson, H; Emilsson, V; Helgadottir, A; Styrkarsdottir, U; Magnusson, KP; Walters, GB; Palsdottir, E; Jonsdottir, T; Gudmundsdottir, T; Gylfason, A; Saemundsdottir, J; Wilensky, RL; Reilly, MP; Rader, DJ; Bagger, Y; Christiansen, C; Gudnason, V; Sigurdsson, G; Thorsteinsdottir, U; Gulcher, JR; Kong, A; Stefansson, K				Grant, SFA; Thorleifsson, G; Reynisdottir, I; Benediktsson, R; Manolescu, A; Sainz, J; Helgason, A; Stefansson, H; Emilsson, V; Helgadottir, A; Styrkarsdottir, U; Magnusson, KP; Walters, GB; Palsdottir, E; Jonsdottir, T; Gudmundsdottir, T; Gylfason, A; Saemundsdottir, J; Wilensky, RL; Reilly, MP; Rader, DJ; Bagger, Y; Christiansen, C; Gudnason, V; Sigurdsson, G; Thorsteinsdottir, U; Gulcher, JR; Kong, A; Stefansson, K			Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes	NATURE GENETICS			English	Article							BETA-CATENIN; LINKAGE; POLYMORPHISM; MELLITUS; DISEASE; MODELS; TCF-4; ONSET	We have previously reported suggestive linkage of type 2 diabetes mellitus to chromosome 10q(1). We genotyped 228 microsatellite markers in Icelandic individuals with type 2 diabetes and controls throughout a 10.5-Mb interval on 10q. A microsatellite, DG10S478, within intron 3 of the transcription factor 7-like 2 gene (TCF7L2; formerly TCF4) was associated with type 2 diabetes (P = 2.1 X 10(-9)). This was replicated in a Danish cohort (P = 4.8 X 10(-3)) and in a US cohort (P = 3.3 X 10(-9)). Compared with non-carriers, heterozygous and homozygous carriers of the at-risk alleles (38% and 7% of the population, respectively) have relative risks of 1.45 and 2.41. This corresponds to a population attributable risk of 21%. The TCF7L2 gene product is a high mobility group box-containing transcription factor previously implicated in blood glucose homeostasis. It is thought to act through regulation of proglucagon gene expression in enteroendocrine cells via the Wnt signaling pathway(2).	deCODE Genet, IS-101 Reykjavik, Iceland; Iceland Heart Assoc, IS-201 Kopavogur, Iceland; Natl Univ Hosp Reykjavik, IS-108 Reykjavik, Iceland; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Ctr Clin & Basic Res AS, DK-2750 Ballerup, Denmark	Icelandic Heart Association; Landspitali National University Hospital; University of Pennsylvania; Center Clinical & Basic Research	Grant, SFA (corresponding author), deCODE Genet, Sturlugata 8, IS-101 Reykjavik, Iceland.	struan.grant@decode.is; kstefans@decode.is	Gudnason, Vilmundur/AAE-7126-2019; Manolescu, Andrei/G-4565-2014; Stefansson, Kari/AAE-7187-2019; Helgason, Agnar/K-1522-2015; Benediktsson, Rafn/R-2457-2018; Magnusson, Kristinn/A-6479-2011; Magnusson, Kristinn P Pétur/X-4907-2019; Walters, G. Bragi/L-4215-2013; Gudnason, Vilmundur/K-6885-2015	Gudnason, Vilmundur/0000-0001-5696-0084; Manolescu, Andrei/0000-0002-0713-4664; Benediktsson, Rafn/0000-0002-2954-9801; Magnusson, Kristinn/0000-0003-4528-6826; Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Walters, G. Bragi/0000-0002-5415-6487; Gudnason, Vilmundur/0000-0001-5696-0084; Emilsson, Valur/0000-0001-9982-0524; Styrkarsdottir, Unnur/0000-0001-8146-8278; Kong, Augustine/0000-0001-8193-5438; Helgason, Agnar/0000-0002-8545-3767; Stefansson, Hreinn/0000-0002-9331-6666; Reilly, Muredach/0000-0002-3035-9386; Reynisdottir, Inga/0000-0002-9730-7476; Grant, Struan/0000-0003-2025-5302				Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Duggirala R, 1999, AM J HUM GENET, V64, P1127, DOI 10.1086/302316; Duval A, 2000, CANCER RES, V60, P3872; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Gloyn AL, 2003, DIABETES, V52, P568, DOI 10.2337/diabetes.52.2.568; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; LEWONTIN RC, 1964, GENETICS, V50, P757; MANTEL N, 1959, J NATL CANCER I, V22, P719; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Noble JA, 2003, DIABETES, V52, P1579, DOI 10.2337/diabetes.52.6.1579; Prunier C, 2004, GROWTH FACTORS, V22, P141, DOI 10.1080/08977190410001720860; Reynisdottir I, 2003, AM J HUM GENET, V73, P323, DOI 10.1086/377139; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; Tanko LB, 2003, BONE, V32, P8, DOI 10.1016/S8756-3282(02)00918-3; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Yi FH, 2005, J BIOL CHEM, V280, P1457, DOI 10.1074/jbc.M411487200; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	25	1597	1703	2	89	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					320	323		10.1038/ng1732	http://dx.doi.org/10.1038/ng1732			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16415884				2022-12-25	WOS:000235589600013
J	Niihori, T; Aoki, Y; Narumi, Y; Neri, G; Cave, H; Verloes, A; Okamoto, N; Hennekam, RCM; Gillessen-Kaesbach, G; Wieczorek, D; Kavamura, MI; Kurosawa, K; Ohashi, H; Wilson, L; Heron, D; Bonneau, D; Corona, G; Kaname, T; Naritomi, K; Baumann, C; Matsumoto, N; Kato, K; Kure, S; Matsubara, Y				Niihori, T; Aoki, Y; Narumi, Y; Neri, G; Cave, H; Verloes, A; Okamoto, N; Hennekam, RCM; Gillessen-Kaesbach, G; Wieczorek, D; Kavamura, MI; Kurosawa, K; Ohashi, H; Wilson, L; Heron, D; Bonneau, D; Corona, G; Kaname, T; Naritomi, K; Baumann, C; Matsumoto, N; Kato, K; Kure, S; Matsubara, Y			Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome	NATURE GENETICS			English	Article							CARDIOFACIOCUTANEOUS CFC SYNDROME; PTPN11 MUTATIONS; B-RAF; COSTELLO-SYNDROME; CANCER	Cardio-facio-cutaneous (CFC) syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. It phenotypically overlaps with Noonan and Costello syndrome, which are caused by mutations in PTPN11 and HRAS, respectively. In 43 individuals with CFC, we identified two heterozygous KRAS mutations in three individuals and eight BRAF mutations in 16 individuals, suggesting that dysregulation of the RAS-RAF-ERK pathway is a common molecular basis for the three related disorders.	Tohoku Univ, Sch Med, Dept Med Genet, Sendai, Miyagi, Japan; Catholic Univ, Ist Genet Med, Rome, Italy; Hop Robert Debre, APHP, Dept Genet, Paris, France; Osaka Med Ctr, Dept Planning & Res, Osaka, Japan; Res Inst Maternal & Child Hlth, Osaka, Japan; Inst Child Hlth, Clin & Mol Genet Unit, London, England; Acad Med Ctr, Dept Pediat, Amsterdam, Netherlands; Univ Essen Gesamthsch, Inst Human Genet, Essen, Germany; UNIFESP, Ctr Med Genet, Sao Paulo, Brazil; Kanagawa Childrens Med Ctr, Div Med Genet, Yokohama, Kanagawa, Japan; Saitama Childrens Med Ctr, Div Med Genet, Saitama, Japan; Great Ormond St Hosp Sick Children, London, England; Pitie Salpetriere Univ Hosp, Dept Genet, Paris, France; Univ Hosp, Dept Genet, Angers, France; Azienda Osped Univ G Martino, Dipartimento Sci Pediat Med & Chirurg, Unita Operat Complessa Patol Neonatale & Terapia, Messina, Italy; Univ Ryukyus, Sch Med, Dept Med Genet, Okinawa, Japan; Yokohama City Univ, Grad Sch Med, Dept Human Genet, Yokohama, Kanagawa, Japan; Tohoku Univ, Comprehens Res & Educ Ctr Planning Drug Dev & Cli, Cent COE Program 21, Sendai, Miyagi, Japan	Tohoku University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Osaka Medical Center for Cancer & Cardiovascular Diseases; University of London; University College London; University of Amsterdam; Academic Medical Center Amsterdam; University of Duisburg Essen; Universidade Federal de Sao Paulo (UNIFESP); Saitama Children's Medical Center; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; AOU Policlinico Gaetano Martino; University of the Ryukyus; Yokohama City University; Tohoku University	Aoki, Y (corresponding author), Tohoku Univ, Sch Med, Dept Med Genet, Sendai, Miyagi, Japan.	aokiy@mail.tains.tohoku.ac.jp	Niihori, Tetsuya/ABE-2350-2021; /AAK-8500-2021; Bonneau, Dominique/K-6110-2015; Kurosawa, Kenji/B-6561-2016; VERLOES, Alain/E-7287-2014	Niihori, Tetsuya/0000-0002-2118-9776; Kurosawa, Kenji/0000-0002-6817-7748; VERLOES, Alain/0000-0003-4819-0264; Cave, Helene/0000-0003-2840-1511				Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ion A, 2002, HUM GENET, V111, P421, DOI 10.1007/s00439-002-0803-6; Kavamura MI, 2003, EUR J HUM GENET, V11, P64, DOI 10.1038/sj.ejhg.5200911; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Musante L, 2003, EUR J HUM GENET, V11, P201, DOI 10.1038/sj.ejhg.5200935; NERI G, 1991, AM J MED GENET, V39, P367, DOI 10.1002/ajmg.1320390323; REYNOLDS JF, 1986, AM J MED GENET, V25, P413, DOI 10.1002/ajmg.1320250303; Tartaglia M, 2005, EUR J MED GENET, V48, P81, DOI 10.1016/j.ejmg.2005.03.001; Van den Berg H, 1999, J MED GENET, V36, P799, DOI 10.1136/jmg.36.10.799; van Eeghen AM, 1999, AM J MED GENET, V82, P187, DOI 10.1002/(SICI)1096-8628(19990115)82:2<187::AID-AJMG17>3.0.CO;2-2; Wieczorek D, 1997, CLIN GENET, V52, P37; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578	15	417	460	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					294	296		10.1038/ng1749	http://dx.doi.org/10.1038/ng1749			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16474404				2022-12-25	WOS:000235589600008
J	Chen, JF; Mandel, EM; Thomson, JM; Wu, QL; Callis, TE; Hammond, SM; Conlon, FL; Wang, DZ				Chen, JF; Mandel, EM; Thomson, JM; Wu, QL; Callis, TE; Hammond, SM; Conlon, FL; Wang, DZ			The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation	NATURE GENETICS			English	Article							SERUM RESPONSE FACTOR; GENE-EXPRESSION; SMALL RNAS; C-ELEGANS; TARGETS; GROWTH; MORPHOGENESIS; DEACETYLASES; ASSOCIATION; INHIBITION	Understanding the molecular mechanisms that regulate cellular proliferation and differentiation is a central theme of developmental biology. MicroRNAs ( miRNAs) are a class of regulatory RNAs of similar to 22 nucleotides that post-transcriptionally regulate gene expression(1,2). Increasing evidence points to the potential role of miRNAs in various biological processes(3-8). Here we show that miRNA-1 (miR-1) and miRNA- 133 (miR-133), which are clustered on the same chromosomal loci, are transcribed together in a tissue-specific manner during development. miR-1 and miR-133 have distinct roles in modulating skeletal muscle proliferation and differentiation in cultured myoblasts in vitro and in Xenopus laevis embryos in vivo. miR-1 promotes myogenesis by targeting histone deacetylase 4 (HDAC4), a transcriptional repressor of muscle gene expression. By contrast, miR-133 enhances myoblast proliferation by repressing serum response factor (SRF). Our results show that two mature miRNAs, derived from the same miRNA polycistron and transcribed together, can carry out distinct biological functions. Together, our studies suggest a molecular mechanism in which miRNAs participate in transcriptional circuits that control skeletal muscle gene expression and embryonic development.	Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wang, DZ (corresponding author), Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA.	dawang@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075256] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL075256] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Brown DD, 2005, DEVELOPMENT, V132, P553, DOI 10.1242/dev.01596; Cao DS, 2005, MOL CELL BIOL, V25, P364, DOI 10.1128/MCB.25.1.364-376.2005; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Conlon FL, 1996, DEVELOPMENT, V122, P2427; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Soulez M, 1996, MOL CELL BIOL, V16, P6065; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Wang D, 2002, COLD SPRING HARB SYM, V67, P97, DOI 10.1101/sqb.2002.67.97; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	30	2097	2328	3	225	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2006	38	2					228	233		10.1038/ng1725	http://dx.doi.org/10.1038/ng1725			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16380711	Green Accepted, Green Submitted			2022-12-25	WOS:000234953200020
J	Rylott, EL; Jackson, RG; Edwards, J; Womack, GL; Seth-Smith, HMB; Rathbone, DA; Strand, SE; Bruce, NC				Rylott, EL; Jackson, RG; Edwards, J; Womack, GL; Seth-Smith, HMB; Rathbone, DA; Strand, SE; Bruce, NC			An explosive-degrading cytochrome P450 activity and its targeted application for the phytoremediation of RDX	NATURE BIOTECHNOLOGY			English	Article							ARMY AMMUNITION PLANT; SP STRAIN DN22; HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE RDX; BIODEGRADATION; DEGRADATION; GENOME; 2,4,6-TRINITROTOLUENE; GROUNDWATER; INSIGHT; GROWTH	The widespread presence in the environment of hexahydro1,3,5-trinitro- 1,3,5-triazine (RDX), one of the most widely used military explosives, has raised concern owing to its toxicity and recalcitrance to degradation. To investigate the potential of plants to remove RDX from contaminated soil and water, we engineered Arabidopsis thaliana to express a bacterial gene xplA encoding an RDX-degrading cytochrome P450 (ref.1). We demonstrate that the P450 domain of XplA is fused to a flavodoxin redox partner and catalyzes the degradation of RDX in the absence of oxygen. Transgenic A. thaliana expressing xplA removed and detoxified RDX from liquid media. As a model system for RDX phytoremediation, A. thaliana expressing xplA was grown in RDX-contaminated soil and found to be resistant to RDX phytotoxicity, producing shoot and root biomasses greater than those of wild-type plants. Our work suggests that expression of xplA in landscape plants may provide a suitable remediation strategy for sites contaminated by this class of explosives.	Univ York, Dept Biol, CNAP, York YO10 5YW, N Yorkshire, England; Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; Univ Washington, Coll Forest Resources, Seattle, WA 98195 USA	University of York - UK; Wellcome Trust Sanger Institute; University of Washington; University of Washington Seattle	Bruce, NC (corresponding author), Univ York, Dept Biol, CNAP, POB 373, York YO10 5YW, N Yorkshire, England.	ncb5@york.ac.uk	Rylott, Elizabeth L/A-6059-2012	Rylott, Elizabeth L/0000-0002-1609-414X; Bruce, Neil Charles/0000-0003-0398-2997				Best EPH, 1999, CHEMOSPHERE, V39, P2057, DOI 10.1016/S0045-6535(99)00117-4; Best EPH, 1997, ANN NY ACAD SCI, V829, P179, DOI 10.1111/j.1749-6632.1997.tb48574.x; Bhadra R, 2001, CHEMOSPHERE, V44, P1259, DOI 10.1016/S0045-6535(00)00272-1; Bhushan B, 2003, APPL ENVIRON MICROB, V69, P1347, DOI 10.1128/AEM.69.3.1347-1351.2003; BINKS PR, 1995, APPL ENVIRON MICROB, V61, P1318, DOI 10.1128/AEM.61.4.1318-1322.1995; Clausen J, 2004, ENVIRON POLLUT, V129, P13, DOI 10.1016/j.envpol.2003.10.002; DILLEY JV, 1982, J TOXICOL ENV HEALTH, V9, P587, DOI 10.1080/15287398209530189; Dong JX, 2003, PLANT MOL BIOL, V51, P21, DOI 10.1023/A:1020780022549; Fournier D, 2004, ENVIRON SCI TECHNOL, V38, P4130, DOI 10.1021/es049671d; Fournier D, 2002, APPL ENVIRON MICROB, V68, P166, DOI 10.1128/AEM.68.1.166-172.2002; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; JACKSON M, 1978, NITRAMINE RDXHMX WAS; Just CL, 2004, ENVIRON SCI TECHNOL, V38, P290, DOI 10.1021/es034744z; Kucukardali Yasar, 2003, J Intensive Care Med, V18, P42, DOI 10.1177/0885066602239123; Lynch JC, 2001, J CHEM ENG DATA, V46, P1549, DOI 10.1021/je0101496; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; Rahman MT, 2003, VET MICROBIOL, V94, P143, DOI 10.1016/S0378-1135(03)00100-7; SCHEIDELER L, 1986, ANAL BIOCHEM, V154, P29, DOI 10.1016/0003-2697(86)90491-4; Seth-Smith HMB, 2002, APPL ENVIRON MICROB, V68, P4764, DOI 10.1128/AEM.68.10.4764-4771.2002; *US EPA TES METH E, 1994, 8330 US EPA TEST MET; Van Aken B, 2004, ENVIRON SCI TECHNOL, V38, P4572, DOI 10.1021/es049837a; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Winfield LE, 2004, ECOTOXICOLOGY, V13, P335, DOI 10.1023/B:ECTX.0000033091.78180.3d	24	112	117	7	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2006	24	2					216	219		10.1038/nbt1184	http://dx.doi.org/10.1038/nbt1184			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	010XW	16429147				2022-12-25	WOS:000235232300040
J	Conrad, DF; Andrews, TD; Carter, NP; Hurles, ME; Pritchard, JK				Conrad, DF; Andrews, TD; Carter, NP; Hurles, ME; Pritchard, JK			A high-resolution survey of deletion polymorphism in the human genome	NATURE GENETICS			English	Article							SEGMENTAL DUPLICATIONS; IDENTIFICATION; REARRANGEMENTS; EVOLUTION	Recent work has shown that copy number polymorphism is an important class of genetic variation in human genomes(1-4). Here we report a new method that uses SNP genotype data from parent-offspring trios to identify polymorphic deletions. We applied this method to data from the International HapMap Project(5) to produce the first high-resolution population surveys of deletion polymorphism. Approximately 100 of these deletions have been experimentally validated using comparative genome hybridization on tiling-resolution oligonucleotide microarrays. Our analysis identifies a total of 586 distinct regions that harbor deletion polymorphisms in one or more of the families. Notably, we estimate that typical individuals are hemizygous for roughly 30 - 50 deletions larger than 5 kb, totaling around 550 - 750 kb of euchromatic sequence across their genomes. The detected deletions span a total of 267 known and predicted genes. Overall, however, the deleted regions are relatively gene-poor, consistent with the action of purifying selection against deletions. Deletion polymorphisms may well have an important role in the genetics of complex traits; however, they are not directly observed in most current gene mapping studies. Our new method will permit the identification of deletion polymorphisms in high-density SNP surveys of trio or other family data.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Sanger Inst, Wellcome Trust, Genome Dynam & Evolut Grp, Cambridge CB10 1SA, England	University of Chicago; Wellcome Trust Sanger Institute	Pritchard, JK (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St, Chicago, IL 60637 USA.	pritch@uchicago.edu	Andrews, Dan/ABG-4815-2020	Andrews, Dan/0000-0003-3922-6376	NIGMS NIH HHS [GM07197] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Amos CI, 2003, HUM HERED, V56, P107, DOI 10.1159/000073738; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bhangale TR, 2005, HUM MOL GENET, V14, P59, DOI 10.1093/hmg/ddi006; Carter NP, 2004, NAT GENET, V36, P931, DOI 10.1038/ng0904-931; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Emes RD, 2003, HUM MOL GENET, V12, P701, DOI 10.1093/hmg/ddg078; FLINT J, 1995, NAT GENET, V9, P132, DOI 10.1038/ng0295-132; Fredman D, 2004, NAT GENET, V36, P861, DOI 10.1038/ng1401; Gardner R. J, 2004, CHROMOSOMES ABNORMAL; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Giglio S, 2001, AM J HUM GENET, V68, P874, DOI 10.1086/319506; HINDS DA, 2005, NAT GENET       1204; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; MCCARROLL SA, 2005, NAT GENET       1204; Olson MV, 1999, AM J HUM GENET, V64, P18, DOI 10.1086/302219; Petrov DA, 2002, THEOR POPUL BIOL, V61, P531, DOI 10.1006/tpbi.2002.1605; SCHMICKEL RD, 1986, J PEDIATR-US, V109, P231, DOI 10.1016/S0022-3476(86)80377-8; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Selzer RR, 2005, GENE CHROMOSOME CANC, V44, P305, DOI 10.1002/gcc.20243; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562; Weber JL, 2002, AM J HUM GENET, V71, P854, DOI 10.1086/342727; Yu CE, 2002, AM J HUM GENET, V71, P100, DOI 10.1086/341291	24	503	538	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					75	81		10.1038/ng1697	http://dx.doi.org/10.1038/ng1697			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16327808				2022-12-25	WOS:000234227200020
J	Li, L; Wang, XF; Stolc, V; Li, XY; Zhang, DF; Su, N; Tongprasit, W; Li, SG; Cheng, ZK; Wang, J; Deng, XW				Li, L; Wang, XF; Stolc, V; Li, XY; Zhang, DF; Su, N; Tongprasit, W; Li, SG; Cheng, ZK; Wang, J; Deng, XW			Genome-wide transcription analyses in rice using tiling microarrays	NATURE GENETICS			English	Article							ORYZA-SATIVA L.; EXPRESSION ANALYSIS; DRAFT SEQUENCE; CHROMOSOME-4	Sequencing and computational annotation revealed several features, including high gene numbers(1-6), unusual composition of the predicted genes(1,7) and a large number of genes lacking homology to known genes(8,9), that distinguish the rice ( Oryza sativa) genome from that of other fully sequenced model species. We report here a full-genome transcription analysis of the indica rice subspecies using high-density oligonucleotide tiling microarrays. Our results provided expression data support for the existence of 35,970 (81.9%) annotated gene models and identified 5,464 unique transcribed intergenic regions that share similar compositional properties with the annotated exons and have significant homology to other plant proteins. Elucidating and mapping of all transcribed regions revealed an association between global transcription and cytological chromosome features, and an overall similarity of transcriptional activity between duplicated segments of the genome. Collectively, our results provide the first whole-genome transcription map useful for further understanding the rice genome.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Natl Inst Biol Sci, Beijing 102206, Peoples R China; Peking Univ, Coll Life Sci, Peking Yale Joint Res Ctr Plant Mol Genet & Agrob, Beijing 100871, Peoples R China; Chinese Acad Sci, Beijing Inst Genom, Beijing 101300, Peoples R China; NASA, Genome Res Facil, Ames Res Ctr, Moffett Field, CA 94035 USA; China Bioway Biotech Grp Co Ltd, Natl Ctr Crop Design, Beijing 100085, Peoples R China; Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China; Eloret Corp, Sunnyvale, CA 94087 USA	Yale University; National Institute of Biological Sciences, Beijing; Peking University; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS	Deng, XW (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	xingwang.deng@yale.edu	Deng, Xing Wang/ABF-4107-2020; Wang, Jun/C-8434-2016; Wang, Jun/B-9503-2016	Wang, Jun/0000-0002-8540-8931; Wang, Xiangfeng/0000-0002-6406-5597; Wang, Jun/0000-0002-2113-5874				Bedell JA, 2005, PLOS BIOL, V3, P103, DOI 10.1371/journal.pbio.0030013; Bennetzen JL, 2004, CURR OPIN PLANT BIOL, V7, P732, DOI 10.1016/j.pbi.2004.09.003; Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Cheng ZK, 2001, GENOME RES, V11, P2133, DOI 10.1101/gr.194601; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Feng Q, 2002, NATURE, V420, P316, DOI 10.1038/nature01183; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Jabbari K, 2004, TRENDS PLANT SCI, V9, P281, DOI 10.1016/j.tplants.2004.04.006; Jiao YL, 2005, PLANT CELL, V17, P1641, DOI 10.1105/tpc.105.031575; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; KIKUCHI S, 2003, SCIENCE, V300, P1566; Li C, 2004, THEOR APPL GENET, V108, P392, DOI 10.1007/s00122-003-1457-z; Li L, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-6-r52; Messing J, 2004, P NATL ACAD SCI USA, V101, P14349, DOI 10.1073/pnas.0406163101; Nagaki K, 2004, NAT GENET, V36, P138, DOI 10.1038/ng1289; Nuwaysir EF, 2002, GENOME RES, V12, P1749, DOI 10.1101/gr.362402; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Sasaki T, 2002, NATURE, V420, P312, DOI 10.1038/nature01184; She XW, 2004, NATURE, V431, P927, DOI 10.1038/nature03062; Stolc V, 2004, SCIENCE, V306, P655, DOI 10.1126/science.1101312; Temnykh S, 2001, GENOME RES, V11, P1441, DOI 10.1101/gr.184001; Wong GKS, 2002, GENOME RES, V12, P851, DOI 10.1101/gr.189102; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305; Yu J, 2005, PLOS BIOL, V3, P266, DOI 10.1371/journal.pbio.0030038; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; Yu YS, 2003, SCIENCE, V300, P1566, DOI 10.1126/science.1083523	30	115	128	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					124	129		10.1038/ng1704	http://dx.doi.org/10.1038/ng1704			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16369532				2022-12-25	WOS:000234227200028
J	Volgraf, M; Gorostiza, P; Numano, R; Kramer, RH; Isacoff, EY; Trauner, D				Volgraf, M; Gorostiza, P; Numano, R; Kramer, RH; Isacoff, EY; Trauner, D			Allosteric control of an ionotropic glutamate receptor with an optical switch	NATURE CHEMICAL BIOLOGY			English	Article							LIGAND-BINDING CORE; CRYSTAL-STRUCTURES; KAINATE RECEPTORS; STRUCTURAL BASIS; ION CHANNELS; ACTIVATION; MECHANISMS; AGONISTS; PROTEIN; AMPA	The precise regulation of protein activity is fundamental to life. The allosteric control of an active site by a remote regulatory binding site is a mechanism of regulation found across protein classes, from enzymes to motors to signaling proteins. We describe a general approach for manipulating allosteric control using synthetic optical switches. Our strategy is exemplified by a ligand-gated ion channel of central importance in neuroscience, the ionotropic glutamate receptor (iGluR). Using structure-based design, we have modified its ubiquitous clamshell-type ligand-binding domain to develop a light-activated channel, which we call LiGluR. An agonist is covalently tethered to the protein through an azobenzene moiety, which functions as the optical switch. The agonist is reversibly presented to the binding site upon photoisomerization, initiating clamshell domain closure and concomitant channel gating. Photoswitching occurs on a millisecond timescale, with channel conductances that reflect the photostationary state of the azobenzene at a given wavelength. Our device has potential uses not only in biology but also in bioelectronics and nanotechnology.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Tokyo, Inst Med Sci, Lab Anim Res Ctr, Tokyo 1088639, Japan; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Phys Biosci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Tokyo; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Isacoff, EY (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	ehud@berkeley.edu; trauner@berkeley.edu	Gorostiza, Pau/Q-2544-2015; isacoff, ehud/AAP-1459-2020	Gorostiza, Pau/0000-0002-7268-5577; Isacoff, Ehud Y./0000-0003-4775-9359	NEI NIH HHS [PN2 EY018241] Funding Source: Medline; NIMH NIH HHS [R01 MH060711] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060711] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; BALZANI A, 2003, MOL DEVICES MACHINES; Banghart M, 2004, NAT NEUROSCI, V7, P1381, DOI 10.1038/nn1356; Bayley H, 2004, MOL MEMBR BIOL, V21, P209, DOI 10.1080/09687680410001716853; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dwyer MA, 2004, CURR OPIN STRUC BIOL, V14, P495, DOI 10.1016/j.sbi.2004.07.004; Erreger Kevin, 2004, Critical Reviews in Neurobiology, V16, P187; EZQUERRA J, 1993, TETRAHEDRON, V49, P8665, DOI 10.1016/S0040-4020(01)96272-6; Feringa B. L., 2001, MOL SWITCHES; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; Goeldner M, 2005, DYNAMIC STUDIES IN BIOLOGY: PHOTOTRIGGERS, PHOTOSWITCHES AND CAGED BIOMOLECULES, P1, DOI 10.1002/3527605592; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Johansen TN, 2003, CHIRALITY, V15, P167, DOI 10.1002/chir.10177; Kandel E., 2000, PRINCIPLES NEURAL SC; Kercher MA, 1997, CURR OPIN STRUC BIOL, V7, P76, DOI 10.1016/S0959-440X(97)80010-3; Knoll H., 2004, CRC HDB ORGANIC PHOT, V89, P1; Kocer A, 2005, SCIENCE, V309, P755, DOI 10.1126/science.1114760; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; LESTER HA, 1980, J GEN PHYSIOL, V75, P207, DOI 10.1085/jgp.75.2.207; Mayer ML, 2005, NEURON, V45, P539, DOI 10.1016/j.neuron.2005.01.031; Nanao MH, 2005, P NATL ACAD SCI USA, V102, P1708, DOI 10.1073/pnas.0409573102; Paas Y, 1998, TRENDS NEUROSCI, V21, P117, DOI 10.1016/S0166-2236(97)01184-3; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; Pedregal C, 2000, J MED CHEM, V43, P1958, DOI 10.1021/jm9911682; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Wilding TJ, 1997, J NEUROSCI, V17, P2713; Willner I, 2001, PURE APPL CHEM, V73, P535, DOI 10.1351/pac200173030535	30	453	472	2	170	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2006	2	1					47	52		10.1038/nchembio756	http://dx.doi.org/10.1038/nchembio756			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993RC	16408092	Green Accepted			2022-12-25	WOS:000233971600014
J	Li, XG; Luo, Y; Starremans, PG; McNamara, CA; Pei, Y; Zhou, J				Li, XG; Luo, Y; Starremans, PG; McNamara, CA; Pei, Y; Zhou, J			Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor ld2	NATURE CELL BIOLOGY			English	Article							KIDNEY-DISEASE; C-MYC; CATION CHANNEL; ID2; PROTEIN; PKD1; GENE; ACTIVATION; KINASE; TARGET	Autosomal-dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is characterized by progressive cyst formation and ultimate loss of renal function. Increased cell proliferation is a key feature of the disease. Here, we show that the ADPKD protein polycystin-2 (PC2) regulates the cell cycle through direct interaction with Id2, a member of the helix-loop-helix (HLH) protein family that is known to regulate cell proliferation and differentiation. Id2 expression suppresses the induction of a cyclin-dependent kinase inhibitor, p21, by either polycystin-1 (PC1) or PC2. The PC2-Id2 interaction is regulated by PC1-dependent phosphorylation of PC2. Enhanced Id2 nuclear localization is seen in human and mouse cystic kidneys. Inhibition of Id2 expression by RNA interference corrects the hyperproliferative phenotype of PC1 mutant cells. We propose that Id2 has a crucial role in cell-cycle regulation that is mediated by PC1 and PC2.	Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA; Toronto Hosp, Dept Med, Div Nephrol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto, ON, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Virginia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Zhou, J (corresponding author), Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA.	zhou@rics.bwh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051050, R01DK053357, R01DK051050, R01DK040703] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53357, DK51050, DK40703] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Calvet J P, 1994, Curr Opin Nephrol Hypertens, V3, P340, DOI 10.1097/00041552-199405000-00017; Deed RW, 1996, FEBS LETT, V393, P113, DOI 10.1016/0014-5793(96)00868-X; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Delmas P, 2004, FASEB J, V18, P740, DOI 10.1096/fj.03-0319fje; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GABOW PA, 1993, AM J KIDNEY DIS, V22, P511, DOI 10.1016/S0272-6386(12)80921-8; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; GRANTHAM JJ, 1993, J AM SOC NEPHROL, V3, P1843; Grantham JJ, 2001, CURR OPIN NEPHROL HY, V10, P533, DOI 10.1097/00041552-200107000-00008; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kondo M, 2004, CELL DEATH DIFFER, V11, P1092, DOI 10.1038/sj.cdd.4401467; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kurooka H, 2005, J BIOL CHEM, V280, P4313, DOI 10.1074/jbc.M412614200; Lakkis M, 2003, NEPHRON EXP NEPHROL, V93, pE3, DOI 10.1159/000066648; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Li Q, 2003, J MOL BIOL, V325, P949, DOI 10.1016/S0022-2836(02)01333-5; Li Q, 2003, BIOCHEMISTRY-US, V42, P450, DOI 10.1021/bi0267792; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Lu WN, 2001, HUM MOL GENET, V10, P2385, DOI 10.1093/hmg/10.21.2385; Luo Y, 2003, MOL CELL BIOL, V23, P2600, DOI 10.1128/MCB.23.7.2600-2607.2003; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NADASDY T, 1995, J AM SOC NEPHROL, V5, P1462; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Pagliuca A, 2000, CANCER RES, V60, P1376; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; REEDERS ST, 1992, NAT GENET, V1, P235, DOI 10.1038/ng0792-235; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Stayner C, 2001, TRENDS PHARMACOL SCI, V22, P543, DOI 10.1016/S0165-6147(00)01832-0; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; Trudel M, 1998, AM J PATHOL, V152, P219; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Wilson PD, 1997, AM J PHYSIOL-RENAL, V272, pF434, DOI 10.1152/ajprenal.1997.272.4.F434; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	45	153	160	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1202	1212		10.1038/ncb1326	http://dx.doi.org/10.1038/ncb1326			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16311606				2022-12-25	WOS:000233748900013
J	Monen, J; Maddox, PS; Hyndman, F; Oegema, K; Desai, A				Monen, J; Maddox, PS; Hyndman, F; Oegema, K; Desai, A			Differential role of CENP-A in the segregation of holocentric C-elegans chromosomes during meiosis and mitosis	NATURE CELL BIOLOGY			English	Article							CAENORHABDITIS-ELEGANS; MEIOTIC PROPHASE; CROSSING-OVER; KINETOCHORE; PROTEIN; CENTROMERE; CELL; ORGANIZATION; COHESION; BIOLOGY	Two distinct chromosome architectures are prevalent among eukaryotes: monocentric, in which localized centromeres restrict kinetochore assembly to a single chromosomal site, and holocentric, in which diffuse kinetochores form along the entire chromosome length. During mitosis, both chromosome types use specialized chromatin, containing the histone H3 variant CENP-A(1-3), to direct kinetochore assembly(4-7). For the segregation of recombined homologous chromosomes during meiosis(8,9), monocentricity is thought to be crucial for limiting spindle-based forces to one side of a crossover and to prevent recombined chromatids from being simultaneously pulled towards both spindle poles. The mechanisms that allow holocentric chromosomes to avert this fate remain uncharacterized. Here, we show that markedly different mechanisms segregate holocentric chromosomes during meiosis and mitosis in the nematode Caenorhabditis elegans. Immediately prior to oocyte meiotic segregation, outer-kinetochore proteins were recruited to cup-like structures on the chromosome surface via a mechanism that is independent of CENP-A. In striking contrast to mitosis, both oocyte meiotic divisions proceeded normally following depletion of either CENP-A or the closely associated centromeric protein CENP-C. These findings highlight a pronounced difference between the segregation of holocentric chromosomes during meiosis and mitosis and demonstrate the potential to uncouple assembly of outer-kinetochore proteins from CENP-A chromatin.	Univ Calif San Diego, Biomed Sci Grad Program, Dept Cellular & Mol Med, Ludwig Inst Canc Res,UCSD CMM E, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Desai, A (corresponding author), Univ Calif San Diego, Biomed Sci Grad Program, Dept Cellular & Mol Med, Ludwig Inst Canc Res,UCSD CMM E, Room 3052,9500 Gilman Dr, La Jolla, CA 92093 USA.	abdesai@ucsd.edu	Barron, Francie/E-5870-2010	Barron, Francie/0000-0001-6568-7358	NIGMS NIH HHS [R01GM074215-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSON DG, 1982, CHROMOSOMA, V86, P409, DOI 10.1007/BF00292267; Albertson DG, 1993, CHROMOSOME RES, V1, P15, DOI 10.1007/BF00710603; Amor DJ, 2004, TRENDS CELL BIOL, V14, P359, DOI 10.1016/j.tcb.2004.05.009; Bernard P, 2001, NAT CELL BIOL, V3, P522, DOI 10.1038/35074598; Blower MD, 2001, NAT CELL BIOL, V3, P730, DOI 10.1038/35087045; Buchwitz BJ, 1999, NATURE, V401, P547, DOI 10.1038/44062; Chan RC, 2004, J CELL BIOL, V167, P613, DOI 10.1083/jcb.200408061; Cheeseman IM, 2004, GENE DEV, V18, P2255, DOI 10.1101/gad.1234104; COMINGS DE, 1972, CHROMOSOMA, V37, P177; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Edgar LG, 1995, METHOD CELL BIOL, V48, P303; Fukushige T, 1999, P NATL ACAD SCI USA, V96, P11883, DOI 10.1073/pnas.96.21.11883; Hauf S, 2004, CELL, V119, P317, DOI 10.1016/j.cell.2004.10.014; Henikoff S, 2004, TRENDS GENET, V20, P320, DOI 10.1016/j.tig.2004.05.004; Hillers KJ, 2003, CURR BIOL, V13, P1641, DOI 10.1016/j.cub.2003.08.026; Howe M, 2001, J CELL BIOL, V153, P1227, DOI 10.1083/jcb.153.6.1227; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Hubbard EJA, 2000, DEV DYNAM, V218, P2, DOI 10.1002/(SICI)1097-0177(200005)218:1<2::AID-DVDY2>3.0.CO;2-W; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; LAIKEN SL, 1972, J MOL BIOL, V66, P143, DOI 10.1016/S0022-2836(72)80012-3; MacQueen AJ, 2002, GENE DEV, V16, P2428, DOI 10.1101/gad.1011602; Maddox PS, 2004, CHROMOSOME RES, V12, P641, DOI 10.1023/B:CHRO.0000036588.42225.2f; Mellone BG, 2003, CURR OPIN GENET DEV, V13, P191, DOI 10.1016/S0959-437X(03)00019-4; Moore LL, 2001, J CELL BIOL, V153, P1199, DOI 10.1083/jcb.153.6.1199; Moore LL, 1999, J CELL BIOL, V147, P471, DOI 10.1083/jcb.147.3.471; Nabeshima K, 2005, J CELL BIOL, V168, P683, DOI 10.1083/jcb.200410144; O'Toole ET, 2003, J CELL BIOL, V163, P451, DOI 10.1083/jcb.200304035; Oegema K, 2001, J CELL BIOL, V153, P1209, DOI 10.1083/jcb.153.6.1209; OEGEMA K, 2005, WORMBOOK; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; PIMPINELLI S, 1989, TRENDS GENET, V5, P310, DOI 10.1016/0168-9525(89)90114-5; Rogers E, 2002, J CELL BIOL, V157, P219, DOI 10.1083/jcb.200110045; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045	33	138	155	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1248	1255		10.1038/ncb1331	http://dx.doi.org/10.1038/ncb1331			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16273096				2022-12-25	WOS:000233748900019
J	Senderek, J; Krieger, M; Stendel, C; Bergmann, C; Moser, M; Breitbach-Faller, N; Rudnik-Schoneborn, S; Blaschek, A; Wolf, NI; Harting, I; North, K; Smith, J; Muntoni, F; Brockington, M; Quijano-Roy, S; Renault, F; Herrmann, R; Hendershot, LM; Schroder, JM; Lochmuller, H; Topaloglu, H; Voit, T; Weis, J; Ebinger, F; Zerres, K				Senderek, J; Krieger, M; Stendel, C; Bergmann, C; Moser, M; Breitbach-Faller, N; Rudnik-Schoneborn, S; Blaschek, A; Wolf, NI; Harting, I; North, K; Smith, J; Muntoni, F; Brockington, M; Quijano-Roy, S; Renault, F; Herrmann, R; Hendershot, LM; Schroder, JM; Lochmuller, H; Topaloglu, H; Voit, T; Weis, J; Ebinger, F; Zerres, K			Mutations in SIL1 cause Marinesco-Sjogren syndrome, a cerebellar ataxia with cataract and myopathy	NATURE GENETICS			English	Article							ENDOPLASMIC-RETICULUM STRESS; PROTEIN TRANSLOCATION; NUCLEOTIDE EXCHANGE; BIP	SIL1 ( also called BAP) acts as a nucleotide exchange factor for the Hsp70 chaperone BiP ( also called GRP78), which is a key regulator of the main functions of the endoplasmic reticulum. We found nine distinct mutations that would disrupt the SIL1 protein in individuals with Marinesco-Sjogren syndrome, an autosomal recessive cerebellar ataxia complicated by cataracts, developmental delay and myopathy. Identification of SIL1 mutations implicates Marinesco-Sjogren syndrome as a disease of endoplasmic reticulum dysfunction and suggests a role for this organelle in multisystem disorders.	Rhein Westfal TH Aachen, Dept Human Genet, Aachen, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Esslingen Community Hosp, Dept Pediat, Esslingen, Germany; Univ Heidelberg, Childrens Hosp, Dept Pediat, D-6900 Heidelberg, Germany; Univ Heidelberg, Dept Neuroradiol, Heidelberg, Germany; Childrens Hosp Westmead, Inst Neuromuscular Res, Sydney, NSW, Australia; Univ London Imperial Coll Sci Technol & Med, Dubowitz Neuromuscular Ctr, London, England; Hop Raymond Poincare, Serv Pediat, Garches, France; Grp Hosp Pitie Salpetriere, Inst Myol, INSERM, U582, F-75634 Paris, France; Hop Enfants Armand Trousseau, Unite Neurophysiol, Paris, France; Univ Hosp Essen, Dept Pediat & Pediat Neurol, Essen, Germany; St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; Rhein Westfal TH Aachen, Dept Neuropathol, Aachen, Germany; Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany; Hacettepe Univ, Dept Pediat Neurol, Ankara, Turkey	RWTH Aachen University; Max Planck Society; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Sydney; Imperial College London; University of London; University College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Duisburg Essen; St Jude Children's Research Hospital; RWTH Aachen University; University of Munich; Hacettepe University	Senderek, J (corresponding author), Rhein Westfal TH Aachen, Dept Human Genet, Aachen, Germany.	jsenderek@ukaachen.de	Wolf, Nicole I/H-3943-2014; Senderek, Jan/F-8405-2015; Quijano-Roy, Susana/GRF-6829-2022; Ebinger, Friedrich/AAO-7697-2020; North, Kathryn N/K-6476-2012; Weis, Joachim/G-1984-2014; Rudnik-Schöneborn, Sabine/F-8473-2015; Hendershot, Linda/N-8124-2018; TOPALOGLU, HALUK AYDIN/I-9318-2013	Wolf, Nicole I/0000-0003-1721-0728; Senderek, Jan/0000-0002-8263-1783; North, Kathryn N/0000-0003-0841-8009; Weis, Joachim/0000-0003-3280-6773; Hendershot, Linda/0000-0002-5473-0274; Lochmuller, Hanns/0000-0003-2324-8001				Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; Boisrame A, 1996, J BIOL CHEM, V271, P11668, DOI 10.1074/jbc.271.20.11668; Chung KT, 2002, J BIOL CHEM, V277, P47557, DOI 10.1074/jbc.M208377200; Hendershot LM, 2004, MT SINAI J MED, V71, P289; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Kitao Y, 2004, J NEUROSCI, V24, P1486, DOI 10.1523/JNEUROSCI.4029-03.2004; Lagier-Tourenne C, 2003, EUR J HUM GENET, V11, P770, DOI 10.1038/sj.ejhg.5201068; Marinesco G, 1931, ENCEPHALE, V26, P97; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; SEWRY CA, 1988, ANN NEUROL, V24, P576, DOI 10.1002/ana.410240416; Shomura Y, 2005, MOL CELL, V17, P367, DOI 10.1016/j.molcel.2004.12.023; Suzuki Y, 1997, ACTA NEUROPATHOL, V94, P410, DOI 10.1007/s004010050727; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; Varon R, 2003, NAT GENET, V35, P185, DOI 10.1038/ng1243	15	173	180	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2005	37	12					1312	1314		10.1038/ng1678	http://dx.doi.org/10.1038/ng1678			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16282977				2022-12-25	WOS:000233657300007
J	de Bakker, PIW; Yelensky, R; Pe'er, I; Gabriel, SB; Daly, MJ; Altshuler, D				de Bakker, PIW; Yelensky, R; Pe'er, I; Gabriel, SB; Daly, MJ; Altshuler, D			Efficiency and power in genetic association studies	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; GENOME-WIDE ASSOCIATION; LINKAGE-DISEQUILIBRIUM; TAGGING SNPS; GENOTYPE DATA; UNRELATED INDIVIDUALS; HAPLOTYPE DIVERSITY; TAG SNPS; SELECTION; TESTS	We investigated selection and analysis of tag SNPs for genome-wide association studies by specifically examining the relationship between investment in genotyping and statistical power. Do pairwise or multimarker methods maximize efficiency and power? To what extent is power compromised when tags are selected from an incomplete resource such as HapMap? We addressed these questions using genotype data from the HapMap ENCODE project, association studies simulated under a realistic disease model, and empirical correction for multiple hypothesis testing. We demonstrate a haplotype-based tagging method that uniformly outperforms single-marker tests and methods for prioritization that markedly increase tagging efficiency. Examining all observed haplotypes for association, rather than just those that are proxies for known SNPs, increases power to detect rare causal alleles, at the cost of reduced power to detect common causal alleles. Power is robust to the completeness of the reference panel from which tags are selected. These findings have implications for prioritizing tag SNPs and interpreting association studies.	Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02138 USA; MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Daly, MJ (corresponding author), Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St,CPZN-6818, Boston, MA 02114 USA.	mjdaly@chgr.mgh.harvard.edu; altshuler@molbio.mgh.harvard.edu	Altshuler, David M/A-4476-2009; Daly, Mark J/B-2453-2017; de Bakker, Paul IW/B-8730-2009	Altshuler, David M/0000-0002-7250-4107; Daly, Mark J/0000-0002-0949-8752; de Bakker, Paul IW/0000-0001-7735-7858				Ahmadi KR, 2005, NAT GENET, V37, P84, DOI 10.1038/ng1488; Ao SI, 2005, BIOINFORMATICS, V21, P1735, DOI 10.1093/bioinformatics/bti201; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chapman JM, 2003, HUM HERED, V56, P18, DOI 10.1159/000073729; Crawford DC, 2004, AM J HUM GENET, V74, P610, DOI 10.1086/382227; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Dudbridge F, 2004, AM J HUM GENET, V75, P424, DOI 10.1086/423738; Fan RZ, 2003, AM J HUM GENET, V72, P850, DOI 10.1086/373966; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Goldstein DB, 2003, TRENDS GENET, V19, P615, DOI 10.1016/j.tig.2003.09.006; Halldorsson BV, 2004, GENOME RES, V14, P1633, DOI 10.1101/gr.2570004; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Hu XL, 2004, HUM HERED, V57, P156, DOI 10.1159/000079246; *INT HAPMAP CONS, IN PRESS NATURE; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Ke XY, 2003, BIOINFORMATICS, V19, P287, DOI 10.1093/bioinformatics/19.2.287; Lin S, 2004, NAT GENET, V36, P1181, DOI 10.1038/ng1457; Meng ZL, 2003, AM J HUM GENET, V73, P115, DOI 10.1086/376561; Nejentsev S, 2004, HUM MOL GENET, V13, P1633, DOI 10.1093/hmg/ddh169; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Rinaldo A, 2005, GENET EPIDEMIOL, V28, P193, DOI 10.1002/gepi.20056; Roeder K, 2005, GENET EPIDEMIOL, V28, P207, DOI 10.1002/gepi.20050; SCHAFFNER SF, IN PRESS GENOME RES; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Stram DO, 2003, HUM HERED, V55, P179, DOI 10.1159/000073202; Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807; Wang WYS, 2003, HUM MOL GENET, V12, P3145, DOI 10.1093/hmg/ddg337; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986; Zhang K, 2005, BIOINFORMATICS, V21, P131, DOI 10.1093/bioinformatics/bth482	36	1435	1468	1	84	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2005	37	11					1217	1223		10.1038/ng1669	http://dx.doi.org/10.1038/ng1669			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16244653				2022-12-25	WOS:000233045200021
J	Patzel, V; Rutz, S; Dietrich, I; Koberle, C; Scheffold, A; Kaufmann, SHE				Patzel, V; Rutz, S; Dietrich, I; Koberle, C; Scheffold, A; Kaufmann, SHE			Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency	NATURE BIOTECHNOLOGY			English	Article							SECONDARY STRUCTURE; EFFICACY; ARGONAUTE2; SEQUENCES; SELECTION	In RNA interference (RNAi), guide RNAs direct RNA-induced silencing complexes (RISC) to their mRNA targets, thus enabling the cleavage that leads to gene silencing. We describe a strong inverse correlation between the degree of guide-RNA secondary structure formation and gene silencing by small interfering (si) RNA. Unstructured guide strands mediate the strongest silencing whereas structures with base-paired ends are inactive. Thus, the availability of terminal nucleotides within guide structures determines the strength of silencing. A to G and C to U base exchanges, which involve wobble base-pairing with the target but preserve complementarity, turned inactive into active guide structures, thereby expanding the space of functional siRNAs. Previously observed base degenerations among mature micro (mi) RNAs together with the data presented here suggest a crucial role of the guide-RNA structures in miRNA action. The analysis of the effect of the secondary structures of guide-RNA sequences on RNAi efficiency provides a basis for better understanding RNA silencing pathways and improving the design of siRNAs.	Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany; Max Planck Inst Infect Biol, Deutsch Rheuma Forsch Zentrum, D-10117 Berlin, Germany	Max Planck Society; Deutsches Rheuma-Forschungszentrum (DRFZ); Max Planck Society	Patzel, V (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Schumannstr 21-22, D-10117 Berlin, Germany.	patzel@mpiib-berlin.mpg.de	Scheffold, Alexander/S-2090-2016; Kaufmann, Stefan HE/I-5454-2014	Scheffold, Alexander/0000-0002-0626-343X; Kaufmann, Stefan HE/0000-0001-9866-8268				Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Far RKK, 2003, NUCLEIC ACIDS RES, V31, P4417, DOI 10.1093/nar/gkg649; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Heale BSE, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni026; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Mathews DH, 1999, RNA, V5, P1458, DOI 10.1017/S1355838299991148; MCCASKILL JS, 1990, BIOPOLYMERS, V29, P1105, DOI 10.1002/bip.360290621; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Overhoff M, 2005, J MOL BIOL, V348, P871, DOI 10.1016/j.jmb.2005.03.012; Patzel V, 1998, NAT BIOTECHNOL, V16, P64, DOI 10.1038/nbt0198-64; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; Schubert S, 2005, J MOL BIOL, V348, P883, DOI 10.1016/j.jmb.2005.03.011; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Vickers TA, 2003, J BIOL CHEM, V278, P7108, DOI 10.1074/jbc.M210326200; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	29	97	120	1	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2005	23	11					1440	1444		10.1038/nbt1151	http://dx.doi.org/10.1038/nbt1151			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	984FN	16258545				2022-12-25	WOS:000233288000041
J	Batourina, E; Tsai, S; Lambert, S; Sprenkle, P; Viana, R; Dutta, S; Hensle, T; Wang, FW; Niederreither, K; McMahon, AP; Carroll, TJ; Mendelsohn, CL				Batourina, E; Tsai, S; Lambert, S; Sprenkle, P; Viana, R; Dutta, S; Hensle, T; Wang, FW; Niederreither, K; McMahon, AP; Carroll, TJ; Mendelsohn, CL			Apoptosis induced by vitamin A signaling is crucial for connecting the ureters to the bladder	NATURE GENETICS			English	Article							RETINOIC ACID; BUD; KIDNEY; ORGANOGENESIS; EXPRESSION; RECEPTORS; PROTEIN; VAGINA; CELLS; DUCTS	Removal of toxic substances from the blood depends on patent connections between the kidney, ureters and bladder that are established when the ureter is transposed from its original insertion site in the male genital tract to the bladder. This transposition is thought to occur as the trigone forms from the common nephric duct and incorporates into the bladder. Here we re-examine this model in the context of normal and abnormal development. We show that the common nephric duct does not differentiate into the trigone but instead undergoes apoptosis, a crucial step for ureter transposition controlled by vitamin A-induced signals from the primitive bladder. Ureter abnormalities occur in 1-2% of the human population and can cause obstruction and end-stage renal disease. These studies provide an explanation for ureter defects underlying some forms of obstruction in humans and redefine the current model of ureter maturation.	Columbia Univ, Dept Urol, New York, NY 10032 USA; Baylor Coll Med, Ctr Cardiovasc Dev, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cardiovasc Dev, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; UT SW Med Ctr, Dept Internal Med Nephrol & Mol Biol, Dallas, TX 75390 USA	Columbia University; Baylor College of Medicine; Baylor College of Medicine; Harvard University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Mendelsohn, CL (corresponding author), Columbia Univ, Dept Urol, 650 W 168th St, New York, NY 10032 USA.	clm20@columbia.edu	McMahon, Andrew P/ABE-7520-2020; Mendelsohn, Cathy/H-4280-2016	Mendelsohn, Cathy/0000-0002-4026-4073	NIDDK NIH HHS [R01 DK061459-09, R01 DK080004, R01 DK061459-07S1, R01 DK061459-06, R01 DK061459-08, R56 DK082963, R01 DK061459-02, R01 DK061459-01A1S1, R01 DK061459-07, R01 DK061459-01A1, R01 DK061459, R01 DK061459-03, R01 DK061459-04, R01 DK061459-05, R56 DK082963-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK095057, R01DK061459, R56DK082963, R01DK080004] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Batourina E, 2002, NAT GENET, V32, P109, DOI 10.1038/ng952; BOK G, 1983, J EMBRYOL EXP MORPH, V73, P275; Brophy PD, 2001, DEVELOPMENT, V128, P4747; Dickman ED, 1997, DEVELOPMENT, V124, P3111; Duester G, 2003, CHEM-BIOL INTERACT, V143, P201, DOI 10.1016/S0009-2797(02)00204-1; Grieshammer U, 2004, DEV CELL, V6, P709, DOI 10.1016/S1534-5807(04)00108-X; HUTCH JA, 1972, ANATOMY PHYSL BLADDE; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kochhar DM, 1996, CHEM-BIOL INTERACT, V100, P1, DOI 10.1016/0009-2797(95)03681-4; Kume T, 2000, DEVELOPMENT, V127, P1387; Larsen WJ, 2001, HUMAN EMBRYOLOGY, V3; MACKIE GG, 1975, J UROLOGY, V114, P274, DOI 10.1016/S0022-5347(17)67007-1; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MAUCH RB, 1985, ANAT EMBRYOL, V172, P75, DOI 10.1007/BF00318946; Mendelsohn C, 1999, DEVELOPMENT, V126, P1139; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MEYER R, 1946, ANAT REC, V96, P355, DOI 10.1002/ar.1090960403; Mic FA, 2002, DEVELOPMENT, V129, P2271; Miyazaki Y, 2000, J CLIN INVEST, V105, P863, DOI 10.1172/JCI8256; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Shakya R, 2005, DEV CELL, V8, P65, DOI 10.1016/j.devcel.2004.11.008; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S, 1999, DEV GENET, V24, P241; STEPHENS FD, 1983, CONGENITAL MALFORMAT; TANAGHO EA, 1981, DEV URETER; Thomas John C, 2005, Curr Urol Rep, V6, P146, DOI 10.1007/s11934-005-0084-4; Watanabe T, 2004, DEV BIOL, V271, P98, DOI 10.1016/j.ydbio.2004.03.025; Willhite CC, 2000, TOXICOL APPL PHARM, V164, P171, DOI 10.1006/taap.1999.8866; WILSON JG, 1948, AM J ANAT, V83, P357, DOI 10.1002/aja.1000830303; YASUDA Y, 1986, TERATOLOGY, V34, P37, DOI 10.1002/tera.1420340106; Yu J, 2002, DEVELOPMENT, V129, P5301; Yu OH, 2004, AM J PHYSIOL-RENAL, V287, pF1123, DOI 10.1152/ajprenal.00444.2003; Yucel S, 2004, J UROLOGY, V171, P1890, DOI 10.1097/01.ju.0000124106.16505.df	36	107	108	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1082	1089		10.1038/ng1645	http://dx.doi.org/10.1038/ng1645			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16186816				2022-12-25	WOS:000232185600019
J	Castigli, E; Wilson, SA; Garibyan, L; Rachid, R; Bonilla, F; Schneider, L; Geha, RS				Castigli, E; Wilson, SA; Garibyan, L; Rachid, R; Bonilla, F; Schneider, L; Geha, RS			TACI is mutant in common variable immunodeficiency and IgA deficiency	NATURE GENETICS			English	Article							B-CELL HOMEOSTASIS; MOLECULAR ANALYSIS; APRIL; GENE; SUSCEPTIBILITY; ACTIVATION; RECEPTOR; BINDING; BAFF; AUTOIMMUNITY	The tumor necrosis factor receptor family member TACI (transmembrane activator and calcium-modulator and cyclophilin ligand interactor) mediates isotype switching in B cells. We found that 4 of 19 unrelated individuals with common variable immunodeficiency (CVID) and 1 of 16 individuals with IgA deficiency (IgAD) had a missense mutation in one allele of TNFRSF13B (encoding TACI). One of the four individuals with CVID had a single nucleotide insertion in the other TNFRSF13B allele. None of these mutations were present in 50 healthy subjects. TNFRSF13B mutations cosegregated with the phenotype of CVID or IgAD in family members of four index individuals that we studied. B cells from individuals with TACI mutations expressed TACI but did not produce IgG and IgA in response to the TACI ligand APRIL, probably reflecting impaired isotype switching. These results suggest that TACI mutations can result in CVID and IgAD.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Garibyan, Lilit/AAR-1638-2020					Asano T, 2004, CLIN EXP IMMUNOL, V136, P284, DOI 10.1111/j.1365-2249.2004.02440.x; Burrows PD, 1997, ADV IMMUNOL, V65, P245, DOI 10.1016/S0065-2776(08)60744-0; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2004, P NATL ACAD SCI USA, V101, P3903, DOI 10.1073/pnas.0307348101; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Cunningham-Rundles C, 2002, AM J HEMATOL, V69, P171, DOI 10.1002/ajh.10050; Cunningham-Rundles C, 2001, J CLIN IMMUNOL, V21, P303, DOI 10.1023/A:1012241117984; De la Concha EG, 2002, J IMMUNOL, V169, P4637, DOI 10.4049/jimmunol.169.8.4637; Di Renzo M, 2004, CLIN EXP MED, V3, P211, DOI 10.1007/s10238-004-0027-2; Eastwood D, 2004, CLIN EXP IMMUNOL, V137, P584, DOI 10.1111/j.1365-2249.2004.02581.x; FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Gorelik L, 2003, J EXP MED, V198, P937, DOI 10.1084/jem.20030789; Grimbacher B, 2004, CURR ALLERGY ASTHM R, V4, P349, DOI 10.1007/s11882-004-0083-4; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Hendriks J, 2005, CELL DEATH DIFFER, V12, P637, DOI 10.1038/sj.cdd.4401647; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; ISLAM KB, 1994, J IMMUNOL, V152, P1442; KANEKO H, 1990, SCAND J IMMUNOL, V32, P483, DOI 10.1111/j.1365-3083.1990.tb03188.x; Kokron CM, 2004, AN ACAD BRAS CIENC, V76, P707, DOI 10.1590/S0001-37652004000400007; Kralovicova J, 2003, J IMMUNOL, V170, P2765, DOI 10.4049/jimmunol.170.5.2765; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Mackay F, 2004, CURR OPIN PHARMACOL, V4, P347, DOI 10.1016/j.coph.2004.02.009; Mackay F, 2002, CURR OPIN IMMUNOL, V14, P783, DOI 10.1016/S0952-7915(02)00407-7; MacLennan ICM, 2002, IMMUNITY, V17, P235, DOI 10.1016/S1074-7613(02)00398-9; RAMESH N, 1995, CLIN IMMUNOL IMMUNOP, V76, pS208, DOI 10.1016/S0090-1229(95)90252-X; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schroeder HW, 2004, J INVEST MED, V52, P90, DOI 10.1136/jim-52-02-17; Schroeder HW, 2000, CLIN REV ALLERG IMMU, V19, P127, DOI 10.1385/CRIAI:19:2:127; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; VOLANAKIS JE, 1992, J CLIN INVEST, V89, P1914, DOI 10.1172/JCI115797; von Bulow GU, 2000, MAMM GENOME, V11, P628, DOI 10.1007/s003350010125; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Weston SA, 2001, CLIN EXP IMMUNOL, V124, P465, DOI 10.1046/j.1365-2249.2001.01556.x; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790	37	497	510	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					829	834		10.1038/ng1601	http://dx.doi.org/10.1038/ng1601			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16007086				2022-12-25	WOS:000230880400012
J	Jacobs, T				Jacobs, T			No pain, no gain?	NATURE BIOTECHNOLOGY			English	Editorial Material												tom@completegrowth.com						2005, PAIN THERAPEUTICS 20	1	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2005	23	8					934	934		10.1038/nbt0805-934	http://dx.doi.org/10.1038/nbt0805-934			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	952QF	16082357	Bronze			2022-12-25	WOS:000231019900016
J	Kitano, H; Funahashi, A; Matsuoka, Y; Oda, K				Kitano, H; Funahashi, A; Matsuoka, Y; Oda, K			Using process diagrams for the graphical representation of biological networks	NATURE BIOTECHNOLOGY			English	Article							INFORMATION	With the increased interest in understanding biological networks, such as protein-protein interaction networks and gene regulatory networks, methods for representing and communicating such networks in both human- and machine-readable form have become increasingly important. Although there has been significant progress in machine-readable representation of networks, as exemplified by the Systems Biology Mark-up Language (SBML) (http:// www.sbml.org) issues in human-readable representation have been largely ignored. This article discusses human- readable diagrammatic representations and proposes a set of notations that enhances the formality and richness of the information represented. The process diagram is a fully state transition - based diagram that can be translated into machine-readable forms such as SBML in a straightforward way. It is supported by CellDesigner, a diagrammatic network editing software ( http:// www. celldesigner.org/), and has been used to represent a variety of networks of various sizes ( from only a few components to several hundred components).	Syst Biol Inst, Shibuya Ku, Tokyo 1500001, Japan; Sony Comp Sci Labs Inc, Shinagawa Ku, Tokyo 1410022, Japan; Japan Sci & Technol Agcy, ERATO SORST Kitano Symbiot Syst Project, Shibuya Ku, Tokyo 1500001, Japan; Keio Univ, Dept Fundamental Sci & Technol, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan	Sony Corporation; Japan Science & Technology Agency (JST); Keio University	Kitano, H (corresponding author), Syst Biol Inst, Shibuya Ku, Suite 6A,M31 6-31-15 Jingumae, Tokyo 1500001, Japan.	kitano@symbio.jst.go.jp	Funahashi, Akira/C-4923-2014; Adiels, Martin/C-9278-2011	Funahashi, Akira/0000-0003-0605-239X; 				ALADJEM MI, 2004, SCI STKE, pPE8; Cook DL, 2001, GENOME BIOL, V2; Funahashi Akira, 2003, Biosilico, V1, P159, DOI 10.1016/S1478-5382(03)02370-9; Hucka M, 2003, BIOINFORMATICS, V19, P524, DOI 10.1093/bioinformatics/btg015; Kitano H, 2004, DIABETES, V53, pS6, DOI 10.2337/diabetes.53.suppl_3.S6; Kitano Hiroaki, 2003, Biosilico, V1, P169, DOI 10.1016/S1478-5382(03)02380-1; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Kohn KW, 2001, CHAOS, V11, P84, DOI 10.1063/1.1338126; MAIMON R, 2001, P 2 INT C SYST BIOL, P311; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Oda K., 2004, AFCS RES REPORTS, V2, P1; Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014; Pirson I, 2000, TRENDS CELL BIOL, V10, P404, DOI 10.1016/S0962-8924(00)01817-1	13	325	333	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2005	23	8					961	966		10.1038/nbt1111	http://dx.doi.org/10.1038/nbt1111			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	952QF	16082367				2022-12-25	WOS:000231019900028
J	Ko, MA; Rosario, CO; Hudson, JW; Kulkarni, S; Pollett, A; Dennis, JW; Swallow, CJ				Ko, MA; Rosario, CO; Hudson, JW; Kulkarni, S; Pollett, A; Dennis, JW; Swallow, CJ			Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis	NATURE GENETICS			English	Article							HEPATOCELLULAR-CARCINOMA; CENTROSOME HYPERAMPLIFICATION; CHROMOSOME INSTABILITY; TUMOR-DEVELOPMENT; MICE; CANCER; CELLS; P53; SUPPRESSOR; EXPRESSION	The polo-like kinase Plk4 (also called Sak) is required for late mitotic progression, cell survival and postgastrulation embryonic development(1). Here we identified a phenotype resulting from Plk4 haploinsufficiency in Plk4 heterozygous cells and mice. Plk4(+/-) embryonic fibroblasts had increased centrosomal amplification, multipolar spindle formation and aneuploidy compared with wild-type cells. The incidence of spontaneous liver and lung cancers was similar to 15 times high in elderly Plk4(+/-) mice than in Plk4(+/+) littermates. Using the in vivo model of partial hepatectomy to induce synchronous cell cycle entry, we determined that the precise regulation of cyclins D1, E and B1 and of Cdk1 was impaired in Plk4(+/-) regenerating liver, and p53 activation and p21 and BubR1 expression were suppressed. These defects were associated with progressive cell cycle delays, increased spindle irregularities and accelerated hepatocellular carcinogenesis in Plk4(+/-) mice. Loss of heterozygosity occurs frequently (similar to 60%) at polymorphic markers adjacent to the PLK4 locus in human hepatoma. Reduced Plk4 gene dosage increases the probability of mitotic errors and cancer development.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Microbiol & Med Genet, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Windsor, Dept Biol Sci, Windsor, ON N9B 3P4, Canada; Univ Toronto, Dept Pathol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Windsor; University of Toronto	Dennis, JW (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave,R988, Toronto, ON M5G 1X5, Canada.	dennis@mshri.on.ca	Pollett, Aaron/AAQ-2540-2021; Pollett, Aaron/J-2308-2016; Dennis, James/E-7268-2013	Pollett, Aaron/0000-0001-5121-8788; Pollett, Aaron/0000-0001-5121-8788; 				Anzola M, 2004, J VIRAL HEPATITIS, V11, P383, DOI 10.1111/j.1365-2893.2004.00521.x; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Black D, 2004, J SURG RES, V117, P306, DOI 10.1016/j.jss.2003.10.026; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Fode C, 1996, MOL CELL BIOL, V16, P4665; Galjart N, 2003, CURR OPIN CELL BIOL, V15, P48, DOI 10.1016/S0955-0674(02)00007-8; Hammond C, 1999, HEPATOLOGY, V29, P1479, DOI 10.1002/hep.510290513; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Jackson RJ, 2003, CANCER RES, V63, P3021; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Seike M, 2002, LUNG CANCER-J IASLC, V38, P229, DOI 10.1016/S0169-5002(02)00218-0; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Swallow CJ, 2005, ONCOGENE, V24, P306, DOI 10.1038/sj.onc.1208275; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Yeh SH, 2001, GASTROENTEROLOGY, V121, P699, DOI 10.1053/gast.2001.27211	30	165	172	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					883	888		10.1038/ng1605	http://dx.doi.org/10.1038/ng1605			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16025114				2022-12-25	WOS:000230880400020
J	Liu, BH; Wang, JM; Chan, KM; Tjia, WM; Deng, W; Guan, XY; Huang, JD; Li, KM; Chau, PY; Chen, DJ; Pei, DQ; Pendas, AM; Cadinanos, J; Lopez-Otin, C; Tse, HF; Hutchison, C; Chen, JJ; Cao, YH; Cheah, KSE; Tryggvason, K; Zhou, ZJ				Liu, BH; Wang, JM; Chan, KM; Tjia, WM; Deng, W; Guan, XY; Huang, JD; Li, KM; Chau, PY; Chen, DJ; Pei, DQ; Pendas, AM; Cadinanos, J; Lopez-Otin, C; Tse, HF; Hutchison, C; Chen, JJ; Cao, YH; Cheah, KSE; Tryggvason, K; Zhou, ZJ			Genomic instability in laminopathy-based premature aging	NATURE MEDICINE			English	Article							HUTCHINSON-GILFORD PROGERIA; DOUBLE-STRAND BREAKS; LAMIN-A; DNA-DAMAGE; CELLULAR SENESCENCE; ZMPSTE24; MICE; RECOMBINATION; METALLOPROTEINASE	Premature aging syndromes often result from mutations in nuclear proteins involved in the maintenance of genomic integrity. Lamin A is a major component of the nuclear lamina and nuclear skeleton. Truncation in lamin A causes Hutchinson-Gilford progerial syndrome (HGPS), a severe form of early-onset premature aging. Lack of functional Zmpste24, a metalloproteinase responsible for the maturation of prelamin A, also results in progeroid phenotypes in mice and humans. We found that Zmpste24-deficient mouse embryonic fibroblasts (MEFs) show increased DNA damage and chromosome aberrations and are more sensitive to DNA-damaging agents. Bone marrow cells isolated from Zmpste24(-/-) mice show increased aneuploidy and the mice are more sensitive to DNA- damaging agents. Recruitment of p53 binding protein 1 (53BP1) and Rad51 to sites of DNA lesion is impaired in Zmpste24(-/-) MEFs and in HGPS fibroblasts, resulting in delayed checkpoint response and defective DNA repair. Wild-type MEFs ectopically expressing unprocessible prelamin A show similar defects in checkpoint response and DNA repair. Our results indicate that unprocessed prelamin A and truncated lamin A act dominant negatively to perturb DNA damage response and repair, resulting in genomic instability which might contribute to laminopathy-based premature aging.	Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Calif San Diego, Dept Mol Med, La Jolla, CA 92093 USA; Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Texas, SW Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Oviedo, Dept Bioquim & Biol Mol, Inst Oncol, E-33006 Oviedo, Spain; Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Durham, Dept Biol & Biomed Sci, Durham DH1 3HP, England; Mayo Clin, Dept Oncol, Rochester, MN 55905 USA; Karolinska Inst, Microbiol & Tumor Ctr, S-17177 Stockholm, Sweden	University of Hong Kong; University of California System; University of California San Diego; University of Hong Kong; University of Hong Kong; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities; University of Oviedo; University of Hong Kong; Durham University; Mayo Clinic; Karolinska Institutet	Zhou, ZJ (corresponding author), Univ Hong Kong, Dept Biochem, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	zhongjun@hkucc.hku.hk	Deng, Wen/C-4154-2009; Deng, Wen/M-5208-2019; Liu, Baohua/C-9594-2014; zhou, zhongjun/D-4818-2012; Chan, Kui Ming June/G-4330-2013; Liu, Baohua/AAH-3685-2020; López-Otín, Carlos/AAB-2106-2020; Liu, Baohua/C-4191-2009; Tse, Hung-Fat/C-4426-2009; Pendas, Alberto M/L-1017-2014; Guan, Xin-Yuan/A-3639-2009; Zhou, Zhongjun/C-4476-2009; /C-4277-2009; /A-3639-2009	Liu, Baohua/0000-0002-1599-8059; Liu, Baohua/0000-0002-1599-8059; López-Otín, Carlos/0000-0001-6964-1904; Tse, Hung-Fat/0000-0002-9578-7808; Guan, Xin-Yuan/0000-0002-4485-6017; Zhou, Zhongjun/0000-0001-7092-8128; CHAN, Kui Ming/0000-0001-6430-3340; Cadinanos, Juan/0000-0001-7561-7759; Pendas, Alberto M/0000-0001-9264-3721; /0000-0001-7531-2816; /0000-0003-1874-9805				Agarwal AK, 2003, HUM MOL GENET, V12, P1995, DOI 10.1093/hmg/ddg213; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Busuttil RA, 2004, ANN NY ACAD SCI, V1019, P245, DOI 10.1196/annals.1297.041; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; GOLDMAN AE, 1992, J CELL BIOL, V119, P725, DOI 10.1083/jcb.119.4.725; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; Karanjawala ZE, 2004, MECH AGEING DEV, V125, P405, DOI 10.1016/j.mad.2004.04.003; Li XT, 2003, NUCLEIC ACIDS RES, V31, P6674, DOI 10.1093/nar/gkg844; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; LUZI P, 1994, CYTOMETRY, V18, P79, DOI 10.1002/cyto.990180205; Mounkes LC, 2003, NATURE, V423, P298, DOI 10.1038/nature01631; Mukherjee AB, 1998, MECH AGEING DEV, V103, P209, DOI 10.1016/S0047-6374(98)00041-4; Navarro CL, 2005, HUM MOL GENET, V14, P1503, DOI 10.1093/hmg/ddi159; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021	25	470	489	4	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					780	785		10.1038/nm1266	http://dx.doi.org/10.1038/nm1266			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15980864				2022-12-25	WOS:000230304200035
J	Paulsen, IT; Press, CM; Ravel, J; Kobayashi, DY; Myers, GSA; Mavrodi, DV; DeBoy, RT; Seshadri, R; Ren, QH; Madupu, R; Dodson, RJ; Durkin, AS; Brinkac, LM; Daugherty, SC; Sullivan, SA; Rosovitz, MJ; Gwinn, ML; Zhou, LW; Schneider, DJ; Cartinhour, SW; Nelson, WC; Weidman, J; Watkins, K; Tran, K; Khouri, H; Pierson, EA; Pierson, LS; Thomashow, LS; Loper, JE				Paulsen, IT; Press, CM; Ravel, J; Kobayashi, DY; Myers, GSA; Mavrodi, DV; DeBoy, RT; Seshadri, R; Ren, QH; Madupu, R; Dodson, RJ; Durkin, AS; Brinkac, LM; Daugherty, SC; Sullivan, SA; Rosovitz, MJ; Gwinn, ML; Zhou, LW; Schneider, DJ; Cartinhour, SW; Nelson, WC; Weidman, J; Watkins, K; Tran, K; Khouri, H; Pierson, EA; Pierson, LS; Thomashow, LS; Loper, JE			Complete genome sequence of the plant commensal Pseudomonas fluorescens Pf-5	NATURE BIOTECHNOLOGY			English	Article							INDUCED DAMPING-OFF; GENE-CLUSTER; ANTIBIOTIC PRODUCTION; BIOLOGICAL-CONTROL; COTTON SEEDLINGS; PUTIDA KT2440; BIOCONTROL; BIOSYNTHESIS; SIDEROPHORES; AERUGINOSA	Pseudomonas fluorescens Pf-5 is a plant commensal bacterium that inhabits the rhizosphere and produces secondary metabolites that suppress soilborne plant pathogens. The complete sequence of the 7.1- Mb Pf- 5 genome was determined. We analyzed repeat sequences to identify genomic islands that, together with other approaches, suggested P. fluorescens Pf-5's recent lateral acquisitions include six secondary metabolite gene clusters, seven phage regions and a mobile genomic island. We identified various features that contribute to its commensal lifestyle on plants, including broad catabolic and transport capabilities for utilizing plant-derived compounds, the apparent ability to use a diversity of iron siderophores, detoxification systems to protect from oxidative stress, and the lack of a type III secretion system and toxins found in related pathogens. In addition to six known secondary metabolites produced by P. fluorescens Pf- 5, three novel secondary metabolite biosynthesis gene clusters were also identified that may contribute to the biocontrol properties of P. fluorescens Pf- 5.	USDA ARS, Hort Crops Res Lab, Corvallis, OR USA; Inst Genom Res, Rockville, MD USA; Rutgers State Univ, Dept Plant Biol & Pathol, New Brunswick, NJ 08903 USA; Washington State Univ, Dept Plant Pathol, Pullman, WA 99164 USA; USDA ARS, Ithaca, NY 14853 USA; Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA; USDA ARS, Root Dis & Biol Control Res Unit, Pullman, WA USA	United States Department of Agriculture (USDA); J. Craig Venter Institute; Rutgers State University New Brunswick; Washington State University; United States Department of Agriculture (USDA); University of Arizona; United States Department of Agriculture (USDA)	Loper, JE (corresponding author), USDA ARS, Hort Crops Res Lab, Corvallis, OR USA.	ipaulsen@tigr.org; loperj@mail.science.oregonstate.edu	Mavrodi, Dmitri V./S-7894-2019; Schneider, David J/H-2236-2012; Ravel, Jacques/D-2530-2009; Nelson, William C/E-9263-2016; Mavrodi, Dmitri/AAH-7712-2020; Mavrodi, Dmitri/J-2745-2013; Paulsen, Ian T/K-3832-2012; Myers, Garry/E-7708-2011	Mavrodi, Dmitri V./0000-0002-9644-2094; Schneider, David J/0000-0002-2124-8385; Nelson, William C/0000-0002-1873-3929; Paulsen, Ian T/0000-0001-9015-9418; Press, Caroline/0000-0003-4741-9776; Ravel, Jacques/0000-0002-0851-2233; Pierson, Elizabeth/0000-0001-8867-0743; Myers, Garry/0000-0002-4756-4810; Loper, Joyce/0000-0003-3501-5969				Aranda-Olmedo I, 2002, NUCLEIC ACIDS RES, V30, P1826, DOI 10.1093/nar/30.8.1826; Bangera MG, 1999, J BACTERIOL, V181, P3155, DOI 10.1128/JB.181.10.3155-3163.1999; Buell CR, 2003, P NATL ACAD SCI USA, V100, P10181, DOI 10.1073/pnas.1731982100; Buysens S, 1996, APPL ENVIRON MICROB, V62, P865, DOI 10.1128/AEM.62.3.865-871.1996; CASTRIC PA, 1977, J BACTERIOL, V130, P826, DOI 10.1128/JB.130.2.826-831.1977; Clarke Teresa E., 2001, Current Topics in Medicinal Chemistry, V1, P7, DOI 10.2174/1568026013395623; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Curl E. A., 1986, RHIZOSPHERE; de Souza JT, 2003, APPL ENVIRON MICROB, V69, P7161, DOI 10.1128/AEM.69.12.7161-7172.2003; Delcher AL, 2002, NUCLEIC ACIDS RES, V30, P2478, DOI 10.1093/nar/30.11.2478; dos Santos VAPM, 2004, ENVIRON MICROBIOL, V6, P1264, DOI 10.1111/j.1462-2920.2004.00734.x; Eisen JA, 2000, GENOME BIOL, V1; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Haas D, 2003, ANNU REV PHYTOPATHOL, V41, P117, DOI 10.1146/annurev.phyto.41.052002.095656; Hammer PE, 1997, APPL ENVIRON MICROB, V63, P2147, DOI 10.1128/AEM.63.6.2147-2154.1997; HOWELL CR, 1979, PHYTOPATHOLOGY, V69, P480, DOI 10.1094/Phyto-69-480; HOWELL CR, 1980, PHYTOPATHOLOGY, V70, P712, DOI 10.1094/Phyto-70-712; Kim KC, 2000, APPL ENVIRON MICROB, V66, P1460, DOI 10.1128/AEM.66.4.1460-1467.2000; Klockgether J, 2004, J BACTERIOL, V186, P518, DOI 10.1128/JB.186.2.518-534.2004; KRAUS J, 1992, PHYTOPATHOLOGY, V82, P264, DOI 10.1094/Phyto-82-264; Krieg NR, 1984, BERGEYS MANUAL SYSTE, V1; Laville J, 1998, J BACTERIOL, V180, P3187, DOI 10.1128/JB.180.12.3187-3196.1998; LESSIE TG, 1984, ANNU REV MICROBIOL, V38, P359, DOI 10.1146/annurev.mi.38.100184.002043; Loper JE, 1999, APPL ENVIRON MICROB, V65, P5357; LOPER JE, 1991, MOL PLANT MICROBE IN, V4, P5, DOI 10.1094/MPMI-4-005; MAZZOLA M, 1992, APPL ENVIRON MICROB, V58, P2616, DOI 10.1128/AEM.58.8.2616-2624.1992; Meyer JM, 2000, ARCH MICROBIOL, V174, P135, DOI 10.1007/s002030000188; Mori IC, 2004, PLANT PHYSIOL, V135, P702, DOI 10.1104/pp.104.042069; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; Nowak-Thompson B, 1999, J BACTERIOL, V181, P2166, DOI 10.1128/JB.181.7.2166-2174.1999; NOWAKTHOMPSON B, 1994, CAN J MICROBIOL, V40, P1064, DOI 10.1139/m94-168; Paulsen IT, 2002, P NATL ACAD SCI USA, V99, P13148, DOI 10.1073/pnas.192319099; PFENDER WF, 1993, PHYTOPATHOLOGY, V83, P1223, DOI 10.1094/Phyto-83-1223; Preston GM, 2001, MOL MICROBIOL, V41, P999, DOI 10.1046/j.1365-2958.2001.02560.x; Raaijmakers JM, 2002, ANTON LEEUW INT J G, V81, P537, DOI 10.1023/A:1020501420831; Ravel J, 2003, TRENDS MICROBIOL, V11, P195, DOI 10.1016/S0966-842X(03)00076-3; Roberts DP, 1999, APPL ENVIRON MICROB, V65, P2513; Rodriguez F, 1997, PHYTOPATHOLOGY, V87, P614, DOI 10.1094/PHYTO.1997.87.6.614; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; Sharifi-Tehrani A, 1998, EUR J PLANT PATHOL, V104, P631, DOI 10.1023/A:1008672104562; Stover C.K., 2000, NATURE, V406, P947; Tettelin H, 1999, GENOMICS, V62, P500, DOI 10.1006/geno.1999.6048; Weller DM, 2002, ANNU REV PHYTOPATHOL, V40, P309, DOI 10.1146/annurev.phyto.40.030402.110010; Whistler CA, 1998, J BACTERIOL, V180, P6635, DOI 10.1128/JB.180.24.6635-6641.1998; XU GW, 1986, PHYTOPATHOLOGY, V76, P414, DOI 10.1094/Phyto-76-414	45	469	1055	1	139	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2005	23	7					873	878		10.1038/nbt1110	http://dx.doi.org/10.1038/nbt1110			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	944KT	15980861	hybrid, Green Published			2022-12-25	WOS:000230427700035
J	Coucke, PJ; Willaert, A; Wessels, MW; Callewaert, B; Zoppi, N; De Backer, J; Fox, JE; Mancini, GMS; Kambouris, M; Gardella, R; Facchetti, F; Willems, PJ; Forsyth, R; Dietz, HC; Barlati, S; Colombi, M; Loeys, B; De Paepe, A				Coucke, PJ; Willaert, A; Wessels, MW; Callewaert, B; Zoppi, N; De Backer, J; Fox, JE; Mancini, GMS; Kambouris, M; Gardella, R; Facchetti, F; Willems, PJ; Forsyth, R; Dietz, HC; Barlati, S; Colombi, M; Loeys, B; De Paepe, A			Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome	NATURE GENETICS			English	Article							FANCONI-BICKEL-SYNDROME; SMOOTH-MUSCLE-CELLS; SLC2A10 GLUT10; CANDIDATE GENE; GROWTH-FACTORS; FAMILY; VERSICAN; SEQUENCE; TRAITS	Arterial tortuosity syndrome (ATS) is an autosomal recessive disorder characterized by tortuosity, elongation, stenosis and aneurysm formation in the major arteries owing to disruption of elastic fibers in the medial layer of the arterial wall(1). Previously, we used homozygosity mapping to map a candidate locus in a 4.1-Mb region on chromosome 20q13.1 (ref. 2). Here, we narrowed the candidate region to 1.2 Mb containing seven genes. Mutations in one of these genes, SLC2A10, encoding the facilitative glucose transporter GLUT10, were identified in six ATS families. GLUT10 deficiency is associated with upregulation of the TGF beta pathway in the arterial wall, a finding also observed in Loeys-Dietz syndrome, in which aortic aneurysms associate with arterial tortuosity(3). The identification of a glucose transporter gene responsible for altered arterial morphogenesis is notable in light of the previously suggested link between GLUT10 and type 2 diabetes(4,5). Our data could provide new insight on the mechanisms causing microangiopathic changes associated with diabetes and suggest that therapeutic compounds intervening with TGF beta signaling represent a new treatment strategy.	Univ Ghent, Ctr Med Genet, B-9000 Ghent, Belgium; Erasmus Univ, Med Ctr, Dept Clin Genet, NL-3015 GD Rotterdam, Netherlands; Univ Brescia, Dept Biomed Sci & Biotechnol, Div Biol & Genet, I-25123 Brescia, Italy; N Shore Univ Hosp, Dept Pediat, Manhasset, NY 11030 USA; Yale Univ, Sch Med, New Haven, CT 06510 USA; Univ Brescia, Dept Pathol, Brescia, Italy; GENDIA, B-2000 Antwerp, Belgium; Ghent Univ, Dept Pathol, B-9000 Ghent, Belgium; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Ghent University; Erasmus University Rotterdam; Erasmus MC; University of Brescia; Northwell Health; North Shore University Hospital; Yale University; University of Brescia; Ghent University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Coucke, PJ (corresponding author), Univ Ghent, Ctr Med Genet, B-9000 Ghent, Belgium.	paul.coucke@ugent.be	Loeys, Bart/B-3236-2017; Forsyth, Ramses/X-8635-2019; Facchetti, Fabio/E-7190-2010; Barlati, Sergio/A-2666-2010; Callewaert, Bert/J-6357-2014; Coucke, Paul J/AAO-2954-2020; Willaert, Andy/AAZ-9111-2020; De Backer, Julie/B-2897-2014	Loeys, Bart/0000-0003-3703-9518; Forsyth, Ramses/0000-0001-8337-5382; Facchetti, Fabio/0000-0003-4975-2388; Callewaert, Bert/0000-0002-9743-4205; Coucke, Paul J/0000-0001-7119-586X; De Backer, Julie/0000-0001-8878-1507; Willaert, Andy/0000-0002-9543-1932; ZOPPI, Nicoletta/0000-0003-0197-8927; Colombi, Marina/0000-0002-3105-5990				Andersen G, 2003, DIABETES, V52, P2445, DOI 10.2337/diabetes.52.9.2445; Barrett MP, 1999, CURR OPIN CELL BIOL, V11, P496, DOI 10.1016/S0955-0674(99)80072-6; BEUREN AJ, 1969, CIRCULATION, V39, P109, DOI 10.1161/01.CIR.39.1.109; Chiarelli F, 2000, HORM RES, V53, P53, DOI 10.1159/000023515; Colombi M, 2003, J BIOL CHEM, V278, P14346, DOI 10.1074/jbc.M211997200; Coucke PJ, 2003, J MED GENET, V40, P747, DOI 10.1136/jmg.40.10.747; Dawson PA, 2001, MOL GENET METAB, V74, P186, DOI 10.1006/mgme.2001.3212; ERTUGRUL A, 1967, CIRCULATION, V36, P400, DOI 10.1161/01.CIR.36.3.400; Fischer JW, 2001, ARTERIOSCL THROM VAS, V21, P777, DOI 10.1161/01.ATV.21.5.777; Franceschini P, 2000, AM J MED GENET, V91, P141, DOI 10.1002/(SICI)1096-8628(20000313)91:2<141::AID-AJMG13>3.0.CO;2-6; Gardella R, 2004, AM J MED GENET A, V126A, P221, DOI 10.1002/ajmg.a.20589; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102; Loeys BL, 2005, NAT GENET, V37, P275, DOI 10.1038/ng1511; McVie-Wylie AJ, 2001, GENOMICS, V72, P113, DOI 10.1006/geno.2000.6457; Mohlke KL, 2005, MOL GENET METAB, V85, P323, DOI 10.1016/j.ymgme.2005.04.011; Pletcher BA, 1996, AM J MED GENET, V66, P121, DOI 10.1002/(SICI)1096-8628(19961211)66:2<121::AID-AJMG1>3.3.CO;2-X; Sakamoto O, 2000, PEDIATR RES, V48, P586, DOI 10.1203/00006450-200011000-00005; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; Scheepers A, 2004, JPEN-PARENTER ENTER, V28, P364, DOI 10.1177/0148607104028005364; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; Seidner G, 1998, NAT GENET, V18, P188, DOI 10.1038/ng0298-188; TANIZAWA Y, 1994, DIABETOLOGIA, V37, P420, DOI 10.1007/BF00408481; Wahab NA, 2000, J AM SOC NEPHROL, V11, P1607, DOI 10.1681/ASN.V1191607; Wessels MW, 2004, AM J MED GENET A, V131A, P134, DOI 10.1002/ajmg.a.30272; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; Wood IS, 2003, BIOCHEM BIOPH RES CO, V308, P43, DOI 10.1016/S0006-291X(03)01322-6	27	249	261	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	2006	38	4					452	457		10.1038/ng1764	http://dx.doi.org/10.1038/ng1764			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16550171	Green Published			2022-12-25	WOS:000236340500018
J	Loh, YH; Wu, Q; Chew, JL; Vega, VB; Zhang, WW; Chen, X; Bourque, G; George, J; Leong, B; Liu, J; Wong, KY; Sung, KW; Lee, CWH; Zhao, XD; Chiu, KP; Lipovich, L; Kuznetsov, VA; Robson, P; Stanton, LW; Wei, CL; Ruan, YJ; Lim, B; Ng, HH				Loh, YH; Wu, Q; Chew, JL; Vega, VB; Zhang, WW; Chen, X; Bourque, G; George, J; Leong, B; Liu, J; Wong, KY; Sung, KW; Lee, CWH; Zhao, XD; Chiu, KP; Lipovich, L; Kuznetsov, VA; Robson, P; Stanton, LW; Wei, CL; Ruan, YJ; Lim, B; Ng, HH			The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells	NATURE GENETICS			English	Article							FACTOR-BINDING-SITES; SELF-RENEWAL; HUMAN RIF1; PROTEIN; GENE; SOX2; EXPRESSION; OCT-3/4; DIFFERENTIATION; IDENTIFICATION	Oct4 and Nanog are transcription factors required to maintain the pluripotency and self-renewal of embryonic stem (ES) cells. Using the chromatin immunoprecipitation paired-end ditags method, we mapped the binding sites of these factors in the mouse ES cell genome. We identified 1,083 and 3,006 high-confidence binding sites for Oct4 and Nanog, respectively. Comparative location analyses indicated that Oct4 and Nanog overlap substantially in their targets, and they are bound to genes in different configurations. Using de novo motif discovery algorithms, we defined the cis-acting elements mediating their respective binding to genomic sites. By integrating RNA interference-mediated depletion of Oct4 and Nanog with microarray expression profiling, we demonstrated that these factors can activate or suppress transcription. We further showed that common core downstream targets are important to keep ES cells from differentiating. The emerging picture is one in which Oct4 and Nanog control a cascade of pathways that are intricately connected to govern pluripotency, self-renewal, genome surveillance and cell fate determination.	Genome Inst Singapore, Cloning & Sequencing Grp, Singapore 138672, Singapore; Genome Inst Singapore, Informat & Math Sci Grp, Singapore 138672, Singapore; Genome Inst Singapore, Gene Regulat Lab, Singapore 138672, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Harvard University; Harvard Medical School	Ruan, YJ (corresponding author), Genome Inst Singapore, Cloning & Sequencing Grp, Singapore 138672, Singapore.	ruanyj@gis.a-star.edu.sg; nghh@gis.a-star.edu.sg	Chiu, Kuo-Ping/AAG-8855-2020; Robson, Paul/A-3464-2009; Chen, Xi/C-6889-2012; George, Joshy/K-4841-2019; Bourque, Guillaume/AFR-2927-2022; Ng, Huck Hui/A-1135-2009; Loh, Yuin-Han/E-1096-2014; Lipovich, Leonard/B-2355-2019; Yang, Chen/G-1379-2010	Chiu, Kuo-Ping/0000-0001-9144-0674; Robson, Paul/0000-0002-0191-3958; Bourque, Guillaume/0000-0002-3933-9656; Loh, Yuin-Han/0000-0002-4715-6454; Lipovich, Leonard/0000-0002-0531-3570; Sung, Wing-Kin/0000-0001-7806-7086; Wu, Qiang/0000-0003-2049-1639; NG, HUCK HUI/0000-0001-6352-8417; George, Joshy/0000-0001-8510-8229; Chen, Xi/0000-0002-7995-6202	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047636] Funding Source: NIH RePORTER; NIAID NIH HHS [AI54973] Funding Source: Medline; NIDDK NIH HHS [DK47636] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams IR, 2004, DEV DYNAM, V229, P733, DOI 10.1002/dvdy.10471; Affolter M, 1990, CURR OPIN CELL BIOL, V2, P485, DOI 10.1016/0955-0674(90)90132-X; Ambrosetti DC, 2000, J BIOL CHEM, V275, P23387, DOI 10.1074/jbc.M000932200; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brandenberger Ralph, 2004, BMC Developmental Biology, V4, P1; Buck MJ, 2004, GENOMICS, V83, P349, DOI 10.1016/j.ygeno.2003.11.004; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; Donovan PJ, 2001, NATURE, V414, P92, DOI 10.1038/35102154; Down TA, 2005, NUCLEIC ACIDS RES, V33, P1445, DOI 10.1093/nar/gki282; Guo Y, 2002, P NATL ACAD SCI USA, V99, P3663, DOI 10.1073/pnas.062041099; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Kim JW, 2005, NAT METHODS, V2, P47, DOI 10.1038/NMETH726; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Mitsunaga K, 2004, MECH DEVELOP, V121, P237, DOI 10.1016/j.mod.2004.01.006; Ng P, 2005, NAT METHODS, V2, P105, DOI 10.1038/NMETH733; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Okumura-Nakanishi S, 2005, J BIOL CHEM, V280, P5307, DOI 10.1074/jbc.m410015200; Pavesi G., 2001, BIOINFORMATICS, V17, pS207; Pera MF, 2000, J CELL SCI, V113, P5; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Pollack JR, 2002, NAT GENET, V32, P515, DOI 10.1038/ng1035; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Silverman J, 2004, GENE DEV, V18, P2108, DOI 10.1101/gad.1216004; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004-0162; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Xu LF, 2004, J CELL BIOL, V167, P819, DOI 10.1083/jcb.200408181; Yeom YI, 1996, DEVELOPMENT, V122, P881	46	1827	1938	4	204	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2006	38	4					431	440		10.1038/ng1760	http://dx.doi.org/10.1038/ng1760			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16518401				2022-12-25	WOS:000236340500015
J	Mak, HY; Nelson, LS; Basson, M; Johnson, CD; Ruvkun, G				Mak, HY; Nelson, LS; Basson, M; Johnson, CD; Ruvkun, G			Polygenic control of Caenorhabditis elegans fat storage	NATURE GENETICS			English	Article							C-ELEGANS; CHEMOSENSORY NEURONS; SENSORY PERCEPTION; LARVAL DEVELOPMENT; GENE FAMILY; TUBBY; PROTEIN; MUTATION; HOMOLOG; INSULIN	Tubby mice(1) and individuals with Bardet-Biedl syndrome(2) have defects in ciliated neuron function and obesity, suggesting an as-yet unknown metabolic signaling axis from ciliated neurons to fat storage tissues. Here we show coordinate regulation of Caenorhabditis elegans fat storage by orthologues of these genes acting in ciliated neurons and by a 3-ketoacyl-coA thiolase (encoded by kat-1) that acts in fat storage tissue. A genetic screen for markedly enhanced fat storage in tub-1 mutants led to the isolation only of kat-1 alleles, which impair fatty acid beta-oxidation. kat-1 acts in the intestine, the major C. elegans fat storage tissue, and is transcriptionally upregulated in animals with high fat storage. A genetic screen for synergistic increase in fat storage of a kat-1 mutant identified bbs-1. bbs-1 acts in 15 ciliated neurons that are poised to sense external and internal nutrient levels, supporting a model in which bbs-1 and tub-1 in ciliated neurons form part of an ancient, conserved neuroendocrine axis. This pathway also includes genes encoding intraflagellar transport proteins and cyclic nucleotide gated channels, demonstrating that C. elegans fat storage is under polygenic control.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Axys Pharmaceut, San Francisco, CA 94080 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ruvkun, G (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	ruvkun@molbio.mgh.harvard.edu		Mak, Ho Yi/0000-0002-1500-5328	NIDDK NIH HHS [R01 DK070147] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070147] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; Coates JC, 2002, NATURE, V419, P925, DOI 10.1038/nature01170; de Bono M, 2002, NATURE, V419, P899, DOI 10.1038/nature01169; Fujiwara M, 2002, NEURON, V36, P1091, DOI 10.1016/S0896-6273(02)01093-0; Fujiwara M, 1999, DEVELOPMENT, V126, P4839; Haycraft CJ, 2001, DEVELOPMENT, V128, P1493; Ikeda A, 2002, J CELL SCI, V115, P9; Katsanis N, 2001, HUM MOL GENET, V10, P2293, DOI 10.1093/hmg/10.20.2293; Kim JC, 2004, NAT GENET, V36, P462, DOI 10.1038/ng1352; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; Li C, 1999, ANN NY ACAD SCI, V897, P239, DOI 10.1111/j.1749-6632.1999.tb07895.x; Li WQ, 2003, GENE DEV, V17, P844, DOI 10.1101/gad.1066503; Mathieu M, 1997, J MOL BIOL, V273, P714, DOI 10.1006/jmbi.1997.1331; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; Perens EA, 2005, DEV CELL, V8, P893, DOI 10.1016/j.devcel.2005.03.009; Pierce SB, 2001, GENE DEV, V15, P672, DOI 10.1101/gad.867301; Qin HM, 2001, CURR BIOL, V11, P457, DOI 10.1016/S0960-9822(01)00122-1; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Sahly I, 1998, HUM MOL GENET, V7, P1437, DOI 10.1093/hmg/7.9.1437; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; Stubdal H, 2000, MOL CELL BIOL, V20, P878, DOI 10.1128/MCB.20.3.878-882.2000; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wicks SR, 2001, NAT GENET, V28, P160, DOI 10.1038/88878	30	146	158	3	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					363	368		10.1038/ng1739	http://dx.doi.org/10.1038/ng1739			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16462744				2022-12-25	WOS:000235589600020
J	Murdoch, S; Djuric, U; Mazhar, B; Seoud, M; Khan, R; Kuick, R; Bagga, R; Kircheisen, R; Ao, A; Ratti, B; Hanash, S; Rouleau, GA; Slim, R				Murdoch, S; Djuric, U; Mazhar, B; Seoud, M; Khan, R; Kuick, R; Bagga, R; Kircheisen, R; Ao, A; Ratti, B; Hanash, S; Rouleau, GA; Slim, R			Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans	NATURE GENETICS			English	Article							NITRIC-OXIDE; MICE; PREGNANCY; PROTEIN; LOCUS	Hydatidiform mole (HM) is an abnormal human pregnancy with no embryo and cystic degeneration of placental villi. We report five mutations in the maternal gene NALP7 in individuals with familial and recurrent HMs. NALP7 is a member of the CATERPILLER protein family involved in inflammation and apoptosis. NALP7 is the first maternal effect gene identified in humans and is also responsible for recurrent spontaneous abortions, stillbirths and intrauterine growth retardation.	McGill Univ, Ctr Hlth, Dept Human Genet, Montreal, PQ H3G 1A4, Canada; McGill Univ, Ctr Hlth, Dept Obstet & Gynecol, Montreal, PQ H3G 1A4, Canada; Pakistan Inst Med Sci, Dept Obstet & Gynecol, Maternal & Child Hlth Ctr Unit 11, Islamabad, Pakistan; Amer Univ Beirut, Dept Obstet & Gynecol, Beirut, Lebanon; Univ Michigan, Dept Pediat & Commun Dis, Ann Arbor, MI 48109 USA; Postgrad Inst Med Educ & Res, Dept Obstet & Gynecol, Chandigarh 160012, India; Inst Klin Genet, D-55131 Mainz, Germany; Notre Dame Hosp, Ctr Study Brain Dis, Montreal, PQ H2L 4M1, Canada	McGill University; McGill University; Pakistan Institute of Medical Sciences; American University of Beirut; University of Michigan System; University of Michigan; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Universite de Montreal	Slim, R (corresponding author), McGill Univ, Ctr Hlth, Dept Human Genet, Montreal, PQ H3G 1A4, Canada.	rima.slim@muhc.mcgill.ca	ao, asangla/Q-5454-2019; Slim, Rima/J-4104-2019; Bagga, Rashmi/Y-1680-2019	Slim, Rima/0000-0002-4060-2159; Bagga, Rashmi/0000-0003-2693-2343; Djuric, Ugljesa/0000-0003-0027-3079				Agarwal P, 2004, ACTA OBSTET GYN SCAN, V83, P213, DOI 10.1111/j.0001-6349.2004.077b.x; Chiu PM, 2001, HISTOPATHOLOGY, V38, P243, DOI 10.1046/j.1365-2559.2001.01065.x; Deb Kaushik, 2004, Archives of Gynecology and Obstetrics, V270, P133, DOI 10.1007/s00404-004-0623-0; Harma M, 2004, EUR J GYNAECOL ONCOL, V25, P333; Hodges MD, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.8.e95; Karmakar S, 2002, AM J REPROD IMMUNOL, V48, P210, DOI 10.1034/j.1600-0897.2002.01151.x; Kinoshita T, 2005, J BIOL CHEM, V280, P21720, DOI 10.1074/jbc.M410057200; Mazhar S, 1995, J PAKISTAN I MED SCI, V6, P383; Moglabey YB, 1999, HUM MOL GENET, V8, P667, DOI 10.1093/hmg/8.4.667; Ogando DG, 2003, REPRODUCTION, V125, P95, DOI 10.1530/rep.0.1250095; Okada K, 2004, CANCER SCI, V95, P949, DOI 10.1111/j.1349-7006.2004.tb03182.x; Savion S, 2002, AM J REPROD IMMUNOL, V47, P118, DOI 10.1034/j.1600-0897.2002.1o027.x; Strakova Z, 2002, J REPROD IMMUNOL, V55, P35, DOI 10.1016/S0165-0378(01)00141-3; Tong ZB, 2000, NAT GENET, V26, P267, DOI 10.1038/81547; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019	15	325	352	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					300	302		10.1038/ng1740	http://dx.doi.org/10.1038/ng1740			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16462743				2022-12-25	WOS:000235589600010
J	Fiedler, U; Reiss, Y; Scharpfenecker, M; Grunow, V; Koidl, S; Thurston, G; Gale, NW; Witzenrath, M; Rosseau, S; Suttorp, N; Sobke, A; Herrmann, M; Preissner, KT; Vajkoczy, P; Augustin, HG				Fiedler, U; Reiss, Y; Scharpfenecker, M; Grunow, V; Koidl, S; Thurston, G; Gale, NW; Witzenrath, M; Rosseau, S; Suttorp, N; Sobke, A; Herrmann, M; Preissner, KT; Vajkoczy, P; Augustin, HG			Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation	NATURE MEDICINE			English	Article							TIE-2 LIGAND ANGIOPOIETIN-2; ANGIOGENESIS; EXPRESSION; GROWTH; VASCULATURE; INHIBITION; PROTECTS; RECEPTOR; TISSUES; LEAKAGE	The angiopoietins Ang-1 and Ang-2 have been identified as ligands of the receptor tyrosine kinase Tie-2 (refs. 1,2). Paracrine Ang-1-mediated activation of Tie-2 acts as a regulator of vessel maturation and vascular quiescence(3,4). In turn, the antagonistic ligand Ang-2 acts by an autocrine mechanism(5-7) and is stored in endothelial Weibel-Palade bodies from where it can be rapidly released upon stimulation(8). The rapid release of Ang-2 implies functions of the angiopoietin-Tie system beyond its established role during vascular morphogenesis as a regulator of rapid vascular responses. Here we show that mice deficient in Ang-2 (encoded by the gene Angpt2) cannot elicit an inflammatory response in thioglycollate-induced or Staphylococcus aureus-induced peritonitis, or in the dorsal skinfold chamber model. Recombinant Ang-2 restores the inflammation defect in Angpt2(-/-) mice. Intravital microscopy showed normal TNF-alpha-induced leukocyte rolling in the vasculature of Angpt2(-/-) mice, but rolling cells did not firmly adhere to activated endothelium. Cellular experiments showed that Ang-2 promotes adhesion by sensitizing endothelial cells toward TNF-alpha and modulating TNF-alpha-induced expression of endothelial cell adhesion molecules. Together, these findings identify Ang-2 as an autocrine regulator of endothelial cell inflammatory responses. Ang-2 thereby acts as a switch of vascular responsiveness exerting a permissive role for the activities of proinflammatory cytokines.	Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, D-79106 Freiburg, Germany; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Humboldt Univ, Charite, Dept Internal Med Infect Dis, D-13353 Berlin, Germany; Univ Saarland Hosp, Dept Med Microbiol & Hyg, D-66421 Homburg, Germany; Univ Giessen, Dept Biochem, D-35392 Giessen, Germany; Univ Heidelberg, Univ Clin Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany	Regeneron; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universitatsklinikum des Saarlandes; Justus Liebig University Giessen; Ruprecht Karls University Heidelberg	Augustin, HG (corresponding author), Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, D-79106 Freiburg, Germany.	augustin@angiogenese.de	Rosseau, Simone/AAO-1201-2020; Augustin, Hellmut/AAA-5246-2020; Herrmann, Mathias/B-6475-2013	Augustin, Hellmut/0000-0002-7173-4242; Herrmann, Mathias/0000-0003-2638-2257; Suttorp, Norbert/0000-0002-3958-1151; Thurston, Gavin/0000-0002-4105-5919				Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Eberhard A, 2000, CANCER RES, V60, P1388; Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685; Folkman J, 1992, Semin Cancer Biol, V3, P65; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HOBSON B, 1984, BRIT J CANCER, V49, P405, DOI 10.1038/bjc.1984.66; Jeon BH, 2003, CIRC RES, V92, P586, DOI 10.1161/01.RES.0000066881.04116.45; Lehr HA, 1999, METHOD ENZYMOL, V300, P462; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Nykanen AI, 2003, CIRCULATION, V107, P1308, DOI 10.1161/01.CIR.0000054623.35669.3F; Oliner J, 2004, CANCER CELL, V6, P507, DOI 10.1016/j.ccr.2004.09.030; Pitera JE, 2004, AM J PATHOL, V165, P1895, DOI 10.1016/S0002-9440(10)63242-7; Ramsauer M, 2002, J CLIN INVEST, V110, P1615, DOI 10.1172/JCI200217326; Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Vajkoczy P, 1998, J CEREBR BLOOD F MET, V18, P510, DOI 10.1097/00004647-199805000-00006; Vajkoczy P, 2002, J CLIN INVEST, V109, P777, DOI 10.1172/JCI200214105; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Zhang L, 2003, CANCER RES, V63, P3403	27	698	729	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					235	239		10.1038/nm1351	http://dx.doi.org/10.1038/nm1351			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16462802				2022-12-25	WOS:000235160600030
J	Vang, T; Congia, M; Macis, MD; Musumeci, L; Orru, V; Zavattari, P; Nika, K; Tautz, L; Tasken, K; Cucca, F; Mustelin, T; Bottini, N				Vang, T; Congia, M; Macis, MD; Musumeci, L; Orru, V; Zavattari, P; Nika, K; Tautz, L; Tasken, K; Cucca, F; Mustelin, T; Bottini, N			Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISM; T-CELLS; GENE; PTPN22; ARTHRITIS; MUTATION; DISEASE; MICE; PEP	A SNP in the gene PTPN22 is associated with type 1 diabetes, rheumatoid arthritis, lupus, Graves thyroiditis, Addison disease and other autoimmune disorders. T cells from carriers of the predisposing allele produce less interleukin-2 upon TCR stimulation, and the encoded phosphatase has higher catalytic activity and is a more potent negative regulator of T lymphocyte activation. We conclude that the autoimmune-predisposing allele is a gain-of-function mutant.	Burnham Inst, Program Inflammatory Dis Res, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA; Univ Sassari, Dipartimento Sci Biomed, Cattedra Genet Med, I-07100 Sassari, Italy; Univ Cagliari, Osped Microcitemico, Dipartimento Sci Biomed & Biotecnol, I-09121 Cagliari, Italy; Univ So Calif, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; Univ Oslo, Ctr Biotechnol, N-0317 Oslo, Norway	Sanford Burnham Prebys Medical Discovery Institute; University of Sassari; University of Cagliari; University of Southern California; University of Southern California; University of Oslo	Bottini, N (corresponding author), Burnham Inst, Program Inflammatory Dis Res, Infect & Inflammatory Dis Ctr, 10901 N torrey Pines Rd, La Jolla, CA 92037 USA.	nunzio@usc.edu	Valeria, Orru/AAY-3805-2020; Congia, Mauro/AAC-2718-2019; Tautz, Lutz/M-9989-2014; Ingegnoli, Francesca/B-6226-2017	Tautz, Lutz/0000-0002-4075-6238; CUCCA, Francesco/0000-0002-7414-1995; Nika, Konstantina/0000-0002-9620-0263; Ingegnoli, Francesca/0000-0002-6727-1273; Orru, Valeria/0000-0002-6047-4625; Tasken, Kjetil/0000-0003-2841-4697; Congia, Mauro/0000-0003-1688-304X; Mustelin, Tomas/0000-0001-5912-8840	Telethon [GJT030477] Funding Source: Medline	Telethon(Fondazione Telethon)		Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Gottlieb PA, 2002, MOL PATHOLOGY AUTOIM, P588; Hasegawa K, 2004, SCIENCE, V303, P685, DOI 10.1126/science.1092138; Ladner MB, 2005, HUM IMMUNOL, V66, P60, DOI 10.1016/j.humimm.2004.09.016; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; Mustelin T, 2005, NAT REV IMMUNOL, V5, P43, DOI 10.1038/nri1530; Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119; Salojin KV, 1998, IMMUNOL TODAY, V19, P468, DOI 10.1016/S0167-5699(98)01326-7; Siminovitch KA, 2004, NAT GENET, V36, P1248, DOI 10.1038/ng1204-1248; Smyth D, 2004, DIABETES, V53, P3020, DOI 10.2337/diabetes.53.11.3020; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; Vang T, 2004, EUR J IMMUNOL, V34, P2191, DOI 10.1002/eji.200425036	15	540	554	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2005	37	12					1317	1319		10.1038/ng1673	http://dx.doi.org/10.1038/ng1673			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16273109				2022-12-25	WOS:000233657300009
J	Cheng, Q; Du, M; Ramanoudjame, G; Jayaraman, V				Cheng, Q; Du, M; Ramanoudjame, G; Jayaraman, V			Evolution of glutamate interactions during binding to a glutamate receptor	NATURE CHEMICAL BIOLOGY			English	Article							MICROSECOND TIME-SCALE; ION CHANNELS; CONFORMATIONAL-CHANGES; DOMAIN; ACTIVATION	Glutamate receptors are the predominant mediators of excitatory synaptic signals in the central nervous system and are important in learning and memory as well as in diverse neuropathologies including epilepsy and ischemia(1-5). Their primary function is to receive the chemical signal glutamate ( 1), which binds to an extracellular domain in the receptor, and convert it into an electrical signal through the formation of cation-permeable transmembrane channels(6-9). Recently described end-state apo and ligated structures of the ligand-binding domain of a rat glutamate receptor provide a first view of specific molecular interactions between the ligand and the receptor that are central to the allosteric regulation of function in this protein(7,10-15). Yet there is little information on the mechanism and the structures of intermediates ( if any) formed during the ligand-binding process(16). Here we have used time-resolved vibrational spectroscopy to show that the process involves a sequence of interleaved ligand and protein changes that starts with the docking of glutamate at the alpha-carboxylate moiety and ends with the establishment of the interactions between the gamma-carboxylate of glutamate and the protein.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Jayaraman, V (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, 6431 Fannin, Houston, TX 77030 USA.	vasanthi.jayaraman@uth.tmc.edu			NIAAA NIH HHS [1R03AA015682-01] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA015682] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abele R, 2000, J BIOL CHEM, V275, P21355, DOI 10.1074/jbc.M909883199; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Bergink V, 2004, EUR NEUROPSYCHOPHARM, V14, P175, DOI 10.1016/S0924-977X(03)00100-7; Cheng Q, 2004, J BIOL CHEM, V279, P26346, DOI 10.1074/jbc.M403111200; Cheng Q, 2002, J AM CHEM SOC, V124, P7676, DOI 10.1021/ja0259988; Dingledine R, 1999, PHARMACOL REV, V51, P7; Du M, 2005, J BIOL CHEM, V280, P8633, DOI 10.1074/jbc.C400590200; Dunn BC, 1999, APPL SPECTROSC, V53, P292, DOI 10.1366/0003702991946677; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jayaraman V, 2004, METHOD ENZYMOL, V380, P170; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Madden DR, 2000, EUR J BIOCHEM, V267, P4281; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Mayer ML, 2005, CURR OPIN NEUROBIOL, V15, P282, DOI 10.1016/j.conb.2005.05.004; Mayer ML, 2004, ANNU REV PHYSIOL, V66, P161, DOI 10.1146/annurev.physiol.66.050802.084104; McFeeters RL, 2004, FASEB J, V18, P428, DOI 10.1096/fj.03-0873rev; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P329; Riedel G, 2003, BEHAV BRAIN RES, V140, P1, DOI 10.1016/S0166-4328(02)00272-3; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; WIEBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752, DOI 10.1073/pnas.91.19.8752	21	34	36	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2005	1	6					329	332		10.1038/nchembio738	http://dx.doi.org/10.1038/nchembio738			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	979GH	16408071				2022-12-25	WOS:000232929900010
J	Shibata, R; Sato, K; Pimentel, DR; Takemura, Y; Kihara, S; Ohashi, K; Funahashi, T; Ouchi, N; Walsh, K				Shibata, R; Sato, K; Pimentel, DR; Takemura, Y; Kihara, S; Ohashi, K; Funahashi, T; Ouchi, N; Walsh, K			Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2 dependent mechanisms	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; ADIPOSE-SPECIFIC PROTEIN; CORONARY-ARTERY-DISEASE; FATTY-ACID OXIDATION; ISCHEMIA/REPERFUSION INJURY; MICE LACKING; STIMULATES ANGIOGENESIS; PLASMA-CONCENTRATIONS; ENDOTHELIAL-CELLS; GLUCOSE-UPTAKE	Obesity-related disorders are associated with the development of ischemic heart disease. Adiponectin is a circulating adipose-derived cytokine that is downregulated in obese individuals and after myocardial infarction. Here, we examine the role of adiponectin in myocardial remodeling in response to acute injury. Ischemia-reperfusion in adiponectin-deficient (APN-KO) mice resulted in increased myocardial infarct size, myocardial apoptosis and tumor necrosis factor (TNF)-alpha expression compared with wild-type mice. Administration of adiponectin diminished infarct size, apoptosis and TNF-alpha production in both APN-KO and wildtype mice. In cultured cardiac cells, adiponectin inhibited apoptosis and TNF-alpha production. Dominant negative AMP-activated protein kinase ( AMPK) reversed the inhibitory effects of adiponectin on apoptosis but had no effect on the suppressive effect of adiponectin on TNF-alpha production. Adiponectin induced cyclooxygenase (COX)-2-dependent synthesis of prostaglandin E-2 in cardiac cells, and COX-2 inhibition reversed the inhibitory effects of adiponectin on TNF-alpha production and infarct size. These data suggest that adiponectin protects the heart from ischemia-reperfusion injury through both AMPK- and COX-2-dependent mechanisms.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Med Ctr, Cardiovasc Med Sect, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Myocardial Biol Unit, Boston, MA 02118 USA; Osaka Univ, Dept Internal Med & Mol Sci, Grad Sch Med, Suita, Osaka 5650871, Japan	Boston University; Boston University; Boston University; Osaka University	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St, Boston, MA 02118 USA.	kxwalsh@bu.edu	OUCHI, Noriyuki/I-7306-2014	Walsh, Kenneth/0000-0001-7580-2276; Pimentel, David/0000-0002-0537-7195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066957, R01HL077774, T32HL007224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R01AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL077774-01A1, R01 HL077774, P01 HL066957, HL77774, HL07224, P01 HL066957-040004, T32 HL007224, HL66957] Funding Source: Medline; NIAMS NIH HHS [R01 AR040197, R01 AR040197-15, AR40197] Funding Source: Medline; NIA NIH HHS [AG15052, R37 AG015052, R01 AG015052-04, R01 AG015052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Arnaud C, 2003, CARDIOVASC RES, V58, P582, DOI 10.1016/S0008-6363(03)00295-5; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bolli R, 2002, CARDIOVASC RES, V55, P506, DOI 10.1016/S0008-6363(02)00414-5; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; Camitta MGW, 2001, CIRCULATION, V104, P2453, DOI 10.1161/hc4401.098429; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Frangogiannis NG, 1998, CIRCULATION, V98, P699, DOI 10.1161/01.CIR.98.7.699; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gurevitch J, 1997, J AM COLL CARDIOL, V30, P1554, DOI 10.1016/S0735-1097(97)00328-8; Hohlfeld T, 2000, J MOL CELL CARDIOL, V32, P285, DOI 10.1006/jmcc.1999.1072; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Iwashima Y, 2004, HYPERTENSION, V43, P1318, DOI 10.1161/01.HYP.0000129281.03801.4b; Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37; Kojima S, 2003, HEART, V89, P667, DOI 10.1136/heart.89.6.667; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; Kupatt C, 1999, CIRC RES, V84, P392, DOI 10.1161/01.RES.84.4.392; Li QH, 2003, CIRC RES, V92, P741, DOI 10.1161/01.RES.0000065441.72685.29; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Maekawa N, 2002, J AM COLL CARDIOL, V39, P1229, DOI 10.1016/S0735-1097(02)01738-2; Meja KK, 1997, BRIT J PHARMACOL, V122, P149, DOI 10.1038/sj.bjp.0701360; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; ORLANDER PR, 1994, DIABETES, V43, P897, DOI 10.2337/diabetes.43.7.897; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Ouchi N, 2003, CIRCULATION, V107, P671, DOI 10.1161/01.CIR.0000055188.83694.B3; Parsa CJ, 2004, J BIOL CHEM, V279, P20655, DOI 10.1074/jbc.M314099200; Pischon T, 2004, JAMA-J AM MED ASSOC, V291, P1730, DOI 10.1001/jama.291.14.1730; PRUIMBOOM WM, 1994, IMMUNOL LETT, V41, P255, DOI 10.1016/0165-2478(94)90142-2; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shibata R, 2004, J BIOL CHEM, V279, P28670, DOI 10.1074/jbc.M402558200; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sugano M, 2004, MOL CELL BIOCHEM, V266, P127, DOI 10.1023/B:MCBI.0000049149.03964.c9; Wagner DR, 1998, CIRC RES, V82, P47; Wolk R, 2003, CIRCULATION, V108, P2206, DOI 10.1161/01.CIR.0000095270.85646.E8; Xiao CY, 2004, CIRCULATION, V109, P2462, DOI 10.1161/01.CIR.0000128046.54681.97; Xiao CY, 2001, CIRCULATION, V104, P2210, DOI 10.1161/hc4301.098058; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	50	816	884	0	80	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1096	1103		10.1038/nm1295	http://dx.doi.org/10.1038/nm1295			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16155579	Green Accepted			2022-12-25	WOS:000232492500031
J	Frey, BJ; Mohammad, N; Morris, QD; Zhang, W; Robinson, MD; Mnaimneh, S; Chang, R; Pan, Q; Sat, E; Rossant, J; Bruneau, BG; Aubin, JE; Blencowe, BJ; Hughes, TR				Frey, BJ; Mohammad, N; Morris, QD; Zhang, W; Robinson, MD; Mnaimneh, S; Chang, R; Pan, Q; Sat, E; Rossant, J; Bruneau, BG; Aubin, JE; Blencowe, BJ; Hughes, TR			Genome-wide analysis of mouse transcripts using exon microarrays and factor graphs	NATURE GENETICS			English	Article							EXPRESSION; ANNOTATION; SEQUENCE	Recent mammalian microarray experiments detected widespread transcription and indicated that there may be many undiscovered multiple- exon protein- coding genes. To explore this possibility, we labeled cDNA from unamplified, polyadenylation- selected RNA samples from 37 mouse tissues to microarrays encompassing 1.14 million exon probes. We analyzed these data using GenRate, a Bayesian algorithm that uses a genome- wide scoring function in a factor graph to infer genes. At a stringent exon false detection rate of 2.7%, GenRate detected 12,145 gene- length transcripts and confirmed 81% of the 10,000 most highly expressed known genes. Notably, our analysis showed that most of the 155,839 exons detected by GenRate were associated with known genes, providing microarray- based evidence that most multiple- exon genes have already been identified. GenRate also detected tens of thousands of potential new exons and reconciled discrepancies in current cDNA databases by ` stitching' new transcribed regions into previously annotated genes.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Toronto, ON M5S 3G4, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Hughes, TR (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	frey@psi.toronto.edu; t.hughes@utoronto.ca	Robinson, Mark D./O-2254-2019; Robinson, Mark D/A-6432-2015; Morris, Quaid/ABE-8343-2020	Robinson, Mark D./0000-0002-3048-5518; Robinson, Mark D/0000-0002-3048-5518; Morris, Quaid/0000-0002-2760-6999; Bruneau, Benoit/0000-0002-0804-7597; Aubin, Jane E./0000-0002-7268-5235				Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Garbarino JE, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-18; Hubbard T, 2005, NUCLEIC ACIDS RES, V33, pD447, DOI 10.1093/nar/gki138; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Krogh A, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P179; Kschischang FR, 2001, IEEE T INFORM THEORY, V47, P498, DOI 10.1109/18.910572; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Pontius J., 2003, NCBI HDB, P1; Pruitt KD, 2003, NUCLEIC ACIDS RES, V31, P34, DOI 10.1093/nar/gkg111; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Schadt EE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r73; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Wang J, 2004, NATURE, V431, DOI 10.1038/nature03016; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wong GKS, 2001, GENOME RES, V11, P1975, DOI 10.1101/gr.202401; Wyers F, 2005, CELL, V121, P725, DOI 10.1016/j.cell.2005.04.030; Xu Y, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P344; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305; Zhang Wen, 2004, J Biol, V3, P21, DOI 10.1186/jbiol16	25	34	36	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					991	996		10.1038/ng1630	http://dx.doi.org/10.1038/ng1630			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16127451				2022-12-25	WOS:000231591900026
J	Kamasaki, T; Arai, R; Osumi, M; Mabuchi, I				Kamasaki, T; Arai, R; Osumi, M; Mabuchi, I			Directionality of F-actin cables changes during the fission yeast cell cycle	NATURE CELL BIOLOGY			English	Article							SCHIZOSACCHAROMYCES-POMBE; V MYOSINS; GROWTH; LOCALIZATION; DIVISION; POLARITY; RING	Longitudinal F- actin cables are thought to be important for transporting materials for polarized cell growth in fission yeast. We show that most F- actin in the cables is oriented such that the barbed end faces the nearest cell tip during interphase; however, this directionality is reversed during mitosis. These orientations of F- actin ensure proper transport of materials to growing sites during these cell- cycle stages.	Univ Tokyo, Grad Sch Arts & Sci, Div Biol, Tokyo 1538902, Japan; Japan Womens Univ, Grad Sch Sci, Div Mat & Biol Funct Sci, Tokyo 1128681, Japan; Teikyo Univ, Inst Med Mycol, Tokyo 1920395, Japan	University of Tokyo; Japan Womens University; Teikyo University	Mabuchi, I (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Div Biol, Tokyo 1538902, Japan.	mabuchi@ims.u-tokyo.ac.jp						Arai R, 2002, J CELL SCI, V115, P887; Arai R, 1998, EUR J CELL BIOL, V76, P288, DOI 10.1016/S0171-9335(98)80007-1; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Feierbach B, 2004, J CELL BIOL, V165, P697, DOI 10.1083/jcb.200403090; Feierbach B, 2001, CURR BIOL, V11, P1656, DOI 10.1016/S0960-9822(01)00525-5; ISHIKAWA H, 1969, J CELL BIOL, V43, P312; LOWEY S, 1969, J MOL BIOL, V42, P1, DOI 10.1016/0022-2836(69)90483-5; MARKS J, 1985, EUR J CELL BIOL, V39, P27; Motegi F, 2001, MOL BIOL CELL, V12, P1367, DOI 10.1091/mbc.12.5.1367; Nakano K, 2002, J CELL SCI, V115, P4629, DOI 10.1242/jcs.00150; Pelham RJ, 2001, NAT CELL BIOL, V3, P235, DOI 10.1038/35060020; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Win TZ, 2001, J CELL SCI, V114, P69	14	45	45	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2005	7	9					916	U74		10.1038/ncb1295	http://dx.doi.org/10.1038/ncb1295			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	960NY	16136186				2022-12-25	WOS:000231601600016
J	Veiga, E; Cossart, P				Veiga, E; Cossart, P			Listeria hijacks the clathrin-dependent endocytic machinery to invade mammalian cells	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; MEDIATED ENDOCYTOSIS; DOWN-REGULATION; PROTEIN; MET; MONOCYTOGENES; INVASION; CBL; DEGRADATION; SUFFICIENT	The bacterial pathogen Listeria monocytogenes uses the surface protein InlB to invade a variety of cell types(1-3). The interaction of InlB with the hepatocyte growth- factor receptor, Met, is crucial for infection to occur(3). Remarkably, the ubiquitin ligase Cbl is rapidly recruited to InlB- activated Met(4). Recent studies have shown that ligand- dependent endocytosis of Met and other receptor tyrosine kinases is triggered by monoubiquitination of the receptor, a process that is mediated by Cbl(5-8). Here, we show that purified InlB induces the Cbl-dependent monoubiquitination and endocytosis of Met. We then demonstrate that the bacterium exploits the ubiquitin-dependent endocytosis machinery to invade mammalian cells. First, we show that L. monocytogenes colocalizes with Met, EEA1, Cbl, clathrin and dynamin during entry. Then, we assess the role of different proteins of the endocytic machinery during L. monocytogenes infection. Over- expression or down-regulation of Cbl, respectively, increases or decreases bacterial invasion. Furthermore, RNA interference- mediated knock- down of major components of the endocytic machinery ( for example, clathrin, dynamin, eps15, Grb2, CIN85, CD2AP, cortactin and Hrs), inhibit bacterial entry, establishing that the endocytic machinery is key to the bacterial internalization process.	Inst Pasteur, Unite Interact Bacteries Cellules, F-75015 Paris, France; INRA, USC2020, INSERM, U604, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cossart, P (corresponding author), Inst Pasteur, Unite Interact Bacteries Cellules, 28 Rue Dr Roux, F-75015 Paris, France.	pcossart@pasteur.fr	veiga, esteban/C-2129-2011	veiga, esteban/0000-0002-7333-2466				AGGELER J, 1982, J CELL BIOL, V94, P613, DOI 10.1083/jcb.94.3.613; Bierne H, 2005, J CELL SCI, V118, P1537, DOI 10.1242/jcs.02285; Bierne H, 2001, J CELL BIOL, V155, P101, DOI 10.1083/jcb.200104037; Braun L, 1997, MOL MICROBIOL, V25, P285, DOI 10.1046/j.1365-2958.1997.4621825.x; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; Cossart P, 2003, TRENDS CELL BIOL, V13, P23, DOI 10.1016/S0962-8924(02)00006-5; Dikic I, 2003, CELL MOL LIFE SCI, V60, P1805, DOI 10.1007/s00018-003-3029-4; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Harvey HA, 2001, MOL MICROBIOL, V42, P659, DOI 10.1046/j.1365-2958.2001.02666.x; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Huang FT, 2005, MOL BIOL CELL, V16, P1268, DOI 10.1091/mbc.E04-09-0832; Ireton K, 1999, J BIOL CHEM, V274, P17025, DOI 10.1074/jbc.274.24.17025; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kermorgant S, 2003, J BIOL CHEM, V278, P28921, DOI 10.1074/jbc.M302116200; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Owen DJ, 2004, BIOCHEM SOC T, V32, P1, DOI 10.1042/BST0320001; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Pizarro-Cerda J, 2002, METHOD MICROBIOL, V31, P161, DOI 10.1016/S0580-9517(02)31009-2; Pizarro-Cerda J, 2002, CELL MICROBIOL, V4, P101, DOI 10.1046/j.1462-5822.2002.00169.x; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; Taher TEI, 2002, J IMMUNOL, V169, P3793, DOI 10.4049/jimmunol.169.7.3793; VanNhieu GT, 1996, J BIOL CHEM, V271, P7665, DOI 10.1074/jbc.271.13.7665; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774	33	240	249	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2005	7	9					894	U46		10.1038/ncb1292	http://dx.doi.org/10.1038/ncb1292			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	960NY	16113677				2022-12-25	WOS:000231601600013
J	Badovinac, VP; Messingham, KAN; Jabbari, A; Haring, JS; Harty, JT				Badovinac, VP; Messingham, KAN; Jabbari, A; Haring, JS; Harty, JT			Accelerated CD8(+) T-cell memory and prime-boost response after dendritic-cell vaccination	NATURE MEDICINE			English	Article							CUTTING EDGE; LISTERIA-MONOCYTOGENES; SELECTIVE EXPRESSION; PROTECTIVE IMMUNITY; VIRAL-INFECTION; EXPANSION; EFFECTOR; RECEPTOR; NAIVE; DIFFERENTIATION	Efficient boosting of memory T- cell numbers to protective levels generally requires a relatively long interval between immunizations. Decreasing this interval could be crucial in biodefense and cancer immunotherapy, in which rapid protective responses are essential. Here, we show that vaccination with peptide- coated dendritic cells (DCs) generated CD8(+) T cells with the phenotype and function of memory cells within 4 - 6 d. These early memory CD8(+) T cells underwent vigorous secondary expansion in response to a variety of booster immunizations, leading to elevated numbers of effector and memory T cells and enhanced protective immunity. Coinjection of CpG oligodeoxynucleotides, potent inducers of inflammation that did not alter the duration of DC antigen display, prevented the rapid generation of memory T cells in wild- type mice but not in mice lacking the interferon (IFN)-gamma receptor. These data show that DC vaccination stimulates a pathway of accelerated generation of memory T cells, and suggest that events of inflammation, including the action of IFN-gamma on the responding T cells, control the rate of development of memory CD8(+) T cells.	Univ Iowa, Dept Microbiol, Iowa City, IA 52240 USA; Univ Iowa, Interdisciplinary Grad Program Immunol, Med Labs 1190, Iowa City, IA 52240 USA	University of Iowa; University of Iowa	Harty, JT (corresponding author), Univ Iowa, Dept Microbiol, 3-512 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52240 USA.	john-harty@uiowa.edu	Messingham, Kelly/AAD-8388-2020; badovinac, Vladimir/O-7760-2015	Messingham, Kelly/0000-0003-4630-0722; Jabbari, Ali/0000-0002-8559-7314; Harty, John/0000-0001-7266-2802; Badovinac, Vladimir/0000-0003-3180-2439	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042767, R01AI046653, R37AI042767, R01AI050073, T32AI007511, R21AI042767] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50073, AI46653, T32AI007511, AI42767, T32AI0726] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		An LL, 1996, INFECT IMMUN, V64, P1685, DOI 10.1128/IAI.64.5.1685-1693.1996; Badovinac VP, 2003, J IMMUNOL, V170, P4933, DOI 10.4049/jimmunol.170.10.4933; Badovinac VP, 2003, IMMUNITY, V18, P463, DOI 10.1016/S1074-7613(03)00079-7; Badovinac VP, 2003, NAT IMMUNOL, V4, P212, DOI 10.1038/ni0303-212; Badovinac VP, 2004, NAT IMMUNOL, V5, P809, DOI 10.1038/ni1098; Badovinac VP, 2000, J IMMUNOL METHODS, V238, P107, DOI 10.1016/S0022-1759(00)00153-8; Badovinac VP, 2000, SCIENCE, V290, P1354, DOI 10.1126/science.290.5495.1354; Badovinac VP, 2002, NAT IMMUNOL, V3, P619, DOI 10.1038/ni804; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bouwer HGA, 1996, INFECT IMMUN, V64, P3728, DOI 10.1128/IAI.64.9.3728-3735.1996; BRUNDAGE RA, 1993, P NATL ACAD SCI USA, V90, P11890, DOI 10.1073/pnas.90.24.11890; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Edelson BT, 1999, J IMMUNOL, V163, P4087; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Foulds KE, 2002, J IMMUNOL, V168, P1528, DOI 10.4049/jimmunol.168.4.1528; Hamilton SE, 2004, NAT IMMUNOL, V5, P159, DOI 10.1038/ni1026; Hamilton SE, 2002, J IMMUNOL, V169, P4936, DOI 10.4049/jimmunol.169.9.4936; Haring JS, 2005, J IMMUNOL, V174, P6791, DOI 10.4049/jimmunol.174.11.6791; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; HARTY JT, 1995, IMMUNITY, V3, P109, DOI 10.1016/1074-7613(95)90163-9; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Huster KM, 2004, P NATL ACAD SCI USA, V101, P5610, DOI 10.1073/pnas.0308054101; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009; Kerksiek KM, 1999, J EXP MED, V190, P195, DOI 10.1084/jem.190.2.195; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; Mercado R, 2000, J IMMUNOL, V165, P6833, DOI 10.4049/jimmunol.165.12.6833; Paczesny S, 2004, J EXP MED, V199, P1503, DOI 10.1084/jem.20032118; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; Roberts AD, 2004, J IMMUNOL, V172, P6533, DOI 10.4049/jimmunol.172.11.6533; SALLUSTO F, 2004, ANNU REV IMMUNOL, V22, P683; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969; Shen H, 1998, CELL, V92, P535, DOI 10.1016/S0092-8674(00)80946-0; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; Wagner H, 2002, CURR OPIN MICROBIOL, V5, P62, DOI 10.1016/S1369-5274(02)00287-4; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Wong P, 2004, J IMMUNOL, V172, P7239, DOI 10.4049/jimmunol.172.12.7239; Wong P, 2001, J IMMUNOL, V166, P5864, DOI 10.4049/jimmunol.166.10.5864; Woodland DL, 2004, TRENDS IMMUNOL, V25, P98, DOI 10.1016/j.it.2003.11.009	50	316	338	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					748	756		10.1038/nm1257	http://dx.doi.org/10.1038/nm1257			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15951824				2022-12-25	WOS:000230304200031
J	Fichtner-Feigl, S; Strober, W; Kawakami, K; Puri, RK; Kitani, A				Fichtner-Feigl, S; Strober, W; Kawakami, K; Puri, RK; Kitani, A			IL-13 signaling through the IL-13 alpha 2 receptor is involved in induction of TGF-beta 1 production and fibrosis	NATURE MEDICINE			English	Article							GROWTH FACTOR-BETA-1 GENE; NK-T-CELLS; PULMONARY-FIBROSIS; ULCERATIVE-COLITIS; OXAZOLONE COLITIS; TISSUE FIBROSIS; ALPHA-2 CHAIN; IN-VIVO; MICE; INTERLEUKIN-13	Interleukin (IL)-13 is a major inducer of fibrosis in many chronic infectious and autoimmune diseases. In studies of the mechanisms underlying such induction, we found that IL-13 induces transforming growth factor (TGF)-beta(1) in macrophages through a two-stage process involving, first, the induction of a receptor formerly considered to function only as a decoy receptor, IL-13R alpha(2). Such induction requires IL-13 (or IL-4) and tumor necrosis factor (TNF)-alpha. Second, it involves IL-13 signaling through IL-13R alpha(2) to activate an AP-1 variant containing c-jun and Fra-2, which then activates the TGFB1 promoter. In vivo, we found that prevention of IL-13R alpha(2) expression reduced production of TGF-beta(1) in oxazolone-induced colitis and that prevention of IL-13Ra2 expression, Il13ra2 gene silencing or blockade of IL-13R alpha(2) signaling led to marked downregulation of TGF-beta(1) production and collagen deposition in bleomycin-induced lung fibrosis. These data suggest that IL-13R alpha(2) signaling during prolonged inflammation is an important therapeutic target for the prevention of TGF-beta(1)-mediated fibrosis.	NIAID, NIH, Mucosal Immun Sect, Lab Host Def, Bethesda, MD 20892 USA; Univ Regensburg, Dept Surg, Med Ctr, D-93053 Regensburg, Germany; US FDA, Lab Mol Tumor Biol, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Regensburg; National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)	Strober, W (corresponding author), NIAID, NIH, Mucosal Immun Sect, Lab Host Def, Bldg 10-CRC 5W3864,10 Ctr Dr, Bethesda, MD 20892 USA.	wstrober@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000432, Z01AI000432] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Belperio JA, 2002, AM J RESP CELL MOL, V27, P419, DOI 10.1165/rcmb.2002-0009OC; Blease K, 2001, J IMMUNOL, V167, P6583, DOI 10.4049/jimmunol.167.11.6583; Blease K, 2002, AM J PATHOL, V160, P481, DOI 10.1016/S0002-9440(10)64867-5; Boirivant M, 1998, J EXP MED, V188, P1929, DOI 10.1084/jem.188.10.1929; Buchwald AB, 2002, J AM COLL CARDIOL, V39, P732, DOI 10.1016/S0735-1097(01)01797-1; Ceponis PJM, 2000, J BIOL CHEM, V275, P29132, DOI 10.1074/jbc.M003516200; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; David MD, 2003, ONCOGENE, V22, P3386, DOI 10.1038/sj.onc.1206352; de Lalla C, 2004, J IMMUNOL, V173, P1417, DOI 10.4049/jimmunol.173.2.1417; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Fuss IJ, 2004, J CLIN INVEST, V113, P1490, DOI 10.1172/JCI200419836; Ha H, 2001, KIDNEY INT, V59, P463, DOI 10.1046/j.1523-1755.2001.059002463.x; Hasegawa M, 1997, J RHEUMATOL, V24, P328; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Jo N, 2002, CURR EYE RES, V24, P465, DOI 10.1076/ceyr.24.6.465.8600; Kaviratne M, 2004, J IMMUNOL, V173, P4020, DOI 10.4049/jimmunol.173.6.4020; Kawakami K, 2001, J EXP MED, V194, P1743, DOI 10.1084/jem.194.12.1743; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kitani A, 2000, J EXP MED, V192, P41, DOI 10.1084/jem.192.1.41; Kitani A, 2003, J EXP MED, V198, P1179, DOI 10.1084/jem.20030917; Kraus J, 2002, FASEB J, V16, P304, DOI 10.1096/fj.02-0482fje; Lee CG, 2004, J EXP MED, V200, P377, DOI 10.1084/jem.20040104; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V300, P464, DOI 10.1016/S0006-291X(02)02807-3; WOOLEY PH, 1993, J IMMUNOL, V151, P6602; Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626; Wu ZL, 2004, CELL BIOCHEM FUNCT, V22, P237, DOI 10.1002/cbf.1096; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Wynn TA, 2004, HEPATOLOGY, V39, P676, DOI 10.1002/hep.20102; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zhang K, 1997, J IMMUNOL, V158, P954; Zhao JS, 2002, AM J PHYSIOL-LUNG C, V282, pL585, DOI 10.1152/ajplung.00151.2001; Zheng T, 2003, J ALLERGY CLIN IMMUN, V111, P720, DOI 10.1067/mai.2003.1383	44	661	715	1	54	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					99	106		10.1038/nm1332	http://dx.doi.org/10.1038/nm1332			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16327802				2022-12-25	WOS:000234419000058
J	Lok, C				Lok, C			Thinking outside the cell	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2006	24	1					111	112		10.1038/nbt0106-111	http://dx.doi.org/10.1038/nbt0106-111			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	001SE	16404400				2022-12-25	WOS:000234555800033
J	Malikov, V; Cytrynbaum, EN; Kashina, A; Mogilner, A; Rodionov, V				Malikov, V; Cytrynbaum, EN; Kashina, A; Mogilner, A; Rodionov, V			Centering of a radial microtubule array by translocation along microtubules spontaneously nucleated in the cytoplasm	NATURE CELL BIOLOGY			English	Article							DYNAMICS; MICROSCOPY	Positioning of a radial array of microtubules (MTs) in the cell centre is crucial for cytoplasmic organization, but the mechanisms of such centering are difficult to study in intact cells that have pre-formed radial arrays. Here, we use cytoplasmic fragments of melanophores, and cytoplasts of BS-C-1 cells to study MT centering mechanisms. Using live imaging and computer modelling, we show that the MT aster finds a central location in the cytoplasm by moving along spontaneously nucleated non-astral MTs towards a point at which MT nucleation events occur equally on all sides. We hypothesize that similar mechanisms, in the presence of the centrosome, contribute to this centering mechanism and ensure the robustness of cytoplasmic organization.	Univ Connecticut, Ctr Hlth, Dept Cell Biol, Farmington, CT 06032 USA; Univ Connecticut, Ctr Hlth, Ctr Cell Anal & Modeling, Farmington, CT 06032 USA; Univ British Columbia, Dept Math, Vancouver, BC V6T 1Z2, Canada; Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Calif Davis, Dept Math, Lab Cell & Computat Biol, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Davis, CA 95616 USA	University of Connecticut; University of Connecticut; University of British Columbia; University of Pennsylvania; University of California System; University of California Davis; University of California System; University of California Davis	Rodionov, V (corresponding author), Univ Connecticut, Ctr Hlth, Dept Cell Biol, Farmington, CT 06032 USA.	rodionov@nso.uchc.edu	Mogilner, Alex/A-3135-2008	Cytrynbaum, Eric/0000-0001-8789-1667	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068952] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM68952] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Burakov A, 2003, J CELL BIOL, V162, P963, DOI 10.1083/jcb.200305082; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; Malikov V, 2004, MOL BIOL CELL, V15, P2742, DOI 10.1091/mbc.E03-10-0770; Nascimento AA, 2003, ANNU REV CELL DEV BI, V19, P469, DOI 10.1146/annurev.cellbio.19.111401.092937; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; Rios RM, 2004, CELL, V118, P323; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; Rodionov V, 2001, METHOD CELL BIOL, V67, P43; Rodionov VI, 1997, NATURE, V386, P170, DOI 10.1038/386170a0; RODIONOV VI, 1994, J CELL BIOL, V126, P1455, DOI 10.1083/jcb.126.6.1455; Rodionov VI, 1997, SCIENCE, V275, P215, DOI 10.1126/science.275.5297.215; Rodionov VI, 1998, CURR BIOL, V8, P165, DOI 10.1016/S0960-9822(98)70064-8; Vallee RB, 2005, TRENDS CELL BIOL, V15, P288, DOI 10.1016/j.tcb.2005.04.005; Vorobiev I, 2001, P NATL ACAD SCI USA, V98, P10160, DOI 10.1073/pnas.181354198; Waterman-Storer CM, 1998, CURR BIOL, V8, P1227, DOI 10.1016/S0960-9822(07)00515-5; Yvon AMC, 1997, J CELL SCI, V110, P2391	17	33	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1213	1218		10.1038/ncb1332	http://dx.doi.org/10.1038/ncb1332			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16273095				2022-12-25	WOS:000233748900014
J	Parekh, SH; Chaudhuri, O; Theriot, JA; Fletcher, DA				Parekh, SH; Chaudhuri, O; Theriot, JA; Fletcher, DA			Loading history determines the velocity of actin-network growth	NATURE CELL BIOLOGY			English	Article							LISTERIA-MONOCYTOGENES; MOTILITY; FORCE; POLYMERIZATION; MICROTUBULES; PROPULSION; FILAMENTS; VESICLES; MYOSIN; DRIVEN	Directional polymerization of actin filaments in branched networks is one of the most powerful force-generating systems in eukaryotic cells(1). Growth of densely cross-linked actin networks drives cell crawling(2), intracellular transport of vesicles and organelles(3,4) and movement of intracellular pathogens such as Listeria monocytogenes'. Using a modified atomic force microscope (AFM), we obtained force-velocity (Fv) measurements of growing actin networks in vitro until network elongation ceased at the stall force. We found that the growth velocity of a branched actin network against increasing forces is load-independent over a wide range of forces before a convex decline to stall. Surprisingly, when force was decreased on a growing network, the velocity increased to a value greater than the previous velocity, such that two or more stable growth velocities can exist at a single load. These results demonstrate that a single Fv relationship does not capture the complete behaviour of this system, unlike other molecular motors in cells, because the growth velocity depends on loading history rather than solely on the instantaneous load.	Univ Calif Berkeley, UCSF UC Berkeley Joint Grad Grp Bioengn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	University of California System; University of California Berkeley; University of California San Francisco; University of California System; University of California Berkeley; Stanford University	Fletcher, DA (corresponding author), Univ Calif Berkeley, UCSF UC Berkeley Joint Grad Grp Bioengn, Berkeley, CA 94720 USA.	fletch@berkeley.edu	Theriot, Julie/HHN-2034-2022	Chaudhuri, Ovijit/0000-0002-9287-3401; Theriot, Julie/0000-0002-2334-2535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036929] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI036929] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bustamante C, 2004, ANNU REV BIOCHEM, V73, P705, DOI 10.1146/annurev.biochem.72.121801.161542; Cameron LA, 2000, NAT REV MOL CELL BIO, V1, P110, DOI 10.1038/35040061; Cameron LA, 1999, P NATL ACAD SCI USA, V96, P4908, DOI 10.1073/pnas.96.9.4908; Carlsson AE, 2003, BIOPHYS J, V84, P2907, DOI 10.1016/S0006-3495(03)70018-6; Dickinson RB, 2002, BIOPHYS J, V82, P605, DOI 10.1016/S0006-3495(02)75425-8; Dogterom M, 1997, SCIENCE, V278, P856, DOI 10.1126/science.278.5339.856; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Gerbal F, 2000, BIOPHYS J, V79, P2259, DOI 10.1016/S0006-3495(00)76473-3; HILL TL, 1982, INT REV CYTOL, V78, P1, DOI 10.1016/S0074-7696(08)60105-9; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Marcy Y, 2004, P NATL ACAD SCI USA, V101, P5992, DOI 10.1073/pnas.0307704101; McGrath JL, 2003, CURR BIOL, V13, P329, DOI 10.1016/S0960-9822(03)00051-4; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Mogilner A, 2003, BIOPHYS J, V84, P1591, DOI 10.1016/S0006-3495(03)74969-8; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Pollard TD, 2003, CELL, V113, P549, DOI 10.1016/S0092-8674(03)00357-X; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schwartz IM, 2004, CURR BIOL, V14, P1094, DOI 10.1016/j.cub.2004.06.023; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Upadhyaya A, 2003, CURR BIOL, V13, pR734, DOI 10.1016/j.cub.2003.08.051; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wiesner S, 2003, J CELL BIOL, V160, P387, DOI 10.1083/jcb.200207148	27	154	158	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1219	1223		10.1038/ncb1336	http://dx.doi.org/10.1038/ncb1336			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16299496				2022-12-25	WOS:000233748900015
J	Bitoun, M; Maugenre, S; Jeannet, PY; Lacene, E; Ferrer, X; Laforet, P; Martin, JJ; Laporte, J; Lochmuller, H; Beggs, AH; Fardeau, M; Eymard, B; Romero, NB; Guicheney, P				Bitoun, M; Maugenre, S; Jeannet, PY; Lacene, E; Ferrer, X; Laforet, P; Martin, JJ; Laporte, J; Lochmuller, H; Beggs, AH; Fardeau, M; Eymard, B; Romero, NB; Guicheney, P			Mutations in dynamin 2 cause dominant centronuclear myopathy	NATURE GENETICS			English	Article							DISEASE	Autosomal dominant centronuclear myopathy is a rare congenital myopathy characterized by delayed motor milestones and muscular weakness. In 11 families affected by centronuclear myopathy, we identified recurrent and de novo missense mutations in the gene dynamin 2 (DNM2, 19p13.2), which encodes a protein involved in endocytosis and membrane trafficking, actin assembly and centrosome cohesion. The transfected mutants showed reduced labeling in the centrosome, suggesting that DNM2 mutations might cause centronuclear myopathy by interfering with centrosome function.	UPMC, Grp Hosp Pitie Salpetriere, IFR14, Inst Myol,INSERM,U582, F-75651 Paris, France; CHU Vaudois, Dept Pediat, Neuropediat Unit, CH-1011 Lausanne, Switzerland; CHU Haut Leveque, Dept Neurol, Bordeaux, France; Born Bunge Inst, Neuropathol Lab, Antwerp, Belgium; Coll France, ULP, INSERM, CNRS,IGBMC,Dept Mol Pathol, Illkirch Graffenstaden, France; Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany; Harvard Univ, Sch Med, Childrens Hosp Boston, Div Genet, Boston, MA USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU Bordeaux; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Munich; Harvard University; Boston Children's Hospital; Harvard Medical School	Guicheney, P (corresponding author), UPMC, Grp Hosp Pitie Salpetriere, IFR14, Inst Myol,INSERM,U582, 47 Blvd Hop, F-75651 Paris, France.	p.guicheney@myologie.chups.jussieu.fr	Laporte, Jocelyn/H-6801-2016; Guicheney, Pascale/D-1034-2017; Bitoun, Marc/M-4720-2017; laporte, jocelyn/J-7008-2012; laporte, jocelyn/O-4888-2019	Guicheney, Pascale/0000-0002-7663-2050; Bitoun, Marc/0000-0002-4188-7918; Beggs, Alan/0000-0001-8818-0568; Lochmuller, Hanns/0000-0003-2324-8001				Chen YJ, 2004, NAT STRUCT MOL BIOL, V11, P574, DOI 10.1038/nsmb762; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; FARDEAU M, 1994, MYOLOGY, P1500; Jeannet PY, 2004, NEUROLOGY, V62, P1484, DOI 10.1212/01.WNL.0000124388.67003.56; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Laporte J, 2003, HUM MOL GENET, V12, pR285, DOI 10.1093/hmg/ddg273; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Reinsch S, 1998, J CELL SCI, V111, P2283; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; SPIRO AJ, 1966, ARCH NEUROL-CHICAGO, V14, P1, DOI 10.1001/archneur.1966.00470070005001; TASSIN AM, 1985, J CELL BIOL, V100, P35, DOI 10.1083/jcb.100.1.35; Thompson HM, 2004, NAT CELL BIOL, V6, P335, DOI 10.1038/ncb1112; Yoo JY, 2005, BIOCHEM BIOPH RES CO, V328, P424, DOI 10.1016/j.bbrc.2004.12.179; Zuchner S, 2005, NAT GENET, V37, P289, DOI 10.1038/ng1514	15	303	310	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2005	37	11					1207	1209		10.1038/ng1657	http://dx.doi.org/10.1038/ng1657			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16227997	Green Submitted			2022-12-25	WOS:000233045200018
J	Silva, JM; Li, MZ; Chang, K; Ge, W; Golding, MC; Rickles, RJ; Siolas, D; Hu, G; Paddison, PJ; Schlabach, MR; Sheth, N; Bradshaw, J; Burchard, J; Kulkarni, A; Cavet, G; Sachidanandam, R; McCombie, WR; Cleary, MA; Elledge, SJ; Hannon, GJ				Silva, JM; Li, MZ; Chang, K; Ge, W; Golding, MC; Rickles, RJ; Siolas, D; Hu, G; Paddison, PJ; Schlabach, MR; Sheth, N; Bradshaw, J; Burchard, J; Kulkarni, A; Cavet, G; Sachidanandam, R; McCombie, WR; Cleary, MA; Elledge, SJ; Hannon, GJ			Second-generation shRNA libraries covering the mouse and human genomes	NATURE GENETICS			English	Article							SHORT HAIRPIN RNAS; MAMMALIAN-CELLS; ESCHERICHIA-COLI; MICROPROCESSOR COMPLEX; CAENORHABDITIS-ELEGANS; INTERFERING RNAS; NUCLEAR EXPORT; MESSENGER-RNAS; POLYMERASE-II; C-ELEGANS	Loss-of-function phenotypes often hold the key to understanding the connections and biological functions of biochemical pathways. We and others previously constructed libraries of short hairpin RNAs that allow systematic analysis of RNA interference-induced phenotypes in mammalian cells. Here we report the construction and validation of second-generation short hairpin RNA expression libraries designed using an increased knowledge of RNA interference biochemistry. These constructs include silencing triggers designed to mimic a natural microRNA primary transcript, and each target sequence was selected on the basis of thermodynamic criteria for optimal small RNA performance. Biochemical and phenotypic assays indicate that the new libraries are substantially improved over first-generation reagents. We generated large-scale-arrayed, sequence-verified libraries comprising more than 140,000 second-generation short hairpin RNA expression plasmids, covering a substantial fraction of all predicted genes in the human and mouse genomes. These libraries are available to the scientific community.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Genet,Ctr Genet & Genom, Boston, MA 02115 USA; Watson Sch Biol Sci, Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Rosetta Inpharmat LLC, Seattle, WA 98109 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cold Spring Harbor Laboratory; Merck & Company	Elledge, SJ (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Genet,Ctr Genet & Genom, Room 158D,NRB,77 Ave Louis Pasteur, Boston, MA 02115 USA.	selledge@genetics.med.harvard.edu; hannon@cshl.edu	Hu, Guang/E-7474-2016; sachidanandam, ravi/Q-6916-2019; Hannon, Gregory/AAB-3568-2019	Hu, Guang/0000-0003-0437-4723; sachidanandam, ravi/0000-0001-9844-4459; GOLDING, MICHAEL/0000-0003-1631-2175; McCombie, W. Richard/0000-0003-1899-0682	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008444] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Carmell MA, 2004, NAT STRUCT MOL BIOL, V11, P214, DOI 10.1038/nsmb729; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; CHALKER AF, 1988, GENE, V71, P201, DOI 10.1016/0378-1119(88)90092-3; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; Cleary MA, 2004, NAT METHODS, V1, P241, DOI 10.1038/nmeth724; Dasgupta R, 2004, ONCOGENE, V23, P8359, DOI 10.1038/sj.onc.1208028; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; ELLEDGE SJ, 1985, J BACTERIOL, V162, P777, DOI 10.1128/JB.162.2.777-783.1985; Fraser A, 2004, ONCOGENE, V23, P8346, DOI 10.1038/sj.onc.1208044; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg158; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Li MZ, 2005, NAT GENET, V37, P311, DOI 10.1038/ng1505; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Nakayashiki H, 2005, FUNGAL GENET BIOL, V42, P275, DOI 10.1016/j.fgb.2005.01.002; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Silva J, 2004, ONCOGENE, V23, P8401, DOI 10.1038/sj.onc.1208176; Siolas D, 2005, NAT BIOTECHNOL, V23, P227, DOI 10.1038/nbt1052; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Stegmeier F, 2005, P NATL ACAD SCI USA, V102, P13212, DOI 10.1073/pnas.0506306102; Tang GL, 2004, TRENDS BIOTECHNOL, V22, P463, DOI 10.1016/j.tibtech.2004.07.009; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100	46	501	560	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2005	37	11					1281	1288		10.1038/ng1650	http://dx.doi.org/10.1038/ng1650			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16200065				2022-12-25	WOS:000233045200031
J	Bryan, NS; Fernandez, BO; Bauer, SM; Gauria-Saura, MF; Milsom, AB; Rassaf, T; Maloney, RE; Bharti, A; Rodriguez, J; Feelisch, M				Bryan, NS; Fernandez, BO; Bauer, SM; Gauria-Saura, MF; Milsom, AB; Rassaf, T; Maloney, RE; Bharti, A; Rodriguez, J; Feelisch, M			Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues	NATURE CHEMICAL BIOLOGY			English	Article							N-NITROSO COMPOUNDS; IN-VIVO; ISCHEMIA-REPERFUSION; HYPOXIC VASODILATION; BIOLOGICAL TISSUES; OXIDE; NITRATE; METABOLISM; OXIDATION; PROTEINS		Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA; Boston Univ, Sch Med, Ctr Mol Stress Response, Boston, MA 02118 USA	Boston University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Boston University	Feelisch, M (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA.	feelisch@bu.edu	Fernandez, Bernadette/AAG-7202-2020; Feelisch, Martin/C-3042-2008	Fernandez, Bernadette/0000-0001-6337-0381; Feelisch, Martin/0000-0003-2320-1158; Bharti, Ajit/0000-0001-7972-6688	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069029] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69029] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balashova N, 2005, J BIOL CHEM, V280, P2186, DOI 10.1074/jbc.M411545200; Bryan NS, 2004, P NATL ACAD SCI USA, V101, P4308, DOI 10.1073/pnas.0306706101; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Crawford JH, 2004, BLOOD, V104, P1375, DOI 10.1182/blood-2004-03-0880; Duranski MR, 2005, J CLIN INVEST, V115, P1232, DOI 10.1172/JCI200522493; Fang J, 2003, CANCER RES, V63, P3567; FEELISCH M, 1995, TRENDS ECOL EVOL, V10, P496, DOI 10.1016/S0169-5347(00)89206-X; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; GANGOLLI SD, 1994, EUR J PHARM-ENVIRON, V292, P1, DOI 10.1016/0926-6917(94)90022-1; Ghosal A, 2003, BIOPHARM DRUG DISPOS, V24, P375, DOI 10.1002/bdd.374; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2004, J CLIN INVEST, V113, P19, DOI 10.1172/JCI200420664; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Kelm M, 1999, BBA-BIOENERGETICS, V1411, P273, DOI 10.1016/S0005-2728(99)00020-1; Kim-Shapiro DB, 2005, J INORG BIOCHEM, V99, P237, DOI 10.1016/j.jinorgbio.2004.10.034; Lundberg JO, 2004, FREE RADICAL BIO MED, V37, P395, DOI 10.1016/j.freeradbiomed.2004.04.027; Lundberg JO, 2004, NAT REV MICROBIOL, V2, P593, DOI 10.1038/nrmicro929; Lundberg JO, 2005, ARTERIOSCL THROM VAS, V25, P915, DOI 10.1161/01.ATV.0000161048.72004.c2; MALYSHEV IY, 1995, FEBS LETT, V370, P159, DOI 10.1016/0014-5793(95)00801-F; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; MEAH MN, 1994, FOOD ADDIT CONTAM, V11, P519, DOI 10.1080/02652039409374250; Motterlini R, 2002, ANTIOXID REDOX SIGN, V4, P615, DOI 10.1089/15230860260220111; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Panesar NS, 2000, TOXICOL APPL PHARM, V169, P222, DOI 10.1006/taap.2000.9079; Papp E, 2003, BIOFACTORS, V17, P249, DOI 10.1002/biof.5520170124; PARKS NJ, 1981, SCIENCE, V212, P58, DOI 10.1126/science.7209517; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; Rath MM, 1942, J PHARMACOL EXP THER, V76, P33; Reichert E. T., 1880, AM J MED SCI, V159, P158; Schulz R, 2004, CARDIOVASC RES, V61, P402, DOI 10.1016/j.cardiores.2003.09.019; SPIEGELHALDER B, 1976, FOOD COSMET TOXICOL, V14, P545, DOI 10.1016/S0015-6264(76)80005-3; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; THAYER JR, 1982, SCIENCE, V217, P151; Thomas DD, 2003, ANTIOXID REDOX SIGN, V5, P307, DOI 10.1089/152308603322110887; Vleeming W, 1997, FOOD CHEM TOXICOL, V35, P615, DOI 10.1016/S0278-6915(97)00015-X; Webb A, 2004, P NATL ACAD SCI USA, V101, P13683, DOI 10.1073/pnas.0402927101; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	41	397	423	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2005	1	5					290	297		10.1038/nchembio734	http://dx.doi.org/10.1038/nchembio734			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GN	16408059				2022-12-25	WOS:000232649100014
J	Itoh, T; Toyoda, A; Taylor, TD; Sakaki, Y; Hattori, M				Itoh, T; Toyoda, A; Taylor, TD; Sakaki, Y; Hattori, M			Identification of large ancient duplications associated with human gene deserts	NATURE GENETICS			English	Article							SEGMENTAL DUPLICATIONS; DNA-SEQUENCE; HUMAN GENOME; EVOLUTION	We identified 15 regions of >1 Mb in the human genome composed of large ancient local duplications corresponding to gene deserts. We detected these intrachromosomal duplications in mouse and dog but not in chicken; they present as patches of similarity as low as 60%. These findings suggest that some human gene deserts originated from duplications of segments lacking genes in a mammalian common ancestor.	Mitsubishi Res Inst Inc, Adv Sci & Technol Res Ctr, Tokyo 1008141, Japan; RIKEN Genom Sci Ctr, Genome Core Technol Facil, Kanagawa 2300045, Japan; RIKEN Genom Sci Ctr, Computat & Expt Syst Biol Grp, Kanagawa 2300045, Japan; Kitasato Univ, Kitasato Inst Life Sci, Kanagawa 2288555, Japan	Mitsubishi Research Institute; RIKEN; RIKEN; Kitasato University	Hattori, M (corresponding author), Mitsubishi Res Inst Inc, Adv Sci & Technol Res Ctr, Tokyo 1008141, Japan.	takehiko@mri.co.jp; hattori@gsc.riken.jp	Hattori, Masahira/C-6958-2016; Itoh, Takehiko/E-8873-2014; Taylor, Todd/A-7121-2009; Hattori, Masahira/AAD-3785-2019	Hattori, Masahira/0000-0001-9467-0344; Itoh, Takehiko/0000-0002-6113-557X; Taylor, Todd/0000-0003-4247-6253; 				Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Grimwood J, 2004, NATURE, V428, P529, DOI 10.1038/nature02399; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Hillier LW, 2005, NATURE, V434, P724, DOI 10.1038/nature03466; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Nobrega MA, 2004, NATURE, V431, P988, DOI 10.1038/nature03022; Ovcharenko I, 2005, GENOME RES, V15, P137, DOI 10.1101/gr.3015505; Pevzner P, 2003, P NATL ACAD SCI USA, V100, P7672, DOI 10.1073/pnas.1330369100; Samonte RV, 2002, NAT REV GENET, V3, P65, DOI 10.1038/nrg705; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	14	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1041	1043		10.1038/ng1648	http://dx.doi.org/10.1038/ng1648			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16186813				2022-12-25	WOS:000232185600013
J	Narushima, M; Kobayashi, N; Okitsu, T; Tanaka, Y; Li, SA; Chen, Y; Miki, A; Tanaka, K; Nakaji, S; Takei, K; Gutierrez, AS; Rivas-Carrillo, JD; Navarro-Alvarez, N; Jun, HS; Westerman, KA; Noguchi, H; Lakey, JRT; Leboulch, P; Tanaka, N; Yoon, JW				Narushima, M; Kobayashi, N; Okitsu, T; Tanaka, Y; Li, SA; Chen, Y; Miki, A; Tanaka, K; Nakaji, S; Takei, K; Gutierrez, AS; Rivas-Carrillo, JD; Navarro-Alvarez, N; Jun, HS; Westerman, KA; Noguchi, H; Lakey, JRT; Leboulch, P; Tanaka, N; Yoon, JW			A human beta-cell line for transplantation therapy to control type 1 diabetes	NATURE BIOTECHNOLOGY			English	Article							INSULIN-PRODUCING CELLS; PANCREATIC-ISLET CELLS; IN-VITRO; GENE; ESTABLISHMENT; MICE; DIFFERENTIATION; IDENTIFICATION; HYPERGLYCEMIA; GROWTH	A human pancreatic b-cell line that is functionally equivalent to primary b-cells has not been available. We established a reversibly immortalized human b-cell clone ( NAKT-15) by transfection of primary human b-cells with a retroviral vector containing simian virus 40 large T-antigen (SV40T) and human telomerase reverse transcriptase ( hTERT) cDNAs flanked by paired loxP recombination targets, which allow deletion of SV40T and TERT by Cre recombinase. Reverted NAKT-15 cells expressed b-cell transcription factors ( Isl-1, Pax 6, Nkx 6.1, Pdx-1), prohormone convertases 1/3 and 2, and secretory granule proteins, and secreted insulin in response to glucose, similar to normal human islets. Transplantation of NAKT-15 cells into streptozotocin-induced diabetic severe combined immunodeficiency mice resulted in perfect control of blood glucose within 2 weeks; mice remained normoglycemic for longer than 30 weeks. The establishment of this cell line is one step toward a potential cure of diabetes by transplantation.	Rosalind Franklin Comprehens Diabet Ctr, Chicago Med Sch, N Chicago, IL 60064 USA; Okayama Univ, Grad Sch Med & Dent, Dept Surg, Okayama 7008558, Japan; Kyoto Univ Hosp, Dept Transplant Surg, Sakyo Ku, Kyoto 6068507, Japan; Kuraray Med Co Ltd, Dept Med Prod, Kurashiki, Okayama 7108622, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Neurosci, Okayama 7008558, Japan; Chosun Univ, Sch Med, Dept Biochem, Kwangju 501759, South Korea; MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Genetix Pharmaceut, Cambridge, MA 02139 USA; Univ Alberta, Human Pancreat Islet Transplant Program, Calgary, AB T2N 4N1, Canada; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Dept Med, Boston, MA 02115 USA	Chicago Medical School; Rosalind Franklin University Medical & Science; Okayama University; Kyoto University; Okayama University; Chosun University; Massachusetts Institute of Technology (MIT); University of Alberta; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Yoon, JW (corresponding author), Rosalind Franklin Comprehens Diabet Ctr, Chicago Med Sch, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	ji-won.yoon@rosalindfranklin.edu	Navarro, Nalu/AAI-1034-2019	Navarro, Nalu/0000-0003-0118-4676; Jun, Hee-Sook/0000-0002-1166-4932; Noguchi, Hirofumi/0000-0002-0880-6805; Takei, Kohji/0000-0002-6555-9425	NIDDK NIH HHS [1R21DK60192] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK060192] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Beattie GM, 2002, DIABETES, V51, P3435, DOI 10.2337/diabetes.51.12.3435; Bollheimer LC, 2003, J MOL ENDOCRINOL, V31, P61, DOI 10.1677/jme.0.0310061; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; de la Tour DD, 2001, MOL ENDOCRINOL, V15, P476; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; Fleischer N, 1998, DIABETES, V47, P1419, DOI 10.2337/diabetes.47.9.1419; GARSON JA, 1987, NUCLEIC ACIDS RES, V15, P4761, DOI 10.1093/nar/15.12.4761; Giannoukakis N, 2003, REV ENDOCR METAB DIS, V4, P369, DOI 10.1023/A:1027306213563; HALBAN PA, 1982, ENDOCRINOLOGY, V111, P86, DOI 10.1210/endo-111-1-86; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Halvorsen TL, 2000, J ENDOCRINOL, V166, P103, DOI 10.1677/joe.0.1660103; HAYEK A, 1995, DIABETES, V44, P1458, DOI 10.2337/diabetes.44.12.1458; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jun HS, 2005, CURR GENE THER, V5, P249, DOI 10.2174/1566523053544209; Kobayashi N, 2000, SCIENCE, V287, P1258, DOI 10.1126/science.287.5456.1258; Korsgren O, 2003, XENOTRANSPLANTATION, V10, P289, DOI 10.1034/j.1399-3089.2003.00077.x; Le Lay J, 2004, J BIOL CHEM, V279, P22228, DOI 10.1074/jbc.M312673200; Linetsky E, 1997, DIABETES, V46, P1120, DOI 10.2337/diabetes.46.7.1120; Lukowiak B, 2001, J HISTOCHEM CYTOCHEM, V49, P519, DOI 10.1177/002215540104900412; Matsumura T, 2004, TRANSPLANTATION, V77, P1357, DOI 10.1097/01.TP.0000124286.82961.7E; Milo-Landesman D, 2001, CELL TRANSPLANT, V10, P645; Moritoh Y, 2003, DIABETES, V52, P1163, DOI 10.2337/diabetes.52.5.1163; Mukai T, 2002, ONCOGENE, V21, P9033, DOI 10.1038/sj.onc.1206095; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Narushima M, 2004, ASAIO J, V50, P586, DOI 10.1097/01.MAT.0000142877.18621.BC; Ohgawara H, 1998, DIABETES RES CLIN PR, V42, P1, DOI 10.1016/S0168-8227(98)00096-5; Ohtani S, 2004, MOL CANCER THER, V3, P93; RICORDI C, 1989, DIABETES, V38, P140, DOI 10.2337/diab.38.1.S140; Ricordi C, 2004, NAT REV IMMUNOL, V4, P258, DOI 10.1038/nri1332; Shapiro AMJ, 2003, IMMUNOL REV, V196, P219, DOI 10.1046/j.1600-065X.2003.00085.x; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Shen LL, 2002, J NATL CANCER I, V94, P755, DOI 10.1093/jnci/94.10.755; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; Watanabe T, 2003, TRANSPLANTATION, V75, P1873, DOI 10.1097/01.TP.0000064621.50907.A6; Westerman KA, 1996, P NATL ACAD SCI USA, V93, P8971, DOI 10.1073/pnas.93.17.8971; YOON JW, 1998, ENCY IMMUNOLOGY, P1390; Zalzman M, 2003, P NATL ACAD SCI USA, V100, P7253, DOI 10.1073/pnas.1136854100	41	117	129	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2005	23	10					1274	1282		10.1038/nbt1145	http://dx.doi.org/10.1038/nbt1145			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QZ	16186810	Green Submitted			2022-12-25	WOS:000232469600029
J	Park, YG; Zhao, XH; Lesueur, F; Lowy, DR; Lancaster, M; Pharoah, P; Qian, XL; Hunter, KW				Park, YG; Zhao, XH; Lesueur, F; Lowy, DR; Lancaster, M; Pharoah, P; Qian, XL; Hunter, KW			Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1	NATURE GENETICS			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-EXPRESSION; BREAST-CANCER; MAMMARY-TUMOR; IMPORTANT DETERMINANT; RAP1 ACTIVATION; SUPPRESSOR GENE; MULTIPLE CROSS; NEW-GENERATION; CELL-ADHESION	We previously identified loci in the mouse genome that substantially influence the metastatic efficiency of mammary tumors. Here, we present data supporting the idea that the signal transduction molecule, Sipa1, is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Analysis of candidate genes identified a nonsynonymous amino acid polymorphism in Sipa1 that affects the Sipa1 Rap-GAP function. Spontaneous metastasis assays using cells ectopically expressing Sipa1 or cells with knocked-down Sipa1 expression showed that metastatic capacity was correlated with cellular Sipa1 levels. We examined human expression data and found that they were consistent with the idea that Sipa1 concentration has a role in metastasis. Taken together, these data suggest that the Sipa1 polymorphism is one of the genetic polymorphisms underlying the Mtes1 locus. This report is also the first demonstration, to our knowledge, of a constitutional genetic polymorphism affecting tumor metastasis.	NCI, Lab Populat Genet, Bethesda, MD 20892 USA; Univ Cambridge, Hutchinson MRC Res Ctr, Dept Oncol, Cambridge CB2 2XZ, England; NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hunter, KW (corresponding author), NCI, Lab Populat Genet, Bldg 41,Room 702,41 Lib Dr, Bethesda, MD 20892 USA.	hunterk@mail.nih.gov	Lesueur, Fabienne/R-2178-2017; Pharoah, Paul/V-6658-2019	Lesueur, Fabienne/0000-0001-7404-4549; Pharoah, Paul/0000-0001-8494-732X	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [Z01 CP010146-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008905, Z01CP010146] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bailly S, 1996, MOL IMMUNOL, V33, P999, DOI 10.1016/S0161-5890(96)00042-9; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bois P, 1998, GENOMICS, V50, P317, DOI 10.1006/geno.1998.5329; Day N, 1999, BRIT J CANCER, V80, P95; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Farina A, 2004, MOL CELL BIOL, V24, P9059, DOI 10.1128/MCB.24.20.9059-9069.2004; Gao QS, 1999, MOL CELL BIOL, V19, P733; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gould KA, 1996, GENETICS, V144, P1777; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HATTORI M, 1995, MOL CELL BIOL, V15, P552, DOI 10.1128/MCB.15.1.552; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Heimann R, 2000, CANCER RES, V60, P298; Hitzemann R, 2003, MAMM GENOME, V14, P733, DOI 10.1007/s00335-003-2277-9; Hitzemann R, 2002, GENES BRAIN BEHAV, V1, P214, DOI 10.1034/j.1601-183X.2002.10403.x; Hogue CWV, 1997, TRENDS BIOCHEM SCI, V22, P314, DOI 10.1016/S0968-0004(97)01093-1; Hunter K, 2003, NAT GENET, V34, P23, DOI 10.1038/ng0503-23b; Hunter KW, 2004, BRIT J CANCER, V90, P752, DOI 10.1038/sj.bjc.6601590; Hunter KW, 2003, CANCER LETT, V200, P97, DOI 10.1016/S0304-3835(03)00420-8; Hunter KW, 2001, CANCER RES, V61, P8866; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; LaTulippe E, 2002, CANCER RES, V62, P4499; Le Voyer T, 2000, MAMM GENOME, V11, P883, DOI 10.1007/s003350010163; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; LIOTTA LA, 1993, PRINCIPLES MOL CELL, P134; Miele ME, 1996, MOL CARCINOGEN, V15, P284, DOI 10.1002/(SICI)1098-2744(199604)15:4<284::AID-MC6>3.0.CO;2-G; Nakamura Y, 1998, J HUM GENET, V43, P149, DOI 10.1007/s100380050059; Noda Y, 2004, FEBS LETT, V568, P139, DOI 10.1016/j.febslet.2004.05.021; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Park YG, 2003, GENOME RES, V13, P118, DOI 10.1101/gr.786403; Park YG, 2002, MAMM GENOME, V13, P289, DOI 10.1007/s00335-001-2151-6; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Seftor EA, 2002, CLIN EXP METASTAS, V19, P233, DOI 10.1023/A:1015591624171; Sekita N, 2001, JPN J CANCER RES, V92, P947, DOI 10.1111/j.1349-7006.2001.tb01185.x; Seraj MJ, 2000, CANCER RES, V60, P2764; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Snove O, 2004, BIOCHEM BIOPH RES CO, V319, P256, DOI 10.1016/j.bbrc.2004.04.175; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; van Ham M, 2003, MOL BIOL REP, V30, P69, DOI 10.1023/A:1023941703493; Wiltshire T, 2003, P NATL ACAD SCI USA, V100, P3380, DOI 10.1073/pnas.0130101100; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7	49	137	145	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1055	1062		10.1038/ng1635	http://dx.doi.org/10.1038/ng1635			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16142231	Green Accepted			2022-12-25	WOS:000232185600016
J	Vaccaro, C; Zhou, JC; Ober, RJ; Ward, ES				Vaccaro, C; Zhou, JC; Ober, RJ; Ward, ES			Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels	NATURE BIOTECHNOLOGY			English	Article							INTRAVENOUS IMMUNE GLOBULIN; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-RESIDUES; SERUM HALF-LIVES; CELL-LINE; ENDOTHELIAL-CELLS; 2.8-A RESOLUTION; EPITHELIAL-CELLS; IGG TRANSPORT; NEONATAL-RAT	We have engineered the Fc region of a human immunoglobulin G ( IgG) to generate a mutated antibody that modulates the concentrations of endogenous IgGs in vivo. This has been achieved by targeting the activity of the Fc receptor, FcRn, which serves through its IgG salvage function to maintain and regulate IgG concentrations in the body. We show that an IgG whose Fc region was engineered to bind with higher affinity and reduced pH dependence to FcRn potently inhibits FcRn-IgG interactions and induces a rapid decrease of IgG levels in mice. Such FcRn blockers ( or 'Abdegs,' for antibodies that enhance IgG degradation) may have uses in reducing IgG levels in antibody-mediated diseases and in inducing the rapid clearance of IgG-toxin or IgG-drug complexes.	Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75390 USA; Univ Texas, Dept Elect Engn, Richardson, TX 75080 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas	Ward, ES (corresponding author), Univ Texas, SW Med Ctr, Ctr Immunol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	sally.ward@utsouthwestern.edu		Ober, Raimund/0000-0002-1290-7430; Ward, E. Sally/0000-0003-3232-7238	NIAID NIH HHS [R01 AI055556, R01 AI 55556, R01 AI039167, R01 AI050747, R01 AI 50747, R01 AI 39167] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055556, R01AI050747, R01AI039167] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akilesh S, 2004, J CLIN INVEST, V113, P1328, DOI 10.1172/JCI200418838; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; Antohe F, 2001, HUM IMMUNOL, V62, P93, DOI 10.1016/S0198-8859(00)00244-5; BERRYMAN M, 1995, J CELL SCI, V108, P2347; Bleeker WK, 2001, BLOOD, V98, P3136, DOI 10.1182/blood.V98.10.3136; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; Claypool SM, 2004, MOL BIOL CELL, V15, P1746, DOI 10.1091/mbc.E03-11-0832; Dall'Acqua WF, 2002, J IMMUNOL, V169, P5171, DOI 10.4049/jimmunol.169.9.5171; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Dickinson BL, 1999, J CLIN INVEST, V104, P903, DOI 10.1172/JCI6968; Firan M, 2001, INT IMMUNOL, V13, P993, DOI 10.1093/intimm/13.8.993; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; Ghetie V, 1997, NAT BIOTECHNOL, V15, P637, DOI 10.1038/nbt0797-637; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; Hinton PR, 2004, J BIOL CHEM, V279, P6213, DOI 10.1074/jbc.C300470200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISRAEL EJ, 1995, J IMMUNOL, V154, P6246; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kabat EA, 1991, SEQUENCES PROTEINS I; Kim JK, 1999, EUR J IMMUNOL, V29, P2819, DOI 10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; Kobayashi N, 2002, AM J PHYSIOL-RENAL, V282, pF358, DOI 10.1152/ajprenal.0164.2001; Lewis E, 2005, LUPUS, V14, P31, DOI 10.1191/0961203305lu2056oa; Martin WL, 1999, BIOCHEMISTRY-US, V38, P12639, DOI 10.1021/bi9913505; Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1; McCarthy KM, 2000, J CELL SCI, V113, P1277; Medesan C, 1997, J IMMUNOL, V158, P2211; Mouthon L, 1996, CLIN EXP IMMUNOL, V104, P3, DOI 10.1111/cei.1996.104.s1.3; Ober RJ, 2004, P NATL ACAD SCI USA, V101, P11076, DOI 10.1073/pnas.0402970101; Ober RJ, 2001, INT IMMUNOL, V13, P1551, DOI 10.1093/intimm/13.12.1551; Ober RJ, 2004, J IMMUNOL, V172, P2021, DOI 10.4049/jimmunol.172.4.2021; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Popov S, 1996, MOL IMMUNOL, V33, P521, DOI 10.1016/0161-5890(96)00004-1; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; RODEWALD R, 1984, J CELL BIOL, V99, P159; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Schuck P, 1999, MOL IMMUNOL, V36, P1117, DOI 10.1016/S0161-5890(99)00093-0; Semple JW, 2002, BLOOD REV, V16, P9, DOI 10.1054/blre.2001.0172; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; Souriau C, 2003, EXPERT OPIN BIOL TH, V3, P305, DOI 10.1517/eobt.3.2.305.21159; Spiekermann GM, 2002, J EXP MED, V196, P303, DOI 10.1084/jem.20020400; Takai T, 2005, J CLIN IMMUNOL, V25, P1, DOI 10.1007/s10875-005-0353-8; Weiner LM, 2005, NAT BIOTECHNOL, V23, P556, DOI 10.1038/nbt0505-556; Yoshida M, 2004, IMMUNITY, V20, P769, DOI 10.1016/j.immuni.2004.05.007; Yu ZY, 1999, NEW ENGL J MED, V340, P227, DOI 10.1056/NEJM199901213400311; Zhou JC, 2003, J MOL BIOL, V332, P901, DOI 10.1016/S0022-2836(03)00952-5; Zhou JC, 2005, J MOL BIOL, V345, P1071, DOI 10.1016/j.jmb.2004.11.014	49	259	344	2	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2005	23	10					1283	1288		10.1038/nbt1143	http://dx.doi.org/10.1038/nbt1143			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QZ	16186811				2022-12-25	WOS:000232469600030
J	Mizukami, Y; Jo, WS; Duerr, EM; Gala, M; Li, JN; Zhang, XB; Zimmer, MA; Iliopoulos, O; Zukerberg, LR; Kohgo, Y; Lynch, MP; Rueda, BR; Chung, DC				Mizukami, Y; Jo, WS; Duerr, EM; Gala, M; Li, JN; Zhang, XB; Zimmer, MA; Iliopoulos, O; Zukerberg, LR; Kohgo, Y; Lynch, MP; Rueda, BR; Chung, DC			Induction of interleukin-8 preserves the angiogenic response in HIF-1 alpha-deficient colon cancer cells	NATURE MEDICINE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; NF-KAPPA-B; TUMOR-GROWTH; GENE-EXPRESSION; TRANSCRIPTION FACTOR; COLORECTAL-CANCER; OXYGEN; HIF-1; RAS; TUMORIGENESIS	Hypoxia inducible factor- 1 ( HIF- 1) is considered a crucial mediator of the cellular response to hypoxia through its regulation of genes that control angiogenesis(1-4). It represents an attractive therapeutic target(5,6) in colon cancer, one of the few tumor types that shows a clinical response to antiangiogenic therapy(7). But it is unclear whether inhibition of HIF- 1 alone is sufficient to block tumor angiogenesis(8,9). In HIF- 1 alpha knockdown DLD- 1 colon cancer cells ( DLD- 1(HIF- kd)), the hypoxic induction of vascular endothelial growth factor ( VEGF) was only partially blocked. Xenografts remained highly vascularized with microvessel densities identical to DLD- 1 tumors that had wild- type HIF- 1 alpha ( DLD- 1(HIF-wt)). In addition to the preserved expression of VEGF, the proangiogenic cytokine interleukin ( IL)- 8 was induced by hypoxia in DLD- 1(HIF-kd) but not DLD- 1(HIF- wt) cells. This induction was mediated by the production of hydrogen peroxide and subsequent activation of NF-kappa B. Furthermore, the KRAS oncogene, which is commonly mutated in colon cancer, enhanced the hypoxic induction of IL- 8. A neutralizing antibody to IL- 8 substantially inhibited angiogenesis and tumor growth in DLD- 1HIF- kd but not DLD-1(HIF-) (wt) xenografts, verifying the functional significance of this IL- 8 response. Thus, compensatory pathways can be activated to preserve the tumor angiogenic response, and strategies that inhibit HIF- 1 alpha may be most effective when IL- 8 is simultaneously targeted.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Oncol Unit, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Asahikawa Med Coll, Dept Internal Med 3, Asahikawa, Hokkaido 0788510, Japan; Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Asahikawa Medical College; Harvard University; Massachusetts General Hospital	Chung, DC (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, 50 Blossom St, Boston, MA 02114 USA.	chung.daniel@mgh.harvard.edu	Kohgo, Yutaka/AAN-4863-2020; Mizukami, Yusuke/AAB-1777-2019; Mizukami, Yusuke/AAU-1767-2021	Mizukami, Yusuke/0000-0002-1068-7024	NCI NIH HHS [CA92594, CA104574, CA098333] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104574, R01CA092594, R01CA098333] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; Beasley NJP, 2002, CANCER RES, V62, P2493; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Brand KA, 1997, FASEB J, V11, P388, DOI 10.1096/fasebj.11.5.9141507; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Koshiji M, 2004, CELL CYCLE, V3, P853; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Mack FA, 2005, MOL CELL BIOL, V25, P4565, DOI 10.1128/MCB.25.11.4565-4578.2005; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891-5849(02)01045-6; Mizukami Y, 2004, CANCER RES, V64, P1765, DOI 10.1158/0008-5472.CAN-03-3017; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Ofori-Darko E, 2000, INFECT IMMUN, V68, P3657, DOI 10.1128/IAI.68.6.3657-3666.2000; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Zhang LB, 2004, J BIOL CHEM, V279, P2053, DOI 10.1074/jbc.M310357200	30	345	397	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					992	997		10.1038/nm1294	http://dx.doi.org/10.1038/nm1294			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16127434	Green Submitted			2022-12-25	WOS:000231724700028
J	Hu, M; Yao, J; Cai, L; Bachman, KE; van den Brule, F; Velculescu, V; Polyak, K				Hu, M; Yao, J; Cai, L; Bachman, KE; van den Brule, F; Velculescu, V; Polyak, K			Distinct epigenetic changes in the stromal cells of breast cancers	NATURE GENETICS			English	Article							HUMAN COLON-CARCINOMA; CPG ISLANDS; ALTERED METHYLATION; PROTEOGLYCAN GENE; DNA METHYLATION; HYPOMETHYLATION; EXPRESSION; HIN-1; TRANSCRIPTOME; EPIGENOMICS	Increasing evidence suggests that changes in the cellular microenvironment contribute to tumorigenesis, but the molecular basis of these alterations is not well understood. Although epigenetic modifications of the neoplastic cells in tumors have been firmly implicated in tumorigenesis(1), it is not known whether epigenetic modifications occur in the non-neoplastic stromal cells. To address this question in an unbiased and genome-wide manner, we developed a new method, methylation-specific digital karyotyping, and applied it to epithelial and myoepithelial cells, stromal fibroblasts from normal breast tissue, and in situ and invasive breast carcinomas. Our analyses showed that distinct epigenetic alterations occur in all three cell types during breast tumorigenesis in a tumor stage- and cell type-specific manner, suggesting that epigenetic changes have a role in the maintenance of the abnormal cellular microenvironment in breast cancer.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Liege, Lab Biol & Dev Biol, B-4000 Liege, Belgium; Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD 21231 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University System of Maryland; University of Maryland Baltimore; University of Liege; Johns Hopkins University	Polyak, K (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	Kornelia_Polyak@dfci.harvard.edu	Velculescu, Victor/ABF-4846-2020	Velculescu, Victor/0000-0003-1195-438X; Cai, Li/0000-0003-3344-337X				ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301; ADANY R, 1990, BIOCHEM BIOPH RES CO, V171, P1402, DOI 10.1016/0006-291X(90)90841-A; ADANY R, 1990, J BIOL CHEM, V265, P11389; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Cai L, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-r51; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Dai ZY, 2002, GENOME RES, V12, P1591, DOI 10.1101/gr.197402; Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kremenskoy M, 2003, BIOCHEM BIOPH RES CO, V311, P884, DOI 10.1016/j.bbrc.2003.10.078; Krop I, 2004, MOL CANCER RES, V2, P489; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Plass C, 2002, HUM MOL GENET, V11, P2479, DOI 10.1093/hmg/11.20.2479; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; Shi HD, 2002, CANCER RES, V62, P3214; Shigematsu H, 2005, INT J CANCER, V113, P600, DOI 10.1002/ijc.20622; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Wang TL, 2002, P NATL ACAD SCI USA, V99, P16156, DOI 10.1073/pnas.202610899	29	408	432	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					899	905		10.1038/ng1596	http://dx.doi.org/10.1038/ng1596			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16007089				2022-12-25	WOS:000230880400023
J	Prasad, SVN; Jayatilleke, A; Madamanchi, A; Rockman, HA				Prasad, SVN; Jayatilleke, A; Madamanchi, A; Rockman, HA			Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis	NATURE CELL BIOLOGY			English	Article							MEDIATED ENDOCYTOSIS; COUPLED RECEPTORS; ACTIN; RECRUITMENT; TROPOMYOSIN; MEMBRANE; AUTOPHOSPHORYLATION; PHOSPHORYLATION; SPECIFICITY; ACTIVATION	Phosphoinositide 3-kinase (PI(3)K) is a unique enzyme characterized by both lipid and protein kinase activities. Here, we demonstrate a requirement for the protein kinase activity of PI(3)K in agonist-dependent beta-adrenergic receptor (beta AR) internalization. Using PI(3)K mutants with either protein or lipid phosphorylation activity, we identify the cytoskeletal protein non-muscle tropomyosin as a substrate of PI(3)K, which is phosphorylated in a wortmannin-sensitive manner on residue Ser 61. A constitutively dephosphorylated (S61A) tropomyosin mutant blocks agonist-dependent beta AR internalization, whereas a tropomyosin mutant that mimics constitutive phosphorylation (S61D) compliments the PI(3)K mutant, with only lipid phosphorylation activity reversing the defective beta AR internalization. Notably, knocking down endogenous tropomyosin expression using siRNAs that target different regions of tropomyosin resulted in complete inhibition of beta AR endocytosis, showing that non-muscle tropomyosin is essential for agonist-mediated receptor internalization. These studies demonstrate a previously unknown role for the protein phosphorylation activity of PI(3)K in beta AR internalization and identify non-muscle tropomyosin as a cellular substrate for protein kinase activity of PI(3)K.	Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA	Duke University	Rockman, HA (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA.	h.rockman@duke.edu	, Proteomics Core UNC/AFQ-7201-2022	Madamanchi, Aasakiran/0000-0003-1047-6646; Jayatilleke, Arundathi/0000-0003-0875-4280	NHLBI NIH HHS [P01 HL 075443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL075443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; Czupalla C, 2003, J BIOL CHEM, V278, P11536, DOI 10.1074/jbc.M210351200; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Horne J, 2002, PROTEIN SCI, V11, P2041, DOI 10.1110/ps.4560102; Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; Koch WJ, 2000, ANNU REV PHYSIOL, V62, P237, DOI 10.1146/annurev.physiol.62.1.237; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Nienaber JJ, 2003, J CLIN INVEST, V112, P1067, DOI 10.1172/JCI200318213; Perrino C, 2005, CIRCULATION, V111, P2579, DOI 10.1161/CIRCULATIONAHA.104.508796; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Prasad SVN, 2002, J CELL BIOL, V158, P563, DOI 10.1083/jcb.200202113; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Sano K, 2000, J BIOCHEM-TOKYO, V127, P1095; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319	36	103	106	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2005	7	8					785	U48		10.1038/ncb1278	http://dx.doi.org/10.1038/ncb1278			18	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	950TU	16094730				2022-12-25	WOS:000230881500013
J	Edghill-Smith, Y; Golding, H; Manischewitz, J; King, LR; Scott, D; Bray, M; Nalca, A; Hooper, JW; Whitehouse, CA; Schmitz, JE; Reimann, KA; Franchini, G				Edghill-Smith, Y; Golding, H; Manischewitz, J; King, LR; Scott, D; Bray, M; Nalca, A; Hooper, JW; Whitehouse, CA; Schmitz, JE; Reimann, KA; Franchini, G			Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus	NATURE MEDICINE			English	Article							INFECTION; RESPONSES; MICE	Vaccination with live vaccinia virus affords long- lasting protection against variola virus, the agent of smallpox. Its mode of protection in humans, however, has not been clearly defined. Here we report that vaccinia- specific B-cell responses are essential for protection of macaques from monkeypox virus, a variola virus ortholog. Antibody- mediated depletion of B cells, but not CD4(+) or CD8(+) T cells, abrogated vaccine- induced protection from a lethal intravenous challenge with monkeypox virus. In addition, passive transfer of human vaccinia-neutralizing antibodies protected nonimmunized macaques from severe disease. Thus, vaccines able to induce long- lasting protective antibody responses may constitute realistic alternatives to the currently available smallpox vaccine (Dryvax).	NCI, Anim Models & Retroviral Vaccines Sect, Bethesda, MD 20892 USA; US FDA, Div Viral Prod, Bethesda, MD 20892 USA; US FDA, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; NIAID, Biodef Clin Res Branch, Off Clin Res, Bethesda, MD 20892 USA; So Res Inst, Frederick, MD 21701 USA; USA, Med Res Inst Infect Dis, Div Virol, Ft Detrick, MD 21702 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Viral Pathogenesis, Boston, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Franchini, G (corresponding author), NCI, Anim Models & Retroviral Vaccines Sect, 41-D804, Bethesda, MD 20892 USA.	franchig@mail.nih.gov	Schmitz, Joern/A-4929-2018; Hooper, Jay/K-2362-2017; Nalca, Aysegul/L-8149-2019	Schmitz, Joern/0000-0001-8803-0922; Hooper, Jay/0000-0002-4475-0415; Nalca, Aysegul/0000-0001-8581-7535	NATIONAL CANCER INSTITUTE [Z01BC005688, ZIABC005688] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR016001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040101] Funding Source: NIH RePORTER; NCRR NIH HHS [R24 RR016001, RR016001] Funding Source: Medline; NIAID NIH HHS [AI040101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belyakov IM, 2003, P NATL ACAD SCI USA, V100, P9458, DOI 10.1073/pnas.1233578100; Bray M, 2004, CLIN INFECT DIS, V38, P882, DOI 10.1086/381976; Bray M, 2003, CLIN INFECT DIS, V36, P766, DOI 10.1086/374244; Centers for Disease Control and Prevention (CDC), 2003, MMWR MORB MORTAL WKL, V52, P642; Centers for Disease Control and Prevention (CDC), 2003, MMWR-MORBID MORTAL W, V23, P537; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; DUNCAN SA, 1992, J VIROL, V66, P1610, DOI 10.1128/JVI.66.3.1610-1621.1992; Earl PL, 2004, NATURE, V428, P182, DOI 10.1038/nature02331; Edghill-Smith Y, 2005, J INFECT DIS, V191, P372, DOI 10.1086/427265; Edghill-Smith Y, 2003, J INFECT DIS, V188, P1181, DOI 10.1086/378518; ENGELSTAD M, 1992, VIROLOGY, V188, P801, DOI 10.1016/0042-6822(92)90535-W; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; HIRT P, 1986, J VIROL, V58, P757, DOI 10.1128/JVI.58.3.757-764.1986; Hooper JW, 2004, J VIROL, V78, P4433, DOI 10.1128/JVI.78.9.4433-4443.2004; Hooper JW, 2003, VIROLOGY, V306, P181, DOI 10.1016/S0042-6822(02)00038-7; ISAACS SN, 1992, J VIROL, V66, P7217, DOI 10.1128/JVI.66.12.7217-7224.1992; Jezek Z, 1988, HUMAN MONKEYPOX; Kemper Alex R, 2002, Eff Clin Pract, V5, P84; Kulesh DA, 2004, J CLIN MICROBIOL, V42, P601, DOI 10.1128/JCM.42.2.601-609.2004; LADNYI ID, 1972, B WORLD HLTH ORG, V55, P613; MACK TM, 1972, AM J TROP MED HYG, V21, P214, DOI 10.4269/ajtmh.1972.21.214; Manischewitz J, 2003, J INFECT DIS, V188, P440, DOI 10.1086/376557; MARENNIKOVA SS, 1989, ACTA VIROL, V33, P246; Moss B, 1996, Adv Exp Med Biol, V397, P7; Mourad GJ, 1998, TRANSPLANTATION, V65, P632, DOI 10.1097/00007890-199803150-00006; REFF ME, 1994, BLOOD, V83, P435; Roper RL, 1996, J VIROL, V70, P3753, DOI 10.1128/JVI.70.6.3753-3762.1996; SALK J, 1977, SCIENCE, V195, P834, DOI 10.1126/science.320661; SARKAR JK, 1975, B WORLD HEALTH ORGAN, V52, P307; Schmitz JE, 2003, J VIROL, V77, P2165, DOI 10.1128/JVI.77.3.2165-2173.2003; Schmitz JE, 1999, AM J PATHOL, V154, P1923, DOI 10.1016/S0002-9440(10)65450-8; TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B; Weltzin R, 2003, NAT MED, V9, P1125, DOI 10.1038/nm916; Wyatt LS, 2004, P NATL ACAD SCI USA, V101, P4590, DOI 10.1073/pnas.0401165101; Zaucha GM, 2001, LAB INVEST, V81, P1581, DOI 10.1038/labinvest.3780373	35	223	227	7	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					740	747		10.1038/nm1261	http://dx.doi.org/10.1038/nm1261			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15951823				2022-12-25	WOS:000230304200030
J	Scheuner, D; Mierde, DV; Song, B; Flamez, D; Creemers, JWM; Tsukamoto, K; Ribick, M; Schuit, FC; Kaufman, RJ				Scheuner, D; Mierde, DV; Song, B; Flamez, D; Creemers, JWM; Tsukamoto, K; Ribick, M; Schuit, FC; Kaufman, RJ			Control of mRNA translation preserves endoplasmic reticulum function in beta cells and maintains glucose homeostasis	NATURE MEDICINE			English	Article							UNFOLDED-PROTEIN RESPONSE; WOLCOTT-RALLISON-SYNDROME; RAT PANCREATIC-ISLETS; PROINSULIN BIOSYNTHESIS; REGULATED PROTEINS; EIF2-ALPHA KINASE; INSULIN RELEASE; ER STRESS; MICE; GENE	Type 2 diabetes is a disorder of hyperglycemia resulting from failure of beta cells to produce adequate insulin to accommodate an increased metabolic demand. Here we show that regulation of mRNA translation through phosphorylation of eukaryotic initiation factor 2 (eIF2 alpha) is essential to preserve the integrity of the endoplasmic reticulum (ER) and to increase insulin production to meet the demand imposed by a high-fat diet. Accumulation of unfolded proteins in the ER activates phosphorylation of eIF2a at Ser51 and inhibits translation. To elucidate the role of this pathway in beta- cell function we studied glucose homeostasis in Eif2s1(tm1Rjk) mutant mice, which have an alanine substitution at Ser51. Heterozygous (Eif2s1(+/tm1Rjk)) mice became obese and diabetic on a high-fat diet. Profound glucose intolerance resulted from reduced insulin secretion accompanied by abnormal distension of the ER lumen, defective trafficking of proinsulin, and a reduced number of insulin granules in beta cells. We propose that translational control couples insulin synthesis with folding capacity to maintain ER integrity and that this signal is essential to prevent diet- induced type 2 diabetes.	Katholieke Univ Leuven, Gene Express Unit, Dept Mol Cell Biol, B-3000 Louvain, Belgium; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Vrije Univ Brussels, Diabet Res Ctr, B-1090 Brussels, Belgium; Katholieke Univ Leuven, Dept Menselijke Erfelijkheid, Louvain, Belgium; Vlaams Interunib, Inst Biotechnol, B-3000 Louvain, Belgium; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	KU Leuven; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Vrije Universiteit Brussel; KU Leuven; University of Michigan System; University of Michigan	Schuit, FC (corresponding author), Katholieke Univ Leuven, Gene Express Unit, Dept Mol Cell Biol, Herestr 49, B-3000 Louvain, Belgium.	frans.schuit@med.kuleuven.be; kaufmanr@umich.edu			NIDDK NIH HHS [DK42394, R01 DK042394, R37 DK042394] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042394, R01DK042394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; BERGSTEN P, 1994, J BIOL CHEM, V269, P8749; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Flamez D, 1998, DIABETES, V47, P646, DOI 10.2337/diabetes.47.4.646; GRIMALDI KA, 1987, BIOCHEM J, V245, P557, DOI 10.1042/bj2450557; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hinke SA, 2004, J PHYSIOL-LONDON, V558, P369, DOI 10.1113/jphysiol.2004.064881; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Jorns A, 1997, J ENDOCRINOL, V155, P283, DOI 10.1677/joe.0.1550283; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Knoch KP, 2004, NAT CELL BIOL, V6, P207, DOI 10.1038/ncb1099; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lee YK, 1999, MOL BIOL CELL, V10, P2209, DOI 10.1091/mbc.10.7.2209; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; SCHUIT FC, 1991, BIOCHEM BIOPH RES CO, V178, P1182, DOI 10.1016/0006-291X(91)91017-7; Senee V, 2004, DIABETES, V53, P1876, DOI 10.2337/diabetes.53.7.1876; Tillmar L, 2002, J BIOL CHEM, V277, P1099, DOI 10.1074/jbc.M108340200; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; Wicksteed B, 2003, J BIOL CHEM, V278, P42080, DOI 10.1074/jbc.M303509200; Wicksteed B, 2001, J BIOL CHEM, V276, P22553, DOI 10.1074/jbc.M011214200; WILLIAMS BRG, 2001, SIGNAL INTEGRATION P; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	43	300	318	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					757	764		10.1038/nm1259	http://dx.doi.org/10.1038/nm1259			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15980866	Green Published			2022-12-25	WOS:000230304200032
J	De Wall, SL; Painter, C; Stone, JD; Bandaranayake, R; Wiley, DC; Mitchison, TJ; Stern, LJ; Dedecker, BS				De Wall, SL; Painter, C; Stone, JD; Bandaranayake, R; Wiley, DC; Mitchison, TJ; Stern, LJ; Dedecker, BS			Noble metals strip peptides from class II MHC proteins	NATURE CHEMICAL BIOLOGY			English	Article							RHEUMATOID-ARTHRITIS; T-CELLS; HLA-DM; COMPLEXES; ANTIGEN; IDENTIFICATION; RECOGNITION; BINDING; HLA-DR1	Class II major histocompatibility complex (MHC) proteins are essential for normal immune system function but also drive many autoimmune responses. They bind peptide antigens in endosomes and present them on the cell surface for recognition by CD4(+) T cells(1). A small molecule could potentially block an autoimmune response by disrupting MHC-peptide interactions, but this has proven difficult because peptides bind tightly and dissociate slowly from MHC proteins. Using a high-throughput screening assay we discovered a class of noble metal complexes that strip peptides from human class II MHC proteins by an allosteric mechanism(2). Biochemical experiments indicate the metal-bound MHC protein adopts a 'peptide-empty' conformation that resembles the transition state of peptide loading. Furthermore, these metal inhibitors block the ability of antigen-presenting cells to activate T cells. This previously unknown allosteric mechanism may help resolve how gold(I) drugs affect the progress of rheumatoid arthritis and may provide a basis for developing a new class of anti-autoimmune drugs.	Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Howard Hughes Medical Institute; Harvard University	Dedecker, BS (corresponding author), Harvard Univ, Sch Med, Inst Chem & Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA.	bdedecker@partners.org		Painter, Corrie/0000-0001-6174-1548	NIAID NIH HHS [R0I-AI 38996, 5 T32 AI07245-20] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007245, R01AI038996] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; Boen E, 2000, J IMMUNOL, V165, P2040, DOI 10.4049/jimmunol.165.4.2040; BOWEN JR, 1974, AGENTS ACTIONS, V4, P108, DOI 10.1007/BF01966819; Carven GJ, 2004, J BIOL CHEM, V279, P16561, DOI 10.1074/jbc.M314315200; DECKER BS, 2000, CHEM BIOL, V7, pR103; Fakih S, 2003, EUR J INORG CHEM, P1206, DOI 10.1002/ejic.200390156; Forestier J, 1935, J LAB CLIN MED, V20, P827; GOEBEL C, 1995, ARCH TOXICOL, V69, P450, DOI 10.1007/s002040050198; Griem P, 1996, EUR J IMMUNOL, V26, P279, DOI 10.1002/eji.1830260202; GRIEM P, 1995, J IMMUNOL, V155, P1575; HASHIMOTO K, 1992, J CLIN INVEST, V89, P1839, DOI 10.1172/JCI115788; ISAB AA, 1977, BIOCHIM BIOPHYS ACTA, V492, P322, DOI 10.1016/0005-2795(77)90083-6; KATO M, 2005, J CHEM SOC DA, V6, P1023; Kean WF, 1997, BRIT J RHEUMATOL, V36, P560; Koch R., 1890, DEUT MED WOCHENSCHR, V16, P756; Lazarski CA, 2005, IMMUNITY, V23, P29, DOI 10.1016/j.immuni.2005.05.009; Louie AY, 1999, CHEM REV, V99, P2711, DOI 10.1021/cr9804285; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; Rau R, 2005, CLIN RHEUMATOL, V24, P189, DOI 10.1007/s10067-004-0869-8; Richens DT, 2005, CHEM REV, V105, P1961, DOI 10.1021/cr030705u; ROMAGNOLI P, 1992, J CLIN INVEST, V89, P254, DOI 10.1172/JCI115569; SANCHEZBURSON J, 1989, BRIT J RHEUMATOL, V28, P358; Shaw III CF, 1994, METAL BASED DRUGS, V1, P351; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; Stratikos E, 2002, J EXP MED, V196, P173, DOI 10.1084/jem.20020117; Takahashi K, 1998, MOL IMMUNOL, V35, P1081, DOI 10.1016/S0161-5890(98)00106-0; VERWILGHEN J, 1992, ARTHRITIS RHEUM-US, V35, P1413, DOI 10.1002/art.1780351203; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618	29	37	38	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	APR	2006	2	4					197	201		10.1038/nchembio773	http://dx.doi.org/10.1038/nchembio773			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	023QU	16505807				2022-12-25	WOS:000236142100011
J	Gold, B; Merriam, JE; Zernant, J; Hancox, LS; Taiber, AJ; Gehrs, K; Cramer, K; Neel, J; Bergeron, J; Barile, GR; Smith, RT; Dean, M; Allikmets, R				Gold, B; Merriam, JE; Zernant, J; Hancox, LS; Taiber, AJ; Gehrs, K; Cramer, K; Neel, J; Bergeron, J; Barile, GR; Smith, RT; Dean, M; Allikmets, R		AMD Genetics Clin Study Grp	Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration	NATURE GENETICS			English	Article							FACTOR-H POLYMORPHISM; DISEASE; DRUSEN; MACULOPATHY; DEFICIENCY; SUSCEPTIBILITY; EPIDEMIOLOGY; HAPLOTYPE; ETIOLOGY; VARIANT	Age-related macular degeneration (AMD) is the most common form of irreversible blindness in developed countries(1,2). Variants in the factor H gene (CFH, also known as HF1), which encodes a major inhibitor of the alternative complement pathway, are associated with the risk for developing AMD(3-8). Here we test the hypothesis that variation in genes encoding other regulatory proteins of the same pathway is associated with AMD. We screened factor B (BF) and complement component 2 (C2) genes, located in the major histocompatibility complex class III region, for genetic variation in two independent cohorts comprising similar to 900 individuals with AMD and similar to 400 matched controls. Haplotype analyses identify a statistically significant common risk haplotype (H1) and two protective haplotypes. The L9H variant of BF and the E318D variant of C2 (H10), as well as a variant in intron 10 of C2 and the R32Q variant of BF (H7), confer a significantly reduced risk of AMD (odds ratio=0.45 and 0.36, respectively). Combined analysis of the C2 and BF haplotypes and CFH variants shows that variation in the two loci can predict the clinical outcome in 74% of the affected individuals and 56% of the controls. These data expand and refine our understanding of the genetic risk for AMD.	Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA; NCI, Lab Genom Divers, Frederick, MD 21702 USA; Univ Iowa, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, Iowa City, IA 52240 USA; Sapio Sci LLC, York, PA 17402 USA; SAIC Frederick, Frederick, MD 21702 USA; Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA	Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Iowa; Science Applications International Corporation (SAIC); SAIC-Frederick; Columbia University	Allikmets, R (corresponding author), Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.	dean@ncifcrf.gov; rla22@columbia.edu	Mohammed, Imran/J-8271-2012; Allikmets, Rando/ABD-4533-2021; Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Mohammed, Imran/0000-0002-8412-0768; Dean, Michael C/0000-0003-2234-0631; smith, theodore/0000-0002-1693-943X; Hancox, Lisa/0000-0003-1940-2619; Gehrs, Karen/0000-0003-4510-9678	NATIONAL CANCER INSTITUTE [Z01BC005652] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011515, R01EY015520, R01EY013435] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-124000] Funding Source: Medline; NEI NIH HHS [R01 EY015520-02, R01 EY015520-05, R01 EY013435, R01 EY015520-01A2, R01 EY015520, EY13435, EY11515, R01 EY015520-03, R01 EY011515, R01 EY015520-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Alper CA, 2003, J CLIN IMMUNOL, V23, P297, DOI 10.1023/A:1024540917593; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102; Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; DAVIS CA, 1980, J LAB CLIN MED, V96, P633; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Hayashi M, 2004, Ophthalmic Genet, V25, P111; Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012; Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237; Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Larsen CE, 2004, CURR OPIN IMMUNOL, V16, P660, DOI 10.1016/j.coi.2004.07.014; LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; Myers S, 2005, SCIENCE, V310, P321, DOI 10.1126/science.1117196; RAUM D, 1979, AM J HUM GENET, V31, P35; Stewart CA, 2004, GENOME RES, V14, P1176, DOI 10.1101/gr.2188104; van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914; Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426	30	860	935	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2006	38	4					458	462		10.1038/ng1750	http://dx.doi.org/10.1038/ng1750			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16518403	Green Accepted			2022-12-25	WOS:000236340500019
J	Gonzalo, S; Jaco, I; Fraga, MF; Chen, TP; Li, E; Esteller, M; Blasco, MA				Gonzalo, S; Jaco, I; Fraga, MF; Chen, TP; Li, E; Esteller, M; Blasco, MA			DNA methyltransferases control telomere length and telomere recombination in mammalian cells	NATURE CELL BIOLOGY			English	Article							MAJOR SATELLITE REPEATS; RB FAMILY; METHYLATION; DNMT3A; MAINTENANCE; SEQUENCES	Here, we describe a role for mammalian DNA methyltransferases ( DNMTs) in telomere length control. Mouse embryonic stem ( ES) cells genetically deficient for DNMT1, or both DNMT3a and DNMT3b have dramatically elongated telomeres compared with wild-type controls. Mammalian telomere repeats ( TTAGGG) lack the canonical CpG methylation site. However, we demonstrate that mouse subtelomeric regions are heavily methylated, and that this modification is decreased in DNMT-deficient cells. We show that other heterochromatic marks, such as histone 3 Lys 9 (H3K9) and histone 4 Lys 20 (H4K20) trimethylation, remain at both subtelomeric and telomeric regions in these cells. Lack of DNMTs also resulted in increased telomeric recombination as indicated by sister-chromatid exchanges involving telomeric sequences, and by the presence of 'alternative lengthening of telomeres' (ALT)-associated promyelocytic leukaemia (PML) bodies (APBs). This increased telomeric recombination may lead to telomere-length changes, although our results do not exclude a potential involvement of telomerase and telomere-binding proteins in the aberrant telomere elongation observed in DNMT-deficient cells. Together, these results demonstrate a previously unappreciated role for DNA methylation in maintaining telomere integrity.	Spanish Natl Canc Ctr CNIO, Telomers & Telomerase Grp, Mol Oncol Program, E-28029 Madrid, Spain; Spanish Natl Canc Ctr CNIO, Epigenet Grp, Mol Pathol Program, E-28029 Madrid, Spain; Novartis Inst Biomed Res, Epigenet Program, Cambridge, MA 02139 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Novartis	Blasco, MA (corresponding author), Spanish Natl Canc Ctr CNIO, Telomers & Telomerase Grp, Mol Oncol Program, E-28029 Madrid, Spain.	mblasco@cnio.es	Gonzalo, Susana/T-8275-2019; Fraga, Mario F/H-7824-2017; Blasco, Maria A./M-1694-2014; Esteller, Manel/L-5956-2014	Fraga, Mario F/0000-0001-8450-2603; Blasco, Maria A./0000-0002-4211-233X; Esteller, Manel/0000-0003-4490-6093; Gonzalo, Susana/0000-0001-9631-1206				Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Bender J, 1998, TRENDS BIOCHEM SCI, V23, P252, DOI 10.1016/S0968-0004(98)01225-0; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Blasco MA, 2004, CARCINOGENESIS, V25, P1083, DOI 10.1093/carcin/bgh185; Brock GJR, 1999, GENE, V240, P269, DOI 10.1016/S0378-1119(99)00442-4; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2004, MOL CELL BIOL, V24, P9048, DOI 10.1128/MCB.24.20.9048-9058.2004; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200; Dominguez-Bendala J, 2004, TRANSGENIC RES, V13, P69, DOI 10.1023/B:TRAG.0000017176.77847.80; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fraga MF, 2002, ELECTROPHORESIS, V23, P1677, DOI 10.1002/1522-2683(200206)23:11&lt;1677::AID-ELPS1677&gt;3.0.CO;2-Z; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Garcia-Cao M, 2002, NAT GENET, V32, P415, DOI 10.1038/ng1011; Gonzalo S, 2005, CELL CYCLE, V4, P752, DOI 10.4161/cc.4.6.1720; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Maloisel L, 1998, GENE DEV, V12, P1381, DOI 10.1101/gad.12.9.1381; Muntoni A, 2005, HUM MOL GENET, V14, pR191, DOI 10.1093/hmg/ddi266; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Steinert S, 2004, MOL CELL BIOL, V24, P4571, DOI 10.1128/MCB.24.10.4571-4580.2004; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	33	464	495	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					416	U66		10.1038/ncb1386	http://dx.doi.org/10.1038/ncb1386			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16565708				2022-12-25	WOS:000236560000021
J	Greenway, MJ; Andersen, PM; Russ, C; Ennis, S; Cashman, S; Donaghy, C; Patterson, V; Swingler, R; Kieran, D; Prehn, J; Morrison, KE; Green, A; Acharya, KR; Brown, RH; Hardiman, O				Greenway, MJ; Andersen, PM; Russ, C; Ennis, S; Cashman, S; Donaghy, C; Patterson, V; Swingler, R; Kieran, D; Prehn, J; Morrison, KE; Green, A; Acharya, KR; Brown, RH; Hardiman, O			ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis	NATURE GENETICS			English	Article							HUMAN ANGIOGENIN; VEGF; DELIVERY; PROTEIN; ALS	We recently identified angiogenin (ANG) as a candidate susceptibility gene for amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by adult-onset loss of motor neurons. We now report the finding of seven missense mutations in 15 individuals, of whom four had familial ALS and 11 apparently 'sporadic' ALS. Our findings provide further evidence that variations in hypoxia-inducible genes have an important role in motor neuron degeneration.	Royal Coll Surgeons Ireland, Dept Clin Neurol Sci, Dublin 2, Ireland; Our Ladys Hosp Sick Children, Natl Ctr Med Genet, Dublin, Ireland; Umea Univ, Dept Neurol, S-90187 Umea, Sweden; Massachusetts Gen Hosp, Day Neuromuscular Res Lab, Boston, MA 02114 USA; Univ Coll Dublin, Sch Med & Med Sci, Conway Inst, Dublin, Ireland; Royal Victoria Hosp, Dept Neurol, Belfast BT12 6BA, Antrim, North Ireland; Univ Dundee, Ninewells Hosp, Dept Neurol, Dundee, Scotland; Royal Coll Surgeons Ireland, Dept Physiol, Dublin 2, Ireland; Univ Birmingham, Dept Clin Neurosci, Birmingham, W Midlands, England; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Beaumont Hosp, Dept Neurol, Dublin 9, Ireland	Royal College of Surgeons - Ireland; Our Ladys Children Hospital Crumlin; Umea University; Harvard University; Massachusetts General Hospital; University College Dublin; University of Dundee; Royal College of Surgeons - Ireland; University of Birmingham; University of Bath	Greenway, MJ (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Neurol Sci, Dublin 2, Ireland.	mattgreenway@rcsi.ie; ohard@iol.ie	Green, Andrew/AAJ-7592-2020; Hardiman, Orla/Y-3441-2019; Prehn, Jochen HM/A-3928-2010	Hardiman, Orla/0000-0003-2610-1291; Prehn, Jochen HM/0000-0003-3479-7794; Ennis, Sean/0000-0002-4330-1386; Green, Andrew/0000-0002-1077-7417; Morrison, Karen Elaine/0000-0003-0216-5717; Acharya, K. Ravi/0000-0002-3009-4058	Wellcome Trust [067288] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACHARYA KR, 1994, P NATL ACAD SCI USA, V91, P2915, DOI 10.1073/pnas.91.8.2915; Achilli F, 2005, AMYOTROPH LATERAL SC, V6, P111, DOI 10.1080/14660820510035351; Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; BOND MD, 1990, BIOCHEMISTRY-US, V29, P3341, DOI 10.1021/bi00465a028; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Greenway MJ, 2004, NEUROLOGY, V63, P1936, DOI 10.1212/01.WNL.0000144344.39103.F6; Hayward C, 1999, NEUROLOGY, V52, P1899, DOI 10.1212/WNL.52.9.1899; Kishimoto K, 2005, ONCOGENE, V24, P445, DOI 10.1038/sj.onc.1208223; Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P1726, DOI 10.1021/bi00430a045; SHAPIRO R, 1992, BIOCHEMISTRY-US, V31, P12477, DOI 10.1021/bi00164a026; Storkebaum E, 2005, NAT NEUROSCI, V8, P85, DOI 10.1038/nn1360	15	523	557	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2006	38	4					411	413		10.1038/ng1742	http://dx.doi.org/10.1038/ng1742			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16501576				2022-12-25	WOS:000236340500011
J	Gurskaya, NG; Verkhusha, VV; Shcheglov, AS; Staroverov, DB; Chepurnykh, TV; Fradkov, AF; Lukyanov, S; Lukyanov, KA				Gurskaya, NG; Verkhusha, VV; Shcheglov, AS; Staroverov, DB; Chepurnykh, TV; Fradkov, AF; Lukyanov, S; Lukyanov, KA			Engineering of a monomeric green-to-red photoactivatable fluorescent protein induced by blue light	NATURE BIOTECHNOLOGY			English	Article							LIVING CELLS; INTERMEDIATE-FILAMENT; HUMAN KERATINOCYTES; CONVERSION; CHROMOPROTEINS; DYNAMICS; CLEAVAGE; CORAL; EOSFP	Green fluorescent protein (GFP) and GFP-like proteins represent invaluable genetically encoded fluorescent probes(1,2). In the last few years a new class of photoactivatable fluorescent proteins (PAFPs) capable of pronounced light-induced spectral changes have been developed(3). Except for tetrameric KFP1 (ref. 4), all known PAFPs, including PA-GFP(5), Kaede(6), EosFP(7), PS-CFP8, Dronpa(9), PA-mRFP1(10) and KikGR(11) require light in the UV-violet spectral region for activation through one-photon excitation-such light can be phototoxic to some biological systems(12). Here, we report a monomeric PAFP, Dendra, derived from octocoral Dendronephthya sp. and capable of 1,000- to 4,500- fold photoconversion from green to red fluorescent states in response to either visible blue or UV-violet light. Dendra represents the first PAFP, which is simultaneously monomeric, efficiently matures at 37 degrees C, demonstrates high photostability of the activated state, and can be photoactivated by a common, marginally phototoxic, 488-nm laser line. We demonstrate the suitability of Dendra for protein labeling and tracking to quantitatively study dynamics of fibrillarin and vimentin in mammalian cells.	Russian Acad Sci, Inst Bioorgan Chem, Moscow 117997, Russia; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Evrogen JSC, Moscow 117997, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Yeshiva University; Albert Einstein College of Medicine	Lukyanov, KA (corresponding author), Russian Acad Sci, Inst Bioorgan Chem, Miklukho Maklaya 16-10, Moscow 117997, Russia.	kluk@ibch.ru	Gurskaya, Nadya G/Q-1750-2016; Lukyanov, Konstantin A/D-4030-2013; Verkhusha, Vladislav/AAU-7784-2020; Lukyanov, Sergey/F-9140-2014	Gurskaya, Nadya G/0000-0002-8028-8176; Lukyanov, Konstantin A/0000-0001-9845-2088; Verkhusha, Vladislav/0000-0002-2083-8121; Staroverov, Dmitry/0000-0001-6789-9442	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA019980] Funding Source: NIH RePORTER; NIDA NIH HHS [DA019980] Funding Source: Medline; NIGMS NIH HHS [GM070358] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599; Ando R, 2004, SCIENCE, V306, P1370, DOI 10.1126/science.1102506; Ballestrem C, 1998, J CELL SCI, V111, P1649; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Chou YH, 1996, J CELL SCI, V109, P817; Chudakov DM, 2003, NAT BIOTECHNOL, V21, P191, DOI 10.1038/nbt778; Chudakov DM, 2004, NAT BIOTECHNOL, V22, P1435, DOI 10.1038/nbt1025; Fradkov AF, 2002, BIOCHEM J, V368, P17, DOI 10.1042/BJ20021191; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; Helfand BT, 2004, J CELL SCI, V117, P133, DOI 10.1242/jcs.00936; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Karasawa S, 2003, J BIOL CHEM, V278, P34167, DOI 10.1074/jbc.M304063200; Labas YA, 2002, P NATL ACAD SCI USA, V99, P4256, DOI 10.1073/pnas.062552299; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Lukyanov KA, 2005, NAT REV MOL CELL BIO, V6, P885, DOI 10.1038/nrm1741; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Mizuno H, 2003, MOL CELL, V12, P1051, DOI 10.1016/S1097-2765(03)00393-9; Nienhaus GU, 2006, PHOTOCHEM PHOTOBIOL, V82, P351, DOI 10.1562/2005-05-19-RA-533; Nienhaus K, 2005, P NATL ACAD SCI USA, V102, P9156, DOI 10.1073/pnas.0501874102; Patterson G, 2001, J CELL SCI, V114, P837; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Post JN, 2005, FEBS LETT, V579, P325, DOI 10.1016/j.febslet.2004.11.092; Provost N, 2003, AM J PHYSIOL-CELL PH, V284, pC51, DOI 10.1152/ajpcell.00205.2002; Rusan NM, 2001, MOL BIOL CELL, V12, P971, DOI 10.1091/mbc.12.4.971; Tsutsui H, 2005, EMBO REP, V6, P233, DOI 10.1038/sj.embor.7400361; Verkhusha VV, 2004, CHEM BIOL, V11, P845, DOI 10.1016/j.chembiol.2004.04.007; Verkhusha VV, 2004, NAT BIOTECHNOL, V22, P289, DOI 10.1038/nbt943; Verkhusha VV, 2005, CHEM BIOL, V12, P279, DOI 10.1016/j.chembiol.2005.01.005; Wiedenmann J, 2004, P NATL ACAD SCI USA, V101, P15905, DOI 10.1073/pnas.0403668101; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	32	518	546	3	119	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2006	24	4					461	465		10.1038/nbt1191	http://dx.doi.org/10.1038/nbt1191			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	032HU	16550175				2022-12-25	WOS:000236766300031
J	Lomberk, G; Bensi, D; Fernandez-Zapico, ME; Urrutia, R				Lomberk, G; Bensi, D; Fernandez-Zapico, ME; Urrutia, R			Evidence for the existence of an HP1-mediated subcode within the histone code	NATURE CELL BIOLOGY			English	Article							HETEROCHROMATIN PROTEIN-1 HP1; TRANSCRIPTIONAL REPRESSION; CHROMO DOMAIN; SHADOW DOMAIN; LYSINE 9; PHOSPHORYLATION; RECOGNITION; DROSOPHILA; MUTATIONS; KINASE	Currently, the mammalian heterochromatic proteins HP1 alpha, HP1 beta and the pan-nuclear HP1 gamma. are considered 'gatekeepers' of methyl-K9-H3-mediated silencing. Understanding how the binding of these proteins to post-translationally modified histones is switched on and off will further our knowledge of how the histone code is modulated. Here, we report that all three HP1 isoforms can be extensively modified, similar to histones, suggesting that the silencing of gene expression may be further regulated beyond the histone code. To assess the potential impact of these modifications, we analysed the phosphorylation of HP1 gamma at Ser 83 as a 'model modification'. We demonstrate that P-Ser 83-HP1 gamma has an exclusively euchromatic localization, interacts with Ku70 ( a regulatory protein involved in multiple nuclear procesess), has impaired silencing activity and serves as a marker for transcription elongation. These observations predict that regulation of silencing by methyl-K9-H3 through modification of mammalian HP1 proteins may be more complex than previously thought and suggests the existence of an HP1-mediated 'silencing subcode' that underlies the instructions of the histone code.	Dept Med, Gastroenterol Res Unit, Rochester, MN 55605 USA; Mayo Clin Canc Ctr, Rochester, MN 55605 USA	Mayo Clinic	Urrutia, R (corresponding author), Dept Med, Gastroenterol Res Unit, Rochester, MN 55605 USA.	urrutia.raul@mayo.edu	Lomberk, Gwen/AAL-8490-2020	Lomberk, Gwen/0000-0001-5463-789X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052913, R01DK056620, R56DK052913] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK052913-08, R01 DK052913, R01 DK052913-09, DK52913, DK56620] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Badugu R, 2005, CHROMOSOMA, V113, P370, DOI 10.1007/s00412-004-0324-2; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X; EISSENBERG JC, 1994, J BIOL CHEM, V269, P21315; Eissenberg JC, 2001, GENE, V275, P19, DOI 10.1016/S0378-1119(01)00628-X; Gaudin V, 2001, DEVELOPMENT, V128, P4847; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; Huang DW, 1998, J CELL BIOL, V142, P307, DOI 10.1083/jcb.142.2.307; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Morris DP, 2005, J BIOL CHEM, V280, P31368, DOI 10.1074/jbc.M501546200; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Song KY, 2001, J BIOL CHEM, V276, P8321, DOI 10.1074/jbc.M008779200; Thiru A, 2004, EMBO J, V23, P489, DOI 10.1038/sj.emboj.7600088; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Zhao T, 1999, J BIOL CHEM, V274, P15095, DOI 10.1074/jbc.274.21.15095; Zhao T, 2001, J BIOL CHEM, V276, P9512, DOI 10.1074/jbc.M010098200; ZHOU XM, 1991, J BIOL CHEM, V266, P7462	23	143	145	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					407	U62		10.1038/ncb1383	http://dx.doi.org/10.1038/ncb1383			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16531993				2022-12-25	WOS:000236560000020
J	Naguibneva, I; Ameyar-Zazoua, M; Polesskaya, A; Ait-Si-Ali, S; Groisman, R; Souidi, M; Cuvellier, S; Harel-Bellan, A				Naguibneva, I; Ameyar-Zazoua, M; Polesskaya, A; Ait-Si-Ali, S; Groisman, R; Souidi, M; Cuvellier, S; Harel-Bellan, A			The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation	NATURE CELL BIOLOGY			English	Letter							STEM-CELLS; MUSCLE; EXPRESSION; INHIBITION; PREDICTION; INITIATION; HOXA-13; MYOD	Deciphering the mechanisms underlying skeletal muscle-cell differentiation in mammals is an important challenge. Cell differentiation involves complex pathways regulated at both transcriptional and post-transcriptional levels. Recent observations have revealed the importance of small (20-25 base pair) non-coding RNAs ( microRNAs or miRNAs) that are expressed in both lower organisms(1) and in mammals(2,3). miRNAs modulate gene expression by affecting mRNA translation(4) or stability(5). In lower organisms, miRNAs are essential for cell differentiation during development(6-9); some miRNAs are involved in maintenance of the differentiated state. Here, we show that miR-181, a microRNA that is strongly upregulated during differentiation, participates in establishing the muscle phenotype. Moreover, our results suggest that miR-181 downregulates the homeobox protein Hox-A11 (a repressor of the differentiation process), thus establishing a functional link between miR-181 and the complex process of mammalian skeletal-muscle differentiation. Therefore, miRNAs can be involved in the establishment of a differentiated phenotype - even when they are not expressed in the corresponding fully differentiated tissue.	Ligue Natl Contre Canc, CNRS, UPR9079, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Harel-Bellan, A (corresponding author), Ligue Natl Contre Canc, CNRS, UPR9079, 7 Rue Guy Moquet, F-94801 Villejuif, France.	ahbellan@vjf.cnrs.fr	SOUIDI, Mouloud/ABI-1444-2020; Harel-Bellan, Annick/M-9795-2015	Naguibneva, Irina/0000-0001-9566-6152; Groisman, Sonia/0000-0003-1153-3841; Harel-Bellan, Annick/0000-0002-2339-153X; Groisman, Regina/0000-0003-3990-7622				Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; DENARDI C, 1993, J CELL BIOL, V123, P823, DOI 10.1083/jcb.123.4.823; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; FUCHTBAUER EM, 1992, DEV DYNAM, V193, P34; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Koshkin AA, 1998, J AM CHEM SOC, V120, P13252, DOI 10.1021/ja9822862; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Patterson LT, 2001, DEVELOPMENT, V128, P2153; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; Takahashi Y, 2004, EXP CELL RES, V293, P144, DOI 10.1016/j.yexcr.2003.09.024; Wahlestedt C, 2000, P NATL ACAD SCI USA, V97, P5633, DOI 10.1073/pnas.97.10.5633; Yamamoto M, 2003, DEV GROWTH DIFFER, V45, P485; Yamamoto M, 1998, DEVELOPMENT, V125, P1325; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434	30	459	539	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2006	8	3					278	284		10.1038/ncb1373	http://dx.doi.org/10.1038/ncb1373			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	017QL	16489342				2022-12-25	WOS:000235708000014
J	Weathington, NM; van Houwelingen, AH; Noerager, BD; Jackson, PL; Kraneveld, AD; Galin, FS; Folkerts, G; Nijkamp, FP; Blalock, JE				Weathington, NM; van Houwelingen, AH; Noerager, BD; Jackson, PL; Kraneveld, AD; Galin, FS; Folkerts, G; Nijkamp, FP; Blalock, JE			A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation	NATURE MEDICINE			English	Article							SMOKE-INDUCED EMPHYSEMA; NEUTROPHIL CHEMOATTRACTANT; CHEMOTACTIC ACTIVITY; INTERLEUKIN-8; COLLAGEN; CHEMOKINES; PROLINE; ANALOGS; CORNEA; COPD	We describe the tripeptide neutrophil chemoattractant N-acetyl Pro-Gly-Pro (PGP), derived from the breakdown of extracellular matrix (ECM), which shares sequence and structural homology with an important domain on alpha chemokines. PGP caused chemotaxis and production of superoxide through CXC receptors, and administration of peptide caused recruitment of neutrophils (PMNs) into lungs of control, but not CXCR2-deficient mice. PGP was generated in mouse lung after exposure to lipopolysaccharide, and in vivo and in vitro blockade of PGP with monoclonal antibody suppressed PMN responses as much as chemokine-specific monoclonal antibody. Extended PGP treatment caused alveolar enlargement and right ventricular hypertrophy in mice. PGP was detectable in substantial concentrations in a majority of bronchoalveolar lavage samples from individuals with chronic obstructive pulmonary disease, but not control individuals. Thus, PGP's activity links degradation of ECM with neutrophil recruitment in airway inflammation, and PGP may be a biomarker and therapeutic target for neutrophilic inflammatory diseases.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, NL-3584 CA Utrecht, Netherlands	University of Alabama System; University of Alabama Birmingham; Utrecht University	Blalock, JE (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, 1918 Univ Blvd, Birmingham, AL 35294 USA.	blalock@uab.edu	Kraneveld, Aletta D/J-3351-2016	Kraneveld, Aletta D/0000-0001-9819-383X; Blalock, J. Edwin/0000-0001-5303-8123	NHLBI NIH HHS [T32HL007553, HL68806] Funding Source: Medline; NIEHS NIH HHS [F30 ES13874] Funding Source: Medline; NIGMS NIH HHS [T32 GM008361, T32 GM63490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007553, R01HL068806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F30ES013874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM063490, T32GM008361] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137; Adair-Kirk TL, 2003, J IMMUNOL, V171, P398, DOI 10.4049/jimmunol.171.1.398; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Beeh KM, 2003, CHEST, V123, P1240, DOI 10.1378/chest.123.4.1240; Belvisi MG, 2003, INFLAMM RES, V52, P95, DOI 10.1007/s000110300020; Boxio R, 2004, J LEUKOCYTE BIOL, V75, P604, DOI 10.1189/jlb.0703340; Brown J.H., 2001, GOODMAN GILMANS PHAR, V10th ed., P10; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CHANG C, 1970, P SOC EXP BIOL MED, V134, P22; Churg A, 2002, AM J RESP CELL MOL, V27, P368, DOI 10.1165/rcmb.4791; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; Corbel M, 2001, INFLAMM RES, V50, P129, DOI 10.1007/s000110050736; Downs JT, 2001, J IMMUNOL METHODS, V247, P25, DOI 10.1016/S0022-1759(00)00302-1; Feniger-Barish R, 2003, BIOCHEMISTRY-US, V42, P2874, DOI 10.1021/bi026783d; Foronjy RF, 2003, AM J PHYSIOL-LUNG C, V284, pL727, DOI 10.1152/ajplung.00349.2002; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haddox JL, 1999, INVEST OPHTH VIS SCI, V40, P2427; Hauert AB, 2002, INT J BIOCHEM CELL B, V34, P838, DOI 10.1016/S1357-2725(02)00010-9; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; KOBZIK L, 1999, ROBBINS PATHOLOGIC B; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LASKIN DL, 1986, J LEUKOCYTE BIOL, V39, P255, DOI 10.1002/jlb.39.3.255; Lee YC, 2001, BIOPOLYMERS, V58, P548, DOI 10.1002/1097-0282(200105)58:6<548::AID-BIP1030>3.0.CO;2-B; Mahler DA, 2004, CHEST, V126, P926, DOI 10.1378/chest.126.3.926; Miller AP, 2004, CIRCULATION, V110, P1664, DOI 10.1161/01.CIR.0000142050.19488.C7; Nishimura T, 2003, CIRCULATION, V108, P1640, DOI 10.1161/01.CIR.0000087592.47401.37; Otterness IG, 1999, MATRIX BIOL, V18, P331, DOI 10.1016/S0945-053X(99)00026-8; PFISTER RR, 1993, INVEST OPHTH VIS SCI, V34, P2297; PFISTER RR, 1995, INVEST OPHTH VIS SCI, V36, P1306; PFISTER RR, 1988, INVEST OPHTH VIS SCI, V29, P955; Pfister RR, 1998, INVEST OPHTH VIS SCI, V39, P1744; POSTLETHWAITE AE, 1976, J EXP MED, V143, P1299, DOI 10.1084/jem.143.6.1299; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; RILEY DJ, 1988, EXP LUNG RES, V14, P549, DOI 10.3109/01902148809087827; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Selman M, 1996, AM J PHYSIOL-LUNG C, V271, pL734, DOI 10.1152/ajplung.1996.271.5.L734; SENIOR RM, 1989, AM J RESP CELL MOL, V1, P479, DOI 10.1165/ajrcmb/1.6.479; Senior RM, 1998, AM J RESP CRIT CARE, V157, pS139, DOI 10.1164/ajrccm.157.4.nhlbi-12; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Turino GM, 2002, CHEST, V122, P1058, DOI 10.1378/chest.122.3.1058; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Weathington NM, 2005, CURR TOP MEMBR, V55, P49, DOI 10.1016/S1063-5823(04)55002-0; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3	50	350	365	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					317	323		10.1038/nm1361	http://dx.doi.org/10.1038/nm1361			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16474398				2022-12-25	WOS:000235802900031
J	Adrian, FJ; Ding, Q; Sim, TB; Velentza, A; Sloan, C; Liu, Y; Zhang, GB; Hur, W; Ding, S; Manley, P; Mestan, J; Fabbro, D; Gray, NS				Adrian, FJ; Ding, Q; Sim, TB; Velentza, A; Sloan, C; Liu, Y; Zhang, GB; Hur, W; Ding, S; Manley, P; Mestan, J; Fabbro, D; Gray, NS			Allosteric inhibitors of Bcr-abl-dependent cell proliferation	NATURE CHEMICAL BIOLOGY			English	Article							TYROSINE KINASE INHIBITOR; CHRONIC MYELOGENOUS LEUKEMIA; SELECTIVE INHIBITOR; CLINICAL RESISTANCE; IMATINIB RESISTANCE; MAP KINASE; C-ABL; STI571; MECHANISMS; MUTATIONS	Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the molecular level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity. Encouraged by the clinical validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacological agents that could target this kinase by a distinct mechanism. We report the discovery of a new class of Bcr-abl inhibitors using an unbiased differential cytotoxicity screen of a combinatorial kinase-directed heterocycle library. Compounds in this class ( exemplified by GNF-2) show exclusive antiproliferative activity toward Bcr-abl-transformed cells, with potencies similar to imatinib, while showing no inhibition of the kinase activity of full-length or catalytic domain of c-abl. We propose that this new class of compounds inhibits Bcr-abl kinase activity through an allosteric non-ATP competitive mechanism.	Novartis Res Fdn, Dept Biol Chem, Genom Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Novartis Inst Biomed Res, Oncol Res, CH-4002 Basel, Switzerland	Novartis; Scripps Research Institute; Scripps Research Institute; Novartis	Gray, NS (corresponding author), Novartis Res Fdn, Dept Biol Chem, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	ngray@gnf.org	manley, paul william/GVT-9482-2022					Barker AJ, 2001, BIOORG MED CHEM LETT, V11, P1911, DOI 10.1016/S0960-894X(01)00344-4; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Branford S, 2003, BLOOD, V102, P276, DOI 10.1182/blood-2002-09-2896; Buchdunger E, 1996, CANCER RES, V56, P100; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cowan-Jacob SW, 2004, MINI-REV MED CHEM, V4, P285, DOI 10.2174/1389557043487321; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Ding S, 2002, J AM CHEM SOC, V124, P1594, DOI 10.1021/ja0170302; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; Gumireddy K, 2005, P NATL ACAD SCI USA, V102, P1992, DOI 10.1073/pnas.0408283102; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Lowinger TB, 2002, CURR PHARM DESIGN, V8, P2269, DOI 10.2174/1381612023393125; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Regan J, 2002, J MED CHEM, V45, P2994, DOI 10.1021/jm020057r; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Topaly J, 2001, LEUKEMIA, V15, P342, DOI 10.1038/sj.leu.2402041; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; von Bubnoff N, 2003, CANCER RES, V63, P6395; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007	35	291	304	1	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2006	2	2					95	102		10.1038/nchembio760	http://dx.doi.org/10.1038/nchembio760			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	005DA	16415863				2022-12-25	WOS:000234801600012
J	Rubinfeld, B; Upadhyay, A; Clark, SL; Fong, SE; Smith, V; Koeppen, H; Ross, S; Polakis, P				Rubinfeld, B; Upadhyay, A; Clark, SL; Fong, SE; Smith, V; Koeppen, H; Ross, S; Polakis, P			Identification and immunotherapeutic targeting of antigens induced by chemotherapy	NATURE BIOTECHNOLOGY			English	Article							SQUAMOUS CARCINOMA-CELLS; NECK-CANCER PATIENTS; MICROARRAY ANALYSIS; CDNA MICROARRAY; E48; HEAD; THERAPY; ENZYME; GENES	Cancer cells differ from normal cells in their response to chemotherapy. We exploited this dissimilarity by identifying and targeting tumor-specific, cell-surface proteins whose expression is induced by the chemotherapeutic irinotecan (CPT-11; Camptosar). A cytotoxin-armed antibody reactive with one of these drug-induced surface proteins, the LY6D/E48 antigen, originally identified as the target of a monoclonal antibody reactive with squamous cell carcinomas, caused complete regression of colorectal tumor xenografts in mice treated with CPT-11, whereas either agent alone was less effective. These results suggest that a positive therapeutic index may be generated for other drug combinations by immunotherapeutic targeting of chemotherapy-induced antigens.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol & Translat Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Polakis, P (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	ppolakis@gene.com		Rubinfeld, Bonnee/0000-0001-9861-6775				Bevins CL, 2004, CURR OPIN GASTROEN, V20, P572, DOI 10.1097/00001574-200411000-00012; BRAKENHOFF RH, 1995, J CELL BIOL, V129, P1677, DOI 10.1083/jcb.129.6.1677; Brakenhoff RH, 1997, J IMMUNOL, V159, P4879; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; de Bree R, 2003, ORAL DIS, V9, P241; deBree R, 1997, BRIT J CANCER, V75, P1049, DOI 10.1038/bjc.1997.179; Doronina SO, 2003, NAT BIOTECHNOL, V21, P778, DOI 10.1038/nbt832; Eshel R, 2002, INT J CANCER, V98, P803, DOI 10.1002/ijc.10301; Eshel R, 2000, J BIOL CHEM, V275, P12833, DOI 10.1074/jbc.275.17.12833; Kudoh K, 2000, CANCER RES, V60, P4161; Li YW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-7; Macdonald JS, 2004, CANCER CHEMOTH PHARM, V54, pS4, DOI 10.1007/s00280-004-0880-4; Mehta K, 2004, MOL CANCER THER, V3, P345; Nieuwenhuis EJC, 2003, LAB INVEST, V83, P1233, DOI 10.1097/01.LAB.0000083532.46536.56; Oosterhoff D, 2003, MOL CANCER THER, V2, P765; Qin LF, 2002, LIFE SCI, V70, P1677, DOI 10.1016/S0024-3205(01)01554-5; QUAK JJ, 1990, AM J PATHOL, V136, P191; Taxman DJ, 2003, CANCER RES, V63, P5095; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; Whiteside MA, 2004, ONCOGENE, V23, P744, DOI 10.1038/sj.onc.1207164; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Zhou Y, 2002, CANCER RES, V62, P1688	22	49	54	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2006	24	2					205	209		10.1038/nbt1185	http://dx.doi.org/10.1038/nbt1185			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	010XW	16444269				2022-12-25	WOS:000235232300038
J	Kusano, KF; Pola, R; Murayama, T; Curry, C; Kawamoto, A; Iwakura, A; Shintani, S; Ii, M; Asai, J; Tkebuchava, T; Thorne, T; Takenaka, H; Aikawa, R; Goukassian, D; von Samson, P; Hamada, H; Yoon, YS; Silver, M; Eaton, E; Ma, H; Heyd, L; Kearney, M; Munger, W; Porter, JA; Kishore, R; Losordo, DW				Kusano, KF; Pola, R; Murayama, T; Curry, C; Kawamoto, A; Iwakura, A; Shintani, S; Ii, M; Asai, J; Tkebuchava, T; Thorne, T; Takenaka, H; Aikawa, R; Goukassian, D; von Samson, P; Hamada, H; Yoon, YS; Silver, M; Eaton, E; Ma, H; Heyd, L; Kearney, M; Munger, W; Porter, JA; Kishore, R; Losordo, DW			Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling	NATURE MEDICINE			English	Article							ENDOTHELIAL PROGENITOR CELLS; MOTOR-NEURON INDUCTION; FLOOR PLATE; TRANSPLANTATION; CARDIOMYOCYTES; ANGIOGENESIS; INFARCTION; EXPRESSION; INJURY; BLIND	Sonic hedgehog ( Shh) is a crucial regulator of organ development during embryogenesis. We investigated whether intramyocardial gene transfer of naked DNA encoding human Shh ( phShh) could promote a favorable effect on recovery from acute and chronic myocardial ischemia in adult animals, not only by promoting neovascularization, but by broader effects, consistent with the role of this morphogen in embryogenesis. After Shh gene transfer, the hedgehog pathway was upregulated in mammalian fibroblasts and cardiomyocytes. This resulted in preservation of left ventricular function in both acute and chronic myocardial ischemia by enhanced neovascularization, and reduced fibrosis and cardiac apoptosis. Shh gene transfer also enhanced the contribution of bone marrow-derived endothelial progenitor cells to myocardial neovascularization. These data suggest that Shh gene therapy may have considerable therapeutic potential in individuals with acute and chronic myocardial ischemia by triggering expression of multiple trophic factors and engendering tissue repair in the adult heart.	Tufts Univ, Sch Med, St Elizabeth Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Univ Cattolica Sacro Cuore, A Gemelli Univ Hosp, Dept Med, Sch Med, I-00168 Rome, Italy; Curis Inc, Cambridge, MA 02138 USA	St. Elizabeth's Medical Center; Tufts University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Losordo, DW (corresponding author), Tufts Univ, Sch Med, St Elizabeth Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA.	douglas.losordo@tufts.edu	Losordo, Douglas W/F-9782-2011; Asai, Jun/AAD-4796-2020	Asai, Jun/0000-0002-7610-0820; Goukassian, David/0000-0001-5270-5270; Losordo, Douglas/0000-0002-6857-7506; Pola, Roberto/0000-0001-5224-2931; Kawamoto, Atsuhiko/0000-0002-2733-8015	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066957, R01HL053354, R01HL057516, R01HL080137, R37HL053354, R01HL063414] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 53354, HL 57516, HL P01 66957, HL 63414, HL 80137] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Aikawa R, 2000, CIRCULATION, V102, P2873; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; Fortuin FD, 2003, AM J CARDIOL, V92, P436, DOI 10.1016/S0002-9149(03)00661-1; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gepstein L, 1998, CIRCULATION, V98, P2055, DOI 10.1161/01.CIR.98.19.2055; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Goukassian DA, 2003, CIRC RES, V93, P162, DOI 10.1161/01.RES.0000082980.94211.3A; Isner JM, 1999, NAT MED, V5, P491, DOI 10.1038/8374; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KASS DA, 1987, CIRCULATION, V76, P1422, DOI 10.1161/01.CIR.76.6.1422; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Losordo DW, 2002, CIRCULATION, V105, P2012, DOI 10.1161/01.CIR.0000015982.70785.B7; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Pola R, 2003, CIRCULATION, V108, P479, DOI 10.1161/01.CIR.0000080338.60981.FA; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Taylor FR, 2001, BIOCHEMISTRY-US, V40, P4359, DOI 10.1021/bi002487u; Vale PR, 2001, CIRCULATION, V103, P2138; WANG MZ, 1995, NAT MED, V1, P1184, DOI 10.1038/nm1195-1184; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Zardoya R, 1996, TRENDS GENET, V12, P496, DOI 10.1016/S0168-9525(96)20014-9	39	249	267	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1197	1204		10.1038/nm1313	http://dx.doi.org/10.1038/nm1313			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16244652				2022-12-25	WOS:000233115400032
J	Aoki, Y; Niihori, T; Kawame, H; Kurosawa, K; Filocamo, M; Kato, K; Suzuki, Y; Kure, S; Matsubara, Y				Aoki, Y; Niihori, T; Kawame, H; Kurosawa, K; Filocamo, M; Kato, K; Suzuki, Y; Kure, S; Matsubara, Y			Germline mutations in HRAS proto-oncogene cause Costello syndrome	NATURE GENETICS			English	Article							NOONAN-SYNDROME; H-RAS; PTPN11; ONCOGENES; LEUKEMIA; GENE	Costello syndrome is a multiple congenital anomaly and mental retardation syndrome characterized by coarse face, loose skin, cardiomyopathy and predisposition to tumors. We identified four heterozygous de novo mutations of HRAS in 12 of 13 affected individuals, all of which were previously reported as somatic and oncogenic mutations in various tumors. Our observations suggest that germline mutations in HRAS perturb human development and increase susceptibility to tumors.	Tohoku Univ, Sch Med, Dept Med Genet, Sendai, Miyagi 9808574, Japan; Nagano Childrens Hosp, Div Med Genet, Nagano, Japan; Kanagawa Childrens Med Ctr, Div Med Genet, Yokohama, Kanagawa, Japan; Saitama Childrens Med Ctr, Div Med Genet, Saitama, Japan; Kanagawa Childrens Med Ctr, Div Pathol, Yokohama, Kanagawa, Japan; IRCCS G Gaslini, Lab Diag Prepostnatale Malattie Metab, Genoa, Italy; Tohoku Univ, 21st Century COE Program Comprehens Res & Educ Ct, Sendai, Miyagi 980, Japan	Tohoku University; Saitama Children's Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini; Tohoku University	Aoki, Y (corresponding author), Tohoku Univ, Sch Med, Dept Med Genet, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	aokiy@mail.tains.tohoku.ac.jp	Kurosawa, Kenji/B-6561-2016; Niihori, Tetsuya/ABE-2350-2021; Filocamo, Mirella/AAG-3948-2021	Kurosawa, Kenji/0000-0002-6817-7748; Niihori, Tetsuya/0000-0002-2118-9776; Filocamo, Mirella/0000-0001-5505-8507	Telethon [GTF04002] Funding Source: Medline	Telethon(Fondazione Telethon)		BOS JL, 1989, CANCER RES, V49, P4682; COLBY WW, 1986, MOL CELL BIOL, V6, P730, DOI 10.1128/MCB.6.2.730; COSTELLO JM, 1971, NEW ZEAL MED J, V74, P397; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; Gripp KW, 2002, AM J MED GENET, V108, P80, DOI 10.1002/ajmg.10241; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hennekam RCM, 2003, AM J MED GENET C, V117C, P42, DOI 10.1002/ajmg.c.10019; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; Niihori T, 2005, J HUM GENET, V50, P192, DOI 10.1007/s10038-005-0239-7; Oliva JL, 2004, J BIOL CHEM, V279, P33480, DOI 10.1074/jbc.M404058200; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, CLIN GENET, V63, P423, DOI 10.1034/j.1399-0004.2003.00076.x; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Troger B, 2003, AM J MED GENET A, V121A, P82, DOI 10.1002/ajmg.a.20122	15	487	502	1	28	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2005	37	10					1038	1040		10.1038/ng1641	http://dx.doi.org/10.1038/ng1641			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16170316				2022-12-25	WOS:000232185600012
J	Pugacheva, EN; Golemis, EA				Pugacheva, EN; Golemis, EA			The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome	NATURE CELL BIOLOGY			English	Article							BREAST-CANCER; CAENORHABDITIS-ELEGANS; TUMOR-SUPPRESSOR; CELL POLARITY; CYTOSKELETON; ORIENTATION; TARGETS; CYCLE; CAS	Although HEF1 has a well-defined role in integrin-dependentattachment signalling at focal adhesions, it relocalizes to the spindle asters at mitosis. We report here that overexpression of HEF1 causes an increase in centrosome numbers and multipolar spindles, resembling defects induced by manipulation of the mitotic regulatory kinase Aurora-A (AurA). We show that HEF1 associates with and controls activation of AurA. We also show that HEF1 depletion causes centrosomal splitting, mono-astral spindles and hyperactivation of Nek2, implying additional action earlier in the cell cycle. These results provide new insight into the role of an adhesion protein in coordination of cell attachment and division.	Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Golemis, EA (corresponding author), Fox Chase Canc Ctr, Div Basic Sci, 333 Cottman Ave, Philadelphia, PA 19111 USA.	EA_Golemis@fccc.edu		Pugacheva, Elena/0000-0001-9814-7446; Golemis, Erica/0000-0003-3618-3673	NCI NIH HHS [R01 CA063366-11, P30 CA006927, R01 CA063366, CA63366, P30 CA006927-44, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063366, R29CA063366, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; D'Assoro AB, 2001, MARC MALPIG SYMP SER, V7, P103; Dieterich C, 2003, NUCLEIC ACIDS RES, V31, P55, DOI 10.1093/nar/gkg007; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; Fashena SJ, 2002, J CELL SCI, V115, P99; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Law SF, 1998, MOL CELL BIOL, V18, P3540, DOI 10.1128/MCB.18.6.3540; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Mayor T, 2002, J CELL SCI, V115, P3275; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Rodriguez-Fernandez JL, 1999, MOL BIOL CELL, V10, P1891, DOI 10.1091/mbc.10.6.1891; Salisbury JL, 2003, CURR BIOL, V13, pR88, DOI 10.1016/S0960-9822(03)00033-2; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; Segal M, 2001, TRENDS CELL BIOL, V11, P160, DOI 10.1016/S0962-8924(01)01954-7; Serebriiskii IG, 2002, GENOME RES, V12, P1785, DOI 10.1101/gr.450702; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Warner SL, 2003, MOL CANCER THER, V2, P589; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yvon AMC, 2002, MOL BIOL CELL, V13, P1871, DOI 10.1091/mbc.01-11-0539	34	188	189	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2005	7	10					937	U18		10.1038/ncb1309	http://dx.doi.org/10.1038/ncb1309			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	971BM	16184168	Green Accepted			2022-12-25	WOS:000232356100007
J	Waza, M; Adachi, H; Katsuno, M; Minamiyama, M; Sang, C; Tanaka, F; Inukai, A; Doyu, M; Sobue, G				Waza, M; Adachi, H; Katsuno, M; Minamiyama, M; Sang, C; Tanaka, F; Inukai, A; Doyu, M; Sobue, G			17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration	NATURE MEDICINE			English	Article							BULBAR MUSCULAR-ATROPHY; TRANSGENIC MOUSE MODEL; RECESSIVE BULBOSPINAL NEURONOPATHY; ANDROGEN RECEPTOR PROTEIN; HUNTINGTONS-DISEASE; PROTEASOMAL DEGRADATION; PHENOTYPIC-EXPRESSION; PROGESTERONE-RECEPTOR; MOLECULAR CHAPERONES; THERAPEUTIC APPROACH	Heat-shock protein 90 (Hsp90) functions as part of a multichaperone complex that folds, activates and assembles its client proteins. Androgen receptor (AR), a pathogenic gene product in spinal and bulbar muscular atrophy (SBMA), is one of the Hsp90 client proteins. We examined the therapeutic effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG), a potent Hsp90 inhibitor, and its ability to degrade polyglutamine-expanded mutant AR. Administration of 17-AAG markedly ameliorated motor impairments in the SBMA transgenic mouse model without detectable toxicity, by reducing amounts of monomeric and aggregated mutant AR. The mutant AR showed a higher affinity for Hsp90-p23 and preferentially formed an Hsp90 chaperone complex as compared to wild-type AR; mutant AR was preferentially degraded in the presence of 17-AAG in both cells and transgenic mice as compared to wild-type AR. 17-AAG also mildly induced Hsp70 and Hsp40. 17-AAG would thus provide a new therapeutic approach to SBMA and probably to other related neurodegenerative diseases.	Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	sobueg@med.nagoya-u.ac.jp	KATSUNO, MASAHISA/I-7502-2014; Adachi, Hiroaki/AAM-7812-2020	KATSUNO, MASAHISA/0000-0001-9453-9311; Adachi, Hiroaki/0000-0002-9302-4663				Adachi H, 2005, BRAIN, V128, P659, DOI 10.1093/brain/awh381; Adachi H, 2003, J NEUROSCI, V23, P2203; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Bagatell R, 2001, CLIN CANCER RES, V7, P2076; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Beliakoff J, 2003, CLIN CANCER RES, V9, P4961; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Bonvini P, 2004, CANCER RES, V64, P3256, DOI 10.1158/0008-5472.CAN-03-3531; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; DOYU M, 1992, ANN NEUROL, V32, P707, DOI 10.1002/ana.410320517; Egorin MJ, 2001, CANCER CHEMOTH PHARM, V47, P291, DOI 10.1007/s002800000242; Felts SJ, 2003, CELL STRESS CHAPERON, V8, P108, DOI 10.1379/1466-1268(2003)008<0108:PASPWC>2.0.CO;2; Ferrante RJ, 2004, J NEUROSCI, V24, P10335, DOI 10.1523/JNEUROSCI.2599-04.2004; Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144; Ishigaki S, 2002, J NEUROCHEM, V82, P576, DOI 10.1046/j.1471-4159.2002.00998.x; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; LA SA, 1991, NATURE, V352, P77; Lieberman AP, 2002, HUM MOL GENET, V11, P1967, DOI 10.1093/hmg/11.17.1967; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Minamiyama M, 2004, HUM MOL GENET, V13, P1183, DOI 10.1093/hmg/ddh131; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Murphy P, 2002, J NEUROSCI RES, V67, P461, DOI 10.1002/jnr.10139; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Neckers L, 2002, CLIN CANCER RES, V8, P962; Page J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P308; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Solit DB, 2002, CLIN CANCER RES, V8, P986; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; Tanaka F, 1996, HUM MOL GENET, V5, P1253, DOI 10.1093/hmg/5.9.1253; Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	50	301	319	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1088	1095		10.1038/nm1298	http://dx.doi.org/10.1038/nm1298			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16155577				2022-12-25	WOS:000232492500030
J	Baker, M				Baker, M			Upping the ante on antibodies	NATURE BIOTECHNOLOGY			English	Article																		EVANS D, 2005, MONOCLONAL ANTIBODIE; Lu D, 2004, J BIOL CHEM, V279, P2856, DOI 10.1074/jbc.M310132200; Mitchell P, 2005, NAT BIOTECHNOL, V23, P906, DOI 10.1038/nbt0805-906; Presta L, 2003, CURR OPIN STRUC BIOL, V13, P519, DOI 10.1016/S0959-440X(03)00103-9	4	80	90	1	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1065	1072		10.1038/nbt0905-1065	http://dx.doi.org/10.1038/nbt0905-1065			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16151393				2022-12-25	WOS:000231790600019
J	Haas, AK; Fuchs, E; Kopajtich, R; Barr, FA				Haas, AK; Fuchs, E; Kopajtich, R; Barr, FA			A GTPase-activating protein controls Rab5 function in endocytic trafficking	NATURE CELL BIOLOGY			English	Article							MEMBRANE-FUSION; EARLY ENDOSOMES; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; NUCLEOTIDE EXCHANGE; YPT1 GTPASE; EEA1; TRANSPORT; BINDING; FAMILY; DOMAIN	Rab- family GTPases are conserved regulators of membrane trafficking that cycle between inactive GDP- bound and activated GTP- bound states(1,2). A key determinant of Rab function is the lifetime of the GTP- bound state(3). As Rabs have a low intrinsic rate of GTP hydrolysis, this process is under the control of GTP-hydrolysis-activating proteins ( GAPs) (1). Due to the large number of Rabs and GAPs that are encoded by the human genome, it has proven difficult to assign specific functional relationships to these proteins. Here, we identify a Rab5- specific GAP ( RabGAP5), and show that RN- Tre ( previously described as a Rab5 GAP) acts on Rab41. RabGAP- 5 overexpression triggers a loss of the Rab5 effector EEA1 from endosomes and blocks endocytic trafficking. By contrast, depletion of RabGAP- 5 results in increased endosome size, more endosome- associated EEA1, and disrupts the trafficking of EGF and LAMP1. RabGAP- 5 therefore limits the amount of activated Rab5, and thereby regulates trafficking through endosomes.	Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Barr, FA (corresponding author), Max Planck Inst Biochem, Dept Cell Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	barr@biochem.mpg.de		Barr, Francis/0000-0001-7518-253X				Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; Albert S, 1999, J BIOL CHEM, V274, P33186, DOI 10.1074/jbc.274.47.33186; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Clague MJ, 2001, J CELL SCI, V114, P3075; Cook NR, 2004, TRAFFIC, V5, P685, DOI 10.1111/j.1600-0854.2004.00212.x; de Leeuw HPJC, 1998, BRIT J HAEMATOL, V103, P15, DOI 10.1046/j.1365-2141.1998.00965.x; Delprato A, 2004, CELL, V118, P607, DOI 10.1016/j.cell.2004.08.009; Du LL, 2001, METHOD ENZYMOL, V329, P91; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Ichioka F, 2005, BIOSCI BIOTECH BIOCH, V69, P861, DOI 10.1271/bbb.69.861; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200; Lee IK, 2004, BIOCHEM BIOPH RES CO, V325, P774, DOI 10.1016/j.bbrc.2004.10.095; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Munro S, 2002, CURR OPIN CELL BIOL, V14, P506, DOI 10.1016/S0955-0674(02)00350-2; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Pfeffer S, 2004, NAT REV MOL CELL BIO, V5, P886, DOI 10.1038/nrm1500; Rak A, 2000, EMBO J, V19, P5105, DOI 10.1093/emboj/19.19.5105; Rak A, 2003, SCIENCE, V302, P646, DOI 10.1126/science.1087761; Richardson CJ, 1998, MOL CELL BIOL, V18, P827, DOI 10.1128/MCB.18.2.827; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Segev N, 2001, SCI STKE, pre11, DOI DOI 10.1126/STKE.2001.100.RE11; Sivars U, 2003, NATURE, V425, P856, DOI 10.1038/nature02057; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	35	161	166	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2005	7	9					887	U36		10.1038/ncb1290	http://dx.doi.org/10.1038/ncb1290			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	960NY	16086013				2022-12-25	WOS:000231601600012
J	Cheng, Q; Yang, WJ; Raimondi, SC; Pui, CH; Relling, MV; Evans, WE				Cheng, Q; Yang, WJ; Raimondi, SC; Pui, CH; Relling, MV; Evans, WE			Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes	NATURE GENETICS			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; THIOPURINE S-METHYLTRANSFERASE; METHOTREXATE-POLYGLUTAMATE ACCUMULATION; IN-VIVO; CATALYTIC-ACTIVITY; MERCAPTOPURINE; PHARMACOGENOMICS; POLYMORPHISM; DISPOSITION; ABERRATIONS	The nature of mendelian inheritance assumes that all tissues in which a phenotype of interest is expressed have a uniform diploid karyotype, which is often not the case in cancer cells. Owing to nonrandom gains of chromosomes, trisomies are present in many cases of leukemia and other malignances. We used polymorphisms in the genes encoding thiopurine S-methyltransferase (TPMT), gamma-glutamyl hydrolase (GGH) and the reduced folate carrier (SLC19A1) to assess the nature of chromosomal acquisition and its influence on genotype-phenotype concordance in cancer cells. TPMT and GGH activities in somatic cells were concordant with germline genotypes, whereas activities in leukemia cells were determined by chromosomal number and whether the acquired chromosomes contained a wild-type or variant allele. Leukemia cells that had acquired an additional chromosome containing a wild-type TPMT or GGH allele had significantly lower accumulation of thioguanine nucleotides or methotrexate polyglutamates, respectively. Among these genes, there was a comparable number of acquired chromosomes with wild-type and variant alleles. Therefore, chromosomal gain can alter the concordance of germline genotype and cancer cell phenotypes, indicating that allele-specific quantitative genotyping may be required to define cancer pharmacogenomics unequivocally.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Hematol Malignancies Program, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Hematol Malignancies Program, 332 N Lauderdale St, Memphis, TN 38105 USA.	william.evans@stjude.org	Raimondi, Susana C/N-8166-2018; Pui, Ching-Hon/N-8076-2018; Evans, William E./C-2069-2012	Pui, Ching-Hon/0000-0003-0303-5658; Evans, William E./0000-0002-9333-5322				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Baak JPA, 2003, EUR J CANCER, V39, P1199, DOI 10.1016/S0959-8049(03)00265-X; Bardi G, 2004, J CLIN ONCOL, V22, P2623, DOI 10.1200/JCO.2004.11.014; Belkov VM, 1999, BLOOD, V93, P1643, DOI 10.1182/blood.V93.5.1643.405k06_1643_1650; Chango A, 2000, MOL GENET METAB, V70, P310, DOI 10.1006/mgme.2000.3034; Cheng Q, 2004, PHARMACOGENETICS, V14, P557, DOI 10.1097/01.fpc.0000114761.78957.7e; Dervieux T, 2002, CLIN CHEM, V48, P61; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Evans WE, 2004, NATURE, V429, P464, DOI 10.1038/nature02626; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; FitzPatrick DR, 2002, HUM MOL GENET, V11, P3249, DOI 10.1093/hmg/11.26.3249; Gollin SM, 2004, CURR OPIN ONCOL, V16, P25, DOI 10.1097/00001622-200401000-00006; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; KRYNETSKI EY, 1995, MOL PHARMACOL, V47, P1141; LILLEYMAN JS, 1994, LANCET, V343, P1188, DOI 10.1016/S0140-6736(94)92400-7; Masson E, 1996, J CLIN INVEST, V97, P73, DOI 10.1172/JCI118409; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Mayr D, 2002, MODERN PATHOL, V15, P951, DOI 10.1097/01.MP.0000024290.55261.14; Mitelman F, 1995, INT SYSTEM HUMAN CYT; Panetta JC, 2002, CLIN CANCER RES, V8, P2423; Paulsson K, 2003, BLOOD, V102, P3010, DOI 10.1182/blood-2003-05-1444; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Pui C.-H., 2004, Annals of Hematology, V83, pS124; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rivera GK, 2005, CANCER-AM CANCER SOC, V103, P368, DOI 10.1002/cncr.20743; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; Tai HL, 1996, AM J HUM GENET, V58, P694; Verdorfer I, 2001, INT J ONCOL, V19, P1263; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003	30	64	65	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2005	37	8					878	882		10.1038/ng1612	http://dx.doi.org/10.1038/ng1612			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16041371				2022-12-25	WOS:000230880400019
J	Sieber, SA; Niessen, S; Hoover, HS; Cravatt, BF				Sieber, SA; Niessen, S; Hoover, HS; Cravatt, BF			Proteomic profiling of metalloprotease activities with cocktails of active-site probes	NATURE CHEMICAL BIOLOGY			English	Article							SERINE HYDROLASE ACTIVITIES; ENZYME-ACTIVITY PROFILES; COMPLEX; INHIBITOR; FAMILY; IDENTIFICATION; STRATEGIES; PROTEASES; INVASION; GROWTH	Metalloproteases are a large, diverse class of enzymes involved in many physiological and disease processes. Metalloproteases are regulated by post-translational mechanisms that diminish the effectiveness of conventional genomic and proteomic methods for their functional characterization. Chemical probes directed at active sites offer a potential way to measure metalloprotease activities in biological systems; however, large variations in structure limit the scope of any single small-molecule probe aimed at profiling this enzyme class. Here, we address this problem by creating a library of metalloprotease-directed probes that show complementary target selectivity. These probes were applied as a 'cocktail' to proteomes and their labeling profiles were analyzed collectively using an advanced liquid chromatography-mass spectrometry platform. More than 20 metalloproteases were identified, including members from nearly all of the major branches of this enzyme class. These findings suggest that chemical proteomic methods can serve as a universal strategy to profile the activity of the metalloprotease superfamily in complex biological systems.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cravatt@scripps.edu	Sieber, Stephan/C-1172-2010		NATIONAL CANCER INSTITUTE [R37CA087660, R01CA087660] Funding Source: NIH RePORTER; NCI NIH HHS [CA087660, R37 CA087660, R01 CA087660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam GC, 2002, NAT BIOTECHNOL, V20, P805, DOI 10.1038/nbt714; Barglow KT, 2004, CHEM BIOL, V11, P1523, DOI 10.1016/j.chembiol.2004.08.023; Bingham J, 2000, BIOINFORMATICS, V16, P660, DOI 10.1093/bioinformatics/16.7.660; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Chan EWS, 2004, J AM CHEM SOC, V126, P14435, DOI 10.1021/ja047044i; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; DAWLINGS ND, 2004, NUCLEIC ACIDS RES, V32, pD160; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Greenbaum DC, 2002, CHEM BIOL, V9, P1085, DOI 10.1016/S1074-5521(02)00238-7; Greenbaum DC, 2002, SCIENCE, V298, P2002, DOI 10.1126/science.1077426; Hekmat O, 2005, J BIOL CHEM, V280, P35126, DOI 10.1074/jbc.M508434200; Jani M, 2005, BIOCHIMIE, V87, P385, DOI 10.1016/j.biochi.2004.09.008; Jessani N, 2005, NAT METHODS, V2, P691, DOI 10.1038/NMETH778; Jessani N, 2004, P NATL ACAD SCI USA, V101, P13756, DOI 10.1073/pnas.0404727101; Jessani N, 2004, CURR OPIN CHEM BIOL, V8, P54, DOI 10.1016/j.cbpa.2003.11.004; Jessani N, 2002, P NATL ACAD SCI USA, V99, P10335, DOI 10.1073/pnas.162187599; Johnson W H, 1987, J Enzyme Inhib, V2, P1, DOI 10.3109/14756368709030352; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kato D, 2005, NAT CHEM BIOL, V1, P33, DOI 10.1038/nchembio707; Kidd D, 2001, BIOCHEMISTRY-US, V40, P4005, DOI 10.1021/bi002579j; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Liu YS, 2005, CHEM BIOL, V12, P99, DOI 10.1016/j.chembiol.2004.11.009; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Mock WL, 2000, BIOCHEMISTRY-US, V39, P13945, DOI 10.1021/bi001497s; Moss ML, 2004, BIOCHEMISTRY-US, V43, P7227, DOI 10.1021/bi049677f; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Saghatelian A, 2005, NAT CHEM BIOL, V1, P130, DOI 10.1038/nchembio0805-130; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Seftor EA, 2005, CANCER RES, V65, P10164, DOI 10.1158/0008-5472.CAN-05-2497; Seftor EA, 2002, CLIN EXP METASTAS, V19, P233, DOI 10.1023/A:1015591624171; Speers AE, 2003, J AM CHEM SOC, V125, P4686, DOI 10.1021/ja034490h; Speers AE, 2005, J AM CHEM SOC, V127, P10018, DOI 10.1021/ja0532842; Speers AE, 2004, CHEM BIOL, V11, P535, DOI 10.1016/j.chembiol.2004.03.012; Speers AE, 2004, CHEMBIOCHEM, V5, P41, DOI 10.1002/cbic.200300721; Stoermer D, 2003, BIOORG MED CHEM LETT, V13, P2097, DOI 10.1016/S0960-894X(03)00407-4; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Vocadlo DJ, 2004, ANGEW CHEM INT EDIT, V43, P5338, DOI 10.1002/anie.200454235; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Whittaker M, 1999, CHEM REV, V99, P2735, DOI 10.1021/cr9804543	46	191	220	5	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAY	2006	2	5					274	281		10.1038/nchembio781	http://dx.doi.org/10.1038/nchembio781			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	034VE	16565715	Green Accepted			2022-12-25	WOS:000236957900014
J	Stephens, M; Sloan, JS; Robertson, PD; Scheet, P; Nickerson, DA				Stephens, M; Sloan, JS; Robertson, PD; Scheet, P; Nickerson, DA			Automating sequence-based detection and genotyping of SNPs from diploid samples	NATURE GENETICS			English	Article							HUMAN GENOME; POLYMORPHISMS; DISCOVERY; PATTERNS; GENES; TOOL	The detection of sequence variation, for which DNA sequencing has emerged as the most sensitive and automated approach, forms the basis of all genetic analysis. Here we describe and illustrate an algorithm that accurately detects and genotypes SNPs from fluorescence-based sequence data. Because the algorithm focuses particularly on detecting SNPs through the identification of heterozygous individuals, it is especially well suited to the detection of SNPs in diploid samples obtained after DNA amplification. It is substantially more accurate than existing approaches and, notably, provides a useful quantitative measure of its confidence in each potential SNP detected and in each genotype called. Calls assigned the highest confidence are sufficiently reliable to remove the need for manual review in several contexts. For example, for sequence data from 47-90 individuals sequenced on both the forward and reverse strands, the highest-confidence calls from our algorithm detected 93% of all SNPs and 100% of high-frequency SNPs, with no false positive SNPs identified and 99.9% genotyping accuracy. This algorithm is implemented in a software package, PolyPhred version 5.0, which is freely available for academic use.	Univ Washington, Dept Stat, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stephens, M (corresponding author), Univ Washington, Dept Stat, Seattle, WA 98195 USA.	stephens@stat.washington.edu			NHGRI NIH HHS [1R01HG/LM-02585, T32 HG00035-06] Funding Source: Medline; NHLBI NIH HHS [HL-66682] Funding Source: Medline; NIEHS NIH HHS [ES-15478] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066682] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002585, T32HG000035] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bhangale TR, 2005, HUM MOL GENET, V14, P59, DOI 10.1093/hmg/ddi006; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Carlson CS, 2001, CURR OPIN CHEM BIOL, V5, P78, DOI 10.1016/S1367-5931(00)00171-X; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; KWOK PY, 1994, GENOMICS, V23, P138, DOI 10.1006/geno.1994.1469; Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Olden K, 2000, NAT REV GENET, V1, P149, DOI 10.1038/35038586; Parker LT, 1996, BIOTECHNIQUES, V21, P694; Weckx S, 2005, GENOME RES, V15, P436, DOI 10.1101/gr.2754005; [No title captured]	17	119	130	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2006	38	3					375	381		10.1038/ng1746	http://dx.doi.org/10.1038/ng1746			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16493422				2022-12-25	WOS:000235589600022
J	Trzupek, JD; Gottesfeld, JM; Boger, DL				Trzupek, JD; Gottesfeld, JM; Boger, DL			Alkylation of duplex DNA in nucleosome core particles by duocarmycin SA and yatakemycin	NATURE CHEMICAL BIOLOGY			English	Article							STREPTOMYCES SP; RECOMBINANT HISTONES; ANGSTROM RESOLUTION; BINDING LIGANDS; SITE; RECONSTITUTION; CATALYSIS; PROTEINS; INSIGHTS; CC-1065	(+)- Yatakemycin ((+)- 1, Fig. 1) and (+)- duocarmycin SA ((+)- 2) are exceptionally potent, naturally occurring antitumor agents that derive their biological properties through a characteristic sequence-selective DNA-alkylation reaction(1-5). Studies have shown that both the AT-rich binding selectivity (shape-selective recognition) and the alkylation catalysis (shape-dependent catalysis) that contribute to the alkylation selectivity are dependent on the DNA minor groove shape and size characteristics of an AT-rich sequence (ref. 6 and references therein; refs. 7,8). Here we report the alkylation properties of yatakemycin and duocarmycin SA on free DNA (alpha-satellite DNA) and the same sequence bound in a nucleosome core particle (NCP) modeling the state of DNA in eukaryotic cells. Both compounds showed a clear, relatively unaltered ability to alkylate DNA packaged in NCPs in terms of both alkylating efficiency and sequence selectivity, despite the steric and conformational perturbations imposed by NCP packaging. These findings highlight the dynamic nature of NCP-bound DNA and illustrate that cell- and protein-free DNA-alkylation studies of members of this class of antitumor drugs provide valuable insights into their properties.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Boger, DL (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	boger@scripps.edu		Gottesfeld, Joel/0000-0002-4643-5777	NATIONAL CANCER INSTITUTE [R01CA041986, R01CA042056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42056, CA 41986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGER DL, 1992, J AM CHEM SOC, V114, P10056, DOI 10.1021/ja00051a045; Boger DL, 1999, ACCOUNTS CHEM RES, V32, P1043, DOI 10.1021/ar9800946; BOGER DL, 1994, J AM CHEM SOC, V116, P1635, DOI 10.1021/ja00084a004; BOGER DL, 1991, TETRAHEDRON, V47, P2661, DOI 10.1016/S0040-4020(01)81798-1; Boger DL, 1997, J AM CHEM SOC, V119, P4987, DOI 10.1021/ja9637210; Boger DL, 1996, ANGEW CHEM INT EDIT, V35, P1438, DOI 10.1002/anie.199614381; Brown PM, 1996, J MOL BIOL, V262, P671, DOI 10.1006/jmbi.1996.0544; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Dyer PN, 2004, METHOD ENZYMOL, V375, P23; Gottesfeld JM, 2001, J MOL BIOL, V309, P615, DOI 10.1006/jmbi.2001.4694; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; ICHIMURA M, 1990, J ANTIBIOT, V43, P1037, DOI 10.7164/antibiotics.43.1037; Igarashi Y, 2003, J ANTIBIOT, V56, P107, DOI 10.7164/antibiotics.56.107; Luger K, 1999, METHOD ENZYMOL, V304, P3; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MAXAM AM, 1980, METHOD ENZYMOL, V65, P497; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MOYER R, 1989, J BIOL CHEM, V264, P12226; Parrish JP, 2003, J AM CHEM SOC, V125, P10971, DOI 10.1021/ja035984h; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Polach KJ, 2000, J MOL BIOL, V298, P211, DOI 10.1006/jmbi.2000.3644; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Suto RK, 2003, J MOL BIOL, V326, P371, DOI 10.1016/S0022-2836(02)01407-9; Tichenor MS, 2004, J AM CHEM SOC, V126, P8396, DOI 10.1021/ja0472735; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; van Holde K.E., 1988, CHROMATIN; YASUZAWA T, 1995, CHEM PHARM BULL, V43, P378	30	60	61	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2006	2	2					79	82		10.1038/nchembio761	http://dx.doi.org/10.1038/nchembio761			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	005DA	16415862				2022-12-25	WOS:000234801600009
J	Pinsky, BA; Kung, C; Shokat, KM; Biggins, S				Pinsky, BA; Kung, C; Shokat, KM; Biggins, S			The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores	NATURE CELL BIOLOGY			English	Article							BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; TENSION; POLE; COMPLEX; ATTACHMENT	The spindle checkpoint ensures accurate chromosome segregation by delaying cell- cycle progression until all sister kinetochores capture microtubules from opposite poles and come under tension ( for reviews, see refs 1, 2). Although the checkpoint is activated by either the lack of kinetochore-microtubule attachments or defects in the tension exerted by microtubule- generated forces, it is not clear whether these signals are linked. We investigated the connection between tension and attachment by studying the conserved budding yeast Ipl1- Aurora protein kinase that is required for checkpoint activation in the absence of tension but not attachment(3). Here, we show that spindle- checkpoint activation in kinetochore mutants that seem to have unattached kinetochores depends on Ipl1 activity. When Ipl1 function was impaired in these kinetochore mutants, the attachments were restored and the checkpoint was turned off. These data indicate that Ipl1 activates the checkpoint in response to tension defects by creating unattached kinetochores. Moreover, although the Dam1 kinetochore complex has been implicated as a key downstream target, we found the existence of unidentified Ipl1 sites on Dam1 or additional important substrates that regulate both microtuble detachment and the checkpoint.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	Fred Hutchinson Cancer Center; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Biggins, S (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,POB 19024, Seattle, WA 98109 USA.	sbiggins@fhcrc.org		Biggins, Susan/0000-0002-4499-6319; Pinsky, Benjamin/0000-0001-8751-4810	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044009] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI44009] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bishop AC, 2001, TRENDS CELL BIOL, V11, P167, DOI 10.1016/S0962-8924(01)01928-6; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; Buvelot S, 2003, J CELL BIOL, V160, P329, DOI 10.1083/jcb.200209018; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Elliott S, 1999, P NATL ACAD SCI USA, V96, P6205, DOI 10.1073/pnas.96.11.6205; Indjeian VB, 2005, SCIENCE, V307, P130, DOI 10.1126/science.1101366; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; King JM, 2000, J CELL SCI, V113, P3815; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Li YM, 2002, GENE DEV, V16, P183, DOI 10.1101/gad.959402; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; McAinsh AD, 2003, ANNU REV CELL DEV BI, V19, P519, DOI 10.1146/annurev.cellbio.19.111301.155607; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; Nicklas RB, 2001, J CELL SCI, V114, P4173; OSBORNE MA, 1994, J CELL BIOL, V125, P853, DOI 10.1083/jcb.125.4.853; Pinsky BA, 2003, DEV CELL, V5, P735, DOI 10.1016/S1534-5807(03)00322-8; Pinsky BA, 2005, TRENDS CELL BIOL, V15, P486, DOI 10.1016/j.tcb.2005.07.005; Rose MD., 1990, METHODS YEAST GENETI; Sherman F., 1974, METHODS YEAST GENETI; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601	29	222	228	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					78	U28		10.1038/ncb1341	http://dx.doi.org/10.1038/ncb1341			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	16327780				2022-12-25	WOS:000234651500015
J	Nybakken, K; Vokes, SA; Lin, TY; McMahon, AP; Perrimon, N				Nybakken, K; Vokes, SA; Lin, TY; McMahon, AP; Perrimon, N			A genome-wide RNA interference screen in Drosophila melanogaster cells for new components of the Hh signaling pathway	NATURE GENETICS			English	Article							MESSENGER-RNA; CUBITUS INTERRUPTUS; PROTEIN-KINASE; SUBCELLULAR-LOCALIZATION; GENE-EXPRESSION; HEDGEHOG; COMPLEX; PHOSPHORYLATION; FAMILY; EXPORT	Members of the Hedgehog (Hh) family of signaling proteins are powerful regulators of developmental processes in many organisms and have been implicated in many human disease states. Here we report the results of a genome-wide RNA interference screen in Drosophila melanogaster cells for new components of the Hh signaling pathway. The screen identified hundreds of potential new regulators of Hh signaling, including many large protein complexes with pleiotropic effects, such as the coat protein complex I ( COPI) complex, the ribosome and the proteasome. We identified the multimeric protein phosphatase 2A (PP2A) and two new kinases, the D. melanogaster orthologs of the vertebrate PITSLRE and cyclin-dependent kinase-9 (CDK9) kinases, as Hh regulators. We also identified a large group of constitutive and alternative splicing factors, two nucleoporins involved in mRNA export and several RNA-regulatory proteins as potent regulators of Hh signal transduction, indicating that splicing regulation and mRNA transport have a previously unrecognized role in Hh signaling. Finally, we showed that several of these genes have conserved roles in mammalian Hh signaling.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Nybakken, K (corresponding author), Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	knybakke@receptor.med.harvard.edu; perrimon@receptor.med.harvard.edu	McMahon, Andrew P/ABE-7520-2020	Vokes, Steven/0000-0002-1724-0102; Perrimon, Norbert/0000-0001-7542-472X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM064232] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM064232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ascano M, 2002, MOL CELL BIOL, V22, P1555, DOI 10.1128/MCB.22.5.1555-1566.2002; Barnard DC, 2004, CELL, V119, P641, DOI 10.1016/j.cell.2004.10.029; Bastos R, 1996, J CELL BIOL, V134, P1141, DOI 10.1083/jcb.134.5.1141; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Burnette JM, 1999, GENETICS, V151, P1517; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Cherry S, 2005, GENE DEV, V19, P445, DOI 10.1101/gad.1267905; Chung SY, 1999, RNA, V5, P1042, DOI 10.1017/S1355838299990635; Collins RT, 2005, GENETICS, V170, P173, DOI 10.1534/genetics.104.039420; DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; De Luca A, 2003, J CELL PHYSIOL, V194, P101, DOI 10.1002/jcp.10196; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Foley E, 2004, PLOS BIOL, V2, P1091, DOI 10.1371/journal.pbio.0020203; Garriga J, 2004, GENE, V337, P15, DOI 10.1016/j.gene.2004.05.007; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hu DL, 2003, J BIOL CHEM, V278, P8623, DOI 10.1074/jbc.M210057200; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Lahti J M, 1995, Prog Cell Cycle Res, V1, P329; Lall S, 1999, CELL, V98, P171, DOI 10.1016/S0092-8674(00)81012-0; Lejeune F, 2005, CURR OPIN CELL BIOL, V17, P309, DOI 10.1016/j.ceb.2005.03.002; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Noureddine MA, 2002, DEV CELL, V2, P757, DOI 10.1016/S1534-5807(02)00164-8; Nybakken K, 2002, CURR OPIN GENET DEV, V12, P503, DOI 10.1016/S0959-437X(02)00333-7; Nybakken KE, 2002, J BIOL CHEM, V277, P24638, DOI 10.1074/jbc.M110730200; Ogden SK, 2004, BIOCHEM PHARMACOL, V67, P805, DOI 10.1016/j.bcp.2004.01.002; Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402; Park JW, 2004, P NATL ACAD SCI USA, V101, P15974, DOI 10.1073/pnas.0407004101; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Pyronnet S, 2005, CELL MOL LIFE SCI, V62, P1267, DOI 10.1007/s00018-005-5020-8; Raisin-Tani S, 2002, BIOCHEM BIOPH RES CO, V296, P288, DOI 10.1016/S0006-291X(02)00863-X; Randsholt NB, 2000, MECH DEVELOP, V95, P89, DOI 10.1016/S0925-4773(00)00342-7; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Taylor FR, 2001, BIOCHEMISTRY-US, V40, P4359, DOI 10.1021/bi002487u; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Wang QT, 1999, DEVELOPMENT, V126, P5097; ZHANG K, 1991, GENE DEV, V5, P1080, DOI 10.1101/gad.5.6.1080	49	145	155	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2005	37	12					1323	1332		10.1038/ng1682	http://dx.doi.org/10.1038/ng1682			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16311596	Green Accepted			2022-12-25	WOS:000233657300011
J	Back, SA; Tuohy, TMF; Chen, HQ; Wallingford, N; Craig, A; Struve, J; Luo, NL; Banine, F; Liu, Y; Chang, A; Trapp, BD; Bebo, BF; Rao, MS; Sherman, LS				Back, SA; Tuohy, TMF; Chen, HQ; Wallingford, N; Craig, A; Struve, J; Luo, NL; Banine, F; Liu, Y; Chang, A; Trapp, BD; Bebo, BF; Rao, MS; Sherman, LS			Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation	NATURE MEDICINE			English	Article							MULTIPLE-SCLEROSIS LESIONS; PRECURSOR CELLS; CD44 EXPRESSION; DENDRITIC CELLS; WHITE-MATTER; SPINAL-CORD; T-CELLS; ASTROCYTES; ADULT; BRAIN	Demyelination is the hallmark of numerous neurodegenerative conditions, including multiple sclerosis. Oligodendrocyte progenitors ( OPCs), which normally mature into myelin- forming oligodendrocytes, are typically present around demyelinated lesions but do not remyelinate affected axons. Here, we find that the glycosaminoglycan hyaluronan accumulates in demyelinated lesions from individuals with multiple sclerosis and in mice with experimental autoimmune encephalomyelitis. A high molecular weight ( HMW) form of hyaluronan synthesized by astrocytes accumulates in chronic demyelinated lesions. This form of hyaluronan inhibits remyelination after lysolecithin- induced white matter demyelination. OPCs accrue and do not mature into myelin- forming cells in demyelinating lesions where HMW hyaluronan is present. Furthermore, the addition of HMW hyaluronan to OPC cultures reversibly inhibits progenitor- cell maturation, whereas degrading hyaluronan in astrocyte- OPC cocultures promotes oligodendrocyte maturation. HMW hyaluronan may therefore contribute substantially to remyelination failure by preventing the maturation of OPCs that are recruited to demyelinating lesions.	Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA; Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Neurol, Sch Med, Portland, OR 97239 USA; NIA, Neurosci Lab, NIH, Baltimore, MD 21224 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Oregon Hlth Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cleveland Clinic Foundation; Oregon Health & Science University	Sherman, LS (corresponding author), Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	shermanl@ohsu.edu	Tuohy, Therese/A-8665-2009; Wallingford, Nicholas/J-1367-2018	Wallingford, Nicholas/0000-0003-2279-0480	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001517] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039550] Funding Source: NIH RePORTER; NCCIH NIH HHS [AT001517] Funding Source: Medline; NCRR NIH HHS [RR00163] Funding Source: Medline; NINDS NIH HHS [NS39550] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agren UM, 1997, FREE RADICAL BIO MED, V23, P996, DOI 10.1016/S0891-5849(97)00098-1; AKIYAMA H, 1993, BRAIN RES, V632, P249, DOI 10.1016/0006-8993(93)91160-T; Alfei L, 1999, EUR J HISTOCHEM, V43, P29; Bebo BF, 2001, J IMMUNOL, V166, P2080, DOI 10.4049/jimmunol.166.3.2080; Blakemore WF, 2003, EXP NEUROL, V184, P955, DOI 10.1016/S0014-4886(03)00347-9; Bouvier-Labit C, 2002, J NEURO-ONCOL, V60, P127, DOI 10.1023/A:1020630732625; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Chang A, 2000, J NEUROSCI, V20, P6404, DOI 10.1523/JNEUROSCI.20-17-06404.2000; Chari DM, 2002, MULT SCLER J, V8, P271, DOI 10.1191/1352458502ms842oa; Craig A, 2003, EXP NEUROL, V181, P231, DOI 10.1016/S0014-4886(03)00032-3; De Groot C J, 2001, Prog Brain Res, V132, P533; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; GIRGRAH N, 1991, J NEUROPATH EXP NEUR, V50, P779, DOI 10.1097/00005072-199111000-00009; HAEGEL H, 1993, J CELL BIOL, V122, P1067, DOI 10.1083/jcb.122.5.1067; Ito M, 2001, J NEUROPATH EXP NEUR, V60, P1004, DOI 10.1093/jnen/60.10.1004; JENKINS HG, 1988, J NEUROCHEM, V51, P1634, DOI 10.1111/j.1471-4159.1988.tb01134.x; JENKINS HG, 1988, J NEUROCHEM, V51, P1641, DOI 10.1111/j.1471-4159.1988.tb01135.x; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; Lassmann H, 2001, CURR OPIN NEUROL, V14, P253, DOI 10.1097/00019052-200106000-00001; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Liu Y, 2002, GLIA, V40, P25, DOI 10.1002/glia.10111; Lynn BD, 2001, J COMP NEUROL, V439, P315, DOI 10.1002/cne.1353; Maeda Y, 2001, ANN NEUROL, V49, P776, DOI 10.1002/ana.1015; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MARRET S, 1994, J NEUROCHEM, V62, P1285; MERRILL JE, 1984, SCIENCE, V224, P1428, DOI 10.1126/science.6610212; MORETTO G, 1993, J NEUROPATH EXP NEUR, V52, P419, DOI 10.1097/00005072-199307000-00009; Moseley R, 1997, BBA-MOL BASIS DIS, V1362, P221, DOI 10.1016/S0925-4439(97)00083-5; Mummert ME, 2002, J IMMUNOL, V169, P4322, DOI 10.4049/jimmunol.169.8.4322; Nait-Oumesmar B, 1999, EUR J NEUROSCI, V11, P4357, DOI 10.1046/j.1460-9568.1999.00873.x; Perosa SR, 2002, EPILEPSIA, V43, P159, DOI 10.1046/j.1528-1157.43.s.5.30.x; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; SAMPSON PM, 1992, J CLIN INVEST, V90, P1492, DOI 10.1172/JCI116017; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Sherman L, 1995, J NEURO-ONCOL, V26, P171, DOI 10.1007/BF01052620; STRUVE J, IN PRESS GLIA; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Tuohy TMF, 2004, GLIA, V47, P335, DOI 10.1002/glia.20042; VOGEL H, 1992, J NEUROCYTOL, V21, P363, DOI 10.1007/BF01191704; Wang H, 2001, STROKE, V32, P1020, DOI 10.1161/01.STR.32.4.1020; Wang MJ, 2004, J NEUROIMMUNOL, V146, P50, DOI 10.1016/j.jneuroim.2003.10.034; WEIGEL PH, 1986, J THEOR BIOL, V119, P219, DOI 10.1016/S0022-5193(86)80076-5; Wolswijk G, 2002, BRAIN, V125, P338, DOI 10.1093/brain/awf031; Wolswijk G, 1998, J NEUROSCI, V18, P601; Zhang SC, 1998, J NEUROCYTOL, V27, P475, DOI 10.1023/A:1006953023845	46	443	450	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					966	972		10.1038/nm1279	http://dx.doi.org/10.1038/nm1279			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16086023				2022-12-25	WOS:000231724700024
J	Clark, M				Clark, M			Empowering the inventor - the case of monoclonal antibodies	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Cambridge	Clark, M (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	mrc7@cam.ac.uk	Clark, Michael R/D-2479-2011	Clark, Michael R/0000-0002-5539-4997				*CAMBR U, 2005, 3 JOINT REP COUNC GE; Hale G, 2000, METH MOLEC MED, V40, P243, DOI 10.1385/1-59259-076-4:243; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Lambert R., 2003, LAMBERT REV BUSINESS; Milstein C, 2000, IMMUNOL TODAY, V21, P359, DOI 10.1016/S0167-5699(00)01660-1	5	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1047	1049		10.1038/nbt0905-1047	http://dx.doi.org/10.1038/nbt0905-1047			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16151388				2022-12-25	WOS:000231790600014
J	Zhu, L; van de Lavoir, MC; Albanese, J; Beenhouwer, DO; Cardarelli, PM; Cuison, S; Deng, DF; Deshpande, S; Diamond, JH; Green, L; Halk, EL; Heyer, BS; Kay, RM; Kerchner, A; Leighton, PA; Mather, CM; Morrison, SL; Nikolov, ZL; Passmore, DB; Pradas-Monne, A; Preston, BT; Rangan, VS; Shi, MX; Srinivasan, M; White, SG; Winters-Digiacinto, P; Wong, S; Zhou, W; Etches, RJ				Zhu, L; van de Lavoir, MC; Albanese, J; Beenhouwer, DO; Cardarelli, PM; Cuison, S; Deng, DF; Deshpande, S; Diamond, JH; Green, L; Halk, EL; Heyer, BS; Kay, RM; Kerchner, A; Leighton, PA; Mather, CM; Morrison, SL; Nikolov, ZL; Passmore, DB; Pradas-Monne, A; Preston, BT; Rangan, VS; Shi, MX; Srinivasan, M; White, SG; Winters-Digiacinto, P; Wong, S; Zhou, W; Etches, RJ			Production of human monoclonal antibody in eggs of chimeric chickens	NATURE BIOTECHNOLOGY			English	Article							DEPENDENT CELLULAR CYTOTOXICITY; EMBRYONIC STEM-CELLS; N-GLYCAN STRUCTURES; TRANSGENIC CHICKENS; OVALBUMIN GENE; MASS-SPECTROMETRY; DOMESTIC-FOWL; OLIGOSACCHARIDES; EXPRESSION; IGG1	The tubular gland of the chicken oviduct is an attractive system for protein expression as large quantities of proteins are deposited in the egg, the production of eggs is easily scalable and good manufacturing practices for therapeutics from eggs have been established. Here we examined the ability of upstream and downstream DNA sequences of ovalbumin, a protein produced exclusively in very high quantities in chicken egg white, to drive tissue-specific expression of human mAb in chicken eggs. To accommodate these large regulatory regions, we established and transfected lines of chicken embryonic stem (cES) cells and formed chimeras that express mAb from cES cell-derived tubular gland cells. Eggs from high-grade chimeras contained up to 3 mg of mAb that possesses enhanced antibody-dependent cellular cytotoxicity (ADCC), nonantigenic glycosylation, acceptable half-life, excellent antigen recognition and good rates of internalization.	Origen Therapeut, Burlingame, CA 94010 USA; Medarex Inc, Milpitas, CA 95035 USA; Texas A&M Univ, Dept Agr & Biol Engn, College Stn, TX 77843 USA; Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA	Texas A&M University System; Texas A&M University College Station; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Etches, RJ (corresponding author), Origen Therapeut, 1450 Rollins Rd, Burlingame, CA 94010 USA.	retches@origentherapeutics.com			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029470, R01AI039187, R37AI029470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM064261, R44GM064261] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29470, AI39187, AI51415] Funding Source: Medline; NIGMS NIH HHS [GM064261] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acloque H, 2001, MECH DEVELOP, V103, P79, DOI 10.1016/S0925-4773(01)00336-7; BOSSELMAN RA, 1989, SCIENCE, V243, P533, DOI 10.1126/science.2536194; CARSIENCE RS, 1993, DEVELOPMENT, V117, P669; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; COOK RF, 1993, POULTRY SCI, V72, P554, DOI 10.3382/ps.0720554; Crooijmans RPMA, 2000, MAMM GENOME, V11, P360, DOI 10.1007/s003350010068; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; Echelard Y, 1996, CURR OPIN BIOTECH, V7, P536, DOI 10.1016/S0958-1669(96)80058-9; Edmunds T, 1998, BLOOD, V91, P4561, DOI 10.1182/blood.V91.12.4561; EYALGILADI H, 1976, DEV BIOL, V49, P321, DOI 10.1016/0012-1606(76)90178-0; Fishwild DM, 1996, NAT BIOTECHNOL, V14, P845, DOI 10.1038/nbt0796-845; Ghirlando R, 1999, IMMUNOL LETT, V68, P47, DOI 10.1016/S0165-2478(99)00029-2; Harvey AJ, 2002, NAT BIOTECHNOL, V20, P396, DOI 10.1038/nbt0402-396; Harvey AJ, 2002, POULTRY SCI, V81, P202, DOI 10.1093/ps/81.2.202; Harvey DJ, 2000, J AM SOC MASS SPECTR, V11, P564, DOI 10.1016/S1044-0305(00)00122-7; HASE S, 1986, J BIOCHEM-TOKYO, V99, P1725, DOI 10.1093/oxfordjournals.jbchem.a135649; HIPPENMEYER PJ, 1988, NUCLEIC ACIDS RES, V16, P7619, DOI 10.1093/nar/16.15.7619; Holmes EH, 2001, EXPERT OPIN INV DRUG, V10, P511, DOI 10.1517/13543784.10.3.511; Ivarie R, 2003, TRENDS BIOTECHNOL, V21, P14, DOI 10.1016/S0167-7799(02)00009-4; IWASE H, 1984, COMP BIOCHEM PHYS B, V79, P321, DOI 10.1016/0305-0491(84)90382-1; KATO A, 1970, AGR BIOL CHEM TOKYO, V34, P1009, DOI 10.1080/00021369.1970.10859728; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KAYE JS, 1986, EMBO J, V5, P277, DOI 10.1002/j.1460-2075.1986.tb04210.x; KAYE JS, 1984, EMBO J, V3, P1137, DOI 10.1002/j.1460-2075.1984.tb01942.x; KODAMA H, 1987, CHROMOSOMA, V96, P18, DOI 10.1007/BF00285878; Kuster B, 1996, J MASS SPECTROM, V31, P1131, DOI 10.1002/(SICI)1096-9888(199610)31:10<1131::AID-JMS401>3.0.CO;2-R; Lillico SG, 2005, DRUG DISCOV TODAY, V10, P191, DOI 10.1016/S1359-6446(04)03317-3; Liu H, 1998, CANCER RES, V58, P4055; Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177; McGrew MJ, 2004, EMBO REP, V5, P728, DOI 10.1038/sj.embor.7400171; Mohammed SM, 1998, IMMUNOTECHNOLOGY, V4, P115, DOI 10.1016/S1380-2933(98)00013-X; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Niwa R, 2004, CLIN CANCER RES, V10, P6248, DOI 10.1158/1078-0432.CCR-04-0850; Niwa R, 2004, CANCER RES, V64, P2127, DOI 10.1158/0008-5472.CAN-03-2068; Okazaki A, 2004, J MOL BIOL, V336, P1239, DOI 10.1016/j.jmb.2004.01.007; Pain B, 1996, DEVELOPMENT, V122, P2339; Petitte JN, 2004, MECH DEVELOP, V121, P1159, DOI 10.1016/j.mod.2004.05.003; PETITTE JN, 2004, HDB STEM CELLS, V1, P471; Pollock DP, 1999, J IMMUNOL METHODS, V231, P147, DOI 10.1016/S0022-1759(99)00151-9; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Rapp JC, 2003, TRANSGENIC RES, V12, P569, DOI 10.1023/A:1025854217349; ROWLETT K, 1987, BRIT POULTRY SCI, V28, P91, DOI 10.1080/00071668708416940; Saba JA, 2001, J MASS SPECTROM, V36, P563, DOI 10.1002/jms.158; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; Suzuki N, 2003, J BIOL CHEM, V278, P46293, DOI 10.1074/jbc.M307132200; TAKAHASHI N, 1993, GLYCOCONJUGATE J, V10, P425, DOI 10.1007/BF00737962; Takahashi N, 2001, J BIOL CHEM, V276, P23230, DOI 10.1074/jbc.M101380200; Ward M, 2004, APPL ENVIRON MICROB, V70, P2567, DOI 10.1128/AEM.70.5.2567-2576.2004	49	144	185	1	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1159	1169		10.1038/nbt1132	http://dx.doi.org/10.1038/nbt1132			11	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16127450				2022-12-25	WOS:000231790600033
J	Rackham, O; Chin, JW				Rackham, O; Chin, JW			A network of orthogonal ribosome center dot mRNA pairs	NATURE CHEMICAL BIOLOGY			English	Article							ESCHERICHIA-COLI; GENE-EXPRESSION; BINDING-SITES; TRANSLATION INITIATION; SECONDARY STRUCTURE; PROTEIN-SYNTHESIS; SINGLE MESSENGER; 16S; SYSTEM; CODON	Synthetic biology promises the ability to program cells with new functions. Simple oscillators, switches, logic functions, cell-cell communication and pattern-forming circuits have been created by the connection of a small set of natural transcription factors and their binding sites in different ways to produce different networks of molecular interactions. However, the controlled synthesis of more complex synthetic networks and functions will require an expanded set of functional molecules with known molecular specificities. Here, we tailored the molecular specificity of duplicated Escherichia coli ribosome center dot mRNA pairs with respect to the wild-type ribosome and mRNAs to produce multiple orthogonal ribosome center dot orthogonal mRNA pairs that can process information in parallel with, but independent of, their wild-type progenitors. In these pairs, the ribosome exclusively translates the orthogonal mRNA, and the orthogonal mRNA is not a substrate for cellular ribosomes. We predicted and measured the network of interactions between orthogonal ribosomes and orthogonal mRNAs, and showed that they can be used to post-transcriptionally program the cell with Boolean logic.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Chin, JW (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	chin@mrc-lmb.cam.ac.uk	Rackham, Oliver/E-1264-2013; Rackham, Oliver/AGO-0005-2022	Rackham, Oliver/0000-0002-5301-9624; Rackham, Oliver/0000-0002-5301-9624				Anderson JC, 2002, CHEM BIOL, V9, P237, DOI 10.1016/S1074-5521(02)00094-7; Basu S, 2005, NATURE, V434, P1130, DOI 10.1038/nature03461; Brent R, 2004, NAT BIOTECHNOL, V22, P1211, DOI 10.1038/nbt1004-1211; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; CHEN HY, 1994, NUCLEIC ACIDS RES, V22, P4953, DOI 10.1093/nar/22.23.4953; Chin JW, 2003, SCIENCE, V301, P964, DOI 10.1126/science.1084772; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FREIER SM, 1986, BIOCHEMISTRY-US, V25, P3209, DOI 10.1021/bi00359a019; Galvao TC, 2005, APPL ENVIRON MICROB, V71, P883, DOI 10.1128/AEM.71.2.883-892.2005; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Gibbs WW, 2004, SCI AM, V290, P74; Gottesman S, 2001, COLD SPRING HARB SYM, V66, P353, DOI 10.1101/sqb.2001.66.353; Guet CC, 2002, SCIENCE, V296, P1466, DOI 10.1126/science.1067407; HUI A, 1987, P NATL ACAD SCI USA, V84, P4762, DOI 10.1073/pnas.84.14.4762; HUI A, 1987, METHOD ENZYMOL, V153, P432; HUI AS, 1988, EMBO J, V7, P4383, DOI 10.1002/j.1460-2075.1988.tb03337.x; Isaacs FJ, 2004, NAT BIOTECHNOL, V22, P841, DOI 10.1038/nbt986; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; Kaern M, 2003, ANNU REV BIOMED ENG, V5, P179, DOI 10.1146/annurev.bioeng.5.040202.121553; Kobayashi H, 2004, P NATL ACAD SCI USA, V101, P8414, DOI 10.1073/pnas.0402940101; Ladner Robert Charles, 1996, P151, DOI 10.1016/B978-012402380-2/50012-5; Laursen BS, 2005, MICROBIOL MOL BIOL R, V69, P101, DOI 10.1128/MMBR.69.1.101-123.2005; Lee K, 1996, RNA, V2, P1270; LESLIE AGW, 1990, J MOL BIOL, V213, P167, DOI 10.1016/S0022-2836(05)80129-9; LIEBHABER SA, 1992, J MOL BIOL, V226, P609, DOI 10.1016/0022-2836(92)90619-U; LOOMAN AC, 1986, NUCLEIC ACIDS RES, V14, P5481, DOI 10.1093/nar/14.13.5481; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Magliery TJ, 2001, J MOL BIOL, V307, P755, DOI 10.1006/jmbi.2001.4518; Neuhard J., 1983, METABOLISM NUCLEOTID, P95; Ohno S., 1970, EVOLUTION GENE DUPLI; Osada Y, 1999, BIOINFORMATICS, V15, P578, DOI 10.1093/bioinformatics/15.7.578; RASMUSSEN UB, 1986, BIOCHIM BIOPHYS ACTA, V881, P268, DOI 10.1016/0304-4165(86)90013-9; SCHURR T, 1993, NUCLEIC ACIDS RES, V21, P4019, DOI 10.1093/nar/21.17.4019; SHINE J, 1974, BIOCHEM J, V141, P609, DOI 10.1042/bj1410609a; Shultzaberger RK, 2001, J MOL BIOL, V313, P215, DOI 10.1006/jmbi.2001.5040; SIGMUND CD, 1984, NUCLEIC ACIDS RES, V12, P4653, DOI 10.1093/nar/12.11.4653; STEITZ JA, 1975, P NATL ACAD SCI USA, V72, P4734, DOI 10.1073/pnas.72.12.4734; STILLMAN B, 2001, RIBOSOME, V66; Taylor JS, 2004, ANNU REV GENET, V38, P615, DOI 10.1146/annurev.genet.38.072902.092831; Teichmann SA, 2004, NAT GENET, V36, P492, DOI 10.1038/ng1340; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; WIKSTROM PM, 1992, J MOL BIOL, V224, P949, DOI 10.1016/0022-2836(92)90462-S; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; WOOD TK, 1991, BIOTECHNOL BIOENG, V38, P891, DOI 10.1002/bit.260380811; Yokobayashi Y, 2002, P NATL ACAD SCI USA, V99, P16587, DOI 10.1073/pnas.252535999; You LC, 2004, NATURE, V428, P868, DOI 10.1038/nature02491; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	49	210	227	1	61	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2005	1	3					159	166		10.1038/nchembio719	http://dx.doi.org/10.1038/nchembio719			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GJ	16408021				2022-12-25	WOS:000232648700016
J	Wang, W; Budhu, A; Forgues, M; Wang, XW				Wang, W; Budhu, A; Forgues, M; Wang, XW			Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication	NATURE CELL BIOLOGY			English	Letter							VIRUS-X PROTEIN; RIBOSOME BIOGENESIS; DEPENDENT KINASE; CELL-DIVISION; RAN GTPASE; RIGHT TIME; CYCLE; P53; PHOSPHORYLATION; LOCALIZATION	Centrosome duplication is tightly controlled during faithful cell division, and unnecessary reduplication can lead to supernumerary centrosomes and multipolar spindles that are associated with most human cancer cells(1-5). In addition to nucleocytoplasmic transport, the Ran-Crm1 network is involved in regulating centrosome duplication to ensure the formation of a bipolar spindle(6-8). Here, we discover that nucleophosmin (NPM) may be a Ran-Crm1 substrate that controls centrosome duplication. NPM contains a functional nuclear export signal (NES) that is responsible for both its nucleocytoplasmic shuttling and its association with centrosomes, which are Ran-Crm1-dependent as they are sensitive to Crm1-specific nuclear export inhibition, either by leptomycin B (LMB) or by the expression of a Ran-binding protein, RanBP1. Notably, LMB treatment induces premature centrosome duplication in quiescent cells, which coincides with NPM dissociation from centrosomes. Moreover, deficiency of NPM by RNA interference results in supernumerary centrosomes, which can be reversed by reintroducing wild-type but not NES-mutated NPM. Mutation of a potential proline-dependent kinase phosphorylation site at residue 95, from threonine to aspartic acid (T95D) within the NES motif, abolishes NPM association and inhibition of centrosome duplication. Our results are consistent with the hypothesis that the Ran-Crm1 complex may promote a local enrichment of NPM on centrosomes, thereby preventing centrosome reduplication.	NCI, Liver Carcinogenesis Sect, Human Carcinogenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, XW (corresponding author), NCI, Liver Carcinogenesis Sect, Human Carcinogenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.	xw3u@nih.gov	Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X	NATIONAL CANCER INSTITUTE [Z01BC005793, ZIABC005793] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Clarke PR, 2001, TRENDS CELL BIOL, V11, P366, DOI 10.1016/S0962-8924(01)02071-2; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Di Fiore B, 2004, CELL CYCLE, V3, P305; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Forgues M, 2003, MOL CELL BIOL, V23, P5282, DOI 10.1128/MCB.23.15.5282-5292.2003; Forgues M, 2001, J BIOL CHEM, V276, P22797, DOI 10.1074/jbc.M101259200; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Keryer G, 2003, MOL BIOL CELL, V14, P4260, DOI 10.1091/mbc.E02-11-0773; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Moudjou M, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P111; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nishimura Y, 2002, BIOSCI BIOTECH BIOCH, V66, P2239, DOI 10.1271/bbb.66.2239; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2002, MOL BIOL CELL, V13, P2016, DOI 10.1091/mbc.02-03-0036; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sluder G, 1999, BIOL CELL, V91, P413, DOI 10.1016/S0248-4900(99)80083-5; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Zatsepina OV, 1999, J CELL SCI, V112, P455	28	225	232	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2005	7	8					823	830		10.1038/ncb1282	http://dx.doi.org/10.1038/ncb1282			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	950TU	16041368				2022-12-25	WOS:000230881500017
J	Difilippantonio, S; Celeste, A; Fernandez-Capetillo, O; Chen, HT; San Martin, BR; Van Laethem, F; Yang, YP; Petukhova, GV; Eckhaus, M; Feigenbaum, L; Manova, K; Kruhlak, M; Camerini-Otero, RD; Sharan, S; Nussenzweig, M; Nussenzweig, A				Difilippantonio, S; Celeste, A; Fernandez-Capetillo, O; Chen, HT; San Martin, BR; Van Laethem, F; Yang, YP; Petukhova, GV; Eckhaus, M; Feigenbaum, L; Manova, K; Kruhlak, M; Camerini-Otero, RD; Sharan, S; Nussenzweig, M; Nussenzweig, A			Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models	NATURE CELL BIOLOGY			English	Article							NIJMEGEN-BREAKAGE-SYNDROME; DOUBLE-STRAND BREAKS; CLASS-SWITCH RECOMBINATION; FORKHEAD-ASSOCIATED DOMAIN; S-PHASE CHECKPOINT; DNA-DAMAGE; MRE11 COMPLEX; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; HISTONE H2AX	Nijmegen breakage syndrome ( NBS) is a chromosomal fragility disorder that shares clinical and cellular features with ataxia telangiectasia. Here we demonstrate that Nbs1- null B cells are defective in the activation of ataxia- telangiectasia- mutated ( Atm) in response to ionizing radiation, whereas ataxia- telangiectasia- and Rad3- related ( Atr)- dependent signalling and Atm activation in response to ultraviolet light, inhibitors of DNA replication, or hypotonic stress are intact. Expression of the main human NBS allele rescues the lethality of Nbs1(-/-) mice, but leads to immunodeficiency, cancer predisposition, a defect in meiotic progression in females and cell- cycle checkpoint defects that are associated with a partial reduction in Atm activity. The Mre11 interaction domain of Nbs1 is essential for viability, whereas the Forkhead- associated ( FHA) domain is required for T- cell and oocyte development and efficient DNA damage signalling. Reconstitution of Nbs1 knockout mice with various mutant isoforms demonstrates the biological impact of impaired Nbs1 function at the cellular and organismal level.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; NCI, Mouse Canc Genet Program, Frederick, MD 21702 USA; NIDDKD, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA; NIH, Div Vet Resources, Off Res Serv, Off Director, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nussenzweig, A (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	andre_nussenzweig@nih.gov	Reina-San-Martin, Bernardo/I-9484-2016; Nussenzweig, Michel/AAE-7292-2019; Fernandez-Capetillo, Oscar/H-3508-2015	Reina-San-Martin, Bernardo/0000-0003-2083-6166; Fernandez-Capetillo, Oscar/0000-0002-2690-6885	NATIONAL CANCER INSTITUTE [ZIABC010283, Z01BC009255, ZICBC009255, Z01BC010283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Cerosaletti K, 2004, J BIOL CHEM, V279, P38813, DOI 10.1074/jbc.M404294200; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Costanzo V, 2004, PLOS BIOL, V2, P600, DOI 10.1371/journal.pbio.0020110; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Davalos AR, 2004, CELL CYCLE, V3, P1579, DOI 10.4161/cc.3.12.1286; Demuth I, 2004, HUM MOL GENET, V13, P2385, DOI 10.1093/hmg/ddh278; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Dumon-Jones V, 2003, CANCER RES, V63, P7263; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; FERNANDEZCAPETILLO, 2003, DEV CELL, V4, P497; FERNANDEZCAPETILLO, 2002, NAT CELL BIOL, V4, P993; Gregorek H, 2002, CLIN EXP IMMUNOL, V130, P319, DOI 10.1046/j.1365-2249.2002.01971.x; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kracker S, 2005, P NATL ACAD SCI USA, V102, P1584, DOI 10.1073/pnas.0409191102; Lee AC, 2005, CELL CYCLE, V4, P177, DOI 10.4161/cc.4.1.1354; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee JH, 2003, MOL CANCER RES, V1, P674; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lista F, 1997, CANCER RES, V57, P4408; Lumsden JM, 2004, J EXP MED, V200, P1111, DOI 10.1084/jem.20041074; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Mochan TA, 2003, CANCER RES, V63, P8586; Pan Q, 2002, EUR J IMMUNOL, V32, P1300, DOI 10.1002/1521-4141(200205)32:5<1300::AID-IMMU1300>3.0.CO;2-L; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Reina-San-Martin B, 2004, J EXP MED, V200, P1103, DOI 10.1084/jem.20041162; SPEED RM, 1982, CHROMOSOMA, V85, P427, DOI 10.1007/BF00330366; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Tauchi H, 1999, GENOMICS, V55, P242, DOI 10.1006/geno.1998.5657; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yang YP, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng080; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	52	178	183	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2005	7	7					675	U56		10.1038/ncb1270	http://dx.doi.org/10.1038/ncb1270			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	941BX	15965469	Green Published			2022-12-25	WOS:000230190800011
J	Reeves, PM; Bommarius, B; Lebeis, S; McNulty, S; Christensen, J; Swimm, A; Chahroudi, A; Chavan, R; Feinberg, MB; Veach, D; Bornmann, W; Sherman, M; Kalman, D				Reeves, PM; Bommarius, B; Lebeis, S; McNulty, S; Christensen, J; Swimm, A; Chahroudi, A; Chavan, R; Feinberg, MB; Veach, D; Bornmann, W; Sherman, M; Kalman, D			Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases	NATURE MEDICINE			English	Article							ACTIN-BASED MOTILITY; VACCINIA VIRUS; INTRACELLULAR MOVEMENT; BCR-ABL; PROTEIN; MICROTUBULES; SMALLPOX; COMPLEX; FORM; RESISTANCE	The Poxviridae family members vaccinia and variola virus enter mammalian cells, replicate outside the nucleus and produce virions that travel to the cell surface along microtubules, fuse with the plasma membrane and egress from infected cells toward apposing cells on actin-filled membranous protrusions. We show that cell- associated enveloped virions (CEV) use Abl- and Src-family tyrosine kinases for actin motility, and that these kinases act in a redundant fashion, perhaps permitting motility in a greater range of cell types. Additionally, release of CEV from the cell requires Abl- but not Src- family tyrosine kinases, and is blocked by STI-571 ( Gleevec), an Abl- family kinase inhibitor used to treat chronic myelogenous leukemia in humans. Finally, we show that STI-571 reduces viral dissemination by five orders of magnitude and promotes survival in infected mice, suggesting possible use for this drug in treating smallpox or complications associated with vaccination. This therapeutic approach may prove generally efficacious in treating microbial infections that rely on host tyrosine kinases, and, because the drug targets host but not viral molecules, this strategy is much less likely to engender resistance compared to conventional antimicrobial therapies.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Microbiol & Mol Genet Grad Program, Atlanta, GA 30322 USA; Aarhus Univ, Dept Epidemiol, NANEA, Inst Publ Hlth, DK-8000 Aarhus, Denmark; Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Texas, MD Anderson Canc Ctr, Organ Chem Sect, Houston, TX 77030 USA	Emory University; Emory University; Aarhus University; Emory University; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kalman, D (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 615 Michael St,Whitehead Res Bldg 144, Atlanta, GA 30322 USA.	dkalman@emory.edu	Reeves, Patrick/I-1066-2018; Swimm, Alyson/D-1025-2013	Reeves, Patrick/0000-0001-8202-0723; Veach, Darren/0000-0002-8201-622X; Bommarius, Bettina/0000-0002-1283-0218; Swimm, Alyson/0000-0001-9975-0247	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046007, R01AI056067] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline; NIAID NIH HHS [P01 AI046007, R01 AI056067, P01 AI 46007, R01-AI056067-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amorosa VK, 2003, CLIN INFECT DIS, V37, P426, DOI 10.1086/375823; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; [Anonymous], 1997, DECONVOLUTION IMAGES; APPLEYARD G, 1971, J GEN VIROL, V13, P9, DOI 10.1099/0022-1317-13-1-9; Baker R, 2003, ANTIVIR RES, V57, P13, DOI 10.1016/S0166-3542(02)00196-1; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLASCO R, 1993, J VIROL, V67, P3319, DOI 10.1128/JVI.67.6.3319-3325.1993; Boulter E A, 1973, Prog Med Virol, V16, P86; Carter GC, 2003, J GEN VIROL, V84, P2443, DOI 10.1099/vir.0.19271-0; CHAHROUDI A, 2005, IN PRESS J VIROL; Kohn William G, 2003, MMWR Recomm Rep, V52, P1; Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969; Dorsey JF, 2000, CANCER RES, V60, P3127; DRUCKER BJ, 2001, HEMATOL-AM SOC HEMAT, P87; Esposito JJ, 2001, FIELDS VIROLOGY, P2885; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; Gould IM, 2002, CURR OPIN INFECT DIS, V15, P395, DOI 10.1097/00001432-200208000-00007; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Harrison SC, 2004, P NATL ACAD SCI USA, V101, P11178, DOI 10.1073/pnas.0403600101; Hollinshead M, 2001, J CELL BIOL, V154, P389, DOI 10.1083/jcb.200104124; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Ichihashi Y, 1996, VIROLOGY, V220, P491, DOI 10.1006/viro.1996.0337; IDEMYOR V, 1993, ANN PHARMACOTHER, V27, P1285, DOI 10.1177/106002809302701023; Kalman D, 1999, MOL BIOL CELL, V10, P1665, DOI 10.1091/mbc.10.5.1665; Kalman D, 1999, NAT CELL BIOL, V1, P389, DOI 10.1038/14087; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Law M, 2002, J GEN VIROL, V83, P209, DOI 10.1099/0022-1317-83-1-209; Law M, 2001, VIROLOGY, V280, P132, DOI 10.1006/viro.2000.0750; Li XZ, 2004, DRUGS, V64, P159, DOI 10.2165/00003495-200464020-00004; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Moss B, 2001, FIELDS VIROLOGY, P2849; Nagar B, 2002, CANCER RES, V62, P4236; *NAT RES COUNC, 1999, ASS FUT SC NEEDS LIV, V126; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Newsome TP, 2004, SCIENCE, V306, P124, DOI 10.1126/science.1101509; PARKINSON JE, 1994, VIROLOGY, V204, P376, DOI 10.1006/viro.1994.1542; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Ramirez JC, 2003, ARCH VIROL, V148, P827, DOI 10.1007/s00705-003-0006-z; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Scaplehorn N, 2002, CURR BIOL, V12, P740, DOI 10.1016/S0960-9822(02)00812-6; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Smith GL, 2003, ANNU REV MICROBIOL, V57, P323, DOI 10.1146/annurev.micro.57.030502.091037; Smith GL, 2002, J GEN VIROL, V83, P2915, DOI 10.1099/0022-1317-83-12-2915; Smith JN, 2003, J BACTERIOL, V185, P1357, DOI 10.1128/JB.185.4.1357-1366.2003; Swimm A, 2004, MOL BIOL CELL, V15, P3520, DOI 10.1091/mbc.E04-02-0093; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Vanderplasschen A, 1998, P NATL ACAD SCI USA, V95, P7544, DOI 10.1073/pnas.95.13.7544; Ward BM, 2003, J VIROL, V77, P4113, DOI 10.1128/JVI.77.7.4113-4126.2003; Ward BM, 2001, J VIROL, V75, P11651, DOI 10.1128/JVI.75.23.11651-11663.2001; Ward BM, 2001, J VIROL, V75, P4802, DOI 10.1128/JVI.75.10.4802-4813.2001; Wisniewski D, 2002, CANCER RES, V62, P4244; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Wolffe EJ, 1998, VIROLOGY, V244, P20, DOI 10.1006/viro.1998.9103; YUWEN H, 1993, VIROLOGY, V195, P732, DOI 10.1006/viro.1993.1424	59	168	182	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					731	739		10.1038/nm1265	http://dx.doi.org/10.1038/nm1265			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15980865				2022-12-25	WOS:000230304200029
J	Jazayeri, A; Falck, J; Lukas, C; Bartek, J; Smith, GCM; Lukas, J; Jackson, SP				Jazayeri, A; Falck, J; Lukas, C; Bartek, J; Smith, GCM; Lukas, J; Jackson, SP			ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks	NATURE CELL BIOLOGY			English	Article							S-PHASE CHECKPOINT; ATAXIA-TELANGIECTASIA; DAMAGE CHECKPOINT; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; GENOTOXIC STRESS; HUMAN RAD17; PHOSPHORYLATION; ACTIVATION; REPAIR	It is generally thought that the DNA- damage checkpoint kinases, ataxia- telangiectasia mutated ( ATM) and ATM- and Rad3-related ( ATR), work independently of one another. Here, we show that ATM and the nuclease activity of meiotic recombination 11 ( Mre11) are required for the processing of DNA double- strand breaks ( DSBs) to generate the replication protein A ( RPA)- coated ssDNA that is needed for ATR recruitment and the subsequent phosphorylation and activation of Chk1. Moreover, we show that efficient ATM- dependent ATR activation in response to DSBs is restricted to the S and G2 cell cycle phases and requires CDK kinase activity. Thus, in response to DSBs, ATR activation is regulated by ATM in a cell- cycle dependent manner.	Univ Cambridge, Wellcome Trust & Canc Res UK Gurdon Inst, Cambridge CB2 1QN, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QN, England; KuDOS Pharmaceut Ltd, Cambridge CB4 0WG, England; Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Danish Canc Soc, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark	University of Cambridge; University of Cambridge; AstraZeneca; Danish Cancer Society; Danish Cancer Society	Jackson, SP (corresponding author), Univ Cambridge, Wellcome Trust & Canc Res UK Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	s.jackson@gurdon.cam.ac.uk	Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014; Bartek, Jiri/G-5870-2014	Jackson, Stephen Philip/0000-0001-9317-7937; Lukas, Claudia/0000-0001-7169-6883; Lukas, Jiri/0000-0001-9087-506X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brown EJ, 2000, GENE DEV, V14, P397; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu QH, 2000, GENE DEV, V14, P1448; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Moreau S, 1999, MOL CELL BIOL, V19, P556; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Nakada D, 2004, MOL CELL BIOL, V24, P10016, DOI 10.1128/MCB.24.22.10016-10025.2004; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Post S, 2001, P NATL ACAD SCI USA, V98, P13102, DOI 10.1073/pnas.231364598; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	45	845	877	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					37	U13		10.1038/ncb1337	http://dx.doi.org/10.1038/ncb1337			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	16327781				2022-12-25	WOS:000234651500010
J	Mori, T; Kuroiwa, H; Higashiyama, T; Kuroiwa, T				Mori, T; Kuroiwa, H; Higashiyama, T; Kuroiwa, T			GENERATIVE CELL SPECIFIC 1 is essential for angiosperm fertilization	NATURE CELL BIOLOGY			English	Article							LILIUM-LONGIFLORUM; CHLAMYDOMONAS-REINHARDTII; ARABIDOPSIS-THALIANA; GAMETIC CELLS; POLLEN; SPERM; PLANTS; MAIZE; GENE; DIFFERENTIATION	The double fertilization process in angiosperms is based on the delivery of a pair of sperm cells by the pollen tube ( the male gametophyte), which elongates towards an embryo sac ( the female gametophyte) enclosing an egg and a central cell. Several studies have described the mechanisms of gametophyte interaction(1), and also the fertilization process - from pollination to pollen tube acceptance(2-5). However, the mechanisms of gamete interaction are not fully understood(6,7). Cytological studies have shown that male gametes possess distinct cell- surface structures(8,9) and genes specific to male gametes have been detected in cDNA libraries(10-14). Thus, studies of isolated gametes may offer clues to understanding the sperm - egg interaction. In this study, we identified a novel protein, designated GCS1 ( GENERATIVE CELL SPECIFIC 1), using generative cells isolated from Lilium longiflorum pollen. GCS1 possesses a carboxy- terminal transmembrane domain, and homologues are present in various species, including non-angiosperms. Immunological assays indicate that GCS1 is accumulated during late gametogenesis and is localized on the plasma membrane of generative cells. In addition, Arabidopsis thaliana GCS1 mutant gametes fail to fuse, resulting in male sterility and suggesting that GCS1 is a critical fertilization factor in angiosperms.	Rikkyo St Pauls Univ, Coll Sci, Dept Life Sci, Toshima Ku, Tokyo 1718501, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Mori, T (corresponding author), Rikkyo St Pauls Univ, Coll Sci, Dept Life Sci, Toshima Ku, Nishiikebukuro 3-34-1, Tokyo 1718501, Japan.	z2002377@tvr.rikkyo.ne.jp	Higashiyama, Tetsuya/C-2882-2012; Mori, Toshiyuki/F-8488-2013	Higashiyama, Tetsuya/0000-0002-7346-360X; 				Bent AF, 2000, PLANT PHYSIOL, V124, P1540, DOI 10.1104/pp.124.4.1540; BLOMSTEDT CK, 1992, PHYSIOL PLANTARUM, V85, P396, DOI 10.1111/j.1399-3054.1992.tb04753.x; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Engel ML, 2003, PLANT J, V34, P697, DOI 10.1046/j.1365-313X.2003.01761.x; ESTELLE MA, 1987, MOL GEN GENET, V206, P200, DOI 10.1007/BF00333575; FAURE JE, 1994, SCIENCE, V263, P1598, DOI 10.1126/science.263.5153.1598; Faure JE, 2003, PLANT J, V33, P1051, DOI 10.1046/j.1365-313X.2003.01692.x; Higashiyama T, 2001, SCIENCE, V293, P1480, DOI 10.1126/science.1062429; Huck N, 2003, DEVELOPMENT, V130, P2149, DOI 10.1242/dev.00458; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; Kim S, 2003, P NATL ACAD SCI USA, V100, P16125, DOI 10.1073/pnas.2533800100; Marton ML, 2005, SCIENCE, V307, P573, DOI 10.1126/science.1104954; May ST, 2002, MOL BIOTECHNOL, V20, P209, DOI 10.1385/MB:20:2:209; Misumi O, 1999, PROTOPLASMA, V209, P273, DOI 10.1007/BF01453455; Mori T, 2000, PROTOPLASMA, V214, P57, DOI 10.1007/BF02524262; Mori T, 2003, BIOCHEM BIOPH RES CO, V306, P564, DOI 10.1016/S0006-291X(03)01005-2; Moriyama Y, 2003, GENETICS, V164, P963; Nishimura Y, 2002, GENE DEV, V16, P1116, DOI 10.1101/gad.979902; Palanivelu R, 2003, CELL, V114, P47, DOI 10.1016/S0092-8674(03)00479-3; Rotman N, 2003, CURR BIOL, V13, P432, DOI 10.1016/S0960-9822(03)00093-9; Rotman N, 2005, CURR BIOL, V15, P244, DOI 10.1016/j.cub.2005.01.013; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Southworth D, 1996, SEX PLANT REPROD, V9, P269, DOI 10.1007/BF02152701; TANAKA I, 1988, PROTOPLASMA, V142, P68, DOI 10.1007/BF01273227; Tanaka I, 1997, SEX PLANT REPROD, V10, P1, DOI 10.1007/s004970050060; Ueda K, 2000, CHROMOSOMA, V108, P491; Weterings K, 2004, PLANT CELL, V16, pS107, DOI 10.1105/tpc.016873; Xu HL, 1999, PLANT MOL BIOL, V39, P607, DOI 10.1023/A:1006162120037; Xu HL, 1999, P NATL ACAD SCI USA, V96, P2554, DOI 10.1073/pnas.96.5.2554; Xu HP, 2002, SEX PLANT REPROD, V14, P339, DOI 10.1007/s00497-002-0128-6; YADEGARI R, 1994, PLANT CELL, V6, P1713, DOI 10.1105/tpc.6.12.1713	31	320	336	4	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					64	71		10.1038/ncb1345	http://dx.doi.org/10.1038/ncb1345			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	16378100				2022-12-25	WOS:000234651500013
J	Yazaki, Y; Kadowaki, T				Yazaki, Y; Kadowaki, T			Combating diabetes and obesity in Japan	NATURE MEDICINE			English	Editorial Material									Natl Hosp Org, Meguro Ku, Tokyo 1528621, Japan; Univ Tokyo, Dept Metab Dis, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Yazaki, Y (corresponding author), Natl Hosp Org, Meguro Ku, 2-5-21, Tokyo 1528621, Japan.	yazaki-yoshio@nho.hosp.go.jp						KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; Mandavilli A, 2004, NAT MED, V10, P325, DOI 10.1038/nm0404-325; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	3	40	41	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2006	12	1					73	74		10.1038/nm0106-73	http://dx.doi.org/10.1038/nm0106-73			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397574				2022-12-25	WOS:000234419000054
J	Sorensen, PW; Fine, JM; Dvornikovs, V; Jeffrey, CS; Shao, F; Wang, JZ; Vrieze, LA; Anderson, KR; Hoye, TR				Sorensen, PW; Fine, JM; Dvornikovs, V; Jeffrey, CS; Shao, F; Wang, JZ; Vrieze, LA; Anderson, KR; Hoye, TR			Mixture of new sulfated steroids functions as a migratory pheromone in the sea lamprey	NATURE CHEMICAL BIOLOGY			English	Article							UNIQUE BILE-ACIDS; PETROMYZON-MARINUS; MANAGEMENT; CONFIGURATION; SQUALAMINE; SUPERIOR; FISHES; SHARK; WATER; LAKES	The sea lamprey is an ancient, parasitic fish that invaded the Great Lakes a century ago, where it triggered the collapse of many fisheries(1). Like many fishes, this species relies on chemical cues to mediate key aspects of its life, including migration and reproduction(2,3). Here we report the discovery of a multicomponent steroidal pheromone that is released by stream-dwelling larval lamprey and guides adults to spawning streams. We isolated three compounds with pheromonal activity ( in submilligram quantities from 8,000 l of larval holding water) and deduced their structures. The most important compound contains an unprecedented 1-(3-aminopropyl) pyrrolidin-2-one subunit and is related to squalamine, an antibiotic produced by sharks(4). We verified its structure by chemical synthesis; it attracts adult lamprey at very low (subpicomolar) concentrations. The second component is another new sulfated steroid and the third is petromyzonol sulfate, a known lamprey-specific bile acid derivative. This mixture is the first migratory pheromone identified in a vertebrate and is being investigated for use in lamprey control	Univ Minnesota, Dept Fisheries Wildlife & Conservat Biol, St Paul, MN 55108 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Sorensen, PW (corresponding author), Univ Minnesota, Dept Fisheries Wildlife & Conservat Biol, St Paul, MN 55108 USA.	psorensen@umn.edu; hoye@chem.umn.edu	Jeffrey, Christopher S/M-7918-2013	Jeffrey, Christopher S/0000-0002-2540-6694; Sorensen, Peter/0000-0003-0321-1279	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065597] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65597] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aidley DJ, 1981, ANIMAL MIGRATION; [Anonymous], 2014, PHEROMONES ANIMAL BE; Applegate VC, 1950, NATURAL HIST SEA LAM; BERGSTEDT RA, 1995, T AM FISH SOC, V124, P235, DOI 10.1577/1548-8659(1995)124<0235:EFLOHB>2.3.CO;2; Bjerselius R, 2000, CAN J FISH AQUAT SCI, V57, P557, DOI 10.1139/cjfas-57-3-557; BOYLE CD, 1995, TETRAHEDRON LETT, V36, P5695, DOI [10.1016/0040-4039(95)01126-3, 10.1016/00404-0399(50)11263-]; Christie GC, 2003, J GREAT LAKES RES, V29, P1, DOI 10.1016/S0380-1330(03)70474-2; Close DA, 2002, FISHERIES, V27, P19, DOI 10.1577/1548-8446(2002)027<0019:TEACIO>2.0.CO;2; DOVING KB, 1980, ACTA PHYSIOL SCAND, V108, P123, DOI 10.1111/j.1748-1716.1980.tb06509.x; Fine JM, 2005, J CHEM ECOL, V31, P2205, DOI 10.1007/s10886-005-6745-4; Fine JM, 2004, J CHEM ECOL, V30, P2091, DOI 10.1023/B:JOEC.0000048776.16091.b1; FOREY P, 1993, NATURE, V361, P129, DOI 10.1038/361129a0; Kleerekoper H., 1972, P373; Kolar CS, 2002, SCIENCE, V298, P1233, DOI 10.1126/science.1075753; Li W, 1997, J COMP PHYSIOL A, V180, P429, DOI 10.1007/s003590050060; LI WM, 1995, J GEN PHYSIOL, V105, P569, DOI 10.1085/jgp.105.5.569; Li WM, 2002, SCIENCE, V296, P138, DOI 10.1126/science.1067797; MOORE HH, 1980, CAN J FISH AQUAT SCI, V37, P1851, DOI 10.1139/f80-227; MOORE KS, 1993, P NATL ACAD SCI USA, V90, P1354, DOI 10.1073/pnas.90.4.1354; Polkinghorne CN, 2001, FISH PHYSIOL BIOCHEM, V24, P15, DOI 10.1023/A:1011159313239; Rao MN, 2000, J NAT PROD, V63, P631, DOI 10.1021/np990514f; Schroeder FC, 2004, ORG LETT, V6, P3019, DOI 10.1021/ol049233b; SMITH BR, 1980, CAN J FISH AQUAT SCI, V37, P1780, DOI 10.1139/f80-222; Sorensen Peter W., 1998, P375; Sorensen PW, 2003, J GREAT LAKES RES, V29, P66, DOI 10.1016/S0380-1330(03)70478-X; TEETER J, 1980, CAN J FISH AQUAT SCI, V37, P2123, DOI 10.1139/f80-254; Twohey MB, 2003, J GREAT LAKES RES, V29, P794, DOI 10.1016/S0380-1330(03)70532-2; Vrieze LA, 2001, CAN J FISH AQUAT SCI, V58, P2374, DOI 10.1139/cjfas-58-12-2374; Zhang DH, 2003, ORG LETT, V5, P3257, DOI 10.1021/ol035062j; ZHU XP, 1987, CAN J CHEM, V65, P2447, DOI 10.1139/v87-408	30	197	202	1	71	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2005	1	6					324	328		10.1038/nchembio739	http://dx.doi.org/10.1038/nchembio739			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	979GH	16408070				2022-12-25	WOS:000232929900009
J	Kube, M; Beck, A; Zinder, SH; Kuhl, H; Reinhardt, R; Adrian, L				Kube, M; Beck, A; Zinder, SH; Kuhl, H; Reinhardt, R; Adrian, L			Genome sequence of the chlorinated compound respiring bacterium Dehalococcoides species strain CBDB1	NATURE BIOTECHNOLOGY			English	Article							VINYL-CHLORIDE REDUCTASE; IDENTIFICATION; TETRACHLOROETHENE; DEHALOGENASE; DATABASE; BIOAUGMENTATION; ETHENOGENES; SOFTWARE; GENES		Tech Univ Berlin, FG Tech Biochem, D-13353 Berlin, Germany; Cornell Univ, Dept Microbiol, Ithaca, NY 14853 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Technical University of Berlin; Cornell University; Max Planck Society	Adrian, L (corresponding author), Tech Univ Berlin, FG Tech Biochem, Seestr 13, D-13353 Berlin, Germany.	lorenz.adrian@tu-berlin.de	Kuhl, Heiner/L-2737-2019; Adrian, Lorenz/A-4443-2012	Adrian, Lorenz/0000-0001-8205-0842; Reinhardt, Richard/0000-0001-9376-2132				Adrian L, 2000, NATURE, V408, P580, DOI 10.1038/35046063; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Baxevanis AD, 2003, NUCLEIC ACIDS RES, V31, P1, DOI 10.1093/nar/gkg120; Bunge M, 2003, NATURE, V421, P357, DOI 10.1038/nature01237; Chien MC, 2004, SCIENCE, V305, P1966, DOI 10.1126/science.1099776; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fennell DE, 2004, ENVIRON SCI TECHNOL, V38, P2075, DOI 10.1021/es034989b; Fukui T, 2005, GENOME RES, V15, P352, DOI 10.1101/gr.3003105; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Jansen R, 2002, MOL MICROBIOL, V43, P1565, DOI 10.1046/j.1365-2958.2002.02839.x; Karlin S, 1998, CURR OPIN MICROBIOL, V1, P598, DOI 10.1016/S1369-5274(98)80095-7; Krajmalnik-Brown R, 2004, APPL ENVIRON MICROB, V70, P6347, DOI 10.1128/AEM.70.10.6347-6351.2004; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Lendvay JM, 2003, ENVIRON SCI TECHNOL, V37, P1422, DOI 10.1021/es025985u; Magnuson JK, 2000, APPL ENVIRON MICROB, V66, P5141, DOI 10.1128/AEM.66.12.5141-5147.2000; Maillard J, 2005, ENVIRON MICROBIOL, V7, P107, DOI 10.1111/j.1462-2920.2004.00671.x; Major DW, 2002, ENVIRON SCI TECHNOL, V36, P5106, DOI 10.1021/es0255711; MaymoGatell X, 1997, SCIENCE, V276, P1568, DOI 10.1126/science.276.5318.1568; Muller JA, 2004, APPL ENVIRON MICROB, V70, P4880, DOI 10.1128/AEM.70.8.4880-4888.2004; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; Rabus R, 2005, ARCH MICROBIOL, V183, P27, DOI 10.1007/s00203-004-0742-9; Rhee SK, 2003, FEMS MICROBIOL ECOL, V43, P317, DOI 10.1111/j.1574-6941.2003.tb01072.x; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Sekizaki T, 2001, J BACTERIOL, V183, P500, DOI 10.1128/JB.183.2.500-511.2001; Seshadri R, 2005, SCIENCE, V307, P105, DOI 10.1126/science.1102226; Smidt H, 2004, ANNU REV MICROBIOL, V58, P43, DOI 10.1146/annurev.micro.58.030603.123600; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tropel D, 2004, MICROBIOL MOL BIOL R, V68, P474, DOI 10.1128/MMBR.68.3.474-500.2004	34	229	482	3	69	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2005	23	10					1269	1273		10.1038/nbt1131	http://dx.doi.org/10.1038/nbt1131			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QZ	16116419	hybrid			2022-12-25	WOS:000232469600028
J	Gribouval, O; Gonzales, M; Neuhaus, T; Aziza, J; Bieth, E; Laurent, N; Bouton, JM; Feuillet, F; Makni, S; Ben Amar, H; Laube, G; Delezoide, AL; Bouvier, R; Dijoud, F; Ollgnon-Roman, E; Roume, J; Joubert, M; Antignac, C; Gubler, MC				Gribouval, O; Gonzales, M; Neuhaus, T; Aziza, J; Bieth, E; Laurent, N; Bouton, JM; Feuillet, F; Makni, S; Ben Amar, H; Laube, G; Delezoide, AL; Bouvier, R; Dijoud, F; Ollgnon-Roman, E; Roume, J; Joubert, M; Antignac, C; Gubler, MC			Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis	NATURE GENETICS			English	Article							II TYPE-1 RECEPTOR; KIDNEY; FETAL; HYPOCALVARIA; EXPRESSION	Autosomal recessive renal tubular dysgenesis is a severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early- onset oligohydramnios ( Potter phenotype). Absence or paucity of differentiated proximal tubules is the histopathological hallmark of the disease and may be associated with skull ossification defects. We studied 11 individuals with renal tubular dysgenesis, belonging to nine families, and found that they had homozygous or compound heterozygous mutations in the genes encoding renin, angiotensinogen, angiotensin converting enzyme or angiotensin II receptor type 1. We propose that renal lesions and early anuria result from chronic low perfusion pressure of the fetal kidney, a consequence of renin- angiotensin system inactivity. This is the first identification to our knowledge of a renal mendelian disorder linked to genetic defects in the renin-angiotensin system, highlighting the crucial role of the renin-angiotensin system in human kidney development.	Univ Paris 05, Hop Necker Enfants Malad, INSERM, U574, F-75743 Paris, France; Hop St Antoine, Unite Foetopathol, F-75012 Paris, France; Univ Zurich, Childrens Hosp, CH-8032 Zurich, Switzerland; Hop Purpan, Serv Genet Med, F-31059 Toulouse, France; Hop Purpan, Anat Pathol Lab, F-31059 Toulouse, France; CHU, Serv Anat Pathol, F-21079 Dijon, France; Hop Prive Antony, F-92160 Antony, France; CHU Brasbois, Hop Enfants, Serv med Infantile, F-54511 Vandoeuvre Les Nancy, France; Hop Habib Bourguiba, Serv Genet Med, Sfax, Tunisia; Hop Hedi Chaker, Serv Neonatol, Sfax 3029, Tunisia; Hop Robert Debre, Unite Foetopathol, F-75019 Paris, France; Hop Edouard Herriot, Anat Pathol Lab, F-69437 Lyon, France; Hop Debrousse, Anat Pathol Lab, F-69322 Lyon, France; Hop Croix Rousse, Ctr Diagnost Antenatal, F-69317 Lyon, France; CHU Poissy St Germain, Serv Histoembryol, F-78303 Poissy, France; Hop Hotel Dieu, Serv Anat Pathol, F-44093 Nantes, France; Univ Paris 05, Hop Necker Enfants Malad, Dept Genet, F-75743 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; University Children's Hospital Zurich; University of Zurich; CHU de Toulouse; CHU de Toulouse; CHU Dijon Bourgogne; CHU de Nancy; Universite de Sfax; Hopital Habib Bourguiba; Universite de Sfax; Hopital Hedi Chaker; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; CHU Lyon; CHU Lyon; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Gubler, MC (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, INSERM, U574, 149 Rue Sevres, F-75743 Paris, France.	gubler@necker.fr	Gribouval, Olivier/A-7689-2015; ANTIGNAC, Corinne/H-8945-2017	Gribouval, Olivier/0000-0003-0238-8224; ANTIGNAC, Corinne/0000-0002-9934-4940; Gubler, Marie-Claire/0000-0002-3526-5661				ALLANSON JE, 1992, AM J MED GENET, V43, P811, DOI 10.1002/ajmg.1320430512; ALLANSON JE, 1983, AM J MED GENET, V16, P57, DOI 10.1002/ajmg.1320160110; ARIEL I, 1995, PEDIATR PATHOL LAB M, V15, P915, DOI 10.3109/15513819509027027; BARR M, 1991, TERATOLOGY, V44, P485, DOI 10.1002/tera.1420440503; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; GENEST DR, 1991, HUM PATHOL, V22, P147, DOI 10.1016/0046-8177(91)90036-O; Gubler MC, 1995, ANN PEDIATR-PARIS, V42, P608; HUBERT C, 1991, J BIOL CHEM, V266, P15377; Johal JS, 1998, PEDIATR DEVEL PATHOL, V1, P433, DOI 10.1007/s100249900059; Kemper M, 2001, CLIN NEPHROL, V56, pS9; Kriegsmann J, 2000, PATHOL RES PRACT, V196, P861, DOI 10.1016/S0344-0338(00)80090-4; Kumar D, 1997, J MED GENET, V34, P541, DOI 10.1136/jmg.34.7.541; LANDING BH, 1994, PEDIATR PATHOL, V14, P87, DOI 10.3109/15513819409022029; Lopez MLSS, 2004, DEV CELL, V6, P719; Mahieu-Caputo D, 2000, AM J PATHOL, V156, P629, DOI 10.1016/S0002-9440(10)64767-0; MARCUSSEN N, 1991, LAB INVEST, V65, P558; Martinovic J, 2001, LANCET, V358, P241, DOI 10.1016/S0140-6736(01)05426-5; McFadden DE, 1997, J MED GENET, V34, P846, DOI 10.1136/jmg.34.10.846; Miura S, 2003, HYPERTENS RES, V26, P937, DOI 10.1291/hypres.26.937; Morris BJ, 1984, J HYPERTENS, V2, P231; Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601; Nishimura H, 1999, MOL CELL, V3, P1, DOI 10.1016/S1097-2765(00)80169-0; Querfeld U, 1996, J Perinatol, V16, P498; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Schutz S, 1996, AM J PATHOL, V149, P2067; SEYLE H, 1946, NATURE, V158, P131; Streatfeild-James RMA, 1998, FEBS LETT, V436, P267, DOI 10.1016/S0014-5793(98)01145-4; Takahashi N, 2004, TRENDS GENET, V20, P136, DOI 10.1016/j.tig.2004.01.004; TUFROMCREDDIE A, 1993, SEMIN NEPHROL, V13, P519; TUFROMCREDDIE A, 1994, AM J PHYSIOL, V266, pF911, DOI 10.1152/ajprenal.1994.266.6.F911	30	155	171	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					964	968		10.1038/ng1623	http://dx.doi.org/10.1038/ng1623			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16116425				2022-12-25	WOS:000231591900021
J	Aleem, E; Kiyokawa, H; Kaldis, P				Aleem, E; Kiyokawa, H; Kaldis, P			Cdc2-cyclin E complexes regulate the G1/S phase transition	NATURE CELL BIOLOGY			English	Letter							DEPENDENT-KINASE INHIBITOR; CYCLIN-E; MAMMALIAN-CELLS; MICE LACKING; P27(KIP1); ENTRY; CDK2; HYPERPLASIA; GROWTH; MOUSE	The cyclin-dependent kinase inhibitor p27(Kip1) is known as a negative regulator of cell-cycle progression and as a tumour suppressor(1). Cdk2 is the main target of p27 (refs 2, 3) and therefore we hypothesized that loss of Cdk2 activity should modify the p27(-/-) mouse phenotype(4-6). Here, we show that although p27(-/-) Cdk2(-/-) mice developed ovary tumours and tumours in the anterior lobe of the pituitary, we failed to detect any functional complementation in p27(-/-) Cdk2(-/-) double-knockout mice, indicating a parallel pathway regulated by p27. We observed elevated levels of S phase and mitosis in tissues of p27(-/-) Cdk2(-/-) mice concomitantly with elevated Cdc2 activity in p27(-/-) Cdk2(-/-) extracts. p27 binds to Cdc2, cyclin B1, cyclin A2, or suc1 complexes in wild-type and Cdk2(-/-) extracts. In addition, cyclin E binds to and activates Cdc2. Our in vivo results provide strong evidence that Cdc2 may compensate the loss of Cdk2 function.	NCI, Mouse Canc Genet Program, Frederick, MD 21702 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kaldis, P (corresponding author), NCI, Mouse Canc Genet Program, Bldg 560-22-56,1050 Boyles St, Frederick, MD 21702 USA.	kaldis@ncifcrf.gov	Kaldis, Philipp/G-2714-2010; Aleem, Eiman/AAK-3208-2021	Kaldis, Philipp/0000-0002-7247-7591; Aleem, Eiman/0000-0002-9215-8213; Kiyokawa, Hiroaki/0000-0002-7942-6455	NATIONAL CANCER INSTITUTE [Z01SC010367] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; Aleem E, 2004, CELL CYCLE, V3, P35; AYSCOUGH K, 1992, MOL GEN GENET, V232, P344, DOI 10.1007/BF00266236; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Brenner RM, 2003, HUM REPROD, V18, P1185, DOI 10.1093/humrep/deg255; Dai Y, 2002, CELL CYCLE, V1, P143, DOI 10.4161/cc.1.2.116; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Harborth J, 2001, J CELL SCI, V114, P4557; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sotillo R, 2005, CANCER RES, V65, P3846, DOI 10.1158/0008-5472.CAN-04-4195; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011	24	312	318	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2005	7	8					831	U93		10.1038/ncb1284	http://dx.doi.org/10.1038/ncb1284			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	950TU	16007079				2022-12-25	WOS:000230881500018
J	McClellan, AJ; Tam, S; Kaganovich, D; Frydman, J				McClellan, AJ; Tam, S; Kaganovich, D; Frydman, J			Protein quality control: chaperones culling corrupt conformations	NATURE CELL BIOLOGY			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; TUMOR-SUPPRESSOR COMPLEX; MOLECULAR CHAPERONES; PARKINSONS-DISEASE; CELLULAR TOXICITY; CYSTIC-FIBROSIS; IN-VIVO; CHIP; PROTEASOME; LIGASE	Achieving the correct balance between folding and degradation of misfolded proteins is critical for cell viability. The importance of defining the mechanisms and factors that mediate cytoplasmic quality control is underscored by the growing list of diseases associated with protein misfolding and aggregation. Molecular chaperones assist protein folding and also facilitate degradation of misfolded polypeptides by the ubiquitin-proteasome system. Here we discuss emerging links between folding and degradation machineries and highlight challenges for future research.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Clark Ctr E200, BioX Program, Stanford, CA 94305 USA	Stanford University; Stanford University	McClellan, AJ (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	jfrydman@stanford.edu	Kaganovich, Daniel/K-2376-2012; McClellan, Amie/V-8950-2019	Kaganovich, Daniel/0000-0003-2398-1596; , judith/0000-0003-2302-6943; McClellan, Amie/0000-0002-8033-6748				Amaral MD, 2005, PEDIATR PULM, V39, P479, DOI 10.1002/ppul.20168; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Dasgupta A, 2004, J BIOL CHEM, V279, P26830, DOI 10.1074/jbc.M400894200; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Esser C, 2004, BBA-MOL CELL RES, V1695, P171, DOI 10.1016/j.bbamcr.2004.09.020; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Gardner RG, 2005, CELL, V120, P803, DOI 10.1016/j.cell.2005.01.016; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Glabe CG, 2004, TRENDS BIOCHEM SCI, V29, P542, DOI 10.1016/j.tibs.2004.08.009; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hatakeyama S, 2004, GENES CELLS, V9, P533, DOI 10.1111/j.1356-9597.2004.00742.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoppe T, 2005, TRENDS BIOCHEM SCI, V30, P183, DOI 10.1016/j.tibs.2005.02.004; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Ito T, 2003, J BIOL CHEM, V278, P29106, DOI 10.1074/jbc.M302763200; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Kalia SK, 2004, NEURON, V44, P931, DOI 10.1016/j.neuron.2004.11.026; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Lee YT, 2004, J BIOL CHEM, V279, P16511, DOI 10.1074/jbc.M400215200; McClellan AJ, 2005, CELL, V121, P739, DOI 10.1016/j.cell.2005.03.024; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Melville MW, 2003, MOL CELL BIOL, V23, P3141, DOI 10.1128/MCB.23.9.3141-3151.2003; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Scott Melissa D, 2003, Methods Mol Biol, V232, P67; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Tanaka K, 2004, BBA-MOL CELL RES, V1695, P235, DOI 10.1016/j.bbamcr.2004.09.026; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Westhoff B, 2005, CURR BIOL, V15, P1058, DOI 10.1016/j.cub.2005.04.058; Wolf DH, 2004, BBA-MOL CELL RES, V1695, P19, DOI 10.1016/j.bbamcr.2004.10.007; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Youker RT, 2004, MOL BIOL CELL, V15, P4787, DOI 10.1091/mbc.E04-07-0584; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065	45	218	220	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2005	7	8					736	741		10.1038/ncb0805-736	http://dx.doi.org/10.1038/ncb0805-736			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	950TU	16056264				2022-12-25	WOS:000230881500003
J	Moreno, JD; Hynes, RO				Moreno, JD; Hynes, RO			Guidelines for human embryonic stem cell research	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Virginia, Ctr Biomed Eth, Charlottesville, VA 22903 USA; MIT, Cambridge, MA 02139 USA	University of Virginia; Massachusetts Institute of Technology (MIT)	Moreno, JD (corresponding author), Univ Virginia, Ctr Biomed Eth, Charlottesville, VA 22903 USA.	JDM8N@hscmail.mcc.virginia.edu; rohynes@mit.edu							0	3	5	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2005	23	7					793	794		10.1038/nbt0705-793	http://dx.doi.org/10.1038/nbt0705-793			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	944KT	16003357				2022-12-25	WOS:000230427700017
J	Alter, J; Lou, F; Rabinowitz, A; Yin, HF; Rosenfeld, J; Wilton, SD; Partridge, TA; Lu, QL				Alter, J; Lou, F; Rabinowitz, A; Yin, HF; Rosenfeld, J; Wilton, SD; Partridge, TA; Lu, QL			Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology	NATURE MEDICINE			English	Article							ANTISENSE; EXON	For the majority of Duchenne muscular dystrophy (DMD) mutations, antisense oligonucleotide (AON)-mediated exon skipping has the potential to restore a functional protein. Here we show that weekly intravenous injections of morpholino phosphorodiamidate (morpholino) AONs induce expression of functional levels of dystrophin in body-wide skeletal muscles of the dystrophic mdx mouse, with resulting improvement in muscle function. Although the level of dystrophin expression achieved varies considerably between muscles, antisense therapy may provide a realistic hope for the treatment of a majority of individuals with DMD.	Carolinas Med Ctr, Neuromuscular ALS Ctr, Muscular Dystrophy Lab, Charlotte, NC 28231 USA; Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England; Univ Hertfordshire, Sch Life Sci, Hatfield AL10 9AB, Herts, England; Univ Western Australia, Queen Elizabeth II Med Ctr, Ctr Neuromuscular & Neurol Disorders, Australian Neuromuscular Res Inst, Nedlands, WA 6009, Australia	Carolinas Medical Center; Imperial College London; University of Hertfordshire; University of Western Australia	Lu, QL (corresponding author), Carolinas Med Ctr, Neuromuscular ALS Ctr, Muscular Dystrophy Lab, 1000 Blythe Blvd, Charlotte, NC 28231 USA.	qi.lu@carolinashealthcare.org	lu, qi/HHS-2115-2022	Wilton, Steve/0000-0002-9400-893X				Aartsma-Rus A, 2002, NEUROMUSCULAR DISORD, V12, pS71, DOI 10.1016/S0960-8966(02)00086-X; Bruno IG, 2004, HUM MOL GENET, V13, P2409, DOI 10.1093/hmg/ddh272; Dickson G, 2002, NEUROMUSCULAR DISORD, V12, pS67, DOI 10.1016/S0960-8966(02)00085-8; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; Gebski BL, 2003, HUM MOL GENET, V12, P1801, DOI 10.1093/hmg/ddg196; Goyenvalle A, 2004, SCIENCE, V306, P1796, DOI 10.1126/science.1104297; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Kurreck J, 2003, EUR J BIOCHEM, V270, P1628, DOI 10.1046/j.1432-1033.2003.03555.x; Laing N G, 1993, Mol Cell Biol Hum Dis Ser, V3, P37; Lu QL, 2005, P NATL ACAD SCI USA, V102, P198, DOI 10.1073/pnas.0406700102; Lu QL, 2003, NAT MED, V9, P1009, DOI 10.1038/nm897; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187	15	402	460	1	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					175	177		10.1038/nm1345	http://dx.doi.org/10.1038/nm1345			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16444267				2022-12-25	WOS:000235160600020
J	Kerjaschki, D; Huttary, N; Raab, I; Regele, H; Bojarski-Nagy, K; Bartel, G; Krober, SM; Greinix, H; Rosenmaier, A; Karlhofer, F; Wick, N; Mazal, PR				Kerjaschki, D; Huttary, N; Raab, I; Regele, H; Bojarski-Nagy, K; Bartel, G; Krober, SM; Greinix, H; Rosenmaier, A; Karlhofer, F; Wick, N; Mazal, PR			Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants	NATURE MEDICINE			English	Article							MACROPHAGES; ANGIOGENESIS; INFLAMMATION; METASTASIS	De novo lymphangiogenesis influences the course of different human diseases as diverse as chronic renal transplant rejection(1) and tumor metastasis(2,3). The cellular mechanisms of lymphangiogenesis in human diseases are currently unknown, and could involve division of local preexisting endothelial cells or incorporation of circulating progenitors. We analyzed renal tissues of individuals with gender-mismatched transplants who had transplant rejection and high rates of overall lymphatic endothelial proliferation as well as massive chronic inflammation. Donor-derived cells were detected by in situ hybridization of the Y chromosome. We compared these tissues with biopsies of essentially normal skin and intestine, and two rare carcinomas with low rates of lymphatic endothelial proliferation that were derived from individuals with gender-mismatched bone marrow transplants. Here, we provide evidence for the participation of recipient-derived lymphatic progenitor cells in renal transplants. In contrast, lymphatic vessels of normal tissues and those around post-transplant carcinomas did not incorporate donor-derived progenitors. This indicates a stepwise mechanism of inflammation-associated de novo lymphangiogenesis, implying that potential lymphatic progenitor cells derive from the circulation, transmigrate through the connective tissue stroma, presumably in the form of macrophages, and finally incorporate into the growing lymphatic vessel.	Med Univ Vienna, Allgemeines Krankenhaus, Dept Pathol, A-1090 Vienna, Austria; Univ Tubingen, Dept Pathol, D-72076 Tubingen, Germany; Austrian Bone Marrow Donor Registry, A-1080 Vienna, Austria; Med Univ Vienna, Allgemeines Krankenhaus, Dept Dermatol, A-1090 Vienna, Austria	Medical University of Vienna; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Medical University of Vienna	Kerjaschki, D (corresponding author), Med Univ Vienna, Allgemeines Krankenhaus, Dept Pathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	dontscho.kerjaschki@meduniwien.ac.at	Bartel, Gregor/C-6654-2008	bond, gregor/0000-0003-0440-3053; Mazal, Peter/0000-0002-9586-6231				Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; He YL, 2004, CANCER RES, V64, P3737, DOI 10.1158/0008-5472.CAN-04-0088; Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163; Ito WD, 2003, ENDOTHELIUM-J ENDOTH, V10, P233, DOI 10.1080/713715240; Jackson DG, 2004, APMIS, V112, P526, DOI 10.1111/j.1600-0463.2004.apm11207-0811.x; Kerjaschki D, 2005, J CLIN INVEST, V115, P2316, DOI 10.1172/JCI26354; Kerjaschki D, 2004, J AM SOC NEPHROL, V15, P603, DOI 10.1097/01.ASN.0000113316.52371.2E; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; Mazal PR, 2002, NEW ENGL J MED, V347, P653, DOI 10.1056/NEJMoa013413; PLUNKETT ML, 1987, J EXP MED, V165, P664, DOI 10.1084/jem.165.3.664; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rajantie I, 2004, BLOOD, V104, P2084, DOI 10.1182/blood-2004-01-0336; Saharinen P, 2004, TRENDS IMMUNOL, V25, P387, DOI 10.1016/j.it.2004.05.003; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051	20	274	295	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2006	12	2					230	234		10.1038/nm1340	http://dx.doi.org/10.1038/nm1340			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16415878				2022-12-25	WOS:000235160600029
J	Butte, AJ; Kohane, IS				Butte, AJ; Kohane, IS			Creation and implications of a phenome-genome network	NATURE BIOTECHNOLOGY			English	Article							NITRIC-OXIDE PRODUCTION; GENE-EXPRESSION; MICROARRAY DATA; RNA EXPRESSION; MOUSE; MAP; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; INFORMATION; BIOLOGY; SYSTEM	Although gene and protein measurements are increasing in quantity and comprehensiveness, they do not characterize a sample's entire phenotype in an environmental or experimental context. Here we comprehensively consider associations between components of phenotype, genotype and environment to identify genes that may govern phenotype and responses to the environment. Context from the annotations of gene expression data sets in the Gene Expression Omnibus is represented using the Unified Medical Language System, a compendium of biomedical vocabularies with nearly 1-million concepts. After showing how data sets can be clustered by annotative concepts, we find a network of relations between phenotypic, disease, environmental and experimental contexts as well as genes with differential expression associated with these concepts. We identify novel genes related to concepts such as aging. Comprehensively identifying genes related to phenotype and environment is a step toward the Human Phenome Project(5).	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Childrens Hosp, Informat Program, Boston, MA 02115 USA; Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Stanford University; Stanford University; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Butte, AJ (corresponding author), Stanford Univ, Sch Med, Dept Med, 251 Campus Dr,Room X-215, Stanford, CA 94305 USA.	abutte@stanford.edu	Kohane, Isaac Kohane/K-3716-2012	Kohane, Isaac Kohane/0000-0003-2192-5160	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062948, R01DK060837, K12DK063696] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [U54LM008748, K22LM008261] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK062948-02, R01 DK62948, K12 DK063696, R01 DK060837-03, K12 DK063696-03, R01 DK060837, R01 DK062948, K12 DK63696] Funding Source: Medline; NLM NIH HHS [K22 LM008261, K22 LM008261-01A1, U54 LM008748-01, U54 LM008748] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ANTHONY JC, 1995, EPIDEMIOL REV, V17, P240, DOI 10.1093/oxfordjournals.epirev.a036182; Aronson AR, 2001, J AM MED INFORM ASSN, P17; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Bodenreider O, 2004, NUCLEIC ACIDS RES, V32, pD267, DOI 10.1093/nar/gkh061; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Butte AJ, 2000, P NATL ACAD SCI USA, V97, P12182, DOI 10.1073/pnas.220392197; Carson JP, 2004, CANCER RES, V64, P2096, DOI 10.1158/0008-5472.CAN-03-2029; Cocco P, 1998, BLOOD, V91, P706, DOI 10.1182/blood.V91.2.706.706_706_709; Freimer N, 2003, NAT GENET, V34, P15, DOI 10.1038/ng0503-15; Gilbertson RJ, 2003, NAT GENET, V35, P197, DOI 10.1038/ng1103-197; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; *INT CLASS DIS, 2003, CLIN MOD ICD 9 CM; Jo K, 2001, MOL CELL BIOL, V21, P1682, DOI 10.1128/MCB.21.5.1682-1687.2001; Kyng KJ, 2003, P NATL ACAD SCI USA, V100, P12259, DOI 10.1073/pnas.2130723100; Lee HK, 2004, GENOME RES, V14, P1085, DOI 10.1101/gr.1910904; Mahner M, 1997, J THEOR BIOL, V186, P55, DOI 10.1006/jtbi.1996.0335; Mirochnitchenko O, 1999, J BIOL CHEM, V274, P10349, DOI 10.1074/jbc.274.15.10349; Muschen M, 2002, P NATL ACAD SCI USA, V99, P10014, DOI 10.1073/pnas.152327399; Nicholson B, 2002, NITRIC OXIDE-BIOL CH, V7, P236, DOI 10.1016/S1089-8603(02)00116-7; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; Ninfali P, 1998, NEUROCHEM RES, V23, P1197, DOI 10.1023/A:1020734203128; Perou CM, 2001, NAT GENET, V29, P373, DOI 10.1038/ng1201-373; PRESS WH, 1993, NUMERICAL RECIPES C; RIKANS LE, 1991, ARCH GERONTOL GERIAT, V13, P263, DOI 10.1016/0167-4943(91)90048-U; Sandre C, 2003, J TRACE ELEM MED BIO, V17, P313; Schulz R, 2003, FASEB J, V17, P1355, DOI 10.1096/fj.02-0975fje; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Spellman PT, 2002, GENOME BIOL, V3; Stoll M, 2001, SCIENCE, V294, P1723, DOI 10.1126/science.1062117; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tettelin H, 2004, NAT GENET, V36, P1028, DOI 10.1038/ng1004-1028b; Topsakal C, 2003, SPINE, V28, P1643, DOI 10.1097/00007632-200308010-00004; Wang Y, 2001, GLYCOBIOLOGY, V11, P1051, DOI 10.1093/glycob/11.12.1051; Wheeler DL, 2004, NUCLEIC ACIDS RES, V32, pD35, DOI 10.1093/nar/gkh073; Yanagisawa K, 2003, LANCET, V362, P433, DOI 10.1016/S0140-6736(03)14068-8; Zhao Y, 2000, GENOMICS, V67, P351, DOI 10.1006/geno.2000.6255; Zhukov TA, 2003, LUNG CANCER, V40, P267, DOI 10.1016/S0169-5002(03)00082-5	41	142	148	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2006	24	1					55	62		10.1038/nbt1150	http://dx.doi.org/10.1038/nbt1150			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	001SE	16404398	Green Accepted			2022-12-25	WOS:000234555800024
J	Hamaratoglu, F; Willecke, M; Kango-Singh, M; Nolo, R; Hyun, E; Tao, CY; Jafar-Nejad, H; Halder, G				Hamaratoglu, F; Willecke, M; Kango-Singh, M; Nolo, R; Hyun, E; Tao, CY; Jafar-Nejad, H; Halder, G			The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis	NATURE CELL BIOLOGY			English	Article							PROMOTES APOPTOSIS; NEUROFIBROMATOSIS TYPE-2; PATTERN-FORMATION; DROSOPHILA EYE; PROTEIN-KINASE; GROWTH-CONTROL; IMAGINAL DISC; ERM PROTEINS; CYCLE EXIT; ORGAN SIZE	Merlin, the protein product of the Neurofibromatosis type- 2 gene, acts as a tumour suppressor in mice and humans. Merlin is an adaptor protein with a FERM domain and it is thought to transduce a growth- regulatory signal. However, the pathway through which Merlin acts as a tumour suppressor is poorly understood. Merlin, and its function as a negative regulator of growth, is conserved in Drosophila, where it functions with Expanded, a related FERM domain protein. Here, we show that Drosophila Merlin and Expanded are components of the Hippo signalling pathway, an emerging tumour- suppressor pathway. We find that Merlin and Expanded, similar to other components of the Hippo pathway, are required for proliferation arrest and apoptosis in developing imaginal discs. Our genetic and biochemical data place Merlin and Expanded upstream of Hippo and identify a pathway through which they act as tumour- suppressor genes.	Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Tubingen, Interfak Inst Zellbiol, Abt Genet Tiere, D-72076 Tubingen, Germany; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Eberhard Karls University of Tubingen; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Halder, G (corresponding author), Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA.	ghalder@mdanderson.org	Jafar-Nejad, Hamed/B-9216-2008; Kango-Singh, Madhuri/F-3647-2011; Halder, Georg/F-2966-2015	Halder, Georg/0000-0001-7580-3236; Hamaratoglu, Fisun/0000-0002-1461-9248				Baker NE, 2001, SEMIN CELL DEV BIOL, V12, P499, DOI 10.1006/scdb.2001.0274; Blaumueller CM, 2000, MECH DEVELOP, V92, P251, DOI 10.1016/S0925-4773(00)00246-X; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Boedigheimer MJ, 1997, DEV GENET, V20, P103, DOI 10.1002/(SICI)1520-6408(1997)20:2<103::AID-DVG3>3.0.CO;2-B; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hay BA, 2003, DEV CELL, V5, P361, DOI 10.1016/S1534-5807(03)00270-3; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Johnston LA, 2002, BIOESSAYS, V24, P54, DOI 10.1002/bies.10021; Jones L, 2000, DEVELOPMENT, V127, P4619; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; LUTCHMAN M, 1995, CANCER RES, V55, P2270; McCartney BM, 2000, DEVELOPMENT, V127, P1315; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; Newsome TP, 2000, DEVELOPMENT, V127, P851; Niehrs C, 2002, NATURE, V417, P35, DOI 10.1038/417035a; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Ryoo HD, 2003, NAT CELL BIOL, V5, P853, DOI 10.1038/ncb1003-853; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Trofatter J A, 1993, Cell, V75, P826; Turenchalk GS, 1999, BBA-REV CANCER, V1424, pM9, DOI 10.1016/S0304-419X(99)00021-9; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; WOLFF T, 1991, DEVELOPMENT, V113, P841; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Xiao GH, 2003, GENE CHROMOSOME CANC, V38, P389, DOI 10.1002/gcc.10282; XU T, 1993, DEVELOPMENT, V117, P1223; XU TA, 1995, DEVELOPMENT, V121, P1053	48	565	581	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					27	U9		10.1038/ncb1339	http://dx.doi.org/10.1038/ncb1339			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	16341207				2022-12-25	WOS:000234651500009
J	Deng, GM; Zheng, LX; Chan, FKM; Lenardo, M				Deng, GM; Zheng, LX; Chan, FKM; Lenardo, M			Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; RHEUMATOID-ARTHRITIS; FACTOR-ALPHA; THERAPEUTIC TARGET; BACTERIAL-DNA; CPG MOTIFS; IN-VIVO; TNF; MICE; JOINT	Tumor necrosis factor (TNF)-alpha has an important role in the pathogenesis of autoimmune and inflammatory diseases such as rheumatoid and septic arthritis. The biological effects of TNF-alpha are mediated by binding to TNF receptors TNFR1 ( also known as P60) or TNFR2 ( also known as P80). The pre-ligand assembly domain (PLAD) is a portion of the extracellular region of TNFRs that mediates receptor-chain association essential for signaling. We found that soluble versions of PLAD, especially those derived from P60, block the biochemical effects of TNF-alpha in vitro and potently inhibit arthritis in animal models. Thus, targeting the PLAD may have clinical value in the treatment of human arthritis and other disorders involving receptors of the TNFR superfamily.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Massachusetts System; University of Massachusetts Worcester	Lenardo, M (corresponding author), NIAID, Immunol Lab, NIH, Bldg 10,Room 11N311,10 Ctr Dr,MSC 1892, Bethesda, MD 20892 USA.	lenardo@nih.gov	Chan, Francis Ka-Ming/E-9647-2014; Chan, Francis/ABB-1895-2021	Chan, Francis Ka-Ming/0000-0002-4803-8353; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000717, Z01AI000717] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Chan FKM, 2000, ANN RHEUM DIS, V59, P50, DOI 10.1136/ard.59.suppl_1.i50; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Deng GM, 2000, ARTHRITIS RHEUM-US, V43, P2283, DOI 10.1002/1529-0131(200010)43:10<2283::AID-ANR16>3.0.CO;2-9; Deng GM, 1999, NAT MED, V5, P702, DOI 10.1038/9554; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Gomez-Reino JJ, 2003, ARTHRITIS RHEUM-US, V48, P2122, DOI 10.1002/art.11137; GutierrezRamos JC, 1997, IMMUNOL TODAY, V18, P329, DOI 10.1016/S0167-5699(97)01085-2; HENDERSON B, 1989, CLIN EXP IMMUNOL, V75, P306; Hultgren O, 1998, J IMMUNOL, V161, P5937; Jarvis B, 1999, DRUGS, V57, P945, DOI 10.2165/00003495-199957060-00014; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MIOSSEC P, 1992, BAILLIERE CLIN RHEUM, V6, P373, DOI 10.1016/S0950-3579(05)80180-3; Mori L, 1996, J IMMUNOL, V157, P3178; Nakashima T, 2003, CURR OPIN RHEUMATOL, V15, P280, DOI 10.1097/00002281-200305000-00016; PETTIPHER ER, 1986, P NATL ACAD SCI USA, V83, P8749, DOI 10.1073/pnas.83.22.8749; Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365-2613.2000.00176.x; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Shakoor N, 2002, LANCET, V359, P579, DOI 10.1016/S0140-6736(02)07714-0; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; Wolfe F, 2004, ARTHRITIS RHEUM-US, V50, P372, DOI 10.1002/art.20009; Wolfe F, 2004, ARTHRITIS RHEUM-US, V50, P1740, DOI 10.1002/art.20311; Zhang ZY, 2003, J IMMUNOL, V171, P3620, DOI 10.4049/jimmunol.171.7.3620	34	105	117	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1066	1072		10.1038/nm1304	http://dx.doi.org/10.1038/nm1304			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16170321				2022-12-25	WOS:000232492500027
J	Bauer, H; Willert, JR; Koschorz, B; Herrmann, BG				Bauer, H; Willert, JR; Koschorz, B; Herrmann, BG			The t complex-encoded GTPase-activating protein Tagap1 acts as a transmission ratio distorter in mice	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; SEGREGATION DISTORTION; BINDING-PROTEIN; MOUSE; HAPLOTYPES; DROSOPHILA; RANGAP; RHO; RHOPHILIN; REGIONS	Transmission ratio distortion in the mouse is caused by several t- complex distorters ( Tcds) acting in trans on the t- complex responder ( Tcr)(1 - 4). Tcds additively affect the flagellar movement of all spermatozoa derived from t/+ males; sperm carrying Tcr are rescued, resulting in an advantage for t sperm in fertilization. Here we show that Tagap1, a GTPase- activating protein, can act as a distorter. Tagap1 maps to the Tcd1 interval and has four t loci, which encode altered proteins including a C- terminally truncated form. Overexpression of wild- type Tagap1 in sperm cells phenocopied Tcd function, whereas a loss- of- function Tagap1 allele reduced the transmission rate of the t(6) haplotype. The combined data strongly suggest that the t loci of Tagap1 produce Tcd1a. Our results unravel the molecular nature of a Tcd and demonstrate the importance of small G proteins in transmission ratio distortion in the mouse.	Max Planck Inst Mol Genet, Dept Dev Genet, D-14195 Berlin, Germany; Max Planck Inst Immunbiol, Dept Dev Biol, D-79108 Freiburg, Germany; Inst Med Genet, D-12200 Berlin, Germany	Max Planck Society; Max Planck Society	Herrmann, BG (corresponding author), Max Planck Inst Mol Genet, Dept Dev Genet, Ihnestr 73, D-14195 Berlin, Germany.	herrmann@molgen.mpg.de						CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dinkel A, 1999, J IMMUNOL METHODS, V223, P255, DOI 10.1016/S0022-1759(99)00005-8; Fujita A, 2000, J CELL SCI, V113, P103; GILMAN M, 1997, RIBONUCLEASE PROTECT; GUMMERE GR, 1986, GENETICS, V114, P235; Herrmann BG, 1999, NATURE, V402, P141, DOI 10.1038/45970; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HINSCH KD, 1993, FEBS LETT, V334, P32, DOI 10.1016/0014-5793(93)81674-O; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; KATZ DF, 1979, J EXP ZOOL, V210, P529, DOI 10.1002/jez.1402100316; KLEENE KC, 1989, DEVELOPMENT, V106, P367; Kusano A, 2002, P NATL ACAD SCI USA, V99, P6866, DOI 10.1073/pnas.102165099; Kusano A, 2001, DEV CELL, V1, P351, DOI 10.1016/S1534-5807(01)00042-9; Lyon C. E., 1992, J APPL POULTRY RES, V1, P27; Lyon MF, 2000, GENETICS, V155, P793; LYON MF, 1984, CELL, V37, P621, DOI 10.1016/0092-8674(84)90393-3; Lyon MF, 2003, ANNU REV GENET, V37, P393, DOI 10.1146/annurev.genet.37.110801.143030; Merrill C, 1999, SCIENCE, V283, P1742, DOI 10.1126/science.283.5408.1742; Nakamura K, 1999, FEBS LETT, V445, P9, DOI 10.1016/S0014-5793(99)00087-3; OLDSCLARKE P, 1993, DEV BIOL, V155, P14, DOI 10.1006/dbio.1993.1002; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; SILVER LM, 1987, GENET RES, V49, P51, DOI 10.1017/S0016672300026720; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118	26	60	64	2	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					969	973		10.1038/ng1617	http://dx.doi.org/10.1038/ng1617			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16116428				2022-12-25	WOS:000231591900022
J	Tergaonkar, V; Correa, RG; Ikawa, M; Verma, IM				Tergaonkar, V; Correa, RG; Ikawa, M; Verma, IM			Distinct roles of I kappa B proteins in regulating constitutive NF-kappa B activity	NATURE CELL BIOLOGY			English	Article							ALPHA; MICE; LOCALIZATION	The inhibitor of NF-kappa B ( I kappa B) family of proteins is believed to regulate NF-kappa B activity by cytoplasmic sequestration. We show that in cells depleted of I kappa B alpha, I kappa B beta and I kappa B epsilon proteins, a small fraction of p65 binds DNA and leads to constitutive activation of NF-kappa B target genes, even without stimulation, whereas most of the p65 remains cytoplasmic. These results indicate that although I kappa B alpha, I kappa B beta and I kappa B epsilon proteins could be dispensable for cytoplasmic retention of NF-kappa B, they are essential for preventing NF-kappa B dependent gene expression in the basal state. We also show that in the absence of I kappa B alpha, I kappa B beta and I kappa B epsilon proteins, cytoplasmic retention of NF-kappa B by other cellular proteins renders the pathway unresponsive to activation.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	Salk Institute	Verma, IM (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	verma@salk.edu	Correa, Ricardo G/G-7613-2012; ikawa, masahito/A-5315-2009	Correa, Ricardo G/0000-0001-6940-7034; ikawa, masahito/0000-0001-9859-6217				BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bell S, 1996, MOL CELL BIOL, V16, P6477; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Memet S, 1999, J IMMUNOL, V163, P5994; Moorthy AK, 2003, J BIOL CHEM, V278, P556, DOI 10.1074/jbc.M207515200; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tergaonkar V, 2003, MOL CELL BIOL, V23, P8070, DOI 10.1128/MCB.23.22.8070-8083.2003; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723	15	124	128	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2005	7	9					921	U89		10.1038/ncb1296	http://dx.doi.org/10.1038/ncb1296			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	960NY	16136188				2022-12-25	WOS:000231601600018
J	Kato, D; Boatright, KM; Berger, AB; Nazif, T; Blum, G; Ryan, C; Chehade, KAH; Salvesen, GS; Bogyo, M				Kato, D; Boatright, KM; Berger, AB; Nazif, T; Blum, G; Ryan, C; Chehade, KAH; Salvesen, GS; Bogyo, M			Activity-based probes that target diverse cysteine protease families	NATURE CHEMICAL BIOLOGY			English	Article							ASPARAGINYL ENDOPEPTIDASE; CATHEPSIN-B; INHIBITORS; ACTIVATION; PEPTIDE; CASPASES; LEGUMAIN; CLAN; PROTEOMICS; CLEAVAGE	Proteases are one of the largest and best-characterized families of enzymes in the human proteome. Unfortunately, the understanding of protease function in the context of complex proteolytic cascades remains in its infancy. One major reason for this gap in understanding is the lack of technologies that allow direct assessment of protease activity. We report here an optimized solid-phase synthesis protocol that allows rapid generation of activity-based probes (ABPs) targeting a range of cysteine protease families. These reagents selectively form covalent bonds with the active-site thiol of a cysteine protease, allowing direct biochemical profiling of protease activities in complex proteomes. We present a number of probes containing either a single amino acid or an extended peptide sequence that target caspases, legumains, gingipains and cathepsins. Biochemical studies using these reagents highlight their overall utility and provide insight into the biochemical functions of members of these protease families.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94030 USA; Stanford Univ, Sch Med, Canc Biol Grad Program, Stanford, CA 94030 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94030 USA	Stanford University; Stanford University; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Francisco; Stanford University	Bogyo, M (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94030 USA.	mbogyo@stanford.edu		Bogyo, Matthew/0000-0003-3753-4412; Nazif, Tamim/0000-0003-1239-2489	NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000044] Funding Source: NIH RePORTER; NCRR NIH HHS [U54 RR020843] Funding Source: Medline; NHGRI NIH HHS [5T32 HG00044] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Asgian JL, 2002, J MED CHEM, V45, P4958, DOI 10.1021/jm025581c; Berger Alicia B, 2004, Am J Pharmacogenomics, V4, P371, DOI 10.2165/00129785-200404060-00004; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Chen JM, 2000, BIOCHEM J, V352, P327, DOI 10.1042/0264-6021:3520327; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; FOX T, 1995, PROTEIN ENG, V8, P53, DOI 10.1093/protein/8.1.53; Halfon S, 1998, FEBS LETT, V438, P114, DOI 10.1016/S0014-5793(98)01281-2; Jeffery DA, 2003, CURR OPIN BIOTECH, V14, P87, DOI 10.1016/S0958-1669(02)00010-1; Lee A, 1999, J AM CHEM SOC, V121, P9907, DOI 10.1021/ja992009a; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Loak K, 2003, BIOL CHEM, V384, P1239, DOI 10.1515/BC.2003.136; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; Meergans T, 2000, BIOCHEM J, V349, P135, DOI 10.1042/0264-6021:3490135; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; Niestroj AJ, 2002, BIOL CHEM, V383, P1205, DOI 10.1515/BC.2002.133; Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v; Speers AE, 2004, CHEMBIOCHEM, V5, P41, DOI 10.1002/cbic.200300721; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; Turk B, 1997, BIOL CHEM, V378, P141; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Wood WJL, 2003, J COMB CHEM, V5, P869, DOI 10.1021/cc034008r; YAMAMOTO A, 1992, J MOL BIOL, V227, P942, DOI 10.1016/0022-2836(92)90234-B	28	276	287	2	80	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2005	1	1					33	38		10.1038/nchembio707	http://dx.doi.org/10.1038/nchembio707			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	974WC	16407991				2022-12-25	WOS:000232621100010
J	Bologa, CG; Revankar, CM; Young, SM; Edwards, BS; Arterburn, JB; Kiselyov, AS; Parker, MA; Tkachenko, SE; Savchuck, NP; Sklar, LA; Oprea, TI; Prossnitz, ER				Bologa, CG; Revankar, CM; Young, SM; Edwards, BS; Arterburn, JB; Kiselyov, AS; Parker, MA; Tkachenko, SE; Savchuck, NP; Sklar, LA; Oprea, TI; Prossnitz, ER			Virtual and biomolecular screening converge on a selective agonist for GPR30	NATURE CHEMICAL BIOLOGY			English	Article							HIGH-THROUGHPUT; FLOW-CYTOMETRY; G-PROTEIN; RECEPTOR; VALIDATION; ACTIVATION	Estrogen is a hormone critical in the development, normal physiology and pathophysiology(1) of numerous human tissues(2). The effects of estrogen have traditionally been solely ascribed to estrogen receptor alpha (ER alpha) and more recently ER beta, members of the soluble, nuclear ligand-activated family of transcription factors(3). We have recently shown that the seven-transmembrane G protein-coupled receptor GPR30 binds estrogen with high affinity and resides in the endoplasmic reticulum, where it activates multiple intracellular signaling pathways(4). To differentiate between the functions of ER alpha or ER beta and GPR30, we used a combination of virtual and biomolecular screening to isolate compounds that selectively bind to GPR30. Here we describe the identification of the first GPR30-specific agonist, G-1 (1), capable of activating GPR30 in a complex environment of classical and new estrogen receptors. The development of compounds specific to estrogen receptor family members provides the opportunity to increase our understanding of these receptors and their contribution to estrogen biology.	Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Div Biocomp, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; New Mexico State Univ, Dept Chem & Biochem, Las Cruces, NM 88003 USA; Chem Divers Labs Inc, San Diego, CA 92121 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; New Mexico State University	Oprea, TI (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA.	TOprea@salud.unm.edu; EProssnitz@salud.unm.edu	Oprea, Tudor I/A-5746-2011; Bologa, Cristian G/A-7952-2010; BOLOGA, CRISTINA/T-8927-2017; Prossnitz, Eric R./B-4543-2008; Prossnitz, Eric/I-4599-2019; TKACHENKO, SERGEY/B-8241-2014	Oprea, Tudor I/0000-0002-6195-6976; Bologa, Cristian G/0000-0003-2232-4244; Prossnitz, Eric/0000-0001-9190-8302; 	NCI NIH HHS [P30 CA118100, R24 CA88339] Funding Source: Medline; NCRR NIH HHS [S10 RR19287, 1 S10 RR14668, P20 RR11830] Funding Source: Medline; NIAID NIH HHS [AI36357] Funding Source: Medline; NIBIB NIH HHS [EB00264] Funding Source: Medline; NIEHS NIH HHS [ES012072] Funding Source: Medline; NIMH NIH HHS [MH074425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA118100, R24CA088339] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014668, S10RR019287, P20RR011830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036357, R01AI036357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R24EB000264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES012072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U54MH074425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Balla Tamas, 2002, Sci STKE, V2002, ppl3, DOI 10.1126/stke.2002.125.pl3; Baudelle R, 1998, TETRAHEDRON, V54, P4125, DOI 10.1016/S0040-4020(98)00140-9; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r; Edwards BS, 2004, CURR OPIN CHEM BIOL, V8, P392, DOI 10.1016/j.cbpa.2004.06.007; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Grant JA, 2001, J COMPUT CHEM, V22, P608, DOI 10.1002/jcc.1032; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Jackson JE, 1991, USERS GUIDE PRINCIPA; Korach KS, 2003, J STEROID BIOCHEM, V86, P387, DOI 10.1016/S0960-0760(03)00348-0; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Olah Marius M, 2004, Curr Drug Discov Technol, V1, P211, DOI 10.2174/1570163043334965; Oprea TI, 2004, CURR OPIN CHEM BIOL, V8, P349, DOI 10.1016/j.cbpa.2004.06.008; OPREA TI, 2003, DESIGNING DRUGS CROP; Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036; Pastor M, 2000, J MED CHEM, V43, P3233, DOI 10.1021/jm000941m; Ramirez S, 2003, CYTOM PART A, V53A, P55, DOI 10.1002/cyto.a.10035; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rich RL, 2002, P NATL ACAD SCI USA, V99, P8562, DOI 10.1073/pnas.142288199; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; Sartori G, 2001, EUR J ORG CHEM, V2001, P2513, DOI 10.1002/1099-0690(200107)2001:13<2513::AID-EJOC2513>3.0.CO;2-A; Savchuk NP, 2005, METH PRIN MED CHEM, V22, P287, DOI 10.1002/3527603743.ch12; TANIMOTO TT, 1961, T NEW YORK ACAD SCI, V23, P576, DOI 10.1111/j.2164-0947.1961.tb01390.x; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; TVERSKY A, 1977, PSYCHOL REV, V84, P327, DOI 10.1037/h0026750; Waller A, 2004, TRENDS PHARMACOL SCI, V25, P663, DOI 10.1016/j.tips.2004.10.009; Walters WP, 1998, DRUG DISCOV TODAY, V3, P160, DOI 10.1016/S1359-6446(97)01163-X; WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	30	632	672	1	70	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	APR	2006	2	4					207	212		10.1038/nchembio775	http://dx.doi.org/10.1038/nchembio775			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	023QU	16520733				2022-12-25	WOS:000236142100013
J	Fontecave, M				Fontecave, M			Iron-sulfur clusters: ever-expanding roles	NATURE CHEMICAL BIOLOGY			English	Editorial Material							S-ADENOSYLMETHIONINE; CRYSTAL-STRUCTURE; MECHANISMS; PROTEINS	Iron-sulfur clusters have critical roles in proteins from diverse organisms and in a broad range of biological processes. Recent discoveries raise exciting challenges for future research by bioinorganic chemists and chemical biologists.	Univ Grenoble 1, CNRS,CEA Grenoble, DRDC CB,UMR 5047, Lab Chim & Biochim,Ctr Redox Biol, F-38504 Grenoble 9, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Fontecave, M (corresponding author), Univ Grenoble 1, CNRS,CEA Grenoble, DRDC CB,UMR 5047, Lab Chim & Biochim,Ctr Redox Biol, 17 Ave Martyrs, F-38504 Grenoble 9, France.	mfontecave@cea.fr						Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; DANIEL RM, 1995, J MOL EVOL, V40, P559, DOI 10.1007/BF00160501; Fontecave M, 2003, CHEM REV, V103, P2149, DOI 10.1021/cr020427j; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Fontecave M, 2005, J BIOL INORG CHEM, V10, P713, DOI 10.1007/s00775-005-0025-1; Frey PA, 2003, CHEM REV, V103, P2129, DOI 10.1021/cr020422m; IMLAY JA, 2006, IN PRESS MOL MICROBI; Jarrett JT, 2005, ARCH BIOCHEM BIOPHYS, V433, P312, DOI 10.1016/j.abb.2004.10.003; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Major TA, 2004, FEMS MICROBIOL LETT, V239, P117, DOI 10.1016/j.femsle.2004.08.027; Puccio H, 2002, CURR OPIN GENET DEV, V12, P272, DOI 10.1016/S0959-437X(02)00298-8; SAZANOV LA, 2006, IN PRESS SCIENCE; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0	18	158	161	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	APR	2006	2	4					171	174		10.1038/nchembio0406-171	http://dx.doi.org/10.1038/nchembio0406-171			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	023QU	16547473				2022-12-25	WOS:000236142100002
J	Palmer, CNA; Irvine, AD; Terron-Kwiatkowski, A; Zhao, YW; Liao, HH; Lee, SP; Goudie, DR; Sandilands, A; Campbell, LE; Smith, FJD; O'Regan, GM; Watson, RM; Cecil, JE; Bale, SJ; Compton, JG; DiGiovanna, JJ; Fleckman, P; Lewis-Jones, S; Arseculeratne, G; Sergeant, A; Munro, CS; El Houate, B; McElreavey, K; Halkjaer, LB; Bisgaard, H; Mukhopadhyay, S; McLean, WHI				Palmer, CNA; Irvine, AD; Terron-Kwiatkowski, A; Zhao, YW; Liao, HH; Lee, SP; Goudie, DR; Sandilands, A; Campbell, LE; Smith, FJD; O'Regan, GM; Watson, RM; Cecil, JE; Bale, SJ; Compton, JG; DiGiovanna, JJ; Fleckman, P; Lewis-Jones, S; Arseculeratne, G; Sergeant, A; Munro, CS; El Houate, B; McElreavey, K; Halkjaer, LB; Bisgaard, H; Mukhopadhyay, S; McLean, WHI			Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis	NATURE GENETICS			English	Article							PARTY DIAGNOSTIC-CRITERIA; ICHTHYOSIS VULGARIS; CORNIFIED ENVELOPE; SKIN; GENE; DIFFERENTIATION; ASTHMA; HYPERRESPONSIVENESS; EPIDEMIOLOGY; POPULATION	Atopic disease, including atopic dermatitis (eczema), allergy and asthma, has increased in frequency in recent decades(1) and now affects similar to 20% of the population in the developed world. Twin and family studies have shown that predisposition to atopic disease is highly heritable(2). Although most genetic studies have focused on immunological mechanisms, a primary epithelial barrier defect has been anticipated(3). Filaggrin is a key protein that facilitates terminal differentiation of the epidermis and formation of the skin barrier. Here we show that two independent loss-of-function genetic variants (R510X and 2282del4) in the gene encoding filaggrin (FLG) are very strong predisposing factors for atopic dermatitis. These variants are carried by similar to 9% of people of European origin. These variants also show highly significant association with asthma occurring in the context of atopic dermatitis. This work establishes a key role for impaired skin barrier function in the development of atopic disease.	Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Epithelial Genet Grp, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Populat Pharmacogenet Grp, Dundee DD1 9SY, Scotland; Our Ladys Hosp Sick Children, Dept Paediat Dermatol, Dublin 12, Ireland; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Univ Hosp NHS Trust, Dundee DD1 9SY, Scotland; Univ St Andrews, Bute Med Sch, St Andrews, Fife, Scotland; GeneDx, Gaithersburg, MD 20877 USA; Brown Med Sch, Dept Dermatol, Div Dermatopharmacol, Providence, RI 02903 USA; Rhode Isl Hosp, Providence, RI 02903 USA; NCI, Basic Res Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Univ Washington, Dept Med, Div Dermatol, Seattle, WA 98195 USA; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Univ Hosp NHS Trust, Dundee DD1 9SY, Scotland; S Glasgow Univ Hosp NHS Trust, Dept Dermatol, Glasgow G51 4TF, Lanark, Scotland; Inst Pasteur, F-75724 Paris, France; Copenhagen Univ Hosp, Danish Paediat Asthma Ctr, DK-2900 Copenhagen, Denmark; Univ Dundee, Ninewells Hosp & Med Sch, Childrens Asthma & Allergy Res Unit, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; Our Ladys Children Hospital Crumlin; University of Dundee; University of St Andrews; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Washington; University of Washington Seattle; University of Dundee; University of Glasgow; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Copenhagen; University of Dundee	McLean, WHI (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Epithelial Genet Grp, Dundee DD1 9SY, Scotland.	w.h.i.mclean@dundee.ac.uk	Palmer, Colin NA/C-7053-2008; McLean, William HI/C-6352-2009; Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011; Cecil, Joanne E/A-3071-2010; Irvine, Alan D/A-3982-2008	Palmer, Colin NA/0000-0002-6415-6560; Bisgaard, Hans/0000-0003-4131-7592; Irvine, Alan D/0000-0002-9048-2044; Brahim, EL HOUATE/0000-0002-7781-426X; DiGiovanna, John J./0000-0002-2750-2313; McLean, William Henry Irwin/0000-0001-5539-5757	Medical Research Council [G0700314] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; BRYDENSHOLT HL, IN PRESS ARCH DERMAT; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cecil JE, 2005, DIABETOLOGIA, V48, P1496, DOI 10.1007/s00125-005-1817-0; Compton JG, 2002, EXP DERMATOL, V11, P518, DOI 10.1034/j.1600-0625.2002.110604.x; Cookson WOCM, 2002, CURR OPIN ALLERGY CL, V2, P383, DOI 10.1097/00130832-200210000-00003; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; Ginger RS, 2005, ARCH DERMATOL RES, V297, P235, DOI 10.1007/s00403-005-0590-8; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Jensen JM, 2004, J INVEST DERMATOL, V122, P1423, DOI 10.1111/j.0022-202X.2004.22621.x; Kuokkanen K, 1969, Acta Derm Venereol Suppl (Stockh), V62, P1; Kurz T, 2005, ALLERGY, V60, P192, DOI 10.1111/j.1398-9995.2005.00646.x; Listwan P, 2004, METHOD CELL BIOL, V78, P817; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Sugiura H, 2005, BRIT J DERMATOL, V152, P146, DOI 10.1111/J.1365-2133.2005.06352.X; Tabata N, 1998, ACTA DERM-VENEREOL, V78, P244; Tay YK, 1999, ASIAN PAC J ALLERGY, V17, P137; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Wang LF, 1996, J IMMUNOL, V156, P4079; WELLS RS, 1966, BRIT MED J, V1, P947, DOI 10.1136/bmj.1.5493.947; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P1	30	1969	2054	6	191	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2006	38	4					441	446		10.1038/ng1767	http://dx.doi.org/10.1038/ng1767			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16550169				2022-12-25	WOS:000236340500016
J	Schubbert, S; Zenker, M; Rowe, SL; Boll, SB; Klein, C; Bollag, G; van der Burgt, I; Musante, L; Kalscheuer, V; Wehner, LE; Nguyen, H; West, B; Zhang, KYJ; Sistermans, E; Rauch, A; Niemeyer, CM; Shannon, K; Kratz, CP				Schubbert, S; Zenker, M; Rowe, SL; Boll, SB; Klein, C; Bollag, G; van der Burgt, I; Musante, L; Kalscheuer, V; Wehner, LE; Nguyen, H; West, B; Zhang, KYJ; Sistermans, E; Rauch, A; Niemeyer, CM; Shannon, K; Kratz, CP			Germline KRAS mutations cause Noonan syndrome	NATURE GENETICS			English	Article							JUVENILE MYELOMONOCYTIC LEUKEMIA; COLONY-STIMULATING FACTOR; MYELOID-LEUKEMIA; PTPN11 MUTATIONS; MOUSE MODEL; RAS; CELLS; GENE; HYPERSENSITIVITY; PROLIFERATION	Noonan syndrome (MIM 163950) is characterized by short stature, facial dysmorphism and cardiac defects(1). Heterozygous mutations in PTPN11, which encodes SHP-2, cause similar to 50% of cases of Noonan syndrome(1,2). The SHP-2 phosphatase relays signals from activated receptor complexes to downstream effectors, including Ras(3). We discovered de novo germline KRAS mutations that introduce V14I, T58I or D153V amino acid substitutions in five individuals with Noonan syndrome and a P34R alteration in a individual with cardio-faciocutaneous syndrome (MIM 115150), which has overlapping features with Noonan syndrome(1,4). Recombinant V14I and T58I K-Ras proteins show defective intrinsic GTP hydrolysis and impaired responsiveness to GTPase activating proteins, render primary hematopoietic progenitors hypersensitive to growth factors and deregulate signal transduction in a cell lineage-specific manner. These studies establish germline KRAS mutations as a cause of human disease and infer that the constellation of developmental abnormalities seen in Noonan syndrome spectrum is, in large part, due to hyperactive Ras.	Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, D-79106 Freiburg, Germany; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Erlangen Nurnberg, Inst Human Genet, D-91054 Erlangen, Germany; Plexxikon Inc, Berkeley, CA 94710 USA; Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Gottingen, Inst Human Genet, D-37075 Gottingen, Germany; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA	University of Freiburg; University of California System; University of California San Francisco; University of Erlangen Nuremberg; Plexxikon; Radboud University Nijmegen; Max Planck Society; University of Gottingen; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Kratz, CP (corresponding author), Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, Mathildenstr 1, D-79106 Freiburg, Germany.	shannonk@peds.ucsf.edu; christian.kratz@uniklinik-freiburg.de	Zhang, Kam Y. J./B-3552-2012; Rauch, Anita/C-5568-2014; Kratz, Christian/AAC-9726-2021; Musante, Luciana/AAA-5726-2021; Sistermans, Erik/B-1109-2009	Zhang, Kam Y. J./0000-0002-9282-8045; Rauch, Anita/0000-0003-2930-3163; Musante, Luciana/0000-0002-2742-1484; Sistermans, Erik/0000-0001-7187-4563; West, Brian/0000-0002-5320-3691; Kalscheuer, Vera/0000-0001-6898-3259	NCI NIH HHS [R01 CA72614, R01 CA104282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104282, R01CA072614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Bollag G, 1996, J BIOL CHEM, V271, P32491, DOI 10.1074/jbc.271.51.32491; BOS JL, 1989, CANCER RES, V49, P4682; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; Donovan S, 2002, CANCER CELL, V2, P507, DOI 10.1016/S1535-6108(02)00214-3; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kavamura MI, 2002, AM J MED GENET, V112, P12, DOI 10.1002/ajmg.10681; Keilhack H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200; Kratz CP, 2005, BLOOD, V106, P2183, DOI 10.1182/blood-2005-02-0531; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LAUCHLE JO, 2005, PEDIAT BLOOD CANC; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Schubert C, 2005, NAT MED, V11, P106, DOI 10.1038/nm0205-106a; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; STONE JC, 1993, MOL CELL BIOL, V13, P7311, DOI 10.1128/MCB.13.12.7311; Tartaglia M, 2005, ANNU REV GENOM HUM G, V6, P45, DOI 10.1146/annurev.genom.6.080604.162305; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Zenker M, 2004, J PEDIATR-US, V144, P368, DOI 10.1016/j.jpeds.2003.11.032	30	524	548	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					331	336		10.1038/ng1748	http://dx.doi.org/10.1038/ng1748			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16474405				2022-12-25	WOS:000235589600015
J	Peisajovich, SG; Rockah, L; Tawfik, DS				Peisajovich, SG; Rockah, L; Tawfik, DS			Evolution of new protein topologies through multistep gene rearrangements	NATURE GENETICS			English	Article							RESTRICTION-MODIFICATION SYSTEM; RANDOM CIRCULAR PERMUTATION; DNA-METHYLTRANSFERASE; MOLECULAR EVOLUTION; SEQUENCES; DOMAINS; ENZYMES; FOLD		Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Tawfik, DS (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	dan.tawfik@weizmann.ac.il	Peisajovich, Sergio/C-6641-2011					Aravind L, 2002, CURR OPIN STRUC BIOL, V12, P392, DOI 10.1016/S0959-440X(02)00334-2; Bujnicki JM, 2002, BMC EVOL BIOL, V2, DOI 10.1186/1471-2148-2-3; Choe W, 2005, BIOCHEM BIOPH RES CO, V334, P1233, DOI 10.1016/j.bbrc.2005.07.017; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CUNNINGHAM BA, 1979, P NATL ACAD SCI USA, V76, P3218, DOI 10.1073/pnas.76.7.3218; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Graf R, 1996, P NATL ACAD SCI USA, V93, P11591, DOI 10.1073/pnas.93.21.11591; Grishin NV, 2001, J STRUCT BIOL, V134, P167, DOI 10.1006/jsbi.2001.4335; Hennecke J, 1999, J MOL BIOL, V286, P1197, DOI 10.1006/jmbi.1998.2531; Iwakura M, 2000, NAT STRUCT BIOL, V7, P580, DOI 10.1038/76811; Jeltsch A, 1999, J MOL EVOL, V49, P161, DOI 10.1007/PL00006529; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; KITA K, 1989, J BIOL CHEM, V264, P5751; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; Koonin EV, 2002, NATURE, V420, P218, DOI 10.1038/nature01256; KUSANO K, 1995, P NATL ACAD SCI USA, V92, P11095, DOI 10.1073/pnas.92.24.11095; Leismann O, 1998, EUR J BIOCHEM, V251, P899, DOI 10.1046/j.1432-1327.1998.2510899.x; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; Ostermeier M, 1999, NAT BIOTECHNOL, V17, P1205, DOI 10.1038/70754; Ostermeier M, 1999, P NATL ACAD SCI USA, V96, P3562, DOI 10.1073/pnas.96.7.3562; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P179, DOI 10.1016/S0968-0004(00)89003-9; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROODVELDT C, 2005, PROTEIN ENG DES SEL; SUGISAKI H, 1989, J BIOL CHEM, V264, P5757; SZOMOLANYI E, 1980, GENE, V10, P219, DOI 10.1016/0378-1119(80)90051-7; Tawfik DS, 1998, NAT BIOTECHNOL, V16, P652, DOI 10.1038/nbt0798-652; Wagner A, 2005, FEBS LETT, V579, P1772, DOI 10.1016/j.febslet.2005.01.063	30	80	84	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					168	174		10.1038/ng1717	http://dx.doi.org/10.1038/ng1717			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16415885				2022-12-25	WOS:000234953200010
J	Smith, UM; Consugar, M; Tee, LJ; McKee, BM; Maina, EN; Whelan, S; Morgan, NV; Goranson, E; Gissen, P; Lilliquist, S; Aligianis, IA; Ward, CJ; Pasha, S; Punyashthiti, R; Sharif, SM; Batman, PA; Bennett, CP; Woods, CG; McKeown, C; Bucourt, M; Miller, CA; Cox, P; Algazali, L; Trembath, RC; Torres, VE; Attie-Bitach, T; Kelly, DA; Maher, ER; Gattone, VH; Harris, PC; Johnson, CA				Smith, UM; Consugar, M; Tee, LJ; McKee, BM; Maina, EN; Whelan, S; Morgan, NV; Goranson, E; Gissen, P; Lilliquist, S; Aligianis, IA; Ward, CJ; Pasha, S; Punyashthiti, R; Sharif, SM; Batman, PA; Bennett, CP; Woods, CG; McKeown, C; Bucourt, M; Miller, CA; Cox, P; Algazali, L; Trembath, RC; Torres, VE; Attie-Bitach, T; Kelly, DA; Maher, ER; Gattone, VH; Harris, PC; Johnson, CA			The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat	NATURE GENETICS			English	Article							BARDET-BIEDL-SYNDROME; POLYCYSTIC KIDNEY-DISEASE; PLANAR CELL POLARITY; CILIARY; MAPS; MALFORMATION; PREDICTION; ANOMALIES; GENES; LOCUS	Meckel-Gruber syndrome is a severe autosomal, recessively inherited disorder characterized by bilateral renal cystic dysplasia, developmental defects of the central nervous system ( most commonly occipital encephalocele), hepatic ductal dysplasia and cysts and polydactyly(1-3). MKS is genetically heterogeneous, with three loci mapped: MKS1, 17q21-24 (ref. 4); MKS2, 11q13 ( ref. 5) and MKS3 ( ref. 6). We have refined MKS3 mapping to a 12.67-Mb interval (8q21.13-q22.1) that is syntenic to the Wpk locus in rat, which is a model with polycystic kidney disease, agenesis of the corpus callosum and hydrocephalus(7,8). Positional cloning of the Wpk gene suggested a MKS3 candidate gene, TMEM67, for which we identified pathogenic mutations for five MKS3-linked consanguineous families. MKS3 is a previously uncharacterized, evolutionarily conserved gene that is expressed at moderate levels in fetal brain, liver and kidney but has widespread, low levels of expression. It encodes a 995 - amino acid seven-transmembrane receptor protein of unknown function that we have called meckelin.	Univ Birmingham, Sch Med, Sect Med & Mol Genet, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England; Mayo Clin, Coll Med, Div Nephrol & Hypertens, Rochester, MN 55904 USA; Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA; Prince Wales Childrens Hosp, Childrens Liver Unit, Birmingham B4 6NH, W Midlands, England; Birmingham Womens Hosp, Clin Genet Unit, Birmingham B15 2TG, W Midlands, England; St James Hosp, Leeds LS9 7TF, W Yorkshire, England; Bradford Royal Infirm, Dept Histopathol, Bradford BD9 6RJ, W Yorkshire, England; Univ Cambridge, Dept Med Genet, Cambridge Inst Med Res, Addenbrookes Hosp, Cambridge CB2 2BP, England; Hop Jean Verdier, Serv Anat Pathol, Bondy, France; Birmingham Womens Hosp, Dept Histopathol, Birmingham B15 2TG, W Midlands, England; United Arab Emirates Univ, Fac Med & Hlth Sci, Al Ain, U Arab Emirates; Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Hop Necker Enfants Malad, Dept Genet, F-75743 Paris, France; Hop Necker Enfants Malad, INSERM, U 393, F-75743 Paris, France	University of Birmingham; Mayo Clinic; Indiana University System; Indiana University-Purdue University Indianapolis; Birmingham Women's Hospital; Saint James's University Hospital; Bradford Royal Infirmary; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Birmingham Women's Hospital; United Arab Emirates University; University of Leicester; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Johnson, CA (corresponding author), Univ Birmingham, Sch Med, Sect Med & Mol Genet, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England.	harris.peter@mayo.edu; c.a.johnson@bham.ac.uk	Gissen, Paul/A-4352-2010; MAHER, EAMONN R/A-9507-2008; woods, christopher g/A-1361-2010; ATTIE-BITACH, Tania/K-1453-2017; Morgan, Neil V/A-5475-2009	Gissen, Paul/0000-0002-9712-6122; MAHER, EAMONN R/0000-0002-6226-6918; ATTIE-BITACH, Tania/0000-0002-1155-3626; Morgan, Neil V/0000-0001-6433-5692; Johnson, Colin/0000-0002-2979-8234; Trembath, Richard/0000-0003-0550-3400; Tammachote, Rachaneekorn/0000-0001-9600-9824	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHDABBARMADA M, 1990, J NEUROPATH EXP NEUR, V49, P610, DOI 10.1097/00005072-199011000-00007; AlGazali LI, 1996, CLIN DYSMORPHOL, V5, P73, DOI 10.1097/00019605-199601000-00011; Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Badano JL, 2005, NAT REV GENET, V6, P194, DOI 10.1038/nrg1557; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Beales PL, 2005, CURR OPIN GENET DEV, V15, P315, DOI 10.1016/j.gde.2005.04.006; Blankenberg T A, 1987, Am J Med Genet Suppl, V3, P395; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Calvet JP, 2003, P NATL ACAD SCI USA, V100, P5583, DOI 10.1073/pnas.1031799100; Consugar MB, 2005, AM J KIDNEY DIS, V45, P77, DOI 10.1053/j.ajkd.2004.09.009; Efimenko E, 2005, DEVELOPMENT, V132, P1923, DOI 10.1242/dev.01775; FRASER FC, 1981, AM J MED GENET, V9, P67, DOI 10.1002/ajmg.1320090112; Gattone VH, 2004, ANAT REC PART A, V277A, P384, DOI 10.1002/ar.a.20022; Jenny A, 2005, NAT CELL BIOL, V7, P691, DOI 10.1038/ncb1271; Karmous-Benailly H, 2005, AM J HUM GENET, V76, P493, DOI 10.1086/428679; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Maina EN, 2005, ONCOGENE, V24, P4549, DOI 10.1038/sj.onc.1208649; Morgan NV, 2002, HUM GENET, V111, P456, DOI 10.1007/s00439-002-0817-0; Nauta J, 2000, J AM SOC NEPHROL, V11, P2272, DOI 10.1681/ASN.V11122272; PAAVOLA P, 1995, NAT GENET, V11, P213, DOI 10.1038/ng1095-213; Pazour GJ, 2004, CURR BIOL, V14, pR575, DOI 10.1016/j.cub.2004.07.017; POVELONES M, IN PRESS GENETICS; Ross AJ, 2005, NAT GENET, V37, P1135, DOI 10.1038/ng1644; Roume J, 1998, AM J HUM GENET, V63, P1095, DOI 10.1086/302062; SALONEN R, 1984, AM J MED GENET, V18, P671, DOI 10.1002/ajmg.1320180414; Salonen R, 1998, J MED GENET, V35, P497, DOI 10.1136/jmg.35.6.497; Sambrook J, 2001, MOL CLONING LAB MANU; SIMPSON JL, 1991, ANN GENET-PARIS, V34, P279; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3	30	197	204	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					191	196		10.1038/ng1713	http://dx.doi.org/10.1038/ng1713			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16415887				2022-12-25	WOS:000234953200013
J	Glebov, OO; Bright, NA; Nichols, BJ				Glebov, OO; Bright, NA; Nichols, BJ			Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells	NATURE CELL BIOLOGY			English	Article							GPI-ANCHORED PROTEINS; LIPID RAFTS; PLASMA-MEMBRANE; GOLGI-COMPLEX; CAVEOLAE; LOCALIZATION; DOMAINS; INTERNALIZATION; IDENTIFICATION; TRANSPORT	Previous studies provide evidence for an endocytic mechanism in mammalian cells that is distinct from both clathrin- coated pits and caveolae(1-5), and is not inhibited by overexpression of GTPase- null dynamin mutants(1-4,6). This mechanism, however, has been defined largely in these negative terms. We applied a ferro- fluid- based purification of endosomes to identify endosomal proteins. One of the proteins identified in this way was flotillin- 1 ( also called reggie- 2)(7,8). Here, we show that flotillin- 1 resides in punctate structures within the plasma membrane and in a specific population of endocytic intermediates. These intermediates accumulate both glycosyl phosphatidylinositol ( GPI)- linked proteins and cholera toxin B subunit(4,9). Endocytosis in flotillin- 1- containing intermediates is clathrin- independent. Total internal reflection microscopy and immuno- electron microscopy revealed that flotillin- 1-containing regions of the plasma membrane seem to bud into the cell, and are distinct from clathrin- coated pits and caveolin- 1- positive caveolae(10). Flotillin- 1 small interfering RNA ( siRNA) inhibited both clathrin- independent uptake of cholera toxin and endocytosis of a GPI- linked protein. We propose that flotillin- 1 is one determinant of a clathrin- independent endocytic pathway in mammalian cells.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Cambridge Inst Med Res, Cambridge CB2 2XY, England	MRC Laboratory Molecular Biology; University of Cambridge	Nichols, BJ (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ben@mrc-lmb.cam.ac.uk	Glebov, Oleg/AAV-3201-2021	Glebov, Oleg/0000-0002-3312-5470	MRC [MC_U105178778] Funding Source: UKRI; Medical Research Council [MC_U105178778] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bright NA, 1997, J CELL SCI, V110, P2027; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Damm EM, 2005, J CELL BIOL, V168, P477, DOI 10.1083/jcb.200407113; Fisher JA, 2004, J NEUROSCI, V24, P10475, DOI 10.1523/JNEUROSCI.3250-04.2004; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; Kokubo H, 2003, BRAIN RES, V965, P83, DOI 10.1016/S0006-8993(02)04140-9; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Liu J, 2005, J BIOL CHEM, V280, P16125, DOI 10.1074/jbc.M500940200; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; Merrifield CJ, 2005, CELL, V121, P593, DOI 10.1016/j.cell.2005.03.015; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2003, CURR BIOL, V13, P686, DOI 10.1016/S0960-9822(03)00209-4; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; NOLTA KV, 1994, BBA-MOL CELL RES, V1224, P237, DOI 10.1016/0167-4889(94)90196-1; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pelkmans L, 2004, CELL, V118, P767, DOI 10.1016/j.cell.2004.09.003; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Rajendran L, 2003, P NATL ACAD SCI USA, V100, P8241, DOI 10.1073/pnas.1331629100; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Sandvig K, 2004, INT J MED MICROBIOL, V293, P483, DOI 10.1078/1438-4221-00294; Santamaria A, 2005, MOL CELL BIOL, V25, P1900, DOI 10.1128/MCB.25.5.1900-1911.2005; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702	35	418	432	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					46	U16		10.1038/ncb1342	http://dx.doi.org/10.1038/ncb1342			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	16341206				2022-12-25	WOS:000234651500011
J	Hayashi, M; Imanaka-Yoshida, K; Yoshida, T; Wood, M; Fearns, C; Tatake, RJ; Lee, JD				Hayashi, M; Imanaka-Yoshida, K; Yoshida, T; Wood, M; Fearns, C; Tatake, RJ; Lee, JD			A crucial role of mitochondrial Hsp40 in preventing dilated cardiomyopathy	NATURE MEDICINE			English	Article							DROSOPHILA TUMOR-SUPPRESSOR; ADENINE-NUCLEOTIDE TRANSLOCATOR; MOLECULAR CHAPERONES; CARDIAC-HYPERTROPHY; INTEGRATIVE BIOLOGY; DNA-POLYMERASE; HUMAN HOMOLOG; PROTEIN; HEART; DISEASES	Many heat-shock proteins (Hsp) are members of evolutionarily conserved families of chaperone proteins that inhibit the aggregation of unfolded polypeptides and refold denatured proteins, thereby remedying phenotypic effects that may result from protein aggregation or protein instability(1,2). Here we report that the mitochondrial chaperone Hsp40, also known as Dnaja3 or Tid1, is differentially expressed during cardiac development and pathological hypertrophy. Mice deficient in Dnaja3 developed dilated cardiomyopathy (DCM) and died before 10 weeks of age. Progressive respiratory chain deficiency and decreased copy number of mitochondrial DNA were evident in cardiomyocytes lacking Dnaja3. Profiling of Dnaja3-interacting proteins identified the alpha-subunit of DNA polymerase gamma (Polga) as a client protein. These findings suggest that Dnaja3 is crucial for mitochondrial biogenesis, at least in part, through its chaperone activity on Polga and provide genetic evidence of the necessity for mitochondrial Hsp40 in preventing DCM.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Mie Univ, Grad Sch Med, Dept Pathol & Matrix Biol, Tsu, Mie 5148507, Japan; Boehringer Ingelheim Pharmaceut Inc, Ctr Res & Dev, Ridgefield, CT 06877 USA	Scripps Research Institute; Mie University; Boehringer Ingelheim	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jdlee@scripps.edu	Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217	NATIONAL CANCER INSTITUTE [R01CA079871] Funding Source: NIH RePORTER; NCI NIH HHS [CA079871] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; Barral JM, 2004, SEMIN CELL DEV BIOL, V15, P17, DOI 10.1016/j.semcdb.2003.12.010; Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Chien KR, 2005, CELL, V120, P533, DOI 10.1016/j.cell.2005.02.006; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Duchniewicz M, 1999, MOL CELL BIOL, V19, P8201; Fernandez-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Lo JF, 2004, MOL CELL BIOL, V24, P2226, DOI 10.1128/MCB.24.6.2226-2236.2004; Marin-Garcia J, 2004, J MOL MED, V82, P565, DOI 10.1007/s00109-004-0567-7; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Olson EN, 2004, NAT MED, V10, P467, DOI 10.1038/nm0504-467; Schonberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	31	69	73	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					128	132		10.1038/nm1327	http://dx.doi.org/10.1038/nm1327			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16327803				2022-12-25	WOS:000234419000062
J	Tsur, D; Tanner, S; Zandi, E; Bafna, V; Pevzner, PA				Tsur, D; Tanner, S; Zandi, E; Bafna, V; Pevzner, PA			Identification of post-translational modifications by blind search of mass spectra	NATURE BIOTECHNOLOGY			English	Article							PROTEIN IDENTIFICATION; ALIGNMENT ALGORITHM; MODIFIED PEPTIDES; DATABASE SEARCH; SPECTROMETRY; SEQUENCES; SEQUEST	Most tandem mass spectrometry (MS/MS) database search algorithms perform a restrictive search that takes into account only a few types of post-translational modifications (PTMs) and ignores all others. We describe an unrestrictive PTM search algorithm, MS-Alignment, that searches for all types of PTMs at once in a blind mode, that is, without knowing which PTMs exist in nature. Blind PTM identification makes it possible to study the extent and frequency of different types of PTMs, still an open problem in proteomics. Application of this approach to lens proteins resulted in the largest set of PTMs reported in human crystallins so far. Our analysis of various MS/MS data sets implies that the biological phenomenon of modification is much more widespread than previously thought. We also argue that MS-Alignment reveals some uncharacterized modifications that warrant further experimental validation.	Univ Calif San Diego, Bioinformat Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA; Univ So Calif, Sch Med, Los Angeles, CA 90033 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Southern California	Tanner, S (corresponding author), Univ Calif San Diego, Bioinformat Program, 9500 Gilman Dr, La Jolla, CA 92093 USA.	stanner@ucsd.edu	Bafna, Vineet/AAY-8111-2020	Bafna, Vineet/0000-0002-5810-6241; Tsur, Dekel/0000-0001-9763-3784	NCRR NIH HHS [1-R01-RR16522] Funding Source: Medline; NEI NIH HHS [EY007755] Funding Source: Medline; NIGMS NIH HHS [R01GM65325] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR016522] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007755, R29EY007755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065325] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DC, 2003, J PROTEOME RES, V2, P137, DOI 10.1021/pr0255654; Cantin GT, 2004, J CHROMATOGR A, V1053, P7, DOI 10.1016/j.chroma.2004.06.046; Craig R, 2003, RAPID COMMUN MASS SP, V17, P2310, DOI 10.1002/rcm.1198; Elias JE, 2004, NAT BIOTECHNOL, V22, P214, DOI 10.1038/nbt930; Frank A, 2005, J PROTEOME RES, V4, P1287, DOI 10.1021/pr050011x; Geer LY, 2004, J PROTEOME RES, V3, P958, DOI 10.1021/pr0499491; Han Yonghua, 2005, Journal of Bioinformatics and Computational Biology, V3, P697; Hansen BT, 2005, J PROTEOME RES, V4, P358, DOI 10.1021/pr0498234; Havilio M, 2003, ANAL CHEM, V75, P435, DOI 10.1021/ac0258913; Keller Andrew, 2002, OMICS A Journal of Integrative Biology, V6, P207, DOI 10.1089/153623102760092805; MacCoss MJ, 2002, ANAL CHEM, V74, P5593, DOI 10.1021/ac025826t; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pevzner PA, 2001, GENOME RES, V11, P290, DOI 10.1101/gr.154101; Pevzner PA, 2000, J COMPUT BIOL, V7, P777, DOI 10.1089/10665270050514927; Razumovskaya J, 2004, PROTEOMICS, V4, P961, DOI 10.1002/pmic.200300656; Searle BC, 2005, J PROTEOME RES, V4, P546, DOI 10.1021/pr049781j; Searle BC, 2004, ANAL CHEM, V76, P2220, DOI 10.1021/ac035258x; Shu HJ, 2004, MOL CELL PROTEOMICS, V3, P279, DOI 10.1074/mcp.D300003-MCP200; Tabb DL, 2003, ANAL CHEM, V75, P1155, DOI 10.1021/ac026122m; Tang WH, 2005, ANAL CHEM, V77, P3931, DOI 10.1021/ac0481046; Tanner S, 2005, ANAL CHEM, V77, P4626, DOI 10.1021/ac050102d; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	24	211	220	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2005	23	12					1562	1567		10.1038/nbt1168	http://dx.doi.org/10.1038/nbt1168			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	992ED	16311586				2022-12-25	WOS:000233866300034
J	Cokol, M; Iossifov, I; Weinreb, C; Rzhetsky, A				Cokol, M; Iossifov, I; Weinreb, C; Rzhetsky, A			Emergent behavior of growing knowledge about molecular interactions	NATURE BIOTECHNOLOGY			English	Editorial Material							NETWORK		Columbia Univ, Dept Biol Sci, New York, NY 10032 USA; Columbia Univ, Judith P Sulzberger MD Columbia Genome Ctr, New York, NY 10032 USA; Columbia Univ, Dept Biomed Informat, New York, NY 10032 USA; Columbia Univ, Ctr Computat Biol & Bioinformat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Cokol, M (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10032 USA.	ar345@columbia.edu	rzhetsky, andrey/B-6118-2012	rzhetsky, andrey/0000-0001-6959-7405				Barabasi AL, 2002, PHYSICA A, V311, P590, DOI 10.1016/S0378-4371(02)00736-7; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Chen CM, 2004, P NATL ACAD SCI USA, V101, P5303, DOI 10.1073/pnas.0307513100; Draper N.R., 1998, WILEY SERIES PROBABI, V326; Friedman C, 2001, Bioinformatics, V17 Suppl 1, pS74; Gilks WR, 1996, MARKOV CHAIN MONTE C; Guimera R, 2005, SCIENCE, V308, P697, DOI 10.1126/science.1106340; HASTINGS WK, 1970, BIOMETRIKA, V57, P97, DOI 10.2307/2334940; Krauthammer Michael, 2002, Bioinformatics, V18 Suppl 1, pS249; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; PRICE DJD, 1965, SCIENCE, V149, P510; Rzhetsky A, 2004, J BIOMED INFORM, V37, P43, DOI 10.1016/j.jbi.2003.10.001	12	43	43	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2005	23	10					1243	1247		10.1038/nbt1005-1243	http://dx.doi.org/10.1038/nbt1005-1243			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QZ	16211067				2022-12-25	WOS:000232469600025
J	Lautru, S; Deeth, RJ; Bailey, LM; Challis, GL				Lautru, S; Deeth, RJ; Bailey, LM; Challis, GL			Discovery of a new peptide natural product by Streptomyces coelicolor genome mining	NATURE CHEMICAL BIOLOGY			English	Article							ESCHERICHIA-COLI; EXTRACELLULAR SIDEROPHORE; STIGMATELLA-AURANTIACA; ADENYLATION DOMAINS; CONJUGAL TRANSFER; IRON TRANSPORT; SYNTHETASES; SEQUENCE; BIOSYNTHESIS; RECONSTITUTION	Analyses of microbial genome sequences reveal numerous examples of gene clusters encoding proteins typically involved in complex natural product biosynthesis but not associated with the production of known natural products(1-3). In Streptomyces coelicolor M145 there are several gene clusters encoding new nonribosomal peptide synthetase (NRPS) systems not associated with known metabolites. Application of structure-based models for substrate recognition by NRPS adenylation domains(4-6) predicts the amino acids incorporated into the putative peptide products of these systems(7,3), but the accuracy of these predictions is untested. Here we report the isolation and structure determination of the new tris-hydroxamate tetrapeptide iron chelator coelichelin from S. coelicolor using a genome mining approach guided by substrate predictions for the trimodular NRPS CchH, and we show that this enzyme, which lacks a C-terminal thioesterase domain, together with a homolog of enterobactin esterase (CchJ), are required for coelichelin biosynthesis. These results demonstrate that accurate prediction of adenylation domain substrate selectivity is possible and raise intriguing mechanistic questions regarding the assembly of a tetrapeptide by a trimodular NRPS.	Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England	University of Warwick	Challis, GL (corresponding author), Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.	G.L.Challis@warwick.ac.uk	Deeth, Robert J/B-8641-2009; Lautru, Sylvie/AAJ-1199-2020	Deeth, Robert J/0000-0001-7933-4406; Lautru, Sylvie/0000-0002-7935-704X; Challis, Gregory/0000-0001-5976-3545	Biotechnology and Biological Sciences Research Council [B16610, EGH16081] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; BRICKMAN TJ, 1992, J BIOL CHEM, V267, P12350; Challis GL, 2000, FEMS MICROBIOL LETT, V187, P111, DOI 10.1111/j.1574-6968.2000.tb09145.x; Challis GL, 2004, CURR OPIN STRUC BIOL, V14, P748, DOI 10.1016/j.sbi.2004.10.005; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; Flett F, 1997, FEMS MICROBIOL LETT, V155, P223, DOI 10.1111/j.1574-6968.1997.tb13882.x; Gaitatzis N, 2001, P NATL ACAD SCI USA, V98, P11136, DOI 10.1073/pnas.201167098; Guenzi E, 1998, J BIOL CHEM, V273, P32857, DOI 10.1074/jbc.273.49.32857; Gust B, 2003, P NATL ACAD SCI USA, V100, P1541, DOI 10.1073/pnas.0337542100; Gust B, 2004, ADV APPL MICROBIOL, V54, P107, DOI 10.1016/S0065-2164(04)54004-2; HIGASHIDE E, 1968, J ANTIBIOT, V21, P126, DOI 10.7164/antibiotics.21.126; Ikeda H, 2003, NAT BIOTECHNOL, V21, P526, DOI 10.1038/nbt820; Ishikawa J, 2004, P NATL ACAD SCI USA, V101, P14925, DOI 10.1073/pnas.0406410101; Keating TA, 2000, BIOCHEMISTRY-US, V39, P15522, DOI 10.1021/bi0016523; LANGMAN L, 1972, J BACTERIOL, V112, P1142, DOI 10.1128/JB.112.3.1142-1149.1972; Lautru S, 2004, MICROBIOL-SGM, V150, P1629, DOI 10.1099/mic.0.26837-0; May JJ, 2002, P NATL ACAD SCI USA, V99, P12120, DOI 10.1073/pnas.182156699; May JJ, 2001, J BIOL CHEM, V276, P7209, DOI 10.1074/jbc.M009140200; Mootz HD, 2002, CHEMBIOCHEM, V3, P490, DOI 10.1002/1439-7633(20020603)3:6<490::AID-CBIC490>3.0.CO;2-N; MULLER G, 1984, J BACTERIOL, V160, P304; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; SHARMAN GJ, 1995, BIOCHEM J, V305, P187, DOI 10.1042/bj3050187; SHARMAN GJ, 1995, CHEM BIOL, V2, P553, DOI 10.1016/1074-5521(95)90189-2; Shaw-Reid CA, 1999, CHEM BIOL, V6, P385, DOI 10.1016/S1074-5521(99)80050-7; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; Wenzel SC, 2005, CHEMBIOCHEM, V6, P375, DOI 10.1002/cbic.200400282; [No title captured]	29	288	300	3	121	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2005	1	5					265	269		10.1038/nchembio731	http://dx.doi.org/10.1038/nchembio731			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GN	16408055				2022-12-25	WOS:000232649100010
J	Castilla, J; Saa, P; Soto, C				Castilla, J; Saa, P; Soto, C			Detection of prions in blood	NATURE MEDICINE			English	Article							CYCLIC AMPLIFICATION; PROTEIN; TRANSMISSION; PROPAGATION; TRANSFUSION; INFECTIVITY; BSE; CJD	Prion diseases are caused by an unconventional infectious agent termed prion, composed mainly of the misfolded prion protein ( PrPSc)(1). The development of highly sensitive assays for biochemical detection of PrPSc in blood is a top priority for minimizing the spread of the disease(2). Here we show that the protein misfolding cyclic amplification ( PMCA) technology(3) can be automated and optimized for high- efficiency amplification of PrPSc. We show that 140 PMCA cycles leads to a 6,600- fold increase in sensitivity over standard detection methods. Two successive rounds of PMCA cycles resulted in a 10 million - fold increase in sensitivity and a capability to detect as little as 8,000 equivalent molecules of PrPSc. Notably, serial PMCA enables detection of PrPSc in blood samples of scrapie- afflicted hamsters with 89% sensitivity and 100% specificity. These findings represent the first time that PrPSc has been detected biochemically in blood, offering promise for developing a noninvasive method for early diagnosis of prion diseases.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Autonoma Madrid, Ctr Mol Biol, E-28049 Madrid, Spain	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Autonomous University of Madrid	Soto, C (corresponding author), Univ Texas, Med Branch, Dept Neurol, 301 Univ Blvd, Galveston, TX 77555 USA.	clsoto@utmb.edu	Castilla, Joaquín/J-8414-2019; Castilla, Joaquin/D-5261-2011; Saa, Paula/AAB-6607-2019	Castilla, Joaquín/0000-0002-2216-1361; Castilla, Joaquin/0000-0002-2216-1361; Saa, Paula/0000-0001-6077-4532	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002246] Funding Source: NIH RePORTER; NIA NIH HHS [AG0224642] Funding Source: Medline; NINDS NIH HHS [NS049173] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barret A, 2003, J VIROL, V77, P8462, DOI 10.1128/JVI.77.15.8462-8469.2003; Bieschke J, 2004, P NATL ACAD SCI USA, V101, P12207, DOI 10.1073/pnas.0404650101; Bradley Ray, 2004, Folia Neuropathol, V42 Suppl A, P55; Brown P, 2001, J LAB CLIN MED, V137, P5, DOI 10.1067/mlc.2001.111951; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Castilla J, 2004, TECHNIQUES PRION RES, P198, DOI [10.1007/978-3-0348-7949-1_14, DOI 10.1007/978-3-0348-7949-1_14]; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Ingrosso L, 2002, TRENDS MOL MED, V8, P273, DOI 10.1016/S1471-4914(02)02358-4; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; Piening N, 2005, BIOCHEM BIOPH RES CO, V326, P339, DOI 10.1016/j.bbrc.2004.11.039; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Saa Paula, 2004, V299, P53; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Soto C, 2004, NAT REV MICROBIOL, V2, P809, DOI 10.1038/nrmicro1003; Soto C, 2005, FEBS LETT, V579, P638, DOI 10.1016/j.febslet.2004.12.035; Soto C, 2002, TRENDS NEUROSCI, V25, P390, DOI 10.1016/S0166-2236(02)02195-1	24	237	260	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					982	985		10.1038/nm1286	http://dx.doi.org/10.1038/nm1286			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16127436				2022-12-25	WOS:000231724700026
J	Lu, DL; Collison, AM; Kowalski, TJ				Lu, DL; Collison, AM; Kowalski, TJ			The patentability of antibodies in the United States	NATURE BIOTECHNOLOGY			English	Editorial Material									Frommer Lawrence & Haug LLP, New York, NY 10151 USA		Lu, DL (corresponding author), Frommer Lawrence & Haug LLP, 745 5th Ave, New York, NY 10151 USA.	tkowalski@flhlaw.com							0	2	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1079	1080		10.1038/nbt0905-1079	http://dx.doi.org/10.1038/nbt0905-1079			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16151395				2022-12-25	WOS:000231790600021
J	Zhao, BQ; Wang, S; Kim, HY; Storrie, H; Rosen, BR; Mooney, DJ; Wang, XY; Lo, EH				Zhao, BQ; Wang, S; Kim, HY; Storrie, H; Rosen, BR; Mooney, DJ; Wang, XY; Lo, EH			Role of matrix metalloproteinases in delayed cortical responses after stroke	NATURE MEDICINE			English	Article							FOCAL CEREBRAL-ISCHEMIA; BLOOD-BRAIN-BARRIER; PLASMINOGEN ACTIVATOR; MATRIX-METALLOPROTEINASE-9; ANGIOGENESIS; INDUCTION; RECOVERY; REGENERATION; PROTEOLYSIS; EXPRESSION	Matrix metalloproteinases ( MMPs) are zinc-endopeptidases with multifactorial actions in central nervous system (CNS) physiology and pathology(1). Accumulating data suggest that MMPs have a deleterious role in stroke. By degrading neurovascular matrix, MMPs promote injury of the blood-brain barrier, edema and hemorrhage(2-4). By disrupting cell-matrix signaling and homeostasis, MMPs trigger brain cell death(5,6). Hence, there is a movement toward the development of MMP inhibitors for acute stroke therapy. But MMPs may have a different role during delayed phases after stroke. Because MMPs modulate brain matrix, they may mediate beneficial plasticity and remodeling during stroke recovery. Here, we show that MMPs participate in delayed cortical responses after focal cerebral ischemia in rats. MMP-9 is upregulated in peri-infarct cortex at 7-14 days after stroke and is colocalized with markers of neurovascular remodeling. Treatment with MMP inhibitors at 7 days after stroke suppresses neurovascular remodeling, increases ischemic brain injury and impairs functional recovery at 14 days. MMP processing of bioavailable VEGF may be involved because inhibition of MMPs reduces endogenous VEGF signals, whereas additional treatment with exogenous VEGF prevents MMP inhibitor-induced worsening of infarction. These data suggest that, contrary to MMP inhibitor therapies for acute stroke, strategies that modulate MMPs may be needed for promoting stroke recovery.	Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA; Massachusetts Gen Hosp, Aninthoula Martinos Ctr Biomed Imaging, MGH E 2, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Lo, EH (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, MGH E 149-2401, Charlestown, MA 02129 USA.	Lo@helix.mgh.harvard.edu		Mooney, David/0000-0001-6299-1194	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048422, R01NS037074, R01NS040529, P50NS010828] Funding Source: NIH RePORTER; NIBIB NIH HHS [R01-EB02066] Funding Source: Medline; NINDS NIH HHS [R01-NS48422, P50-NS10828, R01-NS37074, R01-NS40529] Funding Source: Medline; PHS HHS [R01-EBO2066] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Chmielnicki E, 2002, PROG BRAIN RES, V138, P451, DOI 10.1016/S0079-6123(02)38093-2; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Irving EA, 2005, J CEREBR BLOOD F MET, V25, P98, DOI 10.1038/sj.jcbfm.9600011; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Kaczmarek L, 2002, EMBO J, V21, P6643, DOI 10.1093/emboj/cdf676; Kim YR, 2005, J CEREBR BLOOD F MET, V25, P820, DOI 10.1038/sj.jcbfm.9600084; Larsen PH, 2003, J NEUROSCI, V23, P11127, DOI 10.1523/jneurosci.23-35-11127.2003; Lee SR, 2004, J CEREBR BLOOD F MET, V24, P720, DOI 10.1097/01.WCB.0000122747.72175.47; Lee SR, 2004, J NEUROSCI, V24, P671, DOI 10.1523/JNEUROSCI.4243-03.2004; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Manoonkitiwongsa PS, 2001, J CEREBR BLOOD F MET, V21, P1223, DOI 10.1097/00004647-200110000-00011; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Montaner J, 2001, STROKE, V32, P1759, DOI 10.1161/01.STR.32.8.1759; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Omura K, 2004, BRAIN RES, V1001, P13, DOI 10.1016/j.brainres.2003.10.067; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Reeves TM, 2003, J NEUROSCI, V23, P10182; Silva EA, 2004, CURR TOP DEV BIOL, V64, P181, DOI 10.1016/S0070-2153(04)64008-7; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; WALLACE CS, 1995, MOL BRAIN RES, V32, P211, DOI 10.1016/0169-328X(95)00076-5; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	30	552	586	2	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					441	445		10.1038/nm1387	http://dx.doi.org/10.1038/nm1387			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16565723				2022-12-25	WOS:000236581300033
J	Luesch, H; Chanda, SK; Raya, RM; DeJesus, P; Orth, AP; Walker, JR; Belmonte, JCI; Schultz, PG				Luesch, H; Chanda, SK; Raya, RM; DeJesus, P; Orth, AP; Walker, JR; Belmonte, JCI; Schultz, PG			A functional genomics approach to the mode of action of apratoxin A	NATURE CHEMICAL BIOLOGY			English	Article							FIBROBLAST-GROWTH-FACTOR; TRANSCRIPTION FACTOR; FACTOR RECEPTOR; STAT3; ACTIVATION; EXPRESSION; TYROSINE; FGF8; APOPTOSIS; CDC25A	The cyanobacterial metabolite apratoxin A (1) demonstrates potent cytotoxicity against tumor cell lines by a hitherto unknown mechanism. We have used functional genomics to elucidate the molecular basis for this activity. Gene expression profiling and DNA content analysis showed that apratoxin A induces G1-phase cell cycle arrest and apoptosis. Cell-based functional assays with a genome-wide collection of expression cDNAs showed that ectopic induction of fibroblast growth factor receptor ( FGFR) signaling attenuates the apoptotic activity of apratoxin A. This natural product inhibited phosphorylation and activation of STAT3, a downstream effector of FGFR signaling. It also caused defects in FGF-dependent processes during zebrafish development, with concomitant reductions in expression levels of the FGF target gene mkp3. We conclude that apratoxin A mediates its antiproliferative activity through the induction of G1 cell cycle arrest and an apoptotic cascade, which is at least partially initiated through antagonism of FGF signaling via STAT3.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Genom Inst Novartis Res Fdn, San Diego, CA 92121 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Ctr Regenerat Med Barcelona, Barcelona 08003, Spain	Scripps Research Institute; Novartis; Salk Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Centro de Medicina Regenerativa de Barcelona; University of Barcelona	Luesch, H (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	luesch@cop.ufl.edu; schultz@scripps.edu						Amin HM, 2004, ONCOGENE, V23, P5426, DOI 10.1038/sj.onc.1207703; Barre B, 2005, J BIOL CHEM, V280, P15673, DOI 10.1074/jbc.M413203200; Beissbarth T, 2004, BIOINFORMATICS, V20, P1464, DOI 10.1093/bioinformatics/bth088; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHAMBERS JM, 1992, STAT MODELS S, pCH8; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chen JH, 2004, P NATL ACAD SCI USA, V101, P12067, DOI 10.1073/pnas.0402752101; CHOY BK, 1988, CANCER RES, V48, P2029; Collavin L, 2000, FEBS LETT, V481, P57, DOI 10.1016/S0014-5793(00)01969-4; Dimitroff CJ, 1999, INVEST NEW DRUG, V17, P121, DOI 10.1023/A:1006367032156; Draper BW, 2003, DEVELOPMENT, V130, P4639, DOI 10.1242/dev.00671; Edelman MJ, 2003, LUNG CANCER-J IASLC, V39, P197, DOI 10.1016/S0169-5002(02)00511-1; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Espinet C, 2000, J NEUROSCI METH, V100, P63, DOI 10.1016/S0165-0270(00)00233-8; Fischer S, 2003, DEVELOPMENT, V130, P3515, DOI 10.1242/dev.00537; Fuhrmann G, 2001, ONCOGENE, V20, P4542, DOI 10.1038/sj.onc.1204499; Giaever G, 2004, P NATL ACAD SCI USA, V101, P793, DOI 10.1073/pnas.0307490100; Grandel H, 2000, DEVELOPMENT, V127, P4169; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Jaspars M, 1998, Curr Opin Drug Discov Devel, V1, P77; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kavallaris M, 2001, DRUG RESIST UPDATE, V4, P392, DOI 10.1054/drup.2002.0230; Kawakami Y, 2003, NAT CELL BIOL, V5, P513, DOI 10.1038/ncb989; Kawakami Y, 2004, DEVELOPMENT, V131, P4763, DOI 10.1242/dev.01331; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Liang J, 2005, INVEST NEW DRUG, V23, P213, DOI 10.1007/s10637-005-6729-9; Luesch H, 2005, CHEM BIOL, V12, P55, DOI 10.1016/j.chembiol.2004.10.015; Luesch H, 2002, BIOORGAN MED CHEM, V10, P1973, DOI 10.1016/S0968-0896(02)00014-7; Luesch H, 2001, J NAT PROD, V64, P907, DOI 10.1021/np010049y; Luesch H, 2001, J AM CHEM SOC, V123, P5418, DOI 10.1021/ja010453j; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; Paull K.D., 1995, CANC CHEMOTHERAPEUTI, p9?45; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; Reifers F, 1998, DEVELOPMENT, V125, P2381; Salani D, 2000, AM J PATHOL, V157, P1703, DOI 10.1016/S0002-9440(10)64807-9; Tomono M, 1998, ARCH BIOCHEM BIOPHYS, V353, P374, DOI 10.1006/abbi.1998.0667; Tsang M, 2004, DEVELOPMENT, V131, P2769, DOI 10.1242/dev.01157; Vaishampayan U, 2000, CLIN CANCER RES, V6, P4205; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Westerfield M, 2000, ZEBRAFISH BOOK GUIDE; Xi SC, 2005, ONCOGENE, V24, P970, DOI 10.1038/sj.onc.1208316; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	127	132	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAR	2006	2	3					158	167		10.1038/nchembio769	http://dx.doi.org/10.1038/nchembio769			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013QL	16474387				2022-12-25	WOS:000235424100014
J	Chan, CW; Crafton, E; Fan, HN; Flook, J; Yoshimura, K; Skarica, M; Brockstedt, D; Dubensky, TW; Stins, MF; Lanier, LL; Pardoll, DM; Housseau, F				Chan, CW; Crafton, E; Fan, HN; Flook, J; Yoshimura, K; Skarica, M; Brockstedt, D; Dubensky, TW; Stins, MF; Lanier, LL; Pardoll, DM; Housseau, F			Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity	NATURE MEDICINE			English	Article							HUMAN NK CELLS; IFN-GAMMA; ACTIVATION; RECEPTOR; NKG2D; BETA; EXPRESSION; INFECTION	Natural killer (NK) cells and dendritic cells (DCs) are, respectively, central components of innate and adaptive immune responses(1,2). We describe here a third DC lineage, termed interferon-producing killer DCs (IKDCs), distinct from conventional DCs and plasmacytoid DCs and with the molecular expression profile of both NK cells and DCs. They produce substantial amounts of type I interferons (IFN) and interleukin (IL)-12 or IFN-c, depending on activation stimuli. Upon stimulation with CpG oligodeoxynucleotides, ligands for Toll-like receptor (TLR)-9, IKDCs kill typical NK target cells using NK-activating receptors. Their cytolytic capacity subsequently diminishes, associated with the loss of NKG2D receptor (also known as Klrk1) and its adaptors, Dap10 and Dap12. As cytotoxicity is lost, DC-like antigen-presenting activity is gained, associated with upregulation of surface major histocompatibility complex class II (MHC II) and costimulatory molecules, which formally distinguish them from classical NK cells. In vivo, splenic IKDCs preferentially show NK function and, upon systemic infection, migrate to lymph nodes, where they primarily show antigen-presenting cell activity. By virtue of their capacity to kill target cells, followed by antigen presentation, IKDCs provide a link between innate and adaptive immunity.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Cerus Corp, Concord, CA 94520 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Infect Dis, Baltimore, MD 21205 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	Johns Hopkins University; Johns Hopkins Medicine; Cerus Corporation; Johns Hopkins University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Housseau, F (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, CRB-440,1650 Orleans St, Baltimore, MD 21231 USA.	dmpardol@jhmi.edu; fhousse1@jhmi.edu	Stins, Monique/W-2621-2018; Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952; Skarica, Mario/0000-0002-2478-014X	NATIONAL CANCER INSTITUTE [R01CA089294, R01CA089189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064826] Funding Source: NIH RePORTER; NCI NIH HHS [CA89294, CA89189, R01 CA089189, R01 CA089294] Funding Source: Medline; NIAID NIH HHS [R01 AI064826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson SK, 2001, IMMUNOL REV, V181, P79, DOI 10.1034/j.1600-065X.2001.1810106.x; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Arase H, 2001, J IMMUNOL, V167, P1141, DOI 10.4049/jimmunol.167.3.1141; Ardavin C, 2003, NAT REV IMMUNOL, V3, P582, DOI 10.1038/nri1127; Asselin-Paturel C, 2005, J EXP MED, V201, P1157, DOI 10.1084/jem.20041930; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; del Hoyo GM, 2002, NATURE, V415, P1043, DOI 10.1038/4151043a; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Gilfillan S, 2002, NAT IMMUNOL, V3, P1150, DOI 10.1038/ni857; Hanna J, 2004, J CLIN INVEST, V114, P1612, DOI 10.1172/JCI200422787; Homann D, 2002, IMMUNITY, V16, P403, DOI 10.1016/S1074-7613(02)00290-X; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Josien R, 1997, J EXP MED, V186, P467, DOI 10.1084/jem.186.3.467; Kamath AT, 2005, J IMMUNOL, V174, P767, DOI 10.4049/jimmunol.174.2.767; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Laouar Y, 2005, NAT IMMUNOL, V6, P600, DOI 10.1038/ni1197; Ortaldo JR, 1999, J LEUKOCYTE BIOL, V66, P512, DOI 10.1002/jlb.66.3.512; Pelayo R, 2005, BLOOD, V105, P4407, DOI 10.1182/blood-2004-07-2529; Pillarisetty VG, 2005, J IMMUNOL, V174, P2612, DOI 10.4049/jimmunol.174.5.2612; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; Steinman RM, 2003, APMIS, V111, P675, DOI 10.1034/j.1600-0463.2003.11107802.x; Suzuki H, 1997, J EXP MED, V185, P499, DOI 10.1084/jem.185.3.499; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Walzer T, 2005, BLOOD; Yokoyama WM, 2004, ANNU REV IMMUNOL, V22, P405, DOI 10.1146/annurev.immunol.22.012703.104711; Zingoni A, 2004, J IMMUNOL, V173, P3716, DOI 10.4049/jimmunol.173.6.3716	30	324	355	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					207	213		10.1038/nm1352	http://dx.doi.org/10.1038/nm1352			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16444266				2022-12-25	WOS:000235160600025
J	Rowland, BD; Bernards, R; Peeper, DS				Rowland, BD; Bernards, R; Peeper, DS			The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene	NATURE CELL BIOLOGY			English	Article							KRUPPEL-LIKE FACTOR; CELL-LINE RKO; DOWN-REGULATION; BREAST-CANCER; ONCOSTATIN-M; FACTOR GENE; TGF-BETA; EXPRESSION; GROWTH; RAS	KLF4 (GKLF/EZF) encodes a transcription factor that is associated with both tumour suppression and oncogenesis. We describe the identification of KLF4 in a functional genomic screen for genes that bypass RAS(V12)-induced senescence. However, in untransformed cells, KLF4 acts as a potent inhibitor of proliferation. KLF4-induced arrest is bypassed by oncogenic RAS(V12) or by the RAS target cyclin-D1. Remarkably, inactivation of the cyclin-D1 target and the cell-cycle inhibitor p21(CIP1) not only neutralizes the cytostatic action of KLF4, but also collaborates with KLF4 in oncogenic transformation. Conversely, KLF4 suppresses the expression of p53 by directly acting on its promoter, thereby allowing for RAS(V12)-mediated transformation and causing resistance to DNA-damage-induced apoptosis. Consistently, KLF4 depletion from breast cancer cells restores p53 levels and causes p53-dependent apoptosis. These results unmask KLF4 as a regulator of p53 that oncogenically transforms cells as a function of p21(CIP1) status. Furthermore, they provide a mechanistic explanation for the context-dependent oncogenic or tumour-suppressor functions of KLF4.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Peeper, DS (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	d.peeper@nki.nl	Peeper, Daniel/AAA-2430-2020	Bernards, Rene/0000-0001-8677-3423				Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOS JL, 1989, CANCER RES, V49, P4682; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; FILMUS J, 1994, ONCOGENE, V9, P3627; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Katz JP, 2002, DEVELOPMENT, V129, P2619; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li C, 2001, ONCOGENE, V20, P8193, DOI 10.1038/sj.onc.1205046; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LUO A, 2003, ONCOGENE, V1, P1; Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Peeper DS, 2002, NAT CELL BIOL, V4, P148, DOI 10.1038/ncb742; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	50	444	472	1	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1074	1082		10.1038/ncb1314	http://dx.doi.org/10.1038/ncb1314			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16244670	Green Published			2022-12-25	WOS:000232930400010
J	Yajima, J; Cross, RA				Yajima, J; Cross, RA			A torque component in the kinesin-1 power stroke	NATURE CHEMICAL BIOLOGY			English	Article							SINGLE-HEADED KINESIN; HAND-OVER-HAND; BIASED BINDING; MOTOR DOMAINS; MECHANISM; PROCESSIVITY; MICROTUBULES; TUBULIN; PROTEIN; MOVEMENT	Kinesin-1 is a twin-headed molecular motor that moves along microtubules in 8-nm steps, using a walking action in which the two heads interact alternately with the microtubule(1-4). Constructs with only one head can also produce impulses of force and motion(5-7), indicating that the walking action is an amplification strategy that leverages an underlying force-generating event. Recent work suggests that directional force is produced either by directionally biased selection of microtubule binding sites(8,9) or by a conformational change subsequent to the binding event(10-12). We report here that surface-attached rat kinesin-1 monomers drive counterclockwise rotation of sliding microtubules around their axes, and that by manipulating the assay geometry, we could reduce or block the torsional motion with negligible effects on the axial motion. We can account for this behavior on the simple assumption that kinesin heads tend to bind to the closest available tubulin heterodimer in the lattice, but only in the case where an additional biasing process is present that shifts the start position for diffusion-to-capture toward the microtubule plus end by similar to 1 nm.	Marie Curie Res Inst, Mol Motors Grp, Oxted RH8 0TL, Surrey, England		Cross, RA (corresponding author), Marie Curie Res Inst, Mol Motors Grp, The CHart, Oxted RH8 0TL, Surrey, England.	r.cross@mcri.ac.uk	Cross, Robert A/F-1798-2011	Cross, Robert A/0000-0002-0004-7832; Yajima, Junichiro/0000-0003-3325-7868				Alonso MC, 1998, EMBO J, V17, P945, DOI 10.1093/emboj/17.4.945; Asbury CL, 2003, SCIENCE, V302, P2130, DOI 10.1126/science.1092985; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; Cross RA, 2000, PHILOS T ROY SOC B, V355, P459, DOI 10.1098/rstb.2000.0587; Cross RA, 2004, TRENDS BIOCHEM SCI, V29, P301, DOI 10.1016/j.tibs.2004.04.010; Hancock WO, 1999, P NATL ACAD SCI USA, V96, P13147, DOI 10.1073/pnas.96.23.13147; Higuchi H, 2004, EMBO J, V23, P2993, DOI 10.1038/sj.emboj.7600306; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kamei T, 2005, BIOPHYS J, V88, P2068, DOI 10.1529/biophysj.104.049759; Kaseda K, 2003, NAT CELL BIOL, V5, P1079, DOI 10.1038/ncb1067; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kull FJ, 2002, J CELL SCI, V115, P15; LINCK RW, 1974, J CELL SCI, V14, P551; Naber N, 2003, BIOPHYS J, V84, P3190, DOI 10.1016/S0006-3495(03)70043-5; Nitta R, 2004, SCIENCE, V305, P678, DOI 10.1126/science.1096621; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Okada Y, 2003, NATURE, V424, P574, DOI 10.1038/nature01804; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; Yajima J, 2002, CURR BIOL, V12, P301, DOI 10.1016/S0960-9822(01)00683-2; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753; Young EC, 1998, BIOCHEMISTRY-US, V37, P3467, DOI 10.1021/bi972172n	27	42	42	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2005	1	6					338	341		10.1038/nchembio740	http://dx.doi.org/10.1038/nchembio740			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	979GH	16408073				2022-12-25	WOS:000232929900012
J	Huber, C; Dias-Santagata, D; Glaser, A; O'Sullivan, J; Brauner, R; Wu, K; Xu, XS; Pearce, K; Wang, R; Uzielli, MLG; Dagoneau, N; Chemaitilly, W; Superti-Furga, A; Dos Santos, H; Megarbane, A; Morin, G; Gillessen-Kaesbach, G; Hennekam, R; Van der Burgt, I; Black, GCM; Clayton, PE; Read, A; Le Merrer, M; Scambler, PJ; Munnich, A; Pan, ZQ; Winter, R; Cormier-Daire, V				Huber, C; Dias-Santagata, D; Glaser, A; O'Sullivan, J; Brauner, R; Wu, K; Xu, XS; Pearce, K; Wang, R; Uzielli, MLG; Dagoneau, N; Chemaitilly, W; Superti-Furga, A; Dos Santos, H; Megarbane, A; Morin, G; Gillessen-Kaesbach, G; Hennekam, R; Van der Burgt, I; Black, GCM; Clayton, PE; Read, A; Le Merrer, M; Scambler, PJ; Munnich, A; Pan, ZQ; Winter, R; Cormier-Daire, V			Identification of mutations in CUL7 in 3-M syndrome	NATURE GENETICS			English	Article							PROTEIN; COMPLEX; CULLIN	Intrauterine growth retardation is caused by maternal, fetal or placental factors that result in impaired endovascular trophoblast invasion and reduced placental perfusion(1). Although various causes of intrauterine growth retardation have been identified, most cases remain unexplained. Studying 29 families with 3-M syndrome (OMIM 273750), an autosomal recessive condition characterized by severe pre- and postnatal growth retardation, we first mapped the underlying gene to chromosome 6p21.1 and then identified 25 distinct mutations in the gene cullin 7 (CUL7). CUL7 assembles an E3 ubiquitin ligase complex containing Skp1, Fbx29 (also called Fbw8) and ROC1 and promotes ubiquitination. Using deletion analysis, we found that CUL7 uses its central region to interact with the Skp1-Fbx29 heterodimer. Functional studies indicated that the 3-M-associated CUL7 nonsense and missense mutations R1445X and H1464P, respectively, render CUL7 deficient in recruiting ROC1. These results suggest that impaired ubiquitination may have a role in the pathogenesis of intrauterine growth retardation in humans.	Univ Paris Descartes, Fac Med, INSERM,U393, APHP,Hop Necker Enfants Malad, F-75015 Paris, France; Dept Med Genet, F-75015 Paris, France; Mt Sinai Sch Med, Dept Oncol Sci, New York, NY USA; Inst Child Hlth, London WC1N 1EH, England; St Marys Hosp, Univ Hosp NHS Trust, Dept Clin Genet, Manchester M13 0JH, Lancs, England; CHU Bicetre, Pediat Endocrinol Unit, F-94275 Le Kremlin Bicetre, France; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Univ Florence, Dept Paediat, Genet & Mol Med Unit, Florence, Italy; CHU Vaudois, Div Mol Pediat, CH-1011 Lausanne, Switzerland; Hosp Sta Maria, Med Genet Serv, Lisbon, Portugal; Univ St Joseph, Unite Genet Med, Beirut, Lebanon; Univ Med Ctr Nijmegen, Dept Human Genet, NL-6525 GA Nijmegen, Netherlands; Univ Essen Gesamthsch, Inst Humangenet, D-45122 Essen, Germany; Amiens Univ Hosp, Dept Paediat, Clin Genet Unit, Amiens, France; Univ Manchester, Endocrine Sci Res Grp, Manchester M13 9PT, Lancs, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Icahn School of Medicine at Mount Sinai; University of London; University College London; University of Manchester; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Icahn School of Medicine at Mount Sinai; University of Florence; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Universidade de Lisboa; Hospital Santa Maria; Saint Joseph University Beirut; Radboud University Nijmegen; University of Duisburg Essen; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; University of Manchester	Cormier-Daire, V (corresponding author), Univ Paris Descartes, Fac Med, INSERM,U393, APHP,Hop Necker Enfants Malad, 149 Rue Sevres, F-75015 Paris, France.	cormier@necker.fr	Scambler, Peter J/C-4998-2008; wei, wei/HHR-8613-2022; Wang, Rong/A-8721-2009; Scambler, Peter/AAZ-6026-2020; superti-furga, andrea/E-9162-2015; Megarbane, Andre/ABD-5574-2021; Chemaitilly, Wassim/AAQ-3397-2021; Chemaitilly, Wassim/N-8178-2018; Black, Graeme/K-7374-2015; cormier-daire, valerie/H-6520-2017	Scambler, Peter J/0000-0002-1487-4628; Scambler, Peter/0000-0002-1487-4628; superti-furga, andrea/0000-0002-3543-7531; Black, Graeme/0000-0001-8727-6592; Clayton, Peter/0000-0003-1225-4537; huber, celine/0000-0002-8601-9655; cormier-daire, valerie/0000-0002-2839-9856	MRC [G9901217] Funding Source: UKRI; Medical Research Council [G9901217] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; Charnock-Jones DS, 2004, PLACENTA, V25, P103, DOI 10.1016/j.placenta.2003.10.004; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; GETIN I, 2004, PLACENTA, V25, P753; HENNEKAM RCM, 1987, AM J MED GENET, V28, P195, DOI 10.1002/ajmg.1320280127; KOHRMAN DC, 1992, J VIROL, V66, P1752, DOI 10.1128/JVI.66.3.1752-1760.1992; LEMERRER M, 1991, J MED GENET, V28, P186, DOI 10.1136/jmg.28.3.186; Miller J D, 1975, Birth Defects Orig Artic Ser, V11, P39; MUELLER RF, 1992, J MED GENET, V29, P425, DOI 10.1136/jmg.29.6.425; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; SPRANGER J, 1976, EUR J PEDIATR, V123, P115, DOI 10.1007/BF00442641; van der Wall G, 2001, CLIN DYSMORPHOL, V10, P241, DOI 10.1097/00019605-200110000-00002; WINTER RM, 1984, J MED GENET, V21, P124, DOI 10.1136/jmg.21.2.124; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	16	134	141	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1119	1124		10.1038/ng1628	http://dx.doi.org/10.1038/ng1628			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16142236				2022-12-25	WOS:000232185600025
J	Becskei, A; Kaufmann, BB; van Oudenaarden, A				Becskei, A; Kaufmann, BB; van Oudenaarden, A			Contributions of low molecule number and chromosomal positioning to stochastic gene expression	NATURE GENETICS			English	Article							CELL-CYCLE; NUCLEAR ARCHITECTURE; NOISE-PROPAGATION; POSITIVE-FEEDBACK; SINGLE-CELL; YEAST; TRANSCRIPTION; NETWORKS; BINDING; FLUCTUATIONS	The presence of low- copy- number regulators and switch- like signal propagation in regulatory networks are expected to increase noise in cellular processes. We developed a noise amplifier that detects fluctuations in the level of low- abundance mRNAs in yeast. The observed fluctuations are not due to the low number of molecules expressed from a gene per se but originate in the random, rare events of gene activation. The frequency of these events and the correlation between stochastic expressions of genes in a single cell depend on the positioning of the genes along the chromosomes. Transcriptional regulators produced by such random expression propagate noise to their target genes.	MIT, Dept Phys, Cambridge, MA 02139 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Massachusetts Institute of Technology (MIT); Harvard University	van Oudenaarden, A (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.	avano@mit.edu	van Oudenaarden, Alexander/AAA-1705-2019	Becskei, Attila/0000-0002-9462-0934				Acar M, 2005, NATURE, V435, P228, DOI 10.1038/nature03524; Ahmad K, 2001, CELL, V104, P839, DOI 10.1016/S0092-8674(01)00281-1; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Basu S, 2004, P NATL ACAD SCI USA, V101, P6355, DOI 10.1073/pnas.0307571101; Becskei A, 2004, NAT CELL BIOL, V6, P451, DOI 10.1038/ncb1124; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Carr AJF, 2005, NAT CELL BIOL, V7, P319, DOI 10.1038/ncb1232; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; ERDI P., 1989, MATH MODELS CHEM REA; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GUPTASARMA P, 1995, BIOESSAYS, V17, P987, DOI 10.1002/bies.950171112; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hasty J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.148101; Holland MJ, 2002, J BIOL CHEM, V277, P14363, DOI 10.1074/jbc.C200101200; Hooshangi S, 2005, P NATL ACAD SCI USA, V102, P3581, DOI 10.1073/pnas.0408507102; HORSTHEMKE W, 1992, PHYS REV A, V45, P5492, DOI 10.1103/PhysRevA.45.5492; Hurst LD, 2004, NAT REV GENET, V5, P299, DOI 10.1038/nrg1319; Isaacs FJ, 2003, P NATL ACAD SCI USA, V100, P7714, DOI 10.1073/pnas.1332628100; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Li G, 2004, NAT STRUCT MOL BIOL, V11, P763, DOI 10.1038/nsmb801; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Martin DIK, 2001, TRENDS GENET, V17, P444, DOI 10.1016/S0168-9525(01)02368-X; Melcher K, 2001, EMBO J, V20, P841, DOI 10.1093/emboj/20.4.841; Menon BB, 2005, P NATL ACAD SCI USA, V102, P5749, DOI 10.1073/pnas.0501768102; Misteli T, 2005, BIOESSAYS, V27, P477, DOI 10.1002/bies.20226; Nutt SL, 1999, NAT GENET, V21, P390, DOI 10.1038/7720; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Paulsson J, 2004, NATURE, V427, P415, DOI 10.1038/nature02257; PECCOUD J, 1995, THEOR POPUL BIOL, V48, P222, DOI 10.1006/tpbi.1995.1027; Pedraza JM, 2005, SCIENCE, V307, P1965, DOI 10.1126/science.1109090; Pirone JR, 2004, J THEOR BIOL, V226, P111, DOI 10.1016/j.jtbi.2003.08.008; Pramila T, 2002, GENE DEV, V16, P3034, DOI 10.1101/gad.1034302; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Shibata T, 2005, P NATL ACAD SCI USA, V102, P331, DOI 10.1073/pnas.0403350102; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Sveiczer A, 2000, P NATL ACAD SCI USA, V97, P7865, DOI 10.1073/pnas.97.14.7865; Swain PS, 2004, J MOL BIOL, V344, P965, DOI 10.1016/j.jmb.2004.09.073; Thattai M, 2004, GENETICS, V167, P523, DOI 10.1534/genetics.167.1.523; Thornton BR, 2004, CELL CYCLE, V3, P629; Vashee S, 1998, CURR BIOL, V8, P452, DOI 10.1016/S0960-9822(98)70179-4; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089	50	251	254	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					937	944		10.1038/ng1616	http://dx.doi.org/10.1038/ng1616			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16086016				2022-12-25	WOS:000231591900017
J	Gicquel, C; Rossignol, S; Cabrol, S; Houang, M; Steunou, V; Barbu, V; Danton, F; Thibaud, N; Le Merrer, M; Burglen, L; Bertrand, AM; Netchine, I; Le Bouc, Y				Gicquel, C; Rossignol, S; Cabrol, S; Houang, M; Steunou, V; Barbu, V; Danton, F; Thibaud, N; Le Merrer, M; Burglen, L; Bertrand, AM; Netchine, I; Le Bouc, Y			Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome	NATURE GENETICS			English	Article							BECKWITH-WIEDEMANN-SYNDROME; ENHANCER-BLOCKING ACTIVITY; FACTOR-II GENE; H19 GENE; GROWTH-DEFICIENCY; GENOMIC VARIANTS; IGF2 GENE; METHYLATION; CTCF; PHENOTYPE	Silver- Russell syndrome ( SRS, OMIM 180860) is a congenital disorder characterized by severe intrauterine and postnatal growth retardation, dysmorphic facial features and body asymmetry. SRS is genetically heterogenous with maternal uniparental disomy with respect to chromosome 7 occurring in similar to 10% of affected individuals. Given the crucial role of the 11p15 imprinted region in the control of fetal growth, we hypothesized that dysregulation of genes at 11p15 might be involved in syndromic intrauterine growth retardation. We identified an epimutation ( demethylation) in the telomeric imprinting center region ICR1 of the 11p15 region in several individuals with clinically typical SRS. This epigenetic defect is associated with, and probably responsible for, relaxation of imprinting and biallelic expression of H19 and downregulation of IGF2. These findings provide new insight into the pathogenesis of SRS and strongly suggest that the 11p15 imprinted region, in addition to those of 7p11.2- p13 and 7q31- qter, is involved in SRS.	INSERM, U515, Lab Explorat Fonctionnelles Endocriniennes, F-75012 Paris, France; Univ Paris 06, Hop Armand Trousseau, APHP, F-75012 Paris, France; Fac St Antoine, INSERM, U680, F-75012 Paris, France; Hop Necker Enfants Malad, Dept Genet, F-75015 Paris, France; Hop Armand Trousseau, Unite Genet, F-75012 Paris, France; Hop Besancon, Serv Endocrinol Pediat, F-25030 Besancon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite	Gicquel, C (corresponding author), INSERM, U515, Lab Explorat Fonctionnelles Endocriniennes, 26 Ave Arnold Netter, F-75012 Paris, France.	christine.gicquel@trs.aphp.fr	Rossignol, Sylvie/A-3439-2009; ROSSIGNOL, Sylvie/A-8506-2012	ROSSIGNOL, Sylvie/0000-0001-7559-5764; ROSSIGNOL, Sylvie/0000-0003-1268-0632				Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; Corpechot C, 2002, HEPATOLOGY, V35, P1010, DOI 10.1053/jhep.2002.32524; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Dupont JM, 2004, ANAL BIOCHEM, V333, P119, DOI 10.1016/j.ab.2004.05.007; Eggermann T, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.028936; Engel N, 2004, NAT GENET, V36, P883, DOI 10.1038/ng1399; Fedoriw AM, 2004, SCIENCE, V303, P238, DOI 10.1126/science.1090934; Fisher AM, 2002, HUM GENET, V111, P290, DOI 10.1007/s00439-002-0787-2; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; Gaston V, 2001, EUR J HUM GENET, V9, P409, DOI 10.1038/sj.ejhg.5200649; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Hannula K, 2001, J MED GENET, V38, P273, DOI 10.1136/jmg.38.4.273; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hitchins MP, 2001, J MED GENET, V38, P810, DOI 10.1136/jmg.38.12.810; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Meyer E, 2005, MOL GENET METAB, V84, P376, DOI 10.1016/j.ymgme.2004.12.002; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Murrell A, 2001, EMBO REP, V2, P1101, DOI 10.1093/embo-reports/kve248; Obermann C, 2004, MOL GENET METAB, V82, P246, DOI 10.1016/j.ymgme.2004.04.008; Price SM, 1999, J MED GENET, V36, P837; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; Schoenherr CJ, 2003, NAT GENET, V33, P66, DOI 10.1038/ng1057; Sparago A, 2004, NAT GENET, V36, P958, DOI 10.1038/ng1410; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Ulaner GA, 2003, ENDOCRINOLOGY, V144, P4420, DOI 10.1210/en.2003-0681; Weksberg R, 2002, HUM MOL GENET, V11, P1317, DOI 10.1093/hmg/11.11.1317	30	374	385	0	26	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2005	37	9					1003	1007		10.1038/ng1629	http://dx.doi.org/10.1038/ng1629			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16086014				2022-12-25	WOS:000231591900028
J	Li, XF; Liu, P; Liu, WZ; Maye, P; Zhang, JH; Zhang, YH; Hurley, M; Guo, CY; Boskey, A; Sun, L; Harris, SE; Rowe, DW; Ke, HZ; Wu, DQ				Li, XF; Liu, P; Liu, WZ; Maye, P; Zhang, JH; Zhang, YH; Hurley, M; Guo, CY; Boskey, A; Sun, L; Harris, SE; Rowe, DW; Ke, HZ; Wu, DQ			Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation	NATURE GENETICS			English	Article							RECEPTOR-RELATED PROTEIN-5; HIGH-BONE-MASS; WNT SIGNALING PATHWAY; LRP5; DICKKOPF-1; GENE; MUTATION; DENSITY; AXIN; FAMILY	Human and mouse genetic and in vitro evidence has shown that canonical Wnt signaling promotes bone formation, but we found that mice lacking the canonical Wnt antagonist Dickkopf2 ( Dkk2) were osteopenic. We reaffirmed the finding that canonical Wnt signaling stimulates osteogenesis, including the differentiation from preosteoblasts to osteoblasts, in cultured osteoblast differentiation models, but we also found that canonical Wnts upregulated the expression of Dkk2 in osteoblasts. Although exogenous overexpression of Dkk before the expression of endogenous canonical Wnt ( Wnt7b) suppressed osteogenesis in cultures, its expression after peak Wnt7b expression induced a phenotype resembling terminal osteoblast differentiation leading to mineralization. In addition, osteoblasts from Dkk2- null mice were poorly mineralized upon osteogenic induction in cultures, and Dkk2 deficiency led to attenuation of the expression of osteogenic markers, which could be partially reversed by exogenous expression of Dkk2. Taken together with the finding that Dkk2- null mice have increased numbers of osteoids, these data indicate that Dkk2 has a role in late stages of osteoblast differentiation into mineralized matrices. Because expression of another Wnt antagonist, FRP3, differs from Dkk2 expression in rescuing Dkk2 deficiency and regulating osteoblast differentiation, the effects of Dkk2 on terminal osteoblast differentiation may not be entirely mediated by its Wnt signaling antagonistic activity.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA; Hosp Special Surg, New York, NY 10021 USA; Welson Pharmaceut, Beijing, Peoples R China; Univ Texas, Hlth Sci Ctr, Dept Periodont & Cellular Struct Biol, San Antonio, TX 78229 USA; Pfizer Inc, Global res & Dev, Groton Labs, Groton, CT 06340 USA	University of Connecticut; University of Missouri System; University of Missouri Kansas City; University of Connecticut; University of Texas System; University of Texas Health San Antonio; Pfizer	Wu, DQ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	dwu@neuron.uchc.edu	Liu, Peng/AAH-5688-2020	Maye, Peter/0000-0003-0098-4399; Boskey, Adele/0000-0002-6181-2219				Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Barker N, 2000, BIOESSAYS, V22, P961; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Dale TC, 1998, BIOCHEM J, V329, P209; Dimai HP, 1998, BONE, V22, P211, DOI 10.1016/S8756-3282(97)00268-8; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Heaney RP, 2000, OSTEOPOROSIS INT, V11, P985, DOI 10.1007/s001980070020; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Jee WSS, 1997, HDB BONE MORPHOLOGY, P87; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kannus P, 2000, OSTEOPOROSIS INT, V11, P443, DOI 10.1007/s001980070112; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003-0021; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Lips P, 1997, Am J Med, V103, p3S; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; Pandur P, 2001, BIOESSAYS, V23, P207, DOI 10.1002/1521-1878(200103)23:3<207::AID-BIES1029>3.0.CO;2-0; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004; Zuckerman JD, 1996, NEW ENGL J MED, V334, P1519, DOI 10.1056/NEJM199606063342307	49	246	267	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					945	952		10.1038/ng1614	http://dx.doi.org/10.1038/ng1614			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16056226				2022-12-25	WOS:000231591900018
J	Mentewab, A; Stewart, CN				Mentewab, A; Stewart, CN			Overexpression of an Arabidopsis thaliana ABC transporter confers kanamycin resistance to transgenic plants	NATURE BIOTECHNOLOGY			English	Article							HORIZONTAL GENE-TRANSFER; SELECTABLE MARKER; AGROBACTERIUM-TUMEFACIENS; TRANSFORMATION; PROTEIN; CELLS; EXPRESSION	Selectable markers of bacterial origin such as the neomycin phosphotransferase type II gene, which can confer kanamycin resistance to transgenic plants, represent an invaluable tool for plant engineering. However, since all currently used antibiotic-resistance genes are of bacterial origin, there have been concerns about horizontal gene transfer from transgenic plants back to bacteria, which may result in antibiotic resistance. Here we characterize a plant gene, Atwbc19, the gene that encodes an Arabidopsis thaliana ATP binding cassette (ABC) transporter and confers antibiotic resistance to transgenic plants. The mechanism of resistance is novel, and the levels of resistance achieved are comparable to those attained through expression of bacterial antibiotic-resistance genes in transgenic tobacco using the CaMV 35S promoter. Because ABC transporters are endogenous to plants, the use of Atwbc19 as a selectable marker in transgenic plants may provide a practical alternative to current bacterial marker genes in terms of the risk for horizontal transfer of resistance genes.	Univ Tennessee, Dept Plant Sci, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Stewart, CN (corresponding author), Univ Tennessee, Dept Plant Sci, 252 Ellington Plant Sci,2431 Joe Johnson Dr, Knoxville, TN 37996 USA.	nealstewart@utk.edu	Stewart, Neal/B-4709-2009	Stewart, Neal/0000-0003-3026-9193				AGHARBAOUI Z, 1995, PLANT CELL REP, V15, P102, DOI 10.1007/BF01690263; BARNUN S, 1983, BIOCHIM BIOPHYS ACTA, V741, P123, DOI 10.1016/0167-4781(83)90018-0; BEVAN MW, 1983, NATURE, V304, P184, DOI 10.1038/304184a0; Davison J, 2004, NAT BIOTECHNOL, V22, P1349, DOI 10.1038/nbt1104-1349b; DAY A, 2003, CURRENT INNOVATIONS, P111; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; FRALEY RT, 1983, P NATL ACAD SCI-BIOL, V80, P4803, DOI 10.1073/pnas.80.15.4803; GODDIJN OJM, 1993, PLANT MOL BIOL, V22, P907, DOI 10.1007/BF00027376; Harper BK, 1999, NAT BIOTECHNOL, V17, P1125, DOI 10.1038/15114; Heinemann JA, 2004, NAT BIOTECHNOL, V22, P1105, DOI 10.1038/nbt1009; HERRERAESTRELLA L, 1983, EMBO J, V2, P987, DOI 10.1002/j.1460-2075.1983.tb01532.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Liu HK, 2004, PLANTA, V219, P1042, DOI 10.1007/s00425-004-1310-x; Miki B, 2004, J BIOTECHNOL, V107, P193, DOI 10.1016/j.jbiotec.2003.10.011; Mingeot-Leclercq MP, 1999, ANTIMICROB AGENTS CH, V43, P727, DOI 10.1128/AAC.43.4.727; Nielsen KM, 2004, NAT BIOTECHNOL, V22, P1110, DOI 10.1038/nbt1006; Pighin JA, 2004, SCIENCE, V306, P702, DOI 10.1126/science.1102331; Poulsen GB, 1996, PLANT BREEDING, V115, P209, DOI 10.1111/j.1439-0523.1996.tb00907.x; Rommens CM, 2004, TRENDS PLANT SCI, V9, P457, DOI 10.1016/j.tplants.2004.07.001; Rommens CM, 2004, PLANT PHYSIOL, V135, P421, DOI 10.1104/pp.104.040949; Sanchez-Fernandez R, 2001, TRENDS PLANT SCI, V6, P347, DOI 10.1016/S1360-1385(01)02038-6; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; van Frankenhuyzen K, 2004, CAN J FOREST RES, V34, P1163, DOI [10.1139/X04-024, 10.1139/x04-024]; VASQUEZ D, 1979, MOL BIOL BIOCH BIOPH, V30, P1; Wright GD, 1998, ADV EXP MED BIOL, V456, P27; Zhang BH, 2001, PLANT GROWTH REGUL, V33, P137, DOI 10.1023/A:1017563327264; Zuo JR, 2002, CURR OPIN BIOTECH, V13, P173, DOI 10.1016/S0958-1669(02)00301-4	30	103	115	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1177	1180		10.1038/nbt1134	http://dx.doi.org/10.1038/nbt1134			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16116418				2022-12-25	WOS:000231790600035
J	Mitchell, DA; Marletta, MA				Mitchell, DA; Marletta, MA			Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine	NATURE CHEMICAL BIOLOGY			English	Article							NITRIC-OXIDE; NITROSYLATION; ACTIVATION; KINETICS; NITROSOGLUTATHIONE; TRANSNITROSATION; INHIBITION; REDUCTION; APOPTOSIS	Nitric oxide (NO) signaling through the formation of cGMP is well established; however, there seems to be an increasing role for cGMP-independent NO signaling. Although key molecular details remain unanswered, S-nitrosation represents an example of cGMP-independent NO signaling. This modification has garnered recent attention as it has been shown to modulate the function of several important biochemical pathways(1-3). Although an analogy to O-phosphorylation can be drawn(4), little is known about protein nitrosothiol regulation in vivo. In solution, NO readily reacts with oxygen to yield a nitrosating agent, but this process alone provides no specificity for nitrosation(5). This lack of specificity is exemplified by the in vitro poly-S-nitrosation of caspase-3 (Casp-3, ref. 6) and the ryanodine receptor(7). Previous in vivo work with Casp-3 suggests that a protein-assisted process may be responsible for selective S-nitrosation of the catalytic cysteine (Cys163)(8). We demonstrated that a single cysteine in thioredoxin (Trx) is capable of a targeted, reversible transnitrosation reaction with Cys163 of Casp-3. A greater understanding of how S-nitrosation is mediated has broad implications for cGMP-independent signaling. The example described here also suggests a new role for Trx in the regulation of apoptosis.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Div Phys Biosci, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Marletta, MA (corresponding author), Univ Calif Berkeley, Dept Chem, 211 Lewis Hall, Berkeley, CA 94720 USA.	marletta@berkeley.edu	Mitchell, Douglas/C-4400-2011; Mitchell, Doug/B-6349-2012	Mitchell, Doug/0000-0002-9564-0953	NATIONAL CANCER INSTITUTE [P01CA026731] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Cook JA, 1996, ANAL BIOCHEM, V238, P150, DOI 10.1006/abio.1996.0268; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Keshive M, 1996, CHEM RES TOXICOL, V9, P988, DOI 10.1021/tx960036y; Kim JE, 2004, J BIOL CHEM, V279, P9758, DOI 10.1074/jbc.M312722200; LANE P, 2001, SCI STKE, pRE1; Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Mitchell DA, 2005, BIOCHEMISTRY-US, V44, P4636, DOI 10.1021/bi0474463; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; Rossi R, 1997, ANAL BIOCHEM, V254, P215, DOI 10.1006/abio.1997.2424; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sliskovic I, 2005, J BIOL CHEM, V280, P8733, DOI 10.1074/jbc.M408080200; Tao L, 2004, P NATL ACAD SCI USA, V101, P11471, DOI 10.1073/pnas.0402941101; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang K, 2001, BIOORG MED CHEM LETT, V11, P433, DOI 10.1016/S0960-894X(00)00688-0; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zech B, 1999, J BIOL CHEM, V274, P20931, DOI 10.1074/jbc.274.30.20931; Zech B, 2003, BIOCHEM J, V371, P1055, DOI 10.1042/BJ20021720; Zhang JL, 1998, AM J PHYSIOL-LUNG C, V275, pL288, DOI 10.1152/ajplung.1998.275.2.L288	33	221	228	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2005	1	3					154	158		10.1038/nchembio720	http://dx.doi.org/10.1038/nchembio720			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GJ	16408020				2022-12-25	WOS:000232648700015
J	Nakatani, K; Hagihara, S; Goto, Y; Kobori, A; Hagihara, M; Hayashi, G; Kyo, M; Nomura, M; Mishima, M; Kojima, C				Nakatani, K; Hagihara, S; Goto, Y; Kobori, A; Hagihara, M; Hayashi, G; Kyo, M; Nomura, M; Mishima, M; Kojima, C			Small-molecule ligand induces nucleotide flipping in (CAG)(n) trinucleotide repeats	NATURE CHEMICAL BIOLOGY			English	Article							SURFACE-PLASMON RESONANCE; GUANINE-GUANINE MISMATCHES; HUMAN-DISEASE; HUNTINGTONS-DISEASE; HAIRPIN FORMATION; TRIPLET REPEAT; IN-VITRO; DNA; NMR; RECOGNITION	DNA trinucleotide repeats, particularly CXG, are common within the human genome. However, expansion of trinucleotide repeats is associated with a number of disorders, including Huntington disease, spinobulbar muscular atrophy and spinocerebellar ataxia(1-4). In these cases, the repeat length is known to correlate with decreased age of onset and disease severity(5,6). Repeat expansion of (CAG)(n), (CTG)(n) and (CGG)(n) trinucleotides may be related to the increased stability of alternative DNA hairpin structures consisting of CXG-CXG triads with X-X mismatches(7-11). Small-molecule ligands that selectively bound to CAG repeats could provide an important probe for determining repeat length and an important tool for investigating the in vivo repeat extension mechanism. Here we report that napthyridine-azaquinolone (NA, 1) is a ligand for CAG repeats and can be used as a diagnostic tool for determining repeat length. We show by NMR spectroscopy that binding of NA to CAG repeats induces the extrusion of a cytidine nucleotide from the DNA helix.	Kyoto Univ, Grad Sch Engn, Dept Synth Chem & Biol Chem, Kyoto 6158510, Japan; PRESTO, Japan Sci & Technol Agcy, Saitama 3320012, Japan; TOYOBO Co Ltd, Biotechnol Frontier Project, Fukui 9140047, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Kyoto University; Japan Science & Technology Agency (JST); Toyobo Co., Ltd; Nara Institute of Science & Technology	Nakatani, K (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Synth Chem & Biol Chem, Kyoto 6158510, Japan.	nakatani@sanken.osaka-u.ac.jp; kojima@bs.naist.jp	Kojima, Chojiro/AFV-4592-2022; Hagihara, Shinya/I-6135-2014; Hagihara, Shinya/P-9715-2019	Hagihara, Shinya/0000-0003-0348-7873; Nakatani, Kazuhiko/0000-0002-1705-5265; Kojima, Chojiro/0000-0003-2723-8249				Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; Brockman JM, 2000, ANNU REV PHYS CHEM, V51, P41, DOI 10.1146/annurev.physchem.51.1.41; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; GACY AM, 1995, CELL, V81, P533; Hagihara S, 2004, NUCLEIC ACIDS RES, V32, P278, DOI 10.1093/nar/gkh171; Han XG, 2001, CURR MED CHEM, V8, P551, DOI 10.2174/0929867003373337; Hashem VI, 2004, NUCLEIC ACIDS RES, V32, P6334, DOI 10.1093/nar/gkh976; Kobori A, 2004, J AM CHEM SOC, V126, P557, DOI 10.1021/ja037947w; Kyo M, 2004, GENES CELLS, V9, P153, DOI 10.1111/j.1356-9597.2004.00711.x; Liu H, 1995, J BIOMOL NMR, V6, P390; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; McMurray CT, 1999, P NATL ACAD SCI USA, V96, P1823, DOI 10.1073/pnas.96.5.1823; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Nakatani K, 2004, CHEMBIOCHEM, V5, P1623, DOI 10.1002/cbic.200400161; Nakatani K, 2001, J AM CHEM SOC, V123, P12650, DOI 10.1021/ja0109186; Nakatani K, 2001, NAT BIOTECHNOL, V19, P51, DOI 10.1038/83505; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Smith EA, 2002, J AM CHEM SOC, V124, P6810, DOI 10.1021/ja026356n; Syvanen AC, 2001, NAT REV GENET, V2, P930, DOI 10.1038/35103535; Wells R.D., 1998, GENETIC INSTABILITIE; Wijmenga SS, 1998, PROG NUCL MAG RES SP, V32, P287, DOI 10.1016/S0079-6565(97)00023-X; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZIMMER DP, 1995, P NATL ACAD SCI USA, V92, P3091, DOI 10.1073/pnas.92.8.3091	28	132	133	1	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2005	1	1					39	43		10.1038/nchembio708	http://dx.doi.org/10.1038/nchembio708			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	974WC	16407992				2022-12-25	WOS:000232621100011
J	Carlborg, O; Jacobsson, L; Ahgren, P; Siegel, P; Andersson, L				Carlborg, O; Jacobsson, L; Ahgren, P; Siegel, P; Andersson, L			Epistasis and the release of genetic variation during long-term selection	NATURE GENETICS			English	Article							DROSOPHILA-MELANOGASTER; ARCHITECTURE; POPULATIONS; CHICKENS; GROWTH	It is an enigma how long-term selection in model organisms and agricultural species can lead to marked phenotypic changes without exhausting genetic variation for the selected trait. Here, we show that the genetic architecture of an apparently major locus for growth in chicken dissects into a genetic network of four interacting loci. The interactions in this radial network mediate a considerably larger selection response than predicted by a single-locus model.	Uppsala Univ, Linnaeus Ctr Bioinformat, SE-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Anim Breeding & Genet, SE-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Med Biochem & Microbiol, SE-75124 Uppsala, Sweden; Virginia Polytech Inst & State Univ, Dept Anim & Poultry Sci, Blacksburg, VA 24061 USA	Uppsala University; Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences; Virginia Polytechnic Institute & State University	Carlborg, O (corresponding author), Uppsala Univ, Linnaeus Ctr Bioinformat, Box 598, SE-75124 Uppsala, Sweden.	orjan.carlborg@lcb.uu.se		Carlborg, Orjan/0000-0002-2722-5264; Stromstedt, Lina/0000-0002-9317-7651				Carlborg O, 2004, NAT REV GENET, V5, P618, DOI 10.1038/nrg1407; Carlborg O, 2003, GENOME RES, V13, P413, DOI 10.1101/gr.528003; Dunnington EA, 1996, POULTRY SCI, V75, P1168, DOI 10.3382/ps.0751168; Dworkin I, 2003, CURR BIOL, V13, P1888, DOI 10.1016/j.cub.2003.10.001; Eitan Y, 2004, EVOLUTIONARY THEORY AND PROCESSES: MODERN HORIZONS, P153; FALCONER DS, 1992, ANNU REV GENET, V26, P1, DOI 10.1146/annurev.ge.26.120192.000245; Fedorowicz GM, 1998, GENETICS, V148, P1885; Flint J, 2004, MAMM GENOME, V15, P77, DOI 10.1007/s00335-003-3033-x; Jacobsson L, 2005, GENET RES, V86, P115, DOI 10.1017/S0016672305007767; Keightley P. D., 2004, Plant Breeding Reviews, V24, P227; Laurie CC, 2004, GENETICS, V168, P2141, DOI 10.1534/genetics.104.029686; Mackay TFC, 2004, CURR OPIN GENET DEV, V14, P253, DOI 10.1016/j.gde.2004.04.003; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Segre D, 2005, NAT GENET, V37, P77, DOI 10.1038/ng1489; Ungerer MC, 2003, GENETICS, V163, P277	15	215	224	0	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	2006	38	4					418	420		10.1038/ng1761	http://dx.doi.org/10.1038/ng1761			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16532011				2022-12-25	WOS:000236340500013
J	Rosales-Nieves, AE; Johndrow, JE; Keller, LC; Magie, CR; Pinto-Santini, DM; Parkhurst, SM				Rosales-Nieves, AE; Johndrow, JE; Keller, LC; Magie, CR; Pinto-Santini, DM; Parkhurst, SM			Coordination of microtubule and microfilament dynamics by Drosophila Rho1, Spire and Cappuccino	NATURE CELL BIOLOGY			English	Article							ACTIN NUCLEATION FACTOR; POSTERIOR; OOCYTE; CYTOSKELETON; FORMINS; GENE; EXPRESSION; FILAMENTS; EMBRYO; MDIA1	The actin-nucleation factors Spire and Cappuccino ( Capu) regulate the onset of ooplasmic streaming in Drosophila melanogaster(1-5). Although this streaming event is microtubule-based, actin assembly is required for its timing. It is not understood how the interaction of microtubules and microfilaments is mediated in this context. Here, we demonstrate that Capu and Spire have microtubule and microfilament crosslinking activity. The spire locus encodes several distinct protein isoforms (SpireA, SpireC and SpireD). SpireD was recently shown to nucleate actin, but the activity of the other isoforms has not been addressed. We find that SpireD does not have crosslinking activity, whereas SpireC is a potent crosslinker. We show that SpireD binds to Capu and inhibits F-actin/microtubule crosslinking, and activated Rho1 abolishes this inhibition, establishing a mechanistic basis for the regulation of Capu and Spire activity. We propose that Rho1, cappuccino and spire are elements of a conserved developmental cassette that is capable of directly mediating crosstalk between microtubules and microfilaments.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Parkhurst, SM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.	susanp@fhcrc.org	Rosales-Nieves, Alicia E./ABA-2600-2021	Rosales-Nieves, Alicia E./0000-0001-9119-1604; Parkhurst, Susan/0000-0001-5806-9930	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066847] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066847-02, R01 GM066847-01, R01 GM066847, GM066847, R01 GM066847-04, R01 GM066847-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktories K, 2005, REV PHYSIOL BIOCH P, V152, P1, DOI 10.1007/s10254-004-0034-4; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; Cha BJ, 2002, NAT CELL BIOL, V4, P592, DOI 10.1038/ncb832; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Grieder NC, 2000, DEVELOPMENT, V127, P4253; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Leader B, 2002, NAT CELL BIOL, V4, P921, DOI 10.1038/ncb880; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Magie CR, 1999, DEVELOPMENT, V126, P5353; Magie Craig R., 2002, Development (Cambridge), V129, P3771; Manseau L, 1996, DEVELOPMENT, V122, P2109; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; Miller AL, 2004, J CELL BIOL, V165, P407, DOI 10.1083/jcb.200308055; Olson MF, 2003, CURR BIOL, V13, pR360, DOI 10.1016/S0960-9822(03)00277-X; Palacios IM, 2002, DEVELOPMENT, V129, P5473, DOI 10.1242/dev.00119; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Quinlan ME, 2005, NATURE, V433, P382, DOI 10.1038/nature03241; Ryley DA, 2005, FERTIL STERIL, V83, P1363, DOI 10.1016/j.fertnstert.2004.10.051; Schumacher N, 2004, GENE EXPR PATTERNS, V4, P249, DOI 10.1016/j.modgep.2003.11.006; Serbus LR, 2005, DEVELOPMENT, V132, P3743, DOI 10.1242/dev.01956; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wellington A, 1999, DEVELOPMENT, V126, P5267; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Wittmann T, 2001, J CELL SCI, V114, P3795; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	30	112	117	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					367	U47		10.1038/ncb1385	http://dx.doi.org/10.1038/ncb1385			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16518391	Green Accepted			2022-12-25	WOS:000236560000015
J	Simard, JM; Chen, M; Tarasov, KV; Bhatta, S; Ivanova, S; Melnitchenko, L; Tsymbalyuk, N; West, GA; Gerzanich, V				Simard, JM; Chen, M; Tarasov, KV; Bhatta, S; Ivanova, S; Melnitchenko, L; Tsymbalyuk, N; West, GA; Gerzanich, V			Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic stroke	NATURE MEDICINE			English	Article							ADULT-RAT BRAIN; SENSITIVE POTASSIUM CHANNELS; NONSELECTIVE CATION CHANNEL; REACTIVE ASTROCYTES; K+ CHANNELS; ARTERY OCCLUSION; SULFONYLUREA; RECEPTOR; PH; IDENTIFICATION	Pathological conditions in the central nervous system, including stroke and trauma, are often exacerbated by cerebral edema. We recently identified a nonselective cation channel, the NCCa-ATP channel, in ischemic astrocytes that is regulated by sulfonylurea receptor 1 (SUR1), is opened by depletion of ATP and, when opened, causes cytotoxic edema. Here, we evaluated involvement of this channel in rodent models of stroke. SUR1 protein and mRNA were newly expressed in ischemic neurons, astrocytes and capillaries. Upregulation of SUR1 was linked to activation of the transcription factor Sp1 and was associated with expression of functional NCCa-ATP but not K-ATP channels. Block of SUR1 with low-dose glibenclamide reduced cerebral edema, infarct volume and mortality by 50%, with the reduction in infarct volume being associated with cortical sparing. Our findings indicate that the NCCa-ATP channel is crucially involved in development of cerebral edema, and that targeting SUR1 may provide a new therapeutic approach to stroke.	Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Oregon Hlth Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Oregon Health & Science University	Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite 12SD, Baltimore, MD 21201 USA.	msimard@surgery1.umaryland.edu		Tarasov, Kirill/0000-0001-7799-4670	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048260] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL082517, R01 HL082517-01, R01 HL082517] Funding Source: Medline; NINDS NIH HHS [R01 NS048260, NS048260] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anisimov SV, 2002, MECH DEVELOP, V117, P25, DOI 10.1016/S0925-4773(02)00177-6; Ashfield R, 1998, DIABETES, V47, P1274, DOI 10.2337/diabetes.47.8.1274; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; CHEN H, 1993, J NEUROL SCI, V118, P109, DOI 10.1016/0022-510X(93)90099-K; Chen MK, 2003, J NEUROSCI, V23, P8568; Chen MK, 2001, J NEUROSCI, V21, P6512, DOI 10.1523/JNEUROSCI.21-17-06512.2001; Doerfler A, 2001, STROKE, V32, P2675, DOI 10.1161/hs1101.098369; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; FINDLAY I, 1992, J PHARMACOL EXP THER, V262, P71; Fujita A, 2000, PHARMACOL THERAPEUT, V85, P39, DOI 10.1016/S0163-7258(99)00050-9; Gerzanich V, 2003, CIRC RES, V93, P805, DOI 10.1161/01.RES.0000097872.69043.A0; Gribble FM, 2003, DIABETOLOGIA, V46, P875, DOI 10.1007/s00125-003-1143-3; Hainsworth AH, 2001, NEUROPHARMACOLOGY, V40, P784, DOI 10.1016/S0028-3908(01)00004-1; Hernandez-Sanchez C, 1999, J BIOL CHEM, V274, P18261, DOI 10.1074/jbc.274.26.18261; Hua Y, 2003, J CEREBR BLOOD F MET, V23, P1448, DOI 10.1097/01.WCB.0000090621.86921.D5; Kaluz S, 2003, CANCER RES, V63, P917; Karschin C, 1997, FEBS LETT, V401, P59, DOI 10.1016/S0014-5793(96)01438-X; KAWAMURA S, 1991, ACTA NEUROCHIR, V109, P126, DOI 10.1007/BF01403007; LI PA, 1994, NEUROSCI LETT, V177, P63, DOI 10.1016/0304-3940(94)90045-0; Lindauer U, 2003, J CEREBR BLOOD F MET, V23, P1227, DOI 10.1097/01.WCB.0000088764.02615.B7; Mathews KS, 2000, J NEUROSCI METH, V102, P43, DOI 10.1016/S0165-0270(00)00277-6; Nakabayashi K, 1997, AM J NEURORADIOL, V18, P485; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581, DOI 10.1152/ajpregu.1991.260.3.R581; Perillan PR, 2002, J BIOL CHEM, V277, P1974, DOI 10.1074/jbc.M107984200; Proks P, 2002, DIABETES, V51, pS368, DOI 10.2337/diabetes.51.2007.S368; SCHWANSTECHER M, 1994, J NEUROCHEM, V63, P698; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Tomiyama Y, 1999, STROKE, V30, P1942, DOI 10.1161/01.STR.30.9.1942; Toomey JR, 2002, STROKE, V33, P578, DOI 10.1161/hs0202.102950; TREHERNE JM, 1991, NEUROSCIENCE, V40, P523, DOI 10.1016/0306-4522(91)90138-E; Tsankova NM, 2004, J NEUROSCI, V24, P5603, DOI 10.1523/JNEUROSCI.0589-04.2004; Wang Y, 2000, STROKE, V31, P1386, DOI 10.1161/01.STR.31.6.1386; Wass CT, 1996, MAYO CLIN PROC, V71, P801; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; YOUNG W, 1994, NEUROBIOLOGY CENTRAL; ZUNKLER BJ, 1989, N-S ARCH PHARMACOL, V340, P328	36	290	322	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2006	12	4					433	440		10.1038/nm1390	http://dx.doi.org/10.1038/nm1390			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16550187	Green Accepted			2022-12-25	WOS:000236581300032
J	Zhang, HT; Cheng, X; Richter, M; Greene, MI				Zhang, HT; Cheng, X; Richter, M; Greene, MI			A sensitive and high-throughput assay to detect low-abundance proteins in serum	NATURE MEDICINE			English	Article							METASTATIC BREAST-CANCER; T7 RNA-POLYMERASE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; IN-VITRO; C-ERBB-2; EXPRESSION; QUANTIFICATION; AMPLIFICATION; IMMUNOASSAYS	The ability to detect antigens immunologically is limited by the affinity of the antibodies and the amount of antigens. We have now succeeded in creating a modular, facile amplification system, termed fluorescent amplification catalyzed by T7 polymerase technique (FACTT). Such a system can detect protein targets specifically at subfemtomolar levels (similar to 0.08 fM). We describe here the detection of Her2 ( also known as Neu) from rodent and human sera. FACTT is adaptable to highthroughput screening and automation and provides a practical method to enhance current ELISAs in medical practice.	Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu		Zhang, Hongtao/0000-0001-9173-0049				Arnold S, 2001, BIOTECHNOL BIOENG, V72, P548, DOI 10.1002/1097-0290(20010305)72:5<548::AID-BIT1019>3.0.CO;2-2; COHEN JA, 1989, ONCOGENE, V4, P81; Di Leo A, 2002, ONCOLOGY-BASEL, V63, P25, DOI 10.1159/000066204; Fehm T, 1998, ONCOLOGY-BASEL, V55, P33, DOI 10.1159/000011832; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; Jones LJ, 1998, ANAL BIOCHEM, V265, P368, DOI 10.1006/abio.1998.2914; KANDL H, 1994, BRIT J CANCER, V70, P739, DOI 10.1038/bjc.1994.387; Li P, 2003, CANCER LETT, V193, P139, DOI 10.1016/S0304-3835(03)00017-X; LODATO RF, 1990, MODERN PATHOL, V3, P449; Lubec G, 2003, PROG NEUROBIOL, V69, P193, DOI 10.1016/S0301-0082(03)00036-4; Luftner D, 2004, INT J BIOL MARKER, V19, P1; MAGUIRE HC, 1990, PATHOBIOLOGY, V58, P297; Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; PORSTMANN B, 1985, J IMMUNOL METHODS, V79, P27, DOI 10.1016/0022-1759(85)90388-6; PORSTMANN T, 1992, J IMMUNOL METHODS, V150, P5, DOI 10.1016/0022-1759(92)90061-W; Saghatchian M, 2004, INT J BIOL MARKER, V19, P14, DOI 10.1177/172460080401900102; Schweitzer B, 2000, P NATL ACAD SCI USA, V97, P10113, DOI 10.1073/pnas.170237197; Schweitzer B, 2002, NAT BIOTECHNOL, V20, P359, DOI 10.1038/nbt0402-359; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tannous BA, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf140; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; Yamauchi H, 1997, J CLIN ONCOL, V15, P2518, DOI 10.1200/JCO.1997.15.7.2518; Zhang HT, 1999, EXP MOL PATHOL, V67, P15, DOI 10.1006/exmp.1999.2266; Zhang HT, 2001, P NATL ACAD SCI USA, V98, P5497, DOI 10.1073/pnas.101124598	26	57	70	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					473	477		10.1038/nm1378	http://dx.doi.org/10.1038/nm1378			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16532003				2022-12-25	WOS:000236581300038
J	Pyle, AD; Lock, LF; Donovan, PJ				Pyle, AD; Lock, LF; Donovan, PJ			Neurotrophins mediate human embryonic stem cell survival	NATURE BIOTECHNOLOGY			English	Article							TYROSINE PHOSPHORYLATION; TRK RECEPTORS; PLURIPOTENCY; KINASE; LINES; PROLIFERATION; MAINTENANCE; INHIBITORS; DERIVATION; OXINDOLE	Growth of human embryonic stem (hES) cells as a pluripotent population requires a balance between survival, proliferation and self-renewal signals. Here we demonstrate that hES cells express receptors of the tropomyosin-related kinase (TRK) family, which mediate antiapoptotic signals. We show that three TRK ligands, brain-derived neurotrophic factor, neurotrophin 3 and neurotrophin 4, are survival factors for hES cells. Addition of neurotrophins to hES cell cultures effects a 36-fold improvement in their clonal survival. hES cell cultures maintained in medium containing neurotrophins remain diploid and retain full developmental potency. In the presence of neurotrophins, TRK receptors in hES cells are phosphorylated; TRK receptor inhibition leads to hES cell apoptosis. The survival activity of neurotrophins in hES cells is mediated by the phosphatidylinositol-3-kinase pathway but not the mitogen-activated protein kinase pathway. Neurotrophins improve hES cell survival and may facilitate their manipulation and the development of high-throughput screens to identify factors responsible for hES cell differentiation.	Univ Calif Irvine, Stem Cell Program, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Johns Hopkins Univ, Sch Med, Germ Cell & Stem Cell Grp, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Genet Models Grp, Stem Cell Biol Program,Inst Cell Engn, Baltimore, MD 21205 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Johns Hopkins University; Johns Hopkins University	Donovan, PJ (corresponding author), Univ Calif Irvine, Stem Cell Program, Hewitt Hall, Irvine, CA 92697 USA.	pdonovan@uci.edu						Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Beattie GM, 2005, STEM CELLS, V23, P489, DOI 10.1634/stemcells.2004-0279; BERG MM, 1992, J BIOL CHEM, V267, P13; Bramson HN, 2001, J MED CHEM, V44, P4339, DOI 10.1021/jm010117d; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Daheron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22-5-770; Dalal R, 1997, MOL CELL ENDOCRINOL, V134, P15, DOI 10.1016/S0303-7207(97)00165-2; Donovan PJ, 2001, NATURE, V414, P92, DOI 10.1038/35102154; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Ginty DD, 2002, CURR OPIN NEUROBIOL, V12, P268, DOI 10.1016/S0959-4388(02)00326-4; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Pyle AD, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-235; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0; Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Seifer DB, 2002, J CLIN ENDOCR METAB, V87, P655, DOI 10.1210/jc.87.2.655; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Thomson JA, 2000, TRENDS BIOTECHNOL, V18, P53, DOI 10.1016/S0167-7799(99)01410-9; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Trounson A, 2001, FERTIL STERIL, V76, P660, DOI 10.1016/S0015-0282(01)02880-1; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Wood ER, 2004, BIOORG MED CHEM LETT, V14, P953, DOI 10.1016/j.bmcl.2003.12.002; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744	32	204	223	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2006	24	3					344	350		10.1038/nbt1189	http://dx.doi.org/10.1038/nbt1189			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	019WQ	16444268				2022-12-25	WOS:000235868600038
J	Sampathkumar, SG; Li, AV; Jones, MB; Sun, ZH; Yarema, KJ				Sampathkumar, SG; Li, AV; Jones, MB; Sun, ZH; Yarema, KJ			Metabolic installation of thiols into sialic acid modulates adhesion and stem cell biology	NATURE CHEMICAL BIOLOGY			English	Article							IN-VITRO; DIFFERENTIATION; BIOSYNTHESIS; INHIBITION; EXPRESSION; INDUCTION; MEDICINE; MOLECULE; GOLD	Metabolic 'oligosaccharide engineering' methods based on N-acetyl-D-mannosamine (ManNAc) analogs allow the glycocalyx of living cells to be remodeled(1-3). Herein we report the analog Ac(5)ManNTGc (1) that enables thiols to be expressed in surface sialic acids. By locating this versatile functional group on the outer periphery of normally nonadhesive human Jurkat cells, we obtained spontaneous cell-cell clustering and attachment to complementary maleimide-derivatized substrates. When analyzed in human embryoid body-derived (hEBD) stem cells, Ac5ManNTGc induced beta-catenin expression and altered cell morphology, consistent with neuronal differentiation. Notably, these effects were modulated by the growth substrate of the cells, with a stronger response observed on a gold surface than on glass. Together, these results establish sugar analogs as small-molecule tools for tissue engineering by providing a method for attaching cells to scaffolds via their surface carbohydrates as well as offering a means to influence stem cell fates.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA	Johns Hopkins University	Yarema, KJ (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, 3400 N Charles St,Clark Hall 106A, Baltimore, MD 21218 USA.	kyarema1@jhu.edu	Sampathkumar, Srinivasa-Gopalan/C-9951-2017; Yarema, Kevin/A-3329-2010	Sampathkumar, Srinivasa-Gopalan/0000-0002-0616-8977; 	NATIONAL CANCER INSTITUTE [R01CA112314] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA112314-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbosa JN, 2004, BIOMATERIALS, V25, P2557, DOI [10.1016/j.biomaterials.2003.09.047, 10.1016/j .biomaterials.2003.09.047]; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Collins BE, 2000, GLYCOBIOLOGY, V10, P11, DOI 10.1093/glycob/10.1.11; De Bank PA, 2003, BIOTECHNOL BIOENG, V81, P800, DOI 10.1002/bit.10525; Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987; Edwards BE, 2000, FERTIL STERIL, V74, P1, DOI 10.1016/S0015-0282(00)00583-5; Hou DX, 2001, CELL BIOL INT, V25, P239, DOI 10.1006/cbir.2000.0596; Ille F, 2005, CELL MOL LIFE SCI, V62, P1100, DOI 10.1007/s00018-005-4552-2; Jaiswal JK, 2004, NAT METHODS, V1, P73, DOI 10.1038/nmeth1004-73; Kasai M, 2005, GENES CELLS, V10, P777, DOI 10.1111/j.1365-2443.2005.00876.x; KAYSER H, 1992, J BIOL CHEM, V267, P16934; Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R; Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388; Lemieux GA, 2001, CHEM BIOL, V8, P265, DOI 10.1016/S1074-5521(01)00008-4; Liu J, 2005, ANGEW CHEM INT EDIT, V44, P1987, DOI 10.1002/anie.200462552; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181; Nakashima I, 2002, ANTIOXID REDOX SIGN, V4, P517, DOI 10.1089/15230860260196326; Orner BP, 2004, J AM CHEM SOC, V126, P10808, DOI 10.1021/ja0474291; Ratner DM, 2004, CHEMBIOCHEM, V5, P379, DOI 10.1002/cbic.200300804; Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; Teo JL, 2005, P NATL ACAD SCI USA, V102, P12171, DOI 10.1073/pnas.0504600102; Teo R, 2006, DEV BIOL, V289, P91, DOI 10.1016/j.ydbio.2005.10.009; Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996; Turner N, 2004, CELL BIOL INT, V28, P541, DOI 10.1016/j.cellbi.2004.04.009; Vats A, 2005, LANCET, V366, P592, DOI 10.1016/S0140-6736(05)66879-1; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Yarema KJ, 1998, J BIOL CHEM, V273, P31168, DOI 10.1074/jbc.273.47.31168; Yousaf MN, 2001, P NATL ACAD SCI USA, V98, P5992, DOI 10.1073/pnas.101112898	30	108	116	3	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAR	2006	2	3					149	152		10.1038/nchembio770	http://dx.doi.org/10.1038/nchembio770			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013QL	16474386				2022-12-25	WOS:000235424100012
J	Stray, SJ; Johnson, JM; Kopek, BG; Zlotnick, A				Stray, SJ; Johnson, JM; Kopek, BG; Zlotnick, A			An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly	NATURE BIOTECHNOLOGY			English	Article							PROTEIN-PROTEIN INTERACTIONS; CORE-PROTEIN; CRYSTAL-STRUCTURE; C-TERMINUS; REPLICATION; PARTICLES; INHIBITION; MODEL; RNA	Virus assembly has not been routinely targeted in the development of antiviral drugs, in part because of the lack of tractable methods for screening in vitro. We have developed an in vitro assay of hepatitis B virus (HBV) capsid assembly, based on fluorescence quenching of dye-labeled capsid protein, for testing potential inhibitors. This assay is adaptable to high-throughput screening and can identify small-molecule inhibitors of virus assembly that prevent, inappropriately accelerate and/or misdirect capsid formation to yield aberrant particles. An in vitro primary screen has the advantage of identifying promising lead compounds affecting assembly without the requirement that they be taken up by cells in culture and be nontoxic. Our approach may facilitate the identification of antivirals targeting viruses other than HBV, such as avian influenza and HIV.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Zlotnick, A (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th St,BRC 456, Oklahoma City, OK 73104 USA.	adam-zlotnick@ouhsc.edu		Zlotnick, Adam/0000-0001-9945-6267; Johnson Hays, Jennifer/0000-0001-5855-7352; Kopek, Benjamin/0000-0002-5288-3744	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067417] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI067417] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bergstrom F, 2002, J AM CHEM SOC, V124, P196, DOI 10.1021/ja010983f; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; Ceres P, 2004, J VIROL, V78, P9538, DOI 10.1128/JVI.78.17.9538-9543.2004; Ceres P, 2002, BIOCHEMISTRY-US, V41, P11525, DOI 10.1021/bi0261645; De Clercq E, 2004, NAT REV MICROBIOL, V2, P704, DOI 10.1038/nrmicro975; Deres K, 2003, SCIENCE, V299, P893, DOI 10.1126/science.1077215; Ganem D., 1996, FIELDS VIROLOGY, P2703; Hacker HJ, 2003, BIOCHEM PHARMACOL, V66, P2273, DOI 10.1016/j.bcp.2003.08.001; Harris A, 2001, VIROLOGY, V289, P34, DOI 10.1006/viro.2001.1119; JOHNSON ID, 1991, ANAL BIOCHEM, V198, P228, DOI 10.1016/0003-2697(91)90418-S; Kunkel M, 2001, J VIROL, V75, P2119, DOI 10.1128/JVI.75.5.2119-2129.2001; NASSAL M, 1992, J MOL BIOL, V225, P1013, DOI 10.1016/0022-2836(92)90101-O; NASSAL M, 1992, VIROLOGY, V190, P499, DOI 10.1016/0042-6822(92)91242-M; PREVISANI N, 2002, HEPATITIS B; Singh S, 2003, J BIOL CHEM, V278, P18249, DOI 10.1074/jbc.M211408200; Stray SJ, 2005, P NATL ACAD SCI USA, V102, P8138, DOI 10.1073/pnas.0409732102; Stray SJ, 2004, BIOCHEMISTRY-US, V43, P9989, DOI 10.1021/bi049571k; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; Weber O, 2002, ANTIVIR RES, V54, P69, DOI 10.1016/S0166-3542(01)00216-9; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5; ZHOU S, 1992, P NATL ACAD SCI USA, V89, P10046, DOI 10.1073/pnas.89.21.10046; Zlotnick A, 1997, P NATL ACAD SCI USA, V94, P9556, DOI 10.1073/pnas.94.18.9556; Zlotnick A, 2005, J MOL RECOGNIT, V18, P479, DOI 10.1002/jmr.754; Zlotnick A, 1999, BIOCHEMISTRY-US, V38, P14644, DOI 10.1021/bi991611a; Zlotnick A, 2003, TRENDS BIOTECHNOL, V21, P536, DOI 10.1016/j.tibtech.2003.09.012; Zlotnick A, 2003, VIROLOGY, V315, P269, DOI 10.1016/S0042-6822(03)00586-5; Zlotnick A, 2002, J VIROL, V76, P4848, DOI 10.1128/JVI.76.10.4848-4854.2002; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	29	50	52	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2006	24	3					358	362		10.1038/nbt1187	http://dx.doi.org/10.1038/nbt1187			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	019WQ	16474383				2022-12-25	WOS:000235868600040
J	Aso, Y; Miyamoto, Y; Harada, KM; Momma, K; Kawai, S; Hashimoto, W; Mikami, B; Murata, K				Aso, Y; Miyamoto, Y; Harada, KM; Momma, K; Kawai, S; Hashimoto, W; Mikami, B; Murata, K			Engineered membrane superchannel improves bioremediation potential of dioxin-degrading bacteria	NATURE BIOTECHNOLOGY			English	Article							SPHINGOMONAS SP A1; MACROMOLECULE (ALGINATE)-BINDING PROTEIN; CRYSTAL-STRUCTURE; CELL-SURFACE; ALGINATE; DEGRADATION; DEPOLYMERIZATION; IDENTIFICATION; TRANSPORTER; RESOLUTION	Sphingomonas sp. A1 possesses specialized membrane structures termed 'superchannels' that enable the direct incorporation of macromolecules into the cell. We have engineered two related sphingomonads, the dioxin-degrading S. wittichii RW1 and the polypropylene glycol-degrading S. subarctica IFO 16058(T), to incorporate this superchannel into their cell membranes. In both cases the bioremediation capability of the organisms was substantially increased pointing at the potential of this approach as a general strategy to improve bacterial degradation of hazardous compounds in the environment.	Kyoto Univ, Grad Sch Agr, Lab Basic & Appl Mol Biotechnol, Uji, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Agr, Lab Food Qual Design & Dev, Uji, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Murata, K (corresponding author), Kyoto Univ, Grad Sch Agr, Lab Basic & Appl Mol Biotechnol, Uji, Kyoto 6110011, Japan.	kmurata@kais.kyoto-u.ac.jp						Deziel E, 1999, BIODEGRADATION, V10, P219, DOI 10.1023/A:1008311430525; Hashimoto W, 2000, J BACTERIOL, V182, P4572, DOI 10.1128/JB.182.16.4572-4577.2000; Hashimoto W, 2005, BIOCHEMISTRY-US, V44, P13783, DOI 10.1021/bi050873b; Hashimoto W, 2005, BIOSCI BIOTECH BIOCH, V69, P673, DOI 10.1271/bbb.69.673; Hisano T, 1996, BIOCHEM BIOPH RES CO, V220, P979, DOI 10.1006/bbrc.1996.0526; Hong HB, 2002, APPL ENVIRON MICROB, V68, P2584, DOI 10.1128/AEM.68.5.2584-2588.2002; KAWAHARA K, 1982, BIOCHIM BIOPHYS ACTA, V712, P571, DOI 10.1016/0005-2760(82)90285-5; KIMBARA K, 1989, J BACTERIOL, V171, P2740, DOI 10.1128/jb.171.5.2740-2747.1989; Mishima Y, 2003, J BIOL CHEM, V278, P6552, DOI 10.1074/jbc.M209932200; Momma K, 2000, J BACTERIOL, V182, P3998, DOI 10.1128/JB.182.14.3998-4004.2000; Momma K, 2005, BIOCHEMISTRY-US, V44, P5053, DOI 10.1021/bi047781r; Momma K, 2002, J MOL BIOL, V316, P1051, DOI 10.1006/jmbi.2001.5393; WITTICH RM, 1992, APPL ENVIRON MICROB, V58, P1005, DOI 10.1128/AEM.58.3.1005-1010.1992; Wittich RM, 1998, APPL MICROBIOL BIOT, V49, P489, DOI 10.1007/s002530051203; Yoon HJ, 2000, PROTEIN EXPRES PURIF, V19, P84, DOI 10.1006/prep.2000.1226	15	36	38	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2006	24	2					188	189		10.1038/nbt1181	http://dx.doi.org/10.1038/nbt1181			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	010XW	16415854				2022-12-25	WOS:000235232300035
J	Engelhorn, ME; Guevara-Patino, JA; Noffz, G; Hooper, AT; Lou, O; Gold, JS; Kappel, BJ; Houghton, AN				Engelhorn, ME; Guevara-Patino, JA; Noffz, G; Hooper, AT; Lou, O; Gold, JS; Kappel, BJ; Houghton, AN			Autoimmunity and tumor immunity induced by immune responses to mutations in self	NATURE MEDICINE			English	Article							CYTOLYTIC T-LYMPHOCYTES; SYNGENEIC MICE; IMMUNIZATION; TYROSINASE; PEPTIDE; ANTIGEN; REJECTION; VARIANTS; RECOGNITION; EXPRESSION	Little is known about the consequences of immune recognition of mutated gene products, despite their potential relevance to autoimmunity and tumor immunity. To identify mutations that induce immunity, here we have developed a systematic approach in which combinatorial DNA libraries encoding large numbers of random mutations in two syngeneic tyrosinase-related proteins are used to immunize black mice. We show that the libraries of mutated DNA induce autoimmune hypopigmentation and tumor immunity through cross-recognition of nonmutated gene products. Truncations are present in all immunogenic clones and are sufficient to elicit immunity to self, triggering recognition of normally silent epitopes. Immunity is further enhanced by specific amino acid substitutions that promote T helper cell responses. Thus, presentation of a vast repertoire of antigen variants to the immune system can enhance the generation of adaptive immune responses to self.	Mem Sloan Kettering Canc Ctr, Swim Across Amer Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Sch, New York, NY 10021 USA; Cornell Univ, Grad Sch, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University	Houghton, AN (corresponding author), Mem Sloan Kettering Canc Ctr, Swim Across Amer Lab, 1275 York Ave, New York, NY 10021 USA.	engelho1@mskcc.org; a-houghton@ski.mskcc.org	Gold, Jason S./O-5112-2014; Guevara, Jose/AAD-6707-2020	Gold, Jason S./0000-0002-2925-4755; 	NCI NIH HHS [CA33049, CA56821, CA59350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA033049, R01CA056821, P01CA059350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; BOON T, 1977, P NATL ACAD SCI USA, V74, P272, DOI 10.1073/pnas.74.1.272; BOON T, 1978, P NATL ACAD SCI USA, V75, P1519, DOI 10.1073/pnas.75.3.1519; Bowne WB, 1999, J EXP MED, V190, P1717, DOI 10.1084/jem.190.11.1717; Brandle D, 1996, J EXP MED, V183, P2501, DOI 10.1084/jem.183.6.2501; CADWELL RC, 1994, PCR METH APPL, V3, pS136; Chiari R, 1999, CANCER RES, V59, P5785; COULIE PG, 1995, P NATL ACAD SCI USA, V92, P7976, DOI 10.1073/pnas.92.17.7976; Dyall R, 1998, J EXP MED, V188, P1553, DOI 10.1084/jem.188.9.1553; Effros RB, 2003, IMMUNOL ALLERGY CLIN, V23, P41, DOI 10.1016/S0889-8561(02)00055-3; Gaudin C, 1999, J IMMUNOL, V162, P1730; Gold JS, 2003, J IMMUNOL, V170, P5188, DOI 10.4049/jimmunol.170.10.5188; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanada K, 2004, NATURE, V427, P252, DOI 10.1038/nature02240; HARA I, 1995, J EXP MED, V182, P1609, DOI 10.1084/jem.182.5.1609; Hogan KT, 1998, CANCER RES, V58, P5144; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; LeFur N, 1997, P NATL ACAD SCI USA, V94, P5332, DOI 10.1073/pnas.94.10.5332; Leitner WW, 2003, NAT MED, V9, P33, DOI 10.1038/nm813; Lewis JJ, 2000, INT J CANCER, V87, P391, DOI 10.1002/1097-0215(20000801)87:3<391::AID-IJC13>3.0.CO;2-K; MAKELA O, 1965, J IMMUNOL, V95, P378; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Negroiu G, 2005, BIOCHEM BIOPH RES CO, V328, P914, DOI 10.1016/j.bbrc.2005.01.040; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; PREHN RT, 1957, J NATL CANCER I, V18, P769; RESTIFO NP, 1992, J EXP MED, V175, P1423, DOI 10.1084/jem.175.6.1423; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Robinson J, 2003, NUCLEIC ACIDS RES, V31, P311, DOI [10.1093/nar/gkg070, 10.1093/nar/GKG070]; Ross HM, 1997, CLIN CANCER RES, V3, P2191; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Turk MJ, 2002, IMMUNOL REV, V188, P122, DOI 10.1034/j.1600-065X.2002.18811.x; Vigneron N, 2004, SCIENCE, V304, P587, DOI 10.1126/science.1095522; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Wang RF, 1996, J EXP MED, V183, P1131, DOI 10.1084/jem.183.3.1131; Watahiki A, 2004, NAT METHODS, V1, P233, DOI 10.1038/NMETH719; Weber LW, 1998, J CLIN INVEST, V102, P1258, DOI 10.1172/JCI4004; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zhu YR, 2003, J MOL BIOL, V326, P1157, DOI 10.1016/S0022-2836(02)01437-7; Zorn E, 1999, EUR J IMMUNOL, V29, P592, DOI 10.1002/(SICI)1521-4141(199902)29:02<592::AID-IMMU592>3.0.CO;2-2	40	70	75	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					198	206		10.1038/nm1363	http://dx.doi.org/10.1038/nm1363			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16444264				2022-12-25	WOS:000235160600024
J	Keshet, I; Schlesinger, Y; Farkash, S; Rand, E; Hecht, M; Segal, E; Pikarski, E; Young, RA; Niveleau, A; Cedar, H; Simon, I				Keshet, I; Schlesinger, Y; Farkash, S; Rand, E; Hecht, M; Segal, E; Pikarski, E; Young, RA; Niveleau, A; Cedar, H; Simon, I			Evidence for an instructive mechanism of de novo methylation in cancer cells	NATURE GENETICS			English	Article							DNA METHYLATION; CPG-ISLAND; DEVELOPMENTAL PATTERN; PROMOTER METHYLATION; ABERRANT METHYLATION; GENE-EXPRESSION; MOUSE EMBRYO; HYPERMETHYLATION; SITES; RECRUITMENT	DNA methylation has a role in the regulation of gene expression during normal mammalian development but can also mediate epigenetic silencing of CpG island genes in cancer and other diseases. Many individual genes ( including tumor suppressors) have been shown to undergo de novo methylation in specific tumor types, but the biological logic inherent in this process is not understood. To decipher this mechanism, we have adopted a new approach for detecting CpG island DNA methylation that can be used together with microarray technology. Genome-wide analysis by this technique demonstrated that tumor-specific methylated genes belong to distinct functional categories, have common sequence motifs in their promoters and are found in clusters on chromosomes. In addition, many are already repressed in normal cells. These results are consistent with the hypothesis that cancer-related de novo methylation may come about through an instructive mechanism.	Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Mol Biol, Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Pathol, Jerusalem, Israel; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY USA; Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; Univ Grenoble 1, Lab Virol Struct & Mol, La Tronche, France	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Rockefeller University; Massachusetts Institute of Technology (MIT); Whitehead Institute; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Keshet, I (corresponding author), Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, Jerusalem, Israel.	cedar@md.huji.ac.il	pikarsky, eli/GXV-7099-2022; Young, Richard A/F-6495-2012; Segal, Eran/AAF-4855-2019	Young, Richard A/0000-0001-8855-8647; Simon, Itamar/0000-0002-8517-1903; Segal, Eran/0000-0002-6859-1164; pikarsky, eli/0000-0003-4186-7105	NHGRI NIH HHS [R01 HG002668-03, R01 HG002668] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002668] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Gidekel S, 2002, J BIOL CHEM, V277, P34521, DOI 10.1074/jbc.M203338200; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; JONES A, 1967, ECON BOT, V21, P163, DOI 10.1007/BF02897864; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Maruyama R, 2002, CLIN CANCER RES, V8, P514; MONK M, 1987, DEVELOPMENT, V99, P371; Mukhopadhyay R, 2004, GENOME RES, V14, P1594, DOI 10.1101/gr.2408304; Notterman DA, 2001, CANCER RES, V61, P3124; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Rush LJ, 2002, ANAL BIOCHEM, V307, P191, DOI 10.1016/S0003-2697(02)00033-7; Segal E, 2003, BIOINFORMATICS, V19, pi273, DOI 10.1093/bioinformatics/btg1038; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Toyota M, 1999, CANCER RES, V59, P2307; Toyota M, 1999, CANCER RES, V59, P5438; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; VIRE E, 2005, NATURE          1214, DOI DOI 10.1038/NATURE04431; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007	39	364	394	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					149	153		10.1038/ng1719	http://dx.doi.org/10.1038/ng1719			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16444255				2022-12-25	WOS:000234953200007
J	Koshiba-Takeuchi, K; Takeuchi, JK; Arruda, EP; Kathiriya, IS; Mo, R; Hui, CC; Srivastava, D; Bruneau, BG				Koshiba-Takeuchi, K; Takeuchi, JK; Arruda, EP; Kathiriya, IS; Mo, R; Hui, CC; Srivastava, D; Bruneau, BG			Cooperative and antagonistic interactions between Sall4 and Tbx5 pattern the mouse limb and heart	NATURE GENETICS			English	Article							HOLT-ORAM-SYNDROME; ULNAR-MAMMARY SYNDROME; OKIHIRO-SYNDROME; TRANSCRIPTIONAL REGULATION; DIGIT IDENTITY; MUTATIONS; HINDLIMB; GENE; SHH; MORPHOGENESIS	Human mutations in TBX5, a gene encoding a T-box transcription factor, and SALL4, a gene encoding a zinc-finger transcription factor, cause similar upper limb and heart defects. Here we show that Tbx5 regulates Sall4 expression in the developing mouse forelimb and heart; mice heterozygous for a gene trap allele of Sall4 show limb and heart defects that model human disease. Tbx5 and Sall4 interact both positively and negatively to finely regulate patterning and morphogenesis of the anterior forelimb and heart. Thus, a positive and negative feed-forward circuit between Tbx5 and Sall4 ensures precise patterning of embryonic limb and heart and provides a unifying mechanism for heart/hand syndromes.	Hosp Sick Children, Program Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bruneau, BG (corresponding author), Hosp Sick Children, Program Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	bbruneau@sickkids.ca		Bruneau, Benoit/0000-0002-0804-7597				Agarwal P, 2003, DEVELOPMENT, V130, P623, DOI 10.1242/dev.00191; Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Al-Baradie R, 2002, AM J HUM GENET, V71, P1195, DOI 10.1086/343821; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; Borozdin W, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019505; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brassington AME, 2003, AM J HUM GENET, V73, P74, DOI 10.1086/376436; Bruneau BG, 2002, CIRC RES, V90, P509, DOI 10.1161/01.RES.0000013072.51957.B7; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Chiang C, 2001, DEV BIOL, V236, P421, DOI 10.1006/dbio.2001.0346; Dahn RD, 2000, SCIENCE, V289, P438, DOI 10.1126/science.289.5478.438; Davenport TG, 2003, DEVELOPMENT, V130, P2263, DOI 10.1242/dev.00431; Drossopoulou G, 2000, DEVELOPMENT, V127, P1337; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fan C, 2003, J BIOL CHEM, V278, P8780, DOI 10.1074/jbc.M208120200; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Ghosh TK, 2001, HUM MOL GENET, V10, P1983, DOI 10.1093/hmg/10.18.1983; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Hoogaars WMH, 2004, CARDIOVASC RES, V62, P489, DOI 10.1016/j.cardiores.2004.01.030; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kohlhase J, 2002, HUM MOL GENET, V11, P2979, DOI 10.1093/hmg/11.23.2979; Kohlhase J, 2002, CYTOGENET GENOME RES, V98, P274, DOI 10.1159/000071048; Kohlhase J, 2003, J MED GENET, V40, P473, DOI 10.1136/jmg.40.7.473; Lanctot C, 1999, DEVELOPMENT, V126, P1805; Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071; Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Logan M, 2003, DEVELOPMENT, V130, P6401, DOI 10.1242/dev.00956; Mangan S, 2003, P NATL ACAD SCI USA, V100, P11980, DOI 10.1073/pnas.2133841100; Minguillon C, 2005, DEV CELL, V8, P75, DOI 10.1016/j.devcel.2004.11.013; Mori AD, 2004, CURR OPIN CARDIOL, V19, P211, DOI 10.1097/00001573-200405000-00004; Naiche LA, 2003, DEVELOPMENT, V130, P2681, DOI 10.1242/dev.00504; NewburyEcob RA, 1996, J MED GENET, V33, P300, DOI 10.1136/jmg.33.4.300; Pizard A, 2005, MOL CELL BIOL, V25, P5073, DOI 10.1128/MCB.25.12.5073-5083.2005; POZNANSK AK, 1970, RADIOLOGY, V94, P45, DOI 10.1148/94.1.45; Rallis C, 2003, DEVELOPMENT, V130, P2741, DOI 10.1242/dev.00473; Seidman JG, 2002, J CLIN INVEST, V109, P451, DOI 10.1172/JC1200215043; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Suzuki T, 2004, DEV CELL, V6, P43, DOI 10.1016/S1534-5807(03)00401-5; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Tickle C, 2003, DEV CELL, V4, P449, DOI 10.1016/S1534-5807(03)00095-9; Welscher PT, 2002, SCIENCE, V298, P827, DOI 10.1126/science.1075620	48	124	125	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					175	183		10.1038/ng1707	http://dx.doi.org/10.1038/ng1707			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16380715				2022-12-25	WOS:000234953200011
J	Evgenov, NV; Medarova, Z; Dai, GP; Bonner-Weir, S; Moore, A				Evgenov, NV; Medarova, Z; Dai, GP; Bonner-Weir, S; Moore, A			In vivo imaging of islet transplantation	NATURE MEDICINE			English	Article							MAGNETIC-RESONANCE TRACKING; BETA-CELL MASS; T-CELLS; MRI; NANOPARTICLES; MACROPHAGES	Type 1 diabetes mellitus is characterized by the selective destruction of insulin-producing beta cells, which leads to a deficiency in insulin secretion and, as a result, to hyperglycemia. At present, transplantation of pancreatic islets is an emerging and promising clinical modality, which can render individuals with type 1 diabetes insulin independent without increasing the incidence of hypoglycemic events. To monitor transplantation efficiency and graft survival, reliable noninvasive imaging methods are needed. If such methods were introduced into the clinic, essential information could be obtained repeatedly and noninvasively. Here we report on the in vivo detection of transplanted human pancreatic islets using magnetic resonance imaging (MRI) that allowed noninvasive monitoring of islet grafts in diabetic mice in real time. We anticipate that the information obtained in this study would ultimately result in the ability to detect and monitor islet engraftment in humans, which would greatly aid the clinical management of this disease.	Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Massachusetts Gen Hosp,Mol Imaging Lab,MGH,MIT,HM, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Moore, A (corresponding author), Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Massachusetts Gen Hosp,Mol Imaging Lab,MGH,MIT,HM, Room 2301,Bldg 149,13th St, Charlestown, MA 02129 USA.	amoore@helix.mgh.harvard.edu		Bonner-Weir, Susan/0000-0003-4682-0656	NIDDK NIH HHS [DK071225] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK071225] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arbab AS, 2003, RADIOLOGY, V229, P838, DOI 10.1148/radiol.2293021215; Arbab AS, 2004, BLOOD, V104, P1217, DOI 10.1182/blood-2004-02-0655; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Bulte JWM, 2002, J CEREBR BLOOD F MET, V22, P899, DOI 10.1097/00004647-200208000-00001; Bulte JWM, 1999, P NATL ACAD SCI USA, V96, P15256, DOI 10.1073/pnas.96.26.15256; Davalli AM, 1996, DIABETES, V45, P1161, DOI 10.2337/diabetes.45.9.1161; Fowler M, 2005, TRANSPLANTATION, V79, P768, DOI 10.1097/01.TP.0000152798.03204.5C; Jirak D, 2004, MAGN RESON MED, V52, P1228, DOI 10.1002/mrm.20282; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; Ladriere L, 2001, AM J PHYSIOL-ENDOC M, V281, pE298, DOI 10.1152/ajpendo.2001.281.2.E298; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lu YX, 2004, MOL THER, V9, P428, DOI 10.1016/j.ymthe.2004.01.008; Malaisse WJ, 2001, INT J MOL MED, V7, P405; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Moore A, 2004, DIABETES, V53, P1459, DOI 10.2337/diabetes.53.6.1459; Moore A, 2004, CANCER RES, V64, P1821, DOI 10.1158/0008-5472.CAN-03-3230; Moore A, 2002, MAGNET RESON MED, V47, P751, DOI 10.1002/mrm.10110; Moore A, 1997, J MAGN RESON IMAGING, V7, P1140, DOI 10.1002/jmri.1880070629; Moore A, 2001, DIABETES, V50, P2231, DOI 10.2337/diabetes.50.10.2231; Schmitz A, 2004, NUCL MED BIOL, V31, P483, DOI 10.1016/j.nucmedbio.2003.12.003; Shapiro AMJ, 2003, LANCET, V362, P1242, DOI 10.1016/S0140-6736(03)14526-6; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Zhan YF, 2003, IMMUNOL CELL BIOL, V81, P451, DOI 10.1046/j.1440-1711.2003..x	23	217	227	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					144	148		10.1038/nm1316	http://dx.doi.org/10.1038/nm1316			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16380717				2022-12-25	WOS:000234419000065
J	McCarroll, SA; Hadnott, TN; Perry, GH; Sabeti, PC; Zody, MC; Barrett, JC; Dallaire, S; Gabriel, SB; Lee, C; Daly, MJ; Altshuler, DM				McCarroll, SA; Hadnott, TN; Perry, GH; Sabeti, PC; Zody, MC; Barrett, JC; Dallaire, S; Gabriel, SB; Lee, C; Daly, MJ; Altshuler, DM		Int HapMap Consortium	Common deletion polymorphisms in the human genome	NATURE GENETICS			English	Article							SEGMENTAL DUPLICATIONS; EXPRESSION	The locations and properties of common deletion variants in the human genome are largely unknown. We describe a systematic method for using dense SNP genotype data to discover deletions and its application to data from the International HapMap Consortium to characterize and catalogue segregating deletion variants across the human genome. We identified 541 deletion variants (94% novel) ranging from 1 kb to 745 kb in size; 278 of these variants were observed in multiple, unrelated individuals, 120 in the homozygous state. The coding exons of ten expressed genes were found to be commonly deleted, including multiple genes with roles in sex steroid metabolism, olfaction and drug response. These common deletion polymorphisms typically represent ancestral mutations that are in linkage disequilibrium with nearby SNPs, meaning that their association to disease can often be evaluated in the course of SNP-based whole-genome association studies.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02141 USA; MIT, Cambridge, MA 02141 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Med, Simches Res Ctr, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Altshuler, DM (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, 55 Fruit St, Boston, MA 02114 USA.	altshuler@molbio.mgh.harvard.edu	Altshuler, David M/A-4476-2009; Sabeti, Pardis/GQH-8610-2022; Daly, Mark J/B-2453-2017; McCarroll, Steven A/A-8433-2009; Pillay, Nischalan/F-9536-2012	Altshuler, David M/0000-0002-7250-4107; Daly, Mark J/0000-0002-0949-8752; McCarroll, Steven/0000-0002-6954-8184; Harrison, Tracy Nicole Hadnott/0000-0002-5169-3930				Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697; DAIGER SP, 1983, AM J MED GENET, V14, P43, DOI 10.1002/ajmg.1320140108; DEBAKKER PW, IN PRESS NAT GENET; FRY B, 2005, THESIS MIT; Hinds DA, 2006, NAT GENET, V38, P82, DOI 10.1038/ng1695; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Monks SA, 2004, AM J HUM GENET, V75, P1094, DOI 10.1086/426461; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Nunoya K, 1998, PHARMACOGENETICS, V8, P239, DOI 10.1097/00008571-199806000-00006; PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562; Wilson W, 2004, GENOMICS, V84, P707, DOI 10.1016/j.ygeno.2004.06.011	19	562	588	1	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					86	92		10.1038/ng1696	http://dx.doi.org/10.1038/ng1696			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16468122				2022-12-25	WOS:000234227200022
J	Needham, CJ; Bradford, JR; Bulpitt, AJ; Westhead, DR				Needham, CJ; Bradford, JR; Bulpitt, AJ; Westhead, DR			Inference in Bayesian networks	NATURE BIOTECHNOLOGY			English	Article								Bayesian networks are increasingly important for integrating biological data and for inferring cellular networks and pathways. What are Bayesian networks and how are they used for inference?	Univ Leeds, Sch Comp, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Needham, CJ (corresponding author), Univ Leeds, Sch Comp, Leeds LS2 9JT, W Yorkshire, England.	chrisn@comp.leeds.ac.uk		Bradford, James/0000-0002-7771-914X; Westhead, David/0000-0002-0519-3820	Biotechnology and Biological Sciences Research Council [BBS/B/16585] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		[Anonymous], 2005, PROBABILISTIC MODELI; Beaumont MA, 2004, NAT REV GENET, V5, P251, DOI 10.1038/nrg1318; Eddy SR, 2004, NAT BIOTECHNOL, V22, P1177, DOI 10.1038/nbt0904-1177; Friedman N, 2004, SCIENCE, V303, P799, DOI 10.1126/science.1094068; Heckerman D, 1998, NATO ADV SCI I D-BEH, V89, P301; Sachs K, 2005, SCIENCE, V308, P523, DOI 10.1126/science.1105809	6	63	68	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2006	24	1					51	53		10.1038/nbt0106-51	http://dx.doi.org/10.1038/nbt0106-51			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	001SE	16404397				2022-12-25	WOS:000234555800023
J	Takahashi, C; Contreras, B; Iwanaga, T; Takegami, Y; Bakker, A; Bronson, RT; Noda, M; Loda, M; Hunt, JL; Ewen, ME				Takahashi, C; Contreras, B; Iwanaga, T; Takegami, Y; Bakker, A; Bronson, RT; Noda, M; Loda, M; Hunt, JL; Ewen, ME			Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor	NATURE GENETICS			English	Article							CELL LUNG-CANCER; N-RAS; K-RAS; DIFFERENTIATION; RB; MOUSE; PROTEIN; GENE; ACTIVATION; MUTATIONS	Mutations in the gene encoding the retinoblastoma tumor suppressor predispose humans and mice to tumor development(1,2). Here we have assessed the effect of Nras loss on tumor development in Rb1 heterozygous mice. Loss of one or two Nras alleles is shown to significantly reduce the severity of pituitary tumors arising in Rb1(+/-) animals by enhancing their differentiation. By contrast, C-cell thyroid adenomas occurring in Rb1(+/-) mice progress to metastatic medullary carcinomas after loss of Nras. In Rb1(+/-) Nras(+/-) animals, distant medullary thyroid carcinoma metastases are associated with loss of the remaining wild-type Nras allele. Loss of Nras in Rb1-deficient C cells results in elevated Ras homolog family A ( RhoA) activity, and this is causally linked to the invasiveness and metastatic behavior of these cells. These findings suggest that the loss of the proto-oncogene Nras in certain cellular contexts can promote malignant tumor progression.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Rodent Histopathol Core, Boston, MA 02115 USA; Kyoto Univ, Grad Sch Med, 21st Century Ctr Excellence Program, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068501, Japan; Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Kyoto University; Kyoto University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tufts University	Ewen, ME (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	chtakaha@virus.kyoto-u.ac.jp; mark_ewen@dfci.harvard.edu	Bakker, Arnold B./F-8494-2010	Bakker, Arnold B./0000-0003-1489-1847	NCI NIH HHS [R01 CA065842-11A1, R01 CA065842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BESKID M, 1979, ONCOLOGY, V36, P19, DOI 10.1159/000225312; Capen C. C., 2001, INT CLASSIFICATION R, P269; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HU NP, 1994, ONCOGENE, V9, P1021; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KODAMA T, 1988, SURGERY, V104, P997; Lee KY, 1999, MOL CELL BIOL, V19, P7724; MABRY M, 1989, J CLIN INVEST, V84, P194, DOI 10.1172/JCI114140; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Mills SE, 2002, MODERN PATHOL, V15, P264, DOI 10.1038/modpathol.3880522; MITSUDOMI T, 1991, ONCOGENE, V6, P1352; MOLEY JF, 1991, CANCER RES, V51, P1596; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Takahashi C, 2003, MOL CELL BIOL, V23, P5256, DOI 10.1128/MCB.23.15.5256-5268.2003; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Vooijs M, 1999, ONCOGENE, V18, P5293, DOI 10.1038/sj.onc.1202999; White A, 1998, CLIN ENDOCRINOL, V48, P251, DOI 10.1046/j.1365-2265.1998.00451.x; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	28	37	39	2	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					118	123		10.1038/ng1703	http://dx.doi.org/10.1038/ng1703			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16369533				2022-12-25	WOS:000234227200027
J	Choi, SS; Li, WM; Lahn, BT				Choi, SS; Li, WM; Lahn, BT			Robust signals of coevolution of interacting residues in mammalian proteomes identified by phylogeny-aided structural analysis	NATURE GENETICS			English	Article							SECONDARY STRUCTURE; COMPENSATORY EVOLUTION; CORRELATED MUTATIONS; PROTEIN EVOLUTION; RNA; SUBSTITUTIONS; PERSPECTIVE; SEQUENCES; GENOMICS; CONTACTS	The structure of a protein depends critically on the complex interactions among its amino acid residues. It has long been hypothesized that interacting residues might tend to coevolve, but it is not known whether such coevolution is a general phenomenon across the proteome. Here, we describe a novel methodology called phylogeny-aided structural analysis, which uncovers robust signals of interacting-residue coevolution in mammalian proteomes. Furthermore, this new method allows the magnitude of coevolution to be quantified. Finally, it facilitates a comprehensive evaluation of various factors that affect interacting-residue coevolution, such as the physicochemical properties of the interactions between residues, solvent accessibility of the residues and their secondary structure context.	Univ Chicago, Howard Hughes Med Inst, Dept Human Genet, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Lahn, BT (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Human Genet, 5841 S Maryland Ave, Chicago, IL 60637 USA.	blahn@bsd.uchicago.edu						Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; Baudry J, 2003, PROTEIN ENG, V16, P577, DOI 10.1093/protein/gzg075; Chen Y, 1999, GENES GENET SYST, V74, P271, DOI 10.1266/ggs.74.271; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Fukami-Kobayashi K, 2002, J MOL BIOL, V319, P729, DOI 10.1016/S0022-2836(02)00239-5; Gao LZ, 2003, TRENDS GENET, V19, P678, DOI 10.1016/j.tig.2003.10.002; GILLESPIE JH, 1984, P NATL ACAD SCI-BIOL, V81, P8009, DOI 10.1073/pnas.81.24.8009; GOBEL U, 1994, PROTEINS, V18, P309, DOI 10.1002/prot.340180402; GUTELL RR, 1994, MICROBIOL REV, V58, P10, DOI 10.1128/MMBR.58.1.10-26.1994; HAAS ES, 1994, P NATL ACAD SCI USA, V91, P2527, DOI 10.1073/pnas.91.7.2527; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kern AD, 2004, NAT GENET, V36, P1207, DOI 10.1038/ng1451; Kimura M., 1985, J GENET, V64, P7, DOI [10.1007/BF02923549, DOI 10.1007/BF02923549]; Kondrashov AS, 2002, P NATL ACAD SCI USA, V99, P14878, DOI 10.1073/pnas.232565499; Mackerell AD, 2004, J COMPUT CHEM, V25, P1584, DOI 10.1002/jcc.20082; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; NEHER E, 1994, P NATL ACAD SCI USA, V91, P98, DOI 10.1073/pnas.91.1.98; Ortiz AR, 2000, BIOPHYS J, V79, P1787, DOI 10.1016/S0006-3495(00)76430-7; Pollock DD, 1997, PROTEIN ENG, V10, P647, DOI 10.1093/protein/10.6.647; SHINDYALOV IN, 1994, PROTEIN ENG, V7, P349, DOI 10.1093/protein/7.3.349; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; TAYLOR WR, 1994, PROTEIN ENG, V7, P341, DOI 10.1093/protein/7.3.341; Tramontano A, 2001, PROTEINS, P22, DOI 10.1002/prot.10015; Tuffery P, 2000, MOL BIOL EVOL, V17, P1753, DOI 10.1093/oxfordjournals.molbev.a026273; Westbrook J, 2003, NUCLEIC ACIDS RES, V31, P489, DOI 10.1093/nar/gkg068; YANOFSKY C, 1964, SCIENCE, V146, P1593, DOI 10.1126/science.146.3651.1593; Zhang JZ, 2002, P NATL ACAD SCI USA, V99, P5486, DOI 10.1073/pnas.072626199	28	36	38	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2005	37	12					1367	1371		10.1038/ng1685	http://dx.doi.org/10.1038/ng1685			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16282975				2022-12-25	WOS:000233657300018
J	Hodges, CA; Revenkova, E; Jessberger, R; Hassold, TJ; Hunt, PA				Hodges, CA; Revenkova, E; Jessberger, R; Hassold, TJ; Hunt, PA			SMC1 beta-deficient female mice provide evidence that cohesins are a missing link in age-related nondisjunction	NATURE GENETICS			English	Article							SISTER-CHROMATID COHESION; MEIOTIC RECOMBINATION; MAMMALIAN OOCYTES; MATERNAL AGE; MEIOSIS I; CHROMOSOME; MECHANISM; SMC1-BETA; DYNAMICS; DIVISION	Mitotic chromosome segregation is facilitated by the cohesin complex, which maintains physical connections between sister chromatids until anaphase. Meiotic cell division is considerably more complex, as cohesion must be released sequentially to facilitate orderly segregation of chromosomes at both meiosis I and meiosis II. This necessitates meiosis-specific cohesin components; recent studies in rodents suggest that these influence chromosome behavior during both cell division and meiotic prophase(1,2). To elucidate the role of the meiosis-specific cohesin SMC1 beta ( encoded by Smc1l2) in oogenesis, we carried out meiotic studies of female SMC1 beta-deficient mice. Our results provide the first direct evidence that SMC1 beta acts as a chiasma binder in mammals, stabilizing sites of exchange until anaphase. Additionally, our observations support the hypothesis that deficient cohesion is an underlying cause of human age-related aneuploidy.	Washington State Univ, Ctr Reprod Biol, Pullman, WA 99164 USA; Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA; Dresden Univ Technol, Dept Physiol Chem, Dresden, Germany	Washington State University; Washington State University; Case Western Reserve University; Icahn School of Medicine at Mount Sinai; Technische Universitat Dresden	Hunt, PA (corresponding author), Washington State Univ, Ctr Reprod Biol, Pullman, WA 99164 USA.	pathunt@wsu.edu						Angell R, 1997, AM J HUM GENET, V61, P23, DOI 10.1086/513890; Bickel SE, 2002, CURR BIOL, V12, P925, DOI 10.1016/S0960-9822(02)00846-1; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Chan RC, 2003, NATURE, V423, P1002, DOI 10.1038/nature01697; Eijpe M, 2003, J CELL BIOL, V160, P657, DOI 10.1083/jcb.200212080; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Haering CH, 2004, MOL CELL, V15, P951, DOI 10.1016/j.molcel.2004.08.030; HENDERSON SA, 1968, NATURE, V218, P22, DOI 10.1038/218022a0; Hodges CA, 2002, CHROMOSOMA, V111, P165, DOI 10.1007/s00412-002-0195-3; HOGAN B, 1986, MANIPULATING MOUSE E; Kouznetsova A, 2005, J CELL SCI, V118, P2271, DOI 10.1242/jcs.02362; Lamb NE, 1996, NAT GENET, V14, P400, DOI 10.1038/ng1296-400; Lynn A, 2004, ANNU REV GENOM HUM G, V5, P317, DOI 10.1146/annurev.genom.4.070802.110217; Lynn A, 2002, SCIENCE, V296, P2222, DOI 10.1126/science.1071220; MAGUIRE MP, 1974, J THEOR BIOL, V48, P485, DOI 10.1016/S0022-5193(74)80017-2; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Pellestor F, 2003, HUM GENET, V112, P195, DOI 10.1007/s00439-002-0852-x; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; POLANI PE, 1976, CYTOGENET CELL GENET, V16, P505, DOI 10.1159/000130668; Prieto I, 2004, CHROMOSOME RES, V12, P197, DOI 10.1023/B:CHRO.0000021945.83198.0e; Prieto I, 2001, NAT CELL BIOL, V3, P761, DOI 10.1038/35087082; Rasmussen R, 2001, RAPID CYCLE REAL TIM, P21, DOI [10.1007/978-3-642-59524-0_3, DOI 10.1007/978-3-642-59524-0_3]; Revenkova E, 2004, NAT CELL BIOL, V6, P555, DOI 10.1038/ncb1135; Revenkova E, 2001, MOL CELL BIOL, V21, P6984, DOI 10.1128/MCB.21.20.6984-6998.2001; Sun F, 2004, AM J HUM GENET, V74, P521, DOI 10.1086/382138; TARKOWSKI AK, 1966, CYTOGENETICS, V5, P394, DOI 10.1159/000129914; Uhlmann F, 2004, EXP CELL RES, V296, P80, DOI 10.1016/j.yexcr.2004.03.005; Wolstenholme J, 2000, CHROMOSOMA, V109, P435, DOI 10.1007/s004120000088	29	230	242	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2005	37	12					1351	1355		10.1038/ng1672	http://dx.doi.org/10.1038/ng1672			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16258540				2022-12-25	WOS:000233657300015
J	Zhao, Z; Yu, Y; Meyer, D; Wu, CJ; Shen, WH				Zhao, Z; Yu, Y; Meyer, D; Wu, CJ; Shen, WH			Prevention of early flowering by expression of FLOWERING LOCUS C requires methylation of histone H3K36	NATURE CELL BIOLOGY			English	Article							MADS DOMAIN PROTEIN; RNA-POLYMERASE-II; ARABIDOPSIS-THALIANA; SET DOMAIN; BOX GENE; VERNALIZATION; H3; REPRESSION; REGULATOR; PATHWAYS	Flowering represents a crucial transition from a vegetative to a reproductive phase of the plant life cycle. Despite extensive studies, the molecular mechanisms controlling flowering remain elusive. Although the enzymes involved are unknown, methylation of histone H3 K9 and K27 correlates with repression of FLOWERING LOCUS C (FLC, an essential transcriptional repressor involved in flowering time control in Arabidopsis thaliana; in contrast, methylation of H3K4 correlates with FLC activation(1-4). Here we show that loss-of-function of SET DOMAIN GROUP 8 (SDG 8), which encodes a homologue of the yeast SET2 histone methyltransferase, results in reduced dimethylation of histone H3K36, particularly in chromatin associated with the FLC promoter and the first intron, regions that contain essential cis-elements for transcription. sdg8 mutants display reduced FLC expression and flower early, establishing SDG8-mediated H3K36 methylation as a novel epigenetic memory code required for FLC expression in preventing early flowering. This is the first demonstrated role of H3K36 methylation in eukaryote development.	Univ Louis Pasteur Strasbourg, CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Shen, WH (corresponding author), Univ Louis Pasteur Strasbourg, CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.	Wen-Hui.Shen@ibmp-ulp.u-strasbg.fr	Zhao, Zhong/N-1999-2013; Shen, Wen Hui/E-7941-2017	Zhao, Zhong/0000-0001-8044-0409; Shen, Wen-Hui/0000-0001-7988-6382				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Ausin I, 2004, NAT GENET, V36, P162, DOI 10.1038/ng1295; BANNISTER AJ, J BIOL CHEM, V280, P17732; Bastow R, 2004, NATURE, V427, P164, DOI 10.1038/nature02269; Boss PK, 2004, PLANT CELL, V16, pS18, DOI 10.1105/tpc.015958; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Gatz C, 1995, METHOD CELL BIOL, V50, P411, DOI 10.1016/S0091-679X(08)61047-X; He YH, 2004, GENE DEV, V18, P2774, DOI 10.1101/gad.1244504; He YH, 2003, SCIENCE, V302, P1751, DOI 10.1126/science.1091109; Jackson DP, 1991, MOL PLANT PATHOL, P163; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Lee H, 2000, GENE DEV, V14, P2366, DOI 10.1101/gad.813600; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Oh S, 2004, PLANT CELL, V16, P2940, DOI 10.1105/tpc.104.026062; Perry J, 2003, TRENDS BIOCHEM SCI, V28, P576, DOI 10.1016/j.tibs.2003.09.007; Rayasam GV, 2003, EMBO J, V22, P3153, DOI 10.1093/emboj/cdg288; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Sheldon CC, 2002, PLANT CELL, V14, P2527, DOI 10.1105/tpc.004564; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sung SB, 2004, NATURE, V427, P159, DOI 10.1038/nature02195; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Yu Y, 2004, PLANT J, V40, P699, DOI 10.1111/j.1365-313X.2004.02240.x; Zhang H, 2002, PLANT J, V31, P663, DOI 10.1046/j.1365-313X.2002.01380.x	29	226	246	1	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1256	1260		10.1038/ncb1329	http://dx.doi.org/10.1038/ncb1329			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16299497				2022-12-25	WOS:000233748900020
J	Caussinus, E; Gonzalez, C				Caussinus, E; Gonzalez, C			Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster	NATURE GENETICS			English	Article							GENETIC INSTABILITY; FATE DETERMINANTS; SELF-RENEWAL; POLARITY; PROLIFERATION; NEUROBLAST; CANCER; DLG; LGL; NEUROGENESIS	Loss of cell polarity and cancer are tightly correlated(1), but proof for a causative relationship has remained elusive. In stem cells, loss of polarity and impairment of asymmetric cell division could alter cell fates and thereby render daughter cells unable to respond to the mechanisms that control proliferation(2). To test this hypothesis, we generated Drosophila melanogaster larval neuroblasts containing mutations in various genes that control asymmetric cell division and then assayed their proliferative potential after transplantation into adult hosts. We found that larval brain tissue carrying neuroblasts with mutations in raps (also called pins), mira, numb or pros grew to more than 100 times their initial size, invading other tissues and killing the hosts in 2 weeks. These tumors became immortal and could be retransplanted into new hosts for years. Six weeks after the first implantation, genome instability and centrosome alterations, two traits of malignant carcinomas(3,4), appeared in these tumors. Increasing evidence suggests that some tumors may be of stem cell origin(5,6). Our results show that loss of function of any of several genes that control the fate of a stem cell's daughters may result in hyperproliferation, triggering a chain of events that subverts cell homeostasis in a general sense and leads to cancer.	ICREA & IRBB, Cell Div Grp, Barcelona, Spain; European Mol Biol Lab, Cell Biol & Biophys Program, D-69117 Heidelberg, Germany	ICREA; European Molecular Biology Laboratory (EMBL)	Gonzalez, C (corresponding author), ICREA & IRBB, Cell Div Grp, Parc Cient Barcelona,C Josep Samitier 1-5, Barcelona, Spain.	cgonzalez@pcb.ub.es	Gonzalez, Cayetano/K-3933-2019; Gonzalez, Cayetano/K-3055-2019	Gonzalez, Cayetano/0000-0002-5259-3608	ICREA Funding Source: Custom	ICREA(ICREA)		Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Bardin AJ, 2004, CURR OPIN NEUROBIOL, V14, P6, DOI 10.1016/j.conb.2003.12.002; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Ceron J, 2001, DEV BIOL, V230, P125, DOI 10.1006/dbio.2000.0110; Chia W, 2002, CURR OPIN GENET DEV, V12, P459, DOI 10.1016/S0959-437X(02)00326-X; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Gatewood WB, 1997, AFR AM REV, V31, P365, DOI 10.2307/3042495; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GEHRING W, 1966, J EMBRYOL EXP MORPH, V15, P77; HADORN E, 1966, DEV BIOL, V13, P424, DOI 10.1016/0012-1606(66)90058-3; HADORN E, 1978, GENETICS BIOL DROS C, V2, P557; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li HS, 2003, NEURON, V40, P1105, DOI 10.1016/S0896-6273(03)00755-4; Liu H, 2005, CELL CYCLE, V4, P646, DOI 10.4161/cc.4.5.1674; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; Molofsky AV, 2004, CURR OPIN CELL BIOL, V16, P700, DOI 10.1016/j.ceb.2004.09.004; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Pihan GA, 2003, CANCER RES, V63, P1398; Pihan GA, 1998, CANCER RES, V58, P3974; Shih IM, 2001, CANCER RES, V61, P818; SUNKEL CE, 1995, EMBO J, V14, P28, DOI 10.1002/j.1460-2075.1995.tb06972.x; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; WATSON KL, 1994, J CELL SCI, P19; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8	30	328	341	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1125	1129		10.1038/ng1632	http://dx.doi.org/10.1038/ng1632			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16142234				2022-12-25	WOS:000232185600026
J	Menzella, HG; Reid, R; Carney, JR; Chandran, SS; Reisinger, SJ; Patel, KG; Hopwood, DA; Santi, DV				Menzella, HG; Reid, R; Carney, JR; Chandran, SS; Reisinger, SJ; Patel, KG; Hopwood, DA; Santi, DV			Combinatorial polyketide biosynthesis by de novo design and rearrangement of modular polyketide synthase genes	NATURE BIOTECHNOLOGY			English	Article							DOMAIN; 6-DEOXYERYTHRONOLIDE-B; RECOGNITION; LEADS	Type I polyketide synthase (PKS) genes consist of modules similar to 3-6 kb long, which encode the structures of 2-carbon units in polyketide products. Alteration or replacement of individual PKS modules can lead to the biosynthesis of 'unnatural' natural products but existing techniques for this are time consuming. Here we describe a generic approach to the design of synthetic PKS genes where facile cassette assembly and interchange of modules and domains are facilitated by a repeated set of flanking restriction sites. To test the feasibility of this approach, we synthesized 14 modules from eight PKS clusters and associated them in 154 bimodular combinations spanning over 1.5-million bp of novel PKS gene sequences. Nearly half the combinations successfully mediated the biosynthesis of a polyketide in Escherichia coli, and all individual modules participated in productive bimodular combinations. This work provides a truly combinatorial approach for the production of polyketides.	Kosan Biosci Ins, Hayward, CA 94545 USA; John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England	Bristol-Myers Squibb; Kosan Biosciences, Inc.; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Santi, DV (corresponding author), Kosan Biosci Ins, 3832 Bay Ctr Pl, Hayward, CA 94545 USA.	santi@kosan.com	Menzella, Hugo/GLS-7930-2022	Menzella, Hugo/0000-0001-6930-2400; Carney, John/0000-0002-0461-8890				Ashley GW, 2004, J ANTIBIOT, V57, P224, DOI 10.7164/antibiotics.57.224; Beck BJ, 2003, J AM CHEM SOC, V125, P12551, DOI 10.1021/ja034841s; Beck BJ, 2003, J AM CHEM SOC, V125, P4682, DOI 10.1021/ja029974c; Broadhurst RW, 2003, CHEM BIOL, V10, P723, DOI 10.1016/S1074-5521(03)00156-X; Chuck JA, 1997, CHEM BIOL, V4, P757, DOI 10.1016/S1074-5521(97)90314-8; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; Gokhale RS, 1999, SCIENCE, V284, P482, DOI 10.1126/science.284.5413.482; Hinterding K, 2001, TETRAHEDRON LETT, V42, P8463, DOI 10.1016/S0040-4039(01)01840-8; Jacobsen JR, 1998, BIOCHEMISTRY-US, V37, P4928, DOI 10.1021/bi9729920; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kim BS, 2002, BIOCHEMISTRY-US, V41, P10827, DOI 10.1021/bi0256779; Kodumal SJ, 2004, P NATL ACAD SCI USA, V101, P15573, DOI 10.1073/pnas.0406911101; Lau J, 2004, J BIOTECHNOL, V110, P95, DOI 10.1016/j.jbiotec.2004.02.001; McDaniel R, 1997, CHEM BIOL, V4, P667, DOI 10.1016/S1074-5521(97)90222-2; McDaniel R, 1999, P NATL ACAD SCI USA, V96, P1846, DOI 10.1073/pnas.96.5.1846; Moss SJ, 2004, NAT PROD REP, V21, P575, DOI 10.1039/b315020h; Murli S, 2003, J IND MICROBIOL BIOT, V30, P500, DOI 10.1007/s10295-003-0073-x; Oliynyk M, 1996, CHEM BIOL, V3, P833, DOI 10.1016/S1074-5521(96)90069-1; Pfeifer BA, 2001, MICROBIOL MOL BIOL R, V65, P106, DOI 10.1128/MMBR.65.1.106-118.2001; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; Ranganathan A, 1999, CHEM BIOL, V6, P731, DOI 10.1016/S1074-5521(00)80020-4; Reeves CD, 2003, CRIT REV BIOTECHNOL, V23, P95, DOI 10.1080/713609311; Tsuji SY, 2001, BIOCHEMISTRY-US, V40, P2326, DOI 10.1021/bi002463n; Walsh C., 2003, ANTIBIOTICS ACTIONS; Watanabe K, 2003, J BIOL CHEM, V278, P42020, DOI 10.1074/jbc.M305339200; Wilkinson B, 2000, CHEM BIOL, V7, P111, DOI 10.1016/S1074-5521(00)00076-4; Wu N, 2002, BIOCHEMISTRY-US, V41, P5056, DOI 10.1021/bi012086u; Wu N, 2001, J AM CHEM SOC, V123, P6465, DOI 10.1021/ja010219t	30	220	245	4	73	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1171	1176		10.1038/nbt1128	http://dx.doi.org/10.1038/nbt1128			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16116420				2022-12-25	WOS:000231790600034
J	Celli, GB; de Lange, T				Celli, GB; de Lange, T			DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion	NATURE CELL BIOLOGY			English	Letter							MAMMALIAN TELOMERES; V(D)J RECOMBINATION; HUMAN-CELLS; LIGASE IV; SENESCENCE; DYSFUNCTION; OVERHANG; COMPLEX; LENGTH; TIN2	Telomere attrition and other forms of telomere damage can activate the ATM kinase pathway. What generates the DNA damage signal at mammalian chromosome ends or at other double- strand breaks is not known. Telomere dysfunction is often accompanied by disappearance of the 3 ' telomeric overhang(1,2), raising the possibility that DNA degradation could generate the structure that signals(2). Here we address these issues by studying telomere structure after conditional deletion of mouse TRF2, the protective factor at telomeres. Upon removal of TRF2 from TRF2(Fl/-) p53(-/-) mouse embryo fibroblasts, a telomere damage response is observed at most chromosome ends. As expected, the telomeres lose the 3 ' overhang and are processed by the non- homologous end- joining pathway. Non-homologous end joining of telomeres was abrogated in DNA ligase IV- deficient ( Lig4(-/-)) cells. Unexpectedly, the telomeres of TRF2(-/-) Lig4(-/-) p53(-/-) cells persisted in a free state without undergoing detectable DNA degradation. Notably, the telomeres retained their 3 ' overhangs, but they were recognized as sites of DNA damage, accumulating the DNA damage response factors 53BP1 and gamma-H2AX, and activating the ATM kinase. Thus, activation of the ATM kinase pathway at chromosome ends does not require overhang degradation or other overt DNA processing.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, 1230 York Ave, New York, NY 10021 USA.	delange@mail.rockefeller.edu	de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NIGMS NIH HHS [GM49046-12] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049046, R37GM049046] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakkenist CJ, 2004, CANCER RES, V64, P3748, DOI 10.1158/0008-5472.CAN-04-0453; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Chiang YJ, 2004, MOL CELL BIOL, V24, P6631, DOI 10.1128/mcb.24.15.6631-6634.2004; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs JJL, 2004, CURR BIOL, V14, P2302, DOI 10.1016/j.cub.2004.12.025; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2003, MOL CELL BIOL, V23, P6533, DOI 10.1128/MCB.23.18.6533-6541.2003; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MAKAROV VL, 1993, CELL, V73, P775, DOI 10.1016/0092-8674(93)90256-P; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	36	452	464	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2005	7	7					712	U110		10.1038/ncb1275	http://dx.doi.org/10.1038/ncb1275			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	941BX	15968270				2022-12-25	WOS:000230190800016
J	Pajvani, UB; Trujillo, ME; Combs, TP; Iyengar, P; Jelicks, L; Roth, KA; Kitsis, RN; Scherer, PE				Pajvani, UB; Trujillo, ME; Combs, TP; Iyengar, P; Jelicks, L; Roth, KA; Kitsis, RN; Scherer, PE			Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy	NATURE MEDICINE			English	Article							ADIPOSE-TISSUE; INSULIN-RESISTANCE; LEPTIN; MICE; EXPRESSION; ADIPOCYTE; AGONIST; WHITE; GENE	We describe the generation and characterization of the first inducible 'fatless' model system, the FAT-ATTAC mouse (fat apoptosis through targeted activation of caspase 8). This transgenic mouse develops identically to wild- type littermates. Apoptosis of adipocytes can be induced at any developmental stage by administration of a FK1012 analog leading to the dimerization of a membrane-bound, adipocyte- specific caspase 8 - FKBP fusion protein. Within 2 weeks of dimerizer administration, FAT-ATTAC mice show near- knockout levels of circulating adipokines and markedly reduced levels of adipose tissue. FAT-ATTAC mice are glucose intolerant, have diminished basal and endotoxin-stimulated systemic inflammation, are less responsive to glucose-stimulated insulin secretion and show increased food intake independent of the effects of leptin. Most importantly, we show that functional adipocytes can be recovered upon cessation of treatment, allowing the study of adipogenesis in vivo, as well as a detailed examination of the importance of the adipocyte in the regulation of multiple physiological functions and pathological states.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Alabama System; University of Alabama Birmingham; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Scherer, PE (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Scherer, Philipp E/K-7819-2012; Trujillo, Martha E./L-1763-2014; Jelicks, Linda/L-9740-2019	Scherer, Philipp E/0000-0003-0680-3392; Trujillo, Martha E./0000-0002-9193-1673; Jelicks, Linda/0000-0002-6438-1792; Roth, Kevin/0000-0002-0643-995X	NEI NIH HHS [R03 EYO14935] Funding Source: Medline; NHLBI NIH HHS [1R01HL073163-01] Funding Source: Medline; NIDDK NIH HHS [R01-DK55758, DK61228] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL EYE INSTITUTE [R03EY014935] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758, F32DK061228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berg AH, 2004, AM J PHYSIOL-ENDOC M, V287, pE1178, DOI 10.1152/ajpendo.00002.2004; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Colombo C, 2002, DIABETES, V51, P2727, DOI 10.2337/diabetes.51.9.2727; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Gavrilova O, 2000, DIABETES, V49, P1910, DOI 10.2337/diabetes.49.11.1910; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; Grujic D, 1997, J BIOL CHEM, V272, P17686, DOI 10.1074/jbc.272.28.17686; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; Mallet VO, 2002, NAT BIOTECHNOL, V20, P1234, DOI 10.1038/nbt762; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; ROSS SR, 1993, GENE DEV, V7, P1318, DOI 10.1101/gad.7.7b.1318; ROTH KA, NEUROMETHODS, V37, P205; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664	18	220	240	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					797	803		10.1038/nm1262	http://dx.doi.org/10.1038/nm1262			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15965483				2022-12-25	WOS:000230304200038
J	Weiss, LA; Pan, L; Abney, M; Ober, C				Weiss, LA; Pan, L; Abney, M; Ober, C			The sex-specific genetic architecture of quantitative traits in humans	NATURE GENETICS			English	Article							WHOLE-BLOOD SEROTONIN; FOUNDER POPULATION; LINKAGE ANALYSIS; SUSCEPTIBILITY ALLELES; GENDER-DIFFERENCES; LOCI; HOMOZYGOSITY; ASSOCIATION; EXPRESSION; DEPRESSION	Mapping genetically complex traits remains one of the greatest challenges in human genetics today. In particular, gene-environment and gene-gene interactions, genetic heterogeneity and incomplete penetrance make thorough genetic dissection of complex traits difficult, if not impossible. Sex could be considered an environmental factor that can modify both penetrance and expressivity of a wide variety of traits. Sex is easily determined and has measurable effects on recognizable morphology; neurobiological circuits; susceptibility to autoimmune disease, diabetes, asthma, cardiovascular and psychiatric disease; and quantitative traits like blood pressure, obesity and lipid levels, among others. In this study, we evaluated sex-specific heritability and genome-wide linkages for 17 quantitative traits in the Hutterites. The results of this study could have important implications for mapping complex trait genes.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.	c-ober@genetics.uchicago.edu		Ober, Carole/0000-0003-4626-9809				Abney M, 2000, AM J HUM GENET, V66, P629, DOI 10.1086/302759; Abney M, 2002, AM J HUM GENET, V70, P920, DOI 10.1086/339705; Abney M, 2001, AM J HUM GENET, V68, P1302, DOI 10.1086/320112; Abney MA, 2000, AM J HUM GENET, V67, P327; Bourgain C, 2003, AM J HUM GENET, V73, P612, DOI 10.1086/378208; Cairney J, 2002, SOC PSYCH PSYCH EPID, V37, P401, DOI 10.1007/s00127-002-0569-0; Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; Chen Y, 2003, J CLIN EPIDEMIOL, V56, P180, DOI 10.1016/S0895-4356(02)00593-0; Fisher SA, 2002, EUR J HUM GENET, V10, P259, DOI 10.1038/sj.ejhg.5200792; Fullerton J, 2003, AM J HUM GENET, V72, P879, DOI 10.1086/374178; Korstanje R, 2004, J LIPID RES, V45, P881, DOI 10.1194/jlr.M300460-JLR200; Kurina LM, 2005, J CLIN ENDOCR METAB, V90, P4747, DOI 10.1210/jc.2005-0384; Loughlin J, 2000, RHEUMATOLOGY, V39, P377, DOI 10.1093/rheumatology/39.4.377; Mackay TFC, 2004, CURR OPIN GENET DEV, V14, P253, DOI 10.1016/j.gde.2004.04.003; Newman DL, 2004, EUR J HUM GENET, V12, P584, DOI 10.1038/sj.ejhg.5201191; Newman DL, 2003, HUM MOL GENET, V12, P137, DOI 10.1093/hmg/ddg012; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2001, AM J HUM GENET, V69, P1068, DOI 10.1086/324025; Rinn JL, 2005, TRENDS GENET, V21, P298, DOI 10.1016/j.tig.2005.03.005; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Stone JL, 2004, AM J HUM GENET, V75, P1117, DOI 10.1086/426034; Stromberg Anna, 2003, Eur J Cardiovasc Nurs, V2, P7; Towne B, 1997, GENET EPIDEMIOL, V14, P1053, DOI 10.1002/(SICI)1098-2272(1997)14:6<1053::AID-GEPI82>3.0.CO;2-G; Ueno T, 2004, PHYSIOL GENOMICS, V17, P38, DOI 10.1152/physiolgenomics.00043.2003; Weiss LA, 2005, HUM GENET, V117, P81, DOI 10.1007/s00439-004-1250-3; Weiss LA, 2005, AM J HUM GENET, V76, P33, DOI 10.1086/426697; Weiss LA, 2004, EUR J HUM GENET, V12, P949, DOI 10.1038/sj.ejhg.5201239; Williams AJK, 2003, DIABETOLOGIA, V46, P1354, DOI 10.1007/s00125-003-1197-2; Woods SC, 2003, EXP BIOL MED, V228, P1175; Zubenko GS, 2003, AM J MED GENET B, V123B, P1, DOI 10.1002/ajmg.b.20073	30	311	318	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					218	222		10.1038/ng1726	http://dx.doi.org/10.1038/ng1726			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16429159				2022-12-25	WOS:000234953200018
J	Robicsek, A; Strahilevitz, J; Jacoby, GA; Macielag, M; Abbanat, D; Park, CH; Bush, K; Hooper, DC				Robicsek, A; Strahilevitz, J; Jacoby, GA; Macielag, M; Abbanat, D; Park, CH; Bush, K; Hooper, DC			Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase	NATURE MEDICINE			English	Article							MEDIATED QUINOLONE RESISTANCE; CHLORAMPHENICOL ACETYLTRANSFERASE; UNITED-STATES; FUSIDIC ACID; PLASMID; BINDING	Antimicrobial-modifying resistance enzymes have traditionally been class specific, having coevolved with the antibiotics they inactivate. Fluoroquinolones, antimicrobial agents used extensively in medicine and agriculture, are synthetic and have been considered safe from naturally occurring antimicrobial-modifying enzymes. We describe reduced susceptibility to ciprofloxacin in clinical bacterial isolates conferred by a variant of the gene encoding aminoglycoside acetyltransferase AAC(6')-lb. This enzyme reduces the activity of ciprofloxacin by N-acetylation at the amino nitrogen on its piperazinyl substituent. Although approximately 30 variants of this gene have been reported since 1986, the two base-pair changes responsible for the ciprofloxacin modification phenotype are unique to this variant, first reported in 2003 and now widely disseminated. An intense increase in the medical use of ciprofloxacin seems to have been accompanied by a notable development: a single-function resistance enzyme has crossed class boundaries, and is now capable of enzymatically undermining two unrelated antimicrobial agents, one of them fully synthetic.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Lahey Clin Fdn, Burlington, MA 01805 USA; Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ 08869 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Lahey Hospital & Medical Center; Johnson & Johnson; Johnson & Johnson USA	Hooper, DC (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,GRJ 512, Boston, MA 02114 USA.	dhooper@partners.org	Jacoby, George A/G-2604-2011; Bush, Karen/O-2820-2017		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057576, R01AI043312] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI057576, AI57576, AI43312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENNETT AD, 1983, BIOCHEM J, V215, P29, DOI 10.1042/bj2150029; Boyd DA, 2004, ANTIMICROB AGENTS CH, V48, P3758, DOI 10.1128/AAC.48.10.3758-3764.2004; Davies J. E., 1986, ANTIBIOTICS LABORATO, P790; DOMAGALA JM, 1994, J ANTIMICROB CHEMOTH, V33, P685, DOI 10.1093/jac/33.4.685; HEISIG P, 1994, ANTIMICROB AGENTS CH, V38, P1284, DOI 10.1128/AAC.38.6.1284; Martinez-Freijo P, 1998, J ANTIMICROB CHEMOTH, V42, P689, DOI 10.1093/jac/42.6.689; MURRAY IA, 1995, J MOL BIOL, V254, P993, DOI 10.1006/jmbi.1995.0671; Neuhauser MM, 2003, JAMA-J AM MED ASSOC, V289, P885, DOI 10.1001/jama.289.7.885; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Pechere JC, 2001, INT J ANTIMICROB AG, V18, pS25; Robicsek A, 2005, ANTIMICROB AGENTS CH, V49, P3001, DOI 10.1128/AAC.49.7.3001-3003.2005; TOLMASKY ME, 1986, ANTIMICROB AGENTS CH, V30, P315, DOI 10.1128/AAC.30.2.315; Vetting MW, 2004, CHEM BIOL, V11, P565, DOI 10.1016/j.chembiol.2004.03.017; Wang F, 2001, J Infect Chemother, V7, P117, DOI 10.1007/s101560100019; Wang MG, 2004, ANTIMICROB AGENTS CH, V48, P1295, DOI 10.1128/AAC.48.4.1295-1299.2004; Wang MG, 2003, ANTIMICROB AGENTS CH, V47, P2242, DOI 10.1128/AAC.47.7.2242-2248.2003; Wetzstein HG, 1997, APPL ENVIRON MICROB, V63, P4272, DOI 10.1128/AEM.63.11.4272-4281.1997	17	688	807	5	87	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					83	88		10.1038/nm1347	http://dx.doi.org/10.1038/nm1347			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16369542				2022-12-25	WOS:000234419000056
J	Samakoglu, S; Lisowski, L; Budak-Alpdogan, T; Usachenko, Y; Acuto, S; Di Marzo, R; Maggio, A; Zhu, P; Tisdale, JF; Riviere, I; Sadelain, M				Samakoglu, S; Lisowski, L; Budak-Alpdogan, T; Usachenko, Y; Acuto, S; Di Marzo, R; Maggio, A; Zhu, P; Tisdale, JF; Riviere, I; Sadelain, M			A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference	NATURE BIOTECHNOLOGY			English	Article							MESSENGER-RNAS; DISEASE; ACTIVATION; THERAPY	The application of RNA interference (RNAi) to stem cell-based gene therapies will require highly specific and lineage-restricted gene silencing. Here we show the feasibility and therapeutic potential of coregulating transgene expression and RNAi in hematopoietic stem cells. We encoded promoterless small-hairpin RNA (shRNA) within the intron of a recombinant c-globin gene. Expression of both c-globin and the lariat-embedded small interfering RNA (siRNA) was induced upon erythroid differentiation, specifically downregulating the targeted gene in tissue- and differentiation stage-specific fashion. The position of the shRNA within the intron was critical to concurrently achieve high-level transgene expression, effective siRNA generation and minimal interferon induction. Lentiviral transduction of CD34(+) cells from patients with sickle cell anemia led to erythroid-specific expression of the gamma-globin transgene and concomitant reduction of endogenous beta(S) transcripts, thus providing proof of principle for therapeutic strategies that require synergistic gene addition and gene silencing in stem cell progeny.	Sloan Kettering Inst, Lab Gene Transfer & Gene Express, New York, NY 10021 USA; Sloan Kettering Inst, Gene Transfer & Somat Cell Engn Facil, New York, NY 10021 USA; Univ Med & Dent New Jersey, Dept Med, New Brunswick, NJ 08901 USA; Osped V Cervello, Div Ematol Tallassemia 2, I-90146 Palermo, Italy; NIDDK, MCHB, DHHS, NIH, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Sadelain, M (corresponding author), Sloan Kettering Inst, Lab Gene Transfer & Gene Express, New York, NY 10021 USA.	m-sadelain@ski.mskcc.org	Lisowski, Leszek/AAU-2228-2020; Acuto, Santina/K-7582-2016; Maggio, Aurelio/K-7812-2016	Lisowski, Leszek/0000-0002-4772-8651; Acuto, Santina/0000-0001-7749-2259; Maggio, Aurelio/0000-0002-9601-900X	NATIONAL CANCER INSTITUTE [P30CA008748, P01CA059350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK027011] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748, CA59350] Funding Source: Medline; NHLBI NIH HHS [HL57612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blouin MJ, 2000, NAT MED, V6, P177, DOI 10.1038/72279; Buratti E, 2004, MOL CELL BIOL, V24, P10505, DOI 10.1128/MCB.24.24.10505-10514.2004; Castanotto Daniela, 2004, Methods Mol Biol, V252, P509; Danin-Kreiselman M, 2003, MOL CELL, V11, P1279, DOI 10.1016/S1097-2765(03)00137-0; De Bruyn C, 2003, CYTOTHERAPY, V5, P87, DOI 10.1080/14653240310000119; ErcikanAbali EA, 1996, CANCER RES, V56, P4142; Gallardo HF, 1997, BLOOD, V90, P952, DOI 10.1182/blood.V90.3.952.952_952_957; Graslund T, 2005, J BIOL CHEM, V280, P3707, DOI 10.1074/jbc.M406809200; Ill CR, 2005, GENE THER, V12, P795, DOI 10.1038/sj.gt.3302524; Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051; Kohn DB, 2003, NAT REV CANCER, V3, P477, DOI 10.1038/nrc1122; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Li QL, 2005, BLOOD, V105, P3346, DOI 10.1182/blood-2004-03-0987; MATSUMOTO S, 2005, J BIOL CHEM; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; NATHAN DG, 1990, ANN NY ACAD SCI, V612, P179; Nicolini FE, 2002, BLOOD, V100, P1257, DOI 10.1182/blood-2002-02-0599; Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806; Pebernard S, 2004, DIFFERENTIATION, V72, P103, DOI 10.1111/j.1432-0436.2004.07202001.x; Sadelain M, 2004, BEST PRACT RES CL HA, V17, P517, DOI 10.1016/j.beha.2004.08.002; Scherer L, 2004, ADV GENET, V52, P1, DOI 10.1016/S0065-2660(04)52001-1; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song J, 2004, CANCER RES, V64, P7661, DOI 10.1158/0008-5472.CAN-04-1751; Steinberg MH, 2001, SEMIN HEMATOL, V38, P299, DOI 10.1053/shem.2001.27570; Unwalla HJ, 2004, NAT BIOTECHNOL, V22, P1573, DOI 10.1038/nbt1040; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Xu XXS, 2000, GENE, V242, P219, DOI 10.1016/S0378-1119(99)00522-3; Zeng Y, 2005, J BIOL CHEM, V280, P27595, DOI 10.1074/jbc.M504714200	30	88	106	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2006	24	1					89	94		10.1038/nbt1176	http://dx.doi.org/10.1038/nbt1176			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	001SE	16378095				2022-12-25	WOS:000234555800029
J	Thomas, GV; Tran, C; Mellinghoff, IK; Welsbie, DS; Chan, E; Fueger, B; Czernin, J; Sawyers, CL				Thomas, GV; Tran, C; Mellinghoff, IK; Welsbie, DS; Chan, E; Fueger, B; Czernin, J; Sawyers, CL			Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; MAMMALIAN TARGET; RAPAMYCIN; EXPRESSION; GENE; TUMORS; HIF; SUPPRESSION; THERAPY	Inhibitors of the kinase mammalian target of rapamycin (mTOR) have shown sporadic activity in cancer trials, leading to confusion about the appropriate clinical setting for their use. Here we show that loss of the Von Hippel-Lindau tumor suppressor gene (VHL) sensitizes kidney cancer cells to the mTOR inhibitor CCI-779 in vitro and in mouse models. Growth arrest caused by CCI-779 correlates with a block in translation of mRNA encoding hypoxia-inducible factor (HIF1A), and is rescued by expression of a VHL-resistant HIF1A cDNA lacking the 5' untranslated region. VHL-deficient tumors show increased uptake of the positron emission tomography (PET) tracer fluorodeoxyglucose (FDG) in an mTOR-dependent manner. Our findings provide preclinical rationale for prospective, biomarker-driven clinical studies of mTOR inhibitors in kidney cancer and suggest that FDG-PET scans may have use as a pharmacodynamic marker in this setting.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Sawyers, CL (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	csawyers@mednet.ucla.edu	Tran, Chau/GRX-4633-2022; Sawyers, Charles/G-5327-2016	Thomas, George V/0000-0001-7416-8840				Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; CHEN F, 1995, CANCER RES, V55, P4804; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Gayed I, 2004, J NUCL MED, V45, P17; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hain SF, 2003, BJU INT, V92, P159, DOI 10.1046/j.1464-410X.2003.04284.x; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Joensuu H, 2002, MED KLIN, V97, P28; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Rowinsky EK, 2004, CURR OPIN ONCOL, V16, P564, DOI 10.1097/01.cco.0000143964.74936.d1; Satyamurthy N, 2002, Mol Imaging Biol, V4, P65, DOI 10.1016/S1095-0397(01)00068-1; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Zhong H, 2000, CANCER RES, V60, P1541	24	490	508	0	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					122	127		10.1038/nm1337	http://dx.doi.org/10.1038/nm1337			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16341243				2022-12-25	WOS:000234419000061
J	Kamiya, A; Kubo, K; Tomoda, T; Takaki, M; Youn, R; Ozeki, Y; Sawamura, N; Park, U; Kudo, C; Okawa, M; Ross, CA; Hatten, ME; Nakajima, K; Sawa, A				Kamiya, A; Kubo, K; Tomoda, T; Takaki, M; Youn, R; Ozeki, Y; Sawamura, N; Park, U; Kudo, C; Okawa, M; Ross, CA; Hatten, ME; Nakajima, K; Sawa, A			A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development	NATURE CELL BIOLOGY			English	Article							NEURONAL MIGRATION; CYTOPLASMIC DYNEIN; BRAIN-DEVELOPMENT; MICROTUBULE ORGANIZATION; SCHIZOAFFECTIVE DISORDER; NEURITE OUTGROWTH; LIS1; NUDEL; GENE; DISRUPTED-IN-SCHIZOPHRENIA-1	Disrupted-In-Schizophrenia-1 (DISC1), originally identified at the breakpoint of a chromosomal translocation that is linked to a rare familial schizophrenia, has been genetically implicated in schizophrenia in other populations. Schizophrenia involves subtle cytoarchitectural abnormalities that arise during neurodevelopment, but the underlying molecular mechanisms are unclear. Here, we demonstrate that DISC1 is a component of the microtubule-associated dynein motor complex and is essential for maintaining the complex at the centrosome, hence contributing to normal microtubular dynamics. Carboxy-terminal-truncated mutant DISC1 (mutDISC1), which results from a chromosomal translocation, functions in a dominant-negative manner by redistributing wildtype DISC1 through self-association and by dissociating the DISC1-dynein complex from the centrosome. Consequently, either depletion of endogenous DISC1 or expression of mutDISC1 impairs neurite outgrowth in vitro and proper development of the cerebral cortex in vivo. These results indicate that DISC1 is involved in cerebral cortex development, and suggest that loss of DISCI function may underlie neurodevelopmental dysfunction in schizophrenia.	Johns Hopkins Univ, Sch Med, Dept Psychiat & Neurobiol, Baltimore, MD 21287 USA; Shiga Univ Med Sci, Dept Psychiat, Shiga 52021, Japan; Keio Univ, Sch Med, Dept Anat, Tokyo 1608582, Japan; Rockefeller Univ, Dev Neurobiol Lab, New York, NY 10021 USA; Beckman Res Inst City Hope, Div Neurosci, Duarte, CA 91010 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Jikei Univ, Sch Med, Inst DNA Med, Dept Mol Neurobiol, Tokyo 1058471, Japan; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Grad Program Cellular Mol Med, Baltimore, MD 21205 USA	Johns Hopkins University; Shiga University of Medical Science; Keio University; Rockefeller University; City of Hope; Beckman Research Institute of City of Hope; Johns Hopkins University; Jikei University; Johns Hopkins University; Johns Hopkins University	Sawa, A (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Neurobiol, 600 N Wolfe St,CMSC 8-117, Baltimore, MD 21287 USA.	asawal@jhmi.edu	Nakajima, Kazunori/L-3396-2013; Sawamura, Naoya/K-1663-2018; Takaki, Manabu/AFK-8037-2022; Ross, Christopher A/H-8395-2013; Kubo, Ken-ichiro/B-2520-2015; kamiya, atsushi/L-8550-2016	Nakajima, Kazunori/0000-0003-1864-9425; Sawamura, Naoya/0000-0003-4753-1119; Takaki, Manabu/0000-0002-7371-2821; Kubo, Ken-ichiro/0000-0003-4023-5069; kamiya, atsushi/0000-0002-4274-5567	NCRR NIH HHS [P41 RR001192] Funding Source: Medline; NIMH NIH HHS [MH-069853] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069853] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahmad FJ, 1998, J CELL BIOL, V140, P391, DOI 10.1083/jcb.140.2.391; AKBARIAN S, 1993, ARCH GEN PSYCHIAT, V50, P169; Assadi AH, 2003, NAT GENET, V35, P270, DOI 10.1038/ng1257; Bai JL, 2003, NAT NEUROSCI, V6, P1277, DOI 10.1038/nn1153; Bielas S, 2004, ANNU REV CELL DEV BI, V20, P593, DOI 10.1146/annurev.cellbio.20.082503.103047; Blackwood DHR, 2001, AM J HUM GENET, V69, P428, DOI 10.1086/321969; Brandon NJ, 2004, MOL CELL NEUROSCI, V25, P42, DOI 10.1016/j.mcn.2003.09.009; Ekelund J, 2001, HUM MOL GENET, V10, P1611, DOI 10.1093/hmg/10.15.1611; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; Hatten ME, 2002, SCIENCE, V297, P1660, DOI 10.1126/science.1074572; Hayashi MAF, 2005, P NATL ACAD SCI USA, V102, P3828, DOI 10.1073/pnas.0500330102; Hennah W, 2003, HUM MOL GENET, V12, P3151, DOI 10.1093/hmg/ddg341; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Hodgkinson CA, 2004, AM J HUM GENET, V75, P862, DOI 10.1086/425586; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lewis DA, 2002, ANNU REV NEUROSCI, V25, P409, DOI 10.1146/annurev.neuro.25.112701.142754; Millar JK, 2000, HUM MOL GENET, V9, P1415, DOI 10.1093/hmg/9.9.1415; Millar JK, 2003, BIOCHEM BIOPH RES CO, V311, P1019, DOI 10.1016/j.bbrc.2003.10.101; Miyoshi K, 2004, BIOCHEM BIOPH RES CO, V317, P1195, DOI 10.1016/j.bbrc.2004.03.163; Miyoshi K, 2003, MOL PSYCHIATR, V8, P685, DOI 10.1038/sj.mp.4001352; Morris JA, 2003, HUM MOL GENET, V12, P1591, DOI 10.1093/hmg/ddg162; Nakajima K, 1997, P NATL ACAD SCI USA, V94, P8196, DOI 10.1073/pnas.94.15.8196; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Ozeki Y, 2003, P NATL ACAD SCI USA, V100, P289, DOI 10.1073/pnas.0136913100; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Ross ME, 2001, ANNU REV NEUROSCI, V24, P1041, DOI 10.1146/annurev.neuro.24.1.1041; Sachs NA, 2005, MOL PSYCHIATR, V10, P758, DOI 10.1038/sj.mp.4001667; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Sawa A, 2002, SCIENCE, V296, P692, DOI 10.1126/science.1070532; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Shu TZ, 2004, NEURON, V44, P263, DOI 10.1016/j.neuron.2004.09.030; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; Solecki DJ, 2004, NAT NEUROSCI, V7, P1195, DOI 10.1038/nn1332; Tabata H, 2001, NEUROSCIENCE, V103, P865, DOI 10.1016/S0306-4522(01)00016-1; Tanaka T, 2004, J CELL BIOL, V165, P709, DOI 10.1083/jcb.200309025; Tarricone C, 2004, NEURON, V44, P809, DOI 10.1016/S0896-6273(04)00751-2; Tomoda T, 2004, GENE DEV, V18, P541, DOI 10.1101/gad.1151204; Tsai LH, 2005, NEURON, V46, P383, DOI 10.1016/j.neuron.2005.04.013; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; Wynshaw-Boris A, 2001, GENE DEV, V15, P639, DOI 10.1101/gad.886801; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	46	425	443	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1167	1178		10.1038/ncb1328	http://dx.doi.org/10.1038/ncb1328			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16299498				2022-12-25	WOS:000233748900010
J	Meunier, MC; Delisle, JS; Bergeron, J; Rineau, V; Baron, C; Perreault, C				Meunier, MC; Delisle, JS; Bergeron, J; Rineau, V; Baron, C; Perreault, C			T cells targeted against a single minor histocompatibility antigen can cure solid tumors	NATURE MEDICINE			English	Article							TISSUE DISTRIBUTION; CANCER-IMMUNOTHERAPY; LYMPHOCYTES; EXPRESSION; RECOGNITION; MECHANISMS; IMMUNODOMINANCE; ELIMINATION; ACTIVATION; MOLECULES	T cells responsive to minor histocompatibility ( H) antigens are extremely effective in curing leukemia but it remains unknown whether they can eradicate solid tumors. We report that injection of CD8(+) T cells primed against the immunodominant H7(a) minor H antigen can cure established melanomas in mice. Tumor rejection was initiated by preferential extravasation at the tumor site of interferon ( IFN)-gamma-producing H7(a)-specific T cells. Intratumoral release of IFN-gamma had two crucial effects: inhibition of tumor angiogenesis and upregulation of major histocompatibility complex ( MHC) class I expression on tumor cells. Despite ubiquitous expression of H7(a), dissemination of a few H7(a)-specific T cells in extralymphoid organs caused neither graft-versus-host disease ( GVHD) nor vitiligo because host nonhematopoietic cells were protected by their low expression of MHC class I. Our preclinical model yields unique insights into how minor H antigen-based immunotherapy could be used to treat human solid tumors.	Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada; Hop Maison Neuve Rosemont, Guy Bernier Res Ctr, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal	Perreault, C (corresponding author), Univ Montreal, Inst Res Immunol & Canc, CP 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	c.perreault@videotron.ca	Perreault, Claude/A-7220-2008	Perreault, Claude/0000-0001-9453-7383; Delisle, Jean-Sebastien/0000-0003-1460-7287				Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413; Bleakley M, 2004, NAT REV CANCER, V4, P371, DOI 10.1038/nrc1365; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Byrne GJ, 2000, J NATL CANCER I, V92, P1329, DOI 10.1093/jnci/92.16.1329; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; Dienst A, 2005, JNCI-J NATL CANCER I, V97, P733, DOI 10.1093/jnci/dji130; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Eden PA, 1999, J IMMUNOL, V162, P4502; Finn OJ, 2003, NAT REV IMMUNOL, V3, P630, DOI 10.1038/nri1150; Fontaine P, 2001, NAT MED, V7, P789, DOI 10.1038/89907; Gervois N, 1996, J EXP MED, V183, P2403, DOI 10.1084/jem.183.5.2403; GRIEM P, 1991, CELL, V65, P633, DOI 10.1016/0092-8674(91)90095-G; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; Hernandez J, 2000, J IMMUNOL, V164, P596, DOI 10.4049/jimmunol.164.2.596; Issekutz AC, 2002, J IMMUNOL, V168, P1934, DOI 10.4049/jimmunol.168.4.1934; Klein CA, 2002, J EXP MED, V196, P359, DOI 10.1084/jem.20011838; Korngold R, 1997, Biol Blood Marrow Transplant, V3, P57; KUZU I, 1993, LAB INVEST, V69, P322; Li Y, 2005, NAT BIOTECHNOL, V23, P349, DOI 10.1038/nbt1070; Liu LZ, 2002, NAT MED, V8, P185, DOI 10.1038/nm0202-185; Meunier MC, 2003, BLOOD, V101, P766, DOI 10.1182/blood-2002-04-1032; Molldrem JJ, 2000, NAT MED, V6, P1018, DOI 10.1038/79526; Morgan RA, 2003, J IMMUNOL, V171, P3287, DOI 10.4049/jimmunol.171.6.3287; Nandi A, 2004, IMMUNITY, V20, P455, DOI 10.1016/S1074-7613(04)00077-9; Ogasawara K, 2004, IMMUNITY, V20, P757, DOI 10.1016/j.immuni.2004.05.008; Perreault C, 2002, J MOL MED, V80, P212, DOI 10.1007/s00109-001-0315-1; Pion S, 1997, EUR J IMMUNOL, V27, P421, DOI 10.1002/eji.1830270212; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Roy-Proulx G, 2001, EUR J IMMUNOL, V31, P2284, DOI 10.1002/1521-4141(200108)31:8<2284::AID-IMMU2284>3.0.CO;2-E; Rubio V, 2003, NAT MED, V9, P1377, DOI 10.1038/nm942; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Schuler T, 2003, J IMMUNOL, V170, P4427, DOI 10.4049/jimmunol.170.9.4427; Siegelman MH, 2000, J CLIN INVEST, V105, P683, DOI 10.1172/JCI8692; Spierings E, 2004, TRENDS IMMUNOL, V25, P56, DOI 10.1016/j.it.2003.12.002; Spiotto MT, 2004, NAT MED, V10, P294, DOI 10.1038/nm999; Thatte J, 2003, BLOOD, V101, P4916, DOI 10.1182/blood-2002-10-3159; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Yoshimura Y, 2004, J IMMUNOL, V172, P6666, DOI 10.4049/jimmunol.172.11.6666	40	61	65	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1222	1229		10.1038/nm1311	http://dx.doi.org/10.1038/nm1311			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16227989				2022-12-25	WOS:000233115400035
J	Reddy, P; Maeda, Y; Liu, C; Krijanovski, OI; Korngold, R; Ferrara, JLM				Reddy, P; Maeda, Y; Liu, C; Krijanovski, OI; Korngold, R; Ferrara, JLM			A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses	NATURE MEDICINE			English	Article							HOST DENDRITIC CELLS; MARROW-TRANSPLANTATION; DISEASE; CANCER; IMMUNOTHERAPY; IMMUNOBIOLOGY; MECHANISMS; LYMPHOMA; BLOOD	Graft-versus-leukemia ( GVL) response after allogeneic bone marrow transplantation ( BMT) represents one of the most potent forms of immunotherapy against malignant diseases(1). Antigen-presenting cells ( APCs) are crucial for the induction of graft-versus-host disease ( GVHD)(2-6), the most serious complication of allogeneic BMT, but their role in GVL responses is unclear. Using a series of clinically relevant mouse GVL tumor models, we found that APCs and alloantigen expression on tumors are crucial for GVL. Moreover, APCs of host origin predominated in GVL responses although donor APCs contributed as the acuity of tumor burden decreased.	Univ Michigan, Ctr Canc, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Hackensack Univ, Med Ctr, Ctr Canc, Hackensack, NJ USA; Univ Michigan, Ctr Canc, Dept Pediat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; State University System of Florida; University of Florida; Hackensack University Medical Center; University of Michigan System; University of Michigan	Reddy, P (corresponding author), Univ Michigan, Ctr Canc, Dept Internal Med, 1500 E Mem Ctr Dr, Ann Arbor, MI 48109 USA.	reddypr@umich.edu	Korngold, Robert/AAF-2686-2020	Reddy, Pavan/0000-0001-7264-8429	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI052863] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 49542] Funding Source: Medline; NHLBI NIH HHS [R01 HL55593] Funding Source: Medline; NIAID NIH HHS [K08 AI052863-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Appelbaum FR, 2001, NATURE, V411, P385, DOI 10.1038/35077251; Auffermann-Gretzinger S, 2002, BLOOD, V99, P1442, DOI 10.1182/blood.V99.4.1442; Bierman PJ, 2003, J CLIN ONCOL, V21, P3744, DOI 10.1200/JCO.2003.08.054; Bleakley M, 2004, NAT REV CANCER, V4, P371, DOI 10.1038/nrc1365; Duffner UA, 2004, J IMMUNOL, V172, P7393, DOI 10.4049/jimmunol.172.12.7393; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Eibl B, 1997, GENE CHROMOSOME CANC, V20, P215, DOI 10.1002/(SICI)1098-2264(199711)20:3<215::AID-GCC1>3.0.CO;2-5; Fontaine P, 2001, NAT MED, V7, P789, DOI 10.1038/89907; Gatza E, 2002, J IMMUNOL, V169, P5227, DOI 10.4049/jimmunol.169.9.5227; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huntly BJP, 2005, NATURE, V435, P1169, DOI 10.1038/4351169a; Jones SC, 2003, J CLIN INVEST, V112, P1880, DOI 10.1172/JCI200319427; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kolb HJ, 2004, BLOOD, V103, P767, DOI 10.1182/blood-2003-02-0342; Li JM, 2004, BIOL BLOOD MARROW TR, V10, P540, DOI 10.1016/j.bbmt.2004.05.007; Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041; Matte CC, 2004, NAT MED, V10, P987, DOI 10.1038/nm1089; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Merad M, 2004, NAT MED, V10, P510, DOI 10.1038/nm1038; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Patterson AE, 2000, BIOL BLOOD MARROW TR, V6, P537, DOI 10.1016/S1083-8791(00)70063-2; Patterson AE, 2001, BIOL BLOOD MARROW TR, V7, P187, DOI 10.1053/bbmt.2001.v7.pm11349805; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Reddy P, 2003, BLOOD REV, V17, P187, DOI 10.1016/S0268-960X(03)00009-2; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Stelljes M, 2004, BLOOD, V104, P1210, DOI 10.1182/blood-2003-10-3387; Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602-575; Wilson NS, 2005, ADV IMMUNOL, V86, P241, DOI 10.1016/S0065-2776(04)86007-3; Zhang Y, 2002, J CLIN INVEST, V109, P1335, DOI 10.1172/JCI200214989	30	185	190	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2005	11	11					1244	1249		10.1038/nm1309	http://dx.doi.org/10.1038/nm1309			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16227991				2022-12-25	WOS:000233115400038
J	Taniguchi, Y; Nishiyama, M; Ishii, Y; Yanagida, T				Taniguchi, Y; Nishiyama, M; Ishii, Y; Yanagida, T			Entropy rectifies the Brownian steps of kinesin	NATURE CHEMICAL BIOLOGY			English	Article							HAND-OVER-HAND; MOLECULAR MOTORS; DIMERIC KINESIN; ATP HYDROLYSIS; 8-NM STEP; FORCE; MYOSIN; TEMPERATURE; MICROSCOPY; MECHANICS	Kinesin is a stepping motor that successively produces forward and backward 8-nm steps along microtubules. Under physiological conditions, the steps powering kinesin's motility are biased in one direction and drive various biological motile processes. The physical mechanism underlying the unidirectional bias of the kinesin steps is not fully understood. Here we explored the mechanical kinetics and thermodynamics of forward and backward kinesin steps by analyzing their temperature and load dependence. Results show that the frequency asymmetry between forward and backward steps is produced by entropy. Furthermore, the magnitude of the entropic asymmetry is 6 k(B)T, more than three times greater than expected from a current model, in which a mechanical conformational change within the kinesin molecular structure directly biases the kinesin steps forward. We propose that the stepping direction of kinesin is preferably caused by an entropy asymmetry resulting from the compatibility between the kinesin and microtubule interaction based on their polar structures.	Japan Sci & Technol Agcy, Soft Nanomachine Project, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Engn Sci, Dept Mech Sci & Bioengn, Toyonaka, Osaka 5608531, Japan; Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; Osaka Univ, Grad Sch Frontier Biosci, Lab Nanobiol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Physiol & Biosignaling, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University; Kyoto University; Osaka University; Osaka University	Yanagida, T (corresponding author), Japan Sci & Technol Agcy, Soft Nanomachine Project, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	yanagida@phys1.med.osaka-u.ac.jp	Nishiyama, Masayoshi/AAI-4579-2021; Nishiyama, Masayoshi/F-8857-2012; Taniguchi, Yuichi/N-5986-2015; Yanagida, Toshio/D-1919-2009	Taniguchi, Yuichi/0000-0001-5677-8901; Nishiyama, Masayoshi/0000-0002-0525-3766				Ali MY, 2004, BIOPHYS J, V86, P3804, DOI 10.1529/biophysj.103.037416; Altman D, 2004, CELL, V116, P737, DOI 10.1016/S0092-8674(04)00211-9; Asbury CL, 2003, SCIENCE, V302, P2130, DOI 10.1126/science.1092985; ATKINS PW, 1987, PHYSIOL CHEM PHYS M, V30, P737; Block SM, 2003, P NATL ACAD SCI USA, V100, P2351, DOI 10.1073/pnas.0436709100; Bohm KJ, 2000, FEBS LETT, V466, P59, DOI 10.1016/S0014-5793(99)01757-3; Carter NJ, 2005, NATURE, V435, P308, DOI 10.1038/nature03528; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Cross RA, 2004, TRENDS BIOCHEM SCI, V29, P301, DOI 10.1016/j.tibs.2004.04.010; Endow SA, 2003, BIOESSAYS, V25, P1212, DOI 10.1002/bies.10358; Eyring H, 1935, J CHEM PHYS, V3, P107, DOI 10.1063/1.1749604; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Hirose K, 1999, MOL BIOL CELL, V10, P2063, DOI 10.1091/mbc.10.6.2063; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Howard J., 2001, MECH MOTOR PROTEINS; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Kaseda K, 2003, NAT CELL BIOL, V5, P1079, DOI 10.1038/ncb1067; Kawaguchi K, 2000, BIOCHEM BIOPH RES CO, V272, P895, DOI 10.1006/bbrc.2000.2856; Kawaguchi K, 2003, BIOPHYS J, V84, P1103, DOI 10.1016/S0006-3495(03)74926-1; Kawaguchi K, 2001, CELL MOTIL CYTOSKEL, V49, P41, DOI 10.1002/cm.1019; Kitamura Kazuo, 2005, Biophysics (Nagoya-shi), V1, P1, DOI 10.2142/biophysics.1.1; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Mandelkow E, 1999, CURR OPIN CELL BIOL, V11, P34, DOI 10.1016/S0955-0674(99)80005-2; Mazumdar M, 1998, J BIOL CHEM, V273, P29352, DOI 10.1074/jbc.273.45.29352; Nishiyama M, 2002, NAT CELL BIOL, V4, P790, DOI 10.1038/ncb857; Nishiyama M, 2003, BIOSYSTEMS, V71, P145, DOI 10.1016/S0303-2647(03)00122-9; Nishiyama M, 2001, NAT CELL BIOL, V3, P425, DOI 10.1038/35070116; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rice S, 2003, BIOPHYS J, V84, P1844, DOI 10.1016/S0006-3495(03)74992-3; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Tadakuma H, 2001, BIOCHEM BIOPH RES CO, V287, P323, DOI 10.1006/bbrc.2001.5574; Uemura S, 2003, NAT STRUCT BIOL, V10, P308, DOI 10.1038/nsb911; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; William H., 1992, NUMERICAL RECIPES C; Yang WY, 2003, NATURE, V423, P193, DOI 10.1038/nature01609; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753	44	95	95	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2005	1	6					342	347		10.1038/nchembio741	http://dx.doi.org/10.1038/nchembio741			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	979GH	16408074				2022-12-25	WOS:000232929900013
J	Kuhlenbaumer, G; Hannibal, MC; Nelis, E; Schirmacher, A; Verpoorten, N; Meuleman, J; Watts, GDJ; De Vriendt, E; Young, P; Stogbauer, F; Halfter, H; Irobi, J; Goossens, D; Del-Favero, J; Betz, BG; Hor, H; Kurlemann, G; Bird, TD; Airaksinen, E; Mononen, T; Serradell, AP; Prats, JM; Van Broeckhoven, C; De Jonghe, P; Timmerman, V; Ringelstein, EB; Chance, PF				Kuhlenbaumer, G; Hannibal, MC; Nelis, E; Schirmacher, A; Verpoorten, N; Meuleman, J; Watts, GDJ; De Vriendt, E; Young, P; Stogbauer, F; Halfter, H; Irobi, J; Goossens, D; Del-Favero, J; Betz, BG; Hor, H; Kurlemann, G; Bird, TD; Airaksinen, E; Mononen, T; Serradell, AP; Prats, JM; Van Broeckhoven, C; De Jonghe, P; Timmerman, V; Ringelstein, EB; Chance, PF			Mutations in SEPT9 cause hereditary neuralgic amyotrophy	NATURE GENETICS			English	Article							MAMMALIAN SEPTIN; CHROMOSOME 17Q25; HNA LOCUS; MICROTUBULES; REFINEMENT; GENE	Hereditary neuralgic amyotrophy (HNA) is an autosomal dominant recurrent neuropathy affecting the brachial plexus. HNA is triggered by environmental factors such as infection or parturition. We report three mutations in the gene septin 9 (SEPT9) in six families with HNA linked to chromosome 17q25. HNA is the first monogenetic disease caused by mutations in a gene of the septin family. Septins are implicated in formation of the cytoskeleton, cell division and tumorigenesis.	Univ Munster, Dept Neurol, D-48149 Munster, Germany; Univ Munster, Leibniz Inst Atherosclerosis Res, D-48149 Munster, Germany; Univ Antwerp VIB, Dept Mol Genet, B-2020 Antwerp, Belgium; Univ Washington, Dept Pediat, Div Genet & Dev Med, Seattle, WA 98195 USA; Univ Munster, Dept Pediat Neurol, D-4400 Munster, Germany; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA; Univ Kuopio, Dept Paediat, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Clin Genet, SF-70210 Kuopio, Finland; Autonome Univ Barcelona, Hosp Mar, Dept Neurol, Barcelona, Spain; Hosp Cruces, Div Child Neurol, Baracaldo, Basque Country, Spain; Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium	University of Munster; University of Munster; Flanders Institute for Biotechnology (VIB); University of Antwerp; University of Washington; University of Washington Seattle; University of Munster; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Hospital Universitario Cruces; University of Antwerp	Kuhlenbaumer, G (corresponding author), Univ Munster, Dept Neurol, Domagkstr 3, D-48149 Munster, Germany.	gkuhlen@uni-muenster.de	Chance, Phillip/AAX-5826-2020; Van Broeckhoven, Christine/G-8362-2017; Van Broeckhoven, Christine/M-7853-2019; Kuhlenbäumer, Gregor/A-5110-2009; Timmerman, Vincent/O-7283-2019	Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665; Timmerman, Vincent/0000-0002-2162-0933; Goossens, Dirk/0000-0002-2080-7464; Hannibal, Mark/0000-0002-9077-3837; Del Favero, jurgen/0000-0002-7427-7489				Hall PA, 2004, J PATHOL, V204, P489, DOI 10.1002/path.1654; Meuleman J, 2001, HUM GENET, V108, P390; Meuleman J, 1999, EUR J HUM GENET, V7, P920, DOI 10.1038/sj.ejhg.5200384; Montagna C, 2003, CANCER RES, V63, P2179; Nagata K, 2004, J BIOL CHEM, V279, P55895, DOI 10.1074/jbc.M406153200; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Nagata KI, 2005, ONCOGENE, V24, P65, DOI 10.1038/sj.onc.1208101; Pellegrino JE, 1997, HUM GENET, V101, P277, DOI 10.1007/s004390050629; Pellegrino JE, 1996, NEUROLOGY, V46, P1128, DOI 10.1212/WNL.46.4.1128; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Watts GDJ, 2002, HUM GENET, V110, P166, DOI 10.1007/s00439-001-0647-5; WINDEBANK AJ, 1993, PERIPHERAL NEUROPATH, V2, P1137	12	151	163	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1044	1046		10.1038/ng1649	http://dx.doi.org/10.1038/ng1649			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16186812				2022-12-25	WOS:000232185600014
J	Tiede, S; Storch, S; Lubke, T; Henrissat, B; Bargal, R; Raas-Rothschild, A; Braulke, T				Tiede, S; Storch, S; Lubke, T; Henrissat, B; Bargal, R; Raas-Rothschild, A; Braulke, T			Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase	NATURE MEDICINE			English	Article							LYSOSOMAL-ENZYMES; COMPLEMENTATION; BIOSYNTHESIS; CLONING	Mucolipidosis II (ML II) is a fatal lysosomal storage disorder resulting from defects in the multimeric GlcNAc-1-phosphotransferase responsible for the initial step in the generation of the mannose 6-phosphate (M6P) recognition marker(1). M6P residues on oligosaccharides of newly synthesized lysosomal enzymes are essential for efficient receptor-mediated transport to lysosomes(2). We used the recombinant GlcNAc-1-phosphotransferase c subunit as an affinity matrix to purify an unknown protein identified as the product of GNPTA (encoding GNPTA, previously known as MGC4170). The cDNA encodes a protein of 1,256 amino acids with two putative transmembrane domains and a complex preserved modular structure comprising at least six domains. The N-terminal domain of GNPTA, interrupted by a long insertion, shows similarities to bacterial capsule biosynthesis proteins. We identified seven mutations in GNPTA that lead to premature translational termination in six individuals with ML II. Retroviral transduction of fibroblasts from an individual with ML II resulted in the expression and localization of GNPTA in the Golgi apparatus, accompanied by the correction of hypersecretion of lysosomal enzymes. Our results provide evidence that GNPTA encodes a subunit of GlcNAc-1-phosphotransferase defective in individuals with ML II.	Univ Hamburg, Dept Biochem, Childrens Hosp, D-20246 Hamburg, Germany; Univ Gottingen, Dept Biochem, D-37073 Gottingen, Germany; Univ Aix Marseille 1, UMR6098, CNRS, F-13288 Marseille, France; Univ Aix Marseille 2, UMR6098, CNRS, F-13288 Marseille, France; Hadassah Univ, Hosp Med, Dept Human Genet, IL-91120 Jerusalem, Israel	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Hebrew University of Jerusalem; Hadassah University Medical Center	Braulke, T (corresponding author), Univ Hamburg, Dept Biochem, Childrens Hosp, Martinistr 52, D-20246 Hamburg, Germany.	braulke@uke.uni-hamburg.de	Braulke, Thomas/AAV-9121-2020; Lübke, Torben/B-6019-2012; Henrissat, Bernard/J-2475-2012	Braulke, Thomas/0000-0002-2336-8532; Henrissat, Bernard/0000-0002-3434-8588; Lubke, Torben/0000-0002-3342-0090; Storch, Stephan/0000-0002-8807-5917; Tiede, Stephan/0000-0002-6045-3736				Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Eckert V, 1998, GLYCOBIOLOGY, V8, P77, DOI 10.1093/glycob/8.1.77; HASILIK A, 1980, J BIOL CHEM, V255, P4937; Kornfeld S., 2001, METABOLIC MOL BASES, P3421; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Muschol N, 2002, BIOCHEM J, V368, P845, DOI 10.1042/BJ20020249; Paik KH, 2005, HUM MUTAT, V26, P308, DOI 10.1002/humu.20205; POHLMANN R, 1982, J BIOL CHEM, V257, P5323; Raas-Rothschild A, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015222; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Storch S, 2004, J BIOL CHEM, V279, P53625, DOI 10.1074/jbc.M410930200; Storch Stephan, 2005, P17; Tiede Stephan, 2004, Hum Mutat, V24, P535, DOI 10.1002/humu.9293; Tzeng YL, 2003, INFECT IMMUN, V71, P6712, DOI 10.1128/IAI.71.12.6712-6720.2003	15	144	152	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1109	1112		10.1038/nm1305	http://dx.doi.org/10.1038/nm1305			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16200072				2022-12-25	WOS:000232492500033
J	Tsuge, M; Hamamoto, R; Silva, FP; Ohnishi, Y; Chayama, K; Kamatani, N; Furukawa, Y; Nakamura, Y				Tsuge, M; Hamamoto, R; Silva, FP; Ohnishi, Y; Chayama, K; Kamatani, N; Furukawa, Y; Nakamura, Y			A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5 ' flanking region of SMYD3 is a risk factor for human cancers	NATURE GENETICS			English	Article							BREAST-CANCER; GENE PROMOTER; VNTR MARKERS; ASSOCIATION; PROLIFERATION; METHYLATION; UPSTREAM; PATTERNS; PATHWAY; FAMILY	Histone modification is a crucial step in transcriptional regulation, and deregulation of the modification process is important in human carcinogenesis. We previously reported that upregulation of SMYD3, a histone methyltransferase, promoted cell growth in human colorectal and hepatocellular carcinomas. Here we report significant associations between homozygosity with respect to an allele with three tandem repeats of a CCGCC unit in the regulatory region of SMYD3 and increased risk of colorectal cancer (P = 9.1 x 10(-6), odds ratio 2.58), hepatocellular carcinoma (P = 2.3 x 10(-8), odds ratio 3.50) and breast cancer (P = 7.0 x 10(-10), odds ratio 4.48). This tandem-repeat sequence is a binding site for the transcriptional factor E2F-1. In a reporter assay, plasmids containing three repeats of the binding motif (corresponding to the high-risk allele) had higher activity than plasmids containing two repeats (the low-risk allele). These data suggest that the common variable number of tandem repeats polymorphism in SMYD3 is a susceptibility factor for some types of human cancer.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Med & Mol Sci,Div Frontier Med Sci, Programs Biomed Res,Minami Ku, Hiroshima 7348551, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab SNP Anal,Minato Ku, Tokyo 1088639, Japan; Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, Tokyo 1620054, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Hiroshima University; RIKEN; Tokyo Women's Medical University; University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Silva, Fabio Pittella/B-2621-2013; Hamamoto, Ryuji/AAF-9600-2019; Tsuge, Masataka/G-5246-2019	Silva, Fabio Pittella/0000-0002-9644-7098; Hamamoto, Ryuji/0000-0002-2632-1334; Tsuge, Masataka/0000-0001-7591-8287; Chayama, Kazuaki/0000-0002-5530-5341				Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Bernstein NA, 1999, MOTOR CONTROL, V3, P4; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Cai QY, 2003, CANCER RES, V63, P5727; de la Moureyre CSV, 1999, PHARMACOGENETICS, V9, P189; De Vivo I, 2003, CANCER RES, V63, P5236; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Krippl P, 2004, CLIN CANCER RES, V10, P3518, DOI 10.1158/1078-0432.CCR-04-0010; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Nakamura Y, 1998, J HUM GENET, V43, P149, DOI 10.1007/s100380050059; NAKAMURA Y, 1988, AM J HUM GENET, V43, P854; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; Okabe H, 2003, CANCER RES, V63, P3043; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Tang CJC, 2001, J BIOL CHEM, V276, P19631, DOI 10.1074/jbc.M100170200; Zehbe I, 1999, LANCET, V354, P218, DOI 10.1016/S0140-6736(99)01914-5	22	96	112	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1104	1107		10.1038/ng1638	http://dx.doi.org/10.1038/ng1638			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16155568				2022-12-25	WOS:000232185600022
J	Degterev, A; Huang, ZH; Boyce, M; Li, YQ; Jagtap, P; Mizushima, N; Cuny, GD; Mitchison, TJ; Moskowitz, MA; Yuan, JY				Degterev, A; Huang, ZH; Boyce, M; Li, YQ; Jagtap, P; Mizushima, N; Cuny, GD; Mitchison, TJ; Moskowitz, MA; Yuan, JY			Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury	NATURE CHEMICAL BIOLOGY			English	Article							RECEPTOR-INTERACTING PROTEIN; NECROSIS-FACTOR-ALPHA; POLY(ADP-RIBOSE) POLYMERASE; FAS RECEPTOR; IN-VITRO; APOPTOSIS; AUTOPHAGY; PATHWAY; STROKE; MECHANISMS	The mechanism of apoptosis has been extensively characterized over the past decade, but little is known about alternative forms of regulated cell death. Although stimulation of the Fas/TNFR receptor family triggers a canonical 'extrinsic' apoptosis pathway, we demonstrated that in the absence of intracellular apoptotic signaling it is capable of activating a common nonapoptotic death pathway, which we term necroptosis. We showed that necroptosis is characterized by necrotic cell death morphology and activation of autophagy. We identified a specific and potent small- molecule inhibitor of necroptosis, necrostatin-1, which blocks a critical step in necroptosis. We demonstrated that necroptosis contributes to delayed mouse ischemic brain injury in vivo through a mechanism distinct from that of apoptosis and offers a new therapeutic target for stroke with an extended window for neuroprotection. Our study identifies a previously undescribed basic cell-death pathway with potentially broad relevance to human pathologies.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab, Boston, MA 02129 USA; Harvard Univ, Ctr Neurodegenerat & Repair, Lab Drug Discovery Neurodegenerat, Brigham & Womens Hosp, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Syst Biol, Cambridge, MA 02139 USA; Tokyo Metropolitan Inst Med Sci, Dept Bioregulat & Metab, Tokyo 1138613, Japan	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Tokyo Metropolitan Institute of Medical Science	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	jyuan@hms.harvard.edu	Mizushima, Noboru/C-3635-2009	Mizushima, Noboru/0000-0002-6258-6444; Cuny, Gregory/0000-0002-3188-4748; Boyce, Michael/0000-0002-2729-4876	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012859] Funding Source: NIH RePORTER; NIA NIH HHS [R37 AG012859] Funding Source: Medline; NIGMS NIH HHS [R01 GM64703] Funding Source: Medline; NINDS NIH HHS [R01 NS37141-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Eguchi Y, 1997, CANCER RES, V57, P1835; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Green AR, 2003, TRENDS PHARMACOL SCI, V24, P402, DOI 10.1016/S0165-6147(03)00192-5; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kain SR, 1999, METHOD ENZYMOL, V302, P38, DOI 10.1016/S0076-6879(99)02007-8; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Li M, 2000, J VIROL, V74, P7470, DOI 10.1128/JVI.74.16.7470-7477.2000; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; MATSUYAMA T, 1994, BRAIN RES, V657, P342, DOI 10.1016/0006-8993(94)90989-X; McCully JD, 2004, AM J PHYSIOL-HEART C, V286, pH1923, DOI 10.1152/ajpheart.00935.2003; Nieminen AL, 2003, INT REV CYTOL, V224, P29, DOI 10.1016/S0074-7696(05)24002-0; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Ruemmele FM, 1999, BIOCHEM BIOPH RES CO, V260, P159, DOI 10.1006/bbrc.1999.0734; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Takahashi K, 1999, NEUROREPORT, V10, P2017, DOI 10.1097/00001756-199907130-00005; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9	37	1865	2051	12	287	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2005	1	2					112	119		10.1038/nchembio711	http://dx.doi.org/10.1038/nchembio711			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GE	16408008				2022-12-25	WOS:000232648200016
J	Machado, FS; Johndrow, JE; Esper, L; Dias, A; Bafica, A; Serhan, CN; Aliberti, J				Machado, FS; Johndrow, JE; Esper, L; Dias, A; Bafica, A; Serhan, CN; Aliberti, J			Anti-inflammatory actions of lipoxin A(4) and aspirin-triggered lipoxin are SOCS-2 dependent	NATURE MEDICINE			English	Article							IL-12 PRODUCTION; NEUTROPHIL RECRUITMENT; INFLAMMATION; RECEPTOR; IMMUNOPATHOLOGY; TRAFFICKING; RESOLUTION; MEDIATORS; INFECTION; ANALOG	Control of inflammation is crucial to prevent damage to the host during infection. Lipoxins and aspirin-triggered lipoxins are crucial modulators of proinflammatory responses; however, their intracellular mechanisms have not been completely elucidated. We previously showed that lipoxin A(4) (LXA(4)) controls migration of dendritic cells (DCs) and production of interleukin (IL)-12 in vivo(1). In the absence of LXA(4) biosynthetic pathways, the resulting uncontrolled inflammation during infection is lethal, despite pathogen clearance(2). Here we show that lipoxins activate two receptors in DCs, AhR and LXAR, and that this activation triggers expression of suppressor of cytokine signaling (SOCS)-2. SOCS-2-deficient DCs are hyper-responsive to microbial stimuli, as well as refractory to the inhibitory actions of LXA(4), but not to IL-10. Upon infection with an intracellular pathogen, SOCS-2-deficient mice had uncontrolled production of proinflammatory cytokines, decreased microbial proliferation, aberrant leukocyte infiltration and elevated mortality. We also show that SOCS-2 is a crucial intracellular mediator of the anti-inflammatory actions of aspirin-induced lipoxins in vivo.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27705 USA; NIAID, Lab Parasit Dis, NIH, Bethesda, MD 20892 USA; Fred Hutchinson Canc Res Inst, Seattle, WA 98109 USA; Fd Osvaldo Cruz, Lab Imunorregulacao, BR-40295 Salvador, BA, Brazil; Harvard Univ, Brigham & Womens Hosp, Ctr Expt Therapeut, Boston, MA 02115 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Fred Hutchinson Cancer Center; Harvard University; Brigham & Women's Hospital	Aliberti, J (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27705 USA.	fabiana.machado@duke.edu; julio.aliberti@duke.edu	Aliberti, Julio/I-7354-2013; Aliberti, Julio/G-4565-2012; Bafica, Andre/ABF-5986-2020	Aliberti, Julio/0000-0003-3420-8478; Bafica, Andre/0000-0002-5148-600X; Simao Machado, Fabiana/0000-0001-9272-5209	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R01GM038765, R29GM038765] Funding Source: NIH RePORTER; NIDCR NIH HHS [P50-DE0161912] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745; Aliberti J, 2002, J EXP MED, V196, P1253, DOI 10.1084/jem.20021183; Bafica A, 2005, J CLIN INVEST, V115, P1601, DOI 10.1172/JCI23949; Bandeira-Melo C, 2000, J IMMUNOL, V164, P2267, DOI 10.4049/jimmunol.164.5.2267; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; Davey HW, 1999, MOL CELL ENDOCRINOL, V158, P111, DOI 10.1016/S0303-7207(99)00175-6; Devchand PR, 2003, FASEB J, V17, P652, DOI 10.1096/fj.02-0770com; Goh J, 2003, GASTROENTEROLOGY, V124, P1043, DOI 10.1053/gast.2003.50154; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Karp CL, 2004, NAT IMMUNOL, V5, P388, DOI 10.1038/ni1056; Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Leonard MO, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015795.74094.91; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; Ohira T, 2004, J IMMUNOL, V173, P2091, DOI 10.4049/jimmunol.173.3.2091; Qiu FH, 2001, FASEB J, V15, P2736, DOI 10.1096/fj.01-0576fje; RAMSTEDT U, 1985, J IMMUNOL, V135, P3434; SAMUELSSON B, 1991, Z RHEUMATOL, V50, P3; Schaldach CM, 1999, BIOCHEMISTRY-US, V38, P7594, DOI 10.1021/bi982861e; Sousa CRE, 1999, IMMUNITY, V11, P637, DOI 10.1016/S1074-7613(00)80138-7; Van Dyke TE, 2003, J DENT RES, V82, P82, DOI 10.1177/154405910308200202	23	245	255	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					330	334		10.1038/nm1355	http://dx.doi.org/10.1038/nm1355			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16415877				2022-12-25	WOS:000235802900033
J	Teague, RM; Sather, BD; Sacks, JA; Huang, MZ; Dossett, ML; Morimoto, J; Tan, XX; Sutton, SE; Cooke, MP; Ohlen, C; Greenberg, PD				Teague, RM; Sather, BD; Sacks, JA; Huang, MZ; Dossett, ML; Morimoto, J; Tan, XX; Sutton, SE; Cooke, MP; Ohlen, C; Greenberg, PD			Interleukin-15 rescues tolerant CD8(+) T cells for use in adoptive immunotherapy of established tumors	NATURE MEDICINE			English	Article							HEPATITIS-B-VIRUS; IMMUNOLOGICAL SYNAPSE; CANCER-IMMUNOTHERAPY; BETA-CHAIN; IN-VIVO; MEMORY; ANTIGEN; EFFECTOR; EXPRESSION; IL-15	CD8(+) T cells can mediate eradication of established tumors, and strategies to amplify tumor-reactive T-cell numbers by immunization or ex vivo expansion followed by adoptive transfer are currently being explored in individuals with cancer(1-3). Generating effective CD8(+) T cell-mediated responses to tumors is often impeded by T-cell tolerance to relevant tumor antigens, as most of these antigens are also expressed in normal tissues. We examined whether such tolerant T cells could be rescued and functionally restored for use in therapy of established tumors. We used a transgenic T-cell receptor (TCR) mouse model in which peripheral CD8(+) T cells specific for a candidate tumor antigen also expressed in liver are tolerant, failing to proliferate or secrete interleukin (IL)-2 in response to antigen(4). Molecular and cellular analysis showed that these tolerant T cells expressed the IL-15 receptor alpha chain, and could be induced to proliferate in vitro in response to exogenous IL-15. Such proliferation abrogated tolerance and the rescued cells became effective in treating leukemia. Therefore, high-affinity CD8(+) T cells are not necessarily deleted by encounter with self-antigen in the periphery, and can potentially be rescued and expanded for use in tumor immunotherapy.	Univ Washington, Sch Med, Dept Immunol, HSC Off H 564, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Program Immunol, Seattle, WA 98109 USA; Genom Inst Novartis Res Fdn, San Diego, CA 92121 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Novartis	Greenberg, PD (corresponding author), Univ Washington, Sch Med, Dept Immunol, HSC Off H 564, Box 357650, Seattle, WA 98195 USA.	pgreen@washington.edu	Dossett, Michelle/U-1166-2019	Teague, Ryan/0000-0002-8426-2870; Huang, Maria/0000-0001-6881-4754	NATIONAL CANCER INSTITUTE [R01CA033084, R37CA033084, P01CA018029] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029, CA33084] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Bulanova E, 2001, J IMMUNOL, V167, P6292, DOI 10.4049/jimmunol.167.11.6292; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; DESILVA DR, 1991, J IMMUNOL, V147, P3261; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; Dumortier H, 2005, J IMMUNOL, V175, P855, DOI 10.4049/jimmunol.175.2.855; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Grayson JM, 2000, J IMMUNOL, V164, P3950, DOI 10.4049/jimmunol.164.8.3950; GREENBERG PD, 1984, J IMMUNOL, V133, P3401; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Kershaw MH, 2005, NAT REV IMMUNOL, V5, P928, DOI 10.1038/nri1729; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Limmer A, 1998, EUR J IMMUNOL, V28, P2395, DOI 10.1002/(SICI)1521-4141(199808)28:08<2395::AID-IMMU2395>3.0.CO;2-D; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; Oh S, 2004, P NATL ACAD SCI USA, V101, P15154, DOI 10.1073/pnas.0406649101; Ohlen C, 2002, J EXP MED, V195, P1407, DOI 10.1084/jem.20011063; Ohlen C, 2001, J IMMUNOL, V166, P2863, DOI 10.4049/jimmunol.166.4.2863; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Redmond WL, 2005, IMMUNITY, V22, P275, DOI 10.1016/j.immuni.2005.01.010; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Rosenberg SA, 2004, P NATL ACAD SCI USA, V101, P14639, DOI 10.1073/pnas.0405730101; Scherer A, 2003, BIOTECHNIQUES, V34, P546, DOI 10.2144/03343rr01; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Vamosi G, 2004, P NATL ACAD SCI USA, V101, P11082, DOI 10.1073/pnas.0403916101; Waldmann TA, 2002, J CLIN IMMUNOL, V22, P51, DOI 10.1023/A:1014416616687; WIRTH S, 1995, J IMMUNOL, V154, P2504; Wolint P, 2004, J EXP MED, V199, P925, DOI 10.1084/jem.20031799; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6; Zippelius A, 2004, CANCER RES, V64, P2865, DOI 10.1158/0008-5472.CAN-03-3066	35	189	208	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					335	341		10.1038/nm1359	http://dx.doi.org/10.1038/nm1359			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16474399				2022-12-25	WOS:000235802900034
J	Zhang, K; Zhu, J; Shendure, J; Porreca, GJ; Aach, JD; Mitra, RD; Church, GM				Zhang, K; Zhu, J; Shendure, J; Porreca, GJ; Aach, JD; Mitra, RD; Church, GM			Long-range polony haplotyping of individual human chromosome molecules	NATURE GENETICS			English	Article							POLYMERASE COLONIES; RECOMBINATION RATES; GENE; DNA; RECONSTRUCTION; CROSSOVERS; ACCURACY; BLOCKS; PCR	We report a method for multilocus long-range haplotyping on human chromosome molecules in vitro based on the DNA polymerase colony (polony) technology. By immobilizing thousands of intact chromosome molecules within a polyacrylamide gel on a microscope slide and performing multiple amplifications from single molecules, we determined long-range haplotypes spanning a 153-Mb region of human chromosome 7 and found evidence of rare mitotic recombination events in human lymphocytes. Furthermore, the parallel nature of DNA polony technology allows efficient haplotyping on pooled DNAs from a population on one slide, with a throughput three orders of magnitudes higher than current molecular haplotyping methods. Linkage disequilibrium statistics established by our pooled DNA haplotyping method are more accurate than statistically inferred haplotypes. This haplotyping method is well suited for candidate gene-based association studies as well as for investigating the pattern of recombination in mammalian cells.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Duke Univ, Inst Genome Sci & Policy, Durham, NC 27708 USA; Washington Univ, Dept Genet, St Louis, MO 63108 USA	Harvard University; Harvard Medical School; Duke University; Washington University (WUSTL)	Zhang, K (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	kzhang@genetics.med.harvard.edu	Zhang, Kun/ABE-6349-2020; Shendure, Jay/AAU-3684-2021	Zhang, Kun/0000-0002-7596-5224; church, george/0000-0001-6232-9969; Shendure, Jay/0000-0002-1516-1865; Mitra, Robi/0000-0002-2680-4264				Bersaglieri T, 2004, AM J HUM GENET, V74, P1111, DOI 10.1086/421051; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Cram L. Scott, 2002, Methods in Cell Science, V24, P27, DOI 10.1023/A:1024108923475; Ding CM, 2003, P NATL ACAD SCI USA, V100, P7449, DOI 10.1073/pnas.1232475100; Douglas JA, 2001, NAT GENET, V28, P361, DOI 10.1038/ng582; Forton J, 2005, AM J HUM GENET, V76, P438, DOI 10.1086/428439; Hendricks CA, 2003, P NATL ACAD SCI USA, V100, P6325, DOI 10.1073/pnas.1232231100; Jeffreys AJ, 2005, NAT GENET, V37, P601, DOI 10.1038/ng1565; Kauppi L, 2004, NAT REV GENET, V5, P413, DOI 10.1038/nrg1346; Kehrer-Sawatzki H, 2004, AM J HUM GENET, V75, P410, DOI 10.1086/423624; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MichalatosBeloin S, 1996, NUCLEIC ACIDS RES, V24, P4841, DOI 10.1093/nar/24.23.4841; Mitra RD, 2003, P NATL ACAD SCI USA, V100, P5926, DOI 10.1073/pnas.0936399100; Mitra RD, 2003, ANAL BIOCHEM, V320, P55, DOI 10.1016/S0003-2697(03)00291-4; Mitra RD, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e34; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Patterson N, 2004, AM J HUM GENET, V74, P979, DOI 10.1086/420871; Prado FL, 2003, CURR GENET, V42, P185, DOI 10.1007/s00294-002-0346-3; SantaLucia J, 2004, ANNU REV BIOPH BIOM, V33, P415, DOI 10.1146/annurev.biophys.32.110601.141800; Smith MW, 2004, AM J HUM GENET, V74, P1001, DOI 10.1086/420856; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Tishkoff SA, 2000, AM J HUM GENET, V67, P518, DOI 10.1086/303000; von Ahsen N, 2001, CLIN CHEM, V47, P1956; Wang N, 2002, AM J HUM GENET, V71, P1227, DOI 10.1086/344398; Winckler W, 2005, SCIENCE, V308, P107, DOI 10.1126/science.1105322; Woolley AT, 2000, NAT BIOTECHNOL, V18, P760, DOI 10.1038/77760; Zhu J, 2003, SCIENCE, V301, P836, DOI 10.1126/science.1085792	27	59	74	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2006	38	3					382	387		10.1038/ng1741	http://dx.doi.org/10.1038/ng1741			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16493423				2022-12-25	WOS:000235589600023
J	Folgori, A; Capone, S; Ruggeri, L; Meola, A; Sporeno, E; Ercole, BB; Pezzanera, M; Tafi, R; Arcuri, M; Fattori, E; Lahm, A; Luzzago, A; Vitelli, A; Colloca, S; Cortese, R; Nicosia, A				Folgori, A; Capone, S; Ruggeri, L; Meola, A; Sporeno, E; Ercole, BB; Pezzanera, M; Tafi, R; Arcuri, M; Fattori, E; Lahm, A; Luzzago, A; Vitelli, A; Colloca, S; Cortese, R; Nicosia, A			A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees	NATURE MEDICINE			English	Article							HEPATITIS-C VIRUS; VIRAL CLEARANCE; INFECTION; RESPONSES; PERSISTENCE; ADENOVIRUS; GENE; DETERMINANTS; IMMUNIZATION; PREVALENCE	Three percent of the world's population is chronically infected with the hepatitis C virus (HCV) and at risk of developing liver cancer. Effective cellular immune responses are deemed essential for spontaneous resolution of acute hepatitis C and long-term protection. Here we describe a new T-cell HCV genetic vaccine capable of protecting chimpanzees from acute hepatitis induced by challenge with heterologous virus. Suppression of acute viremia in vaccinated chimpanzees occurred as a result of massive expansion of peripheral and intrahepatic HCV-specific CD8(+) T lymphocytes that cross-reacted with vaccine and virus epitopes. These findings show that it is possible to elicit effective immunity against heterologous HCV strains by stimulating only the cellular arm of the immune system, and suggest a path for new immunotherapy against highly variable human pathogens like HCV, HIV or malaria, which can evade humoral responses.	Ist Ric Biol Mol P Angeletti, I-00040 Rome, Italy	Merck & Company	Nicosia, A (corresponding author), Ist Ric Biol Mol P Angeletti, Via Pontina Km 30,600, I-00040 Rome, Italy.	alfredo_nicasia@merck.com	Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Capone, Stefania/0000-0002-2272-120X				Alter MJ, 1999, J HEPATOL, V31, P88, DOI 10.1016/S0168-8278(99)80381-X; Aste-Amezaga M, 2004, HUM GENE THER, V15, P293, DOI 10.1089/104303404322886147; Bassett SE, 2001, HEPATOLOGY, V33, P1479, DOI 10.1053/jhep.2001.24371; Bassett SE, 1998, J VIROL, V72, P2589, DOI 10.1128/JVI.72.4.2589-2599.1998; Bowen DG, 2005, NATURE, V436, P946, DOI 10.1038/nature04079; CAPONE S, IN PRESS J VIROL; Casimiro DR, 2004, J VIROL, V78, P11434, DOI 10.1128/JVI.78.20.11434-11438.2004; Caulfield MJ, 2002, J VIROL, V76, P10038, DOI 10.1128/JVI.76.19.10038-10043.2002; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; Cox AL, 2005, HEPATOLOGY, V42, P104, DOI 10.1002/hep.20749; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Farci P, 1996, P NATL ACAD SCI USA, V93, P15394, DOI 10.1073/pnas.93.26.15394; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; Forns X, 2000, HEPATOLOGY, V32, P618, DOI 10.1053/jhep.2000.9877; Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7; Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774; Guglietta S, 2005, EUR J IMMUNOL, V35, P2627, DOI 10.1002/eji.200526067; Houghton M, 2005, NATURE, V436, P961, DOI 10.1038/nature04081; Kuiken C, 2005, BIOINFORMATICS, V21, P379, DOI 10.1093/bioinformatics/bth485; LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6; Lanford RE, 2004, J VIROL, V78, P1575, DOI 10.1128/JVI.78.3.1575-1581.2004; Lechner F, 2000, EUR J IMMUNOL, V30, P2479, DOI 10.1002/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Major ME, 2004, HEPATOLOGY, V39, P1709, DOI 10.1002/hep.20239; Mehta SH, 2002, LANCET, V359, P1478, DOI 10.1016/S0140-6736(02)08435-0; Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842; Palitzsch KD, 1999, EUR J GASTROEN HEPAT, V11, P1215, DOI 10.1097/00042737-199911000-00005; Post JJ, 2004, J INFECT DIS, V189, P1846, DOI 10.1086/383279; Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4; Puig M, 2004, VACCINE, V22, P991, DOI 10.1016/j.vaccine.2003.09.010; Riestra S, 2001, EUR J GASTROEN HEPAT, V13, P477, DOI 10.1097/00042737-200105000-00003; Rollier C, 2004, J VIROL, V78, P187, DOI 10.1128/JVI.78.1.187-196.2004; Seeff LB, 2002, HEPATOLOGY, V36, pS35, DOI 10.1053/jhep.2002.36806; Shiver JW, 2004, ANNU REV MED, V55, P355, DOI 10.1146/annurev.med.55.091902.104344; Shoukry NH, 2003, J EXP MED, V197, P1645, DOI 10.1084/jem.20030239; Spada E, 2004, GUT, V53, P1673, DOI 10.1136/gut.2003.037788; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013; Thimme R, 2002, P NATL ACAD SCI USA, V99, P15661, DOI 10.1073/pnas.202608299; Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395; Wedemeyer H, 2002, J IMMUNOL, V169, P3447, DOI 10.4049/jimmunol.169.6.3447; Zampaglione I, 2005, J GENE MED, V7, P1475, DOI 10.1002/jgm.774; Zucchelli S, 2000, J VIROL, V74, P11598, DOI 10.1128/JVI.74.24.11598-11607.2000	45	243	269	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					190	197		10.1038/nm1353	http://dx.doi.org/10.1038/nm1353			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16462801				2022-12-25	WOS:000235160600023
J	Yu, JM; Pressoir, G; Briggs, WH; Bi, IV; Yamasaki, M; Doebley, JF; McMullen, MD; Gaut, BS; Nielsen, DM; Holland, JB; Kresovich, S; Buckler, ES				Yu, JM; Pressoir, G; Briggs, WH; Bi, IV; Yamasaki, M; Doebley, JF; McMullen, MD; Gaut, BS; Nielsen, DM; Holland, JB; Kresovich, S; Buckler, ES			A unified mixed-model method for association mapping that accounts for multiple levels of relatedness	NATURE GENETICS			English	Article							QUANTITATIVE TRAITS; POPULATION-STRUCTURE; COMPLEX TRAITS; LINKAGE DISEQUILIBRIUM; GENOME; DISSECTION; PEDIGREES; DISEASES; LOCI; MAPS	As population structure can result in spurious associations, it has constrained the use of association studies in human and plant genetics. Association mapping, however, holds great promise if true signals of functional association can be separated from the vast number of false signals generated by population structure(1,2). We have developed a unified mixed-model approach to account for multiple levels of relatedness simultaneously as detected by random genetic markers. We applied this new approach to two samples: a family-based sample of 14 human families, for quantitative gene expression dissection, and a sample of 277 diverse maize inbred lines with complex familial relationships and population structure, for quantitative trait dissection. Our method demonstrates improved control of both type I and type II error rates over other methods. As this new method crosses the boundary between family-based and structured association samples, it provides a powerful complement to currently available methods for association mapping.	Cornell Univ, Inst Genom Divers, Ithaca, NY 14853 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Missouri, Div Plant Sci, Columbia, MO 65211 USA; Univ Calif Irvine, Agr Res Serv, USDA, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA; N Carolina State Univ, Dept Crop Sci, Raleigh, NC 27695 USA; Cornell Univ, Dept Genet & Plant Breeding, Ithaca, NY 14853 USA	Cornell University; University of Wisconsin System; University of Wisconsin Madison; University of Missouri System; University of Missouri Columbia; United States Department of Agriculture (USDA); University of California System; University of California Irvine; University of California System; University of California Irvine; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; Cornell University	Buckler, ES (corresponding author), Cornell Univ, Inst Genom Divers, Ithaca, NY 14853 USA.	esb33@cornell.edu	Buckler, Edward/L-7651-2019; Yu, Jianming/Q-6722-2019; Buckler, Edward/GPS-4932-2022; Yamasaki, Masanori/C-5193-2018	Buckler, Edward/0000-0002-3100-371X; Yu, Jianming/0000-0001-5326-3099; Yamasaki, Masanori/0000-0001-7759-3965; Holland, James/0000-0002-4341-9675; Nielsen, Dahlia/0000-0003-0123-6085				Abecasis GR, 2000, AM J HUM GENET, V66, P279, DOI 10.1086/302698; Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Allison DB, 1997, AM J HUM GENET, V60, P676; Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; Cardon LR, 2000, HUM HERED, V50, P350, DOI 10.1159/000022940; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Flint-Garcia SA, 2005, PLANT J, V44, P1054, DOI 10.1111/j.1365-313X.2005.02591.x; Fulker DW, 1999, AM J HUM GENET, V64, P259, DOI 10.1086/302193; Gardiner J, 2004, PLANT PHYSIOL, V134, P1317, DOI 10.1104/pp.103.034538; George AW, 2000, GENETICS, V156, P2081; Hardy OJ, 2002, MOL ECOL NOTES, V2, P618, DOI 10.1046/j.1471-8286.2002.00305.x; Hartl DL, 1997, PRINCIPLES OF POPULA; Henderson C. R, 1984, APPL LINEAR MODELS A; Hey J, 2003, NAT REV GENET, V4, P535, DOI 10.1038/nrg1112; Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521; Jurinke Christian, 2002, Adv Biochem Eng Biotechnol, V77, P57; KENNEDY BW, 1992, J ANIM SCI, V70, P2000, DOI 10.2527/1992.7072000x; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LOISELLE BA, 1995, AM J BOT, V82, P1420, DOI 10.2307/2445869; Long AD, 1999, GENOME RES, V9, P720; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Pritchard JK, 2001, THEOR POPUL BIOL, V60, P227, DOI 10.1006/tpbi.2001.1543; Pritchard JK, 2000, GENETICS, V155, P945; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Ritland K, 1996, GENET RES, V67, P175, DOI 10.1017/S0016672300033620; SAS Institute, 1999, SAS STAT US GUID VER; Thornsberry JM, 2001, NAT GENET, V28, P286, DOI 10.1038/90135; Wright SI, 2005, SCIENCE, V308, P1310, DOI 10.1126/science.1107891; Zhang WH, 2004, P NATL ACAD SCI USA, V101, P18075, DOI 10.1073/pnas.0408251102	30	2565	2666	18	383	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					203	208		10.1038/ng1702	http://dx.doi.org/10.1038/ng1702			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16380716				2022-12-25	WOS:000234953200015
J	Andreotti, AH				Andreotti, AH			Opening the pore hinges on proline	NATURE CHEMICAL BIOLOGY			English	News Item							ISOMERIZATION; PROTEIN	Neurotransmitter binding to a member of the Cys-loop receptor superfamily elicits opening of an ion channel by inducing a change in the configuration of a prolyl imide bond. Engineering a series of mutant receptors to contain proline analogues with a range of cis/trans preferences demonstrates the molecular basis for channel gating.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Andreotti, AH (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, 4208 Mol Biol Bldg, Ames, IA 50011 USA.	amyand@iastate.edu						BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; CHENG HN, 1977, BIOPOLYMERS, V16, P1465, DOI 10.1002/bip.1977.360160707; Eckert B, 2005, NAT STRUCT MOL BIOL, V12, P619, DOI 10.1038/nsmb946; GOLMOHAMMADI R, 1993, J MOL BIOL, V234, P620, DOI 10.1006/jmbi.1993.1616; GRATHWOHL C, 1976, BIOPOLYMERS, V15, P2043, DOI 10.1002/bip.1976.360151013; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; Lummis SCR, 2005, NATURE, V438, P248, DOI 10.1038/nature04130; Mallis RJ, 2002, NAT STRUCT BIOL, V9, P900, DOI 10.1038/nsb864; Santiveri CM, 2004, J BIOL CHEM, V279, P34963, DOI 10.1074/jbc.M405016200; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764	10	17	17	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2006	2	1					13	14		10.1038/nchembio0106-13	http://dx.doi.org/10.1038/nchembio0106-13			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993RC	16408084				2022-12-25	WOS:000233971600007
J	Fischer, E; Legue, E; Doyen, A; Nato, F; Nicolas, JF; Torres, V; Yaniv, M; Pontoglio, M				Fischer, E; Legue, E; Doyen, A; Nato, F; Nicolas, JF; Torres, V; Yaniv, M; Pontoglio, M			Defective planar cell polarity in polycystic kidney disease	NATURE GENETICS			English	Article							CILIA; MODEL	Morphogenesis involves coordinated proliferation, differentiation and spatial distribution of cells. We show that lengthening of renal tubules is associated with mitotic orientation of cells along the tubule axis, demonstrating intrinsic planar cell polarization, and we demonstrate that mitotic orientations are significantly distorted in rodent polycystic kidney models. These results suggest that oriented cell division dictates the maintenance of constant tubule diameter during tubular lengthening and that defects in this process trigger renal tubular enlargement and cyst formation.	CNRS, Gene Express & Dis Unit, FRE 2850, F-75700 Paris, France; CNRS, URA 2578, Dev Mol Biol Unit, Dept Dev Biol, F-75700 Paris, France; Inst Pasteur, Struct Biol & Chem Dept, Recombinant Prot & Antibody Unit, F-75724 Paris, France; Mayo Clin, Coll Med, Div Nephrol, Rochester, MN 55905 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Mayo Clinic	Fischer, E (corresponding author), CNRS, Gene Express & Dis Unit, FRE 2850, F-75700 Paris, France.		fischer, evelyne/GLT-9457-2022; Nicolas, Jean-François/AAW-9289-2020	fischer, evelyne/0000-0001-5054-1444				Ahringer J, 2003, CURR OPIN CELL BIOL, V15, P73, DOI 10.1016/S0955-0674(02)00018-2; Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7; GATTONE VH, 1988, LAB INVEST, V59, P231; Germino GG, 2005, NAT GENET, V37, P455, DOI 10.1038/ng0505-455; Gong Y, 2004, NATURE, V430, P689, DOI 10.1038/nature02796; Gresh L, 2004, EMBO J, V23, P1657, DOI 10.1038/sj.emboj.7600160; Jung AC, 2005, J AM SOC NEPHROL, V16, P322, DOI 10.1681/ASN.2004090729; Lager DJ, 2001, KIDNEY INT, V59, P126, DOI 10.1046/j.1523-1755.2001.00473.x; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Pazour GJ, 2004, J AM SOC NEPHROL, V15, P2528, DOI 10.1097/01.ASN.0000141055.57643.E0; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064; Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161	15	399	408	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2006	38	1					21	23		10.1038/ng1701	http://dx.doi.org/10.1038/ng1701			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16341222				2022-12-25	WOS:000234227200012
J	Murr, R; Loizou, JI; Yang, YG; Cuenin, C; Li, H; Wang, ZQ; Herceg, Z				Murr, R; Loizou, JI; Yang, YG; Cuenin, C; Li, H; Wang, ZQ; Herceg, Z			Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks	NATURE CELL BIOLOGY			English	Article							HAT COFACTOR TRRAP; BINDING PROTEIN; C-MYC; HOMOLOGOUS RECOMBINATION; NUCLEOSOME ACETYLATION; CELLULAR-RESPONSE; DAMAGE RESPONSE; COMPLEX; 53BP1; ROLES	DNA is packaged into chromatin, a highly compacted DNA protein complex; therefore, all cellular processes that use the DNA as a template, including DNA repair, require a high degree of coordination between the DNA- repair machinery and chromatin modification/ remodelling, which regulates the accessibility of DNA in chromatin. Recent studies have implicated histone acetyltransferase ( HAT) complexes and chromatin acetylation in DNA repair; however, the precise underlying mechanism remains poorly understood(1,2). Here, we show that the HAT cofactor Trrap and Tip60 HAT bind to the chromatin surrounding sites of DNA double- strand breaks ( DSBs) in vivo. Trrap depletion impairs both DNA- damage-induced histone H4 hyperacetylation and accumulation of repair molecules at sites of DSBs, resulting in defective homologous recombination ( HR) repair, albeit with the presence of a functional ATM- dependent DNA- damage signalling cascade. Importantly, the impaired loading of repair proteins and the defect in DNA repair in Trrap- deficient cells can be counteracted by chromatin relaxation, indicating that the DNA- repair defect that was observed in the absence of Trrap is due to impeded chromatin accessibility at sites of DNA breaks. Thus, these data reveal that cells may use the same basic mechanism involving HAT complexes to regulate distinct cellular processes, such as transcription and DNA repair.	Int Agcy Res Canc, F-69008 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Herceg, Z (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr		Murr, Rabih/0000-0002-3346-6590; Loizou, Joanna/0000-0003-1853-0424				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)02125-0; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Choy JS, 2002, MOL CELL BIOL, V22, P8215, DOI 10.1128/MCB.22.23.8215-8225.2002; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2003, NUCLEIC ACIDS RES, V31, P7011, DOI 10.1093/nar/gkg902; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Stuck M, 2004, DNA REPAIR, V3, P953, DOI 10.1016/j.dnarep.2004.03.007; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252	35	463	476	3	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					91	U36		10.1038/ncb1343	http://dx.doi.org/10.1038/ncb1343			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	16341205				2022-12-25	WOS:000234651500017
J	Zenker, M; Mayerle, J; Lerch, MM; Tagariello, A; Zerres, K; Durie, PR; Beier, M; Hulskamp, G; Guzman, C; Rehder, H; Beemer, FA; Hamel, B; Vanlieferinghen, P; Gershoni-Baruch, R; Vieira, MW; Dumic, M; Auslender, R; Gil-da-Silva-Lopes, VL; Steinlicht, S; Rauh, M; Shalev, SA; Thiel, C; Winterpacht, A; Kwon, YT; Varshavsky, A; Reis, A				Zenker, M; Mayerle, J; Lerch, MM; Tagariello, A; Zerres, K; Durie, PR; Beier, M; Hulskamp, G; Guzman, C; Rehder, H; Beemer, FA; Hamel, B; Vanlieferinghen, P; Gershoni-Baruch, R; Vieira, MW; Dumic, M; Auslender, R; Gil-da-Silva-Lopes, VL; Steinlicht, S; Rauh, M; Shalev, SA; Thiel, C; Winterpacht, A; Kwon, YT; Varshavsky, A; Reis, A			Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome)	NATURE GENETICS			English	Article							TRYPSINOGEN ACTIVATION; AUTOPSY FINDINGS; CATHEPSIN-B; PROTEIN; PREMATURE; LACKING; SYSTEM; MOUSE; E3	Johanson-Blizzard syndrome (OMIM 243800) is an autosomal recessive disorder that includes congenital exocrine pancreatic insufficiency, multiple malformations such as nasal wing aplasia, and frequent mental retardation(1). We mapped the disease-associated locus to chromosome 15q14 - 21.1 and identified mutations, mostly truncating ones, in the gene UBR1 in 12 unrelated families with Johanson-Blizzard syndrome. UBR1 encodes one of at least four functionally overlapping E3 ubiquitin ligases of the N-end rule pathway, a conserved proteolytic system whose substrates include proteins with destabilizing N-terminal residues(2-5). Pancreas of individuals with Johanson-Blizzard syndrome did not express UBR1 and had intrauterine-onset destructive pancreatitis. In addition, we found that Ubr1(-/-) mice, whose previously reported phenotypes include reduced weight and behavioral abnormalities(6,7), had an exocrine pancreatic insufficiency, with impaired stimulus-secretion coupling and increased susceptibility to pancreatic injury. Our findings indicate that deficiency of UBR1 perturbs the pancreas' acinar cells and other organs, presumably owing to metabolic stabilization of specific substrates of the N-end rule pathway.	Univ Erlangen Nurnberg, Inst Human Genet, D-91054 Erlangen, Germany; Univ Greifswald, Dept Gastroenterol Endocrinol & Nutr, D-17487 Greifswald, Germany; Univ Aachen, Inst Human Genet, Aachen, Germany; Hosp Sick Children, Res Inst, Programme Integrat Biol, Toronto, ON M5G 1X8, Canada; Univ Munster, Dept Pediat, D-4400 Munster, Germany; Univ Costa Rica, Natl Childrens Hosp, San Jose, Costa Rica; Med Univ Vienna, KIMCL, Dept Human Genet, Vienna, Austria; Univ Utrecht, Dept Med Genet, NL-3508 TC Utrecht, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Human Genet, Nijmegen, Netherlands; CHU, Hotel Dieu, Dept Pediat, Neonatol Unit, Clermont Ferrand, France; Rambam Med Ctr, Dept Genet, Haifa, Israel; Catholic Univ Sao Paolo, Dept Med Genet, Sao Paulo, Brazil; Univ Zagreb, Childrens Hosp Rebro, Zagreb 41000, Croatia; Carmel Hosp, Dept Obstet & Gynecol, Haifa, Israel; State Univ Campinas, Dept Med Genet, Sao Paulo, Brazil; Univ Childrens Hosp, Erlangen, Germany; HaEmek Med Ctr, Inst Genet, Afula, Israel; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15260 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of Erlangen Nuremberg; Ernst Moritz Arndt Universitat Greifswald; RWTH Aachen University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Munster; Universidad Costa Rica; Medical University of Vienna; Utrecht University; Radboud University Nijmegen; CHU Clermont Ferrand; Rambam Health Care Campus; Technion Israel Institute of Technology; Pontificia Universidade Catolica de Sao Paulo; University of Zagreb; Clalit Health Services; Carmel Medical Center; Universidade Estadual de Campinas; University of Erlangen Nuremberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Emek Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; California Institute of Technology	Zenker, M (corresponding author), Univ Erlangen Nurnberg, Inst Human Genet, Schwabachanlage 10, D-91054 Erlangen, Germany.	mzenker@humgenet.uni-erlangen.de	Gil-da-Silva-Lopes, Vera Lúcia L/G-2453-2012; Reis, André/D-2309-2009; Thiel, Christian T/H-8964-2012; Lerch, Markus M./E-2206-2016; Mayerle, Julia/W-7907-2019	Gil-da-Silva-Lopes, Vera Lúcia L/0000-0003-1288-0554; Reis, André/0000-0002-6301-6363; Thiel, Christian T/0000-0003-3817-7277; Lerch, Markus M./0000-0002-9643-8263; Rauh, Manfred/0000-0002-4852-7157				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Ciechanover A, 2004, BBA-MOL CELL RES, V1695, P3, DOI 10.1016/j.bbamcr.2004.09.018; Cuschieri A, 2002, AM J MED GENET, V110, P122, DOI 10.1002/ajmg.10371; DAENTL DL, 1979, AM J MED GENET, V3, P129, DOI 10.1002/ajmg.1320030203; Guzman C, 1997, J PEDIATR GASTR NUTR, V25, P350, DOI 10.1097/00005176-199709000-00020; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Halangk W, 2002, AM J PHYSIOL-GASTR L, V282, pG367, DOI 10.1152/ajpgi.00315.2001; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; JOHANSON A, 1971, J PEDIATR-US, V79, P982, DOI 10.1016/S0022-3476(71)80194-4; JONES NL, 1994, J PEDIATR-US, V125, P406, DOI 10.1016/S0022-3476(05)83286-X; Kruger B, 1998, LAB INVEST, V78, P763; Kukor Z, 2002, J BIOL CHEM, V277, P21389, DOI 10.1074/jbc.M200878200; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Kwon YT, 2003, MOL CELL BIOL, V23, P8255, DOI 10.1128/MCB.23.22.8255-8271.2003; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Mayerle J, 2003, GASTROENTEROLOGY, V124, P949, DOI 10.1053/gast.2003.50142; MOESCHLER J B, 1987, American Journal of Medical Genetics, V26, P133, DOI 10.1002/ajmg.1320260120; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; RUDNIKSCHONEBORN S, 1991, KLIN PADIATR, V203, P33, DOI 10.1055/s-2007-1025396; Swanenburg de Veye H F, 1991, Genet Couns, V2, P21; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; Vanlieferinghen P, 2001, GENET COUNSEL, V12, P245; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Vieira Marta W., 2002, J. Pediatr. (Rio J.), V78, P433, DOI 10.1590/S0021-75572002000500016; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Yin JH, 2004, HUM MOL GENET, V13, P2421, DOI 10.1093/hmg/ddh269; ZERRES K, 1986, CLIN GENET, V30, P177; Zeth K, 2002, NAT STRUCT BIOL, V9, P906, DOI 10.1038/nsb869	30	181	186	4	18	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2005	37	12					1345	1350		10.1038/ng1681	http://dx.doi.org/10.1038/ng1681			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16311597				2022-12-25	WOS:000233657300014
J	LaVoie, MJ; Ostaszewski, BL; Weihofen, A; Schlossmacher, MG; Selkoe, DJ				LaVoie, MJ; Ostaszewski, BL; Weihofen, A; Schlossmacher, MG; Selkoe, DJ			Dopamine covalently modifies and functionally inactivates parkin	NATURE MEDICINE			English	Article							RECESSIVE JUVENILE PARKINSONISM; REDOX-CYCLING QUINOPROTEIN; ALPHA-SYNUCLEIN; SUBSTANTIA-NIGRA; TYROSINE-HYDROXYLASE; SYNAPTIC VESICLES; UBIQUITIN LIGASE; S-NITROSYLATION; DISEASE; MUTATIONS	Inherited mutations in PARK2, the gene encoding parkin, cause selective degeneration of catecholaminergic neurons in the substantia nigra and locus coeruleus of the brainstem, resulting in early-onset parkinsonism. But the role of parkin in common, sporadic forms of Parkinson disease remains unclear. Here we report that the neurotransmitter dopamine covalently modifies parkin in living dopaminergic cells, a process that increases parkin insolubility and inactivates its E3 ubiquitin ligase function. In the brains of individuals with sporadic Parkinson disease, we observed decreases in parkin solubility consistent with its functional inactivation. Using a new biochemical method, we detected catechol-modified parkin in the substantia nigra but not other regions of normal human brain. These findings show a vulnerability of parkin to modification by dopamine, the principal transmitter lost in Parkinson disease, suggesting a mechanism for the progressive loss of parkin function in dopaminergic neurons during aging and sporadic Parkinson disease.	Brigham & Womens Hosp, Dept Neurol, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	LaVoie, MJ (corresponding author), Brigham & Womens Hosp, Dept Neurol, Ctr Neurol Dis, 77 Ave Louis Pasteur,HIM 7th Floor, Boston, MA 02115 USA.	mlavoie@rics.bwh.harvard.edu	Weihofen, Andreas/A-1566-2011	Weihofen, Andreas/0000-0001-6265-9087; Schlossmacher, Michael/0000-0002-0394-0300; LaVoie, Matthew/0000-0002-2583-1578	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038375] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ardley HC, 2001, J BIOL CHEM, V276, P19640, DOI 10.1074/jbc.M011028200; Baptista MJ, 2003, J NEUROCHEM, V85, P957, DOI 10.1046/j.1471-4159.2003.01742.x; Berman SB, 1996, J NEUROCHEM, V67, P593; Berman SB, 1997, J NEUROCHEM, V69, P1185; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Cheng FC, 1996, J NEURAL TRANSM, V103, P433, DOI 10.1007/BF01276419; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cookson MR, 2003, HUM MOL GENET, V12, P2957, DOI 10.1093/hmg/ddg328; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dong ZZ, 2003, P NATL ACAD SCI USA, V100, P12438, DOI 10.1073/pnas.2132992100; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; FORNSTEDT B, 1986, NEUROPHARMACOLOGY, V25, P451, DOI 10.1016/0028-3908(86)90242-X; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; Hayashi S, 2000, MOVEMENT DISORD, V15, P884, DOI 10.1002/1531-8257(200009)15:5<884::AID-MDS1019>3.0.CO;2-8; Hedrich K, 2001, HUM MOL GENET, V10, P1649, DOI 10.1093/hmg/10.16.1649; Henn IH, 2005, J NEUROCHEM, V92, P114, DOI 10.1111/j.1471-4159.2004.02854.x; Hilker R, 2002, NEUROSCI LETT, V323, P50, DOI 10.1016/S0304-3940(01)02529-0; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; JIANG H, 2004, HUM MOL GENET; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kuhn DM, 1998, J NEUROSCI, V18, P7111; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; LaVoie MJ, 1999, J NEUROCHEM, V73, P2546, DOI 10.1046/j.1471-4159.1999.0732546.x; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Lotharius J, 2002, J BIOL CHEM, V277, P38884, DOI 10.1074/jbc.M205518200; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; Pawlyk AC, 2003, J BIOL CHEM, V278, P48120, DOI 10.1074/jbc.M306889200; Pramstaller PP, 2005, ANN NEUROL, V58, P411, DOI 10.1002/ana.20587; ROSENGREN E, 1985, J NEURAL TRANSM, V63, P247, DOI 10.1007/BF01252029; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; SRIRAM SR, 2005, HUM MOL GENET; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; SULZER D, 1995, J NEUROSCI, V15, P4102; Sulzer D, 1999, NEUROTOX RES, V1, P181, DOI 10.1007/BF03033289; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Wilson MA, 2004, P NATL ACAD SCI USA, V101, P1531, DOI 10.1073/pnas.0308089100; Winklhofer KF, 2003, J BIOL CHEM, V278, P47199, DOI 10.1074/jbc.M306769200; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Xu YM, 1998, J NEUROSCI RES, V54, P691, DOI 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0.CO;2-F; Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101; Zecca L, 2003, TRENDS NEUROSCI, V26, P578, DOI 10.1016/j.tins.2003.08.009; Zucca FA, 2004, PIGM CELL RES, V17, P610, DOI 10.1111/j.1600-0749.2004.00201.x	50	552	572	2	195	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2005	11	11					1214	1221		10.1038/nm1314	http://dx.doi.org/10.1038/nm1314			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16227987				2022-12-25	WOS:000233115400034
J	Sakamoto, H; Okamoto, K; Aoki, M; Kato, H; Katsume, A; Ohta, A; Tsukuda, T; Shimma, N; Aoki, Y; Arisawa, M; Kohara, M; Sudoh, M				Sakamoto, H; Okamoto, K; Aoki, M; Kato, H; Katsume, A; Ohta, A; Tsukuda, T; Shimma, N; Aoki, Y; Arisawa, M; Kohara, M; Sudoh, M			Host sphingolipid biosynthesis as a target for hepatitis C virus therapy	NATURE CHEMICAL BIOLOGY			English	Article							RNA REPLICATION COMPLEX; SERINE PALMITOYLTRANSFERASE; CRYSTAL-STRUCTURE; CERAMIDE; PROTEIN; SPHINGOSINE; INHIBITOR; REVEALS; ENZYME; HIV-1	An estimated 170 million individuals worldwide are infected with hepatitis C virus (HCV), a serious cause of chronic liver disease. Current interferon-based therapy for treating HCV infection has an unsatisfactory cure rate(1,2), and the development of more efficient drugs is needed. During the early stages of HCV infections, various host genes are differentially regulated(3), and it is possible that inhibition of host proteins affords a therapeutic strategy for treatment of HCV infection. Using an HCV subgenomic replicon cell culture system, here we have identified, from a secondary fungal metabolite, a lipophilic long-chain base compound, NA255 ( 1), a previously unknown small-molecule HCV replication inhibitor. NA255 prevents the de novo synthesis of sphingolipids, major lipid raft components, thereby inhibiting serine palmitoyltransferase, and it disrupts the association among HCV nonstructural (NS) viral proteins on the lipid rafts. Furthermore, we found that NS5B protein has a sphingolipid-binding motif in its molecular structure and that the domain was able to directly interact with sphingomyelin. Thus, NA255 is a new anti-HCV replication inhibitor that targets host lipid rafts, suggesting that inhibition of sphingolipid metabolism may provide a new therapeutic strategy for treatment of HCV infection.	Chugai Pharmaceut Co Ltd, Kamakura Res Labs, Kamakura, Kanagawa 2478530, Japan; Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan	Chugai Pharmaceutical Co., Ltd.; Roche Holding; Tokyo Metropolitan Institute of Medical Science	Sakamoto, H (corresponding author), Chugai Pharmaceut Co Ltd, Kamakura Res Labs, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan.	sakamotohrs@chugai-pharm.co.jp						Aizaki H, 2004, VIROLOGY, V324, P450, DOI 10.1016/j.virol.2004.03.034; BRAUN PE, 1968, J BIOL CHEM, V243, P3775; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; Finnegan CM, 2004, P NATL ACAD SCI USA, V101, P15452, DOI 10.1073/pnas.0402874101; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gao L, 2004, J VIROL, V78, P3480, DOI 10.1128/JVI.78.7.3480-3488.2004; Hammache D, 1998, J BIOL CHEM, V273, P7967, DOI 10.1074/jbc.273.14.7967; Hanada Kentaro, 2003, Methods Mol Biol, V228, P163, DOI 10.1385/1-59259-400-X:163; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; Humpf HU, 1998, J BIOL CHEM, V273, P19060, DOI 10.1074/jbc.273.30.19060; Kapadia SB, 2005, P NATL ACAD SCI USA, V102, P2561, DOI 10.1073/pnas.0409834102; Kenny-Walsh E, 2001, Clin Liver Dis, V5, P969, DOI 10.1016/S1089-3261(05)70204-X; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Li XL, 1998, J VIROL, V72, P2752, DOI 10.1128/JVI.72.4.2752-2759.1998; Lin C, 2004, J BIOL CHEM, V279, P17508, DOI 10.1074/jbc.M313020200; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Ni ZJ, 2004, CURR OPIN DRUG DISC, V7, P446; Shi ST, 2003, J VIROL, V77, P4160, DOI 10.1128/JVI.77.7.4160-4168.2003; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Su AI, 2002, P NATL ACAD SCI USA, V99, P15669, DOI 10.1073/pnas.202608199; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; Yasuda S, 2001, J BIOL CHEM, V276, P43994, DOI 10.1074/jbc.M104884200; Ye J, 2003, P NATL ACAD SCI USA, V100, P15865, DOI 10.1073/pnas.2237238100	28	145	164	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2005	1	6					333	337		10.1038/nchembio742	http://dx.doi.org/10.1038/nchembio742			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	979GH	16408072				2022-12-25	WOS:000232929900011
J	Swarup, R; Kramer, EM; Perry, P; Knox, K; Leyser, HMO; Haseloff, J; Beemster, GTS; Bhalerao, R; Bennett, MJ				Swarup, R; Kramer, EM; Perry, P; Knox, K; Leyser, HMO; Haseloff, J; Beemster, GTS; Bhalerao, R; Bennett, MJ			Root gravitropism requires lateral root cap and epidermal cells for transport and response to a mobile auxin signal	NATURE CELL BIOLOGY			English	Article							ARABIDOPSIS-THALIANA; MEMBRANE-PROTEIN; GRAVITY; ENCODES; GROWTH; REGULATOR; LOCUS; GENE; LOCALIZATION; PATHWAYS	Re-orientation of Arabidopsis seedlings induces a rapid, asymmetric release of the growth regulator auxin from gravity-sensing columella cells at the root apex. The resulting lateral auxin gradient is hypothesized to drive differential cell expansion in elongation-zone tissues. We mapped those root tissues that function to transport or respond to auxin during a gravitropic response. Targeted expression of the auxin influx facilitator AUX1 demonstrated that root gravitropism requires auxin to be transported via the lateral root cap to all elongating epidermal cells. A three-dimensional model of the root elongation zone predicted that AUX1 causes the majority of auxin to accumulate in the epidermis. Selectively disrupting the auxin responsiveness of expanding epidermal cells by expressing a mutant form of the AUX/IAA17 protein, axr3-1, abolished root gravitropism. We conclude that gravitropic curvature in Arabidopsis roots is primarily driven by the differential expansion of epidermal cells in response to an influx-carrier-dependent auxin gradient.	Univ Nottingham, Sch Biosci, Loughborough LE12 5RD, Leics, England; Simons Rock Coll, Dept Phys, Great Barrington, MA 01230 USA; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England; State Univ Ghent VIB, B-9052 Ghent, Belgium; SLU, Umea Plant Sci Ctr, SE-90183 Umea, Sweden	University of Nottingham; University of York - UK; University of Cambridge; Flanders Institute for Biotechnology (VIB); Ghent University; Swedish University of Agricultural Sciences; Umea University	Bennett, MJ (corresponding author), Univ Nottingham, Sch Biosci, Loughborough LE12 5RD, Leics, England.	malcolm.bennett@nottingham.ac.uk	Kramer, Eric M/B-9752-2008; Beemster, Gerrit/E-6668-2016; Leyser, Ottoline/AAC-5577-2019; Bennett, Malcolm/G-4004-2010	Beemster, Gerrit/0000-0001-6014-053X; swarup, Ranjan/0000-0002-6438-9188; Haseloff, Jim/0000-0003-4793-8058; Bhalerao, Rishikesh/0000-0003-4384-7036; Knox, Kirsten/0000-0002-5487-1763; Bennett, Malcolm/0000-0003-0475-390X; Leyser, Ottoline/0000-0003-2161-3829; Kramer, Eric/0000-0002-1424-2356	Biotechnology and Biological Sciences Research Council [REI20541, BB/C514958/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aloni R, 2004, PLANTA, V220, P177, DOI 10.1007/s00425-004-1381-8; Beemster GTS, 2000, PLANT PHYSIOL, V124, P1718, DOI 10.1104/pp.124.4.1718; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; Blancaflor EB, 1998, PLANT PHYSIOL, V116, P213, DOI 10.1104/pp.116.1.213; Blancaflor EB, 2003, PLANT PHYSIOL, V133, P1677, DOI 10.1104/pp.103.032169; Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; Boonsirichai K, 2003, PLANT CELL, V15, P2612, DOI 10.1105/tpc.015560; Boonsirichai K, 2002, ANNU REV PLANT BIOL, V53, P421, DOI 10.1146/annurev.arplant.53.100301.135158; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; Fasano JM, 2002, J PLANT GROWTH REGUL, V21, P71, DOI 10.1007/s003440010049; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Friml J, 2003, PLANT J, V34, P115, DOI 10.1046/j.1365-313X.2003.01705.x; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; Harper RM, 2000, PLANT CELL, V12, P757, DOI 10.1105/tpc.12.5.757; Hu XY, 2005, PLANT PHYSIOL, V137, P663, DOI 10.1104/pp.104.054494; Knox K, 2003, DEVELOPMENT, V130, P5769, DOI 10.1242/dev.00659; KONINGS H, 1967, ACTA BOT NEERL, V16, P161, DOI 10.1111/j.1438-8677.1967.tb00043.x; Kramer EM, 2004, TRENDS PLANT SCI, V9, P578, DOI 10.1016/j.tplants.2004.10.010; KUTSCHERA U, 1989, PHYSIOL PLANTARUM, V77, P157, DOI 10.1111/j.1399-3054.1989.tb05992.x; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; Li H, 2004, DEV CELL, V7, P193, DOI 10.1016/j.devcel.2004.07.002; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Marchant A, 1999, EMBO J, V18, P2066, DOI 10.1093/emboj/18.8.2066; Monshausen GB, 2002, PLANTA, V215, P980, DOI 10.1007/s00425-002-0880-8; Moore I, 2002, CURR BIOL, V12, pR452, DOI 10.1016/S0960-9822(02)00943-0; Morita MT, 2004, CURR OPIN PLANT BIOL, V7, P712, DOI 10.1016/j.pbi.2004.09.001; Muday GK, 2001, J PLANT GROWTH REGUL, V20, P226, DOI 10.1007/s003440010027; Mullen JL, 1998, PLANTA, V206, P598, DOI 10.1007/s004250050437; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Nagpal P, 2000, PLANT PHYSIOL, V123, P563, DOI 10.1104/pp.123.2.563; OHWAKI Y, 1976, PLANT CELL PHYSIOL, V17, P1329; Ottenschlager I, 2003, P NATL ACAD SCI USA, V100, P2987, DOI 10.1073/pnas.0437936100; Peters WS, 2000, PLANT PHYSIOL, V123, P605, DOI 10.1104/pp.123.2.605; Plieth C, 2002, PLANT PHYSIOL, V129, P786, DOI 10.1104/pp.011007; Rashotte AM, 2001, PLANT CELL, V13, P1683, DOI 10.1105/tpc.13.7.1683; Rouse D, 1998, SCIENCE, V279, P1371, DOI 10.1126/science.279.5355.1371; SACK FD, 1991, INT REV CYTOL, V127, P193; Swarup R, 2004, PLANT CELL, V16, P3069, DOI 10.1105/tpc.104.024737; Swarup R, 2001, GENE DEV, V15, P2648, DOI 10.1101/gad.210501; Tanaka A, 2002, J EXP BOT, V53, P683, DOI 10.1093/jexbot/53.369.683; Tian Q, 1999, DEVELOPMENT, V126, P711; Tiwari SB, 2003, PLANT CELL, V15, P533, DOI 10.1105/tpc.008417; TSURUMI S, 1978, PLANT CELL PHYSIOL, V19, P1195; Utsuno K, 1998, PLANT CELL PHYSIOL, V39, P1111, DOI 10.1093/oxfordjournals.pcp.a029310; van der Weele CM, 2003, PLANT PHYSIOL, V132, P1138, DOI 10.1104/pp.103.021345; Weijers D, 2003, PLANT PHYSIOL, V133, P1882, DOI 10.1104/pp.103.030692; Weise SE, 2000, PLANT CELL PHYSIOL, V41, P702, DOI 10.1093/pcp/41.6.702; Wolverton C, 2002, PLANTA, V215, P153, DOI 10.1007/s00425-001-0726-9; Yamamoto M, 1998, PLANT CELL PHYSIOL, V39, P660, DOI 10.1093/oxfordjournals.pcp.a029419	49	430	448	1	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1057	1065		10.1038/ncb1316	http://dx.doi.org/10.1038/ncb1316			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16244669				2022-12-25	WOS:000232930400008
J	Rea, SL; Wu, DQ; Cypser, JR; Vaupel, JW; Johnson, TE				Rea, SL; Wu, DQ; Cypser, JR; Vaupel, JW; Johnson, TE			A stress-sensitive reporter predicts longevity in isogenic populations of Caenorhabditis elegans	NATURE GENETICS			English	Article							LIFE-SPAN; GENE-EXPRESSION; C-ELEGANS; NEMATODES; HORMESIS; AGE	When both genotype and environment are held constant, 'chance' variation in the lifespan of individuals in a population is still quite large. Using isogenic populations of the nematode Caenorhabditis elegans, we show that, on the first day of adult life, chance variation in the level of induction of a green fluorescent protein (GFP) reporter coupled to a promoter from the gene hsp-16.2 predicts as much as a fourfold variation in subsequent survival. The same reporter is also a predictor of ability to withstand a subsequent lethal thermal stress. The level of induction of GFP is not heritable, and GFP expression levels in other reporter constructs are not associated with differences in longevity. HSP-16.2 itself is probably not responsible for the observed differences in survival but instead probably reflects a hidden, heterogeneous, but now quantifiable, physiological state that dictates the ability of an organism to deal with the rigors of living.	Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA; Max Planck Inst Demog Res, D-18057 Rostock, Germany; Univ Colorado, Dept Integrat Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; Max Planck Society; University of Colorado System; University of Colorado Boulder	Johnson, TE (corresponding author), Univ Colorado, Inst Behav Genet, Box 447, Boulder, CO 80309 USA.	johnsont@colorado.edu	Rea, Shane/F-4073-2014	Vaupel, James/0000-0003-0783-3905; /0000-0001-7147-8237; CYPSER, JAMES/0000-0001-8436-6437	NATIONAL INSTITUTE ON AGING [P01AG008761, P30AG034424, R01AG016219] Funding Source: NIH RePORTER; NIA NIH HHS [P30 AG034424, P01 AG008761, R01 AG016219] Funding Source: Medline; NICHD NIH HHS [R03 HD050374] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKER GT, 1988, EXP GERONTOL, V23, P223, DOI 10.1016/0531-5565(88)90025-3; BRENNER S, 1974, GENETICS, V77, P71; Calabrese EJ, 2002, HUM EXP TOXICOL, V21, P91, DOI 10.1191/0960327102ht217oa; Cypser JR, 2002, J GERONTOL A-BIOL, V57, pB109, DOI 10.1093/gerona/57.3.B109; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Fedoroff N, 2002, SCIENCE, V297, P1129, DOI 10.1126/science.1075988; Finch C, 2000, CHANCE DEV AGING; Finch CE, 1997, SCIENCE, V278, P407, DOI 10.1126/science.278.5337.407; Gillooly JF, 2001, SCIENCE, V293, P2248, DOI 10.1126/science.1061967; Golden TR, 2004, AGING CELL, V3, P111, DOI 10.1111/j.1474-9728.2004.00095.x; Herndon LA, 2002, NATURE, V419, P808, DOI 10.1038/nature01135; Herskind AM, 1996, HUM GENET, V97, P319, DOI 10.1007/s004390050042; JOHNSON TE, 1982, P NATL ACAD SCI-BIOL, V79, P6603, DOI 10.1073/pnas.79.21.6603; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; Johnson TE, 2000, EXP GERONTOL, V35, P687, DOI 10.1016/S0531-5565(00)00138-8; Kelly WG, 1997, GENETICS, V146, P227; Kenyon C, 1996, CELL, V84, P501, DOI 10.1016/S0092-8674(00)81024-7; Kirkwood TBL, 2005, MECH AGEING DEV, V126, P439, DOI 10.1016/j.mad.2004.09.008; Kirkwood TBL, 2002, NATURE, V419, P794, DOI 10.1038/419794a; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Link CD, 1999, CELL STRESS CHAPERON, V4, P235, DOI 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; MELOV S, 1995, NUCLEIC ACIDS RES, V23, P1419, DOI 10.1093/nar/23.8.1419; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; STREHLER BL, 1960, SCIENCE, V132, P14, DOI 10.1126/science.132.3418.14; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; Walker GA, 2003, AGING CELL, V2, P131, DOI 10.1046/j.1474-9728.2003.00045.x	29	297	306	1	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					894	898		10.1038/ng1608	http://dx.doi.org/10.1038/ng1608			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16041374	Green Accepted			2022-12-25	WOS:000230880400022
J	Huang, TT; Nijman, SMB; Mirchandani, KD; Galardy, PJ; Cohn, MA; Haas, W; Gygi, SP; Ploegh, HL; Bernards, R; D'Andrea, AD				Huang, TT; Nijman, SMB; Mirchandani, KD; Galardy, PJ; Cohn, MA; Haas, W; Gygi, SP; Ploegh, HL; Bernards, R; D'Andrea, AD			Regulation of monoubiquitinated PCNA by DUB autocleavage	NATURE CELL BIOLOGY			English	Article							DNA-POLYMERASE-ETA; FANCONI-ANEMIA PATHWAY; DEUBIQUITINATING ENZYMES; TRANSLESION SYNTHESIS; DAMAGE RESPONSE; KAPPA-B; UBIQUITIN; FIDELITY; FAMILY; FANCD2	Monoubiquitination is a reversible post-translational protein modification that has an important regulatory function in many biological processes, including DNA repair. Deubiquitinating enzymes (DUBs) are proteases that are negative regulators of monoubiquitination, but little is known about their regulation and contribution to the control of conjugated-substrate levels. Here, we show that the DUB ubiquitin specific protease 1 (USP1) deubiquitinates the DNA replication processivity factor, PCNA, as a safeguard against error-prone translesion synthesis (TLS) of DNA. Ultraviolet (UV) irradiation inactivates USP1 through an autocleavage event, thus enabling monoubiquitinated PCNA to accumulate and to activate TLS. Significantly, the site of USP1 cleavage is immediately after a conserved internal ubiquitin-like diglycine (Gly - Gly) motif. This mechanism is reminiscent of the processing of precursors of ubiquitin and ubiquitin-like modifiers by DUBs. Our results define a regulatory mechanism for protein ubiquitination that involves the signal-induced degradation of an inhibitory DUB.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, Amsterdam, Netherlands; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Netherlands Cancer Institute; Netherlands Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	D'Andrea, AD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St, Boston, MA 02115 USA.	alan_dandrea@dfci.harvard.edu	Galardy, Paul/AAE-9297-2019	Bernards, Rene/0000-0001-8677-3423; Cohn, Martin/0000-0002-2988-3009				Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Choi JH, 2005, DNA REPAIR, V4, P211, DOI 10.1016/j.dnarep.2004.09.006; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Friedberg EC, 2005, MOL CELL, V18, P499, DOI 10.1016/j.molcel.2005.03.032; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Garg P, 2005, P NATL ACAD SCI USA, V102, P18361, DOI 10.1073/pnas.0505949102; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Howlett NG, 2005, HUM MOL GENET, V14, P693, DOI 10.1093/hmg/ddi065; Hussain S, 2004, HUM MOL GENET, V13, P1241, DOI 10.1093/hmg/ddh135; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Kusumoto R, 2004, GENES CELLS, V9, P1139, DOI 10.1111/j.1365-2443.2004.00797.x; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; PARRIS CN, 1994, J MOL BIOL, V236, P491, DOI 10.1006/jmbi.1994.1160; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Reiley W, 2005, MOL CELL BIOL, V25, P3886, DOI 10.1128/MCB.25.10.3886-3895.2005; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Vugmeyster Y, 2002, MOL IMMUNOL, V39, P431, DOI 10.1016/S0161-5890(02)00123-2; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Zhu YA, 1997, J BIOL CHEM, V272, P51	39	418	432	6	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					339	U13		10.1038/ncb1378	http://dx.doi.org/10.1038/ncb1378			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16531995	Green Published			2022-12-25	WOS:000236560000012
J	Smith, FJD; Irvine, AD; Terron-Kwiatkowski, A; Sandilands, A; Campbell, LE; Zhao, YW; Liao, HH; Evans, AT; Goudie, DR; Lewis-Jones, S; Arseculeratne, G; Munro, CS; Sergeant, A; O'Regan, G; Bale, SJ; Compton, JG; DiGiovanna, JJ; Presland, RB; Fleckman, P; McLean, WHI				Smith, FJD; Irvine, AD; Terron-Kwiatkowski, A; Sandilands, A; Campbell, LE; Zhao, YW; Liao, HH; Evans, AT; Goudie, DR; Lewis-Jones, S; Arseculeratne, G; Munro, CS; Sergeant, A; O'Regan, G; Bale, SJ; Compton, JG; DiGiovanna, JJ; Presland, RB; Fleckman, P; McLean, WHI			Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris	NATURE GENETICS			English	Article							EPIDERMAL DIFFERENTIATION COMPLEX; N-TERMINAL DOMAIN; FLAKY TAIL; GENOMIC ORGANIZATION; LAMELLAR ICHTHYOSIS; HUMAN PROFILAGGRIN; SKIN; IDENTIFICATION; EXPRESSION; PROTEINS	Ichthyosis vulgaris (OMIM 146700) is the most common inherited disorder of keratinization and one of the most frequent single-gene disorders in humans. The most widely cited incidence figure is 1 in 250 based on a survey of 6,051 healthy English schoolchildren(1). We have identified homozygous or compound heterozygous mutations R501X and 2282del4 in the gene encoding filaggrin (FLG) as the cause of moderate or severe ichthyosis vulgaris in 15 kindreds. In addition, these mutations are semidominant; heterozygotes show a very mild phenotype with incomplete penetrance. The mutations show a combined allele frequency of similar to 4% in populations of European ancestry, explaining the high incidence of ichthyosis vulgaris. Profilaggrin is the major protein of keratohyalin granules in the epidermis. During terminal differentiation, it is cleaved into multiple filaggrin peptides that aggregate keratin filaments. The resultant matrix is cross-linked to form a major component of the cornified cell envelope. We find that loss or reduction of this major structural protein leads to varying degrees of impaired keratinization.	Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Human Genet Unit,Epithelial Genet Grp, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Univ Hosp NHS Trust, Dundee DD1 9SY, Scotland; Our Ladys Hosp Sick Children, Dept Paediat Dermatol, Dublin 12, Ireland; S Glasgow Univ Hosp NHS Trust, Dept Dermatol, Glasgow G51 4TF, Lanark, Scotland; Gene Dx, Gaithersburg, MD 20877 USA; Rhode Isl Hosp, Providence, RI 02903 USA; Brown Univ, Sch Med, Dept Dermatol, Div Dermatopharmacol, Providence, RI 02903 USA; NCI, Basic Res Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; Univ Washington, Sch Dent, Seattle, WA 98195 USA; Univ Washington, Dept Med, Div Dermatol, Seattle, WA 98195 USA	University of Dundee; University of Dundee; Our Ladys Children Hospital Crumlin; University of Glasgow; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	McLean, WHI (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Human Genet Unit,Epithelial Genet Grp, Dundee DD1 9SY, Scotland.	w.h.i.mclean@dundee.ac.uk	Irvine, Alan D/A-3982-2008; McLean, William HI/C-6352-2009	Irvine, Alan D/0000-0002-9048-2044; DiGiovanna, John J./0000-0002-2750-2313; McLean, William Henry Irwin/0000-0001-5539-5757; Presland, Richard/0000-0003-1440-7402	Medical Research Council [G0700314] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bale SJ, 1996, J INVEST DERMATOL, V107, P140, DOI 10.1111/1523-1747.ep12298430; Bitoun E, 2002, J INVEST DERMATOL, V118, P352, DOI 10.1046/j.1523-1747.2002.01603.x; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Compton JG, 2002, EXP DERMATOL, V11, P518, DOI 10.1034/j.1600-0625.2002.110604.x; DALE BA, 1985, ANN NY ACAD SCI, V455, P330, DOI 10.1111/j.1749-6632.1985.tb50420.x; Eady R. A. J., 1985, METHODS SKIN RES, P1; FLECKMAN P, 1987, J INVEST DERMATOL, V88, P640, DOI 10.1111/1523-1747.ep12470251; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; Ishida-Yamamoto A, 1998, LAB INVEST, V78, P1245; JUDGE MR, 2004, ROOKS TXB DERMATOLOG, V2, P56; Kuokkanen K, 1969, Acta Derm Venereol Suppl (Stockh), V62, P1; LANE PW, 1972, J HERED, V63, P135, DOI 10.1093/oxfordjournals.jhered.a108252; Listwan P, 2004, METHOD CELL BIOL, V78, P817; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MCLEAN WHI, 1994, J INVEST DERMATOL, V102, P24, DOI 10.1111/1523-1747.ep12371726; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Nirunsuksiri W, 1998, J INVEST DERMATOL, V110, P854, DOI 10.1046/j.1523-1747.1998.00208.x; Pearton DJ, 2002, J INVEST DERMATOL, V119, P661, DOI 10.1046/j.1523-1747.2002.01831.x; Penabad CP, 1998, BRIT J DERMATOL, V139, P958; Presland RB, 1997, J INVEST DERMATOL, V108, P170, DOI 10.1111/1523-1747.ep12333356; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; Smith FJD, 1998, J INVEST DERMATOL, V111, P817, DOI 10.1046/j.1523-1747.1998.00371.x; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; SYBERT VP, 1985, J INVEST DERMATOL, V84, P191, DOI 10.1111/1523-1747.ep12264813; Tay YK, 1999, ASIAN PAC J ALLERGY, V17, P137; WELLS RS, 1966, BRIT MED J, V1, P947, DOI 10.1136/bmj.1.5493.947; Zhong W, 2003, J HUM GENET, V48, P390, DOI 10.1007/s10038-003-0043-1	30	685	728	1	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					337	342		10.1038/ng1743	http://dx.doi.org/10.1038/ng1743			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16444271				2022-12-25	WOS:000235589600016
J	English, BP; Min, W; van Oijen, AM; Lee, KT; Luo, GB; Sun, HY; Cherayil, BJ; Kou, SC; Xie, XS				English, BP; Min, W; van Oijen, AM; Lee, KT; Luo, GB; Sun, HY; Cherayil, BJ; Kou, SC; Xie, XS			Ever-fluctuating single enzyme molecules: Michaelis-Menten equation revisited	NATURE CHEMICAL BIOLOGY			English	Article							ESCHERICHIA-COLI; BETA-GALACTOSIDASE; KINETICS; DYNAMICS; MOTIONS	Enzymes are biological catalysts vital to life processes and have attracted century-long investigation. The classic Michaelis-Menten mechanism provides a highly satisfactory description of catalytic activities for large ensembles of enzyme molecules. Here we tested the Michaelis-Menten equation at the single-molecule level. We monitored long time traces of enzymatic turnovers for individual beta-galactosidase molecules by detecting one fluorescent product at a time. A molecular memory phenomenon arises at high substrate concentrations, characterized by clusters of turnover events separated by periods of low activity. Such memory lasts for decades of timescales ranging from milliseconds to seconds owing to the presence of interconverting conformers with broadly distributed lifetimes. We proved that the Michaelis-Menten equation still holds even for a fluctuating single enzyme, but bears a different microscopic interpretation.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Indian Inst Sci, Dept Inorgan & Phys Chem, Bangalore 560012, Karnataka, India; Harvard Univ, Dept Stat, Cambridge, MA 02138 USA	Harvard University; Indian Institute of Science (IISC) - Bangalore; Harvard University	Xie, XS (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	xie@chemistry.harvard.edu	van Oijen, Antoine/I-3167-2014; Wei, Min/GSI-8510-2022; English, Brian P/O-8156-2016	van Oijen, Antoine/0000-0002-1794-5161; English, Brian P/0000-0002-4037-6294				AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; Barsegov V, 2002, J CHEM PHYS, V116, P4240, DOI 10.1063/1.1446433; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Bustamante C, 2003, NATURE, V421, P423, DOI 10.1038/nature01405; Edman L, 1999, CHEM PHYS, V247, P11, DOI 10.1016/S0301-0104(99)00098-1; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Flomenbom O, 2005, BIOPHYS J, V88, P3780, DOI 10.1529/biophysj.104.055905; Flomenbom O, 2005, P NATL ACAD SCI USA, V102, P2368, DOI 10.1073/pnas.0409039102; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Hadd AG, 1997, ANAL CHEM, V69, P3407, DOI 10.1021/ac970192p; Hammes GG, 2002, BIOCHEMISTRY-US, V41, P8221, DOI 10.1021/bi0260839; HOFMANN J, 1984, ANAL CHIM ACTA, V163, P67, DOI 10.1016/S0003-2670(00)81494-4; Ishijima A, 2001, TRENDS BIOCHEM SCI, V26, P438, DOI 10.1016/S0968-0004(01)01860-6; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Karplus M, 2000, J PHYS CHEM B, V104, P11, DOI 10.1021/jp993555t; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; Kou SC, 2005, J PHYS CHEM B, V109, P19068, DOI 10.1021/jp051490q; Lerch HP, 2005, P NATL ACAD SCI USA, V102, P10807, DOI 10.1073/pnas.0504995102; Lippitz M, 2005, CHEMPHYSCHEM, V6, P770, DOI 10.1002/cphc.200400560; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; MARCHESI SL, 1969, BIOCHIM BIOPHYS ACTA, V181, P20, DOI 10.1016/0005-2795(69)90223-2; Matthews BW, 2005, CR BIOL, V328, P549, DOI 10.1016/j.crvi.2005.03.006; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Michaelis L, 1913, BIOCHEM Z, V49, P333; Min W, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.198302; Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670; Qian H, 2002, BIOPHYS CHEM, V101, P565, DOI 10.1016/S0301-4622(02)00145-X; Richard JP, 1996, BIOCHEMISTRY-US, V35, P12387, DOI 10.1021/bi961029b; Sakmann B., 1995, SINGLE CHANNEL RECOR; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; Segel IH., 1993, ENZYME KINETICS BEHA; Seong GH, 2003, ANAL CHEM, V75, P3161, DOI 10.1021/ac034155b; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; van Oijen AM, 2003, SCIENCE, V301, P1235, DOI 10.1126/science.1084387; Velonia K, 2005, ANGEW CHEM INT EDIT, V44, P560, DOI 10.1002/anie.200460625; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; Xie SN, 2001, SINGLE MOL, V2, P229, DOI 10.1002/1438-5171(200112)2:4<229::AID-SIMO229>3.0.CO;2-9; Xie XS, 1998, ANNU REV PHYS CHEM, V49, P441, DOI 10.1146/annurev.physchem.49.1.441; Yang H, 2003, SCIENCE, V302, P262, DOI 10.1126/science.1086911; Yang SL, 2002, J CHEM PHYS, V117, P10996, DOI 10.1063/1.1521155; Yang SL, 2001, J PHYS CHEM B, V105, P6536, DOI 10.1021/jp004349k; Zhuang XW, 2002, SCIENCE, V296, P1473, DOI 10.1126/science.1069013; ZWANZIG R, 1990, ACCOUNTS CHEM RES, V23, P148, DOI 10.1021/ar00173a005	45	590	617	6	289	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2006	2	2					87	94		10.1038/nchembio759	http://dx.doi.org/10.1038/nchembio759			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	005DA	16415859				2022-12-25	WOS:000234801600011
J	Henry, EP; Peterson, JR; Salvarezza, SB; Rodriguez-Boulan, E; Chen, JL; Stamnes, M; Macia, E; Feng, Y; Shair, MD; Kirchhausen, T				Henry, EP; Peterson, JR; Salvarezza, SB; Rodriguez-Boulan, E; Chen, JL; Stamnes, M; Macia, E; Feng, Y; Shair, MD; Kirchhausen, T			Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro	NATURE CHEMICAL BIOLOGY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BINDING PROTEIN CDC42; TRANS-GOLGI NETWORK; N-WASP; BREFELDIN-A; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; ACTIN CYTOSKELETON; CHEMICAL INHIBITOR; LIVING CELLS	Inspired by the usefulness of small molecules to study membrane traffic, we used high-throughput synthesis and phenotypic screening to discover secramine, a molecule that inhibits membrane traffic out of the Golgi apparatus by an unknown mechanism. We report here that secramine inhibits activation of the Rho GTPase Cdc42, a protein involved in membrane traffic, by a mechanism dependent upon the guanine dissociation inhibitor RhoGDI. RhoGDI binds Cdc42 and antagonizes its membrane association, nucleotide exchange and effector binding. In vitro, secramine inhibits Cdc42 binding to membranes, GTP and effectors in a RhoGDI-dependent manner. In cells, secramine mimics the effects of dominant-negative Cdc42 expression on protein export from the Golgi and on Golgi polarization in migrating cells. RhoGDI-dependent Cdc42 inhibition by secramine illustrates a new way to inhibit Rho GTPases with small molecules and provides a new means to study Cdc42, RhoGDI and the cellular processes they mediate.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Harvard Inst Chem & Cell Biol, Boston, MA 02115 USA; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA; Cornell Univ, Weill Med Coll, Dyson Vis Res Inst, New York, NY 10021 USA; Univ Iowa, Coll Med, Iowa City, IA 52242 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard University; Harvard Medical School; Fox Chase Cancer Center; Cornell University; Dyson; University of Iowa	Shair, MD (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA.	shair@chemistry.harvard.edu; kirchhausen@crystal.harvard.edu	Chen, Ji-Long/AAJ-2134-2021; Macia, Eric/AAW-2964-2021	Chen, Ji-Long/0000-0002-4274-0563; Stamnes, Mark/0000-0002-5869-7985; macia, eric/0000-0003-3686-2000; Peterson, Jeffrey/0000-0002-0604-718X	NEI NIH HHS [R01 EY008538] Funding Source: Medline; NIAID NIH HHS [5 U54 AI057159-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM034107, GM068674, GM62566-05] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107, P01GM062566, R01GM068674] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Camera P, 2003, NAT CELL BIOL, V5, P1071, DOI 10.1038/ncb1064; Chen JL, 2005, J CELL BIOL, V169, P383, DOI 10.1083/jcb.200501157; Coleman R Edward, 1998, Clin Positron Imaging, V1, P15, DOI 10.1016/S1095-0397(97)00004-6; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Feng Y, 2003, P NATL ACAD SCI USA, V100, P6469, DOI 10.1073/pnas.0631766100; Feng Y, 2004, EMBO REP, V5, P596, DOI 10.1038/sj.embor.7400152; Fucini RV, 2002, MOL BIOL CELL, V13, P621, DOI 10.1091/mbc.01-11-0547; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; Luna A, 2002, MOL BIOL CELL, V13, P866, DOI 10.1091/mbc.01-12-0579; Ma L, 1998, J CELL BIOL, V140, P1125; Mansour SJ, 1999, P NATL ACAD SCI USA, V96, P7968, DOI 10.1073/pnas.96.14.7968; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Papayannopoulos V, 2005, MOL CELL, V17, P181, DOI 10.1016/j.molcel.2004.11.054; Pelish HE, 2001, J AM CHEM SOC, V123, P6740, DOI 10.1021/ja016093h; Peterson JR, 2001, P NATL ACAD SCI USA, V98, P10624, DOI 10.1073/pnas.201393198; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; SCHACHT J, 1978, J LIPID RES, V19, P1063; Stamnes M, 2002, CURR OPIN CELL BIOL, V14, P428, DOI 10.1016/S0955-0674(02)00349-6; Vasudevan A, 1999, J MED CHEM, V42, P1333, DOI 10.1021/jm9900873; Wang B, 2005, AM J PHYSIOL-CELL PH, V288, pC1411, DOI 10.1152/ajpcell.00533.2004; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200	42	57	65	2	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2006	2	1					39	46		10.1038/nchembio751	http://dx.doi.org/10.1038/nchembio751			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993RC	16408091				2022-12-25	WOS:000233971600013
J	Ohgami, RS; Campagna, DR; Greer, EL; Antiochos, B; McDonald, A; Chen, J; Sharp, JJ; Fujiwara, Y; Barker, JE; Fleming, MD				Ohgami, RS; Campagna, DR; Greer, EL; Antiochos, B; McDonald, A; Chen, J; Sharp, JJ; Fujiwara, Y; Barker, JE; Fleming, MD			Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR GENE; PROSTATE-CANCER; SACCHAROMYCES-CEREVISIAE; FERRIC REDUCTASE; MEMBRANE ANTIGEN; APOPTOSIS; PROTEIN; INDUCTION; MUTATION; PRODUCT	The reduction of iron is an essential step in the transferrin (Tf) cycle, which is the dominant pathway for iron uptake by red blood cell precursors. A deficiency in iron acquisition by red blood cells leads to hypochromic, microcytic anemia. Using a positional cloning strategy, we identified a gene, six-transmembrane epithelial antigen of the prostate 3 (Steap3), responsible for the iron deficiency anemia in the mouse mutant nm1054. Steap3 is expressed highly in hematopoietic tissues, colocalizes with the Tf cycle endosome and facilitates Tf-bound iron uptake. Steap3 shares homology with F420H2:NADP(+) oxidoreductases found in archaea and bacteria, as well as with the yeast FRE family of metalloreductases. Overexpression of Steap3 stimulates the reduction of iron, and mice lacking Steap3 are deficient in erythroid ferrireductase activity. Taken together, these findings indicate that Steap3 is an endosomal ferrireductase required for efficient Tf-dependent iron uptake in erythroid cells.	Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Tosteson Med Educ Ctr, Med Scientist Training Program, Boston, MA 02115 USA; Millennium Pharmaceut Inc, Cambridge, MA 01239 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Childrens Hosp, Div Hematol, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Harvard University; Brigham & Women's Hospital; Jackson Laboratory; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Fleming, MD (corresponding author), Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02115 USA.	mark.fleming@childrens.harvard.edu	Ohgami, R/AAE-1448-2019	Greer, Eric/0000-0002-7501-7371; Fleming, Mark/0000-0003-0948-4024	NHLBI NIH HHS [R01 HL074247-01, R01 HL074247] Funding Source: Medline; NIDDK NIH HHS [R01 DK027726, P30 DK049216] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK049216, R01DK027726] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Dhungana S, 2004, BIOCHEMISTRY-US, V43, P205, DOI 10.1021/bi0353631; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Goldman G L, 1976, J Forensic Sci, V21, P625; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; GUNSHIN HS, 2005, BLOOD           0616, DOI DOI 10.1182/BLOOD-2004-02-0716; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; INMAN RS, 1994, BIOCHEMISTRY-US, V33, P11850, DOI 10.1021/bi00205a022; Labbe RF, 1999, CLIN CHEM, V45, P2060; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; Moldes M, 2001, J BIOL CHEM, V276, P33938, DOI 10.1074/jbc.M105726200; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; OHGAMI RS, 2005, BLOOD           0630, DOI DOI 10.1185/BLOOD-2005-01-0379; Passer BJ, 2003, P NATL ACAD SCI USA, V100, P2284, DOI 10.1073/pnas.0530298100; Ponka P, 1997, BLOOD, V89, P1; Porkka KP, 2002, LAB INVEST, V82, P1573, DOI 10.1097/01.LAB.0000038554.26102.C6; Porkka KP, 2003, INT J CANCER, V106, P729, DOI 10.1002/ijc.11278; Ross JS, 2003, CLIN CANCER RES, V9, P6357; Sanchez-Pulido L, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-98; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; Steiner MS, 2000, CANCER RES, V60, P4419; Su MA, 1998, BLOOD, V92, P2157, DOI 10.1182/blood.V92.6.2157.418k16_2157_2163; Warkentin E, 2001, EMBO J, V20, P6561, DOI 10.1093/emboj/20.23.6561; Yang DM, 2001, CANCER RES, V61, P5857; Zhang XG, 2001, ONCOGENE, V20, P5982, DOI 10.1038/sj.onc.1204831	30	466	485	1	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2005	37	11					1264	1269		10.1038/ng1658	http://dx.doi.org/10.1038/ng1658			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16227996	Green Accepted			2022-12-25	WOS:000233045200028
J	Reichert, JM; Rosensweig, CJ; Faden, LB; Dewitz, MC				Reichert, JM; Rosensweig, CJ; Faden, LB; Dewitz, MC			Monoclonal antibody successes in the clinic	NATURE BIOTECHNOLOGY			English	Article							MOUSE		Tufts Univ, Ctr Study Drug Dev, Boston, MA 02111 USA	Tufts University	Reichert, JM (corresponding author), Tufts Univ, Ctr Study Drug Dev, 192 S St,Suite 550, Boston, MA 02111 USA.	janice.reichert@tufts.edu		Rosensweig, Clark/0000-0001-6364-2025; Reichert, Janice/0000-0003-0400-1951				BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; Carson D A, 1986, Adv Immunol, V38, P275, DOI 10.1016/S0065-2776(08)60009-7; COLE SPC, 1984, MOL CELL BIOCHEM, V62, P109; FLEMING T, 2004, RED BOOK; INGLIS TJJ, 1993, LANCET, V341, P303, DOI 10.1016/0140-6736(93)92651-9; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Milstein C, 1999, BIOESSAYS, V21, P966, DOI 10.1002/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; Pasqualini R, 2004, P NATL ACAD SCI USA, V101, P257, DOI 10.1073/pnas.0305834101; Reichert J, 2004, NAT REV DRUG DISCOV, V3, P383, DOI 10.1038/nrd1386; Reichert JM, 2002, CURR OPIN MOL THER, V4, P110; Reichert JM, 2001, NAT BIOTECHNOL, V19, P819, DOI 10.1038/nbt0901-819	14	559	699	5	90	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1073	1078		10.1038/nbt0905-1073	http://dx.doi.org/10.1038/nbt0905-1073			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16151394				2022-12-25	WOS:000231790600020
J	Verstrepen, KJ; Jansen, A; Lewitter, F; Fink, GR				Verstrepen, KJ; Jansen, A; Lewitter, F; Fink, GR			Intragenic tandem repeats generate functional variability	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; MAMMARY-GLAND; YEAST; DNA; GENES; RECOMBINATION; REPLICATION; MUTATIONS; PROTEINS; FREQUENCIES	Tandemly repeated DNA sequences are highly dynamic components of genomes(1). Most repeats are in intergenic regions, but some are in coding sequences or pseudogenes(2). In humans, expansion of intragenic triplet repeats is associated with various diseases, including Huntington chorea and fragile X syndrome(3,4). The persistence of intragenic repeats in genomes suggests that there is a compensating benefit. Here we show that in the genome of Saccharomyces cerevisiae, most genes containing intragenic repeats encode cell- wall proteins. The repeats trigger frequent recombination events in the gene or between the gene and a pseudogene, causing expansion and contraction in the gene size. This size variation creates quantitative alterations in phenotypes ( e. g., adhesion, flocculation or biofilm formation). We propose that variation in intragenic repeat number provides the functional diversity of cell surface antigens that, in fungi and other pathogens, allows rapid adaptation to the environment and elusion of the host immune system.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Katholieke Univ Leuven, Fac Appl Biosci & Engn, Dept Microbial & Mol Syst, Ctr Malting & Brewing Sci, B-3001 Leuven, Belgium	Massachusetts Institute of Technology (MIT); Whitehead Institute; KU Leuven	Fink, GR (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	GFink@wi.mit.edu	Verstrepen, Kevin/AAA-4343-2021; Jansen, An/T-9228-2018	Jansen, An/0000-0003-2412-0456; Verstrepen, Kevin/0000-0002-3077-6219	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035010] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM035010] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boceta C, 2000, PARASITE IMMUNOL, V22, P55, DOI 10.1046/j.1365-3024.2000.00269.x; Callahan JL, 2003, MOL CELL BIOL, V23, P7849, DOI 10.1128/MCB.23.21.7849-7860.2003; Davis AP, 2001, GENETICS, V159, P515; Debrauwere H, 2001, P NATL ACAD SCI USA, V98, P8263, DOI 10.1073/pnas.121075598; Fondon JW, 2004, P NATL ACAD SCI USA, V101, P18058, DOI 10.1073/pnas.0408118101; Guo B, 2000, P NATL ACAD SCI USA, V97, P12158, DOI 10.1073/pnas.220420397; Harrison P, 2002, J MOL BIOL, V316, P409, DOI 10.1006/jmbi.2001.5343; Hartl DL, 2000, NAT REV GENET, V1, P145, DOI 10.1038/35038580; Hood DW, 1996, P NATL ACAD SCI USA, V93, P11121, DOI 10.1073/pnas.93.20.11121; Jin P, 2004, NAT CELL BIOL, V6, P1048, DOI 10.1038/ncb1104-1048; Keim P, 1999, J APPL MICROBIOL, V87, P215, DOI 10.1046/j.1365-2672.1999.00873.x; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Li YC, 2004, MOL BIOL EVOL, V21, P991, DOI 10.1093/molbev/msh073; Liu HP, 1996, GENETICS, V144, P967; Lovett ST, 2004, MOL MICROBIOL, V52, P1243, DOI 10.1111/j.1365-2958.2004.04076.x; Marinangeli P, 2004, FEMS YEAST RES, V4, P427, DOI 10.1016/S1567-1356(03)00172-7; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; Reynolds TB, 2001, SCIENCE, V291, P878, DOI 10.1126/science.291.5505.878; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; Sakihama N, 2004, PARASITOL INT, V53, P59, DOI 10.1016/j.parint.2003.11.002; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; SHERMAN F, 1991, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Verstrepen KJ, 2004, NAT REV MICROBIOL, V2, P533, DOI 10.1038/nrmicro927; Viguera E, 2001, EMBO J, V20, P2587, DOI 10.1093/emboj/20.10.2587	30	424	457	1	55	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					986	990		10.1038/ng1618	http://dx.doi.org/10.1038/ng1618			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16086015	Green Published, Green Accepted			2022-12-25	WOS:000231591900025
J	Wu, ZH; Guo, H; Chow, NW; Sallstrom, J; Bell, RD; Deane, R; Brooks, AI; Kanagala, S; Rubio, A; Sagare, A; Liu, D; Li, F; Armstrong, D; Gasiewicz, T; Zidovetzki, R; Song, XM; Hofman, F; Zlokovic, BV				Wu, ZH; Guo, H; Chow, NW; Sallstrom, J; Bell, RD; Deane, R; Brooks, AI; Kanagala, S; Rubio, A; Sagare, A; Liu, D; Li, F; Armstrong, D; Gasiewicz, T; Zidovetzki, R; Song, XM; Hofman, F; Zlokovic, BV			Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease	NATURE MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; MICROVASCULAR PATHOLOGY; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; RECEPTOR FAMILY; BETA-PEPTIDE; GAX; EXPRESSION	Neurovascular dysfunction substantially contributes to Alzheimer disease. Here, we show that transcriptional profiling of human brain endothelial cells ( BECs) defines a subset of genes whose expression is age- independent but is considerably altered in Alzheimer disease, including the homeobox gene MEOX2 ( also known as GAX), a regulator of vascular differentiation, whose expression is low in Alzheimer disease. By using viral- mediated MEOX2 gene silencing and transfer, we show that restoring expression of the protein it encodes, GAX, in BECs from individuals with Alzheimer disease stimulates angiogenesis, transcriptionally suppresses AFX1 forkhead transcription factor - mediated apoptosis and increases the levels of a major amyloid- beta peptide ( Ab) clearance receptor, the low- density lipoprotein receptor - related protein 1 ( LRP), at the blood- brain barrier. In mice, deletion of Meox2 ( also known as Gax) results in reductions in brain capillary density and resting cerebral blood flow, loss of the angiogenic response to hypoxia in the brain and an impaired Ab efflux from brain caused by reduced LRP levels. The link of MEOX2 to neurovascular dysfunction in Alzheimer disease provides new mechanistic and therapeutic insights into this illness.	Univ Rochester, Med Ctr, Frank P Smith Labs Neurosci & Neurosurg Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Genom Ctr, Rochester, NY 14642 USA; Socratech Res Labs, Rochester, NY 14620 USA; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA; Univ So Calif, Hoffman Med Res Ctr, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA	University of Rochester; University of Rochester; University of California System; University of California Riverside; University of Rochester; University of Southern California	Zlokovic, BV (corresponding author), Univ Rochester, Med Ctr, Frank P Smith Labs Neurosci & Neurosurg Res, Arthur Kornberg Med Res Bldg,601 Elmwood Ave,Box, Rochester, NY 14642 USA.	berislav_zlokovic@urmc.rochester.edu	Sagare, Abhay/Y-3273-2019	Sagare, Abhay/0000-0002-8178-3785; Armstrong, Don/0000-0002-4904-638X	NATIONAL INSTITUTE ON AGING [R43AG024002, R37AG023084, R43AG023993] Funding Source: NIH RePORTER; NIA NIH HHS [R43 AG24002, R43 AG23993, R37 AG023084] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; ANDRES V, 1995, MOL CELL BIOL, V15, P4272; Atwood CS, 2003, BRAIN RES REV, V43, P1, DOI 10.1016/S0165-0173(03)00174-7; Bailey TL, 2004, NEUROL RES, V26, P573, DOI 10.1179/016164104225016272; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Bu GJ, 2000, TRENDS CARDIOVAS MED, V10, P148, DOI 10.1016/S1050-1738(00)00045-1; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Casserly I, 2004, LANCET, V363, P1139, DOI 10.1016/S0140-6736(04)15900-X; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Davis GE, 2001, J CELL SCI, V114, P917; de la Torre JC, 2004, NEUROL RES, V26, P517, DOI 10.1179/016164104225016254; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Fryer JD, 2003, J NEUROSCI, V23, P7889; Gorelick PB, 2004, STROKE, V35, P2620, DOI 10.1161/01.STR.0000143318.70292.47; Gorski DH, 2003, TRENDS CARDIOVAS MED, V13, P213, DOI 10.1016/S1050-1738(03)00081-1; Gorski DH, 2003, J SURG RES, V111, P91, DOI 10.1016/S0022-4804(03)00042-8; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; Greenberg SA, 2004, STROKE, V35, P2616, DOI 10.1161/01.str.0000143224.36527.44; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Iadecola C, 1999, NAT NEUROSCI, V2, P157, DOI 10.1038/5715; Iscove NN, 2002, NAT BIOTECHNOL, V20, P940, DOI 10.1038/nbt729; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; LaManna JC, 2004, J EXP BIOL, V207, P3163, DOI 10.1242/jeb.00976; LaRue B, 2004, J NEUROSCI METH, V138, P233, DOI 10.1016/j.jneumeth.2004.04.026; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; Mankoo BS, 1999, NATURE, V400, P69, DOI 10.1038/21892; Paris D, 2004, NEUROSCI LETT, V366, P80, DOI 10.1016/j.neulet.2004.05.017; Paris Daniel, 2004, Angiogenesis, V7, P75, DOI 10.1023/B:AGEN.0000037335.17717.bf; Patel S, 2005, CANCER RES, V65, P1414, DOI 10.1158/0008-5472.CAN-04-3431; Perlman H, 1998, EMBO J, V17, P3576, DOI 10.1093/emboj/17.13.3576; Roher AE, 2004, STROKE, V35, P2623, DOI 10.1161/01.STR.0000143317.70478.b3; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Saito T, 2005, REGUL PEPTIDES, V127, P159, DOI 10.1016/j.regpep.2004.11.006; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; Witzenbichler B, 1999, J CLIN INVEST, V104, P1469, DOI 10.1172/JCI7251; Wu ZH, 2003, J NEUROSCI METH, V130, P53, DOI 10.1016/S0165-0270(03)00206-1; Zlokovic BV, 2005, TRENDS NEUROSCI, V28, P202, DOI 10.1016/j.tins.2005.02.001	49	233	240	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					959	965		10.1038/nm1287	http://dx.doi.org/10.1038/nm1287			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16116430				2022-12-25	WOS:000231724700023
J	Aubin, I; Adams, CP; Opsahl, S; Septier, D; Bishop, CE; Auge, N; Salvayre, R; Negre-Salvayre, A; Goldberg, M; Guenet, JL; Poirier, C				Aubin, I; Adams, CP; Opsahl, S; Septier, D; Bishop, CE; Auge, N; Salvayre, R; Negre-Salvayre, A; Goldberg, M; Guenet, JL; Poirier, C			A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse	NATURE GENETICS			English	Article							BRITTLE BONE-DISEASE; FRAGILITAS-OSSIUM; FORM; MINERALIZATION; CERAMIDE; FRO/FRO	The mouse mutation fragilitas ossium (fro) leads to a syndrome of severe osteogenesis and dentinogenesis imperfecta with no detectable collagen defect. Positional cloning of the locus identified a deletion in the gene encoding neutral sphingomyelin phosphodiesterase 3 (Smpd3) that led to complete loss of enzymatic activity. Our knowledge of SMPD3 function is consistent with the pathology observed in mutant mice and provides new insight into human pathologies.	Inst Pasteur, Unite Genet Mammiferes, F-75724 Paris, France; Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Univ Paris 05, Fac Chirurg Dent, EA 2496, F-92120 Montrouge, France; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; CHU Rangueil, INSERM, U466, F-31059 Toulouse, France; CHU Rangueil, Dept Biochem, IFR 31, F-31059 Toulouse, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Baylor College of Medicine; UDICE-French Research Universities; Universite Paris Cite; Baylor College of Medicine; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Guenet, JL (corresponding author), Inst Pasteur, Unite Genet Mammiferes, 25 Rue Docteur Roux, F-75724 Paris, France.	guenet@pasteur.fr	Vital, Sibylle/AAK-3479-2021	Vital, Sibylle/0000-0001-6352-2525; Auge, Nathalie/0000-0003-2088-7211; Negre-Salvayre, Anne/0000-0003-2136-5706				Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; Forlino A, 2000, MOL GENET METAB, V71, P225, DOI 10.1006/mgme.2000.3039; Glorieux FH, 2002, J BONE MINER RES, V17, P30, DOI 10.1359/jbmr.2002.17.1.30; Glorieux FH, 2000, J BONE MINER RES, V15, P1650, DOI 10.1359/jbmr.2000.15.9.1650; Goldberg M, 1996, PROG HISTOCHEM CYTOC, V31, P1; Goni FM, 2002, FEBS LETT, V531, P38, DOI 10.1016/S0014-5793(02)03482-8; Grey A, 2004, CALCIFIED TISSUE INT, V74, P542, DOI 10.1007/s00223-003-0155-9; GUENET JL, 1981, J HERED, V72, P440, DOI 10.1093/oxfordjournals.jhered.a109554; MURIEL MP, 1991, BONE, V12, P241, DOI 10.1016/8756-3282(91)90070-Y; SILLENCE DO, 1993, AM J MED GENET, V45, P276, DOI 10.1002/ajmg.1320450227; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; Takeda H, 1998, FEBS LETT, V422, P255, DOI 10.1016/S0014-5793(98)00005-2; Ward LM, 2002, BONE, V31, P12, DOI 10.1016/S8756-3282(02)00790-1; Wu LNY, 2002, J BIOL CHEM, V277, P5126, DOI 10.1074/jbc.M107899200	14	132	134	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					803	805		10.1038/ng1603	http://dx.doi.org/10.1038/ng1603			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16025116				2022-12-25	WOS:000230880400008
J	Meyre, D; Bouatia-Naji, N; Tounian, A; Samson, C; Lecoeur, C; Vatin, V; Ghoussaini, M; Wachter, C; Hercberg, S; Charpentier, G; Patsch, W; Pattou, F; Charles, MA; Tounian, P; Clement, K; Jouret, B; Weill, J; Maddux, BA; Goldfine, ID; Walley, A; Boutin, P; Dina, C; Froguel, P				Meyre, D; Bouatia-Naji, N; Tounian, A; Samson, C; Lecoeur, C; Vatin, V; Ghoussaini, M; Wachter, C; Hercberg, S; Charpentier, G; Patsch, W; Pattou, F; Charles, MA; Tounian, P; Clement, K; Jouret, B; Weill, J; Maddux, BA; Goldfine, ID; Walley, A; Boutin, P; Dina, C; Froguel, P			Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes	NATURE GENETICS			English	Article							MEMBRANE GLYCOPROTEIN PC-1; GENOME-WIDE SCAN; INSULIN-RESISTANCE; SUSCEPTIBILITY GENES; SIGNIFICANT LINKAGE; FASTING INSULIN; RECEPTOR; MELLITUS; POPULATION; AMERICAN	We identified a locus on chromosome 6q16.3-q24.2 (ref. 1) associated with childhood obesity that includes 2.4 Mb common to eight genome scans for type 2 diabetes (T2D) or obesity(1-8). Analysis of the gene ENPP1 (also called PC-1), a candidate for insulin resistance(9,10), in 6,147 subjects showed association between a three-allele risk haplotype (K121Q, IVS20delT-11 and A -> G+1044TGA; QdelTG) and childhood obesity (odds ratio (OR) = 1.69, P = 0.0006), morbid or moderate obesity in adults (OR = 1.50, P = 0.006 or OR = 1.37, P = 0.02, respectively) and T2D (OR = 1.56, P = 0.00002). The Genotype IBD Sharing Test suggested that this obesity-associated ENPP1 risk haplotype contributes to the observed chromosome 6q linkage with childhood obesity. The haplotype confers a higher risk of glucose intolerance and T2D to obese children and their parents and associates with increased serum levels of soluble ENPP1 protein in children. Expression of a long ENPP1 mRNA isoform, which includes the obesity-associated A -> G+1044TGA SNP, was specific for pancreatic islet beta cells, adipocytes and liver. These findings suggest that several variants of ENPP1 have a primary role in mediating insulin resistance and in the development of both obesity and T2D, suggesting that an underlying molecular mechanism is common to both conditions.	Inst Pasteur, Inst Biol, CNRS 8090, F-59019 Lille, France; Univ London Imperial Coll Sci Technol & Med, Sect Genom Med, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Genome Ctr, London W12 0NN, England; Hop Hotel Dieu, EA3502, Paris, France; ISTNA, INRA, U1125, INSERM,U557, Paris, France; Paracelsus Private Med Sch, Salzburg, Austria; Univ Lille 2, INSERM, ERIT M 0106, Lille, France; Fac Med Paris Sud, IFR69, INSERM, U258, Villejuif, France; Trousseau Hosp, Dept Pediat Gastroenterol & Nutr, Paris, France; Childrens Hosp, INSERM, U563, Toulouse, France; Jeanne de Flandre Hosp, Pediat Endocrine Unit, Lille, France; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Imperial College London; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Paracelsus Private Medical University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Froguel, P (corresponding author), Inst Pasteur, Inst Biol, CNRS 8090, F-59019 Lille, France.	froguel@good.ibl.fr	FROGUEL, Philippe/O-6799-2017; Charles, Marie Aline/S-1866-2019; Dina, Christian R/D-3535-2015; Serge, Hercberg/F-3038-2017; Walley, Andrew J/D-2573-2009; Jouret, Béatrice/AAC-8146-2019; Tounian, Patrick/AAF-6226-2021; Charles, Marie Aline/F-8567-2017; HERCBERG, Serge/B-4429-2008; Clément, karine/R-1120-2017; Meyre, David/D-7315-2011; BOUATIA-NAJI, NABILA/D-5863-2013; Bouatia-Naji, Nabila/AGF-1400-2022; Pattou, Francois/O-6151-2017	FROGUEL, Philippe/0000-0003-2972-0784; Charles, Marie Aline/0000-0003-4025-4390; Dina, Christian R/0000-0002-7722-7348; Serge, Hercberg/0000-0002-3168-1350; Walley, Andrew J/0000-0001-7707-7549; Charles, Marie Aline/0000-0003-4025-4390; HERCBERG, Serge/0000-0002-3168-1350; Meyre, David/0000-0003-4850-7444; Bouatia-Naji, Nabila/0000-0001-5424-2134; Pattou, Francois/0000-0001-8388-3766	MRC [G0000477] Funding Source: UKRI; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056933] Funding Source: NIH RePORTER; Medical Research Council [G0000477] Funding Source: Medline; NIDDK NIH HHS [R01 DK056933, R01 DK056933-04S1] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abney M, 2002, AM J HUM GENET, V70, P920, DOI 10.1086/339705; Atwood LD, 2002, AM J HUM GENET, V71, P1044, DOI 10.1086/343822; Barroso I, 2003, PLOS BIOL, V1, P41, DOI 10.1371/journal.pbio.0000020; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Costanzo BV, 2001, DIABETES, V50, P831, DOI 10.2337/diabetes.50.4.831; Demenais F, 2003, HUM MOL GENET, V12, P1865, DOI 10.1093/hmg/ddg195; Dong HJ, 2005, DIABETES, V54, P367, DOI 10.2337/diabetes.54.2.367; Duggirala R, 2001, AM J HUM GENET, V68, P1149, DOI 10.1086/320100; Eaves IA, 1999, NAT GENET, V22, P324, DOI 10.1038/11890; Ehm MG, 2000, AM J HUM GENET, V66, P1871, DOI 10.1086/302950; Ghosh S, 2000, AM J HUM GENET, V67, P1174, DOI 10.1016/S0002-9297(07)62948-6; Hager J, 1998, NAT GENET, V20, P304, DOI 10.1038/3123; Hercberg S, 1998, CONTROL CLIN TRIALS, V19, P336, DOI 10.1016/S0197-2456(98)00015-4; Johnson MS, 2001, J CLIN ENDOCR METAB, V86, P3182, DOI 10.1210/jc.86.7.3182; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Lafay L, 1997, INT J OBESITY, V21, P567, DOI 10.1038/sj.ijo.0800443; Li C, 2004, AM J HUM GENET, V74, P418, DOI 10.1086/381712; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; Maddux BA, 2000, DIABETES, V49, P13, DOI 10.2337/diabetes.49.1.13; Meyre D, 2004, DIABETES, V53, P803, DOI 10.2337/diabetes.53.3.803; Oberkofler H, 2004, DIABETES, V53, P1385, DOI 10.2337/diabetes.53.5.1385; Rutsch F, 2001, AM J PATHOL, V158, P543, DOI 10.1016/S0002-9440(10)63996-X; SELTZER HS, 1967, J CLIN INVEST, V46, P323, DOI 10.1172/JCI105534; Stefanovic Vladisav, 2004, Clin Lab, V50, P271; Tregouet DA, 2004, ANN HUM GENET, V68, P165, DOI 10.1046/j.1529-8817.2003.00085.x; Weill J, 2004, ARCH DIS CHILD, V89, P502, DOI 10.1136/adc.2003.028548; Xiang KS, 2004, DIABETES, V53, P228, DOI 10.2337/diabetes.53.1.228	27	242	255	0	16	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2005	37	8					863	867		10.1038/ng1604	http://dx.doi.org/10.1038/ng1604			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16025115	Green Submitted, Green Accepted			2022-12-25	WOS:000230880400016
J	Ting, AH; Schuebel, KE; Herman, JG; Baylin, SB				Ting, AH; Schuebel, KE; Herman, JG; Baylin, SB			Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation	NATURE GENETICS			English	Article							DE-NOVO METHYLATION; LYSINE-9 METHYLATION; X-CHROMOSOME; HISTONE H3; E-CADHERIN; INACTIVATION; PROTEIN; MAINTENANCE; MECHANISMS; EXPRESSION	Double-stranded RNA molecules targeted to gene promoter regions can induce transcriptional gene silencing in a DNA cytosine methylation-dependent manner in plants (RNA-dependent DNA methylation)(1-3). Whether a similar mechanism exists in mammalian systems is a vital and controversial issue(4-6). DNA methylation is an important component in mammalian gene silencing for normal processes such as gene imprinting and X-chromosome inactivation(7-9), and aberrant CpG island hypermethylation at tumor-suppressor promoters is associated with transcriptional silencing and loss of gene function in cancer(10). Hence, we investigated whether RNA-dependent DNA methylation might operate in human cancers to mediate epigenetic silencing using the endogenous gene CDH1 as a potential target. The loss of this cell-cell adhesion factor facilitates the metastatic process, and its promoter is frequently hypermethylated in breast and other cancers(11-13). We found that, although small double-stranded RNAs targeted exclusively to the CDH1 promoter could effectively induce transcriptional repression with chromatin changes characteristic of inactive promoters, this was entirely independent of DNA methylation. Moreover, we could accomplish such silencing in a cancer cell line genetically modified to lack virtually any capacity to methylate DNA.	Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Grad Program Cellular & Mol Med, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Canc Biol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Baylin, SB (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Grad Program Cellular & Mol Med, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043318-19, R01 CA043318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aufsatz W, 2004, PLANT MOL BIOL, V54, P793, DOI 10.1007/s11103-004-0179-1; Aufsatz W, 2002, EMBO J, V21, P6832, DOI 10.1093/emboj/cdf663; Cao XF, 2003, CURR BIOL, V13, P2212, DOI 10.1016/j.cub.2003.11.052; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiraguri S, 1998, CANCER RES, V58, P1972; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kanno T, 2004, CURR BIOL, V14, P801, DOI 10.1016/j.cub.2004.04.037; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Matzke M, 2004, BBA-GENE STRUCT EXPR, V1677, P129, DOI 10.1016/j.bbaexp.2003.10.015; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Park CW, 2004, BIOCHEM BIOPH RES CO, V323, P275, DOI 10.1016/j.bbrc.2004.08.096; Pelissier T, 1999, NUCLEIC ACIDS RES, V27, P1625, DOI 10.1093/nar/27.7.1625; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Schmelz K, 2005, LEUKEMIA, V19, P103, DOI 10.1038/sj.leu.2403552; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wassenegger M, 2000, PLANT MOL BIOL, V43, P203, DOI 10.1023/A:1006479327881; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8	30	223	250	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					906	910		10.1038/ng1611	http://dx.doi.org/10.1038/ng1611			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16025112	Green Accepted			2022-12-25	WOS:000230880400024
J	Qi, L; Strong, MA; Karim, BO; Huso, DL; Greider, CW				Qi, L; Strong, MA; Karim, BO; Huso, DL; Greider, CW			Telomere fusion to chromosome breaks reduces oncogenic translocations and tumour formation	NATURE CELL BIOLOGY			English	Letter							ATAXIA-TELANGIECTASIA; SACCHAROMYCES-CEREVISIAE; DEFICIENT MICE; DNA BREAKS; DYSFUNCTION; ATM; LENGTH; INSTABILITY; CANCER; JOIN	Telomeres protect chromosome ends from fusion, degradation and recombination. Loss of telomere function has opposite effects on tumorigenesis: apoptosis, which inhibits tumour growth, and genomic instability, which accelerates tumour formation. Here we describe a new mechanism by which short telomeres inhibit tumorigenesis through interference with oncogenic translocations. In mice that are null for both ataxia-telangiectasia-mutated ( Atm) and telomerase RNA ( mTR), the first generation ( G1) Atm(-/-) mTR(-/-) mice have a lower rate of tumour formation than Atm(-/-) mTR(+/+) mice. These Atm(-/-) mTR(-/-) G1 tumours show no increase in either apoptosis or overall genomic instability. Strikingly, the tumours show a high fraction of translocations containing telomere signals at the translocation junctions. Translocations of the T- cell receptors on chromosome 14, which initiate tumorigenesis, were interrupted by fusion with telomeres. Telomere repeats were also detected at the translocation junctions in pre- malignant thymocytes. We propose that telomere fusion to DNA doublestrand breaks competes with the generation of oncogenic translocations and thus reduces tumour formation.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Comparat Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Greider, CW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	cgreider@jhmi.edu		Qi, Ling/0000-0001-8229-0184; Greider, Carol/0000-0002-5494-8126; Strong, Margaret/0000-0002-0055-6573	NCI NIH HHS [CA16519] Funding Source: Medline; NCRR NIH HHS [RR07002, RR00171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR000171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bailey SM, 2004, DNA REPAIR, V3, P349, DOI 10.1016/j.dnarep.2003.11.007; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; DuBois ML, 2002, GENETICS, V161, P995; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Latre L, 2003, EXP CELL RES, V287, P282, DOI 10.1016/S0014-4827(03)00134-4; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Lustig AJ, 2003, NAT REV GENET, V4, P916, DOI 10.1038/nrg1207; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Qi L, 2003, CANCER RES, V63, P8188; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385	30	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2005	7	7					706	U99		10.1038/ncb1276	http://dx.doi.org/10.1038/ncb1276			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	941BX	15965466				2022-12-25	WOS:000230190800015
J	Ravikumar, B; Acevedo-Arozena, A; Imarisio, S; Berger, Z; Vacher, C; O'Kane, CJ; Brown, SDM; Rubinsztein, DC				Ravikumar, B; Acevedo-Arozena, A; Imarisio, S; Berger, Z; Vacher, C; O'Kane, CJ; Brown, SDM; Rubinsztein, DC			Dynein mutations impair autophagic clearance of aggregate-prone proteins	NATURE GENETICS			English	Article							FAST AXONAL-TRANSPORT; ALPHA-SYNUCLEIN; IN-VITRO; POLYGLUTAMINE; HUNTINGTIN; NEURONS; MICROTUBULE; MICE; DEGENERATION; DISRUPTION	Mutations that affect the dynein motor machinery are sufficient to cause motor neuron disease. It is not known why there are aggregates or inclusions in affected tissues in mice with such mutations and in most forms of human motor neuron disease. Here we identify a new mechanism of inclusion formation by showing that decreased dynein function impairs autophagic clearance of aggregate- prone proteins. We show that mutations of the dynein machinery enhanced the toxicity of the mutation that causes Huntington disease in fly and mouse models. Furthermore, loss of dynein function resulted in premature aggregate formation by mutant huntingtin and increased levels of the autophagosome marker LC3- II in both cell culture and mouse models, compatible with impaired autophagosomelysosome fusion.	Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; MRC, Mammalian Genet Unit, Harwell, Oxon, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Rubinsztein, DC (corresponding author), Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Wellcome MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	dcr1000@hermes.cam.ac.uk	O'Kane, Cahir J/C-4413-2011; Rubinsztein, David C/C-3472-2011; Arozena, Abraham Acevedo/L-6584-2018; O'Kane, Cahir/Q-6681-2019	Arozena, Abraham Acevedo/0000-0001-6127-7116; O'Kane, Cahir/0000-0002-3488-2078	MRC [G0000872] Funding Source: UKRI; Medical Research Council [G0000872] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bananis E, 2000, J CELL BIOL, V151, P179, DOI 10.1083/jcb.151.1.179; Bannai H, 2004, J CELL SCI, V117, P163, DOI 10.1242/jcs.00854; Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285; Cleveland DW, 1999, NEURON, V24, P515, DOI 10.1016/S0896-6273(00)81108-3; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; EKSTROM P, 1984, J NEUROCHEM, V43, P1342, DOI 10.1111/j.1471-4159.1984.tb05392.x; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; LEIGH PN, 1991, BRAIN, V114, P775, DOI 10.1093/brain/114.2.775; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Narain Y, 1999, J MED GENET, V36, P739, DOI 10.1136/jmg.36.10.739; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Rogers DC, 2001, NEUROSCI LETT, V306, P89, DOI 10.1016/S0304-3940(01)01885-7; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Trushina E, 2004, MOL CELL BIOL, V24, P8195, DOI 10.1128/MCB.24.18.8195-8209.2004; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Wubbolts R, 1999, J CELL SCI, V112, P785	30	360	373	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					771	776		10.1038/ng1591	http://dx.doi.org/10.1038/ng1591			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15980862				2022-12-25	WOS:000230196400027
J	Yeh, P; Tschumi, AI; Kishony, R				Yeh, P; Tschumi, AI; Kishony, R			Functional classification of drugs by properties of their pairwise interactions	NATURE GENETICS			English	Article							MULTICOMPONENT THERAPEUTICS; ESCHERICHIA-COLI; NETWORK MOTIFS; ANTIBIOTICS; RESISTANCE; BIOLOGY; PRINCIPLES; MECHANISMS; EPISTASIS; CANCER	Multidrug treatments are increasingly important in medicine and for probing biological systems(1-6). Although many studies have focused on interactions between specific drugs, little is known about the system properties of a full drug interaction network(6). Like their genetic counterparts, two drugs may have no interaction, or they may interact synergistically or antagonistically to increase or suppress their individual effects. Here we use a sensitive bioluminescence technique(7,8) to provide quantitative measurements of pairwise interactions among 21 antibiotics that affect growth rate in Escherichia coli. We find that the drug interaction network possesses a special property: it can be separated into classes of drugs such that any two classes interact either purely synergistically or purely antagonistically. These classes correspond directly to the cellular functions affected by the drugs. This network approach provides a new conceptual framework for understanding the functional mechanisms of drugs and their cellular targets and can be applied in systems intractable to mutant screening, biochemistry or microscopy.	Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	Kishony, R (corresponding author), Harvard Univ, Bauer Ctr Genom Res, 7 Divin Ave, Cambridge, MA 02138 USA.	rkishony@cgr.harvard.edu						Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Bjarnason J, 2003, J BACTERIOL, V185, P4973, DOI 10.1128/JB.185.16.4973-4982.2003; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; Davierwala AP, 2005, NAT GENET, V37, P1147, DOI 10.1038/ng1640; Gardner TS, 2003, SCIENCE, V301, P102, DOI 10.1126/science.1081900; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Hecht SM, 2000, J NAT PROD, V63, P158, DOI 10.1021/np990549f; Hoffman LR, 2005, NATURE, V436, P1171, DOI 10.1038/nature03912; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; Kishony Roy, 2003, J Biol, V2, P14, DOI 10.1186/1475-4924-2-14; Komarova NL, 2005, P NATL ACAD SCI USA, V102, P9714, DOI 10.1073/pnas.0501870102; Leeb M, 2004, NATURE, V431, P892, DOI 10.1038/431892a; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; LOEWE S, 1953, ARZNEIMITTEL-FORSCH, V3, P285; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Nathan C, 2004, NATURE, V431, P899, DOI 10.1038/431899a; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Perlman ZE, 2004, SCIENCE, V306, P1194, DOI 10.1126/science.1100709; Remold SK, 2004, NAT GENET, V36, P423, DOI 10.1038/ng1324; Schreiber SL, 2003, CHEM ENG NEWS, V81, P51, DOI 10.1021/cen-v081n009.p051; SCOTT GM, 2001, HDB ESSENTIAL ANTIBI; Segre D, 2005, NAT GENET, V37, P77, DOI 10.1038/ng1489; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Swinney DC, 2004, NAT REV DRUG DISCOV, V3, P801, DOI 10.1038/nrd1500; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Walsh C., 2003, ANTIBIOTICS ACTIONS	30	252	256	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2006	38	4					489	494		10.1038/ng1755	http://dx.doi.org/10.1038/ng1755			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16550172				2022-12-25	WOS:000236340500025
J	Abas, L; Benjamins, R; Malenica, N; Paciorek, T; Wirniewska, J; Moulinier-Anzola, JC; Sieberer, T; Friml, J; Luschnig, C				Abas, L; Benjamins, R; Malenica, N; Paciorek, T; Wirniewska, J; Moulinier-Anzola, JC; Sieberer, T; Friml, J; Luschnig, C			Intracellular trafficking and proteolysis of the Arabidopsis auxin-efflux facilitator PIN2 are involved in root gravitropism	NATURE CELL BIOLOGY			English	Article							INHIBITORS BLOCK; PLASMA-MEMBRANE; TRANSPORT; THALIANA; PROTEIN; LOCALIZATION; ENDOCYTOSIS; MUTANTS; ENCODES; CARRIER	Root gravitropism describes the orientation of root growth along the gravity vector and is mediated by differential cell elongation in the root meristem. This response requires the coordinated, asymmetric distribution of the phytohormone auxin within the root meristem, and depends on the concerted activities of PIN proteins and AUX1 - members of the auxin transport pathway. Here, we show that intracellular trafficking and proteasome activity combine to control PIN2 degradation during root gravitropism. Following gravi-stimulation, proteasome-dependent variations in PIN2 localization and degradation at the upper and lower sides of the root result in asymmetric distribution of PIN2. Ubiquitination of PIN2 occurs in a proteasome-dependent manner, indicating that the proteasome is involved in the control of PIN2 turnover. Stabilization of PIN2 affects its abundance and distribution, and leads to defects in auxin distribution and gravitropic responses. We describe the effects of auxin on PIN2 localization and protein levels, indicating that redistribution of auxin during the gravitropic response may be involved in the regulation of PIN2 protein.	Univ Nat Resources & Appl Life Sci BOKU, Inst Appl Genet & Cell Biol, A-1190 Vienna, Austria; Univ Tubingen, Ctr Mol Biol Plants, D-72076 Tubingen, Germany; Inst Gen & Mol Biol, Dept Biotechnol, PL-87100 Torun, Poland; Masaryk Univ, Dept Funct Genom & Prote, Lab Mol Plant Physiol, CZ-62500 Brno, Czech Republic	University of Natural Resources & Life Sciences, Vienna; Eberhard Karls University of Tubingen; Nicolaus Copernicus University; Masaryk University Brno	Luschnig, C (corresponding author), Univ Nat Resources & Appl Life Sci BOKU, Inst Appl Genet & Cell Biol, Muthgasse 18, A-1190 Vienna, Austria.	christian.luschnig@boku.ac.at	Friml, Jiri/D-9511-2012; Malenica, Nenad/AAW-4495-2020	Friml, Jiri/0000-0002-8302-7596; Luschnig, Christian/0000-0003-2099-9280; Moulinier-Anzola, Jeanette/0000-0001-8635-7227				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bechtold N, 1998, METH MOL B, V82, P259; Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; Blakeslee JJ, 2005, CURR OPIN PLANT BIOL, V8, P494, DOI 10.1016/j.pbi.2005.07.014; Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; Friml J, 2003, CURR OPIN PLANT BIOL, V6, P7, DOI 10.1016/S1369526602000031; Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Friml J, 2003, PLANT J, V34, P115, DOI 10.1046/j.1365-313X.2003.01705.x; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Kimbrough JM, 2004, PLANT PHYSIOL, V136, P2790, DOI 10.1104/pp.104.044594; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Ottenschlager I, 2003, P NATL ACAD SCI USA, V100, P2987, DOI 10.1073/pnas.0437936100; Pacher TB, 2004, ANAL BIOCHEM, V329, P148, DOI 10.1016/j.ab.2004.02.034; Paciorek T, 2005, NATURE, V435, P1251, DOI 10.1038/nature03633; Paponov IA, 2005, TRENDS PLANT SCI, V10, P170, DOI 10.1016/j.tplants.2005.02.009; Peer WA, 2004, PLANT CELL, V16, P1898, DOI 10.1105/tpc.021501; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Sieberer T, 2000, CURR BIOL, V10, P1595, DOI 10.1016/S0960-9822(00)00861-7; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; Steinmann T, 1999, SCIENCE, V286, P316, DOI 10.1126/science.286.5438.316; Swarup R, 2005, NAT CELL BIOL, V7, P1057, DOI 10.1038/ncb1316; Utsuno K, 1998, PLANT CELL PHYSIOL, V39, P1111, DOI 10.1093/oxfordjournals.pcp.a029310; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; Vieten A, 2005, DEVELOPMENT, V132, P4521, DOI 10.1242/dev.02027; YOUNG LM, 1990, PLANT PHYSIOL, V92, P792, DOI 10.1104/pp.92.3.792	40	450	472	5	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2006	8	3					249	256		10.1038/ncb1369	http://dx.doi.org/10.1038/ncb1369			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	017QL	16489343				2022-12-25	WOS:000235708000010
J	Ripperger, JRA; Schibler, U				Ripperger, JRA; Schibler, U			Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions	NATURE GENETICS			English	Article							HISTONE H3; GENE-EXPRESSION; LYSINE 9; CLOCK; CELLS; METHYLATION; PACEMAKER; DEMETHYLATION; ACETYLATION; MECHANISMS	Mammalian circadian rhythms are based on transcriptional and post-translational feedback loops. Essentially, the activity of the transcription factors BMAL1 (also known as MOP3) and CLOCK is rhythmically counterbalanced by Period (PER) and Cryptochrome (CRY) proteins to govern time of day - dependent gene expression(1). Here we show that circadian regulation of the mouse albumin D element-binding protein (Dbp) gene involves rhythmic binding of BMAL1 and CLOCK and marked daily chromatin transitions. Thus, the Dbp transcription cycle is paralleled by binding of BMAL1 and CLOCK to multiple extra- and intragenic E boxes, acetylation of Lys9 of histone H3, trimethylation of Lys4 of histone H3 and a reduction of histone density. In contrast, the antiphasic daily repression cycle is accompanied by dimethylation of Lys9 of histone H3, the binding of heterochromatin protein 1 alpha and an increase in histone density. The rhythmic conversion of transcriptionally permissive chromatin to facultative heterochromatin relies on the presence of functional BMAL1-CLOCK binding sites.	Univ Fribourg, Dept Med, Biochem Sect, CH-1700 Fribourg, Switzerland; Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Natl Ctr Competence Res Frontiers Genet, CH-1211 Geneva 4, Switzerland	University of Fribourg; University of Geneva; University of Geneva	Schibler, U (corresponding author), Univ Fribourg, Dept Med, Biochem Sect, CH-1700 Fribourg, Switzerland.	Ueli.Schibler@molbio.unige.ch						Akashi M, 2000, GENE DEV, V14, P645; Albrecht U, 2004, FRONT BIOSCI-LANDMRK, V9, P48, DOI 10.2741/1196; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Kimura H, 2005, DNA REPAIR, V4, P939, DOI 10.1016/j.dnarep.2005.04.012; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/j.cell.2004.11.015; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Ripperger JA, 2000, GENE DEV, V14, P679; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schafmeier T, 2005, CELL, V122, P235, DOI 10.1016/j.cell.2005.05.032; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Wirth Dagmar, 2004, Methods Mol Biol, V267, P467; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; Yin L, 1998, HEPATOLOGY, V27, P73, DOI 10.1002/hep.510270113; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	30	430	443	3	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					369	374		10.1038/ng1738	http://dx.doi.org/10.1038/ng1738			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16474407	Green Submitted			2022-12-25	WOS:000235589600021
J	Kyttala, M; Tallila, J; Salonen, R; Kopra, O; Kohlschmidt, N; Paavola-Sakki, P; Peltonen, L; Kestila, M				Kyttala, M; Tallila, J; Salonen, R; Kopra, O; Kohlschmidt, N; Paavola-Sakki, P; Peltonen, L; Kestila, M			MKS1, encoding a component of the flagellar apparatus basal body proteome, is mutated in Meckel syndrome	NATURE GENETICS			English	Article							DISEASE GENE; C-ELEGANS; MAPS; CILIA; INVERSUS; LOCUS; FLOW; MICE	Meckel syndrome (MKS) is a severe fetal developmental disorder reported in most populations. The clinical hallmarks are occipital meningoencephalocele, cystic kidney dysplasia, fibrotic changes of the liver and polydactyly. Here we report the identification of a gene, MKS1, mutated in MKS families linked to 17q. Mks1 expression in mouse embryos, as determined by in situ hybridization, agrees well with the tissue phenotype of MKS. Comparative genomics and proteomics data implicate MKS1 in ciliary functions.	Natl Publ Hlth Inst, Dept Mol Med, FI-00251 Helsinki, Finland; Univ Helsinki, Dept Med Genet, FI-00014 Helsinki, Finland; Dept Med Genet, FI-00101 Helsinki, Finland; Univ Helsinki Hosp, Dept Med, FI-00014 Helsinki, Finland; Harvard Univ, Broad Inst, Cambridge, MA 02139 USA; MIT, Cambridge, MA 02139 USA	Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT)	Peltonen, L (corresponding author), Natl Publ Hlth Inst, Dept Mol Med, FI-00251 Helsinki, Finland.	leena.peltonen@ktl.fi						Blacque OE, 2004, GENE DEV, V18, P1630, DOI 10.1101/gad.1194004; Efimenko E, 2005, DEVELOPMENT, V132, P1923, DOI 10.1242/dev.01775; Hentges KE, 2004, MAMM GENOME, V15, P252, DOI 10.1007/s00335-003-2303-y; Keller LC, 2005, CURR BIOL, V15, P1090, DOI 10.1016/j.cub.2005.05.024; Kramer-Zucker AG, 2005, DEVELOPMENT, V132, P1907, DOI 10.1242/dev.01772; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Morgan NV, 2002, HUM GENET, V111, P456, DOI 10.1007/s00439-002-0817-0; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; PAAVOLA P, 1995, NAT GENET, V11, P213, DOI 10.1038/ng1095-213; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Roume J, 1998, AM J HUM GENET, V63, P1095, DOI 10.1086/302062; SALONEN R, 1984, AM J MED GENET, V18, P671, DOI 10.1002/ajmg.1320180414; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Swoboda P, 2000, MOL CELL, V5, P411, DOI 10.1016/S1097-2765(00)80436-0	15	182	186	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					155	157		10.1038/ng1714	http://dx.doi.org/10.1038/ng1714			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16415886				2022-12-25	WOS:000234953200008
J	Pressman, L; Burgess, R; Cook-Deegan, RM; McCormack, SJ; Nami-Wolk, I; Soucy, M; Walters, LR				Pressman, L; Burgess, R; Cook-Deegan, RM; McCormack, SJ; Nami-Wolk, I; Soucy, M; Walters, LR			The licensing of DNA patents by US academic institutions: an empirical survey	NATURE BIOTECHNOLOGY			English	Article							INTELLECTUAL PROPERTY	A survey of technology transfer of DNA inventions at 19 top US research universities reveals consensus, diversity and flexibility in intellectual property management. Patent filing and license terms are influenced by intended uses of inventions, outside market interest and NIH guidelines.	Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA; IP Data Corp, New Smyrna Beach, FL 32162 USA; Duke Univ, Inst Genome Sci & Policy, Durham, NC 27708 USA; NeuroSystec Corp, Alfred E Mann Fdn Biomed Engn, Valencia, CA 91355 USA; Kennedy Inst Eth, Cambridge, MA 02139 USA	Georgetown University; Duke University	Pressman, L (corresponding author), Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA.	waltersl@georgetown.edu		Cook-Deegan, Robert/0000-0002-8251-4237	NHGRI NIH HHS [R03 HG002683, 1 R03 HG02683, P50 HG003391, R03 HG002683-02, P50 HG003391-030001] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG003391, R03HG002683] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Andrews Lori B, 2005, Yale J Health Policy Law Ethics, V5, P403; *AUSTR LAW REF COM, 2004, GEN ING GEN PAT HUM; *AUTM, 2004, FY 2004 SURV SUMM TE; AXEL R, 1992, Patent No. 5149636; AXEL R, 1993, Patent No. 5179017; AXEL R, 2002, Patent No. 6455275; AXEL R, 1987, Patent No. 4634665; AXEL R, 1983, Patent No. 4399216; Cho MK, 2003, J MOL DIAGN, V5, P3, DOI 10.1016/S1525-1578(10)60444-8; COHEN SN, 1984, Patent No. 4468464; Cohen Stanley N, 1980, US Patent, Patent No. [4,237,224, 4237224]; Commission on Intellectual Property Rights, 2002, INT INT PROP RIGHTS; DRISCOLL C, 2003, CONS BEN SHAR GEN RE; Eisenberg RS, 1997, NAT GENET, V15, P125, DOI 10.1038/ng0297-125; FINNEGAN, 2005, FINN HEND 2005 BIOT; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Hughes SS, 2002, ISIS, V93, P530, DOI 10.1086/374140; Jensen K, 2005, SCIENCE, V310, P239, DOI 10.1126/science.1120014; Malakoff D, 2004, SCIENCE, V303, P1757; MOWERY DC, 2004, IVORY TOWER IND INNO, P158; *NAT RES COUNC COM, 2005, REAP BEN GEN PROT RE; NAT'L RESEARCH COUNCIL, 1997, INT PROP RIGHTS RES; National Institute of Health, 2005, FED REGISTER, V70, P18413; *NIH WORK GROUP RE, 1998, REP NAT I HLTH WORK; *NUFF COUNC BIOETH, 2002, ETH PAT DNA; *ONT REP PROV TERR, 2002, GEN TEST GEN PAT CHA; Paradise J, 2005, SCIENCE, V307, P1566, DOI 10.1126/science.1105162; Rai Arti K., 2003, LAW CONTEMP PROBL, V66, P289; ROSENBERG L, 1997, INTELLECTUAL PROPERT; SPIEGEL J, 2005, AUTM ANN M NOV 11; Walsh J.P., 2005, PATENTS MAT TRANSFER; Walsh JP, 2005, SCIENCE, V309, P2002, DOI 10.1126/science.1115813; *WHO HUM GEN PROGR, 2005, GEN GEN PAT DNA; 1988, Patent No. 4740470; 1999, FED REG, V64, P72090	35	63	65	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2006	24	1					31	39		10.1038/nbt0106-31	http://dx.doi.org/10.1038/nbt0106-31			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	001SE	16404390	Bronze, Green Accepted			2022-12-25	WOS:000234555800018
J	Smyth, S; Heron, A				Smyth, S; Heron, A			Diabetes and obesity: the twin epidemics	NATURE MEDICINE			English	Article									Int Finance Ctr, London EC2N 1HN, England		Smyth, S (corresponding author), Int Finance Ctr, 25 Old Broad St,5th Floor,Tower 42, London EC2N 1HN, England.	andrew.heron@woodmac.com							0	388	399	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					75	80		10.1038/nm0106-75	http://dx.doi.org/10.1038/nm0106-75			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397575				2022-12-25	WOS:000234419000055
J	Anttonen, AK; Mahjneh, I; Hamalainen, RH; Lagier-Tourenne, C; Kopra, O; Waris, L; Anttonen, M; Joensuu, T; Kalimo, H; Paetau, A; Tranebjaerg, L; Chaigne, D; Koenig, M; Eeg-Olofsson, O; Udd, B; Somer, M; Somer, H; Lehesjoki, AE				Anttonen, AK; Mahjneh, I; Hamalainen, RH; Lagier-Tourenne, C; Kopra, O; Waris, L; Anttonen, M; Joensuu, T; Kalimo, H; Paetau, A; Tranebjaerg, L; Chaigne, D; Koenig, M; Eeg-Olofsson, O; Udd, B; Somer, M; Somer, H; Lehesjoki, AE			The gene disrupted in Marinesco-Sjogren syndrome encodes SIL1, an HSPA5 cochaperone	NATURE GENETICS			English	Article							MOLECULAR CHAPERONES; PROTEIN; NEURODEGENERATION; TRANSLOCATION; BIP	We identified the gene underlying Marinesco-Sjogren syndrome, which is characterized by cerebellar ataxia, progressive myopathy and cataracts. We identified four disease-associated, predicted loss-of-function mutations in SIL1, which encodes a nucleotide exchange factor for the heat-shock protein 70 (HSP70) chaperone HSPA5. These data, together with the similar spatial and temporal patterns of tissue expression of Sil1 and Hspa5, suggest that disturbed SIL1-HSPA5 interaction and protein folding is the primary pathology in Marinesco-Sjogren syndrome.	Univ Helsinki, Folkhalsan Inst Genet, FI-00014 Helsinki, Finland; Univ Helsinki, Ctr Neurosci, FI-00014 Helsinki, Finland; Univ Helsinki, Dept Med Genet, FI-00014 Helsinki, Finland; Pietarsaari Hosp, Dept Neurol, FI-68601 Pietarsaari, Finland; Univ Oulu, Dept Neurol, Oulu, Finland; Univ Strasbourg 1, CNRS, INSERM, Inst Genet Biol Mol & Cellulaire, FR-67404 Illkirch Graffenstaden, France; Univ Helsinki, Ctr Neurosci, FI-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Program Dev & Reprod Biol, FI-00014 Helsinki, Finland; Univ Helsinki, Childrens Hosp, FI-00014 Helsinki, Finland; Univ Helsinki, Dept Pathol, FI-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FI-00014 Helsinki, Finland; Univ Tromso Hosp, Dept Med Genet, N-9012 Tromso, Norway; Bispebjerg Hosp, Dept Audiol, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Panum Inst, Inst Med Biochem & Genet IMBG, Wilhelm Johannsen Ctr Funct Genom, DK-2200 Copenhagen, Denmark; Clin St Odile, FR-67100 Strasbourg, France; Uppsala Univ, Dept Womens & Childrens Hlth Pediat, SE-75186 Uppsala, Sweden; Vaasa Cent Hosp, Dept Neurol, Vaasa, Finland; Tampere Univ Hosp, Dept Neurol, Tampere, Finland; Family Federat Finland, FI-00101 Helsinki, Finland; Univ Helsinki, Dept Neurol, FI-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Oulu; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; UiT The Arctic University of Tromso; University Hospital of North Norway; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Uppsala University; Vaasa Central Hospital; Tampere University; Tampere University Hospital; Family Federation of Finland; University of Helsinki	Lehesjoki, AE (corresponding author), Univ Helsinki, Folkhalsan Inst Genet, POB 63, FI-00014 Helsinki, Finland.	anna-elina.lehesjoki@helsinki.fi	Joensuu, Tarja/F-3059-2011; Martikainen, Riikka/AAR-8397-2020	Martikainen, Riikka/0000-0002-5102-0672; Mahjneh, Ibrahim/0000-0002-0752-9949				Barral JM, 2004, SEMIN CELL DEV BIOL, V15, P17, DOI 10.1016/j.semcdb.2003.12.010; Boisrame A, 1998, J BIOL CHEM, V273, P30903, DOI 10.1074/jbc.273.47.30903; Chung KT, 2002, J BIOL CHEM, V277, P47557, DOI 10.1074/jbc.M208377200; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Lagier-Tourenne C, 2002, J MED GENET, V39, P838, DOI 10.1136/jmg.39.11.838; Lagier-Tourenne C, 2003, EUR J HUM GENET, V11, P770, DOI 10.1038/sj.ejhg.5201068; Marinesco G, 1931, ENCEPHALE, V26, P97; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; SEWRY CA, 1988, ANN NEUROL, V24, P576, DOI 10.1002/ana.410240416; SJoGREN TORSTEN, 1950, CONFINIA NEUROL, V10, P293; Steel GJ, 2004, SCIENCE, V303, P98, DOI 10.1126/science.1092287; Suzuki Y, 1997, ACTA NEUROPATHOL, V94, P410, DOI 10.1007/s004010050727; TODOROV A, 1965, J GENET HUM, V14, P197; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440; Zhao LH, 2005, NAT GENET, V37, P974, DOI 10.1038/ng1620	15	155	159	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2005	37	12					1309	1311		10.1038/ng1677	http://dx.doi.org/10.1038/ng1677			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16282978				2022-12-25	WOS:000233657300006
J	Hampoelz, B; Hoeller, O; Bowman, SK; Dunican, D; Knoblich, JA				Hampoelz, B; Hoeller, O; Bowman, SK; Dunican, D; Knoblich, JA			Drosophila Ric-8 is essential for plasma-membrane localization of heterotrimeric G proteins	NATURE CELL BIOLOGY			English	Article							ASYMMETRIC CELL DIVISIONS; CAENORHABDITIS-ELEGANS EMBRYOS; G-BETA-GAMMA; G-ALPHA; C-ELEGANS; SPINDLE POSITION; DISTINCT ROLES; DAUGHTER CELL; SYNEMBRYN; COMPLEX	Heterotrimeric G proteins act during signal transduction in response to extracellular ligands. They are also required for spindle orientation and cell polarity during asymmetric cell division. We show here that, in Drosophila, both functions require the G alpha interaction partner Ric-8. Drosophila Ric-8 is a cytoplasmic protein that binds both the GDP- and GTP-bound form of the G-protein alpha-subunit G alpha i. In ric-8 mutants, neither G alpha i nor its associated beta- subunit G beta 13F are localized at the plasma membrane, which leads to their degradation in the cytosol. During asymmetric cell division, this leads to various defects: apico-basal polarity is not maintained, mitotic spindles are misoriented and the size of the two daughter cells becomes nearly equal. ric-8 mutants also have defects in gastrulation that resemble mutants in the G alpha protein concertina or the extracellular ligand folded gastrulation. Our results indicate a model in which both receptor-dependent and receptor-independent G-protein functions are executed at the plasma membrane and require the Ric-8 protein.	Austrian Acad Sci, IMBA, Inst Mol Biotechnol, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Knoblich, JA (corresponding author), Austrian Acad Sci, IMBA, Inst Mol Biotechnol, Dr Bohr Gasse 3-5, A-1030 Vienna, Austria.	knoblich@imba.oeaw.ac.at	Knoblich, Juergen A/C-2974-2015; Dunican, Dara/A-1208-2010	Knoblich, Juergen A/0000-0002-6751-3404; Dunican, Dara/0000-0001-6563-8089; Hampoelz, Bernhard/0000-0001-7491-0080				Afshar K, 2004, CELL, V119, P219, DOI 10.1016/j.cell.2004.09.026; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; Couwenbergs C, 2004, CURR BIOL, V14, P1871, DOI 10.1016/j.cub.2004.09.059; Du QS, 2004, CELL, V119, P503, DOI 10.1016/j.cell.2004.10.028; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Fuse N, 2003, CURR BIOL, V13, P947, DOI 10.1016/S0960-9822(03)00334-8; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Hampoelz B, 2004, CELL, V119, P453, DOI 10.1016/j.cell.2004.10.025; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Izumi Y, 2004, J CELL BIOL, V164, P729, DOI 10.1083/jcb.200309162; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Lyczak R, 2002, DEV CELL, V3, P157, DOI 10.1016/S1534-5807(02)00226-5; Miller KG, 2000, NEURON, V27, P289, DOI 10.1016/S0896-6273(00)00037-4; Miller KG, 2000, GENETICS, V156, P1649; Ntwasa M, 2001, EXP CELL RES, V262, P134, DOI 10.1006/excr.2000.5086; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Yu FW, 2003, J CELL BIOL, V162, P623, DOI 10.1083/jcb.200303174	32	90	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1099	1105		10.1038/ncb1318	http://dx.doi.org/10.1038/ncb1318			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16228011				2022-12-25	WOS:000232930400013
J	Wang, HY; Ng, KH; Qian, HL; Siderovski, DP; Chia, W; Yu, FW				Wang, HY; Ng, KH; Qian, HL; Siderovski, DP; Chia, W; Yu, FW			Ric-8 controls Drosophila neural progenitor asymmetric division by regulating heterotrimeric G proteins	NATURE CELL BIOLOGY			English	Article							CAENORHABDITIS-ELEGANS EMBRYOS; G-BETA-GAMMA; CELL-DIVISION; G-ALPHA; C-ELEGANS; NERVOUS-SYSTEM/; DISTINCT ROLES; NEUROBLAST; COMPLEX; DETERMINANTS	Asymmetric division of Drosophila neuroblasts (NBs) and the Caenorhabditis elegans zygote uses polarity cues provided by the Par proteins, as well as heterotrimeric G-protein-signalling that is activated by a receptor-independent mechanism mediated by GoLoco/GPR motif proteins(1,2). Another key component of this non-canonical G-protein activation mechanism is a non-receptor guanine nucleotide-exchange factor (GEF) for G alpha, RIC-8, which has recently been characterized in C. elegans and in mammals(3-6). We show here that the Drosophila Ric-8 homologue is required for asymmetric division of both NBs and pI cells. Ric-8 is necessary for membrane targeting of G alpha i, Pins and G beta 13F, presumably by regulating multiple G alpha subunit( s). Ric-8 forms an in vivo complex with Gai and interacts preferentially with GDP - G alpha i, which is consistent with Ric-8 acting as a GEF for G alpha i. Comparisons of the phenotypes of G alpha i, Ric-8, G beta 13F single and Ric-8; G beta 13F double loss-of-function mutants indicate that, in NBs, Ric-8 positively regulates G alpha i activity. In addition, G beta gamma. acts to restrict G alpha i ( and GoLoco proteins) to the apical cortex, where Gai ( and Pins) can mediate asymmetric spindle geometry.	Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117604, Singapore; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA; Natl Univ Singapore, Dept Biol Sci, Singapore 117604, Singapore	National University of Singapore; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National University of Singapore	Chia, W (corresponding author), Natl Univ Singapore, Temasek Life Sci Lab, 1 Res Link, Singapore 117604, Singapore.	wchia@tll.org.sg; fengwei@tll.org.sg	Wang, Hongyan/AAB-3030-2019; Siderovski, David Peter/AAA-9603-2019	Wang, Hongyan/0000-0003-4623-1878; Siderovski, David Peter/0000-0002-0688-8210; Yu, Fengwei/0000-0003-0268-199X				Afshar K, 2004, CELL, V119, P219, DOI 10.1016/j.cell.2004.09.026; Bardin AJ, 2004, CURR OPIN NEUROBIOL, V14, P6, DOI 10.1016/j.conb.2003.12.002; Bellaiche Y, 2001, CELL, V106, P355, DOI 10.1016/S0092-8674(01)00444-5; Bellen HJ, 2004, GENETICS, V167, P761, DOI 10.1534/genetics.104.026427; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; Cismowski MJ, 2001, LIFE SCI, V68, P2301, DOI 10.1016/S0024-3205(01)01019-0; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; Couwenbergs C, 2004, CURR BIOL, V14, P1871, DOI 10.1016/j.cub.2004.09.059; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Fuse N, 2003, CURR BIOL, V13, P947, DOI 10.1016/S0960-9822(03)00334-8; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Hess HA, 2004, CELL, V119, P209, DOI 10.1016/j.cell.2004.09.025; Izumi Y, 2004, J CELL BIOL, V164, P729, DOI 10.1083/jcb.200309162; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; Kaltschmidt JA, 2002, J CELL SCI, V115, P2257; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Knust E, 2001, CELL, V107, P125, DOI 10.1016/S0092-8674(01)00534-7; Matsuzaki F, 2000, CURR OPIN NEUROBIOL, V10, P38, DOI 10.1016/S0959-4388(99)00052-5; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; Tsou MFB, 2003, DEVELOPMENT, V130, P5717, DOI 10.1242/dev.00790; Willard FS, 2004, ANNU REV BIOCHEM, V73, P925, DOI 10.1146/annurev.biochem.73.011303.073756; Wodarz A, 2003, MECH DEVELOP, V120, P1297, DOI 10.1016/j.mod.2003.06.003; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Yu FW, 2003, J CELL BIOL, V162, P623, DOI 10.1083/jcb.200303174	29	96	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1091	1098		10.1038/ncb1317	http://dx.doi.org/10.1038/ncb1317			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16228012				2022-12-25	WOS:000232930400012
J	Burns, CG; Milan, DJ; Grande, EJ; Rottbauer, W; MacRae, CA; Fishman, MC				Burns, CG; Milan, DJ; Grande, EJ; Rottbauer, W; MacRae, CA; Fishman, MC			High-throughput assay for small molecules that modulate zebrafish embryonic heart rate	NATURE CHEMICAL BIOLOGY			English	Article							CARDIOVASCULAR-SYSTEM; VERTEBRATE; DISCOVERY; MUTATION; MODEL	To increase the facility and throughput of scoring phenotypic traits in embryonic zebrafish, we developed an automated micro-well assay for heart rate using automated fluorescence microscopy of transgenic embryos expressing green fluorescent protein in myocardium. The assay measures heart rates efficiently and accurately over a large linear dynamic range, and it rapidly characterizes dose dependence and kinetics of small molecule-induced changes in heart rate. This is the first high-throughput micro-well assay for organ function in an intact vertebrate.	Massachusetts Gen Hosp, Cardiovasc Res Ctr, Dev Biol Lab, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Burns, CG (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Dev Biol Lab, 149 13th St, Boston, MA 02129 USA.	gburns@cvrc.mgh.harvard.edu			NHLBI NIH HHS [5T32HL07208-26] Funding Source: Medline; NIA NIH HHS [1K01AG023562-01, K01 AG023562] Funding Source: Medline; NIGMS NIH HHS [R21 GM075946] Funding Source: Medline; NINDS NIH HHS [1R03NS050806-01, R03 NS050806] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM075946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R03NS050806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG023562] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antkiewicz DS, 2005, TOXICOL SCI, V84, P368, DOI 10.1093/toxsci/kfi073; Chan J, 2004, METHOD CELL BIOL, V76, P475; Chen JN, 1996, DEVELOPMENT, V123, P293; Gilman A.G., 2001, GOODMAN GILMANS PHAR; Hill AJ, 2005, TOXICOL SCI, V86, P6, DOI 10.1093/toxsci/kfi110; Huang CJ, 2003, DEV DYNAM, V228, P30, DOI 10.1002/dvdy.10356; MacRae CA, 2003, CHEM BIOL, V10, P901, DOI 10.1016/j.chembiol.2003.10.003; Milan DJ, 2003, CIRCULATION, V107, P1355, DOI 10.1161/01.CIR.0000061912.88753.87; Peterson RT, 2004, NAT BIOTECHNOL, V22, P595, DOI 10.1038/nbt963; Peterson RT, 2000, P NATL ACAD SCI USA, V97, P12965, DOI 10.1073/pnas.97.24.12965; Peterson RT, 2001, CURR BIOL, V11, P1481, DOI 10.1016/S0960-9822(01)00482-1; Sbafizadeh E, 2004, COMP BIOCHEM PHYS C, V138, P245, DOI 10.1016/j.cca.2004.05.003; Sehnert AJ, 2002, TRENDS GENET, V18, P491, DOI 10.1016/S0168-9525(02)02766-X; Stainier DYR, 1996, DEVELOPMENT, V123, P285; Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606	15	247	260	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2005	1	5					263	264		10.1038/nchembio732	http://dx.doi.org/10.1038/nchembio732			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GN	16408054				2022-12-25	WOS:000232649100009
J	Pautot, S; Lee, H; Isacoff, EY; Groves, JT				Pautot, S; Lee, H; Isacoff, EY; Groves, JT			Neuronal synapse interaction reconstituted between live cells and supported lipid bilayers	NATURE CHEMICAL BIOLOGY			English	Article							REFLECTION FLUORESCENCE MICROSCOPY; ADHESION MOLECULES; NEUROLIGIN 1; SYNAPTOGENESIS; NEUREXINS; LIPOSOMES; MEMBRANES; PROTEINS; BIOLOGY	In the nervous system, homophilic and heterophilic adhesion molecules participate in the induction and differentiation of presynaptic transmitter release sites. We focus on the heterophilic interaction between postsynaptic neuroligin-1 (Nlg) and presynaptic beta-neurexin (Nrx). NIg has previously been shown to trigger presynaptic differentiation in a Nrx-expressing axon even when presented on a non-neuronal cell or on beads coated with lipid bilayers. We have now developed a new method to measure single molecule and ensemble distribution of Nrx and Nlg at the contact site between a non-neuronal Nrx-expressing cell and a flat supported glycosylphosphoinositol-neuroligin-1 (GPI-Nlg) lipid bilayer and relate them to adhesion as measured by cell migration and gravity dissociation. We find that within minutes after cell-bilayer contact, Nrx accumulates at the contact site and the contact area is expanded. The strength of cell-bilayer adhesion depends on the morphology of Nrx accumulation, with the focal concentration strengthening adhesion. The results suggest that Nlg-Nrx interaction rapidly establishes a weak, but specific, adhesion between dynamic pre- and postsynaptic processes, which may ultimately require additional molecules for synapse stabilization.	Univ Calif Berkeley, Lawrence Berkeley Lab, Mat Sci & Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Groves, JT (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Mat Sci & Phys Biosci Div, Berkeley, CA 94720 USA.	ehud@berkeley.edu; JTGroves@lbl.gov	isacoff, ehud/AAP-1459-2020; Pautot, Sophie/A-1578-2011	Pautot, Sophie/0000-0002-6660-4128; Isacoff, Ehud Y./0000-0003-4775-9359	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050833] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS050833] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angrand M, 1997, EUR J BIOCHEM, V250, P168, DOI 10.1111/j.1432-1033.1997.t01-1-00168.x; Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Benson DL, 1998, J NEUROSCI, V18, P6892; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; Dityatev A, 2004, J NEUROSCI, V24, P9372, DOI 10.1523/JNEUROSCI.1702-04.2004; Dustin ML, 2001, J CLIN IMMUNOL, V21, P258, DOI 10.1023/A:1010927208180; FEIN M, 1993, J MEMBRANE BIOL, V135, P83, DOI 10.1007/BF00234654; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Graf ER, 2004, CELL, V119, P1013, DOI 10.1016/j.cell.2004.11.035; Groves JT, 2003, J IMMUNOL METHODS, V278, P19, DOI 10.1016/S0022-1759(03)00193-5; HINTERDORFER P, 1994, J BIOL CHEM, V269, P20360; Hovis JS, 2001, LANGMUIR, V17, P3400, DOI 10.1021/la0017577; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; LEE GM, 1991, P NATL ACAD SCI USA, V88, P6274, DOI 10.1073/pnas.88.14.6274; MCCLAY DR, 1981, P NATL ACAD SCI-BIOL, V78, P4975, DOI 10.1073/pnas.78.8.4975; Nam CI, 2005, P NATL ACAD SCI USA, V102, P6137, DOI 10.1073/pnas.0502038102; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Pierres A, 1998, FARADAY DISCUSS, V111, P321; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; Sapuri AR, 2003, LANGMUIR, V19, P1606, DOI 10.1021/la026296z; Scheiffele P, 2003, ANNU REV NEUROSCI, V26, P485, DOI 10.1146/annurev.neuro.26.043002.094940; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Shapiro L, 1998, CURR OPIN NEUROBIOL, V8, P593, DOI 10.1016/S0959-4388(98)80086-X; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Sonnleitner A, 2002, P NATL ACAD SCI USA, V99, P12759, DOI 10.1073/pnas.192261499; Sytnyk V, 2004, J CELL SCI, V117, P381, DOI 10.1242/jcs.00956; WESTCOTT KR, 1985, J BIOL CHEM, V260, P3116; Yamagata M, 2003, CURR OPIN CELL BIOL, V15, P621, DOI 10.1016/S0955-0674(03)00107-8	29	47	48	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2005	1	5					283	289		10.1038/nchembio737	http://dx.doi.org/10.1038/nchembio737			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GN	16408058	Green Accepted			2022-12-25	WOS:000232649100013
J	Hausser, A; Storz, P; Martens, S; Link, G; Toker, A; Pfizenmaier, K				Hausser, A; Storz, P; Martens, S; Link, G; Toker, A; Pfizenmaier, K			Protein kinase D regulates vesicular transport by phosphorylating and activating phosphatidylinositol-4 kinase III beta at the Golgi complex	NATURE CELL BIOLOGY			English	Article							NF-KAPPA-B; CELL-SURFACE; PLASMA-MEMBRANE; C-MU; 4-KINASE; RECRUITMENT; SUBSTRATE; NETWORK; LOCALIZATION; ORGANIZATION	Protein kinase D ( PKD) regulates the fission of vesicles originating from the trans- Golgi network(1,2). We show that phosphatidylinositol 4- kinase III beta ( PI4KIII beta) - a key player in the structure and function of the Golgi complex(3) - is a physiological substrate of PKD. Of the three PKD isoforms, only PKD1 and PKD2 phosphorylated PI4KIII beta at a motif that is highly conserved from yeast to humans. PKD- mediated phosphorylation stimulated lipid kinase activity of PI4KIII beta and enhanced vesicular stomatitis virus G- protein transport to the plasma membrane. The identification of PI4KIII beta as one of the PKD substrates should help to reveal the molecular events that enable transport- carrier formation.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA	University of Stuttgart; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Hausser, A (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	angelika.hausser@izi.uni-stuttgart.de; klaus.pfizenmaier@izi.uni-stuttgart.de	Hausser, Angelika/AAC-4531-2021		NCI NIH HHS [CA075134, R01 CA075134] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075134] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anel AMD, 2005, J CELL BIOL, V169, P83, DOI 10.1083/jcb.200412089; Arnold R, 2005, MOL CELL BIOL, V25, P2364, DOI 10.1128/MCB.25.6.2364-2383.2005; Balla A, 2005, MOL BIOL CELL, V16, P1282, DOI 10.1091/mbc.E04-07-0578; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Sciorra VA, 2005, MOL BIOL CELL, V16, P776, DOI 10.1091/mbc.e04-08-0700; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Suer S, 2001, EUR J BIOCHEM, V268, P2099, DOI 10.1046/j.1432-1327.2001.02089.x; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090	26	268	274	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2005	7	9					880	U24		10.1038/ncb1289	http://dx.doi.org/10.1038/ncb1289			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	960NY	16100512	Green Accepted			2022-12-25	WOS:000231601600011
J	Morgante, M; Brunner, S; Pea, G; Fengler, K; Zuccolo, A; Rafalski, A				Morgante, M; Brunner, S; Pea, G; Fengler, K; Zuccolo, A; Rafalski, A			Gene duplication and exon shuffling by helitron-like transposons generate intraspecies diversity in maize	NATURE GENETICS			English	Article							ROLLING-CIRCLE TRANSPOSONS; ELEMENTS; EVOLUTION; SEQUENCES; MOVEMENT; NUMBER; RICE	We report a whole- genome comparison of gene content in allelic BAC contigs from two maize inbred lines. Genic content polymorphisms involve as many as 10,000 sequences and are mainly generated by DNA insertions. The termini of eight of the nine genic insertions that we analyzed shared the structural hallmarks of helitron rolling- circle transposons(1-3). DNA segments defined by helitron termini contained multiple gene- derived fragments and had a structure typical of nonautonomous helitron- like transposons. Closely related insertions were found in multiple genomic locations. Some of these produced transcripts containing segments of different genes, supporting the idea that these transposition events have a role in exon shuffling and the evolution of new proteins. We identified putative autonomous helitron elements and found evidence for their transcription. Helitrons in maize seem to continually produce new nonautonomous elements responsible for the duplicative insertion of gene segments into new locations and for the unprecedented genic diversity. The maize genome is in constant flux, as transposable elements continue to change both the genic and nongenic fractions of the genome, profoundly affecting genetic diversity.	Univ Udine, Dipartimento Sci Agr & Ambientali, I-33100 Udine, Italy; DuPont Crop Genet Res, Wilmington, DE 19880 USA	University of Udine; DuPont	Morgante, M (corresponding author), Univ Udine, Dipartimento Sci Agr & Ambientali, Via Sci 208, I-33100 Udine, Italy.	michele.morgante@uniud.it	Zuccolo, Andrea/H-5636-2019	Zuccolo, Andrea/0000-0001-7574-0714; MORGANTE, Michele/0000-0003-2591-2156				Bennetzen JL, 2004, CURR OPIN PLANT BIOL, V7, P732, DOI 10.1016/j.pbi.2004.09.003; Birchler JA, 2003, PLANT CELL, V15, P2236, DOI 10.1105/tpc.151030; Brunner S, 2005, PLANT CELL, V17, P343, DOI 10.1105/tpc.104.025627; Craig NL, 2002, MOBILE DNA 2; Duvick DN, 2001, NAT REV GENET, V2, P69, DOI 10.1038/35047587; Feschotte C, 2001, P NATL ACAD SCI USA, V98, P8923, DOI 10.1073/pnas.171326198; Fu HH, 2002, P NATL ACAD SCI USA, V99, P9573, DOI 10.1073/pnas.132259199; Gardiner J, 2004, PLANT PHYSIOL, V134, P1317, DOI 10.1104/pp.103.034538; Gupta S, 2005, PLANT MOL BIOL, V57, P115, DOI 10.1007/s11103-004-6636-z; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Ilic K, 2003, P NATL ACAD SCI USA, V100, P12265, DOI 10.1073/pnas.1434476100; Jiang N, 2004, NATURE, V431, P569, DOI 10.1038/nature02953; Kapitonov VV, 2001, P NATL ACAD SCI USA, V98, P8714, DOI 10.1073/pnas.151269298; Kynast RG, 2001, PLANT PHYSIOL, V125, P1216, DOI 10.1104/pp.125.3.1216; Lai JS, 2005, P NATL ACAD SCI USA, V102, P9068, DOI 10.1073/pnas.0502923102; Lai JS, 2004, GENOME RES, V14, P1924, DOI 10.1101/gr.2701104; Lal SK, 2003, PLANT CELL, V15, P381, DOI 10.1105/tpc.008375; Le QH, 2000, P NATL ACAD SCI USA, V97, P7376, DOI 10.1073/pnas.97.13.7376; Messing J, 2004, P NATL ACAD SCI USA, V101, P14349, DOI 10.1073/pnas.0406163101; Meyers BC, 2001, GENOME RES, V11, P1660, DOI 10.1101/gr.188201; Meyers BC, 2004, NAT REV GENET, V5, P578, DOI 10.1038/nrg1404; Okagaki RJ, 2001, PLANT PHYSIOL, V125, P1228, DOI 10.1104/pp.125.3.1228; Palmer LE, 2003, SCIENCE, V302, P2115, DOI 10.1126/science.1091265; Poulter RTM, 2003, GENE, V313, P201, DOI 10.1016/S0378-1119(03)00679-6; Ramakrishna W, 2002, PLANT CELL, V14, P3213, DOI 10.1105/tpc.006338; Song R, 2002, GENOME RES, V12, P1549, DOI 10.1101/gr.268302; Song RT, 2003, P NATL ACAD SCI USA, V100, P9055, DOI 10.1073/pnas.1032999100; Swigonova Z, 2005, GENETICS, V169, P891, DOI 10.1534/genetics.104.034629; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; Yu ZH, 2000, GENETICS, V156, P2019	30	360	395	2	58	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					997	1002		10.1038/ng1615	http://dx.doi.org/10.1038/ng1615			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16056225				2022-12-25	WOS:000231591900027
J	Feng, BY; Shelat, A; Doman, TN; Guy, RK; Shoichet, BK				Feng, BY; Shelat, A; Doman, TN; Guy, RK; Shoichet, BK			High-throughput assays for promiscuous inhibitors	NATURE CHEMICAL BIOLOGY			English	Article							DRUG DISCOVERY; IDENTIFICATION; MOLECULES; MECHANISM	High-throughput screening (HTS) searches large libraries of chemical compounds for those that can modulate the activity of a particular biological target; it is the dominant technique used in early-stage drug discovery. A key problem in HTS is the prevalence of nonspecific or 'promiscuous' inhibitors. These molecules have peculiar properties, act on unrelated targets and can dominate the results from screening campaigns(1). Several explanations have been proposed to account for promiscuous inhibitors, including chemical reactivity(1,2), interference in assay read-out(2), high molecular flexibility(3) and hydrophobicity(2,4). The diversity of these models reflects the apparently unrelated molecules whose behaviors they seek to explain. However, a single mechanism may explain the effects of many promiscuous inhibitors: some organic molecules form large colloid-like aggregates that sequester and thereby inhibit enzymes(5). Hits from HTS, leads for drug discovery and even several drugs appear to act through this mechanism at micromolar concentrations(5-9). Here, we report two rapid assays for detecting promiscuous aggregates that we tested against 1,030 'drug-like' molecules. The results from these assays were used to test two preliminary computational models of this phenomenon and as benchmarks to develop new models.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Chem & Chem Biol, San Francisco, CA 94143 USA; Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Eli Lilly	Guy, RK (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 1700 4th St, San Francisco, CA 94143 USA.	rguy@cgl.ucsf.edu; shoichet@cgl.ucsf.edu	Guy, Rodney/J-7107-2013; Shelat, Anang/J-4995-2013	Guy, Rodney/0000-0002-9638-2060; Shelat, Anang/0000-0002-6266-2910	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071630] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Frenkel YV, 2005, J MED CHEM, V48, P1974, DOI 10.1021/jm049439i; Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r; McGovern SL, 2003, J MED CHEM, V46, P1478, DOI 10.1021/jm020427b; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; Rishton GM, 1997, DRUG DISCOV TODAY, V2, P382, DOI 10.1016/S1359-6446(97)01083-0; Roche O, 2002, J MED CHEM, V45, P137, DOI 10.1021/jm010934d; Ryan AJ, 2003, J MED CHEM, V46, P3448, DOI 10.1021/jm0340896; Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r; Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n; Walters WP, 1999, CURR OPIN CHEM BIOL, V3, P384, DOI 10.1016/S1367-5931(99)80058-1; Weston GS, 1998, J MED CHEM, V41, P4577, DOI 10.1021/jm980343w	14	277	292	2	42	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2005	1	3					146	148		10.1038/nchembio718	http://dx.doi.org/10.1038/nchembio718			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GJ	16408018				2022-12-25	WOS:000232648700013
J	Jongejan, A; Bruysters, M; Ballesteros, JA; Haaksma, E; Bakker, RA; Pardo, L; Leurs, R				Jongejan, A; Bruysters, M; Ballesteros, JA; Haaksma, E; Bakker, RA; Pardo, L; Leurs, R			Linking agonist binding to histamine H-1 receptor activation	NATURE CHEMICAL BIOLOGY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; RHODOPSIN STRUCTURE; MUTATIONAL ANALYSIS; CONSERVED ASN; IONIC LOCK; POCKET; CRYSTALLOGRAPHY; REQUIREMENT; PROTONATION	G protein-coupled receptors (GPCRs) constitute a large and functionally diverse family of transmembrane proteins. They are fundamental in the transfer of extracellular stimuli to intracellular signaling pathways and are among the most targeted proteins in drug discovery. The detailed molecular mechanism for agonist-induced activation of rhodopsin-like GPCRs has not yet been described. Using a combination of site-directed mutagenesis and molecular modeling, we characterized important steps in the activation of the human histamine H-1 receptor. Both Ser3.36 and Asn7.45 are important links between histamine binding and previously proposed conformational changes in helices 6 and 7. Ser3.36 acts as a rotamer toggle switch that, upon agonist binding, initiates the activation of the receptor through Asn7.45. The proposed transduction involves specific residues that are conserved among rhodopsin-like GPCRs.	Free Univ Amsterdam, Fac Sci, Div Med Chem, Leiden Amsterda Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands; Novasite Pharmaceut Inc, San Diego, CA 92121 USA; Boehringer Ingelheim Austria GmbH, Dept Med Chem, A-1121 Vienna, Austria; Univ Autonoma Barcelona, Fac Med, Lab Med Comp, Unite Bioestadist, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Fac Med, Inst Neurociencies, E-08193 Barcelona, Spain	Vrije Universiteit Amsterdam; Boehringer Ingelheim; Autonomous University of Barcelona; University of Barcelona; Autonomous University of Barcelona; University of Barcelona	Leurs, R (corresponding author), Free Univ Amsterdam, Fac Sci, Div Med Chem, Leiden Amsterda Ctr Drug Res, De Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.	r.leurs@few.vu.nl	Leurs, Rob/ABB-4299-2021; Leurs, Rob/AAC-8508-2022	Leurs, Rob/0000-0003-1354-2848; Pardo, Leonardo/0000-0003-1778-7420	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH068655] Funding Source: NIH RePORTER; NIMH NIH HHS [R01MH068655-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; Bakker RA, 2001, MOL PHARMACOL, V60, P1133, DOI 10.1124/mol.60.5.1133; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ballesteros JA, 2000, BIOPHYS J, V79, P2754, DOI 10.1016/S0006-3495(00)76514-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruysters M, 2004, EUR J PHARMACOL, V487, P55, DOI 10.1016/j.ejphar.2004.01.028; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; CASE DA, 2004, AMBER 8; Claeysen S, 2002, FEBS LETT, V517, P195, DOI 10.1016/S0014-5793(02)02620-0; Deupi X, 2005, CONTEMPORARY CLIN NE, P363; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Frisch M. J., 2001, GAUSSIAN 98 REVISION; FUKUI H, 1994, BIOCHEM BIOPH RES CO, V201, P894, DOI 10.1006/bbrc.1994.1786; Gether U, 2002, PHARMACOL TOXICOL, V91, P304, DOI 10.1034/j.1600-0773.2002.910607.x; Ghanouni P, 2000, J BIOL CHEM, V275, P3121, DOI 10.1074/jbc.275.5.3121; Gillard M, 2002, MOL PHARMACOL, V61, P391, DOI 10.1124/mol.61.2.391; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Govaerts C, 2001, J BIOL CHEM, V276, P22991, DOI 10.1074/jbc.M102244200; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEURS R, 1994, BIOCHEM BIOPH RES CO, V201, P295, DOI 10.1006/bbrc.1994.1701; LEURS R, 1995, BIOCHEM BIOPH RES CO, V214, P110, DOI 10.1006/bbrc.1995.2263; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lopez-Rodriguez ML, 2002, MOL PHARMACOL, V62, P15, DOI 10.1124/mol.62.1.15; McAllister SD, 2004, J BIOL CHEM, V279, P48024, DOI 10.1074/jbc.M406648200; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Moguilevsky N, 1998, ANIMAL CELL TECHNOLOGY: BASIC & APPLIED ASPECTS, VOL 9, P65; MOGUILEVSKY N, 1995, J RECEPT SIGNAL TR R, V15, P91, DOI 10.3109/10799899509045210; Nonaka H, 1998, EUR J PHARMACOL, V345, P111, DOI 10.1016/S0014-2999(97)01620-8; OHTA K, 1994, BIOCHEM BIOPH RES CO, V203, P1096, DOI 10.1006/bbrc.1994.2295; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Urizar E, 2005, J BIOL CHEM, V280, P17135, DOI 10.1074/jbc.M414678200; Visiers I, 2002, METHOD ENZYMOL, V343, P329; Visiers I, 2002, INT J QUANTUM CHEM, V88, P65, DOI 10.1002/qua.10078; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Wieland K, 1999, J BIOL CHEM, V274, P29994, DOI 10.1074/jbc.274.42.29994	47	84	88	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2005	1	2					98	103		10.1038/nchembio714	http://dx.doi.org/10.1038/nchembio714			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GE	16408006				2022-12-25	WOS:000232648200014
J	Wang, YX; Putnam, CD; Kane, MF; Zhang, WJ; Edelmann, L; Russell, R; Carrion, DV; Chin, L; Kucherlapati, R; Kolodner, RD; Edelmann, W				Wang, YX; Putnam, CD; Kane, MF; Zhang, WJ; Edelmann, L; Russell, R; Carrion, DV; Chin, L; Kucherlapati, R; Kolodner, RD; Edelmann, W			Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability and cancer in mice	NATURE GENETICS			English	Article							REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; GENOME INSTABILITY; HOMOLOGOUS RECOMBINATION; SHORT ARM; REARRANGEMENTS; SUPPRESSION; DAMAGE; GENES; HETEROZYGOSITY	Most cancers have multiple chromosomal rearrangements; the molecular mechanisms that generate them remain largely unknown. Mice carrying a heterozygous missense change in one of the DNA- binding domains of Rpa1 develop lymphoid tumors, and their homozygous littermates succumb to early embryonic lethality. Array comparative genomic hybridization of the tumors identified large- scale chromosomal changes as well as segmental gains and losses. The Rpa1 mutation resulted in defects in DNA double- strand break repair and precipitated chromosomal breaks as well as aneuploidy in primary heterozygous mutant mouse embryonic fibroblasts. The equivalent mutation in yeast is hypomorphic and semidominant and enhanced the formation of gross chromosomal rearrangements in multiple genetic backgrounds. These results indicate that Rpa1 functions in DNA metabolism are essential for the maintenance of chromosomal stability and tumor suppression.	Univ Calif San Diego, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Ctr Genet & Genom, Harvard Med Sch Partners Healthcare Ctr Genet & G, Boston, MA 02115 USA; NYU, Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Icahn School of Medicine at Mount Sinai; New York University; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Dana-Farber Cancer Institute	Kolodner, RD (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA.	rkolodner@ucsd.edu; edelmann@aecom.yu.edu	Kucherlapati, Raju/ABC-8807-2021	Wang, Yuxun/0000-0002-4252-6102; Putnam, Christopher/0000-0002-6145-1265				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Chen C, 1998, MOL CELL, V2, P9, DOI 10.1016/S1097-2765(00)80109-4; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; CHEN LC, 1991, P NATL ACAD SCI USA, V88, P3847, DOI 10.1073/pnas.88.9.3847; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; Cory S, 1999, CANCER RES, V59, p1685S; Debrauwere H, 2001, P NATL ACAD SCI USA, V98, P8263, DOI 10.1073/pnas.121075598; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kim HS, 2001, MOL CELL BIOL, V21, P3725, DOI 10.1128/MCB.21.11.3725-3737.2001; Klein HL, 2001, GENETICS, V159, P1501; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lim DS, 1996, MOL CELL BIOL, V16, P7133; MACKAY J, 1988, LANCET, V2, P1384; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Myung K, 2002, P NATL ACAD SCI USA, V99, P4500, DOI 10.1073/pnas.062702199; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Pennaneach V, 2004, NAT GENET, V36, P612, DOI 10.1038/ng1359; Soustelle C, 2002, GENETICS, V161, P535; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tharapel SA, 2002, AM J MED GENET, V107, P123, DOI 10.1002/ajmg.10105; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; UMBRICHT CB, 1994, GENOMICS, V20, P249, DOI 10.1006/geno.1994.1161; Umezu K, 1998, GENETICS, V148, P989; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	30	122	123	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					750	755		10.1038/ng1587	http://dx.doi.org/10.1038/ng1587			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15965476				2022-12-25	WOS:000230196400023
J	van Hall, T; Wolpert, EZ; van Veelen, P; Laban, S; van der Veer, M; Roseboom, M; Bres, S; Grufman, P; de Ru, A; Meiring, H; de Jong, A; Franken, K; Teixeira, A; Valentijn, R; Drijfhout, JW; Koning, F; Camps, M; Ossendorp, F; Karre, K; Ljunggren, HG; Melief, CJM; Offringa, R				van Hall, T; Wolpert, EZ; van Veelen, P; Laban, S; van der Veer, M; Roseboom, M; Bres, S; Grufman, P; de Ru, A; Meiring, H; de Jong, A; Franken, K; Teixeira, A; Valentijn, R; Drijfhout, JW; Koning, F; Camps, M; Ossendorp, F; Karre, K; Ljunggren, HG; Melief, CJM; Offringa, R			Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants	NATURE MEDICINE			English	Article							I ANTIGEN PRESENTATION; RMA-S CELLS; CTL EPITOPE; PEPTIDES; TRANSPORTER; DEFICIENT; TAP; EXPRESSION; MOLECULES; COMPLEX	Defects in major histocompatibility complex (MHC) class I-restricted antigen presentation are frequently observed in human cancers and result in escape of tumors from cytotoxic T lymphocyte (CTL) immune surveillance in mice. Here, we show the existence of a unique category of CTLs that can prevent this escape. The CTLs target an alternative repertoire of peptide epitopes that emerge in MHC class I at the surface of cells with impaired function of transporter associated with antigen processing (TAP), tapasin or the proteasome. These peptides, although derived from self antigens such as the commonly expressed Lass5 protein (also known as Trh4), are not presented by normal cells. This explains why they act as immunogenic neoantigens. The newly discovered epitopes can be exploited for immune intervention against processing-deficient tumors through adoptive T-cell transfer or peptide vaccination.	Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2300 RC Leiden, Netherlands; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Leiden Univ, Med Ctr, Ctr Med Syst Biol, NL-2300 RC Leiden, Netherlands; Accuro Immunol, S-17177 Stockholm, Sweden; Netherlands Vaccine Inst, Unit Res & Dev, NL-3720 AL Bilthoven, Netherlands; Karolinska Inst, Strateg Res Ctr IRIS, S-17177 Stockholm, Sweden; Karolinska Univ Hosp Huddinge F59, Karolinska Inst, Dept Med, Ctr Infect Med, S-14186 Huddinge, Sweden	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Karolinska Institutet; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Karolinska Institutet; Swedish Foundation for Strategic Research; Karolinska Institutet; Karolinska University Hospital	van Hall, T (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, POB 9600, NL-2300 RC Leiden, Netherlands.	t.van_hall@lumc.nl	Drijfhout, Jan Wouter/ABA-6318-2021; Franken, Kees/ABA-7095-2021; van Hall, Thorbald/Y-5651-2018	Drijfhout, Jan Wouter/0000-0003-4808-5296; Franken, Kees/0000-0002-4747-6060; Koning, Frits/0000-0002-4007-5715; van Veelen, Peter/0000-0002-7898-9408; Laban, Sandra/0000-0003-2710-4531; van Hall, Thorbald/0000-0002-9115-558X				Alimonti J, 2000, NAT BIOTECHNOL, V18, P515, DOI 10.1038/75373; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Chiang EY, 2003, J IMMUNOL, V170, P4515, DOI 10.4049/jimmunol.170.9.4515; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; De Silva AD, 1999, J IMMUNOL, V163, P4413; Evans M, 2001, J IMMUNOL, V167, P5420, DOI 10.4049/jimmunol.167.9.5420; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Garbi N, 2000, NAT IMMUNOL, V1, P234, DOI 10.1038/79775; GLAS R, 1992, J EXP MED, V175, P843, DOI 10.1084/jem.175.3.843; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; Hicklin DJ, 1999, MOL MED TODAY, V5, P178, DOI 10.1016/S1357-4310(99)01451-3; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; Howell D, 2000, IMMUNOGENETICS, V52, P150, DOI 10.1007/s002510000254; Jensen PE, 2004, IMMUNOL RES, V29, P81, DOI 10.1385/IR:29:1-3:081; Johnsen AK, 1999, J IMMUNOL, V163, P4224; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Meiring HD, 2002, J SEP SCI, V25, P557, DOI 10.1002/1615-9314(20020601)25:9<557::AID-JSSC557>3.0.CO;2-F; Melief CJM, 2000, ADV IMMUNOL, V75, P235, DOI 10.1016/S0065-2776(00)75006-1; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; Qin ZH, 2002, CANCER RES, V62, P2856; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Seliger B, 1997, IMMUNOL TODAY, V18, P292, DOI 10.1016/S0167-5699(97)01052-9; Snyder HL, 1998, EUR J IMMUNOL, V28, P1339; Snyder HL, 1997, J EXP MED, V186, P1087, DOI 10.1084/jem.186.7.1087; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Toomey JA, 1999, J IMMUNOL, V163, P3176; van Hall T, 1998, CANCER RES, V58, P3087; van Hall T, 2000, J IMMUNOL, V165, P869, DOI 10.4049/jimmunol.165.2.869; van Hall T, 2000, J EXP MED, V192, P483, DOI 10.1084/jem.192.4.483; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; Vivier E, 2004, NAT REV IMMUNOL, V4, P190, DOI 10.1038/nri1306; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0; Wolpert EZ, 1997, P NATL ACAD SCI USA, V94, P11496, DOI 10.1073/pnas.94.21.11496; Yewdell JW, 2003, NAT REV IMMUNOL, V3, P952, DOI 10.1038/nri1250; Zwaveling S, 2002, J IMMUNOL, V169, P350, DOI 10.4049/jimmunol.169.1.350	38	113	122	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2006	12	4					417	424		10.1038/nm1381	http://dx.doi.org/10.1038/nm1381			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16550190				2022-12-25	WOS:000236581300030
J	Yi, R; O'Carroll, D; Pasolli, HA; Zhang, ZH; Dietrich, FS; Tarakhovsky, A; Fuchs, E				Yi, R; O'Carroll, D; Pasolli, HA; Zhang, ZH; Dietrich, FS; Tarakhovsky, A; Fuchs, E			Morphogenesis in skin is governed by discrete sets of differentially expressed microRNAs	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; HAIR FOLLICLE; ENZYME DICER; ABSENCE; BIOGENESIS; INTEGRIN; TARGETS; NICHE	During embryogenesis, multipotent progenitors within the single-layered surface epithelium differentiate to form the epidermis and its appendages. Here, we show that microRNAs (miRNAs) have an essential role in orchestrating these events. We cloned more than 100 miRNAs from skin and show that epidermis and hair follicles differentially express discrete miRNA families. To explore the functional significance of this finding, we conditionally targeted Dicer1 gene ablation in embryonic skin progenitors. Within the first week after loss of miRNA expression, cell fate specification and differentiation were not markedly impaired, and in the interfollicular epidermis, apoptosis was not markedly increased. Notably, however, developing hair germs evaginate rather than invaginate, thereby perturbing the epidermal organization. Here we characterize miRNAs in skin, the existence of which was hitherto unappreciated, and demonstrate their differential expression and importance in the morphogenesis of epithelial tissues within this vital organ.	Rockefeller Univ, Lab Lymphocyte Signaling, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10021 USA; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Duke University	Fuchs, E (corresponding author), Rockefeller Univ, Lab Lymphocyte Signaling, 1230 York Ave, New York, NY 10021 USA.	tarakho@rockfeller.edu; fuchslb@rockefeller.edu	Fuchs, Elaine/G-1565-2016	O'Carroll, Donal/0000-0002-8626-2217; Pasolli, Hilda Amalia/0000-0003-3899-3530; YI, RUI/0000-0002-6934-7091	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050452] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050452] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen PY, 2005, GENE DEV, V19, P1288, DOI 10.1101/gad.1310605; Cobb BS, 2005, J EXP MED, V201, P1367, DOI 10.1084/jem.20050572; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fukagawa T, 2004, NAT CELL BIOL, V6, P784, DOI 10.1038/ncb1155; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Muljo SA, 2005, J EXP MED, V202, P261, DOI 10.1084/jem.20050678; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Rendl M, 2005, PLOS BIOL, V3, P1910, DOI 10.1371/journal.pbio.0030331; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	29	420	469	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2006	38	3					356	362		10.1038/ng1744	http://dx.doi.org/10.1038/ng1744			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16462742				2022-12-25	WOS:000235589600019
J	Murray, CM; Hutchinson, R; Bantick, JR; Belfield, GP; Benjamin, AD; Brazma, D; Bundick, RV; Cook, ID; Craggs, RI; Edwards, S; Evans, LR; Harrison, R; Holness, E; Jackson, AP; Jackson, CG; Kingston, LP; Perry, MWD; Ross, ARJ; Rugman, PA; Sidhu, SS; Sullivan, M; Taylor-Fishwick, DA; Walker, PC; Whitehead, YM; Wilkinson, DJ; Wright, A; Donald, DK				Murray, CM; Hutchinson, R; Bantick, JR; Belfield, GP; Benjamin, AD; Brazma, D; Bundick, RV; Cook, ID; Craggs, RI; Edwards, S; Evans, LR; Harrison, R; Holness, E; Jackson, AP; Jackson, CG; Kingston, LP; Perry, MWD; Ross, ARJ; Rugman, PA; Sidhu, SS; Sullivan, M; Taylor-Fishwick, DA; Walker, PC; Whitehead, YM; Wilkinson, DJ; Wright, A; Donald, DK			Monocarboxylate transporter MCT1 is a target for immunosuppression	NATURE CHEMICAL BIOLOGY			English	Article							LACTIC-ACID EFFLUX; ACTIVATED T-CELLS; SKELETAL-MUSCLE; LACTATE; LYMPHOCYTES; METABOLISM; INHIBITORS; CD147; EXPRESSION; FAMILY	Current immunosuppressive therapies act on T lymphocytes by modulation of cytokine production, modulation of signaling pathways or by inhibition of the enzymes of nucleotide biosynthesis. We have identified a previously unknown series of immunomodulatory compounds that potently inhibit human and rat T lymphocyte proliferation in vitro and in vivo in immune-mediated animal models of disease, acting by a novel mechanism. Here we identify the target of these compounds, the monocarboxylate transporter MCT1 ( SLC16A1)(1), using a strategy of photoaffinity labeling and proteomic characterization. We show that inhibition of MCT1 during T lymphocyte activation results in selective and profound inhibition of the extremely rapid phase of T cell division essential for an effective immune response. MCT1 activity, however, is not required for many stages of lymphocyte activation, such as cytokine production, or for most normal physiological functions. By pursuing a chemistry-led target identification strategy, we have discovered that MCT1 is a previously unknown target for immunosuppressive therapy and have uncovered an unsuspected role for MCT1 in immune biology.	AstraZeneca R&D Charnwood, Dept Discovery Biosci, Loughborough LE11 5RH, Leics, England; AstraZeneca R&D Charnwood, Dept Med Chem, Loughborough LE11 5RH, Leics, England; AstraZeneca R&D Charnwood, Dept Mol Biol, Loughborough LE11 5RH, Leics, England; AstraZeneca R&D Charnwood, Dept Phys & Metab Sci, Loughborough LE11 5RH, Leics, England	AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca	Murray, CM (corresponding author), AstraZeneca R&D Charnwood, Dept Discovery Biosci, Bakewell Rd, Loughborough LE11 5RH, Leics, England.	Clare.Murray@astrazeneca.com	Taylor, David/S-5508-2019	Taylor, David/0000-0002-6720-7482; Kingston, Lee/0000-0002-6845-6894; Murray, Clare/0000-0002-5499-6857				BAINE Y, 1995, J IMMUNOL, V154, P3667; Bantick J., 1999, [No title captured], Patent No. [WO 9929695 A1, 9929695]; BENTAL M, 1993, MAGN RESON MED, V29, P317, DOI 10.1002/mrm.1910290307; BENTAL M, 1994, AM J PHYSIOL, V266, pC541, DOI 10.1152/ajpcell.1994.266.2.C541; BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163; CHESHIRE D, 1998, Patent No. 9854190; Daberkow RL, 2003, J NUTR, V133, P2703, DOI 10.1093/jn/133.9.2703; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; DROGE W, 1987, CELL IMMUNOL, V108, P405, DOI 10.1016/0008-8749(87)90223-1; FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682; FORD WL, 1970, TRANSPLANTATION, V10, P258, DOI 10.1097/00007890-197009000-00007; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Frauwirth KA, 2004, J IMMUNOL, V172, P4661, DOI 10.4049/jimmunol.172.8.4661; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; LARSSON P, 1990, ARTHRITIS RHEUM, V33, P693, DOI 10.1002/art.1780330512; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; MICHNE WF, 1995, J MED CHEM, V38, P2557, DOI 10.1021/jm00014a009; Poole RC, 1996, BIOCHEM J, V320, P817, DOI 10.1042/bj3200817; Renno T, 2002, J IMMUNOL, V168, P4946, DOI 10.4049/jimmunol.168.10.4946; ROTH S, 1991, EUR J IMMUNOL, V21, P1933, DOI 10.1002/eji.1830210823; Staffler G, 2003, J IMMUNOL, V171, P1707, DOI 10.4049/jimmunol.171.4.1707; WANG XM, 1994, AM J PHYSIOL-HEART C, V267, pH1759, DOI 10.1152/ajpheart.1994.267.5.H1759; Wilson MC, 1998, J BIOL CHEM, V273, P15920, DOI 10.1074/jbc.273.26.15920	29	180	188	2	31	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	DEC	2005	1	7					371	376		10.1038/nchembio744	http://dx.doi.org/10.1038/nchembio744			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986KE	16370372				2022-12-25	WOS:000233447700008
J	Dumitrescu, AM; Liao, XH; Abdullah, MSY; Lado-Abeal, J; Majed, FA; Moeller, LC; Boran, G; Schomburg, L; Weiss, RE; Refetoff, S				Dumitrescu, AM; Liao, XH; Abdullah, MSY; Lado-Abeal, J; Majed, FA; Moeller, LC; Boran, G; Schomburg, L; Weiss, RE; Refetoff, S			Mutations in SECISBP2 result in abnormal thyroid hormone metabolism	NATURE GENETICS			English	Article							SELENOCYSTEINE TRANSFER-RNA; 5'-DEIODINASE ACTIVITY; TARGETED DISRUPTION; SELENOPROTEIN-P; GENE TRSP; SELENIUM; EXPRESSION; MICE; TRANSPORTER; THYROXINE	Incorporation of selenocysteine (Sec), through recoding of the UGA stop codon, creates a unique class of proteins. Mice lacking tRNA(Sec) die in utero(1), but the in vivo role of other components involved in selenoprotein synthesis is unknown, and Sec incorporation defects have not been described in humans. Deiodinases (DIOs) are selenoproteins involved in thyroid hormone metabolism. We identified three of seven siblings with clinical evidence of abnormal thyroid hormone metabolism. Their fibroblasts showed decreased DIO2 enzymatic activity not linked to the DIO2 locus. Systematic linkage analysis of genes involved in DIO2 synthesis and degradation led to the identification of an inherited Sec incorporation defect, caused by a homozygous missense mutation in SECISBP2 (also called SBP2). An unrelated child with a similar phenotype was compound heterozygous with respect to mutations in SECISBP2. Because SBP2 is epistatic to selenoprotein synthesis, these defects had a generalized effect on selenoproteins. Incomplete loss of SBP2 function probably causes the mild phenotype.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Secur Forces Hosp, Dept Pediat Endocrinol, Riyadh, Saudi Arabia; Prince Abdullah Hosp, Bisha, Saudi Arabia; Adelaide & Meath Hosp, Dept Pathol, Dublin, Ireland; Charite Univ Med Berlin, Inst Expt Endocrinol, Berlin, Germany; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Comm Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago; Security Forces Hospital - Saudi Arabia; Trinity College Dublin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Chicago; University of Chicago	Refetoff, S (corresponding author), Univ Chicago, Dept Med, MC 3090,5841 S Maryland Ave, Chicago, IL 60637 USA.	refetoff@uchicago.edu	Schomburg, Lutz/D-8096-2013; Refetoff, Samuel/ABB-1263-2021	Schomburg, Lutz/0000-0001-9445-1555; Refetoff, Samuel/0000-0003-0164-8231; Moeller, Lars/0000-0002-9330-9036; lado-abeal, joaquin/0000-0002-3970-9696				BALZANO S, 1990, ENDOCRINOLOGY, V127, P882, DOI 10.1210/endo-127-2-882; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Botero D, 2002, MOL ENDOCRINOL, V16, P1999, DOI 10.1210/me.2002-0135; Carlson BA, 2005, J BIOL CHEM, V280, P5542, DOI 10.1074/jbc.M411725200; Carlson BA, 2004, J BIOL CHEM, V279, P8011, DOI 10.1074/jbc.M310470200; Chu FF, 2004, CANCER RES, V64, P962, DOI 10.1158/0008-5472.CAN-03-2272; Copeland PR, 2003, GENE, V312, P17, DOI 10.1016/S0378-1119(03)00588-2; Curcio-Morelli C, 2003, J CLIN INVEST, V112, P189, DOI 10.1172/JCI200318348; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Dumitrescu A, 2004, THYROID, V14, P761; Dumitrescu AM, 2004, AM J HUM GENET, V74, P168, DOI 10.1086/380999; Friesema ECH, 2004, LANCET, V364, P1435, DOI 10.1016/S0140-6736(04)17226-7; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2003, MOL CELL BIOL, V23, P1477, DOI 10.1128/MCB.23.5.1477-1488.2003; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; Lescure A, 2002, GENE, V291, P279, DOI 10.1016/S0378-1119(02)00629-7; Moustafa ME, 2003, J NUTR, V133, p2494S, DOI 10.1093/jn/133.7.2494S; Olson GE, 2005, BIOL REPROD, V73, P201, DOI 10.1095/biolreprod.105.040360; Sachdev SW, 2001, BIOCHEM J, V357, P851; Schneider MJ, 2001, MOL ENDOCRINOL, V15, P2137, DOI 10.1210/me.15.12.2137; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; Schomburg L, 2004, CELL MOL LIFE SCI, V61, P1988, DOI 10.1007/s00018-004-4114-z; Schussler GC, 2000, THYROID, V10, P141, DOI 10.1089/thy.2000.10.141; SCHUSSLER GC, 1967, J CLIN ENDOCR METAB, V27, P242, DOI 10.1210/jcem-27-2-242; Schweizer U, 2004, J NUTR, V134, P707, DOI 10.1093/jn/134.4.707	27	280	295	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2005	37	11					1247	1252		10.1038/ng1654	http://dx.doi.org/10.1038/ng1654			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16228000				2022-12-25	WOS:000233045200025
J	Hoshi, N; Langeberg, LK; Scott, JD				Hoshi, N; Langeberg, LK; Scott, JD			Distinct enzyme combinations in AKAP signalling complexes permit functional diversity	NATURE CELL BIOLOGY			English	Article							DEPENDENT PROTEIN-KINASE; SYMPATHETIC NEURONS; CHANNEL SUBUNITS; PHOSPHORYLATION; SUPPRESSION; DOMAINS; GLUR1; INHIBITION; MODULATION; RECEPTORS	Specificity in cell signalling can be influenced by the targeting of different enzyme combinations to substrates. The A-kinase anchoring protein AKAP79/150 is a multivalent scaffolding protein that coordinates the subcellular localization of second-messenger-regulated enzymes, such as protein kinase A, protein kinase C and protein phosphatase 2B. We developed a new strategy that combines RNA interference of the endogenous protein with a protocol that selects cells that have been rescued with AKAP79/150 forms that are unable to anchor selected enzymes. Using this approach, we show that AKAP79/150 coordinates different enzyme combinations to modulate the activity of two distinct neuronal ion channels: AMPA-type glutamate receptors and M-type potassium channels. Utilization of distinct enzyme combinations in this manner provides a means to expand the repertoire of cellular events that the same AKAP modulates.	Oregon Hlth & Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97239 USA	Howard Hughes Medical Institute; Oregon Health & Science University	Scott, JD (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, Howard Hughes Med Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	scott@ohsu.edu			NIGMS NIH HHS [R37 GM048231, R01 GM048231, GM48231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; BOSMA MM, 1989, P NATL ACAD SCI USA, V86, P2943, DOI 10.1073/pnas.86.8.2943; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; Cooper EC, 2000, P NATL ACAD SCI USA, V97, P4914, DOI 10.1073/pnas.090092797; Cruzblanca H, 1998, P NATL ACAD SCI USA, V95, P7151, DOI 10.1073/pnas.95.12.7151; Dell'Acqua ML, 2002, J BIOL CHEM, V277, P48796, DOI 10.1074/jbc.M207833200; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hoshi N, 2003, NAT NEUROSCI, V6, P564, DOI 10.1038/nn1062; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Marrion NV, 1996, NEURON, V16, P163, DOI 10.1016/S0896-6273(00)80033-1; Marrion NV, 1997, ANNU REV PHYSIOL, V59, P483, DOI 10.1146/annurev.physiol.59.1.483; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Smith WB, 2005, NEURON, V45, P765, DOI 10.1016/j.neuron.2005.01.015; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9	29	136	139	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1066	1073		10.1038/ncb1315	http://dx.doi.org/10.1038/ncb1315			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16228013	Green Accepted			2022-12-25	WOS:000232930400009
J	Mito, Y; Henikoff, JG; Henikoff, S				Mito, Y; Henikoff, JG; Henikoff, S			Genome-scale profiling of histone H3.3 replacement patterns	NATURE GENETICS			English	Article							INTERGENIC TRANSCRIPTION; DNA-REPLICATION; ACTIVE GENES; CHROMATIN; METHYLATION; POLYCOMB; ACETYLATION; DEPOSITION; VARIANTS; ELONGATION	Histones of multicellular organisms are assembled into chromatin primarily during DNA replication. When chromatin assembly occurs at other times, the histone H3.3 variant replaces canonical H3. Here we introduce a new strategy for profiling epigenetic patterns on the basis of H3.3 replacement, using microarrays covering roughly one-third of the Drosophila melanogaster genome at 100-bp resolution. We identified patterns of H3.3 replacement over active genes and transposons. H3.3 replacement occurred prominently at sites of abundant RNA polymerase II and methylated H3 Lys4 throughout the genome and was enhanced on the dosage-compensated male X chromosome. Active genes were depleted of histones at promoters and were enriched in H3.3 from upstream to downstream of transcription units. We propose that deposition and inheritance of actively modified H3.3 in regulatory regions maintains transcriptionally active chromatin.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Howard Hughes Med Inst, Coconut Grove, FL 33133 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Henikoff, S (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	steveh@fhcrc.org		Henikoff, Steven/0000-0002-7621-8685				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Ahmad K, 2001, J CELL BIOL, V153, P101, DOI 10.1083/jcb.153.1.101; Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Blower MD, 2002, DEV CELL, V2, P319, DOI 10.1016/S1534-5807(02)00135-1; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chow CM, 2005, EMBO REP, V6, P354, DOI 10.1038/sj.embor.7400366; Copps K, 1998, EMBO J, V17, P5409, DOI 10.1093/emboj/17.18.5409; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; Echalier G., 1997, DROSOPHILA CELLS CUL; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; Henikoff S, 2004, TRENDS GENET, V20, P320, DOI 10.1016/j.tig.2004.05.004; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; HENIKOFF S, 1993, CELL, V72, P1, DOI 10.1016/0092-8674(93)90040-W; Hogga I, 2002, DEVELOPMENT, V129, P4915; Iwaki T, 2003, BIOTECHNIQUES, V35, P482, DOI 10.2144/03353bm08; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Johnson JM, 2005, TRENDS GENET, V21, P93, DOI 10.1016/j.tig.2004.12.009; Johnson L, 2004, NUCLEIC ACIDS RES, V32, P6511, DOI 10.1093/nar/gkh992; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kristjuhan A, 2004, EMBO J, V23, P4243, DOI 10.1038/sj.emboj.7600433; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; LIPSHITZ HD, 1987, GENE DEV, V1, P307, DOI 10.1101/gad.1.3.307; MacAlpine DM, 2004, GENE DEV, V18, P3094, DOI 10.1101/gad.1246404; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rank G, 2002, MOL CELL BIOL, V22, P8026, DOI 10.1128/MCB.22.22.8026-8034.2002; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Roh TY, 2004, NAT BIOTECHNOL, V22, P1013, DOI 10.1038/nbt990; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schmitt S, 2005, GENE DEV, V19, P697, DOI 10.1101/gad.326205; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Schwabish MA, 2004, MOL CELL BIOL, V24, P10111, DOI 10.1128/MCB.24.23.10111-10117.2004; Schwartz BE, 2005, GENE DEV, V19, P804, DOI 10.1101/gad.1259805; Smith ER, 2001, J BIOL CHEM, V276, P31483, DOI 10.1074/jbc.C100351200; Straub T, 2005, FEBS LETT, V579, P3258, DOI 10.1016/j.febslet.2005.03.050; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Thiriet C, 2005, GENE DEV, V19, P677, DOI 10.1101/gad.1265205; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; van Steensel B, 2005, NAT GENET, V37, pS18, DOI 10.1038/ng1559; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; WOLFFE A, 1992, CHROMATIN STRUCTURE; Workman JL, 2004, P NATL ACAD SCI USA, V101, P1429, DOI 10.1073/pnas.0308506101; Wyers F, 2005, CELL, V121, P725, DOI 10.1016/j.cell.2005.04.030; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178	50	407	424	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1090	1097		10.1038/ng1637	http://dx.doi.org/10.1038/ng1637			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16155569				2022-12-25	WOS:000232185600020
J	Reich, D; Patterson, N; De Jager, PL; McDonald, GJ; Waliszewska, A; Tandon, A; Lincoln, RR; DeLoa, C; Fruhan, SA; Cabre, P; Bera, O; Semana, G; Kelly, MA; Francis, DA; Ardlie, K; Khan, O; Cree, BAC; Hauser, SL; Oksenberg, JR; Hafler, DA				Reich, D; Patterson, N; De Jager, PL; McDonald, GJ; Waliszewska, A; Tandon, A; Lincoln, RR; DeLoa, C; Fruhan, SA; Cabre, P; Bera, O; Semana, G; Kelly, MA; Francis, DA; Ardlie, K; Khan, O; Cree, BAC; Hauser, SL; Oksenberg, JR; Hafler, DA			A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility	NATURE GENETICS			English	Article							HLA-DR LOCUS; LINKAGE-DISEQUILIBRIUM; AFRICAN-AMERICANS; ADMIXED POPULATIONS; DIAGNOSTIC-CRITERIA; ETHNIC-DIFFERENCES; DISEASE GENES; MAPPING GENES; GUIDELINES; RISK	Multiple sclerosis is a common disease with proven heritability, but, despite large-scale attempts, no underlying risk genes have been identified. Traditional linkage scans have so far identified only one risk haplotype for multiple sclerosis (at HLA on chromosome 6), which explains only a fraction of the increased risk to siblings. Association scans such as admixture mapping have much more power, in principle, to find the weak factors that must explain most of the disease risk. We describe here the first high-powered admixture scan, focusing on 605 African American cases and 1,043 African American controls, and report a locus on chromosome 1 that is significantly associated with multiple sclerosis.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02138 USA; MIT, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Lab Mol Immunol, Boston, MA 02115 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Hop Quitman, Neurol Clin, Fort De France, France; Univ Rennes 1, Lab Univ Immunol, Rennes, France; Estab Francais Sang Bretagne, Rennes, France; Univ Hosp Birmingham, Dept Med, Div Med Sci, Birmingham, W Midlands, England; Genom Collaborat, Cambridge, MA USA; Wayne State Univ, Sch Med, Dept Neurol, Multiple Sclerosis Ctr, Detroit, MI 48201 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco; CHU Martinique; Universite de Rennes; University of Birmingham; Wayne State University	Reich, D (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	reich@receptor.med.harvard.edu	Hauser, Stephen L/J-2978-2016					BRISCOE D, 1994, J HERED, V85, P59; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; CHAKRABORTY R, 1988, P NATL ACAD SCI USA, V85, P9119, DOI 10.1073/pnas.85.23.9119; Cree BAC, 2004, NEUROLOGY, V63, P2039, DOI 10.1212/01.WNL.0000145762.60562.5D; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Fan JB, 2003, COLD SPRING HARB SYM, V68, P69, DOI 10.1101/sqb.2003.68.69; Hoggart CJ, 2004, AM J HUM GENET, V74, P965, DOI 10.1086/420855; Hoggart CJ, 2003, AM J HUM GENET, V72, P1492, DOI 10.1086/375613; Hosono S, 2003, GENOME RES, V13, P954, DOI 10.1101/gr.816903; KELLY MA, 1995, TISSUE ANTIGENS, V45, P197, DOI 10.1111/j.1399-0039.1995.tb02439.x; Kong X, 2004, AM J HUM GENET, V75, P1143, DOI 10.1086/426405; KURTZKE JF, 1979, NEUROLOGY, V29, P1228, DOI 10.1212/WNL.29.9_Part_1.1228; LAUER K, 1994, J CLIN EPIDEMIOL, V47, P43, DOI 10.1016/0895-4356(94)90032-9; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; McKeigue PM, 1998, AM J HUM GENET, V63, P241, DOI 10.1086/301908; McKeigue PM, 1997, AM J HUM GENET, V60, P188; Montana G, 2004, AM J HUM GENET, V75, P771, DOI 10.1086/425281; Oksenberg JR, 2004, AM J HUM GENET, V74, P160, DOI 10.1086/380997; Patterson N, 2004, AM J HUM GENET, V74, P979, DOI 10.1086/420871; Pericak-Vance MA, 2001, MULT SCLER, V7, P3; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Quelvennec E, 2003, TISSUE ANTIGENS, V61, P166, DOI 10.1046/j.0001-2815.2002.00008.x; Reich D, 2005, PHILOS T ROY SOC B, V360, P1605, DOI 10.1098/rstb.2005.1691; RIFE DC, 1954, AM J HUM GENET, V6, P26; Sawcer S, 2005, AM J HUM GENET, V77, P454; Smith MW, 2004, AM J HUM GENET, V74, P1001, DOI 10.1086/420856; STEPHENS JC, 1994, AM J HUM GENET, V55, P809; Tang K, 1999, P NATL ACAD SCI USA, V96, P10016, DOI 10.1073/pnas.96.18.10016; Wallin MT, 2004, ANN NEUROL, V55, P65, DOI 10.1002/ana.10788; Zhu XF, 2005, NAT GENET, V37, P177, DOI 10.1038/ng1510	30	216	218	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2005	37	10					1113	1118		10.1038/ng1646	http://dx.doi.org/10.1038/ng1646			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16186815				2022-12-25	WOS:000232185600024
J	Blum, G; Mullins, SR; Keren, K; Fonovic, M; Jedeszko, C; Rice, MJ; Sloane, BF; Bogyo, M				Blum, G; Mullins, SR; Keren, K; Fonovic, M; Jedeszko, C; Rice, MJ; Sloane, BF; Bogyo, M			Dynamic imaging of protease activity with fluorescently quenched activity-based probes	NATURE CHEMICAL BIOLOGY			English	Article							ENZYME-ACTIVITY PROFILES; CATHEPSIN-L; CHEMICAL STRATEGIES; CYSTEINE PROTEASES; SUBSTRATE-BINDING; INHIBITORS; PROTEOMICS; SERINE; GROWTH	Protease activity is tightly regulated in both normal and disease conditions. However, it is often difficult to monitor the dynamic nature of this regulation in the context of a live cell or whole organism. To address this limitation, we developed a series of quenched activity-based probes (qABPs) that become fluorescent upon activity-dependent covalent modification of a protease target. These reagents freely penetrate cells and allow direct imaging of protease activity in living cells. Targeted proteases are directly identified and monitored biochemically by virtue of the resulting covalent tag, thereby allowing unambiguous assignment of protease activities observed in imaging studies. We report here the design and synthesis of a selective, cell-permeable qABP for the study of papain-family cysteine proteases. This probe is used to monitor real-time protease activity in live human cells with fluorescence microscopy techniques as well as standard biochemical methods.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 1000, Slovenia	Stanford University; Stanford University; Stanford University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute	Bogyo, M (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.	mbogyo@stanford.edu	Fonović, Marko/X-9957-2019; Sloane, Bonnie F/A-1050-2009	Fonovic, Marko/0000-0002-8375-6713; Keren, Kinneret/0000-0002-2962-6977; Bogyo, Matthew/0000-0003-3753-4412	NCRR NIH HHS [U54 RR020843] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adam GC, 2002, MOL CELL PROTEOMICS, V1, P781, DOI 10.1074/mcp.R200006-MCP200; Barlic-Maganja D, 1998, BIOL CHEM, V379, P1449; Baruch A, 2004, TRENDS CELL BIOL, V14, P29, DOI 10.1016/j.tcb.2003.11.002; Baruch A, 2001, J BIOL CHEM, V276, P28999, DOI 10.1074/jbc.M103628200; Berger Alicia B, 2004, Am J Pharmacogenomics, V4, P371, DOI 10.2165/00129785-200404060-00004; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2; Bogyo M, 1998, CHEM BIOL, V5, P307, DOI 10.1016/S1074-5521(98)90169-7; Borodovsky A, 2005, CHEMBIOCHEM, V6, P287, DOI 10.1002/cbic.200400236; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Chan EWS, 2004, J AM CHEM SOC, V126, P14435, DOI 10.1021/ja047044i; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DEVAL C, 1990, BIOCHEM CELL BIOL, V68, P822, DOI 10.1139/o90-121; Falgueyret JP, 2004, ANAL BIOCHEM, V335, P218, DOI 10.1016/j.ab.2004.09.005; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Greenbaum D, 2002, MOL CELL PROTEOMICS, V1, P60, DOI 10.1074/mcp.T100003-MCP200; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Greenbaum DC, 2002, SCIENCE, V298, P2002, DOI 10.1126/science.1077426; Hemelaar J, 2004, MOL CELL BIOL, V24, P84, DOI 10.1128/MCB.24.1.84-95.2004; Jeffery DA, 2003, CURR OPIN BIOTECH, V14, P87, DOI 10.1016/S0958-1669(02)00010-1; Jessani N, 2004, P NATL ACAD SCI USA, V101, P13756, DOI 10.1073/pnas.0404727101; Jessani N, 2004, CURR OPIN CHEM BIOL, V8, P54, DOI 10.1016/j.cbpa.2003.11.004; Jessani N, 2002, P NATL ACAD SCI USA, V99, P10335, DOI 10.1073/pnas.162187599; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kato D, 2005, NAT CHEM BIOL, V1, P33, DOI 10.1038/nchembio707; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Mahrus S, 2005, CHEM BIOL, V12, P567, DOI 10.1016/j.chembiol.2005.03.006; MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Okerberg ES, 2005, P NATL ACAD SCI USA, V102, P4996, DOI 10.1073/pnas.0501205102; Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; Sando S, 2002, J AM CHEM SOC, V124, P2096, DOI 10.1021/ja017328s; Sando S, 2002, J AM CHEM SOC, V124, P9686, DOI 10.1021/ja026649g; Speers AE, 2004, CHEMBIOCHEM, V5, P41, DOI 10.1002/cbic.200300721; Turk D, 1998, BIOL CHEM, V379, P137, DOI 10.1515/bchm.1998.379.2.137; Yasothornsrikul S, 2003, P NATL ACAD SCI USA, V100, P9590, DOI 10.1073/pnas.1531542100	39	268	281	3	98	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2005	1	4					203	209		10.1038/nchembio728	http://dx.doi.org/10.1038/nchembio728			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GM	16408036				2022-12-25	WOS:000232649000011
J	Janowski, BA; Kaihatsu, K; Huffman, KE; Schwartz, JC; Ram, R; Hardy, D; Mendelson, CR; Corey, DR				Janowski, BA; Kaihatsu, K; Huffman, KE; Schwartz, JC; Ram, R; Hardy, D; Mendelson, CR; Corey, DR			Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids	NATURE CHEMICAL BIOLOGY			English	Article							GENE-EXPRESSION; STRAND DISPLACEMENT; PNA; SEQUENCE; OLIGONUCLEOTIDES; RECOGNITION; BINDING; EZRIN; COMPLEMENTARY; ESTRADIOL	Synthetic molecules that recognize specific sequences within cellular DNA are potentially powerful tools for investigating chromosome structure and function. Here, we designed antigene peptide nucleic acids (agPNAs) to target the transcriptional start sites for the human progesterone receptor B (hPR-B) and A (hPR-A) isoforms at sequences predicted to be single-stranded within the open complex of chromosomal DNA. We found that the agPNAs were potent inhibitors of transcription, showing for the first time that synthetic molecules can recognize transcription start sites inside cells. Breast cancer cells treated with agPNAs showed marked changes in morphology and an unexpected relationship between the strictly regulated levels of hPR-B and hPR-A. We confirmed these phenotypes using siRNAs and antisense PNAs, demonstrating the power of combining antigene and antisense strategies for gene silencing. agPNAs provide a general approach for controlling transcription initiation and a distinct option for target validation and therapeutic development.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Corey, DR (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	david.corey@utsouthwestern.edu	Schwartz, Jacob/J-6477-2012	Schwartz, Jacob/0000-0002-5205-564X; Hardy, Daniel/0000-0001-5445-273X; Mendelson, Carole Ruth/0000-0003-1696-9791	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD011149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073042] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD011149] Funding Source: Medline; NIGMS NIH HHS [R01 GM073042] Funding Source: Medline; PHS HHS [60642, 73042] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bentin T, 1996, BIOCHEMISTRY-US, V35, P8863, DOI 10.1021/bi960436k; Besch R, 2004, J MOL BIOL, V341, P979, DOI 10.1016/j.jmb.2004.05.079; Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100; Conneely OM, 2003, J MAMMARY GLAND BIOL, V8, P205, DOI 10.1023/A:1025952924864; Demidov VV, 2001, CHEMBIOCHEM, V2, P133, DOI 10.1002/1439-7633(20010202)2:2<133::AID-CBIC133>3.3.CO;2-C; Dervan PB, 2003, CURR OPIN STRUC BIOL, V13, P284, DOI 10.1016/S0959-440X(03)00081-2; Doyle DF, 2001, BIOCHEMISTRY-US, V40, P53, DOI 10.1021/bi0020630; Dudouet B, 2003, CHEM BIOL, V10, P859, DOI 10.1016/j.chembiol.2003.09.001; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Faruqi AF, 1998, P NATL ACAD SCI USA, V95, P1398, DOI 10.1073/pnas.95.4.1398; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Hunter KW, 2004, TRENDS MOL MED, V10, P201, DOI 10.1016/j.molmed.2004.03.001; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; JANOWSKI BA, 2005, IN PRESS NAT CHEM BI; Kahl BF, 2000, J MOL BIOL, V299, P75, DOI 10.1006/jmbi.2000.3743; Kaihatsu K, 2004, CHEM BIOL, V11, P749, DOI 10.1016/j.chembiol.2003.09.014; Kaihatsu K, 2004, BIOCHEMISTRY-US, V43, P14340, DOI 10.1021/bi048519l; Karmakar S, 2004, J REPROD IMMUNOL, V64, P9, DOI 10.1016/j.jri.2004.04.005; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Knauert MP, 2001, HUM MOL GENET, V10, P2243, DOI 10.1093/hmg/10.20.2243; Larsen HJ, 1996, NUCLEIC ACIDS RES, V24, P458, DOI 10.1093/nar/24.3.458; Liu YH, 2004, BIOCHEMISTRY-US, V43, P1921, DOI 10.1021/bi0358519; Mattick JS, 2005, HUM MOL GENET, V14, pR121, DOI 10.1093/hmg/ddi101; McGowan EM, 2003, J MOL ENDOCRINOL, V31, P241, DOI 10.1677/jme.0.0310241; Milne L, 2000, P NATL ACAD SCI USA, V97, P3136, DOI 10.1073/pnas.050544597; MISRAHI M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P289, DOI 10.1016/0167-4781(93)90156-8; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Nulf CJ, 2004, NUCLEIC ACIDS RES, V32, P3792, DOI 10.1093/nar/gkh706; Song J, 2005, CANCER LETT, V220, P57, DOI 10.1016/j.canlet.2004.04.024; Stein CA, 1999, NAT BIOTECHNOL, V17, P209, DOI 10.1038/6909; Vienonen A, 2002, J STEROID BIOCHEM, V80, P307, DOI 10.1016/S0960-0760(02)00027-4; Zhang X, 2000, NUCLEIC ACIDS RES, V28, P3332, DOI 10.1093/nar/28.17.3332	35	136	154	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2005	1	4					210	215		10.1038/nchembio724	http://dx.doi.org/10.1038/nchembio724			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GM	16408037				2022-12-25	WOS:000232649000012
J	Elliott, JI; Surprenant, A; Marelli-Berg, FM; Cooper, JC; Cassady-Cain, RL; Wooding, C; Linton, K; Alexander, DR; Higgins, CF				Elliott, JI; Surprenant, A; Marelli-Berg, FM; Cooper, JC; Cassady-Cain, RL; Wooding, C; Linton, K; Alexander, DR; Higgins, CF			Membrane phosphatidylserine distribution as a non-apoptotic signalling mechanism in lymphocytes	NATURE CELL BIOLOGY			English	Article							P2X(7) RECEPTOR; T-CELL; PLASMA-MEMBRANE; MULTIDRUG TRANSPORTER; ENDOTHELIAL-CELLS; P-GLYCOPROTEIN; B-CELL; EXPOSURE; ANTIGEN; MITOCHONDRIAL	Phosphatidylserine (PS) exposure is normally associated with apoptosis and the removal of dying cells. We observed that PS is exposed constitutively at high levels on T lymphocytes that express low levels of the transmembrane tyrosine phosphatase CD45RB. CD45 was shown to be a negative regulator of PS translocation in response to various signals, including activation of the ATP receptor P2X(7). Changes in PS distribution were shown to modulate several membrane activities: Ca2+ and Na+ uptake through the P2X(7) cation channel itself; P2X(7)-stimulated shedding of the homing receptor CD62L; and reversal of activity of the multidrug transporter P-glycoprotein. The data identify a role for PS distribution changes in signal transduction, rapidly modulating the activities of several membrane proteins. This seems to be an all-or-none effect, coordinating the activity of most or all the molecules of a target protein in each cell. The data also suggest a new approach to circumventing multidrug resistance.	Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Ctr Clin Sci, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Immunol, London W12 0NN, England; Univ Sheffield, Dept Biomed Sci, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England; Babraham Inst, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	Imperial College London; Imperial College London; University of Sheffield; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Elliott, JI (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Ctr Clin Sci, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	james.elliott@csc.mrc.ac.uk						Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Balasubramanian K, 2003, ANNU REV PHYSIOL, V65, P701, DOI 10.1146/annurev.physiol.65.092101.142459; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Bucki R, 2001, BIOCHEMISTRY-US, V40, P15752, DOI 10.1021/bi010899c; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Castedo M, 1996, J IMMUNOL, V157, P512; CONNOR J, 1994, J BIOL CHEM, V269, P2399; Elliott JI, 2004, BRIT J PHARMACOL, V143, P899, DOI 10.1038/sj.bjp.0705940; Elliott JI, 2004, DIABETES, V53, P2012, DOI 10.2337/diabetes.53.8.2012; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Faria RX, 2005, AM J PHYSIOL-CELL PH, V288, pC260, DOI 10.1152/ajpcell.00215.2004; Frasch SC, 2004, J BIOL CHEM, V279, P17625, DOI 10.1074/jbc.M313414200; Gadella BM, 2002, BIOL REPROD, V67, P340, DOI 10.1095/biolreprod67.1.340; Galkina E, 2003, J EXP MED, V198, P1323, DOI 10.1084/jem.20030485; Gatti R, 1998, J HISTOCHEM CYTOCHEM, V46, P895, DOI 10.1177/002215549804600804; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; James MJ, 2003, BLOOD, V102, P2173, DOI 10.1182/blood-2003-02-0637; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Kurosaka K, 2003, J IMMUNOL, V171, P4672, DOI 10.4049/jimmunol.171.9.4672; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1; Marelli-Berg FM, 2000, J IMMUNOL, V165, P4182, DOI 10.4049/jimmunol.165.8.4182; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; Marty V, 2005, GLIA, V49, P511, DOI 10.1002/glia.20138; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ogilvy S, 2003, J IMMUNOL, V171, P1792, DOI 10.4049/jimmunol.171.4.1792; Ralevic V, 1998, PHARMACOL REV, V50, P413; Schinkel AH, 2001, ADV EXP MED BIOL, V500, P365; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; Schlegel RA, 2000, ANN NY ACAD SCI, V926, P217; SCOTT DM, 1995, NATURE, V376, P695, DOI 10.1038/376695a0; Shi JL, 2003, BLOOD, V101, P2628, DOI 10.1182/blood-2002-07-1951; Sim JA, 2004, J NEUROSCI, V24, P6307, DOI 10.1523/JNEUROSCI.1469-04.2004; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; van den Eijnde SM, 2001, J CELL SCI, V114, P3631; Wiley JS, 1998, AM J PHYSIOL-CELL PH, V275, pC1224, DOI 10.1152/ajpcell.1998.275.5.C1224	44	177	182	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2005	7	8					808	U76		10.1038/ncb1279	http://dx.doi.org/10.1038/ncb1279			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	950TU	16025105				2022-12-25	WOS:000230881500015
J	Greiner, D; Bonaldi, T; Eskeland, R; Roemer, E; Imhof, A				Greiner, D; Bonaldi, T; Eskeland, R; Roemer, E; Imhof, A			Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9	NATURE CHEMICAL BIOLOGY			English	Article							DROSOPHILA SU(VAR)3-9; CANCER; METHYLATION; H3	Histone methylation plays a key role in establishing and maintaining stable gene expression patterns during cellular differentiation and embryonic development. Here, we report the characterization of the fungal metabolite chaetocin as the first inhibitor of a lysine-specific histone methyltransferase. Chaetocin is specific for the methyltransferase SU(VAR) 3-9 both in vitro and in vivo and may therefore be used to study heterochromatin-mediated gene repression.	Univ Munich, Histone Modificat Grp, Adolf Butenandt Inst, Dept Mol Biol, D-80336 Munich, Germany; Leibniz Inst Nat Forsch & Infekt Biol, Hans Knoll Inst Nat Forsch, Abt Mol Nat Forsch, D-07745 Jena, Germany	University of Munich; Hans Knoll Institute (HKI)	Imhof, A (corresponding author), Univ Munich, Histone Modificat Grp, Adolf Butenandt Inst, Dept Mol Biol, Schillerstr 44, D-80336 Munich, Germany.	imhof@lmu.de	Eskeland, Ragnhild/GSN-9383-2022; Eskeland, Ragnhild/AFM-2892-2022; Eskeland, Ragnhild/K-7018-2014; Imhof, Axel/AAU-5313-2021; Bonaldi, Tiziana/K-5075-2016	Eskeland, Ragnhild/0000-0003-2789-3171; Eskeland, Ragnhild/0000-0003-2789-3171; Imhof, Axel/0000-0003-2993-8249; Bonaldi, Tiziana/0000-0003-3556-1265				Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Bonaldi T, 2004, PROTEOMICS, V4, P1382, DOI 10.1002/pmic.200300743; Eskeland R, 2004, BIOCHEMISTRY-US, V43, P3740, DOI 10.1021/bi035964s; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gardiner DM, 2005, MICROBIOL-SGM, V151, P1021, DOI 10.1099/mic.0.27847-0; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; HAUSER D, 1970, HELV CHIM ACTA, V53, P1061, DOI 10.1002/hlca.19700530521; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Mei SP, 2004, INT J ONCOL, V25, P1509; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Saveliev A, 2003, NATURE, V422, P909, DOI 10.1038/nature01596; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Wolffe A., 1998, CHROMATIN STRUCTURE	14	386	412	0	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2005	1	3					143	145		10.1038/nchembio721	http://dx.doi.org/10.1038/nchembio721			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GJ	16408017				2022-12-25	WOS:000232648700012
J	Morrissey, DV; Lockridge, JA; Shaw, L; Blanchard, K; Jensen, K; Breen, W; Hartsough, K; Machemer, L; Radka, S; Jadhav, V; Vaish, N; Zinnen, S; Vargeese, C; Bowman, K; Shaffer, CS; Jeffs, LB; Judge, A; MacLachlan, I; Polisky, B				Morrissey, DV; Lockridge, JA; Shaw, L; Blanchard, K; Jensen, K; Breen, W; Hartsough, K; Machemer, L; Radka, S; Jadhav, V; Vaish, N; Zinnen, S; Vargeese, C; Bowman, K; Shaffer, CS; Jeffs, LB; Judge, A; MacLachlan, I; Polisky, B			Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs	NATURE BIOTECHNOLOGY			English	Article							PLASMID-LIPID PARTICLES; SHORT INTERFERING RNA; GENE-EXPRESSION; MOUSE MODEL; DNA; REPLICATION; INDUCTION	The efficacy of lipid-encapsulated, chemically modified short interfering RNA ( siRNA) targeted to hepatitis B virus (HBV) was examined in an in vivo mouse model of HBV replication. Stabilized siRNA targeted to the HBV RNA was incorporated into a specialized liposome to form a stable nucleic-acid-lipid particle (SNALP) and administered by intravenous injection into mice carrying replicating HBV. The improved efficacy of siRNA-SNALP compared to unformulated siRNA correlates with a longer half-life in plasma and liver. Three daily intravenous injections of 3 mg/kg/day reduced serum HBV DNA >1.0 log(10). The reduction in HBV DNA was specific, dose-dependent and lasted for up to 7 d after dosing. Furthermore, reductions were seen in serum HBV DNA for up to 6 weeks with weekly dosing. The advances demonstrated here, including persistence of in vivo activity, use of lower doses and reduced dosing frequency are important steps in making siRNA a clinically viable therapeutic approach.	Sirna Therapeut Inc, Boulder, CO 80301 USA; Protiva Biotherapeut Inc, Burnaby, BC V5G 4Y1, Canada		Morrissey, DV (corresponding author), Sirna Therapeut Inc, 2950 Wilderness Pl, Boulder, CO 80301 USA.	morrisseyd@sirna.com						Ambegia E, 2005, BBA-BIOMEMBRANES, V1669, P155, DOI 10.1016/j.bbamem.2005.02.001; Bally MM, 1993, LIPOSOME TECHNOLOGY, P27; Buckwold VE, 1996, J VIROL, V70, P5845, DOI 10.1128/JVI.70.9.5845-5851.1996; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Fenske DB, 2002, METHOD ENZYMOL, V346, P36; Fenske DB, 2001, CURR OPIN MOL THER, V3, P153; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Jeffs LB, 2005, PHARM RES-DORDR, V22, P362, DOI 10.1007/s11095-004-1873-z; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sandberg JA, 2000, J CLIN PHARMACOL, V40, P1462; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Wheeler JJ, 1999, GENE THER, V6, P271, DOI 10.1038/sj.gt.3300821; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599	19	919	1126	4	152	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2005	23	8					1002	1007		10.1038/nbt1122	http://dx.doi.org/10.1038/nbt1122			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	952QF	16041363				2022-12-25	WOS:000231019900034
J	Rajalingam, K; Wunder, C; Brinkmann, V; Churin, Y; Hekman, M; Sievers, C; Rapp, UR; Rudel, T				Rajalingam, K; Wunder, C; Brinkmann, V; Churin, Y; Hekman, M; Sievers, C; Rapp, UR; Rudel, T			Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration	NATURE CELL BIOLOGY			English	Letter							14-3-3 BINDING; C-RAF; KINASE; CHOLESTEROL; RECRUITMENT; MEMBRANE; CAVEOLAE; TARGETS; FAMILY	Ras proteins control the signalling pathways that are responsible for normal growth and malignant transformation(1). Raf protein kinases are direct Ras effector proteins that initiate the mitogen-activated protein kinase (MAPK) cascade(2), which mediates diverse biological functions such as cell growth, survival and differentiation(3). Here we show that prohibitin, a ubiquitously expressed and evolutionarily conserved protein(4) is indispensable for the activation of the Raf-MEK-ERK pathway by Ras. The membrane targeting and activation of C-Raf by Ras needs prohibitin in vivo. In addition, direct interaction with prohibitin is required for C-Raf activation. C-Raf kinase fails to interact with the active Ras induced by epidermal growth factor in the absence of prohibitin. Moreover, in prohibitin-deficient cells the adhesion complex proteins cadherin and beta-catenin relocalize to the plasma membrane and thereby stabilize adherens junctions. Our data show an unexpected role of prohibitin in the activation of the Ras-Raf signalling pathway and in modulating epithelial cell adhesion and migration.	Max Planck Inst Infect Biol, Dept Mol Biol, D-10117 Berlin, Germany; Microscopy Core Facil, D-10117 Berlin, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	Max Planck Society; University of Wurzburg	Rudel, T (corresponding author), Max Planck Inst Infect Biol, Dept Mol Biol, Schumannstr 21-22, D-10117 Berlin, Germany.	rudel@mpiib-berlin.mpg.de	Brinkmann, Volker/A-6015-2009; Rajalingam, krishnaraj/D-3081-2011; Wunder, Christian/K-8542-2017	Wunder, Christian/0000-0001-9091-0080				ASAMOTO M, 1994, CANCER LETT, V83, P201, DOI 10.1016/0304-3835(94)90320-4; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; Hekman M, 2004, J BIOL CHEM, V279, P14074, DOI 10.1074/jbc.M309620200; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Kerkhoff E, 2001, ADV ENZYME REGUL, V41, P261, DOI 10.1016/S0065-2571(00)00023-6; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; Machuy N, 2005, MOL CELL PROTEOMICS, V4, P44, DOI 10.1074/mcp.M400089-MCP200; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Sharma A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI 10.1073/pnas.0407536101; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Srisomsap C, 2002, PROTEOMICS, V2, P706, DOI 10.1002/1615-9861(200206)2:6<706::AID-PROT706>3.0.CO;2-E; Wang KJ, 2004, WORLD J GASTROENTERO, V10, P2179; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498	30	283	297	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2005	7	8					837	843		10.1038/ncb1283	http://dx.doi.org/10.1038/ncb1283			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	950TU	16041367				2022-12-25	WOS:000230881500019
J	Crowder, S; Kirkegaard, K				Crowder, S; Kirkegaard, K			Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses	NATURE GENETICS			English	Article							SITE-DIRECTED MUTAGENESIS; POLIOVIRUS RNA; VPG URIDYLYLATION; POLYMERASE; MUTATIONS; PROTEIN; IDENTIFICATION; CIS; ENTEROVIRUSES; ELEMENT	The high error rates of viral RNA- dependent RNA polymerases create heterogeneous viral populations whose disparate RNA genomes affect each other's survival. We systematically screened the poliovirus genome and identified four sets of dominant mutations. Mutated alleles in capsid- and polymerase- coding regions resulted in dominant negative phenotypes, probably due to the proteins' oligomeric properties. We also identified dominant mutations in an RNA element required for priming RNA synthesis ( CRE) and in the protein primer ( VPg), suggesting that nonproductive priming intermediates are inhibitory. Mutations that inhibit the activity of viral proteinase 2A were dominant, arguing that inhibition of its known intramolecular activity creates a toxic product. Viral products that, when defective, dominantly interfere with growth of nondefective viruses will probably be excellent drug targets because drug- sensitive viruses should be dominant over drug- resistant variants. Accordingly, a virus sensitive to anticapsid compound WIN51711 dominantly inhibited the intracellular growth of a drug- resistant virus. Therefore, dominant inhibitor screening should validate or predict targets for antiviral therapy with reduced risk for drug resistance.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University	Kirkegaard, K (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.	karlak@stanford.edu						AGUT H, 1989, VIROLOGY, V168, P302, DOI 10.1016/0042-6822(89)90270-5; AMBROS V, 1978, J BIOL CHEM, V253, P5263; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; ANSARDI DC, 1995, J VIROL, V69, P1540, DOI 10.1128/JVI.69.3.1540-1547.1995; Barton DJ, 2001, EMBO J, V20, P1439, DOI 10.1093/emboj/20.6.1439; BURNS CC, 1989, J VIROL, V63, P4866, DOI 10.1128/JVI.63.11.4866-4874.1989; CHAPMAN MS, 1991, J MOL BIOL, V217, P455, DOI 10.1016/0022-2836(91)90749-V; CHARINI WA, 1991, J VIROL, V65, P2655, DOI 10.1128/JVI.65.5.2655-2665.1991; COMPTON SR, 1990, J VIROL, V64, P4067, DOI 10.1128/JVI.64.9.4067-4075.1990; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; FOX MP, 1986, ANTIMICROB AGENTS CH, V30, P110, DOI 10.1128/AAC.30.1.110; Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000; Groarke JM, 1999, J INFECT DIS, V179, P1538, DOI 10.1086/314758; HAMBIDGE SJ, 1992, P NATL ACAD SCI USA, V89, P10272, DOI 10.1073/pnas.89.21.10272; HAMMERLE T, 1991, J BIOL CHEM, V266, P5412; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HELLEN CUT, 1992, J VIROL, V66, P3330, DOI 10.1128/JVI.66.6.3330-3338.1992; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobson SD, 2001, EMBO J, V20, P1153, DOI 10.1093/emboj/20.5.1153; HOLLAND JJ, 1964, P NATL ACAD SCI USA, V51, P1082, DOI 10.1073/pnas.51.6.1082; HOLLAND JJ, 1989, J VIROL, V63, P5030, DOI 10.1128/JVI.63.12.5030-5036.1989; Hope DA, 1997, J VIROL, V71, P9490, DOI 10.1128/JVI.71.12.9490-9498.1997; IKEGAMI N, 1964, P NATL ACAD SCI USA, V52, P1419, DOI 10.1073/pnas.52.6.1419; JARVIS TC, 1992, EMBO J, V11, P3135, DOI 10.1002/j.1460-2075.1992.tb05386.x; JOHNSON KL, 1991, J VIROL, V65, P4341, DOI 10.1128/JVI.65.8.4341-4349.1991; JUBELT B, 1989, J INFECT DIS, V159, P866, DOI 10.1093/infdis/159.5.866; KAPLAN G, 1988, J VIROL, V62, P1687, DOI 10.1128/JVI.62.5.1687-1696.1988; KIRKEGAARD K, 1990, J VIROL, V64, P195, DOI 10.1128/JVI.64.1.195-206.1990; LEDINKO N, 1961, VIROLOGY, V14, P207, DOI 10.1016/0042-6822(61)90196-9; Lyle JM, 2002, SCIENCE, V296, P2218, DOI 10.1126/science.1070585; Lyons T, 2001, J VIROL, V75, P10696, DOI 10.1128/JVI.75.22.10696-10708.2001; MACADAM AJ, 1994, EMBO J, V13, P924, DOI 10.1002/j.1460-2075.1994.tb06336.x; MOSSER AG, 1994, J VIROL, V68, P8193, DOI 10.1128/JVI.68.12.8193-8201.1994; Murray KE, 2003, J VIROL, V77, P4739, DOI 10.1128/JVI.77.8.4739-4750.2003; NOVAK JE, 1994, GENE DEV, V8, P1726, DOI 10.1101/gad.8.14.1726; Paul Aniko V., 2002, P227; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Petersen JFW, 1999, EMBO J, V18, P5463, DOI 10.1093/emboj/18.20.5463; Pevear DC, 1999, ANTIMICROB AGENTS CH, V43, P2109, DOI 10.1128/AAC.43.9.2109; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; REYNOLDS C, 1991, VIROLOGY, V184, P391, DOI 10.1016/0042-6822(91)90856-7; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; Thompson AA, 2004, EMBO J, V23, P3462, DOI 10.1038/sj.emboj.7600357; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; Yin J, 2003, J VIROL, V77, P5152, DOI 10.1128/JVI.77.9.5152-5166.2003; YU SF, 1991, VIROLOGY, V182, P615, DOI 10.1016/0042-6822(91)90602-8	48	101	104	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					701	709		10.1038/ng1583	http://dx.doi.org/10.1038/ng1583			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15965477				2022-12-25	WOS:000230196400016
J	Vilardaga, JP; Steinmeyer, R; Harms, GS; Lohse, MJ				Vilardaga, JP; Steinmeyer, R; Harms, GS; Lohse, MJ			Molecular basis of inverse agonism in a G protein-coupled receptor	NATURE CHEMICAL BIOLOGY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; CONFORMATIONAL-CHANGES; ACTIVATION; MECHANISMS; DOMAIN; SWITCH	G protein-coupled receptors (GPCRs) recognize a wide variety of extracellular ligands to control diverse physiological processes. Compounds that bind to such receptors can either stimulate, fully or partially (full or partial agonists), or reduce (inverse agonists) the receptors' basal activity and receptor-mediated signaling. Various studies have shown that the activation of receptors through binding of agonists proceeds by conformational changes as the receptor switches from a resting to an active state leading to G protein signaling(1-5). Yet the molecular basis for differences between agonists and inverse agonists is unclear. These different classes of compounds are assumed to switch the receptors' conformation in distinct ways. It is not known, however, whether such switching occurs along a linear 'on-off' scale or whether agonists and inverse agonists induce different switch mechanisms. Using a fluorescence-based approach to study the alpha(2A)-adrenergic receptor (alpha(2A)AR), we show that inverse agonists are differentiated from agonists in that they trigger a very distinct mode of a receptor's switch. This switch couples inverse agonist binding to the suppression of activity in the receptor.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Univ Wurzburg, Rudolf Virchow Ctr, D-97078 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Vilardaga, JP (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.	vilardaga@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510; Vilardaga, Jean-Pierre/0000-0002-1217-1435				Bunemann M, 2001, J BIOL CHEM, V276, P47512, DOI 10.1074/jbc.M108652200; Cognet L, 2000, APPL PHYS LETT, V77, P4052, DOI 10.1063/1.1332414; DELIGHT RAF, 2003, BRIT J PHARMACOL, V130, P1; GETHER U, 1995, J BIOL CHEM, V270, P28268; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Heikal AA, 2000, P NATL ACAD SCI USA, V97, P11996, DOI 10.1073/pnas.97.22.11996; Kenakin T, 2004, MOL PHARMACOL, V65, P2, DOI 10.1124/mol.65.1.2; REN Q, 1993, J BIOL CHEM, V268, P16483; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Strange PG, 2002, TRENDS PHARMACOL SCI, V23, P89, DOI 10.1016/S0165-6147(02)01993-4; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vilardaga JP, 2001, MOL ENDOCRINOL, V15, P1186, DOI 10.1210/me.15.7.1186; VILARDAGA JP, 1995, BIOTECHNIQUES, V18, P605; Wade SM, 2001, MOL PHARMACOL, V59, P532, DOI 10.1124/mol.59.3.532	16	126	128	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2005	1	1					25	28		10.1038/nchembio705	http://dx.doi.org/10.1038/nchembio705			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	974WC	16407989				2022-12-25	WOS:000232621100008
J	Gambus, A; Jones, RC; Sanchez-Diaz, A; Kanemaki, M; van Deursen, F; Edmondson, RD; Labib, K				Gambus, A; Jones, RC; Sanchez-Diaz, A; Kanemaki, M; van Deursen, F; Edmondson, RD; Labib, K			GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks	NATURE CELL BIOLOGY			English	Article							CELL-FREE-EXTRACTS; YEAST SACCHAROMYCES-CEREVISIAE; SISTER-CHROMATID COHESION; POLYMERASE-ALPHA; S-PHASE; BUDDING YEAST; MULTIPROTEIN COMPLEX; FISSION YEAST; IN-VITRO; PROTEINS	The components of the replisome that preserve genomic stability by controlling the progression of eukaryotic DNA replication forks are poorly understood. Here, we show that the GINS ( go ichi ni san) complex allows the MCM ( minichromosome maintenance) helicase to interact with key regulatory proteins in large replisome progression complexes (RPCs) that are assembled during initiation and disassembled at the end of S phase. RPC components include the essential initiation and elongation factor, Cdc45, the checkpoint mediator Mrc1, the Tof1 - Csm3 complex that allows replication forks to pause at protein - DNA barriers, the histone chaperone FACT ( facilitates chromatin transcription) and Ctf4, which helps to establish sister chromatid cohesion. RPCs also interact with Mcm10 and topoisomerase I. During initiation, GINS is essential for a specific subset of RPC proteins to interact with MCM. GINS is also important for the normal progression of DNA replication forks, and we show that it is required after initiation to maintain the association between MCM and Cdc45 within RPCs.	Univ Manchester, Paterson Inst Canc Res, Canc Res UK, Manchester M20 4BX, Lancs, England; US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA	Cancer Research UK; Paterson Institute for Cancer Research; University of Manchester; US Food & Drug Administration (FDA)	Labib, K (corresponding author), Univ Manchester, Paterson Inst Canc Res, Canc Res UK, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	klabib@picr.man.ac.uk	Gambus, Aga/AAK-4687-2021; Sanchez-Diaz, Alberto/L-2320-2014; Kanemaki, Masato/Q-3246-2019	Gambus, Aga/0000-0002-4648-0332; Sanchez-Diaz, Alberto/0000-0002-3308-4824; Kanemaki, Masato/0000-0002-7657-1649				Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; Calzada A, 2005, GENE DEV, V19, P1905, DOI 10.1101/gad.337205; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Edmondson RD, 2002, MOL CELL PROTEOMICS, V1, P421, DOI 10.1074/mcp.M100036-MCP200; Fien K, 2004, J BIOL CHEM, V279, P16144, DOI 10.1074/jbc.M400142200; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Gotter AL, 2003, J MOL BIOL, V331, P167, DOI 10.1016/S0022-2836(03)00633-8; Hanna JS, 2001, MOL CELL BIOL, V21, P3144, DOI 10.1128/MCB.21.9.3144-3158.2001; Jares P, 2000, GENE DEV, V14, P1528; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; KOUPRINA N, 1992, MOL CELL BIOL, V12, P5736, DOI 10.1128/MCB.12.12.5736; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lee BS, 2004, MOL CELL BIOL, V24, P9813, DOI 10.1128/MCB.24.22.9813-9822.2004; Licklider LJ, 2002, ANAL CHEM, V74, P3076, DOI 10.1021/ac025529o; Makarova KS, 2005, NUCLEIC ACIDS RES, V33, P4626, DOI 10.1093/nar/gki775; Masuda T, 2003, GENES CELLS, V8, P145, DOI 10.1046/j.1365-2443.2003.00621.x; Mayer ML, 2004, MOL BIOL CELL, V15, P1736, DOI 10.1091/mbc.E03-08-0619; MILES J, 1992, P NATL ACAD SCI USA, V89, P1276, DOI 10.1073/pnas.89.4.1276; Mohanty BK, 2006, P NATL ACAD SCI USA, V103, P897, DOI 10.1073/pnas.0506540103; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Obama K, 2005, ONCOL REP, V14, P701; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; Ricke RM, 2004, MOL CELL, V16, P173, DOI 10.1016/j.molcel.2004.09.017; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schlesinger MB, 2000, GENETICS, V155, P1593; Schultz MC, 1999, METHODS, V17, P161, DOI 10.1006/meth.1998.0727; Schultz MC, 1997, P NATL ACAD SCI USA, V94, P9034, DOI 10.1073/pnas.94.17.9034; Seki T, 2000, P NATL ACAD SCI USA, V97, P14115, DOI 10.1073/pnas.97.26.14115; Shechter D, 2004, J BIOL CHEM, V279, P45586, DOI 10.1074/jbc.M407772200; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; Tourriere H, 2005, MOL CELL, V19, P699, DOI 10.1016/j.molcel.2005.07.028; Ueno M, 2005, MOL CELL BIOL, V25, P10528, DOI 10.1128/MCB.25.23.10528-10532.2005; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; Yoshida K, 2001, MOL CELL BIOL, V21, P4598, DOI 10.1128/MCB.21.14.4598-4603.2001; Zhou YJ, 2004, MOL CELL BIOL, V24, P9568, DOI 10.1128/MCB.24.21.9568-9579.2004; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	60	561	569	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					358	U41		10.1038/ncb1382	http://dx.doi.org/10.1038/ncb1382			34	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16531994				2022-12-25	WOS:000236560000014
J	Jiang, ZR; Asplin, JR; Evan, AP; Rajendran, VM; Velazquez, H; Nottoli, TP; Binder, HJ; Aronson, PS				Jiang, ZR; Asplin, JR; Evan, AP; Rajendran, VM; Velazquez, H; Nottoli, TP; Binder, HJ; Aronson, PS			Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6	NATURE GENETICS			English	Article							BRUSH-BORDER MEMBRANE; PROXIMAL TUBULE; DIETARY OXALATE; MOUSE SLC26A6; EXCHANGER; FORMATE; IDENTIFICATION; ABSORPTION; EXCRETION; VESICLES	Urolithiasis is one of the most common urologic diseases in industrialized societies. Calcium oxalate is the predominant component in 70-80% of kidney stones(1), and small changes in urinary oxalate concentration affect the risk of stone formation(2). SLC26A6 is an anion exchanger expressed on the apical membrane in many epithelial tissues, including kidney and intestine(3-6). Among its transport activities, SLC26A6 mediates Cl--oxalate exchange(5-9). Here we show that mutant mice lacking Slc26a6 develop a high incidence of calcium oxalate urolithiasis. Slc26a6-null mice have significant hyperoxaluria and elevation in plasma oxalate concentration that is greatly attenuated by dietary oxalate restriction. In vitro flux studies indicated that mice lacking Slc26a6 have a defect in intestinal oxalate secretion resulting in enhanced net absorption of oxalate. We conclude that the anion exchanger SLC26A6 has a major constitutive role in limiting net intestinal absorption of oxalate, thereby preventing hyperoxaluria and calcium oxalate urolithiasis.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Litholink Corp, Chicago, IL 60612 USA; Univ Chicago, Renal Sect, Chicago, IL 60612 USA; Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46223 USA; Vet Adm Connecticut Healthcare Syst, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Comparat Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; University of Chicago; Indiana University System; Indiana University-Purdue University Indianapolis; Yale University; Yale University	Aronson, PS (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St, New Haven, CT 06520 USA.	peter.aronson@yale.edu			NIDDK NIH HHS [R37 DK033793, DK56788, DK33793, DK60699, DK17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033793, R37DK033793] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asplin J, 1998, J UROLOGY, V159, P1821, DOI 10.1016/S0022-5347(01)63164-1; Asplin JR, 2002, ENDOCRIN METAB CLIN, V31, P927, DOI 10.1016/S0889-8529(02)00030-0; Chernova MN, 2005, J BIOL CHEM, V280, P8564, DOI 10.1074/jbc.M411703200; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; FREEL RW, 2005, AM J PHYSL GASTROINT; HATCH M, 1994, J AM SOC NEPHROL, V5, P1339; Holmes RP, 2005, J UROLOGY, V174, P943, DOI 10.1097/01.ju.0000169476.85935.e2; Holmes RP, 2004, UROL RES, V32, P311, DOI 10.1007/s00240-004-0437-3; Hoppe B, 1998, KIDNEY INT, V53, P1348, DOI 10.1046/j.1523-1755.1998.00891.x; Jiang Z, 2002, J BIOL CHEM, V277, P33963, DOI 10.1074/jbc.M202660200; Karniski LP, 2002, AM J PHYSIOL-RENAL, V283, pF952, DOI 10.1152/ajprenal.00182.2002; Knauf F, 2001, P NATL ACAD SCI USA, V98, P9425, DOI 10.1073/pnas.141241098; Kocinsky HS, 2005, AM J PHYSIOL-RENAL, V289, pF249, DOI 10.1152/ajprenal.00082.2004; Kuo SM, 1996, J BIOL CHEM, V271, P15491, DOI 10.1074/jbc.271.26.15491; Lohi H, 2000, GENOMICS, V70, P102, DOI 10.1006/geno.2000.6355; MCCONNELL KR, 1994, J BIOL CHEM, V269, P21489; Palgi N, 2005, COMP BIOCHEM PHYS A, V141, P48, DOI 10.1016/j.cbpb.2005.03.011; ROBERTSON WG, 1980, NEPHRON, V26, P105, DOI 10.1159/000181963; Vidyasagar S, 2004, AM J PHYSIOL-CELL PH, V287, pC612, DOI 10.1152/ajpcell.00474.2003; Waldegger S, 2001, GENOMICS, V72, P43, DOI 10.1006/geno.2000.6445; WANG T, 1992, AM J PHYSIOL, V263, pF37, DOI 10.1152/ajprenal.1992.263.1.F37; Wang T, 1996, AM J PHYSIOL-RENAL, V271, pF446, DOI 10.1152/ajprenal.1996.271.2.F446; WANG T, 1995, AM J PHYSIOL-RENAL, V268, pF204, DOI 10.1152/ajprenal.1995.268.2.F204; Wang ZH, 2005, AM J PHYSIOL-CELL PH, V288, pC957, DOI 10.1152/ajpcell.00505.2004; Wang ZH, 2002, AM J PHYSIOL-GASTR L, V282, pG573, DOI 10.1152/ajpgi.00338.2001; WERNESS PG, 1985, J UROLOGY, V134, P1242, DOI 10.1016/S0022-5347(17)47703-2; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; Xie QH, 2002, AM J PHYSIOL-RENAL, V283, pF826, DOI 10.1152/ajprenal.00079.2002; YASUE T, 1969, Acta Histochemica et Cytochemica, V2, P83	29	235	240	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2006	38	4					474	478		10.1038/ng1762	http://dx.doi.org/10.1038/ng1762			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	026LN	16532010				2022-12-25	WOS:000236340500022
J	Grossman, Z; Meier-Schellersheim, M; Paul, WE; Picker, LJ				Grossman, Z; Meier-Schellersheim, M; Paul, WE; Picker, LJ			Pathogenesis of HIV infection: what the virus spares is as important as what it destroys	NATURE MEDICINE			English	Review							T-CELL DEPLETION; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE-SYSTEM ACTIVATION; AFRICAN-GREEN MONKEYS; NECROSIS-FACTOR-ALPHA; IN-VIVO ACTIVATION; TYPE-1 INFECTION; SIV INFECTION; MACROPHAGE ACTIVATION; LYMPHOCYTE ACTIVATION	Upon transmission to a new host, HIV targets CCR5(+)CD4(+) effector memory T cells, resulting in acute, massive depletion of these cells from mucosal effector sites. This depletion does not initially compromise the regenerative capacity of the immune system because naive and most central memory T cells are spared. Here, we discuss evidence suggesting that frequent activation of these spared cells during the chronic phase of HIV infection supplies mucosal tissues with short-lived CCR5(+)CD4(+) effector cells that prevent life-threatening infections. This immune activation also facilitates continued viral replication, but infection and killing of target T cells by HIV are selective and the impact on effector-cell lifespan is limited. We propose, however, that persistent activation progressively disrupts the functional organization of the immune system, reducing its regenerative capacity and facilitating viral evolution that leads to loss of the exquisite target cell-sparing selectivity of viral replication, ultimately resulting in AIDS.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Oregon Hlth & Sci Univ, Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tel Aviv University; Sackler Faculty of Medicine; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University	Grossman, Z (corresponding author), NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA.	grossman@helix.nih.gov	Grossman, Zvi/A-9643-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000926, Z01AI000974, R01AI054292, R37AI054292] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [AI054292] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson RW, 1998, J ACQ IMMUN DEF SYND, V17, P245, DOI 10.1097/00042560-199803010-00010; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; ASCHER MS, 1988, CLIN EXP IMMUNOL, V73, P165; Autran B, 1999, IMMUNOL LETT, V66, P207, DOI 10.1016/S0165-2478(98)00159-X; Bentwich Z, 1998, CLIN EXP IMMUNOL, V111, P1; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; BRENCHLEY JM, IN PRESS NAT IMMUNOL; Bromley SK, 2005, NAT IMMUNOL, V6, P895, DOI 10.1038/ni1240; Broussard SR, 2001, J VIROL, V75, P2262, DOI 10.1128/JVI.75.5.2262-2275.2001; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Campbell JJ, 2001, J IMMUNOL, V166, P877, DOI 10.4049/jimmunol.166.2.877; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; Cheynier R, 1998, NAT MED, V4, P421, DOI 10.1038/nm0498-421; De Boer RJ, 2003, J IMMUNOL, V170, P2479, DOI 10.4049/jimmunol.170.5.2479; Debes GF, 2005, NAT IMMUNOL, V6, P889, DOI 10.1038/ni1238; Deeks SG, 2002, J INFECT DIS, V185, P315, DOI 10.1086/338467; Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997; Desrosiers RC, 2004, NAT MED, V10, P221, DOI 10.1038/nm0304-221; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Dion ML, 2004, IMMUNITY, V21, P757, DOI 10.1016/j.immuni.2004.10.013; Doisne JM, 2004, J IMMUNOL, V173, P2410, DOI 10.4049/jimmunol.173.4.2410; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Evans MRW, 1996, J INFECTION, V33, P91, DOI 10.1016/S0163-4453(96)92967-9; Feinberg MB, 2002, NAT MED, V8, P537, DOI 10.1038/nm0602-537a; Feinberg MB, 2002, NAT MED, V8, P207, DOI 10.1038/nm0302-207; Freitas AA, 1999, CURR OPIN IMMUNOL, V11, P152, DOI 10.1016/S0952-7915(99)80026-0; Freitas AA, 2000, ANNU REV IMMUNOL, V18, P83, DOI 10.1146/annurev.immunol.18.1.83; Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711; Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Gratton S, 2000, P NATL ACAD SCI USA, V97, P14566, DOI 10.1073/pnas.97.26.14566; Grossman Z, 2004, NAT REV IMMUNOL, V4, P387, DOI 10.1038/nri1355; Grossman Z, 1997, NAT MED, V3, P486, DOI 10.1038/nm0597-486; Grossman Z, 2002, NAT MED, V8, P319, DOI 10.1038/nm0402-319; GROSSMAN Z, 1993, CLIN IMMUNOL IMMUNOP, V69, P123, DOI 10.1006/clin.1993.1160; Grossman Z, 1998, P NATL ACAD SCI USA, V95, P6314, DOI 10.1073/pnas.95.11.6314; Grossman Z, 1999, SCIENCE, V284, p555a, DOI [DOI 10.1126/SCIENCE.284.5414.555A, 10.1126/science.284.5414.555a]; Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003; Hayashi N, 2002, P NATL ACAD SCI USA, V99, P6187, DOI 10.1073/pnas.092129899; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Hellerstein MK, 2003, J CLIN INVEST, V112, P956, DOI 10.1172/JCI200317533; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hosmalin A, 2001, BLOOD, V97, P2695, DOI 10.1182/blood.V97.9.2695; Jenkins MK, 2001, ANNU REV IMMUNOL, V19, P23, DOI 10.1146/annurev.immunol.19.1.23; Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648; Kornfeld C, 2005, J CLIN INVEST, V115, P1082, DOI 10.1172/JCI200523006; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; Kunkel EJ, 2002, AM J PATHOL, V160, P347, DOI 10.1016/S0002-9440(10)64378-7; Lawn SD, 2001, CLIN MICROBIOL REV, V14, P753, DOI 10.1128/CMR.14.4.753-777.2001; Lee C, 2003, J LEUKOCYTE BIOL, V74, P676, DOI 10.1189/jlb.0503206; Lempicki RA, 2000, P NATL ACAD SCI USA, V97, P13778, DOI 10.1073/pnas.250472097; Li QJ, 2004, NAT IMMUNOL, V5, P791, DOI 10.1038/ni1095; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Little SJ, 1999, J EXP MED, V190, P841, DOI 10.1084/jem.190.6.841; Liu Z, 1998, J ACQ IMMUN DEF SYND, V18, P332, DOI 10.1097/00042560-199808010-00004; Macallan DC, 2003, EUR J IMMUNOL, V33, P2316, DOI 10.1002/eji.200323763; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; McCune JM, 2000, J CLIN INVEST, V105, pR1, DOI 10.1172/JCI8647; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; Min B, 2004, P NATL ACAD SCI USA, V101, P3874, DOI 10.1073/pnas.0400606101; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Moore JP, 2004, AIDS RES HUM RETROV, V20, P111, DOI 10.1089/088922204322749567; Mowat AM, 1997, IMMUNOL REV, V156, P145, DOI 10.1111/j.1600-065X.1997.tb00966.x; Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499; Newberry RD, 2005, IMMUNOL REV, V206, P6, DOI 10.1111/j.0105-2896.2005.00282.x; Picker L.J., 1999, FUNDAMENTAL IMMUNOLO, P479; Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049; Picker LJ, 2005, NAT IMMUNOL, V6, P430, DOI 10.1038/ni0505-430; Pitcher CJ, 2002, J IMMUNOL, V168, P29, DOI 10.4049/jimmunol.168.1.29; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; Roederer M, 1997, Semin Immunol, V9, P389, DOI 10.1006/smim.1997.0097; Roman E, 2002, J EXP MED, V196, P957, DOI 10.1084/jem.20021052; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Salmi M, 2005, IMMUNOL REV, V206, P100, DOI 10.1111/j.0105-2896.2005.00285.x; Schacker TW, 2002, J CLIN INVEST, V110, P1133, DOI [10.1172/JCI200216413, 10.1172/JCI0216413]; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Silvestri G, 2003, J CLIN INVEST, V112, P821, DOI 10.1172/JCI200319799; Sousa AE, 2002, J IMMUNOL, V169, P3400, DOI 10.4049/jimmunol.169.6.3400; Stuart JWTC, 2000, J ACQ IMMUN DEF SYND, V25, P203, DOI 10.1097/00126334-200011010-00001; Swingler S, 2003, NATURE, V424, P213, DOI 10.1038/nature01749; Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129; Veazey RS, 2000, J VIROL, V74, P57, DOI 10.1128/JVI.74.1.57-64.2000; Veazey RS, 2003, J INFECT DIS, V187, P769, DOI 10.1086/368386; Veazey RS, 2000, J VIROL, V74, P11001, DOI 10.1128/JVI.74.23.11001-11007.2000; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang ZQ, 2004, P NATL ACAD SCI USA, V101, P5640, DOI 10.1073/pnas.0308425101	101	302	326	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					289	295		10.1038/nm1380	http://dx.doi.org/10.1038/nm1380			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16520776				2022-12-25	WOS:000235802900025
J	Polyak, K; Hahn, WC				Polyak, K; Hahn, WC			Roots and stems: stem cells in cancer	NATURE MEDICINE			English	Review							BREAST-CANCER; SELF-RENEWAL; SIDE POPULATION; THERAPEUTIC IMPLICATIONS; COLORECTAL-CANCER; TELOMERASE; IDENTIFICATION; PROLIFERATION; LINES; TRANSPLANTATION	Cancer develops from normal tissues through the accumulation of genetic alterations that act in concert to confer malignant phenotypes. Although we have now identified some of the genes that when mutated initiate tumor formation and drive cancer progression, the identity of the cell population(s) susceptible to such transforming events remains undefined for the majority of human cancers. Recent work indicates that a small population of cells endowed with unique self-renewal properties and tumorigenic potential is present in some, and perhaps all, tumors. Although our understanding of the biology of these putative cancer stem cells remains rudimentary, the existence of such cells has implications for current conceptualizations of malignant transformation and therapeutic approaches to cancer.	Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Broad Inst Harvard, Cambridge, MA 02139 USA; MIT, Cambridge, MA 02139 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT)	Polyak, K (corresponding author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.	william_hahn@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [P50CA089393, R01CA094074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023145] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA94074, P50 CA89393] Funding Source: Medline; NIA NIH HHS [R01 AG23145] Funding Source: Medline; PHS HHS [K01 94223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Bates RC, 2005, CANCER BIOL THER, V4, P365; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; BRUCE WR, 1963, NATURE, V199, P79, DOI 10.1038/199079a0; CAUSSINUS E, 2005, NAT GENET; Cohnheim J., 1875, VIRCHOWS ARCH, V65, P64, DOI DOI 10.1007/BF01978936; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Crowe DL, 2004, HISTOL HISTOPATHOL, V19, P505, DOI 10.14670/HH-19.505; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Goodell MA, 2002, CYTOTHERAPY, V4, P507, DOI 10.1080/146532402761624638; Hahn WC, 2003, J CLIN ONCOL, V21, P2034, DOI 10.1200/JCO.2003.06.018; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Kai T, 2004, NATURE, V428, P564, DOI 10.1038/nature02436; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lininger RA, 1998, MODERN PATHOL, V11, P1151; Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931; MAKINO S, 1956, ANN NY ACAD SCI, V63, P818, DOI 10.1111/j.1749-6632.1956.tb50894.x; Masters JRW, 2000, NAT REV MOL CELL BIO, V1, P233, DOI 10.1038/35043102; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Miller SJ, 2005, BBA-REV CANCER, V1756, P25, DOI 10.1016/j.bbcan.2005.07.003; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; PARK CH, 1971, JNCI-J NATL CANCER I, V46, P411; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Prindull G, 2005, EXP HEMATOL, V33, P738, DOI 10.1016/j.exphem.2005.03.002; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Setoguchi T, 2004, CELL CYCLE, V3, P414; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Singh SK, 2003, CANCER RES, V63, P5821; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Tsai RYL, 2004, INT J BIOCHEM CELL B, V36, P684, DOI 10.1016/j.biocel.2003.10.016; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532; Young HE, 2004, CELL BIOCHEM BIOPHYS, V40, P1, DOI 10.1385/CBB:40:1:1	63	284	306	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2006	12	3					296	300		10.1038/nm1379	http://dx.doi.org/10.1038/nm1379			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16520777				2022-12-25	WOS:000235802900026
J	Boyden, ED; Dietrich, WF				Boyden, ED; Dietrich, WF			Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin	NATURE GENETICS			English	Article							STRAIN DISTRIBUTION PATTERN; SSLP MARKERS; PROTEIN; ACTIVATION; INFLAMMASOME; RESISTANCE; RELEASE; SET; MAP	The pathogenesis of Bacillus anthracis, the bacterium that causes anthrax, depends on secretion of three factors that combine to form two bipartite toxins. Edema toxin, consisting of protective antigen (PA) and edema factor (EF), causes the edema associated with cutaneous anthrax infections, whereas lethal toxin (LeTx), consisting of PA and lethal factor (LF), is believed to be responsible for causing death in systemic anthrax infections(1). EF and LF can be transported by PA into the cytosol of many cell types(2). In mouse macrophages, LF can cause rapid necrosis that may be related to the pathology of systemic infections(3-5). Inbred mouse strains display variable sensitivity to LeTx-induced macrophage necrosis(6,7). This trait difference has been mapped to a locus on chromosome 11 named Ltxs1 (refs. 7,8). Here we show that an extremely polymorphic gene in this locus, Nalp1b, is the primary mediator of mouse macrophage susceptibility to LeTx. We also show that LeTx-induced macrophage death requires caspase-1, which is activated in susceptible, but not resistant, macrophages after intoxication, suggesting that Nalp1b directly or indirectly activates caspase-1 in response to LeTx.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Dietrich, WF (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	dietrich@genetics.med.harvard.edu						Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Cordoba-Rodriguez R, 2004, J BIOL CHEM, V279, P20563, DOI 10.1074/jbc.C300539200; Draper BW, 2001, GENESIS, V30, P154, DOI 10.1002/gene.1053; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; FRIEDLANDER AM, 1993, INFECT IMMUN, V61, P245, DOI 10.1128/IAI.61.1.245-252.1993; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Growney JD, 2000, GENOME RES, V10, P1158, DOI 10.1101/gr.10.8.1158; HANNA PC, 1992, MOL BIOL CELL, V3, P1269, DOI 10.1091/mbc.3.11.1269; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Kim SO, 2003, J BIOL CHEM, V278, P7413, DOI 10.1074/jbc.M209279200; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Menard A, 1996, BIOCHEM J, V320, P687, DOI 10.1042/bj3200687; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Reifsnyder PC, 1999, MAMM GENOME, V10, P161, DOI 10.1007/s003359900962; Roberts JE, 1998, MOL MICROBIOL, V29, P581, DOI 10.1046/j.1365-2958.1998.00953.x; Shultz KL, 1996, MAMM GENOME, V7, P526, DOI 10.1007/s003359900156; STEPHEN J, 1981, PHARMACOL THERAPEUT, V12, P501, DOI 10.1016/0163-7258(81)90095-4; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; SVENSON KL, 1995, MAMM GENOME, V6, P867, DOI 10.1007/BF00292437; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Watters JW, 2001, CURR BIOL, V11, P1503, DOI 10.1016/S0960-9822(01)00476-6; Watters JW, 2001, GENOMICS, V73, P223, DOI 10.1006/geno.2001.6453; Yui MA, 1996, MAMM GENOME, V7, P331, DOI 10.1007/s003359900097	30	620	653	0	46	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					240	244		10.1038/ng1724	http://dx.doi.org/10.1038/ng1724			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16429160				2022-12-25	WOS:000234953200022
J	Jordanova, A; Irobi, J; Thomas, FP; Van Dijck, P; Meerschaert, K; Dewil, M; Dierick, I; Jacobs, A; De Vriendt, E; Guergueltcheva, V; Rao, CV; Tournev, I; Gondim, FAA; D'Hooghe, M; Van Gerwen, V; Callaerts, P; Van den Bosch, L; Timmermans, JPR; Robberecht, W; Gettemans, J; Thevelein, JM; De Jonghe, P; Kremensky, I; Timmerman, V				Jordanova, A; Irobi, J; Thomas, FP; Van Dijck, P; Meerschaert, K; Dewil, M; Dierick, I; Jacobs, A; De Vriendt, E; Guergueltcheva, V; Rao, CV; Tournev, I; Gondim, FAA; D'Hooghe, M; Van Gerwen, V; Callaerts, P; Van den Bosch, L; Timmermans, JPR; Robberecht, W; Gettemans, J; Thevelein, JM; De Jonghe, P; Kremensky, I; Timmerman, V			Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy	NATURE GENETICS			English	Article							PROTEIN-PROTEIN INTERACTIONS; SITE-DIRECTED MUTAGENESIS; AMINO-ACID; ENZYME STRUCTURE; CYTOKINE; DISEASE; LOCALIZATION; TRANSLATION; MUTATIONS; HOMOLOGY	Charcot-Marie-Tooth (CMT) neuropathies are common disorders of the peripheral nervous system caused by demyelination or axonal degeneration, or a combination of both features. We previously assigned the locus for autosomal dominant intermediate CMT neuropathy type C (DI-CMTC) to chromosome 1p34-p35. Here we identify two heterozygous missense mutations (G41R and E196K) and one de novo deletion ( 153 - 156delVKQV) in tyrosyl-tRNA synthetase (YARS) in three unrelated families affected with DI-CMTC. Biochemical experiments and genetic complementation in yeast show partial loss of aminoacylation activity of the mutant proteins, and mutations in YARS, or in its yeast ortholog TYS1, reduce yeast growth. YARS localizes to axonal termini in differentiating primary motor neuron and neuroblastoma cultures. This specific distribution is significantly reduced in cells expressing mutant YARS proteins. YARS is the second aminoacyl-tRNA synthetase found to be involved in CMT, thereby linking protein-synthesizing complexes with neurodegeneration.	Univ Antwerp Flanders Interuniv Inst Biotechnol, Dept Mol Genet, B-2610 Antwerp, Belgium; Med Univ Sofia, Lab Mol Pathol, Sofia 1431, Bulgaria; St Louis Univ, Dept Neurol, St Louis, MO 63110 USA; St Louis Univ, St Louis Vet Affairs Med Ctr, Spinal cord Injury Serv, Inst Mol Virol,Dept Mol Microbiol & Immunol, St Louis, MO 63110 USA; Univ Leuven Flanders Interuniv Inst Biotechnol, Mol Cell Biol Lab, Dept Mol Microbiol, B-3001 Louvain, Belgium; Univ Ghent Flanders Interuniv Inst Biotechnol, Dept Med Prot Res, B-9000 Ghent, Belgium; Univ Leuven, Dept Expt Neurol, Neurobiol Lab, B-3000 Louvain, Belgium; Med Univ Sofia, Dept Neurol, Sofia 1431, Bulgaria; St Jan Hosp, Dept Neurol, B-8000 Brugge, Belgium; Univ Leuven Flanders Interuniv Inst Biotechnol, Dept Human Genet, Lab Dev Genet, B-3000 Louvain, Belgium; Univ Leuven Flanders Interuniv Inst Biotechnol, Dept Biol, Lab Dev Genet, B-3000 Louvain, Belgium; Univ Antwerp, Cell Biol & Histol Lab, B-2020 Antwerp, Belgium; Univ Antwerp Hosp, Div Neurol, B-2650 Antwerp, Belgium	Medical University Sofia; Saint Louis University; Saint Louis University; KU Leuven; Ghent University; KU Leuven; Medical University Sofia; KU Leuven; KU Leuven; University of Antwerp; University of Antwerp	Timmerman, V (corresponding author), Univ Antwerp Flanders Interuniv Inst Biotechnol, Dept Mol Genet, Univ Pl 1, B-2610 Antwerp, Belgium.	vincent.timmerman@ua.ac.be	Thomas, Florian P/AAL-3813-2020; Thevelein, Johan M./A-7897-2013; Timmerman, Vincent/O-7283-2019; de Assis Gondim, Francisco/J-1463-2014; Callaerts, Patrick/I-8118-2013; Jordanova, Albena/H-8323-2015; Thevelein, Johan M./AAK-4203-2021; Van Den Bosch, Ludo/B-7258-2012	Thevelein, Johan M./0000-0002-2626-0180; Timmerman, Vincent/0000-0002-2162-0933; de Assis Gondim, Francisco/0000-0002-8957-5796; Jordanova, Albena/0000-0002-3833-3754; Van Den Bosch, Ludo/0000-0003-0104-4067; Callaerts, Patrick/0000-0003-4530-4561; Thomas, Florian P/0000-0002-6103-4138; Timmermans, Jean-Pierre/0000-0003-2506-6252				Antonellis A, 2003, AM J HUM GENET, V72, P1293, DOI 10.1086/375039; BARBARESE E, 1995, J CELL SCI, V108, P2781; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; De Corte V, 2004, J CELL SCI, V117, P5283, DOI 10.1242/jcs.01410; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; Gaete J, 1998, NEUROSCI LETT, V251, P197, DOI 10.1016/S0304-3940(98)00538-2; Giuditta A, 2002, TRENDS NEUROSCI, V25, P400, DOI 10.1016/S0166-2236(02)02188-4; Jordanova A, 2003, AM J HUM GENET, V73, P1423, DOI 10.1086/379792; Kennerson ML, 2001, AM J HUM GENET, V69, P883, DOI 10.1086/323743; Kiga D, 2002, P NATL ACAD SCI USA, V99, P9715, DOI 10.1073/pnas.142220099; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; Nair S, 1997, J MOL BIOL, V269, P1, DOI 10.1006/jmbi.1997.1025; Ohno S, 2001, J BIOCHEM-TOKYO, V130, P417, DOI 10.1093/oxfordjournals.jbchem.a003001; OlinkCoux M, 1996, J NEUROSCI, V16, P1346; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Suter U, 2003, NAT REV NEUROSCI, V4, P714, DOI 10.1038/nrn1196; Tanghe A, 2002, APPL ENVIRON MICROB, V68, P5981, DOI 10.1128/AEM.68.12.5981-5989.2002; Van Damme P, 2003, J NEUROSCI, V23, P4942; Verhoeven K, 2001, AM J HUM GENET, V69, P889, DOI 10.1086/323742; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WINTER G, 1982, NATURE, V299, P756, DOI 10.1038/299756a0; Yang XL, 2004, TRENDS BIOCHEM SCI, V29, P250, DOI 10.1016/j.tibs.2004.03.002; Yang XL, 2002, P NATL ACAD SCI USA, V99, P15369, DOI 10.1073/pnas.242611799; Zheng JQ, 2001, J NEUROSCI, V21, P9291, DOI 10.1523/JNEUROSCI.21-23-09291.2001; Zuchner S, 2005, NAT GENET, V37, P289, DOI 10.1038/ng1514	30	277	294	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2006	38	2					197	202		10.1038/ng1727	http://dx.doi.org/10.1038/ng1727			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16429158	Green Published			2022-12-25	WOS:000234953200014
J	Rodriguez-Ortega, MJ; Norais, N; Bensi, G; Liberatori, S; Capo, S; Mora, M; Scarselli, M; Doro, F; Ferrari, G; Garaguso, I; Maggi, T; Neumann, A; Covre, A; Telford, JL; Grandi, G				Rodriguez-Ortega, MJ; Norais, N; Bensi, G; Liberatori, S; Capo, S; Mora, M; Scarselli, M; Doro, F; Ferrari, G; Garaguso, I; Maggi, T; Neumann, A; Covre, A; Telford, JL; Grandi, G			Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome	NATURE BIOTECHNOLOGY			English	Article							GRAM-POSITIVE BACTERIA; OUTER-MEMBRANE; ESCHERICHIA-COLI; 2-DIMENSIONAL ELECTROPHORESIS; SUBCELLULAR-LOCALIZATION; CAULOBACTER-CRESCENTUS; PYROGENIC EXOTOXIN; MASS-SPECTROMETRY; IMMUNE-RESPONSE; PYOGENES	We describe a proteomic approach for identifying bacterial surface-exposed proteins quickly and reliably for their use as vaccine candidates. Whole cells are treated with proteases to selectively digest protruding proteins that are subsequently identified by mass spectrometry analysis of the released peptides. When applied to the sequenced M1_SF370 group A Streptococcus strain, 68 PSORT-predicted surface-associated proteins were identified, including most of the protective antigens described in the literature. The number of surface-exposed proteins varied from strain to strain, most likely as a consequence of different capsule content. The surface-exposed proteins of the highly virulent M23_DSM2071 strain included 17 proteins, 15 in common with M1_SF370. When 14 of the 17 proteins were expressed in E. coli and tested in the mouse for their capacity to confer protection against a lethal dose of M23_DSM2071, one new protective antigen (Spy0416) was identified. This strategy overcomes the difficulties so far encountered in surface protein characterization and has great potential in vaccine discovery.	Chiron Vaccines, I-53100 Siena, Italy	Novartis	Grandi, G (corresponding author), Chiron Vaccines, Via Fiorentina,1, I-53100 Siena, Italy.	guido_grandi@chiron.com	Liberatori, Sabrina/GYU-1878-2022; Rodriguez-Ortega, Manuel J/L-8244-2014; covre, alessia/AAB-9566-2022; Telford, John Laird/ABG-8144-2020	Rodriguez-Ortega, Manuel J/0000-0002-8744-7045; covre, Alessia/0000-0001-8721-5693; Garaguso, Ignazio/0000-0003-2797-3542; Liberatori, Sabrina/0000-0003-3524-0429; Grandi, Guido/0000-0001-9724-2185	PHS HHS [5U1060595-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akiyama Y, 1998, J BIOL CHEM, V273, P22326, DOI 10.1074/jbc.273.35.22326; Amara RR, 1998, MICROBIOL-UK, V144, P1197, DOI 10.1099/00221287-144-5-1197; Cole JN, 2005, INFECT IMMUN, V73, P3137, DOI 10.1128/IAI.73.5.3137-3146.2005; Courtney H.S., 2002, HDB BACTERIAL ADHESI, P553; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dale JB, 1999, J CLIN INVEST, V103, P1261, DOI 10.1172/JCI5118; Dallo SF, 2002, MOL MICROBIOL, V46, P1041, DOI 10.1046/j.1365-2958.2002.03207.x; Doytchinova IA, 2003, J BIOMED BIOTECHNOL, P267, DOI 10.1155/S1110724303209232; Fernandez-Espla MD, 2000, APPL ENVIRON MICROB, V66, P4772, DOI 10.1128/AEM.66.11.4772-4778.2000; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Galperin MY, 1999, CURR OPIN BIOTECH, V10, P571, DOI 10.1016/S0958-1669(99)00035-X; Guina T, 2003, J AM SOC MASS SPECTR, V14, P742, DOI 10.1016/S1044-0305(03)00133-8; Guzman CA, 1999, J INFECT DIS, V179, P901, DOI 10.1086/314655; Harris TO, 2003, J CLIN INVEST, V111, P61, DOI 10.1172/JCI200316270; Hu MC, 2002, INFECT IMMUN, V70, P2171, DOI 10.1128/IAI.70.4.2171-2177.2002; Janulczyk R, 2001, INFECT IMMUN, V69, P4019, DOI 10.1128/IAI.69.6.4019-4026.2001; Ji YD, 1997, INFECT IMMUN, V65, P2080, DOI 10.1128/IAI.65.6.2080-2087.1997; Kawabata S, 2001, INFECT IMMUN, V69, P924, DOI 10.1128/IAI.69.2.924-930.2001; Kuo CF, 1998, INFECT IMMUN, V66, P3931, DOI 10.1128/IAI.66.8.3931-3935.1998; Kurar E, 1997, VACCINE, V15, P1851, DOI 10.1016/S0264-410X(97)00140-0; LANCEFIELD RC, 1959, J EXP MED, V110, P271, DOI 10.1084/jem.110.2.271; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; Lancefield RC, 1943, J EXP MED, V78, P465, DOI 10.1084/jem.78.6.465; Lei BF, 2004, J INFECT DIS, V189, P79, DOI 10.1086/380491; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Lin J, 2002, MICROBES INFECT, V4, P325, DOI 10.1016/S1286-4579(02)01545-9; Lindahl G, 2005, CLIN MICROBIOL REV, V18, P102, DOI 10.1128/CMR.18.1.102-127.2005; Maione D, 2005, SCIENCE, V309, P148, DOI 10.1126/science.1109869; Marques MAM, 1998, INFECT IMMUN, V66, P2625, DOI 10.1128/IAI.66.6.2625-2631.1998; MASSELL BF, 1968, APPL MICROBIOL, V16, P509, DOI 10.1128/AEM.16.3.509-518.1968; McMillan DJ, 2004, VACCINE, V22, P2783, DOI 10.1016/j.vaccine.2004.01.043; Molloy MP, 2000, EUR J BIOCHEM, V267, P2871, DOI 10.1046/j.1432-1327.2000.01296.x; Molloy MP, 2002, PROTEOMICS, V2, P899, DOI 10.1002/1615-9861(200207)2:7<899::AID-PROT899>3.0.CO;2-Y; Mora M, 2005, P NATL ACAD SCI USA, V102, P15641, DOI 10.1073/pnas.0507808102; Nakai K, 2000, ADV PROTEIN CHEM, V54, P277, DOI 10.1016/S0065-3233(00)54009-1; Niemann HH, 2004, MICROBES INFECT, V6, P101, DOI 10.1016/j.micinf.2003.11.001; Nouwens AS, 2000, ELECTROPHORESIS, V21, P3797, DOI 10.1002/1522-2683(200011)21:17<3797::AID-ELPS3797>3.0.CO;2-P; Padmalayam I, 1997, J BACTERIOL, V179, P4545, DOI 10.1128/jb.179.14.4545-4552.1997; Paterson GK, 2004, TRENDS MICROBIOL, V12, P89, DOI 10.1016/j.tim.2003.12.007; Phadke ND, 2001, PROTEOMICS, V1, P705, DOI 10.1002/1615-9861(200104)1:5<705::AID-PROT705>3.3.CO;2-E; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Reid SD, 2002, J BACTERIOL, V184, P6316, DOI 10.1128/JB.184.22.6316-6324.2002; Rhomberg TA, 2004, PROTEOMICS, V4, P3021, DOI 10.1002/pmic.200400933; Roggiani M, 2000, INFECT IMMUN, V68, P5011, DOI 10.1128/IAI.68.9.5011-5017.2000; Sabarth N, 2002, J BIOL CHEM, V277, P27896, DOI 10.1074/jbc.M204473200; Spence JM, 2000, INFECT IMMUN, V68, P5002, DOI 10.1128/IAI.68.9.5002-5010.2000; Stalhammar-Carlemalm M, 1999, MOL MICROBIOL, V33, P208, DOI 10.1046/j.1365-2958.1999.01470.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; Ton-That H, 2004, BBA-MOL CELL RES, V1694, P269, DOI 10.1016/j.bbamcr.2004.04.014	49	348	372	0	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2006	24	2					191	197		10.1038/nbt1179	http://dx.doi.org/10.1038/nbt1179			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	010XW	16415855				2022-12-25	WOS:000235232300036
J	Skol, AD; Scott, LJ; Abecasis, GR; Boehnke, M				Skol, AD; Scott, LJ; Abecasis, GR; Boehnke, M			Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies	NATURE GENETICS			English	Article							GENE-DISEASE ASSOCIATION; POPULATIONS; DESIGNS; SAMPLE; SNPS	Genome-wide association is a promising approach to identify common genetic variants that predispose to human disease(1-4). Because of the high cost of genotyping hundreds of thousands of markers on thousands of subjects, genome-wide association studies often follow a staged design in which a proportion (pi(samples)) of the available samples are genotyped on a large number of markers in stage 1, and a proportion ( psamples) of these markers are later followed up by genotyping them on the remaining samples in stage 2. The standard strategy for analyzing such two-stage data is to view stage 2 as a replication study and focus on findings that reach statistical significance when stage 2 data are considered alone(2). We demonstrate that the alternative strategy of jointly analyzing the data from both stages almost always results in increased power to detect genetic association, despite the need to use more stringent significance levels, even when effect sizes differ between the two stages. We recommend joint analysis for all two-stage genome-wide association studies, especially when a relatively large proportion of the samples are genotyped in stage 1 (pi(samples) >= 0.30), and a relatively large proportion of markers are selected for follow-up in stage 2 (pi(markers) >= 0.01).	Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Boehnke, M (corresponding author), Univ Michigan, Dept Biostat, 1420 Washington Hts, Ann Arbor, MI 48109 USA.	boehnke@umich.edu	Abecasis, Goncalo R/B-7840-2010	Abecasis, Goncalo/0000-0003-1509-1825				Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; Devlin B, 2001, THEOR POPUL BIOL, V60, P155, DOI 10.1006/tpbi.2001.1542; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Hinds DA, 2004, AM J HUM GENET, V74, P317, DOI 10.1086/381716; Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Ke XY, 2003, BIOINFORMATICS, V19, P287, DOI 10.1093/bioinformatics/19.2.287; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Pritchard JK, 2001, THEOR POPUL BIOL, V60, P227, DOI 10.1006/tpbi.2001.1543; Ripatti S, 2001, GENET EPIDEMIOL, V21, pS409, DOI 10.1002/gepi.2001.21.s1.s409; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Satagopan JM, 2002, BIOMETRICS, V58, P163, DOI 10.1111/j.0006-341X.2002.00163.x; Satagopan JM, 2004, BIOMETRICS, V60, P589, DOI 10.1111/j.0006-341X.2004.00207.x; Satten GA, 2001, AM J HUM GENET, V68, P466, DOI 10.1086/318195; Shmulewitz D, 2004, HUM HERED, V58, P145, DOI 10.1159/000083541; Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807; Thomas D, 2004, GENET EPIDEMIOL, V27, P401, DOI 10.1002/gepi.20047; Yang BZ, 2005, GENET EPIDEMIOL, V28, P302, DOI 10.1002/gepi.20070	21	1014	1033	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					209	213		10.1038/ng1706	http://dx.doi.org/10.1038/ng1706			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16415888				2022-12-25	WOS:000234953200016
J	Helgadottir, A; Manolescu, A; Helgason, A; Thorleifsson, G; Thorsteinsdottir, U; Gudbjartsson, DF; Gretarsdottir, S; Magnusson, KP; Gudmundsson, G; Hicks, A; Jonsson, T; Grant, SFA; Sainz, J; O'Brien, SJ; Sveinbjornsdottir, S; Valdimarsson, EM; Matthiasson, SE; Levey, AI; Abramson, JL; Reilly, MP; Vaccarino, V; Wolfe, ML; Gudnason, V; Quyyumi, AA; Topol, EJ; Rader, DJ; Thorgeirsson, G; Gulcher, JR; Hakonarson, H; Kong, A; Stefansson, K				Helgadottir, A; Manolescu, A; Helgason, A; Thorleifsson, G; Thorsteinsdottir, U; Gudbjartsson, DF; Gretarsdottir, S; Magnusson, KP; Gudmundsson, G; Hicks, A; Jonsson, T; Grant, SFA; Sainz, J; O'Brien, SJ; Sveinbjornsdottir, S; Valdimarsson, EM; Matthiasson, SE; Levey, AI; Abramson, JL; Reilly, MP; Vaccarino, V; Wolfe, ML; Gudnason, V; Quyyumi, AA; Topol, EJ; Rader, DJ; Thorgeirsson, G; Gulcher, JR; Hakonarson, H; Kong, A; Stefansson, K			A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction	NATURE GENETICS			English	Article							POPULATION-STRUCTURE; ADMIXTURE; 5-LIPOXYGENASE; MYELOPEROXIDASE; INFERENCE	Variants of the gene ALOX5AP ( also known as FLAP) encoding arachidonate 5-lipoxygenase activating protein are known to be associated with risk of myocardial infarction(1). Here we show that a haplotype (HapK) spanning the LTA4H gene encoding leukotriene A4 hydrolase, a protein in the same biochemical pathway as ALOX5AP, confers modest risk of myocardial infarction in an Icelandic cohort. Measurements of leukotriene B4 (LTB4) production suggest that this risk is mediated through upregulation of the leukotriene pathway. Three cohorts from the United States also show that HapK confers a modest relative risk (1.16) in European Americans, but it confers a threefold larger risk in African Americans. About 27% of the European American controls carried at least one copy of HapK, as compared with only 6% of African American controls. Our analyses indicate that HapK is very rare in Africa and that its occurrence in African Americans is due to European admixture. Interactions with other genetic or environmental risk factors that are more common in African Americans are likely to account for the greater relative risk conferred by HapK in this group.	deCODE Genet Inc, IS-101 Reykjavik, Iceland; NCI, Lab Genom Divers, Frederick, MD 21702 USA; Natl Univ Hosp Reykjavik, Reykjavik, Iceland; Emory Univ, Sch Med, Atlanta, GA USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Iceland Heart Assoc, Reykjavik, Iceland; Cleveland Clin Fdn, Cleveland, OH 44195 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Landspitali National University Hospital; Emory University; University of Pennsylvania; Icelandic Heart Association; Cleveland Clinic Foundation	Stefansson, K (corresponding author), deCODE Genet Inc, Sturlugata 8, IS-101 Reykjavik, Iceland.	kstefans@decode.is	Magnusson, Kristinn P Pétur/X-4907-2019; OBRIEN, STEPHEN/ABD-1346-2020; Manolescu, Andrei/G-4565-2014; Magnusson, Kristinn/A-6479-2011; Helgason, Agnar/K-1522-2015; Stefansson, Kari/AAE-7187-2019; Gudnason, Vilmundur/K-6885-2015; Gudnason, Vilmundur/AAE-7126-2019; Levey, Allan/F-2104-2011; Hicks, Andrew Anthony/E-9518-2017	Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Manolescu, Andrei/0000-0002-0713-4664; Magnusson, Kristinn/0000-0003-4528-6826; Gudnason, Vilmundur/0000-0001-5696-0084; Gudnason, Vilmundur/0000-0001-5696-0084; Levey, Allan/0000-0002-3153-502X; Hicks, Andrew Anthony/0000-0001-6320-0411; Gudbjartsson, Daniel/0000-0002-5222-9857; Reilly, Muredach/0000-0002-3035-9386; Topol, Eric/0000-0002-1478-4729; Helgason, Agnar/0000-0002-8545-3767; Grant, Struan/0000-0003-2025-5302; OBRIEN, STEPHEN/0000-0001-7857-0757	NCRR NIH HHS [M01-RR00039] Funding Source: Medline; NHLBI NIH HHS [P50 HL077107-01] Funding Source: Medline; NIEHS NIH HHS [U54 ES012068] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000039] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012068] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS J, 1973, SCIENCE, V180, P1137, DOI 10.1126/science.180.4091.1137; Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; [Anonymous], 1979, Circulation, V59, P607; Bamshad M, 2004, NAT REV GENET, V5, P598, DOI 10.1038/nrg1401; Barnholtz-Sloan JS, 2005, CANCER EPIDEM BIOMAR, V14, P1545, DOI 10.1158/1055-9965.EPI-04-0832; Brennan M, 2003, NEW ENGL J MED, V349, P1595, DOI 10.1056/NEJMoa035003; CHAKRABORTY R, 1992, AM J HUM GENET, V50, P145; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; Falush D, 2003, GENETICS, V164, P1567; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Gulcher JR, 2000, EUR J HUM GENET, V8, P739, DOI 10.1038/sj.ejhg.5200530; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Hoggart CJ, 2003, AM J HUM GENET, V72, P1492, DOI 10.1086/375613; Jorde LB, 2004, NAT GENET, V36, pS28, DOI 10.1038/ng1435; LONG JC, 1991, GENETICS, V127, P417; MANTEL N, 1959, J NATL CANCER I, V22, P719; McKeigue PM, 2000, ANN HUM GENET, V64, P171, DOI 10.1017/S0003480000008022; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Nicholls SJ, 2005, ARTERIOSCL THROM VAS, V25, P1102, DOI 10.1161/01.ATV.0000163262.83456.6d; Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Pritchard JK, 2000, GENETICS, V155, P945; Reiner AP, 2005, AM J HUM GENET, V76, P463, DOI 10.1086/428654; Royal CDM, 2004, NAT GENET, V36, pS5, DOI 10.1038/ng1454; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Smith MW, 2004, AM J HUM GENET, V74, P1001, DOI 10.1086/420856; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; Tang H, 2005, AM J HUM GENET, V76, P268, DOI 10.1086/427888; TERWILLIGER JD, 1992, HUM HERED, V42, P337, DOI 10.1159/000154096	30	285	301	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					68	74		10.1038/ng1692	http://dx.doi.org/10.1038/ng1692			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16282974				2022-12-25	WOS:000234227200019
J	Hinds, DA; Kloek, AP; Jen, M; Chen, XY; Frazer, KA				Hinds, DA; Kloek, AP; Jen, M; Chen, XY; Frazer, KA			Common deletions and SNPs are in linkage disequilibrium in the human genome	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; SEGMENTAL DUPLICATIONS; CANDIDATE GENES; DISEASE; IDENTIFICATION; ARRANGEMENT; RESOLUTION; DISORDERS; PATTERNS	Humans show great variation in phenotypic traits such as height, eye color and susceptibility to disease. Genomic DNA sequence differences among individuals are responsible for the inherited components of these complex traits. Reports suggest that intermediate and large-scale DNA copy number and structural variations are prevalent enough to be an important source of genetic variation between individuals(1-8). Because association studies to identify genomic loci associated with particular phenotypic traits have focused primarily on genotyping SNPs, it is important to determine whether common structural polymorphisms are in linkage disequilibrium with common SNPs, and thus can be assessed indirectly in SNP-based studies. Here we examine 100 deletion polymorphisms ranging from 70 bp to 7 kb. We show that common deletions and SNPs ascertained with similar criteria have essentially the same distribution of linkage disequilibrium with surrounding SNPs, indicating that these polymorphisms may share evolutionary history and that most deletion polymorphisms are effectively assayed by proxy in SNP-based association studies.	Perlegen Sci Inc, Mountain View, CA 94043 USA		Frazer, KA (corresponding author), Perlegen Sci Inc, 2021 Stierlin Court, Mountain View, CA 94043 USA.	kelly_frazer@perlegen.com	Jen, Min-Hua/AAP-4200-2021; Pillay, Nischalan/F-9536-2012	Hinds, David/0000-0002-4911-803X; Frazer, Kelly/0000-0002-6060-8902				Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bhangale TR, 2005, HUM MOL GENET, V14, P59, DOI 10.1093/hmg/ddi006; BURN J, 1995, DEVELOPMENTAL MECHANISMS OF HEART DISEASE, P559; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; CONRAD DF, 2005, NAT GENET       1204; Dhami P, 2005, AM J HUM GENET, V76, P750, DOI 10.1086/429588; duMontcel ST, 1996, J MED GENET, V33, P719, DOI 10.1136/jmg.33.8.719; Frazer KA, 2003, GENOME RES, V13, P341, DOI 10.1101/gr.554603; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Goodship J, 1998, ARCH DIS CHILD, V79, P348, DOI 10.1136/adc.79.4.348; GREEN JE, 1990, AIDS RES HUM RETROV, V6, P85; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; HIGGS DR, 1980, NATURE, V284, P632, DOI 10.1038/284632a0; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Inoue K, 2002, ANNU REV GENOM HUM G, V3, P199, DOI 10.1146/annurev.genom.3.032802.120023; LAUER J, 1980, CELL, V20, P119, DOI 10.1016/0092-8674(80)90240-8; Liling J, 1999, J MED GENET, V36, P794, DOI 10.1136/jmg.36.10.794; MCCARROLL SA, 2005, NAT GENET       1204; Nelis E, 1996, EUR J HUM GENET, V4, P25; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; Shaw CJ, 2004, HUM MOL GENET, V13, pR57, DOI 10.1093/hmg/ddh073; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Stefansson H, 2005, NAT GENET, V37, P129, DOI 10.1038/ng1508; Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Weir BS., 1996, GENETIC DATA ANAL	30	293	306	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					82	85		10.1038/ng1695	http://dx.doi.org/10.1038/ng1695			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16327809				2022-12-25	WOS:000234227200021
J	Liu, JD; Rivas, FV; Wohlschlegel, J; Yates, JR; Parker, R; Hannon, GJ				Liu, JD; Rivas, FV; Wohlschlegel, J; Yates, JR; Parker, R; Hannon, GJ			A role for the P-body component GW182 in microRNA function	NATURE CELL BIOLOGY			English	Article							MESSENGER-RNA DEGRADATION; PROCESSING BODIES; PROTEIN-SYNTHESIS; GW BODIES; C-ELEGANS; TRANSLATION; ARGONAUTE2; COMPLEX; MIRNAS; TARGET	In animals, the majority of microRNAs regulate gene expression through the RNA interference (RNAi) machinery without inducing small-interfering RNA (siRNA)-directed mRNA cleavage(1). Thus, the mechanisms by which microRNAs repress their targets have remained elusive. Recently, Argonaute proteins, which are key RNAi effector components, and their target mRNAs were shown to localize to cytoplasmic foci known as P-bodies or GW-bodies(2,3). Here, we show that the Argonaute proteins physically interact with a key P-/GW-body subunit, GW182. Silencing of GW182 delocalizes resident P-/GW-body proteins and impairs the silencing of microRNA reporters. Moreover, mutations that prevent Argonaute proteins from localizing in P-/GW-bodies prevent translational repression of mRNAs even when Argonaute is tethered to its target in a siRNA-independent fashion. Thus, our results support a functional link between cytoplasmic P-bodies and the ability of a microRNA to repress expression of a target mRNA.	Cold Spring Harbor Lab, Howard Hughes Med Inst, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Howard Hughes Med Inst, Tucson, AZ 85721 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Scripps Research Institute; University of Arizona; Howard Hughes Medical Institute; University of Arizona	Hannon, GJ (corresponding author), Cold Spring Harbor Lab, Howard Hughes Med Inst, Watson Sch Biol Sci, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	hannon@cshl.edu	Hannon, Gregory/AAB-3568-2019		NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045443] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM045443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; Ding L, 2005, MOL CELL, V19, P437, DOI 10.1016/j.molcel.2005.07.013; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Eystathioy T, 2003, RNA, V9, P1171, DOI 10.1261/rna.5810203; Eystathioy T, 2002, MOL BIOL CELL, V13, P1338, DOI 10.1091/mbc.01-11-0544; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Nakamura A, 2004, DEV CELL, V6, P69, DOI 10.1016/S1534-5807(03)00400-3; Nakamura A, 2001, DEVELOPMENT, V128, P3233; Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Pillai RS, 2004, RNA, V10, P1518, DOI 10.1261/rna.7131604; Rehwinkel J, 2005, RNA, V11, P1640, DOI 10.1261/rna.2191905; Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Teixeira D, 2005, RNA, V11, P371, DOI 10.1261/rna.7258505; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Yang Z, 2004, J CELL SCI, V117, P5567, DOI 10.1242/jcs.01477	30	501	534	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1261	1266		10.1038/ncb1333	http://dx.doi.org/10.1038/ncb1333			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16284623	Green Accepted			2022-12-25	WOS:000233748900021
J	Grimm, MOW; Grimm, HS; Patzold, AJ; Zinser, EG; Halonen, R; Duering, M; Tschape, JA; De Strooper, B; Muller, U; Shen, J; Hartmann, T				Grimm, MOW; Grimm, HS; Patzold, AJ; Zinser, EG; Halonen, R; Duering, M; Tschape, JA; De Strooper, B; Muller, U; Shen, J; Hartmann, T			Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin	NATURE CELL BIOLOGY			English	Article							GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CEREBROSPINAL-FLUID; IN-VIVO; CELLS; EXPRESSION; PEPTIDES; STRESS; SIMVASTATIN	Amyloid beta peptide (A beta) has a key role in the pathological process of Alzheimer's disease ( AD), but the physiological function of A beta and of the amyloid precursor protein (APP) is unknown(1,2). Recently, it was shown that APP processing is sensitive to cholesterol and other lipids(3-10). Hydroxymethylglutaryl-CoA reductase (HMGR) and sphingomyelinases (SMases) are the main enzymes that regulate cholesterol biosynthesis and sphingomyelin (SM) levels, respectively. We show that control of cholesterol and SM metabolism involves APP processing. A beta 42 directly activates neutral SMase and downregulates SM levels, whereas A beta 40 reduces cholesterol de novo synthesis by inhibition of HMGR activity. This process strictly depends on gamma-secretase activity. In line with altered A beta 40/42 generation, pathological presenilin mutations result in increased cholesterol and decreased SM levels. Our results demonstrate a biological function for APP processing and also a functional basis for the link that has been observed between lipids and Alzheimer's disease (AD).	Ctr Mol Biol Heidelberg, D-69120 Heidelberg, Germany; Dept Human Genet, B-3000 Louvain, Belgium; Katholieke Univ Leuven, B-3000 Louvain, Belgium; Inst Pharm & Mol Biotechnol, D-69120 Heidelberg, Germany; Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA	Ruprecht Karls University Heidelberg; KU Leuven; Ruprecht Karls University Heidelberg; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Hartmann, T (corresponding author), Ctr Mol Biol Heidelberg, INF 282, D-69120 Heidelberg, Germany.	Tobias.Hartmann@zmbh.uni-heidelberg.de	de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012; Duering, Marco/AAE-6949-2021; Hartmann, Tobias/AAB-8297-2022; Grimm, Marcus O. W./F-8134-2011	De Strooper, Bart/0000-0001-5455-5819; Duering, Marco/0000-0003-2302-3136; Grimm, Marcus O. W./0000-0002-4160-6506; Hartmann, Tobias/0000-0001-7481-6430				Abad-Rodriguez J, 2004, J CELL BIOL, V167, P953, DOI 10.1083/jcb.200404149; Beglopoulos V, 2004, J BIOL CHEM, V279, P46907, DOI 10.1074/jbc.M409544200; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Burns M, 2003, J NEUROSCI, V23, P5645; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Grziwa B, 2003, J BIOL CHEM, V278, P6803, DOI 10.1074/jbc.M210047200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Jana A, 2004, J BIOL CHEM, V279, P51451, DOI 10.1074/jbc.M404635200; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Pappolla MA, 2003, NEUROLOGY, V61, P199, DOI 10.1212/01.WNL.0000070182.02537.84; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Qi XL, 2005, NEUROCHEM INT, V46, P613, DOI 10.1016/j.neuint.2005.02.007; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Sawamura N, 2004, J BIOL CHEM, V279, P11984, DOI 10.1074/jbc.M309832200; Shoji M, 2001, NEUROBIOL AGING, V22, P209, DOI 10.1016/S0197-4580(00)00229-3; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Sparks DL, 2005, ARCH NEUROL-CHICAGO, V62, P753, DOI 10.1001/archneur.62.5.753; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Yamazaki T, 2001, J BIOL CHEM, V276, P4454, DOI 10.1074/jbc.M009598200	30	337	345	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1118	1123		10.1038/ncb1313	http://dx.doi.org/10.1038/ncb1313			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16227967				2022-12-25	WOS:000232930400016
J	Penchovsky, R; Breaker, RR				Penchovsky, R; Breaker, RR			Computational design and experimental validation of oligonucleotide-sensing allosteric ribozymes	NATURE BIOTECHNOLOGY			English	Article							CONTROLS GENE-EXPRESSION; RNA SECONDARY STRUCTURE; HAMMERHEAD RIBOZYME; MOLECULAR SWITCHES; SELF-CLEAVAGE; COOPERATIVE BINDING; MESSENGER-RNA; RIBOSWITCH; SELECTION; SENSORS	Allosteric RNAs operate as molecular switches that alter folding and function in response to ligand binding. A common type of natural allosteric RNAs is the riboswitch; designer RNAs with similar properties can be created by RNA engineering. We describe a computational approach for designing allosteric ribozymes triggered by binding oligonucleotides. Four universal types of RNA switches possessing AND, OR, YES and NOT Boolean logic functions were created in modular form, which allows ligand specificity to be changed without altering the catalytic core of the ribozyme. All computationally designed allosteric ribozymes were synthesized and experimentally tested in vitro. Engineered ribozymes exhibit > 1,000-fold activation, demonstrate precise ligand specificity and function in molecular circuits in which the self-cleavage product of one RNA triggers the action of a second. This engineering approach provides a rapid and inexpensive way to create allosteric RNAs for constructing complex molecular circuits, nucleic acid detection systems and gene control elements.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Breaker, RR (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208103, New Haven, CT 06520 USA.	ronald.breaker@yale.edu	Penchovsky, Robert/O-2514-2019; Breaker, Ronald/E-9679-2010; Penchovsky, Robert/GYI-9263-2022	Penchovsky, Robert/0000-0001-9502-3421; Penchovsky, Robert/0000-0001-9502-3421; Breaker, Ronald/0000-0002-2165-536X	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028186] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HV-28186] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayer TS, 2005, NAT BIOTECHNOL, V23, P337, DOI 10.1038/nbt1069; Bock C, 2004, PROTEOMICS, V4, P609, DOI 10.1002/pmic.200300631; BONHOEFFER S, 1993, EUR BIOPHYS J BIOPHY, V22, P13, DOI 10.1007/BF00205808; Breaker RR, 2002, CURR OPIN BIOTECH, V13, P31, DOI 10.1016/S0958-1669(02)00281-1; Breaker RR, 2004, NATURE, V432, P838, DOI 10.1038/nature03195; Burke DH, 2002, BIOCHEMISTRY-US, V41, P6588, DOI 10.1021/bi0201522; Canny MD, 2004, J AM CHEM SOC, V126, P10848, DOI 10.1021/ja046848v; De la Pena M, 2003, EMBO J, V22, P5561, DOI 10.1093/emboj/cdg530; Desai SK, 2004, J AM CHEM SOC, V126, P13247, DOI 10.1021/ja048634j; Ferguson A, 2004, NUCLEIC ACIDS RES, V32, P1756, DOI 10.1093/nar/gkh336; Flamm C, 2000, RNA, V6, P325, DOI 10.1017/S1355838200992161; Flamm C, 2001, RNA, V7, P254, DOI 10.1017/S1355838201000863; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Grate D, 2001, BIOORGAN MED CHEM, V9, P2565, DOI 10.1016/S0968-0896(01)00031-1; Hamaguchi N, 2001, ANAL BIOCHEM, V294, P126, DOI 10.1006/abio.2001.5169; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; Hesselberth JR, 2003, ANAL BIOCHEM, V312, P106, DOI 10.1016/S0003-2697(02)00441-4; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Isaacs FJ, 2004, NAT BIOTECHNOL, V22, P841, DOI 10.1038/nbt986; Jose AM, 2001, NUCLEIC ACIDS RES, V29, P1631, DOI 10.1093/nar/29.7.1631; Khvorova A, 2003, NAT STRUCT BIOL, V10, P708, DOI 10.1038/nsb959; Koizumi M, 1999, NAT STRUCT BIOL, V6, P1062; Komatsu Y, 2000, J MOL BIOL, V299, P1231, DOI 10.1006/jmbi.2000.3825; Kubodera T, 2003, FEBS LETT, V555, P516, DOI 10.1016/S0014-5793(03)01335-8; Lewin AS, 2001, TRENDS MOL MED, V7, P221, DOI 10.1016/S1471-4914(01)01965-7; Mandal M, 2004, NAT REV MOL CELL BIO, V5, P451, DOI 10.1038/nrm1403; Mandal M, 2004, SCIENCE, V306, P275, DOI 10.1126/science.1100829; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MCCASKILL JS, 1990, BIOPOLYMERS, V29, P1109; McCauley TG, 2003, ANAL BIOCHEM, V319, P244, DOI 10.1016/S0003-2697(03)00297-5; Mironov AS, 2002, CELL, V111, P747, DOI 10.1016/S0092-8674(02)01134-0; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Osborne EM, 2005, RNA, V11, P187, DOI 10.1261/rna.7950605; Osborne SE, 1997, CHEM REV, V97, P349, DOI 10.1021/cr960009c; Penchovsky R, 2003, J COMPUT BIOL, V10, P215, DOI 10.1089/106652703321825973; PORTA H, 1995, BIO-TECHNOL, V13, P161, DOI 10.1038/nbt0295-161; Robertson MP, 2004, RNA, V10, P114, DOI 10.1261/rna.5900204; Russell R, 2002, P NATL ACAD SCI USA, V99, P155, DOI 10.1073/pnas.221593598; Schubert S, 2004, CURR DRUG TARGETS, V5, P667, DOI 10.2174/1389450043345092; Seetharaman S, 2001, NAT BIOTECHNOL, V19, P336, DOI 10.1038/86723; Silverman SK, 2003, RNA, V9, P377, DOI 10.1261/rna.2200903; Sosnick TR, 2003, CURR OPIN STRUC BIOL, V13, P309, DOI 10.1016/S0959-440X(03)00066-6; Soukup GA, 1999, TRENDS BIOTECHNOL, V17, P469, DOI 10.1016/S0167-7799(99)01383-9; Soukup GA, 1999, P NATL ACAD SCI USA, V96, P3584, DOI 10.1073/pnas.96.7.3584; Soukup GA, 2000, CURR OPIN STRUC BIOL, V10, P318, DOI 10.1016/S0959-440X(00)00090-7; Srinivasan J, 2004, CHEM BIOL, V11, P499, DOI 10.1016/j.chembiol.2004.03.014; Stojanovic MN, 2002, J AM CHEM SOC, V124, P3555, DOI 10.1021/ja016756v; Stojanovic MN, 2003, J AM CHEM SOC, V125, P6673, DOI 10.1021/ja0296632; Stojanovic MN, 2003, NAT BIOTECHNOL, V21, P1069, DOI 10.1038/nbt862; Sudarsan N, 2003, RNA, V9, P644, DOI 10.1261/rna.5090103; Suess B, 2004, NUCLEIC ACIDS RES, V32, P1610, DOI 10.1093/nar/gkh321; Tang J, 1997, CHEM BIOL, V4, P453, DOI 10.1016/S1074-5521(97)90197-6; Thompson Kristin M, 2002, BMC Biotechnol, V2, P21, DOI 10.1186/1472-6750-2-21; Vitreschak AG, 2004, TRENDS GENET, V20, P44, DOI 10.1016/j.tig.2003.11.008; Wang DY, 2002, NUCLEIC ACIDS RES, V30, P1735, DOI 10.1093/nar/30.8.1735; Werstuck G, 1998, SCIENCE, V282, P296, DOI 10.1126/science.282.5387.296; WICKISER JK, UNPUB ENG OLIGONUCLE; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Winkler WC, 2003, CHEMBIOCHEM, V4, P1024, DOI 10.1002/cbic.200300685; Winkler WC, 2002, P NATL ACAD SCI USA, V99, P15908, DOI 10.1073/pnas.212628899; Woodson SA, 2002, BIOCHEM SOC T, V30, P1166, DOI 10.1042/BST0301166; Yen L, 2004, NATURE, V431, P471, DOI 10.1038/nature02844	64	160	175	2	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2005	23	11					1424	1433		10.1038/nbt1155	http://dx.doi.org/10.1038/nbt1155			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	984FN	16244657				2022-12-25	WOS:000233288000039
J	Ross, AJ; May-Simera, H; Eichers, ER; Kai, M; Hill, J; Jagger, DJ; Leitch, CC; Chapple, JP; Munro, PM; Fisher, S; Tan, PL; Phillips, HM; Leroux, MR; Henderson, DJ; Murdoch, JN; Copp, AJ; Eliot, MM; Lupski, JR; Kemp, DT; Dollfus, H; Tada, M; Katsanis, N; Forge, A; Beales, PL				Ross, AJ; May-Simera, H; Eichers, ER; Kai, M; Hill, J; Jagger, DJ; Leitch, CC; Chapple, JP; Munro, PM; Fisher, S; Tan, PL; Phillips, HM; Leroux, MR; Henderson, DJ; Murdoch, JN; Copp, AJ; Eliot, MM; Lupski, JR; Kemp, DT; Dollfus, H; Tada, M; Katsanis, N; Forge, A; Beales, PL			Disruption of Bardet-Biedl syndrome ciliary proteins perturbs planar cell polarity in vertebrates	NATURE GENETICS			English	Article							NEURAL-TUBE DEFECTS; EAR HAIR-CELLS; GENE; ZEBRAFISH; MOUSE; MICE; MOVEMENTS; IDENTIFICATION; GASTRULATION; STRABISMUS	The evolutionarily conserved planar cell polarity (PCP) pathway (or noncanonical Wnt pathway) drives several important cellular processes, including epithelial cell polarization, cell migration and mitotic spindle orientation(1). In vertebrates, PCP genes have a vital role in polarized convergent extension movements during gastrulation and neurulation(2). Here we show that mice with mutations in genes involved in Bardet-Biedl syndrome (BBS), a disorder associated with ciliary dysfunction(3,4), share phenotypes with PCP mutants including open eyelids, neural tube defects and disrupted cochlear stereociliary bundles. Furthermore, we identify genetic interactions between BBS genes and a PCP gene in both mouse (Ltap, also called Vangl2) and zebrafish (vangl2). In zebrafish, the augmented phenotype results from enhanced defective convergent extension movements. We also show that Vangl2 localizes to the basal body and axoneme of ciliated cells, a pattern reminiscent of that of the BBS proteins. These data suggest that cilia are intrinsically involved in PCP processes.	UCL, Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; UCL, Ear Inst, Ctr Auditory Res, London WC1E 6BT, England; Johns Hopkins Univ, Wilmer Eye Inst, Inst Med Genet, Baltimore, MD 21287 USA; UCL, Inst Ophthalmol, London EC1V 9EL, England; Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; MRC Mammalian Genet Unit, Harwell, Berks, England; UCL, Inst Child Hlth, Neural Dev Unit, London WC1N 1EH, England; Hop Univ Strasbourg, Serv ORL, Strasbourg, France; Hop Univ Strasbourg, Serv Genet Med, Strasbourg, France; Univ Strasbourg 1, Fac Med, Med Genet Lab, Strasbourg, France	University of London; University College London; Baylor College of Medicine; University of London; University College London; University of London; University College London; Johns Hopkins University; Johns Hopkins Medicine; University of London; University College London; Newcastle University - UK; Simon Fraser University; MRC Harwell; University of London; University College London; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Beales, PL (corresponding author), UCL, Inst Child Hlth, Mol Med Unit, 30 Guilford St, London WC1N 1EH, England.	p.beales@ucl.ac.uk	Beales, Philip L/C-7367-2009; Tada, Masazumi/A-1431-2009	Forge, Andrew/0000-0002-0995-0219; Katsanis, Nicholas/0000-0002-2480-0171; Henderson, Deborah/0000-0002-2705-5998; Dollfus, Helene/0000-0002-2249-895X; Chapple, Paul/0000-0003-1876-1505; Johnson, Colin/0000-0002-2979-8234; Copp, Andrew/0000-0002-2544-9117; Phillips, Helen Margaret/0000-0003-4513-9148; Jagger, Daniel/0000-0003-2796-5526; May-Simera, Helen/0000-0002-9477-4036	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068; Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Avidor-Reiss T, 2004, CELL, V117, P527, DOI 10.1016/S0092-8674(04)00412-X; BARTH KA, 1995, DEVELOPMENT, V121, P1755; Beales PL, 1999, J MED GENET, V36, P437; Beales PL, 2005, CURR OPIN GENET DEV, V15, P315, DOI 10.1016/j.gde.2005.04.006; Bingham S, 2002, DEV BIOL, V242, P149, DOI 10.1006/dbio.2001.0532; Blacque OE, 2004, GENE DEV, V18, P1630, DOI 10.1101/gad.1194004; Carreira-Barbosa F, 2003, DEVELOPMENT, V130, P4037, DOI 10.1242/dev.00567; Curtin JA, 2003, CURR BIOL, V13, P1129, DOI 10.1016/S0960-9822(03)00374-9; Denman-Johnson K, 1999, J NEUROCYTOL, V28, P821, DOI 10.1023/A:1007061819934; Fath MA, 2005, HUM MOL GENET, V14, P1109, DOI 10.1093/hmg/ddi123; Frolenkov GI, 2004, NAT REV GENET, V5, P489, DOI 10.1038/nrg1377; Jessen JR, 2002, NAT CELL BIOL, V4, P610, DOI 10.1038/ncb828; Karmous-Benailly H, 2005, AM J HUM GENET, V76, P493, DOI 10.1086/428679; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; KEMP DT, 1986, HEARING RES, V22, P95, DOI 10.1016/0378-5955(86)90087-0; Kim JC, 2005, J CELL SCI, V118, P1007, DOI 10.1242/jcs.01676; Kim JC, 2004, NAT GENET, V36, P462, DOI 10.1038/ng1352; Kulaga HM, 2004, NAT GENET, V36, P994, DOI 10.1038/ng1418; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Lu XW, 2004, NATURE, V430, P93, DOI 10.1038/nature02677; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Morrell CH, 1996, J ACOUST SOC AM, V100, P1949, DOI 10.1121/1.417906; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; Mykytyn K, 2004, P NATL ACAD SCI USA, V101, P8664, DOI 10.1073/pnas.0402354101; Nishimura DY, 2004, P NATL ACAD SCI USA, V101, P16588, DOI 10.1073/pnas.0405496101; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Torban E, 2004, TRENDS GENET, V20, P570, DOI 10.1016/j.tig.2004.09.003; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	30	447	455	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2005	37	10					1135	1140		10.1038/ng1644	http://dx.doi.org/10.1038/ng1644			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16170314				2022-12-25	WOS:000232185600028
J	Tischfield, MA; Bosley, TM; Salih, MAM; Alorainy, IA; Sener, EC; Nester, MJ; Oystreck, DT; Chan, WM; Andrews, C; Erickson, RP; Engle, EC				Tischfield, MA; Bosley, TM; Salih, MAM; Alorainy, IA; Sener, EC; Nester, MJ; Oystreck, DT; Chan, WM; Andrews, C; Erickson, RP; Engle, EC			Homozygous HOXA1 mutations disrupt human brainstem, inner ear, cardiovascular and cognitive development	NATURE GENETICS			English	Article							CRANIAL NERVES; MUTANT MICE; EXPRESSION; HINDBRAIN; DEFECTS; HOX-1.6; AUTISM; HOXB1; GENES; CELLS	We identified homozygous truncating mutations in HOXA1 in three genetically isolated human populations. The resulting phenotype includes horizontal gaze abnormalities, deafness, facial weakness, hypoventilation, vascular malformations of the internal carotid arteries and cardiac outflow tract, mental retardation and autism spectrum disorder. This is the first report to our knowledge of viable homozygous truncating mutations in any human HOX gene and of a mendelian disorder resulting from mutations in a human HOX gene critical for development of the central nervous system.	Childrens Hosp, Dept Med, Program Genom, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Med Sci, Program Neurosci, Boston, MA USA; King Khalid Eye Specialist Hosp, Neuroophthalmol Div, Riyadh 11462, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Neurosci, Riyadh 11211, Saudi Arabia; King Khalid Univ Hosp, Coll Med, Dept Pediat, Div Pediat Neurol, Riyadh 11472, Saudi Arabia; King Saud Univ, Coll Med, Dept Radiol & Diagnost Imaging, Riyadh 11461, Saudi Arabia; Hacettepe Univ Hosp, Dept Ophthalmol, Ankara, Turkey; Univ Arizona, Coll Med, Dept Pediat Mol & Cellular Biol, Tucson, AZ USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; King Khaled Eye Specialist Hospital; King Faisal Specialist Hospital & Research Center; King Saud University; King Khalid University Hospital; King Saud University; Hacettepe University; University of Arizona; Harvard University; Boston Children's Hospital; Harvard Medical School	Engle, EC (corresponding author), Childrens Hosp, Dept Med, Program Genom, Boston, MA 02115 USA.	engle@enders.tch.harvard.edu	Oystreck, Darren T/Q-6135-2017; Salih, Mustafa/C-1222-2014	Oystreck, Darren T/0000-0001-6974-1091; Salih, Mustafa/0000-0002-4379-2111	NEI NIH HHS [R01 EY015298] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015298] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		CHARIOT A, 1995, BIOCHEM BIOPH RES CO, V215, P713, DOI 10.1006/bbrc.1995.2522; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; del Toro ED, 2001, J NEUROSCI, V21, P5637, DOI 10.1523/JNEUROSCI.21-15-05637.2001; Etchevers HC, 2001, DEVELOPMENT, V128, P1059; Gavalas A, 1998, DEVELOPMENT, V125, P1123; Goodman FR, 2002, AM J MED GENET, V112, P256, DOI 10.1002/ajmg.10776; Holve S, 2003, AM J MED GENET A, V120A, P169, DOI 10.1002/ajmg.a.20087; Ingram JL, 2000, TERATOLOGY, V62, P393, DOI 10.1002/1096-9926(200012)62:6<393::AID-TERA6>3.3.CO;2-M; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MARK M, 1993, DEVELOPMENT, V119, P319; McClintock JM, 2003, DEV GENES EVOL, V213, P399, DOI 10.1007/s00427-003-0335-7; MURPHY P, 1991, DEVELOPMENT, V111, P61; Rodier PM, 1996, J COMP NEUROL, V370, P247, DOI 10.1002/(SICI)1096-9861(19960624)370:2<247::AID-CNE8>3.0.CO;2-2; Shrimpton AE, 2004, AM J HUM GENET, V75, P92, DOI 10.1086/422015; Thompson AA, 2000, NAT GENET, V26, P397, DOI 10.1038/82511	15	200	209	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1035	1037		10.1038/ng1636	http://dx.doi.org/10.1038/ng1636			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16155570				2022-12-25	WOS:000232185600011
J	Torres, MA; Jones, JDG; Dangl, JL				Torres, MA; Jones, JDG; Dangl, JL			Pathogen-induced, NADPH oxidase-derived reactive oxygen intermediates suppress spread of cell death in Arabidopsis thaliana	NATURE GENETICS			English	Article							DISEASE RESISTANCE; SALICYLIC-ACID; NITRIC-OXIDE; HYPERSENSITIVE RESPONSE; OXIDATIVE STRESS; PLANT; TOBACCO; GENE; LSD1; LOCALIZATION	Plant immune responses are usually accompanied by the production of extracellular superoxide at and surrounding infection sites(1-3). Extracellular reactive oxygen intermediates (ROIs) in plants were proposed to drive programmed cell death correlated with disease resistance (the hypersensitive response). ROIs derived from this oxidative burst are generated by plasma membrane NADPH oxidases, anchored by gp91(phox) proteins related to those responsible for the respiratory oxidative burst activated in mammalian neutrophils during infection(4,5). Mutation of Arabidopsis thaliana respiratory burst oxidase (Atrboh) genes eliminated pathogen-induced ROI production but had only a modest effect on the hypersensitive response(4). We show that Atrboh function can be activated by exogenous ROIs. Unexpectedly, the subsequent oxidative burst can suppress cell death in cells surrounding sites of NADPH oxidase activation. This cell death requires salicylic acid, a plant immune system activator(6). Thus, ROIs generated by Atrboh proteins can antagonize salicylic acid-dependent pro-death signals. These results have implications for understanding how salicylic acid activates defense signaling in cells spatially removed from infection sites without causing cell death.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Univ N Carolina, Dept Microbiol & Immunol, Curriculum Genet, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Dangl, JL (corresponding author), Univ N Carolina, Dept Biol, CB 3280,Coker Hall,Room 108, Chapel Hill, NC 27599 USA.	dangl@email.unc.edu	Lacruz, Miguel Angel Torres/H-6969-2015; Jones, Jonathan DG/J-5129-2012	Lacruz, Miguel Angel Torres/0000-0002-0435-1786; Jones, Jonathan DG/0000-0002-4953-261X				Allan AC, 1997, PLANT CELL, V9, P1559, DOI 10.1105/tpc.9.9.1559; Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; AUH CK, 1995, PLANT PHYSIOL, V107, P1241, DOI 10.1104/pp.107.4.1241; Aviv DH, 2002, PLANT J, V29, P381, DOI 10.1046/j.0960-7412.2001.01225.x; Bestwick CS, 1997, PLANT CELL, V9, P209, DOI 10.1105/tpc.9.2.209; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Davletova S, 2005, PLANT CELL, V17, P268, DOI 10.1105/tpc.104.026971; Delledonne M, 2001, P NATL ACAD SCI USA, V98, P13454, DOI 10.1073/pnas.231178298; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P345, DOI 10.1016/0048-4059(83)90019-X; Dorey S, 1997, MOL PLANT MICROBE IN, V10, P646, DOI 10.1094/MPMI.1997.10.5.646; Draper J, 1997, TRENDS PLANT SCI, V2, P162, DOI 10.1016/S1360-1385(97)01030-3; Durrant WE, 2004, ANNU REV PHYTOPATHOL, V42, P185, DOI 10.1146/annurev.phyto.42.040803.140421; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Govrin EM, 2000, CURR BIOL, V10, P751, DOI 10.1016/S0960-9822(00)00560-1; Guo FQ, 2003, SCIENCE, V302, P100, DOI 10.1126/science.1086770; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; Joo JH, 2005, PLANT CELL, V17, P957, DOI 10.1105/tpc.104.029603; Kliebenstein DJ, 1999, MOL PLANT MICROBE IN, V12, P1022, DOI 10.1094/MPMI.1999.12.11.1022; Kwak JM, 2003, EMBO J, V22, P2623, DOI 10.1093/emboj/cdg277; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Rusterucci C, 2001, PLANT CELL, V13, P2211, DOI 10.1105/tpc.13.10.2211; Shirasu K, 1997, PLANT CELL, V9, P261, DOI 10.1105/tpc.9.2.261; Torres MA, 2005, CURR OPIN PLANT BIOL, V8, P397, DOI 10.1016/j.pbi.2005.05.014; Torres MA, 2002, P NATL ACAD SCI USA, V99, P517, DOI 10.1073/pnas.012452499; Wendehenne D, 2004, CURR OPIN PLANT BIOL, V7, P449, DOI 10.1016/j.pbi.2004.04.002; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108	30	431	445	5	83	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1130	1134		10.1038/ng1639	http://dx.doi.org/10.1038/ng1639			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16170317				2022-12-25	WOS:000232185600027
J	Pines, J; Lindon, C				Pines, J; Lindon, C			Proteolysis: anytime, any place, anywhere?	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE CONTROL; 26S PROTEASOME; MORPHOGENESIS CHECKPOINT; SACCHAROMYCES-CEREVISIAE; SPINDLE CHECKPOINT; SWE1P DEGRADATION; UBIQUITIN LIGASE; DNA-REPLICATION; NUCLEAR EXPORT	Proteolysis via the ubiquitin-proteasome system (UPS) is a rapid and effective method of degrading a specific protein at a specific time, and in many cases a protein is degraded only in response to a particular cellular signal or event. However, an added dimension to the control of protein degradation is possible because the ubiquitin system can be spatially regulated. Controlling where a protein is degraded can enhance the specificity and timing of proteolysis, generate asymmetry and maintain sub-compartments even in the mitotic cell. Here, we discuss this aspect of the UPS.	Wellcome Trust Canc Res UK, Gurdon Inst, Cambridge CB2 1QN, England; Dept Zool, Cambridge CB2 1QN, England	Cancer Research UK	Pines, J (corresponding author), Wellcome Trust Canc Res UK, Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	jp103@cam.ac.uk		Lindon, Catherine/0000-0003-3554-2574; Pines, Jonathon/0000-0002-5227-6004				Acquaviva C, 2004, NAT CELL BIOL, V6, P892, DOI 10.1038/ncb1167; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; Bartholomew CR, 2001, MOL CELL BIOL, V21, P4949, DOI 10.1128/MCB.21.15.4949-4959.2001; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Blondel M, 2005, EMBO J, V24, P1440, DOI 10.1038/sj.emboj.7600627; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Ehlers MD, 2003, SCIENCE, V302, P800, DOI 10.1126/science.1092546; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang JY, 2002, J CELL SCI, V115, P2847; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Lee RJ, 2004, EMBO J, V23, P2206, DOI 10.1038/sj.emboj.7600232; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lew DJ, 2003, CURR OPIN CELL BIOL, V15, P648, DOI 10.1016/j.ceb.2003.09.001; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; Mathe E, 2004, CURR BIOL, V14, P1723, DOI 10.1016/j.cub.2004.09.023; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McMillan JN, 2002, MOL BIOL CELL, V13, P3560, DOI 10.1091/mbc.E02-05-0283; McMillan JN, 1999, MOL CELL BIOL, V19, P6929; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Riechmann V, 2002, NAT CELL BIOL, V4, P337, DOI 10.1038/ncb782; Rieder CL, 1997, P NATL ACAD SCI USA, V94, P5107, DOI 10.1073/pnas.94.10.5107; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wakefield JG, 2000, CURR BIOL, V10, P1367, DOI 10.1016/S0960-9822(00)00776-4; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980	61	62	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2005	7	8					731	735		10.1038/ncb0805-731	http://dx.doi.org/10.1038/ncb0805-731			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	950TU	16056263				2022-12-25	WOS:000230881500002
J	Bentwich, I; Avniel, A; Karov, Y; Aharonov, R; Gilad, S; Barad, O; Barzilai, A; Einat, P; Einav, U; Meiri, E; Sharon, E; Spector, Y; Bentwich, Z				Bentwich, I; Avniel, A; Karov, Y; Aharonov, R; Gilad, S; Barad, O; Barzilai, A; Einat, P; Einav, U; Meiri, E; Sharon, E; Spector, Y; Bentwich, Z			Identification of hundreds of conserved and nonconserved human microRNAs	NATURE GENETICS			English	Article							CAENORHABDITIS-ELEGANS; GENES; RNAS	MicroRNAs are noncoding RNAs of similar to 22 nucleotides that suppress translation of target genes by binding to their mRNA and thus have a central role in gene regulation in health and disease(1-5). To date, 222 human microRNAs have been identified(6), 86 by random cloning and sequencing, 43 by computational approaches and the rest as putative microRNAs homologous to microRNAs in other species. To prove our hypothesis that the total number of microRNAs may be much larger and that several have emerged only in primates, we developed an integrative approach combining bioinformatic predictions with microarray analysis and sequence- directed cloning. Here we report the use of this approach to clone and sequence 89 new human microRNAs ( nearly doubling the current number of sequenced human microRNAs), 53 of which are not conserved beyond primates. These findings suggest that the total number of human microRNAs is at least 800.	Rosetta Genom, IL-76706 Rehovot, Israel		Bentwich, Z (corresponding author), Rosetta Genom, 10 Plaut St, IL-76706 Rehovot, Israel.	bentwich@rosettagenomics.com	Huang, H/E-9490-2010	Sharon, Eilon/0000-0002-1262-350X				Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bentwich I, 2005, FASEB J, V19, P875, DOI 10.1096/fj.04-3609hyp; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; Siepel A, 2004, J COMPUT BIOL, V11, P413, DOI 10.1089/1066527041410472; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441	17	1448	1700	0	79	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					766	770		10.1038/ng1590	http://dx.doi.org/10.1038/ng1590			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15965474				2022-12-25	WOS:000230196400026
J	Han, S; Collins, BE; Bengtson, P; Paulson, JC				Han, S; Collins, BE; Bengtson, P; Paulson, JC			Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking	NATURE CHEMICAL BIOLOGY			English	Article							LIGAND-BINDING DOMAIN; SURFACE SIALIC ACIDS; NEGATIVE REGULATION; RECEPTOR SIGNAL; RECOGNITION; LECTIN; CD45; SIALYLATION; LYMPHOCYTES; MASKING	CD22 is a negative regulator of B-cell receptor signaling, an activity mediated by recruitment of SH2 domain-containing phosphatase 1 through a phosphorylated immunoreceptor tyrosine inhibitory motif in its cytoplasmic domain(1). As in other members of the sialic acid-binding immunoglobulin-like lectin, or siglec, family, the extracellular N-terminal immunoglobulin domain of CD22 binds to glycan ligands containing sialic acid, which are highly expressed on B-cell glycoproteins(2). B-cell glycoproteins bind to CD22 in cis and 'mask' the ligand-binding domain(3), modulating its activity as a regulator of B-cell signaling(4-6). To assess cell-surface cis ligand interactions, we developed a new method for in situ photoaffinity cross-linking of glycan ligands to CD22. Notably, CD45, surfaceIgM (sIgM) and other glycoproteins that bind to CD22 in vitro(7,8) do not appear to be important cis ligands of CD22 in situ. Instead, CD22 seems to recognize glycans of neighboring CD22 molecules as cis ligands, forming homomultimeric complexes.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Paulson, JC (corresponding author), Scripps Res Inst, Dept Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jpaulson@scripps.edu	Paulson, James/AAG-3565-2019		NIAID NIH HHS [R01 AI050143, AI050143] Funding Source: Medline; NIGMS NIH HHS [R01 GM060938, GM60938] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060938] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borowitz MJ, 1997, BLOOD, V89, P3960, DOI 10.1182/blood.V89.11.3960; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; Chen J, 2004, NAT IMMUNOL, V5, P651, DOI 10.1038/ni1072; Collins BE, 2004, P NATL ACAD SCI USA, V101, P6104, DOI 10.1073/pnas.0400851101; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Cyster JG, 1997, IMMUNITY, V6, P509, DOI 10.1016/S1074-7613(00)80339-8; D'Arena G, 1998, HAEMATOLOGICA, V83, P197; D'Arena G, 2000, AM J HEMATOL, V64, P275; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Greer SF, 1999, J IMMUNOL, V162, P5278; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Jin L, 2002, J EXP MED, V195, P1199, DOI 10.1084/jem.20011796; John BJ, 2003, J IMMUNOL, V170, P3534, DOI 10.4049/jimmunol.170.7.3534; Kelm S, 2002, J EXP MED, V195, P1207, DOI 10.1084/jem.20011783; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Lanoue A, 2002, EUR J IMMUNOL, V32, P348, DOI 10.1002/1521-4141(200202)32:2<348::AID-IMMU348>3.0.CO;2-5; LAW CL, 1995, J IMMUNOL, V155, P3368; Luchansky SJ, 2004, CHEMBIOCHEM, V5, P371, DOI 10.1002/cbic.200300789; Oetke C, 2002, J BIOL CHEM, V277, P6688, DOI 10.1074/jbc.M109973200; Poe JC, 2004, NAT IMMUNOL, V5, P1078, DOI 10.1038/ni1121; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; Razi N, 1998, P NATL ACAD SCI USA, V95, P7469, DOI 10.1073/pnas.95.13.7469; Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007; Sgroi D, 1996, J BIOL CHEM, V271, P18803, DOI 10.1074/jbc.271.31.18803; SGROI D, 1993, J BIOL CHEM, V268, P7011; Shapiro RE, 1997, J BIOL CHEM, V272, P30380, DOI 10.1074/jbc.272.48.30380; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822; Zaccai NR, 2003, STRUCTURE, V11, P557, DOI 10.1016/S0969-2126(03)00073-X; Zhang M, 2004, GLYCOBIOLOGY, V14, P939, DOI 10.1093/glycob/cwh126	30	196	203	3	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2005	1	2					93	97		10.1038/nchembio713	http://dx.doi.org/10.1038/nchembio713			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GE	16408005				2022-12-25	WOS:000232648200013
J	Wu, CJ; Conze, DB; Li, T; Srinivasula, SM; Ashwell, JD				Wu, CJ; Conze, DB; Li, T; Srinivasula, SM; Ashwell, JD			NEMO is a sensor of Lys 63-linked polyubiquitination and functions in NF-kappa B activation	NATURE CELL BIOLOGY			English	Article							DEATH DOMAIN KINASE; GAMMA IKK-GAMMA; UBIQUITINATION; PROTEIN; COMPLEX; RIP; OLIGOMERIZATION; RECRUITMENT; PATHWAY; CHAINS	The transcription factor NF-kappa B is sequestered in the cytoplasm in a complex with I kappa B-1. Almost all NF-kappa B activation pathways converge on I kappa B kinase (IKK), which phosphorylates I kappa B resulting in Lys 48-linked polyubiquitination of I kappa B and its degradation. This allows migration of NF-kappa B to the nucleus where it regulates gene expression(2). IKK has two catalytic subunits, IKK alpha and IKK beta, and a regulatory subunit, IKK gamma or NEMO. NEMO is essential for NF-kappa B activation, and NEMO dysfunction in humans is the cause of incontinentia pigmenti and hypohidrotic ectodermal dysplasia and immunodeficiency (HED-ID)(3). The recruitment of IKK to occupied cytokine receptors, and its subsequent activation, are dependent on the attachment of Lys 63-linked polyubiquitin chains to signalling intermediates such as receptor-interacting protein ( RIP). Here, we show that NEMO binds to Lys 63-but not Lys 48-linked polyubiquitin, and that single point mutations in NEMO that prevent binding to Lys 63-linked polyubiquitin also abrogates the binding of NEMO to RIP in tumour necrosis factor ( TNF)alpha- stimulated cells, the recruitment of IKK to TNF receptor (TNF-R) 1, and the activation of IKK and NF-kappa B. RIP is also destabilized in the absence of NEMO binding and undergoes proteasomal degradation in TNF-alpha-treated cells. These results provide a mechanism for NEMO's critical role in IKK activation, and a key to understanding the link between cytokine-receptor proximal signalling and IKK and NF-kappa B activation.	NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ashwell, JD (corresponding author), NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA.	jda@pop.nci.nih.gov			Intramural NIH HHS Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC009290] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC010629, Z01BC010629] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Conze DB, 2005, MOL CELL BIOL, V25, P3348, DOI 10.1128/MCB.25.8.3348-3356.2005; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kishida S, 2005, GENES CELLS, V10, P447, DOI 10.1111/j.1365-2443.2005.00852.x; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; LEE SY, 1985, COMPUT STAT DATA AN, V2, P279, DOI 10.1016/0167-9473(85)90002-7; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tenno T, 2004, GENES CELLS, V9, P865, DOI 10.1111/j.1365-2443.2004.00780.x; Thome M, 2003, TRENDS IMMUNOL, V24, P419, DOI 10.1016/S1471-4906(03)00177-7; TRAKSHEL GM, 1988, BIOCHEM J, V252, P127, DOI 10.1042/bj2520127; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	35	489	507	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					398	U58		10.1038/ncb1384	http://dx.doi.org/10.1038/ncb1384			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16547522				2022-12-25	WOS:000236560000019
J	Culver-Hanlon, TL; Lex, SA; Stephens, AD; Quintyne, NJ; King, SJ				Culver-Hanlon, TL; Lex, SA; Stephens, AD; Quintyne, NJ; King, SJ			A microtubule-binding domain in dynactin increases dynein processivity by skating along microtubules	NATURE CELL BIOLOGY			English	Article							ONE-DIMENSIONAL DIFFUSION; CYTOPLASMIC DYNEIN; IN-VITRO; MOTOR; PURIFICATION; TRANSPORT; DEGENERATION; PROTEINS; VIVO	Microtubule-associated proteins (MAPs) use particular microtubule-binding domains that allow them to interact with microtubules in a manner specific to their individual cellular functions. Here, we have identified a highly basic microtubule-binding domain in the p150 subunit of dynactin that is only present in the dynactin members of the CAP-Gly family of proteins. Using single-particle microtubule-binding assays, we found that the basic domain of dynactin moves progressively along microtubules in the absence of molecular motors - a process we term 'skating'. In contrast, the previously described CAP-Gly domain of dynactin remains firmly attached to a single point on microtubules. Further analyses showed that microtubule skating is a form of one-dimensional diffusion along the microtubule. To determine the cellular function of the skating phenomenon, dynein and the dynactin microtubule-binding domains were examined in single-molecule motility assays. We found that the basic domain increased dynein processivity fourfold whereas the CAP-Gly domain inhibited dynein motility. Our data show that the ability of the basic domain of dynactin to skate along microtubules is used by dynein to maintain longer interactions for each encounter with microtubules.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	University of Missouri System; University of Missouri Kansas City; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	King, SJ (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA.	kingsj@umkc.edu		Stephens, Andrew/0000-0001-5474-7845; Quintyne, Nicholas/0000-0002-8817-2936	NINDS NIH HHS [R01 NS048501, NS48501] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048501] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bingham JB, 1998, METHOD ENZYMOL, V298, P171, DOI 10.1016/S0076-6879(98)98017-X; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; King SJ, 2003, MOL BIOL CELL, V14, P5089, DOI 10.1091/mbc.E03-01-0025; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; Mallik R, 2005, CURR BIOL, V15, P2075, DOI 10.1016/j.cub.2005.10.039; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Scheel J, 1999, J BIOL CHEM, V274, P25883, DOI 10.1074/jbc.274.36.25883; SLOBODA RD, 1982, METHOD ENZYMOL, V85, P409; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Vaughan PS, 2001, J BIOL CHEM, V276, P26171, DOI 10.1074/jbc.M102649200; Wang ZH, 1999, CELL STRUCT FUNCT, V24, P373, DOI 10.1247/csf.24.373	18	156	160	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2006	8	3					264	270		10.1038/ncb1370	http://dx.doi.org/10.1038/ncb1370			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	017QL	16474384				2022-12-25	WOS:000235708000012
J	Medeiros, NA; Burnette, DT; Forscher, P				Medeiros, NA; Burnette, DT; Forscher, P			Myosin II functions in actin-bundle turnover in neuronal growth cones	NATURE CELL BIOLOGY			English	Article							F-ACTIN; BLEBBISTATIN INHIBITION; RETROGRADE FLOW; 2 POPULATIONS; NERVE GROWTH; DYNAMICS; FILAMENTS; MECHANISM; MICROTUBULES; ORGANIZATION	Retrograde actin flow works in concert with cell adhesion to generate traction forces that are involved in axon guidance in neuronal growth cones. Myosins have been implicated in retrograde flow, but identification of the specific myosin subtype(s) involved has been controversial. Using fluorescent speckle microscopy (FSM) to assess actin dynamics, we report that inhibition of myosin II alone decreases retrograde flow by 51% and the remaining flow can be almost fully accounted for by the 'push' of plus-end actin assembly at the leading edge of the growth cone. Interestingly, actin bundles that are associated with filopodium roots elongated by approximately 83% after inhibition of myosin II. This unexpected result was due to decreased rates of actin-bundle severing near their proximal (minus or pointed) ends which are located in the transition zone of the growth cone. Our study reveals a mechanism for the regulation of actin-bundle length by myosin II that is dependent on actin-bundle severing, and demonstrate that retrograde flow is a steady state that depends on both myosin II contractility and actin-network treadmilling.	Yale Univ, Interdepartmental Neurosci Program, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University	Forscher, P (corresponding author), Yale Univ, Interdepartmental Neurosci Program, New Haven, CT 06520 USA.	paul.forscher@yale.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028695, R01NS051786] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS051786, R01-NS28695] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allingham JS, 2005, NAT STRUCT MOL BIOL, V12, P378, DOI 10.1038/nsmb908; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; Bridgman PC, 2001, J NEUROSCI, V21, P6159, DOI 10.1523/JNEUROSCI.21-16-06159.2001; Brown J, 2003, J HISTOCHEM CYTOCHEM, V51, P421, DOI 10.1177/002215540305100403; Brown ME, 2003, J CELL SCI, V116, P1087, DOI 10.1242/jcs.00335; DE LA CRUZ EM, 1994, BIOCHEMISTRY-US, V33, P14387, DOI 10.1021/bi00252a003; Diefenbach TJ, 2002, J CELL BIOL, V158, P1207, DOI 10.1083/jcb.200202028; FORSCHER P, 1987, J NEUROSCI, V7, P3600; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; Gallo G, 2004, J NEUROBIOL, V58, P92, DOI 10.1002/neu.10282; Gallo G, 2002, J CELL BIOL, V158, P1219, DOI 10.1083/jcb.200204140; Gehler S, 2004, J NEUROSCI, V24, P10741, DOI 10.1523/JNEUROSCI.2836-04.2004; Guha M, 2005, CURR BIOL, V15, P732, DOI 10.1016/j.cub.2005.03.042; Henson JH, 2003, CELL MOTIL CYTOSKEL, V56, P252, DOI 10.1002/cm.10149; Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139; Ishikawa R, 2003, J NEUROCHEM, V87, P676, DOI 10.1046/j.1471-4159.2003.02058.x; Kolega J, 2004, BIOCHEM BIOPH RES CO, V320, P1020, DOI 10.1016/j.bbrc.2004.06.045; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Lebrand C, 2004, NEURON, V42, P37, DOI 10.1016/S0896-6273(04)00108-4; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; Limouze J, 2004, J MUSCLE RES CELL M, V25, P337, DOI 10.1007/s10974-004-6060-7; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; Mallavarapu A, 1999, J CELL BIOL, V146, P1097, DOI 10.1083/jcb.146.5.1097; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; Mogilner A, 2003, CURR BIOL, V13, pR721, DOI 10.1016/j.cub.2003.08.050; Murthy K, 2005, CURR BIOL, V15, P724, DOI 10.1016/j.cub.2005.02.055; Nakhost A, 2002, J BIOL CHEM, V277, P40633, DOI 10.1074/jbc.M205099200; Ramamurthy B, 2004, BIOCHEMISTRY-US, V43, P14832, DOI 10.1021/bi0490284; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; SHIVERICK KT, 1975, BIOCHIM BIOPHYS ACTA, V393, P124, DOI 10.1016/0005-2795(75)90222-6; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; Thompson C, 1996, J CELL SCI, V109, P2843; Torreano PJ, 2005, CELL MOTIL CYTOSKEL, V60, P166, DOI 10.1002/cm.20051; Turney SG, 2005, NAT NEUROSCI, V8, P717, DOI 10.1038/nn1466; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; Waterman-Storer CM, 1998, CURR BIOL, V8, P1227, DOI 10.1016/S0960-9822(07)00515-5; Welnhofer EA, 1999, J NEUROSCI, V19, P7971; Wylie SR, 2003, MOL BIOL CELL, V14, P4654, DOI 10.1091/mbc.E03-03-0187; Yoneda A, 2005, J CELL BIOL, V170, P443, DOI 10.1083/jcb.200412043; Zhang XF, 2003, NEURON, V40, P931, DOI 10.1016/S0896-6273(03)00754-2	47	367	372	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2006	8	3					215	226		10.1038/ncb1367	http://dx.doi.org/10.1038/ncb1367			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	017QL	16501565				2022-12-25	WOS:000235708000007
J	Zhang, HY; Macara, IG				Zhang, HY; Macara, IG			The polarity protein PAR-3 and TIAM1 cooperate in dendritic spine morphogenesis	NATURE CELL BIOLOGY			English	Article							ASYMMETRIC CELL-DIVISION; C-ELEGANS; RAC; COMPLEX; INVOLVEMENT; ACTIVATION; PATHOLOGY; DYNAMICS; ZYGOTE	PAR-3 (partitioning-defective gene 3) is essential for cell polarization in many contexts, including axon specification. However, polarity proteins have not been implicated in later steps of neuronal differentiation, such as dendritic spine morphogenesis. Here, we show that PAR-3 is necessary for normal spine development in primary hippocampal neurons. Depletion of PAR-3 causes the formation of multiple filopodia- and lamellipodia-like dendritic protrusions - a phenotype similar to neurons expressing activated Rac. PAR-3 regulates spine formation by binding the Rac guanine nucleotide-exchange factor (GEF) TIAM1, and spatially restricting it to dendritic spines. Thus, a balance of PAR-3 and TIAM1 is essential to modulate Rac-GTP levels and to allow spine morphogenesis.	Univ Virginia, Sch Med, Dept Microbiol, Ctr Cell Signalling, Charlottesville, VA 22908 USA	University of Virginia	Zhang, HY (corresponding author), Univ Virginia, Sch Med, Dept Microbiol, Ctr Cell Signalling, Charlottesville, VA 22908 USA.	hz5a@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070902] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM070902] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; Fischer M, 2000, NAT NEUROSCI, V3, P887, DOI 10.1038/78791; Goda Y, 2003, NEURON, V40, P243, DOI 10.1016/S0896-6273(03)00608-1; GOSLIN K, 1998, RAT HIPPOCAMPAL NEUR; Halpain S, 2005, PROG BRAIN RES, V147, P29, DOI 10.1016/S0079-6123(04)47003-4; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Hirose T, 2002, J CELL SCI, V115, P2485; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kunda P, 2001, J NEUROSCI, V21, P2361, DOI 10.1523/JNEUROSCI.21-07-02361.2001; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; Munro E, 2004, DEV CELL, V7, P413, DOI 10.1016/j.devcel.2004.08.001; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nishimura T, 2005, NAT CELL BIOL, V7, P270, DOI 10.1038/ncb1227; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Tanaka M, 2004, EMBO J, V23, P1075, DOI 10.1038/sj.emboj.7600128; Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024; Wei XY, 2004, DEV BIOL, V269, P286, DOI 10.1016/j.ydbio.2004.01.017; Zhang HY, 2003, J CELL BIOL, V161, P131, DOI 10.1083/jcb.200211002	28	170	172	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2006	8	3					227	237		10.1038/ncb1368	http://dx.doi.org/10.1038/ncb1368			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	017QL	16474385				2022-12-25	WOS:000235708000008
J	Ait-Oufella, H; Salomon, BL; Potteaux, S; Robertson, AKL; Gourdy, P; Zoll, J; Merval, R; Esposito, B; Cohen, JL; Fisson, S; Flavell, RA; Hansson, GK; Klatzmann, D; Tedgui, A; Mallat, Z				Ait-Oufella, H; Salomon, BL; Potteaux, S; Robertson, AKL; Gourdy, P; Zoll, J; Merval, R; Esposito, B; Cohen, JL; Fisson, S; Flavell, RA; Hansson, GK; Klatzmann, D; Tedgui, A; Mallat, Z			Natural regulatory T cells control the development of atherosclerosis in mice	NATURE MEDICINE			English	Article							HOMEOSTASIS; INTERLEUKIN-4; COSTIMULATION; MECHANISMS; IMMUNITY; LDL	Atherosclerosis is an immunoinflammatory disease elicited by accumulation of lipids in the artery wall and leads to myocardial infarction and stroke(1,2). Here, we show that naturally arising CD4(+)CD25(+) regulatory T cells, which actively maintain immunological tolerance to self and nonself antigens(3,4), are powerful inhibitors of atherosclerosis in several mouse models. These results provide new insights into the immunopathogenesis of atherosclerosis and could lead to new therapeutic approaches that involve immune modulation using regulatory T cells.	Ctr Rech Cardiovasc Lariboisiere, INSERM, U689, F-75010 Paris, France; Grp Hosp Pitie Salpetriere, CNRS, UMR 7087, F-75013 Paris, France; Karolinska Inst, Karolinska Hosp, Dept Med, Ctr Mol Med, SE-17176 Stockholm, Sweden; Inst L Bugnard, INSERM, U589, F-31432 Toulouse 4, France; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Karolinska Institutet; Karolinska University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Yale University; Howard Hughes Medical Institute; Yale University	Mallat, Z (corresponding author), Ctr Rech Cardiovasc Lariboisiere, INSERM, U689, 41 Bd Chapelle, F-75010 Paris, France.	mallat@larib.inserm.fr	Salomon, Benoit/AAP-5209-2021; Mallat, Ziad/D-4041-2012; FISSON, Sylvain/J-8003-2013; Salomon, Benoit L/M-2421-2017; Cohen, José/Q-4816-2018; Hansson, Goran K/B-7423-2012	Salomon, Benoit/0000-0001-9673-5578; Mallat, Ziad/0000-0003-0443-7878; FISSON, Sylvain/0000-0002-0057-363X; Salomon, Benoit L/0000-0001-9673-5578; Cohen, José/0000-0002-5077-6726; Potteaux, Stephane/0000-0003-3068-8769; Klatzmann, David/0000-0002-0054-3422; Gourdy, Pierre/0000-0002-5362-3813; Hansson, Goran/0000-0003-4148-5190				Almeida ARM, 2002, J IMMUNOL, V169, P4850, DOI 10.4049/jimmunol.169.9.4850; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Binder CJ, 2004, J CLIN INVEST, V114, P427, DOI 10.1172/jci200420479; Buono C, 2004, CIRCULATION, V109, P2009, DOI 10.1161/01.CIR.0000127121.16815.F1; Daugherty A, 2002, CIRC RES, V90, P1039, DOI 10.1161/01.RES.0000021397.28936.F9; Davenport P, 2003, AM J PATHOL, V163, P1117, DOI 10.1016/S0002-9440(10)63471-2; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; King VL, 2002, ARTERIOSCL THROM VAS, V22, P456, DOI 10.1161/hq0302.104905; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Mallat Z, 2003, CIRCULATION, V108, P1232, DOI 10.1161/01.CIR.0000089083.61317.A1; Robertson AKL, 2003, J CLIN INVEST, V112, P1342, DOI 10.1172/JCI200318607; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Tang QZ, 2003, J IMMUNOL, V171, P3348, DOI 10.4049/jimmunol.171.7.3348; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180	15	791	837	2	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					178	180		10.1038/nm1343	http://dx.doi.org/10.1038/nm1343			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16462800				2022-12-25	WOS:000235160600021
J	Feng, WY; Collingwood, D; Boeck, ME; Fox, LA; Alvino, GM; Fangman, WL; Raghuraman, MK; Brewer, BJ				Feng, WY; Collingwood, D; Boeck, ME; Fox, LA; Alvino, GM; Fangman, WL; Raghuraman, MK; Brewer, BJ			Genomic mapping of single-stranded DNA in hydroxyurea-challenged yeasts identifies origins of replication	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; FIRING ORIGINS; CELL-CYCLE; DAMAGE; FORK; PHOSPHORYLATION; TELOMERES; PROTEINS; PROFILE; KINASE	During DNA replication one or both strands transiently become single stranded: first at the sites where initiation of DNA synthesis occurs ( known as origins of replication) and subsequently on the lagging strands of replication forks as discontinuous Okazaki fragments are generated. We report a genome-wide analysis of single-stranded DNA (ssDNA) formation in the presence of hydroxyurea during DNA replication in wild-type and checkpoint-deficient rad53 Saccharomyces cerevisiae cells. In wild-type cells, ssDNA was first observed at a subset of replication origins and later 'migrated' bi-directionally, suggesting that ssDNA formation is associated with continuously moving replication forks. In rad53 cells, ssDNA was observed at virtually every known origin, but remained there over time, suggesting that replication forks stall. Telomeric regions seemed to be particularly sensitive to the loss of Rad53 checkpoint function. Replication origins in Schizosaccharomyces pombe were also mapped using our method.	Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Math, Seattle, WA 98195 USA; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Rochester	Brewer, BJ (corresponding author), Univ Washington, Dept Genome Sci, Box 357730, Seattle, WA 98195 USA.	bbrewer@gs.washington.edu		boeck, Max/0000-0001-9668-407X	NIGMS NIH HHS [R01 GM018926] Funding Source: Medline; PHS HHS [18926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018926] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; Early A, 2004, PHILOS T R SOC B, V359, P31, DOI 10.1098/rstb.2003.1362; Friedman KL, 1997, GENES CELLS, V2, P667, DOI 10.1046/j.1365-2443.1997.1520350.x; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; Jia XD, 2004, GENETICS, V166, P753, DOI 10.1534/genetics.166.2.753; Kim SM, 2001, EMBO J, V20, P6115, DOI 10.1093/emboj/20.21.6115; Kumar S, 2004, J BIOL CHEM, V279, P43574, DOI 10.1074/jbc.M407819200; Longhese MP, 2000, GENETICS, V155, P1577; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; MacAlpine D, 2005, CHROMOSOME RES, V13, P309, DOI 10.1007/s10577-005-1508-1; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Patel PK, 2006, MOL BIOL CELL, V17, P308, DOI 10.1091/mbc.E05-07-0657; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Poloumienko A, 2001, MOL BIOL CELL, V12, P3317, DOI 10.1091/mbc.12.11.3317; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Segurado M, 2003, EMBO REP, V4, P1048, DOI 10.1038/sj.embor.7400008; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Toueille M, 2004, CHROMOSOMA, V113, P113, DOI 10.1007/s00412-004-0303-7; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101; Yabuki N, 2002, GENES CELLS, V7, P781, DOI 10.1046/j.1365-2443.2002.00559.x	27	172	176	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2006	8	2					148	U39		10.1038/ncb1358	http://dx.doi.org/10.1038/ncb1358			37	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	008SA	16429127	Green Accepted			2022-12-25	WOS:000235059800009
J	Millan, J; Hewlett, L; Glyn, M; Toomre, D; Clark, P; Ridley, AJ				Millan, J; Hewlett, L; Glyn, M; Toomre, D; Clark, P; Ridley, AJ			Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains	NATURE CELL BIOLOGY			English	Article							NEUTROPHIL TRANSENDOTHELIAL MIGRATION; EVANESCENT-WAVE MICROSCOPY; CELL-SURFACE; TIGHT JUNCTIONS; ADHESION; MEMBRANE; POLYMERIZATION; TRANSCYTOSIS; PERMEABILITY; POLARIZATION	During inflammation, leukocytes bind to the adhesion receptors ICAM-1 and VCAM-1 on the endothelial surface before undergoing transendothelial migration, also called diapedesis. ICAM-1 is also involved in transendothelial migration, independently of its role in adhesion, but the molecular basis of this function is poorly understood. Here we demonstrate that, following clustering, apical ICAM-1 translocated to caveolin-rich membrane domains close to the ends of actin stress fibres. In these F-actin- rich areas, ICAM-1 was internalized and transcytosed to the basal plasma membrane through caveolae. Human T-lymphocytes extended pseudopodia into endothelial cells in caveolin- and F-actin-enriched areas, induced local translocation of ICAM-1 and caveolin-1 to the endothelial basal membrane and transmigrated through transcellular passages formed by a ring of F-actin and caveolae. Reduction of caveolin-1 levels using RNA interference (RNAi) specifically decreased lymphocyte transcellular transmigration. We propose that the translocation of ICAM-1 to caveola- and F-actin-rich domains links the sequential steps of lymphocyte adhesion and transendothelial migration and facilitates lymphocyte migration through endothelial cells from capillaries into surrounding tissue.	Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; Yale Univ, Sch Med, Dept Cell Biol, Ludwig Inst Canc Res, New Haven, CT 06520 USA	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London; University of London; University College London; Imperial College London; Ludwig Institute for Cancer Research; Yale University	Ridley, AJ (corresponding author), Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	anne@ludwig.ucl.ac.uk		Ridley, Anne/0000-0001-8186-5708; Millan, Jaime/0000-0003-3107-147X				Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126; Beardsley A, 2005, J BIOL CHEM, V280, P3541, DOI 10.1074/jbc.M409040200; Burns AR, 2000, J CELL SCI, V113, P45; Burns AR, 1997, J IMMUNOL, V159, P2893; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Carman CV, 2003, J IMMUNOL, V171, P6135, DOI 10.4049/jimmunol.171.11.6135; Dvorak AM, 2001, J HISTOCHEM CYTOCHEM, V49, P419, DOI 10.1177/002215540104900401; Engelhardt B, 2004, EUR J IMMUNOL, V34, P2955, DOI 10.1002/eji.200425327; Etienne S, 1998, J IMMUNOL, V161, P5755; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Feng D, 2002, MICROSC RES TECHNIQ, V57, P289, DOI 10.1002/jemt.10087; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; FIELDING RG, 1987, J ADV NURS, V12, P281, DOI 10.1111/j.1365-2648.1987.tb01334.x; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Johnson-Leger C, 2000, J CELL SCI, V113, P921; Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3; Kvietys PR, 2001, NEWS PHYSIOL SCI, V16, P15; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Millan J, 2002, BLOOD, V99, P978, DOI 10.1182/blood.V99.3.978; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; OPPENHEIMERMARKS N, 1991, J IMMUNOL, V147, P2913; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051; Simionescu M, 2002, MICROSC RES TECHNIQ, V57, P269, DOI 10.1002/jemt.10086; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; Sotgia F, 2002, MOL CELL BIOL, V22, P3905, DOI 10.1128/MCB.22.11.3905-3926.2002; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Thompson PW, 2002, J IMMUNOL, V169, P1007, DOI 10.4049/jimmunol.169.2.1007; Tilghman RW, 2002, FASEB J, V16, P1257, DOI 10.1096/fj.01-0969fje; Toomre D, 2000, J CELL BIOL, V149, P33, DOI 10.1083/jcb.149.1.33; Toomre D, 2001, TRENDS CELL BIOL, V11, P298, DOI 10.1016/S0962-8924(01)02027-X; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942	42	301	310	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2006	8	2					113	U5		10.1038/ncb1356	http://dx.doi.org/10.1038/ncb1356			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	008SA	16429128				2022-12-25	WOS:000235059800006
J	Oh, SW; Mukhopadhyay, A; Dixit, BL; Raha, T; Green, MR; Tissenbaum, HA				Oh, SW; Mukhopadhyay, A; Dixit, BL; Raha, T; Green, MR; Tissenbaum, HA			Identification of direct DAF-16 targets controlling longevity, metabolism and diapause by chromatin immunoprecipitation	NATURE GENETICS			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; REGULATES LIFE-SPAN; C-ELEGANS; SIGNALING PATHWAY; OXIDATIVE STRESS; PROTEIN DAF-16; GENES; MUTANTS; SCREEN; FAMILY	DAF-16, a forkhead transcription factor, is a key regulator of longevity, metabolism and dauer diapause in Caenorhabditis elegans. The precise mechanism by which DAF-16 regulates multiple functions, however, is poorly understood. Here, we used chromatin immunoprecipitation (ChIP) to identify direct targets of DAF-16. We cloned 103 target sequences containing consensus DAF-16 binding sites and selected 33 targets for further analysis. Expression of most of these genes is regulated in a DAF-16-dependent manner, and inactivation of more than half of these genes significantly altered DAF-16-dependent functions, including life span, fat storage and dauer formation. Our results show that the ChIP-based cloning strategy leads to greater enrichment for DAF-16 target genes than previous screening strategies. We also demonstrate that DAF-16 is recruited to multiple promoters to coordinate regulation of its downstream targets. The large number of target genes discovered provides insight into how DAF-16 controls diverse biological functions.	Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Tissenbaum, HA (corresponding author), Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA.	heidi.tissenbaum@umassmed.edu	Mukhopadhyay, Arnab/N-6005-2016	Mukhopadhyay, Arnab/0000-0002-5266-7849; OH, SEUNG WOOK/0000-0001-7632-6822				Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Barbieri M, 2003, AM J PHYSIOL-ENDOC M, V285, pE1064, DOI 10.1152/ajpendo.00296.2003; CONTE D, 2003, CURRENT PROTOCOLS MO; de Belle I, 2003, J BIOL CHEM, V278, P14306, DOI 10.1074/jbc.M210502200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GOTTLIEB S, 1994, GENETICS, V137, P107; Hamilton B, 2005, GENE DEV, V19, P1544, DOI 10.1101/gad.1308205; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; HOSONO R, 1982, EXP GERONTOL, V17, P163, DOI 10.1016/0531-5565(82)90052-3; Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MALONE EA, 1994, GENETICS, V136, P879; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; Mukhopadhyay A, 2005, CELL METAB, V2, P35, DOI 10.1016/j.cmet.2005.06.004; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Raha T, 2005, PLOS BIOL, V3, P221, DOI 10.1371/journal.pbio.0030044; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Weinmann AS, 2004, NAT REV IMMUNOL, V4, P381, DOI 10.1038/nri1353; Yanase S, 2002, MECH AGEING DEV, V123, P1579, DOI 10.1016/S0047-6374(02)00093-3	30	269	303	3	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2006	38	2					251	257		10.1038/ng1723	http://dx.doi.org/10.1038/ng1723			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16380712				2022-12-25	WOS:000234953200024
J	Arias, EE; Walter, JC				Arias, EE; Walter, JC			PCNA functions as a molecular platform to trigger Cdt1 destruction and prevent re-replication	NATURE CELL BIOLOGY			English	Article							XENOPUS EGG EXTRACTS; LICENSING FACTOR CDT1; DNA-REPLICATION; S-PHASE; INITIATION; GEMININ; COMPLEX; DEGRADATION; PROTEOLYSIS; INHIBITION	Ubiquitin- mediated proteolysis of the replication licensing factor Cdt1 ( Cdc10- dependent transcript 1) in S phase is a key mechanism that limits DNA replication to a single round per cell cycle in metazoans(1-6). In Xenopus egg extracts, Cdt1 is destroyed on chromatin during DNA replication(1). Here, we report that replication- dependent proteolysis of Cdt1 requires its interaction with proliferating cell nuclear antigen ( PCNA), a homotrimeric processivity factor for DNA polymerases(7). Cdt1 binds to PCNA through a consensus PCNA- interaction motif that is conserved in Cdt1 of all metazoans, and removal of PCNA from egg extracts inhibits replication- dependent Cdt1 destruction. Mutation of the PCNA- interaction motif yields a stabilized Cdt1 protein that induces re- replication. DDB1, a component of the Cul4 E3 ubiquitin ligase that mediates human Cdt1 proteolysis in response to DNA damage(8), is also required for replication- dependent Cdt1 destruction. Cdt1 and DDB1 interact in extracts, and DDB1 chromatin loading is dependent on the binding of Cdt1 to PCNA, which indicates that PCNA docking activates the pre- formed Cdt1 - Cul4(DDB1) ligase complex. Thus, PCNA functions as a platform for Cdt1 destruction, ensuring efficient and temporally restricted inactivation of a key cell- cycle regulator.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walter, JC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	johannes_walter@hms.harvard.edu		Walter, Johannes/0000-0002-4186-7570				Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Arias EE, 2004, FRONT BIOSCI-LANDMRK, V9, P3029, DOI 10.2741/1457; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chuang LC, 2005, J BIOL CHEM, V280, P35299, DOI 10.1074/jbc.M506429200; Claycomb JM, 2002, J CELL BIOL, V159, P225, DOI 10.1083/jcb.200207046; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Kondo T, 2004, J BIOL CHEM, V279, P27315, DOI 10.1074/jbc.M314023200; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Maiorano D, 2005, CURR BIOL, V15, P146, DOI 10.1016/j.cub.2004.12.002; Mattock H, 2001, EXP CELL RES, V265, P242, DOI 10.1006/excr.2001.5181; May NR, 2005, J CELL SCI, V118, P4207, DOI 10.1242/jcs.02534; Mimura S, 2000, GENES CELLS, V5, P439, DOI 10.1046/j.1365-2443.2000.00340.x; Nishitani H, 2004, J BIOL CHEM, V279, P30807, DOI 10.1074/jbc.M312644200; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Su'etsugu M, 2005, J BIOL CHEM, V280, P6528, DOI 10.1074/jbc.M412060200; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takeda DY, 2005, J BIOL CHEM, V280, P23416, DOI 10.1074/jbc.M501208200; Thomer M, 2004, DEVELOPMENT, V131, P4807, DOI 10.1242/dev.01348; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yoshida K, 2005, GENES CELLS, V10, P63, DOI 10.1111/j.1365-2443.2005.00815.x; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747	33	239	245	2	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					84	U33		10.1038/ncb1346	http://dx.doi.org/10.1038/ncb1346			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	16362051				2022-12-25	WOS:000234651500016
J	Kanter, JL; Narayana, S; Ho, PP; Catz, I; Warren, KG; Sobel, RA; Steinman, L; Robinson, WH				Kanter, JL; Narayana, S; Ho, PP; Catz, I; Warren, KG; Sobel, RA; Steinman, L; Robinson, WH			Lipid microarrays identify key mediators of autoimmune brain inflammation	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; CIRCULATING ANTIGANGLIOSIDE ANTIBODIES; PROGRESSIVE MULTIPLE-SCLEROSIS; ENCEPHALOMYELITIS; DEMYELINATION; DISEASE; EXPRESSION; SULFATIDE; PROTEIN; LESIONS	Recent studies suggest that increased T-cell and autoantibody reactivity to lipids may be present in the autoimmune demyelinating disease multiple sclerosis. To perform large-scale multiplex analysis of antibody responses to lipids in multiple sclerosis, we developed microarrays composed of lipids present in the myelin sheath, including ganglioside, sulfatide, cerebroside, sphingomyelin and total brain lipid fractions. Lipid-array analysis showed lipid-specific antibodies against sulfatide, sphingomyelin and oxidized lipids in cerebrospinal fluid (CSF) derived from individuals with multiple sclerosis. Sulfatide-specific antibodies were also detected in SJL/J mice with acute experimental autoimmune encephalomyelitis (EAE). Immunization of mice with sulfatide plus myelin peptide resulted in a more severe disease course of EAE, and administration of sulfatide-specific antibody exacerbated EAE. Thus, autoimmune responses to sulfatide and other lipids are present in individuals with multiple sclerosis and in EAE, and may contribute to the pathogenesis of autoimmune demyelination.	Stanford Univ, Sch Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Univ Alberta, Dept Med, Edmonton, AB, Canada; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Palo Alto VA Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University; University of Alberta; Stanford University; Geriatric Research Education & Clinical Center	Robinson, WH (corresponding author), Stanford Univ, Sch Med, Div Rheumatol & Immunol, 269 Campus Dr, Stanford, CA 94305 USA.	wrobins@stanford.edu		Sobel, Raymond/0000-0002-0477-9002; Steinman, Lawrence/0000-0002-2437-2250; Robinson, William/0000-0003-4385-704X; /0000-0002-6848-318X	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK061934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018235] Funding Source: NIH RePORTER; Multiple Sclerosis Society [835] Funding Source: Medline; NHLBI NIH HHS [N01 HV 28183] Funding Source: Medline; NIAMS NIH HHS [K08 AR02133] Funding Source: Medline; NIDDK NIH HHS [U19 DK61934] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07276] Funding Source: Medline; NINDS NIH HHS [5R01NS18235] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Multiple Sclerosis Society(National Multiple Sclerosis Society); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLING C, 1971, BRAIN RES, V35, P325, DOI 10.1016/0006-8993(71)90478-1; Battistini L, 1996, J NEUROIMMUNOL, V67, P145; Bjartmar C, 2003, J NEUROL SCI, V206, P165, DOI 10.1016/S0022-510X(02)00069-2; Busshoff U, 2001, J NEUROIMMUNOL, V113, P220, DOI 10.1016/S0165-5728(00)00450-1; Cipriani B, 2003, BRAIN PATHOL, V13, P1; CUMINGS JN, 1955, BRAIN, V78, P554, DOI 10.1093/brain/78.4.554; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fredman P, 1998, ANN NY ACAD SCI, V845, P341, DOI 10.1111/j.1749-6632.1998.tb09686.x; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; GERSTL B, 1961, BRAIN, V84, P310, DOI 10.1093/brain/84.2.310; Giovannoni G, 2000, ANN NEUROL, V47, P684, DOI 10.1002/1531-8249(200005)47:5<684::AID-ANA27>3.3.CO;2-F; Ilyas AA, 2003, J NEUROIMMUNOL, V139, P76, DOI 10.1016/S0165-5728(03)00131-0; Jahng A, 2004, J EXP MED, V199, P947, DOI 10.1084/jem.20031389; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Mazzanti B, 1998, J NEUROIMMUNOL, V82, P96, DOI 10.1016/S0165-5728(97)00194-X; Moody DB, 2005, NAT REV IMMUNOL, V5, P387, DOI 10.1038/nri1605; MOORE GRW, 1984, LAB INVEST, V51, P416; Morell P, 1999, MYELIN FORMATION STR; Pender MP, 2003, J CLIN NEUROSCI, V10, P63, DOI 10.1016/S0967-5868(02)00270-9; Robinson WH, 2003, NAT BIOTECHNOL, V21, P1033, DOI 10.1038/nbt859; Rosenbluth J, 2003, J NEUROCYTOL, V32, P265, DOI 10.1023/B:NEUR.0000010085.91976.a6; Sadatipour BT, 1998, ANN NEUROL, V44, P980, DOI 10.1002/ana.410440621; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; Singh AK, 2001, J EXP MED, V194, P1801, DOI 10.1084/jem.194.12.1801; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; Tettamanti G, 1980, Adv Exp Med Biol, V125, P263; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; UHLIG H, 1989, AUTOIMMUNITY, V5, P87, DOI 10.3109/08916938909029146	30	242	254	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					138	143		10.1038/nm1344	http://dx.doi.org/10.1038/nm1344			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16341241				2022-12-25	WOS:000234419000064
J	Nguyen, DK; Disteche, CM				Nguyen, DK; Disteche, CM			Dosage compensation of the active X chromosome in mammals	NATURE GENETICS			English	Article							LINKED GENE-EXPRESSION; EARLY MOUSE EMBRYOS; DIFFERENTIAL EXPRESSION; TRANSCRIPTOME ANALYSIS; DOWN-SYNDROME; MUS MUSCULUS; MALE MEIOSIS; GENOME-WIDE; INACTIVATION; SPERMATOGENESIS	Monosomy of the X chromosome owing to divergence between the sex chromosomes leads to dosage compensation mechanisms to restore balanced expression between the X and the autosomes. In Drosophila melanogaster, upregulation of the male X leads to dosage compensation. It has been hypothesized that mammals likewise upregulate their active X chromosome. Together with X inactivation, this mechanism would maintain balanced expression between the X chromosome and autosomes and between the sexes. Here, we show that doubling of the global expression level of the X chromosome leads to dosage compensation in somatic tissues from several mammalian species. X-linked genes are highly expressed in brain tissues, consistent with a role in cognitive functions. Furthermore, the X chromosome is expressed but not upregulated in spermatids and secondary oocytes, preserving balanced expression of the genome in these haploid cells. Upon fertilization, upregulation of the active X must occur to achieve the observed dosage compensation in early embryos.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Disteche, CM (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	cdistech@u.washington.edu						Adler DA, 1997, P NATL ACAD SCI USA, V94, P9244, DOI 10.1073/pnas.94.17.9244; Akhtar A, 2003, CURR OPIN GENET DEV, V13, P161, DOI 10.1016/S0959-437X(03)00016-9; Amano K, 2004, HUM MOL GENET, V13, P1333, DOI 10.1093/hmg/ddh154; Birchler JA, 2005, TRENDS GENET, V21, P219, DOI 10.1016/j.tig.2005.02.010; Birchler JA, 2003, GENETICA, V117, P179, DOI 10.1023/A:1022935927763; Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; Charlesworth B, 2000, PHILOS T R SOC B, V355, P1563, DOI 10.1098/rstb.2000.0717; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Cheng MK, 2004, BIOESSAYS, V26, P821, DOI 10.1002/bies.20082; Disteche CM, 2002, CYTOGENET GENOME RES, V99, P36, DOI 10.1159/000071572; FitzPatrick DR, 2002, HUM MOL GENET, V11, P3249, DOI 10.1093/hmg/11.26.3249; Gartler S M, 1976, Adv Hum Genet, V7, P99; Gartler S M, 1972, Cell Differ, V1, P215, DOI 10.1016/0045-6039(72)90039-5; GUPTA V, IN PRESS J BIOL; Hamatani T, 2004, HUM MOL GENET, V13, P2263, DOI 10.1093/hmg/ddh241; Hamra FK, 2004, DEV BIOL, V269, P393, DOI 10.1016/j.ydbio.2004.01.027; HENDRIKSEN PJM, 1995, DEV BIOL, V170, P730, DOI 10.1006/dbio.1995.1252; Huynh KD, 2003, NATURE, V426, P857, DOI 10.1038/nature02222; Khalil AM, 2004, P NATL ACAD SCI USA, V101, P16583, DOI 10.1073/pnas.0406325101; Khil PP, 2004, NAT GENET, V36, P642, DOI 10.1038/ng1368; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Mak W, 2004, SCIENCE, V303, P666, DOI 10.1126/science.1092674; Malkov M, 1998, BIOL REPROD, V59, P84, DOI 10.1095/biolreprod59.1.84; MCCARREY JR, 1992, GENET ANAL-BIOMOL E, V9, P117, DOI 10.1016/1050-3862(92)90051-6; MCMAHON A, 1981, J EMBRYOL EXP MORPH, V64, P251; MIGEON BR, 1982, NATURE, V299, P838, DOI 10.1038/299838a0; MONESI V, 1965, CHROMOSOMA, V17, P11, DOI 10.1007/BF00285153; Odorisio T, 1996, DEV BIOL, V180, P336, DOI 10.1006/dbio.1996.0305; Ohno S., 1967, SEX CHROMOSOMES SEX; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; Rinn JL, 2004, DEV CELL, V6, P791, DOI 10.1016/j.devcel.2004.05.005; Ropers HH, 2005, NAT REV GENET, V6, P46, DOI 10.1038/nrg1501; Saran NG, 2003, HUM MOL GENET, V12, P2013, DOI 10.1093/hmg/ddg217; Schlecht U, 2004, MOL BIOL CELL, V15, P1031, DOI 10.1091/mbc.E03-10-0762; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Straub T, 2005, FEBS LETT, V579, P3258, DOI 10.1016/j.febslet.2005.03.050; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Turner JMA, 2005, NAT GENET, V37, P41, DOI 10.1038/ng1484; Uddin M, 2004, P NATL ACAD SCI USA, V101, P2957, DOI 10.1073/pnas.0308725100; Walker JR, 2004, GENOME RES, V14, P742, DOI 10.1101/gr.2161804; Wang J, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r69; Wang QT, 2004, DEV CELL, V6, P133, DOI 10.1016/S1534-5807(03)00404-0; Welle S, 2003, PHYSIOL GENOMICS, V14, P149, DOI 10.1152/physiolgenomics.00049.2003; Zechner U, 2001, TRENDS GENET, V17, P697, DOI 10.1016/S0168-9525(01)02446-5; Zeng FY, 2004, DEV BIOL, V272, P483, DOI 10.1016/j.ydbio.2004.05.018; Zheng P, 2004, BIOL REPROD, V70, P1419, DOI 10.1095/biolreprod.103.023796; Zhou X, 2005, J MED GENET, V42, P416, DOI 10.1136/jmg.2004.025353	49	356	361	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					47	53		10.1038/ng1705	http://dx.doi.org/10.1038/ng1705			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16341221				2022-12-25	WOS:000234227200016
J	Protas, ME; Hersey, C; Kochanek, D; Zhou, Y; Wilkens, H; Jeffery, WR; Zon, LI; Borowsky, R; Tabin, CJ				Protas, ME; Hersey, C; Kochanek, D; Zhou, Y; Wilkens, H; Jeffery, WR; Zon, LI; Borowsky, R; Tabin, CJ			Genetic analysis of cavefish reveals molecular convergence in the evolution of albinism	NATURE GENETICS			English	Article							PINK-EYED-DILUTION; OCULOCUTANEOUS ALBINISM; REGULATORY EVOLUTION; BLIND CAVEFISH; ASTYANAX; FISH; STICKLEBACKS; POPULATION; DIVERGENCE; UNDERLIES	The genetic basis of vertebrate morphological evolution has traditionally been very difficult to examine in naturally occurring populations. Here we describe the generation of a genome-wide linkage map to allow quantitative trait analysis of evolutionarily derived morphologies in the Mexican cave tetra, a species that has, in a series of independent caves, repeatedly evolved specialized characteristics adapted to a unique and well-studied ecological environment. We focused on the trait of albinism and discovered that it is linked to Oca2, a known pigmentation gene, in two cave populations. We found different deletions in Oca2 in each population and, using a cell-based assay, showed that both cause loss of function of the corresponding protein, OCA2. Thus, the two cave populations evolved albinism independently, through similar mutational events.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Childrens Hosp Boston, Howard Hughes Med Inst, Dept Hematol Oncol, Childrens Hosp Stem Cell Program, Boston, MA 02115 USA; NYU, Dept Biol, Cave Biol Res Grp, New York, NY 10003 USA; Univ Hamburg, Inst Zool, D-20146 Hamburg, Germany; Univ Hamburg, Zool Museum, D-20146 Hamburg, Germany; Univ Maryland, Dept Biol, College Pk, MD 20742 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; New York University; University of Hamburg; University of Hamburg; University System of Maryland; University of Maryland College Park	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	tabin@genetics.med.harvard.edu			NEI NIH HHS [R01 EY014619] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY014619] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Borowsky R, 2002, J HERED, V93, P19, DOI 10.1093/jhered/93.1.19; Colosimo PF, 2005, SCIENCE, V307, P1928, DOI 10.1126/science.1107239; Culver D. C., 1982, CAVE LIFE; Dowling TE, 2002, MOL BIOL EVOL, V19, P446, DOI 10.1093/oxfordjournals.molbev.a004100; Espinasa L, 2001, ENVIRON BIOL FISH, V62, P339, DOI 10.1023/A:1011852603162; Fukamachi S, 2004, GENETICS, V168, P1519, DOI 10.1534/genetics.104.030494; Gompel N, 2005, NATURE, V433, P481, DOI 10.1038/nature03235; Jeffery WR, 2005, J HERED, V96, P185, DOI 10.1093/jhered/esi028; Majerus MEN, 2003, TRENDS GENET, V19, P585, DOI 10.1016/j.tig.2003.09.003; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; Mundy NI, 2005, P ROY SOC B-BIOL SCI, V272, P1633, DOI 10.1098/rspb.2005.3107; Oetting WS, 2005, HUM MUTAT, V25, DOI 10.1002/humu.9318; Page-McCaw PS, 2004, NAT NEUROSCI, V7, P1329, DOI 10.1038/nn1344; Peichel CL, 2001, NATURE, V414, P901, DOI 10.1038/414901a; RINCHIK EM, 1993, NATURE, V361, P72, DOI 10.1038/361072a0; Romero A, 2001, ENVIRON BIOL FISH, V62, P13, DOI 10.1023/A:1011844404235; SADOGLU P, 1969, J HERED, V60, P10, DOI 10.1093/oxfordjournals.jhered.a107917; Shapiro MD, 2004, NATURE, V428, P717, DOI 10.1038/nature02415; Strecker U, 2004, MOL PHYLOGENET EVOL, V33, P469, DOI 10.1016/j.ympev.2004.07.001; Strecker U, 2003, MOL ECOL, V12, P699, DOI 10.1046/j.1365-294X.2003.01753.x; Sucena E, 2003, NATURE, V424, P935, DOI 10.1038/nature01768; Sviderskaya EV, 1997, J INVEST DERMATOL, V108, P30, DOI 10.1111/1523-1747.ep12285621; Van Laere AS, 2003, NATURE, V425, P832, DOI 10.1038/nature02064; Wilkens H, 1988, EVOL BIOL, V23, P271, DOI [10.1007/978-1-4613-1043-3_8, DOI 10.1007/978-1-4613-1043-3_]; Yamamoto Y, 2003, EVOL DEV, V5, P435, DOI 10.1046/j.1525-142X.2003.03050.x; Yi ZH, 2003, AM J HUM GENET, V72, P62, DOI 10.1086/345380	26	379	388	6	133	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					107	111		10.1038/ng1700	http://dx.doi.org/10.1038/ng1700			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16341223				2022-12-25	WOS:000234227200025
J	Rosenbauer, F; Owens, BM; Yu, L; Tumang, JR; Steidl, U; Kutok, JL; Clayton, LK; Wagner, K; Scheller, M; Iwasaki, H; Liu, CH; Hackanson, B; Akashi, K; Leutz, A; Rothstein, TL; Plass, C; Tenen, DG				Rosenbauer, F; Owens, BM; Yu, L; Tumang, JR; Steidl, U; Kutok, JL; Clayton, LK; Wagner, K; Scheller, M; Iwasaki, H; Liu, CH; Hackanson, B; Akashi, K; Leutz, A; Rothstein, TL; Plass, C; Tenen, DG			Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1	NATURE GENETICS			English	Article							HEMATOPOIETIC STEM-CELLS; TRANSCRIPTION FACTOR PU.1; B-1 CELLS; B-LYMPHOCYTE; MICE; LEUKEMIA; METHYLATION; EXPRESSION; PROGENITORS; MACROPHAGE	Tight regulation of transcription factors, such as PU.1, is crucial for generation of all hematopoietic lineages. We previously reported that mice with a deletion of an upstream regulatory element (URE) of the gene encoding PU.1 (Sfpi1) developed acute myeloid leukemia. Here we show that the URE has an essential role in orchestrating the dynamic PU.1 expression pattern required for lymphoid development and tumor suppression. URE deletion ablated B2 cells but stimulated growth of B1 cells in mice. The URE was a PU.1 enhancer in B cells but a repressor in T cell precursors. TCF transcription factors coordinated this repressor function and linked PU.1 to Wnt signaling. Failure of appropriate PU.1 repression in T cell progenitors with URE deletion disrupted differentiation and induced thymic transformation. Genome-wide DNA methylation assessment showed that epigenetic silencing of selective tumor suppressor genes completed PU.1-initiated transformation of lymphoid progenitors with URE deletion. These results elucidate how a single transcription factor, PU.1, through the cell context - specific activity of a key cis-regulatory element, affects the development of multiple cell lineages and can induce cancer.	Harvard Inst Med, Boston, MA 02115 USA; Harvard Stem Cell Inst, Boston, MA 02115 USA; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Ohio State Univ, Div Hematol Oncol, Columbus, OH 43210 USA; Boston Univ, Med Ctr, Evans Mem Dept Clin Res, Dept Med, Boston, MA USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University System of Ohio; Ohio State University; Boston University; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Rosenbauer, F (corresponding author), Harvard Inst Med, Room 954,77 Ave Louis Pasteur, Boston, MA 02115 USA.	f.rosenbauer@mdc-berlin.de; dtenen@bidmc.harvard.edu	Leutz, Achim/K-9643-2013; Plass, Christoph/H-7192-2014	Leutz, Achim/0000-0001-8259-927X; Scheller, Marina/0000-0001-6108-0831; Tenen, Daniel/0000-0002-6423-3888; Rosenbauer, Frank/0000-0001-7977-9421				Amaravadi L, 1999, DNA CELL BIOL, V18, P875, DOI 10.1089/104454999314737; Anderson MK, 2002, IMMUNITY, V16, P285, DOI 10.1016/S1074-7613(02)00277-7; Andres-Barquin PJ, 1999, EXP CELL RES, V247, P347, DOI 10.1006/excr.1998.4360; Balciunaite G, 2005, BLOOD, V105, P1930, DOI 10.1182/blood-2004-08-3087; Berland R, 2002, ANNU REV IMMUNOL, V20, P253, DOI 10.1146/annurev.immunol.20.100301.064833; Boes M, 1998, J IMMUNOL, V160, P4776; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; CALIGARISCAPPIO F, 1982, J EXP MED, V155, P623, DOI 10.1084/jem.155.2.623; Ceredig R, 2002, NAT REV IMMUNOL, V2, P888, DOI 10.1038/nri937; Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Fischer GM, 2001, CELL IMMUNOL, V213, P62, DOI 10.1006/cimm.2001.1860; Hanson P, 2003, EXP HEMATOL, V31, P159, DOI 10.1016/S0301-472X(02)01021-4; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herzenberg LA, 2000, IMMUNOL REV, V175, P9, DOI 10.1111/j.1600-065X.2000.imr017520.x; Holnthoner W, 2002, J BIOL CHEM, V277, P45847, DOI 10.1074/jbc.M209354200; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Kim HG, 2004, BLOOD, V104, P3894, DOI 10.1182/blood-2002-08-2425; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORRIS DL, 1993, J EXP MED, V177, P857, DOI 10.1084/jem.177.3.857; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Rosenbauer F, 2005, BLOOD, V106, P1519, DOI 10.1182/blood-2005-02-0717; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rosenbaum PR, 2003, BIOSTATISTICS, V4, P1, DOI 10.1093/biostatistics/4.1.1; Rothstein TL, 2002, J IMMUNOL, V168, P4257, DOI 10.4049/jimmunol.168.9.4257; Schilham MW, 1998, J IMMUNOL, V161, P3984; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Singh H, 2005, P NATL ACAD SCI USA, V102, P4949, DOI 10.1073/pnas.0500480102; STALL AM, 1988, P NATL ACAD SCI USA, V85, P7312, DOI 10.1073/pnas.85.19.7312; SUZUKI M, IN PRESS ONCOGENE; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDE WM, 2002, CELL S, V109, pS13; WATANABE S, 1995, ELECTROPHORESIS, V16, P218, DOI 10.1002/elps.1150160137; Yu L, 2004, GENOMICS, V84, P647, DOI 10.1016/j.ygeno.2004.06.010; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521	50	169	170	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					27	37		10.1038/ng1679	http://dx.doi.org/10.1038/ng1679			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16311598				2022-12-25	WOS:000234227200014
J	Fournel, S; Wieckowski, S; Sun, WM; Trouche, N; Dumortier, H; Bianco, A; Chaloin, O; Habib, M; Peter, JC; Schneider, P; Vray, B; Toes, RE; Offringa, R; Melief, CJM; Hoebeke, J; Guichard, G				Fournel, S; Wieckowski, S; Sun, WM; Trouche, N; Dumortier, H; Bianco, A; Chaloin, O; Habib, M; Peter, JC; Schneider, P; Vray, B; Toes, RE; Offringa, R; Melief, CJM; Hoebeke, J; Guichard, G			C-3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L	NATURE CHEMICAL BIOLOGY			English	Article							T-CELL TOLERANCE; LIGAND; RECEPTOR; LIGATION; ACTIVATION; HELP; INTERLEUKIN-12; CONVERSION; APOPTOSIS; CAPACITY	Interaction between CD40, a member of the tumor necrosis factor receptor ( TNFR) superfamily, and its ligand CD40L, a 39-kDa glycoprotein, is essential for the development of humoral and cellular immune responses(1,2). Selective blockade or activation of this pathway provides the ground for the development of new treatments against immunologically based diseases(3,4) and malignancies(5,6). Like other members of the TNF superfamily, CD40L monomers self-assemble around a threefold symmetry axis to form noncovalent homotrimers that can each bind three receptor molecules(7,8). Here, we report on the structure-based design of small synthetic molecules with C-3 symmetry that can mimic CD40L homotrimers. These molecules interact with CD40, compete with the binding of CD40L to CD40, and reproduce, to a certain extent, the functional properties of the much larger homotrimeric soluble CD40L. Architectures based on rigid C-3- symmetric cores may thus represent a general approach to mimicking homotrimers of the TNF superfamily.	CNRS, UPR 9021, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; Free Univ Brussels, Fac Med, Expt Immunol Lab, B-1070 Brussels, Belgium; Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, NL-2300 RC Leiden, Netherlands	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Lausanne; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Guichard, G (corresponding author), CNRS, UPR 9021, Inst Biol Mol & Cellulaire, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	s.fournel@ibmc.u-strasbg.fr; G.Guichard@ibmc.u-strasbg.fr	GUICHARD, Gilles/I-3858-2016; Wieckowski, Sébastien/AAF-4147-2020; Fournel, Sylvie/C-1195-2014	GUICHARD, Gilles/0000-0002-2584-7502; Wieckowski, Sébastien/0000-0001-8121-4446; Fournel, Sylvie/0000-0003-3583-6548; Schneider, Pascal/0000-0003-0677-9409; Toes, Rene/0000-0002-9618-6414				BAJORATH J, 1995, BIOCHEMISTRY-US, V34, P9884, DOI 10.1021/bi00031a009; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chaussabel D, 1999, INFECT IMMUN, V67, P1929; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Diehl L, 2000, J MOL MED, V78, P363, DOI 10.1007/s001090000126; Edelmann KH, 2001, J VIROL, V75, P612, DOI 10.1128/JVI.75.2.612-621.2001; Haswell LE, 2001, EUR J IMMUNOL, V31, P3094, DOI 10.1002/1521-4141(2001010)31:10<3094::AID-IMMU3094>3.0.CO;2-F; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Howard LM, 1999, J CLIN INVEST, V103, P281, DOI 10.1172/JCI5388; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; Kiessling LL, 2000, CURR OPIN CHEM BIOL, V4, P696, DOI 10.1016/S1367-5931(00)00153-8; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; Liu YF, 2003, NATURE, V423, P49, DOI 10.1038/nature01543; Lortat-Jacob H, 2001, J BIOL CHEM, V276, P9009, DOI 10.1074/jbc.M009304200; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; O'Sullivan BJ, 2002, J IMMUNOL, V168, P5491, DOI 10.4049/jimmunol.168.11.5491; Pound JD, 1999, INT IMMUNOL, V11, P11, DOI 10.1093/intimm/11.1.11; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schuurhuis DH, 2000, J EXP MED, V192, P145, DOI 10.1084/jem.192.1.145; Singh J, 1998, PROTEIN SCI, V7, P1124, DOI 10.1002/pro.5560070506; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; Tong AW, 2000, LEUKEMIA LYMPHOMA, V36, P543, DOI 10.3109/10428190009148403; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Whitty A, 1999, CHEM BIOL, V6, pR107, DOI 10.1016/S1074-5521(99)80034-9; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	30	60	65	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	DEC	2005	1	7					377	382		10.1038/nchembio746	http://dx.doi.org/10.1038/nchembio746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986KE	16370373	Green Published			2022-12-25	WOS:000233447700009
J	Yasunaga, M; Tada, S; Nishikawa, ST; Nakano, Y; Okada, M; Jakt, LM; Nishikawa, S; Chiba, T; Era, T; Nishikawa, SI				Yasunaga, M; Tada, S; Nishikawa, ST; Nakano, Y; Okada, M; Jakt, LM; Nishikawa, S; Chiba, T; Era, T; Nishikawa, SI			Induction and monitoring of definitive and visceral endoderm differentiation of mouse ES cells	NATURE BIOTECHNOLOGY			English	Article							EMBRYONIC STEM-CELLS; PRIMITIVE STREAK; HEPATIC DIFFERENTIATION; GENE-EXPRESSION; MESENDODERM; MESODERM; GASTRULA; RECEPTOR; LINEAGE; PROTEIN	Preparation of specific lineages at high purities from embryonic stem (ES) cells requires both selective culture conditions and markers to guide and monitor the differentiation. In this study, we distinguished definitive and visceral endoderm by using a mouse ES cell line that bears the gfp and human IL2R alpha (also known as CD25) marker genes in the goosecoid (Gsc) and Sox17 loci, respectively. This cell line allowed us to monitor the generation of Gsc(+)Sox17(+) definitive endoderm and Gsc(-)Sox17(+) visceral endoderm and to define culture conditions that differentially induce definitive and visceral endoderm. By comparing the gene expression profiles of definitive and visceral endoderm, we identified seven surface molecules that are expressed differentially in the two populations. One of the seven markers, Cxcr4, to which a monoclonal antibody is available allowed us to monitor and purify the Gsc+ population from genetically unmanipulated ES cells under the condition that selects definitive endoderm.	RIKEN, Ctr Dev Biol, Lab Stem Cell Biol, Kobe, Hyogo 6500047, Japan; Stem Cell Sci KK, Basic Res Lab, Kobe, Hyogo 6500047, Japan; Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto 6068501, Japan; Fdn Biomed Res & Innovat, Kobe, Hyogo 6500047, Japan	RIKEN; Kyoto University; Institute for Biomedical Research & Innovation (IBRI)	Nishikawa, SI (corresponding author), RIKEN, Ctr Dev Biol, Lab Stem Cell Biol, Kobe, Hyogo 6500047, Japan.	nishikawa@cdb.riken.jp	Jakt, Lars/A-6290-2009; Yasunaga, Masahiro/N-9580-2018	Jakt, Lars Martin/0000-0002-3787-8138; Yasunaga, Masahiro/0000-0003-3356-0197				Abe K, 1996, EXP CELL RES, V229, P27, DOI 10.1006/excr.1996.0340; Asahina K, 2004, GENES CELLS, V9, P1297, DOI 10.1111/j.1365-2443.2004.00809.x; Beck F, 2000, BIOESSAYS, V22, P431, DOI 10.1002/(SICI)1521-1878(200005)22:5<431::AID-BIES5>3.0.CO;2-X; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Blyszczuk P, 2003, P NATL ACAD SCI USA, V100, P998, DOI 10.1073/pnas.0237371100; Couchman JR, 1999, J CELL SCI, V112, P3415; CRAMBERT G, 2003, SCI STKE, pRE1; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Dufort D, 1998, DEVELOPMENT, V125, P3015; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; GARDNER RL, 1982, J EMBRYOL EXP MORPH, V68, P175; Hamazaki T, 2001, FEBS LETT, V497, P15, DOI 10.1016/S0014-5793(01)02423-1; Hart AH, 2002, DEVELOPMENT, V129, P3597; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jones EA, 2002, EXP CELL RES, V272, P15, DOI 10.1006/excr.2001.5396; Kalantry S, 2001, NAT GENET, V27, P412, DOI 10.1038/86912; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kimelman D, 2000, CURR OPIN GENET DEV, V10, P350, DOI 10.1016/S0959-437X(00)00095-2; Kinder SJ, 2001, DEVELOPMENT, V128, P3623; KISPERT A, 1994, DEV BIOL, V161, P179, DOI 10.1006/dbio.1994.1019; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Leitges M, 2000, DEVELOPMENT, V127, P2259; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Ng ES, 2005, DEVELOPMENT, V132, P873, DOI 10.1242/dev.01657; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Pearce JJH, 1999, MECH DEVELOP, V87, P189, DOI 10.1016/S0925-4773(99)00135-5; Perea-Gomez A, 2002, DEV CELL, V3, P745, DOI 10.1016/S1534-5807(02)00321-0; Rossant J, 2004, SEMIN CELL DEV BIOL, V15, P573, DOI 10.1016/j.semcdb.2004.04.003; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; Sousa-Nunes R, 2003, GENOME RES, V13, P2609, DOI 10.1101/gr.1362303; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Tam PPL, 2004, DEV BIOL, V274, P171, DOI 10.1016/j.ydbio.2004.07.005; Tam PPL, 2003, CURR OPIN GENET DEV, V13, P393, DOI 10.1016/S0959-437X(03)00085-6; Trucco M, 2005, J CLIN INVEST, V115, P5, DOI 10.1172/JCI200523935; Vaarala MH, 2001, J PATHOL, V193, P134, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH743>3.0.CO;2-T; Verheijen MHG, 1999, MECH DEVELOP, V81, P151, DOI 10.1016/S0925-4773(98)00240-8; Wadehra M, 2002, J BIOL CHEM, V277, P41094, DOI 10.1074/jbc.M206868200; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Zernicka-Goetz M, 2002, DEVELOPMENT, V129, P815	49	357	390	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2005	23	12					1542	1550		10.1038/nbt1167	http://dx.doi.org/10.1038/nbt1167			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	992ED	16311587				2022-12-25	WOS:000233866300031
J	Lai, Y; Yue, YP; Liu, MJ; Ghosh, A; Engelhardt, JF; Chamberlain, JS; Duan, DS				Lai, Y; Yue, YP; Liu, MJ; Ghosh, A; Engelhardt, JF; Chamberlain, JS; Duan, DS			Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors	NATURE BIOTECHNOLOGY			English	Article							INTERMOLECULAR RECOMBINATION; PACKAGING CAPACITY; VIRUS; DYSTROPHIN; THERAPY; CARDIOMYOPATHY; TRANSDUCTION; UTILITY; MUSCLE; CELLS	Although adeno-associated virus (AAV)-mediated gene therapy has been hindered by the small viral packaging capacity of the vector, trans-splicing AAV vectors are able to package twice the size of the vector genome. Unfortunately, the efficiency of current trans-splicing vectors is very low. Here we show that rational design of the gene splitting site has a profound influence on trans-splicing vector-mediated gene expression. Using mRNA accumulation as a guide, we generated a set of efficient trans-splicing vectors and achieved widespread expression of the 6-kb Delta H2-R19 mini-dystrophin gene in skeletal muscle of mdx mice, a model for Duchenne muscular dystrophy. The dystrophic phenotype was ameliorated in both adult and aged mice. This demonstrates the use of trans-splicing vectors to efficiently express a large therapeutic structural protein. This strategy should be applicable to other large therapeutic genes or large transcription regulatory elements.	Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA; Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA	University of Missouri System; University of Missouri Columbia; University of Iowa; University of Washington; University of Washington Seattle	Duan, DS (corresponding author), Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, 1 Hosp Dr,Room M6010G, Columbia, MO 65212 USA.	duand@missouri.edu		Engelhardt, John/0000-0003-2389-9277; Ghosh, Arkasubhra/0000-0002-6570-5891; Chamberlain, Jeffrey/0000-0001-5299-0059; Lai, Yi/0000-0001-7303-8665; Duan, Dongsheng/0000-0003-4109-1132	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049419] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049419-05, AR-49419, R01 AR049419-03, R01 AR049419-01A1, R01 AR049419-04, R01 AR049419, R01 AR049419-02] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Carter BJ, 2005, HUM GENE THER, V16, P541, DOI 10.1089/hum.2005.16.541; Chao DS, 1996, J EXP MED, V184, P609, DOI 10.1084/jem.184.2.609; Chao HJ, 2002, MOL THER, V5, P716, DOI 10.1006/mthe.2002.0607; Dong JY, 1996, HUM GENE THER, V7, P2101, DOI 10.1089/hum.1996.7.17-2101; Duan DS, 2000, NAT MED, V6, P595, DOI 10.1038/75080; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Duan DS, 1999, VIROLOGY, V261, P8, DOI 10.1006/viro.1999.9821; Duan DS, 2001, MOL THER, V4, P383, DOI 10.1006/mthe.2001.0456; DUAN DS, 2002, LUNG BIOL HEALTH DIS, V169, P51; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Halbert CL, 2001, J VIROL, V75, P6615, DOI 10.1128/JVI.75.14.6615-6624.2001; Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302-253; Ibrahim EC, 2005, P NATL ACAD SCI USA, V102, P5002, DOI 10.1073/pnas.0500543102; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Liu MJ, 2005, MOL THER, V11, P245, DOI 10.1016/j.ymthe.2004.09.013; Nakai H, 2000, NAT BIOTECHNOL, V18, P527, DOI 10.1038/75390; Reich SJ, 2003, HUM GENE THER, V14, P37, DOI 10.1089/10430340360464697; Sironi M, 2001, HUM GENET, V109, P73, DOI 10.1007/s004390100547; Sun LW, 2000, NAT MED, V6, P599, DOI 10.1038/75087; Xu ZP, 2004, HUM GENE THER, V15, P896, DOI 10.1089/1043034041839253; Yan ZY, 2000, P NATL ACAD SCI USA, V97, P6716, DOI 10.1073/pnas.97.12.6716; Yan ZY, 2005, J VIROL, V79, P364, DOI 10.1128/JVI.79.1.364-379.2005; Yue YP, 2004, HUM MOL GENET, V13, P1669, DOI 10.1093/hmg/ddh174; Yue YP, 2003, CIRCULATION, V108, P1626, DOI 10.1161/01.CIR.0000089371.11664.27; Yue YP, 2003, VIROLOGY, V313, P1, DOI 10.1016/S0042-6822(03)00432-X	28	154	163	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2005	23	11					1435	1439		10.1038/nbt1153	http://dx.doi.org/10.1038/nbt1153			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	984FN	16244658	Green Accepted			2022-12-25	WOS:000233288000040
J	Sheridan, C				Sheridan, C			The business of making vaccines	NATURE BIOTECHNOLOGY			English	Article																		*DAT, 2004, COMM PERSP VACC; SCHERER FM, 2004, 040329 AM ANT I; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302	3	14	15	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2005	23	11					1359	1366		10.1038/nbt1105-1359	http://dx.doi.org/10.1038/nbt1105-1359			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	984FN	16273061	Green Published, Bronze			2022-12-25	WOS:000233288000020
J	Levitus, M; Waisfisz, Q; Godthelp, BC; de Vries, Y; Hussain, S; Wiegant, WW; Elghalbzouri-Maghrani, E; Steltenpool, J; Rooimans, MA; Pals, G; Arwert, F; Mathew, CG; Zdzienicka, MZ; Hiom, K; De Winter, JP; Joenje, H				Levitus, M; Waisfisz, Q; Godthelp, BC; de Vries, Y; Hussain, S; Wiegant, WW; Elghalbzouri-Maghrani, E; Steltenpool, J; Rooimans, MA; Pals, G; Arwert, F; Mathew, CG; Zdzienicka, MZ; Hiom, K; De Winter, JP; Joenje, H			The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J	NATURE GENETICS			English	Article							PROTEIN; BACH1	The protein predicted to be defective in individuals with Fanconi anemia complementation group J ( FA- J), FANCJ, is a missing component in the Fanconi anemia pathway of genome maintenance. Here we identify pathogenic mutations in eight individuals with FA- J in the gene encoding the DEAH- box DNA helicase BRIP1, also called FANCJ. This finding is compelling evidence that the Fanconi anemia pathway functions through a direct physical interaction with DNA.	Vrije Univ Amsterdam Med Ctr, Dept Clin Genet & Human Genet, NL-1081 BT Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Toxicogenet, NL-2333 AL Leiden, Netherlands; Kings Coll London, Guys Hosp, Div Med & Mol Genet, London, England; Nicholas Copernicus Univ, Coll Med L Rydygier, Dept Mol Cell Genet, Bydgoszcz, Poland; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Nicolaus Copernicus University; MRC Laboratory Molecular Biology	Joenje, H (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Clin Genet & Human Genet, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	joenje@vumc.nl	Hiom, Kevin/B-4374-2009; Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838; Waisfisz, Quinten/0000-0002-7384-9182; Pals, Gerard/0000-0003-4091-7115				Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Doherty AMO, 2003, MAMM GENOME, V14, P583, DOI 10.1007/s00335-003-4002-0; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Risinger MA, 2004, CANCER CELL, V6, P539, DOI 10.1016/j.ccr.2004.12.001; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753	10	343	353	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					934	935		10.1038/ng1625	http://dx.doi.org/10.1038/ng1625			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16116423				2022-12-25	WOS:000231591900016
J	Zhao, LH; Longo-Guess, C; Harris, BS; Lee, JW; Ackerman, SL				Zhao, LH; Longo-Guess, C; Harris, BS; Lee, JW; Ackerman, SL			Protein accumulation and neurodegeneration in the woozy mutant mouse is caused by disruption of SIL1, a cochaperone of BiP	NATURE GENETICS			English	Article							ENDOPLASMIC-RETICULUM STRESS; CELL-DEATH; GENE; SCA1; SUPPRESSION; ACTIVATION; DISEASE; MICE	Endoplasmic reticulum ( ER) chaperones and ER stress have been implicated in the pathogenesis of neurodegenerative disorders, such as Alzheimer and Parkinson diseases, but their contribution to neuron death remains uncertain(1,2). In this study, we establish a direct in vivo link between ER dysfunction and neurodegeneration. Mice homozygous with respect to the woozy ( wz) mutation develop adult- onset ataxia with cerebellar Purkinje cell loss. Affected cells have intracellular protein accumulations reminiscent of protein inclusions in both the ER and the nucleus. In addition, upregulation of the unfolded protein response, suggestive of ER stress, occurs in mutant Purkinje cells. We report that the wz mutation disrupts the gene Sil1 that encodes an adenine nucleotide exchange factor of BiP(3), a crucial ER chaperone(4). These findings provide evidence that perturbation of ER chaperone function in terminally differentiated neurons leads to protein accumulation, ER stress and subsequent neurodegeneration.	Jackson Lab, Bar Harbor, ME 04609 USA; Howard Hughes Med Inst, Bar Harbor, ME 04609 USA	Jackson Laboratory; Howard Hughes Medical Institute	Ackerman, SL (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	susan.ackerman@jax.org		Zhao, Lihong/0000-0002-9615-6047				Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Altman J, 1997, DEV CEREBELLAR SYSTE; Chung KT, 2002, J BIOL CHEM, V277, P47557, DOI 10.1074/jbc.M208377200; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Goldowitz D, 2000, J NEUROSCI, V20, P4129; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Kabani M, 2000, MOL CELL BIOL, V20, P6923, DOI 10.1128/MCB.20.18.6923-6934.2000; Kimata Y, 2003, MOL BIOL CELL, V14, P2559, DOI 10.1091/mbc.E02-11-0708; Kitao Y, 2004, J NEUROSCI, V24, P1486, DOI 10.1523/JNEUROSCI.4029-03.2004; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Ross CA, 2004, TRENDS CELL BIOL, V14, P703, DOI 10.1016/j.tcb.2004.10.006; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Serra HG, 2004, HUM MOL GENET, V13, P2535, DOI 10.1093/hmg/ddh268; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Slemmer JE, 2005, PROG BRAIN RES, V148, P367, DOI 10.1016/S0079-6123(04)48029-7; Southwood CM, 2002, NEURON, V36, P585, DOI 10.1016/S0896-6273(02)01045-0; Tessitore A, 2004, MOL CELL, V15, P753, DOI 10.1016/j.molcel.2004.08.029; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	30	166	176	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2005	37	9					974	979		10.1038/ng1620	http://dx.doi.org/10.1038/ng1620			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16116427				2022-12-25	WOS:000231591900023
J	Andrews, PW; Benvenisty, N; McKay, R; Pera, MF; Rossant, J; Semb, H; Stacey, GN				Andrews, PW; Benvenisty, N; McKay, R; Pera, MF; Rossant, J; Semb, H; Stacey, GN		Steering Comm Int Stem Cell Initia	The International Stem Cell initiative: toward benchmarks for human embryonic stem cell research	NATURE BIOTECHNOLOGY			English	Editorial Material							GENE-EXPRESSION; LINES; DIFFERENTIATION		Monash Univ, Monash Inst Med Res, Clayton, Vic 3800, Australia; Australian Stem Cell Ctr, Clayton, Vic 3800, Australia; Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England; Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel; NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Lund Univ, Dept Expt Med Sci, Sect Dev Biol, SE-22184 Lund, Sweden; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England	Monash University; University of Sheffield; Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Lund University; National Institute for Biological Standards & Control	Pera, MF (corresponding author), Monash Univ, Monash Inst Med Res, Clayton, Vic 3800, Australia.	p.w.andrews@sheffield.ac.uk; martin.pera@med.monash.edu.au	PERA, MARTIN/A-9812-2012	PERA, MARTIN/0000-0001-6239-0428; Andrews, Peter/0000-0001-7215-4410	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS003008, ZICNS003008] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeyta MJ, 2004, HUM MOL GENET, V13, P601, DOI 10.1093/hmg/ddh068; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Brimble SN, 2004, STEM CELLS DEV, V13, P585, DOI 10.1089/scd.2004.13.585; Dvash T, 2004, HUM REPROD, V19, P2875, DOI 10.1093/humrep/deh529; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; Pera MF, 2004, DEVELOPMENT, V131, P5515, DOI 10.1242/dev.01451; Rao RR, 2004, BIOTECHNOL BIOENG, V88, P273, DOI 10.1002/bit.20245; Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	10	70	73	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2005	23	7					795	797		10.1038/nbt0705-798	http://dx.doi.org/10.1038/nbt0705-798			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	944KT	16003358				2022-12-25	WOS:000230427700018
J	Hashimoto, M; Negi, J; Young, J; Israelsson, M; Schroeder, JI; Iba, K				Hashimoto, M; Negi, J; Young, J; Israelsson, M; Schroeder, JI; Iba, K			Arabidopsis HT1 kinase controls stomatal movements in response to CO2	NATURE CELL BIOLOGY			English	Article							ABSCISIC-ACID; GUARD-CELLS; ANION CHANNELS; SIGNAL-TRANSDUCTION; FAMILY; LIGHT; CONDUCTANCE; MUTANTS; CALCIUM; CLOSURE	Guard cells, which form stomata in leaf epidermes, sense a multitude of environmental signals and integrate this information to regulate stomatal movements(1,2). Compared with the advanced understanding of light and water stress responses in guard cells(2-4), the molecular mechanisms that underlie stomatal CO2 signalling have remained relatively obscure. With a high-throughput leaf thermal imaging CO2 screen, we report the isolation of two allelic Arabidopsis mutants ( high leaf temperature 1; ht1-1 and ht1-2) that are altered in their ability to control stomatal movements in response to CO2. The strong allele, ht1-2, exhibits a markedly impaired CO2 response but shows functional responses to blue light, fusicoccin and abscisic acid (ABA), indicating a role for HT1 in stomatal CO2 signalling. HT1 encodes a protein kinase that is expressed mainly in guard cells. Phosphorylation assays demonstrate that the activity of the HT1 protein carrying the ht1-1 or ht1-2 mutation is greatly impaired or abolished, respectively. Furthermore, dominant-negative HT1(K113W) transgenic plants, which lack HT1 kinase activity, show a disrupted CO2 response. These findings indicate that the HT1 kinase is important for regulation of stomatal movements and its function is more pronounced in response to CO2 than it is to ABA or light.	Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Univ Calif San Diego, Div Biol Sci, Cell & Dev Biol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Kyushu University; University of California System; University of California San Diego; University of California System; University of California San Diego	Iba, K (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan.	koibascb@mbox.nc.kyushu-u.ac.jp	Hashimoto-Sugimoto, Mimi/AAJ-6411-2021; Nordström, Maria/B-4561-2013	Schroeder, Julian/0000-0002-3283-5972	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060396] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM060396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Assmann SM, 1999, PLANT CELL ENVIRON, V22, P629, DOI 10.1046/j.1365-3040.1999.00408.x; Brearley J, 1997, PLANTA, V203, P145, DOI 10.1007/s004250050176; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; Guo FO, 2003, PLANT CELL, V15, P107, DOI 10.1105/tpc.006312; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanstein SM, 2002, PLANT PHYSIOL, V130, P940, DOI 10.1104/pp.004283; Hetherington AM, 2003, NATURE, V424, P901, DOI 10.1038/nature01843; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kinoshita T, 2001, NATURE, V414, P656, DOI 10.1038/414656a; Kinoshita T, 2001, PLANT CELL PHYSIOL, V42, P424, DOI 10.1093/pcp/pce055; Leggett J., 1992, CLIMATE CHANGE 1992, P69; Leonhardt N, 2004, PLANT CELL, V16, P596, DOI 10.1105/tpc.019000; Li JX, 2000, SCIENCE, V287, P300, DOI 10.1126/science.287.5451.300; MacRobbie EAC, 1998, PHILOS T ROY SOC B, V353, P1475, DOI 10.1098/rstb.1998.0303; Medlyn BE, 2001, NEW PHYTOL, V149, P247, DOI 10.1046/j.1469-8137.2001.00028.x; Merlot S, 2002, PLANT J, V30, P601, DOI 10.1046/j.1365-313X.2002.01322.x; Morison J. I. L., 1987, Stomatal function, P229; Mustilli AC, 2002, PLANT CELL, V14, P3089, DOI 10.1105/tpc.007906; Olsen RL, 2002, NEW PHYTOL, V153, P497, DOI 10.1046/j.0028-646X.2001.00337.x; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Pei ZM, 1998, SCIENCE, V282, P287, DOI 10.1126/science.282.5387.287; Raschke K, 2003, PLANTA, V217, P639, DOI 10.1007/s00425-003-1033-4; Roelfsema MRG, 2002, PLANT J, V32, P65, DOI 10.1046/j.1365-313X.2002.01403.x; Schroeder JI, 2001, ANNU REV PLANT PHYS, V52, P627, DOI 10.1146/annurev.arplant.52.1.627; Schroeder JI, 2001, NATURE, V410, P327, DOI 10.1038/35066500; SCHWARTZ A, 1988, PLANT PHYSIOL, V87, P583, DOI 10.1104/pp.87.3.583; Soyano T, 2003, GENE DEV, V17, P1055, DOI 10.1101/gad.1071103; Sugimoto H, 2004, PLANT CELL PHYSIOL, V45, P985, DOI 10.1093/pcp/pch111; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vavasseur A, 2005, NEW PHYTOL, V165, P665, DOI 10.1111/j.1469-8137.2004.01276.x; Webb AAR, 1996, PLANT J, V9, P297, DOI 10.1046/j.1365-313X.1996.09030297.x; Willmer C., 1996, STOMATA, DOI DOI 10.1007/978-94-011-0579-8	33	185	197	4	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					391	U52		10.1038/ncb1387	http://dx.doi.org/10.1038/ncb1387			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16518390				2022-12-25	WOS:000236560000018
J	Gilbert, SL; Zhang, L; Forster, ML; Iwase, T; Soliven, B; Donahue, LR; Sweet, HO; Bronson, RT; Davisson, MT; Wollmann, RL; Lahn, BT				Gilbert, SL; Zhang, L; Forster, ML; Iwase, T; Soliven, B; Donahue, LR; Sweet, HO; Bronson, RT; Davisson, MT; Wollmann, RL; Lahn, BT			Trak1 mutation disrupts GABA(A) receptor homeostasis in hypertonic mice	NATURE GENETICS			English	Article							HUNTINGTIN-ASSOCIATED PROTEIN; COIL DOMAIN PROTEINS; INHIBITORY SYNAPSES; TRAFFICKING; TRANSPORT; GEPHYRIN; SUBUNIT; CLONING; HAP1; IDENTIFICATION	Hypertonia, which results from motor pathway defects in the central nervous system (CNS), is observed in numerous neurological conditions, including cerebral palsy, stroke, spinal cord injury, stiff-person syndrome, spastic paraplegia, dystonia and Parkinson disease. Mice with mutation in the hypertonic (hyrt) gene exhibit severe hypertonia as their primary symptom. Here we show that hyrt mutant mice have much lower levels of gamma-aminobutyric acid type A (GABA(A)) receptors in their CNS, particularly the lower motor neurons, than do wild-type mice, indicating that the hypertonicity of the mutants is likely to be caused by deficits in GABA-mediated motor neuron inhibition. We cloned the responsible gene, trafficking protein, kinesin binding 1 (Trak1), and showed that its protein product interacts with GABAA receptors. Our data implicate Trak1 as a crucial regulator of GABA(A) receptor homeostasis and underscore the importance of hyrt mice as a model for studying the molecular etiology of hypertonia associated with human neurological diseases.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago; Jackson Laboratory	Lahn, BT (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave, Chicago, IL 60637 USA.	blahn@bsd.uchicago.edu						Barnes EM, 2001, INT REV NEUROBIOL, V48, P1, DOI 10.1016/S0074-7742(01)48012-3; Beck M, 2002, J BIOL CHEM, V277, P30079, DOI 10.1074/jbc.M200438200; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; Brickley K, 2005, J BIOL CHEM, V280, P14723, DOI 10.1074/jbc.M409095200; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Fritschy JM, 2003, PHARMACOL THERAPEUT, V98, P299, DOI 10.1016/S0163-7258(03)00037-8; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gorska-Andrzejak J, 2003, J COMP NEUROL, V463, P372, DOI 10.1002/cne.10750; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; Kittler JT, 2002, MOL NEUROBIOL, V26, P251, DOI 10.1385/MN:26:2-3:251; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Levy Lucien M., 1999, Annals of Internal Medicine, V131, P522; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Li YK, 2002, J BIOL CHEM, V277, P28212, DOI 10.1074/jbc.M111612200; LORISH TR, 1989, MAYO CLIN PROC, V64, P629, DOI 10.1016/S0025-6196(12)65339-7; Luscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003; Marcora E, 2003, P NATL ACAD SCI USA, V100, P9578, DOI 10.1073/pnas.1133382100; Mayer R J, 1989, Prog Clin Biol Res, V317, P809; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; Stowers RS, 2002, NEURON, V36, P1063, DOI 10.1016/S0896-6273(02)01094-2; WZIESENDANGER M, 1972, PATHOPHYSIOLOGY MUSC	30	48	50	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					245	250		10.1038/ng1715	http://dx.doi.org/10.1038/ng1715			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16380713				2022-12-25	WOS:000234953200023
J	Halban, PA; Ferrannini, E; Nerup, J				Halban, PA; Ferrannini, E; Nerup, J			Diabetes research investment in the European union	NATURE MEDICINE			English	Editorial Material									Univ Geneva, Med Ctr, Dept Genet Med & Dev, CH-1211 Geneva 4, Switzerland; Univ Pisa, Metabol Unit, Dept Internal Med, Sch Med, I-56100 Pisa, Italy; Univ Pisa, Sch Med, CNR, Inst Clin Physiol, I-56100 Pisa, Italy; Steno Diabet Ctr, DK-2820 Gentofte, Denmark	University of Geneva; University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Pisa; Steno Diabetes Center	Halban, PA (corresponding author), Univ Geneva, Med Ctr, Dept Genet Med & Dev, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	philippe.halban@medecine.unige.ch							0	9	10	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2006	12	1					70	72		10.1038/nm0106-70	http://dx.doi.org/10.1038/nm0106-70			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397573				2022-12-25	WOS:000234419000053
J	Trowbridge, JJ; Xenocostas, A; Moon, RT; Bhatia, M				Trowbridge, JJ; Xenocostas, A; Moon, RT; Bhatia, M			Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation	NATURE MEDICINE			English	Article							UMBILICAL-CORD BLOOD; SONIC HEDGEHOG; SELF-RENEWAL; BETA-CATENIN; BONE-MARROW; GLUCOSE-METABOLISM; UNRELATED DONORS; SKELETAL-MUSCLE; PROTO-ONCOGENE; GENE-THERAPY	The in vivo regulation of hematopoietic stem cell (HSC) function is poorly understood. Here, we show that hematopoietic repopulation can be augmented by administration of a glycogen synthase kinase-3 (GSK-3) inhibitor to recipient mice transplanted with mouse or human HSCs. GSK-3 inhibitor treatment improved neutrophil and megakaryocyte recovery, recipient survival and resulted in enhanced sustained long-term repopulation. The output of primitive Lin(-)c-Kit(+)Sca-1(+) cells and progenitors from HSCs increased upon GSK-3 inhibitor treatment without altering secondary repopulating ability, suggesting that the HSC pool is maintained while overall hematopoietic reconstitution is increased. GSK-3 inhibitors were found to modulate gene targets of Wnt, Hedgehog and Notch pathways in cells comprising the primitive hematopoietic compartment without affecting mature cells. Our study establishes GSK-3 as a specific in vivo modulator of HSC activity, and suggests that administration of GSK-3 inhibitors may provide a clinical means to directly enhance the repopulating capacity of transplanted HSCs.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5B8, Canada; Univ Western Ontario, Dept Med, London, ON N6A 5B8, Canada; London Hlth Sci Ctr, London, ON N6A 5W9, Canada; Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Ctr Dev Biol, Seattle, WA 98195 USA; Krembil Ctr Stem Cell Biol, Robarts Res Inst, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); London Health Sciences Centre; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Western University (University of Western Ontario)	Bhatia, M (corresponding author), McMaster Univ, Fac Hlth Sci, 1200 Main St W,MDCL 5029, Hamilton, ON, Canada.	mbhatia@mcmaster.ca	Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014; Xenocostas, Anargyros/G-3358-2011	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408; 	NIGMS NIH HHS [P01 GM069983] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM069983] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker JN, 2005, BLOOD, V105, P1343, DOI 10.1182/blood-2004-07-2717; Baron F, 2003, ARCH MED RES, V34, P528, DOI 10.1016/j.arcmed.2003.09.010; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Cohen P, 1979, BIOCHEM SOC T, V7, P459, DOI 10.1042/bst0070459; Cohen Y, 2003, LEUKEMIA LYMPHOMA, V44, P1287, DOI 10.1080/1042819031000077016; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Devine SM, 2003, BONE MARROW TRANSPL, V31, P241, DOI 10.1038/sj.bmt.1703813; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Giralt Sergio, 2004, Curr Hematol Rep, V3, P165; Gluckman E, 2000, EXP HEMATOL, V28, P1197, DOI 10.1016/S0301-472X(00)00540-3; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Issack PS, 1998, CELL GROWTH DIFFER, V9, P837; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Laughlin MJ, 2004, NEW ENGL J MED, V351, P2265, DOI 10.1056/NEJMoa041276; Mancini SJC, 2005, BLOOD, V105, P2340, DOI 10.1182/blood-2004-08-3207; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Moscardo F, 2004, LEUKEMIA LYMPHOMA, V45, P11, DOI 10.1080/1042819031000146992; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Nikoulina SE, 2002, DIABETES, V51, P2190, DOI 10.2337/diabetes.51.7.2190; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2003, RECENT PROG HORM RES, V58, P283, DOI 10.1210/rp.58.1.283; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Rocha V, 2004, NEW ENGL J MED, V351, P2276, DOI 10.1056/NEJMoa041469; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Shojaei F, 2005, DEV CELL, V8, P651, DOI 10.1016/j.devcel.2005.03.004; Srour EF, 1999, J HEMATOTHER, V8, P93, DOI 10.1089/106161299320370; Tsirigotis M, 2001, BIOTECHNIQUES, V31, P120, DOI 10.2144/01311rr03; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Vollweiler JL, 2003, BONE MARROW TRANSPL, V32, P1, DOI 10.1038/sj.bmt.1704081; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	48	206	226	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					89	98		10.1038/nm1339	http://dx.doi.org/10.1038/nm1339			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16341242				2022-12-25	WOS:000234419000057
J	Liu, LP; Ni, JQ; Shi, YD; Oakeley, EJ; Sun, FL				Liu, LP; Ni, JQ; Shi, YD; Oakeley, EJ; Sun, FL			Sex-specific role of Drosophila melanogaster HP1 in regulating chromatin structure and gene transcription	NATURE GENETICS			English	Article							CHROMOSOMAL PROTEIN; DOSAGE COMPENSATION; HETEROCHROMATIN; EXPRESSION; METHYLATION; EUCHROMATIN	Drosophila melanogaster heterochromatin protein 1 (HP1a or HP1)(1) is believed to be involved in active transcription, transcriptional gene silencing and the formation of heterochromatin(2-7). But little is known about the function of HP1 during development. Using a Gal4-induced RNA interference system, we showed that conditional depletion of HP1 in transgenic flies resulted in preferential lethality in male flies. Cytological analysis of mitotic chromosomes showed that HP1 depletion caused sex-biased chromosomal defects, including telomere fusions. The global levels of specific histone modifications, particularly the hallmarks of active chromatin, were preferentially increased in males as well. Expression analysis showed that approximately twice as many genes were specifically regulated by HP1 in males than in females. Furthermore, HP1-regulated genes showed greater enrichment for HP1 binding in males. Taken together, these results indicate that HP1 modulates chromosomal integrity, histone modifications and transcription in a sex-specific manner.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Sun, FL (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	fang-lin.sun@fmi.ch						Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Bergmann A, 2003, CURR OPIN CELL BIOL, V15, P717, DOI 10.1016/j.ceb.2003.10.002; Bongiorni S, 2001, DEVELOPMENT, V128, P3809; Christensen TW, 2003, MOL BIOL CELL, V14, P2206, DOI 10.1091/mbc.E02-11-0706; Cryderman DE, 2005, DEV DYNAM, V232, P767, DOI 10.1002/dvdy.20310; De Lucia F, 2005, NUCLEIC ACIDS RES, V33, P2852, DOI 10.1093/nar/gki584; Delattre M, 2004, J CELL SCI, V117, P6239, DOI 10.1242/jcs.01549; Ebert A, 2004, GENE DEV, V18, P2973, DOI 10.1101/gad.323004; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Fanti L, 1998, MOL CELL, V2, P527, DOI 10.1016/S1097-2765(00)80152-5; Giordano E, 2002, GENETICS, V160, P637; Grewal SIS, 2002, CURR OPIN GENET DEV, V12, P178, DOI 10.1016/S0959-437X(02)00284-8; Hauck B, 1999, P NATL ACAD SCI USA, V96, P564, DOI 10.1073/pnas.96.2.564; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kelley RL, 1997, NATURE, V387, P195, DOI 10.1038/387195a0; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Perrini B, 2004, MOL CELL, V15, P467, DOI 10.1016/j.molcel.2004.06.036; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Piacentini L, 2003, J CELL BIOL, V161, P707, DOI 10.1083/jcb.200303012; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; SHAFFER CD, 1994, METHOD CELL BIOL, V44, P99, DOI 10.1016/S0091-679X(08)60908-5; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Sun FL, 2000, P NATL ACAD SCI USA, V97, P5340, DOI 10.1073/pnas.090530797; Th'ng JPH, 2001, BIOCHEM CELL BIOL, V79, P305, DOI 10.1139/bcb-79-3-305	30	62	62	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2005	37	12					1361	1366		10.1038/ng1662	http://dx.doi.org/10.1038/ng1662			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16258543				2022-12-25	WOS:000233657300017
J	Sans, N; Wang, PY; Due, QS; Petralia, RS; Wang, YX; Nakka, S; Blumer, JB; Macara, IG; Wenthold, RJ				Sans, N; Wang, PY; Due, QS; Petralia, RS; Wang, YX; Nakka, S; Blumer, JB; Macara, IG; Wenthold, RJ			Mpins modulates PSD-95 and SAP102 trafficking and influences NMDA receptor surface expression	NATURE CELL BIOLOGY			English	Article							G-PROTEINS; TETRATRICOPEPTIDE REPEAT; MOTIF; AGS3; PHOSPHORYLATION; IDENTIFICATION; DOMAIN; INTERACTS; POLARITY; PARTNER	Appropriate trafficking and targeting of glutamate receptors (GIuRs) to the postsynaptic density is crucial for synaptic function. We show that mPins (mammalian homologue of Drosophila melanogaster partner of inscuteable) interacts with SAP102 and PSD-95 (two PDZ proteins present in neurons), and functions in the formation of the NMDAR-MAGUK (N-methyl-D-aspartate receptor-membrane-associated guanylate kinase) complex. mPins enhances trafficking of SAP102 and NMDARs to the plasma membrane in neurons. Expression of dominant-negative constructs and short-interfering RNA (siRNA)-mediated knockdown of mPins decreases SAP102 in dendrites and modifies surface expression of NMDARs. mPins changes the number and morphology of dendritic spines and these effects depend on its G alpha i interaction domain, thus implicating G-protein signalling in the regulation of postsynaptic structure and trafficking of GluRs.	NIDCD, Neurochem Lab, NIH, Bethesda, MD 20892 USA; Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; LSU Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Virginia; University of Virginia; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Sans, N (corresponding author), INSERM, Inst Neurosci F Magendie, Equipe AVENIR, IFR8, F-33077 Bordeaux, France.	nathalie.sans@bordeaux.inserm.fr	Sans, Nathalie/N-7008-2017	Sans, Nathalie/0000-0001-7658-2471; Du, Quansheng/0000-0003-4079-8662; Blumer, Joe/0000-0002-0020-3815	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH065092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000003] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM070902] Funding Source: Medline; NIMH NIH HHS [F32 MH065092, F32MH65092] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bellaiche Y, 2001, CELL, V106, P355, DOI 10.1016/S0092-8674(01)00444-5; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Blumer JB, 2005, TRENDS PHARMACOL SCI, V26, P470, DOI 10.1016/j.tips.2005.07.003; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Bowers MS, 2004, NEURON, V42, P269, DOI 10.1016/S0896-6273(04)00159-X; Chung HJ, 2004, J NEUROSCI, V24, P10248, DOI 10.1523/JNEUROSCI.0546-04.2004; Du QS, 2004, CELL, V119, P503, DOI 10.1016/j.cell.2004.10.028; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; El-Husseini AE, 2000, J BIOL CHEM, V275, P23904, DOI 10.1074/jbc.M909919199; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Guo W, 2004, J NEUROSCI, V24, P9161, DOI 10.1523/JNEUROSCI.3422-04.2004; Imamura Y, 2003, NEUROREPORT, V14, P1203, DOI 10.1097/00001756-200307010-00003; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Marty C, 2003, MOL CELL BIOL, V23, P3847, DOI 10.1128/MCB.23.11.3847-3858.2003; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Montgomery JM, 2004, CELL MOL LIFE SCI, V61, P911, DOI 10.1007/s00018-003-3364-5; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Sato M, 2006, ANNU REV PHARMACOL, V46, P151, DOI 10.1146/annurev.pharmtox.46.120604.141115; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; van Zundert B, 2004, TRENDS NEUROSCI, V27, P428, DOI 10.1016/j.tins.2004.05.010; Wang YZ, 1997, NATURE, V389, P502, DOI 10.1038/39062; Washbourne P, 2004, J NEUROSCI, V24, P8253, DOI 10.1523/JNEUROSCI.2555-04.2004; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Willard FS, 2004, ANNU REV BIOCHEM, V73, P925, DOI 10.1146/annurev.biochem.73.011303.073756; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	38	100	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1179	1190		10.1038/ncb1325	http://dx.doi.org/10.1038/ncb1325			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16299499				2022-12-25	WOS:000233748900011
J	Catteruccia, F; Benton, JP; Crisanti, A				Catteruccia, F; Benton, JP; Crisanti, A			An Anopheles transgenic sexing strain for vector control	NATURE BIOTECHNOLOGY			English	Article							STERILE INSECT TECHNIQUE; GERMLINE TRANSFORMATION; POPULATION-CONTROL; TRANSPOSON VECTOR; DROSOPHILA-MELANOGASTER; CERATITIS-CAPITATA; MALARIA VECTOR; ALBIMANUS; DIPTERA; MALES	Genetic manipulation of mosquito species that serve as vectors for human malaria is a prerequisite to the implementation of gene transfer technologies for the control of vector-borne diseases. Here we report on the development of transgenic sexing lines for the mosquito Anopheles stephensi, the principal vector of human malaria in Asia. Male mosquitoes, expressing enhanced green fluorescent protein (EGFP) under the control of the beta 2-tubulin promoter, are identified by their fluorescent gonads in as early as their 3(rd) instar larval stage, and can be efficiently separated from females using both manual methods and automated sorting machines. Importantly, beta 2-EGFP males are not impaired in their mating ability and viable fluorescent spermatozoa are also detected in spermathecae of wild-type females mated with transgenic males. The transgenic mosquito lines described here combine most of the features desired and required for a safe application of transgenic methodologies to malariacontrol programs.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England	Imperial College London	Crisanti, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Imperial Coll Rd, London SW7 2AZ, England.	acrs@imperial.ac.uk		Crisanti, Andrea/0000-0002-2406-4426; Catteruccia, Flaminia/0000-0003-3295-6683	Biotechnology and Biological Sciences Research Council [S19551] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alphey L, 2002, SCIENCE, V298, P119, DOI 10.1126/science.1078278; Alphey L, 2002, MOL BIOCHEM PARASIT, V121, P173, DOI 10.1016/S0166-6851(02)00040-3; Benedict MQ, 2003, TRENDS PARASITOL, V19, P349, DOI 10.1016/S1471-4922(03)00144-2; Caceres C, 2002, GENETICA, V116, P107, DOI 10.1023/A:1020967810703; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; CURTIS CF, 1978, B WORLD HEALTH ORGAN, V56, P453; Furlong EEM, 2001, NAT BIOTECHNOL, V19, P153, DOI 10.1038/84422; Grossman GL, 2001, INSECT MOL BIOL, V10, P597, DOI 10.1046/j.0962-1075.2001.00299.x; Handler AM, 1999, INSECT MOL BIOL, V8, P449, DOI 10.1046/j.1365-2583.1999.00139.x; Handler AM, 2004, NAT BIOTECHNOL, V22, P1150, DOI 10.1038/nbt1002; Horn C, 2000, DEV GENES EVOL, V210, P630, DOI 10.1007/s004270000110; KEMPHUES KJ, 1980, CELL, V21, P445, DOI 10.1016/0092-8674(80)90481-X; KNIPLING EF, 1959, SCIENCE, V130, P902, DOI 10.1126/science.130.3380.902; KNIPLING EF, 1968, B WORLD HEALTH ORGAN, V38, P421; KRAFSUR ES, 1987, PARASITOL TODAY, V3, P131, DOI 10.1016/0169-4758(87)90196-7; LINDQUIST DA, 1992, MED VET ENTOMOL, V6, P2, DOI 10.1111/j.1365-2915.1992.tb00027.x; LINES JD, 1985, J ECON ENTOMOL, V78, P848, DOI 10.1093/jee/78.4.848; LOFGREN CS, 1974, AM J TROP MED HYG, V23, P288, DOI 10.4269/ajtmh.1974.23.288; Okanda F.M., 2002, Malaria Journal, pUnpaginated, DOI 10.1186/1475-2875-1-10; PATTERSON RS, 1970, SCIENCE, V168, P1368, DOI 10.1126/science.168.3937.1368; Perera OP, 2002, INSECT MOL BIOL, V11, P291, DOI 10.1046/j.1365-2583.2002.00336.x; Rendon P, 2004, J ECON ENTOMOL, V97, P1547, DOI 10.1603/0022-0493-97.5.1547; Robinson AS, 2002, GENETICA, V116, P5, DOI 10.1023/A:1020951407069; SEAWRIGHT JA, 1978, SCIENCE, V200, P1303, DOI 10.1126/science.663614; SHARMA VP, 1972, B WORLD HEALTH ORGAN, V47, P429; Vreysen MJB, 2000, J ECON ENTOMOL, V93, P123, DOI 10.1603/0022-0493-93.1.123	26	152	167	2	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2005	23	11					1414	1417		10.1038/nbt1152	http://dx.doi.org/10.1038/nbt1152			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	984FN	16244659				2022-12-25	WOS:000233288000037
J	Brotz-Oesterhelt, H; Beyer, D; Kroll, HP; Endermann, R; Ladel, C; Schroeder, W; Hinzen, B; Raddatz, S; Paulsen, H; Henninger, K; Bandow, JE; Sahl, HG; Labischinski, H				Brotz-Oesterhelt, H; Beyer, D; Kroll, HP; Endermann, R; Ladel, C; Schroeder, W; Hinzen, B; Raddatz, S; Paulsen, H; Henninger, K; Bandow, JE; Sahl, HG; Labischinski, H			Dysregulation of bacterial proteolytic machinery by a new class of antibiotics	NATURE MEDICINE			English	Article							DEPENDENT CLP PROTEASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; ATP HYDROLYSIS; HEAT-SHOCK; RESISTANCE; EXPRESSION; SELECTION	Here we show that a new class of antibiotics-acyldepsipeptides-has antibacterial activity against Gram-positive bacteria in vitro and in several rodent models of bacterial infection. The acyldepsipeptides are active against isolates that are resistant to antibiotics in clinical application, implying a new target, which we identify as ClpP, the core unit of a major bacterial protease complex. ClpP is usually tightly regulated and strictly requires a member of the family of Clp-ATPases and often further accessory proteins for proteolytic activation. Binding of acyldepsipeptides to ClpP eliminates these safeguards. The acyldepsipeptide-activated ClpP core is capable of proteolytic degradation in the absence of the regulatory Clp-ATPases. Such uncontrolled proteolysis leads to inhibition of bacterial cell division and eventually cell death.	Bayer HealthCare AG, Pharma Res, Dept Antiinfect, D-42096 Wuppertal, Germany; Bayer HealthCare AG, Pharma Res, Dept Enabling Technol, D-42096 Wuppertal, Germany; Bayer HealthCare AG, Pharma Res, Dept Chem, D-42096 Wuppertal, Germany; Bayer HealthCare AG, Pharma Res, Dept Pharmacokinet, D-42096 Wuppertal, Germany; Univ Greifswald, Inst Microbiol, D-17487 Greifswald, Germany; Univ Bonn, Inst Med Microbiol, D-53105 Bonn, Germany	Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; Ernst Moritz Arndt Universitat Greifswald; University of Bonn	Brotz-Oesterhelt, H (corresponding author), Bayer HealthCare AG, Pharma Res, Dept Antiinfect, Aprather Weg 18a, D-42096 Wuppertal, Germany.	heike.broetz-oesterhelt@bayerhealthcare.com	Ladel, Christoph/ABG-3165-2021; Bandow, Julia/K-8854-2012	Bandow, Julia/0000-0003-4100-8829; Ladel, Christoph/0000-0001-8657-6219				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Appelbaum PC, 2002, CLIN INFECT DIS, V34, P1613, DOI 10.1086/340400; Bandow JE, 2003, ANTIMICROB AGENTS CH, V47, P948, DOI 10.1128/AAC.47.3.948-955.2003; Fritsche TR, 2005, ANTIMICROB AGENTS CH, V49, P1468, DOI 10.1128/AAC.49.4.1468-1476.2005; Gerth U, 2004, J BACTERIOL, V186, P179, DOI 10.1128/JB.186.1.179-191.2004; Hardy CD, 2003, ANTIMICROB AGENTS CH, V47, P941, DOI 10.1128/AAC.47.3.941-947.2003; Hecker M, 1996, MOL MICROBIOL, V19, P417, DOI 10.1046/j.1365-2958.1996.396932.x; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Hiramatsu K, 2002, CURR OPIN INFECT DIS, V15, P407, DOI 10.1097/00001432-200208000-00009; *INF DIS SOC AM, BAD BUGS NO DRUGS; Kock H, 2004, MOL MICROBIOL, V51, P1087, DOI 10.1046/j.1365-2958.2003.03875.x; Kwon HY, 2004, INFECT IMMUN, V72, P5646, DOI 10.1128/IAI.72.10.5646-5653.2004; Kwon HY, 2003, INFECT IMMUN, V71, P3757, DOI 10.1128/IAI.71.7.3757-3765.2003; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Michel K.H., 1985, US Pat., Patent No. [4492650, 4,492,650]; Msadek T, 1998, MOL MICROBIOL, V27, P899, DOI 10.1046/j.1365-2958.1998.00735.x; Porankiewicz J, 1999, MOL MICROBIOL, V32, P449, DOI 10.1046/j.1365-2958.1999.01357.x; Schlothauer T, 2003, P NATL ACAD SCI USA, V100, P2306, DOI 10.1073/pnas.0535717100; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Tsubery H, 2002, MOL PHARMACOL, V62, P1036, DOI 10.1124/mol.62.5.1036; Weigel LM, 2003, SCIENCE, V302, P1569, DOI 10.1126/science.1090956; WOO KM, 1989, J BIOL CHEM, V264, P2088	24	352	367	2	42	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2005	11	10					1082	1087		10.1038/nm1306	http://dx.doi.org/10.1038/nm1306			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16200071				2022-12-25	WOS:000232492500029
J	Levran, O; Attwooll, C; Henry, RT; Milton, KL; Neveling, K; Rio, P; Batish, SD; Kalb, R; Velleuer, E; Barral, S; Ott, J; Petrini, J; Schindler, D; Hanenberg, H; Auerbach, AD				Levran, O; Attwooll, C; Henry, RT; Milton, KL; Neveling, K; Rio, P; Batish, SD; Kalb, R; Velleuer, E; Barral, S; Ott, J; Petrini, J; Schindler, D; Hanenberg, H; Auerbach, AD			The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia	NATURE GENETICS			English	Article							BRCA1; PROTEIN; BACH1	Seven Fanconi anemia - associated proteins ( FANCA, FANCB, FANCC, FANCE, FANCF, FANCG and FANCL) form a nuclear Fanconi anemia core complex that activates the monoubiquitination of FANCD2, targeting FANCD2 to BRCA1-containing nuclear foci. Cells from individuals with Fanconi anemia of complementation groups D1 and J ( FA- D1 and FA- J) have normal FANCD2 ubiquitination. Using genetic mapping, mutation identification and western- blot data, we identify the defective protein in FA- J cells as BRIP1 ( also called BACH1), a DNA helicase that is a binding partner of the breast cancer tumor suppressor BRCA1.	Rockefeller Univ, Lab Human Genet & Hematol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Wurzburg, Inst Human Genet, Wurzburg, Germany; Univ Dusseldorf, Dept Pediat Oncol Hematol & Immunol, Dusseldorf, Germany; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA	Rockefeller University; Memorial Sloan Kettering Cancer Center; University of Wurzburg; Heinrich Heine University Dusseldorf; Rockefeller University	Auerbach, AD (corresponding author), Rockefeller Univ, Lab Human Genet & Hematol, 1230 York Ave, New York, NY 10021 USA.	auerbac@rockefeller.edu	Levran, Orna/H-2772-2019; Velleuer, Eunike/U-6355-2019; Rio, Paula/G-8681-2015; Kalb, Reinhard/AAR-3249-2021; 高, 雨莉/HGU-8187-2022	Velleuer, Eunike/0000-0003-4328-9556; Rio, Paula/0000-0002-5424-5543; Kalb, Reinhard/0000-0003-3906-6907; Auerbach, Arleen/0000-0002-6911-8379; Petrini, John/0000-0001-5102-5679				Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chen JJ, 1999, CANCER RES, V59, p1752S; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gschwend M, 1996, AM J HUM GENET, V59, P377; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Rutter JL, 2003, HUM MUTAT, V22, P121, DOI 10.1002/humu.10238	13	288	293	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2005	37	9					931	933		10.1038/ng1624	http://dx.doi.org/10.1038/ng1624			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	960LK	16116424				2022-12-25	WOS:000231591900015
J	Li, BJ; Tang, QQ; Cheng, D; Qin, C; Xie, FY; Wei, Q; Xu, J; Liu, YJ; Zheng, BJ; Woodle, MC; Zhong, NS; Lu, PY				Li, BJ; Tang, QQ; Cheng, D; Qin, C; Xie, FY; Wei, Q; Xu, J; Liu, YJ; Zheng, BJ; Woodle, MC; Zhong, NS; Lu, PY			Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque	NATURE MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; SMALL INTERFERING RNAS; SPIKE PROTEIN; GENE-TRANSFER; VIRUS; MICE; REPLICATION; INFECTION; SEQUENCE; EXPRESSION	Development of therapeutic agents for severe acute respiratory syndrome ( SARS) viral infection using short interfering RNA ( siRNA) inhibitors exemplifies a powerful new means to combat emerging infectious diseases. Potent siRNA inhibitors of SARS coronavirus ( SCV) in vitro were further evaluated for efficacy and safety in a rhesus macaque ( Macaca mulatta) SARS model using clinically viable delivery while comparing three dosing regimens. Observations of SARS- like symptoms, measurements of SCV RNA presence and lung histopathology and immunohistochemistry consistently showed siRNA- mediated anti- SARS efficacy by either prophylactic or therapeutic regimens. The siRNAs used provided relief from SCV infection - induced fever, diminished SCV viral levels and reduced acute diffuse alveoli damage. The 10 - 40 mg/ kg accumulated dosages of siRNA did not show any sign of siRNA- induced toxicity. These results suggest that a clinical investigation is warranted and illustrate the prospects for siRNA to enable a massive reduction in development time for new targeted therapeutic agents.	Intradigm Corp, Rockville, MD 20852 USA; Sun Yatsen Univ, Biotechnol Res Ctr, Guangzhou, Peoples R China; Minist Educ State, Key Lab Gene Engn, Guangzhou, Peoples R China; Guangzhou Top Genom Ltd, Guangzhou, Peoples R China; Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Guangzhou Inst Resp Dis, Guangzhou, Peoples R China	Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Hong Kong	Lu, PY (corresponding author), Intradigm Corp, 12115 K Parklawn Dr, Rockville, MD 20852 USA.	nanshan@vip.163.com; patricklu@intradigm.com	cheng, du/GPK-2264-2022	cheng, du/0000-0001-5105-7777				Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101; Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Boeckle S, 2004, J GENE MED, V6, P1102, DOI 10.1002/jgm.598; Bonnard E, 2002, PEPTIDES, V23, P1107, DOI 10.1016/S0196-9781(02)00034-7; Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X; Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6; Delepine P, 2003, J GENE MED, V5, P600, DOI 10.1002/jgm.385; Elmen J., 2004, PRECLINICA, V2, P135; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; Ghanayem N S, 2001, Pediatr Crit Care Med, V2, P315, DOI 10.1097/00130478-200110000-00005; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001; Haasnoot J, 2003, J BIOMED SCI, V10, P607, DOI 10.1007/BF02256311; He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002; Heidel JD, 2004, NAT BIOTECHNOL, V22, P1579, DOI 10.1038/nbt1038; Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482; Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; LU PY, 2000, Patent No. 20030148975; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Massaro D, 2004, AM J PHYSIOL-LUNG C, V287, pL1066, DOI 10.1152/ajplung.00067.2004; Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Qin C, 2005, J PATHOL, V206, P251, DOI 10.1002/path.1769; Rowe T, 2004, J VIROL, V78, P11401, DOI 10.1128/JVI.78.20.11401-11404.2004; Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004; Thomas Neal J, 2005, Pediatr Crit Care Med, V6, P160, DOI 10.1097/01.PCC.0000154965.08432.16; Tompkins SM, 2004, P NATL ACAD SCI USA, V101, P8682, DOI 10.1073/pnas.0402630101; Wang Z, 2004, J VIROL, V78, P7523, DOI 10.1128/JVI.78.14.7523-7527.2004; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; Zhang RL, 2003, CHINESE MED J-PEKING, V116, P1262; Zhang YJ, 2004, FEBS LETT, V560, P141, DOI 10.1016/S0014-5793(04)00087-0; Zheng BJ, 2004, ANTIVIR THER, V9, P365; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2	50	361	413	2	99	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					944	951		10.1038/nm1280	http://dx.doi.org/10.1038/nm1280			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16116432	Green Published, Bronze			2022-12-25	WOS:000231724700021
J	Saude, L; Lourenco, R; Goncalves, A; Palmeirim, I				Saude, L; Lourenco, R; Goncalves, A; Palmeirim, I			terra is a left-right asymmetry gene required for left-right synchronization of the segmentation clock	NATURE CELL BIOLOGY			English	Article							DOUBLESEX-RELATED GENE; ZEBRAFISH; SOMITOGENESIS; EXPRESSION; VERTEBRATES; OSCILLATOR; EMBRYO	To establish the vertebrate body plan, it is fundamental to create left - right asymmetry in the lateral- plate mesoderm to correctly position the organs. However, it is also crucial to maintain symmetry between the left and the right sides of the presomitic mesoderm, ensuring the allocation of symmetrical body structures, such as the axial skeleton and skeletal muscles. Here, we show that terra is an early left- sided expressed gene that links left - right patterning with bilateral synchronization of the segmentation clock.	Gulbenkian Inst Sci, Ctr Biol Desenvolvimento, P-2780156 Oeiras, Portugal; Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal	Universidade do Minho	Saude, L (corresponding author), Gulbenkian Inst Sci, Ctr Biol Desenvolvimento, Rua Quinta Grande 6, P-2780156 Oeiras, Portugal.	mlsaude@igc.gulbenkian.pt	Saúde, Leonor/D-2720-2012; Palmeirim, Isabel/F-4522-2012	Saúde, Leonor/0000-0001-5933-8872; Lourenco, Raquel/0000-0002-6176-3066; Palmeirim, Isabel/0000-0003-2282-7829				Amack JD, 2004, CURR BIOL, V14, P685, DOI 10.1016/j.cub.2004.04.002; Brunner B, 2001, GENOMICS, V77, P8, DOI 10.1006/geno.2001.6615; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; Dubrulle J, 2004, DEVELOPMENT, V131, P5783, DOI 10.1242/dev.01519; Essner JJ, 2000, DEVELOPMENT, V127, P1081; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hashimoto H, 2004, DEVELOPMENT, V131, P1741, DOI 10.1242/dev.01070; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Holley SA, 2000, GENE DEV, V14, P1678; Jiang YJ, 2000, NATURE, V408, P475, DOI 10.1038/35044091; Kawakami Y, 2005, NATURE, V435, P165, DOI 10.1038/nature03512; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Long S, 2003, DEVELOPMENT, V130, P2303, DOI 10.1242/dev.00436; Meng AM, 1999, DEVELOPMENT, V126, P1259; Oates AC, 2002, DEVELOPMENT, V129, P2929; Raya A, 2004, NATURE, V427, P121, DOI 10.1038/nature02190; Thisse C., 1998, ZEBRAFISH SCI MON, V5, P8; Vermot J, 2005, SCIENCE, V308, P563, DOI 10.1126/science.1108363; Vermot J, 2005, NATURE, V435, P215, DOI 10.1038/nature03488	20	52	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2005	7	9					918	U82		10.1038/ncb1294	http://dx.doi.org/10.1038/ncb1294			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	960NY	16136187				2022-12-25	WOS:000231601600017
J	Skibinski, G; Parkinson, NJ; Brown, JM; Chakrabarti, L; Lloyd, SL; Hummerich, H; Nielsen, JE; Hodges, JR; Spillantini, MG; Thusgaard, T; Brandner, S; Brun, A; Rossor, MN; Gade, A; Johannsen, P; Sorensen, SA; Gydesen, S; Fisher, EMC; Collinge, J				Skibinski, G; Parkinson, NJ; Brown, JM; Chakrabarti, L; Lloyd, SL; Hummerich, H; Nielsen, JE; Hodges, JR; Spillantini, MG; Thusgaard, T; Brandner, S; Brun, A; Rossor, MN; Gade, A; Johannsen, P; Sorensen, SA; Gydesen, S; Fisher, EMC; Collinge, J			Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia	NATURE GENETICS			English	Article							PROTEIN; TRAFFICKING; DISEASE; FTD-3	We have previously reported a large Danish pedigree with autosomal dominant frontotemporal dementia (FTD) linked to chromosome 3 (FTD3). Here we identify a mutation in CHMP2B, encoding a component of the endosomal ESCRTIII complex, and show that it results in aberrant mRNA splicing in tissue samples from affected members of this family. We also describe an additional missense mutation in an unrelated individual with FTD. Aberration in the endosomal ESCRTIII complex may result in FTD and neurodegenerative disease.	UCL, Inst Neurol, Dept Neurodegenerat Dis, London WC1E 6BT, England; UCL, Inst Neurol, MRC, Prion Unit, London, England; Addenbrookes Hosp, Dept Neurol, MRC, Cognit & Brain Sci Unit, Cambridge, England; Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Neurogenet Sect, DK-1168 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Ctr Neurosci, Memory Disorders Res Unit, DK-2100 Copenhagen, Denmark; Univ Cambridge, Dept Clin Neurosci, Ctr Brain Repair, Cambridge, England; Parkvaenget Nursing Home, Holstebro, Denmark; Univ Lund Hosp, Dept Pathol, S-22185 Lund, Sweden; Univ Copenhagen, Rigshosp, Dept Psychol, DK-1168 Copenhagen, Denmark; Cent Hosp, Dept Psychiat, Holbaek, Denmark	University of London; University College London; University of London; University College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Cambridge; Lund University; Skane University Hospital; Rigshospitalet; University of Copenhagen; Holbaek Hospital	Fisher, EMC (corresponding author), UCL, Inst Neurol, Dept Neurodegenerat Dis, London WC1E 6BT, England.	e.fisher@prion.ucl.ac.uk	Johannsen, Peter/G-1079-2011; Fisher, Elizabeth MC/C-2168-2008; Brandner, Sebastian/J-4562-2014; Chakrabarti, Lisa/G-4236-2011; Rossor, Martin/C-1598-2008	Johannsen, Peter/0000-0002-0528-1070; Fisher, Elizabeth MC/0000-0003-2850-9936; Brandner, Sebastian/0000-0002-9821-0342; Nielsen, Jorgen Erik/0000-0003-0453-5582; Chakrabarti, Lisa/0000-0001-7213-6837; Rossor, Martin/0000-0001-8215-3120				Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; COLLINGE J, 1994, J NEUROL NEUROSUR PS, V57, P762, DOI 10.1136/jnnp.57.6.762; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Gydesen S, 2002, NEUROLOGY, V59, P1585, DOI 10.1212/01.WNL.0000034763.54161.1F; Harrison RE, 2003, MOL CELL BIOL, V23, P6494, DOI 10.1128/MCB.23.18.6494-6506.2003; Hosler BA, 2000, JAMA-J AM MED ASSOC, V284, P1664, DOI 10.1001/jama.284.13.1664; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; KNOPMAN DS, 1990, NEUROLOGY, V40, P251, DOI 10.1212/WNL.40.2.251; Kunita R, 2004, J BIOL CHEM, V279, P38626, DOI 10.1074/jbc.M406120200; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Nixon RA, 2005, NEUROBIOL AGING, V26, P373, DOI 10.1016/j.neurobiolaging.2004.09.018; Reid E, 2005, HUM MOL GENET, V14, P19, DOI 10.1093/hmg/ddi003; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; Yancopoulu D, 2003, J NEUROPATH EXP NEUR, V62, P878, DOI 10.1093/jnen/62.8.878	15	606	624	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2005	37	8					806	808		10.1038/ng1609	http://dx.doi.org/10.1038/ng1609			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16041373	Green Published			2022-12-25	WOS:000230880400009
J	Goldman, S				Goldman, S			Stem and progenitor cell-based therapy of the human central nervous system	NATURE BIOTECHNOLOGY			English	Review							FIBROBLAST GROWTH FACTOR-2; ADULT MAMMALIAN FOREBRAIN; SUBCORTICAL WHITE-MATTER; NEUROGENESIS IN-VITRO; NEURAL STEM; SPINAL-CORD; NEUROTROPHIC FACTOR; HUMAN BRAIN; PRECURSOR CELLS; DOPAMINERGIC-NEURONS	Multipotent neural stem cells, capable of giving rise to both neurons and glia, line the cerebral ventricles of all adult animals, including humans. In addition, distinct populations of nominally glial progenitor cells, which also have the capacity to generate several cell types, are dispersed throughout the subcortical white matter and cortex. A number of approaches have evolved for using neural progenitor cells in cell therapy. Four strategies are especially attractive for clinical translation: first, transplantation of oligodendrocyte progenitor cells as a means of treating the disorders of myelin; second, transplantation of phenotypically restricted neuronal progenitor cells to treat diseases of discrete loss of a single neuronal phenotype, such as Parkinson disease; third, implantation of mixed progenitor pools to treat diseases characterized by the loss of several discrete phenotypes, such as spinal cord injury; and fourth, mobilization of endogenous neural progenitor cells to restore neurons lost as a result of neurodegenerative diseases, in particular Huntington disease. Together, these may present the most compelling strategies and near-term disease targets for cell-based neurological therapy.	Univ Rochester, Dept Neurol, Div Cell & Gene Therapy, Rochester, NY 14642 USA; Univ Rochester, Dept Neurosurg, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Goldman, S (corresponding author), Univ Rochester, Dept Neurol, Div Cell & Gene Therapy, 601 Elmwood Ave,Box 645, Rochester, NY 14642 USA.	steven_goldman@urmc.rochester.edu		Goldman, Steven/0000-0002-5498-4303				Aberg MAI, 2000, J NEUROSCI, V20, P2896; AHMED S, 1995, J NEUROSCI, V15, P5765; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; Arsenijevic Y, 2001, EXP NEUROL, V170, P48, DOI 10.1006/exnr.2001.7691; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Back SA, 2004, SEMIN PERINATOL, V28, P405, DOI 10.1053/j.semperi.2004.10.010; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.0.CO;2-B; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen JH, 2004, P NATL ACAD SCI USA, V101, P16357, DOI 10.1073/pnas.0406795101; Chmielnicki E, 2004, J NEUROSCI, V24, P2133, DOI 10.1523/JNEUROSCI.1554-03.2004; Chmielnicki E, 2002, PROG BRAIN RES, V138, P451, DOI 10.1016/S0079-6123(02)38093-2; Cho SR, 2004, MOL THER, V9, pS86; Craig CG, 1996, J NEUROSCI, V16, P2649; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Follett PL, 2004, J NEUROSCI, V24, P4412, DOI 10.1523/JNEUROSCI.0477-04.2004; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gao Y, 2004, NEURON, V44, P609, DOI 10.1016/j.neuron.2004.10.030; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Goldman S, 2003, TRENDS NEUROSCI, V26, P590, DOI 10.1016/j.tins.2003.09.011; Goldman SA, 2004, CURR OPIN MOL THER, V6, P466; Goldman SA, 1998, J NEUROBIOL, V36, P267, DOI 10.1002/(SICI)1097-4695(199808)36:2<267::AID-NEU12>3.3.CO;2-N; Goldman SA, 1997, J NEUROBIOL, V32, P554, DOI 10.1002/(SICI)1097-4695(19970605)32:6<554::AID-NEU2>3.0.CO;2-Z; Goldman Steven A., 2005, V265, P66; Gomes WA, 2003, DEV BIOL, V255, P164, DOI 10.1016/S0012-1606(02)00037-4; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; Gritti A, 1996, J NEUROSCI, V16, P1091; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Han SSW, 2004, GLIA, V45, P1, DOI 10.1002/glia.10282; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hu FH, 2004, SEMIN PERINATOL, V28, P371, DOI 10.1053/j.semperi.2004.10.001; Ivkovic S, 1999, J NEUROSCI, V19, P5409; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Jin K, 2002, J CLIN INVEST, V110, P311, DOI 10.1172/JCI200215251; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Kawaguchi A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/mcne.2000.0925; Kaye EM, 2001, PEDIATR NEUROL, V24, P11, DOI 10.1016/S0887-8994(00)00232-0; Kerr DA, 2003, J NEUROSCI, V23, P5131; Keyoung HM, 2001, NAT BIOTECHNOL, V19, P843, DOI 10.1038/nbt0901-843; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Lindvall O, 1999, MOVEMENT DISORD, V14, P201, DOI 10.1002/1531-8257(199903)14:2<201::AID-MDS1001>3.3.CO;2-H; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Loeffler Markus, 1997, P1, DOI 10.1016/B978-012563455-7/50002-7; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Mabie PC, 1997, J NEUROSCI, V17, P4112; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Menezes JRL, 1995, MOL CELL NEUROSCI, V6, P496, DOI 10.1006/mcne.1995.0002; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NAKANO T, 2005, IN PRESS DEV BIOL; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Niemann C, 2002, TRENDS CELL BIOL, V12, P185, DOI 10.1016/S0962-8924(02)02263-8; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Nistor GI, 2005, GLIA, V49, P385, DOI 10.1002/glia.20127; NOTLEBOHM F, 2005, PLOS BIOL, V3, pE164; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Packer MA, 2003, P NATL ACAD SCI USA, V100, P9566, DOI 10.1073/pnas.1633579100; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Pincus D W, 1997, Clin Neurosurg, V44, P17; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; Pluchino S, 2004, CURR OPIN NEUROL, V17, P247, DOI 10.1097/00019052-200406000-00003; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Powers J., 2004, MYELIN BIOL DISORDER, P663; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Robinson S, 2005, NEUROBIOL DIS, V18, P568, DOI 10.1016/j.nbd.2004.10.024; ROY N, 2005, IN PRESS EXP NEUROL; Roy NS, 2004, NAT BIOTECHNOL, V22, P297, DOI 10.1038/nbt944; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Roy NS, 2000, NAT MED, V6, P271; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Shihabuddin LS, 2004, J NEUROSCI, V24, P10642, DOI 10.1523/JNEUROSCI.3584-04.2004; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Studer L, 2000, J NEUROSCI, V20, P7377; Svendsen CN, 1999, BRAIN PATHOL, V9, P499, DOI 10.1111/j.1750-3639.1999.tb00538.x; Svendsen CN, 2001, NAT REV NEUROSCI, V2, P831, DOI 10.1038/35097581; Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Urayama A, 2004, P NATL ACAD SCI USA, V101, P12658, DOI 10.1073/pnas.0405042101; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Wang S, 2000, DEV NEUROSCI-BASEL, V22, P167, DOI 10.1159/000017437; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2; Weiss S, 1996, J NEUROSCI, V16, P7599; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Windrem M, 2002, CONT NEUROS, P69; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Windrem MS, 2002, J NEUROSCI RES, V69, P966, DOI 10.1002/jnr.10397; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	141	288	341	0	61	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2005	23	7					862	871		10.1038/nbt1119	http://dx.doi.org/10.1038/nbt1119			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	944KT	16003375				2022-12-25	WOS:000230427700034
J	Boon, EM; Huang, SH; Marletta, MA				Boon, EM; Huang, SH; Marletta, MA			A molecular basis for NO selectivity in soluble guanylate cyclase	NATURE CHEMICAL BIOLOGY			English	Article							LIGAND-BINDING; NITRIC-OXIDE; OXYGEN-AFFINITY; RESONANCE RAMAN; HEME-PROTEINS; MYOGLOBIN; HEMOGLOBIN; DISSOCIATION; DOMAINS; SENSORS	Soluble guanylate cyclases (sGCs) function as heme sensors that selectively bind nitric oxide (NO), triggering reactions essential to animal physiology. Recent discoveries place sGCs in the H-NOX family (heme nitric oxide/oxygen-binding domain), which includes bacterial proteins from aerobic and anaerobic organisms. Some H-NOX proteins tightly bind oxygen (O-2), whereas others show no measurable affinity for O-2, providing the basis for selective NO signaling in aerobic cells. Using a series of wild-type and mutant H-NOXs, we established a molecular basis for ligand discrimination. A distal pocket tyrosine is requisite for O-2 binding in the H-NOX family. These data suggest that sGC uses a kinetic selection against O-2; we propose that the O-2 dissociation rate in the absence of this tyrosine is fast and that a stable O-2 complex does not form.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Lawrence Berkeley Natl Lab, Div Phys Biosci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Marletta, MA (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	marletta@berkeley.edu	Boon, Elizabeth/AAR-8229-2020	Boon, Elizabeth/0000-0003-1891-839X	NIGMS NIH HHS [F32GM069302] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM069302] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dmochowski IJ, 2000, J INORG BIOCHEM, V81, P221, DOI 10.1016/S0162-0134(00)00111-2; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; Gong WM, 2000, BIOCHEMISTRY-US, V39, P3955, DOI 10.1021/bi992346w; Gray JM, 2004, NATURE, V430, P317, DOI 10.1038/nature02714; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hvitved AN, 2001, J BIOL CHEM, V276, P34714, DOI 10.1074/jbc.M105175200; Iyer LM, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-5; Karow DS, 2004, BIOCHEMISTRY-US, V43, P10203, DOI 10.1021/bi049374l; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Kiger L, 1998, BIOPHYS J, V75, P990, DOI 10.1016/S0006-3495(98)77587-3; Kundu S, 2003, TRENDS PLANT SCI, V8, P387, DOI 10.1016/S1360-1385(03)00163-8; MATHEWS AJ, 1994, METHOD ENZYMOL, V232, P363; MOORE EG, 1976, J BIOL CHEM, V251, P2788; Morton DB, 2004, J BIOL CHEM, V279, P50651, DOI 10.1074/jbc.C400461200; Nioche P, 2004, SCIENCE, V306, P1550, DOI 10.1126/science.1103596; OERTLING WA, 1990, INORG CHEM, V29, P2633, DOI 10.1021/ic00339a021; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Pellicena P, 2004, P NATL ACAD SCI USA, V101, P12854, DOI 10.1073/pnas.0405188101; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	31	160	168	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2005	1	1					53	59		10.1038/nchembio704	http://dx.doi.org/10.1038/nchembio704			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	974WC	16407994				2022-12-25	WOS:000232621100013
J	Das, SR; Piccirilli, JA				Das, SR; Piccirilli, JA			General acid catalysis by the hepatitis delta virus ribozyme	NATURE CHEMICAL BIOLOGY			English	Article							BASE CATALYSIS; ACTIVE-SITE; HAIRPIN RIBOZYME; PROTON-TRANSFER; DIVALENT METAL; RNA; MECHANISM; HAMMERHEAD; CLEAVAGE; CYTOSINE	Recent crystallographic and functional analyses of RNA enzymes have raised the possibility that the purine and pyrimidine nucleobases may function as general acid-base catalysts. However, this mode of nucleobase-mediated catalysis has been difficult to establish unambiguously. Here, we used a hyperactivated RNA substrate bearing a 5'-phosphorothiolate to investigate the role of a critical cytosine residue in the hepatitis delta virus ribozyme. The hyperactivated substrate specifically suppressed the deleterious effects of cytosine mutations and pH changes, thereby linking the protonation of the nucleobase to leaving-group stabilization. We conclude that the active-site cytosine provides general acid catalysis, mediating proton transfer to the leaving group through a protonated N3-imino nitrogen. These results establish a specific role for a nucleobase in a ribozyme reaction and support the proposal that RNA nucleobases may function in a manner analogous to that of catalytic histidine residues in protein enzymes.	Univ Chicago, Howard Hughes Med Inst, Dept Biochem, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago	Piccirilli, JA (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Biochem, 5841 S Maryland Ave,MC1028, Chicago, IL 60637 USA.	jpicciri@uchicago.edu	Das, Subha R./H-4733-2014	Das, Subha R./0000-0002-5353-0422				Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BEIGELMAN L, 1995, NUCLEOS NUCLEOT, V14, P895, DOI 10.1080/15257779508012497; BEVERS S, 2000, RIBOZYME BIOCH BIOTE, P171; Bevilacqua PC, 2004, BIOPOLYMERS, V73, P90, DOI 10.1002/bip.10519; Bevilacqua PC, 2003, BIOCHEMISTRY-US, V42, P2259, DOI 10.1021/bi027273m; Chaulk SG, 1998, NUCLEIC ACIDS RES, V26, P3173, DOI 10.1093/nar/26.13.3173; COOK PD, 1977, J HETEROCYCLIC CHEM, V14, P1295; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; FIFE TH, 1969, J ORG CHEM, V34, P4007, DOI 10.1021/jo01264a055; Harris DA, 2002, BIOCHEMISTRY-US, V41, P12051, DOI 10.1021/bi026101m; Hiley SL, 2002, EMBO J, V21, P4691, DOI 10.1093/emboj/cdf462; Hoff RH, 2000, BIOCHEMISTRY-US, V39, P46, DOI 10.1021/bi991570i; Juneau K, 2001, STRUCTURE, V9, P221, DOI 10.1016/S0969-2126(01)00579-2; Kao C, 1999, RNA, V5, P1268, DOI 10.1017/S1355838299991033; Ke AL, 2004, NATURE, V429, P201, DOI 10.1038/nature02522; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Kuimelis RG, 1997, BIOORGAN MED CHEM, V5, P1051, DOI 10.1016/S0968-0896(97)00041-2; Lebruska LL, 2002, CHEM BIOL, V9, P465, DOI 10.1016/S1074-5521(02)00130-8; Lilley DMJ, 2004, RNA, V10, P151, DOI 10.1261/rna.5217104; MacLeod AM, 1996, BIOCHEMISTRY-US, V35, P13165, DOI 10.1021/bi9610616; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Moore MJ, 2000, METHOD ENZYMOL, V317, P109; Murray JB, 1998, CHEM BIOL, V5, P587, DOI 10.1016/S1074-5521(98)90116-8; Nakano S, 2000, SCIENCE, V287, P1493, DOI 10.1126/science.287.5457.1493; Nakano S, 2001, J AM CHEM SOC, V123, P11333, DOI 10.1021/ja0166850; Nakano S, 2001, BIOCHEMISTRY-US, V40, P12022, DOI 10.1021/bi011253n; Ouellet J, 2004, RNA, V10, P1059, DOI 10.1261/rna.7230604; Oyelere AK, 2002, BIOCHEMISTRY-US, V41, P3667, DOI 10.1021/bi011816v; Pereira MJB, 2002, BIOCHEMISTRY-US, V41, P730, DOI 10.1021/bi011963t; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; Pinard R, 2001, EMBO J, V20, P6434, DOI 10.1093/emboj/20.22.6434; Romanova D, 1996, J CHROMATOGR B, V675, P9, DOI 10.1016/0378-4347(95)00334-7; Rupert PB, 2002, SCIENCE, V298, P1421, DOI 10.1126/science.1076093; Searls T, 1999, TETRAHEDRON, V55, P11985, DOI 10.1016/S0040-4020(99)00703-6; Shih I, 2001, P NATL ACAD SCI USA, V98, P1489, DOI 10.1073/pnas.98.4.1489; Shih IH, 2000, BIOCHEMISTRY-US, V39, P9055, DOI 10.1021/bi000499+; Shih IH, 2002, ANNU REV BIOCHEM, V71, P887, DOI 10.1146/annurev.biochem.71.110601.135349; THOMPSON JE, 1994, J AM CHEM SOC, V116, P5467, DOI 10.1021/ja00091a060; Winkler WC, 2004, NATURE, V428, P281, DOI 10.1038/nature02362; Yoshida A, 2000, CHEM BIOL, V7, P85, DOI 10.1016/S1074-5521(00)00074-0; Youngman EM, 2004, CELL, V117, P589, DOI 10.1016/S0092-8674(04)00411-8; Zhao L, 2003, J AM CHEM SOC, V125, P22, DOI 10.1021/ja029019n; Zhou DM, 1997, P NATL ACAD SCI USA, V94, P14343, DOI 10.1073/pnas.94.26.14343	44	187	197	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2005	1	1					45	52		10.1038/nchembio703	http://dx.doi.org/10.1038/nchembio703			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	974WC	16407993				2022-12-25	WOS:000232621100012
J	Huang, CJ; Harootunian, A; Maher, MP; Quan, C; Raj, CD; McCormack, K; Numann, R; Negulescu, PA; Gonzalez, JE				Huang, CJ; Harootunian, A; Maher, MP; Quan, C; Raj, CD; McCormack, K; Numann, R; Negulescu, PA; Gonzalez, JE			Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential	NATURE BIOTECHNOLOGY			English	Article							RESONANCE ENERGY-TRANSFER; RAT HIPPOCAMPAL-NEURONS; CENTRAL-NERVOUS-SYSTEM; STATE-DEPENDENT BLOCK; CELL-BASED ASSAYS; NEUROPATHIC PAIN; NA+ CHANNELS; LOCAL-ANESTHETICS; ION CHANNELS; PHARMACOLOGICAL-PROPERTIES	Voltage-gated ion channels regulate many physiological functions and are targets for a number of drugs. Patch-clamp electrophysiology is the standard method for measuring channel activity because it fulfils the requirements for voltage control, repetitive stimulation and high temporal resolution, but it is laborious and costly. Here we report an electro-optical technology and automated instrument, called the electrical stimulation voltage ion probe reader (E-VIPR), that measures the activity of voltage-gated ion channels using extracellular electrical field stimulation and voltage-sensitive fluorescent probes. We demonstrate that E-VIPR can sensitively detect drug potency and mechanism of block on the neuronal human type III voltage-gated sodium channel expressed in human embryonic kidney cells. Results are compared with voltage-clamp and show that E-VIPR provides sensitive and information-rich compound blocking activity. Furthermore, we screened similar to 400 drugs and observed sodium channel-blocking activity for similar to 25% of them, including the antidepressants sertraline (Zoloft) and paroxetine (Paxil).	Vertex Pharmaceut Inc, San Diego, CA 92121 USA	Vertex Pharmaceuticals	Gonzalez, JE (corresponding author), Vertex Pharmaceut Inc, 11010 Torreyana Rd, San Diego, CA 92121 USA.	Tito_Gonzalez@sd.vrtx.com	Maher, Michael/R-9773-2019	Maher, Michael/0000-0001-9138-0448				Abdi S, 1998, ANESTH ANALG, V87, P1360, DOI 10.1097/00000539-199812000-00027; Akiba I, 2003, RECEPTOR CHANNEL, V9, P291, DOI 10.3109/713745174; Basser PJ, 2000, ANNU REV BIOMED ENG, V2, P377, DOI 10.1146/annurev.bioeng.2.1.377; Baxter DF, 2002, J BIOMOL SCREEN, V7, P79, DOI 10.1177/108705710200700110; Benabid AL, 2005, CR BIOL, V328, P177, DOI 10.1016/j.crvi.2004.10.011; Bennett PB, 2003, TRENDS BIOTECHNOL, V21, P563, DOI 10.1016/j.tibtech.2003.09.014; Bielefeldt K, 2002, DIGEST DIS SCI, V47, P959, DOI 10.1023/A:1015061317793; Black JA, 2004, PAIN, V108, P237, DOI 10.1016/j.pain.2003.12.035; Brau ME, 2001, ANESTHESIOLOGY, V94, P137; Burnett P, 2003, J BIOMOL SCREEN, V8, P660, DOI 10.1177/1087057103258546; Carmeliet E, 1998, PROG BIOPHYS MOL BIO, V70, P1, DOI 10.1016/S0079-6107(98)00002-9; Carter Gregory T, 2002, Curr Opin Investig Drugs, V3, P454; Chen YH, 2000, EUR J NEUROSCI, V12, P4281, DOI 10.1111/j.1460-9568.2000.01336.x; Clare JJ, 2000, DRUG DISCOV TODAY, V5, P506, DOI 10.1016/S1359-6446(00)01570-1; Conti F, 1996, BIOPHYS J, V71, P1295, DOI 10.1016/S0006-3495(96)79330-X; COURTNEY KR, 1975, J PHARMACOL EXP THER, V195, P225; Doran A, 2005, DRUG METAB DISPOS, V33, P165, DOI 10.1124/dmd.104.001230; EICKHORN R, 1990, PFLUG ARCH EUR J PHY, V416, P398, DOI 10.1007/BF00370746; Felix JP, 2004, ASSAY DRUG DEV TECHN, V2, P260, DOI 10.1089/1540658041410696; Gonzalez JE, 1999, DRUG DISCOV TODAY, V4, P431, DOI 10.1016/S1359-6446(99)01383-5; Gonzalez JE, 1997, CHEM BIOL, V4, P269, DOI 10.1016/S1074-5521(97)90070-3; GONZALEZ JE, 1995, BIOPHYS J, V69, P1272, DOI 10.1016/S0006-3495(95)80029-9; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; John VH, 2004, NEUROPHARMACOLOGY, V46, P425, DOI 10.1016/j.neuropharm.2003.09.018; Kim CH, 2001, MOL BRAIN RES, V95, P153, DOI 10.1016/S0169-328X(01)00226-1; Kuo CC, 1997, BRIT J PHARMACOL, V121, P1231, DOI 10.1038/sj.bjp.0701221; LANG DG, 1993, J PHARMACOL EXP THER, V266, P829; Leffler A, 2005, PFLUG ARCH EUR J PHY, V451, P454, DOI 10.1007/s00424-005-1463-x; Lenkowski PW, 2003, EUR J PHARMACOL, V467, P23, DOI 10.1016/S0014-2999(03)01595-4; MAHER MP, 2005, Patent No. 6969449; MAHER MP, 2004, Patent No. 6686193; Maizels M, 2005, AM FAM PHYSICIAN, V71, P483; Mao JR, 2000, PAIN, V87, P7, DOI 10.1016/S0304-3959(00)00229-3; Nau C, 2000, J PHARMACOL EXP THER, V292, P1015; Pera M., 1992, AMBIGUOUS FROG GALVA; POSTMA SW, 1984, MOL PHARMACOL, V25, P219; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; ROTH BJ, 1994, CRIT REV BIOMED ENG, V22, P253; Scholz A, 2002, BRIT J ANAESTH, V89, P52, DOI 10.1093/bja/aef163; Schroeder K, 2003, J BIOMOL SCREEN, V8, P50, DOI 10.1177/1087057102239667; Schulz M, 2003, PHARMAZIE, V58, P447; Song JH, 1997, J PHARMACOL EXP THER, V282, P707; TOMIKO SA, 1986, BIOCHEMISTRY-US, V25, P2162, DOI 10.1021/bi00356a047; Vickery RG, 2004, RECEPTOR CHANNEL, V10, P11, DOI 10.1080/10606820490270410; Wang GK, 2004, PAIN, V110, P166, DOI 10.1016/j.pain.2004.03.018; White HS, 1999, EPILEPSIA, V40, pS2, DOI 10.1111/j.1528-1157.1999.tb00913.x; Wood C, 2004, DRUG DISCOV TODAY, V9, P434, DOI 10.1016/S1359-6446(04)03064-8; Worley JF, 2002, RECEPTOR CHANNEL, V8, P269, DOI 10.1080/10606820290005335; XIE XM, 1995, PFLUG ARCH EUR J PHY, V430, P437, DOI 10.1007/BF00373920; Yang YC, 2002, MOL PHARMACOL, V62, P1228, DOI 10.1124/mol.62.5.1228; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zheng W, 2004, ASSAY DRUG DEV TECHN, V2, P543, DOI 10.1089/1540658042584143	52	90	99	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2006	24	4					439	446		10.1038/nbt1194	http://dx.doi.org/10.1038/nbt1194			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	032HU	16550174				2022-12-25	WOS:000236766300028
J	Schauer, N; Semel, Y; Roessner, U; Gur, A; Balbo, I; Carrari, F; Pleban, T; Perez-Melis, A; Bruedigam, C; Kopka, J; Willmitzer, L; Zamir, D; Fernie, AR				Schauer, N; Semel, Y; Roessner, U; Gur, A; Balbo, I; Carrari, F; Pleban, T; Perez-Melis, A; Bruedigam, C; Kopka, J; Willmitzer, L; Zamir, D; Fernie, AR			Comprehensive metabolic profiling and phenotyping of interspecific introgression lines for tomato improvement	NATURE BIOTECHNOLOGY			English	Article							QUANTITATIVE TRAIT; LYCOPERSICON-PENNELLII; MESSENGER-RNA; SUGAR CONTENT; QTL ANALYSIS; FRUIT; GENE; EXPRESSION; NETWORKS; GENOMICS	Tomato represents an important source of fiber and nutrients in the human diet and is a central model for the study of fruit biology. To identify components of fruit metabolic composition, here we have phenotyped tomato introgression lines (ILs) containing chromosome segments of a wild species in the genetic background of a cultivated variety. Using this high-diversity population, we identify 889 quantitative fruit metabolic loci and 326 loci that modify yield-associated traits. The mapping analysis indicates that at least 50% of the metabolic loci are associated with quantitative trait loci (QTLs) that modify whole-plant yield-associated traits. We generate a cartographic network based on correlation analysis that reveals whole-plant phenotype associated and independent metabolic associations, including links with metabolites of nutritional and organoleptic importance. The results of our genomic survey illustrate the power of genome-wide metabolic profiling and detailed morphological analysis for uncovering traits with potential for crop breeding.	Max Planck Inst Mol Pflanzenphysiol, D-14476 Golm, Germany; Hebrew Univ Jerusalem, Fac Agr, Inst Plant Sci & Genet, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Fac Agr, Otto Warburg Ctr Biotechnol, IL-76100 Rehovot, Israel	Max Planck Society; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Fernie, AR (corresponding author), Max Planck Inst Mol Pflanzenphysiol, Muhlengerg 1, D-14476 Golm, Germany.	fernie@mpimp-golm.mpg.de	Willmitzer, Lothar/F-7377-2011; Bruedigam, Claudia/P-6326-2018; Bruedigam, Claudia/ABC-8681-2020; Gur, Amit/AFT-6744-2022; Roessner, Ute/E-9446-2015	Bruedigam, Claudia/0000-0002-9580-1446; Bruedigam, Claudia/0000-0002-9580-1446; Roessner, Ute/0000-0002-6482-2615; Kopka, Joachim/0000-0001-9675-4883				Alba R, 2005, PLANT CELL, V17, P2954, DOI 10.1105/tpc.105.036053; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Baxter CJ, 2005, PLANT CELL PHYSIOL, V46, P425, DOI 10.1093/pcp/pci040; Bovy A, 2002, PLANT CELL, V14, P2509, DOI 10.1105/tpc.004218; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Brown JKM, 2002, CURR OPIN PLANT BIOL, V5, P339, DOI 10.1016/S1369-5266(02)00270-4; Causse M, 2004, J EXP BOT, V55, P1671, DOI 10.1093/jxb/erh207; Causse M, 2002, J EXP BOT, V53, P2089, DOI 10.1093/jxb/erf058; Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518; Davuluri GR, 2004, PLANT J, V40, P344, DOI 10.1111/j.1365-313X.2004.02218.x; Dudley NR, 2005, METH MOL B, V309, P29; EMERY GC, 1970, J AM SOC HORTIC SCI, V95, P51; ESHED Y, 1995, GENETICS, V141, P1147; Fernie AR, 2004, NAT REV MOL CELL BIO, V5, P763, DOI 10.1038/nrm1451; Fernie AR, 2004, HDB PLANT BIOTECHNOL; Fridman E, 2004, SCIENCE, V305, P1786, DOI 10.1126/science.1101666; Fridman E, 2000, P NATL ACAD SCI USA, V97, P4718, DOI 10.1073/pnas.97.9.4718; Fridman E, 2002, MOL GENET GENOMICS, V266, P821, DOI 10.1007/s00438-001-0599-4; Fulton TM, 2002, EUPHYTICA, V127, P163, DOI 10.1023/A:1020209930031; Galili G, 2002, METAB ENG, V4, P3, DOI 10.1006/mben.2001.0203; Gibon Y, 2004, PLANT CELL, V16, P3304, DOI 10.1105/tpc.104.025973; Giovannoni J, 2001, ANNU REV PLANT PHYS, V52, P725, DOI 10.1146/annurev.arplant.52.1.725; Grandillo S, 1999, EUPHYTICA, V110, P85, DOI 10.1023/A:1003760015485; Guimera R, 2005, NATURE, V433, P895, DOI 10.1038/nature03288; Gur A, 2004, TRENDS PLANT SCI, V9, P107, DOI 10.1016/j.tplants.2004.01.003; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Huang T, 2005, SCIENCE, V309, P1694, DOI 10.1126/science.1117768; Kissebah AH, 2000, OBES RES, V8, p4S; Kliebenstein DJ, 2001, PLANT PHYSIOL, V126, P811, DOI 10.1104/pp.126.2.811; Koyama H, 2000, PLANT CELL PHYSIOL, V41, P1030, DOI 10.1093/pcp/pcd029; Liu YS, 2003, PLANT BIOTECHNOL J, V1, P195, DOI 10.1046/j.1467-7652.2003.00018.x; Lumba S, 2005, CURR OPIN PLANT BIOL, V8, P501, DOI 10.1016/j.pbi.2005.07.015; McCouch S, 2004, PLOS BIOL, V2, P1507, DOI 10.1371/journal.pbio.0020347; Montooth KL, 2000, AM ZOOL, V40, P1135; Moose SP, 2004, TRENDS PLANT SCI, V9, P358, DOI 10.1016/j.tplants.2004.05.005; Mueller LA, 2005, COMP FUNCT GENOM, V6, P153, DOI 10.1002/cfg.468; Oksman-Caldentey KM, 2005, CURR OPIN BIOTECH, V16, P174, DOI 10.1016/j.copbio.2005.02.007; Pnueli L, 1998, DEVELOPMENT, V125, P1979; Raamsdonk LM, 2001, NAT BIOTECHNOL, V19, P45, DOI 10.1038/83496; Roessner U, 2001, PLANT CELL, V13, P11, DOI 10.1105/tpc.13.1.11; Roessner-Tunali U, 2003, PLANT PHYSIOL, V133, P84, DOI 10.1104/pp.103.023572; Rousseaux MC, 2005, THEOR APPL GENET, V111, P1396, DOI 10.1007/s00122-005-0071-7; Schauer N, 2005, J EXP BOT, V56, P297, DOI 10.1093/jxb/eri057; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; Stitt M, 2003, CURR OPIN BIOTECH, V14, P136, DOI 10.1016/S0958-1669(03)00023-5; Tanksley SD, 1997, SCIENCE, V277, P1063, DOI 10.1126/science.277.5329.1063; Weckwerth W, 2004, P NATL ACAD SCI USA, V101, P7809, DOI 10.1073/pnas.0303415101; Wigge PA, 2005, SCIENCE, V309, P1056, DOI 10.1126/science.1114358; Zamir D, 2001, NAT REV GENET, V2, P983, DOI 10.1038/35103590	49	542	574	6	163	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2006	24	4					447	454		10.1038/nbt1192	http://dx.doi.org/10.1038/nbt1192			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	032HU	16531992				2022-12-25	WOS:000236766300029
J	Bohnsack, MT; Stuven, T; Kuhn, C; Cordes, VC; Gorlich, D				Bohnsack, MT; Stuven, T; Kuhn, C; Cordes, VC; Gorlich, D			A selective block of nuclear actin export stabilizes the giant nuclei of Xenopus oocytes	NATURE CELL BIOLOGY			English	Article							PORE COMPLEXES; NUCLEOCYTOPLASMIC TRANSPORT; CYTOPLASMIC ACTIN; TRANSFER-RNA; DIMETHYLSULFOXIDE; TRANSCRIPTION; PROTEINS; INDUCTION; MIGRATION; MEDIATOR	Actin is a major cytoskeletal element and is normally kept cytoplasmic by exportin 6 (Exp6)-driven nuclear export. Here, we show that Exp6 recognizes actin features that are conserved from yeast to human. Surprisingly however, microinjected actin was not exported from Xenopus laevis oocyte nuclei, unless Exp6 was co-injected, indicating that the pathway is inactive in this cell type. Indeed, Exp6 is undetectable in oocytes, but is synthesized from meiotic maturation onwards, which explains how actin export resumes later in embryogenesis. Exp6 thus represents the first example of a strictly developmentally regulated nuclear transport pathway. We asked why Xenopus oocytes lack Exp6 and observed that ectopic application of Exp6 renders the giant oocyte nuclei extremely fragile. This effect correlates with the selective disappearance of a sponge-like intranuclear scaffold of F-actin. These nuclei have a normal G2-phase DNA content in a volume 100,000 times larger than nuclei of somatic cells. Apparently, their mechanical integrity cannot be maintained by chromatin and the associated nuclear matrix, but instead requires an intranuclear actin-scaffold.	Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Gorlich, D (corresponding author), Heidelberg Univ, Zentrum Mol Biol, INF 282, D-69120 Heidelberg, Germany.	dg@zmbh.uni-heidelberg.de	Bohnsack, Markus T./D-3076-2011; Görlich, Dirk/B-8296-2017	Bohnsack, Markus T./0000-0001-7063-5456; Görlich, Dirk/0000-0002-4343-5210				AEBI U, 1986, ANN NY ACAD SCI, V483, P100, DOI 10.1111/j.1749-6632.1986.tb34502.x; Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370; Blessing CA, 2004, TRENDS CELL BIOL, V14, P435, DOI 10.1016/j.tcb.2004.07.009; Boal D. H., 2002, MECH CELL; Bohnsack MT, 2002, EMBO J, V21, P6205, DOI 10.1093/emboj/cdf613; Calado A, 2002, EMBO J, V21, P6216, DOI 10.1093/emboj/cdf620; CLARK TG, 1977, CELL, V12, P883, DOI 10.1016/0092-8674(77)90152-0; Cordes VC, 1997, EXP CELL RES, V237, P419, DOI 10.1006/excr.1997.3806; Dahl KN, 2004, J CELL SCI, V117, P4779, DOI 10.1242/jcs.01357; DANCKER P, 1975, BIOCHIM BIOPHYS ACTA, V400, P407, DOI 10.1016/0005-2795(75)90196-8; DEROBERTIS EM, 1978, NATURE, V272, P254, DOI 10.1038/272254a0; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; FUKUI Y, 1979, EXP CELL RES, V120, P451, DOI 10.1016/0014-4827(79)90412-9; Gard DL, 1999, MICROSC RES TECHNIQ, V44, P388; Gonsior SM, 1999, J CELL SCI, V112, P797; Gorlich D, 2003, EMBO J, V22, P1088, DOI 10.1093/emboj/cdg113; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Handwerger KE, 2005, MOL BIOL CELL, V16, P202, DOI 10.1091/mbc.E04-08-0742; Hausen P., 1991, EARLY DEV XENOPUS LA; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; Hu P, 2004, GENE DEV, V18, P3010, DOI 10.1101/gad.1250804; IIDA K, 1986, EXP CELL RES, V165, P207, DOI 10.1016/0014-4827(86)90545-8; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kiseleva E, 2004, J CELL SCI, V117, P2481, DOI 10.1242/jcs.01098; Kwak IH, 2004, CANCER RES, V64, P572, DOI 10.1158/0008-5472.CAN-03-1856; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Mingot JM, 2004, EMBO J, V23, P3227, DOI 10.1038/sj.emboj.7600338; Mingot JM, 2001, EMBO J, V20, P3685, DOI 10.1093/emboj/20.14.3685; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; OSBORN M, 1980, EXP CELL RES, V129, P103, DOI 10.1016/0014-4827(80)90335-3; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Pollard TD, 2002, CELL BIOL; Ribbeck K, 2002, EMBO J, V21, P2664, DOI 10.1093/emboj/21.11.2664; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Roeder Amy D., 1994, Zygote, V2, P111; SANGER JW, 1980, J EXP ZOOL, V213, P227, DOI 10.1002/jez.1402130210; SCHEER U, 1984, CELL, V39, P111, DOI 10.1016/0092-8674(84)90196-X; Stuven T, 2003, EMBO J, V22, P5928, DOI 10.1093/emboj/cdg565; THIEBAUD CH, 1977, CHROMOSOMA, V59, P253, DOI 10.1007/BF00292781; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X	43	123	132	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2006	8	3					257	263		10.1038/ncb1357	http://dx.doi.org/10.1038/ncb1357			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	017QL	16489345	Green Published			2022-12-25	WOS:000235708000011
J	Dunoyer, P; Himber, C; Voinnet, O				Dunoyer, P; Himber, C; Voinnet, O			Induction, suppression and requirement of RNA silencing pathways in virulent Agrobacterium tumefaciens infections	NATURE GENETICS			English	Article							T-DNA INTEGRATION; INTERFERING RNA; CO-SUPPRESSION; GENE; ARABIDOPSIS; MICRORNA; VIRUS; PLANTS; TRANS; STEP	Regulation of gene expression through microRNAs ( miRNAs) and antiviral defense through small interfering RNAs (siRNAs) are aspects of RNA silencing(1), a process originally discovered as an unintended consequence of plant transformation by disarmed Agrobacterium tumefaciens strains(2). Although RNA silencing protects cells against foreign genetic elements(3), its defensive role against virulent, tumor-inducing bacteria has remained unexplored. Here, we show that siRNAs corresponding to transferred-DNA oncogenes initially accumulate in virulent A. tumefaciens - infected tissues and that RNA interference - deficient plants are hypersusceptible to the pathogen. Successful infection relies on a potent antisilencing state established in tumors whereby siRNA synthesis is specifically inhibited. This inhibition has only modest side effects on the miRNA pathway, shown here to be essential for disease development. The similarities and specificities of the A. tumefaciens RNA silencing interaction are discussed and contrasted with the situation encountered with plant viruses.	IBMP, CNRS, UPR2357, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Voinnet, O (corresponding author), IBMP, CNRS, UPR2357, Strasbourg, France.	olivier.voinnet@ibmp-ulp.u-strasbg.fr		Voinnet, Olivier/0000-0001-6982-9544				Allen E, 2005, CELL, V121, P207, DOI 10.1016/j.cell.2005.04.004; Bartel B, 2003, PLANT PHYSIOL, V132, P709, DOI 10.1104/pp.103.023630; Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Chapman EJ, 2004, GENE DEV, V18, P1179, DOI 10.1101/gad.1201204; Chateau S, 2000, J EXP BOT, V51, P1961, DOI 10.1093/jexbot/51.353.1961; Cluster PD, 1996, PLANT MOL BIOL, V32, P1197, DOI 10.1007/BF00041406; Dalmay T, 2000, PLANT CELL, V12, P369, DOI 10.1105/tpc.12.3.369; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Dunoyer P, 2004, PLANT CELL, V16, P1235, DOI 10.1105/tpc.020719; Ekwall K, 2004, MOL CELL, V13, P304, DOI 10.1016/S1097-2765(04)00057-7; Escobar MA, 2003, TRENDS PLANT SCI, V8, P380, DOI 10.1016/S1360-1385(03)00162-6; Gasciolli V, 2005, CURR BIOL, V15, P1494, DOI 10.1016/j.cub.2005.07.024; Gazzani S, 2004, SCIENCE, V306, P1046, DOI 10.1126/science.1101092; Gelvin SB, 2005, NATURE, V433, P583, DOI 10.1038/433583a; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Himber C, 2003, EMBO J, V22, P4523, DOI 10.1093/emboj/cdg431; HOOD EE, 1986, J BACTERIOL, V168, P1291, DOI 10.1128/jb.168.3.1291-1301.1986; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; Jones-Rhoades MW, 2004, MOL CELL, V14, P787, DOI 10.1016/j.molcel.2004.05.027; Nam J, 1997, PLANT CELL, V9, P317, DOI 10.1105/tpc.9.3.317; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; OOMS G, 1982, CELL, V30, P589, DOI 10.1016/0092-8674(82)90255-0; Parizotto EA, 2004, GENE DEV, V18, P2237, DOI 10.1101/gad.307804; Tzfira T, 2004, TRENDS GENET, V20, P375, DOI 10.1016/j.tig.2004.06.004; Voinnet O, 2005, NAT REV GENET, V6, P206, DOI 10.1038/nrg1555; Voinnet O, 2003, PLANT J, V33, P949, DOI 10.1046/j.1365-313X.2003.01676.x; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Yu B, 2005, SCIENCE, V307, P932, DOI 10.1126/science.1107130	30	96	106	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2006	38	2					258	263		10.1038/ng1722	http://dx.doi.org/10.1038/ng1722			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16429161				2022-12-25	WOS:000234953200025
J	Taieb, J; Chaput, N; Menard, C; Apetoh, L; Ullrich, E; Bonmort, M; Pequignot, M; Casares, N; Terme, M; Flament, C; Opolon, P; Lecluse, Y; Metivier, D; Tomasello, E; Vivier, E; Ghiringhelli, F; Martin, F; Klatzmann, D; Poynard, T; Tursz, T; Raposo, G; Yagita, H; Ryffel, B; Kroemer, G; Zitvogel, L				Taieb, J; Chaput, N; Menard, C; Apetoh, L; Ullrich, E; Bonmort, M; Pequignot, M; Casares, N; Terme, M; Flament, C; Opolon, P; Lecluse, Y; Metivier, D; Tomasello, E; Vivier, E; Ghiringhelli, F; Martin, F; Klatzmann, D; Poynard, T; Tursz, T; Raposo, G; Yagita, H; Ryffel, B; Kroemer, G; Zitvogel, L			A novel dendritic cell subset involved in tumor immunosurveillance	NATURE MEDICINE			English	Article							INTERFERON-GAMMA; IFN-GAMMA; TRAIL; CANCER; IMMUNOTHERAPY; MACROPHAGES; RECEPTORS; APOPTOSIS; IMATINIB; PATHWAY	The interferon (IFN)-gamma-induced TRAIL effector mechanism is a vital component of cancer immunosurveillance by natural killer (NK) cells in mice(1,2). Here we show that the main source of IFN-gamma is not the conventional NK cell but a subset of B220(+)Ly6C(-) dendritic cells, which are atypical insofar as they express NK cell-surface molecules. Upon contact with a variety of tumor cells that are poorly recognized by NK cells, B220(+)NK1.1(+) dendritic cells secrete high levels of IFN-gamma and mediate TRAIL-dependent lysis of tumor cells. Adoptive transfer of these IFN-producing killer dendritic cells (IKDCs) into tumor-bearing Rag2(-/-)Il2rg(-/-) mice prevented tumor outgrowth, whereas transfer of conventional NK cells did not. In conclusion, we identified IKDCs as pivotal sensors and effectors of the innate antitumor immune response.	Inst Gustave Roussy, Fac Med Kremlin Bicetre, INSERM, ERM0208, Villejuif, France; Inst Gustave Roussy, CNRS, UMR8125, Villejuif, France; Inst Gustave Roussy, IFR54, Flow Cytometry Core Facil, Villejuif, France; Univ Mediterranee, Ctr Immunol Marseille Luminy, CNRS, INSERM, Marseille, France; Fac Med, INSERM, U517, Dijon, France; Grp Hosp Pitie Salpetriere, CERVI, UPMC, CNRS,UMR7087, F-75634 Paris, France; Hop La Pitie Salpetriere, AH HP, Dept Gastroenterol, Paris, France; Inst Curie, CNRS, UMR144, F-75231 Paris, France; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; Inst Transgenose, CNRS, IEM 2815, Orleans, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Juntendo University; Centre National de la Recherche Scientifique (CNRS)	Zitvogel, L (corresponding author), Inst Gustave Roussy, Fac Med Kremlin Bicetre, INSERM, ERM0208, Villejuif, France.	zitvogel@igr.fr	Poynard, Thierry/C-1355-2010; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Vivier, Eric/F-8939-2010; Apetoh, Lionel/G-3310-2014; TERME, Magali/GZK-9661-2022; Serei, Virian D/B-4616-2015; Casares, Noelia/AAA-5568-2019; Pequignot, Marie O/P-1994-2017; Ménard, Cédric/AAB-3180-2020	Poynard, Thierry/0000-0002-3726-7230; KROEMER, Guido/0000-0002-9334-4405; Vivier, Eric/0000-0001-7022-8287; Apetoh, Lionel/0000-0002-2774-438X; TERME, Magali/0000-0003-0857-7237; Casares, Noelia/0000-0003-3817-6434; Ménard, Cédric/0000-0002-2207-361X; Raposo, graca/0000-0001-9590-1298; ghiringhelli, francois/0000-0002-5465-8305; Klatzmann, David/0000-0002-0054-3422; Tomasello, Elena/0000-0002-6839-5219; Ullrich, Evelyn/0000-0001-8530-1192; ZITVOGEL, laurence/0000-0003-1596-0998; Poynard, Thierry/0000-0002-2050-640X; Pequignot, Marie/0000-0002-8866-3778				Bonnotte B, 2001, J IMMUNOL, V167, P5077, DOI 10.4049/jimmunol.167.9.5077; Borg C, 2004, J CLIN INVEST, V114, P379, DOI 10.1172/jci20041102; CHAN CW, IN PRESS NAT MED; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Durali D, 2003, BLOOD, V102, P4084, DOI 10.1182/blood-2003-02-0518; Fukao T, 2000, J IMMUNOL, V164, P64, DOI 10.4049/jimmunol.164.1.64; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; Hochrein H, 2001, J IMMUNOL, V166, P5448, DOI 10.4049/jimmunol.166.9.5448; Homann D, 2002, IMMUNITY, V16, P403, DOI 10.1016/S1074-7613(02)00290-X; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Mohty M, 2004, BLOOD, V103, P4666, DOI 10.1182/blood-2003-09-3220; Munder M, 1998, J EXP MED, V187, P2103, DOI 10.1084/jem.187.12.2103; Ohteki T, 1999, J EXP MED, V189, P1981, DOI 10.1084/jem.189.12.1981; Pelayo R, 2005, BLOOD, V105, P4407, DOI 10.1182/blood-2004-07-2529; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shin EC, 2001, INT J CANCER, V93, P262, DOI 10.1002/ijc.1310; Smyth MJ, 2004, J EXP MED, V200, P1325, DOI 10.1084/jem.20041522; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Trinite B, 2000, J IMMUNOL, V165, P4202, DOI 10.4049/jimmunol.165.8.4202; Vidalain PO, 2000, J VIROL, V74, P556, DOI 10.1128/JVI.74.1.556-559.2000; Wang HW, 2005, BLOOD, V105, P1135, DOI 10.1182/blood-2004-01-0027; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x	26	320	347	2	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					214	219		10.1038/nm1356	http://dx.doi.org/10.1038/nm1356			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16444265				2022-12-25	WOS:000235160600026
J	Toebes, M; Coccoris, M; Bins, A; Rodenko, B; Gomez, R; Nieuwkoop, NJ; van de Kasteele, W; Rimmelzwaan, GF; Haanen, JBAG; Ovaa, H; Schumacher, TNM				Toebes, M; Coccoris, M; Bins, A; Rodenko, B; Gomez, R; Nieuwkoop, NJ; van de Kasteele, W; Rimmelzwaan, GF; Haanen, JBAG; Ovaa, H; Schumacher, TNM			Design and use of conditional MHC class I ligands	NATURE MEDICINE			English	Article							STEM-CELL TRANSPLANTATION; T-LYMPHOCYTES; REACTIVE CTL; PEPTIDE; MOLECULES; CYTOMEGALOVIRUS; TETRAMERS; INFECTION; RESPONSES; SELECTION	Major histocompatibility complex (MHC) class I molecules associate with a variety of peptide ligands during biosynthesis and present these ligands on the cell surface for recognition by cytotoxic T cells. We have designed conditional MHC ligands that form stable complexes with MHC molecules but degrade on command, by exposure to a defined photostimulus. 'Empty MHC molecules' generated in this manner can be loaded with arrays of peptide ligands to determine MHC binding properties and to monitor antigen-specific T-cell responses in a high-throughput manner. We document the value of this approach by identifying cytotoxic T-cell epitopes within the H5N1 influenza A/Vietnam/1194/04 genome.	Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Erasmus MC, Dept Virol, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, WHO, Natl Influenza Ctr, NL-3000 DR Rotterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; World Health Organization	Schumacher, TNM (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.ovaa@nki.nl; t.schumacher@nki.nl	Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Schumacher, Ton/Y-2432-2019; Rodenko, Boris/E-5492-2010; ovaa, huib/M-2334-2016	Haanen, John/0000-0001-5884-7704; Schumacher, Ton/0000-0003-0517-8804; Rodenko, Boris/0000-0001-5223-4296; ovaa, huib/0000-0002-0068-054X; Bins, Adriaan/0000-0002-9794-6526				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bins AD, 2005, NAT MED, V11, P899, DOI 10.1038/nm1264; Bosques CJ, 2003, J AM CHEM SOC, V125, P7530, DOI 10.1021/ja035360b; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; Choi EM, 2002, J IMMUNOL METHODS, V268, P35, DOI 10.1016/S0022-1759(02)00198-9; Cobbold M, 2005, J EXP MED, V202, P379, DOI 10.1084/jem.20040613; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Falkenburg JHF, 2003, EXP HEMATOL, V31, P743, DOI 10.1016/S0301-472X(03)00190-5; Firat H, 1999, EUR J IMMUNOL, V29, P3112, DOI 10.1002/(SICI)1521-4141(199910)29:10<3112::AID-IMMU3112>3.0.CO;2-Q; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Moss P, 2005, NAT REV IMMUNOL, V5, P9, DOI 10.1038/nri1526; Oelke M, 2004, CLIN IMMUNOL, V110, P243, DOI 10.1016/j.clim.2003.11.014; Peggs KS, 2003, LANCET, V362, P1375, DOI 10.1016/S0140-6736(03)14634-X; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; Soen Y, 2003, PLOS BIOL, V1, P429, DOI 10.1371/journal.pbio.0000065; Stone JD, 2005, P NATL ACAD SCI USA, V102, P3744, DOI 10.1073/pnas.0407019102; Sulyok GAG, 2001, J MED CHEM, V44, P1938, DOI 10.1021/jm0004953; Valmori D, 1998, J IMMUNOL, V160, P1750; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wieboldt R, 2002, J ORG CHEM, V67, P8827, DOI 10.1021/jo0201373; Yee C, 1999, J IMMUNOL, V162, P2227	30	249	275	2	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2006	12	2					246	251		10.1038/nm1360	http://dx.doi.org/10.1038/nm1360			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16462803				2022-12-25	WOS:000235160600032
J	Watt, PM				Watt, PM			Screening for peptide drugs from the natural repertoire of biodiverse protein folds	NATURE BIOTECHNOLOGY			English	Article							SMALL-MOLECULE ANTAGONISTS; KINASE INTERACTION MOTIF; GENETIC SELECTION; IN-VITRO; INHIBITORS; FAMILIES; HIV-1; SEQUENCES; INTEGRASE; DOMAIN	Although monoclonal antibody (mAb) drugs targeting protein interactions exist, these therapeutics cannot access intracellular proteins involved in disease complexes. Moreover, mAbs are more difficult to deliver and are frequently associated with a prohibitive 'royaltystack.' Outlined here is an alternative approach based on libraries of natural, highly structured peptides that offers new opportunities for identifying effective, specific inhibitors of protein-protein interactions. Libraries of such peptides ( referred to hereafter as phylomers) comprise both random and structured peptides encoded by natural genes of diverse bacterial genomes. Because the number of protein subdomain structures found in nature is limited, diverse libraries containing millions of phylomers constitute virtually all of the available classes of protein fold structures, providing a rich source of peptides that interact specifically and with high affinity to human proteins. This approach may help not only in understanding the implications of each interaction identified within the interactome but also in the development of effective drugs targeted to particular protein functions. Although phylomers are active in animal models, the challenge remains to demonstrate efficacy and safety in a clinical setting.	Phylog Ltd, Perth, WA 6008, Australia		Watt, PM (corresponding author), Phylog Ltd, 105 Roberts Rd, Perth, WA 6008, Australia.	paulw@phylogica.com						ADLER M, 1995, J BIOL CHEM, V270, P23366, DOI 10.1074/jbc.270.40.23366; Archakov AI, 2003, PROTEOMICS, V3, P380, DOI 10.1002/pmic.200390053; Barr RK, 2004, J BIOL CHEM, V279, P43178, DOI 10.1074/jbc.M405900200; Barr RK, 2004, J BIOL CHEM, V279, P36327, DOI 10.1074/jbc.M402181200; Baud F, 1999, P NATL ACAD SCI USA, V96, P12494, DOI 10.1073/pnas.96.22.12494; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Bleicher KH, 2003, NAT REV DRUG DISCOV, V2, P369, DOI 10.1038/nrd1086; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Bray BL, 2003, NAT REV DRUG DISCOV, V2, P587, DOI 10.1038/nrd1133; Caponigro G, 1998, P NATL ACAD SCI USA, V95, P7508, DOI 10.1073/pnas.95.13.7508; Chan B, 2005, P NATL ACAD SCI USA, V102, P13075, DOI 10.1073/pnas.0503846102; Chirino AJ, 2004, DRUG DISCOV TODAY, V9, P82, DOI 10.1016/S1359-6446(03)02953-2; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Coulson AFW, 2002, PROTEINS, V46, P61, DOI 10.1002/prot.10011; Cudic M, 2003, PEPTIDES, V24, P807, DOI 10.1016/S0196-9781(03)00172-4; Cudic M, 2002, PEPTIDES, V23, P2071, DOI 10.1016/S0196-9781(02)00244-9; Cudic M, 2002, BIOORGAN MED CHEM, V10, P3859, DOI 10.1016/S0968-0896(02)00388-7; Cudic M, 2002, CURR DRUG TARGETS, V3, P101, DOI 10.2174/1389450024605445; Cudic P, 2002, CHEM BIOL, V9, P897, DOI 10.1016/S1074-5521(02)00191-6; Cudic P, 2002, P NATL ACAD SCI USA, V99, P7384, DOI 10.1073/pnas.102192099; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; de Soultrait VR, 2002, J MOL BIOL, V318, P45, DOI 10.1016/S0022-2836(02)00033-5; Ernst JT, 2003, ANGEW CHEM INT EDIT, V42, P535, DOI 10.1002/anie.200390154; Fischer PM, 2004, TRENDS PHARMACOL SCI, V25, P343, DOI 10.1016/j.tips.2004.04.011; Gonzales NR, 2005, TUMOR BIOL, V26, P31, DOI 10.1159/000084184; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Harrison A, 2003, BIOINFORMATICS, V19, P1748, DOI 10.1093/bioinformatics/btg240; Irback A, 1996, P NATL ACAD SCI USA, V93, P9533, DOI 10.1073/pnas.93.18.9533; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Koch MA, 2005, DRUG DISCOV TODAY, V10, P471, DOI 10.1016/S1359-6446(05)03419-7; Ladner RC, 2001, CURR OPIN BIOTECH, V12, P406, DOI 10.1016/S0958-1669(00)00235-4; Lewis RJ, 2003, NAT REV DRUG DISCOV, V2, P790, DOI 10.1038/nrd1197; Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200; Maroun RG, 2001, BIOCHEMISTRY-US, V40, P13840, DOI 10.1021/bi011328n; Matthews LJ, 2002, J IMMUNOL, V169, P837, DOI 10.4049/jimmunol.169.2.837; Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331; Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710; Nibbering PH, 2001, INFECT IMMUN, V69, P1469, DOI 10.1128/IAI.69.3.1469-1476.2001; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; PANDE VS, 1994, P NATL ACAD SCI USA, V91, P12972, DOI 10.1073/pnas.91.26.12972; Parish CA, 2001, BIOORGAN MED CHEM, V9, P377; Parissi V, 2001, J VIROL, V75, P11344, DOI 10.1128/JVI.75.23.11344-11353.2001; Park HS, 2002, P NATL ACAD SCI USA, V99, P5105, DOI 10.1073/pnas.082675899; Park SH, 2000, NAT BIOTECHNOL, V18, P847, DOI 10.1038/78451; Pazos F, 2004, P NATL ACAD SCI USA, V101, P14754, DOI 10.1073/pnas.0404569101; Pritchard JF, 2003, NAT REV DRUG DISCOV, V2, P542, DOI 10.1038/nrd1131; Rappocciolo E, 2004, DRUG DISCOV TODAY, V9, P470, DOI 10.1016/S1359-6446(04)03123-X; Riechmann L, 2000, P NATL ACAD SCI USA, V97, P10068, DOI 10.1073/pnas.170145497; Schmelzl B, 2002, EMBO REP, V3, P682, DOI 10.1093/embo-reports/kvf131; Service R, 2005, SCIENCE, V307, P1554, DOI 10.1126/science.307.5715.1554; Short JM, 1997, NAT BIOTECHNOL, V15, P1322, DOI 10.1038/nbt1297-1322; Silverman J, 2005, NAT BIOTECHNOL, V23, P1556, DOI 10.1038/nbt1166; Stockton RA, 2004, J BIOL CHEM, V279, P46621, DOI 10.1074/jbc.M408877200; Strosberg AD, 2002, CURR OPIN MOL THER, V4, P594; Szymkowski DE, 2005, CURR OPIN DRUG DISC, V8, P590; Vassilev LT, 2004, CELL CYCLE, V3, P419; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vranken WF, 2002, PROTEINS, V47, P14, DOI 10.1002/prot.10077; Wheeler DA, 2004, J CLIN VIROL, V30, P183, DOI 10.1016/j.jcv.2003.10.006; Wolf YI, 2000, J MOL BIOL, V299, P897, DOI 10.1006/jmbi.2000.3786; Xu CW, 2002, ONCOGENE, V21, P5753, DOI 10.1038/sj.onc.1205680; Yang AS, 2000, J MOL BIOL, V301, P691, DOI 10.1006/jmbi.2000.3975; Zhang CT, 1997, PROTEIN ENG, V10, P757, DOI 10.1093/protein/10.7.757; Zhao L, 2003, BIOORG MED CHEM LETT, V13, P1175, DOI 10.1016/S0960-894X(03)00040-4	67	89	120	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2006	24	2					177	183		10.1038/nbt1190	http://dx.doi.org/10.1038/nbt1190			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	010XW	16465163				2022-12-25	WOS:000235232300033
J	Bayley, H				Bayley, H			Ion channels get flashy	NATURE CHEMICAL BIOLOGY			English	News Item							REMOTE-CONTROL; PROTEIN	Ion channels have essential roles in the nervous system. An engineered ligand-gated channel with a photoactivated switch will be useful for addressing several issues in neuronal signaling.	Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England	University of Oxford	Bayley, H (corresponding author), Univ Oxford, Dept Chem, Chem Res Lab, Mansfield Rd, Oxford OX1 3TA, England.	hagan.bayley@chem.ox.ac.uk		Bayley, Hagan/0000-0003-2499-6116				ASTIER Y, CURR OPIN CHEM; Banghart M, 2004, NAT NEUROSCI, V7, P1381, DOI 10.1038/nn1356; CHANG CY, 1995, CHEM BIOL, V2, P391, DOI 10.1016/1074-5521(95)90220-1; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Kocer A, 2005, SCIENCE, V309, P755, DOI 10.1126/science.1114760; Kramer RH, 2005, NAT CHEM BIOL, V1, P360, DOI 10.1038/nchembio750; LESTER HA, 1980, J GEN PHYSIOL, V75, P207, DOI 10.1085/jgp.75.2.207; Loudwig S, 2005, DYNAMIC STUDIES IN BIOLOGY: PHOTOTRIGGERS, PHOTOSWITCHES AND CAGED BIOMOLECULES, P253, DOI 10.1002/3527605592.ch5; Miller JC, 1998, NEURON, V20, P619, DOI 10.1016/S0896-6273(00)81001-6; Tour O, 2003, NAT BIOTECHNOL, V21, P1505, DOI 10.1038/nbt914; Volgraf M, 2006, NAT CHEM BIOL, V2, P47, DOI 10.1038/nchembio756	11	10	10	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2006	2	1					11	13		10.1038/nchembio0106-11	http://dx.doi.org/10.1038/nchembio0106-11			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993RC	16408083				2022-12-25	WOS:000233971600006
J	Nowack, MK; Grini, PE; Jakoby, MJ; Lafos, M; Koncz, C; Schnittger, A				Nowack, MK; Grini, PE; Jakoby, MJ; Lafos, M; Koncz, C; Schnittger, A			A positive signal from the fertilization of the egg cell sets off endosperm proliferation in angiosperm embryogenesis	NATURE GENETICS			English	Article							SEED DEVELOPMENT; ARABIDOPSIS-THALIANA; FEMALE GAMETOPHYTE; PLANT DEVELOPMENT; MUTANTS; IDENTIFICATION; EXPRESSION; KINASE; CYCLE; DIVISION	Double fertilization of the egg cell and the central cell by one sperm cell each produces the diploid embryo and the typically triploid endosperm and is one of the defining characteristics of flowering plants (angiosperms). Endosperm and embryo develop in parallel to form the mature seed, but little is known about the coordination between these two organisms. We characterized a mutation of the Arabidopsis thaliana Cdc2 homolog CDC2A ( also called CDKA; 1), which has a paternal effect. In cdc2a mutant pollen, only one sperm cell, instead of two, is produced. Mutant pollen is viable but can fertilize only one cell in the embryo sac, allowing for a genetic dissection of the double fertilization process. We observed exclusive fertilization of the egg cell by cdc2a sperm cells. Moreover, we found that unfertilized endosperm developed, suggesting that a previously unrecognized positive signal from the fertilization of the egg cell initiates proliferation of the central cell.	Univ Cologne, Lehrstuhl Bot 3, Max Delbruck Lab, Unigrp Max Planck Inst, D-50829 Cologne, Germany; Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; Max Planck Inst Zuchtungsforsch, D-50829 Cologne, Germany	Max Planck Society; University of Cologne; University of Oslo; Max Planck Society	Schnittger, A (corresponding author), Univ Cologne, Lehrstuhl Bot 3, Max Delbruck Lab, Unigrp Max Planck Inst, Carl Von Linne Weg 10, D-50829 Cologne, Germany.	schnitt@mpiz-koeln.mpg.de	Schnittger, Arp/AAO-6920-2020; chang, grace/E-2047-2012; Grini, Paul/N-5948-2019; Schnittger, Arp/F-8989-2010; Grini, Paul/H-9471-2016	Schnittger, Arp/0000-0001-7067-0091; Grini, Paul/0000-0003-3898-6277; Schnittger, Arp/0000-0001-7067-0091; Grini, Paul/0000-0003-3898-6277; Nowack, Moritz/0000-0001-8918-7577				Berger F, 2003, CURR OPIN PLANT BIOL, V6, P42, DOI 10.1016/S1369526602000043; Chaudhury AM, 1997, P NATL ACAD SCI USA, V94, P4223, DOI 10.1073/pnas.94.8.4223; Chaudhury AM, 2001, ANNU REV CELL DEV BI, V17, P677, DOI 10.1146/annurev.cellbio.17.1.677; Drews GN, 2002, ANNU REV GENET, V36, P99, DOI 10.1146/annurev.genet.36.040102.131941; Ebel C, 2004, NATURE, V429, P776, DOI 10.1038/nature02637; FERREIRA PCG, 1991, PLANT CELL, V3, P531, DOI 10.1105/tpc.3.5.531; Friedman WE, 1999, DEVELOPMENT, V126, P1065; Grini PE, 2002, GENETICS, V162, P1911; Grossniklaus U, 2001, CURR OPIN PLANT BIOL, V4, P21, DOI 10.1016/S1369-5266(00)00130-8; Guitton AE, 2004, DEVELOPMENT, V131, P2971, DOI 10.1242/dev.01168; HEMERLY A, 1995, EMBO J, V14, P3925, DOI 10.1002/j.1460-2075.1995.tb00064.x; Hemerly AS, 2000, PLANT J, V23, P123, DOI 10.1046/j.1365-313x.2000.00800.x; HIRAYAMA T, 1991, GENE, V105, P159, DOI 10.1016/0378-1119(91)90146-3; Hsieh TF, 2003, TRENDS PLANT SCI, V8, P439, DOI 10.1016/S1360-1385(03)00189-4; Leiva-Neto JT, 2004, PLANT CELL, V16, P1854, DOI 10.1105/tpc.022178; McCormick S, 2004, PLANT CELL, V16, pS142, DOI 10.1105/tpc.016659; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Rios G, 2002, PLANT J, V32, P243, DOI 10.1046/j.1365-313X.2002.01416.x; Rotman N, 2005, CURR BIOL, V15, P244, DOI 10.1016/j.cub.2005.01.013; Sessions A, 1999, PLANT J, V20, P259, DOI 10.1046/j.1365-313x.1999.00594.x; Vandepoele K, 2002, PLANT CELL, V14, P903, DOI 10.1105/tpc.010445; Vinkenoog R, 2003, MOL BIOTECHNOL, V25, P149, DOI 10.1385/MB:25:2:149	22	203	214	1	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2006	38	1					63	67		10.1038/ng1694	http://dx.doi.org/10.1038/ng1694			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16311592	Green Published			2022-12-25	WOS:000234227200018
J	Rovelet-Lecrux, A; Hannequin, D; Raux, G; Le Meur, N; Laquerriere, A; Vital, A; Dumanchin, C; Feuillette, S; Brice, A; Vercelletto, M; Dubas, F; Frebourg, T; Campion, D				Rovelet-Lecrux, A; Hannequin, D; Raux, G; Le Meur, N; Laquerriere, A; Vital, A; Dumanchin, C; Feuillette, S; Brice, A; Vercelletto, M; Dubas, F; Frebourg, T; Campion, D			APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy	NATURE GENETICS			English	Article							DOWNS-SYNDROME; DIAGNOSIS; TAU	We report duplication of the APP locus on chromosome 21 in five families with autosomal dominant early-onset Alzheimer disease (ADEOAD) and cerebral amyloid angiopathy (CAA). Among these families, the duplicated segments had a minimal size ranging from 0.58 to 6.37 Mb. Brains from individuals with APP duplication showed abundant parenchymal and vascular deposits of amyloid-beta peptides. Duplication of the APP locus, resulting in accumulation of amyloid-beta peptides, causes ADEOAD with CAA.	INSERM, U614, IFRMP, Fac Med, Rouen, France; Univ Hosp, Dept Neurol, Rouen, France; EFS Normandy, Lab Cytogenet, Bois Guillaume, France; Univ Hosp, Dept Pathol, Rouen, France; Univ Hosp, Dept Pathol, Bordeaux, France; Salpetriere Hosp, INSERM, U679, Paris, France; Univ Hosp, Dept Neurol, Nantes, France; Univ Hosp, Dept Neurol, Angers, France; CHSR, Dept Res, Sotteville Les Rouen, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Rouen; CHU de Rouen; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Nantes Universite; CHU de Nantes; Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Campion, D (corresponding author), INSERM, U614, IFRMP, Fac Med, Rouen, France.	dominique.campion@univ-rouen.fr	brice, alexis/AAE-8275-2019; Rovelet-Lecrux, Anne/AAL-4305-2020; Frebourg, Thierry/AAK-8390-2020; Brice, Alexis/A-2170-2009	brice, alexis/0000-0002-0941-3990; Frebourg, Thierry/0000-0003-0399-4007; FEUILLETTE, Sebastien/0000-0001-8042-2745				BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; DELABAR JM, 1987, SCIENCE, V235, P1390, DOI 10.1126/science.2950593; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; JACKSON JF, 1976, CLIN GENET, V9, P483; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; OYAMA F, 1994, J NEUROCHEM, V62, P1062; Prasher VP, 1998, ANN NEUROL, V43, P380, DOI 10.1002/ana.410430316; RAHMANI Z, 1989, P NATL ACAD SCI USA, V86, P5958, DOI 10.1073/pnas.86.15.5958; Raux G, 2005, J MED GENET, V42, P793, DOI 10.1136/jmg.2005.033456; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tapiola T, 2001, NEUROLOGY, V56, P979, DOI 10.1212/WNL.56.7.979; Tournier I, 2004, CANCER RES, V64, P8143, DOI 10.1158/0008-5472.CAN-04-2467; VONSATTEL JPG, 1991, ANN NEUROL, V30, P637, DOI 10.1002/ana.410300503	15	865	904	0	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2006	38	1					24	26		10.1038/ng1718	http://dx.doi.org/10.1038/ng1718			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	997EG	16369530				2022-12-25	WOS:000234227200013
J	Deutschbauer, AM; Davis, RW				Deutschbauer, AM; Davis, RW			Quantitative trait loci mapped to single-nucleotide resolution in yeast	NATURE GENETICS			English	Article							DELETION STRAINS; GENE DISRUPTION; SACCHAROMYCES; SPORULATION; GENOME; ARCHITECTURE; MUTAGENESIS; EXPRESSION; DISEASES; MEIOSIS	Identifying the genetic variation underlying quantitative trait loci remains problematic. Consequently, our molecular understanding of genetically complex, quantitative traits is limited. To address this issue directly, we mapped three quantitative trait loci that control yeast sporulation efficiency to single-nucleotide resolution in a noncoding regulatory region (RME1) and to two missense mutations (TAO3 and MKT1). For each quantitative trait locus, the responsible polymorphism is rare among a diverse set of 13 yeast strains, suggestive of genetic heterogeneity in the control of yeast sporulation. Additionally, under optimal conditions, we reconstituted similar to 92% of the sporulation efficiency difference between the two genetically distinct parents by engineering three nucleotide changes in the appropriate yeast genome. Our results provide the highest resolution to date of the molecular basis of a quantitative trait, showing that the interaction of a few genetic variants can have a profound phenotypic effect.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA	Stanford University; Stanford University	Deutschbauer, AM (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	AMDeutschbauer@lbl.gov; dbowe@stanford.edu						Brachmann CB, 1998, YEAST, V14, P115; Brem RB, 2005, P NATL ACAD SCI USA, V102, P1572, DOI 10.1073/pnas.0408709102; Briza P, 2002, YEAST, V19, P403, DOI 10.1002/yea.843; Carlborg O, 2004, NAT REV GENET, V5, P618, DOI 10.1038/nrg1407; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; CODON AC, 1995, APPL ENVIRON MICROB, V61, P630; Deutschbauer AM, 2002, P NATL ACAD SCI USA, V99, P15530, DOI 10.1073/pnas.202604399; Du LL, 2002, MOL BIOL CELL, V13, P503, DOI 10.1091/mbc.01-07-0365; Enyenihi AH, 2003, GENETICS, V163, P47; ESPOSITO RE, 1981, MEIOSIS ASCOSPORE DE; Farrall M, 2004, HUM MOL GENET, V13, pR1, DOI 10.1093/hmg/ddh084; Flint J, 2001, NAT REV GENET, V2, P437, DOI 10.1038/35076585; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gray M, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-7; Guthrie C, 1991, GUIDE YEAST GENETICS; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521; Issel-Tarver L, 2002, METHOD ENZYMOL, V350, P329, DOI 10.1016/S0076-6879(02)50972-1; Jorgensen P, 2002, GENETICS, V162, P1091; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Mackay TFC, 2001, ANNU REV GENET, V35, P303, DOI 10.1146/annurev.genet.35.102401.090633; MCCUSKER JH, 1994, GENETICS, V136, P1261; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; MITCHELL AP, 1986, NATURE, V319, P738, DOI 10.1038/319738a0; Page GP, 2003, AM J HUM GENET, V73, P711, DOI 10.1086/378900; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Rozen S, 2000, Methods Mol Biol, V132, P365; Singer JB, 2004, SCIENCE, V304, P445, DOI 10.1126/science.1093139; Steinmetz LM, 2002, NATURE, V416, P326, DOI 10.1038/416326a; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796; Tadauchi T, 2004, MOL CELL BIOL, V24, P3670, DOI 10.1128/MCB.24.9.3670-3681.2004; WICKNER RB, 1987, J BACTERIOL, V169, P4941, DOI 10.1128/jb.169.11.4941-4945.1987; Winzeler EA, 2003, GENETICS, V163, P79; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	43	177	229	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2005	37	12					1333	1340		10.1038/ng1674	http://dx.doi.org/10.1038/ng1674			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16273108				2022-12-25	WOS:000233657300012
J	Jakymiw, A; Lian, SL; Eystathioy, T; Li, SQ; Satoh, M; Hamel, JC; Fritzler, MJ; Chan, EKL				Jakymiw, A; Lian, SL; Eystathioy, T; Li, SQ; Satoh, M; Hamel, JC; Fritzler, MJ; Chan, EKL			Disruption of GW bodies impairs mammalian RNA interference	NATURE CELL BIOLOGY			English	Article							MESSENGER-RNA; CYTOPLASMIC AUTOANTIGEN; HUMAN-CELLS; P-BODIES; GW182; COMPLEX; LOCALIZATION; PROTEINS; SIRNAS; DECAY	The GW182 RNA-binding protein was initially shown to associate with a specific subset of mRNAs and to reside within discrete cytoplasmic foci named GW bodies (GWBs)(1). GWBs are enriched in proteins that are involved in mRNA degradation(2). Recent reports have shown that exogenously introduced human Argonaute-2 (Ago2) is also enriched in GWBs, indicating that RNA interference function may be somehow linked to these structures(3,4). In this report, we demonstrate that endogenous Agog and transfected small interfering RNAs (siRNAs) are also present within these same cytoplasmic bodies and that the GW182 protein interacts with Agog. Disruption of these cytoplasmic foci in HeLa cells interferes with the silencing capability of a siRNA that is specific to lamin-A/C. Our data support a model in which GW182 and/or the microenvironment of the cytoplasmic GWBs contribute to the RNA-induced silencing complex and to RNA silencing.	Univ Florida, Dept Oral Biol, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Florida, Dept Med, Div Clin Immunol & Rheumatol, Gainesville, FL 32610 USA; Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Calgary; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Chan, EKL (corresponding author), Univ Florida, Dept Oral Biol, Gainesville, FL 32610 USA.	echan@ufl.edu	Chan, Edward K. L./B-5671-2009; Satoh, Minoru/E-2421-2011	Chan, Edward K. L./0000-0003-3938-9503; Jakymiw, Andrew/0000-0001-6431-8753; Satoh, Minoru/0000-0001-8769-5105	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047859, R01AI039645, R21AI047859] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47859, AI39645] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Ding L, 2005, MOL CELL, V19, P437, DOI 10.1016/j.molcel.2005.07.013; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Eystathioy T, 2003, J MOL MED, V81, P811, DOI 10.1007/s00109-003-0495-y; Eystathioy T, 2003, RNA, V9, P1171, DOI 10.1261/rna.5810203; Eystathioy T, 2003, HYBRIDOMA HYBRIDOM, V22, P79, DOI 10.1089/153685903321947996; Eystathioy T, 2002, ARTHRITIS RHEUM, V46, P726, DOI 10.1002/art.10220; Eystathioy T, 2002, MOL BIOL CELL, V13, P1338, DOI 10.1091/mbc.01-11-0544; Gazzani S, 2004, SCIENCE, V306, P1046, DOI 10.1126/science.1101092; Harborth J, 2003, ANTISENSE NUCLEIC A, V13, P83, DOI 10.1089/108729003321629638; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Liu ST, 2003, NAT CELL BIOL, V5, P341, DOI 10.1038/ncb953; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Ou Y, 2004, CLIN EXP IMMUNOL, V136, P379, DOI 10.1111/j.1365-2249.2004.02432.x; Rehwinkel J, 2005, RNA, V11, P1640, DOI 10.1261/rna.2191905; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Souret FF, 2004, MOL CELL, V15, P173, DOI 10.1016/j.molcel.2004.06.006; Tahbaz N, 2001, J BIOL CHEM, V276, P43294, DOI 10.1074/jbc.M107808200; Yang Z, 2004, J CELL SCI, V117, P5567, DOI 10.1242/jcs.01477	30	314	335	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1267	1274		10.1038/ncb1334	http://dx.doi.org/10.1038/ncb1334			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16284622				2022-12-25	WOS:000233748900022
J	Lu, H; Bilder, D				Lu, H; Bilder, D			Endocytic control of epithelial polarity and proliferation in Drosophila	NATURE CELL BIOLOGY			English	Article							CELL POLARITY; MEMBRANE TRAFFICKING; SYNTAXIN 7; NOTCH; GROWTH; RAB5; EYE; ORGANIZATION; JUNCTIONS; HOMOLOG	Intracellular protein transport is a key factor in epithelial cell polarity. Here we report that mutations in two core components of the vesicle trafficking machinery - a syntaxin and a Rab protein - cause an expansion of the apical membrane domain of Drosophila melanogaster epithelia; this polarity defect is coupled with overproliferation to form neoplastic tumours. Surprisingly, these proteins are associated with the endocytic, and not the exocytic, pathway. The syntaxin Avalanche (Avl) localizes to early endosomes, and loss of avl results in the cellular accumulation of specific membrane proteins, including the Notch signalling receptor and the polarity determinant Crumbs (Crb). Protein accumulation results from a failure in endosomal entry and progression towards lysosomal degradation; these and other avl phenotypes are also detected in Rab5 null mutant cells. Overexpression of Crb alone is sufficient to induce overproliferation of wild-type imaginal tissue, suggesting that polarity alterations in avl and Rab5 mutants directly contribute to tumour formation. Our findings reveal a critical and specific role for endocytic traffic in the control of both apico-basal polarity and cell proliferation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Bilder, D (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 142 LSA 3200, Berkeley, CA 94720 USA.	bilder@berkeley.edu		Bilder, David/0000-0002-1842-4966	NIGMS NIH HHS [R01 GM068675, R01 GM090150, GM 068675-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068675, R01GM090150] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdelilah-Seyfried S, 2003, DEVELOPMENT, V130, P1927, DOI 10.1242/dev.00420; Aldaz S, 2003, DEVELOPMENT, V130, P4473, DOI 10.1242/dev.00643; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Chao JL, 2004, DEVELOPMENT, V131, P3839, DOI 10.1242/dev.01258; Cooper MTD, 2000, DEV BIOL, V221, P390, DOI 10.1006/dbio.2000.9691; Dollar G, 2002, DEVELOPMENT, V129, P517; Dominguez M, 2004, NAT GENET, V36, P31, DOI 10.1038/ng1281; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jekely G, 2003, EMBO REP, V4, P1163, DOI 10.1038/sj.embor.7400019; Kanwar R, 2004, CURR BIOL, V14, pR1043, DOI 10.1016/j.cub.2004.11.041; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Kramer H, 1996, J CELL BIOL, V133, P1205, DOI 10.1083/jcb.133.6.1205; Le Borgne R, 2003, DEV CELL, V5, P139, DOI 10.1016/S1534-5807(03)00187-4; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Littleton JT, 2000, J CELL BIOL, V150, pF77, DOI 10.1083/jcb.150.2.F77; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Lloyd TE, 2000, NEURON, V26, P45, DOI 10.1016/S0896-6273(00)81136-8; McDonald JA, 2003, DEVELOPMENT, V130, P3469, DOI 10.1242/dev.00574; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Newsome TP, 2000, DEVELOPMENT, V127, P851; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; Sevrioukov EA, 1999, MOL CELL, V4, P479, DOI 10.1016/S1097-2765(00)80199-9; Sotillos S, 2004, J CELL BIOL, V166, P549, DOI 10.1083/jcb.200311031; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Wucherpfennig T, 2003, J CELL BIOL, V161, P609, DOI 10.1083/jcb.200211087	34	259	260	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1232	1239		10.1038/ncb1324	http://dx.doi.org/10.1038/ncb1324			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16258546				2022-12-25	WOS:000233748900017
J	Maisnier-Patin, S; Roth, JR; Fredriksson, A; Nystrom, T; Berg, OG; Andersson, DI				Maisnier-Patin, S; Roth, JR; Fredriksson, A; Nystrom, T; Berg, OG; Andersson, DI			Genomic buffering mitigates the effects of deleterious mutations in bacteria	NATURE GENETICS			English	Article							ESCHERICHIA-COLI; SYNERGISTIC EPISTASIS; GENETIC INTERACTIONS; ADAPTIVE MUTATION; FITNESS; POPULATIONS; LOAD; RECOMBINATION; DROSOPHILA; CAPACITOR	The relationship between the number of randomly accumulated mutations in a genome and fitness is a key parameter in evolutionary biology(1-5). Mutations may interact such that their combined effect on fitness is additive ( no epistasis), reinforced ( synergistic epistasis) or mitigated ( antagonistic epistasis). We measured the decrease in fitness caused by increasing mutation number in the bacterium Salmonella typhimurium using a regulated, error-prone DNA polymerase ( polymerase IV, DinB). As mutations accumulated, fitness costs increased at a diminishing rate. This suggests that random mutations interact such that their combined effect on fitness is mitigated and that the genome is buffered against the fitness reduction caused by accumulated mutations. Levels of the heat shock chaperones DnaK and GroEL increased in lineages that had accumulated many mutations, and experimental overproduction of GroEL further increased the fitness of lineages containing deleterious mutations. These findings suggest that overexpression of chaperones contributes to antagonistic epistasis.	Swedish Inst Infect Dis Control, Dept Bacteriol, S-17182 Stockholm, Sweden; Karolinska Inst, Microbiol & Tumor Ctr, S-17182 Stockholm, Sweden; Univ Calif Davis, DBS Sect Microbiol, Davis, CA 95616 USA; Univ Gothenburg, Lundberg Lab, Dept Microbiol, S-40530 Gothenburg, Sweden; Uppsala Univ, Dept Mol Evolut, S-75236 Uppsala, Sweden; Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Swedish Institute for Infectious Disease Control; Karolinska Institutet; University of California System; University of California Davis; University of Gothenburg; Uppsala University; Uppsala University	Andersson, DI (corresponding author), Swedish Inst Infect Dis Control, Dept Bacteriol, S-17182 Stockholm, Sweden.	Dan.Andersson@imbim.uu.se	Fredriksson, Asa U/B-8614-2011	Andersson, Dan/0000-0001-6640-2174				Bonhoeffer S, 2004, SCIENCE, V306, P1547, DOI 10.1126/science.1101786; Burch CL, 2004, GENETICS, V167, P559, DOI 10.1534/genetics.103.021196; Carroll R. J., 1988, TRANSFORMATION WEIGH; Davidian M., 1995, NONLINEAR MODELS REP; deVisser JAGM, 1997, GENETICS, V145, P815; deVisser JAGM, 1997, EVOLUTION, V51, P1499, DOI 10.1111/j.1558-5646.1997.tb01473.x; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Fares MA, 2002, NATURE, V417, P398, DOI 10.1038/417398a; Kibota TT, 1996, NATURE, V381, P694, DOI 10.1038/381694a0; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; KIMURA M, 1966, GENETICS, V54, P1337; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; LANDE R, 1994, EVOLUTION, V48, P1460, DOI [10.2307/2410240, 10.1111/j.1558-5646.1994.tb02188.x]; Lenski RE, 1999, NATURE, V400, P661, DOI 10.1038/23245; MUKAI T, 1969, GENETICS, V61, P749; MULLER HJ, 1964, MUTAT RES, V16, P2; Peters AD, 2000, GENETICS, V156, P1635; Poon A, 2000, EVOLUTION, V54, P1467, DOI 10.1111/j.0014-3820.2000.tb00693.x; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Roth JR, 2003, GENETICS, V163, P1483; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sanjuan R, 2004, P NATL ACAD SCI USA, V101, P15376, DOI 10.1073/pnas.0404125101; Szafraniec K, 2003, GENET RES, V82, P19, DOI 10.1017/S001667230300630X; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Torkelson J, 1997, EMBO J, V16, P3303, DOI 10.1093/emboj/16.11.3303; WAGNER GP, 1990, EVOLUTION, V44, P715, DOI 10.1111/j.1558-5646.1990.tb05950.x; WHITLOCK MC, 1995, ANNU REV ECOL SYST, V26, P601, DOI 10.1146/annurev.es.26.110195.003125; Whitlock MC, 2000, EVOLUTION, V54, P1654, DOI 10.1111/j.0014-3820.2000.tb00709.x; Wilke CO, 2001, P ROY SOC B-BIOL SCI, V268, P1469, DOI 10.1098/rspb.2001.1690; Wolf J.B., 2000, EPISTASIS EVOLUTIONA	30	118	121	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2005	37	12					1376	1379		10.1038/ng1676	http://dx.doi.org/10.1038/ng1676			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	989FC	16273106				2022-12-25	WOS:000233657300020
J	David, NB; Martin, CA; Segalen, M; Rosenfeld, F; Schweisguth, F; Bellaiche, Y				David, NB; Martin, CA; Segalen, M; Rosenfeld, F; Schweisguth, F; Bellaiche, Y			Drosophila Ric-8 regulates G alpha i cortical localization to promote G alpha i-dependent planar orientation of the mitotic spindle during asymmetric cell division	NATURE CELL BIOLOGY			English	Article							HETEROTRIMERIC G-PROTEINS; C-ELEGANS; MICROCHAETE LINEAGE; POLARITY; PINS; DETERMINANTS; ACTIVATION; SYNEMBRYN; ROTATION; BAZOOKA	Localization and activation of heterotrimeric G proteins have a crucial role during asymmetric cell division. The asymmetric division of the Drosophila sensory precursor cell (pI) is polarized along the antero-posterior axis by Frizzled signalling and, during this division, activation of G alpha i depends on Partner of Inscuteable ( Pins). We establish here that Ric-8, which belongs to a family of guanine nucleotide-exchange factors for G alpha i, regulates cortical localization of the subunits Gai and G beta 13F. Ric-8, G alpha i and Pins are not necessary for the control of the anteroposterior orientation of the mitotic spindle during pI cell division downstream of Frizzled signalling, but they are required for maintainance of the spindle within the plane of the epithelium. On the contrary, Frizzled signalling orients the spindle along the antero-posterior axis but also tilts it along the apico-basal axis. Thus, Frizzled and heterotrimeric G-protein signalling act in opposition to ensure that the spindle aligns both in the plane of the epithelium and along the tissue polarity axis.	Inst Curie, CNRS, UMR 144, F-75248 Paris, France; Ecole Normale Super, CNRS, UMR 8542, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	David, NB (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris, France.	nicolas.david@curie.fr; yohanns.bellaiche@curie.fr	David, Nicolas/A-1699-2008	David, Nicolas/0000-0003-1166-6732; Manil-Segalen, Marion/0000-0002-3922-3194; bellaiche, yohanns/0000-0003-1686-2943				Adams RJ, 1996, J NEUROSCI, V16, P7610; Adler PN, 2001, CURR BIOL, V11, pR233, DOI 10.1016/S0960-9822(01)00113-0; Afshar K, 2004, CELL, V119, P219, DOI 10.1016/j.cell.2004.09.026; Bellaiche Y, 2004, DEVELOPMENT, V131, P469, DOI 10.1242/dev.00928; Bellaiche Y, 2001, CELL, V106, P355, DOI 10.1016/S0092-8674(01)00444-5; Bellaiche Y, 2001, NAT CELL BIOL, V3, P50, DOI 10.1038/35050558; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Billuart P, 2001, CELL, V107, P195, DOI 10.1016/S0092-8674(01)00522-0; Couwenbergs C, 2004, CURR BIOL, V14, P1871, DOI 10.1016/j.cub.2004.09.059; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Das T, 2003, NEURON, V37, P597, DOI 10.1016/S0896-6273(03)00066-7; Du QS, 2004, CELL, V119, P503, DOI 10.1016/j.cell.2004.10.028; Fichelson P, 2003, DEVELOPMENT, V130, P123, DOI 10.1242/dev.00198; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; Gho M, 1999, DEVELOPMENT, V126, P3573; Gong Y, 2004, NATURE, V430, P689, DOI 10.1038/nature02796; Hampoelz B, 2004, CELL, V119, P453, DOI 10.1016/j.cell.2004.10.025; Izumi Y, 2004, J CELL BIOL, V164, P729, DOI 10.1083/jcb.200309162; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Kusch J, 2003, TRENDS CELL BIOL, V13, P562, DOI 10.1016/j.tcb.2003.09.008; Langevin J, 2005, CURR BIOL, V15, P955, DOI 10.1016/j.cub.2005.04.054; Le Borgne R, 2003, DEV CELL, V5, P139, DOI 10.1016/S1534-5807(03)00187-4; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Miller KG, 2000, NEURON, V27, P289, DOI 10.1016/S0896-6273(00)00037-4; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Roegiers F, 2001, P NATL ACAD SCI USA, V98, P14469, DOI 10.1073/pnas.261555598; Roegiers F, 2001, NAT CELL BIOL, V3, P58, DOI 10.1038/35050568; Sausedo RA, 1997, J COMP NEUROL, V381, P473; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; Tsou MFB, 2003, DEVELOPMENT, V130, P5717, DOI 10.1242/dev.00790; Yu FW, 2005, GENE DEV, V19, P1341, DOI 10.1101/gad.1295505	35	99	101	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1083	1090		10.1038/ncb1319	http://dx.doi.org/10.1038/ncb1319			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16228010	Green Submitted			2022-12-25	WOS:000232930400011
J	de Vries, IJM; Lesterhuis, WJ; Barentsz, JO; Verdijk, P; van Krieken, JH; Boerman, OC; Oyen, WJG; Bonenkamp, JJ; Boezeman, JB; Adema, GJ; Bulte, JWM; Scheenen, TWJ; Punt, CJA; Heerschap, A; Figdor, CG				de Vries, IJM; Lesterhuis, WJ; Barentsz, JO; Verdijk, P; van Krieken, JH; Boerman, OC; Oyen, WJG; Bonenkamp, JJ; Boezeman, JB; Adema, GJ; Bulte, JWM; Scheenen, TWJ; Punt, CJA; Heerschap, A; Figdor, CG			Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy	NATURE BIOTECHNOLOGY			English	Article							SUPERPARAMAGNETIC IRON-OXIDE; IN-VIVO; T-CELLS; CONTRAST AGENT; LYMPH-NODES; STEM-CELLS; MIGRATION; MATURATION; METASTASES	The success of cellular therapies will depend in part on accurate delivery of cells to target organs. In dendritic cell therapy, in particular, delivery and subsequent migration of cells to regional lymph nodes is essential for effective stimulation of the immune system. We show here that in vivo magnetic resonance tracking of magnetically labeled cells is feasible in humans for detecting very low numbers of dendritic cells in conjunction with detailed anatomical information. Autologous dendritic cells were labeled with a clinical superparamagnetic iron oxide formulation or In-111-oxine and were co-injected intranodally in melanoma patients under ultrasound guidance. In contrast to scintigraphic imaging, magnetic resonance imaging (MRI) allowed assessment of the accuracy of dendritic cell delivery and of inter- and intra-nodal cell migration patterns. MRI cell tracking using iron oxides appears clinically safe and well suited to monitor cellular therapy in humans.	Univ Nijmegen, Radboud Med Ctr, Dept Tumor Immunol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Radboud Med Ctr, Dept Pediat Oncol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Radboud Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Radboud Med Ctr, Dept Radiol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Radboud Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Radboud Med Ctr, Dept Nucl Med, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Radboud Med Ctr, Dept Surg, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Radboud Med Ctr, Cent Hematol Lab, NL-6500 HB Nijmegen, Netherlands; Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Div MR Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Johns Hopkins University; Johns Hopkins University	Figdor, CG (corresponding author), Univ Nijmegen, Radboud Med Ctr, Dept Tumor Immunol, Geert Grooteplein 28, NL-6500 HB Nijmegen, Netherlands.	c.figdor@ncrnls.ru.nl	Barentsz, Jelle/D-3515-2009; Figdor, Carl G/A-4232-2010; Adema, G.J./H-8007-2014; de Vries, Jolanda I.J.M./F-5563-2010; Scheenen, Tom W.J./I-5921-2013; Heerschap, Arend/G-5228-2010; Bulte, Jeff W.M./A-3240-2008; Oyen, Wim J.G./D-4178-2009; van Krieken, Joannes H J M/D-4138-2009; Boezeman, J.B.M./L-4209-2015; Boerman, Otto C/A-8112-2014; Bonenkamp, J.J./L-4213-2015	Figdor, Carl G/0000-0002-2366-9212; de Vries, Jolanda I.J.M./0000-0002-8653-4040; Bulte, Jeff W.M./0000-0003-1202-1610; Oyen, Wim J.G./0000-0001-8235-7078; van Krieken, Joannes H J M/0000-0001-6544-1040; Boerman, Otto C/0000-0001-6832-101X; Verdijk, Pauline/0000-0003-2272-2736; Lesterhuis, Willem Joost/0000-0002-2718-276X	NINDS NIH HHS [R01 NS045062] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045062] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adema GJ, 2005, CURR OPIN IMMUNOL, V17, P170, DOI 10.1016/j.coi.2005.01.004; Ahrens ET, 2003, MAGN RESON MED, V49, P1006, DOI 10.1002/mrm.10465; Anderson SA, 2005, BLOOD, V105, P420, DOI 10.1182/blood-2004-06-2222; Anderson SA, 2004, ANN NEUROL, V55, P654, DOI 10.1002/ana.20066; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Blocklet D, 2003, EUR J NUCL MED MOL I, V30, P440, DOI 10.1007/s00259-002-1001-4; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Bulte JWM, 2004, METHOD ENZYMOL, V386, P275; Bulte JWM, 1997, MAGN RESON MED, V37, P530, DOI 10.1002/mrm.1910370409; Bulte JWM, 1999, P NATL ACAD SCI USA, V96, P15256, DOI 10.1073/pnas.96.26.15256; Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924; de Vries IJM, 2002, J IMMUNOTHER, V25, P429, DOI 10.1097/00002371-200209000-00007; de Vries IJM, 2003, CANCER RES, V63, P12; de Vries IJM, 2003, CLIN CANCER RES, V9, P5091; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; Hennig J, 2001, MAGNET RESON MED, V46, P6, DOI 10.1002/mrm.1153; Hill JM, 2003, CIRCULATION, V108, P1009, DOI 10.1161/01.CIR.0000084537.66419.7A; Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499; Kircher MF, 2003, CANCER RES, V63, P6838; Kraitchman DL, 2003, CIRCULATION, V107, P2290, DOI 10.1161/01.CIR.0000070931.62772.4E; Nair S, 2003, J IMMUNOL, V171, P6275, DOI 10.4049/jimmunol.171.11.6275; STARK DD, 1988, RADIOLOGY, V168, P297, DOI 10.1148/radiology.168.2.3393649; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; VANCHEREAU J, 1998, NATURE, V392, P245; WEISSLEDER R, 1989, AM J ROENTGENOL, V152, P167, DOI 10.2214/ajr.152.1.167; WEISSLEDER R, 1990, RADIOLOGY, V175, P494, DOI 10.1148/radiology.175.2.2326475; YEH TC, 1995, MAGN RESON MED, V33, P200, DOI 10.1002/mrm.1910330209	29	671	687	3	129	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2005	23	11					1407	1413		10.1038/nbt1154	http://dx.doi.org/10.1038/nbt1154			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	984FN	16258544				2022-12-25	WOS:000233288000036
J	Dickins, RA; Hemann, MT; Zilfou, JT; Simpson, DR; Ibarra, I; Hannon, GJ; Lowe, SW				Dickins, RA; Hemann, MT; Zilfou, JT; Simpson, DR; Ibarra, I; Hannon, GJ; Lowe, SW			Probing tumor phenotypes using stable and regulated synthetic microRNA precursors	NATURE GENETICS			English	Article							SHORT HAIRPIN RNAS; MAMMALIAN-CELLS; GENE-EXPRESSION; POLYMERASE-II; IN-VITRO; SYSTEM; INTERFERENCE; SENESCENCE; P53; CHEMORESISTANCE	RNA interference is a powerful method for suppressing gene expression in mammalian cells. Stable knock-down can be achieved by continuous expression of synthetic short hairpin RNAs, typically from RNA polymerase III promoters. But primary microRNA transcripts, which are endogenous triggers of RNA interference, are normally synthesized by RNA polymerase II. Here we show that RNA polymerase II promoters expressing rationally designed primary microRNA based short hairpin RNAs produce potent, stable and regulatable gene knock-down in cultured cells and in animals, even when present at a single copy in the genome. Most notably, by tightly regulating Trp53 knock-down using tetracycline-based systems, we show that cultured mouse fibroblasts can be switched between proliferative and senescent states and that tumors induced by Trp53 suppression and cooperating oncogenes regress upon re-expression of Trp53. In practice, this primary microRNA-based short hairpin RNA vector system is markedly similar to cDNA overexpression systems and is a powerful tool for studying gene function in cells and animals.	Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA	Howard Hughes Medical Institute; Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory	Lowe, SW (corresponding author), Howard Hughes Med Inst, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.edu	Hannon, Gregory/AAB-3568-2019; Dickins, Ross A/K-2852-2012	Dickins, Ross A/0000-0003-4112-5304	NCI NIH HHS [P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boden D, 2004, NUCLEIC ACIDS RES, V32, P1154, DOI 10.1093/nar/gkh278; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Chen YC, 2003, CANCER RES, V63, P4801; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Felsher DW, 2004, CURR OPIN GENET DEV, V14, P37, DOI 10.1016/j.gde.2003.12.008; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gupta S, 2004, P NATL ACAD SCI USA, V101, P1927, DOI 10.1073/pnas.0306111101; HARVEY M, 1993, ONCOGENE, V8, P2457; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hosono T, 2004, HUM GENE THER, V15, P813, DOI 10.1089/1043034041648462; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Miyagishi M, 2004, J GENE MED, V6, P715, DOI 10.1002/jgm.556; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2004, NAT METHODS, V1, P163, DOI 10.1038/nmeth1104-163; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Song J, 2004, CANCER RES, V64, P7661, DOI 10.1158/0008-5472.CAN-04-1751; Stegmeier F, 2005, P NATL ACAD SCI USA, V102, P13212, DOI 10.1073/pnas.0506306102; Unwalla HJ, 2004, NAT BIOTECHNOL, V22, P1573, DOI 10.1038/nbt1040; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Zeng Y, 2005, METHOD ENZYMOL, V392, P371, DOI 10.1016/S0076-6879(04)92022-8; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	35	417	442	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2005	37	11					1289	1295		10.1038/ng1651	http://dx.doi.org/10.1038/ng1651			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16200064				2022-12-25	WOS:000233045200032
J	Zvetkova, I; Apedaile, A; Ramsahoye, B; Mermoud, JE; Crompton, LA; John, R; Feil, R; Brockdorff, N				Zvetkova, I; Apedaile, A; Ramsahoye, B; Mermoud, JE; Crompton, LA; John, R; Feil, R; Brockdorff, N			Global hypomethylation of the genome in XX embryonic stem cells	NATURE GENETICS			English	Article							METHYLATION PATTERNS; DNA METHYLTRANSFERASES; CHROMOSOME; EXPRESSION; DNMT3A; GENE; MAINTENANCE; MICE	Embryonic stem (ES) cells are important tools in the study of gene function and may also become important in cell therapy applications(1). Establishment of stable XX ES cell lines from mouse blastocysts is relatively problematic owing to frequent loss of one of the two X chromosomes. Here we show that DNA methylation is globally reduced in XX ES cell lines and that this is attributable to the presence of two active X chromosomes. Hypomethylation affects both repetitive and unique sequences, the latter including differentially methylated regions that regulate expression of parentally imprinted genes. Methylation of differentially methylated regions can be restored coincident with elimination of an X chromosome in early-passage parthenogenetic ES cells, suggesting that selection against loss of methylation may provide the basis for X-chromosome instability. Finally, we show that hypomethylation is associated with reduced levels of the de novo DNA methyltransferases Dnmt3a and Dnmt3b and that ectopic expression of these factors restores global methylation levels.	Hammersmith Hosp, ICFM, MRC, Ctr Clin Sci, London W12 0NN, England; Univ Edinburgh, Western Gen Hosp, John Hughes Bennett Lab, Edinburgh EH4 2XU, Midlothian, Scotland; Cardiff Sch Biosci, Cardiff CF10 3US, Wales; Inst Mol Genet, CNRS, UMR 5535, Montpellier, France; Univ Montpellier 2, Montpellier, France	Imperial College London; University of Edinburgh; Cardiff University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier	Brockdorff, N (corresponding author), Hammersmith Hosp, ICFM, MRC, Ctr Clin Sci, DuCane Rd, London W12 0NN, England.	neil.brockdorff@csc.mrc.ac.uk	John, Rosalind M/A-4491-2010; John, Ros/AAF-4229-2022; Feil, Robert P/D-2087-2013; John, Ros/AFI-8619-2022; John, Rosalind/AAQ-8221-2021	John, Rosalind M/0000-0002-3827-7617; John, Ros/0000-0002-3827-7617; Feil, Robert P/0000-0002-5671-5860; John, Ros/0000-0002-3827-7617; Brockdorff, Neil/0000-0003-4838-2653; CROMPTON, LUCY/0000-0002-2642-1183; Mermoud, Jacqueline/0000-0002-7718-646X				BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Dean W, 1998, DEVELOPMENT, V125, P2273; Durcova-Hills G, 2001, DIFFERENTIATION, V68, P220, DOI 10.1046/j.1432-0436.2001.680409.x; Durcova-Hills G, 2004, DEV BIOL, V268, P105, DOI 10.1016/j.ydbio.2003.12.018; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; LUBINSKY MS, 1991, LANCET, V337, P1288, DOI 10.1016/0140-6736(91)92956-3; Mermoud JE, 1999, J CELL BIOL, V147, P1399, DOI 10.1083/jcb.147.7.1399; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; O'Neill LP, 2003, HUM MOL GENET, V12, P1783, DOI 10.1093/hmg/ddg193; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Ramsahoye Bernard H, 2002, Methods Mol Biol, V200, P9; ROBERTSON EJ, 1983, J EMBRYOL EXP MORPH, V74, P297; Sado T, 1996, DEV DYNAM, V205, P421, DOI 10.1002/(SICI)1097-0177(199604)205:4<421::AID-AJA6>3.0.CO;2-K; SANFORD J, 1984, NUCLEIC ACIDS RES, V12, P2823, DOI 10.1093/nar/12.6.2823; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; SURANI MA, 1993, PHILOS T R SOC B, V339, P165, DOI 10.1098/rstb.1993.0013; Tada T, 1998, DEV GENES EVOL, V207, P551, DOI 10.1007/s004270050146; Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371; Weksberg R, 2002, HUM MOL GENET, V11, P1317, DOI 10.1093/hmg/11.11.1317; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	28	187	194	0	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2005	37	11					1274	1279		10.1038/ng1663	http://dx.doi.org/10.1038/ng1663			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16244654				2022-12-25	WOS:000233045200030
J	Evans, MJ; Saghatelian, A; Sorensen, EJ; Cravatt, BF				Evans, MJ; Saghatelian, A; Sorensen, EJ; Cravatt, BF			Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling	NATURE BIOTECHNOLOGY			English	Article							PHOSPHOGLYCERATE MUTASE; ACTIVE-SITE; IDENTIFICATION; INHIBITORS; COMPLEX; TUMOR; GLYCOLYSIS; ENZYMES; DRUGS; YEAST	Chemical genomics aims to discover small molecules that affect biological processes through the perturbation of protein function(1,2). However, determining the protein targets of bioactive compounds remains a formidable challenge(3). We address this problem here through the creation of a natural product - inspired small-molecule library bearing protein-reactive elements. Cell-based screening identified a compound, MJE3, that inhibits breast cancer cell proliferation. In situ proteome reactivity profiling revealed that MJE3, but not other library members, covalently labeled the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1), resulting in enzyme inhibition. Interestingly, MJE3 labeling and inhibition of PGAM1 were observed exclusively in intact cells. These results support the hypothesis that cancer cells depend on glycolysis for viability and promote PGAM1 as a potential therapeutic target. More generally, the incorporation of protein-reactive compounds into chemical genomics screens offers a means to discover targets of bioactive small molecules in living systems, thereby enabling downstream mechanistic investigations.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Princeton University	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.	cravatt@scripps.edu			NATIONAL CANCER INSTITUTE [R37CA087660, R01CA087660] Funding Source: NIH RePORTER; NCI NIH HHS [CA087660, R01 CA087660-05, R01 CA087660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2; Burdine L, 2004, CHEM BIOL, V11, P593, DOI 10.1016/j.chembiol.2004.05.001; Clemons PA, 2004, CURR OPIN CHEM BIOL, V8, P334, DOI 10.1016/j.cbpa.2004.04.002; Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3; Drahl C, 2005, ANGEW CHEM INT EDIT, V44, P5788, DOI 10.1002/anie.200500900; Engel M, 2004, J BIOL CHEM, V279, P35803, DOI 10.1074/jbc.M402768200; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; Kondoh H, 2005, CANCER RES, V65, P177; Kung C, 2005, P NATL ACAD SCI USA, V102, P3587, DOI 10.1073/pnas.0407170102; Leung D, 2003, NAT BIOTECHNOL, V21, P687, DOI 10.1038/nbt826; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Luesch H, 2005, CHEM BIOL, V12, P55, DOI 10.1016/j.chembiol.2004.10.015; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; Nakajima H, 1996, J ANTIBIOT, V49, P1204; Rigden DJ, 1999, J MOL BIOL, V289, P691, DOI 10.1006/jmbi.1999.2848; Robertson JG, 2005, BIOCHEMISTRY-US, V44, P5561, DOI 10.1021/bi050247e; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Sirois S, 2005, COMPUT BIOL CHEM, V29, P55, DOI 10.1016/j.compbiolchem.2004.11.003; Speers AE, 2003, J AM CHEM SOC, V125, P4686, DOI 10.1021/ja034490h; Speers AE, 2005, J AM CHEM SOC, V127, P10018, DOI 10.1021/ja0532842; Speers AE, 2004, CHEM BIOL, V11, P535, DOI 10.1016/j.chembiol.2004.03.012; Stockwell BR, 2004, NATURE, V432, P846, DOI 10.1038/nature03196; Strausberg RL, 2003, SCIENCE, V300, P294, DOI 10.1126/science.1083395; Taunton J, 1997, CHEM BIOL, V4, P493, DOI 10.1016/S1074-5521(97)90320-3; Wakabayashi T, 2000, J ANTIBIOT, V53, P591, DOI 10.7164/antibiotics.53.591; Wang YL, 2005, BIOCHEM BIOPH RES CO, V331, P1207, DOI 10.1016/j.bbrc.2005.03.243; WHITE MF, 1992, EUR J BIOCHEM, V207, P709, DOI 10.1111/j.1432-1033.1992.tb17099.x; Wong S, 2004, P NATL ACAD SCI USA, V101, P17456, DOI 10.1073/pnas.0407061101; Wu X, 2004, J AM CHEM SOC, V126, P1590, DOI 10.1021/ja038950i	30	190	193	2	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2005	23	10					1303	1307		10.1038/nbt1149	http://dx.doi.org/10.1038/nbt1149			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QZ	16200062				2022-12-25	WOS:000232469600033
J	Harvey, NL; Srinivasan, RS; Dillard, ME; Johnson, NC; Witte, MH; Boyd, K; Sleeman, MW; Oliver, G				Harvey, NL; Srinivasan, RS; Dillard, ME; Johnson, NC; Witte, MH; Boyd, K; Sleeman, MW; Oliver, G			Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity	NATURE GENETICS			English	Article							ENDOTHELIAL-CELL-LINEAGE; ADIPOSE-TISSUE; LYMPHOID-CELLS; LIVER; RECEPTOR; NODES; GENE; DIFFERENTIATION; LYMPHEDEMA; EXPRESSION	Multiple organs cooperate to regulate appetite, metabolism, and glucose and fatty acid homeostasis. Here, we identified and characterized lymphatic vasculature dysfunction as a cause of adult-onset obesity. We found that functional inactivation of a single allele of the homeobox gene Prox1 led to adult-onset obesity due to abnormal lymph leakage from mispatterned and ruptured lymphatic vessels. Prox1 heterozygous mice are a new model for adult-onset obesity and lymphatic vascular disease.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Anim Resources Ctr, Memphis, TN 38105 USA; Univ Arizona, Coll Med, Dept Surg, Tucson, AZ 85724 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Arizona; Regeneron	Oliver, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	guillermo.oliver@stjude.org		Harvey, Natasha/0000-0001-9839-8966				Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Brorson H, 2003, Scand J Surg, V92, P287; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Burke Z, 2002, MECH DEVELOP, V118, P147, DOI 10.1016/S0925-4773(02)00240-X; DIGIROLAMO M, 1971, AM J PHYSIOL, V221, P850, DOI 10.1152/ajplegacy.1971.221.3.850; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Esther CR, 2004, PEDIATR PULM, V38, P308, DOI 10.1002/ppul.20100; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; HO MK, 1982, J IMMUNOL, V128, P1221; Jandacek RJ, 2004, GASTROENTEROLOGY, V127, P139, DOI 10.1053/j.gastro.2004.04.007; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Mattacks CA, 2003, J ANAT, V202, P551, DOI 10.1046/j.1469-7580.2003.00188.x; NOUGUES J, 1988, INT J OBESITY, V12, P321; POND CM, 1995, J LIPID RES, V36, P2219; Pond CM, 2003, BRIT J NUTR, V89, P375, DOI 10.1079/BJN2002784; Pond CM, 2003, TRENDS IMMUNOL, V24, P13, DOI 10.1016/S1471-4906(02)00004-2; Rosen ED, 2002, ANN NY ACAD SCI, V979, P143, DOI 10.1111/j.1749-6632.2002.tb04875.x; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yuan L, 2002, DEVELOPMENT, V129, P4797; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	33	392	412	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2005	37	10					1072	1081		10.1038/ng1642	http://dx.doi.org/10.1038/ng1642			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16170315				2022-12-25	WOS:000232185600018
J	Lincoln, MR; Montpetit, A; Cader, MZ; Saarela, J; Dyment, DA; Tiislar, M; Ferretti, V; Tienari, PJ; Sadovnick, AD; Peltonen, L; Ebers, GC; Hudson, TJ				Lincoln, MR; Montpetit, A; Cader, MZ; Saarela, J; Dyment, DA; Tiislar, M; Ferretti, V; Tienari, PJ; Sadovnick, AD; Peltonen, L; Ebers, GC; Hudson, TJ			A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis	NATURE GENETICS			English	Article							GENETIC SUSCEPTIBILITY; HAPLOTYPES; DISEASE; MAPS; DISSECTION; FAMILIES; PROJECT; LINKAGE; GENOME; LOCUS	Genetic susceptibility to multiple sclerosis is associated with genes of the major histocompatibility complex (MHC), particularly HLA-DRB1 and HLA-DQB1 (ref. 1). Both locus and allelic heterogeneity have been reported in this genomic region(2,3). To clarify whether HLA-DRB1 itself, nearby genes in the region encoding the MHC or combinations of these loci underlie susceptibility to multiple sclerosis, we genotyped 1,185 Canadian and Finnish families with multiple sclerosis (n = 4,203 individuals) with a high-density SNP panel spanning the genes encoding the MHC and flanking genomic regions. Strong associations in Canadian and Finnish samples were observed with blocks in the HLA class II genomic region (P < 4.9 x 10(-13) and P < 2.0 x 10(-16), respectively), but the strongest association was with HLA-DRB1 (P < 4.4 x 10(-17)). Conditioning on either HLA-DRB1 or the most significant HLA class II haplotype block found no additional block or SNP association independent of the HLA class II genomic region. This study therefore indicates that MHC-associated susceptibility to multiple sclerosis is determined by HLA class II alleles, their interactions and closely neighboring variants.	Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; McGill Univ, Montreal, PQ H3A 1A4, Canada; Genome Quebec Innovat Ctr, Montreal, PQ H3A 1A4, Canada; McGill Univ, Ctr Hlth, Res Inst, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Ctr Hlth, Res Inst, Dept Human Genet, Montreal, PQ H3G 1A4, Canada; Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland; Univ Helsinki, Dept Neurol, Neurosci Programme, Biomedicum Helsinki, Helsinki, Finland; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 2B5, Canada; Univ British Columbia, Fac Med, Div Neurol, Vancouver, BC V6T 2B5, Canada; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA; Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland	Radcliffe Infirmary; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; McGill University; McGill University; McGill University; Finland National Institute for Health & Welfare; University of Helsinki; University of British Columbia; University of British Columbia; University of California System; University of California Los Angeles; University of Helsinki	Ebers, GC (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England.	george.ebers@clneuro.ox.ac.uk	Tienari, Pentti J/A-4893-2012; Lincoln, Matthew R/ABD-1504-2020; Saarela, Janna S/E-5369-2014	Lincoln, Matthew R/0000-0003-2962-6253; Ebers, George/0000-0003-4771-4177; Hudson, Thomas/0000-0002-1376-4849; Cader, Zameel/0000-0002-6952-406X; Saarela, Janna/0000-0002-0853-6219; Sadovnick, Dessa/0000-0003-2987-2008				Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Allcock RJN, 1999, HUM IMMUNOL, V60, P1266, DOI 10.1016/S0198-8859(99)00127-5; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Caballero A, 1999, TISSUE ANTIGENS, V54, P524, DOI 10.1034/j.1399-0039.1999.540511.x; Cordell HJ, 2004, GENET EPIDEMIOL, V26, P186, DOI 10.1002/gepi.10306; Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007; De la Vega FM, 2005, GENOME RES, V15, P454, DOI 10.1101/gr.3241705; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Dyment DA, 2005, HUM MOL GENET, V14, P2019, DOI 10.1093/hmg/ddi206; Dyment DA, 2004, LANCET NEUROL, V3, P104, DOI 10.1016/S1474-4422(03)00663-X; Ebers GC, 2004, LANCET, V363, P1773, DOI 10.1016/S0140-6736(04)16304-6; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; Fan JB, 2004, GENOME RES, V14, P878, DOI 10.1101/gr.2167504; Fernandez-Arquero M, 1999, NEUROLOGY, V53, P1361, DOI 10.1212/WNL.53.6.1361; Fogdell-Hahn A, 2000, TISSUE ANTIGENS, V55, P140, DOI 10.1034/j.1399-0039.2000.550205.x; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Harbo HF, 2004, TISSUE ANTIGENS, V63, P237, DOI 10.1111/j.0001-2815.2004.00173.x; Johannesson M, 2005, GENES IMMUN, V6, P175, DOI 10.1038/sj.gene.6364155; Koeleman BPC, 2000, ANN HUM GENET, V64, P207, DOI 10.1017/S0003480000008095; Kuokkanen S, 1997, AM J HUM GENET, V61, P1379, DOI 10.1086/301637; Laaksonen M, 2002, J NEUROIMMUNOL, V122, P140, DOI 10.1016/S0165-5728(01)00456-8; Ligers A, 2001, AM J HUM GENET, V69, P900, DOI 10.1086/323480; Marrosu MG, 2001, HUM MOL GENET, V10, P2907, DOI 10.1093/hmg/10.25.2907; Oksenberg JR, 2004, AM J HUM GENET, V74, P160, DOI 10.1086/380997; Rubio JP, 2002, AM J HUM GENET, V70, P1125, DOI 10.1086/339932; Saarela J, 2002, HUM MOL GENET, V11, P2257, DOI 10.1093/hmg/11.19.2257; Sadovnick AD, 1998, CAN J NEUROL SCI, V25, P216, DOI 10.1017/S0317167100034041; Stewart CA, 2004, GENOME RES, V14, P1176, DOI 10.1101/gr.2188104; Willer CJ, 2003, P NATL ACAD SCI USA, V100, P12877, DOI 10.1073/pnas.1932604100	30	245	249	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1108	1112		10.1038/ng1647	http://dx.doi.org/10.1038/ng1647			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16186814				2022-12-25	WOS:000232185600023
J	Prakash, A; Tompa, M				Prakash, A; Tompa, M			Discovery of regulatory elements in vertebrates through comparative genomics	NATURE BIOTECHNOLOGY			English	Article							TRANSCRIPTIONAL REGULATION; ALIGNMENT; GENES; EVOLUTION; SEQUENCES; FEATURES; TOOLS	We have analyzed issues of reliability in studies in which comparative genomic approaches have been applied to the discovery of regulatory elements at a genome-wide level in vertebrates. We point out some potential problems with such studies, including difficulties in accurately identifying orthologous promoter regions. Many of these subtle analytical problems have become apparent only when studying the more complex vertebrate genomes. By determining motif reliability, we compared existing tools when applied to the discovery of vertebrate regulatory elements. We then used a statistical clustering method to produce a computational catalog of high quality putative regulatory elements from vertebrates, some of which are widely conserved among vertebrates and many of which are novel regulatory elements. The results provide a glimpse into the wealth of information that comparative genomics can yield and suggest the need for further improvement of genome-wide comparative computational techniques.	Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Tompa, M (corresponding author), Univ Washington, Dept Comp Sci & Engn, Box 352350, Seattle, WA 98195 USA.	tompa@cs.washington.edu			NHGRI NIH HHS [R01 HG02602] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002602] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; Blanchette M, 2004, GENOME RES, V14, P708, DOI 10.1101/gr.1933104; Blanchette M, 2003, NUCLEIC ACIDS RES, V31, P3840, DOI 10.1093/nar/gkg606; Bray N, 2004, GENOME RES, V14, P693, DOI 10.1101/gr.1960404; Brudno M, 2003, GENOME RES, V13, P721, DOI 10.1101/gr.926603; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Dieterich C, 2003, NUCLEIC ACIDS RES, V31, P55, DOI 10.1093/nar/gkg007; Elemento O, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-r18; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; *INT CHICK GEN SEQ, 2004, GENOME BIOL, V432, P695; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Margulies EH, 2003, GENOME RES, V13, P2507, DOI 10.1101/gr.1602203; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Olson MV, 2003, NAT REV GENET, V4, P20, DOI 10.1038/nrg981; Pollard DA, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-6; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Scholz H, 2005, PHYSIOLOGY, V20, P54, DOI 10.1152/physiol.00048.2004; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; Thiel G, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-2; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yamazaki Y, 2003, J BIOL CHEM, V278, P30642, DOI 10.1074/jbc.M212242200; Zhang B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-16	25	44	46	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2005	23	10					1249	1256		10.1038/nbt1140	http://dx.doi.org/10.1038/nbt1140			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QZ	16211068				2022-12-25	WOS:000232469600026
J	Forde, GM				Forde, GM			Rapid-response vaccines - does DNA offer a solution?	NATURE BIOTECHNOLOGY			English	Editorial Material							REVERSE GENETICS; VIRUS-VACCINE; PLASMID DNA; INFLUENZA; INJECTION					gareth.forde@eng.monash.edu.au						Agrawal S, 2004, NAT BIOTECHNOL, V22, P1533, DOI 10.1038/nbt1042; [Anonymous], 2004, GENE THERAPY CLIN TR; BOEHRINGER I, 2003, Patent No. 00351483; BOUCHIE A, 2003, NAT BIOTECHNOL, V21, P11; Chase HA, 1998, J MOL RECOGNIT, V11, P217, DOI 10.1002/(SICI)1099-1352(199812)11:1/6<217::AID-JMR426>3.0.CO;2-D; Check E, 2005, NATURE, V435, P404, DOI 10.1038/435404a; Davis HL, 1997, CURR OPIN BIOTECH, V8, P635, DOI 10.1016/S0958-1669(97)80041-9; Diogo MM, 2001, J GENE MED, V3, P577, DOI 10.1002/jgm.218; *GLOB ALL VACC IMM, 2004, IMM FIN OPT; Hehme N, 2004, VIRUS RES, V103, P163, DOI 10.1016/j.virusres.2004.02.029; *I MED, 2004, FOR MICR THREATS BOA; Johansen P, 2003, IMMUNOL LETT, V90, P81, DOI 10.1016/S0165-2478(03)00176-7; Lipatov AS, 2005, J INFECT DIS, V191, P1216, DOI 10.1086/428951; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; MICHEL ML, 1995, P NATL ACAD SCI USA, V92, P5307, DOI 10.1073/pnas.92.12.5307; Plotkin SA, 2005, HEALTH AFFAIR, V24, P631, DOI 10.1377/hlthaff.24.3.631; Scherman D, 2001, B ACAD NAT MED PARIS, V185, P1683, DOI 10.1016/S0001-4079(19)34399-7; SELLERS LJ, 2004, PHARM EXECUTIVE, V24, P60; Subbarao K, 2003, VIROLOGY, V305, P192, DOI 10.1006/viro.2002.1742; *UK VACC IND GROUP, 2004, PROD VACC MAD; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WAHLBERG D, 2004, NEW YORK TIMES SYNDI; Webby RJ, 2004, LANCET, V363, P1099, DOI 10.1016/S0140-6736(04)15892-3; WEISS R, 2002, WASHINGTON POST 1228; *WHO, 2004, EP AL RESP VACC PAN; *WHO, 2005, INF PAND PREP RESP; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Woodgate J, 2002, BIOTECHNOL BIOENG, V79, P450, DOI 10.1002/bit.10296	28	56	62	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2005	23	9					1059	1062		10.1038/nbt0905-1059	http://dx.doi.org/10.1038/nbt0905-1059			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	963GA	16151391	Green Published			2022-12-25	WOS:000231790600017
J	Janowski, BA; Huffman, KE; Schwartz, JC; Ram, R; Hardy, D; Shames, DS; Minna, JD; Corey, DR				Janowski, BA; Huffman, KE; Schwartz, JC; Ram, R; Hardy, D; Shames, DS; Minna, JD; Corey, DR			Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs	NATURE CHEMICAL BIOLOGY			English	Article							BREAST-CANCER; RECEPTOR GENE; HUMAN-CELLS; METHYLATION; PROMOTER; PROTEIN; INTERFERENCE; ESTROGEN; LINES; LUNG	Transcription start sites are critical switches for converting recognition of chromosomal DNA into active synthesis of RNA. Their functional importance suggests that they may be ideal targets for regulating gene expression. Here, we report potent inhibition of gene expression by antigene RNAs (agRNAs) complementary to transcription start sites within human chromosomal DNA. Silencing does not require methylation of DNA and differs from all known mechanisms for inhibiting transcription. agRNAs overlap DNA sequences within the open complex formed by RNA polymerase, and silencing is acutely sensitive to single base shifts. agRNAs effectively silence both TATA-less and TATA-box-containing promoters. Transcription start sites occur within every gene, providing predictable targets for agRNAs. Potent inhibition of multiple genes suggests that agRNAs may represent a natural mechanism for controlling transcription, may complement siRNAs and miRNAs that target mRNA, and will be valuable agents for silencing gene expression.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Corey, DR (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	david.corey@utsouthwestern.edu	Schwartz, Jacob/J-6477-2012	Schwartz, Jacob/0000-0002-5205-564X; Hardy, Daniel/0000-0001-5445-273X	NCI NIH HHS [P50CA70907] Funding Source: Medline; NIGMS NIH HHS [R01 GM073042] Funding Source: Medline; PHS HHS [60642, 73042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYNE EH, 2005, TRENDS GENETICS; Castanotto D, 2005, MOL THER, V12, P179, DOI 10.1016/j.ymthe.2005.03.003; Chan SWL, 2004, SCIENCE, V303, P1336, DOI 10.1126/science.1095989; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conneely OM, 2003, J MAMMARY GLAND BIOL, V8, P205, DOI 10.1023/A:1025952924864; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Huffman KE, 2005, BIOCHEMISTRY-US, V44, P2253, DOI 10.1021/bi047948g; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; JANOWSKI BA, 2005, IN PRESS NAT CHEM BI; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Kinoshita H, 2000, CANCER RES, V60, P3623; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Lange C, 2000, BIOCHEM BIOPH RES CO, V278, P125, DOI 10.1006/bbrc.2000.3782; Ma XR, 2004, BREAST CANCER RES, V6, pR316, DOI 10.1186/bcr793; Mattick JS, 2005, HUM MOL GENET, V14, pR121, DOI 10.1093/hmg/ddi101; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; MISRAHI M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P289, DOI 10.1016/0167-4781(93)90156-8; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; Park CW, 2004, BIOCHEM BIOPH RES CO, V323, P275, DOI 10.1016/j.bbrc.2004.08.096; Sasaki M, 2001, CANCER RES, V61, P97; Sigova A, 2004, GENE DEV, V18, P2359, DOI 10.1101/gad.1218004; Sugiyama T, 2005, P NATL ACAD SCI USA, V102, P152, DOI 10.1073/pnas.0407641102; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; Vienonen A, 2002, J STEROID BIOCHEM, V80, P307, DOI 10.1016/S0960-0760(02)00027-4	30	127	197	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2005	1	4					216	222		10.1038/nchembio725	http://dx.doi.org/10.1038/nchembio725			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GM	16408038				2022-12-25	WOS:000232649000013
J	Kagan, VE; Tyurin, VA; Jiang, JF; Tyurina, YY; Ritov, VB; Amoscato, AA; Osipov, AN; Belikova, NA; Kapralov, AA; Kini, V; Vlasova, II; Zhao, Q; Zou, MM; Di, P; Svistunenko, DA; Kurnikov, IV; Borisenko, GG				Kagan, VE; Tyurin, VA; Jiang, JF; Tyurina, YY; Ritov, VB; Amoscato, AA; Osipov, AN; Belikova, NA; Kapralov, AA; Kini, V; Vlasova, II; Zhao, Q; Zou, MM; Di, P; Svistunenko, DA; Kurnikov, IV; Borisenko, GG			Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors	NATURE CHEMICAL BIOLOGY			English	Article							RAT-LIVER MITOCHONDRIA; CELL-DEATH; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; HORSE HEART; HEME IRON; MEMBRANE; RADICALS; PHOSPHATIDYLSERINE; PHOSPHOLIPIDS	Programmed death (apoptosis) is turned on in damaged or unwanted cells to secure their clean and safe self-elimination. The initial apoptotic events are coordinated in mitochondria, whereby several proapoptotic factors, including cytochrome c, are released into the cytosol to trigger caspase cascades. The release mechanisms include interactions of B-cell/lymphoma 2 family proteins with a mitochondria-specific phospholipid, cardiolipin, to cause permeabilization of the outer mitochondrial membrane. Using oxidative lipidomics, we showed that cardiolipin is the only phospholipid in mitochondria that undergoes early oxidation during apoptosis. The oxidation is catalyzed by a cardiolipin-specific peroxidase activity of cardiolipin-bound cytochrome c. In a previously undescribed step in apoptosis, we showed that oxidized cardiolipin is required for the release of proapoptotic factors. These results provide insight into the role of reactive oxygen species in triggering the cell-death pathway and describe an early role for cytochrome c before caspase activation.	Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England; Res Inst PhysicoChem Med, Moscow 119992, Russia	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Essex; Lopukhin Federal Research & Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency	Kagan, VE (corresponding author), Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA.	vkagan@eoh.pitt.edu	Di, Yuanpu Peter/H-4191-2016	Di, Yuanpu Peter/0000-0003-2028-2087; Kapralov, Oleksandr/0000-0002-3006-916X; Amoscato, Andrew/0000-0002-1340-9150; Tyurina, Yulia/0000-0003-0287-2091; Svistunenko, Dimitri/0000-0001-8060-2738; Tyurin, Vladimir/0000-0002-3474-1697; Kagan, Valerian E./0000-0002-7245-1885	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070807, R01HL070755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH008282] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01 HL70755, P01 HL070807] Funding Source: Medline; NIOSH CDC HHS [1R01 OH008282] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIOSH CDC HHS		BAINES CP, NATURE, V434, P658; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; Bernad S, 2004, BIOPHYS J, V86, P3863, DOI 10.1529/biophysj.103.025114; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; Chen YR, 2004, J BIOL CHEM, V279, P18054, DOI 10.1074/jbc.M307706200; CORTESE JD, 1995, BBA-BIOENERGETICS, V1228, P216, DOI 10.1016/0005-2728(94)00178-8; Cossarizza A, 2002, J INFECT DIS, V185, P299, DOI 10.1086/338564; Cristea IM, 2004, CHEM PHYS LIPIDS, V129, P133, DOI 10.1016/j.chemphyslip.2004.02.002; Crouser ED, 2003, ANAL BIOCHEM, V317, P67, DOI 10.1016/S0003-2697(03)00044-7; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Dunford H. B., 1999, HEME PEROXIDASES; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; FEIX JB, 1989, BIOCHIM BIOPHYS ACTA, V992, P230, DOI 10.1016/0304-4165(89)90015-9; Fernandez MG, 2002, CELL GROWTH DIFFER, V13, P449; Giudetti AM, 2002, COMP BIOCHEM PHYS B, V133, P227, DOI 10.1016/S1096-4959(02)00128-8; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P614, DOI 10.1038/sj.cdd.4401571; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; IGARASHI Y, 1986, J BIOL CHEM, V261, P14118; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Jiang JF, 2004, LIPIDS, V39, P1133, DOI 10.1007/s11745-004-1340-1; Kagan V. E, 1988, LIPID PEROXIDATION B; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu J, 2004, APOPTOSIS, V9, P533, DOI 10.1023/B:APPT.0000038034.16230.ea; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Marnett LJ, 2000, CURR OPIN CHEM BIOL, V4, P545, DOI 10.1016/S1367-5931(00)00130-7; Matsura T, 2004, CHEM RES TOXICOL, V17, P685, DOI 10.1021/tx030050s; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakagawa Y, 2004, ANN NY ACAD SCI, V1011, P177, DOI 10.1196/annals.1293.018; Nantes IL, 2001, J BIOL CHEM, V276, P153, DOI 10.1074/jbc.M006338200; NILSSON OS, 1977, BIOCHIM BIOPHYS ACTA, V464, P453, DOI 10.1016/0005-2736(77)90019-0; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; PETIT JM, 1992, EUR J BIOCHEM, V209, P267, DOI 10.1111/j.1432-1033.1992.tb17285.x; Petrosillo G, 2004, J BIOL CHEM, V279, P53103, DOI 10.1074/jbc.M407500200; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Ritov VB, 2004, ANAL BIOCHEM, V333, P27, DOI 10.1016/j.ab.2004.05.014; ROBINSON NC, 1990, BIOCHEMISTRY-US, V29, P8962, DOI 10.1021/bi00490a012; ROUACH H, 1984, BIOCHIM BIOPHYS ACTA, V795, P125, DOI 10.1016/0005-2760(84)90112-7; SCHLAME M, 1991, EUR J BIOCHEM, V199, P459, DOI 10.1111/j.1432-1033.1991.tb16144.x; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Shidoji Yoshihiro, 2002, Subcell Biochem, V36, P19; Siemankowski LM, 1999, FREE RADICAL BIO MED, V26, P919, DOI 10.1016/S0891-5849(98)00273-1; STELLWAGEN E, 1968, BIOCHEMISTRY-US, V7, P2496, DOI 10.1021/bi00847a008; Svistunenko DA, 2004, BIOPHYS J, V87, P582, DOI 10.1529/biophysj.104.041046; Svistunenko DA, 2001, BBA-PROTEIN STRUCT M, V1546, P365, DOI 10.1016/S0167-4838(01)00157-1; Svistunenko DA, 2005, BBA-BIOENERGETICS, V1707, P127, DOI 10.1016/j.bbabio.2005.01.004; TSAI AL, 1993, J BIOL CHEM, V268, P8554; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200; Tyurina YY, 2004, ANTIOXID REDOX SIGN, V6, P209, DOI 10.1089/152308604322899288; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Zucchi MR, 2003, BIOCHEM J, V370, P671, DOI 10.1042/BJ20021521	56	949	984	11	146	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2005	1	4					223	232		10.1038/nchembio727	http://dx.doi.org/10.1038/nchembio727			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GM	16408039				2022-12-25	WOS:000232649000014
J	Bang, D; Gribenko, AV; Tereshko, V; Kossiakoff, AA; Kent, SB; Makhatadze, GI				Bang, D; Gribenko, AV; Tereshko, V; Kossiakoff, AA; Kent, SB; Makhatadze, GI			Dissecting the energetics of protein alpha-helix C-cap termination through chemical protein synthesis	NATURE CHEMICAL BIOLOGY			English	Article							SIDE-CHAINS; LIGATION; SUBSTITUTION; PREFERENCES; PROPENSITY; STABILITY; PEPTIDES; RESIDUES; POSITION; GLYCINE	The alpha-helix is a fundamental protein structural motif and is frequently terminated by a glycine residue(1-5). Explanations for the predominance of glycine at the C-cap terminal portions of alpha-helices have invoked uniquely favorable energetics of this residue in a left-handed conformation(4) or enhanced solvation of the peptide backbone because of the absence of a side chain(6). Attempts to quantify the contributions of these two effects have been made previously, but the issue remains unresolved. Here we have used chemical protein synthesis to dissect the energetic basis of alpha-helix termination by comparing a series of ubiquitin variants containing an L-amino acid or the corresponding D-amino acid at the C-cap Gly35 position. D-Amino acids can adopt a left-handed conformation without energetic penalty, so the contributions of conformational strain and backbone solvation can thus be separated. Analysis of the thermodynamic data revealed that the preference for glycine at the C' position of a helix is predominantly a conformational effect.	Univ Chicago, Inst Biophys Dynam, Chicago, IL 60637 USA; Univ Chicago, Dept Chem, Ctr Integrat Sci, Chicago, IL 60637 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Univ Chicago, Ctr Integrat Sci, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Chicago	Kent, SB (corresponding author), Univ Chicago, Inst Biophys Dynam, 929 E 57th St, Chicago, IL 60637 USA.	skent@uchicago.edu; makhatadze@psu.edu		Gribenko, Alexey/0000-0002-4285-4608	NIGMS NIH HHS [GM54537] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054537] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anil B, 2004, J AM CHEM SOC, V126, P13194, DOI 10.1021/ja047119i; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; Bang D, 2005, ANGEW CHEM INT EDIT, V44, P3852, DOI 10.1002/anie.200463040; Bang D, 2004, ANGEW CHEM INT EDIT, V43, P2534, DOI 10.1002/anie.200353540; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; DOIG AJ, 1995, PROTEIN SCI, V4, P1325, DOI 10.1002/pro.5560040708; Ermolenko DN, 2002, J MOL BIOL, V322, P123, DOI 10.1016/S0022-2836(02)00734-9; Hackeng TM, 1999, P NATL ACAD SCI USA, V96, P10068, DOI 10.1073/pnas.96.18.10068; HERMANS J, 1992, BIOCHEMISTRY-US, V31, P5646, DOI 10.1021/bi00139a031; Kapp GT, 2004, BIOCHEMISTRY-US, V43, P3814, DOI 10.1021/bi035683k; Krantz BA, 2000, BIOCHEMISTRY-US, V39, P11696, DOI 10.1021/bi000792+; PAULING L, 1950, J AM CHEM SOC, V72, P5349, DOI 10.1021/ja01167a545; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Schneider JP, 1998, J AM CHEM SOC, V120, P2764, DOI 10.1021/ja9726771; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SERRANO L, 1992, J MOL BIOL, V227, P544, DOI 10.1016/0022-2836(92)90906-Z; Thomas ST, 2001, P NATL ACAD SCI USA, V98, P10670, DOI 10.1073/pnas.191381798; Yan LZ, 2001, J AM CHEM SOC, V123, P526, DOI 10.1021/ja003265m	20	52	54	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAR	2006	2	3					139	143		10.1038/nchembio766	http://dx.doi.org/10.1038/nchembio766			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013QL	16446709				2022-12-25	WOS:000235424100010
J	Hsu, KL; Pilobello, KT; Mahal, LK				Hsu, KL; Pilobello, KT; Mahal, LK			Analyzing the dynamic bacterial glycome with a lectin microarray approach	NATURE CHEMICAL BIOLOGY			English	Article							ANGUILLA-ANGUILLA AGGLUTININ; ESCHERICHIA-COLI; HELICOBACTER-PYLORI; BINDING-SPECIFICITY; MASS-SPECTROMETRY; LIPOPOLYSACCHARIDES; ARRAY; POLYSACCHARIDES; DIFFERENTIATION; IDENTIFICATION	Glycosylation of bacterial cell surfaces is emerging as a critical factor in symbiosis, pathogenesis, cell-cell interactions and immune evasion(1-3). The lack of high-throughput analytical tools to examine bacterial glycans has been a major obstacle to the field and has hindered closer examination of the dynamics of carbohydrate variation. We have recently developed a lectin microarray for the analysis of glycoproteins(4). Herein we present a rapid analytical system based on this technology for the examination of bacterial glycans. The glycosylation pattern observed distinguishes closely related Escherichia coli strains from one another, providing a facile means of fingerprinting bacteria. In addition, dynamic alterations in the carbohydrate coat of a pathogenic E. coli strain are readily observed. The fast evaluation of real-time alterations in surface-carbohydrate epitopes allows examination of the dynamic role of bacterial sugars in response to external stimuli such as the immune system.	Univ Texas, Inst Cellular & Mol Biol, Ctr Syst & Synth Biol, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Mahal, LK (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Ctr Syst & Synth Biol, Dept Chem & Biochem, 1 Univ Stn A5300, Austin, TX 78712 USA.	lmahal@cm.utexas.edu	Hsu, Ku-Lung/L-6256-2019; Hsu, Ku-Lung/J-2885-2014; Mahal, Lara/GRY-7287-2022	Hsu, Ku-Lung/0000-0001-5620-3972; Hsu, Ku-Lung/0000-0001-5620-3972; Mahal, Lara/0000-0003-4791-8524				Aabenhus R, 2002, J CLIN MICROBIOL, V40, P715, DOI 10.1128/JCM.40.2.715-717.2002; Alvarez RA, 2005, GLYCOBIOLOGY, V15, P1207; Angeloni S, 2005, GLYCOBIOLOGY, V15, P31, DOI 10.1093/glycob/cwh143; Annuk H, 2001, J MED MICROBIOL, V50, P1069, DOI 10.1099/0022-1317-50-12-1069; Badger JL, 1998, INFECT IMMUN, V66, P5692, DOI 10.1128/IAI.66.12.5692-5697.1998; Baldus SE, 1996, GLYCOCONJUGATE J, V13, P585, DOI 10.1007/BF00731446; BUTTKE TM, 1975, J BACTERIOL, V124, P1566, DOI 10.1128/JB.124.3.1566-1573.1975; Caroff M, 2003, CARBOHYD RES, V338, P2431, DOI 10.1016/j.carres.2003.07.010; Coyne MJ, 2005, SCIENCE, V307, P1778, DOI 10.1126/science.1106469; Disney MD, 2004, CHEM BIOL, V11, P1701, DOI 10.1016/j.chembiol.2004.10.011; Ertl P, 2001, ANAL CHEM, V73, P4241, DOI 10.1021/ac010324l; Friis LM, 2005, J MICROBIOL METH, V61, P145, DOI 10.1016/j.mimet.2004.12.003; GAMIAN A, 1994, EUR J BIOCHEM, V225, P1211, DOI 10.1111/j.1432-1033.1994.1211b.x; Harvey DJ, 1999, MASS SPECTROM REV, V18, P349, DOI 10.1002/(SICI)1098-2787(1999)18:6<349::AID-MAS1>3.3.CO;2-8; Hynes SO, 1999, J CLIN MICROBIOL, V37, P1994, DOI 10.1128/JCM.37.6.1994-1998.1999; Karlsson KA, 2000, GLYCOBIOLOGY, V10, P761, DOI 10.1093/glycob/10.8.761; Kuno A, 2005, NAT METHODS, V2, P851, DOI 10.1038/NMETH803; Lerouge I, 2002, FEMS MICROBIOL REV, V26, P17, DOI 10.1111/j.1574-6976.2002.tb00597.x; Manimala JC, 2005, CHEMBIOCHEM, V6, P2229, DOI 10.1002/cbic.200500165; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Pilobello KT, 2005, CHEMBIOCHEM, V6, P985, DOI 10.1002/cbic.200400403; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; Schmidt MA, 2003, TRENDS MICROBIOL, V11, P554, DOI 10.1016/j.tim.2003.10.004; Sletmoen M, 2003, CARBOHYD RES, V338, P2459, DOI 10.1016/j.carres.2003.07.007; Szymanski CM, 2003, J BIOL CHEM, V278, P24509, DOI 10.1074/jbc.M301273200; van der Woude MW, 2004, CLIN MICROBIOL REV, V17, P581, DOI 10.1128/CMR.17.3.581-611.2004; Vimr ER, 2004, MICROBIOL MOL BIOL R, V68, P132, DOI 10.1128/MMBR.68.1.132-153.2004; Weintraub A, 2003, CARBOHYD RES, V338, P2539, DOI 10.1016/j.carres.2003.07.008; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Wu AM, 2004, LIFE SCI, V75, P1085, DOI 10.1016/j.lfs.2004.02.016; YAO ZJ, 1994, J BACTERIOL, V176, P4133, DOI 10.1128/JB.176.13.4133-4143.1994; Zheng T, 2005, J AM CHEM SOC, V127, P9982, DOI 10.1021/ja0505550	32	196	208	3	62	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAR	2006	2	3					153	157		10.1038/nchembio767	http://dx.doi.org/10.1038/nchembio767			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013QL	16462751				2022-12-25	WOS:000235424100013
J	Ji, SP; Zhang, Y; Van Cleemput, J; Jiang, W; Liao, MX; Li, L; Wan, Q; Backstrom, JR; Zhang, X				Ji, SP; Zhang, Y; Van Cleemput, J; Jiang, W; Liao, MX; Li, L; Wan, Q; Backstrom, JR; Zhang, X			Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse	NATURE MEDICINE			English	Article							SEROTONIN; PROTEIN; INHIBITION; NEURONS; REWARD; CELLS; RATS	The widespread distribution of the tumor suppressor PTEN (phosphatase and tensin homolog deleted on chromosome 10) in the adult brain(1) suggests its role in a broad range of brain functions. Here we show evidence supporting a physical interaction of PTEN with a region in the third intracellular loop (3L4F) of the serotonin 5-HT2C receptor (5-HT2cR, formerly 5-HT1c receptor(2)) in cell cultures. PTEN limits agonist-induced phosphorylation of 5-HT2cR through its protein phosphatase activity. We showed the probable existence of PTEN:5-HT2cR complexes in putative dopaminergic neurons in the rat ventral tegmental area (VTA), a brain region in which virtually all abused drugs exert rewarding effects by activating its dopamine neurons(3,4). We synthesized the interfering peptide Tat-3L4F, which is able to disrupt PTEN coupling with 5-HT2cR. Systemic application of Tat-3L4F or the 5-HT2cR agonist Ro600175 suppressed the increased firing rate of VTA dopaminergic neurons induced by Delta 9-tetrahydrocannabinol (THC), the psychoactive ingredient of marijuana. Using behavioral tests, we found that Tat-3L4F or Ro600175 blocks conditioned place preference of THC or nicotine, and that Ro600175, but not Tat-3L4F, produces anxiogenic effects, penile erection, hypophagia and motor functional suppression. These results suggest a potential strategy for treating drug addiction with the Tat-3L4F peptide.	Univ Saskatchewan, Neuropsychiat Res Unit, Dept Psychiat, Saskatoon, SK S7N 5E4, Canada; Toronto Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Toronto Hosp, Dept Physiol, Toronto, ON M5T 2S8, Canada; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA	University of Saskatchewan; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Vanderbilt University	Zhang, X (corresponding author), Univ Saskatchewan, Neuropsychiat Res Unit, Dept Psychiat, 103 Wiggins Rd, Saskatoon, SK S7N 5E4, Canada.	zhangxia@duke.usask.ca		Zhang, Xia/0000-0002-4811-3229				Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Alves SH, 2004, BEHAV PHARMACOL, V15, P37, DOI 10.1097/00008877-200402000-00005; Backstrom JR, 1997, J NEUROSCI METH, V77, P109, DOI 10.1016/S0165-0270(97)00102-7; Backstrom JR, 2000, J BIOL CHEM, V275, P23620, DOI 10.1074/jbc.M000922200; Braida D, 2004, EUR J PHARMACOL, V506, P63, DOI 10.1016/j.ejphar.2004.10.043; BUNNEY BS, 1973, J PHARMACOL EXP THER, V185, P560; Cheer JF, 2000, NEUROSCIENCE, V99, P661, DOI 10.1016/S0306-4522(00)00241-4; Clifton PG, 2000, PSYCHOPHARMACOLOGY, V152, P256, DOI 10.1007/s002130000504; Di Matteo V, 2002, PHARMACOL BIOCHEM BE, V71, P727, DOI 10.1016/S0091-3057(01)00705-5; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Grottick AJ, 2000, J PHARMACOL EXP THER, V295, P1183; Hannesson DK, 2001, J NEUROSCI, V21, P4443, DOI 10.1523/JNEUROSCI.21-12-04443.2001; Higgins GA, 2003, EUR J PHARMACOL, V480, P151, DOI 10.1016/j.ejphar.2003.08.102; JOHNSON SW, 1992, J NEUROSCI, V12, P483; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Li L, 2003, J CELL BIOCHEM, V88, P24, DOI 10.1002/jcb.10312; Lupica CR, 2004, BRIT J PHARMACOL, V143, P227, DOI 10.1038/sj.bjp.0705931; Nestler EJ, 2004, TRENDS PHARMACOL SCI, V25, P210, DOI 10.1016/j.tips.2004.02.005; Ning K, 2004, J NEUROSCI, V24, P4052, DOI 10.1523/JNEUROSCI.5449-03.2004; POMPEIANO M, 1994, MOL BRAIN RES, V23, P163, DOI 10.1016/0169-328X(94)90223-2; Rice HB, 2002, PHARMACOL BIOCHEM BE, V73, P545, DOI 10.1016/S0091-3057(02)00839-0; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Steelman LS, 2004, EXPERT OPIN THER TAR, V8, P537, DOI 10.1517/14728222.8.6.537; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szabo B, 2002, EUR J NEUROSCI, V15, P2057, DOI 10.1046/j.1460-9568.2002.02041.x; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wood MD, 2003, CNS NEUROL DISORD-DR, V2, P383, DOI 10.2174/1568007033482698; Zhang X, 2001, J NEUROSCI, V21, P3674, DOI 10.1523/JNEUROSCI.21-10-03674.2001	30	123	126	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					324	329		10.1038/nm1349	http://dx.doi.org/10.1038/nm1349			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16474401				2022-12-25	WOS:000235802900032
J	Park, TJ; Haigo, SL; Wallingford, JB				Park, TJ; Haigo, SL; Wallingford, JB			Ciliogenesis defects in embryos lacking inturned or fuzzy function are associated with failure of planar cell polarity and Hedgehog signaling	NATURE GENETICS			English	Article							DROSOPHILA TISSUE POLARITY; INTRAFLAGELLAR TRANSPORT PROTEINS; NEURAL-TUBE CLOSURE; CONVERGENT EXTENSION; XENOPUS-LAEVIS; SONIC HEDGEHOG; QUAIL OVIDUCT; FLOOR PLATE; GENE; CILIA	The vertebrate planar cell polarity (PCP) pathway has previously been found to control polarized cell behaviors rather than cell fate. We report here that disruption of Xenopus laevis orthologs of the Drosophila melanogaster PCP effectors inturned (in) or fuzzy (fy) affected not only PCP-dependent convergent extension but also elicited embryonic phenotypes consistent with defective Hedgehog signaling. These defects in Hedgehog signaling resulted from a broad requirement for Inturned and Fuzzy in ciliogenesis. We show that these proteins govern apical actin assembly and thus control the orientation, but not assembly, of ciliary microtubules. Finally, accumulation of Dishevelled and Inturned near the basal apparatus of cilia suggests that these proteins function in a common pathway with core PCP components to regulate ciliogenesis. Together, these data highlight the interrelationships between cell polarity, cellular morphogenesis, signal transduction and cell fate specification.	Univ Texas, Dept Mol Cell & Dev Biol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of California System; University of California Berkeley	Wallingford, JB (corresponding author), Univ Texas, Dept Mol Cell & Dev Biol, Austin, TX 78712 USA.	wallingford@mail.utexas.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074104] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM074104] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler PN, 2004, CURR BIOL, V14, P2046, DOI 10.1016/j.cub.2004.11.007; Adler PN, 2001, CURR OPIN CELL BIOL, V13, P635, DOI 10.1016/S0955-0674(00)00263-5; ASSHETON R, 1896, Q J MICROSC SCI, V38, P465; BOISVIEUXULRICH E, 1990, CELL TISSUE RES, V259, P443, DOI 10.1007/BF01740770; BOISVIEUXULRICH E, 1991, BIOL CELL, V72, P3, DOI 10.1016/0248-4900(91)90072-U; CHAILLEY B, 1989, BIOL CELL, V67, P81, DOI 10.1111/j.1768-322X.1989.tb03012.x; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collier S, 1997, DEVELOPMENT, V124, P4029; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Curtin JA, 2003, CURR BIOL, V13, P1129, DOI 10.1016/S0960-9822(03)00374-9; Draper BW, 2001, GENESIS, V30, P154, DOI 10.1002/gene.1053; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; EKKER SC, 1995, DEVELOPMENT, V121, P2337; Feiguin F, 2001, DEV CELL, V1, P93, DOI 10.1016/S1534-5807(01)00010-7; Hagiwara H, 2004, INT REV CYTOL, V234, P101, DOI 10.1016/S0074-7696(04)34003-9; Hallonet M, 1999, GENE DEV, V13, P3106, DOI 10.1101/gad.13.23.3106; Han YG, 2003, CURR BIOL, V13, P1679, DOI 10.1016/j.cub.2003.08.034; Hu D, 1999, DEVELOPMENT, V126, P4873; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Jenny A, 2005, NAT CELL BIOL, V7, P691, DOI 10.1038/ncb1271; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; KELLER R, 1992, DEV DYNAM, V193, P199, DOI 10.1002/aja.1001930302; Keller R, 2000, PHILOS T R SOC B, V355, P897, DOI 10.1098/rstb.2000.0626; Kim JC, 2004, NAT GENET, V36, P462, DOI 10.1038/ng1352; Kimmel CB, 1998, DEV BIOL, V203, P245, DOI 10.1006/dbio.1998.9016; KONIG G, 1993, DEV BIOL, V160, P355, DOI 10.1006/dbio.1993.1312; Kramer-Zucker AG, 2005, DEVELOPMENT, V132, P1907, DOI 10.1242/dev.01772; Kulaga HM, 2004, NAT GENET, V36, P994, DOI 10.1038/ng1418; Lee H, 2002, GENETICS, V160, P1535; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Lopez SL, 2003, DEVELOPMENT, V130, P2225, DOI 10.1242/dev.00443; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; NISHIKAWA S, 1992, HISTOCHEMISTRY, V98, P355, DOI 10.1007/BF00271070; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Pan JM, 2005, LAB INVEST, V85, P452, DOI 10.1038/labinvest.3700253; Park WJ, 1996, DEVELOPMENT, V122, P961; Pichon B, 2002, DEV GENES EVOL, V212, P491, DOI 10.1007/s00427-002-0270-z; Ross AJ, 2005, NAT GENET, V37, P1135, DOI 10.1038/ng1644; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Take-uchi M, 2003, DEVELOPMENT, V130, P955, DOI 10.1242/dev.00305; TAMM S, 1988, J CELL SCI, V89, P67; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; TRUEB L, 1992, J MORPHOL, V214, P1, DOI 10.1002/jmor.1052140102; Wada N, 2005, DEVELOPMENT, V132, P3977, DOI 10.1242/dev.01943; Wallingford JB, 2005, AM J MED GENET C, V135C, P59, DOI 10.1002/ajmg.c.30054; Wallingford JB, 2002, DEVELOPMENT, V129, P5815, DOI 10.1242/dev.00123; Wallingford JB, 2001, DEVELOPMENT, V128, P2581; Watanabe D, 2003, DEVELOPMENT, V130, P1725, DOI 10.1242/dev.00407	50	292	302	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					303	311		10.1038/ng1753	http://dx.doi.org/10.1038/ng1753			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16493421				2022-12-25	WOS:000235589600011
J	Sato, TK; Yamada, RG; Ukai, H; Baggs, JE; Miraglia, LJ; Kobayashi, TJ; Welsh, DK; Kay, SA; Ueda, HR; Hogenesch, JB				Sato, TK; Yamada, RG; Ukai, H; Baggs, JE; Miraglia, LJ; Kobayashi, TJ; Welsh, DK; Kay, SA; Ueda, HR; Hogenesch, JB			Feedback repression is required for mammalian circadian clock function	NATURE GENETICS			English	Article							KAIC PHOSPHORYLATION; GENE-EXPRESSION; TRANSCRIPTION; MPER1; LOOP; CRYPTOCHROMES; MECHANISM; RHYTHMS; PROTEIN; PERIOD	Direct evidence for the requirement of transcriptional feedback repression in circadian clock function has been elusive. Here, we developed a molecular genetic screen in mammalian cells to identify mutants of the circadian transcriptional activators CLOCK and BMAL1, which were uncoupled from CRYPTOCHROME (CRY)- mediated transcriptional repression. Notably, mutations in the PER-ARNT-SIM domain of CLOCK and the C terminus of BMAL1 resulted in synergistic insensitivity through reduced physical interactions with CRY. Coexpression of these mutant proteins in cultured fibroblasts caused arrhythmic phenotypes in population and single-cell assays. These data demonstrate that CRY-mediated repression of the CLOCK/BMAL1 complex activity is required for maintenance of circadian rhythmicity and provide formal proof that transcriptional feedback is required for mammalian clock function.	Genom Inst, San Diego, CA 92121 USA; Novartis Res Fdn, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Genome Technol, Jupiter, FL 33458 USA; RIKEN, Ctr Dev Biol, Lab Syst Biol, Kobe, Hyogo 6500047, Japan; Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92037 USA; Vet Adm San Diego Healthcare Syst, La Jolla, CA 92161 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Novartis; Scripps Research Institute; Scripps Research Institute; RIKEN; Scripps Research Institute; University of California System; University of California San Diego; Scripps Research Institute	Ueda, HR (corresponding author), Genom Inst, 10675 John J Hopkins Dr, San Diego, CA 92121 USA.	uedah-tky@umin.ac.jp; hogenesch@scripps.edu	Kay, Steve A/F-6025-2011; Ueda, Hiroki R/C-5037-2014; Welsh, David K/G-2277-2011	Kay, Steve A/0000-0002-0402-2878; Ueda, Hiroki R/0000-0001-8342-9176; 	NIMH NIH HHS [P50 MH074924, P50 MH074924-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH074924] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Akashi M, 2005, NAT STRUCT MOL BIOL, V12, P441, DOI 10.1038/nsmb925; Cook E. R., 1981, Tree-Ring Bulletin, V41, P45; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Nakajima M, 2005, SCIENCE, V308, P414, DOI 10.1126/science.1108451; Okamura H, 1999, SCIENCE, V286, P2531, DOI 10.1126/science.286.5449.2531; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Tomita J, 2005, SCIENCE, V307, P251, DOI 10.1126/science.1102540; Ueda HR, 2005, NAT GENET, V37, P187, DOI 10.1038/ng1504; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Welsh DK, 2004, CURR BIOL, V14, P2289, DOI 10.1016/j.cub.2004.11.057; Yildiz O, 2005, MOL CELL, V17, P69, DOI 10.1016/j.molcel.2004.11.022; Yoo SH, 2005, P NATL ACAD SCI USA, V102, P2608, DOI 10.1073/pnas.0409763102; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	33	274	279	3	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2006	38	3					312	319		10.1038/ng1745	http://dx.doi.org/10.1038/ng1745			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	015ZG	16474406	Green Accepted			2022-12-25	WOS:000235589600012
J	Kawauchi, T; Chihama, K; Nabeshima, Y; Hoshino, M				Kawauchi, T; Chihama, K; Nabeshima, Y; Hoshino, M			Cdk5 phosphorylates and stabilizes p27(kip1) contributing to actin organization and cortical neuronal migration	NATURE CELL BIOLOGY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-MIGRATION; MICE LACKING; CEREBRAL-CORTEX; NERVOUS-SYSTEM; NUCLEAR EXPORT; P27; GROWTH; MOUSE; EXPRESSION	p(27kip1), a cyclin- dependent kinase ( CDK) inhibitor ( CKI), generally suppresses CDK activity in proliferating cells. Although another role of p27 in cell migration has been recently suggested in vitro, the physiological importance of p27 in cell migration remains elusive, as p27- deficient mice have not shown any obvious migration- defect- related phenotypes. Here, we show that Cdk5, an unconventional neuronal CDK, phosphorylates and stabilizes p27 as an upstream regulator, maintaining the amount of p27 in post- mitotic neurons. In vivo RNA interference ( RNAi) experiments showed that reduced amounts of p27 caused inhibition of cortical neuronal migration and decreased the amount of F- actin in the processes of migrating neurons. The Cdk5 p27 pathway activates an actin- binding protein, cofilin, which is also shown to be involved in cortical neuronal migration in vivo. Our findings shed light on a previously unknown new relationship between CDK and CKI in GO- arrested cells that regulates cytoskeletal reorganization and neuronal migration during corticogenesis.	Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi 3320012, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Hoshino, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan.	mikio@lmls.med.kyoto-u.ac.jp	Kawauchi, Takeshi/L-4770-2013	Kawauchi, Takeshi/0000-0002-8650-4474				Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Bai JL, 2003, NAT NEUROSCI, V6, P1277, DOI 10.1038/nn1153; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Bielas S, 2004, ANNU REV CELL DEV BI, V20, P593, DOI 10.1146/annurev.cellbio.20.082503.103047; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Corbo JC, 2002, J NEUROSCI, V22, P7548; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gilmore EC, 1998, J NEUROSCI, V18, P6370; Goto T, 2004, DEV NEUROSCI-BASEL, V26, P208, DOI 10.1159/000082138; Gotz M, 2003, NAT NEUROSCI, V6, P1245, DOI 10.1038/nn1203-1245; Gungabissoon RA, 2003, J HISTOCHEM CYTOCHEM, V51, P411, DOI 10.1177/002215540305100402; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Kawauchi T, 2005, BIOCHEM BIOPH RES CO, V331, P50, DOI 10.1016/j.bbrc.2005.03.132; Kawauchi T, 2003, EMBO J, V22, P4190, DOI 10.1093/emboj/cdg413; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kotake Y, 2005, J BIOL CHEM, V280, P1095, DOI 10.1074/jbc.M406117200; Lacy ER, 2005, J MOL BIOL, V349, P764, DOI 10.1016/j.jmb.2005.04.019; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Matsuo N, 2003, MOL CELL NEUROSCI, V24, P69, DOI 10.1016/S1044-7431(03)00122-2; Matsuo N, 2002, J BIOL CHEM, V277, P2860, DOI 10.1074/jbc.M106186200; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Mitsuhashi T, 2001, P NATL ACAD SCI USA, V98, P6435, DOI 10.1073/pnas.111051398; Mochida GH, 2001, CURR OPIN NEUROL, V14, P151, DOI 10.1097/00019052-200104000-00003; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Nagahama H, 2001, ANAT EMBRYOL, V203, P77, DOI 10.1007/s004290000146; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nikolic M, 2004, TRENDS CELL BIOL, V14, P1, DOI 10.1016/j.tcb.2003.10.010; Noctor SC, 2004, NAT NEUROSCI, V7, P136, DOI 10.1038/nn1172; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tabata H, 2003, J NEUROSCI, V23, P9996; Tarui T, 2005, CEREB CORTEX, V15, P1343, DOI 10.1093/cercor/bhi017; TSAI LH, 1993, DEVELOPMENT, V119, P1029; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Yoshizawa M, 2005, J NEUROSCI, V25, P4406, DOI 10.1523/JNEUROSCI.4955-04.2005; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	49	221	229	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					17	U6		10.1038/ncb1338	http://dx.doi.org/10.1038/ncb1338			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	16341208				2022-12-25	WOS:000234651500008
J	Pedelacq, JD; Cabantous, S; Tran, T; Terwilliger, TC; Waldo, GS				Pedelacq, JD; Cabantous, S; Tran, T; Terwilliger, TC; Waldo, GS			Engineering and characterization of a superfolder green fluorescent protein	NATURE BIOTECHNOLOGY			English	Article							CIRCULAR PERMUTATION; CRYSTAL-STRUCTURE; FOLDING DEFECTS; BETA-LACTAMASE; IN-VITRO; MUTATIONS; STABILITY; EVOLUTION; GFP; SUPPRESSORS	Existing variants of green fluorescent protein (GFP) often misfold when expressed as fusions with other proteins. We have generated a robustly folded version of GFP, called 'superfolder' GFP, that folds well even when fused to poorly folded polypeptides. Compared to 'folding reporter' GFP, a folding-enhanced GFP containing the 'cycle-3' mutations and the 'enhanced GFP' mutations F64L and S65T, superfolder GFP shows improved tolerance of circular permutation, greater resistance to chemical denaturants and improved folding kinetics. The fluorescence of Escherichia coli cells expressing each of eighteen proteins from Pyrobaculum aerophilum as fusions with superfolder GFP was proportional to total protein expression. In contrast, fluorescence of folding reporter GFP fusion proteins was strongly correlated with the productive folding yield of the passenger protein. X-ray crystallographic structural analyses helped explain the enhanced folding of superfolder GFP relative to folding reporter GFP.	Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14851 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Cornell University	Waldo, GS (corresponding author), Los Alamos Natl Lab, Biosci Div, MS-M888, Los Alamos, NM 87545 USA.	waldo@lanl.gov	Terwilliger, Thomas C/K-4109-2012; Terwilliger, Thomas/AAM-4079-2020; Cabantous, Stephanie/AAB-5113-2020; Terwilliger, Thomas/AEF-4827-2022; Pedelacq, Jean-Denis/C-6053-2011; Cabantous, Stephanie/M-3282-2014	Terwilliger, Thomas C/0000-0001-6384-0320; Terwilliger, Thomas/0000-0001-6384-0320; Cabantous, Stephanie/0000-0002-8406-9421; Cabantous, Stephanie/0000-0002-8406-9421; PEDELACQ, Jean-Denis/0000-0002-3202-2517				Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Ayoob JC, 2001, MOL BIOTECHNOL, V17, P65, DOI 10.1385/MB:17:1:65; Babiychuk E, 2001, PLANT J, V28, P245, DOI 10.1046/j.1365-313X.2001.01143.x; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Battistutta R, 2000, PROTEINS, V41, P429, DOI 10.1002/1097-0134(20001201)41:4<429::AID-PROT10>3.0.CO;2-D; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Brumwell C, 2002, EXP CELL RES, V279, P310, DOI 10.1006/excr.2002.5604; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabantous S, 2005, NAT BIOTECHNOL, V23, P102, DOI 10.1038/nbt1044; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DAOPIN S, 1991, CIBA F SYMP, V161, P52; Davis TN, 2004, CURR OPIN CHEM BIOL, V8, P49, DOI 10.1016/j.cbpa.2003.11.003; Ewert S, 2003, BIOCHEMISTRY-US, V42, P1517, DOI 10.1021/bi026448p; FANE B, 1991, GENETICS, V127, P263; FANE B, 1991, J BIOL CHEM, V266, P11640; Gautier I, 2001, BIOPHYS J, V80, P3000, DOI 10.1016/S0006-3495(01)76265-0; Goldman A, 1995, STRUCTURE, V3, P1277, DOI 10.1016/S0969-2126(01)00263-5; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Huang WZ, 1997, P NATL ACAD SCI USA, V94, P8801, DOI 10.1073/pnas.94.16.8801; Magliery TJ, 2004, EUR J BIOCHEM, V271, P1595, DOI 10.1111/j.1432-1033.2004.04075.x; Martin BR, 2005, NAT BIOTECHNOL, V23, P1308, DOI 10.1038/nbt1136; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MITRAKI A, 1993, J BIOL CHEM, V268, P20071; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; Nakayama M, 2003, BIOCHEM BIOPH RES CO, V312, P825, DOI 10.1016/j.bbrc.2003.10.193; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Pace C N, 1986, Methods Enzymol, V131, P266; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; Pedelacq JD, 2002, NAT BIOTECHNOL, V20, P927, DOI 10.1038/nbt732; Peelle B, 2001, CHEM BIOL, V8, P521, DOI 10.1016/S1074-5521(01)00031-X; Phillips GN, 1997, CURR OPIN STRUC BIOL, V7, P821, DOI 10.1016/S0959-440X(97)80153-4; Shagin DA, 2004, MOL BIOL EVOL, V21, P841, DOI 10.1093/molbev/msh079; Sideraki V, 2001, P NATL ACAD SCI USA, V98, P283, DOI 10.1073/pnas.011454198; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Stepanenko OV, 2004, BIOCHEMISTRY-US, V43, P14913, DOI 10.1021/bi048725t; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Topell S, 1999, FEBS LETT, V457, P283, DOI 10.1016/S0014-5793(99)01044-3; Topell Simon, 2002, Methods Mol Biol, V183, P31; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Waldo GS, 2003, CURR OPIN CHEM BIOL, V7, P33, DOI 10.1016/S1367-5931(02)00017-0; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	47	1378	1427	15	344	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2006	24	1					79	88		10.1038/nbt1172	http://dx.doi.org/10.1038/nbt1172			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	001SE	16369541				2022-12-25	WOS:000234555800028
J	Sakamoto, T; Morinaka, Y; Ohnishi, T; Sunohara, H; Fujioka, S; Ueguchi-Tanaka, M; Mizutani, M; Sakata, K; Takatsuto, S; Yoshida, S; Tanaka, H; Kitano, H; Matsuoka, M				Sakamoto, T; Morinaka, Y; Ohnishi, T; Sunohara, H; Fujioka, S; Ueguchi-Tanaka, M; Mizutani, M; Sakata, K; Takatsuto, S; Yoshida, S; Tanaka, H; Kitano, H; Matsuoka, M			Erect leaves caused by brassinosteroid deficiency increase biomass production and grain yield in rice	NATURE BIOTECHNOLOGY			English	Article							GENETIC MANIPULATION; GIBBERELLIN METABOLISM; LAMINA INCLINATION; GREEN-REVOLUTION; ENZYME; MUTANT; CYTOCHROME-P450; ELONGATION; OXIDATION; PREVENTS	New cultivars with very erect leaves, which increase light capture for photosynthesis and nitrogen storage for grain filling, may have increased grain yields(1). Here we show that the erect leaf phenotype of a rice brassinosteroid-deficient mutant, osdwarf4-1, is associated with enhanced grain yields under conditions of dense planting, even without extra fertilizer. Molecular and biochemical studies reveal that two different cytochrome P450s, CYP90B2/OsDWARF4 and CYP724B1/D11, function redundantly in C-22 hydroxylation, the rate-limiting step of brassinosteroid biosynthesis. Therefore, despite the central role of brassinosteroids in plant growth and development, mutation of OsDWARF4 alone causes only limited defects in brassinosteroid biosynthesis and plant morphology. These results suggest that regulated genetic modulation of brassinosteroid biosynthesis can improve crops without the negative environmental effects of fertilizers.	Univ Tokyo, Field Protect Sci Ctr, Grad Sch Agr & Life Sci, Tokyo 1880002, Japan; Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan; RIKEN, Wako, Saitama 3510198, Japan; Joetsu Univ Educ, Dept Chem, Niigata 9438512, Japan; Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058602, Japan	University of Tokyo; Nagoya University; Kyoto University; RIKEN; Joetsu University Education; National Institute of Agrobiological Sciences - Japan	Sakamoto, T (corresponding author), Univ Tokyo, Field Protect Sci Ctr, Grad Sch Agr & Life Sci, 1-1-1 Midoricho, Tokyo 1880002, Japan.	orchardist@fm.a.u-tokyo.ac.jp		Mizutani, Masaharu/0000-0002-4321-0644				Bancos S, 2002, PLANT PHYSIOL, V130, P504, DOI 10.1104/pp.005439; Bishop GJ, 1999, P NATL ACAD SCI USA, V96, P1761, DOI 10.1073/pnas.96.4.1761; Choe S, 2001, PLANT J, V26, P573, DOI 10.1046/j.1365-313x.2001.01055.x; Choe SW, 1998, PLANT CELL, V10, P231, DOI 10.1105/tpc.10.2.231; Evans LT., 1993, CROP EVOLUTION ADAPT; Fujioka S, 2002, PLANT PHYSIOL, V130, P930, DOI 10.1104/pp.008722; FUJITA S, IN PRESS PLANT J, V45; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; Hong Z, 2003, PLANT CELL, V15, P2900, DOI 10.1105/tpc.014712; Hong Z, 2002, PLANT J, V32, P495, DOI 10.1046/j.1365-313X.2002.01438.x; Horton P, 2000, J EXP BOT, V51, P475, DOI 10.1093/jexbot/51.suppl_1.475; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; MAEDA E, 1965, PHYSIOL PLANTARUM, V18, P813, DOI 10.1111/j.1399-3054.1965.tb06940.x; Mann CC, 1999, SCIENCE, V283, P310, DOI 10.1126/science.283.5400.310; Neff MM, 1999, P NATL ACAD SCI USA, V96, P15316, DOI 10.1073/pnas.96.26.15316; Peng JR, 1999, NATURE, V400, P256, DOI 10.1038/22307; Saito S, 2004, PLANT PHYSIOL, V134, P1439, DOI 10.1104/pp.103.037614; Sakamoto T, 2004, CURR OPIN BIOTECH, V15, P144, DOI 10.1016/j.copbio.2004.02.003; Sakamoto T, 2004, PLANT PHYSIOL, V134, P1642, DOI 10.1104/pp.103.033696; Sakamoto T, 2003, NAT BIOTECHNOL, V21, P909, DOI 10.1038/nbt847; Sasaki A, 2002, NATURE, V416, P701, DOI 10.1038/416701a; Sinclair TR, 1999, SCIENCE, V283, P1456; Tanabe S, 2005, PLANT CELL, V17, P776, DOI 10.1105/tpc.104.024950; WADA K, 1981, PLANT CELL PHYSIOL, V22, P323; Yamamuro C, 2000, PLANT CELL, V12, P1591, DOI 10.1105/tpc.12.9.1591	25	443	504	10	181	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2006	24	1					105	109		10.1038/nbt1173	http://dx.doi.org/10.1038/nbt1173			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	001SE	16369540				2022-12-25	WOS:000234555800032
J	Yach, D; Stuckler, D; Brownell, KD				Yach, D; Stuckler, D; Brownell, KD			Epidemiologic and economic consequences of the global epidemics of obesity and diabetes	NATURE MEDICINE			English	Editorial Material							CHRONIC DISEASES; CARE; PERFORMANCE; OVERWEIGHT; EMPLOYMENT; MELLITUS; CHILDREN; CANADA; GROWTH; RISKS		Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Dept Psychol, New Haven, CT 06520 USA; Yale Univ, Rudd Ctr Food Policy & Obes, New Haven, CT 06520 USA	Yale University; Yale University; Yale University		derek.yach@yale.edu	Stuckler, David/H-2261-2012	Stuckler, David/0000-0002-1288-8401				Anderson PM, 2003, J HEALTH ECON, V22, P477, DOI 10.1016/S0167-6296(03)00022-5; [Anonymous], 2000, Pediatrics, V105, P671; [Anonymous], 2005, PREV CHRON DIS VIT I; Barcelo A, 2003, B WORLD HEALTH ORGAN, V81, P19; Bloomgarden ZT, 2004, DIABETES CARE, V27, P998, DOI 10.2337/diacare.27.4.998; Cawley J, 2004, J HUM RESOUR, V39, P451, DOI 10.2307/3559022; CAWLEY J, 2004, NATL BUREAU EC RES W; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P80; CHALE SS, 1992, BRIT MED J, V304, P1215, DOI 10.1136/bmj.304.6836.1215; Chou SY, 2004, J HEALTH ECON, V23, P565, DOI 10.1016/j.jhealeco.2003.10.003; Cockram C. S., 2000, Hong Kong Medical Journal, V6, P43; Cutler DM, 2003, J ECON PERSPECT, V17, P93, DOI 10.1257/089533003769204371; Datar A, 2004, OBES RES, V12, P58, DOI 10.1038/oby.2004.9; Dawson KG, 2002, DIABETES CARE, V25, P1303, DOI 10.2337/diacare.25.8.1303; Drewnowski A, 2004, AM J PREV MED, V27, P154, DOI 10.1016/j.amepre.2004.06.011; Ezzati M, 2005, PLOS MED, V2, P404, DOI 10.1371/journal.pmed.0020133; Finkelstein EA, 2005, ANNU REV PUBL HEALTH, V26, P239, DOI 10.1146/annurev.publhealth.26.021304.144628; Goetzel RZ, 2005, J OCCUP ENVIRON MED, V47, P759, DOI 10.1097/01.jom.0000172868.05935.67; Gura T, 2003, SCIENCE, V299, P849, DOI 10.1126/science.299.5608.849; HENRYLEE A, 1999, SMALL APPL RES, V6; James WPT, 2003, COMP QUANTIFICATION; Katzmarzyk PT, 2004, CAN J APPL PHYSIOL, V29, P90, DOI 10.1139/h04-008; Kibriya MG, 1999, DIABETES RES CLIN PR, V46, P253, DOI 10.1016/S0168-8227(99)00093-5; Kraut A, 2001, DIABETES CARE, V24, P64, DOI 10.2337/diacare.24.1.64; Kuchler F., 2002, FoodReview, V25, P33; LAKDAWALLA D, 2005, J AM EC REV, V95; Lee WJ, 2005, OBES SURG, V15, P751, DOI 10.1381/0960892054222614; Leeder S, 2004, RACE TIME CHALLENGE; Lin T, 2001, DIABETES RES CLIN PR, V54, pS43; MACKINTOSH M, 2003, RUIG RES U INT GENEV; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mete C., 2002, 846 YAL U EC GROWTH; Mo-Suwan L, 1999, INT J OBESITY, V23, P272, DOI 10.1038/sj.ijo.0800808; Neuhann HF, 2002, DIABETIC MED, V19, P509, DOI 10.1046/j.1464-5491.2002.00673.x; Niefeld MR, 2003, DIABETES CARE, V26, P1344, DOI 10.2337/diacare.26.5.1344; Nielsen Samara Joy, 2003, JAMA (Journal of the American Medical Association), V289, P450, DOI 10.1001/jama.289.4.450; *OXF HLTH ALL WORK, 2005, EC COSTS CHRON DIS E; Pereira MA, 2005, LANCET, V365, P36, DOI 10.1016/S0140-6736(04)17663-0; Petersen M, 2003, DIABETES CARE, V26, P917; Philipson T, 2001, HEALTH ECON, V10, P1, DOI 10.1002/1099-1050(200101)10:1<1::AID-HEC586>3.0.CO;2-1; Philipson TJ, 2003, PERSPECT BIOL MED, V46, pS87; Pinhas-Hamiel O, 2005, J PEDIATR-US, V146, P693, DOI 10.1016/j.jpeds.2004.12.042; Popkin BM, 2001, J NUTR, V131, p871S, DOI 10.1093/jn/131.3.871S; Putnam J., 2002, FoodReview, V25, P2; Reddy KS, 2005, LANCET, V366, P1744, DOI [10.1016/s0140-6736(05)67343-6, 10.1016/S0140-6736(05)67343-6]; Roglic G, 2005, DIABETES CARE, V28, P2130, DOI 10.2337/diacare.28.9.2130; Sander Beate, 2003, Eur J Health Econ, V4, P248; Santry HP, 2005, JAMA-J AM MED ASSOC, V294, P1909, DOI 10.1001/jama.294.15.1909; Sarlio-Lahteenkorva S, 1999, INT J EPIDEMIOL, V28, P445, DOI 10.1093/ije/28.3.445; Schmid A, 2005, SOZ PRAVENTIV MED, V50, P87, DOI 10.1007/s00038-004-4067-x; Shobhana R, 2000, DIABETES RES CLIN PR, V48, P37, DOI 10.1016/S0168-8227(99)00130-8; Sturm R, 2002, HEALTH AFFAIR, V21, P245, DOI 10.1377/hlthaff.21.2.245; TSHABALALAMSIMA.M, 2005, COMMUNICATION   0915; U.S. Department of Health and Human Services, 2001, SURG GEN CALL ACT PR; Uauy R., 2004, OBES REV S1, V5, P4, DOI [10.1111/j.1467-789X.2004.00133.x, DOI 10.1111/J.1467-789X.2004.00133.X]; Variyam JN, 2005, NUTR LABELING FOOD A; Wang LD, 2005, LANCET, V366, P1821, DOI 10.1016/S0140-6736(05)67344-8; *WHO FOOD AGR ORG, 2003, 916 WHO	58	548	563	3	67	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					62	66		10.1038/nm0106-62	http://dx.doi.org/10.1038/nm0106-62			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397571				2022-12-25	WOS:000234419000051
J	Mukherjee, A; Veraksa, A; Bauer, A; Rosse, C; Camonis, J; Artavanis-Tsakonas, S				Mukherjee, A; Veraksa, A; Bauer, A; Rosse, C; Camonis, J; Artavanis-Tsakonas, S			Regulation of notch signalling by non-visual beta-arrestin	NATURE CELL BIOLOGY			English	Article							FACTOR-I RECEPTOR; DROSOPHILA-MELANOGASTER; ANKYRIN REPEATS; DOWN-REGULATION; PROTEIN; DELTEX; PATHWAY; ENDOCYTOSIS; BETA-ARRESTIN-2; UBIQUITINATION	Signalling activity of the Notch receptor, which plays a fundamental role in metazoan cell fate determination, is controlled at multiple levels. We uncovered a Notch signal-controlling mechanism that depends on the ability of the non-visual P-arrestin, Kurtz (Krz), to influence the degradation and, consequently, the function of the Notch receptor. We identified Krz as a binding partner of a known Notch-pathway modulator, Deltex (Dx), and demonstrated the existence of a trimeric Notch-Dx-Krz protein complex. This complex mediates the degradation of the Notch receptor through a ubiquitination-dependent pathway. Our results establish a novel mode of regulation of Notch signalling and define a new function for non-visual beta-arrestins.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Ctr,Dept Cell Biol, Charlestown, MA 02129 USA; Inst Curie, F-75248 Paris, France; Cellzome AG, D-69117 Heidelberg, Germany; Coll France, F-75231 Paris, France	Harvard University; Massachusetts General Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; GlaxoSmithKline; Cellzome GmbH; UDICE-French Research Universities; PSL Research University Paris; College de France	Artavanis-Tsakonas, S (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Ctr,Dept Cell Biol, Charlestown, MA 02129 USA.	tsakonas@helix.mgh.harvard.edu	Rosse, Carine/L-4775-2017	Veraksa, Alexey/0000-0003-2920-080X	NCI NIH HHS [CA098402] Funding Source: Medline; NIGMS NIH HHS [GM62931] Funding Source: Medline; NINDS NIH HHS [NS26084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026084, R37NS026084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aravind L, 2001, TRENDS BIOCHEM SCI, V26, P273, DOI 10.1016/S0968-0004(01)01787-X; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; BUSSEAU I, 1994, GENETICS, V136, P585; Chen B, 2003, ATHEROSCLEROSIS SUPP, V4, P301, DOI 10.1016/S1567-5688(03)91288-8; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Chen W, 2004, SCIENCE, V306, P2257, DOI 10.1126/science.1104135; Cornell M, 1999, GENETICS, V152, P567; deCelis JF, 1996, DEVELOPMENT, V122, P359; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Harper JA, 2003, CLIN GENET, V64, P461, DOI 10.1046/j.1399-0004.2003.00194.x; Hori K, 2004, DEVELOPMENT, V131, P5527, DOI 10.1242/dev.01448; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Luttrell LM, 2002, J CELL SCI, V115, P455; Matsuno K, 2002, DEVELOPMENT, V129, P1049; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Nellesen DT, 1999, DEV BIOL, V213, P33, DOI 10.1006/dbio.1999.9324; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Ramain P, 2001, CURR BIOL, V11, P1729, DOI 10.1016/S0960-9822(01)00562-0; RAMOS RGP, 1989, GENETICS, V123, P337; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Roman G, 2000, GENETICS, V155, P1281; Sakata T, 2004, CURR BIOL, V14, P2228, DOI 10.1016/j.cub.2004.12.028; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Takeyama K, 2003, J BIOL CHEM, V278, P21930, DOI 10.1074/jbc.M301157200; Tsuda L, 2002, CELL, V110, P625, DOI 10.1016/S0092-8674(02)00875-9; Veraksa A, 2005, DEV DYNAM, V232, P827, DOI 10.1002/dvdy.20272; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilbanks AM, 2004, SCIENCE, V306, P2264, DOI 10.1126/science.1104193; Wilkin MB, 2004, CURR BIOL, V14, P2237, DOI 10.1016/j.cub.2004.11.030; Witherow DS, 2004, P NATL ACAD SCI USA, V101, P8603, DOI 10.1073/pnas.0402851101; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu JH, 2003, J BIOL CHEM, V278, P44238, DOI 10.1074/jbc.M309450200; XU T, 1993, DEVELOPMENT, V117, P1223; XU T, 1990, GENETICS, V126, P665; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200	50	166	169	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2005	7	12					1191	1201		10.1038/ncb1327	http://dx.doi.org/10.1038/ncb1327			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	990MW	16284625				2022-12-25	WOS:000233748900012
J	Silverman, J; Lu, Q; Bakker, A; To, W; Duguay, A; Alba, BM; Smith, R; Rivas, A; Li, P; Le, H; Whitehorn, E; Moore, KW; Swimmer, C; Perlroth, V; Vogt, M; Kolkman, J; Stemmer, WPC				Silverman, J; Lu, Q; Bakker, A; To, W; Duguay, A; Alba, BM; Smith, R; Rivas, A; Li, P; Le, H; Whitehorn, E; Moore, KW; Swimmer, C; Perlroth, V; Vogt, M; Kolkman, J; Stemmer, WPC			Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains	NATURE BIOTECHNOLOGY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LDL RECEPTOR; BINDING; EVOLUTION; LIGANDS; MODULES	We have developed a class of binding proteins, called avimers, to overcome the limitations of antibodies and other immunoglobulin-based therapeutic proteins. Avimers are evolved from a large family of human extracellular receptor domains by in vitro exon shuffling and phage display, generating multidomain proteins with binding and inhibitory properties. Linking multiple independent binding domains creates avidity and results in improved affinity and specificity compared with conventional single-epitope binding proteins. Other potential advantages over immunoglobulin domains include simple and efficient production of multitarget-specific molecules in Escherichia coli, improved thermostability and resistance to proteases. Avimers with sub-nM affinities were obtained aganist five targets. An avimer that inhibits interleukin 6 with 0.8 pM IC(50) in cell-based assays is biologically active in two animal models.	Avidia Inc, Mountain View, CA 94043 USA		Silverman, J (corresponding author), Avidia Inc, 2450 Bayshore Pkwy, Mountain View, CA 94043 USA.	josh.silverman@avidia.com; pstemmer@mproteins.com						Binz HK, 2005, CURR OPIN BIOTECH, V16, P459, DOI 10.1016/j.copbio.2005.06.005; Chang CCJ, 1999, NAT BIOTECHNOL, V17, P793, DOI 10.1038/11737; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Gliemann J, 1998, BIOL CHEM, V379, P951; HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213; Huang W, 1999, J BIOL CHEM, V274, P14130, DOI 10.1074/jbc.274.20.14130; Koduri V, 2001, BIOCHEMISTRY-US, V40, P12801, DOI 10.1021/bi011344k; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; Patten P A, 2003, Dev Biol (Basel), V112, P81; Rettenberger PM, 1999, J BIOL CHEM, V274, P8973, DOI 10.1074/jbc.274.13.8973; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; Suffredini AF, 1999, J CLIN IMMUNOL, V19, P203, DOI 10.1023/A:1020563913045; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; TEMMER WPC, 1996, ENCY MOL BIOL, P447; 2005, PHYS DESK REFERENCE, V59	18	162	379	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2005	23	12					1556	1561		10.1038/nbt1166	http://dx.doi.org/10.1038/nbt1166			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	992ED	16299519				2022-12-25	WOS:000233866300033
J	Ishitani, T; Matsumoto, K; Chitnis, AB; Itoh, M				Ishitani, T; Matsumoto, K; Chitnis, AB; Itoh, M			Nrarp functions to modulate neural-crest-cell differentiation by regulating LEF1 protein stability	NATURE CELL BIOLOGY			English	Article							ANKYRIN-REPEAT PROTEIN; SIGNALING PATHWAY; ZEBRAFISH; EXPRESSION; HOMOLOG; FATE; DOMAIN; NOTCH1; DELTA	Nrarp (Notch-regulated ankyrin repeat protein) is a small protein that has two ankyrin repeats(1-5). Although Nrarp is known to be an inhibitory component of the Notch signalling pathway that operates in different developmental processes(1,2,4,5), the in vivo roles of Nrarp have not been fully characterized. Here, we show that Nrarp is a positive regulator in the Wnt signalling pathway. In zebrafish, knockdown of Nrarp-a expression by an antisense morpholino oligonucleotide (MO) results in altered Wnt-signalling-dependent neural-crest-cell development. Nrarp stabilizes LEF1 protein, a pivotal transcription factor in the Wnt signalling cascade, by blocking LEF1 ubiquitination. In accordance with this, the knockdown phenotype of lef1 is similar to that of nrarp-a, at least in part, in its effect on the development of multiple tissues in zebrafish. Furthermore, activation of LEF1 does not affect Notch activity or vice versa. These findings reveal that Nrarp independently regulates canonical Wnt and Notch signalling by modulating LEF1 and Notch protein turnover, respectively.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Lab Cell Regulat,Unit Nervous Syst Dev, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Lab Cell Regulat,Grp Signal Transduct,Chikusa Ku, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; NICHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA	Nagoya University; Nagoya University; Japan Science & Technology Agency (JST); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Itoh, M (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Lab Cell Regulat,Unit Nervous Syst Dev, Nagoya, Aichi 4648602, Japan.	mito@bunshi3.bio.nagoya-u.ac.jp	, Tohru/AAH-8979-2020; Ishitani, Tohru/E-9781-2014	, Tohru/0000-0002-6200-7043; 				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Dorsky RI, 2000, BIOESSAYS, V22, P708, DOI 10.1002/1521-1878(200008)22:8<708::AID-BIES4>3.3.CO;2-E; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Dorsky RI, 2000, GENE DEV, V14, P158; Dorsky RI, 1999, MECH DEVELOP, V86, P147, DOI 10.1016/S0925-4773(99)00101-X; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Holley SA, 2000, GENE DEV, V14, P1678; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Kato H, 1997, DEVELOPMENT, V124, P4133; Krebs LT, 2001, DEV BIOL, V238, P110, DOI 10.1006/dbio.2001.0408; Lamar E, 2001, GENE DEV, V15, P1885, DOI 10.1101/gad.908101; Luo RS, 2001, DEV DYNAM, V220, P169, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1097>3.0.CO;2-1; MOURY JD, 1990, DEV BIOL, V141, P243, DOI 10.1016/0012-1606(90)90380-2; Odenthal J, 1998, DEV GENES EVOL, V208, P245, DOI 10.1007/s004270050179; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pirot P, 2004, BIOCHEM BIOPH RES CO, V322, P526, DOI 10.1016/j.bbrc.2004.07.157; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Takke C, 1999, DEVELOPMENT, V126, P1811; Topczewska JM, 2003, GENE EXPR PATTERNS, V3, P169, DOI 10.1016/S1567-133X(03)00009-7; Wang YF, 2003, BIOESSAYS, V25, P317, DOI 10.1002/bies.10255; Wettstein DA, 1997, DEVELOPMENT, V124, P693; Yun TJ, 2003, J IMMUNOL, V170, P5834, DOI 10.4049/jimmunol.170.12.5834	26	63	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1106	1112		10.1038/ncb1311	http://dx.doi.org/10.1038/ncb1311			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16228014				2022-12-25	WOS:000232930400014
J	Chattopadhyay, PK; Yu, J; Roederer, M				Chattopadhyay, PK; Yu, J; Roederer, M			A live-cell assay to detect antigen-specific CD4(+) T cells with diverse cytokine profiles	NATURE MEDICINE			English	Article							IMMUNE-RESPONSES; FLOW-CYTOMETRY; CD40 LIGAND; IDENTIFICATION; EXPRESSION; MOLECULES; MICE	Recently activated, but not resting, CD4(+) T cells express CD154, providing costimulatory signals to B cells and antigen-presenting cells (APCs). Therefore, de novo CD154 expression after stimulation identifies antigen-specific CD4+ T cells. Previous assays were limited by the transient nature of surface CD154 expression; we overcame this by including fluorescently conjugated CD154-specific antibody during stimulation. Our assay is fully compatible with intracellular cytokine staining, and can be used for stimulations as long as 24 h. Notably, it is nonlethal, providing a means to purify viable antigen-specific CD4+ T cells for further analysis. Using this assay, we found that stimulated cells expressing tumor necrosis factor (TNF)-alpha, interleukin (IL)-2 or interferon (IFN)-alpha were predominantly CD154(+). Furthermore, some cells expressing none of these cytokines also expressed CD154, suggesting that CD154 marks cells with other effector functions. For vaccine- or pathogen-specific responses, we found substantial heterogeneity in expression of CD154 and cytokines, suggesting previously unrecognized diversity in abilities of responding cells to stimulate APCs through CD40.	NIAID, ImmunoTechnol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Roederer, M (corresponding author), NIAID, ImmunoTechnol Sect, Vaccine Res Ctr, NIH, 40 Convent Dr,Room 5509, Bethesda, MD 20892 USA.	roederer@nih.gov	Roederer, Mario/G-1887-2011; Chattopadhyay, Pratip/B-9227-2008	Chattopadhyay, Pratip/0000-0002-5457-9666	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005021, Z01AI005020] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AI999999] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Berhanu D, 2003, J IMMUNOL METHODS, V279, P199, DOI 10.1016/S0022-1759(03)00186-8; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Betts MR, 2001, IMMUNOL LETT, V79, P117, DOI 10.1016/S0165-2478(01)00273-5; BRINES RD, 1993, INT IMMUNOL, V5, P1445, DOI 10.1093/intimm/5.11.1445; COSULICH ME, 1987, P NATL ACAD SCI USA, V84, P4205, DOI 10.1073/pnas.84.12.4205; De Rosa SC, 2004, J IMMUNOL, V173, P5372, DOI 10.4049/jimmunol.173.9.5372; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021; Klenerman P, 2002, NAT REV IMMUNOL, V2, P263, DOI 10.1038/nri777; Lyerly HK, 2003, SEMIN ONCOL, V30, P9, DOI 10.1016/S0093-7754(03)00230-6; Maino VC, 1998, CYTOMETRY, V34, P207, DOI 10.1002/(SICI)1097-0320(19981015)34:5<207::AID-CYTO1>3.0.CO;2-J; MANZ R, 1995, P NATL ACAD SCI USA, V92, P1921, DOI 10.1073/pnas.92.6.1921; Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; ROY M, 1993, J IMMUNOL, V151, P2497; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Skov S, 2000, J IMMUNOL, V164, P3500, DOI 10.4049/jimmunol.164.7.3500; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YELLIN MJ, 1994, J IMMUNOL, V152, P598	21	254	280	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1113	1117		10.1038/nm1293	http://dx.doi.org/10.1038/nm1293			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16186817				2022-12-25	WOS:000232492500034
J	Davierwala, AP; Haynes, J; Li, ZJ; Brost, RL; Robinson, MD; Yu, L; Mnaimneh, S; Ding, HM; Zhu, HW; Chen, YQ; Cheng, X; Brown, GW; Boone, C; Andrews, BJ; Hughes, TR				Davierwala, AP; Haynes, J; Li, ZJ; Brost, RL; Robinson, MD; Yu, L; Mnaimneh, S; Ding, HM; Zhu, HW; Chen, YQ; Cheng, X; Brown, GW; Boone, C; Andrews, BJ; Hughes, TR			The synthetic genetic interaction spectrum of essential genes	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; COMPLEX; IDENTIFICATION; PATHWAY; GENOME; COMPONENT; VACUOLE; REPAIR; AP-3	The nature of synthetic genetic interactions involving essential genes (those required for viability) has not been previously examined in a broad and unbiased manner. We crossed yeast strains carrying promoter-replacement alleles for more than half of all essential yeast genes(1) to a panel of 30 different mutants with defects in diverse cellular processes. The resulting genetic network is biased toward interactions between functionally related genes, enabling identification of a previously uncharacterized essential gene (PGA1) required for specific functions of the endoplasmic reticulum. But there are also many interactions between genes with dissimilar functions, suggesting that individual essential genes are required for buffering many cellular processes. The most notable feature of the essential synthetic genetic network is that it has an interaction density five times that of nonessential synthetic genetic networks(2,3), indicating that most yeast genetic interactions involve at least one essential gene.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto	Hughes, TR (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	t.hughes@utoronto.ca	Robinson, Mark D/A-6432-2015; Haynes, Jennifer/P-8565-2019; Robinson, Mark D./O-2254-2019	Robinson, Mark D/0000-0002-3048-5518; Robinson, Mark D./0000-0002-3048-5518; Brown, Grant/0000-0002-9002-5003				Avaro S, 2002, YEAST, V19, P351, DOI 10.1002/yea.838; Belgareh-Touze N, 2003, TRAFFIC, V4, P607, DOI 10.1034/j.1600-0854.2003.00116.x; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r23; Christie KR, 2004, NUCLEIC ACIDS RES, V32, pD311, DOI 10.1093/nar/gkh033; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Finger FP, 2000, GENETICS, V156, P943; Fujioka Y, 2002, J BIOL CHEM, V277, P21585, DOI 10.1074/jbc.M201523200; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Goddijn M, 2000, BEST PRACT RES CL OB, V14, P855, DOI 10.1053/beog.2000.0124; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Hartwell L, 2004, SCIENCE, V303, P774, DOI 10.1126/science.1094731; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kile BT, 2003, NATURE, V425, P81, DOI 10.1038/nature01865; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Mitchell P, 2003, MOL CELL BIOL, V23, P6982, DOI 10.1128/MCB.23.19.6982-6992.2003; Mnaimneh S, 2004, CELL, V118, P31, DOI 10.1016/j.cell.2004.06.013; Peng WT, 2003, CELL, V113, P919, DOI 10.1016/S0092-8674(03)00466-5; Phillips PC, 1998, GENETICS, V150, P449; Popolo L, 1999, BBA-GEN SUBJECTS, V1426, P385, DOI 10.1016/S0304-4165(98)00138-X; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810	29	170	176	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2005	37	10					1147	1152		10.1038/ng1640	http://dx.doi.org/10.1038/ng1640			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	968TP	16155567				2022-12-25	WOS:000232185600030
J	Ny, A; Koch, M; Schneider, M; Neven, E; Tong, RT; Maity, S; Fischer, C; Plaisance, S; Lambrechts, D; Heligon, C; Terclavers, S; Ciesiolka, M; Kalin, R; Man, WY; Senn, I; Wyns, S; Lupu, F; Brandli, A; Vleminckx, K; Collen, D; Dewerchin, M; Conway, EM; Moons, L; Jain, RK; Carmeliet, P				Ny, A; Koch, M; Schneider, M; Neven, E; Tong, RT; Maity, S; Fischer, C; Plaisance, S; Lambrechts, D; Heligon, C; Terclavers, S; Ciesiolka, M; Kalin, R; Man, WY; Senn, I; Wyns, S; Lupu, F; Brandli, A; Vleminckx, K; Collen, D; Dewerchin, M; Conway, EM; Moons, L; Jain, RK; Carmeliet, P			A genetic Xenopus laevis tadpole model to study lymphangiogenesis	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; LYMPHATIC-SYSTEM; VASCULAR DEVELOPMENT; TYROSINE KINASES; VEGF-C; VEINS; ANGIOGENESIS; METASTASIS; ZEBRAFISH; EMBRYOS	Lymph vessels control fluid homeostasis, immunity and metastasis. Unraveling the molecular basis of lymphangiogenesis has been hampered by the lack of a small animal model that can be genetically manipulated. Here, we show that Xenopus tadpoles develop lymph vessels from lymphangioblasts or, through transdifferentiation, from venous endothelial cells. Lymphangiography showed that these lymph vessels drain lymph, through the lymph heart, to the venous circulation. Morpholino- mediated knockdown of the lymphangiogenic factor Prox1 caused lymph vessel defects and lymphedema by impairing lymphatic commitment. Knockdown of vascular endothelial growth factor C ( VEGF- C) also induced lymph vessel defects and lymphedema, but primarily by affecting migration of lymphatic endothelial cells. Knockdown of VEGF- C also resulted in aberrant blood vessel formation in tadpoles. This tadpole model offers opportunities for the discovery of new regulators of lymphangiogenesis.	Katholieke Univ Leuven VIB, Ctr Trasgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Univ Ghent, Dept Mol Biomed Res, B-9052 Ghent, Belgium; Harvard Univ, Sch Med, Edwin L Steele Lab Tumor Biol, Dept Radiat Oncol,Massachusetts Gen Hosp, Boston, MA 02114 USA; Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, CH-8057 Zurich, Switzerland; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	Flanders Institute for Biotechnology (VIB); KU Leuven; Ghent University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; Oklahoma Medical Research Foundation	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Trasgene Technol & Gene Therapy, Campus Gasthuisberg O&N,Herestr 49, B-3000 Louvain, Belgium.	peter.carmeliet@med.kuleuven.be	Schneider, Martin/H-3745-2011; Kälin, Roland/AAG-9161-2020; Vleminckx, Kris/J-5699-2013; Plaisance, Stephane/B-3488-2009; Lambrechts, Diether/AAJ-3167-2020; Lupu, Florea/C-3162-2009; Lupu, Florea/AAV-3257-2021; Jain, Rakesh K/I-1384-2017; Carmeliet, Peter/AAQ-5140-2020; Brandli, Andre/N-1620-2013; Verdrengh, Evelien/H-4571-2012; Plaisance, Stephane/ABI-6307-2020; Ny, Annelii/R-7712-2018	Plaisance, Stephane/0000-0002-1651-241X; Lambrechts, Diether/0000-0002-3429-302X; Lupu, Florea/0000-0003-1249-9278; Lupu, Florea/0000-0003-1249-9278; Jain, Rakesh K/0000-0001-7571-3548; Carmeliet, Peter/0000-0001-7961-1821; Brandli, Andre/0000-0002-8932-3644; Plaisance, Stephane/0000-0002-1651-241X; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Maity, Sunit/0000-0001-6667-3249; Conway, Edward/0000-0003-0081-0305; HELIGON, Christophe/0000-0001-7557-3565; Ny, Annelii/0000-0002-3678-5941	NCI NIH HHS [CA-85140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085140, R24CA085140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Asellius G, 1627, LACTEIBUS SIVE LACTE; Baldwin ME, 2005, MOL CELL BIOL, V25, P2441, DOI 10.1128/MCB.25.6.2441-2449.2005; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Cleaver O, 1997, DEV DYNAM, V210, P66, DOI 10.1002/(SICI)1097-0177(199709)210:1<66::AID-AJA7>3.3.CO;2-S; Daniels CB, 2003, FASEB J, V17, P479, DOI 10.1096/fj.02-0579fje; Devic E, 1996, MECH DEVELOP, V59, P129, DOI 10.1016/0925-4773(96)00585-0; Faber J., 1994, NORMAL TABLE XENOPUS, P2; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HOYER M, 2005, B ACAD CRACOV 2, P451; Jain RK, 2002, COLD SPRING HARB SYM, V67, P239, DOI 10.1101/sqb.2002.67.239; Joukov V, 1996, EMBO J, V15, P290; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Lawson ND, 2002, NAT REV GENET, V3, P674, DOI 10.1038/nrg888; Levine AJ, 2003, DEV BIOL, V254, P50, DOI 10.1016/S0012-1606(02)00029-5; LIU ZY, 1989, LYMPHOLOGY, V22, P31; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Ober EA, 2004, EMBO REP, V5, P78, DOI 10.1038/sj.embor.7400047; OLSZEWSKI W, 1993, LYMPHOLOGY, V26, P154; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Saaristo A, 2002, FASEB J, V16, P1041, DOI 10.1096/fj.01-1042com; Sabin FR, 1902, AM J ANAT, V1, P367, DOI 10.1002/aja.1000010310; Saharinen P, 2004, TRENDS IMMUNOL, V25, P387, DOI 10.1016/j.it.2004.05.003; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505; Wilting J, 2000, LYMPHOLOGY, V33, P81; Wilting J, 2001, MICROSC RES TECHNIQ, V55, P81, DOI 10.1002/jemt.1159	28	176	186	1	9	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2005	11	9					998	1004		10.1038/nm1285	http://dx.doi.org/10.1038/nm1285			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16116431				2022-12-25	WOS:000231724700029
J	Hillebrandt, S; Wasmuth, HE; Weiskirchen, R; Hellerbrand, C; Keppeler, H; Werth, A; Schirin-Sokhan, R; Wilkens, G; Geier, A; Lorenzen, J; Kohl, J; Gressner, AM; Matern, S; Lammert, F				Hillebrandt, S; Wasmuth, HE; Weiskirchen, R; Hellerbrand, C; Keppeler, H; Werth, A; Schirin-Sokhan, R; Wilkens, G; Geier, A; Lorenzen, J; Kohl, J; Gressner, AM; Matern, S; Lammert, F			Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans	NATURE GENETICS			English	Article							CHRONIC HEPATITIS-C; FIBROSIS PROGRESSION; C5A; RECEPTOR; EXPRESSION; RESPONSES; REGENERATION; ANTAGONISTS; COMPONENT; GENOTYPES	Fibrogenesis or scarring of the liver is a common consequence of all chronic liver diseases. Here we refine a quantitative trait locus that confers susceptibility to hepatic fibrosis by in silico mapping and show, using congenic mice and transgenesis with recombined artificial chromosomes, that the gene Hc (encoding complement factor C5) underlies this locus. Small molecule inhibitors of the C5a receptor had antifibrotic effects in vivo, and common haplotype-tagging polymorphisms of the human gene C5 were associated with advanced fibrosis in chronic hepatitis C virus infection. Thus, the mouse quantitative trait gene led to the identification of an unknown gene underlying human susceptibility to liver fibrosis, supporting the idea that C5 has a causal role in fibrogenesis across species.	Univ Aachen, Univ Hosp Aachen, Dept Med 3, D-5100 Aachen, Germany; Univ Bonn, Bonner Forum Biomed, Univ Hosp Bonn, Dept Internal Med 1, D-53127 Bonn, Germany; Univ Aachen, Univ Hosp Aachen, Inst Clin Chem & Pathobiochem, D-5100 Aachen, Germany; Univ Regensburg, Univ Hosp Regensburg, Dept Med 1, D-8400 Regensburg, Germany; Univ Aachen, Univ Hosp Aachen, Inst Pathol, D-5100 Aachen, Germany; Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Res Fdn, Div Mol Immunol, Cincinnati, OH 45221 USA	RWTH Aachen University; RWTH Aachen University Hospital; University of Bonn; RWTH Aachen University; RWTH Aachen University Hospital; University of Regensburg; RWTH Aachen University; RWTH Aachen University Hospital; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Lammert, F (corresponding author), Univ Aachen, Univ Hosp Aachen, Dept Med 3, D-5100 Aachen, Germany.	frank.lammert@ukb.uni-bonn.de	Koehl, Joerg/C-8531-2011; Weiskirchen, Ralf/O-1734-2018	Koehl, Joerg/0000-0003-1121-3178; Weiskirchen, Ralf/0000-0003-3888-0931				Abiola O, 2003, NAT REV GENET, V4, P911, DOI 10.1038/nrg1206; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; CHURCHILL GA, 1994, GENETICS, V138, P963; Czermak BJ, 1998, J LEUKOCYTE BIOL, V64, P40, DOI 10.1002/jlb.64.1.40; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; ELLISON RT, 1990, DIGEST DIS SCI, V35, P231, DOI 10.1007/BF01536768; ELSTON RC, 1977, BIOMETRICS, V33, P536, DOI 10.2307/2529370; Fehrenbach H, 2001, HEPATOLOGY, V34, P943, DOI 10.1053/jhep.2001.28788; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; Flint J, 2005, NAT REV GENET, V6, P271, DOI 10.1038/nrg1576; Friedman SL, 2004, NAT CLIN PRACT GASTR, V1, P98, DOI 10.1038/ncpgasthep0055; Friedman SL, 2003, J HEPATOL, V38, pS38, DOI 10.1016/S0168-8278(02)00429-4; Geier A, 2004, LIVER INT, V24, P285, DOI 10.1111/j.1478-3231.2004.0928.x; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; HALEY CS, 1992, HEREDITY, V69, P315, DOI 10.1038/hdy.1992.131; Hawlisch H, 2005, IMMUNITY, V22, P415, DOI 10.1016/j.immuni.2005.02.006; Hillebrandt S, 2002, GASTROENTEROLOGY, V123, P2041, DOI 10.1053/gast.2002.37069; Hillmen P, 2004, NEW ENGL J MED, V350, P552, DOI 10.1056/NEJMoa031688; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; Imbert-Bismut F, 2001, LANCET, V357, P1069, DOI 10.1016/S0140-6736(00)04258-6; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; KONTEATIS ZD, 1994, J IMMUNOL, V153, P4200; Korstanje R, 2002, NAT GENET, V31, P235, DOI 10.1038/ng0702-235; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479; Neumann UP, 2004, J HEPATOL, V41, P830, DOI 10.1016/j.jhep.2004.06.029; PHAN SH, 1982, AM J PATHOL, V107, P25; Pletcher MT, 2004, PLOS BIOL, V2, P2159, DOI 10.1371/journal.pbio.0020393; POUPON R, 1996, HEPATOLOGY TXB LIVER, V2, P1329; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4; Riedemann NC, 2002, J CLIN INVEST, V110, P101, DOI 10.1172/JCI200215409; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; Schlaf G, 2003, HISTOL HISTOPATHOL, V18, P299, DOI 10.14670/HH-18.299; Schulz KF, 2002, LANCET, V359, P431, DOI 10.1016/S0140-6736(02)07605-5; Sebastiani P, 2003, P NATL ACAD SCI USA, V100, P9900, DOI 10.1073/pnas.1633613100; SENALDI G, 1989, GASTROENTEROLOGY, V97, P1430, DOI 10.1016/0016-5085(89)90386-7; Sheerin NS, 2002, CLIN EXP IMMUNOL, V130, P1, DOI 10.1046/j.1365-2249.2002.01979.x; Shi ZD, 1997, P NATL ACAD SCI USA, V94, P10663, DOI 10.1073/pnas.94.20.10663; Smithies O, 2005, NAT REV GENET, V6, P419, DOI 10.1038/nrg1605; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Wasmuth HE, 2004, HEPATOLOGY, V39, P604, DOI 10.1002/hep.20150; Wasmuth HE, 2004, J MOL MED-JMM, V82, P64, DOI 10.1007/s00109-003-0505-0; WETSEL RA, 1990, J BIOL CHEM, V265, P2435; Whaley K, 1997, SEMIN LIVER DIS, V17, P297, DOI 10.1055/s-2007-1007206; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417; Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270	50	205	215	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					835	843		10.1038/ng1599	http://dx.doi.org/10.1038/ng1599			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	15995705				2022-12-25	WOS:000230880400013
J	Choudhury, A; Marks, DL; Proctor, KM; Gould, GW; Pagano, RE				Choudhury, A; Marks, DL; Proctor, KM; Gould, GW; Pagano, RE			Regulation of caveolar endocytosis by syntaxin 6-dependent delivery of membrane components to the cell surface	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; LIPID RAFTS; 3T3-L1 ADIPOCYTES; TRAFFICKING; TRANSPORT; GLUT4; INTERNALIZATION; INVOLVEMENT; PROTEINS; INSULIN	Caveolar endocytosis has an important function in the cellular uptake of some bacterial toxins, viruses and circulating proteins. However, the molecular machinery involved in regulating caveolar uptake is poorly defined. Here, we demonstrate that caveolar endocytosis is regulated by syntaxin 6, a target membrane soluble N-ethylmaleimide attachment protein receptor (t-SNARE) involved in membrane fusion events along the secretory pathway. When syntaxin 6 function was inhibited, internalization through caveolae was dramatically reduced, whereas other endocytic mechanisms were unaffected. Syntaxin 6 inhibition also reduced the presence of caveolin-1 and caveolae at the plasma membrane. In addition, syntaxin 6 inhibition decreased the delivery of GM1 ganglioside ( GM1) and glycosylphosphatidylinositol (GPI)- GFP ( but not vesicular stomatitis virus-glycoprotein G; VSV-G) protein from the Golgi complex to the plasma membrane. Addition of GM1 to syntaxin 6-inhibited cells resulted in the reappearance of caveolin-1 and caveolae at the plasma membrane, and restored caveolar uptake. These results suggest that syntaxin 6 regulates the delivery of microdomain-associated lipids and proteins to the cell surface, which are required for caveolar endocytosis.	Mayo Clin Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Glasgow G12 8QQ, Lanark, Scotland	Mayo Clinic; University of Glasgow	Pagano, RE (corresponding author), Mayo Clin Coll Med, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	pagano.richard@mayo.edu	Gould, Gwyn/AAF-6721-2019	Gould, Gwyn/0000-0001-6571-2875	NIGMS NIH HHS [GM-22942] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022942, R01GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Duncan MJ, 2002, CELL MICROBIOL, V4, P783, DOI 10.1046/j.1462-5822.2002.00230.x; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Kim YN, 2002, ENDOCRINOLOGY, V143, P1726, DOI 10.1210/en.143.5.1726; Kuliawat R, 2004, MOL BIOL CELL, V15, P1690, DOI 10.1091/mbc.E03-08-0554; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; MARJOMAKI VS, 1990, J HISTOCHEM CYTOCHEM, V38, P1155, DOI 10.1177/38.8.2164059; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Martin-Martin B, 2000, BLOOD, V96, P2574; McIntosh DP, 1999, AM J PHYSIOL-HEART C, V277, pH2222, DOI 10.1152/ajpheart.1999.277.6.H2222; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 2001, HISTOCHEM CELL BIOL, V116, P109; Morcos PA, 2001, GENESIS, V30, P94, DOI 10.1002/gene.1039; Norkin LC, 2001, ADV DRUG DELIVER REV, V49, P301, DOI 10.1016/S0169-409X(01)00143-0; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Perera HKI, 2003, MOL BIOL CELL, V14, P2946, DOI 10.1091/mbc.E02-11-0722; PREDESCU D, 1994, P NATL ACAD SCI USA, V91, P3014, DOI 10.1073/pnas.91.8.3014; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Puri V, 2003, J BIOL CHEM, V278, P20961, DOI 10.1074/jbc.M300304200; Richterova Z, 2001, J VIROL, V75, P10880, DOI 10.1128/JVI.75.22.10880-10891.2001; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Sharma DK, 2005, CANCER RES, V65, P8233, DOI 10.1158/0008-5472.CAN-05-0803; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Wendler F, 2001, MOL BIOL CELL, V12, P1699, DOI 10.1091/mbc.12.6.1699; Wendler F, 2001, TRAFFIC, V2, P606, DOI 10.1034/j.1600-0854.2001.20903.x	48	75	75	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					317	U6		10.1038/ncb1380	http://dx.doi.org/10.1038/ncb1380			17	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16565709				2022-12-25	WOS:000236560000010
J	Cardona, K; Korbutt, GS; Milas, Z; Lyon, J; Cano, J; Jiang, W; Bello-Laborn, H; Hacquoil, B; Strobert, E; Gangappa, S; Weber, CJ; Pearson, TC; Rajotte, RV; Larsen, CP				Cardona, K; Korbutt, GS; Milas, Z; Lyon, J; Cano, J; Jiang, W; Bello-Laborn, H; Hacquoil, B; Strobert, E; Gangappa, S; Weber, CJ; Pearson, TC; Rajotte, RV; Larsen, CP			Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; VASCULAR REJECTION; XENOGRAFTS; CELLS; XENOTRANSPLANTATION; TRANSPLANTATION; BLOCKADE; REVERSAL; ANTIGENS	We evaluated the ability of neonatal porcine islets to engraft and restore glucose control in pancreatectomized rhesus macaques. Although porcine islets transplanted into nonimmunosuppressed macaques were rapidly rejected by a process consistent with cellular rejection, recipients treated with a CD28-CD154 costimulation blockade regimen achieved sustained insulin independence ( median survival, > 140 days) without evidence of porcine endogenous retrovirus dissemination. Thus, neonatal porcine islets represent a promising solution to the crucial supply problem in clinical islet transplantation.	Univ Alberta, Surg Med Res Inst, Dent Pharm Ctr 1074, Edmonton, AB T6G 2N8, Canada; Emory Univ, Sch Med, Emory Transplant Ctr, Dept Surg, Atlanta, GA 30322 USA; Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA	University of Alberta; Emory University; Emory University	Rajotte, RV (corresponding author), Univ Alberta, Surg Med Res Inst, Dent Pharm Ctr 1074, Edmonton, AB T6G 2N8, Canada.	rrajotte@ualberta.ca; clarsen@emoryhealthcare.org	Sano, Michael/E-1715-2011; Larsen, Christian P./B-6906-2012	Larsen, Christian P./0000-0001-6573-2649	NCRR NIH HHS [P51-RR000165-45] Funding Source: Medline; NIAID NIH HHS [U19-AI51731] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI051731] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams AB, 2005, J IMMUNOL, V174, P542, DOI 10.4049/jimmunol.174.1.542; Adams AB, 2001, J IMMUNOL, V167, P1103, DOI 10.4049/jimmunol.167.2.1103; Adams AB, 2002, DIABETES, V51, P265, DOI 10.2337/diabetes.51.2.265; Chen G, 2005, NAT MED, V11, P1295, DOI 10.1038/nm1330; COLLINS BH, 1995, J IMMUNOL, V154, P5500; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Kin T, 2005, DIABETES, V54, P1032, DOI 10.2337/diabetes.54.4.1032; Kirchhof N, 2004, XENOTRANSPLANTATION, V11, P396, DOI 10.1111/j.1399-3089.2004.00157.x; Korbutt GS, 1996, J CLIN INVEST, V97, P2119, DOI 10.1172/JCI118649; Lin SS, 2000, TRANSPLANTATION, V70, P1667, DOI 10.1097/00007890-200012270-00002; ORIOL R, 1993, TRANSPLANTATION, V56, P1433, DOI 10.1097/00007890-199312000-00031; Trivedi N, 2001, ENDOCRINOLOGY, V142, P2115, DOI 10.1210/en.142.5.2115; YE Y, 1994, TRANSPLANTATION, V58, P330, DOI 10.1097/00007890-199408000-00014	14	362	376	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					304	306		10.1038/nm1375	http://dx.doi.org/10.1038/nm1375			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16501570				2022-12-25	WOS:000235802900028
J	Kozuka, J; Yokota, H; Arai, Y; Ishii, Y; Yanagida, T				Kozuka, J; Yokota, H; Arai, Y; Ishii, Y; Yanagida, T			Dynamic polymorphism of single actin molecules in the actin filament	NATURE CHEMICAL BIOLOGY			English	Article							RESONANCE ENERGY-TRANSFER; F-ACTIN; RADIAL COORDINATE; AQUEOUS-SOLUTION; MYOSIN; MOVEMENT; PROTEIN; TRANSDUCTION; SPECTROSCOPY; MOTILITY	Actin filament dynamics are critical in cell motility(1,2). The structure of actin filament changes spontaneously and can also be regulated by actin-binding proteins, allowing actin to readily function in response to external stimuli(1). The interaction with the motor protein myosin changes the dynamic nature of actin filaments(3,4). However, the molecular bases for the dynamic processes of actin filaments are not well understood. Here, we observed the dynamics of rabbit skeletal-muscle actin conformation by monitoring individual molecules in the actin filaments using single-molecule fluorescence resonance energy transfer (FRET)(5-7) imaging with total internal reflection fluorescence microscopy ( TIRFM)(8). The time trajectories of FRET show that actin switches between low- and high-FRET efficiency states on a timescale of seconds. If actin filaments are chemically cross-linked, a state that inhibits myosin motility(9), the equilibrium shifts to the low- FRET conformation, whereas when the actin filament is interacting with myosin, the high-FRET conformation is favored. This dynamic equilibrium suggests that actin can switch between active and inactive conformations in response to external signals.	Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Format Soft Nanomachines, Osaka 5630871, Japan; Osaka Univ, Dept Biophys Engn, Osaka 5608531, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Physiol, Bunkyo Ku, Tokyo 1138613, Japan; Osaka Univ, Grad Sch Frontier Biosci, Labs Nanobiol, Soft Biosyst Grp, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University; Tokyo Metropolitan Institute of Medical Science; Osaka University	Yanagida, T (corresponding author), Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Format Soft Nanomachines, Osaka 5630871, Japan.	yanagida@phys1.med.osaka-u.ac.jp	Yokota, Hiroaki/H-4990-2014; Yanagida, Toshio/D-1919-2009	Yokota, Hiroaki/0000-0002-3435-9121; 				EGELMAN EH, 1982, NATURE, V298, P131, DOI 10.1038/298131a0; Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Galkin VE, 2002, CURR BIOL, V12, P570, DOI 10.1016/S0960-9822(02)00742-X; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; Humphrey D, 2002, NATURE, V416, P413, DOI 10.1038/416413; Ishii Y, 1999, CHEM PHYS, V247, P163, DOI 10.1016/S0301-0104(99)00174-3; Ito Y, 1997, BIOCHEMISTRY-US, V36, P9109, DOI 10.1021/bi970296u; James LC, 2003, TRENDS BIOCHEM SCI, V28, P361, DOI 10.1016/S0968-0004(03)00135-X; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kirschner M, 2000, CELL, V100, P79, DOI 10.1016/S0092-8674(00)81685-2; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Mendelson R, 1997, P NATL ACAD SCI USA, V94, P8533, DOI 10.1073/pnas.94.16.8533; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Moens PDJ, 1997, BIOCHEMISTRY-US, V36, P7353, DOI 10.1021/bi962588l; MOENS PDJ, 1994, BIOCHEMISTRY-US, V33, P13102, DOI 10.1021/bi00248a020; NG CM, 1994, BIOCHEMISTRY-US, V33, P9098, DOI 10.1021/bi00197a011; ORLOVA A, 1995, J MOL BIOL, V245, P582, DOI 10.1006/jmbi.1994.0048; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; PROCHNIEWICZ E, 1990, J MOL BIOL, V216, P761, DOI 10.1016/0022-2836(90)90397-5; Rafelski SM, 2004, ANNU REV BIOCHEM, V73, P209, DOI 10.1146/annurev.biochem.73.011303.073844; Schmid MF, 2004, NATURE, V431, P104, DOI 10.1038/nature02881; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0	28	78	79	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2006	2	2					83	86		10.1038/nchembio763	http://dx.doi.org/10.1038/nchembio763			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	005DA	16415860				2022-12-25	WOS:000234801600010
J	Zhang, CC; Kaba, M; Ge, GT; Xie, K; Tong, W; Hug, C; Lodish, HF				Zhang, CC; Kaba, M; Ge, GT; Xie, K; Tong, W; Hug, C; Lodish, HF			Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells	NATURE MEDICINE			English	Article							IN-VITRO; MOLECULAR-CLONING; GROWTH-FACTOR; SIGNAL PEPTIDES; SELF-RENEWAL; GENE; IDENTIFICATION; DIFFERENTIATION; PREDICTION; LIVER	Successful ex vivo expansion of hematopoietic stem cells (HSCs) would greatly benefit the treatment of disease and the understanding of crucial questions of stem cell biology. Here we show, using microarray studies, that the HSC-supportive mouse fetal liver CD3(+) cells specifically express the proteins angiopoietin-like 2 (Angptl2) and angiopoietin-like 3 (Angptl3). We observed a 24- or 30-fold net expansion of long- term HSCs by reconstitution analysis when we cultured highly enriched HSCs for 10 days in the presence of Angptl2 or Angptl3 together with saturating levels of other growth factors. The coiled-coil domain of Angptl2 was capable of stimulating expansion of HSCs. Furthermore, angiopoietin-like 5, angiopoietin-like 7 and microfibril-associated glycoprotein 4 also supported expansion of HSCs in culture.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Childrens Hosp, Div Resp Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu		Xie, Kathleen/0000-0002-3178-8959; Tong, Wei/0000-0001-9951-2273	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067356] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 067356, R01 DK067356-04, R01 DK067356] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; de Haan G, 2003, DEV CELL, V4, P241, DOI 10.1016/S1534-5807(03)00018-2; FRASER CC, 1990, BLOOD, V76, P1071; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; LI CL, 1994, BLOOD, V84, P408, DOI 10.1182/blood.V84.2.408.bloodjournal842408; Miller CL, 1997, P NATL ACAD SCI USA, V94, P13648, DOI 10.1073/pnas.94.25.13648; Moore KA, 1997, BLOOD, V89, P4337, DOI 10.1182/blood.V89.12.4337; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oike Y, 2005, NAT MED, V11, P400, DOI 10.1038/nm1214; Oike Y, 2004, INT J HEMATOL, V80, P21, DOI 10.1532/ijh97.04034; Peek R, 1998, INVEST OPHTH VIS SCI, V39, P1782; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Sauvageau G, 2004, ONCOGENE, V23, P7223, DOI 10.1038/sj.onc.1207942; Shizuru JA, 2005, ANNU REV MED, V56, P509, DOI 10.1146/annurev.med.54.101601.152334; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; Sorrentino BP, 2004, NAT REV IMMUNOL, V4, P878, DOI 10.1038/nri1487; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P681, DOI 10.1006/bbrc.1993.1678; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Zeng L, 2003, J HUM GENET, V48, P159, DOI 10.1007/s100380300025; Zhang CC, 2005, BLOOD, V105, P4314, DOI 10.1182/blood-2004-11-4418; Zhang CC, 2004, BLOOD, V103, P2513, DOI 10.1182/blood-2003-08-2955; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	30	281	301	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					240	245		10.1038/nm1342	http://dx.doi.org/10.1038/nm1342			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16429146	Green Accepted			2022-12-25	WOS:000235160600031
J	Clackson, T				Clackson, T			Breaking and entering	NATURE CHEMICAL BIOLOGY			English	News Item							PROTEIN-PROTEIN INTERACTIONS; INHIBITORS; DIMERIZATION; DISCOVERY; POTENT	A new small molecule inhibitor of TNF has an unexpected mechanism: it disrupts the trimeric structure of the protein.	ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Takeda Oncology	Clackson, T (corresponding author), ARIAD Pharmaceut Inc, 26 Landsdowne St, Cambridge, MA 02139 USA.	clackson@ariad.com						Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Blasko E, 2002, J BIOL CHEM, V277, P295, DOI 10.1074/jbc.M105691200; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Braisted AC, 2003, J AM CHEM SOC, V125, P3714, DOI 10.1021/ja034247i; Capps KJ, 2005, BIOORG MED CHEM LETT, V15, P2840, DOI 10.1016/j.bmcl.2005.03.094; He MM, 2005, SCIENCE, V310, P1022, DOI 10.1126/science.1116304; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Samanen J, 1996, ANNU REP MED CHEM, V31, P91, DOI 10.1016/S0065-7743(08)60449-2; Toogood PL, 2002, J MED CHEM, V45, P1543, DOI 10.1021/jm010468s	10	6	6	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2006	2	1					14	15		10.1038/nchembio0106-14	http://dx.doi.org/10.1038/nchembio0106-14			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993RC	16408085				2022-12-25	WOS:000233971600008
J	Chaillou, S; Champomier-Verges, MC; Cornet, M; Crutz-Le Coq, AM; Dudez, AM; Martin, V; Beaufils, S; Darbon-Rongere, E; Bossy, R; Loux, V; Zagorec, M				Chaillou, S; Champomier-Verges, MC; Cornet, M; Crutz-Le Coq, AM; Dudez, AM; Martin, V; Beaufils, S; Darbon-Rongere, E; Bossy, R; Loux, V; Zagorec, M			The complete genome sequence of the meat-borne lactic acid bacterium Lactobacillus sakei 23K	NATURE BIOTECHNOLOGY			English	Article							LISTERIA-MONOCYTOGENES; ESCHERICHIA-COLI; GLYCINE BETAINE; HUMAN FECES; PROTEIN; SURFACE; TRANSPORTERS; ADAPTATION; VIRULENCE; CARNITINE	Lactobacillus sakei is a psychrotrophic lactic acid bacterium found naturally on fresh meat and fish. This microorganism is widely used in the manufacture of fermented meats and has biotechnological potential in biopreservation and food safety. We have explored the 1,884,661-base-pair (bp) circular chromosome of strain 23K encoding 1,883 predicted genes. Genome sequencing revealed a specialized metabolic repertoire, including purine nucleoside scavenging that may contribute to an ability to successfully compete on raw meat products. Many genes appear responsible for robustness during the rigors of food processing-particularly resilience against changing redox and oxygen levels. Genes potentially responsible for biofilm formation and cellular aggregation that may assist the organism to colonize meat surfaces were also identified. This genome project is an initial step for investigating new biotechnological approaches to meat and fish processing and for exploring fundamental aspects of bacterial adaptation to these specific environments.	INRA, Unite Flore Lact & Environm Carne, F-78350 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Zagorec, M (corresponding author), INRA, Unite Flore Lact & Environm Carne, Domaine Vilvert, F-78350 Jouy En Josas, France.	monique.zagorec@jouy.inra.fr	Chaillou, Stephane/C-5755-2016; Loux, Valentin/C-6270-2008	Chaillou, Stephane/0000-0003-2229-0697; Bossy, Robert/0000-0001-6652-9319; Zagorec, Monique/0000-0001-6439-983X; Loux, Valentin/0000-0002-8268-915X				Altermann E, 2005, P NATL ACAD SCI USA, V102, P3906, DOI 10.1073/pnas.0409188102; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Angelidis AS, 2003, APPL ENVIRON MICROB, V69, P7492, DOI 10.1128/AEM.69.12.7492-7498.2003; Angelidis AS, 2003, APPL ENVIRON MICROB, V69, P1013, DOI 10.1128/AEM.69.2.1013-1022.2003; BARDOCZ S, 1995, TRENDS FOOD SCI TECH, V6, P341, DOI 10.1016/S0924-2244(00)89169-4; Bredholt S, 2001, INT J FOOD MICROBIOL, V66, P191, DOI 10.1016/S0168-1605(00)00519-5; Champomier-Verges MC, 2002, RES MICROBIOL, V153, P115, DOI 10.1016/S0923-2508(01)01296-7; Chetouani F, 2001, MICROBIOL-SGM, V147, P2643, DOI 10.1099/00221287-147-10-2643; CHUNG KT, 1989, J FOOD PROTECT, V52, P173, DOI 10.4315/0362-028X-52.3.173; CONDON S, 1987, FEMS MICROBIOL LETT, V46, P269, DOI 10.1111/j.1574-6968.1987.tb02465.x; Cucarella C, 2001, J BACTERIOL, V183, P2888, DOI 10.1128/JB.183.9.2888-2896.2001; Dal Bello F, 2003, MICROB ECOL, V45, P455, DOI 10.1007/s00248-003-2001-z; Davidson P. M., 2013, Food microbiology: fundamentals and frontiers, P765; DE MAN J. C., 1960, JOUR APPL BACT, V23, P130, DOI 10.1111/j.1365-2672.1960.tb00188.x; Devlieghere F, 2004, INT DAIRY J, V14, P273, DOI 10.1016/j.idairyj.2003.07.002; Dudez AM, 2002, MICROBIOL-SGM, V148, P421, DOI 10.1099/00221287-148-2-421; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gill C. O., 1982, MEAT MICROBIOLOGY, P225; Gopal S, 2005, J BACTERIOL, V187, P3839, DOI 10.1128/JB.187.11.3839-3847.2005; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gram L, 2002, CURR OPIN BIOTECH, V13, P262, DOI 10.1016/S0958-1669(02)00309-9; HAMMES WP, 1990, FEMS MICROBIOL LETT, V87, P165, DOI 10.1016/0378-1097(90)90704-T; Hertel C, 1998, APPL ENVIRON MICROB, V64, P1359; Hoebeke M, 2003, BIOINFORMATICS, V19, P859, DOI 10.1093/bioinformatics/btg101; Horsburgh MJ, 2001, INFECT IMMUN, V69, P3744, DOI 10.1128/IAI.69.6.3744-3754.2001; Jonquieres R, 1999, MOL MICROBIOL, V34, P902, DOI 10.1046/j.1365-2958.1999.01652.x; Klappenbach JA, 2000, APPL ENVIRON MICROB, V66, P1328, DOI 10.1128/AEM.66.4.1328-1333.2000; Kleerebezem M, 2003, P NATL ACAD SCI USA, V100, P1990, DOI 10.1073/pnas.0337704100; Mansuy D, 1998, COMP BIOCHEM PHYS C, V121, P5, DOI 10.1016/S0742-8413(98)10026-9; Marceau A, 2004, APPL ENVIRON MICROB, V70, P7260, DOI 10.1128/AEM.70.12.7260-7268.2004; Masson F, 1996, INT J FOOD MICROBIOL, V32, P199, DOI 10.1016/0168-1605(96)01104-X; McGraw WT, 1999, INFECT IMMUN, V67, P3248, DOI 10.1128/IAI.67.7.3248-3256.1999; Moretro T, 2005, RES MICROBIOL, V156, P949, DOI 10.1016/j.resmic.2005.05.005; PANDEY A, 1994, APPL MICROBIOL BIOT, V40, P735, DOI [10.1007/BF00173337, 10.1007/s002530050058]; Pridmore RD, 2004, P NATL ACAD SCI USA, V101, P2512, DOI 10.1073/pnas.0307327101; Rea RB, 2004, INFECT IMMUN, V72, P717, DOI 10.1128/IAI.72.2.717-727.2004; Saier MH, 2000, MICROBIOL MOL BIOL R, V64, P354, DOI 10.1128/MMBR.64.2.354-411.2000; Schachtsiek M, 2004, APPL ENVIRON MICROB, V70, P7078, DOI 10.1128/AEM.70.12.7078-7085.2004; Schuch R, 1999, MICROBIOL-SGM, V145, P2957, DOI 10.1099/00221287-145-10-2957; Sillanpaa J, 2000, J BACTERIOL, V182, P6440, DOI 10.1128/JB.182.22.6440-6450.2000; Skaugen M, 2000, MICROBIOL-SGM, V146, P1163, DOI 10.1099/00221287-146-5-1163; Ventura M, 2002, APPL ENVIRON MICROB, V68, P6172, DOI 10.1128/AEM.68.12.6172-6181.2002; Verges MCC, 1999, FEMS MICROBIOL LETT, V180, P297, DOI 10.1016/S0378-1097(99)00492-9; Vermeiren L, 2004, INT J FOOD MICROBIOL, V96, P149, DOI 10.1016/j.ijfoodmicro.2004.03.016; Vold L, 2000, INT J FOOD MICROBIOL, V56, P219, DOI 10.1016/S0168-1605(00)00215-4; Walter J, 2001, APPL ENVIRON MICROB, V67, P2578, DOI 10.1128/AEM.67.6.2578-2585.2001; Weber J, 2005, MICROBIOL-SGM, V151, P707, DOI 10.1099/mic.0.27482-0; ZALKIN H, 1996, ESCHERICHIA COLI SAL, P5561; Zuniga M, 1998, J BACTERIOL, V180, P4154	50	307	639	3	36	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2005	23	12					1527	1533		10.1038/nbt1160	http://dx.doi.org/10.1038/nbt1160			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	992ED	16273110	hybrid			2022-12-25	WOS:000233866300029
J	Mehrabian, M; Allayee, H; Stockton, J; Lum, PY; Drake, TA; Castellani, LW; Suh, M; Armour, C; Edwards, S; Lamb, J; Lusis, AJ; Schadt, EE				Mehrabian, M; Allayee, H; Stockton, J; Lum, PY; Drake, TA; Castellani, LW; Suh, M; Armour, C; Edwards, S; Lamb, J; Lusis, AJ; Schadt, EE			Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits	NATURE GENETICS			English	Article							GENOMICS APPROACH; MICE; ATHEROSCLEROSIS; IDENTIFICATION; DISSECTION; RESISTANCE; DISCOVERY; NETWORKS; LOCUS	Forward genetic approaches to identify genes involved in complex traits such as common human diseases have met with limited success. Fine mapping of linkage regions and validation of positional candidates are time-consuming and not always successful. Here we detail a hybrid procedure to map loci involved in complex traits that leverages the strengths of forward and reverse genetic approaches. By integrating genotypic and expression data in a segregating mouse population, we show how clusters of expression quantitative trait loci linking to regions of the genome accurately reflect the underlying perturbation to the transcriptional network induced by DNA variations in genes that control the complex traits. By matching patterns of gene expression in a segregating population with expression responses induced by single-gene perturbation experiments, we show how genes controlling clusters of expression and clinical quantitative trait loci can be mapped directly. We demonstrate the utility of this approach by identifying 5-lipoxygenase as underlying previously identified quantitative trait loci in an F-2 cross between strains C57BL/6J and DBA/2J and showing that it has pleiotropic effects on body fat, lipid levels and bone density.	Rosetta Inpharmat, Seattle, WA 98109 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90089 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	Merck & Company; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schadt, EE (corresponding author), Rosetta Inpharmat, 401 Terry Ave N, Seattle, WA 98109 USA.	eric_schadt@merck.com	Edwards, Stephen W/G-4482-2011	Edwards, Stephen/0000-0002-7985-111X				Beattie JH, 1998, P NATL ACAD SCI USA, V95, P358, DOI 10.1073/pnas.95.1.358; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Bystrykh L, 2005, NAT GENET, V37, P225, DOI 10.1038/ng1497; Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Doss S, 2005, GENOME RES, V15, P681, DOI 10.1101/gr.3216905; Drake TA, 2001, PHYSIOL GENOMICS, V5, P205, DOI 10.1152/physiolgenomics.2001.5.4.205; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grupe A, 2001, SCIENCE, V292, P1915, DOI 10.1126/science.1058889; He YDD, 2003, BIOINFORMATICS, V19, P956, DOI 10.1093/bioinformatics/btg126; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Hubner N, 2005, NAT GENET, V37, P243, DOI 10.1038/ng1522; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; Klose J, 2002, NAT GENET, V30, P385, DOI 10.1038/ng861; Kuhn H, 2003, ARTERIOSCL THROM VAS, V23, P1072, DOI 10.1161/01.ATV.0000074167.01184.48; Liao GC, 2004, SCIENCE, V306, P690, DOI 10.1126/science.1100636; McClung JP, 2004, P NATL ACAD SCI USA, V101, P8852, DOI 10.1073/pnas.0308096101; Mehrabian M, 2003, CURR OPIN LIPIDOL, V14, P447, DOI 10.1097/00041433-200310000-00005; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Mehrabian M, 2001, CIRC RES, V89, P125, DOI 10.1161/hh1401.093458; Monks SA, 2004, AM J HUM GENET, V75, P1094, DOI 10.1086/426461; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Parhami F, 2001, J BONE MINER RES, V16, P182, DOI 10.1359/jbmr.2001.16.1.182; Pei LM, 2004, J CLIN INVEST, V113, P805, DOI 10.1172/JCI200421311; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; Villa-Colinayo V, 2000, Curr Atheroscler Rep, V2, P380, DOI 10.1007/s11883-000-0076-2; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zhang Wen, 2004, J Biol, V3, P21, DOI 10.1186/jbiol16; Zhu J, 2004, CYTOGENET GENOME RES, V105, P363, DOI 10.1159/000078209	41	174	175	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2005	37	11					1224	1233		10.1038/ng1619	http://dx.doi.org/10.1038/ng1619			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	980VB	16200066				2022-12-25	WOS:000233045200022
J	Washietl, S; Hofacker, IL; Lukasser, M; Huttenhofer, A; Stadler, PF				Washietl, S; Hofacker, IL; Lukasser, M; Huttenhofer, A; Stadler, PF			Mapping of conserved RNA secondary structures predicts thousands of functional noncoding RNAs in the human genome	NATURE BIOTECHNOLOGY			English	Article							COMPUTATIONAL IDENTIFICATION; ULTRACONSERVED ELEMENTS; SELECTIVE CONSTRAINT; ESCHERICHIA-COLI; MESSENGER-RNAS; SEQUENCES; HUMAN-CHROMOSOME-21; TRANSCRIPTOME; ANNOTATION; REGIONS	In contrast to the fairly reliable and complete annotation of the protein coding genes in the human genome, comparable information is lacking for noncoding RNAs (ncRNAs). We present a comparative screen of vertebrate genomes for structural noncoding RNAs, which evaluates conserved genomic DNA sequences for signatures of structural conservation of base-pairing patterns and exceptional thermodynamic stability. We predict more than 30,000 structured RNA elements in the human genome, almost 1,000 of which are conserved across all vertebrates. Roughly a third are found in introns of known genes, a sixth are potential regulatory elements in untranslated regions of protein-coding mRNAs and about half are located far away from any known gene. Only a small fraction of these sequences has been described previously. A comparison with recent tiling array data shows that more than 40% of the predicted structured RNAs overlap with experimentally detected sites of transcription. The widespread conservation of secondary structure points to a large number of functional ncRNAs and cis-acting mRNA structures in the human genome.	Univ Leipzig, Dept Comp Sci, D-04107 Leipzig, Germany; Univ Leipzig, Interdisciplinary Ctr Bioinformat, D-04107 Leipzig, Germany; Univ Vienna, Inst Theoret Chem, A-1090 Vienna, Austria; Innsbruck Med Univ, Bioctr, Div Genom & RNom, A-6020 Innsbruck, Austria; Santa Fe Inst, Santa Fe, NM 87501 USA	Leipzig University; Leipzig University; University of Vienna; Medical University of Innsbruck; The Santa Fe Institute	Washietl, S (corresponding author), Univ Leipzig, Dept Comp Sci, Hartelstr 16-18, D-04107 Leipzig, Germany.	studla@bioinf.uni-leipzig.de	Stadler, Peter F. F/L-7857-2015; Hofacker, Ivo L/A-2378-2013	Stadler, Peter F. F/0000-0002-5016-5191; Hofacker, Ivo L/0000-0001-7132-0800				Accardo MC, 2004, BIOINFORMATICS, V20, P3293, DOI 10.1093/bioinformatics/bth394; Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Childs JL, 2003, RNA, V9, P1437, DOI 10.1261/rna.5780503; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Cooper GM, 2004, GENOME RES, V14, P539, DOI 10.1101/gr.2034704; Dermitzakis ET, 2003, SCIENCE, V302, P1033, DOI 10.1126/science.1087047; Doudna JA, 2000, NAT STRUCT BIOL, V7, P954, DOI 10.1038/80729; Glazov EA, 2005, GENOME RES, V15, P800, DOI 10.1101/gr.3545105; Griffiths-Jones S, 2005, NUCLEIC ACIDS RES, V33, pD121, DOI 10.1093/nar/gki081; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Hartig JS, 2004, J AM CHEM SOC, V126, P722, DOI 10.1021/ja038822u; Hofacker IL, 1998, NUCLEIC ACIDS RES, V26, P3825, DOI 10.1093/nar/26.16.3825; Hofacker IL, 2002, J MOL BIOL, V319, P1059, DOI 10.1016/S0022-2836(02)00308-X; Huttenhofer A, 2005, TRENDS GENET, V21, P289, DOI 10.1016/j.tig.2005.03.007; Huttenhofer A, 2001, EMBO J, V20, P2943, DOI 10.1093/emboj/20.11.2943; Imanishi T, 2004, PLOS BIOL, V2, P856, DOI 10.1371/journal.pbio.0020162; Johnson JM, 2005, TRENDS GENET, V21, P93, DOI 10.1016/j.tig.2004.12.009; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; LE SY, 1988, COMPUT APPL BIOSCI, V4, P153; Lin J, 2004, P NATL ACAD SCI USA, V101, P14713, DOI 10.1073/pnas.0405879101; Liu CN, 2005, NUCLEIC ACIDS RES, V33, pD112, DOI 10.1093/nar/gki041; Margulies EH, 2003, GENOME RES, V13, P2507, DOI 10.1101/gr.1602203; Mattick JS, 2004, NAT REV GENET, V5, P316, DOI 10.1038/nrg1321; Missal K, 2005, BIOINFORMATICS, V21, P77, DOI 10.1093/bioinformatics/bti1113; Moulton V, 2005, P NATL ACAD SCI USA, V102, P2269, DOI 10.1073/pnas.0500129102; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Pang KC, 2005, NUCLEIC ACIDS RES, V33, pD125, DOI 10.1093/nar/gri089; Pesole G, 2002, NUCLEIC ACIDS RES, V30, P335, DOI 10.1093/nar/30.1.335; Rivas E, 2001, CURR BIOL, V11, P1369, DOI 10.1016/S0960-9822(01)00401-8; Rougeulle C, 2002, TRENDS GENET, V18, P434, DOI 10.1016/S0168-9525(02)02749-X; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Shabalina SA, 1999, GENET RES, V74, P23, DOI 10.1017/S0016672399003821; Shabalina SA, 2001, TRENDS GENET, V17, P373, DOI 10.1016/S0168-9525(01)02344-7; Washietl S, 2004, J MOL BIOL, V342, P19, DOI 10.1016/j.jmb.2004.07.018; Washietl S, 2005, P NATL ACAD SCI USA, V102, P2454, DOI 10.1073/pnas.0409169102; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	43	314	334	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2005	23	11					1383	1390		10.1038/nbt1144	http://dx.doi.org/10.1038/nbt1144			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	984FN	16273071	Green Published			2022-12-25	WOS:000233288000033
J	Ianoul, A; Grant, DD; Rouleau, Y; Bani-Yaghoub, M; Johnston, LJ; Pezacki, JP				Ianoul, A; Grant, DD; Rouleau, Y; Bani-Yaghoub, M; Johnston, LJ; Pezacki, JP			Imaging nanometer domains of beta-adrenergic receptor complexes on the surface of cardiac myocytes	NATURE CHEMICAL BIOLOGY			English	Article							SCANNING OPTICAL MICROSCOPY; BETA-2-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; ADENYLYL-CYCLASE; LIVING CELLS; HEART-RATE; CAVEOLAE; OLIGOMERIZATION; COLOCALIZATION; MICRODOMAINS	The contraction of cardiac myocytes is initiated by ligand binding to adrenergic receptors(1,2) contained in nanoscale multiprotein complexes called signalosomes(3). The composition and number of functional signalosomes within cardiac myocytes defines the molecular basis of the response to adrenergic stimuli(3-6). For the first time, we demonstrated the ability of near-field scanning optical microscopy to visualize beta-adrenergic receptors at the nanoscale in situ. On H9C2 cells, mouse neonatal and mouse embryonic cardiac myocytes, we showed that functional receptors are organized into multiprotein domains of similar to 140 nm average diameter. Colocalization experiments in primary cells at the nanometer scale showed that 15 - 20% of receptors were preassociated in caveolae. These nanoscale complexes were sufficient to effect changes in ligand-induced contraction rate without the requirement for substantial changes in receptor distribution in the cellular membrane. Using fluorescence intensities associated with these nanodomains, we estimated the receptor density within the observed nanometer features and established a lower limit for the number of receptors in the signalosome.	Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada; National Research Council Canada	Johnston, LJ (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	linda.johnston@nrc-cnrc.gc.ca; john.pezacki@nrc-cnrc.gc.ca	ianoul, anatoli/C-1247-2015; ianoul, anatoli/H-8918-2013	Johnston, Linda/0000-0002-9136-4920				Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Burgos P, 2003, J MICROSC-OXFORD, V211, P37, DOI 10.1046/j.1365-2818.2003.01197.x; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Flesch M, 2001, CARDIOVASC RES, V49, P371, DOI 10.1016/S0008-6363(00)00277-7; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Hegener O, 2004, BIOCHEMISTRY-US, V43, P6190, DOI 10.1021/bi035928t; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; Ianoul A, 2004, BIOPHYS J, V87, P3525, DOI [10.1529/biophysj.104.046383, 10.1529/biophysj.104.046393]; Koopman M, 2004, FEBS LETT, V573, P6, DOI 10.1016/j.febslet.2004.07.035; Lewis A, 2003, NAT BIOTECHNOL, V21, P1377, DOI 10.1038/nbt898; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Portbury AL, 2003, AM J PHYSIOL-HEART C, V284, pH2069, DOI 10.1152/ajpheart.00588.2002; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Rohrer DK, 1998, AM J PHYSIOL-HEART C, V274, pH1184, DOI 10.1152/ajpheart.1998.274.4.H1184; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Steinberg SF, 1999, CIRC RES, V85, P1101; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	30	97	100	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2005	1	4					196	202		10.1038/nchembio726	http://dx.doi.org/10.1038/nchembio726			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GM	16408035				2022-12-25	WOS:000232649000010
J	Veigel, C; Schmitz, S; Wang, F; Sellers, JR				Veigel, C; Schmitz, S; Wang, F; Sellers, JR			Load-dependent kinetics of myosin-V can explain its high processivity	NATURE CELL BIOLOGY			English	Article							SMOOTH-MUSCLE MYOSIN; STEPPING KINETICS; WORKING STROKE; MOTOR; FORCE; MOVEMENT; BINDING; HEADS; MODEL; ADP	Recent studies provide strong evidence that single myosin class V molecules transport vesicles and organelles processively along F- actin, taking several 36- nm steps, ' hand over hand', for each diffusional encounter. The mechanisms regulating myosin- V's processivity remain unknown. Here, we have used an optical- tweezers- based transducer to measure the effect of load on the mechanical interactions between rabbit skeletal F- actin and a single head of mouse brain myosin- V, which produces its working stroke in two phases. We found that the lifetimes of the first phase of the working stroke changed exponentially and about 10-fold over a range of pushing and pulling forces of +/- 1.5 pN. Stiffness measurements suggest that intramolecular forces could approach 3.6 pN when both heads are bound to F- actin, in which case extrapolation would predict the detachment kinetics of the front head to slow down 50- fold and the kinetics of the rear head to accelerate respectively. This synchronizing effect on the chemo- mechanical cycles of the heads increases the probability of the trail head detaching first and causes a strong increase in the number of forward steps per diffusional encounter over a system with no strain dependence.	Natl Inst Med Res, London NW7 1AA, England; NHLBI, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA	MRC National Institute for Medical Research; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Veigel, C (corresponding author), Natl Inst Med Res, Ridgeway,Mill Hill, London NW7 1AA, England.	cveigel@nimr.mrc.ac.uk			Medical Research Council [MC_U117570593] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004229, ZIAHL004229] Funding Source: NIH RePORTER; MRC [MC_U117570593] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ali MY, 2002, NAT STRUCT BIOL, V9, P464, DOI 10.1038/nsb803; Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Berger CEM, 2001, J BIOL CHEM, V276, P23240, DOI 10.1074/jbc.M100524200; Burgess S, 2002, J CELL BIOL, V159, P983, DOI 10.1083/jcb.200208172; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Clemen AEM, 2005, BIOPHYS J, V88, P4402, DOI 10.1529/biophysj.104.053504; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; Howard J., 2001, MECH MOTOR PROTEINS; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Kolomeisky AB, 2003, BIOPHYS J, V84, P1642, DOI 10.1016/S0006-3495(03)74973-X; Lan GH, 2005, BIOPHYS J, V88, P4107, DOI 10.1529/biophysj.104.056846; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mehta AD, 1997, P NATL ACAD SCI USA, V94, P7927, DOI 10.1073/pnas.94.15.7927; Miller KE, 2000, J BIOL CHEM, V275, P2598, DOI 10.1074/jbc.275.4.2598; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Moore JR, 2001, J CELL BIOL, V155, P625, DOI 10.1083/jcb.200103128; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; Sellers J. R., 1999, MYOSINS; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; Uemura S, 2004, NAT STRUCT MOL BIOL, V11, P877, DOI 10.1038/nsmb806; Vale RD, 2003, J CELL BIOL, V163, P445, DOI 10.1083/jcb.200308093; Veigel C, 2003, NAT CELL BIOL, V5, P980, DOI 10.1038/ncb1060; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	41	206	207	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2005	7	9					861	869		10.1038/ncb1287	http://dx.doi.org/10.1038/ncb1287			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	960NY	16100513				2022-12-25	WOS:000231601600009
J	Cote, JF; Motoyama, AB; Bush, JA; Vuori, K				Cote, JF; Motoyama, AB; Bush, JA; Vuori, K			A novel and evolutionarily conserved PtdIns(3,4,5)P-3-binding domain is necessary for DOCK180 signalling	NATURE CELL BIOLOGY			English	Article							FOCAL ADHESION KINASE; CELL-MIGRATION; MYOBLAST CITY; C2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; CRKII/DOCK180/RAC PATHWAY; MEMBRANE ASSOCIATION; LIVING CELLS; PROTEIN; BINDING	The evolutionarily conserved DOCK180 protein has an indispensable role in cell migration by functioning as an exchange factor for Rac GTPase via its DOCK homology region (DHR)-2 domain. We report here that the conserved DHR-1 domain also has an important signalling role. A form of DOCK180 that lacks DHR-1 fails to promote cell migration, although it is capable of inducing Rac GTP-loading. The DHR-1 domain interacts with PtdIns(3,4,5)P-3 in vitro and in vivo, and mediates the DOCK180 signalling complex localization at sites of PtdIns(3,4,5)P-3 accumulation in the cell's leading edge. A form of DOCK180 in which the DHR-1 domain has been replaced by a canonical PtdIns(3,4,5)P-3-binding pleckstrin homology domain is fully functional at inducing cell elongation and migration, suggesting that the main function of DHR-1 is to bind PtdIns(3,4,5)P-3. These results demonstrate that DOCK180, via its DHR-1 and DHR-2 domains, couples PtdIns(3,4,5)P-3 signalling to Rac GTP-loading, which is essential for directional cell movement.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	kvuori@burnham.org	Motoyama, Andrea/AAB-9362-2019		NATIONAL CANCER INSTITUTE [P01CA102583] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA102583] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Catz SD, 2002, P NATL ACAD SCI USA, V99, P11652, DOI 10.1073/pnas.172382799; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; DOWLER S, 2002, SCI STKE, pPL6, DOI DOI 10.1126/STKE.2002.129.PL6; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Dunn R, 2004, J CELL BIOL, V165, P135, DOI 10.1083/jcb.200309026; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kobayashi S, 2001, BIOCHEM J, V354, P73, DOI 10.1042/0264-6021:3540073; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Postma M, 2004, EMBO REP, V5, P35, DOI 10.1038/sj.embor.7400051; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P193, DOI 10.1146/annurev.cellbio.20.022003.114619; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Shirai T, 1998, BBA-MOL CELL RES, V1402, P292, DOI 10.1016/S0167-4889(98)00014-7; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Takenawa T, 2001, J CELL SCI, V114, P1801; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wu YC, 2001, DEV CELL, V1, P491, DOI 10.1016/S1534-5807(01)00056-9; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	43	179	184	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2005	7	8					797	U63		10.1038/ncb1280	http://dx.doi.org/10.1038/ncb1280			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	950TU	16025104	Green Accepted			2022-12-25	WOS:000230881500014
J	Salzer, U; Chapel, HM; Webster, ADB; Pan-Hammarstrom, Q; Schmitt-Graeff, A; Schlesier, M; Peter, HH; Rockstroh, JK; Schneider, P; Schaffer, AA; Hammarstrom, L; Grimbacher, B				Salzer, U; Chapel, HM; Webster, ADB; Pan-Hammarstrom, Q; Schmitt-Graeff, A; Schlesier, M; Peter, HH; Rockstroh, JK; Schneider, P; Schaffer, AA; Hammarstrom, L; Grimbacher, B			Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans	NATURE GENETICS			English	Article							TNF RECEPTOR; B-CELLS; LYMPHOPROLIFERATIVE SYNDROME; LINKAGE ANALYSIS; IGA DEFICIENCY; T-CELL; BAFF-R; FAMILY; APRIL; MEMBERS	The functional interaction of BAFF and APRIL with TNF receptor superfamily members BAFFR, TACI and BCMA is crucial for development and maintenance of humoral immunity in mice and humans. Using a candidate gene approach, we identified homozygous and heterozygous mutations in TNFRSF13B, encoding TACI, in 13 individuals with common variable immunodeficiency. Homozygosity with respect to mutations causing the amino acid substitutions S144X and C104R abrogated APRIL binding and resulted in loss of TACI function, as evidenced by impaired proliferative response to IgM-APRIL costimulation and defective class switch recombination induced by IL-10 and APRIL or BAFF. Family members heterozygous with respect to the C104R mutation and individuals with sporadic common variable immunodeficiency who were heterozygous with respect to the amino acid substitutions A181E, S194X and R202H had humoral immunodeficiency. Although signs of autoimmunity and lymphoproliferation are evident, the human phenotype differs from that of the Tnfrsf13b(-/-) mouse model.	Univ Hosp, Med Ctr, Div Clin Immunol & Rheumatol, D-79106 Freiburg, Germany; Oxford Radcliffe Hosp, Dept Immunol, Oxford, England; Royal Free Hosp, Dept Clin Immunol, London NW3 2QG, England; Karolinska Inst Huddinge, Div Clin Immunol, Stockholm, Sweden; Univ Freiburg, Inst Pathol, D-7800 Freiburg, Germany; Med Univ Klin 1, Bonn, Germany; Univ Lausanne, Dept Biochem, CH-1015 Lausanne, Switzerland; NIH, Natl Ctr Biotechnol Informat, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	University of Freiburg; University of Oxford; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Karolinska Institutet; University of Freiburg; University of Bonn; University of Lausanne; National Institutes of Health (NIH) - USA	Grimbacher, B (corresponding author), Univ Hosp, Med Ctr, Div Clin Immunol & Rheumatol, Hugstetterstr 55, D-79106 Freiburg, Germany.	grimbacher@medizin.ukl.uni-freiburg.de	hammarstrom, qiang pan/ABA-4589-2021; Schaffer, Alejandro/N-1222-2019; Schaffer, Alejandro A/F-2902-2012	Schneider, Pascal/0000-0003-0677-9409; pan-hammarstrom, qiang/0000-0003-1990-8804	NATIONAL LIBRARY OF MEDICINE [Z01LM000097, ZIALM000097] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Avery DT, 2003, J CLIN INVEST, V112, P286, DOI 10.1172/JCI200318025; Baker KP, 2003, ARTHRITIS RHEUM-US, V48, P3253, DOI 10.1002/art.11299; Burrows PD, 1997, ADV IMMUNOL, V65, P245, DOI 10.1016/S0065-2776(08)60744-0; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2004, P NATL ACAD SCI USA, V101, P3903, DOI 10.1073/pnas.0307348101; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Gross JA, 2001, IMMUNITY, V15, P289, DOI 10.1016/S1074-7613(01)00183-2; HANNELIUS U, IN PRESS J MED GENET; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Infante AJ, 1998, J PEDIATR-US, V133, P629, DOI 10.1016/S0022-3476(98)70102-7; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Kralovicova J, 2003, J IMMUNOL, V170, P2765, DOI 10.4049/jimmunol.170.5.2765; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Mackay F, 2003, CYTOKINE GROWTH F R, V14, P311, DOI 10.1016/S1359-6101(03)00023-6; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Ng LG, 2004, J IMMUNOL, V173, P807, DOI 10.4049/jimmunol.173.2.807; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Pan Q, 1997, EUR J IMMUNOL, V27, P2920, DOI 10.1002/eji.1830271126; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Riva A, 2002, BIOINFORMATICS, V18, P1681, DOI 10.1093/bioinformatics/18.12.1681; Salzer U, 2004, CLIN IMMUNOL, V113, P234, DOI 10.1016/j.clim.2004.07.002; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Shulga-Morskaya S, 2004, J IMMUNOL, V173, P2331, DOI 10.4049/jimmunol.173.4.2331; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Varfolomeev E, 2004, MOL CELL BIOL, V24, P997, DOI 10.1128/MCB.24.3.997-1006.2004; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; Vorechovsky I, 2000, J IMMUNOL, V164, P4408, DOI 10.4049/jimmunol.164.8.4408; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Wu H, 2004, ADV PROTEIN CHEM, V68, P225; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790	41	488	502	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2005	37	8					820	828		10.1038/ng1600	http://dx.doi.org/10.1038/ng1600			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	16007087				2022-12-25	WOS:000230880400011
J	Schadt, EE; Lamb, J; Yang, X; Zhu, J; Edwards, S; GuhaThakurta, D; Sieberts, SK; Monks, S; Reitman, M; Zhang, CS; Lum, PY; Leonardson, A; Thieringer, R; Metzger, JM; Yang, LM; Castle, J; Zhu, HY; Kash, SF; Drake, TA; Sachs, A; Lusis, AJ				Schadt, EE; Lamb, J; Yang, X; Zhu, J; Edwards, S; GuhaThakurta, D; Sieberts, SK; Monks, S; Reitman, M; Zhang, CS; Lum, PY; Leonardson, A; Thieringer, R; Metzger, JM; Yang, LM; Castle, J; Zhu, HY; Kash, SF; Drake, TA; Sachs, A; Lusis, AJ			An integrative genomics approach to infer causal associations between gene expression and disease	NATURE GENETICS			English	Article							QUANTITATIVE TRAIT LOCI; TRANSFORMING GROWTH FACTOR-BETA(1); SELECTIVE-INHIBITION; INSULIN SENSITIVITY; HYPERGLYCEMIC MICE; SERUM COMPLEMENT; MICROARRAYS; OBESITY; ACTIVATION; MARKERS	A key goal of biomedical research is to elucidate the complex network of gene interactions underlying complex traits such as common human diseases. Here we detail a multistep procedure for identifying potential key drivers of complex traits that integrates DNA- variation and gene- expression data with other complex trait data in segregating mouse populations. Ordering gene expression traits relative to one another and relative to other complex traits is achieved by systematically testing whether variations in DNA that lead to variations in relative transcript abundances statistically support an independent, causative or reactive function relative to the complex traits under consideration. We show that this approach can predict transcriptional responses to single gene- perturbation experiments using gene- expression data in the context of a segregating mouse population. We also demonstrate the utility of this approach by identifying and experimentally validating the involvement of three new genes in susceptibility to obesity.	Rosetta Inpharmat, Seattle, WA 98109 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; Oklahoma State Univ, Dept Stat, Stillwater, OK 74078 USA; Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA; Merck Res Labs, Dept Cardiovasc Dis, Rahway, NJ 07065 USA; Merck Res Labs, Dept Pharmacol, Rahway, NJ 07065 USA; Deltagen Inc, San Carlos, CA 94070 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	Merck & Company; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Oklahoma State University System; Oklahoma State University - Stillwater; Merck & Company; Merck & Company; Merck & Company; University of California System; University of California Los Angeles	Schadt, EE (corresponding author), Rosetta Inpharmat, Seattle, WA 98109 USA.	eric_schadt@merck.com	Edwards, Stephen W/G-4482-2011; Pillay, Nischalan/F-9536-2012; Longo, Kenneth A/A-5631-2010; Reitman, Marc/B-4448-2013; Califano, Andrea/F-7239-2012	Reitman, Marc/0000-0002-0426-9475; Edwards, Stephen/0000-0002-7985-111X	NHLBI NIH HHS [P01 HL028481-21A1, P01 HL028481, P01 HL028481-21A10010, R01 HL094322, P01 HL030568-220009, P01 HL030568, P01 HL030568-220011] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, P01HL028481, R01HL094322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Alberts P, 2002, DIABETOLOGIA, V45, P1528, DOI 10.1007/s00125-002-0959-6; Alessi MC, 2000, DIABETES, V49, P1374, DOI 10.2337/diabetes.49.8.1374; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; BROMAN KW, 1997, THESIS U CALIFORNIA; Carlborg O, 2005, BIOINFORMATICS, V21, P2383, DOI 10.1093/bioinformatics/bti241; Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518; Choy LN, 1996, OBES RES, V4, P521, DOI 10.1002/j.1550-8528.1996.tb00266.x; DePrimo SE, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-3; Drake TA, 2001, PHYSIOL GENOMICS, V5, P205, DOI 10.1152/physiolgenomics.2001.5.4.205; GHAZALPOUR A, IN PRESS GENOME BIOL; Goodarzi MO, 2004, DIABETES, V53, P214, DOI 10.2337/diabetes.53.1.214; Grant GR, 2005, BIOINFORMATICS, V21, P2684, DOI 10.1093/bioinformatics/bti407; HALEY CS, 1992, HEREDITY, V69, P315, DOI 10.1038/hdy.1992.131; He YDD, 2003, BIOINFORMATICS, V19, P956, DOI 10.1093/bioinformatics/btg126; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Jiang CJ, 1997, GENETICA, V101, P47, DOI 10.1023/A:1018394410659; JIANG CJ, 1995, GENETICS, V140, P1111; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Kao CH, 2002, GENETICS, V160, P1243; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Klose J, 2002, NAT GENET, V30, P385, DOI 10.1038/ng861; Langfitt T W, 1981, Prog Neurol Surg, V10, P14, DOI 10.1159/000384767; Laurie CC, 2004, GENETICS, V168, P2141, DOI 10.1534/genetics.104.029686; Luscombe NM, 2004, NATURE, V431, P308, DOI 10.1038/nature02782; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Miller A., 1990, SUBSET SELECTION REG; Monks SA, 2004, AM J HUM GENET, V75, P1094, DOI 10.1086/426461; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Pearl J., 1988, PROBABILISTIC REASON, DOI 10.1016/B978-0-08-051489-5.50008-4; Pomeroy C, 1997, CLIN EXP IMMUNOL, V108, P507, DOI 10.1046/j.1365-2249.1997.3921287.x; Rask E, 2002, J CLIN ENDOCR METAB, V87, P3330, DOI 10.1210/jc.87.7.3330; Romano M, 2003, J CLIN ENDOCR METAB, V88, P5321, DOI 10.1210/jc.2003-030508; Rosmond R, 2003, HORM RES, V59, P191, DOI 10.1159/000069323; Sakamoto Y, 1986, AKAIKE INFORMATION C; Samad TA, 1997, P NATL ACAD SCI USA, V94, P14349, DOI 10.1073/pnas.94.26.14349; Schadt EE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r73; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; SCHUPF N, 1983, J NEUROIMMUNOL, V5, P305, DOI 10.1016/0165-5728(83)90051-6; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Sillanpaa MJ, 2002, TRENDS GENET, V18, P301, DOI 10.1016/S0168-9525(02)02688-4; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Waring JF, 2002, TOXICOLOGY, V181, P537, DOI 10.1016/S0300-483X(02)00477-8; Ylitalo K, 1997, ATHEROSCLEROSIS, V129, P271, DOI 10.1016/S0021-9150(96)06054-6; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222; Zeng ZB, 2000, GENETICS, V154, P299; Zhu J, 2004, CYTOGENET GENOME RES, V105, P363, DOI 10.1159/000078209	49	735	764	1	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2005	37	7					710	717		10.1038/ng1589	http://dx.doi.org/10.1038/ng1589			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	941EA	15965475	Green Accepted			2022-12-25	WOS:000230196400017
J	Brummelkamp, TR; Fabius, AWM; Mullenders, J; Madiredjo, M; Velds, A; Kerkhoven, RM; Bernards, R; Beijersbergen, RL				Brummelkamp, TR; Fabius, AWM; Mullenders, J; Madiredjo, M; Velds, A; Kerkhoven, RM; Bernards, R; Beijersbergen, RL			An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors	NATURE CHEMICAL BIOLOGY			English	Article							DNA-DAMAGE CHECKPOINT; P53; 53BP1; ACTIVATION; PATHWAY; GROWTH; ATM	The identification of the cellular targets of small molecules with anticancer activity is crucial to their further development as drug candidates. Here, we present the application of a large-scale RNA interference-based short hairpin RNA (shRNA) barcode screen to gain insight in the mechanism of action of nutlin-3 (1). Nutlin-3 is a small-molecule inhibitor of MDM2, which can activate the p53 pathway. Nutlin-3 shows strong antitumor effects in mice, with surprisingly few side effects on normal tissues(1). Aside from p53, we here identify 53BP1 as a critical mediator of nutlin-3-induced cytotoxicity. 53BP1 is part of a signaling network induced by DNA damage that is frequently activated in cancer but not in healthy tissues(2). Our results suggest that nutlin-3's tumor specificity may result from its ability to turn a cancer cell-specific property (activated DNA damage signaling(3)) into a weakness that can be exploited therapeutically.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Cent Microarray Facil, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl; r.beijersbergen@nki.nl	Mullenders, Jasper/J-2398-2015	Mullenders, Jasper/0000-0003-3737-6901; Beijersbergen, Roderick/0000-0003-0116-4130; Bernards, Rene/0000-0001-8677-3423; Velds, Arno/0000-0003-4333-8872				Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brummelkamp TR, 2004, COLD SPRING HARB SYM, V69, P439, DOI 10.1101/sqb.2004.69.439; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Harris MP, 1996, CANCER GENE THER, V3, P121; Heetebrij RJ, 2003, CHEMBIOCHEM, V4, P573, DOI 10.1002/cbic.200200498; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane DP, 2004, NATURE, V427, P789, DOI 10.1038/427789a; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Moumen A, 2005, CELL, V123, P1065, DOI 10.1016/j.cell.2005.09.032; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Reinholz MM, 2004, BREAST CANCER RES TR, V86, P75, DOI 10.1023/B:BREA.0000032926.74216.7d; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wong J, 2002, J BIOL CHEM, V277, P26699, DOI 10.1074/jbc.M203020200; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Zheng XFS, 2004, CHEM BIOL, V11, P609, DOI 10.1016/j.chembiol.2003.08.011; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	30	167	177	0	19	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	APR	2006	2	4					202	206		10.1038/nchembio774	http://dx.doi.org/10.1038/nchembio774			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	023QU	16474381	Green Published			2022-12-25	WOS:000236142100012
J	Dyce, PW; Wen, LH; Li, JL				Dyce, PW; Wen, LH; Li, JL			In vitro germline potential of stem cells derived from fetal porcine skin	NATURE CELL BIOLOGY			English	Article							OVARIAN FOLLICULAR DEVELOPMENT; ZONA-PELLUCIDA; MOUSE; EXPRESSION; OOCYTES; GENE; PRODUCT; FAMILY; PROLIFERATION; DERIVATION	Two of the unanswered questions in mammalian developmental biology are when and where the fate of the germ cell is specified. Here, we report that stem cells isolated from the skin of porcine fetuses have the intrinsic ability to differentiate into oocyte-like cells. When differentiation was induced, a subpopulation of these cells expressed markers such as Oct4, Growth differentiation factor 9b (GDF9b), the Deleted in Azoospermia-like (DAZL) gene and Vasa - all consistent with germ-cell formation. On further differentiation, these cells formed follicle-like aggregates that secreted oestradiol and progesterone and responded to gonadotropin stimulation. Some of these aggregates extruded large oocyte-like cells that expressed oocyte markers, such as zona pellucida, and the meiosis marker, synaptonemal complex protein 3 (SCP3). Some of these oocyte-like cells spontaneously developed into parthenogenetic embryo-like structures. The ability to generate oocyte-like cells from skin-derived cells may offer new possibilities for tissue therapy and provide a new in vitro model to study germ-cell formation and oogenesis.	Univ Guelph, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada	University of Guelph	Li, JL (corresponding author), Univ Guelph, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada.	jli@uoguelph.ca		Dyce, Paul/0000-0002-4574-3321				Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; DUNBAR BS, 1994, REPROD FERT DEVELOP, V6, P331, DOI 10.1071/RD9940331; Dyce PW, 2004, BIOCHEM BIOPH RES CO, V316, P651, DOI 10.1016/j.bbrc.2004.02.093; Geijsen N, 2004, NATURE, V427, P148, DOI 10.1038/nature02247; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; HILLIER SG, 1994, MOL CELL ENDOCRINOL, V100, P51, DOI 10.1016/0303-7207(94)90278-X; Hubner K, 2003, SCIENCE, V300, P1251, DOI 10.1126/science.1083452; Jiang JY, 2003, FRONT BIOSCI-LANDMRK, V8, pD222, DOI 10.2741/949; Johnson J, 2004, NATURE, V428, P145, DOI 10.1038/nature02316; Kirchhof N, 2000, BIOL REPROD, V63, P1698, DOI 10.1095/biolreprod63.6.1698; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; Miyano T, 2005, J REPROD DEVELOP, V51, P169, DOI 10.1262/jrd.16014; Moe-Behrens GHG, 2003, MOL ENDOCRINOL, V17, P2630, DOI 10.1210/me.2003-0006; O'Brien MJ, 2003, BIOL REPROD, V68, P1682, DOI 10.1095/biolreprod.102.013029; Parra MT, 2004, J CELL SCI, V117, P1221, DOI 10.1242/jcs.00947; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; Pesce M, 1997, MECH DEVELOP, V68, P37, DOI 10.1016/S0925-4773(97)00120-2; RICHARDS JS, 1988, ANNU REV PHYSIOL, V50, P441; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; Shim H, 1998, THERIOGENOLOGY, V49, P521, DOI 10.1016/S0093-691X(98)00003-X; Spargo SC, 2003, BIOL REPROD, V68, P358, DOI 10.1095/biolreprod.102.008086; Tam PPL, 1996, DEV BIOL, V178, P124, DOI 10.1006/dbio.1996.0203; TAYA T, 1995, BIOCHEM BIOPH RES CO, V207, P790, DOI 10.1006/bbrc.1995.1256; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Toyooka Y, 2000, MECH DEVELOP, V93, P139, DOI 10.1016/S0925-4773(00)00283-5; Toyooka Y, 2003, P NATL ACAD SCI USA, V100, P11457, DOI 10.1073/pnas.1932826100; Webb R, 2003, REPRODUCTION, P71; Yen PH, 2004, INT J ANDROL, V27, P125, DOI 10.1111/j.1365-2605.2004.00469.x	30	198	223	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2006	8	4					384	U50		10.1038/ncb1388	http://dx.doi.org/10.1038/ncb1388			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	029KA	16565707				2022-12-25	WOS:000236560000017
J	Bonnen, PE; Pe'er, I; Plenge, RM; Salit, J; Lowe, JK; Shapero, MH; Lifton, RP; Breslow, JL; Daly, MJ; Reich, DE; Jones, KW; Stoffel, M; Altshuler, D; Friedman, JM				Bonnen, PE; Pe'er, I; Plenge, RM; Salit, J; Lowe, JK; Shapero, MH; Lifton, RP; Breslow, JL; Daly, MJ; Reich, DE; Jones, KW; Stoffel, M; Altshuler, D; Friedman, JM			Evaluating potential for whole-genome studies in Kosrae, an isolated population in Micronesia	NATURE GENETICS			English	Article							COMMON DISEASE GENES; LINKAGE-DISEQUILIBRIUM; ASSOCIATION; TESTS; PATTERNS; FINLAND; TRAITS; LOCI	Whole-genome association studies are predicted to be especially powerful in isolated populations owing to increased linkage disequilibrium (LD) and decreased allelic diversity, but this possibility has not been empirically tested(1-3). We compared genome-wide data on 113,240 SNPs typed on 30 trios from the Pacific island of Kosrae to the same markers typed in the 270 samples from the International HapMap Project(4,5). The extent of LD is longer and haplotype diversity is lower in Kosrae than in the HapMap populations. More than 98% of Kosraen haplotypes are present in HapMap populations, indicating that HapMap will be useful for genetic studies on Kosrae. The long-range LD around common alleles and limited diversity result in improved efficiency in genetic studies in this population and augments the power to detect association of 'hidden SNPs'.	Rockefeller Univ, New York, NY 10021 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Harvard Univ, Broad Inst, Cambridge, MA 02138 USA; MIT, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Affymetrix Inc, Santa Clara, CA 95051 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Rockefeller University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Affymetrix; Yale University; Yale University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Friedman, JM (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	friedj@rockefeller.edu	Altshuler, David M/A-4476-2009; Breslow, Jan L/B-7544-2008; Daly, Mark J/B-2453-2017	Altshuler, David M/0000-0002-7250-4107; Daly, Mark J/0000-0002-0949-8752; Stoffel, Markus/0000-0003-1304-5817				Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Angius A, 2002, HUM GENET, V111, P9, DOI 10.1007/s00439-002-0753-z; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; CHURCHILL GA, 1994, GENETICS, V138, P963; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; Doerge RW, 1996, GENETICS, V142, P285; Eaves IA, 2000, NAT GENET, V25, P320; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; JORDE LB, 1995, AM J HUM GENET, V56, P11; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Laan M, 1997, NAT GENET, V17, P435, DOI 10.1038/ng1297-435; Lee N, 2001, AM J HUM GENET, V68, P397, DOI 10.1086/318197; Lin S, 2004, NAT GENET, V36, P1181, DOI 10.1038/ng1457; Ober C, 2001, AM J HUM GENET, V69, P1068, DOI 10.1086/324025; Patterson N, 2004, AM J HUM GENET, V74, P979, DOI 10.1086/420871; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SEGAL HG, 1995, SLEEPING LADY AWAKEN; Shifman S, 2003, HUM MOL GENET, V12, P771, DOI 10.1093/hmg/ddg088; Shifman S, 2001, NAT GENET, V28, P309, DOI 10.1038/91060; SHMULEWITZ D, IN PRESS P NATL ACAD; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Van Steen K, 2005, NAT GENET, V37, P683, DOI 10.1038/ng1582; Wilk JB, 2001, GENET EPIDEMIOL, V21, pS364, DOI 10.1002/gepi.2001.21.s1.s364; Wright AF, 1999, NAT GENET, V23, P397, DOI 10.1038/70501; Zhang J, 2005, GENET EPIDEMIOL, V29, P128, DOI 10.1002/gepi.20081	27	54	54	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					214	217		10.1038/ng1712	http://dx.doi.org/10.1038/ng1712			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16429162				2022-12-25	WOS:000234953200017
J	Malek, RL; Wang, HY; Kwitek, AE; Greene, AS; Bhagabati, N; Borchardt, G; Cahill, L; Currier, T; Frank, B; Fu, XP; Hasinoff, M; Howe, E; Letwin, N; Luu, TV; Saeed, A; Sajadi, H; Salzberg, SL; Sultana, R; Thiagarajan, M; Tsai, J; Veratti, K; White, J; Quackenbush, J; Jacob, HJ; Lee, NH				Malek, RL; Wang, HY; Kwitek, AE; Greene, AS; Bhagabati, N; Borchardt, G; Cahill, L; Currier, T; Frank, B; Fu, XP; Hasinoff, M; Howe, E; Letwin, N; Luu, TV; Saeed, A; Sajadi, H; Salzberg, SL; Sultana, R; Thiagarajan, M; Tsai, J; Veratti, K; White, J; Quackenbush, J; Jacob, HJ; Lee, NH			Physiogenomic resources for rat models of heart, lung and blood disorders	NATURE GENETICS			English	Article							HYPERTENSION; GENES; MAP; SINGLE	Cardiovascular disorders are influenced by genetic and environmental factors. The TIGR rodent expression web-based resource (TREX) contains over 2,200 microarray hybridizations, involving over 800 animals from 18 different rat strains. These strains comprise genetically diverse parental animals and a panel of chromosomal substitution strains derived by introgressing individual chromosomes from normotensive Brown Norway (BN/NHsdMcwi) rats into the background of Dahl salt sensitive (SS/JrHsdMcwi) rats. The profiles document gene-expression changes in both genders, four tissues ( heart, lung, liver, kidney) and two environmental conditions (normoxia, hypoxia). This translates into almost 400 high-quality direct comparisons ( not including replicates) and over 100,000 pairwise comparisons. As each individual chromosomal substitution strain represents on average less than a 5% change from the parental genome, consomic strains provide a useful mechanism to dissect complex traits and identify causative genes. We performed a variety of data-mining manipulations on the profiles and used complementary physiological data from the PhysGen resource to demonstrate how TREX can be used by the cardiovascular community for hypothesis generation.	TREX Inst Genom Res, Rockville, MD 20850 USA; Med Coll Wisconsin, PhysGen, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Lee, NH (corresponding author), TREX Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	nhlee@tigr.org	Salzberg, Steven/Q-6514-2019; Greene, Andrew S/B-9696-2015; Salzberg, Steven L/F-6162-2011	Salzberg, Steven/0000-0002-8859-7432; Salzberg, Steven L/0000-0002-8859-7432; Kwitek, Anne/0000-0003-1024-4116; Quackenbush, John/0000-0002-2702-5879; Greene, Andrew/0000-0002-3191-2112	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066619] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM006845] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01 HL066619-04S1, U01 HL066619] Funding Source: Medline; NLM NIH HHS [R01 LM006845-08, R01 LM006845] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Chen YF, 1997, HYPERTENSION, V29, P75, DOI 10.1161/01.HYP.29.1.75; Cowley AW, 2001, HYPERTENSION, V37, P456, DOI 10.1161/01.HYP.37.2.456; Cui ZH, 1997, ALLERGY, V52, P739, DOI 10.1111/j.1398-9995.1997.tb01231.x; de la Cruz N, 2005, NUCLEIC ACIDS RES, V33, pD485, DOI 10.1093/nar/gki050; Flint J, 2005, NAT REV GENET, V6, P271, DOI 10.1038/nrg1576; Freimer N, 2003, NAT GENET, V34, P15, DOI 10.1038/ng0503-15; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; GROVER RF, 1963, AM HEART J, V66, P1, DOI 10.1016/0002-8703(63)90062-0; Guryev V, 2004, GENOME RES, V14, P1438, DOI 10.1101/gr.2154304; Hoshikawa Y, 2003, PHYSIOL GENOMICS, V12, P209, DOI 10.1152/physiolgenomics.00081.2001; Hubner N, 2005, NAT GENET, V37, P243, DOI 10.1038/ng1522; Hunter DJ, 2005, NAT REV GENET, V6, P287, DOI 10.1038/nrg1578; Jacob HJ, 2002, NAT REV GENET, V3, P33, DOI 10.1038/nrg702; KUIJPERS MHM, 1986, J HYPERTENS, V4, pS41; Kwitek-Black A E, 2001, Curr Hypertens Rep, V3, P12, DOI 10.1007/s11906-001-0072-0; Madjdpour C, 2003, AM J PHYSIOL-LUNG C, V284, pL360, DOI 10.1152/ajplung.00158.2002; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Molthen RC, 2004, J APPL PHYSIOL, V97, P2372, DOI 10.1152/japplphysiol.00454.2004; Moreno C, 2003, PHYSIOL GENOMICS, V15, P243, DOI 10.1152/physiolgenomics.00105.2003; Rapp JP, 2000, PHYSIOL REV, V80, P135, DOI 10.1152/physrev.2000.80.1.135; Rozen S, 2000, Methods Mol Biol, V132, P365; Steen RG, 1999, GENOME RES, V9, pAP1; Stoll M, 2001, SCIENCE, V294, P1723, DOI 10.1126/science.1062117; Thomas MA, 2003, MAMM GENOME, V14, P61, DOI 10.1007/s00335-002-2204-5; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Twigger SN, 2004, GENOME RES, V14, P651, DOI 10.1101/gr.1974504; Wildhirt SM, 1999, CARDIOVASC RES, V43, P698, DOI 10.1016/S0008-6363(99)00080-2; Zan YH, 2003, NAT BIOTECHNOL, V21, P645, DOI 10.1038/nbt830; Zimdahl H, 2004, SCIENCE, V303, P807, DOI 10.1126/science.1092427	30	40	42	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2006	38	2					234	239		10.1038/ng1693	http://dx.doi.org/10.1038/ng1693			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	007FE	16415889				2022-12-25	WOS:000234953200021
J	Chang, P; Coughlin, M; Mitchison, TJ				Chang, P; Coughlin, M; Mitchison, TJ			Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function	NATURE CELL BIOLOGY			English	Article							COMPONENT; PHOSPHORYLATION; GLYCOHYDROLASE; ORGANIZATION; ASSOCIATION; INHIBITORS; MITOSIS; IRAP; PARP; NUMA	Poly(ADP-ribose) (PAR) is a large, negatively charged posttranslational modification that is produced by polymerization of NAD+ by PAR polymerases (PARPs)(1). There are at least 18 PARPs in the human genome, several of which have functions that are unknown(1). PAR modifications are dynamic; PAR structure depends on the balance between synthesis and hydrolysis by PAR glycohydrolase(2). We previously found that PAR is enriched in vertebrate somatic-cell mitotic spindles and demonstrated a requirement for PAR in the assembly of Xenopus egg extract spindles(3). Here, we knockdown all characterized PARPs using RNA interference (RNAi), and identify tankyrase-1 as the PARP that is required for mitosis. Tankyrase-1 localizes to mitotic spindle poles, to telomeres(4) and to the Golgi apparatus(5). Tankyrase-1 RNAi was recently shown to result in mitotic arrest, with abnormal chromosome distributions and spindle morphology observed - data that is interpreted as evidence of post-anaphase arrest induced by failure of telomere separation(6). We show that tankyrase-1 RNAi results in pre-anaphase arrest, with intact sister-chromatid cohesion. We also demonstrate a requirement for tankyrase-1 in the assembly of bipolar spindles, and identify the spindle-pole protein NuMA(7) as a substrate for covalent modification by tankyrase-1.	Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Chang, P (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.	paul_chang2@hms.harvard.edu			NIGMS NIH HHS [F32 GM070090, GM39565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM070090, R37GM039565, R01GM039565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; BOYLES J, 1985, J HISTOCHEM CYTOCHEM, V33, P1116, DOI 10.1177/33.11.3902963; Bryant HE, 2004, BIOCHEM SOC T, V32, P959, DOI 10.1042/BST0320959; Chang P, 2004, NATURE, V432, P645, DOI 10.1038/nature03061; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; DeBonis S, 2004, MOL CANCER THER, V3, P1079; Dynek JN, 2004, SCIENCE, V304, P97, DOI 10.1126/science.1094754; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Kameoka M, 2004, J VIROL, V78, P8931, DOI 10.1128/JVI.78.16.8931-8934.2004; Mitchison TJ, 2004, MOL BIOL CELL, V15, P5603, DOI 10.1091/mbc.E04-05-0440; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Sbodio JI, 2002, J BIOL CHEM, V277, P31887, DOI 10.1074/jbc.M203916200; SLAMA JT, 1995, J MED CHEM, V38, P389, DOI 10.1021/jm00002a021; Smith S, 1999, J CELL SCI, V112, P3649; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405	26	210	222	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1133	1139		10.1038/ncb1322	http://dx.doi.org/10.1038/ncb1322			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16244666				2022-12-25	WOS:000232930400018
J	Wynder, C; Hakimi, MA; Epstein, JA; Shilatifard, A; Shiekhattar, R				Wynder, C; Hakimi, MA; Epstein, JA; Shilatifard, A; Shiekhattar, R			Recruitment of MLL by HMG-domain protein iBRAF promotes neural differentiation	NATURE CELL BIOLOGY			English	Article							CELLS IN-VITRO; CHROMATIN-STRUCTURE; TARGET GENES; COMPLEX; METHYLTRANSFERASE; TRANSCRIPTION; REPRESSION; NEURONS	Differentiation of progenitor cells into post-mitotic neurons requires the engagement of mechanisms by which the repressive effects of the neuronal silencer, RE-1 silencing transcription factor (REST), can be overcome(1,2). Previously, we described a high-mobility group (HMG)-containing protein, BRAF35, which is a component of a co-repressor complex that is required for the repression of REST-responsive genes(3). Here, we show that the BRAF35 family member inhibitor of BRAF35 (iBRAF) activates REST-responsive genes through the modulation of histone methylation. In contrast to BRAF35, iBRAF expression leads to the abrogation of REST-mediated transcriptional repression and the resultant activation of neuronal-specific genes. Analysis of P19 cells during neuronal differentiation revealed an increased concentration of iBRAF at the promoter of neuronal-specific genes coincident with augmented expression of synapsin, recruitment of the methyltransferase MLL and enhanced trimethylation of histone H3 lysine 4 (H3K4). Importantly, ectopic expression of iBRAF is sufficient to induce neuronal differentiation through recruitment of MLL, resulting in increased histone H3K4 trimethylation and activation of neuronal-specific genes. Moreover, depletion of iBRAF abrogates recruitment of MLL and enhancement of histone H3K4 trimethylation. Together, these results indicate that the HMG-domain protein iBRAF has a key role in the initiation of neuronal differentiation.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Grenoble 1, CNRS, UMR5163, F-38700 La Tronche, France; Univ Penn, Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA; St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63108 USA	The Wistar Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Pennsylvania; Saint Louis University	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	shiekhattar@wistar.org	HAKIMI, Mohamed-ali/GYJ-0879-2022; HAKIMI, Mohamed-Ali/F-9806-2014; HAKIMI, Mohamed-ali/Q-6475-2019	HAKIMI, Mohamed-Ali/0000-0002-2547-8233; HAKIMI, Mohamed-ali/0000-0002-2547-8233	NIGMS NIH HHS [GM 61204] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061204] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Kanda S, 2004, INT J DEV NEUROSCI, V22, P149, DOI 10.1016/j.ijdevneu.2004.01.002; Lichota J, 2003, BIOL CHEM, V384, P1019, DOI 10.1515/BC.2003.114; MacPherson Paul A., 1995, Methods (Orlando), V7, P238, DOI 10.1006/meth.1995.1029; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MORASSUTTI DJ, 1994, NEUROSCIENCE, V58, P753, DOI 10.1016/0306-4522(94)90452-9; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nishimura E, 1996, NEUROSCI LETT, V211, P101, DOI 10.1016/0304-3940(96)12722-1; Olson JM, 2001, DEV BIOL, V234, P174, DOI 10.1006/dbio.2001.0245; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Tagoh H, 2004, BLOOD, V103, P2950, DOI 10.1182/blood-2003-09-3323; Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741	19	66	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1113	1117		10.1038/ncb1312	http://dx.doi.org/10.1038/ncb1312			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16227968				2022-12-25	WOS:000232930400015
J	Xie, Y; Ding, YQ; Hong, Y; Feng, Z; Navarre, S; Xi, CX; Zhu, XJ; Wang, CL; Ackerman, SL; Kozlowski, D; Mei, L; Xiong, WC				Xie, Y; Ding, YQ; Hong, Y; Feng, Z; Navarre, S; Xi, CX; Zhu, XJ; Wang, CL; Ackerman, SL; Kozlowski, D; Mei, L; Xiong, WC			Phosphatidylinositol transfer protein-alpha in netrin-1-induced PLC signalling and neurite outgrowth	NATURE CELL BIOLOGY			English	Article							COLORECTAL-CANCER; NETRIN RECEPTOR; AXON GUIDANCE; PITP-ALPHA; DCC; GROWTH; ZEBRAFISH; KINASE; SLIT; ACTIVATION	Neurite extension is essential for wiring the nervous system during development. Although several factors are known to regulate neurite outgrowth, the underlying mechanisms remain unclear. Here, we provide evidence for a role of phosphatidylinositol transfer protein-alpha ( PITP alpha) in neurite extension in response to netrin-1, an extracellular guidance cue. PITP alpha interacts with the netrin receptor DCC ( deleted in colorectal cancer) and neogenin. Netrin-1 stimulates PITP alpha binding to DCC and to phosphatidylinositol ( 5) phosphate [ PI( 5) P], increases its lipid-transfer activity and elevates hydrolysis of phosphatidylinositol bisphosphate (PIP2). In addition, the stimulated PIP2 hydrolysis requires PITP alpha. Furthermore, cortical explants of PITP alpha mutant mice are defective in extending neurites in response to netrin-1. Commissural neurons from chicken embryos expressing a dominant-negative PITP alpha mutant show reduced axon outgrowth. Morpholino-mediated knockdown of PITP alpha expression in zebrafish embryos leads to dose-dependent defects in motor-neuron axons and reduced numbers of spinal-cord neurons. Taken together, these results identify a crucial role for PITP alpha in netrin-1-induced neurite outgrowth, revealing a signalling mechanism for DCC/neogenin and PITP alpha regulation.	Med Coll Georgia, Inst Mol Med & Genom, Augusta, GA 30912 USA; Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Neurobiol, Shanghai 200031, Peoples R China; Howard Hughes Med Inst, Bar Harbor, ME 04609 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of Alabama System; University of Alabama Birmingham; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Howard Hughes Medical Institute; Jackson Laboratory	Xiong, WC (corresponding author), Med Coll Georgia, Inst Mol Med & Genom, Augusta, GA 30912 USA.	wxiong@mcg.edu	Wang, Chunlei/G-7652-2014; Mei, Lin/G-8755-2012	Ding, Yu-Qiang/0000-0003-1202-4635	NIAMS NIH HHS [AR48120] Funding Source: Medline; NIDCD NIH HHS [DC006140] Funding Source: Medline; NIGMS NIH HHS [GM63861] Funding Source: Medline; NINDS NIH HHS [NS40480, NS045710, NS44521] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044521, R01NS045710, R01NS040480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006140] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Allen-Baume V, 2002, FEBS LETT, V531, P74, DOI 10.1016/S0014-5793(02)03412-9; Braisted JE, 2000, J NEUROSCI, V20, P5792, DOI 10.1523/JNEUROSCI.20-15-05792.2000; Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Culotti JG, 1998, CURR OPIN CELL BIOL, V10, P609, DOI 10.1016/S0955-0674(98)80036-7; Finger JH, 2002, J NEUROSCI, V22, P10346; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; Hara S, 1997, J BIOL CHEM, V272, P14908, DOI 10.1074/jbc.272.23.14908; Hiramoto M, 2000, NATURE, V406, P886, DOI 10.1038/35022571; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kennedy TE, 2000, BIOCHEM CELL BIOL, V78, P569, DOI 10.1139/bcb-78-5-569; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Mawdsley DJ, 2004, DEV BIOL, V269, P302, DOI 10.1016/j.ydbio.2004.02.001; Metin C, 1997, DEVELOPMENT, V124, P5063; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Morgan CP, 2004, J BIOL CHEM, V279, P47159, DOI 10.1074/jbc.M405827200; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ren XR, 2004, NAT NEUROSCI, V7, P1204, DOI 10.1038/nn1330; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Richards LJ, 1997, J NEUROSCI, V17, P2445; Schouten A, 2002, EMBO J, V21, P2117, DOI 10.1093/emboj/21.9.2117; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Stein E, 2001, SCIENCE, V291, P1976, DOI 10.1126/science.1059391; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; VANPARIDON PA, 1988, BIOCHIM BIOPHYS ACTA, V943, P76, DOI 10.1016/0005-2736(88)90348-3; Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036; Yoder MD, 2001, J BIOL CHEM, V276, P9246, DOI 10.1074/jbc.M010131200	35	78	82	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2005	7	11					1124	1132		10.1038/ncb1321	http://dx.doi.org/10.1038/ncb1321			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	979GM	16244667				2022-12-25	WOS:000232930400017
J	Ghosh, K; Lau, CK; Gupta, K; Van Duyne, GD				Ghosh, K; Lau, CK; Gupta, K; Van Duyne, GD			Preferential synapsis of loxP sites drives ordered strand exchange in Cre-loxP site-specific recombination	NATURE CHEMICAL BIOLOGY			English	Article							HOLLIDAY JUNCTION INTERMEDIATE; CRYSTAL-STRUCTURE; SPACER REGION; DNA; MECHANISM; SEQUENCE; FLP	The bacteriophage P1 Cre recombinase catalyzes site-specific recombination between 34-base-pair loxP sequences in a variety of topological contexts. This reaction is widely used to manipulate DNA molecules in applications ranging from benchtop cloning to genome modifications in transgenic animals. Despite the simple, highly symmetric nature of the Cre-loxP system, there is strong evidence that the reaction is asymmetric; the 'bottom' strands in the recombining loxP sites are preferentially exchanged before the 'top' strands. Here, we address the mechanistic basis for ordered strand exchange in the Cre-loxP recombination pathway. Using suicide substrates containing 5'-bridging phosphorothioate linkages at both cleavage sites, fluorescence resonance energy transfer between synapsed loxP sites and a Cre mutant that can cleave the bridging phosphorothioate linkage but not a normal phosphodiester linkage, we showed that preferential formation of a specific synaptic complex between loxP sites imposes ordered strand exchange during recombination and that synapsis stimulates cleavage of loxP sites.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Van Duyne, GD (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.	vanduyne@mail.med.upenn.edu	Lau, Terrence/ABB-7900-2021	Lau, Terrence/0000-0002-7505-7306; Gupta, Kushol/0000-0002-7006-2667				ABREMSKI K, 1986, J BIOL CHEM, V261, P391; ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; Azaro MA., 2002, MOBILE DNA-UK, P118, DOI DOI 10.1128/9781555817954.CH7; Barre FX, 2000, GENE DEV, V14, P2976, DOI 10.1101/gad.188700; BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; BURGIN AB, 1992, P NATL ACAD SCI USA, V89, P9642, DOI 10.1073/pnas.89.20.9642; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Ennifar E, 2003, NUCLEIC ACIDS RES, V31, P5449, DOI 10.1093/nar/gkg732; Ghosh K, 2005, J BIOL CHEM, V280, P8290, DOI 10.1074/jbc.M411668200; Ghosh K, 2002, METHODS, V28, P374, DOI 10.1016/S1046-2023(02)00244-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; KITTS PA, 1988, J MOL BIOL, V204, P95, DOI 10.1016/0022-2836(88)90602-X; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; Lee L, 2005, PROG NUCLEIC ACID RE, V80, P1, DOI 10.1016/S0079-6603(05)80001-7; Lee L, 2003, J BIOL CHEM, V278, P23118, DOI 10.1074/jbc.M302272200; Lee L, 2003, J MOL BIOL, V326, P397, DOI 10.1016/S0022-2836(02)01429-8; Lee L, 2001, J BIOL CHEM, V276, P31092, DOI 10.1074/jbc.M103739200; Martin SS, 2002, J MOL BIOL, V319, P107, DOI 10.1016/S0022-2836(02)00246-2; MCCULLOCH R, 1994, EMBO J, V13, P1844, DOI 10.1002/j.1460-2075.1994.tb06453.x; Miller GP, 2002, ORG LETT, V4, P3599, DOI 10.1021/ol0264915; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; Ringrose L, 1998, J MOL BIOL, V284, P363, DOI 10.1006/jmbi.1998.2149; Sauer B., 2002, MOBILE DNA, P38; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STERNBERG N, 1980, COLD SPRING HARB SYM, V45, P297, DOI 10.1101/SQB.1981.045.01.042; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; Voziyanov Y, 1996, J MOL BIOL, V256, P720, DOI 10.1006/jmbi.1996.0120; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0; Xu YZ, 1997, TETRAHEDRON LETT, V38, P5595, DOI 10.1016/S0040-4039(97)01266-5	42	36	38	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2005	1	5					275	282		10.1038/nchembio733	http://dx.doi.org/10.1038/nchembio733			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	975GN	16408057				2022-12-25	WOS:000232649100012
J	Hammarlund, E; Lewis, MW; Carter, SV; Amanna, I; Hansen, SG; Strelow, LI; Wong, SW; Yoshihara, P; Hanifin, JM; Slifka, MK				Hammarlund, E; Lewis, MW; Carter, SV; Amanna, I; Hansen, SG; Strelow, LI; Wong, SW; Yoshihara, P; Hanifin, JM; Slifka, MK			Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox	NATURE MEDICINE			English	Article							EMERGING INFECTIONS; SMALLPOX; DISEASE; VARIOLA; COWPOX; CONGO	Approximately 50% of the US population received smallpox vaccinations before routine immunization ceased in 1972 for civilians and in 1990 for military personnel. Several studies have shown long- term immunity after smallpox vaccination, but skepticism remains as to whether this will translate into full protection against the onset of orthopoxvirus- induced disease. The US monkeypox outbreak of 2003 provided the opportunity to examine this issue. Using independent and internally validated diagnostic approaches with >= 95% sensitivity and >= 90% specificity for detecting clinical monkeypox infection, we identified three previously unreported cases of monkeypox in preimmune individuals at 13, 29 and 48 years after smallpox vaccination. These individuals were unaware that they had been infected because they were spared any recognizable disease symptoms. Together, this shows that the US monkeypox outbreak was larger than previously realized and, more importantly, shows that cross- protective antiviral immunity against West African monkeypox can potentially be maintained for decades after smallpox vaccination.	Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA	Oregon Health & Science University	Slifka, MK (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 NW 185th Ave, Beaverton, OR 97006 USA.	slifkam@ohsu.edu		Amanna, Ian/0000-0001-7545-4013; Lewis, Matthew/0000-0002-6241-3690	NCRR NIH HHS [M01 RR000334, RR00163, P51 RR000163, 5 M01 RR00334] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000334, P51RR000163] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Amara RR, 2004, J VIROL, V78, P3811, DOI 10.1128/JVI.78.8.3811-3816.2004; Anderson MG, 2003, PEDIATR INFECT DIS J, V22, P1093, DOI 10.1097/01.inf.0000101821.61387.a5; BAXBY D, 1994, BRIT J DERMATOL, V131, P598, DOI 10.1111/j.1365-2133.1994.tb04969.x; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P537; Centers for Disease Control and Prevention (CDC), 2003, MMWR MORB MORTAL WKL, V52, P642; Di Giulio DB, 2004, LANCET INFECT DIS, V4, P15, DOI 10.1016/S1473-3099(03)00856-9; ESPOSITO JJ, 1977, J MED VIROL, V1, P35, DOI 10.1002/jmv.1890010107; Gross E, 2003, ANN EMERG MED, V42, P660, DOI 10.1016/S0196-0644(03)00819-9; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Hawranek T, 2003, J AM ACAD DERMATOL, V49, P513, DOI 10.1067/S0190-9622(03)00762-X; HEINER GG, 1971, AM J EPIDEMIOL, V94, P252, DOI 10.1093/oxfordjournals.aje.a121319; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; HUTCHINSON HD, 1977, B WORLD HEALTH ORGAN, V55, P613; Hutin YJF, 2001, EMERG INFECT DIS, V7, P434; Ibrahim MS, 2003, J CLIN MICROBIOL, V41, P3835, DOI 10.1128/JCM.41.8.3835-3839.2003; JEZEK Z, 1986, J INFECT DIS, V154, P551, DOI 10.1093/infdis/154.4.551; JEZEK Z, 1987, J INFECT DIS, V156, P293, DOI 10.1093/infdis/156.2.293; JEZEK Z, 1988, TROP GEOGR MED, V40, P73; JEZEK Z, 1987, J TROP MED HYG, V90, P31; Klein Kelly R, 2004, Prehosp Disaster Med, V19, P256; MACK TM, 1972, AM J TROP MED HYG, V21, P214, DOI 10.4269/ajtmh.1972.21.214; Meyer H, 2002, J CLIN MICROBIOL, V40, P2919, DOI 10.1128/JCM.40.8.2919-2921.2002; Pelkonen PM, 2003, EMERG INFECT DIS, V9, P1458, DOI 10.3201/eid0911.020814; Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299; SARKAR JK, 1975, B WORLD HEALTH ORGAN, V52, P307; Seward JF, 2004, CLIN INFECT DIS, V39, P1477, DOI 10.1086/425500; Shchelkunov SN, 2002, VIROLOGY, V297, P172, DOI 10.1006/viro.2002.1446; Slifka MK, 2004, CURR OPIN IMMUNOL, V16, P443, DOI 10.1016/j.coi.2004.05.013; Smith GL, 2002, NAT REV IMMUNOL, V2, P521, DOI 10.1038/nri845; 2003, MMWR MORB MORTAL WKL, V52, P561	30	107	112	4	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					1005	1011		10.1038/nm1273	http://dx.doi.org/10.1038/nm1273			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16086024				2022-12-25	WOS:000231724700030
J	Cam, HP; Sugiyama, T; Chen, ES; Chen, X; FitzGerald, PC; Grewal, SIS				Cam, HP; Sugiyama, T; Chen, ES; Chen, X; FitzGerald, PC; Grewal, SIS			Comprehensive analysis of heterochromatin- and RNAi-mediated epigenetic control of the fission yeast genome	NATURE GENETICS			English	Article							HISTONE LYSINE METHYLATION; SCHIZOSACCHAROMYCES-POMBE; TRANSPOSABLE ELEMENTS; CHROMODOMAIN PROTEIN; DNA METHYLATION; H3 METHYLATION; INTERFERENCE; DISTINCT; DOMAIN; POLYMERASE	The organization of eukaryotic genomes into distinct structural and functional domains is important for the regulation and transduction of genetic information. Here, we investigated heterochromatin and euchromatin profiles of the entire fission yeast genome and explored the role of RNA interference (RNAi) in genome organization. Histone H3 methylated at Lys4, which defines euchromatin, was not only distributed across most of the chromosomal landscape but was also present at the centromere core, the site of kinetochore assembly. In contrast, histone H3 methylated at Lys9 and its interacting protein Swi6/HP1, which define heterochromatin, coated extended domains associated with a variety of repeat elements and small islands corresponding to meiotic genes. Notably, RNAi components were distributed throughout all these heterochromatin domains, and their localization depended on Clr4/Suv39h histone methyltransferase. Sequencing of small interfering RNAs (siRNAs) associated with the RITS RNAi effector complex identified hot spots of siRNAs, which mapped to a diverse array of elements in these RNAi-heterochromatin domains. We found that Clr4/Suv39h predominantly silenced repeat elements whose derived transcripts, transcribed mainly by RNA polymerase II, serve as a source for siRNAs. Our analyses also uncover an important role for the RNAi machinery in maintaining genomic integrity.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Genome Anal Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Grewal, SIS (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.	grewals@mail.nih.gov		Sugiyama, Tomoyasu/0000-0001-5704-6606	NATIONAL CANCER INSTITUTE [ZIABC010523, Z01BC010523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059772] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Bowen NJ, 2003, GENOME RES, V13, P1984, DOI 10.1101/gr.1191603; Chan SWL, 2005, NAT REV GENET, V6, P351, DOI 10.1038/nrg1601; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Grewal SIS, 2004, CURR OPIN CELL BIOL, V16, P230, DOI 10.1016/j.ceb.2004.04.002; Hall IM, 2003, P NATL ACAD SCI USA, V100, P193, DOI 10.1073/pnas.232688099; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hansen KR, 2005, MOL CELL BIOL, V25, P590, DOI 10.1128/MCB.25.2.590-601.2005; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; Herr AJ, 2005, SCIENCE, V308, P118, DOI 10.1126/science.1106910; Jia ST, 2004, CELL, V119, P469, DOI 10.1016/j.cell.2004.10.020; Jia ST, 2004, SCIENCE, V304, P1971, DOI 10.1126/science.1099035; KANNO T, 2005, NAT GENET       0529; Kanoh J, 2001, CURR BIOL, V11, P1624, DOI 10.1016/S0960-9822(01)00503-6; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Lippman Z, 2004, NATURE, V430, P471, DOI 10.1038/nature02651; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Mandell JG, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2004-6-1-r1; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; Mochizuki K, 2004, CURR OPIN GENET DEV, V14, P181, DOI 10.1016/j.gde.2004.01.004; Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Noma K, 2004, NAT GENET, V36, P1174, DOI 10.1038/ng1452; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Onodera Y, 2005, CELL, V120, P613, DOI 10.1016/j.cell.2005.02.007; Partridge JF, 2000, GENE DEV, V14, P783; Petrie VJ, 2005, MOL CELL BIOL, V25, P2331, DOI 10.1128/MCB.25.6.2331-2346.2005; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Sadaie M, 2004, EMBO J, V23, P3825, DOI 10.1038/sj.emboj.7600401; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shankaranarayana GD, 2003, CURR BIOL, V13, P1240, DOI 10.1016/S0960-9822(03)00489-5; Sijen T, 2003, NATURE, V426, P310, DOI 10.1038/nature02107; Sugiyama T, 2005, P NATL ACAD SCI USA, V102, P152, DOI 10.1073/pnas.0407641102; Sullivan BA, 2004, NAT STRUCT MOL BIOL, V11, P1076, DOI 10.1038/nsmb845; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Thon G, 2000, GENETICS, V155, P551; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104	49	381	395	0	15	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2005	37	8					809	819		10.1038/ng1602	http://dx.doi.org/10.1038/ng1602			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	950TK	15976807				2022-12-25	WOS:000230880400010
J	Levenberg, S; Rouwkema, J; Macdonald, M; Garfein, ES; Kohane, DS; Darland, DC; Marini, R; van Blitterswijk, CA; Mulligan, RC; D'Amore, PA; Langer, R				Levenberg, S; Rouwkema, J; Macdonald, M; Garfein, ES; Kohane, DS; Darland, DC; Marini, R; van Blitterswijk, CA; Mulligan, RC; D'Amore, PA; Langer, R			Engineering vascularized skeletal muscle tissue	NATURE BIOTECHNOLOGY			English	Article							EMBRYONIC STEM-CELLS; ENDOTHELIAL SURVIVAL; DIFFERENTIATION; ANGIOGENESIS; MECHANISMS; DELIVERY; MATRICES	One of the major obstacles in engineering thick, complex tissues such as muscle is the need to vascularize the tissue in vitro. Vascularization in vitro could maintain cell viability during tissue growth, induce structural organization and promote vascularization upon implantation. Here we describe the induction of endothelial vessel networks in engineered skeletal muscle tissue constructs using a three-dimensional multiculture system consisting of myoblasts, embryonic fibroblasts and endothelial cells coseeded on highly porous, biodegradable polymer scaffolds. Analysis of the conditions for induction and stabilization of the vessels in vitro showed that addition of embryonic fibroblasts increased the levels of vascular endothelial growth factor expression in the construct and promoted formation and stabilization of the endothelial vessels. We studied the survival and vascularization of the engineered muscle implants in vivo in three different models. Prevascularization improved the vascularization, blood perfusion and survival of the muscle tissue constructs after transplantation.	Technion Israel Inst Technol, Dept Biomed Engn, IL-32000 Haifa, Israel; MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Div Comparat Med, Cambridge, MA 02139 USA; Univ Twente, Inst Biomed Technol, NL-3723 MB Bilthoven, Netherlands; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; Schepens Eye Res Inst, Boston, MA 02114 USA; Dept Ophthalmol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Mol Med, Childrens Hosp, Boston, MA 02115 USA	Technion Israel Institute of Technology; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Twente; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Schepens Eye Research Institute; Harvard University; Boston Children's Hospital; Harvard Medical School	Langer, R (corresponding author), Technion Israel Inst Technol, Dept Biomed Engn, IL-32000 Haifa, Israel.	shulamit@bm.technion.ac.il; rlanger@mit.edu	D'Amore, Patricia A/G-5660-2017; Rouwkema, Jeroen/H-8440-2019	D'Amore, Patricia A/0000-0001-9652-8974; Rouwkema, Jeroen/0000-0001-9666-9064; van Blitterswijk, Clemens/0000-0003-2371-4615; Levenberg, Shulamit/0000-0001-5471-7339	NEI NIH HHS [EY05318] Funding Source: Medline; NHLBI NIH HHS [HL60435] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060435] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bach AD, 2003, CLIN PLAST SURG, V30, P589, DOI 10.1016/S0094-1298(03)00077-4; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Darland D. C., 2001, Angiogenesis, V4, P11, DOI 10.1023/A:1016611824696; Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015; Flamme I, 1997, J CELL PHYSIOL, V173, P206, DOI 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Holder WD, 1998, J BIOMED MATER RES, V41, P412, DOI 10.1002/(SICI)1097-4636(19980905)41:3<412::AID-JBM11>3.0.CO;2-K; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999; Levenberg S, 2003, P NATL ACAD SCI USA, V100, P12741, DOI 10.1073/pnas.1735463100; Lu YX, 2001, CIRCULATION, V104, P594, DOI 10.1161/hc3101.092215; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Neumann T, 2003, MICROVASC RES, V66, P59, DOI 10.1016/S0026-2862(03)00040-2; Rossant J, 2003, CURR OPIN GENET DEV, V13, P408, DOI 10.1016/S0959-437X(03)00080-7; Saxena AK, 1999, TISSUE ENG, V5, P525, DOI 10.1089/ten.1999.5.525; Shinoka T, 2002, ARTIF ORGANS, V26, P402, DOI 10.1046/j.1525-1594.2002.07004.x; Sieminski AL, 2002, TISSUE ENG, V8, P1057, DOI 10.1089/107632702320934155; von Degenfeld G, 2003, BRIT J PHARMACOL, V140, P620, DOI 10.1038/sj.bjp.0705492; Wigmore PM, 2002, INT REV CYTOL, V216, P175; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zisch AH, 2003, CARDIOVASC PATHOL, V12, P295, DOI 10.1016/S1054-8807(03)00089-9	26	940	988	6	273	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2005	23	7					879	884		10.1038/nbt1109	http://dx.doi.org/10.1038/nbt1109			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	944KT	15965465				2022-12-25	WOS:000230427700036
J	Ferreras, JA; Ryu, JS; Di Lello, F; Tan, DS; Quadri, LEN				Ferreras, JA; Ryu, JS; Di Lello, F; Tan, DS; Quadri, LEN			Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis	NATURE CHEMICAL BIOLOGY			English	Article							IRON TRANSPORT; IN-VITRO; SYNTHETASES; EXOCHELINS; ADENYLATE; DOMAINS; ANALOGS	Mycobacterium tuberculosis and Yersinia pestis, the causative agents of tuberculosis and plague, respectively, are pathogens with serious ongoing impact on global public health(1,2) and potential use as agents of bioterrorism(3). Both pathogens have iron acquisition systems based on siderophores, secreted iron-chelating compounds with extremely high Fe3+ affinity(4,5). Several lines of evidence suggest that siderophores have a critical role in bacterial iron acquisition inside the human host(6-9), where the free iron concentration is well below that required for bacterial growth and virulence(10). Thus, siderophore biosynthesis is an attractive target in the development of new antibiotics to treat tuberculosis and plague(2,5,8,11). In particular, such drugs, alone or as part of combination therapies, could provide a valuable new line of defense against intractable multiple-drug-resistant infections. Here, we report the design, synthesis and biological evaluation of a mechanism-based inhibitor of domain salicylation enzymes required for siderophore biosynthesis in M. tuberculosis and Y. pestis. This new antibiotic inhibits siderophore biosynthesis and growth of M. tuberculosis and Y. pestis under iron-limiting conditions.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Tri Inst Res Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Quadri, LEN (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave,Box 62, New York, NY 10021 USA.	tand@mskcc.org; leq2001@med.cornell.edu	Ferreras, Julian/U-5032-2019	Ferreras, Julian/0000-0003-4189-2917; Di Lello, Federico Alejandro/0000-0001-9771-9705				[Anonymous], 2000, MMWR Recomm Rep, V49, P1; BARCLAY R, 1988, J GEN MICROBIOL, V134, P771; Bearden SW, 1997, INFECT IMMUN, V65, P1659, DOI 10.1128/IAI.65.5.1659-1668.1997; Brodin P, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P143; CASTROPICHEL J, 1987, TETRAHEDRON, V43, P383, DOI 10.1016/S0040-4020(01)89967-1; Copeland R.A., 2000, ENZYMES PRACTICAL IN, P305; Crosa JH, 2002, MICROBIOL MOL BIOL R, V66, P223, DOI 10.1128/MMBR.66.2.223-249.2002; Darwin KH, 2003, SCIENCE, V302, P1963, DOI 10.1126/science.1091176; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; Finking R, 2003, CHEMBIOCHEM, V4, P903, DOI 10.1002/cbic.200300666; FLORINI JR, 1966, J BIOL CHEM, V241, P1091; Forrest AK, 2000, BIOORG MED CHEM LETT, V10, P1871, DOI 10.1016/S0960-894X(00)00360-7; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P11637, DOI 10.1021/bi9812571; Gobin J, 1996, J EXP MED, V183, P1527, DOI 10.1084/jem.183.4.1527; Gong SM, 2001, INFECT IMMUN, V69, P2829, DOI 10.1128/IAI.67.5.2829-2837.2001; Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549; Kim S, 2003, APPL MICROBIOL BIOT, V61, P278, DOI 10.1007/s00253-003-1243-5; May JJ, 2002, P NATL ACAD SCI USA, V99, P12120, DOI 10.1073/pnas.182156699; *NIH NIAID, 2002, COUNT BIOT RES AG NA; PERROW C, 1997, ORG ENV, V10, P66, DOI DOI 10.1177/0921810697101009; Perry RD, 1999, MICROBIOL-UK, V145, P1181, DOI 10.1099/13500872-145-5-1181; Quadri LEN, 1999, BIOCHEMISTRY-US, V38, P14941, DOI 10.1021/bi991787c; Quadri LEN, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P341; Quadri LEN, 1998, CHEM BIOL, V5, P631, DOI 10.1016/S1074-5521(98)90291-5; Quadri LEN, 2000, MOL MICROBIOL, V37, P1, DOI 10.1046/j.1365-2958.2000.01941.x; Smith I, 2003, CLIN MICROBIOL REV, V16, P463, DOI 10.1128/CMR.16.3.463-496.2003; ZHU XF, 2000, J CHEM SOC P1, V1, P2305	27	229	247	1	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2005	1	1					29	32		10.1038/nchembio706	http://dx.doi.org/10.1038/nchembio706			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	974WC	16407990				2022-12-25	WOS:000232621100009
